PT	AU	BA	BE	GP	AF	BF	CA	TI	SO	SE	BS	LA	DT	CT	CY	CL	SP	HO	DE	ID	AB	C1	C3	RP	EM	RI	OI	FU	FP	FX	CR	NR	TC	Z9	U1	U2	PU	PI	PA	SN	EI	BN	J9	JI	PD	PY	VL	IS	PN	SU	SI	MA	BP	EP	AR	DI	DL	D2	EA	PG	WC	WE	SC	GA	PM	OA	HC	HP	DA	UT
J	GWILT, DJ				GWILT, DJ			CARDIOLOGISTS IN CASUALTY	LANCET			English	Editorial Material							ACUTE MYOCARDIAL-INFARCTION; EMERGENCY ROOM; CHEST PAIN				GWILT, DJ (corresponding author), MILTON KEYNES DIST GEN HOSP, MILTON KEYNES, BUCKS, ENGLAND.							[Anonymous], 1988, LANCET, V2, P349; APPLEBY P, 1994, LANCET, V343, P311, DOI 10.1016/S0140-6736(94)91161-4; AUFDERHEIDE TP, 1992, AM J CARDIOL, V69, P991, DOI 10.1016/0002-9149(92)90852-P; GOLDMAN L, 1988, NEW ENGL J MED, V318, P797, DOI 10.1056/NEJM198803313181301; HEDEN B, 1994, AM J CARDIOL, V74, P5, DOI 10.1016/0002-9149(94)90482-0; HIMBERT D, 1993, AM J CARDIOL, V71, P377, DOI 10.1016/0002-9149(93)90435-F; KAUL S, 1994, ANN INTERN MED, V121, P976, DOI 10.7326/0003-4819-121-12-199412150-00013; LEE HS, 1994, BRIT HEART J, V71, P311; LEE TH, 1987, AM J CARDIOL, V60, P219, DOI 10.1016/0002-9149(87)90217-7; MCLEOD AA, 1994, BRIT HEART J, V72, P303; OKEEFE JH, 1993, AM J CARDIOL, V72, pG107, DOI 10.1016/0002-9149(93)90115-S; PEELS CH, 1990, AM J CARDIOL, V65, P687, DOI 10.1016/0002-9149(90)90143-O; TIMMIS AD, 1990, BMJ-BRIT MED J, V301, P941, DOI 10.1136/bmj.301.6758.941; VARETTO T, 1993, J AM COLL CARDIOL, V22, P1804, DOI 10.1016/0735-1097(93)90761-O; WEISSMAN I, 1995, ANN INTERN MED, V123, P314, DOI 10.7326/0003-4819-123-4-199508150-00013	15	0	0	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	DEC 16	1995	346	8990					1571	1572		10.1016/S0140-6736(95)91923-6	http://dx.doi.org/10.1016/S0140-6736(95)91923-6			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TK481	7500745	Bronze			2022-12-28	WOS:A1995TK48100004
J	TSAI, CC; FOLLIS, KE; SABO, A; BECK, TW; GRANT, RF; BISCHOFBERGER, N; BENVENISTE, RE; BLACK, R				TSAI, CC; FOLLIS, KE; SABO, A; BECK, TW; GRANT, RF; BISCHOFBERGER, N; BENVENISTE, RE; BLACK, R			PREVENTION OF SIV INFECTION IN MACAQUES BY (R)-9-(2-PHOSPHONYLMETHOXYPROPYL)ADENINE	SCIENCE			English	Article							SIMIAN IMMUNODEFICIENCY VIRUS; ACYCLIC NUCLEOSIDE PHOSPHONATES; RHESUS-MONKEYS; ANTIRETROVIRAL AGENTS; INVITRO; PROPHYLAXIS; RESISTANCE; ZIDOVUDINE; LENTIVIRUS; METABOLISM	The efficacy of pre- and postexposure treatment with the antiviral compound (R)-9-(2-phosphonylmethoxypropyl)adenine (PMPA) was tested against simian immunodeficiency virus (SIV) in macaques as a model for human immunodeficiency virus (HIV). PMPA was administered subcutaneously once daily beginning either 48 hours before, 4 hours after, or 24 hours after virus inoculation. Treatment continued for 4 weeks and the virologic, immunologic, and clinical status of the macaques was monitored for up to 56 weeks. PMPA prevented SIV infection in all macaques without toxicity, whereas all control macaques became infected. These results suggest a potential role for PMPA prophylaxis against early HIV infection in cases of known exposure.	GILEAD SCI INC,FOSTER CITY,CA 94404; NCI,FREDERICK,MD 21701; NIAID,DIV AIDS,BETHESDA,MD 20852	Gilead Sciences; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID)	TSAI, CC (corresponding author), UNIV WASHINGTON,REG PRIMATE RES CTR,SEATTLE,WA 98195, USA.				NCRR NIH HHS [RR00166] Funding Source: Medline; NIAID NIH HHS [N01-AI-15120] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [P51RR000166] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [N01AI015120] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BALZARINI J, 1991, AIDS, V5, P21, DOI 10.1097/00002030-199101000-00003; BALZARINI J, 1993, ANTIMICROB AGENTS CH, V37, P332, DOI 10.1128/AAC.37.2.332; BENVENISTE RE, 1986, J VIROL, V60, P483, DOI 10.1128/JVI.60.2.483-490.1986; CALIENDO AM, 1994, CLIN INFECT DIS, V18, P516, DOI 10.1093/clinids/18.4.516; DECLERCQ E, 1986, NATURE, V323, P464, DOI 10.1038/323464a0; FAZELY F, 1991, J ACQ IMMUN DEF SYND, V4, P1093; Follis Kathryn E., 1994, Journal of Medical Primatology, V23, P255; GARDNER MB, 1991, ANTIVIR RES, V15, P267, DOI 10.1016/0166-3542(91)90009-G; HO HT, 1992, MOL PHARMACOL, V41, P197; LEGRAND R, 1994, AIDS RES HUM RETROV, V10, P1279, DOI 10.1089/aid.1994.10.1279; LUNDGREN B, 1991, J ACQ IMMUN DEF SYND, V4, P489; MARTIN LN, 1993, J INFECT DIS, V168, P825, DOI 10.1093/infdis/168.4.825; MCCLURE HM, 1990, ANN NY ACAD SCI, V616, P287; MONTANER JSG, 1993, AIDS, V7, P189, DOI 10.1097/00002030-199302000-00006; MONTANER JSG, 1995, LANCET, V345, P377, DOI 10.1016/S0140-6736(95)90356-9; PAUWELS R, 1988, ANTIMICROB AGENTS CH, V32, P1025, DOI 10.1128/AAC.32.7.1025; RICHMAN DD, 1993, ANTIMICROB AGENTS CH, V37, P1207, DOI 10.1128/AAC.37.6.1207; RICHMANN DD, 1994, AIDS, V7, P135; SRINIVAS RV, 1993, ANTIMICROB AGENTS CH, V37, P2247, DOI 10.1128/AAC.37.10.2247; TOKARS JI, 1993, ANN INTERN MED, V118, P193; Tsai C.-E., UNPUB; TSAI CC, 1993, J ACQ IMMUN DEF SYND, V6, P1086; TSAI CC, 1990, ANTIVIR RES, V14, P87, DOI 10.1016/0166-3542(90)90046-A; TSAI CC, 1994, J INFECT DIS, V169, P260, DOI 10.1093/infdis/169.2.260; TSAI CC, 1994, J MED PRIMATOL, V23, P175, DOI 10.1111/j.1600-0684.1994.tb00119.x; TSAI CC, 1995, J INFECT DIS, V171, P1338, DOI 10.1093/infdis/171.5.1338; TSAI CC, 1993, LAB ANIM SCI, V43, P441; VANROMPAY KKA, 1992, ANTIMICROB AGENTS CH, V36, P2381, DOI 10.1128/AAC.36.11.2381; VELLA S, 1994, AIDS, V8, pS25, DOI 10.1097/00002030-199409001-00006; WYAND MS, 1992, AIDS RES HUM RETROV, V8, P349, DOI 10.1089/aid.1992.8.349	30	462	482	0	19	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	NOV 17	1995	270	5239					1197	1199		10.1126/science.270.5239.1197	http://dx.doi.org/10.1126/science.270.5239.1197			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TE905	7502044				2022-12-28	WOS:A1995TE90500056
J	KLENERMAN, P; ROWLANDJONES, S; MCADAM, S; EDWARDS, J; DAENKE, S; LALLOO, D; KOPPE, B; ROSENBERG, W; BOYD, D; EDWARDS, A; GIANGRANDE, P; PHILLIPS, RE; MCMICHAEL, AJ				KLENERMAN, P; ROWLANDJONES, S; MCADAM, S; EDWARDS, J; DAENKE, S; LALLOO, D; KOPPE, B; ROSENBERG, W; BOYD, D; EDWARDS, A; GIANGRANDE, P; PHILLIPS, RE; MCMICHAEL, AJ			CYTOTOXIC T-CELL ACTIVITY ANTAGONIZED BY NATURALLY-OCCURRING HIV-1 GAG VARIANTS	NATURE			English	Article							LYMPHOCYTES-T; RECEPTOR; PEPTIDES; INDIVIDUALS; RECOGNITION; VIRUS	MOST asymptomatic individuals infected with HIV-1 have a cytotoxic T lymphocyte (CTL) response to the virus Gag proteins which can be demonstrated in vitro(1,2). Epitopes have been mapped in p17 Gag and p24 Gag restricted by HLA-B8 (p17-3 and p24-13) and -B27 (p24-14)(2,3). Viruses isolated from patients who make CTL responses to these peptides vary within the genetic sequences encoding these epitopes and some mutations lead to reduction in killing activity in vitro(4). This mas attributed to either failure of the variant epitope to bind major histocompatibility complex class I or failure of T-cell receptors to bind the presented peptide. But peptide variants of class I-restricted epitopes cause 'antagonism', that is, the presence of a variant epitope (in the form of peptide) inhibits normal lysis of targets presenting the original epitope(5,6). This mirrors similar findings in class II-restricted systems(7-10). Here we report that naturally occurring variant forms of p17-3, p24-13 and p24-14 may cause antagonism of CTL lines derived from the same individuals. The effect is present if the epitopes are derived from synthetic peptides and when they are processed from full-length proteins expressed by either recombinant vaccinia constructs or replicating HIV.	UNIV OXFORD,INST MOLEC MED,OXFORD OX3 9DU,ENGLAND; RADCLIFFE INFIRM,DEPT GENITOURINARY MED,OXFORD OX3 7LJ,ENGLAND; CHURCHILL HOSP,OXFORD HAEMOPHILIA CTR,OXFORD OX3 7LV,ENGLAND	University of Oxford; Radcliffe Infirmary	KLENERMAN, P (corresponding author), UNIV OXFORD,NUFFIELD DEPT CLIN MED,DIV MOLEC SCI,OXFORD OX3 9DU,ENGLAND.		Rosenberg, William/ABA-1071-2021	Rosenberg, William/0000-0002-2732-2304; klenerman, paul/0000-0003-4307-9161; Daenke, Susan/0000-0003-3290-6627; Lalloo, David/0000-0001-7680-2200	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		DEMAGISTRIS MT, 1992, CELL, V68, P625, DOI 10.1016/0092-8674(92)90139-4; DOUGHERTY JP, 1988, J VIROL, V62, P2817, DOI 10.1128/JVI.62.8.2817-2822.1988; EVAVOLD BD, 1991, SCIENCE, V252, P1308, DOI 10.1126/science.1833816; EVAVOLD BD, 1993, IMMUNOL TODAY, V14, P602, DOI 10.1016/0167-5699(93)90200-5; HOGQUIST KA, 1994, CELL, V76, P17, DOI 10.1016/0092-8674(94)90169-4; JAMESON SC, 1993, J EXP MED, V177, P1541, DOI 10.1084/jem.177.6.1541; MACKETT M, 1984, J VIROL, V49, P854; Maniatis T., 1982, MOL CLONING; MYERS G, 1992, HUMAN RETROVIRUSES A; NIXON DF, 1988, NATURE, V336, P484, DOI 10.1038/336484a0; NIXON DF, 1991, AIDS, V5, P1049; OSTROV D, 1993, J IMMUNOL, V150, P4277; PHILLIPS RE, 1991, NATURE, V354, P453, DOI 10.1038/354453a0; RACIOPPI L, 1993, J EXP MED, V177, P1947; ROWLANDJONES SL, 1993, EUR J IMMUNOL, V23, P1999, DOI 10.1002/eji.1830230841; SUTTON J, 1993, EUR J IMMUNOL, V23, P447, DOI 10.1002/eji.1830230222; WALKER BD, 1988, SCIENCE, V240, P64, DOI 10.1126/science.2451288; ZHANG LQ, 1991, AIDS, V5, P675, DOI 10.1097/00002030-199106000-00006	18	401	409	0	7	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JUN 2	1994	369	6479					403	407		10.1038/369403a0	http://dx.doi.org/10.1038/369403a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	NP174	7515165				2022-12-28	WOS:A1994NP17400058
J	LEVINE, A; BASHANAHREND, A; BUDAIHADRIAN, O; GARTENBERG, D; MENASHEROW, S; WIDES, R				LEVINE, A; BASHANAHREND, A; BUDAIHADRIAN, O; GARTENBERG, D; MENASHEROW, S; WIDES, R			ODD OZ - A NOVEL DROSOPHILA PAIR RULE GENE	CELL			English	Article							ELEMENT INSERTIONAL MUTAGENESIS; MEDIATED ENHANCER DETECTION; HOMOEOTIC MUTATIONS; EXPRESSION; PROTEIN; TENASCIN; PATTERN; SEGMENTATION; MELANOGASTER; POLARITY	We have identified a novel pair rule gene in Drosophila, odd Oz (odz). Every odd-numbered body segment is deleted in odz mutant embryos. The odz gene product is strongly expressed in the embryonic central nervous system and heart, and both of these tissues are malformed in mutant embryos. odz represents the only known pair rule gene that does not encode a transcription factor. Instead, it encodes a protein with EGF-like repeats homologous to those of the extracellular matrix protein tenascin. The protein is also a putative transmembrane tyrosine kinase substrate. On the basis of its structure, odz must act in a cellularized embryo. This is consistent with odz expression, whose temporal appearance is indicative of a very late-acting pair rule gene.			LEVINE, A (corresponding author), BAR ILAN UNIV,DEPT LIFE SCI,IL-52900 RAMAT GAN,ISRAEL.							AKAM M, 1987, DEVELOPMENT, V101, P1; BAUMGARTNER S, 1993, MECH DEVELOP, V40, P165, DOI 10.1016/0925-4773(93)90074-8; BAUMGARTNER S, 1990, MECH DEVELOP, V33, P1, DOI 10.1016/0925-4773(90)90130-E; BELLEN HJ, 1989, GENE DEV, V3, P1288, DOI 10.1101/gad.3.9.1288; Campos-Ortega J.A., 2013, EMBRYONIC DEV DROSOP; CHIQUETEHRISMANN R, 1990, FASEB J, V4, P2598, DOI 10.1096/fasebj.4.9.1693347; COOLEY L, 1988, TRENDS GENET, V4, P254, DOI 10.1016/0168-9525(88)90032-7; DOE CQ, 1988, SCIENCE, V239, P170, DOI 10.1126/science.2892267; ERICKSON HP, 1989, ANNU REV CELL BIOL, V5, P71, DOI 10.1146/annurev.cb.05.110189.000443; HARTENSTEIN AY, 1992, DEVELOPMENT, V116, P1203; HAYNIE JL, 1983, DEV BIOL, V100, P399, DOI 10.1016/0012-1606(83)90234-8; HEFFETZ D, 1990, J BIOL CHEM, V265, P2896; Hooper J.E., 1992, Results and Problems in Cell Differentiation, V18, P1; HUNTER T, 1985, ANNU REV BIOCHEM, V54, P897, DOI 10.1146/annurev.biochem.54.1.897; JURGENS G, 1984, ROUX ARCH DEV BIOL, V193, P283, DOI 10.1007/BF00848157; KARPEN GH, 1992, GENETICS, V132, P737; KENNISON JA, 1987, GENETICS, V116, P75; KILCHHERR F, 1986, NATURE, V321, P493, DOI 10.1038/321493a0; KOCH CA, 1991, SCIENCE, V252, P668, DOI 10.1126/science.1708916; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; MLODZIK M, 1992, METHODS NEUROSCIENCE, V9, P397; NUSSLEINVOLHARD C, 1980, NATURE, V287, P795, DOI 10.1038/287795a0; PATEL NH, 1989, GENE DEV, V3, P890, DOI 10.1101/gad.3.6.890; PEARSON WR, 1988, P NATL ACAD SCI USA, V85, P2444, DOI 10.1073/pnas.85.8.2444; RUBIN GM, 1983, NUCLEIC ACIDS RES, V11, P6341, DOI 10.1093/nar/11.18.6341; SAGA Y, 1991, GENE, V104, P177, DOI 10.1016/0378-1119(91)90248-A; Sambrook J, 1989, MOL CLONING LABORATO; SATO T, 1983, GENETICS, V105, P357; SPRING J, 1989, CELL, V59, P325, DOI 10.1016/0092-8674(89)90294-8; STJOHNSTON D, 1992, CELL, V68, P201; TAUTZ D, 1989, CHROMOSOMA, V98, P81, DOI 10.1007/BF00291041; TEPASS U, 1990, CELL, V61, P787, DOI 10.1016/0092-8674(90)90189-L; THOMAS U, 1991, DEVELOPMENT, V111, P749; WHARTON KA, 1985, CELL, V43, P567, DOI 10.1016/0092-8674(85)90229-6; WIDES RJ, 1990, EUR J BIOCHEM, V189, P637, DOI 10.1111/j.1432-1033.1990.tb15532.x; Wieschaus E., 1986, P199; WILSON C, 1989, GENE DEV, V3, P1301, DOI 10.1101/gad.3.9.1301; ZAK NB, 1990, DEVELOPMENT, V109, P865; ZINN K, 1988, CELL, V53, P577, DOI 10.1016/0092-8674(88)90574-0	39	129	132	0	2	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	MAY 20	1994	77	4					587	598		10.1016/0092-8674(94)90220-8	http://dx.doi.org/10.1016/0092-8674(94)90220-8			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	NM832	7514504				2022-12-28	WOS:A1994NM83200013
J	BURMAN, P; HETTA, J; KARLSSON, A				BURMAN, P; HETTA, J; KARLSSON, A			EFFECT OF GROWTH-HORMONE ON BRAIN NEUROTRANSMITTERS	LANCET			English	Letter									UNIV HOSP UPPSALA, DEPT PSYCHIAT, S-75185 UPPSALA, SWEDEN	Uppsala University; Uppsala University Hospital	BURMAN, P (corresponding author), UNIV HOSP UPPSALA, DEPT INTERNAL MED, S-75185 UPPSALA, SWEDEN.							ALMQVIST O, 1986, PSYCHONEUROENDOCRINO, V11, P347, DOI 10.1016/0306-4530(86)90020-X; MCGAULEY GA, 1989, ACTA PAEDIATR SCAND, P70; RISBY ED, 1987, CLIN PHARMACOL THER, V42, P547, DOI 10.1038/clpt.1987.195; SVENSSON A, 1991, J NEURAL TRANSM-GEN, V85, P117, DOI 10.1007/BF01244704; ZHENNAN L, 1991, BRAIN RES, V546, P222	5	27	28	0	1	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	DEC 11	1993	342	8885					1492	1493		10.1016/0140-6736(93)92975-Y	http://dx.doi.org/10.1016/0140-6736(93)92975-Y			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ML217	7504154				2022-12-28	WOS:A1993ML21700054
J	Klag, MJ; Whelton, PK; Randall, BL; Neaton, JD; Brancati, FL; Ford, CE; Shulman, NB; Stamler, J				Klag, MJ; Whelton, PK; Randall, BL; Neaton, JD; Brancati, FL; Ford, CE; Shulman, NB; Stamler, J			Blood pressure and end-stage renal disease in men	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							FACTOR INTERVENTION TRIAL; CORONARY HEART-DISEASE; DIABETES-MELLITUS; RISK-FACTORS; PROGRESSION; INSUFFICIENCY; HYPERTENSION; FAILURE; DEATH; RACE	Background, End-stage renal disease in the United States creates a large burden for both individuals and society as a whole, Efforts to prevent the condition require an understanding of modifiable risk factors. Methods. We assessed the development of end-stage renal disease through 1990 in 332,544 men, 35 to 57 years of age, who were screened between 1973 and 1975 for entry into the Multiple Risk Factor Intervention Trial (MRFIT). We used data from the national registry for treated end-stage renal disease of the Health Care Financing Administration and from records on death from renal disease from the National Death Index and the Social Security Administration. Results. During an average of 16 years of follow-up, 814 subjects either died of end-stage renal disease or were treated for that condition (15.6 cases per 100,000 person-years of observation), A strong, graded relation between both systolic and diastolic blood pressure and end-stage renal disease was identified, independent of associations between the disease and age, race, income, use of medication for diabetes mellitus, history of my-ocardial infarction, serum cholesterol concentration, and cigarette smoking. As compared with men with an optimal level of blood pressure (systolic pressure <120 mm Hg and diastolic pressure <80 mm Hg), the relative risk of end-stage renal disease for those with stage 4 hypertension (systolic pressure greater than or equal to 210 mm Hg or diastolic pressure greater than or equal to 120 mm Hg) was 22.1 (P<0.001). These relations were not due to end-stage renal disease that occurred soon after screening and, in the 12,866 screened men who entered the MRFIT study, were not changed by taking into account the base-line serum creatinine concentration and urinary protein excretion, The estimated risk of end-stage renal disease associated with elevations of systolic pressure was greater than that linked with elevations of diastolic pressure when both variables were considered together, Conclusions. Elevations of blood pressure are a strong independent risk factor for end-stage renal disease; interventions to prevent the disease need to emphasize the prevention and control of both high-normal and high blood pressure. (C) 1996, Massachusetts Medical Society.	JOHNS HOPKINS UNIV, SCH MED, DEPT MED, BALTIMORE, MD 21205 USA; JOHNS HOPKINS UNIV, SCH MED, DEPT EPIDEMIOL, BALTIMORE, MD 21205 USA; JOHNS HOPKINS UNIV, SCH MED, DEPT HLTH POLICY & MANAGEMENT, BALTIMORE, MD 21205 USA; JOHNS HOPKINS UNIV, SCH HYG & PUBL HLTH, BALTIMORE, MD USA; UNIV MINNESOTA, SCH PUBL HLTH, DIV BIOSTAT, MINNEAPOLIS, MN 55455 USA; UNIV TEXAS, HLTH SCI CTR, HOUSTON, TX USA; EMORY UNIV, DEPT MED, ATLANTA, GA 30322 USA; NORTHWESTERN UNIV, SCH MED, DEPT PREVENT MED, CHICAGO, IL USA	Johns Hopkins University; Johns Hopkins University; Johns Hopkins University; Johns Hopkins University; University of Minnesota System; University of Minnesota Twin Cities; University of Texas System; University of Texas Health Science Center Houston; Emory University; Northwestern University					NHLBI NIH HHS [R01 HL28715] Funding Source: Medline; NIDDK NIH HHS [R01 DK41837] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL028715] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK041837] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BERGSTROM J, 1986, CLIN NEPHROL, V25, P1; BRAZY PC, 1990, KIDNEY INT, V37, P1113, DOI 10.1038/ki.1990.93; COX DR, 1972, J R STAT SOC B, V34, P187; DISCHINGER P, 1986, CONTROL CLIN TRIALS, V7, pS137; KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868; KINCAIDSMITH P, 1958, Q J MED, V27, P117; KJELSBERG MO, 1982, JAMA-J AM MED ASSOC, V248, P1465; KLAHR S, 1988, NEW ENGL J MED, V318, P1657; MACMAHON S, 1990, LANCET, V335, P765, DOI 10.1016/0140-6736(90)90878-9; MAMDANI BH, 1974, NEW ENGL J MED, V291, P1343, DOI 10.1056/NEJM197412192912509; MROCZEK WJ, 1969, CIRCULATION, V40, P893, DOI 10.1161/01.CIR.40.6.893; NEATON JD, 1987, CONTROL CLIN TRIALS, V8, pS41; NEATON JD, 1992, ARCH INTERN MED, V152, P56, DOI 10.1001/archinte.152.1.56; PARVING HH, 1983, LANCET, V1, P1175; PERERA G A, 1955, J Chronic Dis, V1, P33, DOI 10.1016/0021-9681(55)90019-9; PERNEGER TV, 1995, AM J EPIDEMIOL, V141, P10, DOI 10.1093/oxfordjournals.aje.a117338; PERNEGER TV, 1993, JAMA-J AM MED ASSOC, V269, P488, DOI 10.1001/jama.269.4.488; PERNEGER TV, 1994, ANN INTERN MED, V121, P912, DOI 10.7326/0003-4819-121-12-199412150-00002; PERRY HM, 1995, HYPERTENSION, V25, P587, DOI 10.1161/01.HYP.25.4.587; PETTINGER WA, 1989, HYPERTENSION, V13, P766, DOI 10.1161/01.HYP.13.6.766; RAVID M, 1992, ARCH INTERN MED, V152, P1225, DOI 10.1001/archinte.152.6.1225; ROSANSKY SJ, 1990, ARCH INTERN MED, V150, P2073, DOI 10.1001/archinte.150.10.2073; ROSTAND SG, 1989, NEW ENGL J MED, V320, P684, DOI 10.1056/NEJM198903163201102; SHERWIN R, 1981, PREV MED, V10, P402, DOI 10.1016/0091-7435(81)90058-X; SHULMAN N B, 1989, Hypertension (Dallas), V13, pI80; STAMLER J, 1993, ARCH INTERN MED, V153, P598, DOI 10.1001/archinte.153.5.598; STAMLER J, 1993, DIABETES CARE, V16, P434, DOI 10.2337/diacare.16.2.434; Statistical design considerations in the multiple risk factor intervention trial (MRFIT), 1977, J CHRON DIS, V30, P261; TIERNEY WM, 1989, AM J KIDNEY DIS, V13, P485, DOI 10.1016/S0272-6386(89)80006-X; WALKER WG, 1992, JAMA-J AM MED ASSOC, V268, P3085, DOI 10.1001/jama.268.21.3085; WENTWORTH DN, 1983, AM J PUBLIC HEALTH, V73, P1270, DOI 10.2105/AJPH.73.11.1270; WHELTON PK, 1993, ARCH INTERN MED, V153, P186, DOI 10.1001/archinte.153.2.186; WHELTON PK, 1989, HYPERTENSION S1, V13, P19, DOI DOI 10.1161/HYPERTENSIONAHA.113.02250; WHITTLE JC, 1991, ARCH INTERN MED, V151, P1359, DOI 10.1001/archinte.151.7.1359; ZUCCHELLI P, 1992, KIDNEY INT, V42, P452, DOI 10.1038/ki.1992.309; 1994, NIH943176 PUBL; 1994, REPORT TASK FORCE RE; 1993, ARCH INTERN MED, V153, P598; 1987, HCFA03274 HLTH CAR F; 1974, DHEW NIH75628 NAT HE; 1980, DHHS PHS801260 DEP H	41	1231	1278	0	28	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JAN 4	1996	334	1					13	18		10.1056/NEJM199601043340103	http://dx.doi.org/10.1056/NEJM199601043340103			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TM482	7494564	Bronze			2022-12-28	WOS:A1996TM48200003
J	Fein, R				Fein, R			Assessing the proposed Medicare reforms	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material											Fein, R (corresponding author), HARVARD UNIV,SCH MED,BOSTON,MA 02115, USA.								0	1	1	0	0	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	DEC 28	1995	333	26					1777	1780		10.1056/NEJM199512283332613	http://dx.doi.org/10.1056/NEJM199512283332613			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TM169	7491146				2022-12-28	WOS:A1995TM16900013
J	RODDEY, OF; CLEGG, HW; MARTIN, ES; SWETENBURG, RL; KOONCE, EW				RODDEY, OF; CLEGG, HW; MARTIN, ES; SWETENBURG, RL; KOONCE, EW			COMPARISON OF THROAT CULTURE METHODS FOR THE RECOVERY OF GROUP-A STREPTOCOCCI IN A PEDIATRIC OFFICE SETTING	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Note							GROUP-A STREPTOCOCCI; SPECIMENS	Objective.--To compare a single-plate method for the recovery of group A streptococci with other methods that have recently been reported as being significantly more sensitive. Design.-Throat swabs were allowed to dry for 2 to 6 hours before inoculating 5% sheep blood agar plates. Stabs were made into the agar, bacitracin disks were placed on the primary plates, and the cultures were incubated aerobically. Using duplicate throat swabs, the recovery rates of the above method were compared with the following ones: a carbon dioxide-enhanced incubation atmosphere, an anaerobic atmosphere with a selective blood agar medium, and a Todd-Hewitt broth medium. Setting.-A five-pediatrician office. Patients.-A total of 301 pediatric patients with pharyngitis were evaluated using all comparative methods. In addition, duplicate swabs from 590 pediatric patients were compared with each other using the same single-plate method. Results.-There were no significant differences between any of the methods. The sensitivity of the single-plate method compared with selective plates incubated anaerobically was 96%. Conclusions.-In a pediatric office setting, a single-plate method using aerobic incubation was adequately sensitive for the recovery of group A beta-hemolytic streptococci. Transport medium, selective medium, carbon dioxide enhancement, and anaerobic incubation did not significantly improve recovery. The present federal regulations that restrict the use of nonselective media and bacitracin disks on primary plates should be reevaluated.			RODDEY, OF (corresponding author), EASTOVER PEDIAT & PRESBYTERIAN HOSP,CHARLOTTE,NC, USA.							BEERMAN CA, 1982, J PEDIATR-US, V101, P70, DOI 10.1016/S0022-3476(82)80185-6; BISNO AL, 1993, 33RD INT C ANT AG CH; BREESE BB, 1965, PEDIATRICS, V36, P599; BREESE BB, 1960, AM J CLIN PATHOL, V33, P511; DYKSTRA MA, 1979, J CLIN MICROBIOL, V9, P236; Ehrlich T P, 1993, Arch Fam Med, V2, P866, DOI 10.1001/archfami.2.8.866; Facklam R R, 1976, CRC Crit Rev Clin Lab Sci, V6, P287, DOI 10.3109/10408367609151573; HARBECK RJ, 1993, J CLIN MICROBIOL, V31, P839, DOI 10.1128/JCM.31.4.839-844.1993; KELLOGG JA, 1990, J CLIN MICROBIOL, V28, P165, DOI 10.1128/JCM.28.2.165-169.1990; LAURER BA, 1976, J CLIN MICROBIOL, V17, P338; MURRAY PR, 1976, J CLIN MICROBIOL, V10, P54; RODDEY OF, 1986, J PEDIATR-US, V108, P347, DOI 10.1016/S0022-3476(86)80871-X; RODDEY OF, 1989, PEDIATR INFECT DIS J, V8, P710, DOI 10.1097/00006454-198910000-00010; RODDEY OF, 1995, J PEDIATR-US, V126, P931, DOI 10.1016/S0022-3476(95)70212-1; SCHWARTZ B, 1994, JAMA-J AM MED ASSOC, V271, P234, DOI 10.1001/jama.271.3.234; SHULMAN ST, 1994, PEDIATR INFECT DIS J, V13, P567, DOI 10.1097/00006454-199406000-00034; TODD JK, 1982, PEDIATR INFECT DIS J, V1, P265, DOI 10.1097/00006454-198207000-00017; WANNAMAKER LW, 1965, CIRCULATION, V32, P1054, DOI 10.1161/01.CIR.32.6.1054; WEGNER DL, 1992, JAMA-J AM MED ASSOC, V267, P695, DOI 10.1001/jama.267.5.695; 1993, FED REG         0726, V58, P39879	20	19	19	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	DEC 20	1995	274	23					1863	1865		10.1001/jama.274.23.1863	http://dx.doi.org/10.1001/jama.274.23.1863			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TK147	7500536				2022-12-28	WOS:A1995TK14700028
J	RAMIREZSOLIS, R; LIU, PT; BRADLEY, A				RAMIREZSOLIS, R; LIU, PT; BRADLEY, A			CHROMOSOME ENGINEERING IN MICE	NATURE			English	Article							SITE-SPECIFIC RECOMBINATION; GENE; DROSOPHILA; GENOME; TUMORS	CHROMOSOMAL rearrangements are the major cause of inherited human disease and fetal loss(1). Translocations(2) and loss of heterorygosity(3) are important genetic changes causally involved in neoplasia. Chromosomal variants, such as deficiencies, are commonly exploited in genetic screens in organisms such as Dlosophila because a small portion of the genome is functionally hemizygous(4) In the mouse, deficiencies are not generally available, thus genetic screens for recessive mutations are cumbersome(5). We report here that defined deficiencies, inversions and duplications extending to 3-4 cM can be constructed in embryonic stem cells, This was achieved by consecutive targeting of loxP recombination substrates to thf end points of a genetic interval followed by Cre-induced recombination, This reconstructs a positive selectable marker which facilitates direct selection of clones with a chromosome structure specific to the relative orientation of the loxP sites, Duplication and deletion alleles have been transmitted into the mouse germ line. The availability of mice with defined regions of segmental haploidy will allow their use in genetic screens and enable accurate models of human 'chromosomal' diseases to be generated.	BAYLOR COLL MED, DEPT MOLEC & HUMAN GENET, HOUSTON, TX 77030 USA; BAYLOR COLL MED, HOWARD HUGHES MED INST, HOUSTON, TX 77030 USA	Baylor College of Medicine; Baylor College of Medicine; Howard Hughes Medical Institute				Bradley, Allan/0000-0002-2349-8839; Ramirez-Solis, Ramiro/0000-0003-4182-173X				CROPP CS, 1994, CANCER RES, V54, P2548; Epstein C.J, 1986, CONSEQUENCES CHROMOS; FULLER PJ, 1987, MOL ENDOCRINOL, V1, P306, DOI 10.1210/mend-1-4-306; GAO X, 1995, CANCER RES, V55, P1002; GOLIC KG, 1989, CELL, V59, P499, DOI 10.1016/0092-8674(89)90033-0; GOLIC KG, 1991, SCIENCE, V252, P958, DOI 10.1126/science.2035025; GU H, 1994, SCIENCE, V265, P103, DOI 10.1126/science.8016642; HOLDENERKENNY B, 1992, BIOESSAYS, V14, P831, DOI 10.1002/bies.950141208; LASKO D, 1991, ANNU REV GENET, V25, P281, DOI 10.1146/annurev.ge.25.120191.001433; MATZUK MM, 1992, NATURE, V360, P313, DOI 10.1038/360313a0; MEDBERRY SL, 1995, NUCLEIC ACIDS RES, V23, P485, DOI 10.1093/nar/23.3.485; MIKI Y, 1994, SCIENCE, V266, P66, DOI 10.1126/science.7545954; MORI T, 1994, CANCER RES, V54, P1638; Muller H J, 1927, Science, V66, P84, DOI 10.1126/science.66.1699.84; NEUHAUSEN SL, 1994, CANCER RES, V54, P6069; QIN MM, 1994, P NATL ACAD SCI USA, V91, P1706, DOI 10.1073/pnas.91.5.1706; RABBITTS TH, 1994, NATURE, V372, P143, DOI 10.1038/372143a0; RAMIREZSOLIS R, 1992, ANAL BIOCHEM, V201, P331, DOI 10.1016/0003-2697(92)90347-A; Rinchik E.M., 1990, GENOME ANAL, P121; ROELINK H, 1990, P NATL ACAD SCI USA, V87, P4519, DOI 10.1073/pnas.87.12.4519; RUBOCK MJ, 1990, P NATL ACAD SCI USA, V87, P4751, DOI 10.1073/pnas.87.12.4751; SAITO H, 1993, CANCER RES, V53, P3382; SAUER B, 1993, METHOD ENZYMOL, V225, P890; SAUER B, 1989, NUCLEIC ACIDS RES, V17, P147, DOI 10.1093/nar/17.1.147; SMITH AJH, 1995, NAT GENET, V9, P376, DOI 10.1038/ng0495-376; SORIANO P, 1991, CELL, V64, P693, DOI 10.1016/0092-8674(91)90499-O; STERNBERG N, 1981, J MOL BIOL, V150, P467, DOI 10.1016/0022-2836(81)90375-2; THE VL, 1989, MOL ENDOCRINOL, V3, P1301, DOI 10.1210/mend-3-8-1301; VITATERNA MH, 1994, SCIENCE, V264, P719, DOI 10.1126/science.8171325; ZHANG HB, 1994, MOL CELL BIOL, V14, P2404, DOI 10.1128/MCB.14.4.2404	30	394	437	1	8	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	0028-0836	1476-4687		NATURE	Nature	DEC 14	1995	378	6558					720	724		10.1038/378720a0	http://dx.doi.org/10.1038/378720a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TK379	7501018				2022-12-28	WOS:A1995TK37900053
J	RAO, ZH; BELYAEV, AS; FRY, E; ROY, P; JONES, IM; STUART, DI				RAO, ZH; BELYAEV, AS; FRY, E; ROY, P; JONES, IM; STUART, DI			CRYSTAL-STRUCTURE OF SIV MATRIX ANTIGEN AND IMPLICATIONS FOR VIRUS ASSEMBLY	NATURE			English	Article							IMMUNODEFICIENCY-VIRUS; PROTEIN	SIMIAN immunodeficiency virus (SIV) is closely related to human immunodeficiency virus (HIV)(1), their matrix antigens (MAs) sharing some 50% sequence identity. MA is a component of Pr55Gag, the sole protein required for assembly of the virion shell(2). MA targets Pr55 to the plasma membrane(3), and facilitates incorporation of the virus envelope protein(4) and assembly of the Pr55Gag shell(5). Cleavage of Pr55 by the viral protease produces the mature protein of relative molecular mass 17-18K, which underlies the host-derived membrane and is important in both virus entry(6) and nuclear localization of the virion core(7). Here we report the crystal structure of SIV MA. The molecule forms a trimer consistent with oligomerization in vitro(8), the observed virion architecture(9), and various biological properties of MA.	UNIV OXFORD,MOLEC BIOPHYS LAB,OXFORD OX1 3QU,ENGLAND; NERC,INST VIROL & ENVIRONM MICROBIOL,OXFORD OX1 3SR,ENGLAND; UNIV ALABAMA,SCH PUBL HLTH,BIRMINGHAM,AL 35294; OXFORD CTR MOLEC SCI,OXFORD OX1 3QT,ENGLAND	University of Oxford; UK Centre for Ecology & Hydrology (UKCEH); UK Research & Innovation (UKRI); Natural Environment Research Council (NERC); University of Alabama System; University of Alabama Birmingham; University of Oxford			Rao, Zihe/HCH-6944-2022	Roy, Polly/0000-0001-6535-6911; Fry, Elizabeth/0000-0001-9754-5303; Stuart, David/0000-0002-3426-4210				[Anonymous], 1994, ACTA CRYSTALLOGR D, V50, P760; BELYAEV AS, 1994, J MOL BIOL, V241, P744, DOI 10.1006/jmbi.1994.1550; BrUnger A. T., 1992, X PLOR VERSION 3 1 S; BUKRINSKY MI, 1993, NATURE, V365, P666, DOI 10.1038/365666a0; CHOTHIA C, 1986, EMBO J, V5, P823, DOI 10.1002/j.1460-2075.1986.tb04288.x; DANIEL MD, 1985, SCIENCE, V228, P1201, DOI 10.1126/science.3159089; DELACHAMBRE M, 1989, EMBO J, V8, P2653; EHRLICH LS, 1994, VIROLOGY, V204, P515, DOI 10.1006/viro.1994.1565; ENGH RA, 1991, ACTA CRYSTALLOGR A, V47, P392, DOI 10.1107/S0108767391001071; FREED EO, 1995, J VIROL, V69, P1984, DOI 10.1128/JVI.69.3.1984-1989.1995; FREED EO, 1994, J VIROL, V68, P5311, DOI 10.1128/JVI.68.8.5311-5320.1994; Fry E, 1990, SEMIN VIROL, V1, P439; GRIMES J, 1995, NATURE, V373, P167, DOI 10.1038/373167a0; JONES TA, 1985, METHOD ENZYMOL, V115, P157; KABSCH W, 1983, BIOPOLYMERS, V22, P2577, DOI 10.1002/bip.360221211; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LEVINE M, 1984, ACTA CRYSTALLOGR A, V40, P600, DOI 10.1107/S0108767384001239; MASSIAH MA, 1994, J MOL BIOL, V244, P194; MATTHEWS S, 1994, NATURE, V370, P666, DOI 10.1038/370666a0; MERRITT EA, 1994, ACTA CRYSTALLOGR D, V50, P869, DOI 10.1107/S0907444994006396; MORIKAWA Y, 1995, J VIROL, V69, P4519, DOI 10.1128/JVI.69.7.4519-4523.1995; NERMUT MV, 1993, AIDS RES HUM RETROV, V9, P929, DOI 10.1089/aid.1993.9.929; NERMUT MV, 1994, VIROLOGY, V198, P288, DOI 10.1006/viro.1994.1032; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; OTWINOWSKI Z, 1993, P CCP4 STUDY WEEKEND, P1; PRONGAY AJ, 1990, P NATL ACAD SCI USA, V87, P9980, DOI 10.1073/pnas.87.24.9980; SMITH TJ, 1986, SCIENCE, V233, P1233; YU XF, 1992, J VIROL, V66, P5667, DOI 10.1128/JVI.66.9.5667-5670.1992; YUAN X, 1993, J VIROL, V67, P6387, DOI 10.1128/JVI.67.11.6387-6394.1993	29	174	174	0	13	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	DEC 14	1995	378	6558					743	747		10.1038/378743a0	http://dx.doi.org/10.1038/378743a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TK379	7501025				2022-12-28	WOS:A1995TK37900060
J	MAHER, VMG; BROWN, BG; MARCOVINA, SM; HILLGER, LA; ZHAO, XQ; ALBERS, JJ				MAHER, VMG; BROWN, BG; MARCOVINA, SM; HILLGER, LA; ZHAO, XQ; ALBERS, JJ			EFFECTS OF LOWERING ELEVATED LDL CHOLESTEROL ON THE CARDIOVASCULAR RISK OF LIPOPROTEIN(A)	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							CORONARY HEART-DISEASE; LOW-DENSITY-LIPOPROTEIN; MYOCARDIAL-INFARCTION; APOLIPOPROTEIN-B; LP(A); PLASMINOGEN; MACROPHAGES; ACTIVATION; POPULATION; PHENOTYPES	Objective.-To determine if lowering elevated low-density lipoprotein cholesterol (LDL-C) levels offsets the adverse effect of raised lipoprotein(a) (Lp[a]) levels on coronary artery disease (CAD) in men. Design.-Randomized, double-blind, placebo-controlled trial of lipid lowering for CAD. Setting.-Post hoc analysis of the Familial Atherosclerosis Treatment Study. Participants.-A total of 146 men aged 62 years or younger with CAD and apolipoprotein B levels of at least 125 mg/dL. Intervention.-Patients received a Step II Diet and lovastatin (40 mg daily) plus colestipol (30 g daily), niacin (4 g daily) plus colestipol, or placebo (plus colestipol if LDL-C >90th percentile) for 2.5 years. They were grouped by their LDL-C responses: ''minimal'' if LDL-C decreased by 10% or less from baseline (mean [SD] change, +6% [13%]) and ''substantial'' if LDL-C decreased more than 10% (mean [SD] change, -40% [16%]). Main Outcome Measure.-Impact of lowering elevated LDL-C on the cardiac event rate (death, myocardial infarction, and revascularization for refractory ischemia) and CAD change associated with elevated Lp(a). Results.-In multivariate analyses, the best correlate of baseline CAD severity was Lp(a) (r=0.30; P<.001). For 36 patients with minimal LDL-C reduction, CAD progression correlated only with in-treatment Lp(a) levels (r=0.45; P<.01), but for 84 patients with substantial LDL-C reduction, disease regressed and its change correlated with in-treatment LDL-C (r=0.24; P<.05) but not with Lp(a) (r=-0.05), Lipoprotein(a) levels were not significantly altered in either group. For 40 patients with Lp(a) at the 90th percentile or higher, events were frequent (39%) if reduction of LDL-C was minimal, but were few (9%) if reduction was substantial (relative risk, 0.23; 95% confidence interval, 0.06 to 0.99). Conclusions.-In men with CAD and elevated LDL-C, Lp(a) levels were dominant correlates of baseline disease severity, its progression, and event rate over 2.5 years, However, with substantial LDL-C reductions, persistent elevations of Lp(a) were no longer atherogenic or clinically threatening. This provides a possible direction for treatment in such patients with elevated Lp(a) and LDL-C.	UNIV WASHINGTON,SCH MED,DIV METAB ENDOCRINOL & NUTR,SEATTLE,WA 98195	University of Washington; University of Washington Seattle	MAHER, VMG (corresponding author), UNIV WASHINGTON,SCH MED,DEPT MED,DIV CARDIOL,RG-22,SEATTLE,WA 98195, USA.			Maher, Vincent/0000-0002-3592-4508	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL042419, P01HL030086, R01HL019451] Funding Source: NIH RePORTER; NHLBI NIH HHS [R01 HL 42419, P01 HL 30086, R01 HL 19451] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ALBERS JJ, 1989, CLIN LAB MED, V9, P137, DOI 10.1016/S0272-2712(18)30646-2; ALBERS JJ, 1975, METABOLISM, V24, P1339, DOI 10.1016/0026-0495(75)90050-5; ARMSTRONG VW, 1986, ATHEROSCLEROSIS, V62, P249, DOI 10.1016/0021-9150(86)90099-7; BIHARIVARGA M, 1988, ARTERIOSCLEROSIS, V8, P851, DOI 10.1161/01.ATV.8.6.851; BOTTALICO LA, 1993, J BIOL CHEM, V268, P8569; BROWN G, 1990, NEW ENGL J MED, V323, P1289, DOI 10.1056/NEJM199011083231901; CREMER P, 1994, EUR J CLIN INVEST, V24, P444, DOI 10.1111/j.1365-2362.1994.tb02373.x; EZRATTY A, 1993, BIOCHEMISTRY-US, V32, P4628, DOI 10.1021/bi00068a021; FARRER M, 1994, ARTERIOSCLER THROMB, V14, P1272, DOI 10.1161/01.ATV.14.8.1272; GAUBATZ JW, 1983, J BIOL CHEM, V258, P4582; HABERLAND ME, 1992, J BIOL CHEM, V267, P4143; JAUHIAINEN M, 1991, ATHEROSCLEROSIS, V89, P59, DOI 10.1016/0021-9150(91)90007-P; LOSCALZO J, 1990, ARTERIOSCLEROSIS, V10, P240, DOI 10.1161/01.ATV.10.2.240; MARCOVINA SM, 1993, ARTERIOSCLER THROMB, V13, P1037, DOI 10.1161/01.ATV.13.7.1037; MARCOVINA SM, 1995, CLIN CHEM, V41, P246; MCLEAN JW, 1987, NATURE, V330, P132, DOI 10.1038/330132a0; RHOADS GG, 1986, JAMA-J AM MED ASSOC, V256, P2540, DOI 10.1001/jama.256.18.2540; RIDKER PM, 1993, JAMA-J AM MED ASSOC, V270, P2195, DOI 10.1001/jama.270.18.2195; ROSENGREN A, 1990, BRIT MED J, V301, P1248, DOI 10.1136/bmj.301.6763.1248; SANDHOLZER C, 1992, J CLIN INVEST, V89, P1040, DOI 10.1172/JCI115645; SANDKAMP M, 1990, CLIN CHEM, V36, P20; SCHAEFER EJ, 1994, JAMA-J AM MED ASSOC, V271, P999, DOI 10.1001/jama.271.13.999; SEED M, 1990, NEW ENGL J MED, V322, P1494, DOI 10.1056/NEJM199005243222104; SMITH EB, 1990, ATHEROSCLEROSIS, V84, P173, DOI 10.1016/0021-9150(90)90088-Z; THOMPSON GR, 1965, LANCET, V346, P811; TRIEU VN, 1991, J BIOL CHEM, V266, P5480; WARNICK G, 1986, METHOD ENZYMOL, P101	27	228	231	0	2	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	DEC 13	1995	274	22					1771	1774		10.1001/jama.274.22.1771	http://dx.doi.org/10.1001/jama.274.22.1771			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TJ225	7500507				2022-12-28	WOS:A1995TJ22500026
J	COON, SL; ROSEBOOM, PH; BALER, R; WELLER, JL; NAMBOODIRI, MAA; KOONIN, EV; KLEIN, DC				COON, SL; ROSEBOOM, PH; BALER, R; WELLER, JL; NAMBOODIRI, MAA; KOONIN, EV; KLEIN, DC			PINEAL SEROTONIN N-ACETYLTRANSFERASE - EXPRESSION CLONING AND MOLECULAR ANALYSIS	SCIENCE			English	Article							RAT PINEAL; GLAND; MELATONIN; DECREASE	Pineal serotonin N-acetyltransferase (arylalkylamine N-acetyltransferase, or AA-NAT) generates the large circadian rhythm in melatonin, the hormone that coordinates daily and seasonal physiology in some mammals. Complementary DNA encoding ovine AA-NAT was cloned. The abundance of AA-NAT messenger RNA (mRNA) during the day was high in the ovine pineal gland and somewhat lower in retina. AA-NAT mRNA was found unexpectedly in the pituitary gland and in some brain regions. The night-to-day ratio of ovine pineal AA-NAT mRNA is less than 2. In contrast, the ratio exceeds 150 in rats. AA-NAT represents a family within a large superfamily of acetyltransferases.	NICHHD, DEV NEUROBIOL LAB, NEUROBIOL SECT, BETHESDA, MD 20892 USA; GEORGETOWN UNIV, DEPT BIOL, WASHINGTON, DC 20057 USA; NATL LIB MED, NATL CTR BIOTECHNOL INFORMAT, BETHESDA, MD 20894 USA	National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD); Georgetown University; National Institutes of Health (NIH) - USA; NIH National Library of Medicine (NLM)				Klein, David/0000-0002-1792-5806				ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; Arendt J., 1995, MELATONIN MAMMALIAN, p[201, 27]; AXELROD J, 1974, SCIENCE, V184, P1341, DOI 10.1126/science.184.4144.1341; BALER R, UNPUB; BALER R, IN PRESS J BIOL CHEM; BERNARD M, 1995, BRAIN RES, V696, P37, DOI 10.1016/0006-8993(95)00651-6; DEGUCHI T, 1975, J NEUROCHEM, V24, P1083, DOI 10.1111/j.1471-4159.1975.tb03682.x; DISTRIA M, 1994, GEN COMP ENDOCR, V96, P6, DOI 10.1006/gcen.1994.1153; DOLLINS AB, 1994, P NATL ACAD SCI USA, V91, P1824, DOI 10.1073/pnas.91.5.1824; IUVONE PM, 1986, J NEUROCHEM, V46, P82, DOI 10.1111/j.1471-4159.1986.tb12928.x; JANAVS JL, 1991, BRAIN RES, V540, P138, DOI 10.1016/0006-8993(91)90500-U; KARSCH FJ, 1991, SUPRACHIASMATIC NUCL, P217; KLEIN DC, 1970, SCIENCE, V169, P1093, DOI 10.1126/science.169.3950.1093; KLEIN DC, 1985, CIBA F SYMP, V117, P38; KLEIN DC, 1972, SCIENCE, V177, P532, DOI 10.1126/science.177.4048.532; KLEIN DC, 1992, BIOCHEM SOC T, V20, P299, DOI 10.1042/bst0200299; KLEIN DC, 1978, SCIENCE, V199, P309, DOI 10.1126/science.202027; MEFFORD IN, 1983, ENDOCRINOLOGY, V113, P1582, DOI 10.1210/endo-113-5-1582; NAMBOODIRI MAA, 1985, J NEUROCHEM, V45, P832, DOI 10.1111/j.1471-4159.1985.tb04069.x; NAMBOODIRI MAA, 1981, SCIENCE, V213, P571, DOI 10.1126/science.7017937; NAMBOODIRI MAA, 1980, J BIOL CHEM, V255, P6032; NAMBOODIRI MAA, 1984, J COMP BIOCH B, V80, P731; O'Brien PJ, 1986, PINEAL RETINAL RELAT; RIODAN JF, 1972, METHODS ENZYMOL B, V25, P494; ROLLAG MD, 1976, ENDOCRINOLOGY, V98, P482, DOI 10.1210/endo-98-2-482; ROSEBOOM PH, UNPUB; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHULER GD, 1991, PROTEINS, V9, P180, DOI 10.1002/prot.340090304; SCHULZ GE, 1992, CURR OPIN STRUC BIOL, V2, P61; SKENE DJ, 1992, BIOCHEM SOC T, V20, P312, DOI 10.1042/bst0200312; TATUSOV RL, 1994, P NATL ACAD SCI USA, V91, P12091, DOI 10.1073/pnas.91.25.12091; TERCERO JC, 1992, J BIOL CHEM, V267, P20270; VOISIN P, 1984, J BIOL CHEM, V259, P913; WATANABE M, 1992, J BIOL CHEM, V267, P8429; YU L, 1993, J NEUROCHEM, V60, P1436, DOI 10.1111/j.1471-4159.1993.tb03306.x; ZATZ M, 1978, BIOCHEM PHARMACOL, V27, P2549, DOI 10.1016/0006-2952(78)90324-6; ZAWILSKA JB, 1992, NEUROSCI LETT, V135, P21	37	295	305	1	12	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	DEC 8	1995	270	5242					1681	1683		10.1126/science.270.5242.1681	http://dx.doi.org/10.1126/science.270.5242.1681			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TJ293	7502081				2022-12-28	WOS:A1995TJ29300053
J	VANLEUSDEN, HAIM				VANLEUSDEN, HAIM			PREMENSTRUAL-SYNDROME NO PROGESTERONE - PREMENSTRUAL DYSPHORIC DISORDER NO SEROTONIN DEFICIENCY	LANCET			English	Editorial Material							SYMPTOMS; WOMEN				VANLEUSDEN, HAIM (corresponding author), ZIEKENHUIS RIJNSTATE,DEPT OBSTET & GYNAECOL,ARNHEM,NETHERLANDS.							BACKSTROM CT, 1981, BRIT J OBSTET GYNAEC, V88, P530, DOI 10.1111/j.1471-0528.1981.tb01028.x; FREEMAN E, 1990, JAMA-J AM MED ASSOC, V264, P349; FREEMAN EW, 1995, JAMA-J AM MED ASSOC, V274, P51, DOI 10.1001/jama.274.1.51; HUSSAIN SY, 1992, GYNECOL ENDOCRINOL, V6, P57, DOI 10.3109/09513599209081007; Schmidt P.J., 1992, ENDOCRINOLOGIST, V2, P47, DOI 10.1097/00019616-199201000-00008; SCHMIDT PJ, 1991, NEW ENGL J MED, V324, P1174, DOI 10.1056/NEJM199104253241705; STEINER M, 1995, NEW ENGL J MED, V332, P1529, DOI 10.1056/NEJM199506083322301; 1994, DIAGNOSTIC STATISTIC, P715	8	6	7	0	2	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	DEC 2	1995	346	8988					1443	1444		10.1016/S0140-6736(95)92468-X	http://dx.doi.org/10.1016/S0140-6736(95)92468-X			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TH156	7490987				2022-12-28	WOS:A1995TH15600005
J	HERMISTON, ML; GORDON, JI				HERMISTON, ML; GORDON, JI			INFLAMMATORY BOWEL-DISEASE AND ADENOMAS IN MICE EXPRESSING A DOMINANT-NEGATIVE N-CADHERIN	SCIENCE			English	Article							TRANSGENIC MICE; CELL LINEAGE; APC GENE; DIFFERENTIATION; ASSOCIATION; MUTATION; PROTEIN	Cadherins mediate cell adhesion and are essential for normal development. Embryonic stem cells were transfected with a dominant negative N-cadherin mutant (NCAD Delta) under the control of promoters active in small intestinal epithelial cells and then introduced into C57BL/6 mouse blastocysts. Analysis of adult chimeric mice revealed that expression of NCAD Delta along the entire crypt-villus axis, but not in the villus epithelium alone, produced an inflammatory bowel disease resembling Crohn's disease. NCAD Delta perturbed proliferation, migration, and death programs in crypts, which lead to adenomas. This model provides insights about cadherin function in an adult organ and the factors underlying inflammatory bowel disease and intestinal neoplasia.	WASHINGTON UNIV, SCH MED, DEPT MOLEC BIOL & PHARMACOL, ST LOUIS, MO 63110 USA	Washington University (WUSTL)					NIDDK NIH HHS [DK39760, DK30292] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R37DK030292, R01DK030292] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AHNEN DJ, 1994, J PATHOL, V173, P317, DOI 10.1002/path.1711730406; BIRCHMEIER W, 1994, BBA-REV CANCER, V1198, P11, DOI 10.1016/0304-419X(94)90003-5; CEPEK KL, 1994, NATURE, V372, P190, DOI 10.1038/372190a0; GORDON JI, 1994, CURR OPIN CELL BIOL, V6, P795, DOI 10.1016/0955-0674(94)90047-7; HERMISTON ML, 1993, P NATL ACAD SCI USA, V90, P8866, DOI 10.1073/pnas.90.19.8866; HERMISTON ML, 1995, J CELL BIOL, V129, P489, DOI 10.1083/jcb.129.2.489; HERMISTON ML, UNPUB; HINCK L, 1994, J CELL BIOL, V125, P1327, DOI 10.1083/jcb.125.6.1327; KEMIER R, 1993, TRENDS GENET, V9, P317; KINTNER C, 1992, CELL, V69, P225, DOI 10.1016/0092-8674(92)90404-Z; KOMANO H, 1995, P NATL ACAD SCI USA, V92, P6147, DOI 10.1073/pnas.92.13.6147; KUHN R, 1993, CELL, V75, P263, DOI 10.1016/0092-8674(93)80068-P; LARUE L, 1994, P NATL ACAD SCI USA, V91, P8263, DOI 10.1073/pnas.91.17.8263; LEVIN B, 1995, INFLAMM BOWEL DIS, P461; LEVINE E, 1994, DEVELOPMENT, V120, P901; MOMBAERTS P, 1993, CELL, V75, P275, DOI 10.1016/0092-8674(93)80069-Q; MOSER AR, 1992, J CELL BIOL, V116, P1517, DOI 10.1083/jcb.116.6.1517; NAGAFUCHI A, 1994, J CELL BIOL, V127, P235, DOI 10.1083/jcb.127.1.235; NATHKE IS, 1994, J CELL BIOL, V125, P1341, DOI 10.1083/jcb.125.6.1341; PODOLSKY DK, 1991, NEW ENGL J MED, V325, P928, DOI 10.1056/NEJM199109263251306; RANSCHT B, 1994, CURR OPIN CELL BIOL, V6, P740, DOI 10.1016/0955-0674(94)90102-3; RIDDELL RH, 1995, INFLAMM BOWEL DIS, P517; RUBINFELD B, 1993, SCIENCE, V262, P1731, DOI 10.1126/science.8259518; RUBINFELD B, 1995, J BIOL CHEM, V270, P5549, DOI 10.1074/jbc.270.10.5549; SADLACK B, 1993, CELL, V75, P253, DOI 10.1016/0092-8674(93)80067-O; SCHMIDT GH, 1988, DEVELOPMENT, V103, P785; SIMON TC, 1993, J BIOL CHEM, V268, P18345; SU LK, 1992, SCIENCE, V256, P668, DOI 10.1126/science.1350108; SU LK, 1993, SCIENCE, V262, P1734, DOI 10.1126/science.8259519; TRAHAIR JF, 1989, J CELL BIOL, V109, P3231, DOI 10.1083/jcb.109.6.3231; WATABE M, 1994, J CELL BIOL, V127, P247, DOI 10.1083/jcb.127.1.247; WRIGHT NA, 1990, NATURE, V343, P82, DOI 10.1038/343082a0	32	561	578	0	23	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	NOV 17	1995	270	5239					1203	1207		10.1126/science.270.5239.1203	http://dx.doi.org/10.1126/science.270.5239.1203			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TE905	7502046				2022-12-28	WOS:A1995TE90500058
J	MILLMAN, A; LEE, N; KEALY, K				MILLMAN, A; LEE, N; KEALY, K			ABC OF MEDICAL COMPUTING - THE INTERNET	BRITISH MEDICAL JOURNAL			English	Article									WESTERN EYE HOSP,LONDON,ENGLAND; HILLINGDON HOSP,LONDON,ENGLAND	Brunel University; Imperial College London	MILLMAN, A (corresponding author), GLOUCESTERSHIRE ROYAL HOSP,GLOUCESTER GL1 3NN,ENGLAND.								0	28	28	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	AUG 12	1995	311	7002					440	443		10.1136/bmj.311.7002.440	http://dx.doi.org/10.1136/bmj.311.7002.440			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RP554	7503911	Green Published			2022-12-28	WOS:A1995RP55400024
J	ALDRICH, CJ; DECLOUX, A; WOODS, AS; COTTER, RJ; SOLOSKI, MJ; FORMAN, J				ALDRICH, CJ; DECLOUX, A; WOODS, AS; COTTER, RJ; SOLOSKI, MJ; FORMAN, J			IDENTIFICATION OF A TAP-DEPENDENT LEADER PEPTIDE RECOGNIZED BY ALLOREACTIVE T-CELLS SPECIFIC FOR A CLASS IB ANTIGEN	CELL			English	Article							CYTOTOXIC LYMPHOCYTES-T; HISTOCOMPATIBILITY ANTIGEN; ALPHA-3 DOMAIN; SELF-PEPTIDES; BINDING-SITE; MHC MOLECULE; Q-REGION; RMA-S; EXPRESSION; DELTA	Recognition of the class Ib antigen Qa-1 by a portion of alloreactive cytotoxic T lymphocyte (CTL) clones requires that the target cell express a second gene, termed Qa-1 determinant modifier (Qdm). We show that Qdm is identical to most D allele genes, excepting D-k, and that a nonamer peptide derived from D alloantigens restores CTL. recognition on cells that lack the Qdm-encoded determinant. The equivalent D-k peptide has an Ala-->Val interchange at P3 and requires similar to 4 logs more peptide than the Ala(P3) peptide for target cell lysis. Two of five CTL clones, not dependent on Qdm for target cell recognition, also recognize the Qdm peptide as well as the Val(P3) variant. Although the adm peptide spans residues 3-11 from the leader, it requires the Tap transporters for its expression. Thus, the response against this class Ib molecule provides a tool for dissecting alloreactivity as well as pathways for antigen presentation.	JOHNS HOPKINS UNIV,SCH MED,DEPT PHARMACOL & MOLEC SCI,BALTIMORE,MD 21205	Johns Hopkins University	ALDRICH, CJ (corresponding author), UNIV TEXAS,SW MED CTR,DEPT MICROBIOL,DALLAS,TX 75235, USA.				NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI028332, R01AI020922, R01AI013111, R23AI020922] Funding Source: NIH RePORTER; NIAID NIH HHS [AI28332, AI20922, AI13111] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ALDRICH CJ, 1991, NATURE, V352, P718, DOI 10.1038/352718a0; ALDRICH CJ, 1988, IMMUNOGENETICS, V28, P334, DOI 10.1007/BF00364232; ALDRICH CJ, 1991, J IMMUNOL, V146, P3082; ALDRICH CJ, 1992, J IMMUNOL, V149, P3773; ANDERSON K, 1991, J EXP MED, V174, P489, DOI 10.1084/jem.174.2.489; AOSAI F, 1991, EUR J IMMUNOL, V21, P2767, DOI 10.1002/eji.1830211118; BEVAN MJ, 1984, IMMUNOL TODAY, V5, P128, DOI 10.1016/0167-5699(84)90233-0; BLUESTONE JA, 1988, J EXP MED, V168, P1899, DOI 10.1084/jem.168.5.1899; BRACIALE TJ, 1987, J EXP MED, V166, P678, DOI 10.1084/jem.166.3.678; CHEVRIER MR, 1991, RAPID COMMUN MASS SP, V5, P611, DOI 10.1002/rcm.1290051209; CONNOLLY DJ, 1993, J IMMUNOL, V151, P6089; CONNOLLY JM, 1994, IN PRESS P NATL ACAD, V91; EGHTESADY P, 1992, IMMUNOGENETICS, V36, P377, DOI 10.1007/BF00218045; EISENLOHR LC, 1992, CELL, V71, P963, DOI 10.1016/0092-8674(92)90392-P; ELLIOTT TJ, 1990, P NATL ACAD SCI USA, V87, P5213, DOI 10.1073/pnas.87.13.5213; ESQUIVEL F, 1992, J EXP MED, V175, P163, DOI 10.1084/jem.175.1.163; FALK K, 1990, NATURE, V348, P248, DOI 10.1038/348248a0; FLAHERTY L, 1990, CRIT REV IMMUNOL, V10, P131; GERAGHTY DE, 1993, CURR OPIN IMMUNOL, V5, P3, DOI 10.1016/0952-7915(93)90073-2; HEATH WR, 1991, EUR J IMMUNOL, V21, P153, DOI 10.1002/eji.1830210123; HENDERSON RA, 1992, SCIENCE, V255, P1264, DOI 10.1126/science.1546329; HOMER RJ, 1987, J IMMUNOL, V138, P4322; HOSKEN NA, 1992, J EXP MED, V175, P719, DOI 10.1084/jem.175.3.719; HUNT DF, 1992, SCIENCE, V255, P1261, DOI 10.1126/science.1546328; IMANI F, 1991, P NATL ACAD SCI USA, V88, P10475, DOI 10.1073/pnas.88.23.10475; ITO K, 1990, CELL, V62, P549, DOI 10.1016/0092-8674(90)90019-B; JARDETZKY TS, 1991, NATURE, V353, P326, DOI 10.1038/353326a0; JOYCE S, 1994, J EXP MED, V179, P579, DOI 10.1084/jem.179.2.579; KEENE JA, 1982, J EXP MED, V155, P768, DOI 10.1084/jem.155.3.768; KURLANDER RJ, 1992, SCIENCE, V257, P678, DOI 10.1126/science.1496381; LECHLER R, 1991, CURR OPIN IMMUNOL, V3, P715, DOI 10.1016/0952-7915(91)90102-7; LINDAHL KF, 1991, ANNU REV IMMUNOL, V9, P351, DOI 10.1146/annurev.iy.09.040191.002031; LINDAHL KF, 1983, TRANSPLANT P, V15, P2042; LJUNGGREN HG, 1990, NATURE, V346, P476, DOI 10.1038/346476a0; LOVELAND B, 1990, CELL, V60, P971, DOI 10.1016/0092-8674(90)90345-F; LOWEN LC, 1993, J IMMUNOL, V151, P6155; MARYANSKI JL, 1988, J EXP MED, V167, P1391, DOI 10.1084/jem.167.4.1391; MATSUMURA M, 1992, SCIENCE, V257, P927, DOI 10.1126/science.1323878; MATZINGER P, 1977, CELL IMMUNOL, V29, P1, DOI 10.1016/0008-8749(77)90269-6; MORIWAKI S, 1993, P NATL ACAD SCI USA, V90, P11396, DOI 10.1073/pnas.90.23.11396; MULLBACHER A, 1991, J IMMUNOL, V147, P1765; ORTMANN B, 1994, NATURE, V368, P864, DOI 10.1038/368864a0; PAMER EG, 1992, CELL, V70, P215, DOI 10.1016/0092-8674(92)90097-V; PEASE LR, 1991, CRIT REV IMMUNOL, V11, P1; RAMMENSEE HG, 1993, ANNU REV IMMUNOL, V11, P213, DOI 10.1146/annurev.iy.11.040193.001241; ROTZSCHKE O, 1991, J EXP MED, V174, P1059, DOI 10.1084/jem.174.5.1059; SCHENDEL DJ, 1990, HUM IMMUNOL, V27, P229, DOI 10.1016/0198-8859(90)90053-R; SCHILD H, 1994, CELL, V76, P29, DOI 10.1016/0092-8674(94)90170-8; SCHUMACHER TNM, 1994, J EXP MED, V179, P533, DOI 10.1084/jem.179.2.533; SHAWAR SM, 1994, ANNU REV IMMUNOL, V12, P839, DOI 10.1146/annurev.immunol.12.1.839; SHERMAN LA, 1993, ANNU REV IMMUNOL, V11, P385, DOI 10.1146/annurev.immunol.11.1.385; SIJTS AJAM, 1992, EUR J IMMUNOL, V22, P1639, DOI 10.1002/eji.1830220644; STROMINGER JL, 1989, CELL, V57, P895, DOI 10.1016/0092-8674(89)90326-7; STROYNOWSKI I, 1990, ANNU REV IMMUNOL, V8, P501, DOI 10.1146/annurev.iy.08.040190.002441; SUH WK, 1994, SCIENCE, V264, P1322, DOI 10.1126/science.8191286; UDAKA K, 1992, CELL, V69, P989, DOI 10.1016/0092-8674(92)90617-L; UDAKA K, 1993, P NATL ACAD SCI USA, V90, P11272, DOI 10.1073/pnas.90.23.11272; VANBLEEK GM, 1991, P NATL ACAD SCI USA, V88, P11032, DOI 10.1073/pnas.88.24.11032; VANKAER L, 1992, CELL, V71, P1206; VIDOVIC D, 1989, NATURE, V340, P646, DOI 10.1038/340646a0; WATKINS DI, 1990, NATURE, V346, P60, DOI 10.1038/346060a0; WATKINS DI, 1988, P NATL ACAD SCI USA, V85, P7714, DOI 10.1073/pnas.85.20.7714; WEI ML, 1992, NATURE, V356, P443, DOI 10.1038/356443a0; WOODS AS, 1994, TUNE FLIGHT MASS SPE, P194; ZEMMOUR J, 1992, J IMMUNOL, V148, P1941; Zinkernagel R M, 1979, Adv Immunol, V27, P51, DOI 10.1016/S0065-2776(08)60262-X	66	245	254	0	1	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	NOV 18	1994	79	4					649	658		10.1016/0092-8674(94)90550-9	http://dx.doi.org/10.1016/0092-8674(94)90550-9			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	PT481	7525079				2022-12-28	WOS:A1994PT48100012
J	OKWERA, A; WHALEN, C; BYEKWASO, F; VJECHA, M; JOHNSON, J; HUEBNER, R; MUGERWA, R; ELLNER, J; AISU, T; MORRISEY, A; HOM, D; DAYLALLY, C; ERIKI, P; DANIEL, T; NAKIBALI, J; NYOLE, S; WALLIS, R; EDMONDS, K				OKWERA, A; WHALEN, C; BYEKWASO, F; VJECHA, M; JOHNSON, J; HUEBNER, R; MUGERWA, R; ELLNER, J; AISU, T; MORRISEY, A; HOM, D; DAYLALLY, C; ERIKI, P; DANIEL, T; NAKIBALI, J; NYOLE, S; WALLIS, R; EDMONDS, K			RANDOMIZED TRIAL OF THIACETAZONE AND RIFAMPICIN-CONTAINING REGIMENS FOR PULMONARY TUBERCULOSIS IN HIV-INFECTED UGANDANS	LANCET			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; CUTANEOUS HYPERSENSITIVITY REACTIONS; MORTALITY; SURVIVAL; COHORT; KENYA; RISK	Among HIV-positive patients who received treatment for active tuberculosis, thiacetazone has been associated with cutaneous hypersensitivity and recurrent tuberculosis. No controlled trials have investigated the safety and efficacy of thiacetazone-containing regimens compared with alternative regimens among patients with HIV. In a randomised clinical trial of 191 HIV-positive patients with active pulmonary tuberculosis, we examined the safety and short-term efficacy of isoniazid, rifampicin, and pyrazinamide for two months followed by isoniazid and rifampicin for seven months (RHZ) compared with streptomycin, thiacetazone, and isoniazid for two months followed by thiacetazone and isoniazid for ten months (STH). Between May, 1990, and September, 1991, 191 HIV-positive adult Ugandan patients with acid-fast sputum smear-positive pulmonary tuberculosis confirmed by culture) received either STH or RHZ. Subjects had a standard evaluation that included Mantoux shin test, complete blood count with differential white blood cell count, and chest radiography. After starting therapy, subjects were followed-up over one year for three outcomes: complications of anti-tuberculosis therapy, early sterilisation of cultures, and survival. Of 191 eligible subjects, 90 received STH and 101 received RHZ. The overall one-year survival was similar for STH and RHZ (65% vs 72%), but when controlled for baseline differences in Mantoux reaction size and absolute lymphocyte count, the relative risk of death for STH compared with RHZ was 1.57 (95% Cl 1.0-2.48). Overall, 12 adverse drug reactions occurred in the STH arm (18.2 reactions per 100 person years [PYO]) compared with one in the RHZ arm (1.6 reactions per 100 PYO) for a relative risk of 11.7 (95% Cl 1.52-90.0). 10 cutaneous reactions occurred in the STH arm (15.2 events per 100 PYO) compared with one event in the RHZ arm (1.6 events per 100 PYO) for a relative risk of 9.7 (95% Cl: 1.24, 75.8). A greater proportion of RHZ patients compared with STH patients had sterilised their sputum within two months (74% vs 37%, p<0.001). In developing countries, rifampicin-containing regimens should be given, when possible, to HIV-positive patients to reduce drug toxicity and to prolong survival.	CASE WESTERN RESERVE UNIV,SCH MED,DEPT EPIDEMIOL & BIOSTAT,CLEVELAND,OH 44106; MAKERERE UNIV,UGANDAN MINIST HLTH,KAMPALA,UGANDA; MAKERERE UNIV,DEPT MED,KAMPALA,UGANDA; UGANDAN NATL TB & LEPROSY CONTROL PROGRAMME,KAMPALA,UGANDA; CASE WESTERN RESERVE UNIV,SCH MED,DEPT MED,DIV INFECT DIS,CLEVELAND,OH 44106; CTR DIS CONTROL & PREVENT,DIV TB ELIMINAT,ATLANTA,GA 30341	Case Western Reserve University; Makerere University; Makerere University; Case Western Reserve University; Centers for Disease Control & Prevention - USA				Ellner, Jerrold/0000-0001-6150-0082	PHS HHS [CCU 501881] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		BARNUM HN, 1986, SOC SCI MED, V23, P847, DOI 10.1016/0277-9536(86)90212-1; CHAISSON RE, 1987, AM REV RESPIR DIS, V136, P570, DOI 10.1164/ajrccm/136.3.570; COOPMAN SA, 1993, NEW ENGL J MED, V328, P1670, DOI 10.1056/NEJM199306103282304; DALEY CL, 1992, NEW ENGL J MED, V326, P231, DOI 10.1056/NEJM199201233260404; DECOCK KM, 1992, JAMA-J AM MED ASSOC, V268, P1581, DOI 10.1001/jama.1992.03490120095035; DIPERRI G, 1989, LANCET, V2, P1502; DUKES CS, 1992, TROP GEOGR MED, V44, P308; ERIKI PP, 1991, AM REV RESPIR DIS, V143, P185, DOI 10.1164/ajrccm/143.1.185; FERGUSON G C, 1971, Tubercle, V52, P166, DOI 10.1016/0041-3879(71)90040-7; GORDIN FM, 1984, ANN INTERN MED, V100, P495, DOI 10.7326/0003-4819-100-4-495; HAWKEN M, 1993, LANCET, V342, P332, DOI 10.1016/0140-6736(93)91474-Z; HIRA SK, 1988, J AM ACAD DERMATOL, V19, P541; Karnofsky D., 1949, CLIN EVALUATION CHEM, P191; Keers R.Y., 1978, PULMONARY TUBERCULOS; Miller A B, 1966, Tubercle, V47, P33; MITICHSON D, 1979, CHEST S, V76, P771; MORENO S, 1993, ANN INTERN MED, V119, P194, DOI 10.7326/0003-4819-119-3-199308010-00003; NUNN P, 1992, AM REV RESPIR DIS, V146, P849, DOI 10.1164/ajrccm/146.4.849; NUNN P, 1991, LANCET, V337, P627; PERRIENS JH, 1991, AM REV RESPIR DIS, V144, P750, DOI 10.1164/ajrccm/144.4.750; SELWYN PA, 1989, NEW ENGL J MED, V320, P545, DOI 10.1056/NEJM198903023200901; SMALL PM, 1991, NEW ENGL J MED, V324, P289, DOI 10.1056/NEJM199101313240503; STONEBURNER R, 1992, ARCH INTERN MED, V152, P2033, DOI 10.1001/archinte.152.10.2033; STYBLO K, 1989, REV INFECT DIS, V11, pS339; WHALEN C, IN PRESS AM J RESP C; 1973, TUBERCLE, V54, P169; 1986, B IUATLD S2, V61, P1; 1992, WEEKLY EPIDEMIO 0110; 1969, CLASSIFICATION PULMO, pCH6	29	96	97	0	4	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	NOV 12	1994	344	8933					1323	1328		10.1016/S0140-6736(94)90693-9	http://dx.doi.org/10.1016/S0140-6736(94)90693-9			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PQ926	7526098				2022-12-28	WOS:A1994PQ92600009
J	FIDLER, IJ; ELLIS, LM				FIDLER, IJ; ELLIS, LM			THE IMPLICATIONS OF ANGIOGENESIS FOR THE BIOLOGY AND THERAPY OF CANCER METASTASIS	CELL			English	Review							TUMOR ANGIOGENESIS; INTERFERON; RESISTANCE; CARCINOMA; MEMORIAL; LECTURE		UNIV TEXAS,MD ANDERSON CANCER CTR,DEPT SURG,HOUSTON,TX 77030	University of Texas System; UTMD Anderson Cancer Center	FIDLER, IJ (corresponding author), UNIV TEXAS,MD ANDERSON CANCER CTR,DEPT CELL BIOL,HOUSTON,TX 77030, USA.							CLAPP C, 1993, ENDOCRINOLOGY, V133, P1292, DOI 10.1210/en.133.3.1292; DAMERON KM, 1994, SCIENCE, V265, P1582, DOI 10.1126/science.7521539; EZEKOWITZ RAB, 1992, NEW ENGL J MED, V326, P1456, DOI 10.1056/NEJM199205283262203; FIDLER IJ, 1987, CURR PROB SURG, V24, P137, DOI 10.1016/0011-3840(87)90002-5; FIDLER IJ, 1985, SEMIN ONCOL, V12, P207; FIDLER IJ, 1990, CANCER RES, V50, P6130; FIDLER IJ, 1977, SCIENCE, V197, P893, DOI 10.1126/science.887927; FOLKMAN J, 1986, CANCER RES, V46, P467; Folkman J, 1992, Semin Cancer Biol, V3, P65; FOLKMAN J, 1987, SCIENCE, V235, P444; GORELIK E, 1983, CANCER RES, V43, P138; HORI A, 1991, CANCER RES, V51, P6189; KIM KJ, 1993, NATURE, V362, P841, DOI 10.1038/362841a0; KRIPKE ML, 1988, JNCI-J NATL CANCER I, V80, P722, DOI 10.1093/jnci/80.10.722; OLSON KA, 1994, CANCER RES, V54, P4576; OREILLY MS, 1994, CELL, V79, P315, DOI 10.1016/0092-8674(94)90200-3; Paget S., 1889, LANCET, V1, P571, DOI DOI 10.1016/S0140-6736(00)49915-0; POSTE G, 1980, NATURE, V283, P139, DOI 10.1038/283139a0; PREHN RT, 1993, CANCER RES, V53, P3266; REAL FX, 1986, J CLIN ONCOL, V4, P544, DOI 10.1200/JCO.1986.4.4.544; SINGH RK, 1994, AM J PATHOL, V145, P365; Sugarbaker E V, 1979, Curr Probl Cancer, V3, P1, DOI 10.1016/S0147-0272(79)80008-2; SUGARBAKER EV, 1977, PROGR CANC RES THERA, P227; TEICHER BA, 1992, CANCER RES, V52, P6702; TEICHER BA, 1994, INT J CANCER, V57, P1; WEIDNER N, 1991, NEW ENGL J MED, V324, P1, DOI 10.1056/NEJM199101033240101; WEIDNER N, 1993, AM J PATHOL, V143, P401; XIE B, 1994, J IMMUNOL, V152, P3637; [No title captured]	29	994	1087	0	38	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	OCT 21	1994	79	2					185	188		10.1016/0092-8674(94)90187-2	http://dx.doi.org/10.1016/0092-8674(94)90187-2			4	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	PN630	7525076				2022-12-28	WOS:A1994PN63000002
J	LAU, LL; JAMIESON, BD; SOMASUNDARAM, T; AHMED, R				LAU, LL; JAMIESON, BD; SOMASUNDARAM, T; AHMED, R			CYTOTOXIC T-CELL MEMORY WITHOUT ANTIGEN	NATURE			English	Article							LYMPHOCYTIC CHORIOMENINGITIS VIRUS; PERSISTING ANTIGEN; SELECTION	Memory is a hallmark of the immune system and ever since its recognition there has been considerable interest in understanding how immunity is maintained(1-5). The current model is that long-term memory is dependent on persistent antigenic stimulation(6-11). We report here results that challenge this view and provide evidence that antigen is not essential for the maintenance of CD8(+) T-cell memory. We show that memory CD8(+) cytotoxic T lymphocytes persist indefinitely in the absence of priming antigen, retain the memory phenotype (CD44(hi)), and provide protection against virus challenge. These findings suggest a re-evaluation of our current thinking on mechanisms involved in maintaining immunity and have implications towards designing effective vaccination strategies.	UNIV CALIF LOS ANGELES, SCH MED, DEPT MICROBIOL & IMMUNOL, LOS ANGELES, CA 90024 USA	University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA								Ahmed R, 1992, Semin Immunol, V4, P105; AHMED R, 1984, J EXP MED, V160, P521, DOI 10.1084/jem.160.2.521; ASHTONRICKARDT PG, 1993, CELL, V73, P1041, DOI 10.1016/0092-8674(93)90281-T; BEVERLEY PCL, 1990, CURR TOP MICROBIOL, V159, P111; BRADLEY LM, 1993, IMMUNOL TODAY, V14, P197, DOI 10.1016/0167-5699(93)90161-D; CELADA F, 1971, PROG ALLERGY, V15, P223; GRAY D, 1991, J EXP MED, V174, P969, DOI 10.1084/jem.174.5.969; GRAY D, 1988, NATURE, V336, P70, DOI 10.1038/336070a0; HOGQUIST KA, 1993, J EXP MED, V177, P1469, DOI 10.1084/jem.177.5.1469; JAMIESON BD, 1989, J EXP MED, V169, P1993, DOI 10.1084/jem.169.6.1993; MACDONALD HR, 1990, CURR TOP MICROBIOL, V159, P97; MACKAY CR, 1993, ADV IMMUNOL, V53, P217, DOI 10.1016/S0065-2776(08)60501-5; Matloubian M., 1993, J VIROL, V67, P7340; OEHEN S, 1992, J EXP MED, V176, P1273, DOI 10.1084/jem.176.5.1273; PAUL W, 1993, FUNDAMENTAL IMMUNOLO, P1211; SPRENT J, 1993, CURR OPIN IMMUNOL, V5, P433, DOI 10.1016/0952-7915(93)90065-Z; TABI Z, 1988, CELL IMMUNOL, V113, P268, DOI 10.1016/0008-8749(88)90026-3; TASWELL C, 1981, J IMMUNOL, V126, P1614; TEW JG, 1980, IMMUNOL REV, V53, P175; WHITTON JL, 1988, VIROLOGY, V162, P321, DOI 10.1016/0042-6822(88)90471-0; ZINKERNAGEL RM, 1990, CURR TOP MICROBIOL, V159, P65	21	583	595	0	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JUN 23	1994	369	6482					648	652		10.1038/369648a0	http://dx.doi.org/10.1038/369648a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	NT459	7516038				2022-12-28	WOS:A1994NT45900055
J	BRILLANTES, AMB; ONDRIAS, K; SCOTT, A; KOBRINSKY, E; ONDRIASOVA, E; MOSCHELLA, MC; JAYARAMAN, T; LANDERS, M; EHRLICH, BE; MARKS, AR				BRILLANTES, AMB; ONDRIAS, K; SCOTT, A; KOBRINSKY, E; ONDRIASOVA, E; MOSCHELLA, MC; JAYARAMAN, T; LANDERS, M; EHRLICH, BE; MARKS, AR			STABILIZATION OF CALCIUM-RELEASE CHANNEL (RYANODINE RECEPTOR) FUNCTION BY FK506-BINDING PROTEIN	CELL			English	Article							MUSCLE SARCOPLASMIC-RETICULUM; SKELETAL-MUSCLE; MOLECULAR-CLONING; SMOOTH-MUSCLE; MALIGNANT HYPERTHERMIA; ENDOPLASMIC-RETICULUM; PROLYL ISOMERASE; PLANAR BILAYERS; FEET STRUCTURES; CYCLOSPORINE-A	FK506-binding protein (FKBP12) was originally identified as the cytosolic receptor for the immunosuppressant drugs FK506 and rapamycin. The cellular function of FKBP12, a ubiquitously expressed 12,000-dalton proline isomerase, has been unknown. FKBP12 copurifies with the 565,000-dalton ryanodine receptor (RyR), four of which form intracellular Ca2+ release channels of the sarcoplasmic and endoplasmic reticula. By coexpressing the RyR and FKBP12 in insect cells, we have demonstrated that FKBP12 modulates channel gating by increasing channels with full conductance levels (by >400%), decreasing open probability after caffeine activation (from 0.63 +/- 0.09 to 0.04 +/- 0.02), and increasing mean open time (from 4.4 +/- 0.6 ms to 75 +/- 41 ms). FK506 or rapamycin, inhibitors of FKBP12 isomerase activity, reverse these stabilizing effects. These results provide the first natural cellular function for FKBP12, and establish that the functional Ca2+ release channel complex includes FKBP12.	CUNY MT SINAI SCH MED,BROOKDALE CTR MOLEC BIOL,NEW YORK,NY 10029; UNIV CONNECTICUT,CTR HLTH,DEPT MED,FARMINGTON,CT 06030; UNIV CONNECTICUT,CTR HLTH,DEPT PHYSIOL,FARMINGTON,CT 06030	City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai; University of Connecticut; University of Connecticut	BRILLANTES, AMB (corresponding author), CUNY MT SINAI SCH MED,DEPT MED,PROGRAM MOLEC MED,NEW YORK,NY 10029, USA.		/AAX-8408-2021	/0000-0001-9657-9704; Ondrias, Karol/0000-0001-8329-3563; Ondriasova, Elena/0000-0002-2990-990X				BERRIDGE MJ, 1993, NATURE, V361, P315, DOI 10.1038/361315a0; BEZPROZVANNY I, 1991, NATURE, V351, P751, DOI 10.1038/351751a0; BIERER BE, 1990, SCIENCE, V250, P556, DOI 10.1126/science.1700475; BIERER BE, 1990, P NATL ACAD SCI USA, V87, P9231, DOI 10.1073/pnas.87.23.9231; BRANDL CJ, 1986, P NATL ACAD SCI USA, V83, P917, DOI 10.1073/pnas.83.4.917; CATTERALL WA, 1991, CELL, V64, P871, DOI 10.1016/0092-8674(91)90309-M; CHEN SRW, 1993, BIOCHEMISTRY-US, V32, P3743, DOI 10.1021/bi00065a029; CHU A, 1990, MOL PHARMACOL, V37, P735; CHUNG J, 1992, CELL, V69, P1227, DOI 10.1016/0092-8674(92)90643-Q; CORONADO R, 1992, METHOD ENZYMOL, V207, P699; DEFRANCO AL, 1991, NATURE, V352, P754, DOI 10.1038/352754a0; DUMONT FJ, 1990, J IMMUNOL, V144, P251; FILL M, 1991, BIOCHEM J, V273, P449, DOI 10.1042/bj2730449; FILL M, 1991, BIOPHYS J, V59, P1085, DOI 10.1016/S0006-3495(91)82323-2; FLANAGAN WM, 1991, NATURE, V352, P803, DOI 10.1038/352803a0; FLEISCHER S, 1989, ANNU REV BIOPHYS BIO, V18, P333, DOI 10.1146/annurev.bb.18.060189.002001; FRANZINIARMSTRONG C, 1983, J MUSCLE RES CELL M, V4, P233, DOI 10.1007/BF00712033; FRESKGARD PO, 1992, SCIENCE, V258, P466, DOI 10.1126/science.1357751; FUJII J, 1991, SCIENCE, V253, P448, DOI 10.1126/science.1862346; GILLO B, 1993, BLOOD, V81, P783; HAKAMATA Y, 1992, FEBS LETT, V312, P229, DOI 10.1016/0014-5793(92)80941-9; HARDING MW, 1989, NATURE, V341, P758, DOI 10.1038/341758a0; HAWKES MJ, 1992, J BIOL CHEM, V267, P6702; HERRMANNFRANK A, 1991, PFLUG ARCH EUR J PHY, V418, P353, DOI 10.1007/BF00550873; HYMEL L, 1988, P NATL ACAD SCI USA, V85, P441, DOI 10.1073/pnas.85.2.441; IMAGAWA T, 1987, J BIOL CHEM, V262, P16636; INUI M, 1987, J BIOL CHEM, V262, P15637; INUI M, 1987, J BIOL CHEM, V262, P1740; JAYARAMAN T, 1993, J BIOL CHEM, V268, P25385; JAYARAMAN T, 1992, J BIOL CHEM, V267, P9474; KAO JPY, 1989, J BIOL CHEM, V264, P8179; KUME S, 1993, CELL, V73, P555, DOI 10.1016/0092-8674(93)90142-D; KUO CJ, 1992, NATURE, V358, P70, DOI 10.1038/358070a0; LAI FA, 1988, NATURE, V331, P315, DOI 10.1038/331315a0; LEE YS, 1991, J MEMBRANE BIOL, V122, P155, DOI 10.1007/BF01872638; LESH RE, 1993, CIRC RES, V72, P481, DOI 10.1161/01.RES.72.2.481; LINDSAY ARG, 1991, BIOCHIM BIOPHYS ACTA, V1064, P89, DOI 10.1016/0005-2736(91)90415-5; LIU J, 1991, CELL, V66, P807, DOI 10.1016/0092-8674(91)90124-H; LIU QY, 1989, BIOPHYS J, V55, P415, DOI 10.1016/S0006-3495(89)82835-8; MARKS AR, 1990, J BIOL CHEM, V265, P13143; MARKS AR, 1990, J BIOL CHEM, V265, P20719; MARKS AR, 1991, J CELL BIOL, V114, P303, DOI 10.1083/jcb.114.2.303; MARKS AR, 1989, P NATL ACAD SCI USA, V86, P8683, DOI 10.1073/pnas.86.22.8683; MAYRLEITNER M, 1991, CELL CALCIUM, V12, P505, DOI 10.1016/0143-4160(91)90032-A; MCPHERSON PS, 1991, NEURON, V7, P17, DOI 10.1016/0896-6273(91)90070-G; MCPHERSON SM, 1992, J CELL BIOL, V116, P1111, DOI 10.1083/jcb.116.5.1111; MEISSNER G, 1992, MOL CELL BIOCHEM, V114, P119; MEISSNER G, 1991, ADV EXP MED BIOL, V304, P241; MIGNERY GA, 1989, NATURE, V342, P192, DOI 10.1038/342192a0; MORICE WG, 1993, J BIOL CHEM, V268, P3734; Morris R.E., 1992, TRANSPLANT REV-ORLAN, P39; MOSCHELLA MC, 1993, J CELL BIOL, V120, P1137, DOI 10.1083/jcb.120.5.1137; MOUREY RJ, 1990, BIOCHEM J, V272, P383, DOI 10.1042/bj2720383; NAKAI J, 1990, FEBS LETT, V271, P169, DOI 10.1016/0014-5793(90)80399-4; OTSU K, 1990, J BIOL CHEM, V265, P13472; PENNER R, 1989, FEBS LETT, V259, P217, DOI 10.1016/0014-5793(89)81532-7; PRICE DJ, 1992, SCIENCE, V257, P973, DOI 10.1126/science.1380182; RANATUNGA KW, 1982, J PHYSIOL-LONDON, V329, P465, DOI 10.1113/jphysiol.1982.sp014314; ROSS CA, 1989, NATURE, V339, P468, DOI 10.1038/339468a0; ROUSSEAU E, 1989, AM J PHYSIOL, V256, P328; SCHREIBER SL, 1991, SCIENCE, V251, P283, DOI 10.1126/science.1702904; SMITH JS, 1986, J GEN PHYSIOL, V88, P573, DOI 10.1085/jgp.88.5.573; SMITH KA, 1988, INTERLEUKIN, V2, P1; STAMNES MA, 1991, CELL, V65, P219, DOI 10.1016/0092-8674(91)90156-S; STANDAERT RF, 1990, NATURE, V346, P671, DOI 10.1038/346671a0; SUCHYNA TM, 1993, NATURE, V365, P847, DOI 10.1038/365847a0; SUKO J, 1993, BIOCHIM BIOPHYS ACTA, V1175, P193, DOI 10.1016/0167-4889(93)90023-I; SUPATTAPONE S, 1988, J BIOL CHEM, V263, P1530; TAKESHIMA H, 1989, NATURE, V339, P439, DOI 10.1038/339439a0; TIEBOSCH A, 1990, TRANSPLANT P, V22, P1652; TIMERMAN AP, 1993, J BIOL CHEM, V268, P22992; WHITING PH, 1991, TRANSPLANTATION, V52, P203, DOI 10.1097/00007890-199108000-00004; WILLIAMS AJ, 1992, J MUSCLE RES CELL M, V13, P7, DOI 10.1007/BF01738423; WITCHER DR, 1991, J BIOL CHEM, V266, P11144; ZORZATO F, 1990, J BIOL CHEM, V265, P2244	75	692	707	0	27	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	MAY 20	1994	77	4					513	523		10.1016/0092-8674(94)90214-3	http://dx.doi.org/10.1016/0092-8674(94)90214-3			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	NM832	7514503				2022-12-28	WOS:A1994NM83200007
J	GUO, YJ; WU, MC; CHEN, H; WANG, XN; LIU, GL; LI, GL; MA, J; SY, MS				GUO, YJ; WU, MC; CHEN, H; WANG, XN; LIU, GL; LI, GL; MA, J; SY, MS			EFFECTIVE TUMOR VACCINE GENERATED BY FUSION OF HEPATOMA-CELLS WITH ACTIVATED B-CELLS	SCIENCE			English	Article							RECEPTOR	Fusion of BERH-2 rat hepatocellular carcinoma cells with activated B cells produced hybrid cells that lost their tumorigenicity and became immunogenic. Syngeneic rats injected with BERH-2-B hybrid cells became resistant to challenge with parental BERH-2 cells, and rats with established BERH-2 hepatomas were cured by subsequent injection of BERH-2-B cells. Both CD4+ and CD8+ cells were essential for the induction of protective immunity; however, only CD8+ cells were required for the eradication of BERH-2 tumors. The generation of hybrid tumor cells that elicit antitumor immune responses may be a useful strategy for cancer immunotherapy.	CASE WESTERN RESERVE UNIV,INST PATHOL,CLEVELAND,OH 44106	Case Western Reserve University	GUO, YJ (corresponding author), EASTERN INST HEPATOBILIARY SURG,CTR TUMOR IMMUNOL & BIOTHERAPY,SHANGHAI 200433,PEOPLES R CHINA.							ALAN J, 1988, IMMUNOCHEMISTRY PRAC, pCH2; BLANKENSTEIN T, 1991, J EXP MED, V173, P1047, DOI 10.1084/jem.173.5.1047; CHEN LP, 1992, CELL, V71, P1093, DOI 10.1016/S0092-8674(05)80059-5; CHESTNUT RW, 1981, J IMMUNOL, V128, P1075; ELIOT BE, 1989, ADV CANCER RES, V53, P181; FEARON ER, 1990, CELL, V60, P397, DOI 10.1016/0092-8674(90)90591-2; GEORGE JT, 1993, CANCER RES, V53, P2374; Guo Y., UNPUB; GUO YJ, 1988, J MIL MED COLL PEOPL, V3, P272; LANZAVECCHIA A, 1990, ANNU REV IMMUNOL, V8, P773, DOI 10.1146/annurev.immunol.8.1.773; LINSLEY PS, 1991, J EXP MED, V174, P561, DOI 10.1084/jem.174.3.561; MUUL LM, 1987, J IMMUNOL, V138, P989; OSBAND ME, 1990, IMMUNOL TODAY, V11, P193, DOI 10.1016/0167-5699(90)90080-S; RESTIFO NP, 1993, J EXP MED, V177, P265, DOI 10.1084/jem.177.2.265; TEPPER RI, 1989, CELL, V57, P503, DOI 10.1016/0092-8674(89)90925-2; TOWNSEND SE, 1993, SCIENCE, V259, P368, DOI 10.1126/science.7678351; TROJAN J, 1993, SCIENCE, V259, P94, DOI 10.1126/science.8418502; WATANABE Y, 1989, P NATL ACAD SCI USA, V86, P9459	18	143	184	0	10	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JAN 28	1994	263	5146					518	520		10.1126/science.7507262	http://dx.doi.org/10.1126/science.7507262			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	MT966	7507262				2022-12-28	WOS:A1994MT96600032
J	FOSS, HM; ROBERTS, CJ; CLAEYS, KM; SELKER, EU				FOSS, HM; ROBERTS, CJ; CLAEYS, KM; SELKER, EU			ABNORMAL CHROMOSOME BEHAVIOR IN NEUROSPORA MUTANTS DEFECTIVE IN DNA METHYLATION	SCIENCE			English	Article							TANDEM DUPLICATION; CRASSA; RECOMBINATION; 5-AZACYTIDINE; SEQUENCES; INDUCTION; SIGNAL; CYCLE	The function and regulation of DNA methylation in eukaryotes remain unclear. Genes affecting methylation were identified in the fungus Neurospora crassa. A mutation in one gene, dim-2, resulted in the loss of all detectable DNA methylation. Abnormal segregation of the methylation defects in crosses led to the discovery that the methylation mutants frequently generate strains with extra chromosomes or chromosomal parts. Starvation for S-adenosylmethionine, the presumed methyl group donor for DNA methylation, also produced aneuploidy. These results suggest that DNA methylation plays a role in the normal control of chromosome behavior.	UNIV OREGON,INST MOLEC BIOL,EUGENE,OR 97403; UNIV OREGON,DEPT BIOL,EUGENE,OR 97403	University of Oregon; University of Oregon					NIGMS NIH HHS [GM-35690] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM035690, R37GM035690] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BIRD A, 1992, CELL, V70, P5, DOI 10.1016/0092-8674(92)90526-I; BIRD AP, 1986, NATURE, V321, P209, DOI 10.1038/321209a0; BOND DJ, 1987, MUTAT RES, V181, P257, DOI 10.1016/0027-5107(87)90103-5; BULL JH, 1984, NATURE, V310, P701, DOI 10.1038/310701a0; COCK JM, 1990, J PHYCOL, V26, P361, DOI 10.1111/j.0022-3646.1990.00361.x; CULP LA, 1971, BIOCHIM BIOPHYS ACTA, V247, P220, DOI 10.1016/0005-2787(71)90672-1; Davis RH, 1970, METHODS ENZYMOL A, V17A, P47; FOSS H, 1989, FUNGAL GENET NEWSL, V36, P82; FOSS HM, UNPUB; GOUNARI F, 1987, GENE DEV, V1, P899, DOI 10.1101/gad.1.9.899; GRAYBURN WS, 1989, MOL CELL BIOL, V9, P4416, DOI 10.1128/MCB.9.10.4416; HAACK KJ, UNPUB; HAGEMANN A, UNPUB; HORI T, 1983, MUTAT RES, V121, P47, DOI 10.1016/0165-7992(83)90085-4; JACOBSON ES, 1977, J BACTERIOL, V132, P747, DOI 10.1128/JB.132.2.747-748.1977; LI E, 1992, CELL, V69, P915, DOI 10.1016/0092-8674(92)90611-F; METZENBERG RL, 1985, P NATL ACAD SCI USA, V82, P2067, DOI 10.1073/pnas.82.7.2067; NEVES N, 1992, GENOME, V35, P650, DOI 10.1139/g92-098; NEWMEYER D, 1967, GENETICS, V56, P771; PERKINS DD, 1975, GENETICS, V80, P87; PERKINS DD, 1986, GENETICS, V114, P791; PERKINS DD, 1982, MICROBIOL REV, V46, P426, DOI 10.1128/MMBR.46.4.426-570.1982; PITTENGER TH, 1954, GENETICS, V39, P326; POOT M, 1990, HUM GENET, V84, P258; ROBERTS CJ, UNPUB; RUSSELL PJ, 1987, J BACTERIOL, V169, P2902, DOI 10.1128/jb.169.6.2902-2905.1987; SCHROEDER AL, 1991, MOL GEN GENET, V231, P41, DOI 10.1007/BF00293819; SELKER E, UNPUB; SELKER EU, 1987, SCIENCE, V238, P48, DOI 10.1126/science.2958937; SELKER EU, 1987, MOL CELL BIOL, V7, P1032, DOI 10.1128/MCB.7.3.1032; SELKER EU, 1985, P NATL ACAD SCI USA, V82, P8114, DOI 10.1073/pnas.82.23.8114; SELKER EU, 1990, TRENDS BIOCHEM SCI, V15, P103, DOI 10.1016/0968-0004(90)90193-F; SELKER EU, 1990, ANNU REV GENET, V24, P579, DOI 10.1146/annurev.ge.24.120190.003051; SHAFER DA, 1984, AM J HUM GENET, V30, P534; SMITH DA, 1974, GENETICS, V76, P1; SMITH DA, 1975, GENETICS, V80, P125; SOUTHERN EM, 1975, J MOL BIOL, V98, P503, DOI 10.1016/S0022-2836(75)80083-0; STABEN C, 1990, P NATL ACAD SCI USA, V87, P4917, DOI 10.1073/pnas.87.13.4917; THRELKELD SF, 1970, GENET RES, V16, P29, DOI 10.1017/S0016672300002251; VIEGASPEQUIGNOT E, 1976, HUM GENET, V34, P247, DOI 10.1007/BF00295287; VONGS A, 1993, SCIENCE, V260, P1926, DOI 10.1126/science.8316832	41	110	115	0	10	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	DEC 10	1993	262	5140					1737	1741		10.1126/science.7505062	http://dx.doi.org/10.1126/science.7505062			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ML220	7505062				2022-12-28	WOS:A1993ML22000043
J	SPENCER, K; MALLARD, AS; COOMBES, EJ; MACRI, JN				SPENCER, K; MALLARD, AS; COOMBES, EJ; MACRI, JN			PRENATAL SCREENING FOR TRISOMY-18 WITH FREE BETA-HUMAN CHORIONIC-GONADOTROPIN AS A MARKER	BRITISH MEDICAL JOURNAL			English	Article							SERUM ALPHA-FETOPROTEIN; MATERNAL SERUM; DOWNS-SYNDROME; CHROMOSOME-ABNORMALITIES; UNCONJUGATED ESTRIOL; HUMAN CHORIOGONADOTROPIN; PREGNANCY; AGE; RATES; RISK	Objective-To determine the relation between maternal serum alpha fetoprotein and free beta human chorionic gonadotrophin concentrations in pregnancies complicated by trisomy 18 and establish whether prenatal biochemical screening for this condition could be developed in a way similar to that proposed for trisomy 21. Design-Serum alpha fetoprotein and free beta human chorionic gonadotrophin concentrations in women with singleton pregnancies affected by cytogenetically confirmed trisomy 18, uncomplicated by neural tube defect or ventral wall defect, were identified from prospective trisomy 21 screening programmes. Additionally, stored maternal serum from similar pregnancies was analysed retrospectively. Analyte concentrations from singleton unaffected pregnancies were identified from a prospective screening programme as controls. Statistical parameters of the affected and unaffected populations were compiled. Setting-Biochemical screening laboratories in Britain and the United States. Subjects-52 women with singleton pregnancies complicated by trisomy 18; control population of 6661 women with unaffected singleton pregnancies. Main outcome measures-Median values of each analyte and their distribution in the affected and unaffected populations; detection rate of trisomy 18 and the false positive rate. Results-Maternal serum alpha fetoprotein and free beta human chorionic gonadotrophin concentrations were significantly lower in pregnancies complicated by trisomy 18 (median values 0.71 and 0.37 respectively). By using a multivariate risk algorithm incorporating maternal age risk of trisomy 18 and the concentration of the two biochemical markers it was predicted that 50% of trisomy 18 cases (unaffected by neural tube defect or ventral wall defect) could be detected with a 1% false positive rate. Conclusion-Second trimester biochemical screening for trisomy 18 could be a valuable addition to trisomy 21 screening programmes.	ROYAL CORNWALL HOSP,DEPT CLIN BIOCHEM,TRURO,CORNWALL,ENGLAND; QUEEN ALEXANDRA HOSP,DEPT CHEM PATHOL,PORTSMOUTH,HANTS,ENGLAND; NTD LABS INC,DIV RES,NEW YORK,NY 11514	Royal Cornwall Hospital; Portsmouth Hospitals NHS Trust; Queen Alexandra Hospital	SPENCER, K (corresponding author), OLDCHURCH HOSP,DEPT CLIN BIOCHEM,ENDOCRINE UNIT,ROMFORD RM7 0BE,ESSEX,ENGLAND.							Aitken D. A., 1993, Clinical Chemistry, V39, P1170; BOGART MH, 1987, PRENATAL DIAG, V7, P623, DOI 10.1002/pd.1970070904; CANICK JA, 1990, PRENATAL DIAG, V10, P546, DOI 10.1002/pd.1970100813; CROSSLEY JA, 1991, PRENATAL DIAG, V11, P83, DOI 10.1002/pd.1970110204; CUCKLE HS, 1987, BRIT J OBSTET GYNAEC, V94, P387, DOI 10.1111/j.1471-0528.1987.tb03115.x; DARNULE A, 1990, AM J HUM GENET S, V47, pA272; FERGUSONSMITH MA, 1984, PRENATAL DIAG, V4, P5, DOI 10.1002/pd.1970040704; GREENBERG F, 1992, AM J OBSTET GYNECOL, V166, P1388, DOI 10.1016/0002-9378(92)91610-M; HEYL PS, 1990, OBSTET GYNECOL, V76, P1025; HOOK EB, 1981, OBSTET GYNECOL, V58, P282; HOOK EB, 1983, AM J HUM GENET, V35, P110; LINDENBAUM RH, 1987, PRENATAL DIAG, V7, P511, DOI 10.1002/pd.1970070707; MACRI JN, 1990, AM J OBSTET GYNECOL, V163, P1248, DOI 10.1016/0002-9378(90)90700-H; MACRI JN, 1993, ANN CLIN BIOCHEM, V30, P94, DOI 10.1177/000456329303000117; MACRI JN, 1993, PRENATAL DIAG, V13, P557, DOI 10.1002/pd.1970130704; MERKATZ IR, 1984, AM J OBSTET GYNECOL, V148, P886, DOI 10.1016/0002-9378(84)90530-1; NORGAARDPEDERSEN B, 1990, CLIN GENET, V37, P35; PALOMAKI GE, 1992, PRENATAL DIAG, V12, P925, DOI 10.1002/pd.1970121112; REYNOLDS TM, 1990, ANN CLIN BIOCHEM, V27, P452, DOI 10.1177/000456329002700506; SPENCER K, 1985, BRIT MED J, V290, P1940, DOI 10.1136/bmj.290.6486.1940; SPENCER K, 1993, BRIT MED J, V307, P764, DOI 10.1136/bmj.307.6907.764; SPENCER K, 1992, ANN CLIN BIOCHEM, V29, P506, DOI 10.1177/000456329202900504; SPENCER K, 1991, CLIN CHEM, V37, P809; SPENCER K, 1992, LANCET, V339, P1480, DOI 10.1016/0140-6736(92)92073-O; SPENCER K, 1992, BRIT MED J, V305, P769, DOI 10.1136/bmj.305.6856.769; SPENCER K, 1992, ANN CLIN BIOCHEM, V29, P349, DOI 10.1177/000456329202900319; STAPLES AJ, 1991, AM J HUM GENET, V49, P1025; WALD NJ, 1988, BRIT MED J, V297, P883, DOI 10.1136/bmj.297.6653.883	28	39	40	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	DEC 4	1993	307	6917					1455	1458		10.1136/bmj.307.6917.1455	http://dx.doi.org/10.1136/bmj.307.6917.1455			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MK797	7506599	Bronze, Green Published			2022-12-28	WOS:A1993MK79700021
J	MILLER, D; MADGE, N; DIAMOND, J; WADSWORTH, J; ROSS, E				MILLER, D; MADGE, N; DIAMOND, J; WADSWORTH, J; ROSS, E			PERTUSSIS IMMUNIZATION AND SERIOUS ACUTE NEUROLOGICAL ILLNESSES IN CHILDREN	BRITISH MEDICAL JOURNAL			English	Article							VACCINE; IMMUNIZATION	Objective-To determine long term outcome in children who had a severe acute neurological illness in early childhood associated with pertussis immunisation. Design-Follow up study of cases and matched controls. Setting-Assessment of children at home and at school throughout Britain. Subjects-Children recruited into the national childhood encephalopathy study in 1976-9 were followed up, with one of their two original matched controls, in 1986-9. Main outcome measures-Performance in educational attainment tests; behaviour problems reported by teachers and parents; continuing convulsions; evidence of other neurological or physical dysfunction. Results-Over 80% of cases and controls were traced. Case children were significantly more likely than controls to have died or to have some form of educational, behavioural, neurological, or physical dysfunction a decade after their illness. The prevalence of one or more of these adverse outcomes in case children who had been immunised with diphtheria, tetanus, and pertussis vaccine within seven days before onset of their original illness was similar to that in case children who had not been immunised recently. The relative risk for recent diphtheria, tetanus, and pertussis immunisation in children who had died or had any dysfunction in comparison with controls was 5.5 (95% confidence interval 1.6 to 23.7). However, the number of cases associated with vaccine (12) was extremely small and statistically vulnerable, and other possible agents or predisposing factors could not be excluded. Conclusions-Diphtheria, tetanus, and pertussis vaccine may on rare occasions be associated with the development of severe acute neurological illnesses that can have serious sequelae. Some cases may occur by chance or have other causes. The role of pertussis vaccine as a prime or concomitant factor in the aetiology of these illnesses cannot be determined in any individual case. The balance of possible risk against known benefits from pertussis immunisation supports continued use of the vaccine.	UNIV LONDON,KINGS COLL HOSP,SCH MED & DENT,DEPT COMMUNITY PAEDIAT,LONDON,ENGLAND	King's College Hospital NHS Foundation Trust; King's College Hospital; University of London	MILLER, D (corresponding author), UNIV LONDON,SCH MED,ST MARYS HOSP,ACAD DEPT PUBL HLTH,LONDON W2 1PG,ENGLAND.			Madge, Nicola/0000-0003-3028-7690				ALDERSLADE R, 1981, WHOOPING COUGH, P79; [Anonymous], 1983, MANUAL RAVENS PROGR; BELLMAN MH, 1985, CHILD CARE HLTH DEV, V11, P309, DOI 10.1111/j.1365-2214.1985.tb00472.x; BELLMAN MH, 1983, LANCET, V1, P1031; BOWIE C, 1990, LANCET, V335, P397, DOI 10.1016/0140-6736(90)90220-Y; BRIMER A, 1984, WIDE SPAN READING TE; FINE PEM, 1992, AM J EPIDEMIOL, V136, P121, DOI 10.1093/oxfordjournals.aje.a116479; GALE JL, 1990, DHSS FDA901162 DEP H, P228; GRIFFITH AH, 1989, VACCINE, V7, P199, DOI 10.1016/0264-410X(89)90229-6; HOWSON CP, 1991, ADVERSE EFFECTS PERT, P65; KULENKAMPFF M, 1974, ARCH DIS CHILD, V49, P46, DOI 10.1136/adc.49.1.46; Madge N, 1993, Dev Med Child Neurol Suppl, V68, P1; MARCUSE EK, 1990, VACCINE, V8, P531, DOI 10.1016/0264-410X(90)90003-5; MIETTINEN OS, 1970, BIOMETRICS, V26, P75, DOI 10.2307/2529046; MILLER D, 1990, LANCET, V335, P655, DOI 10.1016/0140-6736(90)90438-B; MILLER D, 1988, Tokai Journal of Experimental and Clinical Medicine, V13, P145; MILLER DL, 1982, EPIDEMIOL REV, V4, P1; MILLER DL, 1989, VACCINE, V7, P487, DOI 10.1016/0264-410X(89)90268-5; MILLER DL, 1981, BRIT MED J, V282, P1595, DOI 10.1136/bmj.282.6276.1595; MILLER DL, 1985, DEV BIOL STAND, V16, P389; RAVEN JC, 1982, MANUAL RAVENS PROGR; RUTTER M, 1967, J CHILD PSYCHOL PSYC, V8, P1, DOI 10.1111/j.1469-7610.1967.tb02175.x; RUTTER M, 1970, ED HLTH BEHAVIOR; STEWART GT, 1977, LANCET, V1, P234; VERNON PE, 1906, GRADED ARITHMETIC MA; VERNON PE, 1977, GRADED WORD SPELLING; WENTZ KR, 1991, PEDIATRICS, V87, P287; 1981, WHOOPING COUGH REPOR, P170	28	65	72	0	4	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	NOV 6	1993	307	6913					1171	1176		10.1136/bmj.307.6913.1171	http://dx.doi.org/10.1136/bmj.307.6913.1171			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MF824	7504540	Green Published, Bronze			2022-12-28	WOS:A1993MF82400020
J	Ciulla, TA; Johnson, K				Ciulla, TA; Johnson, K			Herpes simplex virus corneal dendrite	NEW ENGLAND JOURNAL OF MEDICINE			English	Article											Ciulla, TA (corresponding author), MASSACHUSETTS EYE & EAR INFIRM,BOSTON,MA 02114, USA.		Ciulla, Thomas/AAA-1299-2020	Ciulla, Thomas/0000-0001-5557-6777					0	0	0	0	0	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	DEC 28	1995	333	26					1743	1743		10.1056/NEJM199512283332605	http://dx.doi.org/10.1056/NEJM199512283332605			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TM169	7491138				2022-12-28	WOS:A1995TM16900005
J	JAY, GT; CHOW, MSS				JAY, GT; CHOW, MSS			INTERACTION OF EPINEPHRINE AND BETA-BLOCKERS	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Letter							PROPRANOLOL; HYPERTENSION; BLOCKADE				JAY, GT (corresponding author), UNIV CONNECTICUT,HARTFORD,CT 06112, USA.							DZUBOW LM, 1986, J AM ACAD DERMATOL, V15, P71, DOI 10.1016/S0190-9622(86)70145-X; FOSTER CA, 1983, PLAST RECONSTR SURG, V72, P74, DOI 10.1097/00006534-198307000-00017; GANDY W, 1989, ANN EMERG MED, V18, P98, DOI 10.1016/S0196-0644(89)80324-5; HANSBROUGH JF, 1980, ANN INTERN MED, V92, P717, DOI 10.7326/0003-4819-92-5-717_2; HOFFMAN B B, 1990, P187; HOUBEN H, 1982, CLIN PHARMACOL THER, V31, P685, DOI 10.1038/clpt.1982.96; MACKIE K, 1991, J CLIN MONITOR, V7, P213, DOI 10.1007/BF01619262; MALTBAEK N, 1984, ACTA MED SCAND S677, V215, P21; REEVES RA, 1984, CLIN PHARMACOL THER, V35, P461, DOI 10.1038/clpt.1984.60; Smith TW, 1988, HEART DIS, P524; VANZWIETEN PA, 1990, CARDIOVASCULAR PHARM, P1; WHELAN TV, 1987, ANN INTERN MED, V106, P327, DOI 10.7326/0003-4819-106-2-327_1	12	1	1	0	3	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	DEC 20	1995	274	23					1830	&		10.1001/jama.274.23.1830	http://dx.doi.org/10.1001/jama.274.23.1830			0	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TK147	7500521				2022-12-28	WOS:A1995TK14700007
J	MARRE, M; LIEVRE, M; CHATELLIER, G; PLOUIN, PF				MARRE, M; LIEVRE, M; CHATELLIER, G; PLOUIN, PF			ACE-INHIBITORS AND DIABETICS WITH ALBUMINURIA	LANCET			English	Letter											MARRE, M (corresponding author), CHU ANGERS,SERV MED B,F-49033 ANGERS 01,FRANCE.			Marre, Michel/0000-0002-3071-1837				FABBRI P, 1995, DIABETES, V44, pA24; HERING SRM, 1995, LANCET, V345, P1195; MATHIESEN ER, 1995, DIABETOLOGIA, V38, P1746; MOGENSEN, 1995, LANCET, V346, P1080; RAVID M, 1993, ANN INTERN MED, V118, P577, DOI 10.7326/0003-4819-118-8-199304150-00001; 1992, NEW ENGL J MED, V327, P227	6	3	3	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	DEC 16	1995	346	8990					1638	1638		10.1016/S0140-6736(95)91976-7	http://dx.doi.org/10.1016/S0140-6736(95)91976-7			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TK481	7500787				2022-12-28	WOS:A1995TK48100063
J	CUMMINGS, BJ; COTMAN, CW				CUMMINGS, BJ; COTMAN, CW			IMAGE-ANALYSIS OF BETA-AMYLOID LOAD IN ALZHEIMERS-DISEASE AND RELATION TO DEMENTIA SEVERITY	LANCET			English	Article							INTELLECTUAL STATUS; PRECURSOR PROTEIN; NEURITIC PLAQUES; DOWNS-SYNDROME; ACCUMULATION; PATHOLOGY; TANGLES; NEURONS	The protein beta-amyloid is said to be central to the disease process of Alzheimer's disease (AD). Several groups have developed transgenic models that overexpress the amyloid precursor protein or beta-amyloid and then develop AD-like neuropathology. Another report suggests that beta-amyloid accumulation in old dogs correlates with cognitive impairment. However, many other researchers argue that beta-amyloid deposition in senile plaques is a secondary event because plaque numbers in man do not correlate well with cognition. We set out to analyse this conumdrum in man. We selected 16 mild to severely demented AD cases on the basis of mini-mental state exam scores (MMSE; n=16). We also included 4 controls who represented the upper range of cognitive ability. We used a computer-based image analysis of cross-sectional area of the brain occupied by beta-amyloid immunopositive deposition. We used this technique in preference to conventional methods of manual plaque counts and found a strong relation between beta-amyloid load in entorhinal cortex and cognition measured on various scales (r=-0 . 93 versus the Blessed IMC). Our study suggests that the size of cortical area affected by beta-amyloid deposition is an important factor in the clinical manifestation of dementia, and lends support to the possibility that beta-amyloid is central to the aetiology of AD.	UNIV CALIF IRVINE,INST BRAIN AGING & DEMENTIA,IRVINE,CA 92717	University of California System; University of California Irvine			Cummings, Brian J/C-9180-2012	Cummings, Brian J/0000-0003-3628-5290				ARISPE N, 1993, P NATL ACAD SCI USA, V90, P10573, DOI 10.1073/pnas.90.22.10573; BAHR BA, 1994, EXP NEUROL, V129, P81, DOI 10.1006/exnr.1994.1149; BLESSED G, 1968, BRIT J PSYCHIAT, V114, P797, DOI 10.1192/bjp.114.512.797; CITRON M, 1992, NATURE, V360, P672, DOI 10.1038/360672a0; CUMMINGS B, IN PRESS NEUROBIOL A; CUMMINGS BJ, 1992, NEUROSCIENCE, V48, P763, DOI 10.1016/0306-4522(92)90265-4; CUMMINGS BJ, 1993, NEUROBIOL AGING, V14, P547, DOI 10.1016/0197-4580(93)90038-D; DUYCKAERTS C, 1990, J NEUROL SCI, V97, P295, DOI 10.1016/0022-510X(90)90226-D; DUYCKAERTS C, 1988, NEUROSCI LETT, V91, P354, DOI 10.1016/0304-3940(88)90706-9; GALDZICKI Z, 1994, BRAIN RES, V646, P332, DOI 10.1016/0006-8993(94)90101-5; GAMES D, 1995, NATURE, V373, P523, DOI 10.1038/373523a0; HE Y, 1993, ACTA NEUROPATHOL, V86, P109, DOI 10.1007/BF00454909; HYMAN BT, 1984, SCIENCE, V225, P1168, DOI 10.1126/science.6474172; JORM AF, 1989, PSYCHOL MED, V19, P1015, DOI 10.1017/S0033291700005742; KIMURA H, 1993, P NATL ACAD SCI USA, V90, P7508, DOI 10.1073/pnas.90.16.7508; LAFERLA FM, 1995, NAT GENET, V9, P21, DOI 10.1038/ng0195-21; LOO DT, 1993, P NATL ACAD SCI USA, V90, P7951, DOI 10.1073/pnas.90.17.7951; MANN DMA, 1986, NEUROPATH APPL NEURO, V12, P447, DOI 10.1111/j.1365-2990.1986.tb00053.x; MCKEE AC, 1991, ANN NEUROL, V30, P156, DOI 10.1002/ana.410300206; MCKEEL DW, 1993, ALZ DIS ASSOC DIS, V7, P136, DOI 10.1097/00002093-199307030-00003; MORRIS J, 1991, ANN NEUROL, V20, P249; MORRIS JC, 1993, NEUROLOGY, V43, P2412, DOI 10.1212/WNL.43.11.2412-a; Price D L, 1990, Adv Neurol, V51, P83; RAFALOWSKA J, 1988, ACTA NEUROPATHOL, V77, P21, DOI 10.1007/BF00688238; ROSES AD, 1994, J NEUROPATH EXP NEUR, V53, P429, DOI 10.1097/00005072-199409000-00002; SALMON DP, 1990, NEUROLOGY, V40, P1225, DOI 10.1212/WNL.40.8.1225; SELKOE DJ, 1994, J NEUROPATH EXP NEUR, V53, P438, DOI 10.1097/00005072-199409000-00003; TERRY RD, 1991, ANN NEUROL, V30, P572, DOI 10.1002/ana.410300410; WILCOCK GK, 1982, J NEUROL SCI, V56, P343, DOI 10.1016/0022-510X(82)90155-1; WISNIEWSKI HM, 1989, ACTA NEUROPATHOL, V78, P22, DOI 10.1007/BF00687398	30	254	259	1	19	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	DEC 9	1995	346	8989					1524	1528		10.1016/S0140-6736(95)92053-6	http://dx.doi.org/10.1016/S0140-6736(95)92053-6			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TJ291	7491048				2022-12-28	WOS:A1995TJ29100012
J	ZAKIAN, VA				ZAKIAN, VA			TELOMERES - BEGINNING TO UNDERSTAND THE END	SCIENCE			English	Review							TERMINAL TRANSFERASE-ACTIVITY; OXYTRICHA MACRONUCLEAR DNA; CELL-CYCLE ARREST; SACCHAROMYCES-CEREVISIAE; CHROMOSOME ENDS; BINDING-PROTEIN; YEAST TELOMERES; LINEAR PLASMID; RIBOSOMAL-RNA; DROSOPHILA-MELANOGASTER	Telomeres are the protein-DNA structures at the ends of eukaryotic chromosomes. In yeast, and probably most other eukaryotes, telomeres are essential. They allow the cell to distinguish intact from broken chromosomes, protect chromosomes from degradation, and are substrates for novel replication mechanisms. Telomeres are usually replicated by telomerase, a telomere-specific reverse transcriptase, although telomerase-independent mechanisms of telomere maintenance exist. Telomere replication is both cell cycle- and developmentally regulated, and its control is likely to be complex. Because telomere loss causes the kinds of chromosomal changes associated with cancer and aging, an understanding of telomere biology has medical relevance.			ZAKIAN, VA (corresponding author), PRINCETON UNIV,DEPT MOLEC BIOL,PRINCETON,NJ 08544, USA.							ALLSOPP RC, 1992, P NATL ACAD SCI USA, V89, P10114, DOI 10.1073/pnas.89.21.10114; APARICIO OM, 1991, CELL, V66, P1279, DOI 10.1016/0092-8674(91)90049-5; BAROIN A, 1987, NUCLEIC ACIDS RES, V15, P1717, DOI 10.1093/nar/15.4.1717; BERNARDS A, 1983, NATURE, V303, P592, DOI 10.1038/303592a0; BIESSMANN H, 1988, EMBO J, V7, P1081, DOI 10.1002/j.1460-2075.1988.tb02916.x; BIESSMANN H, 1992, EMBO J, V11, P4459, DOI 10.1002/j.1460-2075.1992.tb05547.x; BIESSMANN H, 1990, P NATL ACAD SCI USA, V87, P1758, DOI 10.1073/pnas.87.5.1758; BIESSMANN H, 1990, CELL, V61, P663, DOI 10.1016/0092-8674(90)90478-W; BLACKBURN EH, 1978, J MOL BIOL, V120, P33, DOI 10.1016/0022-2836(78)90294-2; BLACKBURN EH, 1984, CELL, V36, P447, DOI 10.1016/0092-8674(84)90238-1; BLACKBURN EH, 1981, P NATL ACAD SCI-BIOL, V78, P2263, DOI 10.1073/pnas.78.4.2263; BLASCO MA, 1995, SCIENCE, V269, P1267, DOI 10.1126/science.7544492; BRAUNSTEIN M, 1993, GENE DEV, V7, P592, DOI 10.1101/gad.7.4.592; BRINDLE PK, 1990, MOL CELL BIOL, V10, P4872, DOI 10.1128/MCB.10.9.4872; BRYAN TM, 1995, EMBO J, V14, P4340; BUCHMAN AR, 1988, MOL CELL BIOL, V8, P210, DOI 10.1128/MCB.8.1.210; CARDENAS ME, 1993, GENE DEV, V7, P870; CHAN CSM, 1983, CELL, V33, P563, DOI 10.1016/0092-8674(83)90437-3; CHUNG HMM, 1990, EMBO J, V9, P2611, DOI 10.1002/j.1460-2075.1990.tb07443.x; COCKELL M, 1995, J CELL BIOL, V129, P909, DOI 10.1083/jcb.129.4.909; COHN M, 1995, SCIENCE, V269, P396, DOI 10.1126/science.7618104; COLEMAN MJ, 1993, GENE, V132, P67, DOI 10.1016/0378-1119(93)90515-5; COLLINS K, 1995, CELL, V81, P677, DOI 10.1016/0092-8674(95)90529-4; CONRAD MN, 1990, CELL, V63, P739, DOI 10.1016/0092-8674(90)90140-A; CORCORAN LM, 1988, CELL, V53, P807, DOI 10.1016/0092-8674(88)90097-9; COUNTER CM, 1994, P NATL ACAD SCI USA, V91, P2900, DOI 10.1073/pnas.91.8.2900; COUNTER CM, 1992, EMBO J, V11, P1921, DOI 10.1002/j.1460-2075.1992.tb05245.x; DANI GM, 1983, P NATL ACAD SCI-BIOL, V80, P3406, DOI 10.1073/pnas.80.11.3406; EDMAN JC, 1992, MOL CELL BIOL, V12, P2777, DOI 10.1128/MCB.12.6.2777; EMERY HS, 1981, CELL, V26, P411, DOI 10.1016/0092-8674(81)90210-5; FANG GW, 1993, CELL, V74, P875, DOI 10.1016/0092-8674(93)90467-5; FENG JL, 1995, SCIENCE, V269, P1236, DOI 10.1126/science.7544491; FORNEY J, 1987, NUCLEIC ACIDS RES, V15, P9143, DOI 10.1093/nar/15.22.9143; FUNABIKI H, 1993, J CELL BIOL, V121, P961, DOI 10.1083/jcb.121.5.961; GANAL MW, 1991, PLANT CELL, V3, P87, DOI 10.1105/tpc.3.1.87; GILSON E, 1993, J MOL BIOL, V231, P293, DOI 10.1006/jmbi.1993.1283; GIRALDO R, 1994, EMBO J, V13, P2411, DOI 10.1002/j.1460-2075.1994.tb06526.x; GOTTSCHLING DE, 1984, CELL, V38, P501, DOI 10.1016/0092-8674(84)90505-1; GOTTSCHLING DE, 1990, CELL, V63, P751, DOI 10.1016/0092-8674(90)90141-Z; GOTTSCHLING DE, 1986, CELL, V47, P195, DOI 10.1016/0092-8674(86)90442-3; GRAY JT, 1991, CELL, V67, P807, DOI 10.1016/0092-8674(91)90075-A; GREENWELL PW, 1995, CELL, V82, P823, DOI 10.1016/0092-8674(95)90479-4; GREIDER CW, 1989, NATURE, V337, P331, DOI 10.1038/337331a0; GREIDER CW, 1991, MOL CELL BIOL, V11, P4572, DOI 10.1128/MCB.11.9.4572; GREIDER CW, 1987, CELL, V51, P887, DOI 10.1016/0092-8674(87)90576-9; GREIDER CW, 1985, CELL, V43, P405, DOI 10.1016/0092-8674(85)90170-9; HARDY CFJ, 1992, GENE DEV, V6, P801, DOI 10.1101/gad.6.5.801; HARLEY CB, 1990, NATURE, V345, P458, DOI 10.1038/345458a0; HASTIE ND, 1990, NATURE, V346, P866, DOI 10.1038/346866a0; HICKE BJ, 1990, P NATL ACAD SCI USA, V87, P1481, DOI 10.1073/pnas.87.4.1481; HIGASHIYAMA T, 1995, MOL GEN GENET, V249, P29; ISHIKAWA F, 1993, MOL CELL BIOL, V13, P4301, DOI 10.1128/MCB.13.7.4301; JAVERZAT JP, 1993, NUCLEIC ACIDS RES, V21, P497, DOI 10.1093/nar/21.3.497; KIM NW, 1994, SCIENCE, V266, P2011, DOI 10.1126/science.7605428; KIMMERLY W, 1988, EMBO J, V7, P2241, DOI 10.1002/j.1460-2075.1988.tb03064.x; KIPLING D, 1990, NATURE, V347, P400, DOI 10.1038/347400a0; KLOBUTCHER LA, 1981, P NATL ACAD SCI-BIOL, V78, P3015, DOI 10.1073/pnas.78.5.3015; LARSON DD, 1987, CELL, V50, P477, DOI 10.1016/0092-8674(87)90501-0; LEBLANCQ SM, 1991, NUCLEIC ACIDS RES, V19, P5790, DOI 10.1093/nar/19.20.5790; LEVIS R, 1985, SCIENCE, V229, P558, DOI 10.1126/science.2992080; LEVIS RW, 1989, CELL, V58, P791, DOI 10.1016/0092-8674(89)90112-8; LEVIS RW, 1993, CELL, V75, P1083, DOI 10.1016/0092-8674(93)90318-K; LEVY MZ, 1992, J MOL BIOL, V225, P951, DOI 10.1016/0022-2836(92)90096-3; LIN JJ, 1994, NUCLEIC ACIDS RES, V22, P4906, DOI 10.1093/nar/22.23.4906; LIN JJ, 1995, CELL, V81, P1127, DOI 10.1016/S0092-8674(05)80017-0; LINGNER J, 1994, GENE DEV, V8, P1984, DOI 10.1101/gad.8.16.1984; LOUIS EJ, 1994, GENETICS, V136, P789; LOUIS EJ, 1992, GENETICS, V131, P559; LUE NF, 1995, J BIOL CHEM, V270, P21453, DOI 10.1074/jbc.270.37.21453; LUNDBLAD V, 1989, CELL, V57, P633, DOI 10.1016/0092-8674(89)90132-3; LUNDBLAD V, 1993, CELL, V73, P347, DOI 10.1016/0092-8674(93)90234-H; LUSTIG AJ, 1990, SCIENCE, V250, P549, DOI 10.1126/science.2237406; LUSTIG AJ, 1986, P NATL ACAD SCI USA, V83, P1398, DOI 10.1073/pnas.83.5.1398; MAKAROV VL, 1993, CELL, V73, P775, DOI 10.1016/0092-8674(93)90256-P; MANTELL LL, 1994, EMBO J, V13, P3211, DOI 10.1002/j.1460-2075.1994.tb06620.x; MASON JM, 1995, TRENDS GENET, V11, P58, DOI 10.1016/S0168-9525(00)88998-2; MATHOG D, 1984, NATURE, V308, P414, DOI 10.1038/308414a0; MATSUMOTO T, 1987, MOL CELL BIOL, V7, P4424, DOI 10.1128/MCB.7.12.4424; McClintock B, 1939, P NATL ACAD SCI USA, V25, P405, DOI 10.1073/pnas.25.8.405; McClintock B, 1941, GENETICS, V26, P234; MCEACHERN MJ, 1994, P NATL ACAD SCI USA, V91, P3453, DOI 10.1073/pnas.91.8.3453; MCEACHERN MJ, 1995, NATURE, V376, P403, DOI 10.1038/376403a0; MCEACHERN MJ, 1993, MOL CELL BIOL, V13, P551, DOI 10.1128/MCB.13.1.551; MCKAY SJ, 1992, NUCLEIC ACIDS RES, V20, P6461, DOI 10.1093/nar/20.24.6461; MEYNE J, 1989, P NATL ACAD SCI USA, V86, P7049, DOI 10.1073/pnas.86.18.7049; MEYNE J, 1990, CHROMOSOMA, V99, P3, DOI 10.1007/BF01737283; MORIN GB, 1988, CELL, V52, P367, DOI 10.1016/S0092-8674(88)80029-1; MORIN GB, 1989, CELL, V59, P521, DOI 10.1016/0092-8674(89)90035-4; MOSIG G, 1987, ANNU REV GENET, V21, P347, DOI 10.1146/annurev.ge.21.120187.002023; MULLER F, 1991, CELL, V67, P815, DOI 10.1016/0092-8674(91)90076-B; Muller H.J., 1938, COLLECTING NET, V13, P181; MURNANE JP, 1994, EMBO J, V13, P4953, DOI 10.1002/j.1460-2075.1994.tb06822.x; NIMMO ER, 1994, EMBO J, V13, P3801, DOI 10.1002/j.1460-2075.1994.tb06691.x; OKA Y, 1980, GENE, V10, P301; OKAZAKI S, 1993, MOL CELL BIOL, V13, P1424, DOI 10.1128/MCB.13.3.1424; PALLADINO F, 1993, CELL, V7, P543; PETRACEK ME, 1990, P NATL ACAD SCI USA, V87, P8222, DOI 10.1073/pnas.87.21.8222; PLUTA AF, 1989, NATURE, V337, P429, DOI 10.1038/337429a0; PLUTA AF, 1984, P NATL ACAD SCI-BIOL, V81, P1475, DOI 10.1073/pnas.81.5.1475; PONZI M, 1985, EMBO J, V4, P2991, DOI 10.1002/j.1460-2075.1985.tb04034.x; PRESCOTT DM, 1994, MICROBIOL REV, V58, P233, DOI 10.1128/MMBR.58.2.233-267.1994; PROWSE KR, 1993, P NATL ACAD SCI USA, V90, P1493, DOI 10.1073/pnas.90.4.1493; PROWSE KR, 1995, P NATL ACAD SCI USA, V92, P4818, DOI 10.1073/pnas.92.11.4818; RICHARDS EJ, 1988, CELL, V53, P127, DOI 10.1016/0092-8674(88)90494-1; ROGAN EM, 1995, MOL CELL BIOL, V15, P4745; ROMERO DP, 1991, CELL, V67, P343, DOI 10.1016/0092-8674(91)90186-3; SANDELL LJ, UNPUB; SANDELL LL, 1993, CELL, V75, P729, DOI 10.1016/0092-8674(93)90493-A; SANDELL LL, 1994, P NATL ACAD SCI USA, V91, P12061, DOI 10.1073/pnas.91.25.12061; SCHECHTMAN MG, 1990, GENE, V88, P159, DOI 10.1016/0378-1119(90)90027-O; SCHIESTL RH, 1989, MOL CELL BIOL, V9, P1882, DOI 10.1128/MCB.9.5.1882; SCHULZ VP, 1994, CELL, V76, P145, DOI 10.1016/0092-8674(94)90179-1; SEN D, 1990, NATURE, V344, P410, DOI 10.1038/344410a0; SHAMPAY J, 1984, NATURE, V310, P154, DOI 10.1038/310154a0; SHAMPAY J, 1988, P NATL ACAD SCI USA, V85, P534, DOI 10.1073/pnas.85.2.534; SHEEN FM, 1994, P NATL ACAD SCI USA, V91, P12510, DOI 10.1073/pnas.91.26.12510; SHIPPENLENTZ D, 1990, SCIENCE, V247, P546, DOI 10.1126/science.1689074; SHIPPENLENTZ D, 1989, MOL CELL BIOL, V9, P2761, DOI 10.1128/MCB.9.6.2761; SINGER MS, 1994, SCIENCE, V266, P404, DOI 10.1126/science.7545955; STARLING JA, 1990, NUCLEIC ACIDS RES, V18, P6881, DOI 10.1093/nar/18.23.6881; STAVENHAGEN JB, 1994, GENE DEV, V8, P1411, DOI 10.1101/gad.8.12.1411; SUNDQUIST WI, 1989, NATURE, V342, P825, DOI 10.1038/342825a0; SZOSTAK JW, 1982, CELL, V29, P245, DOI 10.1016/0092-8674(82)90109-X; TESCHKE C, 1991, NUCLEIC ACIDS RES, V19, P2677, DOI 10.1093/nar/19.10.2677; TOMMERUP H, 1994, MOL CELL BIOL, V14, P5777, DOI 10.1128/MCB.14.9.5777; VANDERPLOEG LHT, 1984, CELL, V36, P459, DOI 10.1016/0092-8674(84)90239-3; WALKER CL, 1991, P NATL ACAD SCI USA, V88, P6191, DOI 10.1073/pnas.88.14.6191; WALMSLEY RM, 1984, NATURE, V310, P157, DOI 10.1038/310157a0; WALMSLEY RM, 1983, NATURE, V302, P84, DOI 10.1038/302084a0; WANG SG, UNPUB; WANG SS, 1990, MOL CELL BIOL, V10, P4415, DOI 10.1128/MCB.10.8.4415; WANG SS, 1990, NATURE, V345, P456, DOI 10.1038/345456a0; WATSON JD, 1972, NATURE-NEW BIOL, V239, P197, DOI 10.1038/newbio239197a0; WEINERT TA, 1988, SCIENCE, V241, P317, DOI 10.1126/science.3291120; WEINERT TA, 1990, MOL CELL BIOL, V10, P6554, DOI 10.1128/MCB.10.12.6554; WELLINGER RJ, 1993, MOL CELL BIOL, V13, P4057, DOI 10.1128/MCB.13.7.4057; WELLINGER RJ, 1993, CELL, V72, P51, DOI 10.1016/0092-8674(93)90049-V; WELLS RA, 1990, GENOMICS, V8, P699, DOI 10.1016/0888-7543(90)90257-U; WHITE CI, 1990, EMBO J, V9, P633; WILEY EA, 1995, GENETICS, V139, P67; WILLIAMSON JR, 1989, CELL, V59, P871, DOI 10.1016/0092-8674(89)90610-7; WRIGHT JH, 1995, NUCLEIC ACIDS RES, V23, P1454, DOI 10.1093/nar/23.9.1454; WRIGHT JH, 1992, GENE DEV, V6, P197, DOI 10.1101/gad.6.2.197; YU GL, 1990, NATURE, V344, P126, DOI 10.1038/344126a0; ZAHLER AM, 1988, NUCLEIC ACIDS RES, V16, P6953, DOI 10.1093/nar/16.14.6953; ZAHLER AM, 1991, NATURE, V350, P718, DOI 10.1038/350718a0; ZAKIAN VA, 1989, ANNU REV GENET, V23, P579, DOI 10.1146/annurev.genet.23.1.579	147	749	789	3	59	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	DEC 8	1995	270	5242					1601	1607		10.1126/science.270.5242.1601	http://dx.doi.org/10.1126/science.270.5242.1601			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TJ293	7502069				2022-12-28	WOS:A1995TJ29300031
J	LIP, GYH; BEEVERS, DG				LIP, GYH; BEEVERS, DG			ABC OF ATRIAL-FIBRILLATION - HISTORY, EPIDEMIOLOGY, AND IMPORTANCE OF ATRIAL-FIBRILLATION	BRITISH MEDICAL JOURNAL			English	Article									CITY HOSP,DEPT CARDIOL,BIRMINGHAM,W MIDLANDS,ENGLAND; UNIV BIRMINGHAM,CITY HOSP,DEPT MED,BIRMINGHAM,W MIDLANDS,ENGLAND	University of Birmingham; University of Birmingham								FLEGEL KM, 1995, ANN INTERN MED, V122, P867, DOI 10.7326/0003-4819-122-11-199506010-00010; KANNEL WB, 1982, NEW ENGL J MED, V306, P1018, DOI 10.1056/NEJM198204293061703; LIP GYH, 1994, BRIT HEART J, V71, P92; LOWN B, 1967, BRIT HEART J, V29, P469	4	99	101	0	2	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	NOV 18	1995	311	7016					1361	1363		10.1136/bmj.311.7016.1361	http://dx.doi.org/10.1136/bmj.311.7016.1361			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TF901	7496293	Green Published			2022-12-28	WOS:A1995TF90100033
J	ROMAO, MJ; ARCHER, M; MOURA, I; MOURA, JJG; LEGALL, J; ENGH, R; SCHNEIDER, M; HOF, P; HUBER, R				ROMAO, MJ; ARCHER, M; MOURA, I; MOURA, JJG; LEGALL, J; ENGH, R; SCHNEIDER, M; HOF, P; HUBER, R			CRYSTAL-STRUCTURE OF THE XANTHINE OXIDASE-RELATED ALDEHYDE OXIDOREDUCTASE FROM D-GIGAS	SCIENCE			English	Article							DESULFOVIBRIO-GIGAS; ELECTRON-TRANSFER; MOLYBDENUM COFACTOR; PULSE-RADIOLYSIS; DEHYDROGENASE; PROTEIN; MECHANISM; OXIDOREDUCTASE; EXAFS; CRYSTALLIZATION	The crystal structure of the aldehyde oxido-reductase (Mop) from the sulfate reducing anaerobic Gram-negative bacterium Desulfovibrio gigas has been determined at 2.25 Angstrom resolution by multiple isomorphous replacement and refined. The protein, a homodimer of 907 amino acid residues subunits, is a member of the xanthine oxidase family. The protein contains a molybdopterin cofactor (Mo-co) and two different [2Fe-2S] centers. It is folded into four domains of which the first two bind the iron sulfur centers and the last two are involved in Mo-co binding, Mo-co is a molybdenum molybdopterin cytosine dinucleotide. Molybdopterin forms a tricyclic system with the pterin bicycle annealed to a pyran ring. The molybdopterin dinucleotide is deeply buried in the protein, The cis-dithiolene group of the pyran ring binds the molybdenum, which is coordinated by three more (oxygen) ligands.	MAX PLANCK INST BIOCHEM, D-82152 MARTINSRIED, GERMANY; INST TECNOL QUIM & BIOQUIM, P-2780 OEIRAS, PORTUGAL; DEPT QUIM, P-1096 LISBON, PORTUGAL; UNIV NOVA LISBOA, DEPT QUIM, P-2825 MONTE DE CAPARICA, PORTUGAL; UNIV NOVA LISBOA, FAC CIENCIAS & TECNOL, CQFB, P-2825 MONTE DE CAPARICA, PORTUGAL; UNIV GEORGIA, DEPT BIOCHEM & MOLEC BIOL, ATHENS, GA 30602 USA	Max Planck Society; Universidade Nova de Lisboa; Universidade Nova de Lisboa; University System of Georgia; University of Georgia			Moura, Isabel/D-6339-2013; Moura, José J G/D-6426-2013; Romao, Maria J/A-4115-2013; UCIBIO, U Cienc Biom Apl/F-7948-2017	Moura, Isabel/0000-0003-0971-4977; Moura, José J G/0000-0002-4726-2388; Romao, Maria J/0000-0002-3004-0543; UCIBIO, U Cienc Biom Apl/0000-0002-3004-0543; Archer, Margarida/0000-0001-8419-5420; Engh, Richard/0000-0002-6207-0560				BARATA BAS, 1992, EUR J BIOCHEM, V204, P773, DOI 10.1111/j.1432-1033.1992.tb16693.x; BARATA BAS, 1993, BIOCHEMISTRY-US, V32, P11559, DOI 10.1021/bi00094a012; Bray R. C., 1980, BIOL MAGN RESON, V2, P45; BRAY RC, 1982, BIOCHEMISTRY-US, V21, P5992, DOI 10.1021/bi00266a041; BRUNGER AT, 1990, X PLOR VERSION 2 1 M; CALDEIRA J, 1995, J INORG BIOCHEM, V59, P739; CHAN MK, 1995, SCIENCE, V267, P1463, DOI 10.1126/science.7878465; CRAMER SP, 1981, J AM CHEM SOC, V103, P7721, DOI 10.1021/ja00416a005; CRAMER SP, 1985, J AM CHEM SOC, V107, P8164, DOI 10.1021/ja00312a059; CRAMER SP, 1984, J INORG BIOCHEM, V20, P275, DOI 10.1016/0162-0134(84)85026-6; DUGGAN DE, 1975, J MED CHEM, V18, P900, DOI 10.1021/jm00243a008; ENGH RA, 1991, ACTA CRYSTALLOGR A, V47, P392, DOI 10.1107/S0108767391001071; FUKUYAMA K, 1980, NATURE, V286, P522, DOI 10.1038/286522a0; GREENWOOD RJ, 1993, J AM CHEM SOC, V115, P5385, DOI 10.1021/ja00066a005; GUTTERIDGE S, 1978, BIOCHEM J, V175, P887, DOI 10.1042/bj1750887; HABER R, 1994, ACTA CRYSTALLOGR D, V50, P760; Hille R., 1985, Metal Ions in Biology, V7, P443; HILLE R, 1993, ACS SYM SER, V535, P22; HILLE R, 1991, J BIOL CHEM, V266, P5608; HILLE R, 1987, J BIOL CHEM, V262, P10914; HILLE R, 1984, J BIOL CHEM, V259, P1570; HILLE R, 1982, J BIOL CHEM, V257, P8898; HUNT J, 1993, J BIOL CHEM, V268, P18685; JOHNSON JL, 1990, ARCH BIOCHEM BIOPHYS, V283, P542, DOI 10.1016/0003-9861(90)90681-N; JONES TA, 1978, J APPL CRYSTALLOGR, V11, P268, DOI 10.1107/S0021889878013308; KABSCH W, 1983, BIOPOLYMERS, V22, P2577, DOI 10.1002/bip.360221211; KEITH TP, 1987, GENETICS, V116, P67; KOBAYASHI K, 1993, J BIOL CHEM, V268, P24642; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; MASSEY V, 1970, J BIOL CHEM, V245, P6595; MEYER O, 1993, ACS SYM SER, V535, P50; MOURA JJG, 1978, BIOCHEM J, V173, P419, DOI 10.1042/bj1730419; NISHINO T, 1989, J BIOL CHEM, V264, P5468; OERTLING WA, 1990, J BIOL CHEM, V265, P17446; RAJAGOPALAN KV, 1993, ACS SYM SER, V535, P38; RAJAGOPALAN KV, 1991, ADV ENZYMOL RAMB, V64, P215; ROMAO MJ, 1993, EUR J BIOCHEM, V215, P729, DOI 10.1111/j.1432-1033.1993.tb18085.x; RYPNIEWSKI WR, 1991, BIOCHEMISTRY-US, V30, P4126, DOI 10.1021/bi00231a003; SPENCE JT, 1982, BIOCHEMISTRY-US, V21, P1656, DOI 10.1021/bi00536a028; Steigemann W., 1974, THESIS TU MUNCHEN GE; STIEFEL EI, 1993, ACS SYM SER, V535, P1; THOENES U, 1994, EUR J BIOCHEM, V220, P901, DOI 10.1111/j.1432-1033.1994.tb18693.x; Turk D., 1992, THESIS TU MUNCHEN GE; TURNER N, 1987, BIOCHEM J, V243, P755, DOI 10.1042/bj2430755; TURNER NA, 1989, BIOCHEM J, V260, P563, DOI 10.1042/bj2600563; WALKER MC, 1991, BIOCHEMISTRY-US, V30, P5912, DOI 10.1021/bi00238a015; WOOTTON JC, 1991, BIOCHIM BIOPHYS ACTA, V1057, P157, DOI 10.1016/S0005-2728(05)80100-8; ZHIGUONG X, 1992, J AM CHEM SOC, V114, P9194; 1994, 4 COLL COMP PROJ	49	457	461	0	50	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	NOV 17	1995	270	5239					1170	1176						7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TE905	7502041				2022-12-28	WOS:A1995TE90500047
J	FERRIE, JE; SHIPLEY, MJ; MARMOT, MG; STANSFELD, S; SMITH, GD				FERRIE, JE; SHIPLEY, MJ; MARMOT, MG; STANSFELD, S; SMITH, GD			HEALTH-EFFECTS OF ANTICIPATION OF JOB CHANGE AND NONEMPLOYMENT - LONGITUDINAL DATA FROM THE WHITEHALL-II STUDY	BRITISH MEDICAL JOURNAL			English	Article							BRITISH CIVIL-SERVANTS; MENTAL-HEALTH; UNEMPLOYMENT; CHOLESTEROL; REDUNDANCY; MORTALITY; DISEASE; CANADA; RISK	Objective-To assess the effect of anticipating job change or non-employment on self reported health status in a group of middle aged male and female white collar civil servants. Design-Longitudinal cohort study (Whitehall II study), Questionnaire data on self reported health status and health behaviour were obtained at initial screening and four years later, during the period when employees of the department facing privatisation were anticipating job change or job loss. Setting-London based office staff in 20 civil service departments. Subject-666 members of one department threatened with early privatisation were compared with members of the 19 other departments. Main outcome measures-Self reported health status measures and health related behaviours, before and during anticipation of privatisation. Results-In comparison to the remainder of the cohort, the profile of health related behaviours of cohort members who faced privatisation was more favourable, both before and during anticipation of privatisation. There were no significant differences in the changes in health behaviours between cohort members moving into a period of job insecurity and the remainder of the cohort. Self reported health status, however, tended to deteriorate among employees anticipating privatisation when compared with that of the rest of the cohort. Conclusion-The application of a longitudinal design, allowing the same individuals to be followed from job security into anticipation, provides more robust evidence than has previously been available that anticipation of job loss affects health even before employment status has changed.	UNIV BRISTOL, DEPT SOCIAL MED, BRISTOL BS8 2PR, AVON, ENGLAND	University of Bristol	FERRIE, JE (corresponding author), UCL, SCH MED, DEPT EPIDEMIOL & PUBL HLTH, LONDON WC1E 6BT, ENGLAND.		Davey Smith, George/A-7407-2013; Ferrie, Jane/AAZ-2009-2020; Marmot, M G/Y-3920-2019	Davey Smith, George/0000-0002-1407-8314; Marmot, M G/0000-0002-2431-6419; s, hema/0000-0002-3440-9475	Medical Research Council [G8802774] Funding Source: Medline; Wellcome Trust Funding Source: Medline	Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Wellcome Trust(Wellcome Trust)		[Anonymous], 1994, OECD JOBS STUDY FACT; BEALE N, 1985, J ROY COLL GEN PRACT, V35, P510; BEALE N, 1987, J ROY COLL GEN PRACT, V37, P390; BILL P, 1988, BUILDING        0318, P5; BILL P, 1988, BUILDING        1202, P7; CAIN KC, 1992, STAT MED, V11, P783, DOI 10.1002/sim.4780110609; COBB S, 1977, DHEW NIOSH77224 PUBL; COOK DG, 1982, LANCET, V1, P1290; DARCY C, 1985, INT J HEALTH SERV, V15, P609, DOI 10.2190/0Q1G-RJG7-DPR9-V6XN; GLYNN RJ, 1982, CIRCULATION, V66, P724, DOI 10.1161/01.CIR.66.4.724; GRAYSON JP, 1993, INT J HEALTH SERV, V23, P743, DOI 10.2190/W5NR-A7A4-BX4A-T4F7; GUEST P, 1989, BUILDING        1208, P10; HAMILTON VL, 1990, J HEALTH SOC BEHAV, V31, P123, DOI 10.2307/2137167; Hartley J., 1991, JOBINSECURITY; Hennessy Peter., 1990, WHITEHALL; IDLER EL, 1991, J GERONTOL, V46, pS55, DOI 10.1093/geronj/46.2.S55; Jahoda M., 1972, MARIENTHAL SOCIOGRAP; KASL SV, 1979, STRESS MENTAL DISORD, P179; KITCHEN S, 1989, BUILDING        0825, P5; MARMOT MG, 1991, LANCET, V337, P1387, DOI 10.1016/0140-6736(91)93068-K; MATTIASSON I, 1990, BRIT MED J, V301, P461, DOI 10.1136/bmj.301.6750.461; McGonigle G., 1936, POVERTY PUBLIC HLTH; MORRIS JK, 1994, BMJ-BRIT MED J, V308, P1135, DOI 10.1136/bmj.308.6937.1135; MORRIS JK, 1991, BRIT J IND MED, V48, P1; MORRIS JN, 1944, MED OFFICER, V2, P69; MORRIS JN, 1944, MED OFFICER, V2, P85; MORRIS JN, 1944, MED OFFICER, V2, P77; MOSER KA, 1984, LANCET, V2, P1324; PLATT S, 1984, BMJ-BRIT MED J, V289, P1029, DOI 10.1136/bmj.289.6451.1029; STANSFELD SA, 1992, PSYCHOL MED, V22, P739, DOI 10.1017/S0033291700038186; STANSFELD SA, 1993, J PSYCHOSOM RES, V37, P1; Vogler C., 1994, SOCIAL CHANGE EXPERI, P188; WALKER D, 1989, TIMES           1206, P4; WARR P, 1988, J SOC ISSUES, V44, P47, DOI 10.1111/j.1540-4560.1988.tb02091.x; 1979, GENERAL HOUSEHOLD SU; 1994, CIVIL SERVICE YB 199; 1986, USING PRIVATE ENTERP	37	222	225	0	22	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	NOV 11	1995	311	7015					1264	1269		10.1136/bmj.311.7015.1264	http://dx.doi.org/10.1136/bmj.311.7015.1264			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	TE859	7496235	Green Published			2022-12-28	WOS:A1995TE85900020
J	BARKER, DJP; OSMOND, C; RODIN, I; FALL, CHD; WINTER, PD				BARKER, DJP; OSMOND, C; RODIN, I; FALL, CHD; WINTER, PD			LOW-WEIGHT GAIN IN INFANCY AND SUICIDE IN ADULT LIFE	BRITISH MEDICAL JOURNAL			English	Article									UNIV SOUTHAMPTON,ROYAL S HANTS HOSP,DEPT PSYCHIAT,SOUTHAMPTON SO14 0YG,HANTS,ENGLAND	University of Southampton; University Hospital Southampton NHS Foundation Trust; Royal South Hants Hospital	BARKER, DJP (corresponding author), UNIV SOUTHAMPTON,SOUTHAMPTON GEN HOSP,MRC,ENVIRONM EPIDEMIOL UNIT,SOUTHAMPTON SO16 6YD,HANTS,ENGLAND.			Osmond, Clive/0000-0002-9054-4655				BARKER DJP, 1995, LANCET, V345, P1087, DOI 10.1016/S0140-6736(95)90821-8; BARRACLOUGH BM, 1974, BR J PSYCH, V74, P443; CHECKLEY S, 1992, HDB AFFECTIVE DISORD; OSMOND C, 1993, BRIT MED J, V307, P1519, DOI 10.1136/bmj.307.6918.1519; VANKNORRING AL, 1982, ACTA PSYCHIAT SCAND, V65, P283	5	92	96	0	8	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	NOV 4	1995	311	7014					1203	1203		10.1136/bmj.311.7014.1203	http://dx.doi.org/10.1136/bmj.311.7014.1203			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	TD768	7488897	Green Published			2022-12-28	WOS:A1995TD76800021
J	LOWSKY, R; ARCHER, GL; FYLES, G; MINDEN, M; CURTIS, J; MESSNER, H; ATKINS, H; PATTERSON, B; WILLEY, BM; MCGEER, A				LOWSKY, R; ARCHER, GL; FYLES, G; MINDEN, M; CURTIS, J; MESSNER, H; ATKINS, H; PATTERSON, B; WILLEY, BM; MCGEER, A			DIAGNOSIS OF WHIPPLES-DISEASE BY MOLECULAR ANALYSIS OF PERIPHERAL-BLOOD	NEW ENGLAND JOURNAL OF MEDICINE			English	Note							RIBOSOMAL-RNA SEQUENCES; BACILLARY ANGIOMATOSIS; IDENTIFICATION; BACTERIUM; DNA		PRINCESS MARGARET HOSP, DEPT MED, TORONTO M4X 1K9, ON, CANADA; PRINCESS MARGARET HOSP, DEPT LAB MED, TORONTO M4X 1K9, ON, CANADA; PRINCESS MARGARET MT SINAI HOSP, DEPT MICROBIOL, TORONTO, ON, CANADA; UNIV TORONTO, TORONTO, ON, CANADA; VIRGINIA COMMONWEALTH UNIV, MED COLL VIRGINIA, DEPT MED, DIV INFECT DIS, RICHMOND, VA 23298 USA	University of Toronto; University Toronto Affiliates; University Health Network Toronto; Princess Margaret Cancer Centre; University of Toronto; University Toronto Affiliates; University Health Network Toronto; Princess Margaret Cancer Centre; University of Toronto; University Toronto Affiliates; Sinai Health System Toronto; Lunenfeld Tanenbaum Research Institute; University Health Network Toronto; Princess Margaret Cancer Centre; University of Toronto; Virginia Commonwealth University			mcgeer, allison/H-7747-2014; McGeer, Allison/AAB-6885-2020	mcgeer, allison/0000-0001-5647-6137; McGeer, Allison/0000-0001-5647-6137				ARCHER GL, 1979, NEW ENGL J MED, V301, P897, DOI 10.1056/NEJM197910253011701; CHEN K, 1989, FEMS MICROBIOL LETT, V57, P19, DOI 10.1016/S0378-1097(97)00476-X; CLARK KGA, 1975, BRIT J HAEMATOL, V29, P301, DOI 10.1111/j.1365-2141.1975.tb01824.x; DOBBINS WO, 1981, GASTROENTEROLOGY, V80, P1468; DOBBINS WO, 1987, WHIPPLES DISEASE; DOOLEY JR, 1980, LANCET, V2, P1237; FEY MF, 1987, BRIT J HAEMATOL, V67, P489, DOI 10.1111/j.1365-2141.1987.tb06174.x; FLEMING JL, 1988, MAYO CLIN PROC, V63, P539, DOI 10.1016/S0025-6196(12)64884-8; GREER CE, 1991, AM J CLIN PATHOL, V95, P117, DOI 10.1093/ajcp/95.2.117; HEGELE RA, 1986, NEW ENGL J MED, V315, P1509, DOI 10.1056/NEJM198612113152403; KALLICK CA, 1972, NATURE-NEW BIOL, V236, P145, DOI 10.1038/newbio236145a0; LANE DJ, 1985, P NATL ACAD SCI USA, V82, P6955, DOI 10.1073/pnas.82.20.6955; LEE GR, 1993, WINTROBES CLIN HEMAT, V1, P1197; METTLER NE, 1969, NEW ENGL J MED, V281, P1023, DOI 10.1056/NEJM196911062811901; MULLER C, 1993, LANCET, V341, P701, DOI 10.1016/0140-6736(93)90475-V; RELMAN DA, 1992, NEW ENGL J MED, V327, P293, DOI 10.1056/NEJM199207303270501; RELMAN DA, 1990, NEW ENGL J MED, V323, P1573, DOI 10.1056/NEJM199012063232301; SILVA MT, 1985, J GEN MICROBIOL, V131, P1001; STEINMAN CR, 1993, NEW ENGL J MED, V328, P62; TAPPERO JW, 1993, ANN INTERN MED, V118, P363, DOI 10.7326/0003-4819-118-5-199303010-00007; WARD DM, 1990, NATURE, V345, P63, DOI 10.1038/345063a0; WHITAKER JA, 1966, NATURE, V212, P855, DOI 10.1038/212855a0; WILSON KH, 1991, LANCET, V338, P474, DOI 10.1016/0140-6736(91)90545-Z; WOESE CR, 1987, MICROBIOL REV, V51, P221, DOI 10.1128/MMBR.51.2.221-271.1987	24	65	66	0	1	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	NOV 17	1994	331	20					1343	1346		10.1056/NEJM199411173312004	http://dx.doi.org/10.1056/NEJM199411173312004			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PR216	7523949				2022-12-28	WOS:A1994PR21600004
J	GABRIEL, SE; BRIGMAN, KN; KOLLER, BH; BOUCHER, RC; STUTTS, MJ				GABRIEL, SE; BRIGMAN, KN; KOLLER, BH; BOUCHER, RC; STUTTS, MJ			CYSTIC-FIBROSIS HETEROZYGOTE RESISTANCE TO CHOLERA-TOXIN IN THE CYSTIC-FIBROSIS MOUSE MODEL	SCIENCE			English	Article							TRANSMEMBRANE CONDUCTANCE REGULATOR; GENE; SECRETION; ADVANTAGE; TRANSPORT; CFTR; IDENTIFICATION; ENTEROTOXIN; EPITHELIUM; HYPOTHESIS	The effect of the number of cystic fibrosis (CF) alleles on cholera toxin (CT)-induced intestinal secretion was examined in the CF mouse model. CF mice that expressed no CF transmembrane conductance regulator (CFTR) protein did not secrete fluid in response to CT. Heterozygotes expressed 50 percent of the normal amount of CFTR protein in the intestinal epithelium and secreted 50 percent of the normal fluid and chloride ion in response to CT. This correlation between CFTR protein and CT-induced chloride ion and fluid secretion suggests that CF heterozygotes might possess a selective advantage of resistance to cholera.			GABRIEL, SE (corresponding author), UNIV N CAROLINA,DEPT MED,CHAPEL HILL,NC 27599, USA.				NHLBI NIH HHS [HL42384, HL34322] Funding Source: Medline; NIDDK NIH HHS [DK46003] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL034322, P50HL042384] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK046003] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ANDERSON MP, 1991, P NATL ACAD SCI USA, V88, P6003, DOI 10.1073/pnas.88.14.6003; BAXTER PS, 1988, NATURE, V335, P211, DOI 10.1038/335211a0; BEAR CE, 1992, CELL, V68, P809, DOI 10.1016/0092-8674(92)90155-6; BEHM JK, 1987, PEDIATR RES, V22, P271, DOI 10.1203/00006450-198709000-00007; CHENG SH, 1990, CELL, V63, P827, DOI 10.1016/0092-8674(90)90148-8; CLARKE LL, 1992, SCIENCE, V257, P1125, DOI 10.1126/science.257.5073.1125; EGGERMONT E, 1991, EUR J PEDIATR, V150, P824, DOI 10.1007/BF01954999; FIELD M, 1972, J CLIN INVEST, V51, P796, DOI 10.1172/JCI106874; FIELD M, 1974, GASTROENTEROLOGY, V66, P1063; FIELD M, 1971, NEW ENGL J MED, V284, P1137; GABRIEL S, UNPUB; HITCHIN BW, 1991, GUT, V32, P893, DOI 10.1136/gut.32.8.893; JORDE LB, 1988, AM J HUM GENET, V42, P808; KARTNER N, 1992, NAT GENET, V1, P321, DOI 10.1038/ng0892-321; KEREM BS, 1989, SCIENCE, V245, P1073, DOI 10.1126/science.2570460; KIMBERG DV, 1971, J CLIN INVEST, V50, P1218, DOI 10.1172/JCI106599; KNOWLES MR, 1983, SCIENCE, V221, P1067, DOI 10.1126/science.6308769; KNUDSON AG, 1967, AM J HUM GENET, V19, P388; LAWSON LD, 1987, AM J PHYSIOL, V252, pG783, DOI 10.1152/ajpgi.1987.252.6.G783; MEINDL RS, 1987, AM J PHYS ANTHROPOL, V74, P39, DOI 10.1002/ajpa.1330740104; MORRAL N, 1994, NAT GENET, V7, P169, DOI 10.1038/ng0694-169; QUINTON PM, 1983, NATURE, V301, P421, DOI 10.1038/301421a0; QUINTON PM, 1982, FLUID ELECTROLYTE AB, P53; RICHARDSON SH, 1986, INFECT IMMUN, V54, P522, DOI 10.1128/IAI.54.2.522-528.1986; RIORDAN JR, 1989, SCIENCE, V245, P1066; RODMAN DM, 1991, MED HYPOTHESES, V36, P253, DOI 10.1016/0306-9877(91)90144-N; ROMEO G, 1989, HUM GENET, V84, P1, DOI 10.1007/BF00210660; SARKADI B, 1992, J BIOL CHEM, V267, P2087; SATO K, 1988, J LAB CLIN MED, V111, P511; SCHAAP P, 1993, J BIOL CHEM, V268, P6323; SHIER WT, 1979, MED HYPOTHESES, V5, P661, DOI 10.1016/0306-9877(79)90087-2; SNOUWAERT JN, 1992, SCIENCE, V257, P1083, DOI 10.1126/science.257.5073.1083; TATA F, 1991, GENOMICS, V10, P301, DOI 10.1016/0888-7543(91)90312-3; TAYLOR CJ, 1988, GUT, V29, P957, DOI 10.1136/gut.29.7.957; WILLUMSEN NJ, 1989, AM J PHYSIOL, V256, pC1033, DOI 10.1152/ajpcell.1989.256.5.C1033; WRIGHT SW, 1968, AM J HUM GENET, V20, P157	36	352	372	4	81	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	OCT 7	1994	266	5182					107	109		10.1126/science.7524148	http://dx.doi.org/10.1126/science.7524148			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PK582	7524148				2022-12-28	WOS:A1994PK58200034
J	GISSELBRECHT, C; PRENTICE, HG; BACIGALUPO, A; BIRON, P; MILPIED, N; RUBIE, H; CUNNINGHAM, D; LEGROS, M; PICO, JL; LINCH, DC; BURNETT, AK; SCARFFE, JH; SIEGERT, W; YVER, A				GISSELBRECHT, C; PRENTICE, HG; BACIGALUPO, A; BIRON, P; MILPIED, N; RUBIE, H; CUNNINGHAM, D; LEGROS, M; PICO, JL; LINCH, DC; BURNETT, AK; SCARFFE, JH; SIEGERT, W; YVER, A			PLACEBO-CONTROLLED PHASE-III TRIAL OF LENOGRASTIM IN BONE-MARROW TRANSPLANTATION	LANCET			English	Article							COLONY-STIMULATING FACTOR; HIGH-DOSE CHEMOTHERAPY; LYMPHOBLASTIC-LEUKEMIA; RECOVERY	Haemopoietic growth factors are accepted as accelerating haemopoietic recovery after bone-marrow grafting, yet no large randomised trials have been published that convincingly show benefit. Lenograstim (glycosylated recombinant human granulocyte colony-stimulating factor) was given to 315 patients after bone-marrow transplantation in a prospective randomised placebo-controlled multicentre trial. 1 day after bone-marrow infusion, 163 patients received lenograstim 5 mu g/kg per day by 30-min infusion, and 152 patients received placebo daily for 28 days or until neutrophil recovery. 137 patients had lymphoma, 35 myeloma, 85 acute lymphoblastic leukaemia, and 58 a solid tumour. Patients were stratified by age and by type of bone-marrow transplantation (BMT). Neutrophil recovery to above 1O(9)/L for 3 consecutive days was seen earlier in lenograstim-treated patients (16 vs 27 days, p<0.001). Time to neutrophil recovery above 0.5 x 10(9)/L was reduced (14 vs 20 days, p<0.001). The difference was significant both in autograft (20 vs 14 days, p<0.001) and allograft (20 vs 14 days, p<0.01) patients, in children (20 vs 13 days, p<0.001), and adults. Lenograstim-treated patients had fewer days of infection, and of antibiotic administration, and also spent less time in hospital. However, clinical and microbiological sepsis was similar in both groups. There was no significant toxicity ascribed to lenograstim. Survival was the same at days 100 and 365. In patients undergoing autologous or allogeneic BMT for neoplastic disease, lenograstim significantly reduced duration of neutropenia and led to earlier hospital discharge.	ROYAL FREE HOSP,LONDON,ENGLAND; INST HEMATOL,GENOA,ITALY; CTR LEON BERARD,LYON,FRANCE; HOP HOTEL DIEU,NANTES,FRANCE; HOP PURPAN,TOULOUSE,FRANCE; ROYAL MARSDEN HOSP,SUTTON,SURREY,ENGLAND; CTR JEAN PERRIN,CLERMONT FERRAND,FRANCE; INST GUSTAVE ROUSSY,VILLEJUIF,FRANCE; UNIV COLL HOSP LONDON,LONDON,ENGLAND; ROYAL INFIRM,GLASGOW,SCOTLAND; CHRISTIE HOSP,MANCHESTER,LANCS,ENGLAND; KLINIKUM RUDOLF VIRCHOW,BERLIN,GERMANY; CHUGAL RHONE POULENC,ANTONY,FRANCE	University of London; University College London; Royal Free London NHS Foundation Trust; UCL Medical School; UNICANCER; Centre Leon Berard; Nantes Universite; CHU de Nantes; CHU de Toulouse; Royal Marsden NHS Foundation Trust; UNICANCER; Centre Jean Perrin; UNICANCER; Gustave Roussy; University College London Hospitals NHS Foundation Trust; University of London; University College London; Royal Infirmary of Edinburgh; Christie NHS Foundation Trust; Christie Hospital; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Sanofi-Aventis	GISSELBRECHT, C (corresponding author), HOP ST LOUIS,INST HAEMATOL,1 AVE CLAUDE VELLEFAUX,F-75010 PARIS,FRANCE.			Milpied, Noel/0000-0002-5177-014X; Cunningham, David/0000-0001-5158-1069				BRICE P, 1992, BONE MARROW TRANSPL, V9, P337; LINCH DC, 1993, BONE MARROW TRANSPL, V11, P307; LINK H, 1992, BLOOD, V80, P2188; NEMUNAITIS J, 1991, NEW ENGL J MED, V324, P1773, DOI 10.1056/NEJM199106203242504; SANTOS GW, 1990, CANCER, V65, P786, DOI 10.1002/1097-0142(19900201)65:3+<786::AID-CNCR2820651326>3.0.CO;2-H; Schwartzberg L S, 1992, J Hematother, V1, P317, DOI 10.1089/scd.1.1992.1.317; SHERIDAN WP, 1992, LANCET, V339, P640, DOI 10.1016/0140-6736(92)90795-5; SHERIDAN WP, 1989, LANCET, V2, P891; TAYLOR KM, 1989, J CLIN ONCOL, V7, P1791, DOI 10.1200/JCO.1989.7.12.1791; TESHIMA H, 1989, EXP HEMATOL, V17, P853; TO LB, 1987, BONE MARROW TRANSPL, V2, P103	11	161	163	0	3	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAR 19	1994	343	8899					696	700		10.1016/S0140-6736(94)91579-2	http://dx.doi.org/10.1016/S0140-6736(94)91579-2			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NB809	7510813				2022-12-28	WOS:A1994NB80900008
J	HAY, RJ				HAY, RJ			SICK LIBRARY SYNDROME	LANCET			English	Editorial Material							MYCOTOXINS				HAY, RJ (corresponding author), GUYS HOSP,ST JOHNS INST DERMATOL,LONDON,ENGLAND.							BHAT RV, 1977, INDIAN J MED RES, V66, P55; BROOK SJ, 1994, J CLIN EPIDEMIOL, V47, P1171; CROFT WA, 1986, ATMOS ENVIRON, V20, P549, DOI 10.1016/0004-6981(86)90096-X; HENDRY KM, 1993, J TOXICOL ENV HEALTH, V38, P183, DOI 10.1080/15287399309531711; HUXLEY A, 1962, ISLAND, P140; LEON FE, 1995, J CLIN EPIDEMIOL, V48, P1183, DOI 10.1016/0895-4356(95)00006-P; NORTHRUP SC, 1978, ENCY HDB, V3, P91; SMORAGIEWICZ W, 1993, INT ARCH OCC ENV HEA, V65, P113, DOI 10.1007/BF00405729	8	3	3	0	2	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	DEC 16	1995	346	8990					1573	1574		10.1016/S0140-6736(95)91925-2	http://dx.doi.org/10.1016/S0140-6736(95)91925-2			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TK481	7500747	Bronze			2022-12-28	WOS:A1995TK48100006
J	WAGNER, RL; APRILETTI, JW; MCGRATH, ME; WEST, BL; BAXTER, JD; FLETTERICK, RJ				WAGNER, RL; APRILETTI, JW; MCGRATH, ME; WEST, BL; BAXTER, JD; FLETTERICK, RJ			A STRUCTURAL ROLE FOR HORMONE IN THE THYROID-HORMONE RECEPTOR	NATURE			English	Article							V-ERBA; ESTROGEN-RECEPTOR; NUCLEAR RECEPTOR; DNA-BINDING; C-ERBA; SUPERFAMILY; REFINEMENT; ACTIVATION; MODEL	The crystal structure of the rat a, thyroid hormone receptor ligand-binding domain bound with a thyroid hormone agonist reveals that ligand is completely buried within the domain as part of the hydrophobic core. In addition, the carboxy-terminal activation domain forms an amphipathic helix, with its hydrophobic face constituting part of the hormone binding cavity. These observations suggest a structural role for ligand, in establishing the active conformation of the receptor, that is likely to underlie hormonal regulation of gene expression for the nuclear receptors.	UNIV CALIF SAN FRANCISCO, METAB RES UNIT, SAN FRANCISCO, CA 94143 USA; UNIV CALIF SAN FRANCISCO, DEPT MED, SAN FRANCISCO, CA 94143 USA; UNIV CALIF SAN FRANCISCO, DEPT BIOCHEM & BIOPHYS, SAN FRANCISCO, CA 94143 USA; KHEPRI PHARMACEUT INC, San Francisco, CA 94080 USA	University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco	WAGNER, RL (corresponding author), UNIV CALIF SAN FRANCISCO, GRAD GRP BIOPHYS, SAN FRANCISCO, CA 94143 USA.		Wood, David W/B-2992-2012	West, Brian/0000-0002-5320-3691				APRILETTI JW, 1995, PROTEIN EXPRES PURIF, V6, P363, DOI 10.1006/prep.1995.1048; AUFLIEGNER M, 1993, MOL CELL BIOL, V13, P5725, DOI 10.1128/MCB.13.9.5725; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; BANIAHMAD A, 1995, MOL CELL BIOL, V15, P76, DOI 10.1128/MCB.15.1.76; BARETTINO D, 1994, EMBO J, V13, P3039, DOI 10.1002/j.1460-2075.1994.tb06603.x; BENDIK I, 1995, J BIOL CHEM, V270, P3107, DOI 10.1074/jbc.270.7.3107; BHAT MK, 1995, BIOCHEM BIOPH RES CO, V210, P464, DOI 10.1006/bbrc.1995.1683; BLAKE CCF, 1977, NATURE, V268, P115, DOI 10.1038/268115a0; BLAKE CCF, 1978, J MOL BIOL, V121, P339, DOI 10.1016/0022-2836(78)90368-6; BOURGUET W, 1995, NATURE, V375, P377, DOI 10.1038/375377a0; BRUNGER AT, 1987, SCIENCE, V235, P458, DOI 10.1126/science.235.4787.458; CAVAILLES V, 1995, EMBO J, V14, P3741, DOI 10.1002/j.1460-2075.1995.tb00044.x; CHATTERJEE VKK, 1994, J CLIN ENDOCR METAB, V78, P990, DOI 10.1210/jcem.78.4.8157732; CHEN JD, 1995, NATURE, V377, P454, DOI 10.1038/377454a0; Cowtan K., 1994, JOINT CCP4 ESF EACBM, V31, P34; DANIELIAN PS, 1992, EMBO J, V11, P1025, DOI 10.1002/j.1460-2075.1992.tb05141.x; DURAND B, 1994, EMBO J, V13, P5370, DOI 10.1002/j.1460-2075.1994.tb06872.x; EVANS RM, 1988, SCIENCE, V240, P889, DOI 10.1126/science.3283939; FAWELL SE, 1990, CELL, V60, P953, DOI 10.1016/0092-8674(90)90343-D; FORMAN BM, 1990, MOL ENDOCRINOL, V4, P1293, DOI 10.1210/mend-4-9-1293; GLASS CK, 1994, ENDOCR REV, V15, P391, DOI 10.1210/er.15.3.391; HORLEIN AJ, 1995, NATURE, V377, P397, DOI 10.1038/377397a0; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Jorgensen E.C., 1978, Hormonal Proteins and Peptides, V6, P107; KABSCH W, 1993, J APPL CRYSTALLOGR, V26, P795, DOI 10.1107/S0021889893005588; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; LATHAM KR, 1981, J BIOL CHEM, V256, P2088; LAUDET V, 1992, EMBO J, V11, P1003, DOI 10.1002/j.1460-2075.1992.tb05139.x; LEDOUARIN B, 1995, EMBO J, V14, P2020, DOI 10.1002/j.1460-2075.1995.tb07194.x; LEE JW, 1995, MOL ENDOCRINOL, V9, P243; LEE JW, 1995, NATURE, V374, P91, DOI 10.1038/374091a0; LENG XH, 1995, MOL CELL BIOL, V15, P255, DOI 10.1128/MCB.15.1.255; LIN KH, 1991, MOL ENDOCRINOL, V5, P485, DOI 10.1210/mend-5-4-485; LUISI BF, 1991, NATURE, V352, P497, DOI 10.1038/352497a0; MCGRATH ME, 1994, J MOL BIOL, V237, P236, DOI 10.1006/jmbi.1994.1224; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; Otwinowski Z., 1991, ISOMORPHOUS REPLACEM, P80; RATINEJAD F, 1995, NATURE, V375, P203; REFETOFF S, 1993, ENDOCR REV, V14, P348, DOI 10.1210/er.14.3.348; RIBEIRO RC, 1992, MOL ENDOCRINOL, V6, P1142, DOI 10.1210/me.6.7.1142; RIBEIRO RCJ, 1995, ANN NY ACAD SCI, V758, P366, DOI 10.1111/j.1749-6632.1995.tb24843.x; RIBEIRO RCJ, 1995, ANNU REV MED, V46, P443, DOI 10.1146/annurev.med.46.1.443; SAATCIOGLU F, 1993, MOL CELL BIOL, V13, P3675, DOI 10.1128/MCB.13.6.3675; SCHWABE JWR, 1993, CELL, V75, P567, DOI 10.1016/0092-8674(93)90390-C; SELMI S, 1991, J BIOL CHEM, V266, P11589; TONE Y, 1994, J BIOL CHEM, V269, P31157; TSAI MJ, 1994, ANNU REV BIOCHEM, V63, P451, DOI 10.1146/annurev.bi.63.070194.002315; WALLACE AC, 1995, PROTEIN ENG, V8, P127, DOI 10.1093/protein/8.2.127; ZENKE M, 1990, CELL, V61, P1035, DOI 10.1016/0092-8674(90)90068-P	49	771	795	0	20	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	DEC 14	1995	378	6558					690	697		10.1038/378690a0	http://dx.doi.org/10.1038/378690a0			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TK379	7501015				2022-12-28	WOS:A1995TK37900043
J	GRZYBOWSKI, S; ALLEN, EA				GRZYBOWSKI, S; ALLEN, EA			HISTORY AND IMPORTANCE OF SCROFULA	LANCET			English	Article							TUBERCULOSIS				GRZYBOWSKI, S (corresponding author), UNIV BRITISH COLUMBIA, DEPT MED, DIV RESP, VANCOUVER, BC V5Z 3J5, CANADA.							Allen EA, 1995, PATHOLOGY LUNG, P253; [Anonymous], 1910, ENCY BRITANNICA, V11th; BATES JH, 1993, MED CLIN N AM, V77, P1205, DOI 10.1016/S0025-7125(16)30188-2; BRANCKER A, 1992, HLTH REP, V4; CUMMINS SL, 1939, PRIMITIVE TUBERCULOS, P47; Daniel Thomas M., 1994, P13; ENARSON DA, 1980, AM J EPIDEMIOL, V112, P341, DOI 10.1093/oxfordjournals.aje.a113000; FOWLER KJ, 1921, PULMONARY TUBERCULOS, P3; FRANCIS J, 1950, LANCET, V258, P34; HARDY JP, 1979, S JOHNSON CRITICAL S, P27; HIRSCH A, 1885, HDB GEOGRAPHICAL HIS, V2, P604; KEERS RY, 1978, PULMONARY TUBERCULOS, P6; LEITCH AG, 1995, THORAX, V50, pP442; Lin H T, 1986, Bull Int Union Tuberc, V61, P28; MAGNUS K, 1966, B WORLD HEALTH ORGAN, V35, P483; MARFAN A, 1886, ARCH GEN MED, V57, P575; MILLER FJW, 1958, LANCET, V1, P286; OSLER W, 1892, PRINCIPLES PRACTICE, P184; PALMER CE, 1966, AM REV RESPIR DIS, V94, P553; ROBAKIEWICZ M, 1974, AM REV RESPIR DIS, V109, P613; SJOGREN I, 1975, TUBERCLE, V56, P113, DOI 10.1016/0041-3879(75)90022-7; SPALDING M, 1991, NURTURING YESTERDAYS, P175; STRADLIN.P, 1973, TUBERCLE, V54, P249; VONPIRQUET C, 1909, TUBERCULOSIS TREATIS, P147; WANG JS, 1989, TUBERCLE, V70, P179, DOI 10.1016/0041-3879(89)90048-2; WILSON GS, 1952, NONPULMONARY TUBERCU; WOLINSKY E, 1979, AM REV RESPIR DIS, V119, P107; 1989, OXFORD HIST FRENCH R, P1	28	41	42	0	5	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	DEC 2	1995	346	8988					1472	1474		10.1016/S0140-6736(95)92478-7	http://dx.doi.org/10.1016/S0140-6736(95)92478-7			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TH156	7490997				2022-12-28	WOS:A1995TH15600015
J	MCNAIR, ANB; TIBBS, CJ; WILLIAMS, R				MCNAIR, ANB; TIBBS, CJ; WILLIAMS, R			RECENT ADVANCES - HEPATOLOGY	BRITISH MEDICAL JOURNAL			English	Article							FULMINANT HEPATIC-FAILURE; BLEEDING ESOPHAGEAL-VARICES; ACUTE LIVER-FAILURE; ENDOSCOPIC LIGATION; SCLEROTHERAPY; PREVENTION; HEMORRHAGE; TRIAL; TRANSPLANTATION; ACETYLCYSTEINE		QUEEN MARYS HOSP,LONDON SW15 5PN,ENGLAND	University of London; Queen Mary University London				opoku, anita/0000-0001-7243-8157				ABECASSIS M, 1987, J CLIN INVEST, V80, P881, DOI 10.1172/JCI113147; [Anonymous], 1994, HEPATOLOGY, V20, p63S; BERNUAU J, 1986, HEPATOLOGY, V6, P648, DOI 10.1002/hep.1840060417; BESSON I, 1995, NEW ENGL J MED, V333, P555, DOI 10.1056/NEJM199508313330904; BLEI AT, 1993, LANCET, V341, P157, DOI 10.1016/0140-6736(93)90016-A; BOUDJEMA K, 1995, TRANSPLANTATION, V59, P218, DOI 10.1097/00007890-199501270-00011; BRILLANTI S, 1994, GASTROENTEROLOGY, V107, P812, DOI 10.1016/0016-5085(94)90131-7; CHEMELLO L, 1995, J VIRAL HEPATITIS, V2, P91, DOI 10.1111/j.1365-2893.1995.tb00012.x; CONN HO, 1991, HEPATOLOGY, V13, P902, DOI 10.1002/hep.1840130517; Devlin J., 1994, Hepatology, V20, p123A; DEVLIN J, 1994, HEPATOLOGY, V20, pA124; DIENSTAG JL, 1994, HEPATOLOGY, V20, pA199; DONOHUE JG, 1992, NEW ENGL J MED, V327, P369; ELLIS AJ, 1994, HEPATOLOGY, V20, pA140; GIMSON AES, 1993, LANCET, V342, P391, DOI 10.1016/0140-6736(93)92812-8; GONZALEZ A, 1995, HEPATOLOGY, V22, P439, DOI 10.1016/0270-9139(95)90563-4; HAMASAKI K, 1994, HEPATOLOGY, V20, P8, DOI 10.1002/hep.1840200103; HARRISON PM, 1990, LANCET, V335, P1572, DOI 10.1016/0140-6736(90)91388-Q; HARRISON PM, 1991, NEW ENGL J MED, V324, P1852, DOI 10.1056/NEJM199106273242604; HAYES PC, 1990, LANCET, V336, P153, DOI 10.1016/0140-6736(90)91668-Z; LABERGE JM, 1995, GASTROENTEROLOGY, V108, P1143, DOI 10.1016/0016-5085(95)90213-9; LAINE L, 1993, ANN INTERN MED, V119, P1, DOI 10.7326/0003-4819-119-1-199307010-00001; MCOMISH F, 1994, J CLIN MICROBIOL, V32, P884, DOI 10.1128/JCM.32.4.884-892.1994; NODA Y, 1986, J HEPATOL, V2, P53, DOI 10.1016/S0168-8278(86)80008-3; OGRADY JG, 1993, LANCET, V342, P273; OGRADY JG, 1989, GASTROENTEROLOGY, V97, P439, DOI 10.1016/0016-5085(89)90081-4; POYNARD T, 1995, NEW ENGL J MED, V332, P1457, DOI 10.1056/NEJM199506013322201; ROLANDO N, 1993, HEPATOLOGY, V17, P196, DOI 10.1016/0270-9139(93)90076-Y; ROLLES K, 1994, LANCET, V343, P263, DOI 10.1016/S0140-6736(94)91113-4; ROZGA J, 1993, HEPATOLOGY, V17, P258, DOI 10.1016/0270-9139(93)90086-3; SALMERON JM, 1992, J HEPATOL, V14, P280, DOI 10.1016/0168-8278(92)90171-K; SCHALUDER GG, 1995, J MED VIROL, V46, P81; SEKIYAMA K, 1994, DIGEST DIS SCI, V39, P240, DOI 10.1007/BF02090192; SHEINER P, 1992, HEPATOLOGY S, V9, pS114; SILINI E, 1994, J HEPATOL, V22, P691; SIMMONDS P, 1994, HEPATOLOGY, V19, P1321, DOI 10.1016/0270-9139(94)90887-7; SIMONS JN, 1995, P NATL ACAD SCI USA, V92, P3401, DOI 10.1073/pnas.92.8.3401; STARZL TE, 1993, HEPATOLOGY, V17, P1127; STEFFEN R, 1994, JAMA-J AM MED ASSOC, V272, P885, DOI 10.1001/jama.272.11.885; STIEGMANN GV, 1992, NEW ENGL J MED, V326, P1527, DOI 10.1056/NEJM199206043262304; SUNG JJY, 1993, LANCET, V342, P637, DOI 10.1016/0140-6736(93)91758-E; SUSSMAN NL, 1992, HEPATOLOGY, V16, P60, DOI 10.1002/hep.1840160112; SUSSMAN NL, 1994, ARTIF ORGANS, V18, P390, DOI 10.1111/j.1525-1594.1994.tb02221.x; WHITINGTON PF, 1993, LANCET, V342, P779, DOI 10.1016/0140-6736(93)91543-U; WHITTLE HC, 1995, LANCET, V345, P1089, DOI 10.1016/S0140-6736(95)90822-6; YUKI N, 1995, J HEPATOL, V22, P457, DOI 10.1016/0168-8278(95)80109-X; 1994, LANCET, V344, P423; 1994, NEW ENGL J MED, V331, P1110	48	1	1	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	NOV 18	1995	311	7016					1351	1355		10.1136/bmj.311.7016.1351	http://dx.doi.org/10.1136/bmj.311.7016.1351			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TF901	7496290	Green Published			2022-12-28	WOS:A1995TF90100029
J	BACH, EA; SZABO, SJ; DIGHE, AS; ASHKENAZI, A; AGUET, M; MURPHY, KM; SCHREIBER, RD				BACH, EA; SZABO, SJ; DIGHE, AS; ASHKENAZI, A; AGUET, M; MURPHY, KM; SCHREIBER, RD			LIGAND-INDUCED AUTOREGULATION OF IFN-GAMMA RECEPTOR-BETA CHAIN EXPRESSION IN T-HELPER CELL SUBSETS	SCIENCE			English	Article							INTERFERON-GAMMA; IDENTIFICATION; ANTIBODIES	Interferon gamma (IFN-gamma) responsiveness in certain cells depends on the state of cellular differentiation or activation. Here an in vitro developmental system was used to show that IFN-gamma produced during generation of the CD4(+) T helper cell type 1 (T(H)1) subset extinguishes expression of the IFN-gamma receptor beta subunit, resulting in T(H)1 cells that are unresponsive to IFN-gamma. This beta chain loss also occurred in IFN-gamma-treated T(H)2 cells and thus represents a specific response of CD4(+) T cells to IFN-gamma rather than a T(H)1-specific differentiation event. These results define a mechanism of cellular desensitization where a cytokine down-regulates expression of a receptor subunit required primarily for signaling and not ligand binding.	WASHINGTON UNIV,SCH MED,CTR IMMUNOL,ST LOUIS,MO 63110; WASHINGTON UNIV,SCH MED,DEPT PATHOL,ST LOUIS,MO 63110; GENENTECH INC,DEPT MOLEC BIOL,S SAN FRANCISCO,CA 94080	Washington University (WUSTL); Washington University (WUSTL); Roche Holding; Genentech			Ashkenazi, Avi/ABG-2712-2020; Schreiber, Robert D/A-1276-2013; Schreiber, Robert/Q-7550-2019; Dighe, Anand/AAP-9640-2020	Ashkenazi, Avi/0000-0002-6890-4589; Schreiber, Robert D/0000-0001-6311-0432; Dighe, Anand/0000-0003-4130-0758; Bach, Erika/0000-0002-5997-4489; Schreiber, Robert/0000-0003-1590-2341				BACH E, UNPUB; FARRAR MA, 1991, J BIOL CHEM, V266, P19626; FARRAR MA, 1993, ANNU REV IMMUNOL, V11, P571, DOI 10.1146/annurev.iy.11.040193.003035; FARRAR MA, 1992, P NATL ACAD SCI USA, V89, P11706, DOI 10.1073/pnas.89.24.11706; HEINZEL FP, 1989, J EXP MED, V169, P59, DOI 10.1084/jem.169.1.59; HEMMI S, 1994, CELL, V76, P803, DOI 10.1016/0092-8674(94)90355-7; HSIEH CS, 1993, SCIENCE, V260, P547, DOI 10.1126/science.8097338; HUANG S, 1993, SCIENCE, V259, P1742, DOI 10.1126/science.8456301; LECLAIRE RD, 1992, J LEUKOCYTE BIOL, V51, P507, DOI 10.1002/jlb.51.5.507; MURPHY KM, 1990, SCIENCE, V250, P1720, DOI 10.1126/science.2125367; PENNICA D, 1995, P NATL ACAD SCI USA, V92, P5401; PEREZ VL, 1995, INT IMMUNOL, V7, P869, DOI 10.1093/intimm/7.5.869; PERNIS A, 1995, SCIENCE, V269, P245, DOI 10.1126/science.7618088; REINER SL, 1994, J EXP MED, V179, P447, DOI 10.1084/jem.179.2.447; SCHREIBER RD, 1994, GUIDEBOOK CYTOKINES, P120; SHEEHAN KCF, 1989, J IMMUNOL, V142, P3884; SOH J, 1994, CELL, P796; SZABO SJ, 1995, IMMUNITY, V2, P665, DOI 10.1016/1074-7613(95)90011-X	18	194	195	0	9	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	NOV 17	1995	270	5239					1215	1218		10.1126/science.270.5239.1215	http://dx.doi.org/10.1126/science.270.5239.1215			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TE905	7502050				2022-12-28	WOS:A1995TE90500062
J	ZUREIK, M; DUCIMETIERE, P; WARNET, JM; ORSSAUD, G				ZUREIK, M; DUCIMETIERE, P; WARNET, JM; ORSSAUD, G			FATTY-ACID PROPORTIONS IN CHOLESTEROL ESTERS AND RISK OF PREMATURE DEATH FROM CANCER IN MIDDLE-AGED FRENCH MEN	BMJ-BRITISH MEDICAL JOURNAL			English	Article							CORONARY HEART-DISEASE; ESTERIFYING SERUM-CHOLESTEROL; LUNG-CANCER; DIETARY-CHOLESTEROL; ASSOCIATION; MORTALITY; CONSUMPTION; PREVENTION; LIPIDS; PLASMA	Objective-To assess the association of proportions of fatty acids in cholesterol esters with the risk of premature death ti om cancer in middle aged men. Design-Prospective cohort study. Setting-Paris, France. Subjects-3277 working men aged 36-52 in 1981-5. Main outcome measures-Cancer mortality during an average of 9.3 years of follow up. Results-59 men died of cancer during follow up. The age adjusted relative risks for men in the highest thirds of the distribution of the proportions of linoleic, palmitoleic, and oleic acid in cholesterol esters as compared with those in the corresponding lowest thirds were 0.16 (95% confidence interval 0.05 to 0.51), 3.39 (1.63 to 7.05), and 4.22 (1.95 to 9.12), respectively. Adjustment for and stratification by smoking, alcohol consumption, serum cholesterol concentration, and body mass index did not alter the results. At the time of examination subjects with cancer had a lower intake of polyunsaturated fats, assessed by 24 hour recall, than those without cancer (13.2 v 17.4 g/day, P< 0.01). Conclusions-Monounsaturated and polyunsaturated fatty acids of cholesterol esters are strong biological markers that predict premature death from cancer in French men. Consistently, intake of polyunsaturated fats did not seem to increase the risk of death from cancer. The association of biological markers of dietary fat intake with incidence of and mortality from cancer should be investigated prospectively in other populations.	CTR MEDICOSOCIAL, DIRECT ACT SOCIALE ENFANCE & SANTE LAB, F-75013 PARIS, FRANCE		ZUREIK, M (corresponding author), HOP BROUSSAIS, INSERM, U258, F-75014 PARIS, FRANCE.		Zureik, Mahmoud/F-7855-2018	Zureik, Mahmoud/0000-0002-8393-4217				AITCHISON J, 1986, MONOGRAPHS STATISTIC; AUSTOKER J, 1994, BRIT MED J, V308, P1610, DOI 10.1136/bmj.308.6944.1610; BLOCK G, 1982, AM J EPIDEMIOL, V115, P492, DOI 10.1093/oxfordjournals.aje.a113331; BYERS TE, 1987, AM J EPIDEMIOL, V125, P351, DOI 10.1093/oxfordjournals.aje.a114542; CAMBIEN F, 1988, AM J EPIDEMIOL, V127, P75, DOI 10.1093/oxfordjournals.aje.a114793; CAMBIEN F, 1980, AM J EPIDEMIOL, V112, P388, DOI 10.1093/oxfordjournals.aje.a113004; CAROLL KK, 1986, PROG CLIN BIOL RES, V206, P237; COX DR, 1972, J R STAT SOC B, V34, P187; CRIQUI MH, 1994, LANCET, V344, P1719, DOI 10.1016/S0140-6736(94)92883-5; DEBACKER G, 1989, ATHEROSCLEROSIS, V78, P237, DOI 10.1016/0021-9150(89)90229-3; Ducimetiere P., 1992, Nutrition Metabolism and Cardiovascular Diseases, V2, P195; ETIENNE G, 1963, ANN BIOL CLIN, V21, P851; FOLCH J, 1957, J BIOL CHEM, V226, P497; FREUDENHEIM JL, 1989, EPIDEMIOL REV, V11, P229, DOI 10.1093/oxfordjournals.epirev.a036039; GOODMAN MT, 1988, AM J EPIDEMIOL, V128, P1241, DOI 10.1093/oxfordjournals.aje.a115078; ISLES CG, 1989, BMJ-BRIT MED J, V298, P920, DOI 10.1136/bmj.298.6678.920; ISO H, 1994, J CLIN EPIDEMIOL, V47, P961, DOI 10.1016/0895-4356(94)90110-4; Karmali R A, 1986, Prog Clin Biol Res, V222, P687; KNEKT P, 1991, NUTR CANCER, V16, P267, DOI 10.1080/01635589109514165; KOLONEL LN, 1988, AM J EPIDEMIOL, V127, P999, DOI 10.1093/oxfordjournals.aje.a114903; KRITCHEVSKY SB, 1992, AM J EPIDEMIOL, V135, P509, DOI 10.1093/oxfordjournals.aje.a116318; LAW MR, 1991, CANCER CAUSE CONTROL, V2, P253, DOI 10.1007/BF00052142; LAW MR, 1994, BRIT MED J, V308, P373, DOI 10.1136/bmj.308.6925.373; MCGEE D, 1985, INT J EPIDEMIOL, V14, P97, DOI 10.1093/ije/14.1.97; MOILANEN T, 1985, AM J CLIN NUTR, V42, P708, DOI 10.1093/ajcn/42.4.708; NIKKARI T, 1983, AM J CLIN NUTR, V37, P848, DOI 10.1093/ajcn/37.5.848; PRENTICE RL, 1990, CANCER CAUSE CONTROL, V1, P81, DOI 10.1007/BF00053187; RENAUD S, 1979, TABLE COMPOSITION AL, P63; RICHARD JL, 1981, NOUV PRESSE MED, V10, P1111; ROSSENEU M, 1994, ATHEROSCLEROSIS, V108, P127, DOI 10.1016/0021-9150(94)90107-4; SANTOS MT, 1984, ATHEROSCLEROSIS, V50, P53, DOI 10.1016/0021-9150(84)90007-8; SARKKINEN ES, 1994, AM J CLIN NUTR, V59, P364, DOI 10.1093/ajcn/59.2.364; SCHUIT AJ, 1993, AM J EPIDEMIOL, V137, P966, DOI 10.1093/oxfordjournals.aje.a116769; SHEKELLE RB, 1981, LANCET, V2, P1185; SHEPHERD J, 1987, BRIT MED J, V295, P1245, DOI 10.1136/bmj.295.6608.1245; TUCKEY RC, 1979, ANAL BIOCHEM, V94, P402, DOI 10.1016/0003-2697(79)90381-6; TUYNS AJ, 1988, NUTR CANCER, V11, P189, DOI 10.1080/01635588809513986; ULBRICHT TLV, 1991, LANCET, V338, P985, DOI 10.1016/0140-6736(91)91846-M; URSIN G, 1993, AM J EPIDEMIOL, V137, P916, DOI 10.1093/oxfordjournals.aje.a116753; WARNET JM, 1985, BRIT MED J, V290, P1859, DOI 10.1136/bmj.290.6485.1859; WILLETT W, 1989, NATURE, V338, P389, DOI 10.1038/338389a0	41	28	29	0	1	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	NOV 11	1995	311	7015					1251	1254		10.1136/bmj.311.7015.1251	http://dx.doi.org/10.1136/bmj.311.7015.1251			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TE859	7496232	Green Published			2022-12-28	WOS:A1995TE85900017
J	HARRIS, J; HOLM, S				HARRIS, J; HOLM, S			IS THERE A MORAL OBLIGATION NOT TO INFECT OTHERS	BRITISH MEDICAL JOURNAL			English	Article							AIDS; ATTITUDES; WORKERS	The emergence of HIV infection and AIDS has refocused concern on the obligations surrounding the carrying and transmission of communicable diseases. This article asks three related questions: Is there a general duty not to spread contagion? Are there special obligations not to communicate disease in the workplace? And does the mode of transmission of the disease affect the ethics of transmission and, if so, how and to what extent? There seems to be a strong prima facie obligation not to harm others by making them ill where this is avoidable, and this obligation not to communicate disease applies as much to relatively trivial diseases like the common cold as it does to HIV disease. The reasonableness of expecting people to live up to this obligation, however, depends on society reciprocating the obligation in the form of providing protection and compensation.	UNIV COPENHAGEN,DEPT MED PHILOSOPHY & CLIN THEORY,DK-2200 COPENHAGEN,DENMARK	University of Copenhagen	HARRIS, J (corresponding author), UNIV MANCHESTER,CTR SOCIAL ETHICS & POLICY,MANCHESTER M13 9PL,LANCS,ENGLAND.			Holm, Soren/0000-0002-7200-5607				DIXON RE, 1985, AM J MED, V78, P45, DOI 10.1016/0002-9343(85)90363-8; Erin Charles A, 1993, J Appl Philos, V10, P165, DOI 10.1111/j.1468-5930.1993.tb00073.x; FRIEDLAND G, 1990, J AM ACAD DERMATOL, V22, P1171, DOI 10.1016/0190-9622(90)70160-J; HANDLER A, 1994, AIDS EDUC PREV, V6, P175; HARRIS J, 1993, HASTINGS CENT REP, V23, P6, DOI 10.2307/3562917; HARRIS J, 1985, VALUE LIFE, pCH9; KRASNIK A, 1990, SCAND J SOC MED, V18, P103, DOI 10.1177/140349489001800204; ORNATO JP, 1990, ANN EMERG MED, V19, P151, DOI 10.1016/S0196-0644(05)81800-1; SPRENGER MJ, 1993, INT J EPIDEMIOL, V22, P335	9	65	66	1	6	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	NOV 4	1995	311	7014					1215	1217		10.1136/bmj.311.7014.1215	http://dx.doi.org/10.1136/bmj.311.7014.1215			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	TD768	7488907	Green Published			2022-12-28	WOS:A1995TD76800031
J	OBRIEN, J; LONG, H				OBRIEN, J; LONG, H			URINARY-INCONTINENCE - LONG-TERM EFFECTIVENESS OF NURSING INTERVENTION IN PRIMARY-CARE	BRITISH MEDICAL JOURNAL			English	Article											OBRIEN, J (corresponding author), SOMERSET HLTH COMMISS,DEPT PUBL HLTH MED,TAUNTON TA1 7PQ,SOMERSET,ENGLAND.							HAHN I, 1993, BRIT J UROL, V72, P421, DOI 10.1111/j.1464-410X.1993.tb16170.x; LARGOJANSSEN TLM, 1992, FAM PRACT, V9, P284; MOURITSEN L, 1991, BRIT J UROL, V68, P32, DOI 10.1111/j.1464-410X.1991.tb15252.x; OBRIEN J, 1991, BRIT MED J, V303, P1308, DOI 10.1136/bmj.303.6813.1308; 1991, AGENDA ACTION CONTIN	5	20	20	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	NOV 4	1995	311	7014					1208	1208		10.1136/bmj.311.7014.1208	http://dx.doi.org/10.1136/bmj.311.7014.1208			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TD768	7488903	Green Published			2022-12-28	WOS:A1995TD76800027
J	LEAPE, LL				LEAPE, LL			ERROR IN MEDICINE	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							HOSPITALIZED-PATIENTS; ADVERSE EVENTS; MISTAKES; CARE; PREVENTION; FAILURES				LEAPE, LL (corresponding author), HARVARD UNIV, SCH PUBL HLTH, DEPT HLTH POLICY & MANAGEMENT, 677 HUNTINGTON AVE, BOSTON, MA 02115 USA.							ALLNUTT MF, 1987, BRIT J ANAESTH, V59, P856, DOI 10.1093/bja/59.7.856; ANDERSON RE, 1989, JAMA-J AM MED ASSOC, V261, P1610, DOI 10.1001/jama.261.11.1610; BATES DW, IN PRESS J GEN INTER; BEDELL SE, 1991, JAMA-J AM MED ASSOC, V265, P2815, DOI 10.1001/jama.265.21.2815; BERWICK DM, 1989, MILBANK Q, V67, P262, DOI 10.2307/3350141; BERWICK DM, 1989, NEW ENGL J MED, V320, P53, DOI 10.1056/NEJM198901053200110; BRENNAN TA, 1991, NEW ENGL J MED, V324, P370, DOI 10.1056/NEJM199102073240604; CAMERON HM, 1981, J PATHOL, V133, P273, DOI 10.1002/path.1711330402; CHRISTENSEN JF, 1992, J GEN INTERN MED, V7, P424, DOI 10.1007/BF02599161; CLASSEN DC, 1991, JAMA-J AM MED ASSOC, V266, P2847, DOI 10.1001/jama.266.20.2847; COOPER JB, 1984, ANESTHESIOLOGY, V60, P34, DOI 10.1097/00000542-198401000-00008; CULLEN DJ, 1992, ANESTH ANALG, V74, P181, DOI 10.1213/00000539-199202000-00002; Deming W. E, 1982, QUALITY PRODUCTIVITY; DUBOIS RW, 1988, ANN INTERN MED, V109, P582, DOI 10.7326/0003-4819-109-7-582; FOLLI HL, 1987, PEDIATRICS, V79, P718; GABA DM, 1989, INT ANESTHESIOL CLIN, V27, P137, DOI 10.1097/00004311-198902730-00002; GOLDMAN L, 1983, NEW ENGL J MED, V308, P1000, DOI 10.1056/NEJM198304283081704; GOPHER D, 1989, 33RD ANN M HUM FACT; HILFIKER D, 1984, NEW ENGL J MED, V310, P118, DOI 10.1056/NEJM198401123100211; Leape L L, 1993, QRB Qual Rev Bull, V19, P144; LEAPE LL, 1991, NEW ENGL J MED, V324, P377, DOI 10.1056/NEJM199102073240605; LESAR TS, 1990, JAMA-J AM MED ASSOC, V263, P2329, DOI 10.1001/jama.263.17.2329; MCINTYRE N, 1983, BRIT MED J, V287, P1919, DOI 10.1136/bmj.287.6409.1919; Nightingale F., 1863, NOTES ON HOSP, V3rd; NORMAN DA, 1984, ERR IS HUMAN; ORKIN FK, 1993, MONITORING ANESTHESI; PALMER RH, 1983, MED DECIS MAKING, V3, P299, DOI 10.1177/0272989X8300300306; RAJU TNK, 1989, LANCET, V2, P374; RASMUSSEN J, 1974, ERGONOMICS, V17, P293, DOI 10.1080/00140137408931355; RESON J, 1992, HUMAN ERROR; SCHIMMEL EM, 1964, ANN INTERN MED, V60, P100, DOI 10.7326/0003-4819-60-1-100; STEEL K, 1981, NEW ENGL J MED, V304, P638, DOI 10.1056/NEJM198103123041104; TVERSKY A, 1981, SCIENCE, V211, P453, DOI 10.1126/science.7455683; WU AW, 1991, JAMA-J AM MED ASSOC, V265, P2089, DOI 10.1001/jama.265.16.2089; Yerkes RM, 1908, J COMP NEUROL PSYCHO, V18, P459, DOI 10.1002/cne.920180503	36	1473	1510	1	46	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	DEC 21	1994	272	23					1851	1857		10.1001/jama.272.23.1851	http://dx.doi.org/10.1001/jama.272.23.1851			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PW980	7503827				2022-12-28	WOS:A1994PW98000034
J	LIU, MY; CHEN, TY; AHAMED, B; LI, J; YAU, KW				LIU, MY; CHEN, TY; AHAMED, B; LI, J; YAU, KW			CALCIUM-CALMODULIN MODULATION OF THE OLFACTORY CYCLIC NUCLEOTIDE-GATED CATION CHANNEL	SCIENCE			English	Article							OUTER RENAL MEDULLA; ION CHANNELS; FUNCTIONAL EXPRESSION; PHOTORECEPTOR CELLS; POTASSIUM CHANNEL; BINDING DOMAIN; PROTEIN; ACTIVATION; MEMBRANE; ROD	Although several ion channels have been reported to be directly modulated by calcium-calmodulin, they have not been conclusively shown to bind calmodulin, nor are the modulatory mechanisms understood. Study of the olfactory cyclic nucleotide-activated cation channel, which is modulated by calcium-calmodulin, indicates that calcium-calmodulin directly binds to a specific domain on the amino terminus of the channel. This binding reduces the effective affinity of the channel for cyclic nucleotides, apparently by acting on channel gating, which is tightly coupled to ligand binding. The data reveal a control mechanism that resembles those underlying the regulation of enzymes by calmodulin. The results also point to the amino-terminal part of the olfactory channel as an element for gating, which may have general significance in the operation of ion channels with similar overall structures.	JOHNS HOPKINS UNIV, SCH MED, DEPT NEUROSCI, BALTIMORE, MD 21205 USA; JOHNS HOPKINS UNIV, SCH MED, HOWARD HUGHES MED INST, BALTIMORE, MD 21205 USA; JOHNS HOPKINS UNIV, SCH MED, DEPT OPHTHALMOL, BALTIMORE, MD 21205 USA	Johns Hopkins University; Howard Hughes Medical Institute; Johns Hopkins University; Johns Hopkins University					NATIONAL EYE INSTITUTE [R37EY006837, R01EY006837] Funding Source: NIH RePORTER; NEI NIH HHS [EY 06837] Funding Source: Medline	NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		BERTRAND B, 1994, J BIOL CHEM, V269, P13703; BONIGK W, 1993, NEURON, V10, P865, DOI 10.1016/0896-6273(93)90202-3; BRADLEY J, 1994, P NATL ACAD SCI USA, V91, P8890, DOI 10.1073/pnas.91.19.8890; CHEN TY, 1994, NATURE, V368, P545, DOI 10.1038/368545a0; CHEN TY, 1994, P NATL ACAD SCI USA, V91, P11757, DOI 10.1073/pnas.91.24.11757; CHEN TY, 1993, NATURE, V362, P764, DOI 10.1038/362764a0; COLQUHOUN D, 1993, NATURE, V366, P510, DOI 10.1038/366510b0; DHALLAN RS, 1990, NATURE, V347, P184, DOI 10.1038/347184a0; EISENBERG D, 1984, P NATL ACAD SCI-BIOL, V81, P140, DOI 10.1073/pnas.81.1.140; EISENBERG D, 1984, J MOL BIOL, V179, P125, DOI 10.1016/0022-2836(84)90309-7; ENYEDI A, 1989, J BIOL CHEM, V264, P12313; FALCHETTO R, 1991, J BIOL CHEM, V266, P2930; GOULDING EH, 1993, NATURE, V364, P61, DOI 10.1038/364061a0; GOULDING EH, 1992, NEURON, V8, P45, DOI 10.1016/0896-6273(92)90107-O; GUY HR, 1991, SCIENCE, V254, P730, DOI 10.1126/science.1658932; HARDIE RC, 1992, NEURON, V8, P643, DOI 10.1016/0896-6273(92)90086-S; HAYNES LW, 1990, J PHYSIOL-LONDON, V429, P451, DOI 10.1113/jphysiol.1990.sp018267; HEGINBOTHAM L, 1992, SCIENCE, V258, P1152, DOI 10.1126/science.1279807; Hille B., 1992, IONIC CHANNELS EXCIT; HSU YT, 1993, NATURE, V361, P76, DOI 10.1038/361076a0; HU YF, 1994, BIOCHEM BIOPH RES CO, V201, P1050, DOI 10.1006/bbrc.1994.1808; IKURA M, 1992, SCIENCE, V256, P632, DOI 10.1126/science.1585175; JAN LY, 1990, NATURE, V345, P672, DOI 10.1038/345672a0; JARRETT HW, 1991, J BIOL CHEM, V266, P362; Kaczmarek LK, 1987, NEUROMODULATION BIOC; KAUPP UB, 1989, NATURE, V342, P762, DOI 10.1038/342762a0; KINCAID RL, 1982, J BIOL CHEM, V257, P638; KLAERKE DA, 1987, J MEMBRANE BIOL, V95, P105, DOI 10.1007/BF01869155; KLAERKE DA, 1987, FEBS LETT, V216, P211, DOI 10.1016/0014-5793(87)80691-9; KRAMER RH, 1992, NEURON, V9, P897, DOI 10.1016/0896-6273(92)90242-6; KRINKS MH, 1984, ADV CYCLIC NUCL PROT, V16, P31; KUBALSKI A, 1989, J MEMBRANE BIOL, V112, P91, DOI 10.1007/BF01871167; KURAHASHI T, 1990, BRAIN RES, V515, P261, DOI 10.1016/0006-8993(90)90605-B; LEVITAN IB, 1994, ANNU REV PHYSIOL, V56, P193, DOI 10.1146/annurev.ph.56.030194.001205; LI M, 1994, CURR BIOL, V4, P110, DOI 10.1016/S0960-9822(94)00026-6; LIMAN ER, 1994, NEURON, V13, P611, DOI 10.1016/0896-6273(94)90029-9; LUDWIG J, 1990, FEBS LETT, V270, P24, DOI 10.1016/0014-5793(90)81226-E; MACKINNON R, 1991, NATURE, V350, P232, DOI 10.1038/350232a0; MATTHEWS G, 1988, J PHYSIOL-LONDON, V403, P389, DOI 10.1113/jphysiol.1988.sp017255; MEADOR WE, 1993, SCIENCE, V262, P1718, DOI 10.1126/science.8259515; MEANS AR, 1988, RECENT PROG HORM RES, V44, P223; MUNIER H, 1991, FEBS LETT, V190, P409; ONEIL KT, 1990, TRENDS BIOCHEM SCI, V15, P59, DOI 10.1016/0968-0004(90)90177-D; PHILLIPS AM, 1992, NEURON, V8, P631, DOI 10.1016/0896-6273(92)90085-R; REED R, COMMUNICATION; SAIMI Y, 1990, SCIENCE, V249, P1441, DOI 10.1126/science.2169650; SAIMI Y, 1993, HDB MEMBRANE CHANNEL, P435; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; SMITH JS, 1989, CIRC RES, V64, P352, DOI 10.1161/01.RES.64.2.352; SODERLING TR, 1990, J BIOL CHEM, V265, P1823; STRYER L, 1987, CHEM SCRIPTA, V27B, P161; VANBERKUM MFA, 1990, J BIOL CHEM, V265, P3750; WAKABAYASHI S, 1994, J BIOL CHEM, V269, P13710	53	232	237	0	17	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	NOV 25	1994	266	5189					1348	1354		10.1126/science.266.5189.1348	http://dx.doi.org/10.1126/science.266.5189.1348			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PT632	7526466				2022-12-28	WOS:A1994PT63200034
J	BURCH, HB; SOLOMON, BL; WARTOFSKY, L; BURMAN, KD				BURCH, HB; SOLOMON, BL; WARTOFSKY, L; BURMAN, KD			DISCONTINUING ANTITHYROID DRUG-THERAPY BEFORE ABLATION WITH RADIOIODINE IN GRAVES-DISEASE	ANNALS OF INTERNAL MEDICINE			English	Article						GRAVES DISEASE; IODINE RADIOISOTOPES; HYPERTHYROIDISM; THYROID ANTAGONISTS; THYROID CRISIS	THYROID STORM; HYPERTHYROIDISM	Objective: To determine the relative effects on thyroid hormone levels of discontinuing antithyroid drug therapy and subsequent ablation with radioiodine in patients with hyperthyroid Graves disease. Design: A clinical trial with a prospective analysis of the relative change in thyroid hormone levels over time in response to therapy in two study groups. Setting: An outpatient endocrine clinic at a tertiary care hospital. Patients: 21 patients with a clinical diagnosis of hyperthyroid Graves disease scheduled to receive ablation therapy with radioiodine (I-131): 17 patients were pretreated with antithyroid drugs, and 4 were not. Methods: Antithyroid drugs were stopped 6 days before radioiodine therapy. Patients were monitored clinically and biochemically with measurement of free and total levels of thyroxine (T-4) and triiodothyronine (T-3) on days -6, -3, -1;the day of radioiodine therapy; and days 1, 2, 3, 4, 5, 7, and 14. Results: Before radioiodine treatment and compared with baseline measurement, the mean increase in free T-4 levels after discontinuation of antithyroid therapy was 86% (95% CI, 16.1% to 156%), with a concurrent mean increase in free T-3 levels of 71.6% (CI, 31% to 112%). Radioiodine therapy resulted in a mean decrease in free T-3 levels of 28.7% (CI, -44.1% to -13.2%), a mean decrease in total T-3 levels of 22.9% (CI, -39.4% to -6.4%), and stability in free and total T-4 levels rather than aggravation of thyrotoxicosis. A smaller group of patients not receiving antithyroid drugs experienced a course qualitatively similar to that of pretreated patients after I-131 treatment, with a mean reduction in free T-4 levels of 39.8% (CI, -69.9% to -9.7%) and a mean decrease in free T-3 levels of 49.4% (CI, -93.7% to -5.1%). Conclusion: Short-term increases in thyroid hormone levels in patients with Graves disease receiving radioiodine ablation occur primarily as a result of discontinuing antithyroid therapy rather than as a result of treatment with I-131. Stability or decrease in thyroid hormone levels, rather than further elevation, occurs during the 2-week interval after ablation therapy with I-131. Antithyroid drug therapy before radioiodine ablation may have little effect on the short-term biochemical course after I-131 therapy for Graves disease. The homogeneity of our sample regarding age, diagnosis, and general health may prevent application of these findings to other populations without further study.	WASHINGTON HOSP CTR, DEPT MED, WASHINGTON, DC 20010 USA	MedStar Washington Hospital Center	BURCH, HB (corresponding author), WALTER REED ARMY MED CTR, ENDOCRINE METAB SERV, WASHINGTON, DC 20307 USA.							BECKER D V, 1971, Seminars in Nuclear Medicine, V1, P442; BROOKS MH, 1980, ANN INTERN MED, V93, P694, DOI 10.7326/0003-4819-93-5-694; BURCH HB, 1993, ENDOCRIN METAB CLIN, V22, P263, DOI 10.1016/S0889-8529(18)30165-8; BURCH HB, 1994, CURRENT THERAPY ENDO, P64; COLEBUNDERS R, 1984, J ENDOCRINOL INVEST, V7, P379, DOI 10.1007/BF03351020; CREUTZIG H, 1976, LANCET, V2, P145; CROOKS J, 1960, BRIT MED J, V1, P151, DOI 10.1136/bmj.1.5167.151; EDSMYR F, 1966, ACTA RADIOL THER PHY, V4, P49, DOI 10.3109/02841866609133131; JACOBS HS, 1973, LANCET, V2, P236; LIVOLSI VA, 1990, SURGICAL PATHOLOGY T, V43, P107; MAHONEY KM, 1992, J INTENSIVE CARE MED, V7, P318; MALOOF F, 1951, J CLIN ENDOCRINOL, V11, P1296, DOI 10.1210/jcem-11-11-1296; MCDERMOTT MT, 1983, AM J MED, V75, P353, DOI 10.1016/0002-9343(83)91217-2; PARSONS V, 1967, POSTGRAD MED J, V43, P756, DOI 10.1136/pgmj.43.506.756; REYNOLDS LR, 1979, ARCH INTERN MED, V139, P651, DOI 10.1001/archinte.139.6.651; SHAFER RB, 1975, LANCET, V2, P635; SOLEY MH, 1948, MED CLIN N AM, P3; SOLOMON B, 1990, J CLIN ENDOCR METAB, V70, P1518, DOI 10.1210/jcem-70-6-1518; TAMAGNA EI, 1979, J NUCL MED, V20, P387; WARTOFSKY L, 1982, ENDOCR REV, V3, P164, DOI 10.1210/edrv-3-2-164; WERNER SIDNEY C., 1957, BULL NEW YORK ACAD MED, V33, P783; WISE PH, 1975, LANCET, V2, P1231	22	47	49	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	OCT 15	1994	121	8					553	+		10.7326/0003-4819-121-8-199410150-00001	http://dx.doi.org/10.7326/0003-4819-121-8-199410150-00001			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PL486	7521992				2022-12-28	WOS:A1994PL48600001
J	NAKAGAWA, H; ETOH, T; ISHIBASHI, Y; HIGAKI, Y; KAWASHIMA, M; TORII, H; HARADA, S				NAKAGAWA, H; ETOH, T; ISHIBASHI, Y; HIGAKI, Y; KAWASHIMA, M; TORII, H; HARADA, S			TACROLIMUS OINTMENT FOR ATOPIC-DERMATITIS	LANCET			English	Letter							PSORIASIS		TOKYO WOMENS MED COLL,DEPT DERMATOL,TOKYO 162,JAPAN; KANTO TEISHIN HOSP,DIV DERMATOL,TOKYO,JAPAN	Tokyo Women's Medical University; Kanto Medical Center NTT EC	NAKAGAWA, H (corresponding author), UNIV TOKYO,FAC MED,DEPT DERMATOL,TOKYO 113,JAPAN.			Torii, Hideshi/0000-0003-2123-3033				ABUELMAGD K, 1991, TRANSPLANT P, V23, P3322; LAUERMA AI, 1992, LANCET, V340, P556, DOI 10.1016/0140-6736(92)91757-Y; MIZOGUCHI M, 1992, LANCET, V339, P1120, DOI 10.1016/0140-6736(92)90719-J; MORI A, 1994, INT ARCH ALLERGY IMM, V104, P32, DOI 10.1159/000236745; MROWIETZ U, 1992, ACTA DERM-VENEREOL, V72, P321	5	173	179	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	SEP 24	1994	344	8926					883	883		10.1016/S0140-6736(94)92855-X	http://dx.doi.org/10.1016/S0140-6736(94)92855-X			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PH253	7522297				2022-12-28	WOS:A1994PH25300038
J	BEZRUKOV, SM; VODYANOY, I; PARSEGIAN, VA				BEZRUKOV, SM; VODYANOY, I; PARSEGIAN, VA			COUNTING POLYMERS MOVING THROUGH A SINGLE-ION CHANNEL	NATURE			English	Article							PROBING ALAMETHICIN CHANNELS; WATER-SOLUBLE POLYMERS; MEMBRANES; MODEL	THE change in conductance of a small electrolyte-filled capillary owing to the passage of sub-micrometre-sized particles has long been used for particle counting and sizing. A commercial device for such measurements, the Coulter counter, is able to detect particles of sizes down to several tenths of a micrometre(1-3). Nuclepore technology (in which pores are etched particle tracks) has extended the lower limit of size detection to 60-nm particles by using a capillary of diameter 0.45 mu m (ref. 4). Here we show that natural channel-forming peptides incorporated into a bilayer lipid membrane can be used to detect the passage of single molecules with gyration radii as small as 5-15 Angstrom. From our experiments with alamethicin pores we infer both the average number and the diffusion coefficients of poly(ethylene glycol) molecules in the pore. Our approach provides a means of observing the statistics and mechanics of flexible polymers moving within the confines of precisely defined single-molecule structures.	NIH,DCRT,STRUCT BIOL LAB,BETHESDA,MD 20892; RUSSIAN ACAD SCI,INST NUCL PHYS,ST PETERSBURG 188350,RUSSIA; OFF NAVAL RES,ARLINGTON,VA 22217	National Institutes of Health (NIH) - USA; National Research Centre - Kurchatov Institute; Institute of High Energy Physics - IHEP; Russian Academy of Sciences; United States Department of Defense; United States Navy	BEZRUKOV, SM (corresponding author), NIDDK,DIV INTRAMURAL RES,BETHESDA,MD 20892, USA.							ALLEN T, 1967, PARTICLE SIZE ANAL, P110; BALASUBRAMANIAN TM, 1981, J AM CHEM SOC, V103, P6127, DOI 10.1021/ja00410a024; BEAN CP, 1972, MEMBRANES, P1; BEZRUKOV SM, 1993, BIOPHYS J, V64, P16, DOI 10.1016/S0006-3495(93)81336-5; BEZRUKOV SM, IN PRESS ADV CHEM SE, V235; BUNVILLE LG, 1984, MODERN METHODS PARTI, P1; COUPER A, 1969, T FARADAY SOC, V65, P2486, DOI 10.1039/tf9696502486; DEBLOIS RW, 1977, J COLLOID INTERF SCI, V61, P323, DOI 10.1016/0021-9797(77)90395-2; FEHER G, 1973, P NATL ACAD SCI USA, V70, P870, DOI 10.1073/pnas.70.3.870; GORDON LGM, 1975, PHILOS T ROY SOC B, V270, P433, DOI 10.1098/rstb.1975.0021; HALL JE, 1984, BIOPHYS J, V45, P233, DOI 10.1016/S0006-3495(84)84151-X; HEINEMANN SH, 1989, BIOCHIM BIOPHYS ACTA, V987, P8, DOI 10.1016/0005-2736(89)90448-3; HESS P, 1984, NATURE, V309, P453, DOI 10.1038/309453a0; KRASILNIKOV OV, 1992, FEMS MICROBIOL IMMUN, V105, P93; KUBITSCHEK HE, 1958, NATURE, V182, P234, DOI 10.1038/182234a0; KUGA S, 1981, J CHROMATOGR, V206, P449, DOI 10.1016/S0021-9673(00)88914-1; MONTAL M, 1972, P NATL ACAD SCI USA, V69, P3561, DOI 10.1073/pnas.69.12.3561; SANSOM MSP, 1993, EUR BIOPHYS J BIOPHY, V22, P105, DOI 10.1007/BF00196915; SIMON SM, 1991, CELL, V65, P371, DOI 10.1016/0092-8674(91)90455-8; VODYANOY I, 1993, BIOPHYS J, V65, P2097, DOI 10.1016/S0006-3495(93)81245-1	20	336	389	1	71	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JUL 28	1994	370	6487					279	281		10.1038/370279a0	http://dx.doi.org/10.1038/370279a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	NZ229	7518571				2022-12-28	WOS:A1994NZ22900058
J	POLLOCK, SG				POLLOCK, SG			PRESSURE TRACINGS IN OBSTRUCTIVE CARDIOMYOPATHY	NEW ENGLAND JOURNAL OF MEDICINE			English	Note											POLLOCK, SG (corresponding author), HARRISONBURG MED ASSOCIATES,HARRISONBURG,VA 22801, USA.								0	8	8	0	2	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JUL 28	1994	331	4					238	238						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NY335	7517014				2022-12-28	WOS:A1994NY33500005
J	NILSEN, TW				NILSEN, TW			RNA-RNA INTERACTIONS IN THE SPLICEOSOME - UNRAVELING THE TIES THAT BIND	CELL			English	Review							SMALL NUCLEAR RNAS; MESSENGER-RNA; U6 SNRNA; ACTIVE-SITE; U1 SNRNA; YEAST; U2; MUTATIONS; SPECIFICITY; MECHANISM				NILSEN, TW (corresponding author), CASE WESTERN RESERVE UNIV,SCH MED,DEPT MOLEC BIOL & MICROBIOL,CLEVELAND,OH 44106, USA.							CHECH TR, 1993, RNA WORLD, P239; CORTES JJ, 1993, EMBO J, V12, P5191; DATTA B, 1991, NATURE, V352, P821, DOI 10.1038/352821a0; DOWNS WD, 1994, GENE DEV, V8, P1198, DOI 10.1101/gad.8.10.1198; GUTHRIE C, 1991, SCIENCE, V253, P157, DOI 10.1126/science.1853200; KANDELSLEWIS S, 1993, SCIENCE, V262, P2035, DOI 10.1126/science.8266100; LESSER CF, 1993, SCIENCE, V262, P1982, DOI 10.1126/science.8266093; MADHANI H, 1994, IN PRESS ANN REV GEN; MADHANI HD, 1994, GENE DEV, V8, P1071, DOI 10.1101/gad.8.9.1071; MADHANI HD, 1992, CELL, V71, P803, DOI 10.1016/0092-8674(92)90556-R; MCPHEETERS DS, 1992, CELL, V71, P819, DOI 10.1016/0092-8674(92)90557-S; Moore M., 1993, RNA WORLD, P303; MOORE MJ, 1993, NATURE, V365, P364, DOI 10.1038/365364a0; NEWMAN A, 1991, CELL, V65, P115, DOI 10.1016/0092-8674(91)90413-S; Pan  T., 1993, RNA WORLD, P271; PARKER R, 1993, NATURE, V361, P660, DOI 10.1038/361660a0; QUERY CC, 1994, GENE DEV, V8, P587, DOI 10.1101/gad.8.5.587; REICH CI, 1992, CELL, V69, P1159, DOI 10.1016/0092-8674(92)90637-R; SCHWER B, 1992, EMBO J, V11, P5033, DOI 10.1002/j.1460-2075.1992.tb05610.x; SERAPHIN B, 1993, CELL, V73, P803, DOI 10.1016/0092-8674(93)90258-R; SONTHEIMER EJ, 1993, SCIENCE, V262, P1989, DOI 10.1126/science.8266094; STEITZ TA, 1993, P NATL ACAD SCI USA, V90, P6498, DOI 10.1073/pnas.90.14.6498; STETIZ JA, 1992, SCIENCE, V257, P888; WASSARMAN DA, 1992, SCIENCE, V257, P1918, DOI 10.1126/science.1411506; WEINER AM, 1993, CELL, V72, P161, DOI 10.1016/0092-8674(93)90654-9; WISE JA, 1993, SCIENCE, V262, P1978, DOI 10.1126/science.8266091; WU J, 1991, NATURE, V352, P818, DOI 10.1038/352818a0; WYATT JR, 1992, GENE DEV, V6, P2542, DOI 10.1101/gad.6.12b.2542; YARUS M, 1993, FASEB J, V7, P31, DOI 10.1096/fasebj.7.1.8422972; YEAN SL, 1991, MOL CELL BIOL, V11, P5571, DOI 10.1128/MCB.11.11.5571; YU YT, 1993, CELL, V75, P1049, DOI 10.1016/0092-8674(93)90315-H	31	180	181	0	8	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	JUL 15	1994	78	1					1	4		10.1016/0092-8674(94)90563-0	http://dx.doi.org/10.1016/0092-8674(94)90563-0			4	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	NX328	7518355				2022-12-28	WOS:A1994NX32800001
J	GHADIRI, MR; GRANJA, JR; BUEHLER, LK				GHADIRI, MR; GRANJA, JR; BUEHLER, LK			ARTIFICIAL TRANSMEMBRANE ION CHANNELS FROM SELF-ASSEMBLING PEPTIDE NANOTUBES	NATURE			English	Article							SYNTHETIC PROTEINS; MEMBRANES; TRANSPORT; VESICLES; DESIGN; GRAMICIDIN; LIPOSOMES; BILAYERS; MODEL	NATURALLY occurring membrane channels and pores are formed from a large family of diverse proteins, peptides and organic secondary metabolites whose vital biological functions include control of ion flow, signal transduction, molecular transport and production of cellular toxins. But despite the availability of a large amount of biochemical information about these molecules(1), the design and synthesis of artificial systems that can mimic the biological function of natural compounds remains a formidable task(2-12). Here we present a simple strategy for the design of artificial membrane ion channels based on a self-assembled cylindrical beta-sheet peptide architecture(13). Our systems-essentially stacks of peptide rings-display good channel-mediated ion-transport activity with rates exceeding 10(7) ions s(-1), rivalling the performance of many naturally occurring counterparts. Such molecular assemblies should find use in the design of novel cytotoxic agents, membrane transport vehicles and drug-delivery systems.	SCRIPPS RES INST, DEPT MOLEC BIOL & CELL BIOL, LA JOLLA, CA 92307 USA	Scripps Research Institute	GHADIRI, MR (corresponding author), SCRIPPS RES INST, DEPT CHEM, LA JOLLA, CA 92307 USA.		Granja, Juan R/P-7646-2014	Granja, Juan R/0000-0002-5842-7504				AKERFELDT KS, 1993, ACCOUNTS CHEM RES, V26, P191, DOI 10.1021/ar00028a009; ALLEN LC, 1975, P NATL ACAD SCI USA, V72, P4701, DOI 10.1073/pnas.72.12.4701; ANZAI K, 1991, BIOCHIM BIOPHYS ACTA, V1064, P256, DOI 10.1016/0005-2736(91)90310-5; BAMBERG E, 1974, BIOCHIM BIOPHYS ACTA, V367, P127, DOI 10.1016/0005-2736(74)90037-6; CARMICHAEL VE, 1989, J AM CHEM SOC, V111, P767, DOI 10.1021/ja00184a075; CLEMENT NR, 1981, BIOCHEMISTRY-US, V20, P1544, DOI 10.1021/bi00509a021; CLEMENT NR, 1981, BIOCHEMISTRY-US, V20, P1539, DOI 10.1021/bi00509a020; ENGELMAN DM, 1986, ANNU REV BIOPHYS BIO, V15, P321, DOI 10.1146/annurev.bb.15.060186.001541; ENGELMAN DM, 1981, CELL, V23, P411, DOI 10.1016/0092-8674(81)90136-7; FUHRHOP JH, 1988, J AM CHEM SOC, V110, P6840, DOI 10.1021/ja00228a037; FYLES TM, 1993, J AM CHEM SOC, V115, P12315, DOI 10.1021/ja00079a011; GHADIRI MR, 1993, NATURE, V366, P324, DOI 10.1038/366324a0; GROVE A, 1993, J AM CHEM SOC, V115, P5919, DOI 10.1021/ja00067a004; Hille B., 1992, IONIC CHANNELS EXCIT; JAYASURIYA N, 1990, J AM CHEM SOC, V112, P5844, DOI 10.1021/ja00171a026; KHAZANOVICH N, IN PRESS J AM CHEM S; LAUGER P, 1985, ANGEW CHEM INT EDIT, V24, P905, DOI 10.1002/anie.198509051; LAUGER P, 1985, ANGEW CHEM, V97, P939; MONTAL M, 1990, FASEB J, V4, P2623, DOI 10.1096/fasebj.4.9.1693348; MONTAL M, 1990, P NATL ACAD SCI USA, V87, P6929, DOI 10.1073/pnas.87.18.6929; NABEDRYK E, 1982, BIOPHYS J, V38, P243, DOI 10.1016/S0006-3495(82)84555-4; NAKANO A, 1990, J AM CHEM SOC, V112, P1287, DOI 10.1021/ja00159a083; New RR, 1990, LIPOSOMES; OLSON F, 1979, BIOCHIM BIOPHYS ACTA, V557, P9, DOI 10.1016/0005-2736(79)90085-3; Pregel M. J., 1992, ANGEW CHEM, V104, P1695; PREGEL MJ, 1992, ANGEW CHEM INT EDIT, V31, P1637, DOI 10.1002/anie.199216371; ROKS MFM, 1992, MACROMOLECULES, V25, P5398, DOI 10.1021/ma00046a042; ROVERO P, 1991, TETRAHEDRON LETT, V32, P2639, DOI 10.1016/S0040-4039(00)78806-X; SPENCER DM, 1993, SCIENCE, V262, P1019, DOI 10.1126/science.7694365; SUAREZISLA BA, 1983, BIOCHEMISTRY-US, V22, P2319, DOI 10.1021/bi00279a003; SZOKA F, 1978, P NATL ACAD SCI USA, V75, P4194, DOI 10.1073/pnas.75.9.4194; WEINSTEIN JN, 1977, SCIENCE, V195, P489, DOI 10.1126/science.835007	32	809	843	9	263	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	MAY 26	1994	369	6478					301	304		10.1038/369301a0	http://dx.doi.org/10.1038/369301a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	NN109	7514275				2022-12-28	WOS:A1994NN10900043
J	HUANG, AYC; GOLUMBEK, P; AHMADZADEH, M; JAFFEE, E; PARDOLL, D; LEVITSKY, H				HUANG, AYC; GOLUMBEK, P; AHMADZADEH, M; JAFFEE, E; PARDOLL, D; LEVITSKY, H			ROLE OF BONE-MARROW-DERIVED CELLS IN PRESENTING MHC CLASS I-RESTRICTED TUMOR-ANTIGENS	SCIENCE			English	Article							COLONY-STIMULATING FACTOR; CYTOLYTIC LYMPHOCYTE-T; MINOR H-ANTIGENS; INFILTRATING LYMPHOCYTES; PERIPHERAL LYMPH; DENDRITIC CELLS; HUMAN-MELANOMA; CROSS-REACT; RECOGNITION; EXPRESSION	Many tumors express tumor-specific antigens capable of being presented to CD8(+) T cells by major histocompatibility complex (MHC) class I molecules. Antigen presentation models predict that the tumor cell itself should present these antigens to T cells. However, when conditions for the priming of tumor-specific responses were examined in mice, no detectable presentation of MHC class I-restricted tumor antigens by the tumor itself was found. Rather, tumor antigens were exclusively presented by host bone marrow-derived cells. Thus, MHC class I-restricted antigens are efficiently transferred in vivo to bone marrow-derived antigen-presenting cells, which suggests that human leukocyte antigen matching may be less critical in the application of tumor vaccines than previously thought.	JOHNS HOPKINS UNIV, SCH MED, DEPT ONCOL, BALTIMORE, MD 21205 USA	Johns Hopkins University			Huang, Alex/R-4662-2017	Huang, Alex/0000-0002-5701-4521; Jaffee, Elizabeth/0000-0003-3841-6549				Balfour B M, 1981, Ciba Found Symp, V84, P281; BEVAN MJ, 1987, NATURE, V325, P192, DOI 10.1038/325192b0; BEVAN MJ, 1977, NATURE, V269, P417, DOI 10.1038/269417a0; BEVAN MJ, 1976, J IMMUNOL, V117, P2233; BEVAN MJ, 1976, J EXP MED, V143, P1283, DOI 10.1084/jem.143.5.1283; BLUM JS, 1988, P NATL ACAD SCI USA, V85, P3975, DOI 10.1073/pnas.85.11.3975; BRACIALE TJ, 1978, J EXP MED, V147, P1236, DOI 10.1084/jem.147.4.1236; BROWN MG, 1991, NATURE, V353, P355, DOI 10.1038/353355a0; CAUX C, 1992, NATURE, V360, P258, DOI 10.1038/360258a0; COLOMBO MP, 1992, CANCER RES, V52, P4853; DARROW TL, 1989, J IMMUNOL, V142, P3329; DRANOFF G, 1993, P NATL ACAD SCI USA, V90, P3539, DOI 10.1073/pnas.90.8.3539; DREXHAGE HA, 1979, CELL TISSUE RES, V202, P407, DOI 10.1007/BF00220434; DREXHAGE HA, 1980, FUNCTIONAL ASPECTS D, P235; DURST M, 1983, P NATL ACAD SCI-BIOL, V80, P3812, DOI 10.1073/pnas.80.12.3812; ERTL H, 1981, IMMUNOBIOLOGY, V158, P239, DOI 10.1016/S0171-2985(81)80073-3; FEARON ER, 1990, CELL, V60, P397, DOI 10.1016/0092-8674(90)90591-2; FETTEN JV, 1991, J IMMUNOL, V147, P2697; GANSBACHER B, 1990, J EXP MED, V172, P1217, DOI 10.1084/jem.172.4.1217; GERMAIN RN, 1986, NATURE, V322, P687, DOI 10.1038/322687a0; GERMAIN RN, 1991, NATURE, V353, P134, DOI 10.1038/353134a0; GLYNNE R, 1991, NATURE, V353, P357, DOI 10.1038/353357a0; GOLUMBEK PT, 1991, SCIENCE, V254, P713, DOI 10.1126/science.1948050; GRAF LH, 1984, SOMAT CELL MOLEC GEN, V10, P139, DOI 10.1007/BF01534903; GREENBERG PD, 1991, ADV IMMUNOL, V49, P281; HOCK H, 1991, J EXP MED, V174, P1291, DOI 10.1084/jem.174.6.1291; HOM SS, 1991, J IMMUNOTHER, V10, P153; HUANG AYC, UNPUB; HUI K, 1984, NATURE, V311, P750, DOI 10.1038/311750a0; INABA K, 1992, J EXP MED, V176, P1693, DOI 10.1084/jem.176.6.1693; INABA K, 1992, J EXP MED, V175, P1157, DOI 10.1084/jem.175.5.1157; JUNG S, 1991, J EXP MED, V173, P273, DOI 10.1084/jem.173.1.273; KAWAKAMI Y, 1992, J IMMUNOL, V148, P638; KNIGHT SC, 1984, IMMUNOBIOLOGY, V168, P349, DOI 10.1016/S0171-2985(84)80122-9; KOSZINOWSKI UH, 1980, J EXP MED, V151, P945, DOI 10.1084/jem.151.4.945; LEVITSKY HI, 1994, J EXP MED, V179, P1215, DOI 10.1084/jem.179.4.1215; LO D, 1986, NATURE, V319, P672, DOI 10.1038/319672a0; MCCOY KL, 1989, J IMMUNOL, V143, P29; MORRISON LA, 1986, J EXP MED, V163, P903, DOI 10.1084/jem.163.4.903; NABEL GJ, 1993, P NATL ACAD SCI USA, V90, P11307, DOI 10.1073/pnas.90.23.11307; NEEFJES JJ, 1990, CELL, V61, P171, DOI 10.1016/0092-8674(90)90224-3; PARDOLL DM, 1993, TRENDS PHARMACOL SCI, V14, P202, DOI 10.1016/0165-6147(93)90209-3; PEACE DJ, 1991, J IMMUNOL, V146, P2059; PLAUTZ GE, 1993, P NATL ACAD SCI USA, V90, P4645, DOI 10.1073/pnas.90.10.4645; REID CDL, 1992, J IMMUNOL, V149, P2681; RESTIFO NP, 1992, J EXP MED, V175, P1423, DOI 10.1084/jem.175.6.1423; ROCK KL, 1993, J IMMUNOL, V150, P438; ROSENBERG SA, 1991, CANCER RES, V51, pS5074; ROTZSCHKE O, 1990, NATURE, V348, P252, DOI 10.1038/348252a0; SEUNG S, 1993, J EXP MED, V178, P933, DOI 10.1084/jem.178.3.933; Srivastava P K, 1991, Semin Immunol, V3, P57; TANAKA K, 1985, SCIENCE, V228, P26, DOI 10.1126/science.3975631; TANAKA K, 1986, P NATL ACAD SCI USA, V83, P8723, DOI 10.1073/pnas.83.22.8723; VANDERBRUGGEN P, 1991, SCIENCE, V254, P1643, DOI 10.1126/science.1840703; WALLICH R, 1985, NATURE, V315, P301, DOI 10.1038/315301a0; YEWDELL JW, 1990, CELL, V62, P203, DOI 10.1016/0092-8674(90)90356-J; YOUNG L, 1989, NEW ENGL J MED, V321, P1080, DOI 10.1056/NEJM198910193211604; YOUNG LS, 1988, J GEN VIROL, V69, P1051, DOI 10.1099/0022-1317-69-5-1051; ZINKERNAGEL R, 1993, UCLA S ANTIVIRAL ANT, V18, P4; ZINKERNAGEL RM, 1978, J EXP MED, V147, P882, DOI 10.1084/jem.147.3.882	60	1055	1142	0	30	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAY 13	1994	264	5161					961	965		10.1126/science.7513904	http://dx.doi.org/10.1126/science.7513904			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	NK974	7513904				2022-12-28	WOS:A1994NK97400034
J	TAYLOR, SJ; SHALLOWAY, D				TAYLOR, SJ; SHALLOWAY, D			AN RNA-BINDING PROTEIN ASSOCIATED WITH SRC THROUGH ITS SH2 AND SH3 DOMAINS IN MITOSIS	NATURE			English	Article							MOLECULAR-CLONING; ACTIVATION; P60C-SRC; PHOSPHORYLATION; PP60C-SRC	THE tyrosine kinase activity of c-Src is stimulated during mitosis by dephosphorylation of its regulatory tyrosine residue(1-3). This is associated with increased accessibility of its Src homology-2 (SH2) domain for binding a phosphotyrosine-containing peptide(4). But physiological targets of activated c-Src in mitosis have not yet been identified. Here we report that a 68K protein (p68) becomes tyrosine-phosphorylated and physically associates with Src during mitosis in mouse fibroblasts. p68 independently binds the Src SH2 and SH3 domains in vitro and both domains are required for p68 phosphorylation and binding in vivo. p68 is closely related to the p62 protein that is associated with the Ras GTPase-activating protein (GAP)(5) and selectively binds, directly or indirectly, polyribonucleotides. Because the Src SH3 domain also binds heterogeneous nuclear ribonucleoprotein K, these results raise the intriguing possibility that c-Src may regulate the processing, trafficking or translation of RNA in a cell-cycle-dependent manner.			TAYLOR, SJ (corresponding author), CORNELL UNIV,BIOCHEM MOLEC & CELL BIOL SECT,ITHACA,NY 14853, USA.							ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; ASHLEY CT, 1993, SCIENCE, V262, P563, DOI 10.1126/science.7692601; BAGRODIA S, 1993, MOL CELL BIOL, V13, P1464, DOI 10.1128/MCB.13.3.1464; BAGRODIA S, 1991, NATURE, V349, P172, DOI 10.1038/349172a0; BAGRODIA S, 1994, J BIOL CHEM, V269, P10247; BIBBINS KB, 1993, MOL CELL BIOL, V13, P7278, DOI 10.1128/MCB.13.12.7278; ENGEBRECHT J, 1991, CELL, V66, P1257, DOI 10.1016/0092-8674(91)90047-3; FLYNN DC, 1993, MOL CELL BIOL, V13, P7892, DOI 10.1128/MCB.13.12.7892; GIBSON TJ, 1993, FEBS LETT, V324, P361, DOI 10.1016/0014-5793(93)80152-K; GOUT I, 1993, CELL, V75, P25, DOI 10.1016/0092-8674(93)90676-H; JOHNSON PJ, 1985, MOL CELL BIOL, V5, P1073, DOI 10.1128/MCB.5.5.1073; KAECH S, 1991, NATURE, V350, P431, DOI 10.1038/350431a0; KMIECIK TE, 1987, CELL, V49, P65, DOI 10.1016/0092-8674(87)90756-2; LIU XQ, 1993, MOL CELL BIOL, V13, P5225, DOI 10.1128/MCB.13.9.5225; MATUNIS MJ, 1992, MOL CELL BIOL, V12, P164, DOI 10.1128/MCB.12.1.164; OBAR RA, 1990, NATURE, V347, P256, DOI 10.1038/347256a0; OBRIEN MC, 1990, MOL CELL BIOL, V10, P2855, DOI 10.1128/MCB.10.6.2855; PINOLROMA S, 1991, SCIENCE, V253, P312, DOI 10.1126/science.1857966; SEIDELDUGAN C, 1992, MOL CELL BIOL, V12, P1835, DOI 10.1128/MCB.12.4.1835; SIOMI H, 1993, CELL, V74, P291, DOI 10.1016/0092-8674(93)90420-U; SIOMI H, 1993, NUCLEIC ACIDS RES, V21, P1193, DOI 10.1093/nar/21.5.1193; TAYLOR SJ, 1993, CURR OPIN GENET DEV, V3, P26, DOI 10.1016/S0959-437X(05)80337-5; VANDERBLIEK AM, 1991, NATURE, V351, P411, DOI 10.1038/351411a0; VANDERBLIEK AM, 1993, J CELL BIOL, V122, P553, DOI 10.1083/jcb.122.3.553; WONG G, 1992, CELL, V69, P551, DOI 10.1016/0092-8674(92)90455-L; XING Z, IN PRESS MOL BIOL CE	26	391	400	0	7	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	APR 28	1994	368	6474					867	871		10.1038/368867a0	http://dx.doi.org/10.1038/368867a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	NH717	7512694				2022-12-28	WOS:A1994NH71700075
J	SILVENNOINEN, O; IHLE, JN; SCHLESSINGER, J; LEVY, DE				SILVENNOINEN, O; IHLE, JN; SCHLESSINGER, J; LEVY, DE			INTERFERON-INDUCED NUCLEAR SIGNALING BY JAK PROTEIN-TYROSINE KINASES	NATURE			English	Article								INTERFERONS IFN-alpha/beta and IFN-gamma act through independent cell-surface receptors, inducing gene expression through tyrosine phosphorylation of cytoplasmic transcription factors1-5. IFN-alpha stimulates phosphorylation and nuclear localization of the 84/91K and 113K subunits of latent ISGF3 (interferon-stimulated gene factor 3), which combine with the 48K DNA-binding subunit6,7 to bind regulatory elements of IFN-alpha-responsive genes8-10. IFN-gamma activates p91 alone2, inducing IFN-gamma-responsive genes through a distinct DNA element11,12. Genetic complementation studies implicated the tyrosine kinase Tyk2 in IFN-alpha signalling13 and, more recently, the related Jak2 kinase in IFN-gamma signalling14. We now present biochemical evidence for Jak-family kinase involvement in IFN signal transduction. Jak1 was activated in response to IFN-alpha and IFN-gamma; Jak2 responded exclusively to IFN-gamma. Overexpression of either Jak1 or Jak2 stimulated p91 DNA-binding activity and p91-dependent transcription. Overexpression also activated endogenous Jak kinases, suggesting that interactions between Jak kinases are required during interferon signalling.	NYU, SCH MED, KAPLAN COMPREHENS, CANC CTR, NEW YORK, NY 10016 USA; NYU, SCH MED, DEPT PHARMACOL, NEW YORK, NY 10016 USA; NYU, SCH MED, DEPT PATHOL, NEW YORK, NY 10016 USA; ST JUDE CHILDRENS RES HOSP, DEPT BIOCHEM, MEMPHIS, TN 38105 USA	New York University; New York University; New York University; St Jude Children's Research Hospital			Levy, David/AAG-6202-2019; Levy, David/GPS-4945-2022	Levy, David/0000-0002-7320-7788; 				CARTWRIGHT CA, 1987, CELL, V49, P83, DOI 10.1016/0092-8674(87)90758-6; DALE TC, 1989, P NATL ACAD SCI USA, V86, P1203, DOI 10.1073/pnas.86.4.1203; DECKER T, 1991, EMBO J, V10, P927, DOI 10.1002/j.1460-2075.1991.tb08026.x; FU XY, 1993, CELL, V74, P1135, DOI 10.1016/0092-8674(93)90734-8; GUTCH MJ, 1992, P NATL ACAD SCI USA, V89, P11411, DOI 10.1073/pnas.89.23.11411; KESSLER DS, 1991, J BIOL CHEM, V266, P23471; KESSLER DS, 1990, GENE DEV, V4, P1753, DOI 10.1101/gad.4.10.1753; KMIECIK TE, 1987, CELL, V49, P65, DOI 10.1016/0092-8674(87)90756-2; LEVY DE, 1989, GENE DEV, V3, P1362, DOI 10.1101/gad.3.9.1362; LEW DJ, 1991, MOL CELL BIOL, V11, P182, DOI 10.1128/MCB.11.1.182; MARTH JD, 1988, MOL CELL BIOL, V8, P540, DOI 10.1128/MCB.8.2.540; MARTH JD, 1985, CELL, V43, P393, DOI 10.1016/0092-8674(85)90169-2; MULLER M, 1993, NATURE, V366, P129, DOI 10.1038/366129a0; PIWNICAWORMS H, 1987, CELL, V49, P75, DOI 10.1016/0092-8674(87)90757-4; REYNOLDS AB, 1987, EMBO J, V6, P2359, DOI 10.1002/j.1460-2075.1987.tb02512.x; SADOWSKI HB, 1993, SCIENCE, V261, P1739, DOI 10.1126/science.8397445; SCHINDLER C, 1992, SCIENCE, V257, P809, DOI 10.1126/science.1496401; SCHUAI K, 1992, SCIENCE, V258, P1808; SHUAI K, 1993, SCIENCE, V261, P1744, DOI 10.1126/science.7690989; SHUAL K, 1993, NATURE, V366, P580, DOI 10.1038/366580a0; SILVENNOINEN O, 1993, P NATL ACAD SCI USA, V90, P8429, DOI 10.1073/pnas.90.18.8429; SILVENNOINEN O, 1993, SCIENCE, V261, P1736, DOI 10.1126/science.8378775; TAKEYA T, 1983, CELL, V32, P881, DOI 10.1016/0092-8674(83)90073-9; VEALS SA, 1993, MOL CELL BIOL, V13, P196, DOI 10.1128/MCB.13.1.196; VEALS SA, 1992, MOL CELL BIOL, V12, P3315, DOI 10.1128/MCB.12.8.3315; VELAZQUEZ L, 1992, CELL, V70, P313, DOI 10.1016/0092-8674(92)90105-L; WATING D, 1993, NATURE, V366, P166; WITTHUHN BA, 1993, CELL, V74, P227, DOI 10.1016/0092-8674(93)90414-L	28	325	332	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	DEC 9	1993	366	6455					583	585		10.1038/366583a0	http://dx.doi.org/10.1038/366583a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ML218	7504785				2022-12-28	WOS:A1993ML21800075
J	Keljo, DJ; Squires, RH				Keljo, DJ; Squires, RH			Just in time	NEW ENGLAND JOURNAL OF MEDICINE			English	Article											Keljo, DJ (corresponding author), UNIV TEXAS,SW MED CTR,DEPT PEDIAT,DIV PEDIAT GASTROENTEROL & NUTR,5323 HARRY HINES BLVD,DALLAS,TX 75235, USA.							BETHUNE JE, 1989, ENDOCRINOLOGY, V2, P1647; NERUP J, 1974, ACTA ENDOCRINOL-COP, V76, P127, DOI 10.1530/acta.0.0760127	2	18	18	0	0	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JAN 4	1996	334	1					46	48		10.1056/NEJM199601043340111	http://dx.doi.org/10.1056/NEJM199601043340111			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TM482	7494572				2022-12-28	WOS:A1996TM48200011
J	KINGMA, JH				KINGMA, JH			WAITING FOR CORONARY-ARTERY BYPASS-SURGERY - ABUSIVE, APPROPRIATE, OR ACCEPTABLE	LANCET			English	Editorial Material											KINGMA, JH (corresponding author), ST ANTONIUS HOSP,DEPT CARDIOL,NIEUWEGEIN,NETHERLANDS.							CARROLL RJ, 1995, J AM COLL CARDIOL, V25, P557, DOI 10.1016/0735-1097(94)00442-S; JAMBROES G, 1993, HART B, V24, P241; NAYLOR CD, 1990, LANCET, V335, P1070, DOI 10.1016/0140-6736(90)92640-4; PHELPS CE, 1993, NEW ENGL J MED, V329, P1241, DOI 10.1056/NEJM199310213291707; SUTTORP MJ, 1992, EUR HEART J, V13, P238, DOI 10.1093/oxfordjournals.eurheartj.a060153	5	5	5	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	DEC 16	1995	346	8990					1570	1571		10.1016/S0140-6736(95)91922-8	http://dx.doi.org/10.1016/S0140-6736(95)91922-8			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TK481	7500744				2022-12-28	WOS:A1995TK48100003
J	LAFONT, A; GUEROT, C; LEMARCHAND, P				LAFONT, A; GUEROT, C; LEMARCHAND, P			WHICH GENE FOR WHICH RESTENOSIS	LANCET			English	Editorial Material									INSERM,U25,PARIS,FRANCE	Institut National de la Sante et de la Recherche Medicale (Inserm)	LAFONT, A (corresponding author), FAC NECKER ENFANTS MALAD,PARIS,FRANCE.		lemarchand, patricia/C-3247-2011	lemarchand, patricia/0000-0002-5330-2008				CHANG MW, 1995, SCIENCE, V267, P518, DOI 10.1126/science.7824950; GUZMAN RJ, 1994, P NATL ACAD SCI USA, V91, P10732, DOI 10.1073/pnas.91.22.10732; ISNER JM, 1994, LANCET, V344, P1653, DOI 10.1016/S0140-6736(94)90454-5; KAKUTA T, 1994, CIRCULATION, V89, P2809, DOI 10.1161/01.CIR.89.6.2809; LAFONT A, 1995, CIRC RES, V76, P996, DOI 10.1161/01.RES.76.6.996; MINTZ GS, 1994, CIRCULATION, V90, P1; NUNES GL, 1995, ARTERIOSCL THROM VAS, V15, P156, DOI 10.1161/01.ATV.15.1.156; OBRIEN ER, 1993, CIRC RES, V73, P223, DOI 10.1161/01.RES.73.2.223; OHNO T, 1994, SCIENCE, V265, P781, DOI 10.1126/science.8047883; POST MJ, 1994, CIRCULATION, V89, P2816, DOI 10.1161/01.CIR.89.6.2816; STRAUSS BH, 1994, CIRC RES, V75, P650, DOI 10.1161/01.RES.75.4.650; TANAKA H, 1995, ANN NY ACAD SCI, V748, P526; VONDERLEYEN HE, 1995, P NATL ACAD SCI USA, V92, P1137, DOI 10.1073/pnas.92.4.1137; WALLER BF, 1991, CIRCULATION S2, V83, P128	14	19	24	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	DEC 2	1995	346	8988					1442	1443		10.1016/S0140-6736(95)92467-1	http://dx.doi.org/10.1016/S0140-6736(95)92467-1			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TH156	7490986				2022-12-28	WOS:A1995TH15600004
J	PUGLISI, JD; CHEN, L; BLANCHARD, S; FRANKEL, AD				PUGLISI, JD; CHEN, L; BLANCHARD, S; FRANKEL, AD			SOLUTION STRUCTURE OF A BOVINE IMMUNODEFICIENCY VIRUS TAT-TAR PEPTIDE-RNA COMPLEX	SCIENCE			English	Article							LONG TERMINAL REPEAT; CRYSTAL-STRUCTURE; NMR-SPECTROSCOPY; MINOR-GROOVE; RECOGNITION; SYNTHETASE; DNA; CONFORMATION; SPECIFICITY; RESOLUTION	The Tat protein of bovine immunodeficiency virus (BIV) binds to its target RNA, TAR, and activates transcription. A 14-amino acid arginine-rich peptide corresponding to the RNA-binding domain of BIV Tat binds specifically to BIV TAR, and biochemical and in vivo experiments have identified the amino acids and nucleotides required for binding, The solution structure of the RNA-peptide complex has now been determined by nuclear magnetic resonance spectroscopy. TAR forms a virtually continuous A-form helix with two unstacked bulged nucleotides. The peptide adopts a beta-turn conformation and sits in the major groove of the RNA. Specific contacts are apparent between critical amino acids in the peptide and bases and phosphates in the RNA. The structure is consistent with ail biochemical data and demonstrates ways in which proteins can recognize the major groove of RNA.	UNIV CALIF SAN FRANCISCO,DEPT BIOCHEM & BIOPHYS,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,GLADSTONE INST VIROL & IMMUNOL,SAN FRANCISCO,CA 94143	University of California System; University of California San Francisco; University of California System; University of California San Francisco; The J David Gladstone Institutes	PUGLISI, JD (corresponding author), UNIV CALIF SANTA CRUZ,DEPT CHEM & BIOCHEM,SANTA CRUZ,CA 95064, USA.		Blanchard, Scott C./A-5804-2009	Blanchard, Scott C./0000-0003-2717-9365	NIAID NIH HHS [AI08591, AI29135] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI029135, F32AI008591] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BATEY RT, 1992, NUCLEIC ACIDS RES, V20, P4515, DOI 10.1093/nar/20.17.4515; BATTISTE JL, 1994, BIOCHEMISTRY-US, V33, P2741, DOI 10.1021/bi00176a001; BREG JN, 1990, NATURE, V346, P586, DOI 10.1038/346586a0; CARPENTER S, 1993, J VIROL, V67, P4399, DOI 10.1128/JVI.67.7.4399-4403.1993; CAVARELLI J, 1993, NATURE, V362, P181, DOI 10.1038/362181a0; CHEN L, 1995, P NATL ACAD SCI USA, V92, P5077, DOI 10.1073/pnas.92.11.5077; CHEN L, 1994, BIOCHEMISTRY-US, V33, P2708, DOI 10.1021/bi00175a046; CLORE GM, 1990, BIOCHEMISTRY-US, V29, P8172, DOI 10.1021/bi00487a027; Creighton T. E., 1993, PROTEINS STRUCTURES; KIM JL, 1993, NATURE, V365, P520, DOI 10.1038/365520a0; KIM YC, 1993, NATURE, V365, P512, DOI 10.1038/365512a0; KING CY, 1993, P NATL ACAD SCI USA, V90, P11990, DOI 10.1073/pnas.90.24.11990; NIKONOWICZ EP, 1993, J MOL BIOL, V232, P1141, DOI 10.1006/jmbi.1993.1466; NIKONOWICZ EP, 1992, NUCLEIC ACIDS RES, V20, P4507, DOI 10.1093/nar/20.17.4507; OTTING G, 1990, Q REV BIOPHYS, V23, P39, DOI 10.1017/S0033583500005412; OUBRIDGE C, 1994, NATURE, V372, P432, DOI 10.1038/372432a0; PALLANSCH LA, 1992, J VIROL, V66, P2647, DOI 10.1128/JVI.66.5.2647-2652.1992; PETERSON RD, 1994, BIOCHEMISTRY-US, V33, P5357, DOI 10.1021/bi00184a001; Puglisi JD, 1995, METHOD ENZYMOL, V261, P323; PUGLISI JD, 1992, SCIENCE, V257, P76, DOI 10.1126/science.1621097; RAUMANN BE, 1994, NATURE, V367, P754, DOI 10.1038/367754a0; ROULD MA, 1989, SCIENCE, V246, P1135, DOI 10.1126/science.2479982; ROULD MA, 1991, NATURE, V352, P213, DOI 10.1038/352213a0; RUFF M, 1991, SCIENCE, V252, P1682, DOI 10.1126/science.2047877; SANTORO J, 1992, J MAGN RESON, V97, P202, DOI 10.1016/0022-2364(92)90250-B; SHUMACHER MA, 1994, SCIENCE, V266, P763; SMALLCOMBE SH, 1993, J AM CHEM SOC, V115, P4776, DOI 10.1021/ja00064a043; SOMERS WS, 1992, NATURE, V359, P387, DOI 10.1038/359387a0; TAN RY, 1995, P NATL ACAD SCI USA, V92, P5282, DOI 10.1073/pnas.92.12.5282; TAN RY, 1993, CELL, V73, P1031, DOI 10.1016/0092-8674(93)90280-4; TAO JS, 1992, P NATL ACAD SCI USA, V89, P2723, DOI 10.1073/pnas.89.7.2723; VALEGARD K, 1994, NATURE, V371, P623, DOI 10.1038/371623a0; WEEKS KM, 1992, BIOCHEMISTRY-US, V31, P10281, DOI 10.1021/bi00157a015; WEEKS KM, 1993, SCIENCE, V261, P1574, DOI 10.1126/science.7690496; WERNER MH, 1995, CELL, V81, P705, DOI 10.1016/0092-8674(95)90532-4; XU WG, 1995, CELL, V80, P639, DOI 10.1016/0092-8674(95)90518-9	36	317	328	1	21	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	NOV 17	1995	270	5239					1200	1203		10.1126/science.270.5239.1200	http://dx.doi.org/10.1126/science.270.5239.1200			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TE905	7502045				2022-12-28	WOS:A1995TE90500057
J	COONEY, C; NAGY, A				COONEY, C; NAGY, A			ANGIO-EDEMA ASSOCIATED WITH RISPERIDONE	BRITISH MEDICAL JOURNAL			English	Letter																		JANSSEN PAJ, 1988, J PHARMACOL EXP THER, V244, P685; WARD AM, 1993, PRU HDB CLIN IMMUNOC	2	33	35	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	NOV 4	1995	311	7014					1204	1204		10.1136/bmj.311.7014.1204c	http://dx.doi.org/10.1136/bmj.311.7014.1204c			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TD768	7488898	Green Published			2022-12-28	WOS:A1995TD76800024
J	GRACEYWHITMAN, L; ELL, S				GRACEYWHITMAN, L; ELL, S			ARTIFICIAL COLORINGS AND ADVERSE REACTIONS	BRITISH MEDICAL JOURNAL			English	Letter																		MULLINS PD, 1994, BRIT MED J, V309, P1411, DOI 10.1136/bmj.309.6966.1411a; [No title captured]	2	0	0	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	NOV 4	1995	311	7014					1204	1204		10.1136/bmj.311.7014.1204	http://dx.doi.org/10.1136/bmj.311.7014.1204			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TD768	7488899	Green Published			2022-12-28	WOS:A1995TD76800025
J	GROSHEIDE, PM; WLADIMIROFF, JW; HEIJTINK, RA; MAZEL, JA; CHRISTIAENS, GCML; NUIJTEN, ASM; SCHALM, SW; DUERLOOVOLLAARD, A; ZWIJNENBERG, J; VANDERLAAR, T; BANFFER, JRJ; BAKKERBENDIK, M; BORRIAN, MJ; RIBBERTSMEENK, H; DEGAST, GG; GERARDS, LJ; VANDIJK, H; FETTER, WPF; BAERTS, W				GROSHEIDE, PM; WLADIMIROFF, JW; HEIJTINK, RA; MAZEL, JA; CHRISTIAENS, GCML; NUIJTEN, ASM; SCHALM, SW; DUERLOOVOLLAARD, A; ZWIJNENBERG, J; VANDERLAAR, T; BANFFER, JRJ; BAKKERBENDIK, M; BORRIAN, MJ; RIBBERTSMEENK, H; DEGAST, GG; GERARDS, LJ; VANDIJK, H; FETTER, WPF; BAERTS, W			PROPOSAL FOR ROUTINE ANTENATAL SCREENING AT 14 WEEKS FOR HEPATITIS-B SURFACE-ANTIGEN	BRITISH MEDICAL JOURNAL			English	Article							VIRUS CARRIER STATE; PERINATAL TRANSMISSION; ACTIVE IMMUNIZATION; CONTROLLED TRIAL; PREVENTION; INFECTION; EFFICACY; VACCINE; MOTHERS; INFANTS	Objective-To develop a low cost, high compliance screening programme for identification of carriers of hepatitis B surface antigen in the obstetric population of the Netherlands. Design-A seven year open, descriptive study of screening for hepatitis B surface antigen as part of routine prenatal laboratory testing at 14 weeks of gestation. Compliance with programme evaluated by checking delivery records (hospitals) or registration of births in the 30 participating municipalities (rural area). Setting-Three large city hospitals (two tertiary referral centres) and one rural area with a large number of home deliveries. Subjects-99 706 pregnant women applying for prenatal care for the first time. Main outcome measures-Proportion of pregnant women routinely screened; prevalence of hepatitis B surface antigen in large cities and rural area. Results-Uptake of screening reached 97% in the hospitals after inclusion of 10% screened at delivery; the estimated uptake in the rural area was >95%. Prevalence of hepatitis B surface antigen was 1.6% in the large cities and 0.3% in the rural area. For screening at delivery the prevalence was 2.5 times higher (4%, P < 0.01) than for screening at week 14 of gestation. Conclusion-Incorporation of universal testing for hepatitis B surface antigen into routine prenatal laboratory testing is practical; high compliance is achieved when screening is supplemented with rapid screening at delivery for those who escaped routine prenatal care.	UNIV HOSP DIJKZIGT,DEPT INTERNAL MED 2,3015 GD ROTTERDAM,NETHERLANDS; UNIV HOSP DIJKZIGT,DEPT OBSTET,3015 GD ROTTERDAM,NETHERLANDS; ERASMUS UNIV ROTTERDAM,DEPT VIROL,3000 DR ROTTERDAM,NETHERLANDS; ACAD HOSP,DEPT OBSTET & GYNAECOL,UTRECHT,NETHERLANDS; STATE SCH TRAINING MIDWIVES,ROTTERDAM,NETHERLANDS; RUWAARD VAN PUTTEN HOSP,DEPT PAEDIAT,SPIJKERVISSE,NETHERLANDS; REG PUBL HLTH LAB,ROTTERDAM,NETHERLANDS; ACAD HOSP ROTTERDAM DIJKZIGT,DEPT INTERNAL MED,3000 DR ROTTERDAM,NETHERLANDS; REG LAB PATHOL & MICROBIOL,ENSCHEDE,NETHERLANDS; BLOOD TRANSFUS LAB,UTRECHT,NETHERLANDS; WILHELMINA CHILDRENS HOSP,UTRECHT,NETHERLANDS; SOPHIA HOSP,DEPT PAEDIAT,ZWOLLA,NETHERLANDS	Erasmus University Rotterdam; Erasmus MC; Erasmus University Rotterdam; Erasmus MC; Erasmus University Rotterdam; Erasmus University Rotterdam; Erasmus MC; Wilhelmina Kinderziekenhuis								AREVALO JA, 1988, JAMA-J AM MED ASSOC, V259, P365, DOI 10.1001/jama.259.3.365; BEASLEY RP, 1983, HEPATOLOGY, V3, P135; DELCANHO R, 1994, J HEPATOL, V20, P483, DOI 10.1016/S0168-8278(05)80494-5; FRANCIS DP, 1985, PEDIATRICS, V76, P851; GREENSPOON JS, 1989, J REPROD MED, V34, P655; GROSHEIDE PM, 1993, AM J DIS CHILD, V147, P1316, DOI 10.1001/archpedi.1993.02160360058019; IP HMH, 1989, LANCET, V1, P406; JONAS MM, 1987, ANN INTERN MED, V107, P335, DOI 10.7326/0003-4819-107-2-335; MAUPAS P, 1981, LANCET, V1, P289; MAYNARD JE, 1983, INT J EPIDEMIOL, V61, P731; MAZEL JA, 1984, BRIT MED J, V288, P513, DOI 10.1136/bmj.288.6416.513; SCHALM SW, 1989, PEDIATRICS, V83, P1041; SILVERMAN NS, 1991, JAMA-J AM MED ASSOC, V20, P2852; TADA H, 1982, PEDIATRICS, V70, P613; WAINWRIGHT RB, 1986, INT J EPIDEMIOL, V15, P567, DOI 10.1093/ije/15.4.567; 1984, MMWR-MORBID MORTAL W, V33, P285; 1983, B WORLD HEALTH ORGAN, V61, P731	17	14	15	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	NOV 4	1995	311	7014					1197	1199		10.1136/bmj.311.7014.1197	http://dx.doi.org/10.1136/bmj.311.7014.1197			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TD768	7488895	Green Published			2022-12-28	WOS:A1995TD76800019
J	NIGHTINGALE, SL				NIGHTINGALE, SL			CONFERENCE ON FDA-REGULATED PRODUCTS AND PREGNANT-WOMEN	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material											NIGHTINGALE, SL (corresponding author), US FDA,OFF HLTH AFFAIRS,PARKLAWN BLDG,5600 FISHERS LN,ROCKVILLE,MD 20857, USA.								0	3	3	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 19	1994	272	15					1160	1160		10.1001/jama.272.15.1160	http://dx.doi.org/10.1001/jama.272.15.1160			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PL212	7523738				2022-12-28	WOS:A1994PL21200010
J	WU, HH; WILLIAMS, CV; MCLOON, SC				WU, HH; WILLIAMS, CV; MCLOON, SC			INVOLVEMENT OF NITRIC-OXIDE IN THE ELIMINATION OF A TRANSIENT RETINOTECTAL PROJECTION IN DEVELOPMENT	SCIENCE			English	Article							LONG-TERM POTENTIATION; RECEPTOR ANTAGONISTS DISRUPT; RETINAL GANGLION-CELLS; MOUSE CENTRAL NEURONS; NMDA RECEPTORS; INTERCELLULAR MESSENGER; ACTIVATED CHANNELS; NADPH DIAPHORASE; IMPULSE ACTIVITY; DEVELOPING CHICK	The adult pattern of axonal connections from the eye to the brain arises during development through the refinement of a roughly ordered set of connections. In the chick visual system, refinement normally results in the loss of the ipsilateral retinotectal connections. Inhibition of nitric oxide synthesis reduced the loss of these transient connections. Because nitric oxide is expressed by tectal cells with which retinal axons connect and because reduction of nitric oxide synthesis by tectal cells resulted in a change in the connections of retinal axons, nitric oxide probably serves as a messenger from tectal cells back to retinal axons during development.	UNIV MINNESOTA,DEPT CELL BIOL & NEUROANAT,MINNEAPOLIS,MN 55455	University of Minnesota System; University of Minnesota Twin Cities					NATIONAL EYE INSTITUTE [R01EY005371, T32EY007133] Funding Source: NIH RePORTER; NEI NIH HHS [EY05371, EY07133] Funding Source: Medline	NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		AHMAD I, 1994, NEURON, V12, P155, DOI 10.1016/0896-6273(94)90160-0; ASCHER P, 1988, J PHYSIOL-LONDON, V399, P207; BOHME GA, 1991, EUR J PHARMACOL, V199, P379, DOI 10.1016/0014-2999(91)90505-K; BREDT DS, 1989, P NATL ACAD SCI USA, V86, P9030, DOI 10.1073/pnas.86.22.9030; BREDT DS, 1990, P NATL ACAD SCI USA, V87, P682, DOI 10.1073/pnas.87.2.682; CLINE HT, 1989, NEURON, V3, P413, DOI 10.1016/0896-6273(89)90201-8; CLINE HT, 1987, P NATL ACAD SCI USA, V84, P4342, DOI 10.1073/pnas.84.12.4342; CONNOR JA, 1986, P NATL ACAD SCI USA, V83, P6179, DOI 10.1073/pnas.83.16.6179; CONSTANTINEPATON M, 1990, ANNU REV NEUROSCI, V13, P129, DOI 10.1146/annurev.neuro.13.1.129; DAWSON TM, 1991, P NATL ACAD SCI USA, V88, P7797, DOI 10.1073/pnas.88.17.7797; DWYER MA, 1991, BIOCHEM BIOPH RES CO, V176, P1136, DOI 10.1016/0006-291X(91)90403-T; FIELDS RD, 1990, J NEUROSCI, V10, P2950; FOX K, 1993, TRENDS NEUROSCI, V16, P116, DOI 10.1016/0166-2236(93)90136-A; GALLI L, 1988, SCIENCE, V242, P90, DOI 10.1126/science.3175637; GALLY JA, 1990, P NATL ACAD SCI USA, V87, P3547, DOI 10.1073/pnas.87.9.3547; GARTHWAITE J, 1988, NATURE, V336, P385, DOI 10.1038/336385a0; HAHM JO, 1991, NATURE, V351, P568, DOI 10.1038/351568a0; HALEY JE, 1992, NEURON, V8, P211, DOI 10.1016/0896-6273(92)90288-O; HAMBURGER V, 1951, J MORPHOL, V88, P49, DOI 10.1002/jmor.1050880104; IADECOLA C, 1994, NEUROCHEM RES, V19, P501, DOI 10.1007/BF00967330; JAHR CE, 1987, NATURE, V325, P522, DOI 10.1038/325522a0; JESSELL TM, 1993, CELL 72 NEURON S, V10, P1; KANDEL ER, 1992, SCIENCE, V258, P243, DOI 10.1126/science.1411522; KOBAYASHI T, 1990, DEV BRAIN RES, V57, P29, DOI 10.1016/0165-3806(90)90181-W; LONART G, 1992, EUR J PHARMACOL, V220, P271, DOI 10.1016/0014-2999(92)90759-W; MAFFEI L, 1990, P NATL ACAD SCI USA, V87, P2861, DOI 10.1073/pnas.87.7.2861; MATTSON MP, 1987, J NEUROSCI, V7, P4034; MAYER ML, 1985, J PHYSIOL-LONDON, V361, P65, DOI 10.1113/jphysiol.1985.sp015633; MAYER ML, 1984, NATURE, V309, P261, DOI 10.1038/309261a0; MCLOON SC, 1982, EXP BRAIN RES, V45, P277; MCLOON SC, 1982, SCIENCE, V215, P1418, DOI 10.1126/science.7063855; MEISTER M, 1991, SCIENCE, V252, P939, DOI 10.1126/science.2035024; MONCADA S, 1991, PHARMACOL REV, V43, P109; MONTAGUE PR, 1994, SCIENCE, V263, P973, DOI 10.1126/science.7508638; NELSON PG, 1989, SCIENCE, V244, P565; NICHOLS RA, 1990, NATURE, V343, P647, DOI 10.1038/343647a0; NOWAK L, 1984, NATURE, V307, P462, DOI 10.1038/307462a0; ODELL TJ, 1991, P NATL ACAD SCI USA, V88, P11285, DOI 10.1073/pnas.88.24.11285; OLEARY DDM, 1983, DEV BRAIN RES, V10, P93, DOI 10.1016/0165-3806(83)90124-4; Prusky G., 1992, Society for Neuroscience Abstracts, V18, P1311; REH TA, 1985, J NEUROSCI, V5, P1132; SANDELL JH, 1985, J COMP NEUROL, V238, P466, DOI 10.1002/cne.902380410; SCHUMAN EM, 1991, SCIENCE, V254, P1503, DOI 10.1126/science.1720572; SHATZ CJ, 1988, SCIENCE, V242, P87, DOI 10.1126/science.3175636; SHATZ CJ, 1990, NEURON, V5, P745, DOI 10.1016/0896-6273(90)90333-B; SIMON DK, 1992, P NATL ACAD SCI USA, V89, P10593, DOI 10.1073/pnas.89.22.10593; STRYKER MP, 1986, J NEUROSCI, V6, P2117; TANAKA K, 1991, NEUROSCI LETT, V127, P129, DOI 10.1016/0304-3940(91)90911-C; THANOS S, 1984, J COMP NEUROL, V224, P407, DOI 10.1002/cne.902240308; WILLIAMS CV, 1994, J NEUROSCI, V14, P1746, DOI 10.1523/JNEUROSCI.14-03-01746.1994; WILLIAMS CV, 1991, J NEUROSCI, V11, P445; WU HH, IN PRESS SOC NEUR AB; ZHUO M, 1993, SCIENCE, V260, P1946, DOI 10.1126/science.8100368	53	210	213	0	0	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	SEP 9	1994	265	5178					1593	1596		10.1126/science.7521541	http://dx.doi.org/10.1126/science.7521541			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PF336	7521541				2022-12-28	WOS:A1994PF33600040
J	AUSTOKER, J				AUSTOKER, J			CANCER PREVENTION IN PRIMARY-CARE - SCREENING FOR OVARIAN, PROSTATIC, AND TESTICULAR CANCERS .8.	BRITISH MEDICAL JOURNAL			English	Article							SURVIVAL; ANTIGEN; ULTRASONOGRAPHY; DIAGNOSIS; DELAY	Screening for cancer should not be offered routinely to a symptomatic people on a population basis unless it has been shown to be effective in reducing mortality in randomised controlled trials. A suitable screening test should have high sensitivity and specificity and a high positive predictive value. There is an ethical imperative to ensure that the benefit to each person from screening is likely to outweigh the possible harm. Preliminary studies have identified suitable screening tests for ovarian cancer. and a randomised controlled trial is about to start. There is considerable controversy about whether to screen for prostatic cancer. Likewise, there is uncertainty about the best means of treating localised prostatic cancer. Screening for prostatic cancer raises important ethical considerations which should not be ignored. Testicular self examination is of unproved benefit. Although there is a need for education about the early signs and symptoms of testicular cancer to reduce delay at presentation, a case cannot be made for screening.			AUSTOKER, J (corresponding author), UNIV OXFORD,DEPT PUBL HLTH & PRIMARY CARE,CANC RES CAMPAIGN,PRIMARY CARE EDUC RES GRP,OXFORD OX2 6PE,ENGLAND.							ADAMI HO, 1994, LANCET, V343, P958, DOI 10.1016/S0140-6736(94)90071-X; ADAMI HO, 1994, CANCER EPIDEM BIOMAR, V3, P193; BOURNE TH, 1993, BRIT MED J, V306, P1025, DOI 10.1136/bmj.306.6884.1025; BOURNE TH, IN PRESS GYNECOL ONC; CAMPBELL S, 1992, OVARIAN CANCER, V2, P237; CATALONA WJ, 1993, JAMA-J AM MED ASSOC, V270, P948, DOI 10.1001/jama.270.8.948; CHAMBERLAIN J, 1993, LANCET, V342, P902; CUCKLE HS, 1991, CANC SCREENING, P228; DEARNALEY DP, 1994, BRIT MED J, V308, P780, DOI 10.1136/bmj.308.6931.780; DIECKMANN KP, 1987, UROL INT, V42, P241, DOI 10.1159/000281948; DORR VJ, 1993, ARCH INTERN MED, V153, P2529, DOI 10.1001/archinte.153.22.2529; Fleming C, 1993, JAMA, V269, P2650; GERBER GS, 1991, J NATL CANCER I, V83, P329, DOI 10.1093/jnci/83.5.329; GERBER GS, 1993, JAMA-J AM MED ASSOC, V269, P61, DOI 10.1001/jama.269.1.61; JACOBS I, 1993, BRIT MED J, V306, P1030, DOI 10.1136/bmj.306.6884.1030; JACOBS I, 1994, LANCET, V343, P337; JACOBS I, 1992, OVARIAN CANCER, V2, P265; JOHANSSON JE, 1992, JAMA-J AM MED ASSOC, V267, P2191, DOI 10.1001/jama.267.16.2191; LUYAO GL, 1993, JAMA-J AM MED ASSOC, V269, P2633, DOI 10.1001/jama.269.20.2633; LUYAO GL, 1994, LANCET, V343, P251, DOI 10.1016/S0140-6736(94)91109-6; MEFFAN PJ, 1991, NEW ZEAL MED J, V104, P393; MOUL JW, 1990, J UROLOGY, V143, P520, DOI 10.1016/S0022-5347(17)40007-3; OESTERLING JE, 1992, JAMA-J AM MED ASSOC, V267, P2236, DOI 10.1001/jama.267.16.2236; RENO DR, 1988, CANCER NURS, V11, P112; ROETZHEIM RG, 1992, CANCER EPIDEMIOLOGY, V19, P637; SCHRODER FH, 1993, EUR J CANCER, V29A, P656, DOI 10.1016/S0959-8049(05)80339-9; SCOTT IV, 1992, OVARIAN CANCER, V2, P277; SHEARER RJ, 1993, LANCET, V342, P903; SHELDON K, 1991, BYTE, V16, P117; VANNAGELL JR, 1991, CANCER, V68, P679, DOI 10.1002/1097-0142(19910815)68:4<679::AID-CNCR2820680402>3.0.CO;2-J; VOGT HB, 1992, POSTGRAD MED, V92, P93; VOGT HB, 1992, POSTGRAD MED, V92, P99; WALD N, 1993, BRIT MED J, V306, P1684, DOI 10.1136/bmj.306.6893.1684; WALD N, 1994, J MED SCREENING, V1, P135; WARDLE J, 1994, PREV MED, V23, P206, DOI 10.1006/pmed.1994.1028; WESTLAKE SJ, 1987, FAM PRACT, V4, P143, DOI 10.1093/fampra/4.2.143; WHITMORE WF, 1994, LANCET, V343, P1263, DOI 10.1016/S0140-6736(94)92156-3; WHITMORE WF, 1993, JAMA-J AM MED ASSOC, V269, P2676, DOI 10.1001/jama.269.20.2676; Wilson JMG, 1968, WHO PUBLIC HLTH PAPE, V34; WOOLF SH, 1990, PREVENTING DISEASE R, P291; 1990, GUIDE CLIN PREVENTIV; 1991, FACTSHEET 17 OVARIAN; 1994, BRIT MED J, V308, P1393; 1991, FACTSHEET 16 TESTICU; 1994, FACTSHEET 20 CANCER	45	35	35	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUL 30	1994	309	6950					315	320		10.1136/bmj.309.6950.315	http://dx.doi.org/10.1136/bmj.309.6950.315			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PA373	7522074	Green Published			2022-12-28	WOS:A1994PA37300022
J	PELLETIER, H; SAWAYA, MR; KUMAR, A; WILSON, SH; KRAUT, J				PELLETIER, H; SAWAYA, MR; KUMAR, A; WILSON, SH; KRAUT, J			STRUCTURES OF TERNARY COMPLEXES OF RAT DNA-POLYMERASE-BETA, A DNA TEMPLATE-PRIMER, AND DDCTP	SCIENCE			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; HIV-1 REVERSE-TRANSCRIPTASE; STEADY-STATE KINETICS; BACTERIOPHAGE-T7 RNA-POLYMERASE; I KLENOW FRAGMENT; ESCHERICHIA-COLI; CRYSTAL-STRUCTURE; ANGSTROM RESOLUTION; 3'-5' EXONUCLEASE; ZIDOVUDINE AZT	Two ternary complexes of rat DNA polymerase beta (pol beta), a DNA template-primer, and dideoxycytidine triphosphate (ddCTP) have been determined at 2.9 Angstrom and 3.6 Angstrom resolution, respectively, ddCTP is the triphosphate of dideoxycytidine (ddC), a nucleoside analog that targets the reverse transcriptase of human immunodeficiency virus (HIV) and is at present used to treat AIDS, Although crystals of the two complexes belong to different space groups, the structures are similar, suggesting that the polymerase-DNA-ddCTP interactions are not affected by crystal packing forces. In the pol beta active site, the attacking 3'-OH of the elongating primer, the ddCTP phosphates, and two Mg2+ ions are all clustered around Asp(190), Asp(192), and Asp(256). Two of these residues, Asp(190) and Asp(256), are present in the amino acid sequences of all polymerases so far studied and are also spatially similar in the four polymerases-the Klenow fragment of Escherichia coli DNA polymerase I, HIV-1 reverse transcriptase, T7 RNA polymerase, and rat DNA pol beta-whose crystal structures are now known. A two-metal ion mechanism is described for the nucleotidyl transfer reaction and may apply to all polymerases. In the ternary complex structures analyzed, pol beta binds to the DNA template-primer in a different manner from that recently proposed for other polymerase-DNA models.	UNIV TEXAS, MED BRANCH, SEALY CTR MOLEC SCI, GALVESTON, TX 77555 USA	University of Texas System; University of Texas Medical Branch Galveston	PELLETIER, H (corresponding author), UNIV CALIF SAN DIEGO, DEPT CHEM, LA JOLLA, CA 92093 USA.		Wilson, Samuel H/E-6644-2019	Wilson, Samuel H/0000-0002-1702-5293	NATIONAL CANCER INSTITUTE [R01CA017374] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES006839] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM010928] Funding Source: NIH RePORTER; NCI NIH HHS [CA17374] Funding Source: Medline; NIEHS NIH HHS [ES06839] Funding Source: Medline; NIGMS NIH HHS [GM10928] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABBOTTS J, 1988, BIOCHEMISTRY-US, V27, P901, DOI 10.1021/bi00403a010; BARRESINOUSSI F, 1983, SCIENCE, V220, P868, DOI 10.1126/science.6189183; BARTEL DP, 1993, SCIENCE, V261, P1411, DOI 10.1126/science.7690155; BASU A, 1989, BIOCHEMISTRY-US, V28, P6305, DOI 10.1021/bi00441a023; BEARD WA, 1993, BIOCHEMISTRY-US, V32, P9745, DOI 10.1021/bi00088a029; BEEN MD, 1988, SCIENCE, V239, P1412, DOI 10.1126/science.2450400; BEESE LS, 1991, EMBO J, V10, P25, DOI 10.1002/j.1460-2075.1991.tb07917.x; BEESE LS, 1993, BIOCHEMISTRY-US, V32, P14095, DOI 10.1021/bi00214a004; BEESE LS, 1993, SCIENCE, V260, P352, DOI 10.1126/science.8469987; BRUNGER AT, 1990, ACTA CRYSTALLOGR A, V46, P46, DOI 10.1107/S0108767389009633; BRUNGER AT, 1992, XPLOR MANUAL; BURGERS PMJ, 1979, J BIOL CHEM, V254, P6889; CARROLL SS, 1990, CHEM REV, V90, P1291, DOI 10.1021/cr00105a011; CECH TR, 1987, SCIENCE, V236, P1532, DOI 10.1126/science.2438771; CHENG YC, 1990, ANN NY ACAD SCI, V616, P217; CONNER BN, 1982, NATURE, V295, P294, DOI 10.1038/295294a0; DATE T, 1991, BIOCHEMISTRY-US, V30, P5286, DOI 10.1021/bi00235a023; DATE T, 1990, BIOCHEMISTRY-US, V29, P5027, DOI 10.1021/bi00473a005; DELARUE M, 1990, PROTEIN ENG, V3, P461, DOI 10.1093/protein/3.6.461; DERBYSHIRE V, 1991, EMBO J, V10, P17, DOI 10.1002/j.1460-2075.1991.tb07916.x; DERBYSHIRE V, 1988, SCIENCE, V240, P199, DOI 10.1126/science.2832946; DREW HR, 1981, J MOL BIOL, V151, P535, DOI 10.1016/0022-2836(81)90009-7; FITZGIBBON JE, 1992, ANTIMICROB AGENTS CH, V36, P153, DOI 10.1128/AAC.36.1.153; FREEMONT PS, 1988, P NATL ACAD SCI USA, V85, P8924, DOI 10.1073/pnas.85.23.8924; FURMAN PA, 1986, P NATL ACAD SCI USA, V83, P8333, DOI 10.1073/pnas.83.21.8333; GALLO RC, 1984, SCIENCE, V224, P500, DOI 10.1126/science.6200936; GILBOA E, 1979, CELL, V18, P93, DOI 10.1016/0092-8674(79)90357-X; GOFF SP, 1990, J ACQ IMMUN DEF SYND, V3, P817; GOPALAKRISHNAN V, 1992, P NATL ACAD SCI USA, V89, P10763, DOI 10.1073/pnas.89.22.10763; GREENE R, 1970, J BIOL CHEM, V245, P254; GUPTA AP, 1984, BIOCHEMISTRY-US, V23, P5874, DOI 10.1021/bi00319a029; HAMLIN R, 1985, METHOD ENZYMOL, V114, P416; HASELTINE WA, 1976, J MOL BIOL, V106, P109, DOI 10.1016/0022-2836(76)90303-X; HOWARD AJ, 1985, METHOD ENZYMOL, V114, P452; HUBER HE, 1989, J BIOL CHEM, V264, P4669; JABLONSKI SA, 1993, J VIROL, V67, P373, DOI 10.1128/JVI.67.1.373-381.1993; JACOBOMOLINA A, 1993, P NATL ACAD SCI USA, V90, P6320, DOI 10.1073/pnas.90.13.6320; JENKINS TM, 1992, SCIENCE, V258, P475, DOI 10.1126/science.1411545; JOHNSON MA, 1988, J BIOL CHEM, V263, P15354; JOYCE CM, 1987, TRENDS BIOCHEM SCI, V12, P288, DOI 10.1016/0968-0004(87)90143-5; KOHLSTAEDT LA, 1992, P NATL ACAD SCI USA, V89, P9652, DOI 10.1073/pnas.89.20.9652; KOHLSTAEDT LA, 1992, SCIENCE, V256, P1783, DOI 10.1126/science.1377403; Kornberg A., 1991, DNA REPLICATION; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; KUCHTA RD, 1987, BIOCHEMISTRY-US, V26, P8410, DOI 10.1021/bi00399a057; KUMAR A, 1990, J BIOL CHEM, V265, P2124; KUMAR A, 1990, BIOCHEMISTRY-US, V29, P7156, DOI 10.1021/bi00483a002; LARDER BA, 1987, NATURE, V327, P716, DOI 10.1038/327716a0; LARDER BA, 1989, SCIENCE, V243, P1731, DOI 10.1126/science.2467383; LARDER BA, 1989, SCIENCE, V246, P1155, DOI 10.1126/science.2479983; LAVERY R, 1989, J BIOMOL STRUCT DYN, V6, P655, DOI 10.1080/07391102.1989.10507728; LINN S, 1991, CELL, V66, P185, DOI 10.1016/0092-8674(91)90608-2; LOBEL LI, 1985, J VIROL, V53, P447, DOI 10.1128/JVI.53.2.447-455.1985; MAJUMDAR C, 1988, J BIOL CHEM, V263, P15657; MCCLURE WR, 1975, J BIOL CHEM, V250, P4073; MITSUYA H, 1987, P NATL ACAD SCI USA, V84, P2033, DOI 10.1073/pnas.84.7.2033; MULLER DK, 1988, BIOCHEMISTRY-US, V27, P5763, DOI 10.1021/bi00415a055; OLLIS DL, 1985, NATURE, V313, P762, DOI 10.1038/313762a0; PATRA D, 1992, J MOL BIOL, V224, P307, DOI 10.1016/0022-2836(92)90996-W; PELISKA JA, 1992, SCIENCE, V258, P1112, DOI 10.1126/science.1279806; POLESKY AH, 1992, J BIOL CHEM, V267, P8417; POLESKY AH, 1990, J BIOL CHEM, V265, P14579; POPOVIC M, 1984, SCIENCE, V224, P497, DOI 10.1126/science.6200935; PRASAD R, IN PRESS J BIOL CHEM; PYLE AM, 1993, SCIENCE, V261, P709, DOI 10.1126/science.7688142; RASKIN CA, 1992, J MOL BIOL, V228, P506, DOI 10.1016/0022-2836(92)90838-B; REARDON JE, 1990, J BIOL CHEM, V265, P20302; REARDON JE, 1992, BIOCHEMISTRY-US, V31, P4473, DOI 10.1021/bi00133a013; REARDON JE, 1993, J BIOL CHEM, V268, P8743; REIN DC, 1990, EUKARYOTIC NUCLEUS M, V1, pCH5; RICCHETTI M, 1993, EMBO J, V12, P387, DOI 10.1002/j.1460-2075.1993.tb05670.x; SADAKANE Y, 1994, BIOCHEM BIOPH RES CO, V200, P219, DOI 10.1006/bbrc.1994.1437; SAWAYA MR, 1994, SCIENCE, V264, P1930, DOI 10.1126/science.7516581; Schinazi Raymond F., 1993, Perspectives in Drug Discovery and Design, V1, P151, DOI 10.1007/BF02171660; SENGUPTA DN, 1986, BIOCHEM BIOPH RES CO, V136, P341, DOI 10.1016/0006-291X(86)90916-2; SINGHAL RK, 1993, J BIOL CHEM, V268, P15906; SOMMADOSSI JP, 1989, MOL PHARMACOL, V36, P9; SOUSA R, 1993, NATURE, V364, P593, DOI 10.1038/364593a0; STCLAIR MH, 1987, ANTIMICROB AGENTS CH, V31, P1972, DOI 10.1128/AAC.31.12.1972; STCLAIR MH, 1991, SCIENCE, V253, P1557, DOI 10.1126/science.1716788; STEITZ TA, 1987, COLD SPRING HARB SYM, V52, P465, DOI 10.1101/SQB.1987.052.01.053; STEITZ TA, 1993, P NATL ACAD SCI USA, V90, P6498, DOI 10.1073/pnas.90.14.6498; TANABE K, 1979, BIOCHEMISTRY-US, V18, P3401, DOI 10.1021/bi00582a029; THIMMIG RL, 1993, J BIOL CHEM, V268, P16528; TRONRUD DE, 1987, ACTA CRYSTALLOGR A, V43, P489, DOI 10.1107/S0108767387099124; VANDESANDE JH, 1972, J BIOL CHEM, V247, P6140; WANG LM, 1992, CANCER RES, V52, P4824; WAQAR MA, 1984, J CELL PHYSIOL, V121, P402, DOI 10.1002/jcp.1041210218; WARWICKER J, 1985, J MOL BIOL, V186, P645, DOI 10.1016/0022-2836(85)90136-6; WILSON SH, 1990, EUKARYOTIC NUCLEUS M, V1, pCH8; YARCHOAN R, 1989, NEW ENGL J MED, V321, P726, DOI 10.1056/NEJM198909143211106; ZMUDZKA BZ, 1986, P NATL ACAD SCI USA, V83, P5106, DOI 10.1073/pnas.83.14.5106	92	763	794	1	34	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUN 24	1994	264	5167					1891	1903		10.1126/science.7516580	http://dx.doi.org/10.1126/science.7516580			13	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	NT847	7516580				2022-12-28	WOS:A1994NT84700035
J	IMPERIALE, TF; SPEROFF, T				IMPERIALE, TF; SPEROFF, T			A METAANALYSIS OF METHODS TO PREVENT VENOUS THROMBOEMBOLISM FOLLOWING TOTAL HIP-REPLACEMENT	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							DEEP-VEIN THROMBOSIS; MOLECULAR-WEIGHT HEPARIN; LOW-DOSE HEPARIN; MAJOR ORTHOPEDIC-SURGERY; UNFRACTIONATED HEPARIN; CLINICAL-TRIALS; ASPIRIN PROPHYLAXIS; COST-EFFECTIVENESS; DIHYDROERGOTAMINE; WARFARIN	Objective.-While several methods of prophylaxis have been shown to reduce the risk of venous thromboembolism following total hip replacement, the safest and most effective agent is unclear. To clarify this issue, we performed a meta-analysis of the randomized trials of methods used to prevent venous thromboembolism following total hip replacement. Data Source.-English-language human studies articles from 1966 through 1993 were obtained from a MEDLINE database search with indexing terms including thromboembolism, hip replacement or hip prosthesis, and randomized controlled trials. Additional references were obtained from study bibliographies. Study Selection.-The following criteria were used to select studies for inclusion: study design-randomized clinical trial; study population-patients undergoing elective total hip replacement; interventions-aspirin, warfarin, dextran, heparin, low-molecular-weight heparin, compression stockings; and outcomes-venous thromboembolism, major hemorrhage. Data Extraction.-Methodological and descriptive data from each study were abstracted by one author who was blinded to quantitative outcomes data. Data Synthesis.-Ninety-one treatment groups and 25 control groups were identified from 56 trials. Four treatment groups were excluded because of rarely used combinations. Trial populations were clinically homogeneous. When compared with the control arm, all treatments except aspirin reduced the risk of all deep venous thromboses (risk differences range, 0.18 to 0.31; all P values <.05). All treatments except aspirin reduced the risk of proximal venous thrombosis (risk differences range, 0.09 to 0.18; all P values <.05). Only low-molecular-weight heparin and stockings reduced the risk of pulmonary embolism, both with risk differences equal to 0.02. The crude risks of clinically important bleeding as defined by the individual trials were 0% for stockings, 0.3% for controls, and 1.8% for low-molecular-weight heparin. Conclusions.-The results suggest that low-molecular-weight heparin and compression stockings have the greatest relative efficacy in preventing venous thromboembolism following total hip replacement. Low-molecular-weight heparin may be more effective, though at a small risk of clinically important bleeding.	CASE WESTERN RESERVE UNIV, METROHLTH MED CTR, DEPT EPIDEMIOL & BIOSTAT, DIV GASTROENTEROL, CLEVELAND, OH USA	Case Western Reserve University; MetroHealth System	IMPERIALE, TF (corresponding author), CASE WESTERN RESERVE UNIV, METROHLTH MED CTR,DEPT MED,DIV GEN MED, 2500 METROHLTH DR, ROOM W603, CLEVELAND, OH 44109 USA.			Imperiale, Thomas/0000-0001-7586-1073				ALFARO MJ, 1986, THROMB HAEMOSTASIS, V56, P53; ANGELL M, 1989, NEW ENGL J MED, V321, P464, DOI 10.1056/NEJM198908173210708; BARBER HM, 1977, POSTGRAD MED J, V53, P130, DOI 10.1136/pgmj.53.617.130; BARNES RW, 1978, CLIN ORTHOP RELAT R, V132, P61; BEISAW NE, 1988, J BONE JOINT SURG AM, V70A, P2, DOI 10.2106/00004623-198870010-00002; BERGQVIST D, 1984, BRIT J SURG, V71, P516, DOI 10.1002/bjs.1800710714; BERGQVIST D, 1979, ACTA CHIR SCAND, V145, P213; BERLIN JA, 1989, STAT MED, V8, P141, DOI 10.1002/sim.4780080202; BORRIS LC, 1991, ARCH INTERN MED, V151, P1621; BRENKEL I, 1989, BRIT J HOSP MED, V42, P282; BUSSEY HI, 1992, ARCH INTERN MED, V152, P278, DOI 10.1001/archinte.152.2.278; CHALMERS TC, 1981, CONTROL CLIN TRIALS, V2, P31, DOI 10.1016/0197-2456(81)90056-8; DECHAVANNE M, 1989, HAEMOSTASIS, V19, P5; DERSIMONIAN R, 1986, CONTROL CLIN TRIALS, V7, P177, DOI 10.1016/0197-2456(86)90046-2; ERIKSSON BI, 1991, J BONE JOINT SURG AM, V73A, P484, DOI 10.2106/00004623-199173040-00002; ERIKSSON BI, 1988, BRIT J SURG, V75, P1053, DOI 10.1002/bjs.1800751104; EVARTS CM, 1971, J BONE JOINT SURG AM, VA 53, P1271, DOI 10.2106/00004623-197153070-00002; FELSON DT, 1990, ARTHRITIS RHEUM, V33, P1449, DOI 10.1002/art.1780331001; FLICOTEAUX H, 1977, PATHOL BIOL, V25, P55; FORDYCE MJF, 1991, BRIT MED J, V303, P219, DOI 10.1136/bmj.303.6796.219; FRANCIS CW, 1989, J BONE JOINT SURG AM, V71A, P327, DOI 10.2106/00004623-198971030-00003; FRANCIS CW, 1983, JAMA-J AM MED ASSOC, V249, P374, DOI 10.1001/jama.249.3.374; FRANCIS CW, 1992, JAMA-J AM MED ASSOC, V267, P2911, DOI 10.1001/jama.267.21.2911; FREDIN H, 1989, ACTA ORTHOP SCAND, V60, P678, DOI 10.3109/17453678909149602; FREDIN HO, 1984, BRIT J SURG, V71, P58, DOI 10.1002/bjs.1800710118; FREICK H, 1991, THROMB RES, V63, P133, DOI 10.1016/0049-3848(91)90276-3; GERBARG ZB, 1988, J CLIN EPIDEMIOL, V41, P503, DOI 10.1016/0895-4356(88)90053-4; GOLDHABER SZ, 1985, PULMONARY EMBOLISM D, P135; HAAS S, 1987, DRUG RES, V37, P839; HAMPSON WGJ, 1974, LANCET, V2, P795; HARRIS WH, 1974, J BONE JOINT SURG AM, VA 56, P1552, DOI 10.2106/00004623-197456080-00002; HARRIS WH, 1967, J BONE JOINT SURG AM, VA 49, P81, DOI 10.2106/00004623-196749010-00006; HARRIS WH, 1972, J AMER MED ASSOC, V220, P1319, DOI 10.1001/jama.220.10.1319; HARRIS WH, 1985, J BONE JOINT SURG AM, V67A, P57, DOI 10.2106/00004623-198567010-00008; HARRIS WH, 1977, NEW ENGL J MED, V297, P1246, DOI 10.1056/NEJM197712082972302; HARRIS WH, 1982, J BONE JOINT SURG AM, V64, P63, DOI 10.2106/00004623-198264010-00010; HEDGES LV, 1992, J EDUC STAT, V17, P279, DOI 10.2307/1165125; HOEK JA, 1992, THROMB HAEMOSTASIS, V67, P28; HULL R, 1993, NEW ENGL J MED, V329, P1370, DOI 10.1056/NEJM199311043291902; HULL RD, 1990, JAMA-J AM MED ASSOC, V263, P2313, DOI 10.1001/jama.263.17.2313; ISHAK MA, 1981, BRIT J SURG, V68, P429, DOI 10.1002/bjs.1800680622; JOSEFSSON G, 1987, ACTA ORTHOP SCAND, V58, P626, DOI 10.3109/17453678709146500; KAEMPFFE FA, 1991, CLIN ORTHOP RELAT R, P89; KROON C, 1991, LANCET, V337, P945, DOI 10.1016/0140-6736(91)91573-D; LAGUARDIA AM, 1992, CURR MED RES OPIN, V12, P584, DOI 10.1185/03007999209111525; Laird N M, 1990, Int J Technol Assess Health Care, V6, P5; LASSEN MR, 1991, ACTA ORTHOP SCAND, V62, P33, DOI 10.3109/17453679108993088; LASSEN MR, 1988, BRIT J SURG, V75, P686, DOI 10.1002/bjs.1800750720; LAUPACIS A, 1988, NEW ENGL J MED, V318, P1728, DOI 10.1056/NEJM198806303182605; LEVINE MN, 1991, ANN INTERN MED, V114, P545, DOI 10.7326/0003-4819-114-7-545; Leyvraz P, 1988, J Arthroplasty, V3, P81, DOI 10.1016/S0883-5403(88)80056-1; LEYVRAZ PF, 1991, BRIT MED J, V303, P543, DOI 10.1136/bmj.303.6802.543; LEYVRAZ PF, 1983, NEW ENGL J MED, V309, P954, DOI 10.1056/NEJM198310203091605; MANNUCCI PM, 1976, THROMB HAEMOSTASIS, V36, P157; Matzsch T, 1988, Acta Chir Scand Suppl, V543, P80; MATZSCH T, 1990, ACTA CHIR SCAND, V156, P445; MORRIS GK, 1974, LANCET, V2, P797; MORRIS WT, 1981, BRIT J SURG, V68, P301, DOI 10.1002/bjs.1800680503; MOSKOVITZ PA, 1978, J BONE JOINT SURG AM, V60, P1065, DOI 10.2106/00004623-197860080-00008; OMEARA PM, 1990, ORTHOPEDICS, V13, P173; OSTER G, 1987, JAMA-J AM MED ASSOC, V257, P203, DOI 10.1001/jama.257.2.203; PARKERWILLIAMS J, 1991, BRIT MED J, V303, P531, DOI 10.1136/bmj.303.6802.531; PLANES A, 1988, THROMB HAEMOSTASIS, V60, P407; PLANES A, 1991, J BONE JOINT SURG BR, V73, P418, DOI 10.1302/0301-620X.73B3.1670442; PLANES A, 1990, ACTA CHIR SCAND, P108; RANSOHOFF DF, 1978, NEW ENGL J MED, V299, P926, DOI 10.1056/NEJM197810262991705; ROGERS PH, 1978, J BONE JOINT SURG AM, V60, P758, DOI 10.2106/00004623-197860060-00005; ROTHERMEL JE, 1973, ARCH SURG-CHICAGO, V106, P135; SAGAR S, 1976, LANCET, V1, P1151; SALZMAN EW, 1980, ANN SURG, V191, P207, DOI 10.1097/00000658-198002000-00013; SAUTTER RD, 1983, JAMA-J AM MED ASSOC, V250, P2649, DOI 10.1001/jama.250.19.2649; SCHONDORF TH, 1978, THROMB RES, V12, P153, DOI 10.1016/0049-3848(78)90093-2; TORHOLM C, 1991, J BONE JOINT SURG BR, V73, P434, DOI 10.1302/0301-620X.73B3.1670445; TURPIE AGG, 1986, NEW ENGL J MED, V315, P925, DOI 10.1056/NEJM198610093151503; TURPIE AGG, 1990, ACTA CHIR SCAND, P103; VITOUX JF, 1988, THROMB HAEMOSTASIS, V59, P120; WOOLSON ST, 1991, J BONE JOINT SURG AM, V73A, P507, DOI 10.2106/00004623-199173040-00005; 1975, BRIT J SURG, V62, P348; 1988, SAS LANGUAGE GUIDE P	79	199	203	0	2	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 8	1994	271	22					1780	1785		10.1001/jama.271.22.1780	http://dx.doi.org/10.1001/jama.271.22.1780			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NN725	7515115				2022-12-28	WOS:A1994NN72500029
J	YOUNG, NS				YOUNG, NS			AGRANULOCYTOSIS	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Discussion							DRUG-INDUCED AGRANULOCYTOSIS; HEMATOPOIETIC GROWTH-FACTORS; METABOLITES; PRECURSORS; ANTIBODIES				YOUNG, NS (corresponding author), NHLBI,HEMATOL BRANCH,BLDG 10,ROOM 7C103,BETHESDA,MD 20892, USA.							Alter BF, 1993, APLASTIC ANEMIA ACQU, P227; BOTTIGER LE, 1979, ACTA MED SCAND, V205, P457; CURRIE MS, 1987, BLOOD, V69, P529; DUNBAR CE, IN PRESS BLOOD TXB H; FELDMAN AM, 1993, CIRCULATION, V88, P301; GERSON WT, 1983, BLOOD, V61, P889; GLASPY JA, 1990, EXP HEMATOL, V18, P1137; HEIMPEL H, 1988, MED TOXICOL ADV DRUG, V3, P449, DOI 10.1007/BF03259896; HEIT W, 1985, SCAND J HAEMATOL, V35, P459; HODINKA L, 1981, INT ARCH ALLER A IMM, V65, P460, DOI 10.1159/000232788; JULIA A, 1991, BRIT J HAEMATOL, V79, P366, DOI 10.1111/j.1365-2141.1991.tb08042.x; Kaufman DW, 1991, DRUG ETIOLOGY AGRANU; Kracke RR, 1935, J AMER MED ASSOC, V105, P0960, DOI 10.1001/jama.1935.92760380004011; LAVER J, 1989, JNCI-J NATL CANCER I, V81, P1370, DOI 10.1093/jnci/81.18.1370; LEVITT LJ, 1987, BLOOD, V69, P394; Madison FW, 1934, J AMER MED ASSOC, V102, P755, DOI 10.1001/jama.1934.02750100021006; MOESCHLIN S, 1952, ACTA HAEMATOL-BASEL, V8, P29, DOI 10.1159/000204146; NEBERT DW, 1987, ANNU REV BIOCHEM, V56, P945, DOI 10.1146/annurev.biochem.56.1.945; PISCIOTTA AV, 1969, J AMER MED ASSOC, V208, P1862, DOI 10.1001/jama.208.10.1862; PISCIOTTA AV, 1990, BLOOD REV, V4, P226, DOI 10.1016/0268-960X(90)90002-A; PRICE DA, 1986, ETHNIC DIFFERENCES R, P209; ROUVEIX B, 1989, BRIT J HAEMATOL, V71, P7, DOI 10.1111/j.1365-2141.1989.tb06266.x; ROWE JM, 1992, J CLIN PHARMACOL, V32, P486, DOI 10.1177/009127009203200602; RUDOVIC R, 1972, SCAND J HAEMATOL, V9, P18; SALAMA A, 1989, BRIT J HAEMATOL, V72, P127, DOI 10.1111/j.1365-2141.1989.tb07672.x; Schultz W, 1922, DEUT MED WOCHENSCHR, V48, P1495; SHASTRI KA, 1993, BLOOD, V81, P1984; SINGHVI SM, 1982, CLIN PHARMACOL THER, V32, P182, DOI 10.1038/clpt.1982.145; STROM BL, 1992, ARCH INTERN MED, V152, P1475, DOI 10.1001/archinte.152.7.1475; TAJIRI J, 1993, ARCH INTERN MED, V153, P509, DOI 10.1001/archinte.153.4.509; TERKELSEN KG, 1990, HOSP COMMUNITY PSYCH, V41, P863; Weinshilboum R M, 1983, Prog Clin Biol Res, V135, P167	32	38	38	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAR 23	1994	271	12					935	938		10.1001/jama.271.12.935	http://dx.doi.org/10.1001/jama.271.12.935			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NA743	7509883				2022-12-28	WOS:A1994NA74300031
J	SCOLNIK, D; NULMAN, I; ROVET, J; GLADSTONE, D; CZUCHTA, D; GARDNER, HA; GLADSTONE, R; ASHBY, P; WEKSBERG, R; EINARSON, T; KOREN, G				SCOLNIK, D; NULMAN, I; ROVET, J; GLADSTONE, D; CZUCHTA, D; GARDNER, HA; GLADSTONE, R; ASHBY, P; WEKSBERG, R; EINARSON, T; KOREN, G			NEURODEVELOPMENT OF CHILDREN EXPOSED IN-UTERO TO PHENYTOIN AND CARBAMAZEPINE MONOTHERAPY	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							PREGNANCY; WOMEN; DRUG	Objective.-To compare pregnancy outcome prospectively after phenytoin and carbamazepine monotherapy with outcome in matched mother-child pairs exposed to nonteratogens to evaluate the relative fetal safety of these drugs. Design.-A prospective, controlled, and blinded observational study. Patients.-Thirty-six mother-child pairs exposed to carbamazepine monotherapy and 34 pairs exposed to phenytoin monotherapy, all prospectively studied, were compared with mother-child pairs exposed to nonteratogens. The controls were matched for maternal age, time of consultation, obstetric history, and socioeconomic status. Main Outcome Measure.-The primary end point of interest was the children's global IQ measured by either the Bayley or the McCarthy scale according to their ages. Setting.-A teratology consultation program and two neurology services in Toronto, Ontario. Results.- Children exposed to phenytoin in utero had a mean (+/-SD) global IQ 10 points lower (95% confidence interval, 4.9 to 15.8 points) than their matched controls (113.4+/-13.1 and 103.1+/-25.1; P=.038). The Reynell language development scores followed a similar trend, with children exposed to phenytoin scoring significantly lower than their controls. Phenytoin-exposed children had a global IQ of 84 or less significantly more often than the control group (P<.01). Children exposed in utero to carbamazepine did not differ from their controls on any of the neurobehavioral tests. Conclusions.-Our study suggests a clinically important negative effect of phenytoin on neurobehavioral development, independent of maternal or environmental factors, causing a substantial number of children to achieve a lower score than expected on cognitive tests. No similar effects could be shown after gestational use of carbamazepine.	HOSP SICK CHILDREN,DIV CLIN PHARMACOL,TORONTO M5G 1X8,ON,CANADA; HOSP SICK CHILDREN,DIV CLIN PHARMACOL TOXICOL,MOTHERISK PROGRAM,TORONTO,ON,CANADA; HOSP SICK CHILDREN,DEPT PEDIAT,TORONTO M5G 1X8,ON,CANADA; HOSP SICK CHILDREN,DEPT PSYCHOL,TORONTO,ON,CANADA; HOSP SICK CHILDREN,RES INST,TORONTO M5G 1X8,ON,CANADA; GEN HOSP,GENET SERV,OSHAWA,ON,CANADA; GEN HOSP,DEPT NEUROL,N YORK,ON,CANADA; TORONTO HOSP,DEPT NEUROL,WESTERN DIV,TORONTO,ON,CANADA; UNIV TORONTO,DEPT PEDIAT,TORONTO,ON,CANADA; UNIV TORONTO,DEPT PHARMACOL,TORONTO,ON,CANADA; UNIV TORONTO,DEPT PHARM,TORONTO,ON,CANADA	University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); University of Ottawa; University of Toronto; University Toronto Affiliates; University Health Network Toronto; Toronto General Hospital; University of Toronto; University Toronto Affiliates; University Health Network Toronto; University of Toronto; University of Toronto; University of Toronto			Koren, Gideon/AAG-7726-2019	Koren, Gideon/0000-0002-9234-0875; Gladstone, David/0000-0003-0612-5544				Bayley N., 1993, BAYLEY SCALES INFANT, Vsecond; BERTOLLINI R, 1987, EUR J EPIDEMIOL, V3, P164; ESCUETA AVD, 1992, NEUROLOGY S5, V42, P149; FELDMAN Y, 1989, TERATOLOGY, V40, P37, DOI 10.1002/tera.1420400106; GAILY E, 1990, DEV MED CHILD NEUROL, V32, P403; GLADSTONE DJ, 1992, REPROD TOXICOL, V6, P257, DOI 10.1016/0890-6238(92)90181-R; HANSON JW, 1975, J PEDIATR-US, V87, P285, DOI 10.1016/S0022-3476(75)80604-4; Hollingshead August B., 1958, SOCIAL CLASS MENTAL; JONES KL, 1989, NEW ENGL J MED, V320, P1661, DOI 10.1056/NEJM198906223202505; KANEKO S, 1991, REPROD TOXICOL, V5, P179, DOI 10.1016/0890-6238(91)90050-P; McCarthy D, 1972, MCCARTHY SCALES CHIL; Reynell J., 1977, REYNELL DEV LANGUAGE; ROBERT E, 1982, LANCET, V2, P937, DOI 10.1016/s0140-6736(82)90908-4; ROZA FW, 1991, NEW ENGL J MED, V324, P674; SAUNDERS M, 1989, BRIT MED J, V299, P581, DOI 10.1136/bmj.299.6699.581; SCHARDEIN JL, 1985, CHEM INDUCED BIRTH D, P142; STRICKLER SM, 1985, LANCET, V2, P746; VINING EPG, 1987, EPILEPSIA, V28, pS18, DOI 10.1111/j.1528-1157.1987.tb05767.x; VORHEES CV, 1986, NEUROTOXICOLOGY, V7, P235; Wechsler D, 1981, ADULT INTELLIGENCE S	20	190	193	0	2	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAR 9	1994	271	10					767	770		10.1001/jama.271.10.767	http://dx.doi.org/10.1001/jama.271.10.767			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MY288	7509419				2022-12-28	WOS:A1994MY28800031
J	CLEELAND, CS; GONIN, R; HATFIELD, AK; EDMONSON, JH; BLUM, RH; STEWART, JA; PANDYA, KJ				CLEELAND, CS; GONIN, R; HATFIELD, AK; EDMONSON, JH; BLUM, RH; STEWART, JA; PANDYA, KJ			PAIN AND ITS TREATMENT IN OUTPATIENTS WITH METASTATIC CANCER	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							CARE; PREVALENCE; BREAST; BLACK	Background and Methods. Pain is often inadequately treated in patients with cancer. A total of 1308 outpatients with metastatic cancer from 54 treatment locations affiliated with the Eastern Cooperative Oncology Group rated the severity of their pain during the preceding week, as well as the degree of pain-related functional impairment and the degree of relief provided by analgesic drugs. Their physicians attributed the pain to various factors, described its treatment, and estimated the impact of pain on the patients' ability to function. We assessed the adequacy of prescribed analgesic drugs using guidelines developed by the World Health Organization, studied the factors that influenced whether analgesia was adequate, and determined the effects of inadequate analgesia on the patients' perception of pain relief and functional status. Results. Sixty-seven percent of the patients (871 of 1308) reported that they had had pain or had taken analgesic drugs daily during the week preceding the study, and 36 percent (475 of 1308) had pain severe enough to impair their ability to function. Forty-two percent of those with pain (250 of the 597 patients for whom we had complete information) were not given adequate analgesic therapy. Patients seen at centers that treated predominantly minorities were three times more likely than those treated elsewhere to have inadequate pain management. A discrepancy between patient and physician in judging the severity of the patient's pain was predictive of inadequate pain management (odds ratio, 2.3). Other factors that predicted inadequate pain management included pain that physicians did not attribute to cancer (odds ratio, 1.9), better performance status (odds ratio, 1.8), age of 70 years or older (odds ratio, 2.4), and female sex (odds ratio, 1.5). Patients with less adequate analgesia reported less pain relief and greater pain-related impairment of function. Conclusions. Despite published guidelines for pain management, many patients with cancer have considerable pain and receive inadequate analgesia.	UNIV WISCONSIN, CTR COMPREHENS CANC, MADISON, WI USA; DANA FARBER CANC INST, BOSTON, MA USA; CARLE CANC CTR, URBANA, IL USA; MAYO CLIN & MAYO FDN, ROCHESTER, MN USA; NYU MED CTR, NEW YORK, NY USA; UNIV ROCHESTER, CTR CANC, ROCHESTER, NY USA	University of Wisconsin System; University of Wisconsin Madison; Harvard University; Dana-Farber Cancer Institute; Mayo Clinic; New York University; University of Rochester	CLEELAND, CS (corresponding author), UNIV WISCONSIN, DEPT NEUROL, PAIN RES GRP, 1900 UNIV AVE, MADISON, WI 53705 USA.				NATIONAL CANCER INSTITUTE [R18CA026582, R01CA026582, U10CA021115] Funding Source: NIH RePORTER; NCI NIH HHS [CA 26582, CA 21115, R01 CA026582] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AHLES TA, 1983, PAIN, V17, P277, DOI 10.1016/0304-3959(83)90100-8; [Anonymous], 1991, EFFECT CANC QUALITY; BLENDON RJ, 1989, JAMA-J AM MED ASSOC, V261, P278, DOI 10.1001/jama.261.2.278; BONICA JJ, 1985, ADV PAIN RES THER, V9, P589; CLEELAND C, 1991, CANCER, V67, P823, DOI 10.1002/1097-0142(19910201)67:3+<823::AID-CNCR2820671412>3.0.CO;2-S; CLEELAND CS, 1986, CANCER, V58, P796, DOI 10.1002/1097-0142(19860801)58:3<796::AID-CNCR2820580331>3.0.CO;2-#; CLEELAND CS, 1984, CANCER, V53, P2264; Cleeland CS, 1989, ADV PAIN RES THER, P391, DOI DOI 10.1093/BRAIN/113.5.1589; CLEELAND CS, 1992, PAIN ASSESSMENT, P360; DAUT RL, 1982, CANCER-AM CANCER SOC, V50, P1913, DOI 10.1002/1097-0142(19821101)50:9<1913::AID-CNCR2820500944>3.0.CO;2-R; DONOVAN M, 1987, PAIN, V30, P69, DOI 10.1016/0304-3959(87)90084-4; Ferrell B, 1991, Hosp J, V7, P9; FISHMAN B, 1987, CANCER-AM CANCER SOC, V60, P1151, DOI 10.1002/1097-0142(19870901)60:5<1151::AID-CNCR2820600538>3.0.CO;2-G; Foley K., 1979, ADV PAIN RES THER, V2, P59; FOLEY KM, 1985, NEW ENGL J MED, V313, P84, DOI 10.1056/NEJM198507113130205; FREEMAN HP, 1989, CANCER, V63, P2562, DOI 10.1002/1097-0142(19890615)63:12<2562::AID-CNCR2820631234>3.0.CO;2-0; GREENFIELD S, 1987, JAMA-J AM MED ASSOC, V257, P2766, DOI 10.1001/jama.257.20.2766; GREENWALD HP, 1987, CANCER, V60, P2563, DOI 10.1002/1097-0142(19871115)60:10<2563::AID-CNCR2820601036>3.0.CO;2-L; GROSSMAN SA, 1991, J PAIN SYMPTOM MANAG, V6, P53, DOI 10.1016/0885-3924(91)90518-9; HATFIELD AK, 1991, MAY ANN AM SOC CLIN; HOSMER DW, 1989, APPL LOGISTIC REGRES, P25; JAGOX A, 1994, NEW ENGL J MED, V330, P651, DOI 10.1056/NEJM199403033300926; MCGIVNEY WT, 1984, JAMA-J AM MED ASSOC, V251, P1182; MEHTA CR, 1983, J AM STAT ASSOC, V78, P427, DOI 10.2307/2288652; MORRISON DF, 1990, MULTIVARIATE STATIST, P164; OKEN MM, 1982, AM J CLIN ONCOL-CANC, V5, P649, DOI 10.1097/00000421-198212000-00014; PETEET J, 1986, CANCER, V57, P1259, DOI 10.1002/1097-0142(19860315)57:6<1259::AID-CNCR2820570633>3.0.CO;2-L; PORTENOY RK, 1989, CANCER, V63, P2298, DOI 10.1002/1097-0142(19890601)63:11<2298::AID-CNCR2820631140>3.0.CO;2-A; TODD KH, 1993, JAMA-J AM MED ASSOC, V269, P1537, DOI 10.1001/jama.269.12.1537; VONROENN JH, 1993, ANN INTERN MED, V119, P121, DOI 10.7326/0003-4819-119-2-199307150-00005; Zar J.H., 1999, ZAR KUHR 5 2019, V4th; 1986, CANCER PAIN RELIEF; 1989, PRINCIPLES ANALGESIC	33	1439	1482	0	40	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	MAR 3	1994	330	9					592	596		10.1056/NEJM199403033300902	http://dx.doi.org/10.1056/NEJM199403033300902			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MY573	7508092				2022-12-28	WOS:A1994MY57300002
J	Childs, NL; Mercer, WN				Childs, NL; Mercer, WN			Late improvement in consciousness after post-traumatic - Brief report	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							PERSISTENT VEGETATIVE STATE; HEAD-INJURY; COMA		HENRY FORD HOSP, DEPT PSYCHIAT, DIV NEUROPSYCHOL, DETROIT, MI 48202 USA	Henry Ford Health System; Henry Ford Hospital	Childs, NL (corresponding author), HEALTHCARE REHABIL CTR, INPATIENT BRAIN INJURY PROGRAM, 1106 W DITTMAR RD, POB 43148, AUSTIN, TX 78745 USA.							ANDREWS K, 1993, BRIT MED J, V306, P1597, DOI 10.1136/bmj.306.6892.1597; [Anonymous], 1989, NEUROLOGY, V39, P125; ARTS WFM, 1985, J NEUROL NEUROSUR PS, V48, P1300, DOI 10.1136/jnnp.48.12.1300; ASHWAL S, 1994, NEW ENGL J MED, V330, P1499; ASHWAL S, 1994, NEW ENGL J MED, V330, P1572; CHILDS NL, 1993, NEUROLOGY, V43, P1465, DOI 10.1212/WNL.43.8.1465; GIACINO JT, 1995, ARCH PHYS MED REHAB, V76, P205; HARRIS DP, 1990, EAR HEARING, V11, P340, DOI 10.1097/00003446-199010000-00004; JENNETT B, 1972, LANCET, V1, P734; JENNETT B, 1976, ARCH NEUROL-CHICAGO, V33, P595, DOI 10.1001/archneur.1976.00500090001001; LEVIN HS, 1991, ARCH NEUROL-CHICAGO, V48, P580, DOI 10.1001/archneur.1991.00530180032013; PATRICK DL, 1994, MED DECIS MAKING, V14, P9, DOI 10.1177/0272989X9401400102; SHIN DY, 1989, ARCH PHYS MED REHAB, V70, P189; Sutherland H J, 1982, Med Decis Making, V2, P299, DOI 10.1177/0272989X8200200306; TEASDALE G, 1974, LANCET, V2, P81; 1990, JAMA-J AM MED ASSOC, V263, P426	16	82	82	0	0	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JAN 4	1996	334	1					24	25		10.1056/NEJM199601043340105	http://dx.doi.org/10.1056/NEJM199601043340105			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TM482	7494566				2022-12-28	WOS:A1996TM48200005
J	LI, B; TOM, JYK; OARE, D; YEN, R; FAIRBROTHER, WJ; WELLS, JA; CUNNINGHAM, BC				LI, B; TOM, JYK; OARE, D; YEN, R; FAIRBROTHER, WJ; WELLS, JA; CUNNINGHAM, BC			MINIMIZATION OF A POLYPEPTIDE HORMONE	SCIENCE			English	Article							HUMAN GROWTH-HORMONE; NATRIURETIC PEPTIDE RECEPTORS; EXTRACELLULAR DOMAIN; FUNCTIONAL EPITOPE; CYCLASE ACTIVATION; ANTIBODY; MUTAGENESIS; INHIBITORS; PROTEINS; ANALOGS	A stepwise approach for reducing the size of a polypeptide hormone, atrial natriuretic peptide (ANP), from 28 residues to 15 while retaining high biopotency is described. Systematic structural and functional analysis identified a discontinuous functional epitope for receptor binding and activation, most of which was placed onto a smaller ring (Cys(6) to Cys(17)) that was created by repositioning the ANP native disulfide bond (Cys(7) to Cys(23)). High affinity was subsequently restored by optimizing the remaining noncritical residues by means of phage display. Residues that flanked the mini-ring structure were then deleted in stages, and affinity losses were rectified by additional phage-sorting experiments. Thus, structural and functional data on hormones, coupled with phage display methods, can be used to shrink the hormones to moieties more amenable to small-molecule design.	GENENTECH INC,DEPT PROT ENGN,S SAN FRANCISCO,CA 94080; GENENTECH INC,BIOORGAN CHEM,S SAN FRANCISCO,CA 94080; GENENTECH INC,MED & ANALYT CHEM,S SAN FRANCISCO,CA 94080	Roche Holding; Genentech; Roche Holding; Genentech; Roche Holding; Genentech			Wells, Jim A/O-9854-2016					BASS S, 1990, PROTEINS, V8, P309, DOI 10.1002/prot.340080405; BENNETT BD, 1991, J BIOL CHEM, V266, P23060; BOVY PR, 1989, J BIOL CHEM, V264, P20309; BOVY PR, 1992, J MED CHEM, V35, P808; CLACKSON T, 1995, SCIENCE, V267, P383, DOI 10.1126/science.7529940; COREY DR, 1994, P NATL ACAD SCI USA, V91, P4106, DOI 10.1073/pnas.91.10.4106; CUNNINGHAM BC, 1993, J MOL BIOL, V234, P554, DOI 10.1006/jmbi.1993.1611; CUNNINGHAM BC, 1990, SCIENCE, V247, P1461, DOI 10.1126/science.2321008; CUNNINGHAM BC, 1989, SCIENCE, V244, P1081, DOI 10.1126/science.2471267; CUNNINGHAM BC, 1994, EMBO J, V13, P2508, DOI 10.1002/j.1460-2075.1994.tb06540.x; DAVIES DR, 1990, ANNU REV BIOCHEM, V59, P439, DOI 10.1146/annurev.bi.59.070190.002255; DEVOS AM, 1992, SCIENCE, V255, P306, DOI 10.1126/science.1549776; FAIRBROTHER WJ, 1994, BIOCHEMISTRY-US, V33, P8897, DOI 10.1021/bi00196a006; JANIN J, 1990, J BIOL CHEM, V265, P16027; JIN L, 1992, J MOL BIOL, V226, P851, DOI 10.1016/0022-2836(92)90636-X; JONES PT, 1986, NATURE, V321, P522, DOI 10.1038/321522a0; KELLEY RF, 1993, BIOCHEMISTRY-US, V32, P6828, DOI 10.1021/bi00078a005; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; LAM PYS, 1994, SCIENCE, V263, P380, DOI 10.1126/science.8278812; LOWMAN HB, 1993, J MOL BIOL, V234, P564, DOI 10.1006/jmbi.1993.1612; LUNNEY EA, 1994, J MED CHEM, V37, P2664, DOI 10.1021/jm00043a006; MAACK T, 1992, ANNU REV PHYSIOL, V54, P11, DOI 10.1146/annurev.physiol.54.1.11; MCDOWELL RS, 1994, J AM CHEM SOC, V116, P5069, DOI 10.1021/ja00091a007; NAVIA MA, 1992, CURR OPIN STRUC BIOL, V2, P202; NUSS JM, 1993, PROTEINS, V15, P121, DOI 10.1002/prot.340150204; NUTT RF, 1989, SYNTHETIC PEPTIDES A, P267; NUTT RF, 1988, PEPTIDES CHEM BIOL, P444; PRESTA L, 1994, ANNU REP MED CHEM, V29, P317; SCARBOROUGH RM, 1986, J BIOL CHEM, V261, P2960; SHOICHET BK, 1993, SCIENCE, V259, P1445, DOI 10.1126/science.8451640; TULIP WR, 1994, BIOCHEMISTRY-US, V33, P7986, DOI 10.1021/bi00192a002; VONGELDERN TW, 1992, J MED CHEM, V35, P808, DOI 10.1021/jm00083a003; VONITZSTEIN M, 1993, NATURE, V363, P418, DOI 10.1038/363418a0; Wells J. A., 1992, CURR OPIN STRUC BIOL, V2, P597; WELLS JA, 1994, P NATL ACAD SCI USA, V91, P4110, DOI 10.1073/pnas.91.10.4110; WELLS JA, 1991, METHODS ENZYMOL, V202	36	123	142	0	9	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	DEC 8	1995	270	5242					1657	1660		10.1126/science.270.5242.1657	http://dx.doi.org/10.1126/science.270.5242.1657			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TJ293	7502074				2022-12-28	WOS:A1995TJ29300046
J	BARRETT, TG; BUNDEY, SE; MACLEOD, AF				BARRETT, TG; BUNDEY, SE; MACLEOD, AF			NEURODEGENERATION AND DIABETES - UK NATIONWIDE STUDY OF WOLFRAM (DIDMOAD) SYNDROME	LANCET			English	Article							OPTIC ATROPHY; MELLITUS; INSIPIDUS	Wolfram syndrome is the association of diabetes mellitus and optic atrophy, and is sometimes called DIDMOAD (diabetes insipidus, diabetes mellitus, optic atrophy, and deafness). Incomplete characterisation of this autosomal recessive syndrome has relied on case-reports, and there is confusion with mitochondrial genome disorders. We therefore undertook a UK nationwide cross-sectional case-finding study to describe the natural history, complications, prevalence, and inheritance of the syndrome. We identified 45 patients with Wolfram syndrome-a prevalence of one per 770000. Non-autoimmune, insulin-deficient diabetes mellitus presented at a median age of 6 years, followed by optic atrophy (11 years). Cranial diabetes insipidus occurred in 33 patients (73%) with sensorineural deafness (28, 62%) in the second decade; renal;tract abnormalities (26, 58%) presented in the third decade followed by neurological complications (cerebellar ataxia, myoclonus [28, 62%]) in the fourth decade. Other abnormalities included gastrointestinal dysmotility in 11 (24%), and primary gonadal atrophy in seven of ten males investigated. Median age at death (commonly central respiratory failure with brain-stem atrophy) was 30 years (range 25-49). The natural history of Wolfram syndrome suggests that most patients will eventually develop most complications of this progressive, neurodegenerative disorder. Family studies indicate autosomal recessive inheritance with a carrier frequency of one in 354, an absence of a maternal history of diabetes or deafness, and an absence of the mitochondrial tRNA Leu (3243) mutation. Juvenile-onset diabetes mellitus and optic atrophy are the best available diagnostic criteria for Wolfram syndrome, the differential diagnosis of which includes other causes of neurodegeneration.	UNIV BIRMINGHAM, DEPT PAEDIAT & CHILD HLTH, CLIN GENET UNIT, BIRMINGHAM, W MIDLANDS, ENGLAND; ROYAL SHREWSBURY HOSP NHS TRUST, SHREWSBURY, SALOP, ENGLAND	University of Birmingham			Barrett, Timothy/F-1682-2010	Barrett, Timothy/0000-0002-6873-0750				BARRETT TG, 1995, J INHERIT METAB DIS, V18, P218, DOI 10.1007/BF00711771; BLASI C, 1986, DIABETES CARE, V9, P521, DOI 10.2337/diacare.9.5.521; BORNAPIGNATTI C, 1989, J PEDIATR, V114, P405; BU XD, 1993, LANCET, V342, P598, DOI 10.1016/0140-6736(93)91416-J; BUNDEY S, 1992, J INHERIT METAB DIS, V15, P315, DOI 10.1007/BF02435965; CARSON MJ, 1977, AM J DIS CHILD, V131, P1382, DOI 10.1001/archpedi.1977.02120250064010; CREMERS C W R J, 1977, Acta Paediatrica Scandinavica Supplement, P1; DIDMOAD, 1986, LANCET, V1, P1075; EMERY AEH, 1986, METHODOLOGY MED GENE; FRASER FC, 1977, J MED GENET, V14, P190, DOI 10.1136/jmg.14.3.190; GARCIALUNA PP, 1988, ACTA PAEDIATR SCAND, V77, P413, DOI 10.1111/j.1651-2227.1988.tb10669.x; GOTO Y, 1990, NATURE, V348, P651, DOI 10.1038/348651a0; GUNN T, 1976, J PEDIATR-US, V89, P565, DOI 10.1016/S0022-3476(76)80387-3; HAGOPIAN WA, 1993, DIABETES, V42, P631, DOI 10.2337/diabetes.42.4.631; HAMPTON SM, 1988, CLIN ENDOCRINOL, V29, P9, DOI 10.1111/j.1365-2265.1988.tb00244.x; JACKSON MJ, 1994, DIABETES CARE, V17, P728, DOI 10.2337/diacare.17.7.728; MCCARTY DJ, 1993, INT J EPIDEMIOL, V22, P559, DOI 10.1093/ije/22.3.559; MONSON JP, 1983, LANCET, V1, P1286; PAGE MM, 1976, Q J MED, V45, P505; PEDEN NR, 1986, Q J MED, V58, P167; PILZ D, 1994, J MED GENET, V31, P328, DOI 10.1136/jmg.31.4.328; POLYMEROPOULOS MH, 1994, NAT GENET, V8, P95, DOI 10.1038/ng0994-95; RANDO TA, 1992, NEUROLOGY, V42, P1220, DOI 10.1212/WNL.42.6.1220; ROSE FC, 1966, Q J MED, V35, P385; ROTIG A, 1993, J CLIN INVEST, V91, P1095, DOI 10.1172/JCI116267; SWIFT RG, 1990, LANCET, V336, P667, DOI 10.1016/0140-6736(90)92157-D; VANDENOUWELAND JMW, 1992, NUCLEIC ACIDS RES, V20, P679, DOI 10.1093/nar/20.4.679; Wolfram D.J., 1938, MAYO CLIN PROC, V13, P715	28	402	423	0	13	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	DEC 2	1995	346	8988					1458	1463		10.1016/S0140-6736(95)92473-6	http://dx.doi.org/10.1016/S0140-6736(95)92473-6			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TH156	7490992				2022-12-28	WOS:A1995TH15600010
J	MORISHITA, T; MITSUZAWA, H; NAKAFUKU, M; NAKAMURA, S; HATTORI, S; ANRAKU, Y				MORISHITA, T; MITSUZAWA, H; NAKAFUKU, M; NAKAMURA, S; HATTORI, S; ANRAKU, Y			REQUIREMENT OF SACCHAROMYCES-CEREVISIAE RAS FOR COMPLETION OF MITOSIS	SCIENCE			English	Article							PROTEIN-KINASE; ADENYLATE-CYCLASE; SHUTTLE VECTORS; YEAST; GENE; INTERACTS; ENCODES; RSR1	In the yeast Saccharomyces cerevisiae, Ras regulates adenylate cyclase, which is essential for progression through the G(1) phase of the cell cycle. However, even when the adenosine 3',5'-monophosph (cAMP) pathway was bypassed, the double disruption of RAS1 and RAS2 resulted in defects in growth at both low and high temperatures. Furthermore, the simultaneous disruption of RAS1, RAS2, and the RAS-related gene RSR1 was lethal at any temperature. The triple-disrupted cells were arrested late in the mitotic (M) phase, which was accompanied by an accumulation of cells with divided chromosomes and sustained histone H1 kinase activity. The lethality of the triple disruption was suppressed by the multicopies of CDC5, CDC15, DBF2, SPO12, and TEM1, all of which function in the completion of the M phase. Mammalian ras also suppressed the lethality, which suggests that a similar signaling pathway exists in higher eukaryotes. These results demonstrate that S. cerevisiae Ras functions in the completion of the M phase in a manner independent of the Ras-cAMP pathway.	NATL CTR NEUROL & PSYCHIAT,NATL INST NEUROSCI,DIV BIOCHEM & CELLULAR BIOL,KODAIRA 187,TOKYO,JAPAN; UNIV TOKYO,GRAD SCH SCI,DEPT PLANT SCI,BUNKYO KU,TOKYO 113,JAPAN; UNIV TOKYO,INST MOLEC & CELLULAR BIOSCI,BUNKYO KU,TOKYO 113,JAPAN	National Center for Neurology & Psychiatry - Japan; University of Tokyo; University of Tokyo			Nakafuku, Masato/J-3068-2013	Nakafuku, Masato/0000-0001-7783-9005				AVRUCH J, 1994, TRENDS BIOCHEM SCI, V19, P279, DOI 10.1016/0968-0004(94)90005-1; BARBACID M, 1987, ANNU REV BIOCHEM, V56, P779, DOI 10.1146/annurev.bi.56.070187.004023; BECKNER SK, 1985, NATURE, V317, P71, DOI 10.1038/317071a0; BENDER A, 1989, P NATL ACAD SCI USA, V86, P9976, DOI 10.1073/pnas.86.24.9976; BIRCHMEIER C, 1985, CELL, V43, P615, DOI 10.1016/0092-8674(85)90233-8; Broach J R, 1990, Adv Cancer Res, V54, P79, DOI 10.1016/S0065-230X(08)60809-X; CHANG EC, 1994, CELL, V79, P131, DOI 10.1016/0092-8674(94)90406-5; CHANT J, 1991, CELL, V65, P1213, DOI 10.1016/0092-8674(91)90016-R; DAAR I, 1991, SCIENCE, V253, P74, DOI 10.1126/science.1829549; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; FUKUI Y, 1986, CELL, V44, P329, DOI 10.1016/0092-8674(86)90767-1; GIBBS JB, 1987, J BIOL CHEM, V262, P10426; HILL JE, 1986, YEAST, V2, P163, DOI 10.1002/yea.320020304; KITADA K, 1993, MOL CELL BIOL, V13, P4445, DOI 10.1128/MCB.13.7.4445; MORISHITA T, UNPUB; POWERS S, 1991, CELL, V65, P1231; RIDLEY AJ, 1988, EMBO J, V7, P1635, DOI 10.1002/j.1460-2075.1988.tb02990.x; RODRIGUEZVICIAN.P, 1994, NATURE, V370, P527; RUGGIERI R, 1992, MOL CELL BIOL, V12, P758, DOI 10.1128/MCB.12.2.758; SATOH T, 1992, J BIOL CHEM, V267, P24149; SCHWEITZER B, 1991, YEAST, V7, P265, DOI 10.1002/yea.320070308; SHIRAYAMA M, 1994, MOL CELL BIOL, V14, P7476, DOI 10.1128/MCB.14.11.7476; SHIRAYAMA M, 1994, YEAST, V10, P451, DOI 10.1002/yea.320100404; SIKORSKI RS, 1989, GENETICS, V122, P19; SURANA U, 1991, CELL, V65, P145, DOI 10.1016/0092-8674(91)90416-V; TODA T, 1987, CELL, V50, P277, DOI 10.1016/0092-8674(87)90223-6; TODA T, 1985, CELL, V40, P27, DOI 10.1016/0092-8674(85)90305-8; TODA T, 1987, ONCOGENES CANCER, P253; TOYN JH, 1993, GENETICS, V135, P963; TOYN JH, 1994, EMBO J, V13, P1103, DOI 10.1002/j.1460-2075.1994.tb06359.x; WIGLER M, 1988, COLD SPRING HARB SYM, V53, P649, DOI 10.1101/SQB.1988.053.01.074	31	57	58	0	2	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	NOV 17	1995	270	5239					1213	1215		10.1126/science.270.5239.1213	http://dx.doi.org/10.1126/science.270.5239.1213			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TE905	7502049				2022-12-28	WOS:A1995TE90500061
J	MCDOWELL, JC; ROBERTS, JW; JIN, DJ; GROSS, C				MCDOWELL, JC; ROBERTS, JW; JIN, DJ; GROSS, C			DETERMINATION OF INTRINSIC TRANSCRIPTION TERMINATION EFFICIENCY BY RNA-POLYMERASE ELONGATION RATE	SCIENCE			English	Article							ESCHERICHIA-COLI RNA; OPERON LEADER REGION; PHAGE-LAMBDA; BACTERIOPHAGE-LAMBDA; PAUSE SITE; INVITRO; RHO; GENE; REQUIREMENTS; SEQUENCES	Transcription terminators recognized by several RNA polymerases include a DNA segment encoding uridine-rich RNA and, for bacterial RNA polymerase, a hairpin loop located immediately upstream. Here, mutationally altered Escherichia coli RNA polymerase enzymes that have different termination efficiencies were used to show that the extent of transcription through the uridine-rich encoding segment is controlled by the substrate concentration of nucleoside triphosphate. This result implies that the rate of elongation determines the probability of transcript release. Moreover, the position of release sites suggests an important spatial relation between the RNA hairpin and the boundary of the terminator.	CORNELL UNIV,BIOCHEM MOLEC & CELL BIOL SECT,ITHACA,NY 14853; NCI,MOLEC BIOL LAB,BETHESDA,MD 20892; UNIV WISCONSIN,DEPT BACTERIOL,MADISON,WI 53706	Cornell University; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); University of Wisconsin System; University of Wisconsin Madison								ALTMANN CR, 1994, P NATL ACAD SCI USA, V91, P3784, DOI 10.1073/pnas.91.9.3784; BENTLEY DL, 1988, CELL, V53, P245, DOI 10.1016/0092-8674(88)90386-8; BOGENHAGEN DF, 1981, CELL, V24, P261, DOI 10.1016/0092-8674(81)90522-5; CHAN CL, 1993, J MOL BIOL, V233, P25, DOI 10.1006/jmbi.1993.1482; CHAN CL, 1994, TRANSCRIPTION MECHAN, P297; DEDRICK RL, 1987, J BIOL CHEM, V262, P9098; FARNHAM PJ, 1981, NUCLEIC ACIDS RES, V9, P563, DOI 10.1093/nar/9.3.563; FARNHAM PJ, 1980, CELL, V20, P739, DOI 10.1016/0092-8674(80)90320-7; FISHER RF, 1983, J BIOL CHEM, V258, P8146; Friedman DI., 1983, LAMBDA 2, P21; GRAYHACK EJ, 1985, CELL, V42, P259, DOI 10.1016/S0092-8674(85)80121-5; GUO HC, 1990, J BACTERIOL, V173, P1554; JIN DJ, 1988, J MOL BIOL, V202, P245, DOI 10.1016/0022-2836(88)90455-X; JIN DJ, 1991, J BIOL CHEM, V266, P14478; JIN DJ, 1992, P NATL ACAD SCI USA, V89, P1453, DOI 10.1073/pnas.89.4.1453; KERPPOLA TK, 1990, BIOCHEMISTRY-US, V29, P269, DOI 10.1021/bi00453a037; LANDICK R, 1984, J BIOL CHEM, V259, P1550; LAU LF, 1983, J BIOL CHEM, V258, P9391; LEVIN JR, 1987, J MOL BIOL, V196, P61, DOI 10.1016/0022-2836(87)90511-0; MARTIN FH, 1980, NUCLEIC ACIDS RES, V8, P2295, DOI 10.1093/nar/8.10.2295; MASON SW, 1992, J BIOL CHEM, V267, P19418; MCDOWELL JC, UNPUB; MORGAN WD, 1983, J BIOL CHEM, V258, P9565; REYNOLDS R, 1992, J MOL BIOL, V224, P53, DOI 10.1016/0022-2836(92)90575-5; REYNOLDS R, 1992, J MOL BIOL, V224, P31, DOI 10.1016/0022-2836(92)90574-4; ROBERTS J, 1992, TRANSCRIPTIONAL REGU, P389; ROSENBERG M, 1978, NATURE, V272, P414, DOI 10.1038/272414a0; VONHIPPEL PH, 1991, P NATL ACAD SCI USA, V88, P2307, DOI 10.1073/pnas.88.6.2307; WIEST DK, 1990, MOL CELL BIOL, V10, P5782, DOI 10.1128/MCB.10.11.5782; YAGER TD, 1987, CELLULAR MOL BIOL, P1241; YANG XJ, 1989, P NATL ACAD SCI USA, V86, P5301, DOI 10.1073/pnas.86.14.5301	31	107	112	0	8	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	NOV 4	1994	266	5186					822	825		10.1126/science.7526463	http://dx.doi.org/10.1126/science.7526463			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PP753	7526463				2022-12-28	WOS:A1994PP75300046
J	FINCK, BK; LINSLEY, PS; WOFSY, D				FINCK, BK; LINSLEY, PS; WOFSY, D			TREATMENT OF MURINE LUPUS WITH CTLA4IG	SCIENCE			English	Article							T-CELL ACTIVATION; COSTIMULATORY SIGNAL; MONOCLONAL-ANTIBODY; CTLA-4; CD28; ANTIGEN; LIGAND; RECEPTOR; INTERLEUKIN-2; PROLIFERATION	The interaction of B7-related molecules on antigen-presenting cells with CD28 or CTLA-4 antigens on T cells provides a second signal for T cell activation. Selective inhibition of the B7-CD28 or B7-CTLA-4 interactions produces antigen-specific T cell unresponsiveness in vitro and suppresses immune function in vivo. To determine whether selective inhibition of the B7-CD28 or B7-CTLA-4 interactions could suppress spontaneous autoimmune disease, a B7-binding protein was generated by genetic fusion of the extracellular domain of murine CTLA-4 to the Fe portion of a mouse immunoglobulin G2a monoclonal antibody (muCTLA4lg). In lupus-prone NZB/NZW filial generation (F-1) mice, treatment with muCTLA4lg blocked autoantibody production and prolonged life, even when treatment was delayed until the most advanced stage of clinical illness. These findings suggest a possible role for human CTLA4lg in the treatment of autoimmune diseases in humans.	UNIV CALIF SAN FRANCISCO,DEPT MED,SAN FRANCISCO,CA 94121; VET ADM MED CTR,SAN FRANCISCO,CA 94121; BRISTOL MYERS SQUIBB PHARMACEUT RES INST,SEATTLE,WA 98121	University of California System; University of California San Francisco; US Department of Veterans Affairs; Veterans Health Administration (VHA); Bristol-Myers Squibb								AZUMA M, 1993, NATURE, V366, P76, DOI 10.1038/366076a0; BRUNET JF, 1987, NATURE, V328, P267, DOI 10.1038/328267a0; FELL HP, 1992, J BIOL CHEM, V267, P15552; FINCK BK, UNPUB; FREEMAN GJ, 1993, SCIENCE, V262, P909, DOI 10.1126/science.7694363; GIMMI CD, 1991, P NATL ACAD SCI USA, V88, P6575, DOI 10.1073/pnas.88.15.6575; HARDING FA, 1992, NATURE, V356, P607, DOI 10.1038/356607a0; HATHCOCK KS, 1993, SCIENCE, V262, P905, DOI 10.1126/science.7694361; Isaacs J D, 1990, Semin Immunol, V2, P449; LANE P, 1994, J EXP MED, V179, P819, DOI 10.1084/jem.179.3.819; LEDBETTER JA, 1990, BLOOD, V75, P1531; LENSCHOW DJ, 1992, SCIENCE, V257, P789, DOI 10.1126/science.1323143; LINSLEY PS, 1991, J EXP MED, V173, P721, DOI 10.1084/jem.173.3.721; LINSLEY PS, 1991, J EXP MED, V174, P561, DOI 10.1084/jem.174.3.561; LINSLEY PS, 1992, SCIENCE, V257, P792, DOI 10.1126/science.1496399; MORELAND LW, 1994, ARTHRITIS RHEUM, V37, P834, DOI 10.1002/art.1780370610; MUELLER DL, 1989, ANNU REV IMMUNOL, V7, P445, DOI 10.1146/annurev.iy.07.040189.002305; NORTON SD, 1992, J IMMUNOL, V149, P1556; RONCHESE F, 1994, J EXP MED, V179, P809, DOI 10.1084/jem.179.3.809; STEINBERG AD, 1991, ANN INTERN MED, V115, P548, DOI 10.7326/0003-4819-115-7-548; SWAIN SL, 1984, J IMMUNOL, V132, P1118; TAN P, 1993, J EXP MED, V177, P165, DOI 10.1084/jem.177.1.165; TURKA LA, 1992, P NATL ACAD SCI USA, V89, P11102, DOI 10.1073/pnas.89.22.11102; WALLACE PM, IN PRESS TRANSPLANTA; WEISS A, 1986, ANNU REV IMMUNOL, V4, P593, DOI 10.1146/annurev.iy.04.040186.003113; WOFSY D, 1985, J EXP MED, V161, P378, DOI 10.1084/jem.161.2.378	26	629	695	0	3	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	AUG 26	1994	265	5176					1225	1227		10.1126/science.7520604	http://dx.doi.org/10.1126/science.7520604			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PD422	7520604				2022-12-28	WOS:A1994PD42200035
J	MILLER, FG; QUILL, TE; BRODY, H; FLETCHER, JC; GOSTIN, LO; MEIER, DE				MILLER, FG; QUILL, TE; BRODY, H; FLETCHER, JC; GOSTIN, LO; MEIER, DE			REGULATING PHYSICIAN-ASSISTED DEATH	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material							EUTHANASIA; LIFE; SUICIDE; PATIENT; DOCTOR; AID		GENESEE HOSP,ROCHESTER,NY 14607; MICHIGAN STATE UNIV,E LANSING,MI 48824; GEORGETOWN JOHNS HOPKINS PROGRAM LAW & PUBL HLTH,WASHINGTON,DC 20001; CUNY MT SINAI SCH MED,NEW YORK,NY 10029	Michigan State University; Johns Hopkins University; City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai	MILLER, FG (corresponding author), UNIV VIRGINIA,HLTH SCI CTR,SCH MED,BOX 348,CHARLOTTESVILLE,VA 22908, USA.		Brody, Howard/GQA-6310-2022					ANNAS GJ, 1990, JAMA-J AM MED ASSOC, V263, P858, DOI 10.1001/jama.263.6.858; BATTIN MP, 1994, LEAST WORST DEATH ES, P130; BLENDON RJ, 1992, JAMA-J AM MED ASSOC, V267, P2658, DOI 10.1001/jama.267.19.2658; BRODY H, 1992, NEW ENGL J MED, V327, P1384, DOI 10.1056/NEJM199211053271912; CELOCRUZ MT, 1992, AM J LAW MED, V18, P369; EGAN T, 1994, NY TIMES        0307, pA1; Glantz L H, 1987, Law Med Health Care, V15, P231; GOMEZ CF, 1991, REGULATING DEATH; GOSTIN L, 1991, MILBANK Q, V69, P143, DOI 10.2307/3350124; Gostin Lawrence O, 1993, J Law Med Ethics, V21, P94, DOI 10.1111/j.1748-720X.1993.tb01234.x; Margolick David, 1994, N Y Times Web, pB8; McGough P M, 1993, Camb Q Healthc Ethics, V2, P63; MEIER D, 1994, PHYSICIAN ASSISTED D, P5; MILLER FG, 1993, PERSPECT BIOL MED, V36, P159; PIJNENBORG L, 1993, LANCET, V341, P1196, DOI 10.1016/0140-6736(93)91014-D; QUILL T. E., 1993, DEATH DIGNITY; QUILL TE, 1993, JAMA-J AM MED ASSOC, V270, P870, DOI 10.1001/jama.270.7.870; QUILL TE, 1992, NEW ENGL J MED, V327, P1380, DOI 10.1056/NEJM199211053271911; TENHAVE HA, 1992, EUTHANASIA NORMAL ME, V22, P34; van der Maas PJ, 1991, LANCET, V338, P669, DOI 10.1016/0140-6736(91)91241-L; 1992, HARVARD LAW REV, V105, P2021	21	103	104	0	3	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JUL 14	1994	331	2					119	123		10.1056/NEJM199407143310211	http://dx.doi.org/10.1056/NEJM199407143310211			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NW712	7516037				2022-12-28	WOS:A1994NW71200011
J	STANGL, R; ALTENDORFHOFMANN, A; CHARNLEY, RM; SCHEELE, J				STANGL, R; ALTENDORFHOFMANN, A; CHARNLEY, RM; SCHEELE, J			FACTORS INFLUENCING THE NATURAL-HISTORY OF COLORECTAL LIVER METASTASES	LANCET			English	Article							HEPATIC METASTASES; REGIONAL CHEMOTHERAPY; CARCINOMA; CANCER; RESECTION; SURVIVAL; INTRAARTERIAL; PROGNOSIS; TRIAL; COLON	Palliative treatment of unresectable colorectal liver metastases is common and often justified with reference to historical data on the natural history of the disease. However, in view of the improved diagnostic accuracy of modern imaging techniques, these previously published series do not provide sufficient guidance to judge the prognostic efficacy of palliative treatment. In the late 1970s we started prospectively to collect data on consecutive patients with colorectal liver metastases according to a standard protocol. We now present data derived from this series on factors that may affect outcome in untreated patients. Between January, 1980, and December, 1990, 1099 consecutive patients were recorded, of whom 566 (51.5%) received no treatment for their hepatic tumour. Excluding 34 early deaths and 48 patients with a second malignant tumour, 484 patients provided the basis for analysis. All patients were followed up to July 1, 1993, or death. At the closing date of the study only 1 untreated patient was still alive. The impact of various factors on survival was analysed by univariate and multivariate analyses. Six independent determinants of survival were identified in the following order: percentage liver volume replaced by tumour (LVRT), grade of malignancy of the primary tumour, presence of extra hepatic disease, mesenteric lymph-node involvement, serum carcino-embryonic antigen, and age. The subsequent combination of the independently significant factors, separately for patients with up to or more than 25% LVRT, yielded a prognostic tree that displayed median survival times of various subgroups of 3.8 to 21.3 months. These findings provide a framework to estimate the survival expectancy of untreated patients, thereby allowing improved assessment of the prognostic significance of palliative therapeutic approaches.	UNIV ERLANGEN NURNBERG,CHIRURG KLIN & POLIKLIN,D-91054 ERLANGEN,GERMANY	University of Erlangen Nuremberg								ADSON MA, 1987, WORLD J SURG, V11, P511, DOI 10.1007/BF01655817; ADSON MA, 1984, ARCH SURG-CHICAGO, V119, P647; BALCH CM, 1984, CHIRURG, V55, P485; BENGMARK S, 1969, CANCER, V23, P198, DOI 10.1002/1097-0142(196901)23:1<198::AID-CNCR2820230126>3.0.CO;2-J; BENGTSSON G, 1981, AM J SURG, V141, P586, DOI 10.1016/0002-9610(81)90057-X; BROOKMEYER R, 1982, BIOMETRICS, V38, P29, DOI 10.2307/2530286; CHANG AE, 1989, J SURG ONCOL, V40, P245, DOI 10.1002/jso.2930400409; FINAN PJ, 1985, BRIT J SURG, V72, P373, DOI 10.1002/bjs.1800720514; FLANAGAN L, 1967, AM J SURG, V113, P551, DOI 10.1016/0002-9610(67)90206-1; GENNARI L, 1986, ANN SURG, V203, P49, DOI 10.1097/00000658-198601000-00009; GOSLIN R, 1982, DIS COLON RECTUM, V25, P749, DOI 10.1007/BF02553304; HUNT TM, 1990, BRIT J SURG, V77, P779; JAFFE BM, 1968, SURG GYNECOL OBSTETR, V127, P1; LAHR CJ, 1983, J CLIN ONCOL, V1, P720, DOI 10.1200/JCO.1983.1.11.720; NIELSEN J, 1971, ACTA CHIR SCAND, V137, P463; PETRELLI NJ, 1984, DIS COLON RECTUM, V27, P249, DOI 10.1007/BF02553797; PETTAVEL J, 1984, LIVER METASTASES, P154; SAFI F, 1989, CANCER-AM CANCER SOC, V64, P379, DOI 10.1002/1097-0142(19890715)64:2<379::AID-CNCR2820640207>3.0.CO;2-8; SCHEELE J, 1990, BRIT J SURG, V77, P1241, DOI 10.1002/bjs.1800771115; SCHEELE J, 1991, SURGERY, V110, P13; SCHEELE J, 1991, ZBL CHIR, V116, P1215; SUGARBAKER PH, 1986, J SURG ONCOL, V31, P94, DOI 10.1002/jso.2930310204; WAGNER JS, 1984, ANN SURG, V199, P502, DOI 10.1097/00000658-198405000-00002; WANEBO HJ, 1978, AM J SURG, V135, P81, DOI 10.1016/0002-9610(78)90014-4; Wood C B, 1976, Clin Oncol, V2, P285; WOOD CB, 1984, LIVER METASTASIS BAS, P47	26	579	607	0	13	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUN 4	1994	343	8910					1405	1410		10.1016/S0140-6736(94)92529-1	http://dx.doi.org/10.1016/S0140-6736(94)92529-1			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NP955	7515134				2022-12-28	WOS:A1994NP95500015
J	WILLNOW, TE; SHENG, ZQ; ISHIBASHI, S; HERZ, J				WILLNOW, TE; SHENG, ZQ; ISHIBASHI, S; HERZ, J			INHIBITION OF HEPATIC CHYLOMICRON REMNANT UPTAKE BY GENE-TRANSFER OF A RECEPTOR ANTAGONIST	SCIENCE			English	Article							DENSITY-LIPOPROTEIN RECEPTOR; PROTEIN ALPHA-2-MACROGLOBULIN RECEPTOR; APOLIPOPROTEIN-E; LDL-RECEPTOR; PLASMINOGEN-ACTIVATOR; PROTEIN-ALPHA-2-MACROGLOBULIN RECEPTOR; MULTIFUNCTIONAL RECEPTOR; CULTURED-CELLS; HIGH-AFFINITY; IN-VIVO	The low density lipoprotein receptor-related protein (LRP) has been proposed to mediate in concert with the LDL receptor (LDLR) the uptake of dietary lipoproteins into the hepatocytes. This hypothesis was tested by transient inactivation of LRP in vivo. Receptor-associated protein (RAP), a dominant negative regulator of LRP function, was transferred by an adenoviral vector to the livers of mice lacking LDLR (LDLR(-/-)). The inactivation of LRP by RAP was associated with a marked accumulation of chylomicron remnants in LDLR(-/-) mice and to a lesser degree in normal mice, suggesting that both LDLR and LRP are involved in remnant clearance.	UNIV TEXAS,SW MED CTR,DEPT MOLEC GENET,DALLAS,TX 75235	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas				Willnow, Thomas/0000-0001-9515-7921	NHLBI NIH HHS [HL20948] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL020948] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ASHWELL G, 1982, ANNU REV BIOCHEM, V51, P531, DOI 10.1146/annurev.bi.51.070182.002531; BEISIEGEL U, 1989, NATURE, V341, P162, DOI 10.1038/341162a0; BEISIEGEL U, 1991, P NATL ACAD SCI USA, V88, P8342, DOI 10.1073/pnas.88.19.8342; BROWN MS, 1991, CURR OPIN LIPIDOL, V2, P65; BU GJ, 1992, P NATL ACAD SCI USA, V89, P7427, DOI 10.1073/pnas.89.16.7427; CHAN L, 1992, J BIOL CHEM, V267, P25621; CHOI SY, 1993, J BIOL CHEM, V268, P15804; GAMBLE W, 1978, J LIPID RES, V19, P1068; GINSBERG HS, 1991, P NATL ACAD SCI USA, V88, P1651, DOI 10.1073/pnas.88.5.1651; GOFF SP, 1993, CURR OPIN GENET DEV, V3, P71, DOI 10.1016/S0959-437X(05)80343-0; HAMILTON RL, 1990, J LIPID RES, V31, P1589; HAVEL RJ, 1989, METABOLIC BASIS INHE, P1129; HERZ J, 1993, CELL, V73, P428, DOI 10.1016/0092-8674(93)90130-I; HERZ J, 1992, CELL, V71, P411, DOI 10.1016/0092-8674(92)90511-A; HERZ J, 1988, EMBO J, V7, P4119, DOI 10.1002/j.1460-2075.1988.tb03306.x; HERZ J, 1993, P NATL ACAD SCI USA, V90, P2812, DOI 10.1073/pnas.90.7.2812; HERZ J, 1991, J BIOL CHEM, V266, P21232; Herz Joachim, 1993, Current Opinion in Lipidology, V4, P107, DOI 10.1097/00041433-199304000-00006; HUSSAIN MM, 1991, J BIOL CHEM, V266, P13936; ISHIBASHI S, 1993, J CLIN INVEST, V92, P883, DOI 10.1172/JCI116663; JI ZS, 1993, J BIOL CHEM, V268, P10160; KITA T, 1982, P NATL ACAD SCI-BIOL, V79, P3623, DOI 10.1073/pnas.79.11.3623; KOUNNAS MZ, 1993, J BIOL CHEM, V268, P21862; KOWAL RC, 1989, P NATL ACAD SCI USA, V86, P5810, DOI 10.1073/pnas.86.15.5810; KOWAL RC, 1990, J BIOL CHEM, V265, P10771; KRISTENSEN T, 1990, FEBS LETT, V276, P151, DOI 10.1016/0014-5793(90)80530-V; LEBOEUF RC, 1990, J LIPID RES, V31, P91; Mahley R. W., 1991, CURR OPIN LIPIDOL, V2, P170; MOESTRUP SK, 1991, J BIOL CHEM, V266, P14011; MOKUNO H, 1994, J BIOL CHEM, V269, P13238; NAGATA Y, 1988, J BIOL CHEM, V263, P15151; NYKJAER A, 1992, J BIOL CHEM, V267, P14543; ORLANDO RA, 1992, P NATL ACAD SCI USA, V89, P6698, DOI 10.1073/pnas.89.15.6698; ORTH K, 1992, P NATL ACAD SCI USA, V89, P7422, DOI 10.1073/pnas.89.16.7422; PLUMP AS, 1992, CELL, V71, P343, DOI 10.1016/0092-8674(92)90362-G; RUBINSZTEIN DC, 1990, J CLIN INVEST, V86, P1306, DOI 10.1172/JCI114839; SCHAEFER EJ, 1986, J CLIN INVEST, V78, P1206, DOI 10.1172/JCI112704; SCOTT J, 1989, MOL BIOL MED, V6, P65; SHAFI S, 1994, J LIPID RES, V35, P709; SMITH TAG, 1993, NAT GENET, V5, P397, DOI 10.1038/ng1293-397; STRICKLAND DK, 1990, J BIOL CHEM, V265, P17401; WARSHAWSKY I, 1993, J CLIN INVEST, V92, P937, DOI 10.1172/JCI116669; WILLIAMS SE, 1992, J BIOL CHEM, V267, P9035; WILLNOW TE, UNPUB; WINDLER EET, 1988, BIOCHEM J, V252, P553, DOI 10.1042/bj2520553; ZHANG SH, 1992, SCIENCE, V258, P468, DOI 10.1126/science.1411543	46	264	265	0	4	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUN 3	1994	264	5164					1471	1474		10.1126/science.7515194	http://dx.doi.org/10.1126/science.7515194			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	NP221	7515194				2022-12-28	WOS:A1994NP22100046
J	SHUAI, K; HORVATH, CM; HUANG, LHT; QURESHI, SA; COWBURN, D; DARNELL, JE				SHUAI, K; HORVATH, CM; HUANG, LHT; QURESHI, SA; COWBURN, D; DARNELL, JE			INTERFERON ACTIVATION OF THE TRANSCRIPTION FACTOR STAT91 INVOLVES DIMERIZATION THROUGH SH2-PHOSPHOTYROSYL PEPTIDE INTERACTIONS	CELL			English	Article							SRC HOMOLOGY-2 DOMAIN; CYTOPLASMIC ACTIVATION; ALPHA-INTERFERON; SH3 DOMAINS; C-ABL; PROTEIN; ISGF3; PHOSPHORYLATION; SUBUNIT; CELLS	Stat91 (a 91 kd protein that acts as a signal transducer and activator of transcription) is inactive in the cytoplasm of untreated cells but is activated by phosphorylation on tyrosine in response to a number of polypeptide ligands, including interferon alpha (IFN-alpha) and lFN-gamma. We report here that the inactive Stat91 in the cytoplasm of untreated cells is a monomer and that upon IFN-gamma-induced phosphorylation it forms a stable homodimer. Only the dimer is capable of binding to a specific DNA sequence directing transcription. Through dissociation and reassociation assays, we show that dimerization of Stat91 is mediated through SH2-phosphotyrosyl peptide interactions. Dimerization involving SH2 recognition of specific phosphotyrosyl peptides may well provide a prototype for interactions among family members of STAT proteins to form different transcription complexes.	ROCKEFELLER UNIV, PLANT BIOCHEM LAB, NEW YORK, NY 10021 USA	Rockefeller University	SHUAI, K (corresponding author), ROCKEFELLER UNIV, MOLEC CELL BIOL LAB, NEW YORK, NY 10021 USA.		Cowburn, David/A-8448-2008	Cowburn, David/0000-0001-6770-7172; Horvath, Curt/0000-0003-2449-225X	NIAID NIH HHS [AI32489] Funding Source: Medline; NIGMS NIH HHS [GM47021] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI032489] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM047021] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AMSTERCHODER O, 1992, SCIENCE, V257, P1395, DOI 10.1126/science.1382312; BOOKER GW, 1992, NATURE, V358, P684, DOI 10.1038/358684a0; BRYAN JK, 1977, ANAL BIOCHEM, V78, P513, DOI 10.1016/0003-2697(77)90111-7; DALE TC, 1989, P NATL ACAD SCI USA, V86, P1203, DOI 10.1073/pnas.86.4.1203; DECKER T, 1991, EMBO J, V10, P927, DOI 10.1002/j.1460-2075.1991.tb08026.x; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; ECK MJ, 1993, NATURE, V362, P87, DOI 10.1038/362087a0; FELDER S, 1993, MOL CELL BIOL, V13, P1449, DOI 10.1128/MCB.13.3.1449; FU XY, 1992, P NATL ACAD SCI USA, V89, P7840, DOI 10.1073/pnas.89.16.7840; FU XY, 1992, CELL, V70, P323, DOI 10.1016/0092-8674(92)90106-M; FU XY, 1990, P NATL ACAD SCI USA, V87, P8555, DOI 10.1073/pnas.87.21.8555; FU XY, 1993, CELL, V74, P1135, DOI 10.1016/0092-8674(93)90734-8; JONES N, 1990, CELL, V61, P9, DOI 10.1016/0092-8674(90)90207-U; KESSLER DS, 1990, GENE DEV, V4, P1753, DOI 10.1101/gad.4.10.1753; KHAN KD, 1993, P NATL ACAD SCI USA, V90, P6806, DOI 10.1073/pnas.90.14.6806; KOCH CA, 1991, SCIENCE, V252, P668, DOI 10.1126/science.1708916; LARNER AC, 1993, SCIENCE, V261, P1730, DOI 10.1126/science.8378773; LEVY DE, 1989, GENE DEV, V3, P1362, DOI 10.1101/gad.3.9.1362; MCKENDRY R, 1991, P NATL ACAD SCI USA, V88, P11455, DOI 10.1073/pnas.88.24.11455; MENDEL DB, 1991, SCIENCE, V254, P1762, DOI 10.1126/science.1763325; MULLER M, 1993, EMBO J, V12, P4221, DOI 10.1002/j.1460-2075.1993.tb06106.x; OVERDUIN M, 1992, P NATL ACAD SCI USA, V89, P11673, DOI 10.1073/pnas.89.24.11673; OVERDUIN M, 1992, CELL, V70, P697, DOI 10.1016/0092-8674(92)90437-H; PAWSON T, 1993, CURR BIOL, V3, P434, DOI 10.1016/0960-9822(93)90350-W; PEARSE RN, 1993, P NATL ACAD SCI USA, V90, P4314, DOI 10.1073/pnas.90.9.4314; RUFFJAMISON S, 1993, SCIENCE, V261, P1733, DOI 10.1126/science.8378774; SADOWSKI HB, 1993, SCIENCE, V261, P1739, DOI 10.1126/science.8397445; SCHINDLER C, 1992, P NATL ACAD SCI USA, V89, P7836, DOI 10.1073/pnas.89.16.7836; SCHINDLER C, 1992, SCIENCE, V257, P809, DOI 10.1126/science.1496401; SHUAI K, 1993, SCIENCE, V261, P1744, DOI 10.1126/science.7690989; SHUAL K, 1993, NATURE, V366, P580, DOI 10.1038/366580a0; SILVENNOINEN O, 1993, SCIENCE, V261, P1736, DOI 10.1126/science.8378775; VEALS SA, 1992, MOL CELL BIOL, V12, P3315, DOI 10.1128/MCB.12.8.3315; WAKSMAN G, 1992, NATURE, V358, P646, DOI 10.1038/358646a0; ZHOU SY, 1993, CELL, V72, P767, DOI 10.1016/0092-8674(93)90404-E	36	708	728	0	11	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	MAR 11	1994	76	5					821	828		10.1016/0092-8674(94)90357-3	http://dx.doi.org/10.1016/0092-8674(94)90357-3			8	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	NA890	7510216				2022-12-28	WOS:A1994NA89000008
J	CHUNG, SCS; STUART, RC; LI, AKC				CHUNG, SCS; STUART, RC; LI, AKC			SURGICAL THERAPY FOR SQUAMOUS-CELL CARCINOMA OF THE ESOPHAGUS	LANCET			English	Article							ESOPHAGEAL CANCER; PREOPERATIVE RADIOTHERAPY; LYMPH-NODE; THORACIC ANASTOMOSIS; CHEMOTHERAPY; RESECTION; SURVIVAL; TRIAL; MULTICENTER; SURGERY		CHINESE UNIV HONG KONG, PRINCE WALES HOSP, DEPT SURG, SHA TIN, HONG KONG	Chinese University of Hong Kong; Prince of Wales Hospital								AKIYAMA H, 1981, ANN SURG, V194, P438, DOI 10.1097/00000658-198110000-00007; ANDERSON LL, 1982, CANCER, V50, P1587, DOI 10.1002/1097-0142(19821015)50:8<1587::AID-CNCR2820500820>3.0.CO;2-S; ARNOTT SJ, 1992, RADIOTHER ONCOL, V24, P108, DOI 10.1016/0167-8140(92)90287-5; BARTELS H, 1993, BRIT J SURG, V80, P1141, DOI 10.1002/bjs.1800800924; Becker H D, 1993, Adv Surg, V26, P397; BOWN SG, 1991, GUT, V32, P841, DOI 10.1136/gut.32.8.841; CHASSERAY VM, 1989, SURG GYNECOL OBSTET, V169, P55; CHUNG SCS, 1990, SURG GYNECOL OBSTET, V170, P68; Coia L R, 1989, Oncology (Williston Park), V3, P101; COLLARD JM, 1993, ANN THORAC SURG, V56, P675, DOI 10.1016/0003-4975(93)90949-I; EARLAM R, 1980, BRIT J SURG, V67, P381, DOI 10.1002/bjs.1800670602; FOK M, 1991, AM J SURG, V162, P447, DOI 10.1016/0002-9610(91)90258-F; FOK M, 1993, SURGERY, V113, P138; FORASTIERE AA, 1993, J CLIN ONCOL, V11, P1118, DOI 10.1200/JCO.1993.11.6.1118; Fujita Hiromasa, 1992, Kurume Medical Journal, V39, P167; GIGNOUX M, 1987, WORLD J SURG, V11, P426, DOI 10.1007/BF01655805; GOLDMINC M, 1993, BRIT J SURG, V80, P367, DOI 10.1002/bjs.1800800335; GOSSOT D, 1993, ANN THORAC SURG, V56, P667, DOI 10.1016/0003-4975(93)90947-G; GRIFFIN S M, 1991, Journal of the Royal College of Surgeons of Edinburgh, V36, P170; HENNESSY TPJ, 1988, BRIT J SURG, V75, P193, DOI 10.1002/bjs.1800750302; KATO H, 1991, ANN THORAC SURG, V51, P931, DOI 10.1016/0003-4975(91)91008-J; KAVANAGH B, 1992, INT J RADIAT ONCOL, V24, P633, DOI 10.1016/0360-3016(92)90708-P; KOZAREK RA, 1992, GASTROINTEST ENDOSC, V38, P1, DOI 10.1016/S0016-5107(92)70321-6; LAUNOIS B, 1981, SURG GYNECOL OBSTET, V153, P690; MAETA M, 1987, SURG GYNECOL OBSTET, V165, P235; MAILAND P, 1993, SPR P AUSTR SOC AN M, P79; MATTHEWS HR, 1986, BRIT J SURG, V73, P621, DOI 10.1002/bjs.1800730811; MULLER JM, 1990, BRIT J SURG, V77, P845, DOI 10.1002/bjs.1800770804; NYGAARD K, 1992, WORLD J SURG, V16, P1104, DOI 10.1007/BF02067069; POPP MB, 1986, ARCH SURG-CHICAGO, V121, P1330, DOI 10.1001/archsurg.121.11.1330; RIBET M, 1992, J THORAC CARDIOV SUR, V103, P784; ROTH JA, 1988, J THORAC CARDIOV SUR, V96, P242; ROTH JA, 1992, J SURG ONCOL, V50, P67, DOI 10.1002/jso.2930500202; SCHLAG P, 1992, CHIRURG, V63, P709; SKINNER DB, 1983, J THORAC CARDIOV SUR, V85, P59; SKINNER DB, 1986, ANN SURG, V204, P391, DOI 10.1097/00000658-198610000-00007; TENIERE P, 1991, SURG GYNECOL OBSTET, V173, P123; WALSH TN, 1993, BR J SURG S, V80, pS61	38	26	29	1	1	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	FEB 26	1994	343	8896					521	524		10.1016/S0140-6736(94)91467-2	http://dx.doi.org/10.1016/S0140-6736(94)91467-2			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MX888	7509430				2022-12-28	WOS:A1994MX88800015
J	DILWORTH, SM; BREWSTER, CEP; JONES, MD; LANFRANCONE, L; PELICCI, G; PELICCI, PG				DILWORTH, SM; BREWSTER, CEP; JONES, MD; LANFRANCONE, L; PELICCI, G; PELICCI, PG			TRANSFORMATION BY POLYOMA-VIRUS MIDDLE T-ANTIGEN INVOLVES THE BINDING AND TYROSINE PHOSPHORYLATION OF SHC	NATURE			English	Article							PHOSPHATIDYLINOSITOL KINASE-ACTIVITY; SITE-DIRECTED MUTAGENESIS; PROTEIN; INVITRO; PP60C-SRC; 3-KINASE; DOMAIN; CELLS	POLYOMA virus middle T-antigen converts normal fibroblasts to a fully transformed, tumorigenic phenotype1. It achieves this, at least in part, by binding and activating one of the non-receptor tyrosine kinases, pp60c-src, pp62c-yes or pp59c-fyn (reviewed in refs 2 and 3). As a result, middle T-antigen itself is phosphorylated on tyrosine residues4,5, one of which (Tyr 315) acts as a binding site for the SH2 domains of phosphatidylinositol-3'OH kinase 85K sub-unit6-8. Here we show that another tyrosine phosphorylation site in middle T-antigen (Tyr 250; refs 4, 5) acts as a binding region for the SH2 domain of the transforming protein Shc9. This results in Shc also becoming tyrosine-phosphorylated and binding to the SH2 domain of Grb2 (ref. 10). This probably stimulates p21ras activity through the mammalian homologue of the Drosophila guanine-nucleotide-exchange factor Sos (reviewed in ref. 11). We suggest that middle T-antigen transforms cells by acting as a functional homologue of an activated tyrosine kinase-associated growth-factor receptor.	ROYAL POSTGRAD MED SCH, DEPT VIROL, LONDON W12 0NN, ENGLAND; UNIV PERUGIA, IST CLIN MED 1, I-06100 PERUGIA, ITALY	Imperial College London; University of Perugia	DILWORTH, SM (corresponding author), ROYAL POSTGRAD MED SCH, DEPT CHEM PATHOL, DU CANE RD, LONDON W12 0NN, ENGLAND.		Lanfrancone, Luisa/AAC-8671-2019; Pelicci, Giuliana/AAA-8921-2022; Pelicci, Pier Giuseppe/AAL-6572-2020	Lanfrancone, Luisa/0000-0002-4523-3815; Pelicci, Giuliana/0000-0003-0986-8255; 				AUGER KR, 1992, J BIOL CHEM, V267, P5408; CARMICHAEL G, 1984, P NATL ACAD SCI-BIOL, V81, P679, DOI 10.1073/pnas.81.3.679; COURTNEIDGE SA, 1987, CELL, V50, P1031, DOI 10.1016/0092-8674(87)90169-3; COURTNEIDGE SA, 1986, CANCER SURV, V5, P173; DILWORTH SM, 1993, J VIROL, V67, P2235, DOI 10.1128/JVI.67.4.2235-2244.1993; DILWORTH SM, 1982, EMBO J, V1, P1319, DOI 10.1002/j.1460-2075.1982.tb01317.x; DRUKER BJ, 1990, J VIROL, V64, P4454, DOI 10.1128/JVI.64.9.4454-4461.1990; GRIFFIN BE, 1979, COLD SPRING HARB SYM, V44, P271; HARVEY R, 1984, MOL CELL BIOL, V4, P1334, DOI 10.1128/MCB.4.7.1334; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; HUNTER T, 1984, EMBO J, V3, P73, DOI 10.1002/j.1460-2075.1984.tb01763.x; JELINEK MA, 1992, ONCOGENE, V7, P1687; KAPLAN DR, 1989, BIOCHIM BIOPHYS ACTA, V948, P345, DOI 10.1016/0304-419X(89)90006-1; KAPLAN DR, 1987, CELL, V50, P1021, DOI 10.1016/0092-8674(87)90168-1; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LOWENSTEIN EJ, 1992, CELL, V70, P431, DOI 10.1016/0092-8674(92)90167-B; MARKLAND W, 1986, J VIROL, V59, P384, DOI 10.1128/JVI.59.2.384-391.1986; MARKLAND W, 1987, BIOCHIM BIOPHYS ACTA, V907, P299, DOI 10.1016/0304-419X(87)90011-4; MCCORMICK F, 1993, NATURE, V363, P15, DOI 10.1038/363015a0; MCGLADE J, 1992, P NATL ACAD SCI USA, V89, P8869, DOI 10.1073/pnas.89.19.8869; PELICCI G, 1992, CELL, V70, P93, DOI 10.1016/0092-8674(92)90536-L; RAPTIS L, 1991, J VIROL, V65, P5203, DOI 10.1128/JVI.65.10.5203-5210.1991; ROZAKISADCOCK M, 1992, NATURE, V360, P689, DOI 10.1038/360689a0; SEGATTO O, 1993, ONCOGENE, V8, P2105; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; TALMAGE DA, 1989, CELL, V59, P55, DOI 10.1016/0092-8674(89)90869-6; TREISMAN R, 1981, NATURE, V292, P595, DOI 10.1038/292595a0; YOAKIM M, 1992, J VIROL, V66, P5485, DOI 10.1128/JVI.66.9.5485-5491.1992; ZHOU SY, 1993, CELL, V72, P767, DOI 10.1016/0092-8674(93)90404-E	29	199	200	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JAN 6	1994	367	6458					87	90		10.1038/367087a0	http://dx.doi.org/10.1038/367087a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	MP865	7509037				2022-12-28	WOS:A1994MP86500066
J	LYMAN, SD; JAMES, L; VANDENBOS, T; DEVRIES, P; BRASEL, K; GLINIAK, B; HOLLINGSWORTH, LT; PICHA, KS; MCKENNA, HJ; SPLETT, RR; FLETCHER, FA; MARASKOVSKY, E; FARRAH, T; FOXWORTHE, D; WILLIAMS, DE; BECKMANN, MP				LYMAN, SD; JAMES, L; VANDENBOS, T; DEVRIES, P; BRASEL, K; GLINIAK, B; HOLLINGSWORTH, LT; PICHA, KS; MCKENNA, HJ; SPLETT, RR; FLETCHER, FA; MARASKOVSKY, E; FARRAH, T; FOXWORTHE, D; WILLIAMS, DE; BECKMANN, MP			MOLECULAR-CLONING OF A LIGAND FOR THE FLT3/FLK-2 TYROSINE KINASE RECEPTOR - A PROLIFERATIVE FACTOR FOR PRIMITIVE HEMATOPOIETIC-CELLS	CELL			English	Article							COLONY-STIMULATING FACTOR; GROWTH-FACTOR; STEM-CELLS; C-KIT; BONE-MARROW; SOYBEAN AGGLUTININ; PROGENITOR CELLS; PDGF RECEPTOR; B-CELLS; MURINE	Cloning of a ligand for the murine flt3/flk-2 tyrosine kinase receptor was undertaken using a soluble form of the receptor to identify a source of ligand. A murine T cell line, P7B-0.3A4, was identified that appeared to express a cell surface ligand for this receptor. A cDNA clone was isolated from an expression library prepared from these cells that was capable, when transfected into cells, of conferring binding to a soluble form of the flt3/flk-2 receptor. The cDNA for this ligand encodes a type I transmembrane protein that stimulates the proliferation of cells transfected with the flt3/flk-2 receptor. A soluble form of the ligand stimulates the proliferation of defined subpopulations of murine bone marrow and fetal liver cells as well as human bone marrow cells that are highly enriched for hematopoietic stem cells and primitive uncommitted progenitor cells.			LYMAN, SD (corresponding author), IMMUNEX RES & DEV CORP, 51 UNIV ST, SEATTLE, WA 98101 USA.							ANDERSON DM, 1990, CELL, V63, P235, DOI 10.1016/0092-8674(90)90304-W; BIRG F, 1992, BLOOD, V80, P2584; BOSENBERG MW, 1992, CELL, V71, P1157, DOI 10.1016/S0092-8674(05)80064-9; BRANNAN CI, 1991, P NATL ACAD SCI USA, V88, P4671, DOI 10.1073/pnas.88.11.4671; BRANNAN CI, 1992, GENE DEV, V6, P1832, DOI 10.1101/gad.6.10.1832; CASKEY CT, 1992, SCIENCE, V256, P784, DOI 10.1126/science.1589758; CERRETTI DP, 1988, MOL IMMUNOL, V25, P761, DOI 10.1016/0161-5890(88)90112-5; CLAESSONWELSH L, 1989, P NATL ACAD SCI USA, V86, P4917, DOI 10.1073/pnas.86.13.4917; CLARK SP, 1992, COMPUT APPL BIOSCI, V8, P535; DEVRIES P, 1992, J EXP MED, V176, P1503, DOI 10.1084/jem.176.6.1503; DEVRIES P, 1991, J EXP MED, V173, P1205, DOI 10.1084/jem.173.5.1205; DOVER GA, 1991, CELL, V65, P9, DOI 10.1016/0092-8674(91)90401-J; DOWER SK, 1984, J IMMUNOL, V132, P751; EBELL W, 1985, BLOOD, V65, P1105; EISENBERG D, 1984, J MOL BIOL, V179, P125, DOI 10.1016/0022-2836(84)90309-7; FLANAGAN JG, 1991, CELL, V64, P1025, DOI 10.1016/0092-8674(91)90326-T; GAULT N, 1991, GENE, V107, P285; GOLDFARB M, 1990, CELL GROWTH DIFFER, V1, P439; GOODWIN RG, 1993, CELL, V73, P447, DOI 10.1016/0092-8674(93)90133-B; HATAKEYAMA M, 1989, CELL, V59, P837, DOI 10.1016/0092-8674(89)90607-7; HOLMES WE, 1992, SCIENCE, V256, P1205, DOI 10.1126/science.256.5060.1205; HOPP TP, 1988, BIO-TECHNOL, V6, P1204, DOI 10.1038/nbt1088-1204; HUNTER WM, 1962, NATURE, V194, P495, DOI 10.1038/194495a0; IKUTA K, 1992, P NATL ACAD SCI USA, V89, P1502, DOI 10.1073/pnas.89.4.1502; JORDAN CT, 1990, CELL, V61, P953, DOI 10.1016/0092-8674(90)90061-I; KOZAK M, 1989, J CELL BIOL, V108, P229, DOI 10.1083/jcb.108.2.229; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LEBKOWSKI JS, 1992, TRANSPLANTATION, V53, P1011, DOI 10.1097/00007890-199205000-00009; LU HS, 1991, J BIOL CHEM, V266, P8102; LYMAN SD, 1993, ONCOGENE, V8, P815; LYMAN SD, 1992, AM J PEDIAT HEMATOL, V14, P1; LYMAN SD, 1991, BLOOD CELL GROWTH FACTORS : THEIR PRESENT AND FUTURE USE IN HEMATOLOGY AND ONCOLOGY, P183; MAROC N, 1993, ONCOGENE, V8, P909; MATSUI T, 1989, SCIENCE, V243, P800, DOI 10.1126/science.2536956; MATTHEWS W, 1991, CELL, V65, P1143, DOI 10.1016/0092-8674(91)90010-V; MCKEARN JP, 1984, J IMMUNOL, V132, P332; MCKEARN JP, 1985, P NATL ACAD SCI USA, V82, P7414, DOI 10.1073/pnas.82.21.7414; MCMAHAN CJ, 1991, EMBO J, V10, P2821, DOI 10.1002/j.1460-2075.1991.tb07831.x; MCRAE BL, 1992, J NEUROIMMUNOL, V38, P229, DOI 10.1016/0165-5728(92)90016-E; MOSLEY B, 1989, CELL, V59, P335, DOI 10.1016/0092-8674(89)90295-X; MULLIS KB, 1987, METHOD ENZYMOL, V155, P335; NICOLA NA, 1981, BLOOD, V58, P376; OKADA S, 1992, BLOOD, V80, P3044; PANDIT J, 1992, SCIENCE, V258, P1358, DOI 10.1126/science.1455231; QIU F, 1988, EMBO J, V7, P1003, DOI 10.1002/j.1460-2075.1988.tb02907.x; REISNER Y, 1982, BLOOD, V59, P360; ROSEN EM, 1991, CELL GROWTH DIFFER, V2, P603; ROSNET O, 1991, ONCOGENE, V6, P1641; ROSS CA, 1993, TRENDS NEUROSCI, V16, P254, DOI 10.1016/0166-2236(93)90175-L; SCATCHARD G, 1949, ANN NY ACAD SCI, V51, P660, DOI 10.1111/j.1749-6632.1949.tb27297.x; SHERR CJ, 1985, CELL, V41, P665, DOI 10.1016/S0092-8674(85)80047-7; SPANGRUDE GJ, 1988, SCIENCE, V241, P58, DOI 10.1126/science.2898810; SROUR EF, 1991, BLOOD CELLS, V17, P287; STANLEY ER, 1983, J CELL BIOCHEM, V21, P151, DOI 10.1002/jcb.240210206; VANDENBERG JA, 1990, BIO-TECHNOL, V8, P135, DOI 10.1038/nbt0290-135; VISSER JWM, 1994, IN PRESS METH CELL B; VONHEIJNE G, 1986, NUCLEIC ACIDS RES, V14, P4683, DOI 10.1093/nar/14.11.4683; WEN DZ, 1992, CELL, V69, P559, DOI 10.1016/0092-8674(92)90456-M; WILLIAMS D E, 1991, Progress in Growth Factor Research, V3, P235, DOI 10.1016/0955-2235(91)90002-L; YARDEN Y, 1986, NATURE, V323, P226, DOI 10.1038/323226a0; YOSHIDA H, 1990, NATURE, V345, P442, DOI 10.1038/345442a0; 1991, PROGRAM MANUAL GCG P	62	489	540	1	10	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	DEC 17	1993	75	6					1157	1167		10.1016/0092-8674(93)90325-K	http://dx.doi.org/10.1016/0092-8674(93)90325-K			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	MM893	7505204				2022-12-28	WOS:A1993MM89300014
J	KELLEY, RL; KURODA, MI				KELLEY, RL; KURODA, MI			EQUALITY FOR X-CHROMOSOMES	SCIENCE			English	Article							DOSAGE COMPENSATION; SEX DETERMINATION; CAENORHABDITIS-ELEGANS; DROSOPHILA-MELANOGASTER; C-ELEGANS; MALELESS PROTEIN; ZINC-FINGER; GENE; LETHAL; BINDING	In many species, females possess two X chromosomes and males have one X chromosome. This difference is critical for the initial determination of sex. However, the X encodes many functions required equally in males and females; thus, X chromosome expression must be adjusted to compensate for the difference in dosage between the sexes. Distinct dosage compensation mechanisms have evolved in different species. A common theme in the Drosophila melanogaster and Caenorhabditis elegans systems is that a subtle alteration of chromatin structure may impose this modest, but vital adjustment of the X chromosome transcription level.			KELLEY, RL (corresponding author), BAYLOR COLL MED,DEPT CELL BIOL,HOWARD HUGHES MED INST,HOUSTON,TX 77030, USA.							AKERIB CC, 1994, GENETICS, V138, P1105; BAKER BS, 1994, ANNU REV GENET, V28, P491, DOI 10.1146/annurev.ge.28.120194.002423; BASHAW GJ, 1995, DEVELOPMENT, V121, P3245; BELL LR, 1991, CELL, V65, P229, DOI 10.1016/0092-8674(91)90157-T; BELL LR, 1988, CELL, V55, P1037, DOI 10.1016/0092-8674(88)90248-6; BERLIN D, COMMUNICATION; BERNSTEIN M, 1994, GENETICS, V136, P1051; BONE JR, 1994, GENE DEV, V8, P96, DOI 10.1101/gad.8.1.96; CHUANG PT, 1994, CELL, V79, P459, DOI 10.1016/0092-8674(94)90255-0; CLINE TW, 1984, GENETICS, V107, P231; CLINE TW, 1993, TRENDS GENET, V9, P385, DOI 10.1016/0168-9525(93)90138-8; Davis Timothy A, COMMUNICATION; DELONG L, 1993, GENETICS, V133, P875; GERGEN JP, 1987, GENETICS, V117, P477; GIBSON TJ, 1994, NUCLEIC ACIDS RES, V22, P2552, DOI 10.1093/nar/22.13.2552; GORMAN M, 1995, DEVELOPMENT, V121, P463; GORMAN M, 1993, CELL, V72, P39, DOI 10.1016/0092-8674(93)90048-U; HIEBERT JC, 1994, GENETICS, V136, P913; HIRANO T, 1994, CELL, V79, P449, DOI 10.1016/0092-8674(94)90254-2; HODGKIN J, 1994, DEVELOPMENT, V120, P3681; HODGKIN J, 1983, MOL GEN GENET, V192, P452, DOI 10.1007/BF00392190; HODGKIN J, 1995, GENETICS, V141, P527; Hsu David R., 1993, Seminars in Developmental Biology, V4, P93, DOI 10.1006/sedb.1993.1012; HSU DR, 1995, DEVELOPMENT, V121, P3323; HSU DR, 1994, GENETICS, V137, P999; KELLEY RL, 1995, CELL, V81, P867, DOI 10.1016/0092-8674(95)90007-1; KLEIN RD, 1993, CELL, V72, P349, DOI 10.1016/0092-8674(93)90113-5; KURODA MI, 1991, CELL, V66, P935, DOI 10.1016/0092-8674(91)90439-6; LEE CG, 1993, J BIOL CHEM, V268, P16822; LOVERING R, 1993, P NATL ACAD SCI USA, V90, P2112, DOI 10.1073/pnas.90.6.2112; LUCCHESI JC, 1981, CHROMOSOMA, V82, P217, DOI 10.1007/BF00286106; Meyer B., UNPUB; MILLER LM, 1988, CELL, V55, P167, DOI 10.1016/0092-8674(88)90019-0; NICOLL M, COMMUNICATION; NONET ML, 1991, NATURE, V351, P65, DOI 10.1038/351065a0; NUSBAUM C, 1989, GENETICS, V122, P579; PALMER MJ, 1993, GENETICS, V134, P545; PALMER MJ, 1994, GENE DEV, V8, P698, DOI 10.1101/gad.8.6.698; PETERSON CL, 1994, CELL, V79, P389, DOI 10.1016/0092-8674(94)90247-X; PLENEFISCH JD, 1989, GENETICS, V121, P57; RASTAN S, 1994, CURR OPIN GENET DEV, V4, P292, DOI 10.1016/S0959-437X(05)80056-5; RASTELLI L, 1993, EMBO J, V12, P1513, DOI 10.1002/j.1460-2075.1993.tb05795.x; RASTELLI L, 1995, MECH DEVELOP, V53, P223, DOI 10.1016/0925-4773(95)00438-7; RHIND NR, 1995, CELL, V80, P71, DOI 10.1016/0092-8674(95)90452-2; RICHTER LJ, UNPUB; ROSENBLUTH RE, 1988, GENET RES, V52, P105, DOI 10.1017/S0016672300027476; SAITOH N, 1995, BIOESSAYS, V17, P759, DOI 10.1002/bies.950170905; SKRIPSKY T, 1982, DEV BIOL, V94, P153, DOI 10.1016/0012-1606(82)90078-1; SOSNOWSKI BA, 1989, CELL, V58, P449, DOI 10.1016/0092-8674(89)90426-1; STRUNNIKOV AV, 1993, J CELL BIOL, V123, P1635, DOI 10.1083/jcb.123.6.1635; TURNER BM, 1992, CELL, V69, P375, DOI 10.1016/0092-8674(92)90417-B; TURNER BM, 1993, CELL, V75, P5, DOI 10.1016/S0092-8674(05)80078-9; VILLENEUVE AM, 1987, CELL, V48, P25, DOI 10.1016/0092-8674(87)90352-7; ZHOU SB, 1995, EMBO J, V14, P2884, DOI 10.1002/j.1460-2075.1995.tb07288.x	54	91	102	0	2	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	DEC 8	1995	270	5242					1607	1610		10.1126/science.270.5242.1607	http://dx.doi.org/10.1126/science.270.5242.1607			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TJ293	7502070				2022-12-28	WOS:A1995TJ29300032
J	HELLER, RF; STEELE, PL; FISHER, JD; ALEXANDER, HM; DOBSON, AJ				HELLER, RF; STEELE, PL; FISHER, JD; ALEXANDER, HM; DOBSON, AJ			SUCCESS OF CARDIOPULMONARY-RESUSCITATION AFTER HEART-ATTACK IN-HOSPITAL AND OUTSIDE HOSPITAL	BRITISH MEDICAL JOURNAL			English	Article							CARDIAC-ARREST; SURVIVAL	Objectives-To determine factors associated with cardiopulmonary resuscitation being attempted after cardiac arrest from myocardial infarction, in or outside hospital, and estimate short term and long term survival rates. Design-Descriptive cross sectional and cohort study. Setting-Community based register of all suspected heart attacks and sudden cardiac deaths in Lower Hunter region of New South Wales, Australia. Subject-4924 men and women aged 25-69. Main outcome measures-Rates of attempted cardiopulmonary resuscitation and survival after successful resuscitation. Results-Cardiopulmonary resuscitation was attempted in 41% of cases of cardiac arrest after myocardial infarction outside hospital and 63% of cases in hospital, Survival rates at 28 days were 12% and 39% respectively, Among the survivors, although 41% had another myocardial infarction (or coronary death), 81% of both groups were still alive two years later. Younger and better educated people were more likely to receive cardiopulmonary resuscitation in either setting, and being married predicted cardiopulmonary resuscitation being attempted outside hospital. Younger age predicted better survival rates after attempted resuscitation in hospital. Conclusions-The reasons for better education to predict cardiopulmonary resuscitation being attempted need explanation. The higher survival rate after cardiopulmonary resuscitation in hospital compared with outside hospital and the good long term prognosis for survivors in both settings suggest that attempts to improve success of cardiopulmonary resuscitation outside hospital may be worth while.	UNIV NEWCASTLE,FAC MED & HLTH SCI,CTR CLIN EPIDEMIOL & BIOSTAT,NEWCASTLE,NSW 2308,AUSTRALIA	University of Newcastle			Dobson, Annette J/B-5273-2008	Heller, Richard/0000-0003-3161-5967				BECKER LB, 1993, NEW ENGL J MED, V329, P600, DOI 10.1056/NEJM199308263290902; BEURET P, 1993, RESUSCITATION, V25, P171, DOI 10.1016/0300-9572(93)90093-6; DOBSON AJ, 1988, ACTA MED SCAND S, V728, P84; EBELL MH, 1992, J FAM PRACTICE, V34, P551; EISENBERG MS, 1990, ANN EMERG MED, V19, P179, DOI 10.1016/S0196-0644(05)81805-0; HALLSTROM A, 1993, AM J PUBLIC HEALTH, V83, P245, DOI 10.2105/AJPH.83.2.245; JOSLYN SA, 1993, AM J EMERG MED, V11, P200, DOI 10.1016/0735-6757(93)90124-T; KELLERMANN AL, 1993, JAMA-J AM MED ASSOC, V270, P1433, DOI 10.1001/jama.270.12.1433; SOLOMON NA, 1993, ARCH INTERN MED, V153, P1218, DOI 10.1001/archinte.153.10.1218; TRESCH DD, 1993, AM J MED, V95, P123, DOI 10.1016/0002-9343(93)90252-K; TUNSTALLPEDOE H, 1992, BRIT MED J, V304, P1347, DOI 10.1136/bmj.304.6838.1347; TUNSTALLPEDOE H, 1994, CIRCULATION, V90, P583, DOI 10.1161/01.CIR.90.1.583	12	18	18	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	NOV 18	1995	311	7016					1332	1336		10.1136/bmj.311.7016.1332	http://dx.doi.org/10.1136/bmj.311.7016.1332			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TF901	7496282	Green Published			2022-12-28	WOS:A1995TF90100019
J	GRIFFITH, TS; BRUNNER, T; FLETCHER, SM; GREEN, DR; FERGUSON, TA				GRIFFITH, TS; BRUNNER, T; FLETCHER, SM; GREEN, DR; FERGUSON, TA			FAS LIGAND-INDUCED APOPTOSIS AS A MECHANISM OF IMMUNE PRIVILEGE	SCIENCE			English	Article							CELL-DEATH	The eye is a privileged site that cannot tolerate destructive inflammatory responses. inflammatory cells entering the anterior chamber of the eye in response to viral infection underwent apoptosis that was dependent on Fas (CD95)-Fas ligand (FasL) and produced no tissue damage. In contrast, viral infection in gld mice, which lack functional Fast, resulted in an inflammation and invasion of ocular tissue without apoptosis. Fas-positive but not Fas-negative tumor cells were killed by apoptosis when placed within isolated anterior segments of the eyes of normal but not Fast-negative mice. Fast messenger RNA and protein were detectable in the eye. Thus, Fas-FasL interactions appear to be:an important mechanism for the maintenance of immune privilege.	WASHINGTON UNIV,SCH MED,DEPT OPHTHALMOL & VISUAL SCI,ST LOUIS,MO 63110; WASHINGTON UNIV,SCH MED,DEPT PATHOL,ST LOUIS,MO 63110; LA JOLLA INST ALLERGY & IMMUNOL,DIV CELLULAR IMMUNOL,LA JOLLA,CA 92037	Washington University (WUSTL); Washington University (WUSTL); La Jolla Institute for Immunology			Green, Douglas R/N-8083-2018	Green, Douglas R/0000-0002-7332-1417	NATIONAL EYE INSTITUTE [P30EY002687] Funding Source: NIH RePORTER; NEI NIH HHS [EY06765, EY02687] Funding Source: Medline	NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		ATHERTON SS, 1987, INVEST OPHTH VIS SCI, V28, P859; BRUNNER T, 1995, NATURE, V373, P441, DOI 10.1038/373441a0; CASPI RR, 1986, J IMMUNOL, V136, P928; FERGUSON TA, 1995, J IMMUNOL, V155, P1746; GAO EK, UNPUB; GAVRIELI Y, 1992, J CELL BIOL, V119, P493, DOI 10.1083/jcb.119.3.493; GREENE HSN, 1949, CANCER RES, V9, P728; GRIFFITH TS, UNPUB; HOOPER P, 1991, CURR EYE RES, V10, P363, DOI 10.3109/02713689108996342; IWAI K, 1994, BLOOD, V4, P1201; JU ST, 1995, NATURE, V373, P444, DOI 10.1038/373444a0; MEDAWAR PB, 1948, BRIT J EXP PATHOL, V29, P58; MOGIL RJ, 1995, INT IMMUNOL, V7, P1451, DOI 10.1093/intimm/7.9.1451; NIEDERKORN JY, 1983, J IMMUNOL, V131, P2587; ROUVIER E, 1993, J EXP MED, V177, P195, DOI 10.1084/jem.177.1.195; SHI YF, 1989, NATURE, V339, P625, DOI 10.1038/339625a0; SINGER GG, 1994, IMMUNITY, V1, P365, DOI 10.1016/1074-7613(94)90067-1; SMITH CA, 1989, NATURE, V337, P181, DOI 10.1038/337181a0; SPANGRUDE GJ, 1994, CURRENT PROTOCOLS IM, V1; STREILEIN JW, 1992, J NEUROIMMUNOL, V39, P185, DOI 10.1016/0165-5728(92)90253-H; SUDA T, 1995, J IMMUNOL, V154, P3806; SUDA T, 1993, CELL, V75, P1169, DOI 10.1016/0092-8674(93)90326-L; TAKAHASHI T, 1994, CELL, V76, P969, DOI 10.1016/0092-8674(94)90375-1; van Dooremaal J. C., 1873, A VONGRAEFES ARCH OP, V19, P359; WATANABEFUKUNAGA R, 1992, NATURE, V356, P314, DOI 10.1038/356314a0; WILBANKS GA, 1992, EUR J IMMUNOL, V22, P165, DOI 10.1002/eji.1830220125	26	1737	1812	2	57	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	NOV 17	1995	270	5239					1189	1192		10.1126/science.270.5239.1189	http://dx.doi.org/10.1126/science.270.5239.1189			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TE905	7502042				2022-12-28	WOS:A1995TE90500053
J	MULDER, JWR; KRUYT, PM; SEWNATH, M; OOSTING, J; SELDENRIJK, CA; WEIDEMA, WF; OFFERHAUS, GJA; PALS, ST				MULDER, JWR; KRUYT, PM; SEWNATH, M; OOSTING, J; SELDENRIJK, CA; WEIDEMA, WF; OFFERHAUS, GJA; PALS, ST			COLORECTAL-CANCER PROGNOSIS AND EXPRESSION OF EXON-V6-CONTAINING CD44 PROTEINS	LANCET			English	Note							METASTASIS-ASSOCIATED VARIANT; CARCINOMAS; HOMOLOG	CD44 variants containing v6 confer metastatic potential to rat carcinoma cell-lines. In man, CD44v6 is increasingly expressed during colorectal tumour progression. In 68 colorectal carcinoma patients, survival analysis showed that CD44v6 expression in the tumours was associated with tumour-related death. In patients who had an apparently radical resection of their primary tumour, CD44v6 expression had prognostic value independent of Dukes' stage. CD44v6 expression may reflect propensity for metastasis after apparently curative surgery, making adjuvant therapy an option in these patients.	UNIV AMSTERDAM,ACAD MED CTR,DEPT PATHOL,1105 AZ AMSTERDAM,NETHERLANDS; UNIV AMSTERDAM,ACAD MED CTR,DEPT CLIN EPIDEMIOL,1105 AZ AMSTERDAM,NETHERLANDS; REINIER DE GRAAF HOSP,DEPT SURG,DELFT,NETHERLANDS; REINIER DE GRAAF HOSP,DEPT PATHOL,DELFT,NETHERLANDS	University of Amsterdam; Academic Medical Center Amsterdam; Vrije Universiteit Amsterdam; University of Amsterdam; Academic Medical Center Amsterdam; Reinier de Graaf Hospital; Reinier de Graaf Hospital				Pals, Steven/0000-0002-1419-0939				ARCH R, 1992, SCIENCE, V257, P682, DOI 10.1126/science.1496383; GUNTHERT U, 1991, CELL, V65, P13, DOI 10.1016/0092-8674(91)90403-L; HEIDER KH, 1993, J CELL BIOL, V120, P227, DOI 10.1083/jcb.120.1.227; KOOPMAN G, 1993, J EXP MED, V177, P897, DOI 10.1084/jem.177.4.897; MATSUMURA Y, 1992, LANCET, V340, P1053, DOI 10.1016/0140-6736(92)93077-Z; MOERTEL CG, 1994, NEW ENGL J MED, V330, P1136; SCREATON GR, 1992, P NATL ACAD SCI USA, V89, P12160, DOI 10.1073/pnas.89.24.12160; TANABE KK, 1993, LANCET, V341, P725, DOI 10.1016/0140-6736(93)90490-8; WIELENGA VJM, 1993, CANCER RES, V53, P4754; 1990, JAMA-J AM MED ASSOC, V264, P1444	10	302	315	0	6	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	NOV 26	1994	344	8935					1470	1472		10.1016/S0140-6736(94)90290-9	http://dx.doi.org/10.1016/S0140-6736(94)90290-9			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PT995	7526103				2022-12-28	WOS:A1994PT99500009
J	PLEY, HW; FLAHERTY, KM; MCKAY, DB				PLEY, HW; FLAHERTY, KM; MCKAY, DB			MODEL FOR AN RNA TERTIARY INTERACTION FRONT THE STRUCTURE OF AN INTERMOLECULAR COMPLEX BETWEEN A GAAA TETRALOOP AND AN RNA HELIX	NATURE			English	Article							ARCHITECTURE; SEQUENCE; LOOPS	IN large structured RNAs, RNA hairpins in which the strands of the duplex stem are connected by a tetraloop of the consensus sequence 5'-GNRA (where N is any nucleotide, and R is either G or A) are unusually frequent(1). In group I introns there is a covariation in sequence between nucleotides in the third and fourth positions of the loop with specific distant base pairs in putative RNA duplex stems(2): GNAA loops correlate with successive 5'-C-C.G-G base pairs in stems, whereas GNGA loops correlate with 5'-C-U.G-A. This has led to the suggestion that GNRA tetraloops may be involved in specific long-range tertiary interactions, with each A in position 3 or 4 of the loop interacting with a C-G base pair in the duplex, and G in position 3 interacting with a U-A base pair. This idea is supported experimentally for the GAAA loop of the P5b extension of the group I intron of Tetrahymena thermophila(3) and the L9 GUGA terminal loop of the td intron of bacteriophage T4 (ref. 4). NMR has revealed the overall structure of the tetraloop for 12-nucleotide hairpins with GCAA and GAAA loops(5) and models have been proposed for the interaction of GNRA tetraloops with base pairs in the minor groove of A-form RNA(2,4). Here we describe the crystal structure of an intermolecular complex between a GAAA tetraloop and an RNA helix. The interactions we observe correlate with tbe specificity of GNRA tetraloops inferred from phylogenetic studies, suggesting that this complex is a legitimate model for intramolecular tertiary interactions mediated by GNRA tetraloops in large structured RNAs.	STANFORD UNIV,SCH MED,DEPT BIOL STRUCT,BECKMAN LABS STRUCT BIOL,STANFORD,CA 94305	Stanford University								HEUS HA, 1991, SCIENCE, V253, P191, DOI 10.1126/science.1712983; JAEGER L, 1994, J MOL BIOL, V236, P1271, DOI 10.1016/0022-2836(94)90055-8; MICHEL F, 1990, J MOL BIOL, V216, P585, DOI 10.1016/0022-2836(90)90386-Z; MURPHY FL, 1994, J MOL BIOL, V236, P49, DOI 10.1006/jmbi.1994.1117; PLEY HW, 1994, NATURE, V372, P68, DOI 10.1038/372068a0; WOESE CR, 1990, P NATL ACAD SCI USA, V87, P8467, DOI 10.1073/pnas.87.21.8467	6	263	265	0	7	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	NOV 3	1994	372	6501					111	113		10.1038/372111a0	http://dx.doi.org/10.1038/372111a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PQ348	7526219				2022-12-28	WOS:A1994PQ34800085
J	MCCANN, RM; HALL, WJ; GROTHJUNCKER, A				MCCANN, RM; HALL, WJ; GROTHJUNCKER, A			COMFORT CARE FOR TERMINALLY ILL PATIENTS - THE APPROPRIATE USE OF NUTRITION AND HYDRATION	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							PARENTERAL-NUTRITION; ELDERLY PATIENTS; CANCER; DEPRIVATION	Objective.-To determine the frequency of symptoms of hunger and thirst in a group of terminally ill patients and determine whether these symptoms could be palliated without forced feeding, forced hydration, or parenteral alimentation. Design.-Prospective evaluation of consecutively admitted terminally ill patients treated in a comfort care unit. Setting.-Ten-bed comfort care unit in a 471-bed long-term care facility. Participants.-Mentally aware, competent patients with terminal illnesses monitored from time of admission to time of death while residing in the comfort care unit. Main Outcome Measures.-Symptoms of hunger, thirst, and dry mouth were recorded, and the amounts and types of food and fluids necessary to relieve these symptoms were documented. The subjective level of comfort was assessed longitudinally in all patients. Results.-Of the 32 patients monitored during the 12 months of study, 20 patients (63%) never experienced any hunger, white 11 patients (34%) had symptoms only initially. Similarly, 20 patients (62%) experienced either no thirst or thirst only initially during their terminal illness. In all patients, symptoms of hunger, thirst, and dry mouth could be alleviated, usually with smalt amounts of food, fluids, and/or by the application of ice chips and lubrication to the lips. Comfort care included use of narcotics for relief of pain or shortness of breath in 94% of patients. Conclusions.-In this series, patients terminally ill with cancer generally did not experience hunger and those who did needed only small amounts of food for alleviation. Complaints of thirst and dry mouth were relieved with mouth care and sips of liquids far less than that needed to prevent dehydration. Food and fluid administration beyond the specific requests of patients may play a minimal role in providing comfort to terminally ill patients.	UNIV ROCHESTER, SCH MED & DENT, DEPT MED, ROCHESTER, NY 14642 USA; ST JOHNS HOME, ROCHESTER, NY USA	University of Rochester								[Anonymous], 1992, ANN INTERN MED, V117, P947; BILLINGS JA, 1985, J AM GERIATR SOC, V33, P808, DOI 10.1111/j.1532-5415.1985.tb04196.x; CIOCON JO, 1988, ARCH INTERN MED, V148, P429, DOI 10.1001/archinte.148.2.429; CLAMON GH, 1985, CANCER TREAT REP, V69, P167; FELIG P, 1969, J CLIN INVEST, V48, P584, DOI 10.1172/JCI106017; FELIG P, 1970, NEW ENGL J MED, V282, P166; Gershan J A, 1985, Crit Care Nurse, V5, P32; HAMM RJ, 1984, PHYSIOL BEHAV, V33, P499, DOI 10.1016/0031-9384(84)90176-8; HAMM RJ, 1985, PHYSIOL BEHAV, V35, P879, DOI 10.1016/0031-9384(85)90254-9; HARDY C, 1986, J AM GERIATR SOC, V34, P219, DOI 10.1111/j.1532-5415.1986.tb04207.x; HEBER D, 1986, CANCER-AM CANCER SOC, V58, P1867, DOI 10.1002/1097-0142(19861015)58:8+<1867::AID-CNCR2820581413>3.0.CO;2-A; KERNDT PR, 1982, WESTERN J MED, V137, P379; KORETZ RL, 1984, J CLIN ONCOL, V2, P534, DOI 10.1200/JCO.1984.2.5.534; LO B, 1986, ARCH INTERN MED, V146, P1613, DOI 10.1001/archinte.146.8.1613; MCHUGH JT, 1990, ISSUES LAW MED, V6, P89; NIXON DW, 1981, CANCER TREAT REP, V65, P121; NORBERG A, 1980, BRIT MED J, V280, P377, DOI 10.1136/bmj.280.6211.377; OWEN OE, 1983, CLIN ENDOCRINOL META, V12, P359, DOI 10.1016/S0300-595X(83)80046-2; PHILLIPS PA, 1984, NEW ENGL J MED, V311, P753, DOI 10.1056/NEJM198409203111202; President's Commission for the Study of Ethical Problems in Medicine and Biomedical and Behavioral Research, 1983, DECIDING FOREGO LIFE; PRINTZ LA, 1988, GERIATRICS, V43, P84; QUILL TE, 1989, ARCH INTERN MED, V149, P1937, DOI 10.1001/archinte.149.9.1937; SAUDEK CD, 1976, AM J MED, V60, P117, DOI 10.1016/0002-9343(76)90540-4; SULLIVAN RJ, 1993, J GEN INTERN MED, V8, P220, DOI 10.1007/BF02599271; VANDERPOOL H, 1978, ENCY BIOETHICS, P1373; 1988, GUIDELINES WITHHOLDI; 1989, WITHHOLDING WITHDRAW	27	327	336	0	23	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 26	1994	272	16					1263	1266		10.1001/jama.272.16.1263	http://dx.doi.org/10.1001/jama.272.16.1263			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PN068	7523740				2022-12-28	WOS:A1994PN06800031
J	CYSTER, JG; HARTLEY, SB; GOODNOW, CC				CYSTER, JG; HARTLEY, SB; GOODNOW, CC			COMPETITION FOR FOLLICULAR NICHES EXCLUDES SELF-REACTIVE CELLS FROM THE RECIRCULATING B-CELL REPERTOIRE	NATURE			English	Article							LYMPHOCYTES-B; TRANSGENIC MICE; BONE-MARROW; CLONAL DELETION; GENES; EXPRESSION; TOLERANCE; LYSOZYME; ANTIGEN; MOUSE	Two different approaches to follow clones of B lymphocytes in a diverse preimmune repertoire reveal a new process for eliminating self-reactive cells in the periphery which depends on competition between cells with different specificities. A key feature of this censoring mechanism is the selective exclusion of self-antigen-binding B cells from the normal migration route into lymphoid follicles, resulting in their premature death. This is a striking example of homeostasis by cellular competition for limiting niches and may explain the paradoxical association between immunodeficiency and autoimmunity.	STANFORD UNIV, BECKMAN CTR, SCH MED, HOWARD HUGHES MED INST, STANFORD, CA 94305 USA	Howard Hughes Medical Institute; Stanford University	CYSTER, JG (corresponding author), STANFORD UNIV, BECKMAN CTR, SCH MED, DEPT MICROBIOL & IMMUNOL, STANFORD, CA 94305 USA.		Goodnow, Christopher C/V-8108-2018	Goodnow, Christopher C/0000-0001-5296-6155				ADELSTEIN S, 1991, SCIENCE, V251, P1223, DOI 10.1126/science.1900950; AHEARN JM, 1989, ADV IMMUNOL, V46, P183, DOI 10.1016/S0065-2776(08)60654-9; ALLMAN DM, 1993, J IMMUNOL, V151, P4431; AUGUST CS, 1989, IMMUNOLOGICAL DISORD, P634; BELL EB, 1975, EUR J IMMUNOL, V5, P1; BONA CA, 1988, ANNU REV IMMUNOL, V6, P327, DOI 10.1146/annurev.iy.06.040188.001551; COOKE MP, 1994, J EXP MED, V179, P425, DOI 10.1084/jem.179.2.425; DAVIS MM, 1988, NATURE, V334, P395, DOI 10.1038/334395a0; ERIKSON J, 1991, NATURE, V349, P331, DOI 10.1038/349331a0; FORSTER I, 1990, P NATL ACAD SCI USA, V87, P4781, DOI 10.1073/pnas.87.12.4781; FORSTER I, 1991, EUR J IMMUNOL, V21, P1779, DOI 10.1002/eji.1830210732; FREITAS AA, 1990, INT IMMUNOL, V2, P15, DOI 10.1093/intimm/2.1.15; GOODNOW CC, 1992, ANNU REV IMMUNOL, V10, P489, DOI 10.1146/annurev.iy.10.040192.002421; GOODNOW CC, 1989, NATURE, V342, P385, DOI 10.1038/342385a0; GOODNOW CC, 1988, NATURE, V334, P676, DOI 10.1038/334676a0; GOWANS JL, 1964, PROC R SOC SER B-BIO, V159, P257, DOI 10.1098/rspb.1964.0001; GRAY D, 1988, J EXP MED, V167, P805, DOI 10.1084/jem.167.3.805; GU H, 1991, J EXP MED, V173, P1357, DOI 10.1084/jem.173.6.1357; GUTMAN GA, 1973, TRANSPLANTATION, V16, P621, DOI 10.1097/00007890-197312000-00014; HARTLEY SB, 1993, CELL, V72, P325, DOI 10.1016/0092-8674(93)90111-3; HARTLEY SB, 1991, NATURE, V353, P765, DOI 10.1038/353765a0; HOWARD JC, 1972, J EXP MED, V135, P185, DOI 10.1084/jem.135.2.185; Kearney J F, 1992, Int Rev Immunol, V8, P247, DOI 10.3109/08830189209055577; KOOPMAN G, 1992, IMMUNOL REV, V126, P21, DOI 10.1111/j.1600-065X.1992.tb00629.x; LIU YJ, 1991, EUR J IMMUNOL, V21, P2951, DOI 10.1002/eji.1830211209; LORTAN JE, 1987, EUR J IMMUNOL, V17, P1311, DOI 10.1002/eji.1830170914; MACLENNAN ICM, 1990, CURR TOP MICROBIOL, V159, P37; MAKELA O, 1965, IMMUNOLOGY, V8, P539; MASON DY, 1992, INT IMMUNOL, V4, P163, DOI 10.1093/intimm/4.2.163; NEMAZEE D, 1991, IMMUNOL REV, V122, P117, DOI 10.1111/j.1600-065X.1991.tb00600.x; NEMAZEE DA, 1989, NATURE, V337, P562, DOI 10.1038/337562a0; NIEUWENHUIS P, 1976, CELL IMMUNOL, V23, P254, DOI 10.1016/0008-8749(76)90191-X; OKAMOTO M, 1992, J EXP MED, V175, P71, DOI 10.1084/jem.175.1.71; OPPENHEIM RW, 1991, ANNU REV NEUROSCI, V14, P453, DOI 10.1146/annurev.ne.14.030191.002321; OPSTELTEN D, 1983, J IMMUNOL, V131, P2635; PADLAN EA, 1989, P NATL ACAD SCI USA, V86, P5938, DOI 10.1073/pnas.86.15.5938; PELLAS TC, 1990, AM J ANAT, V187, P347, DOI 10.1002/aja.1001870404; PICKER LJ, 1992, ANNU REV IMMUNOL, V10, P561, DOI 10.1146/annurev.immunol.10.1.561; POPPEMA S, 1992, IMMUNOL REV, V126, P163, DOI 10.1111/j.1600-065X.1992.tb00636.x; RAFF MC, 1992, NATURE, V356, P397, DOI 10.1038/356397a0; ROLINK A, 1993, ADV IMMUNOL, V53, P123, DOI 10.1016/S0065-2776(08)60499-X; SMITHGILL SJ, 1987, J IMMUNOL, V139, P4135; SPRENT J, 1972, EUR J IMMUNOL, V2, P384, DOI 10.1002/eji.1830020420; STORB U, 1987, ANNU REV IMMUNOL, V5, P151, DOI 10.1146/annurev.iy.05.040187.001055; STRASSER A, 1991, P NATL ACAD SCI USA, V88, P8661, DOI 10.1073/pnas.88.19.8661; VANDENEERTWEGH AJM, 1993, J EXP MED, V178, P1555, DOI 10.1084/jem.178.5.1555; YANCOPOULOS GD, 1984, NATURE, V311, P727, DOI 10.1038/311727a0	47	476	478	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	SEP 29	1994	371	6496					389	395		10.1038/371389a0	http://dx.doi.org/10.1038/371389a0			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PJ285	7522305				2022-12-28	WOS:A1994PJ28500033
J	LI, VW; FOLKERTH, RD; WATANABE, H; YU, CN; RUPNICK, M; BARNES, P; SCOTT, RM; BLACK, PM; SALLAN, SE; FOLKMAN, J				LI, VW; FOLKERTH, RD; WATANABE, H; YU, CN; RUPNICK, M; BARNES, P; SCOTT, RM; BLACK, PM; SALLAN, SE; FOLKMAN, J			MICROVESSEL COUNT AND CEREBROSPINAL-FLUID BASIC FIBROBLAST GROWTH-FACTOR IN CHILDREN WITH BRAIN-TUMORS	LANCET			English	Article							CAPILLARY ENDOTHELIAL-CELLS; CONTRAST ENHANCEMENT; ANGIOGENESIS; METASTASIS; AFFINITY; MEMBRANE; BINDING; CULTURE; TUMORS	Tumour growth is angiogenesis-dependent; brain tumours have more intense neovascularisation than other tumours and produce basic fibroblast growth factor, a potent angiogenic mediator. Because little is known about the release of basic fibroblast growth factor from brain tumours into extracellular fluids, we tested cerebrospinal fluid (CSF) from 26 children and young adults with brain tumours and 18 controls for basic fibroblast growth factor and for proliferative activity on cultured capillary endothelial cells. We also measured the density of microvessels in tumours by immunohistochemical staining. Basic fibroblast growth factor was detected in the CSF of 62% (16 of 26) patients with brain tumours but in none of the controls. Specimens with basic fibroblast growth factor stimulated DNA synthesis of capillary endothelial cells in vitro. Endothelial proliferative activity was blocked by neutralising antibodies to basic fibroblast growth factor. Basic fibroblast growth factor correlated with mitogenic activity in CSF in vitro (p less than or equal to 0.0001), and with density of microvessels in histological sections (p less than or equal to 0.005). A microvessel count of greater than or equal to 68 per 200 x field was associated with tumour recurrence (p = 0.005) and with mortality (p = 0.02). Basic fibroblast growth factor in brain tumours may mediate angiogenesis as measured by microvessel density in histological sections, so has potential as both a marker for neoplasia and a target for tumour treatments. Furthermore, evaluation of cerebrospinal fluid basic fibroblast growth factor, along with microvessel quantitation in biopsied tumours, may provide improved prognostic information for the management of patients with brain tumours.	CHILDRENS HOSP, DEPT SURG, BOSTON, MA 02115 USA; CHILDRENS HOSP, DEPT NEUROSURG, BOSTON, MA 02115 USA; CHILDRENS HOSP, DEPT PATHOL, BOSTON, MA 02115 USA; CHILDRENS HOSP, DEPT RADIOL, BOSTON, MA 02115 USA; CHILDRENS HOSP, HOWARD HUGHES MED INST, BOSTON, MA 02115 USA; HARVARD UNIV, SCH MED, DEPT MED, BOSTON, MA USA; TAKEDA CHEM IND LTD, OSAKA 532, JAPAN	Harvard University; Boston Children's Hospital; Harvard University; Boston Children's Hospital; Harvard University; Boston Children's Hospital; Harvard University; Boston Children's Hospital; Harvard University; Boston Children's Hospital; Howard Hughes Medical Institute; Harvard University; Harvard Medical School; Takeda Chemical Industries				Yu, Channing/0000-0002-3231-2565	NATIONAL CANCER INSTITUTE [T32CA009535, R01CA037395, R37CA037395] Funding Source: NIH RePORTER; NCI NIH HHS [5T32CA09535-06, CA37395-09] Funding Source: Medline; NINDS NIH HHS [NINDS NS-92-01] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		BIGNER SH, 1992, J NEUROPATH EXP NEUR, V51, P235, DOI 10.1097/00005072-199205000-00001; BREM H, 1980, SURG FORUM, V31, P471; BREM S, 1992, CANCER, V70, P2673, DOI 10.1002/1097-0142(19921201)70:11<2673::AID-CNCR2820701118>3.0.CO;2-F; CONNOLLY DT, 1986, ANAL BIOCHEM, V152, P136, DOI 10.1016/0003-2697(86)90131-4; Finklestein S P, 1990, Restor Neurol Neurosci, V1, P387, DOI 10.3233/RNN-1990-1603; FOLKMAN J, 1979, P NATL ACAD SCI USA, V76, P5217, DOI 10.1073/pnas.76.10.5217; FOLKMAN J, 1989, NATURE, V339, P58, DOI 10.1038/339058a0; FOLKMAN J, 1988, AM J PATHOL, V130, P393; GOSPODAROWICZ D, 1976, P NATL ACAD SCI USA, V73, P4120, DOI 10.1073/pnas.73.11.4120; HAMADA J, 1992, BRIT J CANCER, V66, P349, DOI 10.1038/bjc.1992.269; HESSELINK JR, 1988, RADIOL CLIN N AM, V26, P873; HORI A, 1991, CANCER RES, V51, P6180; KANDEL J, 1991, CELL, V66, P1095, DOI 10.1016/0092-8674(91)90033-U; KIM KJ, 1993, NATURE, V362, P841, DOI 10.1038/362841a0; Klagsbrun M, 1989, Prog Growth Factor Res, V1, P207, DOI 10.1016/0955-2235(89)90012-4; LOPEZPOUSA S, 1981, EXPERIENTIA, V37, P413; MOSCATELLI D, 1987, J CELL PHYSIOL, V131, P123, DOI 10.1002/jcp.1041310118; NAKAGAWA H, 1992, J NEURO-ONCOL, V12, P111; PINKUS GS, 1986, AM J CLIN PATHOL, V85, P269, DOI 10.1093/ajcp/85.3.269; RAK JW, IN PRESS J CELL PHYS; Russell D., 1989, PATHOLOGY TUMORS NER; SHING Y, 1984, SCIENCE, V223, P1296, DOI 10.1126/science.6199844; SHING Y, 1991, METHOD ENZYMOL, V198, P91; SHING Y, 1992, INVEST OPHTH VIS SCI, V33, pA1683; TAKAHASHI A, 1993, NEUROSCI LETT, V160, P214, DOI 10.1016/0304-3940(93)90416-I; TAKAHASHI JA, 1990, P NATL ACAD SCI USA, V87, P5710, DOI 10.1073/pnas.87.15.5710; WALICKE PA, 1988, J NEUROSCI, V8, P2618; WATANABE H, 1991, BIOCHEM BIOPH RES CO, V175, P229, DOI 10.1016/S0006-291X(05)81224-0; WEIDNER N, 1991, NEW ENGL J MED, V324, P1, DOI 10.1056/NEJM199101033240101; ZAGZAG D, 1989, AM J ROENTGENOL, V153, P141, DOI 10.2214/ajr.153.1.141	30	200	214	0	1	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	JUL 9	1994	344	8915					82	86		10.1016/S0140-6736(94)91280-7	http://dx.doi.org/10.1016/S0140-6736(94)91280-7			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NV732	7516992				2022-12-28	WOS:A1994NV73200008
J	BORST, P; RUDENKO, G				BORST, P; RUDENKO, G			ANTIGENIC VARIATION IN AFRICAN TRYPANOSOMES	SCIENCE			English	Editorial Material							GENE-EXPRESSION SITE; BLOOD-STREAM-FORM; T-BRUCEI; POINT MUTATIONS; TRANSCRIPTION; SEQUENCE; PROMOTER; RECEPTOR; PROTEIN; GROWTH				BORST, P (corresponding author), NETHERLANDS CANC INST,DIV MOLEC BIOL,PLESMANLAAN 121,1066 CX AMSTERDAM,NETHERLANDS.							BALTZ T, 1991, EMBO J, V10, P1653, DOI 10.1002/j.1460-2075.1991.tb07688.x; BARRY JD, 1991, PARASITOL TODAY, V7, P207, DOI 10.1016/0169-4758(91)90143-C; BLUM ML, 1993, NATURE, V362, P603, DOI 10.1038/362603a0; BORST P, 1986, ANNU REV BIOCHEM, V55, P701, DOI 10.1146/annurev.bi.55.070186.003413; BORST P, 1991, IMMUNOPARASITOL TOD, pA29, DOI 10.1016/S0167-5699(05)80009-X; BORST P, 1991, TRENDS GENET, V7, P307, DOI 10.1016/0168-9525(91)90406-G; CARRUTHERS VB, 1992, P NATL ACAD SCI USA, V89, P8818, DOI 10.1073/pnas.89.18.8818; CHAUDHRI M, IN PRESS P NATL ACAD; CLAYTON C, 1992, PROG NUCLEIC ACID RE, V43, P37, DOI 10.1016/S0079-6603(08)61043-0; COPPENS I, 1987, J PROTOZOOL, V34, P465, DOI 10.1111/j.1550-7408.1987.tb03216.x; CROSS GAM, 1990, ANNU REV IMMUNOL, V8, P83, DOI 10.1146/annurev.iy.08.040190.000503; EID J, 1991, P NATL ACAD SCI USA, V88, P2118, DOI 10.1073/pnas.88.6.2118; GOMMERSAMPT JH, 1993, CELL, V75, P1129, DOI 10.1016/0092-8674(93)90322-H; GOTTESDIENER KM, 1992, MOL CELL BIOL, V12, P4784, DOI 10.1128/MCB.12.10.4784; JOHNSON PJ, 1987, CELL, V51, P273, DOI 10.1016/0092-8674(87)90154-1; KAMPER SM, 1992, MOL BIOCHEM PARASIT, V53, P33, DOI 10.1016/0166-6851(92)90004-4; KOOTER JM, 1987, CELL, V51, P261, DOI 10.1016/0092-8674(87)90153-X; LEE MGS, 1990, SCIENCE, V258, P1588; LIGTENBERG M, IN PRESS EMBO J; LIPS S, 1993, MOL BIOCHEM PARASIT, V62, P135, DOI 10.1016/0166-6851(93)90189-5; LODES MJ, 1993, MOL CELL BIOL, V13, P7036, DOI 10.1128/MCB.13.11.7036; LU Y, 1993, CELL, V72, P397, DOI 10.1016/0092-8674(93)90116-8; LU Y, IN PRESS MOL CELL BI; PAINDAVOINE P, 1992, MOL CELL BIOL, V12, P1218, DOI 10.1128/MCB.12.3.1218; PAYS E, 1989, CELL, V57, P835, DOI 10.1016/0092-8674(89)90798-8; Pays Etienne, 1993, Symposium of the Society for General Microbiology, V50, P127; SALMON D, IN PRESS CELL; SCHELL D, 1991, EMBO J, V10, P1061, DOI 10.1002/j.1460-2075.1991.tb08045.x; STEVERDING D, IN PRESS EUR J CELL; TENASBROEK ALMA, 1990, NATURE, V348, P174, DOI 10.1038/348174a0; ZOMERDIJK JCBM, 1991, NUCLEIC ACIDS RES, V19, P1359, DOI 10.1093/nar/19.7.1359	31	97	100	0	4	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUN 24	1994	264	5167					1872	1873		10.1126/science.7516579	http://dx.doi.org/10.1126/science.7516579			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	NT847	7516579				2022-12-28	WOS:A1994NT84700029
J	DAS, KM; PRASAD, I; GARLA, S; AMENTA, PS				DAS, KM; PRASAD, I; GARLA, S; AMENTA, PS			DETECTION OF A SHARED COLON EPITHELIAL EPITOPE ON BARRETT EPITHELIUM BY A NOVEL MONOCLONAL-ANTIBODY	ANNALS OF INTERNAL MEDICINE			English	Article						EPITHELIUM; BARRETT ESOPHAGUS; EPITOPES; COLON; ESOPHAGITIS, PEPTIC	COLUMNAR-LINED ESOPHAGUS; ADENOCARCINOMA; DIAGNOSIS	Objective: To determine if there is a reactive epitope common to colonic epithelium and Barrett epithelium, a premalignant metaplastic columnar-lined esophagus, usually arising as a complication of chronic reflux esophagitis. Design: A monoclonal antibody, 7E(12)H(12) (IgM isotype), developed against a colonic epithelial protein was used in a sensitive immunoperoxidase assay using formalin-fixed, paraffin-embedded tissue. One hundred sixteen tissue specimens from the esophagus, stomach, duodenum, and jejunum were examined. Twenty-two biopsy specimens were taken from 22 patients with benign Barrett epithelium, and 12 specimens were obtained from 12 patients with adenocarcinoma of the esophagus arising in Barrett epithelium. The remaining 85 tissue specimens were obtained from various parts of the upper gastrointestinal tract of patients with or without disease states. Results: 21 of 22 (95%) Barrett epithelium specimens and all 12 adenocarcinomas arising from Barrett epithelium reacted with the 7E(12)H(12) monoclonal antibody. Other tissues from esophagus, gastroesophageal junction, stomach, duodenum, or jejunum did not react. Squamous cell carcinoma of the esophagus also did not react. Conclusions: Barrett epithelium shares phenotypic expression of colonic epithelium. The 7E(12)H(12) monoclonal antibody may provide insight into the origin and cellular lineage of Barrett epithelium.	ROBERT WOOD JOHNSON UNIV HOSP, NEW BRUNSWICK, NJ USA	Rutgers State University New Brunswick; Rutgers State University Medical Center	DAS, KM (corresponding author), UNIV MED & DENT NEW JERSEY, ROBERT WOOD JOHNSON MED SCH, DEPT MED, 1 ROBERT WOOD JOHNSON PL, NEW BRUNSWICK, NJ 08903 USA.				NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK044314] Funding Source: NIH RePORTER; NIDDK NIH HHS [R01 DK 44314] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AMENTA PS, 1987, METHOD ENZYMOL, V145, P133; CAMERON AJ, 1985, NEW ENGL J MED, V313, P857, DOI 10.1056/NEJM198510033131404; DAS KM, 1987, J IMMUNOL, V139, P77; FEURLE GE, 1990, DIGEST DIS SCI, V35, P86, DOI 10.1007/BF01537228; GOTTFRIED MR, 1989, AM J CLIN PATHOL, V92, P741, DOI 10.1093/ajcp/92.6.741; Goyal RK, 1985, BARRETTS ESOPHAGUS P, P1; Haggitt RC, 1985, BARRETTS ESOPHAGUS P, P153; HALSTENSEN TS, 1993, GUT, V34, P650, DOI 10.1136/gut.34.5.650; HAMILTON SR, 1987, AM J CLIN PATHOL, V87, P301, DOI 10.1093/ajcp/87.3.301; KALISH RJ, 1984, GASTROENTEROLOGY, V86, P461; LEVINE DS, 1989, LAB INVEST, V60, P418; MCCLAVE SA, 1987, GASTROINTEST ENDOSC, V33, P413, DOI 10.1016/S0016-5107(87)71676-9; POST AB, 1993, AM J GASTROENTEROL, V88, P877; ROBERTSON DAF, 1989, BRIT MED J, V298, P650, DOI 10.1136/bmj.298.6674.650; SONTAG SJ, 1985, LANCET, V1, P946; SPECHLER SJ, 1986, NEW ENGL J MED, V315, P362, DOI 10.1056/NEJM198608073150605	16	75	76	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	MAY 1	1994	120	9					753	756		10.7326/0003-4819-120-9-199405010-00006	http://dx.doi.org/10.7326/0003-4819-120-9-199405010-00006			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NH251	7511878				2022-12-28	WOS:A1994NH25100006
J	LORENZ, W; DUDA, D; DICK, W; SITTER, H; DOENICKE, A; BLACK, A; WEBER, D; MENKE, H; STINNER, B; JUNGINGER, T; ROTHMUND, M; OHMANN, C; HEALY, MJR; BLACK, J; BROUWER, A; BRUER, HJ; DIETZ, W; ENNIS, M; GAJEK, H; HEINTZBAMBERG, D; HENNES, HJ; KAPP, B; KUNNEKE, M; MARSTALLER, M; MCPEEK, B; MOSS, J; OTTO, S; REHBOCK, C; REHN, D; REIMUND, KP; ROHER, HD; RUGELES, MS; SATTLER, J; SCHERHAG, A; TESCHNER, M; ZACZYK, R				LORENZ, W; DUDA, D; DICK, W; SITTER, H; DOENICKE, A; BLACK, A; WEBER, D; MENKE, H; STINNER, B; JUNGINGER, T; ROTHMUND, M; OHMANN, C; HEALY, MJR; BLACK, J; BROUWER, A; BRUER, HJ; DIETZ, W; ENNIS, M; GAJEK, H; HEINTZBAMBERG, D; HENNES, HJ; KAPP, B; KUNNEKE, M; MARSTALLER, M; MCPEEK, B; MOSS, J; OTTO, S; REHBOCK, C; REHN, D; REIMUND, KP; ROHER, HD; RUGELES, MS; SATTLER, J; SCHERHAG, A; TESCHNER, M; ZACZYK, R			INCIDENCE AND CLINICAL IMPORTANCE OF PERIOPERATIVE HISTAMINE-RELEASE - RANDOMIZED STUDY OF VOLUME LOADING AND ANTIHISTAMINES AFTER INDUCTION OF ANESTHESIA	LANCET			English	Article							ANAPHYLACTOID REACTIONS; ANESTHESIA; SURGERY; SEVERITY	Although histamine release is recognised as a common event during anaesthesia and surgery, few clinicians judge the resultant cardiorespiratory disturbances serious enough to warrant prophylaxis with antihistamines. We have assessed the incidence and importance of histamine release in a randomised 2 x 2 factorial study. 240 patients representing a routine throughput of major general surgery were studied during a standardised induction of anaesthesia and preoperative loading of the circulation with either Ringer solution or Haemaccel-35, with or without antihistamine prophylaxis with dimetindene (H-1) plus cimetidine (H-2). Cardiorespiratory disturbances were graded as detectable, clinically relevant, or life-threatening from observers' records of the anaesthesia and the actions taken by the anaesthetists. Disturbances that were accompanied by significant rises in plasma histamine were further designated histamine-related, and those that were not were designated histamine-unrelated. Anaesthetists, observers, and designators were blinded to whether or not the patients had received antihistamines and to which solution was used for circulatory volume loading. Clinically relevant or life-threatening histamine-related disturbances occurred in 8% of the patients who after induction of anaesthesia received Ringer without antihistamines, in 26% of those who received Haemaccel without antihistamines, and in 2% or less of those who received antihistamines (p less-than-or-equal-to .0001). There were 4 life-threatening histamine-related disturbances, all in patients who received Haemaccel without antihistamines (p<0.01). Histamine-unrelated disturbances occurred in 16% overall, with no obvious effect of Haemaccel or antihistamines.The histamine-related disturbances under anaesthesia were remarkable for their severity (even with small rises in histamine concentrations), for the prevalence of bradycardia, and for the absence of skin signs. Their likelihood and severity were increased in patients with tumours. The results of the trial make a case for routine prophylaxis with antihistamines as part of anaesthetic management.	UNIV MARBURG,DEPT GEN SURG,W-3550 MARBURG,GERMANY; UNIV MAINZ,ANAESTHESIOL CLIN,W-6500 MAINZ,GERMANY; UNIV MAINZ,GEN SURG CLIN,W-6500 MAINZ,GERMANY; UNIV MUNICH,INST ANAESTHESIOL,W-8000 MUNICH 2,GERMANY; UNIV DUSSELDORF,DEPT SURG,THEORET SURG UNIT,W-4000 DUSSELDORF 1,GERMANY; BRISTOL ROYAL INFIRM & GEN HOSP,DEPT ANAESTHESIA,BRISTOL BS2 8HW,AVON,ENGLAND; UNIV LONDON LONDON SCH HYG & TROP MED,DEPT MED STAT,LONDON WC1E 7HT,ENGLAND; UNIV LONDON LONDON SCH HYG & TROP MED,DEPT EPIDEMIOL,LONDON WC1E 7HT,ENGLAND	Philipps University Marburg; Johannes Gutenberg University of Mainz; Johannes Gutenberg University of Mainz; University of Munich; Heinrich Heine University Dusseldorf; Bristol Royal Infirmary; University of London; London School of Hygiene & Tropical Medicine; University of London; London School of Hygiene & Tropical Medicine	LORENZ, W (corresponding author), PHILIPPS UNIV MARBURG,INST THEORET CHIRURG,ZENTRUM OPERAT MED 1,D-35033 MARBURG,GERMANY.		Ohmann, Christian/AAV-8608-2020; Ennis, Madeleine/GZG-4070-2022					ALTMAN DG, 1990, LANCET, V335, P149, DOI 10.1016/0140-6736(90)90014-V; ASSEM ESK, 1992, MONOGR ALLERGY, V30, P1; Chalmers T. C., 1989, THEOR SURG, V4, P98; CLARKE RSJ, 1988, THEOR SURG, V3, P142; Dale HH, 1929, LANCET, V1, P1285; DICK W, 1992, ANAESTHESIST, V41, P239; DUDE D, 1992, AGENTS ACTIONS, V36, pC149; FISHER MM, 1984, CLIN ANAESTHESIOL, V2, P677; GENOVESE A, 1988, J PHARMACOL EXP THER, V247, P844; HOBSLEY M, 1983, THEORY SURG, V3, P55; LAXER RM, 1990, J RHEUMATOL, V17, P1; LEVI R, 1991, HDB EXPT PHARM, P347; LEVY JH, 1992, ANAPHYLACTIC REACTIO, P1; LORENZ W, 1976, BRIT J ANAESTH, V48, P151, DOI 10.1093/bja/48.2.151; LORENZ W, 1991, AGENT ACTION SUPPL, V33, P197; LORENZ W, 1985, NEW ENGL REG ALLERGY, V6, P174; LORENZ W, 1982, KLIN WOCHENSCHR, V60, P896, DOI 10.1007/BF01716946; LORENZ W, 1988, THEOR SURG, V3, P55; LORENZ W, 1983, ADVERSE RESPONSE INT, P83; LORENZ W, 1981, DEV BIOL STAND, V48, P207; LORENZ W, 1991, HDB EXP PHARM, V97, P9009; LORENZ W, 1905, N ENGL J REG ALLERGY, V6, P37; LORENZ W, 1992, AGENTS ACTIONS, V36, pC231; LORENZ W, 1991, HDB EXPT PHARM, V97, P385; MANGANO DT, 1991, J AM COLL CARDIOL, V17, P843, DOI 10.1016/0735-1097(91)90863-5; Neugebauer E. A., 1993, HDB MEDIATORS SEPTIC, P1; OOSTING E, 1990, CLIN EXP ALLERGY, V20, P349; SITTER H, 1992, AGENTS ACTIONS, V36, pC219; STELLATO C, 1992, ANESTHESIOLOGY, V77, P932, DOI 10.1097/00000542-199211000-00016; WATKINS J, 1988, GUIDE IMMEDIATE ANAE, P1; WILLIAMS JG, 1983, BRIT MED J, V286, P775, DOI 10.1136/bmj.286.6367.775	31	115	116	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	APR 16	1994	343	8903					933	940		10.1016/S0140-6736(94)90063-9	http://dx.doi.org/10.1016/S0140-6736(94)90063-9			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NF700	7512679	Green Submitted			2022-12-28	WOS:A1994NF70000007
J	CHEN, TY; YAU, KW				CHEN, TY; YAU, KW			DIRECT MODULATION BY CA2+-CALMODULIN OF CYCLIC NUCLEOTIDE-ACTIVATED CHANNEL OF RAT OLFACTORY RECEPTOR NEURONS	NATURE			English	Article							SENSITIVE ADENYLATE-CYCLASE; GATED CHANNELS; CELLS; CILIA; TRANSDUCTION; CONDUCTANCE; ODORANTS; NEWT; CURRENTS; CALCIUM	OLFACTORY receptor neurons depolarize in response to odorant stimulation of their sensory cilia1-3. One transduction mechanism involves a G-protein-mediated increase in adenylate cyclase activity4-8, raising the internal cyclic AMP concentration to open a cyclic nucleotide-activated cation channel on the plasma membrane9-14. An influx of Ca2+ through this channel, which is permeable to both monovalent and divalent cations, triggers olfactory adaptation15. Previous work has indicated that at least art of this Ca2+ mediated adaptation resides in the channel itself15-17, but the mechanism remains unclear and controversial16-18. Here we use the cloned channel from rat19 expressed in a cell line and the native channel from rat olfactory receptor cells to show that Ca2+ reduces the apparent affinity of the channel for cAMP by up to 20-fold in the presence of calmodulin, an abundant protein in olfactory cilia20. This decrease in apparent affinity appears to involve a direct interaction between Ca2+-calmodulin and the channel, and it can reduce the activation of the channel by cAMP by up to a few hundred-fold, suggesting that it may be a key component of the Ca2+-triggered olfactory adaptation.	JOHNS HOPKINS UNIV,SCH MED,HOWARD HUGHES MED INST,BALTIMORE,MD 21205	Howard Hughes Medical Institute; Johns Hopkins University	CHEN, TY (corresponding author), JOHNS HOPKINS UNIV,SCH MED,DEPT NEUROSCI,BALTIMORE,MD 21205, USA.							ANHOLT RRH, 1990, BIOCHEMISTRY-US, V29, P4049, DOI 10.1021/bi00469a004; BAKALYAR HA, 1990, SCIENCE, V250, P1403, DOI 10.1126/science.2255909; BOEKHOFF I, 1990, EMBO J, V9, P2453, DOI 10.1002/j.1460-2075.1990.tb07422.x; BORISY FF, 1992, J NEUROSCI, V12, P915; BRADLEY J, 1992, NEUR ABSTR, V18, P596; CHEN TY, 1993, NATURE, V362, P764, DOI 10.1038/362764a0; DHALLAN RS, 1990, NATURE, V347, P184, DOI 10.1038/347184a0; FIRESTEIN S, 1989, SCIENCE, V244, P79, DOI 10.1126/science.2704991; FIRESTEIN S, 1991, NEURON, V6, P825, DOI 10.1016/0896-6273(91)90178-3; FRINGS S, 1991, J GEN PHYSIOL, V97, P1, DOI 10.1085/jgp.97.1.1; FRINGS S, 1992, J GEN PHYSIOL, V100, P45, DOI 10.1085/jgp.100.1.45; HSU YT, 1993, NATURE, V361, P76, DOI 10.1038/361076a0; JAWORSKY DE, IN PRESS J NEUROSCI; JONES DT, 1989, SCIENCE, V244, P790, DOI 10.1126/science.2499043; KLEE CB, 1982, ADV PROTEIN CHEM, V35, P213, DOI 10.1016/S0065-3233(08)60470-2; KLEENE SJ, 1994, BRIT J PHARMACOL, V111, P469, DOI 10.1111/j.1476-5381.1994.tb14760.x; KLEENE SJ, 1993, J MEMBRANE BIOL, V131, P237, DOI 10.1007/BF02260112; KLEENE SJ, 1991, J NEUROSCI, V11, P3624; KRAMER RH, 1992, NEURON, V9, P897, DOI 10.1016/0896-6273(92)90242-6; KURAHASHI T, 1990, J PHYSIOL-LONDON, V430, P355, DOI 10.1113/jphysiol.1990.sp018295; KURAHASHI T, 1990, BRAIN RES, V515, P261, DOI 10.1016/0006-8993(90)90605-B; KURAHASHI T, 1989, J PHYSIOL-LONDON, V419, P177, DOI 10.1113/jphysiol.1989.sp017868; KURAHASHI T, 1993, NATURE, V363, P71, DOI 10.1038/363071a0; LIMAN ER, 1994, BIOPHYS J, V66, pA350; LOWE G, 1991, J PHYSIOL-LONDON, V442, P147, DOI 10.1113/jphysiol.1991.sp018787; LOWE G, 1993, NATURE, V366, P283, DOI 10.1038/366283a0; LOWE G, 1993, J PHYSIOL-LONDON, V462, P175, DOI 10.1113/jphysiol.1993.sp019550; NAKAMURA T, 1987, NATURE, V325, P442, DOI 10.1038/325442a0; PACE U, 1985, NATURE, V316, P255, DOI 10.1038/316255a0; SKLAR PB, 1986, J BIOL CHEM, V261, P5538; ZUFALL F, 1991, P ROY SOC B-BIOL SCI, V246, P225, DOI 10.1098/rspb.1991.0148	31	269	274	0	4	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	APR 7	1994	368	6471					545	548		10.1038/368545a0	http://dx.doi.org/10.1038/368545a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	NE335	7511217				2022-12-28	WOS:A1994NE33500054
J	YU, RC; CHU, C; BULUWELA, L; CHU, AC				YU, RC; CHU, C; BULUWELA, L; CHU, AC			CLONAL PROLIFERATION OF LANGERHANS CELLS IN LANGERHANS CELL HISTIOCYTOSIS	LANCET			English	Note								X-chromosome-inactivation assays can be used to assess clonality. We used such an assay at the human androgen-receptor gene locus in th ree female patients with histologically proven Langerhans cell histiocytosis. All patients were heterozygous for this locus. Cells bearing the Langerhans cell phenotype were purified from involved tissue after fluorescence-activated cell sorting with monoclonal antibodies against the CD1a complex. After Hhal digestion of DNA, these CD1a positive cells demonstrated a non-random X-chromosome-inactivation pattern, whereas CD1a negative cells in the same tissue showed a random pattern. Our data suggest that Langerhans cell histiocytosis represents a clonal proliferation of cells bearing the Langerhans cell phenotype.	ROYAL HOSP SICK CHILDREN, DEPT CHILD HLTH, GLASGOW G3 8SJ, SCOTLAND; CHARING CROSS & WESTMINSTER MED SCH, DEPT BIOCHEM, LONDON W6, ENGLAND	University of Glasgow; Imperial College London	YU, RC (corresponding author), ROYAL POSTGRAD MED SCH, DERMATOL UNIT, LONDON W12 0NN, ENGLAND.							ALLEN RC, 1992, AM J HUM GENET, V51, P1229; [Anonymous], 1987, Lancet, V1, P208; BIRBECK MS, 1961, J INVEST DERMATOL, V37, P51, DOI 10.1038/jid.1961.80; FITHIAN E, 1981, P NATL ACAD SCI-BIOL, V78, P2541, DOI 10.1073/pnas.78.4.2541; MCLELLAND J, 1989, BRIT J DERMATOL, V120, P485, DOI 10.1111/j.1365-2133.1989.tb01321.x; STINGL G, 1978, J IMMUNOL, V121, P2005	6	292	306	0	5	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	MAR 26	1994	343	8900					767	768		10.1016/S0140-6736(94)91842-2	http://dx.doi.org/10.1016/S0140-6736(94)91842-2			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NC351	7510816				2022-12-28	WOS:A1994NC35100014
J	WIEDLOCHA, A; FALNES, PO; MADSHUS, IH; SANDVIG, K; OLSNES, S				WIEDLOCHA, A; FALNES, PO; MADSHUS, IH; SANDVIG, K; OLSNES, S			DUAL-MODE OF SIGNAL-TRANSDUCTION BY EXTERNALLY ADDED ACIDIC FIBROBLAST GROWTH-FACTOR	CELL			English	Article							DIPHTHERIA-TOXIN ENTRY; NUCLEAR TRANSLOCATION SEQUENCE; TYROSINE KINASE-ACTIVITY; FACTOR-I; VERO CELLS; LOW PH; A-FRAGMENT; HEPARIN; PROTEINS; ASSOCIATION	Acidic fibroblast growth factor (aFGF), fused to diphtheria toxin and translocated into cells, stimulated DNA synthesis in toxin-resistant cells lacking functional aFGF receptors while having a high number of diphtheria toxin receptors. In NIH 3T3 cells that lack diphtheria toxin receptors, but have receptors for aFGF, both aFGF and the fusion protein induced tyrosine phosphorylation, but only aFGF as such entered the nuclei and stimulated DNA synthesis. The results indicate that signaling occurs partly through cell surface receptors and partly by transport of the growth factor into the cell.			WIEDLOCHA, A (corresponding author), NORWEGIAN RADIUM HOSP,INST CANC RES,N-0310 OSLO 3,NORWAY.		Falnes, Pål Ø./AAA-4581-2020	Falnes, Pal/0000-0001-8114-6025				BASILICO C, 1992, ADV CANCER RES, V59, P115, DOI 10.1016/S0065-230X(08)60305-X; BOYER B, 1993, J CELL BIOL, V120, P767, DOI 10.1083/jcb.120.3.767; BURGESS WH, 1989, ANNU REV BIOCHEM, V58, P575, DOI 10.1146/annurev.bi.58.070189.003043; CAO Y, 1993, J CELL SCI, V104, P77; COLLIER RJ, 1975, BACTERIOL REV, V39, P54, DOI 10.1128/MMBR.39.1.54-85.1975; COPELAND RA, 1991, ARCH BIOCHEM BIOPHYS, V289, P53, DOI 10.1016/0003-9861(91)90441-K; COUGHLIN SR, 1988, J BIOL CHEM, V263, P988; CUEVAS P, 1991, SCIENCE, V254, P1208, DOI 10.1126/science.1957172; DRAPER RK, 1980, J CELL BIOL, V87, P849, DOI 10.1083/jcb.87.3.849; FALNES PO, 1994, IN PRESS J BIOL CHEM; FOLKMAN J, 1992, J BIOL CHEM, V267, P10931; FRIESEL R, 1989, MOL CELL BIOL, V9, P1857, DOI 10.1128/MCB.9.5.1857; HUANG SS, 1986, J BIOL CHEM, V261, P9568; IMAMURA T, 1990, SCIENCE, V249, P1567, DOI 10.1126/science.1699274; IMAMURA T, 1992, J BIOL CHEM, V267, P5676; JACKSON A, 1992, P NATL ACAD SCI USA, V89, P10691, DOI 10.1073/pnas.89.22.10691; JOHNSON DE, 1993, ADV CANCER RES, V60, P1; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MACIAG T, 1984, SCIENCE, V225, P902; MCGILL S, 1989, EMBO J, V8, P2843, DOI 10.1002/j.1460-2075.1989.tb08431.x; MIDDLEBROOK JL, 1978, J BIOL CHEM, V253, P7325; MOSKAUG JO, 1988, J BIOL CHEM, V263, P2518; MUESCH A, 1990, TRENDS BIOCHEM SCI, V15, P86, DOI 10.1016/0968-0004(90)90186-F; NAGLICH JG, 1992, CELL, V69, P1051, DOI 10.1016/0092-8674(92)90623-K; NURCOMBE V, 1993, SCIENCE, V260, P103, DOI 10.1126/science.7682010; OLSNES S, 1986, J BIOL CHEM, V261, P1553; OLSNES S, 1988, TRENDS BIOCHEM SCI, V13, P348, DOI 10.1016/0968-0004(88)90105-3; Olsnes S., 1988, IMMUNOTOXINS, P39; OLWIN BB, 1992, J CELL BIOL, V118, P6323; ORTEGA S, 1991, J BIOL CHEM, V266, P5842; PAPPENHEIMER AM, 1977, ANNU REV BIOCHEM, V46, P69, DOI 10.1146/annurev.bi.46.070177.000441; SANDVIG K, 1981, J BIOL CHEM, V256, P9068; SANDVIG K, 1980, J CELL BIOL, V87, P828, DOI 10.1083/jcb.87.3.828; SANO H, 1990, J CELL BIOL, V110, P1417, DOI 10.1083/jcb.110.4.1417; STENMARK H, 1991, J CELL BIOL, V113, P1025, DOI 10.1083/jcb.113.5.1025; STENMARK H, 1992, BIOCHEM J, V281, P619, DOI 10.1042/bj2810619; SUNDAN A, 1982, J BIOL CHEM, V257, P9733; TAMM I, 1991, P NATL ACAD SCI USA, V88, P3372, DOI 10.1073/pnas.88.8.3372; THORNTON SC, 1983, SCIENCE, V222, P623, DOI 10.1126/science.6635659; WIEDLOCHA A, 1992, EMBO J, V11, P4835, DOI 10.1002/j.1460-2075.1992.tb05589.x; ZHAN X, 1992, BIOCHEM BIOPH RES CO, V188, P982, DOI 10.1016/0006-291X(92)91328-N; ZHAN X, 1993, J BIOL CHEM, V268, P9611	42	222	229	0	3	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	MAR 25	1994	76	6					1039	1051		10.1016/0092-8674(94)90381-6	http://dx.doi.org/10.1016/0092-8674(94)90381-6			13	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	ND246	7511061				2022-12-28	WOS:A1994ND24600010
J	SUDA, T; TAKAHASHI, T; GOLSTEIN, P; NAGATA, S				SUDA, T; TAKAHASHI, T; GOLSTEIN, P; NAGATA, S			MOLECULAR-CLONING AND EXPRESSION OF THE FAS LIGAND, A NOVEL MEMBER OF THE TUMOR-NECROSIS-FACTOR FAMILY	CELL			English	Article							CELL-SURFACE ANTIGEN; MONOCLONAL-ANTIBODY; APOPTOSIS; RECEPTOR; DEATH; BINDING; CDNA; TNF; ELECTROPORATION; LYMPHOTOXIN	The Fas antigen (Fas) belongs to the tumor necrosis factor (TNF)/nerve growth factor receptor family, and it mediates apoptosis. Using a soluble form of mouse Fas, prepared by fusion with human immunoglobulin Fc, Fas ligand was detected on the cell surface of a cytotoxic T cell hybridoma, PC60-d10S. A cell population that highly expresses Fas ligand was sorted using a fluorescence-activated cell sorter, and its cDNA was isolated from the sorted cells by expression cloning. The amino acid sequence indicated that Fas ligand is a type II transmembrane protein that belongs to the TNF family. The recombinant Fas ligand expressed in COS cells induced apoptosis in Fas-expressing target cells. Northern hybridization revealed that Fas ligand is expressed in activated splenocytes and thymocytes, consistent with its involvement in T cell-mediated cytotoxicity and in several nonlymphoid tissues, such as testis.	CTR NATL RECH SCI MARSEILLE LUMINY,CTR IMMUNOL,INSERM,F-13288 MARSEILLE 9,FRANCE	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Aix-Marseille Universite	SUDA, T (corresponding author), OSAKA BIOSCI INST,6-2-4 FURUEDAI,SUITA,OSAKA 565,JAPAN.		Nagata, Shigekazu/AAG-3203-2019; Golstein, Pierre/A-4954-2014	Nagata, Shigekazu/0000-0001-9758-8426; Golstein, Pierre/0000-0003-1750-3483				ADACHI M, 1993, P NATL ACAD SCI USA, V90, P1756, DOI 10.1073/pnas.90.5.1756; ALLAN DJ, 1992, CELL PROLIFERAT, V25, P241, DOI 10.1111/j.1365-2184.1992.tb01399.x; ALLEN RD, 1990, J EXP MED, V172, P1367, DOI 10.1084/jem.172.5.1367; APASOV S, 1993, CURR OPIN IMMUNOL, V5, P404, DOI 10.1016/0952-7915(93)90060-6; ARMITAGE RJ, 1992, NATURE, V357, P80, DOI 10.1038/357080a0; ARUFFO A, 1990, CELL, V61, P1303, DOI 10.1016/0092-8674(90)90694-A; BANNER DW, 1993, CELL, V73, P431, DOI 10.1016/0092-8674(93)90132-A; BEUTLER B, 1986, NATURE, V320, P584, DOI 10.1038/320584a0; BROWNING JL, 1993, CELL, V72, P847, DOI 10.1016/0092-8674(93)90574-A; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; COHEN JJ, 1992, ANNU REV IMMUNOL, V10, P267, DOI 10.1146/annurev.immunol.10.1.267; COHEN PL, 1991, ANNU REV IMMUNOL, V9, P243, DOI 10.1146/annurev.iy.09.040191.001331; COMPTON MM, 1992, CANCER METAST REV, V11, P105, DOI 10.1007/BF00048058; CONZELMANN A, 1982, NATURE, V298, P170, DOI 10.1038/298170a0; DHEIN J, 1992, J IMMUNOL, V149, P3166; DOWER WJ, 1988, NUCLEIC ACIDS RES, V16, P6127, DOI 10.1093/nar/16.13.6127; ECK MJ, 1992, J BIOL CHEM, V267, P2119; ECK MJ, 1989, J BIOL CHEM, V264, P17595; ELLIS RE, 1991, ANNU REV CELL BIOL, V7, P663, DOI 10.1146/annurev.cb.07.110191.003311; FUKUNAGA R, 1990, CELL, V61, P341, DOI 10.1016/0092-8674(90)90814-U; GOLSTEIN P, 1991, IMMUNOL REV, V121, P29, DOI 10.1111/j.1600-065X.1991.tb00822.x; GOODWIN RG, 1993, CELL, V73, P447, DOI 10.1016/0092-8674(93)90133-B; HARADA N, 1990, P NATL ACAD SCI USA, V87, P857, DOI 10.1073/pnas.87.3.857; ITOH N, 1993, J IMMUNOL, V151, P621; ITOH N, 1991, CELL, V66, P233, DOI 10.1016/0092-8674(91)90614-5; JONES EY, 1989, NATURE, V338, P225, DOI 10.1038/338225a0; JU ST, 1991, J IMMUNOL, V146, P812; KOZAK M, 1991, J CELL BIOL, V115, P887, DOI 10.1083/jcb.115.4.887; KRIEGLER M, 1988, CELL, V53, P45, DOI 10.1016/0092-8674(88)90486-2; LAIRD PW, 1991, NUCLEIC ACIDS RES, V19, P4293, DOI 10.1093/nar/19.15.4293; LOETSCHER H, 1991, J BIOL CHEM, V266, P18324; MEIER T, 1992, ANAL BIOCHEM, V204, P220, DOI 10.1016/0003-2697(92)90165-4; MIETHING A, 1992, CELL TISSUE RES, V267, P583, DOI 10.1007/BF00319381; NAGATA S, 1993, APOPTOSIS, V2; NISHIMURA Y, 1987, CANCER RES, V47, P999; OEHM A, 1992, J BIOL CHEM, V267, P10709; OGASAWARA J, 1993, NATURE, V364, P806, DOI 10.1038/364806a0; OLD LJ, 1987, NATURE, V330, P602, DOI 10.1038/330602a0; OZDEMIRLI M, 1992, J IMMUNOL, V149, P1889; PENNICA D, 1984, NATURE, V312, P724, DOI 10.1038/312724a0; PEREZ C, 1990, CELL, V63, P251, DOI 10.1016/0092-8674(90)90158-B; PODACK ER, 1991, ANNU REV IMMUNOL, V9, P129, DOI 10.1146/annurev.iy.09.040191.001021; POTTER H, 1984, P NATL ACAD SCI-BIOL, V81, P7161, DOI 10.1073/pnas.81.22.7161; RAFF MC, 1992, NATURE, V356, P397, DOI 10.1038/356397a0; RAMSDELL F, 1990, SCIENCE, V248, P1342, DOI 10.1126/science.1972593; ROUVIER E, 1993, J EXP MED, V177, P195, DOI 10.1084/jem.177.1.195; RUSSELL JH, 1993, P NATL ACAD SCI USA, V90, P4409, DOI 10.1073/pnas.90.10.4409; Sambrook J, 1989, MOL CLONING LABORATO; SEDIVY JM, 1988, BIO-TECHNOL, V6, P1192, DOI 10.1038/nbt1088-1192; SMITH CA, 1993, CELL, V73, P1349, DOI 10.1016/0092-8674(93)90361-S; SMITH RA, 1987, J BIOL CHEM, V262, P6951; TRAUTH BC, 1989, SCIENCE, V245, P301, DOI 10.1126/science.2787530; UETSUKI T, 1989, J BIOL CHEM, V264, P5791; Walker N I, 1988, Methods Achiev Exp Pathol, V13, P18; WATANABEFUKUNAGA R, 1992, J IMMUNOL, V148, P1274; WATANABEFUKUNAGA R, 1992, NATURE, V356, P314, DOI 10.1038/356314a0; Wyllie A H, 1980, Int Rev Cytol, V68, P251; YONEHARA S, 1989, J EXP MED, V169, P1747, DOI 10.1084/jem.169.5.1747; ZHOU T, 1993, J IMMUNOL, V150, P3651	59	2410	2552	1	74	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	DEC 17	1993	75	6					1169	1178		10.1016/0092-8674(93)90326-L	http://dx.doi.org/10.1016/0092-8674(93)90326-L			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	MM893	7505205				2022-12-28	WOS:A1993MM89300015
J	KERWIN, R				KERWIN, R			ADVERSE REACTION REPORTING AND NEW ANTIPSYCHOTICS	LANCET			English	Editorial Material							CLOZAPINE				KERWIN, R (corresponding author), INST PSYCHIAT,LONDON SE5 8AF,ENGLAND.							Aretz H T, 1987, Am J Cardiovasc Pathol, V1, P3; GERLACH J, 1991, SCHIZOPHRENIA BULL, V17, P289, DOI 10.1093/schbul/17.2.289; KANE J, 1988, ARCH GEN PSYCHIAT, V45, P789; LARGACTIL, 1993, ABPI DATA SHEET COMP, P1266; MALMBERG A, 1993, MOL PHARMACOL, V43, P749; PETERS NS, 1991, J ROY SOC MED, V84, P1; PILOWSKY LS, 1992, LANCET, V340, P199, DOI 10.1016/0140-6736(92)90467-H; VINCENT PC, 1986, DRUGS, V31, P52, DOI 10.2165/00003495-198631010-00004; 1993, CURR PROB PHARM B, V19, P9	9	7	7	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	DEC 11	1993	342	8885					1440	1440		10.1016/0140-6736(93)92929-N	http://dx.doi.org/10.1016/0140-6736(93)92929-N			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ML217	7504153				2022-12-28	WOS:A1993ML21700005
J	JONTES, JD; WILSONKUBALEK, EM; MILLIGAN, RA				JONTES, JD; WILSONKUBALEK, EM; MILLIGAN, RA			A 32-DEGREES TAIL SWING IN BRUSH-BORDER MYOSIN-I ON ADP RELEASE	NATURE			English	Article							MUSCLE-CONTRACTION; ACTOMYOSIN ATPASE; EPITHELIAL-CELLS; ACTIN; CALMODULIN; PROTEIN; COMPLEX; ORGANIZATION; CYTOSKELETON; MECHANISM	BRUSH border myosin I (BBMI) is a single-headed, unconventional myosin from intestinal microvilli, composed of a heavy chain of relative molecular mass 119,000 (M(r) 119K) and three calmodulin light chains(1-3). Although believed to have a largely structural role, it exhibits the normal actin-activated ATPase and motility properties of a member of the myosin superfamily(4,5). Here we present three-dimensional maps of BBMI-decorated actin filaments with and without bound MgADP. While the motor domain remains in a state similar to rigor, the light-chain-binding domain swings through similar to 32 degrees, resulting in a similar to 50-Angstrom movement at the end of the region visualized (the second calmodulin light chain). This could correspond to similar to 72-Angstrom movement of the entire domain, Although qualitatively similar to the movement observed in myosin II6, the magnitude of the change is sufficiently different to suggest that structural changes during the actomyosin ATPase cycle differ among myosins, possibly reflecting adaptation for specialized functional demands.	Scripps Res Inst, DEPT CELL BIOL, LA JOLLA, CA 92037 USA	Scripps Research Institute								BRENNER B, 1987, ANNU REV PHYSIOL, V49, P655; COLLINS K, 1990, J CELL BIOL, V110, P1137, DOI 10.1083/jcb.110.4.1137; COOKE R, 1986, CRIT REV BIOCHEM MOL, V21, P53, DOI 10.3109/10409238609113609; DEROSIER DJ, 1970, J MOL BIOL, V52, P355, DOI 10.1016/0022-2836(70)90036-7; DRENCKHAHN D, 1988, J CELL BIOL, V107, P1037, DOI 10.1083/jcb.107.3.1037; DUBOCHET J, 1988, Q REV BIOPHYS, V21, P129, DOI 10.1017/S0033583500004297; EISENBERG E, 1980, ANNU REV PHYSIOL, V42, P293, DOI 10.1146/annurev.ph.42.030180.001453; EISENBERG E, 1985, SCIENCE, V227, P999, DOI 10.1126/science.3156404; FATH KR, 1993, J CELL BIOL, V120, P117, DOI 10.1083/jcb.120.1.117; FISHER AJ, 1995, BIOPHYS J, V68, pS19; GARCIA A, 1989, J CELL BIOL, V109, P2895, DOI 10.1083/jcb.109.6.2895; GEEVES MA, 1992, PHILOS T ROY SOC B, V336, P63, DOI 10.1098/rstb.1992.0045; GOODY RS, 1983, BIOCHIM BIOPHYS ACTA, V726, P13, DOI 10.1016/0304-4173(83)90009-5; Hill T.L., 1974, Progress Biophys Molec Biol, V28, P267, DOI 10.1016/0079-6107(74)90020-0; HOWE CL, 1983, J CELL BIOL, V97, P974, DOI 10.1083/jcb.97.4.974; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; MATSUDAIRA PT, 1979, J CELL BIOL, V83, P667, DOI 10.1083/jcb.83.3.667; POLLARD TD, 1991, ANNU REV PHYSIOL, V53, P653, DOI 10.1146/annurev.ph.53.030191.003253; RAYMENT I, 1993, SCIENCE, V261, P58, DOI 10.1126/science.8316858; RAYMENT I, 1993, SCIENCE, V261, P50, DOI 10.1126/science.8316857; REEDY MC, 1988, J MOL BIOL, V204, P357, DOI 10.1016/0022-2836(88)90582-7; SPUDICH JA, 1971, J BIOL CHEM, V246, P4866; WHITTAKER M, 1995, ULTRAMICROSCOPY, V58, P245, DOI 10.1016/0304-3991(95)00057-8; WHITTAKER M, 1995, NATURE, V378, P748, DOI 10.1038/378748a0; WOLENSKI JS, 1993, J CELL BIOL, V122, P613, DOI 10.1083/jcb.122.3.613; [No title captured]	26	166	167	0	6	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	DEC 14	1995	378	6558					751	753		10.1038/378751a0	http://dx.doi.org/10.1038/378751a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TK379	7501027				2022-12-28	WOS:A1995TK37900062
J	EHRENHOFERMURRAY, AE; GOSSEN, M; PAK, DTS; BOTCHAN, MR; RINE, J				EHRENHOFERMURRAY, AE; GOSSEN, M; PAK, DTS; BOTCHAN, MR; RINE, J			SEPARATION OF ORIGIN RECOGNITION COMPLEX FUNCTIONS BY CROSS-SPECIES COMPLEMENTATION	SCIENCE			English	Article							SACCHAROMYCES-CEREVISIAE; DNA-REPLICATION; TRANSCRIPTIONAL STATES; S-CEREVISIAE; YEAST; GENE; VECTORS	Transcriptional silencing at the HMRa locus of Saccharomyces cerevisiae requires the function of the origin recognition complex (ORC), the replication initiator of yeast. Expression of a Drosophila melanogaster Orc2 complementary DNA in the yeast orc2-1 strain, which is defective for replication and silencing, complemented the silencing defect but not the replication defect; this result indicated that the replication and silencing functions of ORC were separable. The orc2-1 mutation mapped to the region of greatest homology between the Drosophila and yeast proteins. The silent state mediated by DmOrc2 was epigenetic; it was propagated during mitotic divisions in a relatively stable way, whereas the nonsilent state was metastable. In contrast, the silent state was erased during meiosis.	UNIV CALIF BERKELEY,DEPT CELL & MOLEC BIOL,DIV GENET,BERKELEY,CA 94720; UNIV CALIF BERKELEY,DEPT CELL & MOLEC BIOL,DIV BIOCHEM & MOLEC BIOL,BERKELEY,CA 94720	University of California System; University of California Berkeley; University of California System; University of California Berkeley			Gossen, Manfred/K-9602-2013	Gossen, Manfred/0000-0002-1761-4063	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM031105, R01GM031105] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM31105] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BELL SP, 1993, SCIENCE, V262, P1844, DOI 10.1126/science.8266072; BOEKE JD, 1984, MOL GEN GENET, V197, P345, DOI 10.1007/BF00330984; BREWER BJ, 1987, CELL, V51, P463, DOI 10.1016/0092-8674(87)90642-8; BROWN NH, 1988, J MOL BIOL, V203, P425, DOI 10.1016/0022-2836(88)90010-1; FOSS M, 1993, SCIENCE, V262, P1838, DOI 10.1126/science.8266071; FOX CA, 1995, GENE DEV, V9, P911, DOI 10.1101/gad.9.8.911; GAVIN KA, 1995, SCIENCE, V270, P1667, DOI 10.1126/science.270.5242.1667; GIETZ RD, 1988, GENE, V74, P527, DOI 10.1016/0378-1119(88)90185-0; GOSSEN M, 1995, SCIENCE, V270, P1674, DOI 10.1126/science.270.5242.1674; GRIGLIATTI T, 1991, METHOD CELL BIOL, V35, P587; HAMPTON RY, 1994, J CELL BIOL, V125, P299, DOI 10.1083/jcb.125.2.299; KLEBE RJ, 1983, GENE, V25, P333, DOI 10.1016/0378-1119(83)90238-X; LAURENSON P, 1992, MICROBIOL REV, V56, P543, DOI 10.1128/MMBR.56.4.543-560.1992; LOO S, 1995, MOL BIOL CELL, V6, P741, DOI 10.1091/mbc.6.6.741; MCNALLY FJ, 1991, MOL CELL BIOL, V11, P5648, DOI 10.1128/MCB.11.11.5648; PATTERSON M, 1986, MOL CELL BIOL, V6, P1590, DOI 10.1128/MCB.6.5.1590; PILLUS L, 1989, CELL, V59, P637, DOI 10.1016/0092-8674(89)90009-3; RASTAN S, 1994, CURR OPIN GENET DEV, V4, P292, DOI 10.1016/S0959-437X(05)80056-5; RIVIER DH, 1992, SCIENCE, V256, P659, DOI 10.1126/science.1585179; SCHENA M, 1991, METHOD ENZYMOL, V194, P389; Weiler KS, 1995, ANNU REV GENET, V29, P577, DOI 10.1146/annurev.ge.29.120195.003045; ZHOU C, 1989, J BIOL CHEM, V264, P9022	22	56	56	0	3	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	DEC 8	1995	270	5242					1671	1674		10.1126/science.270.5242.1671	http://dx.doi.org/10.1126/science.270.5242.1671			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TJ293	7502078				2022-12-28	WOS:A1995TJ29300050
J	HAQ, IU; JACKSON, PR; YEO, WW; RAMSAY, LE				HAQ, IU; JACKSON, PR; YEO, WW; RAMSAY, LE			SHEFFIELD RISK AND TREATMENT TABLE FOR CHOLESTEROL-LOWERING FOR PRIMARY PREVENTION OF CORONARY HEART-DISEASE	LANCET			English	Article							SERUM-CHOLESTEROL; MORTALITY; MANAGEMENT; FRAMINGHAM; REDUCTION; TRIALS	When used for the secondary prevention of coronary heart disease, treatment with an inhibitor of hydroxymethylglutaryl-coenzyme-A reductase results in worthwhile benefit that clearly exceeds any risk in patients whose risk of coronary death is 1.5% or more per year. This evidence can be extrapolated logically to primary prevention of coronary disease provided that treatment is targeted at those with similar or higher risk. We present a table that refines previously proposed methods of risk prediction. The table identifies subjects who have the specified degree of coronary risk; shows the serum cholesterol concentration that confers that degree of risk in the individual; and identifies subjects who will not have this degree of risk, irrespective of their cholesterol concentration. It is simple enough for use in ordinary practice. The table highlights the predominant effect of age on coronary risk; a person who is free of vascular disease and younger than 52 years is unlikely to have the specified degree of risk. Even in older people (60-70 years) several risk factors are generally required to attain this degree of risk. Some people are candidates for lipid-lowering drug treatment with serum cholesterol as low as 5.5 mmol/L, whereas others with cholesterol as high as 9.0 mmol/L are not. Although cholesterol lowering is a powerful method for preventing coronary events in people at high risk, cholesterol measurement by itself is not a good way to identify those with high coronary risk. The method can be adapted readily to target a different level of coronary-risk as new evidence on the benefit and risk of treatment becomes available.	ROYAL HALLAMSHIRE HOSP, DEPT MED & PHARMACOL, CLIN PHARMACOL & THERAPEUT SECT, SHEFFIELD S10 2JF, S YORKSHIRE, ENGLAND	University of Sheffield				Yeo, Wilfred/0000-0001-9554-5203				ANDERSON KM, 1991, AM HEART J, V121, P293, DOI 10.1016/0002-8703(91)90861-B; ANDRADE SE, 1995, NEW ENGL J MED, V332, P1125, DOI 10.1056/NEJM199504273321703; [Anonymous], 1988, BRIT MED J, V296, P316; ASSMANN G, 1986, PROCAM TRIAL; CRIQUI MH, 1992, NEW ENGL J MED, V326, P381, DOI 10.1056/NEJM199202063260605; EVANS P, 1994, BRIT MED J, V309, P509, DOI 10.1136/bmj.309.6953.509; GORDON T, 1977, AM J MED, V62, P707, DOI 10.1016/0002-9343(77)90874-9; GROVER SA, 1995, BRIT MED J, V310, P975, DOI 10.1136/bmj.310.6985.975; HOLME I, 1990, CIRCULATION, V82, P1916, DOI 10.1161/01.CIR.82.6.1916; JACKSON R, 1993, BRIT MED J, V307, P107, DOI 10.1136/bmj.307.6896.107; KANNEL WB, 1971, ANN INTERN MED, V74, P1, DOI 10.7326/0003-4819-74-1-1; KRUMHOLZ HM, 1994, JAMA-J AM MED ASSOC, V272, P1335, DOI 10.1001/jama.272.17.1335; LAW MR, 1994, BMJ-BRIT MED J, V308, P367, DOI 10.1136/bmj.308.6925.367; MANN JI, 1988, BRIT MED J, V296, P1702, DOI 10.1136/bmj.296.6638.1702; MANNINEN V, 1988, JAMA-J AM MED ASSOC, V260, P641, DOI 10.1001/jama.260.5.641; MULDOON MF, 1990, BMJ-BRIT MED J, V301, P309, DOI 10.1136/bmj.301.6747.309; National Cholesterol Education Program, 1994, CIRCULATION, V89, P1333, DOI [10.1161/01.CIR.89.3.1333, DOI 10.1161/01.CIR.89.3.1333]; OLIVER M, 1995, BMJ-BRIT MED J, V310, P1280, DOI 10.1136/bmj.310.6990.1280; PEDERSEN TR, 1994, LANCET, V344, P1383; PYORALA K, 1994, EUR HEART J, V15, P1300; RAMSAY LE, 1991, BMJ-BRIT MED J, V303, P953, DOI 10.1136/bmj.303.6808.953; RIFKIND BM, 1984, JAMA-J AM MED ASSOC, V251, P351; SEVER P, 1993, BMJ-BRIT MED J, V306, P983, DOI 10.1136/bmj.306.6883.983; SHAPER AG, 1986, BRIT MED J, V293, P474, DOI 10.1136/bmj.293.6545.474; SMITH GD, 1993, BMJ-BRIT MED J, V306, P1367, DOI 10.1136/bmj.306.6889.1367; THOMPSON SG, 1990, J CLIN EPIDEMIOL, V43, P783, DOI 10.1016/0895-4356(90)90238-K; TUNSTALLPEDOE H, 1991, BRIT MED J, V303, P744, DOI 10.1136/bmj.303.6805.744; TURNER RC, 1993, J HYPERTENS, V11, P309; WHINCUP PH, 1994, TXB HYPERTENSION, P38; 1989, WORLD HLTH STATISTIC	30	126	127	0	2	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	DEC 2	1995	346	8988					1467	1471		10.1016/S0140-6736(95)92477-9	http://dx.doi.org/10.1016/S0140-6736(95)92477-9			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TH156	7490996				2022-12-28	WOS:A1995TH15600014
J	DEVILE, CJ; SUFRAZ, R; LASK, BD; STANHOPE, R				DEVILE, CJ; SUFRAZ, R; LASK, BD; STANHOPE, R			LESSON OF THE WEEK - OCCULT INTRACRANIAL TUMORS MASQUERADING AS EARLY-ONSET ANOREXIA-NERVOSA	BRITISH MEDICAL JOURNAL			English	Article									INST CHILD HLTH,MED UNIT,LONDON WC1N 1EH,ENGLAND; INST CHILD HLTH,DEPT PSYCHOL MED,LONDON WC1N 1EH,ENGLAND; GREAT ORMOND ST HOSP CHILDREN NHS TRUST,LONDON WC1N 1EH,ENGLAND	University of London; University College London; University of London; University College London; University of London; University College London; Great Ormond Street Hospital for Children NHS Foundation Trust								BARRY A, 1990, POSTGRAD MED, V87, P161; Bryant-Waugh R, 1993, CHILDHOOD ONSET ANOR, P17; BRYANTWAUGH RJ, 1992, ARCH DIS CHILD, V67, P103, DOI 10.1136/adc.67.1.103; CHIPKEVITCH E, 1994, BRAIN DEV-JPN, V16, P175, DOI 10.1016/0387-7604(94)90064-7; FOSSON A, 1987, ARCH DIS CHILD, V62, P114, DOI 10.1136/adc.62.2.114; HAWLEY RM, 1985, BRIT J PSYCHIAT, V146, P657, DOI 10.1192/bjp.146.6.657; KENDALL BE, 1989, CLIN PAEDIATRIC ENDO, P641	7	37	38	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	NOV 18	1995	311	7016					1359	1360		10.1136/bmj.311.7016.1359	http://dx.doi.org/10.1136/bmj.311.7016.1359			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TF901	7496292	Green Published			2022-12-28	WOS:A1995TF90100031
J	BOONE, KE; WATTERS, DAK				BOONE, KE; WATTERS, DAK			THE INCIDENCE OF MALARIA AFTER SPLENECTOMY IN PAPUA-NEW-GUINEA	BRITISH MEDICAL JOURNAL			English	Article							MANAGEMENT	In the tropics, as in the developed world, the spleen is the commonest intra-abdominal organ to be injured. Splenic enlargement due to chronic malaria predisposes to splenic injury, particularly in low velocity blunt trauma due to domestic violence or assault, both of which are common in Papua New Guinea. In developed countries the risk of sepsis after splenectomy has resulted in a more conservative approach to splenic trauma. In the tropics death from malaria after splenectomy has been reported, but no formal study has been undertaken. We studied the sequelae of splenic trauma and splenectomy in patients living in an area of Papua New Guinea where malaria is endemic.	DIV SURG,BOROKO,PAPUA N GUINEA				Watters, David Allan/AAI-1022-2020	Watters, David Allan/0000-0002-5742-8417				CULLINGFORD GL, 1991, BRIT J SURG, V78, P716, DOI 10.1002/bjs.1800780626; DEODHAR HA, 1993, BRIT MED J, V307, P1408, DOI 10.1136/bmj.307.6916.1408; HAMILTON DR, 1982, AUST NZ J SURG, V52, P310, DOI 10.1111/j.1445-2197.1982.tb05407.x; LOOAREESUWAN S, 1993, CLIN INFECT DIS, V16, P361, DOI 10.1093/clind/16.3.361; WILSON RH, 1992, INJURY, V23, P5, DOI 10.1016/0020-1383(92)90116-A	5	46	47	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	NOV 11	1995	311	7015					1273	1273		10.1136/bmj.311.7015.1273	http://dx.doi.org/10.1136/bmj.311.7015.1273			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TE859	7496237	Green Published			2022-12-28	WOS:A1995TE85900023
J	HEARING, SD; PLAYFOR, S; BENTLEY, SJ				HEARING, SD; PLAYFOR, S; BENTLEY, SJ			HIGH FEVER INDUCED BY SULFASALAZINE	BRITISH MEDICAL JOURNAL			English	Letter							RHEUMATOID-ARTHRITIS											AMOS RS, 1986, BMJ-BRIT MED J, V293, P420, DOI 10.1136/bmj.293.6544.420; BRISTOW MF, 1993, BRIT MED J, V307, P1223, DOI 10.1136/bmj.307.6914.1223; DONOVAN S, 1990, BRIT J RHEUMATOL, V29, P201; FARR M, 1986, DRUGS, V32, P49, DOI 10.2165/00003495-198600321-00010; WATKINSON G, 1986, DRUGS, V32, P1, DOI 10.2165/00003495-198600321-00003	5	2	3	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	NOV 4	1995	311	7014					1204	1204		10.1136/bmj.311.7014.1204b	http://dx.doi.org/10.1136/bmj.311.7014.1204b			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TD768	7488900	Green Published			2022-12-28	WOS:A1995TD76800023
J	MADDOX, J				MADDOX, J			FRONTIERS OF IGNORANCE - GUESSWORK AND RANDOMNESS (FOR NOW AT LEAST)	NATURE			English	Editorial Material																		BARTEL DP, 1993, SCIENCE, V261, P1411, DOI 10.1126/science.7690155; ELLINGTON AD, 1990, NATURE, V346, P818, DOI 10.1038/346818a0; Ourisson G, 1994, CHEM BIOL, V1, P11, DOI 10.1016/1074-5521(94)90036-1; WACHTERSHAUSER G, 1988, MICROBIOL REV, V52, P452	4	1	1	0	3	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	NOV 3	1994	372	6501					30	30						1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PQ348	7526220				2022-12-28	WOS:A1994PQ34800041
J	STEINBACH, S; SUN, L; JIANG, RZ; FLUME, P; GILLIGAN, P; EGAN, TM; GOLDSTEIN, R				STEINBACH, S; SUN, L; JIANG, RZ; FLUME, P; GILLIGAN, P; EGAN, TM; GOLDSTEIN, R			TRANSMISSIBILITY OF PSEUDOMONAS-CEPACIA INFECTION IN CLINIC PATIENTS AND LUNG-TRANSPLANT RECIPIENTS WITH CYSTIC-FIBROSIS	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							UROPATHOGENIC ESCHERICHIA-COLI; FIELD GEL-ELECTROPHORESIS; POLYMERASE CHAIN-REACTION; MOLECULAR EPIDEMIOLOGY; PREOPERATIVE ASSESSMENT; COLONIZATION; ADHESIN; GENE	Background. In patients with cystic fibrosis, infection with Pseudomonas cepacia is associated with poor outcomes. However, the extent of person-to-person transmission and the source of P. cepacia infection after lung transplantation are not well defined. Using DNA-based typing systems, we sought to determine the genetic relatedness of P. cepacia infection at one cystic fibrosis center. Methods. We analyzed 65 P. cepacia isolates gathered over a period of eight years at a single cystic fibrosis center from 17 clinic patients and from 5 patients who underwent double-lung transplantation. The isolates were analyzed by ribotyping and chromosomal fingerprinting based on pulsed-field gel electrophoresis. Results. Analyses of serial isolates revealed that each clinic patient and transplant recipient harbored a different P. cepacia clone that was persistent. In the transplant recipients, the preoperative and postoperative isolates were identical. In the two patients with disseminated infection after lung transplantation, isolates from multiple sites were identical and indicated clonal expansion of the previous respiratory P. cepacia strain. Pulsed-field gel electrophoresis proved both more discriminative and more practical than ribotyping as a means of defining the genetic relatedness of the P. cepacia isolates. Conclusions. Our serial analyses in patients with cystic fibrosis at one center found distinct strains of P. cepacia persistently infecting each patient and no evidence of person-to-person transmission of this organism. P. cepacia infection after lung transplantation was due to the persistence of the strain present before transplantation.	BOSTON UNIV,SCH MED,MOLEC GENET SECT,MAXWELL FINLAND LAB INFECT DIS,BOSTON,MA 02118; BOSTON UNIV,SCH MED,DEPT PEDIAT,BOSTON,MA 02118; BOSTON CITY HOSP,BOSTON,MA; UNIV N CAROLINA,SCH MED & HOSP,CTR CYST FIBROSIS,CHAPEL HILL,NC; UNIV N CAROLINA,SCH MED & HOSP,CLIN MICROBIOL LAB,CHAPEL HILL,NC; UNIV N CAROLINA,SCH MED & HOSP,CHAPEL HILL,NC	Boston University; Boston University; Boston Medical Center; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill				Egan, Thomas/0000-0002-1382-8881	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK050838] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ANDERSON DJ, 1991, J CLIN MICROBIOL, V29, P648, DOI 10.1128/JCM.29.3.648-649.1991; ARBEIT RD, 1990, J INFECT DIS, V161, P230, DOI 10.1093/infdis/161.2.230; ARTHUR M, 1989, INFECT IMMUN, V57, P314, DOI 10.1128/IAI.57.2.314-321.1989; ARTHUR M, 1989, INFECT IMMUN, V57, P303, DOI 10.1128/IAI.57.2.303-313.1989; ARTHUR M, 1990, INFECT IMMUN, V58, P471, DOI 10.1128/IAI.58.2.471-479.1990; BERG KL, 1987, J BACTERIOL, V169, P1691, DOI 10.1128/jb.169.4.1691-1701.1987; BINGEN EH, 1993, J CLIN MICROBIOL, V31, P2589, DOI 10.1128/JCM.31.10.2589-2593.1993; DEHOYOS AL, 1992, J THORAC CARDIOV SUR, V103, P295; DELEVAL MR, 1991, J THORAC CARDIOV SUR, V101, P633; DICE LR, 1945, ECOLOGY, V26, P297, DOI 10.2307/1932409; FLUME PA, 1994, AM J RESP CRIT CARE, V149, P1601, DOI 10.1164/ajrccm.149.6.7516251; GLADMAN G, 1992, ARCH DIS CHILD, V67, P192, DOI 10.1136/adc.67.2.192; GOVAN JRW, 1993, LANCET, V342, P15, DOI 10.1016/0140-6736(93)91881-L; HERITIER F, 1992, EUR RESPIR J, V5, P1262; HOPFL P, 1989, EUR J BIOCHEM, V185, P355, DOI 10.1111/j.1432-1033.1989.tb15123.x; Knight S R, 1992, Semin Thorac Cardiovasc Surg, V4, P107; KOSTMAN JR, 1992, J CLIN MICROBIOL, V30, P2084, DOI 10.1128/JCM.30.8.2084-2087.1992; LIPUMA JJ, 1990, LANCET, V336, P1094, DOI 10.1016/0140-6736(90)92571-X; LIPUMA JJ, 1988, J PEDIATR-US, V113, P859, DOI 10.1016/S0022-3476(88)80018-0; MORRISON DL, 1990, CLIN CHEST MED, V11, P207; NEI M, 1979, P NATL ACAD SCI USA, V76, P5269, DOI 10.1073/pnas.76.10.5269; NOYES BE, 1994, J PEDIATR-US, V124, P261, DOI 10.1016/S0022-3476(94)70315-9; PREVOST G, 1992, J CLIN MICROBIOL, V30, P967, DOI 10.1128/JCM.30.4.967-973.1992; RABKIN CS, 1989, REV INFECT DIS, V11, P600; RAMIREZ JC, 1992, J THORAC CARDIOV SUR, V103, P287; SCOTT J, 1988, LANCET, V2, P192; SNELL GI, 1993, CHEST, V103, P466, DOI 10.1378/chest.103.2.466; THOMASSEN MJ, 1985, AM REV RESPIR DIS, V131, P791; THOMASSEN MJ, 1986, AM REV RESPIR DIS, V134, P669	29	88	89	0	1	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	OCT 13	1994	331	15					981	987		10.1056/NEJM199410133311504	http://dx.doi.org/10.1056/NEJM199410133311504			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PK504	7521938				2022-12-28	WOS:A1994PK50400004
J	LOWIN, B; HAHNE, M; MATTMANN, C; TSCHOPP, J				LOWIN, B; HAHNE, M; MATTMANN, C; TSCHOPP, J			CYTOLYTIC T-CELL CYTOTOXICITY IS MEDIATED THROUGH PERFORIN AND FAS LYTIC PATHWAYS	NATURE			English	Article							LYMPHOCYTES-T; APOPTOSIS; ANTIBODY; MICE	THE recent generation of perforin knock-out mice(1,2) has demonstrated a crucial role for the pore-forming perforin in cytolytic T-lymphocyte (CTL)-mediated cytolysis. Perforin-deficient mice failed to clear lymphocytic choriomeningitis virus in vivo, yet substantial killing activity still remained in perforin-free CTLs in vitro, indicating the presence of (a) further lytic pathway(s). Fas is an apoptosis-signalling receptor molecule on the surface of a number of different cells. Here we report that both perforin-deficient and Fas-ligand-deficient CTLs show impaired lytic activity on all target cells tested, The killing activity was completely abolished when both pathways were inactivated by using target cells from Fas-receptor-deficient lpr mice and perforin-free CTL effector cells. Fas-ligand-based killing activity was triggered upon T-cell receptor occupancy and was directed to the cognate target cell. Thus, two complementary, specific cytotoxic mechanisms are functional in CTLs, one based on the secretion of lytic proteins and one which depends on cell-surface ligand-receptor interaction.	UNIV LAUSANNE,INST BIOCHEM,CH-1066 EPALINGES,SWITZERLAND	University of Lausanne								CEROTTINI JC, 1974, J EXP MED, V140, P703, DOI 10.1084/jem.140.3.703; COLIGAN JE, 1992, CURRENT PROTOCOLS IM, P3121; ITOH N, 1991, CELL, V66, P233, DOI 10.1016/0092-8674(91)90614-5; ITOH N, 1993, J EXP MED, V178, P461; KAGI D, 1994, NATURE, V369, P31, DOI 10.1038/369031a0; KUPFER A, 1986, J EXP MED, V163, P489, DOI 10.1084/jem.163.3.489; LOWIN B, IN PRESS P NATN ACAD; MARYANSKI JL, 1980, J IMMUNOL, V124, P42; OGASAWARA J, 1993, NATURE, V364, P806, DOI 10.1038/364806a0; PETERS PJ, 1989, EUR J IMMUNOL, V19, P1469, DOI 10.1002/eji.1830190819; RAMSDELL F, 1994, EUR J IMMUNOL, V24, P928, DOI 10.1002/eji.1830240422; ROUVIER E, 1993, J EXP MED, V177, P195, DOI 10.1084/jem.177.1.195; RUSSELL JH, 1993, P NATL ACAD SCI USA, V90, P4409, DOI 10.1073/pnas.90.10.4409; SUDA T, 1993, CELL, V75, P1169, DOI 10.1016/0092-8674(93)90326-L; TAKAHASHI T, 1994, CELL, V76, P969, DOI 10.1016/0092-8674(94)90375-1; TRAUTH BC, 1989, SCIENCE, V245, P301, DOI 10.1126/science.2787530; TSCHOPP J, 1989, NATURE, V337, P272, DOI 10.1038/337272a0; UCKER DS, 1992, MOL CELL BIOL, V12, P3060, DOI 10.1128/MCB.12.7.3060; VIGNAUX F, 1994, EUR J IMMUNOL, V24, P923, DOI 10.1002/eji.1830240421	19	961	980	0	13	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	AUG 25	1994	370	6491					650	652		10.1038/370650a0	http://dx.doi.org/10.1038/370650a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PD310	7520535				2022-12-28	WOS:A1994PD31000050
J	PALLER, AS				PALLER, AS			HISTOLOGY OF LIPOID PROTEINOSIS	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Letter							METABOLISM; INVITRO; SKIN				PALLER, AS (corresponding author), NORTHWESTERN UNIV,SCH MED,CHICAGO,IL, USA.							BAUER EA, 1981, J INVEST DERMATOL, V76, P119, DOI 10.1111/1523-1747.ep12525454; FLEISCHMAJER R, 1984, J INVEST DERMATOL, V82, P252, DOI 10.1111/1523-1747.ep12260200; FLEISCHMAJER R, 1969, J INVEST DERMATOL, V52, P495, DOI 10.1038/jid.1969.84; HARPER JI, 1985, BRIT J DERMATOL, V113, P145, DOI 10.1111/j.1365-2133.1985.tb02056.x; MOY LS, 1987, J AM ACAD DERMATOL, V16, P1193, DOI 10.1016/S0190-9622(87)70157-1; NEWTON JA, 1991, CLIN EXP DERMATOL, V16, P350, DOI 10.1111/j.1365-2230.1991.tb00399.x; OLSEN DR, 1988, J INVEST DERMATOL, V90, P734, DOI 10.1111/1523-1747.ep12560934; SHORE RN, 1974, ARCH DERMATOL, V110, P591, DOI 10.1001/archderm.110.4.591	8	14	16	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	AUG 17	1994	272	7					564	565						2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PB229	7519275				2022-12-28	WOS:A1994PB22900039
J	BALK, SP; BURKE, S; POLISCHUK, JE; FRANTZ, ME; YANG, L; PORCELLI, S; COLGAN, SP; BLUMBERG, RS				BALK, SP; BURKE, S; POLISCHUK, JE; FRANTZ, ME; YANG, L; PORCELLI, S; COLGAN, SP; BLUMBERG, RS			BETA(2)-MICROGLOBULIN-INDEPENDENT MHC CLASS IB MOLECULE EXPRESSED BY HUMAN INTESTINAL EPITHELIUM	SCIENCE			English	Article							T-CELL RECEPTOR; INTRAEPITHELIAL LYMPHOCYTES; SURFACE EXPRESSION; IMMUNE RECOGNITION; HEAVY-CHAINS; BETA-2-MICROGLOBULIN; ANTIGEN; CD1; ASSOCIATION; COMPLEX	A major histocompatibility complex class Ib protein, CD1d, is expressed by human intestinal epithelial cells (IECs) and is a ligand for CD8(+) T cells. CD1d was found to be expressed on the surface of human IECs as a 37-kilodalton protein that was beta(2)-microglobulin (beta(2)M) independent with no N-linked carbohydrate. Transfection into a beta(2)M(-) cell line confirmed that CD1d could be expressed at the cell surface in the absence of beta(2)M. These data indicate that IECs use a specialized pathway for CD1d synthesis and that a beta(2)M-independent class Ib protein may be the normal ligand for some intestinal T cells.	HARVARD UNIV,BRIGHAM & WOMENS HOSP,SCH MED,DIV GASTROENTEROL,BOSTON,MA 02115; HARVARD UNIV,BETH ISRAEL HOSP,SCH MED,DIV HEMATOL ONCOL,BOSTON,MA 02215; HARVARD UNIV,BRIGHAM & WOMENS HOSP,SCH MED,DEPT RHEUMATOL IMMUNOL,LYMPHOCYTE BIOL SECT,BOSTON,MA 02115; HARVARD UNIV,BRIGHAM & WOMENS HOSP,SCH MED,DEPT ANESTHESIA,BOSTON,MA 02115	Harvard University; Brigham & Women's Hospital; Harvard Medical School; Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School; Harvard University; Brigham & Women's Hospital; Harvard Medical School; Harvard University; Brigham & Women's Hospital; Harvard Medical School			Colgan, Sean P./B-4573-2009		NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI033911] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK044319] Funding Source: NIH RePORTER; NIAID NIH HHS [R01 AI33911] Funding Source: Medline; NIDDK NIH HHS [R01 DK44319] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AMIOT M, 1986, J IMMUNOL, V136, P1752; BALK SP, 1991, J IMMUNOL, V146, P768; BALK SP, 1991, SCIENCE, V253, P1411, DOI 10.1126/science.1716785; BILSLAND CAG, 1991, EUR J IMMUNOL, V21, P71, DOI 10.1002/eji.1830210112; BLEICHER PA, 1990, SCIENCE, V250, P679, DOI 10.1126/science.1700477; BLUMBERG RL, UNPUB; BLUMBERG RS, 1993, J IMMUNOL, V150, P5144; BLUMBERG RS, 1991, EUR J IMMUNOL, V21, P473, DOI 10.1002/eji.1830210233; BLUMBERG RS, 1991, J IMMUNOL, V147, P2518; BLUMBERG RS, 1990, J BIOL CHEM, V265, P14036; CALABI F, 1991, TISSUE ANTIGENS, V37, P1, DOI 10.1111/j.1399-0039.1991.tb01836.x; CAPPS GG, 1993, J IMMUNOL, V151, P159; CORREA I, 1992, P NATL ACAD SCI USA, V89, P653, DOI 10.1073/pnas.89.2.653; GERMAIN RN, 1994, CELL, V76, P287, DOI 10.1016/0092-8674(94)90336-0; HEDRICK SM, 1992, CELL, V70, P177, DOI 10.1016/0092-8674(92)90092-Q; HERSHBERG R, 1990, P NATL ACAD SCI USA, V87, P9727, DOI 10.1073/pnas.87.24.9727; HRLOW E, 1988, ANTIBODIES, P641; KATZOUMI P, 1993, AM J PHYSIOL, V264, pC1327; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LANDOLFI NF, 1985, J IMMUNOL, V134, P423; MIYAZAKI J, 1986, J EXP MED, V163, P856, DOI 10.1084/jem.163.4.856; NEEFJES JJ, 1988, EUR J IMMUNOL, V18, P801, DOI 10.1002/eji.1830180522; PANJA A, 1993, J EXP MED, V178, P1115, DOI 10.1084/jem.178.3.1115; RADEMACHER TW, 1988, ANNU REV BIOCHEM, V57, P785, DOI 10.1146/annurev.bi.57.070188.004033; ROCK KL, 1991, CELL, V65, P611, DOI 10.1016/0092-8674(91)90093-E; RUBOCKI RJ, 1991, J IMMUNOL, V146, P2352; SHAWAR SM, 1994, ANNU REV IMMUNOL, V12, P839, DOI 10.1146/annurev.immunol.12.1.839; SMITH JD, 1992, J EXP MED, V175, P191, DOI 10.1084/jem.175.1.191; STROMINGER JL, 1989, CELL, V57, P895, DOI 10.1016/0092-8674(89)90326-7; STROYNOWSKI I, 1990, ANNU REV IMMUNOL, V8, P501, DOI 10.1146/annurev.iy.08.040190.002441; SYDORA BC, 1993, J IMMUNOL, V150, P2179; TABOR S, 1985, P NATL ACAD SCI USA, V82, P1074, DOI 10.1073/pnas.82.4.1074; TAKEBE Y, 1988, MOL CELL BIOL, V8, P466, DOI 10.1128/MCB.8.1.466; TAUNK J, 1992, GASTROENTEROLOGY, V102, P69, DOI 10.1016/0016-5085(92)91785-3; VANKERCKHOVE C, 1992, J EXP MED, V175, P57, DOI 10.1084/jem.175.1.57; WILLIAMS DB, 1989, J IMMUNOL, V142, P2796; WU M, 1991, J EXP MED, V174, P213, DOI 10.1084/jem.174.1.213; YEWDELL JW, 1992, ADV IMMUNOL, V52, P1, DOI 10.1016/S0065-2776(08)60875-5; ZIJLSTRA M, 1990, NATURE, V344, P742, DOI 10.1038/344742a0	39	146	147	0	0	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUL 8	1994	265	5169					259	262		10.1126/science.7517575	http://dx.doi.org/10.1126/science.7517575			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	NV957	7517575				2022-12-28	WOS:A1994NV95700044
J	YU, HT; CHEN, JK; FENG, SB; DALGARNO, DC; BRAUER, AW; SCHREIBER, SL				YU, HT; CHEN, JK; FENG, SB; DALGARNO, DC; BRAUER, AW; SCHREIBER, SL			STRUCTURAL BASIS FOR THE BINDING OF PROLINE-RICH PEPTIDES TO SH3 DOMAINS	CELL			English	Article							RECEPTOR TYROSINE KINASES; NMR-SPECTROSCOPY; GENE-PRODUCT; AMINO-ACID; PROTEIN; SRC; MAGNETIZATION; EXPRESSION; SPECTRA; CLONING	A common RXL motif was found in proline rich ligands that were selected from a biased combinatorial peptide library on the basis of their ability to bind specifically to the SH3 domains from phosphatidylinositol 3-kinase (PI3K) or c-Src. The solution structure of the PI3K SH3 domain complexed to one of these ligands, RKLPPRPSK (RLP1), was determined. Structure-based mutations were introduced into the PI3K SH3 domain and the RLP1 ligand, and the influence of these mutations on binding was evaluated. We conclude that SH3 domains recognize proline-rich motifs possessing the left-handed type II polyproline (PPII) helix conformation. Two proline residues directly contact the receptor. Other prolines in the ligands appear to function as a molecular scaffold, promoting the formation of the PPII helix. Three nonproline residues consisting of combinations of arginine and leucine interact extensively with the SH3 domain and appear to confer ligand specificity.	ARIAD PHARMACEUT INC, CAMBRIDGE, MA 02139 USA	Takeda Pharmaceutical Company Ltd; Takeda Oncology	YU, HT (corresponding author), HARVARD UNIV, DEPT CHEM, CAMBRIDGE, MA 02138 USA.		Chen, James/G-9972-2011	Chen, James/0000-0002-9220-8436; Yu, Hongtao/0000-0002-8861-049X	NIGMS NIH HHS [GM-44993] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM044993] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ADZHUBEI AA, 1993, J MOL BIOL, V229, P472, DOI 10.1006/jmbi.1993.1047; BABA T, 1989, FEBS LETT, V244, P296, DOI 10.1016/0014-5793(89)80549-6; BARFOD ET, 1993, J BIOL CHEM, V268, P26059; BAX A, 1985, J MAGN RESON, V65, P355, DOI 10.1016/0022-2364(85)90018-6; BAX A, 1990, J MAGN RESON, V88, P425, DOI 10.1016/0022-2364(90)90202-K; BOOKER GW, 1993, CELL, V73, P813, DOI 10.1016/0092-8674(93)90259-S; BRUNGER AT, 1988, XPLOR VERSION 20 MAN; BRUNGER AT, 1992, XPLOR VERSION 30 MAN; BUDAY L, 1993, CELL, V73, P611, DOI 10.1016/0092-8674(93)90146-H; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; CHENTLEY LC, 1993, J AM CHEM SOC, V115, P12591; CICCHETTI P, 1992, SCIENCE, V257, P803, DOI 10.1126/science.1379745; CLARK SG, 1992, NATURE, V356, P340, DOI 10.1038/356340a0; EGAN SE, 1993, NATURE, V363, P45, DOI 10.1038/363045a0; FODOR SPA, 1991, SCIENCE, V251, P767, DOI 10.1126/science.1990438; FURKA A, 1991, INT J PEPT PROT RES, V37, P487, DOI 10.1111/j.1399-3011.1991.tb00765.x; GEOGHEGAN KF, 1992, BIOCONJUGATE CHEM, V3, P138, DOI 10.1021/bc00014a008; GEYSEN HM, 1984, P NATL ACAD SCI-BIOL, V81, P3998, DOI 10.1073/pnas.81.13.3998; GOUT I, 1993, CELL, V75, P25, DOI 10.1016/0092-8674(93)90676-H; Higuchi R, 1990, PCR PROTOCOLS GUIDE, P177; HILES ID, 1992, CELL, V70, P419, DOI 10.1016/0092-8674(92)90166-A; IKURA M, 1992, SCIENCE, V256, P632, DOI 10.1126/science.1585175; IKURA M, 1992, J AM CHEM SOC, V114, P2433, DOI 10.1021/ja00033a019; KATO JY, 1986, MOL CELL BIOL, V6, P4155, DOI 10.1128/MCB.6.12.4155; KAY LE, 1990, J MAGN RESON, V86, P110, DOI 10.1016/0022-2364(90)90215-U; KOCH CA, 1991, SCIENCE, V252, P668, DOI 10.1126/science.1708916; KOHDA D, 1993, CELL, V72, P953, DOI 10.1016/0092-8674(93)90583-C; KOYAMA S, 1993, FEBS LETT, V324, P93, DOI 10.1016/0014-5793(93)81539-C; KOYAMA S, 1993, CELL, V72, P945, DOI 10.1016/0092-8674(93)90582-B; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LAM KS, 1991, NATURE, V354, P82, DOI 10.1038/354082a0; LEVY JB, 1987, MOL CELL BIOL, V7, P4142, DOI 10.1128/MCB.7.11.4142; LIU XQ, 1993, MOL CELL BIOL, V13, P5225, DOI 10.1128/MCB.13.9.5225; LOWENSTEIN EJ, 1992, CELL, V70, P431, DOI 10.1016/0092-8674(92)90167-B; MACURA S, 1981, J MAGN RESON, V43, P259, DOI 10.1016/0022-2364(81)90037-8; MARION D, 1989, BIOCHEMISTRY-US, V28, P6150, DOI 10.1021/bi00441a004; MARTINEZ R, 1987, SCIENCE, V237, P441; MICHNICK SW, 1991, SCIENCE, V252, P836, DOI 10.1126/science.1709301; MUSACCHIO A, 1992, NATURE, V359, P851, DOI 10.1038/359851a0; MUSACCHIO A, 1992, FEBS LETT, V307, P55, DOI 10.1016/0014-5793(92)80901-R; NAHARRO G, 1984, SCIENCE, V223, P63, DOI 10.1126/science.6318314; NEMETH SP, 1989, MOL CELL BIOL, V9, P1109, DOI 10.1128/MCB.9.3.1109; NOBLE MEM, 1993, EMBO J, V12, P2617, DOI 10.1002/j.1460-2075.1993.tb05922.x; OLIVIER JP, 1993, CELL, V73, P179, DOI 10.1016/0092-8674(93)90170-U; OMICHINSKI JG, 1993, SCIENCE, V261, P438, DOI 10.1126/science.8332909; OTSU M, 1991, CELL, V65, P91, DOI 10.1016/0092-8674(91)90411-Q; OTTING G, 1990, Q REV BIOPHYS, V23, P39, DOI 10.1017/S0033583500005412; PARMLEY SF, 1988, GENE, V73, P305, DOI 10.1016/0378-1119(88)90495-7; PAWSON T, 1993, CURR BIOL, V3, P434, DOI 10.1016/0960-9822(93)90350-W; PAWSON T, 1992, CELL, V71, P359, DOI 10.1016/0092-8674(92)90504-6; Potts W M, 1988, Oncogene Res, V3, P343; REN RB, 1993, SCIENCE, V259, P1157, DOI 10.1126/science.8438166; SEIDEL DC, 1992, MOL CELL BIOL, V12, P1835; SIMON MA, 1993, CELL, V73, P169, DOI 10.1016/0092-8674(93)90169-Q; SKOLNIK EY, 1991, CELL, V65, P83, DOI 10.1016/0092-8674(91)90410-Z; TAMKUN MM, 1991, FASEB J, V5, P331, DOI 10.1096/fasebj.5.3.2001794; VARTICOVSKI L, 1989, NATURE, V342, P699, DOI 10.1038/342699a0; WAGES DS, 1992, J VIROL, V66, P1866, DOI 10.1128/JVI.66.4.1866-1874.1992; WEBER C, 1991, BIOCHEMISTRY-US, V30, P6563, DOI 10.1021/bi00240a029; WENG ZG, 1993, J BIOL CHEM, V268, P14956; YU HT, 1992, SCIENCE, V258, P1665, DOI 10.1126/science.1280858; ZUIDERWEG ERP, 1989, BIOCHEMISTRY-US, V28, P2387, DOI 10.1021/bi00432a008	62	938	995	3	58	CELL PRESS	CAMBRIDGE	600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA	0092-8674			CELL	Cell	MAR 11	1994	76	5					933	945		10.1016/0092-8674(94)90367-0	http://dx.doi.org/10.1016/0092-8674(94)90367-0			13	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	NA890	7510218				2022-12-28	WOS:A1994NA89000018
J	YUN, D; HEYWOOD, JT				YUN, D; HEYWOOD, JT			METASTATIC CARCINOID DISEASE PRESENTING SOLELY AS HIGH-OUTPUT HEART-FAILURE	ANNALS OF INTERNAL MEDICINE			English	Note							SUBSTANCE-P ANTAGONIST; RECEPTOR SELECTIVITY; NK1				HEYWOOD, JT (corresponding author), LOMA LINDA JERRY L PETTIS MEM VET HOSP, CARDIOL SECT, 11201 BENTON ST, LOMA LINDA, CA 92357 USA.							GARRET C, 1991, P NATL ACAD SCI USA, V88, P10208, DOI 10.1073/pnas.88.22.10208; LUNDIN L, 1988, CIRCULATION, V77, P264, DOI 10.1161/01.CIR.77.2.264; MACCANON DM, 1954, AM J PHYSIOL, V179, P131, DOI 10.1152/ajplegacy.1954.179.1.131; MORIMOTO H, 1992, BRIT J PHARMACOL, V106, P123, DOI 10.1111/j.1476-5381.1992.tb14303.x; MORIMOTO H, 1992, J PHARMACOL EXP THER, V262, P398; OKUMURA K, 1992, J AM COLL CARDIOL, V20, P838, DOI 10.1016/0735-1097(92)90181-L; RUDOLPH AM, 1957, AM J PHYSIOL, V189, P263, DOI 10.1152/ajplegacy.1957.189.2.263; SCHWABER JR, 1962, AM J MED, V32, P846, DOI 10.1016/0002-9343(62)90031-1	8	0	0	0	2	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JAN 1	1994	120	1					45	46		10.7326/0003-4819-120-1-199401010-00008	http://dx.doi.org/10.7326/0003-4819-120-1-199401010-00008			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MP280	7504425				2022-12-28	WOS:A1994MP28000008
J	Pasic, M; Turina, M				Pasic, M; Turina, M			Abdominal aortic aneurysm	NEW ENGLAND JOURNAL OF MEDICINE			English	Article											Pasic, M (corresponding author), UNIV ZURICH HOSP,CH-8091 ZURICH,SWITZERLAND.								0	0	0	0	0	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JAN 4	1996	334	1					26	26		10.1056/NEJM199601043340106	http://dx.doi.org/10.1056/NEJM199601043340106			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TM482	7494567				2022-12-28	WOS:A1996TM48200006
J	SUGARMAN, J; REISNER, EG; KURTZBERG, J				SUGARMAN, J; REISNER, EG; KURTZBERG, J			ETHICAL ASPECTS OF BANKING PLACENTAL BLOOD FOR TRANSPLANTATION	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							RECONSTITUTION; BODY	Transplantation of blood cells harvested from the umbilical cord immediately after birth has been effective in repopulating the bone marrow. These placental blood transplantations may be safer than conventional bone marrow transplantations and may suspend the need to harvest bone marrow, a process fraught with difficulties. Further understanding and advancement of this emerging technology require developing large banks of placental blood. In this article, we examine some of the ethical issues associated with placental blood banking, including (1) questions about ownership of the tissue, (2) the necessity and nature of obtaining informed consent from parents for harvesting placental blood and the information-gathering process associated with it, (3) obligations to notify parents and children of the results of medical testing for infectious diseases and genetic information, (4) matters of privacy and confidentiality related to such information, and (5) the need for fair and equitable harvesting of and access to placental blood.	DUKE UNIV,MED CTR,CTR HLTH POLICY RES & EDUC,DURHAM,NC 27710; DUKE UNIV,MED CTR,DEPT PATHOL,DURHAM,NC 27710; DUKE UNIV,MED CTR,PEDIAT BONE MARROW TRANSPLANT PROGRAM,DURHAM,NC 27710	Duke University; Duke University; Duke University	SUGARMAN, J (corresponding author), DUKE UNIV,MED CTR,CTR STUDY AGING & HUMAN DEV,DIV GEN INTERNAL MED,PROGRAM MED ETH,BOX 3040,DURHAM,NC 27710, USA.			Sugarman, Jeremy/0000-0001-7022-8332				ANDREWS LB, 1986, HASTINGS CENT REP, V16, P28, DOI 10.2307/3562693; [Anonymous], 1986, HIST THEORY INFORM C; AUERBACH AD, 1994, BLOOD CELLS, V20, P303; Campbell C S, 1993, Second Opin, V19, P69; DULA A, 1994, CAMB Q HEALTHC ETHIC, V3, P347, DOI 10.1017/S0963180100005168; GALE RP, 1995, NEW ENGL J MED, V332, P392, DOI 10.1056/NEJM199502093320612; GLUCKMAN E, 1989, NEW ENGL J MED, V321, P1174, DOI 10.1056/NEJM198910263211707; KURTZBERG J, 1994, BLOOD CELLS, V20, P275; MCCULLOUGH J, 1994, BLOOD CELLS, V20, P609; McCullough J, 1989, BONE MARROW TRANSPL, P641; MURRAY TH, 1987, HASTINGS CENT REP, V17, P30, DOI 10.2307/3562041; ROBERTSON JA, 1991, FERTIL STERIL, V55, P681; ROBERTSON JA, 1989, HASTINGS CENT REP, V19, P7, DOI 10.2307/3561979; RUBINSTEIN P, 1993, BLOOD, V81, P1679; RUBINSTEIN P, 1994, BLOOD CELLS, V20, P587; WAGNER JE, 1994, BLOOD CELLS, V20, P227	16	61	62	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	DEC 13	1995	274	22					1783	1785		10.1001/jama.274.22.1783	http://dx.doi.org/10.1001/jama.274.22.1783			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	TJ225	7500510				2022-12-28	WOS:A1995TJ22500029
J	SHENEP, JL; SRINIVAS, RV; JENKINS, JJ; FURMAN, WL				SHENEP, JL; SRINIVAS, RV; JENKINS, JJ; FURMAN, WL			A YOUNG WOMAN WITH LYMPHOMA AND ENDOCARDITIS	LANCET			English	Note									ST JUDE CHILDRENS RES HOSP, DEPT PATHOL, MEMPHIS, TN 38105 USA; ST JUDE CHILDRENS RES HOSP, DEPT HAEMATOL ONCOL, MEMPHIS, TN 38105 USA	St Jude Children's Research Hospital; St Jude Children's Research Hospital	SHENEP, JL (corresponding author), ST JUDE CHILDRENS RES HOSP, DEPT INFECT DIS, 332 N LAUDERDALE ST, MEMPHIS, TN 38105 USA.		Furman, Wayne/N-8179-2018		NATIONAL CANCER INSTITUTE [P30CA021765] Funding Source: NIH RePORTER; NCI NIH HHS [P30 CA 21765] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BHARUCHA PE, 1975, CLIN PEDIATR, V14, P186, DOI 10.1177/000992287501400210; BLAILOCK ZR, 1967, SCIENCE, V157, P69, DOI 10.1126/science.157.3784.69; MCDONOUGH M, 1993, DIAGNOSTIC MOL MICRO, P369; SIXBEY JW, 1992, SCIENCE, V255, P1578, DOI 10.1126/science.1312750; WRIGHT DK, 1990, PCR PROTOCOLS GUIDE, P153	5	2	2	0	0	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736			LANCET	Lancet	DEC 9	1995	346	8989					1532	1532		10.1016/S0140-6736(95)92056-0	http://dx.doi.org/10.1016/S0140-6736(95)92056-0			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TJ291	7491051				2022-12-28	WOS:A1995TJ29100015
J	DOWRICK, C; BUCHAN, I				DOWRICK, C; BUCHAN, I			12 MONTH OUTCOME OF DEPRESSION IN GENERAL-PRACTICE - DOES DETECTION OR DISCLOSURE MAKE A DIFFERENCE	BMJ-BRITISH MEDICAL JOURNAL			English	Article							MEDICAL PATIENTS; NATURAL-HISTORY; RECOGNITION; DISORDERS	Objectives-To assess the extent to which the outcome of depression among primary care attenders may be affected by medical diagnosis or by feedback of questionnaire results in unrecognised cases. Design-Prospective 12 month study including a randomised controlled trial of the effects of disclosure, with data on depression status and clinical management collected by questionnaire and interview. Setting-Two group practices in north Liverpool. Subjects-1099/1444 (76%) consecutive adult attenders completed the Beck depression inventory, of whom 179 with scores of at least 14 were followed up. Interventions-Disclosure of a random 45% (52/116) of depression scores to general practitioners for subjects whose depression was undetected. Main outcome measures-Depression status estimated by depression score at start of study and at six and 12 months, with subsample validation against ICD-10 criteria. Results-Questionnaire response rates were 76% (136/179) at six months and 68% (122/179) at 12 months and were higher for women than men. The median depression score was 19 (interquartile range 15 to 22) initially, decreasing to 16 (11 to 23) at 12 months. The median depression score decreased significantly (two sided test, P=0 019) in subjects whose depression was unrecognised at the index consultation but increased in those whose depression had been detected by their general practitioners. Disclosure of cases of unrecognised depression to general practitioners had no effect on outcome. Intention to treat was associated with a worse prognosis, although only a minority of subjects received adequate treatment. Conclusions-Disclosure of undetected depression did not improve prognosis. A diagnosis of depression in general practice should be considered simply as a marker of its severity.	UNIV LIVERPOOL, DEPT MED, LIVERPOOL, MERSEYSIDE, ENGLAND	University of Liverpool	DOWRICK, C (corresponding author), UNIV LIVERPOOL, DEPT PRIMARY CARE, LIVERPOOL L69 3BX, MERSEYSIDE, ENGLAND.		Buchan, Iain E/H-5767-2013	Buchan, Iain E/0000-0003-3392-1650				[Anonymous], 1990, INT CLASSIFICATION D; BEBBINGTON P, 1981, PSYCHOL MED, V11, P561, DOI 10.1017/S0033291700052879; Beck A.T., 1987, BECK DEPRESSION INVE; BRODATY H, 1983, THESIS U NEW S WALES; BROWN GW, 1994, BRIT J PSYCHIAT, V165, P447, DOI 10.1192/bjp.165.4.447; CONOVER W. J, 1980, PRACTICAL NONPARAMET; DOWRICK C, 1995, IN PRESS FAM PRACT; DUNN G, 1981, PSYCHOL MED, V11, P755, DOI 10.1017/S003329170004126X; FREEMANTLE N, 1993, EFFECTIVE HLTH CARE, V5; HUTCHINSON A, 1989, BRIT MED J, V299, P1142, DOI 10.1136/bmj.299.6708.1142; Johnson D A, 1977, J R Coll Gen Pract, V27, P419; JOHNSTONE A, 1976, LANCET, V1, P605, DOI 10.1016/S0140-6736(76)90415-3; LEENSTRA AS, 1995, BRIT J PSYCHIAT, V166, P333, DOI 10.1192/bjp.166.3.333; MAGRUDERHABIB K, 1989, GEN HOSP PSYCHIAT, V11, P201, DOI 10.1016/0163-8343(89)90042-X; NIELSEN AC, 1980, ARCH GEN PSYCHIAT, V37, P999; ORMEL J, 1990, PSYCHOL DISORDERS GE, P146; PARKER G, 1986, J AFFECT DISORDERS, V10, P27, DOI 10.1016/0165-0327(86)90046-7; Sartorius N, 1986, ASSESSMENT DEPRESSIO; SCHULBERG HC, 1987, J GEN INTERN MED, V2, P312, DOI 10.1007/BF02596165; SCOTT J, 1992, BRIT J PSYCHIAT, V161, P633, DOI 10.1192/bjp.161.5.633; USTUN TB, 1995, BRIT J GEN PRACT, V45, P211; WILKIN D, 1992, MEASURES NEED OUTCOM, P80; WRIGHT AF, 1995, BRIT J GEN PRACT, V45, P83; ZUNG WWK, 1983, J CLIN PSYCHIAT, V44, P3; 1992, BRIT NATIONAL FORMUL	25	174	176	0	9	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	NOV 11	1995	311	7015					1274	1276		10.1136/bmj.311.7015.1274	http://dx.doi.org/10.1136/bmj.311.7015.1274			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	TE859	7496238	Green Published			2022-12-28	WOS:A1995TE85900025
J	DSOUZA, SE; HAAS, TA; PIOTROWICZ, RS; BYERSWARD, V; MCGRATH, DE; SOULE, HR; CIERNIEWSKI, C; PLOW, EF; SMITH, JW				DSOUZA, SE; HAAS, TA; PIOTROWICZ, RS; BYERSWARD, V; MCGRATH, DE; SOULE, HR; CIERNIEWSKI, C; PLOW, EF; SMITH, JW			LIGAND AND CATION-BINDING ARE DUAL FUNCTIONS OF A DISCRETE SEGMENT OF THE INTEGRIN BETA(3) SUBUNIT - CATION DISPLACEMENT IS INVOLVED IN LIGAND-BINDING	CELL			English	Article							FIBRINOGEN GAMMA-CHAIN; GLYCOPROTEIN-IIB-IIIA; CALCIUM-BINDING; PLATELET INTEGRIN; GPIIB-IIIA; VITRONECTIN RECEPTOR; ADHESION RECEPTOR; CELL-ADHESION; RECOGNITION SITE; BONE-RESORPTION	The alpha(IIb)beta(3) integrin binds Arg-Gly-Asp-containing (RGD-containing) ligands in a cation-dependent interaction. A fourteen amino acid sequence, beta(3)(118-131), and an antibody to it, inhibited ligand binding functions of alpha(IIb)beta s, and a 1:1 stoichiometric beta(3)(118-131)-RGD complex was detected by mass spectroscopy. Cation binding to Ps(118-131) was demonstrated by terbium luminescence and mass spectroscopy. Notably, ligand displaced cation from the beta(3)(118-131) peptide and also from purified alpha(IIb)beta(3). Thus, beta(3)(118-131), a highly conserved region in integrin beta subunits, binds both ligand and cation. Formation of a ternary complex between cation, ligand, and receptor, with subsequent displacement of cation from beta(3)(118-131)and a second site within the receptor, may be central to the mechanism of ligand recognition by integrins.	Scripps Res Inst, DEPT VASC BIOL, LA JOLLA, CA 92037 USA; CORVAS INT INC, SAN DIEGO, CA 92121 USA	Scripps Research Institute	DSOUZA, SE (corresponding author), CLEVELAND CLIN FDN, DEPT MOLEC CARDIOL, CTR THROMBOSIS & VASC RES, FF20, CLEVELAND, OH 44195 USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL038292, R29HL043721, R01HL043721] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL-43721, HL-38292] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ANDRIEUX A, 1991, J BIOL CHEM, V266, P14202; BACA M, 1992, J AM CHEM SOC, V114, P3992, DOI 10.1021/ja00036a066; BAIROCH A, 1989, PROSITE DICT PROTEIN; BRITTAIN HG, 1976, J AM CHEM SOC, V98, P8255, DOI 10.1021/ja00441a060; CALVETE JJ, 1988, BIOCHEM J, V250, P697, DOI 10.1042/bj2500697; CHERESH DA, 1987, P NATL ACAD SCI USA, V84, P6471, DOI 10.1073/pnas.84.18.6471; DAVIES J, 1989, J CELL BIOL, V109, P1817, DOI 10.1083/jcb.109.4.1817; DRANSFIELD I, 1992, J CELL BIOL, V116, P219, DOI 10.1083/jcb.116.1.219; DSOUZA SE, 1991, NATURE, V350, P66, DOI 10.1038/350066a0; DSOUZA SE, 1988, SCIENCE, V242, P91, DOI 10.1126/science.3262922; DSOUZA SE, 1990, J BIOL CHEM, V265, P3440; DU XP, 1991, CELL, V65, P409, DOI 10.1016/0092-8674(91)90458-B; FRELINGER AL, 1990, J BIOL CHEM, V265, P6346; GARCIAGONZALEZ M, 1988, J IMMUNOL METHODS, V111, P17, DOI 10.1016/0022-1759(88)90054-3; GARVEY JS, 1977, METHOD IMMUNOL, V1, P89; GINSBERG M, 1985, J BIOL CHEM, V260, P3931; GINSBERG MH, 1993, THROMB HAEMOSTASIS, V70, P87; GINSBERG MH, 1986, J CLIN INVEST, V78, P1103, DOI 10.1172/JCI112667; Goding JW, 1983, MONOCLONAL ANTIBODIE; GRZESIAK JJ, 1992, J CELL BIOL, V117, P1109, DOI 10.1083/jcb.117.5.1109; HOGUE CWV, 1992, J BIOL CHEM, V267, P13340; Horrocks W.D. Jr., 1983, PROG INORG CHEM, V31, P1; HUTCHENS TW, 1992, FEBS LETT, V309, P170, DOI 10.1016/0014-5793(92)81088-4; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; KIRCHHOFER D, 1991, J BIOL CHEM, V266, P4471; KLOCZEWIAK M, 1982, BIOCHEM BIOPH RES CO, V107, P181, DOI 10.1016/0006-291X(82)91686-2; KLOCZEWIAK M, 1983, THROMB RES, V29, P249, DOI 10.1016/0049-3848(83)90147-0; LAKKAKORPI PT, 1991, J CELL BIOL, V115, P1179, DOI 10.1083/jcb.115.4.1179; LOFTUS JC, 1990, SCIENCE, V249, P915, DOI 10.1126/science.2392682; MARGUERIE GA, 1980, J BIOL CHEM, V255, P154; MARGUERIE GA, 1981, BIOCHEMISTRY-US, V20, P1074, DOI 10.1021/bi00508a005; MARGUERIE GA, 1983, ANN NY ACAD SCI, V408, P556, DOI 10.1111/j.1749-6632.1983.tb23272.x; MARTINI JL, 1993, EUR J BIOCHEM, V211, P467, DOI 10.1111/j.1432-1033.1993.tb17572.x; Morrison M, 1980, Methods Enzymol, V70, P214; PHILLIPS DR, 1988, BLOOD, V71, P831; PLOW EF, 1992, SEMIN THROMB HEMOST, V18, P324, DOI 10.1055/s-2007-1002571; PLOW EF, 1989, PROG HEMOST THROMB, V9, P117; PLOW EF, 1982, P NATL ACAD SCI-BIOL, V79, P3711, DOI 10.1073/pnas.79.12.3711; PRADOS R, 1974, J INORG NUCL CHEM, V36, P689, DOI 10.1016/0022-1902(74)80135-1; RIVAS GA, 1991, BIOCHEM J, V276, P35, DOI 10.1042/bj2760035; RUOSLAHTI E, 1991, J CLIN INVEST, V87, P1, DOI 10.1172/JCI114957; RUOSLAHTI E, 1987, SCIENCE, V238, P491, DOI 10.1126/science.2821619; SAVAGE B, 1991, J BIOL CHEM, V266, P11227; SMITH JW, 1988, J BIOL CHEM, V263, P18726; SMITH JW, 1991, J BIOL CHEM, V266, P11429; SMITH JW, 1994, J BIOL CHEM, V269, P960; SMYTH SS, 1993, BLOOD, V81, P2827; SNYDER AP, 1981, BIOCHEMISTRY-US, V20, P3334, DOI 10.1021/bi00515a003; STAATZ WD, 1989, J CELL BIOL, V108, P1917, DOI 10.1083/jcb.108.5.1917; STEINER B, 1989, J BIOL CHEM, V264, P13102; STRYNADKA NCJ, 1989, ANNU REV BIOCHEM, V58, P951, DOI 10.1146/annurev.bi.58.070189.004511; TAKADA Y, 1992, J CELL BIOL, V119, P913, DOI 10.1083/jcb.119.4.913; TAYLOR DB, 1992, J BIOL CHEM, V267, P11729; TUCKWELL DS, 1992, BIOCHEM J, V285, P325, DOI 10.1042/bj2850325; VANKOOYK Y, 1991, J CELL BIOL, V112, P345, DOI 10.1083/jcb.112.2.345	55	215	217	0	7	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	NOV 18	1994	79	4					659	667		10.1016/0092-8674(94)90551-7	http://dx.doi.org/10.1016/0092-8674(94)90551-7			9	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	PT481	7525080				2022-12-28	WOS:A1994PT48100013
J	OAKLANDER, AL; EKENBERG, SJ				OAKLANDER, AL; EKENBERG, SJ			SMALL-SCALE MAGNETIC ISOLATION OF MESSENGER-RNA AND SYNTHESIS OF CDNA IN 96-WELL PLATES	NATURE			English	Article							REVERSE-TRANSCRIPTASE-PCR	Multiple small biological samples can be simultaneously prepared for RT-PCR by magnetically isolating mRNA and synthesizing cDNA in 96-well plates. The resulting accuracy, high throughput and ease of use facilitate commercial and clinical applications.	PROMEGA CORP,MADISON,WI	Promega Corporation	OAKLANDER, AL (corresponding author), JOHNS HOPKINS MED INST,DEPT NEUROL,BALTIMORE,MD 21205, USA.							Chelly Jamel, 1994, P97; Dilworth D D, 1992, PCR Methods Appl, V1, P279; HOPPE BL, 1992, BIOTECHNIQUES, V12, P679; KOTEWICZ ML, 1988, NUCLEIC ACIDS RES, V16, P265, DOI 10.1093/nar/16.1.265; NORTHRUP MA, 1993, 7TH P INT C SOL STAT; SELA M, 1957, BIOCHIM BIOPHYS ACTA, V26, P502, DOI 10.1016/0006-3002(57)90096-3; Yamaguchi M, 1992, PCR Methods Appl, V1, P286	7	8	9	0	9	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	OCT 13	1994	371	6498					631	632		10.1038/371631a0	http://dx.doi.org/10.1038/371631a0			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PL559	7523954				2022-12-28	WOS:A1994PL55900060
J	SAWAYA, MR; PELLETIER, H; KUMAR, A; WILSON, SH; KRAUT, J				SAWAYA, MR; PELLETIER, H; KUMAR, A; WILSON, SH; KRAUT, J			CRYSTAL-STRUCTURE OF RAT DNA-POLYMERASE-BETA - EVIDENCE FOR A COMMON POLYMERASE MECHANISM	SCIENCE			English	Article							ESCHERICHIA-COLI; BINDING DOMAIN; REVERSE-TRANSCRIPTASE; 3-DIMENSIONAL STRUCTURE; ANGSTROM RESOLUTION; KLENOW FRAGMENT; RNA-POLYMERASE; IDENTIFICATION; PROTEIN; SYNTHETASE	Structures of the 31-kilodalton catalytic domain of rat DNA polymerase beta (pol beta) and the whole 39-kilodalton enzyme were determined at 2.3 and 3.6 angstrom resolution, respectively. The 31-kilodalton domain is composed of fingers, palm, and thumb subdomains arranged to form a DNA binding channel reminiscent of the polymerase domains of the Klenow fragment of Escherichia coli DNA polymerase I, HIV-1 reverse transcriptase, and bacteriophage T7 RNA polymerase. The amino-terminal 8-kilodalton domain is attached to the fingers subdomain by a flexible hinge. The two invariant aspartates found in all polymerase sequences and implicated in catalytic activity have the same geometric arrangement within structurally similar but topologically distinct palms, indicating that the polymerases have maintained, or possibly re-evolved, a common nucleotidyl transfer mechanism. The location of Mn2+ and deoxyadenosine triphosphate in pot beta confirms the role of the invariant aspartates in metal ion and deoxynucleoside triphosphate binding.	UNIV TEXAS,MED BRANCH,SEALY CTR MOLEC SCI,GALVESTON,TX 77555	University of Texas System; University of Texas Medical Branch Galveston	SAWAYA, MR (corresponding author), UNIV CALIF SAN DIEGO,DEPT CHEM,LA JOLLA,CA 92093, USA.		Wilson, Samuel H/E-6644-2019	Wilson, Samuel H/0000-0002-1702-5293	NCI NIH HHS [CA17374] Funding Source: Medline; NIEHS NIH HHS [ES06839] Funding Source: Medline; NIGMS NIH HHS [GM10928] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA017374] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES006839] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM010928] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BASU A, 1989, BIOCHEMISTRY-US, V28, P6305, DOI 10.1021/bi00441a023; BEESE LS, 1993, BIOCHEMISTRY-US, V32, P14095, DOI 10.1021/bi00214a004; BEESE LS, 1993, SCIENCE, V260, P352, DOI 10.1126/science.8469987; BONNER G, 1992, EMBO J, V11, P3767, DOI 10.1002/j.1460-2075.1992.tb05462.x; BORK P, 1992, PROTEIN SCI, V1, P1677, DOI 10.1002/pro.5560011216; BRUNGER A, 1992, X PLOR MANUAL; CASASFINET JR, 1991, J BIOL CHEM, V266, P19618; COLL M, 1991, EMBO J, V10, P1; DATE T, 1991, BIOCHEMISTRY-US, V30, P5286, DOI 10.1021/bi00235a023; DAVIES JF, 1994, CELL, V76, P1123, DOI 10.1016/0092-8674(94)90388-3; DELARUE M, 1990, PROTEIN ENG, V3, P461, DOI 10.1093/protein/3.6.461; EVANS RK, 1989, BIOCHEMISTRY-US, V28, P713, DOI 10.1021/bi00428a045; FITZGERALD PMD, 1988, J APPL CRYSTALLOGR, V21, P273, DOI 10.1107/S0021889887012299; GOUAUX JE, 1990, BIOCHEMISTRY-US, V29, P7702, DOI 10.1021/bi00485a020; HAMLIN R, 1985, METHOD ENZYMOL, V114, P416; HEGDE RS, 1992, NATURE, V359, P505, DOI 10.1038/359505a0; HERZBERG O, 1992, P NATL ACAD SCI USA, V89, P2499, DOI 10.1073/pnas.89.6.2499; HOWARD AJ, 1985, METHOD ENZYMOL, V114, P452; JACOBOMOLINA A, 1993, P NATL ACAD SCI USA, V90, P6320, DOI 10.1073/pnas.90.13.6320; JONES TA, 1985, METHOD ENZYMOL, V115, P157; KOHLSTAEDT LA, 1992, SCIENCE, V256, P1783, DOI 10.1126/science.1377403; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; KUMAR A, 1990, J BIOL CHEM, V265, P2124; LARDER BA, 1987, NATURE, V327, P716, DOI 10.1038/327716a0; MATSUKAGE A, 1987, J BIOL CHEM, V262, P8960; MORAS D, 1993, NATURE, V364, P572, DOI 10.1038/364572a0; NAGAI K, 1990, NATURE, V348, P515, DOI 10.1038/348515a0; NIKOLOV DB, 1992, NATURE, V360, P40, DOI 10.1038/360040a0; OLLIS DL, 1985, NATURE, V313, P762, DOI 10.1038/313762a0; ORENGO CA, 1993, STRUCTURE, V1, P105, DOI 10.1016/0969-2126(93)90026-D; PASTORE A, 1992, J MOL BIOL, V224, P427, DOI 10.1016/0022-2836(92)91005-A; PELLETIER H, 1994, SCIENCE, V264, P1891, DOI 10.1126/science.7516580; POLESKY AH, 1992, J BIOL CHEM, V267, P8417; POLESKY AH, 1990, J BIOL CHEM, V265, P14579; PRASAD R, IN PRESS J BIOL CHEM; RAABE T, 1991, NATURE, V353, P229, DOI 10.1038/353229a0; READ RJ, 1986, ACTA CRYSTALLOGR A, V42, P140, DOI 10.1107/S0108767386099622; SARASTE M, 1990, TRENDS BIOCHEM SCI, V15, P430, DOI 10.1016/0968-0004(90)90281-F; SCHULZ GE, 1992, CURR OPIN STRUC BIOL, V2, P61; SINGHAL RK, 1993, J BIOL CHEM, V268, P15906; SOUSA R, 1993, NATURE, V364, P593, DOI 10.1038/364593a0; STRAUSS P, 1993, FASEB J, V7, pA1291; SWINDELLS MB, 1993, NATURE, V362, P299, DOI 10.1038/362299a0; TANABE K, 1979, BIOCHEMISTRY-US, V18, P3401, DOI 10.1021/bi00582a029; TRONRUD DE, 1987, ACTA CRYSTALLOGR A, V43, P489, DOI 10.1107/S0108767387099124; VRIEND G, 1991, PROTEINS, V11, P52, DOI 10.1002/prot.340110107; WANG BC, 1985, METHOD ENZYMOL, V115, P90; WANG TSF, 1982, BIOCHEMISTRY-US, V21, P1597, DOI 10.1021/bi00536a021; WILSON KP, 1992, P NATL ACAD SCI USA, V89, P9257, DOI 10.1073/pnas.89.19.9257; WILSON KS, 1986, P NATL ACAD SCI USA, V83, P7251, DOI 10.1073/pnas.83.19.7251; Wilson SH, 1990, EUKARYOTIC NUCLEUS, V1, P199; YAMASHITA MM, 1989, J BIOL CHEM, V264, P17681	52	415	428	1	19	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUN 24	1994	264	5167					1930	1935		10.1126/science.7516581	http://dx.doi.org/10.1126/science.7516581			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	NT847	7516581				2022-12-28	WOS:A1994NT84700045
J	DAVIS, CL; HARDY, JR				DAVIS, CL; HARDY, JR			CURRENT ISSUES IN CANCER - PALLIATIVE CARE .10.	BMJ-BRITISH MEDICAL JOURNAL			English	Article							PARADOXICAL PAIN; NEBULIZED MORPHINE; BONE METASTASES; BREAST-CANCER; MORPHINE-6-GLUCURONIDE; PHARMACOKINETICS; PAMIDRONATE; OBSTRUCTION; OCTREOTIDE; KETOROLAC	Though many of the treatment strategies used in palliative care have never been subjected to clinical trial, it has been argued that advances in palliative care have outstripped those in many other specialties. This article is not a comprehensive review of therapeutic options, nor even of recent advances in this topic, but concentrates on the latest developments and controversies in the pharmacological treatment of four frequent and important symptoms: neuropathic pain, anorexia and cachexia, intestinal obstruction, and breathlessness. It is difficult to perform blinded, randomised trials in patients with advanced disease and poor performance status, yet it is these patients who may gain most from the adoption of new well evaluated treatment strategies.	ROYAL MARSDEN HOSP, LONDON SW3 6JJ, ENGLAND	Royal Marsden NHS Foundation Trust	DAVIS, CL (corresponding author), ROYAL MARSDEN HOSP, SUTTON SM2 5PT, SURREY, ENGLAND.		Hardy, Janet/F-2501-2012					AHMEDZAI S, 1990, ANN ONCOL, V1, P396, DOI 10.1093/oxfordjournals.annonc.a057788; AHMEDZAI S, 1993, OXFORD TXB PALLIATIV, P362; [Anonymous], 1989, NEW ENGL J MED, V321, P406; ASHBY M A, 1991, Palliative Medicine, V5, P147; BEAUFORD W, 1993, CHEST, V104, P175, DOI 10.1378/chest.104.1.175; Blackwell N., 1993, Palliative Medicine, V7, P63, DOI 10.1177/026921639300700110; BOONEKAMP PM, 1986, BONE MINER, V1, P27; BOWSHER D, 1993, BRIT MED J, V306, P473, DOI 10.1136/bmj.306.6876.473; CABOT PJ, 1993, 7TH P WORLD C PAIN, P330; CLARKE NW, 1991, BRIT J CANCER, V63, P420, DOI 10.1038/bjc.1991.97; DAVIS CL, 1993, BRIT MED J, V306, P793, DOI 10.1136/bmj.306.6880.793-c; DAVIS CL, 1992, BRIT J CANCER S16, V65, P12; DUNLOP R, 1988, LANCET, V1, P420; DUNLOP RJ, 1991, LANCET, V337, P1347; DYER C, 1992, BRIT MED J, V305, P731; FILSHIE J, 1988, CANCER SURV, V7, P161; GILLIES GWA, 1987, ANAESTHESIA, V42, P727, DOI 10.1111/j.1365-2044.1987.tb05317.x; GRAY JMB, 1981, POSTGRAD MED J, V57, P279, DOI 10.1136/pgmj.57.667.279; HANKS GWC, 1993, BRIT MED J, V306, P793, DOI 10.1136/bmj.306.6880.793-b; HANNA MH, 1990, BRIT J ANAESTH, V64, P547, DOI 10.1093/bja/64.5.547; HARDY PAJ, 1993, BRIT MED J, V306, P793, DOI 10.1136/bmj.306.6880.793-d; HOSKIN PJ, 1989, BRIT J CLIN PHARMACO, V27, P499, DOI 10.1111/j.1365-2125.1989.tb05399.x; JESSOP J, 1993, BRIT MED J, V306, P794, DOI 10.1136/bmj.306.6880.794; KHOO D, 1994, EUR J CANCER, V30A, P28, DOI 10.1016/S0959-8049(05)80012-7; LANGSTEIN HN, 1991, HEMATOL ONCOL CLIN N, V5, P103, DOI 10.1016/S0889-8588(18)30457-X; LIPTON SA, 1994, NEW ENGL J MED, V330, P613; LITVAK KM, 1990, CLIN PHARMACY, V9, P921; LOPRINZI CL, 1992, DRUGS, V43, P499, DOI 10.2165/00003495-199243040-00006; MacDonald Neil, 1993, Palliative Medicine, V7, P65; MERCADANTE S, 1992, J PAIN SYMPTOM MANAG, V7, P496, DOI 10.1016/0885-3924(92)90137-7; MORLEY JS, 1992, LANCET, V340, P1045, DOI 10.1016/0140-6736(92)93067-W; MORTON AR, 1991, BRIT J CANCER, V63, P556; MULVIHILL S, 1986, SURGERY, V100, P467; NOTT DM, 1990, GUT, V31, pA591; OSBORNE R, 1992, BRIT J CLIN PHARMACO, V34, P130, DOI 10.1111/j.1365-2125.1992.tb04121.x; OSBORNE R, 1990, CLIN PHARMACOL THER, V47, P12, DOI 10.1038/clpt.1990.2; PATERSON AHG, 1993, J CLIN ONCOL, V11, P59, DOI 10.1200/JCO.1993.11.1.59; PORTENOY RK, 1993, OXFORD TXB PALLIATIV, P187; TCHEKMEDYIAN NS, 1992, CANCER, V69, P1268; THIEBAUD D, 1991, EUR J CANCER, V27, P37, DOI 10.1016/0277-5379(91)90056-J; TWYCROSS R, 1993, BRIT MED J, V306, P793, DOI 10.1136/bmj.306.6880.793-a; WALSH TD, 1984, RECENT RESULTS CANC, V89, P115; YOSHIMURA H, 1969, BIOCHEM PHARMACOL, V18, P279; YOUNG IH, 1989, THORAX, V44, P387, DOI 10.1136/thx.44.5.387; 1990, WHO TECH REP SER, V804	45	14	14	0	0	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	MAY 21	1994	308	6940					1359	1362		10.1136/bmj.308.6940.1359	http://dx.doi.org/10.1136/bmj.308.6940.1359			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NM989	7517247	Green Published			2022-12-28	WOS:A1994NM98900031
J	WEYAND I; GODDE, M; FRINGS, S; WEINER, J; MULLER, F; ALTENHOFEN, W; HATT, H; KAUPP, UB				WEYAND, I; GODDE, M; FRINGS, S; WEINER, J; MULLER, F; ALTENHOFEN, W; HATT, H; KAUPP, UB			CLONING AND FUNCTIONAL EXPRESSION OF A CYCLIC-NUCLEOTIDE-GATED CHANNEL FROM MAMMALIAN SPERM	NATURE			English	Article							OLFACTORY EPITHELIUM; ROD PHOTORECEPTORS; IONIC SELECTIVITY; EXCISED PATCHES; MEMBRANE; RECEPTOR; PORES; CELL; DNA	CYCLIC nucleotide-gated (CNG) channels serve as downstream targets of signalling pathways in vertebrate photoreceptor cells and olfactory sensory neurons (see ref. 1 for review). Ca2+ ions that enter through CNG channels(2-5) intimately control these signalling pathways by regulating synthesis(6) or hydrolysis(7) of cyclic nucleotides, and by decreasing ligand sensitivity of CNG channels(8). Several lines of evidence suggest that cyclic nucleotides and Ca2+ play important roles in chemotaxis of invertebrate sperm and fertilization (see ref. 9 for review), whereas their mechanisms of action in vertebrate sperm are largely unknown. Here we report the cloning and functional expression of a novel CNG channel from bovine testis. The channel polypeptide was functionally localized in sperm, but is also specifically expressed in cone photoreceptor cells. These channels might be involved in chemotaxis of sperm by controlling Ca2+ entry through a cyclic-nucleotide signalling pathway.	RUHR UNIV BOCHUM, INST PHYSIOL, D-44780 BOCHUM, GERMANY	Ruhr University Bochum	WEYAND I (corresponding author), FORSCHUNGSZENTRUM JULICH, INST BIOL INFORMAT VERARBEITUNG, POSTFACH 1913, D-52425 JULICH, GERMANY.		Mueller, Frank/I-7196-2013	Mueller, Frank/0000-0001-7264-1227				ALTENHOFEN W, 1991, P NATL ACAD SCI USA, V88, P9868, DOI 10.1073/pnas.88.21.9868; BONIGK W, 1993, NEURON, V10, P865, DOI 10.1016/0896-6273(93)90202-3; CERVETTO L, 1988, J PHYSIOL-LONDON, V406, P181, DOI 10.1113/jphysiol.1988.sp017375; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; CHEN TY, 1993, NATURE, V362, P764, DOI 10.1038/362764a0; COOK NJ, 1989, J BIOL CHEM, V264, P6996; DAWSON TM, 1993, SCIENCE, V259, P825, DOI 10.1126/science.8381559; EISMANN E, 1994, P NATL ACAD SCI USA, V91, P1109, DOI 10.1073/pnas.91.3.1109; FRANKE C, 1987, NEUROSCI LETT, V77, P199, DOI 10.1016/0304-3940(87)90586-6; GARBERS DL, 1989, ANNU REV BIOCHEM, V58, P719, DOI 10.1146/annurev.bi.58.070189.003443; HAYNES LW, 1986, NATURE, V321, P66, DOI 10.1038/321066a0; HEGINBOTHAM L, 1992, SCIENCE, V258, P1152, DOI 10.1126/science.1279807; HINSCH KD, 1992, BIOL REPROD, V47, P337, DOI 10.1095/biolreprod47.3.337; HODGKIN AL, 1985, J PHYSIOL-LONDON, V358, P447, DOI 10.1113/jphysiol.1985.sp015561; HSU YT, 1993, NATURE, V361, P76, DOI 10.1038/361076a0; JAN LY, 1990, NATURE, V345, P672, DOI 10.1038/345672a0; KAUPP UB, 1989, NATURE, V342, P762, DOI 10.1038/342762a0; KAUPP UB, 1991, TRENDS NEUROSCI, V14, P150; KAWAMURA S, 1993, NATURE, V362, P855, DOI 10.1038/362855a0; KOCH KW, 1988, NATURE, V334, P64, DOI 10.1038/334064a0; KOZAK M, 1984, NUCLEIC ACIDS RES, V12, P857, DOI 10.1093/nar/12.2.857; KURAHASHI T, 1991, NEUROREPORT, V2, P5, DOI 10.1097/00001756-199101000-00001; KURAHASHI T, 1993, NATURE, V363, P71, DOI 10.1038/363071a0; LOWE G, 1993, NATURE, V366, P283, DOI 10.1038/366283a0; LUDWIG J, 1990, FEBS LETT, V270, P24, DOI 10.1016/0014-5793(90)81226-E; METHFESSEL C, 1986, PFLUG ARCH EUR J PHY, V407, P577, DOI 10.1007/BF00582635; MOLDAY RS, 1991, J BIOL CHEM, V266, P21917; VANDERHAEGHEN P, 1993, J CELL BIOL, V123, P1441, DOI 10.1083/jcb.123.6.1441; WARD CR, 1993, DEV BIOL, V158, P9, DOI 10.1006/dbio.1993.1165; ZIMMERMAN AL, 1986, NATURE, V321, P70, DOI 10.1038/321070a0	30	232	243	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	APR 28	1994	368	6474					859	863		10.1038/368859a0	http://dx.doi.org/10.1038/368859a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	NH717	7512693				2022-12-28	WOS:A1994NH71700073
J	GHIARA, JB; STURA, EA; STANFIELD, RL; PROFY, AT; WILSON, IA				GHIARA, JB; STURA, EA; STANFIELD, RL; PROFY, AT; WILSON, IA			CRYSTAL-STRUCTURE OF THE PRINCIPAL NEUTRALIZATION SITE OF HIV-1	SCIENCE			English	Article							IMMUNODEFICIENCY-VIRUS TYPE-1; MOUTH-DISEASE VIRUS; MONOCLONAL-ANTIBODY; V3 DOMAIN; DETERMINANT; GP120; INFECTIVITY; SEQUENCE; PROTEIN; RESOLUTION	The crystal structure of a complex between a 24-amino acid peptide from the third variable (V3) loop of human immunodeficiency virus-type 1 (HIV-1) gp120 and the Fab fragment of a broadly neutralizing antibody (59.1) was determined to 3 angstrom resolution. The tip of the V3 loop containing the Gly-Pro-Gly-Arg-Ala-Phe sequence adopts a double-turn conformation, which may be the basis ot its conservation in many HIV-1 isolates. A complete map of the HIV-1 principal neutralizing determinant was constructed by stitching together structures of V3 loop peptides bound to 59.1 and to an isolate-specific (MN) neutralizing antibody (50.1). Structural conservation of the overlapping epitopes suggests that this biologically relevant conformation could be of use in the design of synthetic vaccines and drugs to inhibit HIV-1 entry and virus-related cellular fusion.	SCRIPPS RES INST, DEPT MOLEC BIOL, LA JOLLA, CA 92037 USA; REPLIGEN CORP, CAMBRIDGE, MA 02139 USA	Scripps Research Institute			Stanfield, Robyn/AAH-3190-2019; Stura, Enrico A./A-2793-2010	Stura, Enrico A./0000-0001-6718-2118; stanfield, robyn/0000-0001-9521-9184	NIGMS NIH HHS [GM-46192] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ACHARYA R, 1989, NATURE, V337, P709, DOI 10.1038/337709a0; BAXT B, 1980, VIROLOGY, V104, P42, DOI 10.1016/0042-6822(80)90364-5; BRUNGER AT, 1990, ACTA CRYSTALLOGR A, V46, P46, DOI 10.1107/S0108767389009633; CALLEBAUT C, 1993, SCIENCE, V262, P2045, DOI 10.1126/science.7903479; CHANDRASEKHAR K, 1991, BIOCHEMISTRY-US, V30, P9187, DOI 10.1021/bi00102a009; COHEN J, 1993, SCIENCE, V262, P1971, DOI 10.1126/science.7903478; CONNOLLY ML, 1983, J APPL CRYSTALLOGR, V16, P548, DOI 10.1107/S0021889883010985; EMINI EA, 1992, NATURE, V355, P728, DOI 10.1038/355728a0; FITZGERALD PMD, 1988, J APPL CRYSTALLOGR, V21, P273, DOI 10.1107/S0021889887012299; FOX G, 1989, J GEN VIROL, V70, P625, DOI 10.1099/0022-1317-70-3-625; FREED EO, 1991, J VIROL, V65, P190, DOI 10.1128/JVI.65.1.190-194.1991; GELIN BR, 1979, BIOCHEMISTRY-US, V18, P1256, DOI 10.1021/bi00574a022; GORNY MK, 1992, J VIROL, V66, P7538, DOI 10.1128/JVI.66.12.7538-7542.1992; GRIMAILA RJ, 1992, J VIROL, V66, P1875, DOI 10.1128/JVI.66.4.1875-1883.1992; HATTORI T, 1989, FEBS LETT, V248, P48, DOI 10.1016/0014-5793(89)80429-6; HELSETH E, 1990, J VIROL, V64, P2416, DOI 10.1128/JVI.64.5.2416-2420.1990; HOWARD AJ, 1987, J APPL CRYSTALLOGR, V20, P383, DOI 10.1107/S0021889887086436; ISOGAI Y, 1980, BIOPOLYMERS, V19, P1183, DOI 10.1002/bip.1980.360190607; IVANOFF LA, 1992, VIROLOGY, V187, P423, DOI 10.1016/0042-6822(92)90444-T; JAVAHERIAN K, 1990, SCIENCE, V250, P1590, DOI 10.1126/science.1703322; JONES TA, 1978, J APPL CRYSTALLOGR, V11, P268, DOI 10.1107/S0021889878013308; JONES TA, 1982, COMPUTATIONAL CRYSTA, P303; Kabat EA, 1991, SEQUENCES PROTEINS I; LAROSA GJ, 1990, SCIENCE, V249, P932, DOI 10.1126/science.2392685; MADDON PJ, 1986, CELL, V47, P333, DOI 10.1016/0092-8674(86)90590-8; Moore J P, 1991, AIDS, V5 Suppl 2, pS21, DOI 10.1097/00002030-199101001-00004; PAGE KA, 1992, J VIROL, V66, P524, DOI 10.1128/JVI.66.1.524-533.1992; Richardson J S, 1981, Adv Protein Chem, V34, P167, DOI 10.1016/S0065-3233(08)60520-3; RINI JM, 1993, P NATL ACAD SCI USA, V90, P6325, DOI 10.1073/pnas.90.13.6325; SATOW Y, 1986, J MOL BIOL, V190, P593, DOI 10.1016/0022-2836(86)90245-7; SHERIFF S, 1987, J MOL BIOL, V197, P273, DOI 10.1016/0022-2836(87)90124-0; SHERIFF S, 1993, IMMUNOMETHODS, V3, P191; SKINNER MA, 1988, J VIROL, V62, P4195, DOI 10.1128/JVI.62.11.4195-4200.1988; STANFIELD RL, 1990, SCIENCE, V248, P712, DOI 10.1126/science.2333521; STANFIELD RL, UNPUB; Stanfield RL., 1993, IMMUNOMETHODS, V3, P211, DOI 10.1006/immu.1993.1055; VERONESE FD, 1993, J BIOL CHEM, V268, P25894; Weiss R. A., 1992, Seminars in Virology, V3, P79; WHITESCHARF ME, 1993, VIROLOGY, V192, P197, DOI 10.1006/viro.1993.1022; WILMOT CM, 1988, J MOL BIOL, V203, P221, DOI 10.1016/0022-2836(88)90103-9; WILMOT CM, 1990, PROTEIN ENG, V3, P479, DOI 10.1093/protein/3.6.479; WILSON IA, 1991, METHOD ENZYMOL, V203, P153; WILSON IA, 1993, CURR OPIN STRUC BIOL, V3, P113, DOI 10.1016/0959-440X(93)90210-C	43	244	254	0	3	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	APR 1	1994	264	5155					82	85		10.1126/science.7511253	http://dx.doi.org/10.1126/science.7511253			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ND536	7511253				2022-12-28	WOS:A1994ND53600034
J	KAMIJO, R; HARADA, H; MATSUYAMA, T; BOSLAND, M; GERECITANO, J; SHAPIRO, D; LE, J; KOH, SI; KIMURA, T; GREEN, SJ; MAK, TW; TANIGUCHI, T; VILCEK, J				KAMIJO, R; HARADA, H; MATSUYAMA, T; BOSLAND, M; GERECITANO, J; SHAPIRO, D; LE, J; KOH, SI; KIMURA, T; GREEN, SJ; MAK, TW; TANIGUCHI, T; VILCEK, J			REQUIREMENT FOR TRANSCRIPTION FACTOR IRF-1 IN NO SYNTHASE INDUCTION IN MACROPHAGES	SCIENCE			English	Article							IFN-INDUCIBLE GENES; DNA-BINDING PROTEIN; NITRIC-OXIDE; BCG INFECTION; MYCOBACTERIUM-TUBERCULOSIS; MURINE MACROPHAGES; INTERFERON-ALPHA; BETA; ACTIVATION; CELLS	Production of nitric oxide (NO) by macrophages is important for the killing of intracellular infectious agents. Interferon (IFN)-gamma and lipopolysaccharide stimulate NO production by transcriptionally up-regulating the inducible NO synthase (iNOS). Macrophages from mice with a targeted disruption of the IFN regulatory factor-1 (IRF-1) gene (IRF-1(-/-) mice) produced little or no NO and synthesized barely detectable iNOS messenger RNA in response to stimulation. Two adjacent IRF-1 response elements were identified in the iNOS promoter. Infection with Mycobacterium bovis (BCG) was more severe in IRF-1(-/-) mice than in wild-type mice. Thus, IRF-1 is essential for iNOS activation in murine macrophages.	NYU MED CTR,DEPT MICROBIOL,NEW YORK,NY 10016; NYU MED CTR,KAPLAN CANC CTR,NEW YORK,NY 10016; OSAKA UNIV,INST MOLEC & CELLULAR BIOL,OSAKA 565,JAPAN; UNIV TORONTO,PRINCESS MARGARET HOSP,ONTARIO CANC INST,DEPT MED BIOPHYS,TORONTO M4X 1K9,ON,CANADA; UNIV TORONTO,PRINCESS MARGARET HOSP,ONTARIO CANC INST,DEPT IMMUNOL,TORONTO M4X 1K9,ON,CANADA; NYU MED CTR,INST ENVIRONM MED,TUXEDO PK,NY 10987; NYU MED CTR,KAPLAN CANC CTR,TUXEDO PK,NY; ENTREMED INC,ROCKVILLE,MD 20850	New York University; New York University; Osaka University; University of Toronto; University Toronto Affiliates; University Health Network Toronto; Princess Margaret Cancer Centre; University of Toronto; University Toronto Affiliates; University Health Network Toronto; Princess Margaret Cancer Centre; New York University; New York University			Harada, Hisashi/H-2815-2019	Harada, Hisashi/0000-0001-5993-1289; le, junming/0000-0003-4726-521X; Green, Shawn J./0000-0003-4361-5454; Kimura, Tohru/0000-0001-9227-0996	NATIONAL CANCER INSTITUTE [P30CA013343, R35CA049731] Funding Source: NIH RePORTER; NCI NIH HHS [R35CA49731, P30CA13343] Funding Source: Medline; PHS HHS [A128993] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		ABDOLLAHI A, 1991, CELL GROWTH DIFFER, V2, P401; BECKERMAN KP, 1993, J IMMUNOL, V150, P888; BEUTLER B, 1986, J EXP MED, V164, P1791, DOI 10.1084/jem.164.5.1791; BLANDEN RV, 1969, J EXP MED, V129, P1079, DOI 10.1084/jem.129.5.1079; CAPUT D, 1986, P NATL ACAD SCI USA, V83, P1670, DOI 10.1073/pnas.83.6.1670; CHAN J, 1992, J EXP MED, V175, P1111, DOI 10.1084/jem.175.4.1111; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; COLIART MA, 1986, J EXP MED, V164, P2113; CROEN KD, 1993, J CLIN INVEST, V91, P2446, DOI 10.1172/JCI116479; DALE TC, 1989, P NATL ACAD SCI USA, V86, P1203, DOI 10.1073/pnas.86.4.1203; DALTON DK, 1993, SCIENCE, V259, P1739, DOI 10.1126/science.8456300; DENG WL, 1993, J IMMUNOL, V151, P322; DING AH, 1988, J IMMUNOL, V141, P2407; DUNGWORTH DL, 1985, PATHOLOGY DOMESTIC A, V2, P413; FLYNN JL, 1992, P NATL ACAD SCI USA, V89, P12013, DOI 10.1073/pnas.89.24.12013; FUJITA T, 1987, CELL, V49, P357, DOI 10.1016/0092-8674(87)90288-1; FUJITA T, 1989, P NATL ACAD SCI USA, V86, P9936, DOI 10.1073/pnas.86.24.9936; FUJITA T, 1989, NATURE, V337, P270, DOI 10.1038/337270a0; GREEN SJ, 1993, INFECT IMMUN, V61, P689, DOI 10.1128/IAI.61.2.689-698.1993; GREEN SJ, 1993, CURR OPIN INFECT DIS, V6, P384; GREEN SJ, 1990, J IMMUNOL, V144, P278; HARADA H, 1990, CELL, V63, P303, DOI 10.1016/0092-8674(90)90163-9; HARADA H, 1989, CELL, V58, P729, DOI 10.1016/0092-8674(89)90107-4; KAMIJO R, 1993, J EXP MED, V178, P1435, DOI 10.1084/jem.178.4.1435; KAMIJO R, UNPUB; KAMLJO R, 1993, P NATL ACAD SCI USA, V90, P6626; KINDLER V, 1989, CELL, V56, P731, DOI 10.1016/0092-8674(89)90676-4; KRUPIAH G, 1993, SCIENCE, V261, P1445; LEVY DE, 1989, GENE DEV, V3, P1362, DOI 10.1101/gad.3.9.1362; LIEW FY, 1991, IMMUNOPARASITOL TOD, pA17, DOI 10.1016/S0167-5699(05)80006-4; LOWENSTEIN CJ, 1992, CELL, V70, P705, DOI 10.1016/0092-8674(92)90301-R; LOWENSTEIN CJ, 1993, P NATL ACAD SCI USA, V90, P9730, DOI 10.1073/pnas.90.20.9730; MATSUYAMA T, 1993, CELL, V75, P83, DOI 10.1016/S0092-8674(05)80086-8; NATHAN C, 1992, FASEB J, V6, P3051, DOI 10.1096/fasebj.6.12.1381691; NATHAN CF, 1991, CURR OPIN IMMUNOL, V3, P65, DOI 10.1016/0952-7915(91)90079-G; PELLETIER M, 1982, J IMMUNOL, V129, P2179; PINE R, 1990, MOL CELL BIOL, V10, P2448, DOI 10.1128/MCB.10.6.2448; REIS LFL, 1992, EMBO J, V11, P185, DOI 10.1002/j.1460-2075.1992.tb05041.x; STUEHR DJ, 1987, J IMMUNOL, V139, P518; TANAKA N, 1993, MOL CELL BIOL, V13, P4531, DOI 10.1128/MCB.13.8.4531; VODOVOTZ Y, 1993, J EXP MED, V178, P605, DOI 10.1084/jem.178.2.605; WATANABE N, 1991, NUCLEIC ACIDS RES, V19, P4421, DOI 10.1093/nar/19.16.4421; XIE QW, 1992, SCIENCE, V256, P225, DOI 10.1126/science.1373522; XIE QW, 1993, J EXP MED, V177, P1779, DOI 10.1084/jem.177.6.1779	45	776	796	1	20	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAR 18	1994	263	5153					1612	1615		10.1126/science.7510419	http://dx.doi.org/10.1126/science.7510419			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	NB673	7510419				2022-12-28	WOS:A1994NB67300032
J	PRAGNELL, M; DEWAARD, M; MORI, Y; TANABE, T; SNUTCH, TP; CAMPBELL, KP				PRAGNELL, M; DEWAARD, M; MORI, Y; TANABE, T; SNUTCH, TP; CAMPBELL, KP			CALCIUM-CHANNEL BETA-SUBUNIT BINDS TO A CONSERVED MOTIF IN THE I-II CYTOPLASMIC LINKER OF THE ALPHA(1)-SUBUNIT	NATURE			English	Article							FUNCTIONAL EXPRESSION; SKELETAL-MUSCLE; MOLECULAR-CLONING; ALPHA-1 SUBUNIT; ALPHA-1-SUBUNIT; ALPHA-2-SUBUNIT	THE beta-subunit is an integral component of purified voltage-sensitive Ca2+ channels(1-3). Modulation of Ca2+ channel activity by the beta-subunit, which includes significant increases in transmembrane current and/or changes in kinetics, is observed on coexpression of six alpha(1)-subunit genes with four beta-subunit genes in all alpha(1)-beta combinations tested(4-12). Recent reports suggest that this regulation is not due to targeting of the alpha(1)-subunit to the plasma membrane but is probably a result of a conformational change induced by the beta-subunit(11,13). Here we report that the beta-subunit binds to the cytoplasmic linker between repeats I and II of the dihydropyridine-sensitive alpha(1)-subunits from skeletal (alpha(1S)) and cardiac muscles (alpha(1C-a)), and also with the more distantly related neuronal alpha(1A) and omega-conotoxin GVIA-sensitive alpha 1B-subunits. Sequence analysis of the beta-subunit binding site identifies a conserved motif (QQ-E--L-GY--WI---E) positioned 24 amino acids from the IS6 transmembrane domain in each alpha(1)-subunit. Mutations within this motif reduce the stimulation of peak currents by the beta-subunit and alter inactivation kinetics and voltage-dependence of activation. Conservation of the beta-subunit binding motif in these functonally distinct calcium channels suggests a critical role for the I-II cytoplasmic linker of the alpha(1)-subunit in channel modulation by the beta-subunit.	UNIV IOWA,COLL MED,PROGRAM NEUROSCI,IOWA CITY,IA 52242; KYOTO UNIV,DEPT MED CHEM,KYOTO 606,JAPAN; YALE UNIV,HOWARD HUGHES MED INST,DEPT CELLULAR & MOLEC PHYSIOL,NEW HAVEN,CT 06536; UNIV BRITISH COLUMBIA,BIOTECHNOL LAB,VANCOUVER V6T 1Z3,BC,CANADA; UNIV BRITISH COLUMBIA,DEPT ZOOL,VANCOUVER V6T 1Z3,BC,CANADA; UNIV BRITISH COLUMBIA,DEPT NEUROSCI,VANCOUVER V6T 1Z3,BC,CANADA	University of Iowa; Kyoto University; Howard Hughes Medical Institute; Yale University; University of British Columbia; University of British Columbia; University of British Columbia	PRAGNELL, M (corresponding author), UNIV IOWA,COLL MED,HOWARD HUGHES MED INST,DEPT PHYSIOL & BIOPHYS,400 EMRB,IOWA CITY,IA 52242, USA.		De Waard, Michel/G-7406-2014; Snutch, Terrance P/L-3464-2019; Tuluc, Petronel/C-2527-2011	De Waard, Michel/0000-0002-2782-9615; Snutch, Terrance P/0000-0001-5182-1296; Campbell, Kevin/0000-0003-2066-5889				ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; BIEL M, 1990, FEBS LETT, V269, P409, DOI 10.1016/0014-5793(90)81205-3; CAMPBELL KP, 1988, TRENDS NEUROSCI, V11, P425, DOI 10.1016/0166-2236(88)90193-2; CASTELLANO A, 1993, J BIOL CHEM, V268, P12359; CASTELLANO A, 1993, J BIOL CHEM, V268, P3450; CATTERALL WA, 1988, J BIOL CHEM, V263, P3535; DUBEL SJ, 1992, P NATL ACAD SCI USA, V89, P5058, DOI 10.1073/pnas.89.11.5058; ELLIS SB, 1988, SCIENCE, V241, P1661, DOI 10.1126/science.2458626; GRABNER M, 1991, P NATL ACAD SCI USA, V88, P727, DOI 10.1073/pnas.88.3.727; HORNE WA, 1993, P NATL ACAD SCI USA, V90, P3787, DOI 10.1073/pnas.90.9.3787; HUI A, 1991, NEURON, V7, P35, DOI 10.1016/0896-6273(91)90072-8; LACERDA AE, 1991, NATURE, V352, P527, DOI 10.1038/352527a0; LEUNG AT, 1987, J BIOL CHEM, V262, P7943; MARCHUK D, 1991, NUCLEIC ACIDS RES, V19, P1154, DOI 10.1093/nar/19.5.1154; MORI Y, 1991, NATURE, V350, P398, DOI 10.1038/350398a0; NEELY A, 1993, SCIENCE, V262, P575, DOI 10.1126/science.8211185; NISHIMURA S, 1993, FEBS LETT, V324, P283, DOI 10.1016/0014-5793(93)80135-H; PEREZREYES E, 1992, J BIOL CHEM, V267, P1792; PRAGNELL M, 1991, FEBS LETT, V291, P253, DOI 10.1016/0014-5793(91)81296-K; SOONG TW, 1993, SCIENCE, V260, P1133, DOI 10.1126/science.8388125; STEA A, 1993, NEUROPHARMACOLOGY, V32, P1103, DOI 10.1016/0028-3908(93)90005-N; WILLIAMS ME, 1992, NEURON, V8, P71, DOI 10.1016/0896-6273(92)90109-Q; WITCHER DR, 1993, SCIENCE, V261, P486, DOI 10.1126/science.8392754	23	532	551	0	18	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	MAR 3	1994	368	6466					67	70		10.1038/368067a0	http://dx.doi.org/10.1038/368067a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	MY569	7509046				2022-12-28	WOS:A1994MY56900055
J	FRANKS, NP; LIEB, WR				FRANKS, NP; LIEB, WR			MOLECULAR AND CELLULAR MECHANISMS OF GENERAL-ANESTHESIA	NATURE			English	Review							NICOTINIC ACETYLCHOLINE-RECEPTOR; RAT HIPPOCAMPAL-NEURONS; INHIBITORY POSTSYNAPTIC CURRENTS; AMINOBUTYRIC ACID(A) RECEPTORS; ANESTHETIC TARGET SITES; GH3 PITUITARY-CELLS; VOLATILE ANESTHETICS; XENOPUS OOCYTES; OPTICAL ISOMERS; CALCIUM CURRENT	General anaesthetics are much more selective than Is usually appreciated and may act by binding to only a small number of targets in the central nervous system. At surgical concentrations their principal effects are on ligand;gated (rather than voltage-gated) ion channels, with potentiation of postsynaptic inhibitory channel activity best fitting the pharmacological profile observed in general anaesthesia. Although the role of second messengers remains uncertain, it is now clear that anaesthetics act directly on proteins rather than on lipids.			FRANKS, NP (corresponding author), IMPERIAL COLL SCI TECHNOL & MED, BLACKETT LAB, BIOPHYS SECT, PRINCE CONSORT RD, LONDON SW7 2BZ, ENGLAND.			Franks, Nicholas/0000-0003-4874-4212				ABADJI VC, 1993, BIOCHIM BIOPHYS ACTA, V1147, P143, DOI 10.1016/0005-2736(93)90325-T; ABRAHAM MH, 1991, J PHARM SCI-US, V80, P719, DOI 10.1002/jps.2600800802; ADAM HK, 1983, BRIT J ANAESTH, V55, P97, DOI 10.1093/bja/55.2.97; AKESON MA, 1989, BIOCHEMISTRY-US, V28, P5120, DOI 10.1021/bi00438a032; ALIFIMOFF JK, 1989, BRIT J PHARMACOL, V96, P9, DOI 10.1111/j.1476-5381.1989.tb11777.x; ANDREWS PR, 1982, ANESTHESIOLOGY, V57, P314, DOI 10.1097/00000542-198210000-00014; ANIS NA, 1983, BRIT J PHARMACOL, V79, P565, DOI 10.1111/j.1476-5381.1983.tb11031.x; ARIMURA H, 1986, BRIT J PHARMACOL, V89, P573, DOI 10.1111/j.1476-5381.1986.tb11158.x; BANGHAM AD, 1980, ANESTHESIOLOGY, V53, P135, DOI 10.1097/00000542-198008000-00007; BAZIL CW, 1989, J PHARMACOL EXP THER, V248, P143; BAZIL CW, 1989, J NEUROCHEM, V53, P962, DOI 10.1111/j.1471-4159.1989.tb11799.x; BECKER KE, 1978, ANESTHESIOLOGY, V49, P192, DOI 10.1097/00000542-197809000-00008; BECKER KE, 1977, RES COMMUN CHEM PATH, V18, P23; BOWSERRILEY F, 1988, BRIT J PHARMACOL, V94, P1069, DOI 10.1111/j.1476-5381.1988.tb11624.x; BRADLEY RJ, 1984, BRAIN RES, V295, P101, DOI 10.1016/0006-8993(84)90820-5; BROCKERHOFF H, 1990, NEUROCHEM INT, V17, P15, DOI 10.1016/0197-0186(90)90062-X; BURCH PG, 1983, ANESTHESIOLOGY, V58, P146, DOI 10.1097/00000542-198302000-00008; CHIOU JS, 1992, BIOCHIM BIOPHYS ACTA, V1110, P225, DOI 10.1016/0005-2736(92)90363-Q; COCKSHOTT ID, 1992, XENOBIOTICA, V22, P369, DOI 10.3109/00498259209046648; COLLINS GGS, 1980, BRAIN RES, V190, P517, DOI 10.1016/0006-8993(80)90293-0; COOK CE, 1987, J PHARMACOL EXP THER, V241, P779; COTTRELL GA, 1987, BRIT J PHARMACOL, V90, P491, DOI 10.1111/j.1476-5381.1987.tb11198.x; CURRY S, 1990, BIOCHEMISTRY-US, V29, P4641, DOI 10.1021/bi00471a020; DANIELL LC, 1988, J PHARMACOL EXP THER, V245, P1; DESHMUKH DS, 1989, NEUROPHARMACOLOGY, V28, P1317, DOI 10.1016/0028-3908(89)90005-1; DICKINSON R, 1993, BIOPHYS J, V64, P1264, DOI 10.1016/S0006-3495(93)81491-7; DILDYMAYFIELD JE, 1992, J PHARMACOL EXP THER, V262, P487; DILGER JP, 1992, MOL PHARMACOL, V41, P127; DODSON BA, 1990, BRIT J PHARMACOL, V101, P710, DOI 10.1111/j.1476-5381.1990.tb14145.x; DOLIN SJ, 1986, BRIT J PHARMACOL, V88, P909, DOI 10.1111/j.1476-5381.1986.tb16265.x; EHRNEBO M, 1977, EUR J CLIN PHARMACOL, V11, P37, DOI 10.1007/BF00561786; ELBEHEIRY H, 1989, EXP BRAIN RES, V77, P87; ELLIOTT JR, 1989, BIOCHIM BIOPHYS ACTA, V988, P257, DOI 10.1016/0304-4157(89)90021-X; ELMAGHRABI EA, 1992, P NATL ACAD SCI USA, V89, P4329, DOI 10.1073/pnas.89.10.4329; FIRESTONE LL, 1986, ANESTHESIOLOGY, V64, P694, DOI 10.1097/00000542-198606000-00004; FRANKS NP, 1987, TRENDS PHARMACOL SCI, V8, P169, DOI 10.1016/0165-6147(87)90160-X; FRANKS NP, 1986, P NATL ACAD SCI USA, V83, P5116, DOI 10.1073/pnas.83.14.5116; FRANKS NP, 1982, NATURE, V300, P487, DOI 10.1038/300487a0; FRANKS NP, 1985, NATURE, V316, P349, DOI 10.1038/316349a0; FRANKS NP, 1993, BRIT J ANAESTH, V71, P65, DOI 10.1093/bja/71.1.65; FRANKS NP, 1991, SCIENCE, V254, P427, DOI 10.1126/science.1925602; FRANKS NP, 1988, NATURE, V333, P662, DOI 10.1038/333662a0; FRANKS NP, 1991, ANN NY ACAD SCI, V625, P54, DOI 10.1111/j.1749-6632.1991.tb33829.x; FRANKS NP, 1984, NATURE, V310, P599, DOI 10.1038/310599a0; FUJIWARA N, 1988, J PHYSIOL-LONDON, V402, P155, DOI 10.1113/jphysiol.1988.sp017198; GAGE PW, 1985, BRIT J PHARMACOL, V85, P229, DOI 10.1111/j.1476-5381.1985.tb08851.x; GAGE PW, 1985, BRIT J PHARMACOL, V85, P675, DOI 10.1111/j.1476-5381.1985.tb10563.x; GRUNER SM, 1991, ANN NY ACAD SCI, V625, P685, DOI 10.1111/j.1749-6632.1991.tb33902.x; GUNDERSEN CB, 1988, J PHARMACOL EXP THER, V247, P824; HALES TG, 1991, BRIT J PHARMACOL, V104, P619, DOI 10.1111/j.1476-5381.1991.tb12479.x; HARRIS B, 1992, EUR J PHARMACOL, V217, P215, DOI 10.1016/0014-2999(92)90875-5; HARRISON NL, 1987, J NEUROSCI, V7, P604; HASINOFF BB, 1989, BIOCHEM J, V258, P101, DOI 10.1042/bj2580101; HAYDON DA, 1986, J PHYSIOL-LONDON, V373, P311, DOI 10.1113/jphysiol.1986.sp016049; HERRINGTON J, 1991, J NEUROSCI, V11, P2226; HITZEMANN RJ, 1989, BIOCHIM BIOPHYS ACTA, V983, P205, DOI 10.1016/0005-2736(89)90235-6; HUANG LYM, 1980, SCIENCE, V207, P195, DOI 10.1126/science.7350656; HUNG OR, 1992, ANESTHESIOLOGY, V77, P237, DOI 10.1097/00000542-199208000-00003; JANES N, 1992, BIOCHEMISTRY-US, V31, P9467, DOI 10.1021/bi00154a020; JANOFF AS, 1981, BIOCHIM BIOPHYS ACTA, V649, P125, DOI 10.1016/0005-2736(81)90017-1; JONES MV, 1993, J NEUROPHYSIOL, V70, P1339, DOI 10.1152/jn.1993.70.4.1339; JONES MV, 1992, J PHYSIOL-LONDON, V449, P279, DOI 10.1113/jphysiol.1992.sp019086; JONG RHD, 1975, ANESTHESIOLOGY, V42, P384, DOI 10.1097/00000542-197504000-00003; KENDALL TJG, 1982, BRIT J PHARMACOL, V75, P219, DOI 10.1111/j.1476-5381.1982.tb08776.x; KENDIG JJ, 1993, EFFECTS HIGH PRESSUR; KISSIN I, 1983, ANESTHESIOLOGY, V58, P88, DOI 10.1097/00000542-198301000-00012; KLEMM WR, 1990, ALCOHOL, V7, P49, DOI 10.1016/0741-8329(90)90060-P; KRESS HG, 1991, ANESTHESIOLOGY, V74, P309, DOI 10.1097/00000542-199102000-00018; KRNJEVIC K, 1988, CAN J PHYSIOL PHARM, V66, P1570, DOI 10.1139/y88-257; KULLMANN DM, 1989, J PHYSIOL-LONDON, V412, P277, DOI 10.1113/jphysiol.1989.sp017615; LABELLA FS, 1993, CAN J PHYSIOL PHARM, V71, P48, DOI 10.1139/y93-007; LAMBERT JJ, 1990, CIBA F SYMP, V153, P56; LIN LH, 1992, J PHARMACOL EXP THER, V263, P569; LIN LH, 1993, J NEUROCHEM, V60, P1548, DOI 10.1111/j.1471-4159.1993.tb03320.x; LIU J, 1993, ANESTH ANALG, V77, P12; LODGE D, 1982, NEUROSCI LETT, V29, P281, DOI 10.1016/0304-3940(82)90330-5; LOVINGER DM, 1989, SCIENCE, V243, P1721, DOI 10.1126/science.2467382; LYON RC, 1981, J PHARMACOL EXP THER, V218, P669; MACDONALD RL, 1989, J PHYSIOL-LONDON, V417, P483, DOI 10.1113/jphysiol.1989.sp017814; MACIVER MB, 1991, ANN NY ACAD SCI, V625, P91, DOI 10.1111/j.1749-6632.1991.tb33832.x; MARSZALEC W, 1993, BRAIN RES, V608, P7, DOI 10.1016/0006-8993(93)90766-G; MAZE M, 1983, ANESTHESIOLOGY, V59, P327, DOI 10.1097/00000542-198310000-00010; MCFARLANE C, 1992, ANESTHESIOLOGY, V77, P1165, DOI 10.1097/00000542-199212000-00018; MILLER KW, 1989, P NATL ACAD SCI USA, V86, P1084, DOI 10.1073/pnas.86.3.1084; MINCHIN MCW, 1981, BRIT J PHARMACOL, V73, P681, DOI 10.1111/j.1476-5381.1981.tb16803.x; MORGAN WW, 1984, NEUROPHARMACOLOGY, V23, P773, DOI 10.1016/0028-3908(84)90110-2; MOSS GWJ, 1991, BIOPHYS J, V60, P1309, DOI 10.1016/S0006-3495(91)82168-3; MOSS GWJ, 1991, P NATL ACAD SCI USA, V88, P134, DOI 10.1073/pnas.88.1.134; MURRELL RD, 1991, J PHYSIOL-LONDON, V437, P431, DOI 10.1113/jphysiol.1991.sp018604; NAKAHIRO M, 1991, J PHARMACOL EXP THER, V259, P235; NAKAHIRO M, 1989, FASEB J, V3, P1850, DOI 10.1096/fasebj.3.7.2541038; NISHI K, 1983, BRIT J PHARMACOL, V79, P645, DOI 10.1111/j.1476-5381.1983.tb10001.x; PARKER I, 1986, J NEUROSCI, V6, P2290; POCOCK G, 1988, BRIT J PHARMACOL, V95, P209, DOI 10.1111/j.1476-5381.1988.tb16566.x; PRINGLE MJ, 1981, MOL PHARMACOL, V19, P49; PUIL E, 1990, J PHARMACOL EXP THER, V255, P955; RAINES DE, 1993, ANESTHESIOLOGY, V78, P918, DOI 10.1097/00000542-199305000-00017; RAMPIL IJ, 1993, ANESTHESIOLOGY, V78, P707, DOI 10.1097/00000542-199304000-00014; RAYMOND SA, 1991, ANN NY ACAD SCI, V625, P307, DOI 10.1111/j.1749-6632.1991.tb33857.x; RICHTER JA, 1982, PROG NEUROBIOL, V18, P275, DOI 10.1016/0301-0082(82)90013-2; ROBINSONWHITE AJ, 1990, ANESTHESIOLOGY, V72, P996, DOI 10.1097/00000542-199006000-00009; ROTH SH, 1989, MOL PHARMACOL, V36, P874; RYDER S, 1978, EUR J PHARMACOL, V49, P15, DOI 10.1016/0014-2999(78)90217-0; SAINT DA, 1992, BRIT J PHARMACOL, V107, P895, DOI 10.1111/j.1476-5381.1992.tb14543.x; SANDORFY C, 1990, Spectroscopy (Amsterdam), V8, P1; SAPP DW, 1992, J PHARMACOL EXP THER, V262, P801; SCHELLER MS, 1989, NEUROPHARMACOLOGY, V28, P677, DOI 10.1016/0028-3908(89)90150-0; SCHOLFIELD CN, 1980, PFLUG ARCH EUR J PHY, V383, P249, DOI 10.1007/BF00587527; SCHROEDER F, 1988, BIOCHIM BIOPHYS ACTA, V946, P85, DOI 10.1016/0005-2736(88)90460-9; SEGAL IS, 1988, ANESTHESIOLOGY, V69, P818, DOI 10.1097/00000542-198812000-00004; SERVIN F, 1988, ANESTHESIOLOGY, V69, P887, DOI 10.1097/00000542-198812000-00014; SILL JC, 1991, MOL PHARMACOL, V40, P1006; SLATER SJ, 1993, NATURE, V364, P82, DOI 10.1038/364082a0; SMITH EB, 1984, NATURE, V311, P56, DOI 10.1038/311056a0; STERN RC, 1991, J NEUROSCI, V11, P2217; TAKAHASHI T, 1993, NATURE, V366, P156, DOI 10.1038/366156a0; TAKENOSHITA M, 1991, J NEUROSCI, V11, P1404; TAKENOSHITA M, 1987, BRAIN RES, V402, P303, DOI 10.1016/0006-8993(87)90037-0; TINKLENBERG JA, 1991, ANN NY ACAD SCI, V625, P532, DOI 10.1111/j.1749-6632.1991.tb33884.x; TORDA TA, 1977, BRIT J ANAESTH, V49, P771, DOI 10.1093/bja/49.8.771; WAFFORD KA, 1991, NEURON, V7, P27, DOI 10.1016/0896-6273(91)90071-7; WAHLSTROM G, 1970, ACTA PHARMACOL TOX, V28, P493; WAKAMORI M, 1991, J NEUROPHYSIOL, V66, P2014, DOI 10.1152/jn.1991.66.6.2014; WANN KT, 1988, PROG NEUROBIOL, V30, P271, DOI 10.1016/0301-0082(88)90025-1; WERZ MA, 1985, MOL PHARMACOL, V28, P269; WHITE PF, 1985, BRIT J ANAESTH, V57, P197, DOI 10.1093/bja/57.2.197; WOOD SC, 1991, MOL PHARMACOL, V39, P332; YEH JZ, 1991, ANN NY ACAD SCI, V625, P155, DOI 10.1111/j.1749-6632.1991.tb33839.x; ZEILHOFER HU, 1992, EUR J PHARMACOL, V213, P155	129	1553	1611	2	123	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	FEB 17	1994	367	6464					607	614		10.1038/367607a0	http://dx.doi.org/10.1038/367607a0			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	MW688	7509043				2022-12-28	WOS:A1994MW68800043
J	YOUNG, ACM; ZHANG, WG; SACCHETTINI, JC; NATHENSON, SG				YOUNG, ACM; ZHANG, WG; SACCHETTINI, JC; NATHENSON, SG			THE 3-DIMENSIONAL STRUCTURE OF H-2D(B) AT 2.4 ANGSTROM RESOLUTION - IMPLICATIONS FOR ANTIGEN-DETERMINANT SELECTION	CELL			English	Article							MAJOR HISTOCOMPATIBILITY COMPLEX; CLASS-I MOLECULES; TOXIC LYMPHOCYTES-T; INFLUENZA NUCLEOPROTEIN; SELF-PEPTIDES; TRANSPLANTATION ANTIGENS; SYNTHETIC PEPTIDES; BINDING MOTIF; SIDE-CHAINS; MHC	Solution at 2.4 angstrom resolution of the structure of H-2D(b) with the influenza virus peptide NP366-374 (ASNENMETM) and comparison with the H-2K(b)-VSV (RGYVYQGL) structure allow description of the molecular details of MHC class I peptide binding interactions for mice of the H-2b haplotype, revealing a strategy that maximizes the repertoire of peptides that can be presented. The H-2D(b) cleft has a mouse-specific hydrophobic ridge that causes a compensatory arch in the backbone of the peptide, exposing the arch residues to TCR contact and requiring the peptide to be at least 9 residues. This ridge occurs in about 40% of the known murine D and L allelic molecules, classifying them as a structural subgroup.	YESHIVA UNIV ALBERT EINSTEIN COLL MED,DEPT BIOCHEM,BRONX,NY 10461; YESHIVA UNIV ALBERT EINSTEIN COLL MED,DEPT MICROBIOL & IMMUNOL,BRONX,NY 10461; YESHIVA UNIV ALBERT EINSTEIN COLL MED,DEPT CELL BIOL,BRONX,NY 10461	Yeshiva University; Albert Einstein College of Medicine; Yeshiva University; Albert Einstein College of Medicine; Yeshiva University; Albert Einstein College of Medicine					NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R56AI007289, R37AI007289, R01AI007289] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM045859] Funding Source: NIH RePORTER; NIAID NIH HHS [AI-10792, AI-07289] Funding Source: Medline; NIGMS NIH HHS [GM45859] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BASTIN J, 1987, J EXP MED, V165, P1508, DOI 10.1084/jem.165.6.1508; BJORKMAN PJ, 1990, ANNU REV BIOCHEM, V59, P253, DOI 10.1146/annurev.bi.59.070190.001345; BJORKMAN PJ, 1987, NATURE, V329, P506, DOI 10.1038/329506a0; BJORKMAN PJ, 1987, NATURE, V329, P512, DOI 10.1038/329512a0; BOYD LF, 1992, IMMUNOLOGY, V89, P2242; BRUNGER AT, 1987, SCIENCE, V235, P458, DOI 10.1126/science.235.4787.458; CONNOLLY JM, 1990, P NATL ACAD SCI USA, V87, P2137, DOI 10.1073/pnas.87.6.2137; CORR M, 1992, J EXP MED, V176, P1681, DOI 10.1084/jem.176.6.1681; FALK K, 1990, NATURE, V348, P248, DOI 10.1038/348248a0; FALK K, 1991, J EXP MED, V174, P425, DOI 10.1084/jem.174.2.425; FALK K, 1991, NATURE, V351, P290, DOI 10.1038/351290a0; FREMONT DH, 1992, SCIENCE, V257, P919, DOI 10.1126/science.1323877; GARRETT TPJ, 1989, NATURE, V342, P692, DOI 10.1038/342692a0; GUO HC, 1992, NATURE, V360, P364, DOI 10.1038/360364a0; HUNT DF, 1992, SCIENCE, V255, P1261, DOI 10.1126/science.1546328; JANCARIK J, 1991, J APPL CRYSTALLOGR, V24, P409, DOI 10.1107/S0021889891004430; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; MADDEN DR, 1991, NATURE, V353, P321, DOI 10.1038/353321a0; MADDEN DR, 1992, CELL, V70, P1035, DOI 10.1016/0092-8674(92)90252-8; MARYANSKI JL, 1989, COLD SH Q B, V54, P545; MARYANSKI JL, 1990, CELL, V60, P63, DOI 10.1016/0092-8674(90)90716-R; MATSUMURA M, 1992, SCIENCE, V257, P927, DOI 10.1126/science.1323878; NATHENSON SG, 1981, ANNU REV BIOCHEM, V50, P1025, DOI 10.1146/annurev.bi.50.070181.005113; OTTEN GR, 1992, J IMMUNOL, V148, P3723; POTTEN JK, 1992, I IMMUNOLOGY, V148, P953; PULLEN JK, 1992, J IMMUNOL, V148, P953; ROMERO P, 1991, J EXP MED, V174, P603, DOI 10.1084/jem.174.3.603; SALTER RD, 1989, NATURE, V338, P345, DOI 10.1038/338345a0; SAPER MA, 1991, J MOL BIOL, V219, P227; SHIBATA K, 1992, P NATL ACAD SCI USA, V89, P3135, DOI 10.1073/pnas.89.7.3135; SILVER ML, 1992, NATURE, V360, P367, DOI 10.1038/360367a0; TOWNSEND ARM, 1986, CELL, V44, P959, DOI 10.1016/0092-8674(86)90019-X; TOWNSEND ARM, 1985, CELL, V42, P457, DOI 10.1016/0092-8674(85)90103-5; TRONRUD DE, 1987, ACTA CRYSTALLOGR A, V43, P489, DOI 10.1107/S0108767387099124; TROWSDALE J, 1992, EUR J IMMUNOGENET, V19, P45; VANBLEEK GM, 1991, P NATL ACAD SCI USA, V88, P11032, DOI 10.1073/pnas.88.24.11032; VANBLEEK GM, 1990, NATURE, V348, P213; ZHANG WG, 1992, P NATL ACAD SCI USA, V89, P8403, DOI 10.1073/pnas.89.17.8403; Zinkernagel R M, 1979, Adv Immunol, V27, P51, DOI 10.1016/S0065-2776(08)60262-X	39	244	249	0	5	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	JAN 14	1994	76	1					39	50		10.1016/0092-8674(94)90171-6	http://dx.doi.org/10.1016/0092-8674(94)90171-6			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	MR495	7506996				2022-12-28	WOS:A1994MR49500005
J	MANNUCCI, PM; GDOVIN, S; GRINGERI, A; COLOMBO, M; MELE, A; SCHINAIA, N; CIAVARELLA, N; EMERSON, SU; PURCELL, RH				MANNUCCI, PM; GDOVIN, S; GRINGERI, A; COLOMBO, M; MELE, A; SCHINAIA, N; CIAVARELLA, N; EMERSON, SU; PURCELL, RH			TRANSMISSION OF HEPATITIS-A TO PATIENTS WITH HEMOPHILIA BY FACTOR-VIII CONCENTRATES TREATED WITH ORGANIC-SOLVENT AND DETERGENT TO INACTIVATE VIRUSES	ANNALS OF INTERNAL MEDICINE			English	Article							COMPLETE NUCLEOTIDE-SEQUENCE; EPIDEMIOLOGY; STRAINS; RNA; PCR	Objective: To determine whether an outbreak of hepatitis A virus (HAV) infection that occurred in 52 patients with hemophilia in Italy was acquired through infusion of contaminated factor VIII or through environmental enteric transmission. Design: A case-control study and a molecular analysis of HAV sequences from implicated lots of factor VIII and from infected patients. Patients: The first 29 patients with hemophilia and jaundice in whom hepatitis A developed were compared with one to three matched controls with hemophilia but no jaundice. Measurements: Type of concentrate and batches infused, number of doses, contacts with persons who had jaundice or hepatitis A, travel abroad to countries reported to have a high attack rate for hepatitis A, and consumption of raw shellfish. Hepatitis A viral sequences sought by polymerase chain reaction in lots of factor VIII and in serial serum samples from two patients with hemophilia in whom hepatitis A developed. Amplification by polymerase chain reaction of cDNA transcribed with reverse transcriptase from matched sets of factor VIII and recipient serum samples. Determination of nucleotide sequence of amplified hepatitis A virus genome. Main Results: Case patients were neither more nor less likely than controls to have traveled to high-risk countries, consumed raw shellfish, or had contact with persons with jaundice. Case patients were more likely than controls to have received a factor VIII concentrate treated with a solvent-detergent mixture to inactivate viruses (odds ratio, infinity; 95% CI, 4.5 to infinity) and to have had larger infusions of the concentrate during the presumed HAV incubation period (odds ratio, 8.54; CI, 2.78 to 27.5). Hepatitis A viral sequences were found in 5 of 12 tested lots of factor VIII. Genomic sequences of HAV obtained for two matched sets of factor VIII and recipient serum samples were identical within each set but different for the two sets. Conclusion: Hepatitis A was transmitted by a factor VIII concentrate treated by a virucidal method (solvent-detergent) that ineffectively inactivates nonenveloped viruses.							NIAID NIH HHS [N01-AI-05069] Funding Source: Medline	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		AZZI A, 1992, AM J HEMATOL, V39, P228, DOI 10.1002/ajh.2830390315; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; COHEN JI, 1987, P NATL ACAD SCI USA, V84, P2497, DOI 10.1073/pnas.84.8.2497; COHEN JI, 1987, J VIROL, V61, P50, DOI 10.1128/JVI.61.1.50-59.1987; FROSNER GG, 1979, AM J EPIDEMIOL, V110, P63; GERRITZEN A, 1992, LANCET, V340, P1231, DOI 10.1016/0140-6736(92)92937-B; HIJIKATA M, 1993, J VIROL, V67, P1953, DOI 10.1128/JVI.67.4.1953-1958.1993; HOROWITZ B, 1985, TRANSFUSION, V25, P516, DOI 10.1046/j.1537-2995.1985.25686071422.x; JANSEN RW, 1990, P NATL ACAD SCI USA, V87, P2867, DOI 10.1073/pnas.87.8.2867; KREUZ W, 1993, LANCET, V341, P446, DOI 10.1016/0140-6736(93)93050-B; KWOK S, 1989, NATURE, V339, P237, DOI 10.1038/339237a0; MANNUCCI PM, 1992, LANCET, V339, P819, DOI 10.1016/0140-6736(92)91955-8; MELE A, 1991, ITAL J GASTROENTEROL, V23, P341; NORMANN A, 1992, LANCET, V340, P1232, DOI 10.1016/0140-6736(92)92938-C; PEERLINCK K, 1993, LANCET, V341, P179, DOI 10.1016/0140-6736(93)90044-H; PURCELL RH, 1984, VIRAL HEPATITIS LIVE, P9; Sambrook J, 1989, MOL CLONING LABORATO; SCHWINN H, 1989, ARZNEIMITTEL-FORSCH, V39-2, P1302; SHERERTZ RJ, 1984, ARCH INTERN MED, V144, P1579, DOI 10.1001/archinte.144.8.1579; TEMPERLEY IJ, 1992, LANCET, V340, P1466; THOMAS DG, 1975, COMPUT BIOMED RES, V8, P423, DOI 10.1016/0010-4809(75)90048-8; TSAREV SA, 1993, J INFECT DIS, V168, P369, DOI 10.1093/infdis/168.2.369; TSAREV SA, 1991, J GEN VIROL, V72, P1677, DOI 10.1099/0022-1317-72-7-1677; WINSHIP PR, 1989, NUCLEIC ACIDS RES, V17, P1266, DOI 10.1093/nar/17.3.1266; 1992, LANCET, V339, P1198	25	176	180	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JAN 1	1994	120	1					1	7		10.7326/0003-4819-120-1-199401010-00001	http://dx.doi.org/10.7326/0003-4819-120-1-199401010-00001			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MP280	7504424				2022-12-28	WOS:A1994MP28000001
J	ASCH, AS; LIU, I; BRICCETTI, FM; BARNWELL, JW; KWAKYEBERKO, F; DOKUN, A; GOLDBERGER, J; PERNAMBUCO, M				ASCH, AS; LIU, I; BRICCETTI, FM; BARNWELL, JW; KWAKYEBERKO, F; DOKUN, A; GOLDBERGER, J; PERNAMBUCO, M			ANALYSIS OF CD36 BINDING DOMAINS - LIGAND SPECIFICITY CONTROLLED BY DEPHOSPHORYLATION OF AN ECTODOMAIN	SCIENCE			English	Article							PLATELET MEMBRANE GLYCOPROTEIN; FALCIPARUM-INFECTED ERYTHROCYTES; CIRCUMSPOROZOITE PROTEIN; IIB-IIIA; IV CD36; THROMBOSPONDIN; RECEPTOR; COLLAGEN; PHOSPHORYLATION; ADHESION	The protein CD36 is a membrane receptor for thrombospondin (TSP), malaria-infected erythrocytes, and collagen. Three functional sequences were identified within a single disulfide loop of CD36: one that mediates TSP binding (amino acids 87 to 99) and two that support malarial cytoadhesion (amino acids 8 to 21 and 97 to 110). One of these peptides (p87-99) is a consensus protein kinase C (PKC) phosphorylation site. Dephosphorylation of constitutively phosphorylated CD36 in resting platelets and a megakaryocytic cell line led to the loss of collagen adhesion and platelet reactivity to collagen, with a reciprocal increase in TSP binding. PKC-mediated phosphorylation of this ectodomain resulted in a loss of TSP binding and the reciprocal acquisition of collagen binding. In site-directed mutagenesis studies, when the threonine phosphorylation site was changed to alanine, CD36 was expressed in a dephosphorylated state and bound to TSP constitutively.	NYU,SCH MED,DEPT MOLEC PARASITOL,NEW YORK,NY 10010	New York University	ASCH, AS (corresponding author), CORNELL UNIV,MED CTR,COLL MED,DIV HEMATOL ONCOL,NEW YORK,NY 10021, USA.				NHLBI NIH HHS [HL18828, HL44389, HL02541] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL044389, P50HL018828] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ASCH A, UNPUB; ASCH AS, 1992, BIOCHEM BIOPH RES CO, V182, P1208, DOI 10.1016/0006-291X(92)91860-S; ASCH AS, 1987, J CLIN INVEST, V79, P1054, DOI 10.1172/JCI112918; BARNWELL JW, 1985, J IMMUNOL, V135, P3494; BARNWELL JW, 1989, J CLIN INVEST, V84, P765, DOI 10.1172/JCI114234; CERAMI C, 1992, CELL, V70, P1021, DOI 10.1016/0092-8674(92)90251-7; ERDODI F, 1992, ARCH BIOCHEM BIOPHYS, V298, P682, DOI 10.1016/0003-9861(92)90466-A; FERRELL JE, 1989, P NATL ACAD SCI USA, V86, P2234, DOI 10.1073/pnas.86.7.2234; FEUERSTEIN N, 1983, J BIOL CHEM, V258, P786; GOLDEN A, 1990, J CELL BIOL, V111, P3117, DOI 10.1083/jcb.111.6.3117; GREENBERG SM, 1988, BLOOD, V72, P1968; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; HUANG MM, 1991, P NATL ACAD SCI USA, V88, P7844, DOI 10.1073/pnas.88.17.7844; KEHREL B, 1988, BLOOD, V71, P1074; KIEFFER N, 1988, BIOCHIM BIOPHYS ACTA, V967, P408, DOI 10.1016/0304-4165(88)90104-3; KUNICKI TJ, 1988, J BIOL CHEM, V263, P4516; Legrand C, 1991, Platelets, V2, P99, DOI 10.3109/09537109109113695; LEUNG LLK, 1992, J BIOL CHEM, V267, P18244; MARCUS AJ, 1966, J CLIN INVEST, V45, P14, DOI 10.1172/JCI105318; MCGREGOR JL, 1989, J BIOL CHEM, V264, P501; MORTON LF, 1987, BIOCHEM J, V248, P483, DOI 10.1042/bj2480483; NAIK UP, 1991, BIOCHIM BIOPHYS ACTA, V1092, P256, DOI 10.1016/0167-4889(91)90165-T; NIEUWENHUIS HK, 1986, BLOOD, V68, P692; NIEUWENHUIS HK, 1985, NATURE, V318, P470, DOI 10.1038/318470a0; OCKENHOUSE CF, 1989, SCIENCE, V243, P1469, DOI 10.1126/science.2467377; OQUENDO P, 1989, CELL, V58, P95, DOI 10.1016/0092-8674(89)90406-6; PRATER CA, 1991, J CELL BIOL, V112, P1031, DOI 10.1083/jcb.112.5.1031; RICH KA, 1990, SCIENCE, V249, P1574, DOI 10.1126/science.2120774; STOMSKI FC, 1992, EXP CELL RES, V198, P85, DOI 10.1016/0014-4827(92)90152-X; TANDON NN, 1989, J BIOL CHEM, V264, P7576; WOODGETT JR, 1986, EUR J BIOCHEM, V161, P177, DOI 10.1111/j.1432-1033.1986.tb10139.x	31	182	187	0	3	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	NOV 26	1993	262	5138					1436	1440		10.1126/science.7504322	http://dx.doi.org/10.1126/science.7504322			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	MJ046	7504322				2022-12-28	WOS:A1993MJ04600038
J	Kane, JM				Kane, JM			Drug therapy - Schizophrenia	NEW ENGLAND JOURNAL OF MEDICINE			English	Review							INTERMITTENT NEUROLEPTIC PROPHYLAXIS; CLOZAPINE-INDUCED AGRANULOCYTOSIS; D2-DOPAMINE RECEPTOR OCCUPANCY; HIGH DOSAGE HALOPERIDOL; DOUBLE-BLIND; MAINTENANCE TREATMENT; DOPAMINE-RECEPTORS; CLINICAL-RESPONSE; SCHIZOAFFECTIVE PSYCHOSES; OUTPATIENT SCHIZOPHRENICS		ALBERT EINSTEIN COLL MED, DEPT PSYCHIAT, BRONX, NY USA	Yeshiva University; Albert Einstein College of Medicine	Kane, JM (corresponding author), HILLSIDE HOSP, LONG ISL JEWISH MED CTR, DEPT PSYCHIAT, 75-79 263RD ST, GLEN OAKS, NY 11004 USA.							ALVIR JMJ, 1993, NEW ENGL J MED, V329, P162, DOI 10.1056/NEJM199307153290303; ANDEN NE, 1970, EUR J PHARMACOL, V11, P303, DOI 10.1016/0014-2999(70)90006-3; ARANA GW, 1986, PSYCHOPHARMACOL BULL, V22, P77; Bailine SH, 1987, PSYCHIAT HOSP, V18, P127; BAKER RW, 1992, J CLIN PSYCHIAT, V53, P439; BARBEE JG, 1992, AM J PSYCHIAT, V149, P1129; BARBEE JG, 1992, AM J PSYCHIAT, V149, P506; BJORNDAL N, 1980, PSYCHOPHARMACOLOGY, V67, P17, DOI 10.1007/BF00427590; BORISON RL, 1992, PSYCHOPHARMACOL BULL, V28, P213; CARMAN JS, 1981, J CLIN PSYCHIAT, V42, P124; CARPENTER WT, 1990, AM J PSYCHIAT, V147, P1138; CARPENTER WT, 1991, ARCH GEN PSYCHIAT, V48, P69; CARPENTER WT, 1991, AM J PSYCHIAT, V148, P819; CASEY DE, 1989, PSYCHOPHARMACOLOGY, V99, pS47, DOI 10.1007/BF00442559; CESKOVA E, 1993, PHARMACOPSYCHIATRY, V26, P121, DOI 10.1055/s-2007-1014355; CHIEN CP, 1974, AM J PSYCHIAT, V131, P86, DOI 10.1176/ajp.131.1.86; CHOUINARD G, 1993, J CLIN PSYCHOPHARM, V13, P25; CHRISTISON GW, 1991, SCHIZOPHRENIA BULL, V17, P217, DOI 10.1093/schbul/17.2.217; CLAUS A, 1992, ACTA PSYCHIAT SCAND, V85, P295, DOI 10.1111/j.1600-0447.1992.tb01473.x; CREESE I, 1976, SCIENCE, V192, P481, DOI 10.1126/science.3854; CSERNANSKY JG, 1988, ARCH GEN PSYCHIAT, V45, P655; DAVIS JM, 1994, DRUGS, V48, P616, DOI 10.1007/BF03259620; DAVIS JM, 1975, AM J PSYCHIAT, V132, P1237; DAVIS JM, 1994, DRUGS, V47, P741, DOI 10.2165/00003495-199447050-00004; DAVIS JM, 1989, COMPREHENSIVE TXB PS, V5, P1591; DEVINSKY O, 1994, J CLIN PSYCHIAT, V55, P153; ERICKSEN S E, 1978, Psychopharmacology Bulletin, V14, P15; FARDE L, 1990, ACTA PSYCHIAT SCAND, V82, P67, DOI 10.1111/j.1600-0447.1990.tb05292.x; FARDE L, 1992, ARCH GEN PSYCHIAT, V49, P538; FITTON A, 1990, DRUGS, V40, P727, DOI 10.2165/00003495-199040050-00007; FREEMAN TW, 1992, AM J PSYCHIAT, V149, P108; GARZATREVINO ES, 1989, AM J PSYCHIAT, V146, P1598; GLAZER WM, 1992, J CLIN PSYCHIAT, V53, P426; GOLDBERG SC, 1972, ARCH GEN PSYCHIAT, V26, P367; GRATZ SS, 1992, ADVERSE EFFECTS PSYC, P266; GROWE GA, 1979, AM J PSYCHIAT, V136, P454; HANLON TE, 1970, DIS NERV SYST, V31, P171; HANLON TE, 1966, PSYCHOPHARMACOLOGIA, V9, P328, DOI 10.1007/BF00408332; HEINRICH K, 1994, PROG NEURO-PSYCHOPH, V18, P129, DOI 10.1016/0278-5846(94)90029-9; HERZ MI, 1991, ARCH GEN PSYCHIAT, V48, P333; HIRSCHOWITZ J, 1980, AM J PSYCHIAT, V137, P916; HOGARTY GE, 1988, ARCH GEN PSYCHIAT, V45, P797; JANICAK PG, 1993, PRINCIPLES PRACTICE, P104; JOHNSON DAW, 1987, BRIT J PSYCHIAT, V151, P634, DOI 10.1192/bjp.151.5.634; JOLLEY AG, 1989, BRIT MED J, V298, P985, DOI 10.1136/bmj.298.6679.985; JOLLEY AG, 1990, BRIT MED J, V301, P837, DOI 10.1136/bmj.301.6756.837; KANE J, 1988, ARCH GEN PSYCHIAT, V45, P789; KANE JM, 1987, SCHIZOPHRENIA BULL, V13, P133, DOI 10.1093/schbul/13.1.133; KANE JM, 1993, J CLIN PSYCHIAT, V54, P327; KANE JM, 1983, ARCH GEN PSYCHIAT, V40, P893; KANE JM, 1986, J CLIN PSYCHIAT, V47, P30; KANE JM, 1993, SCHIZOPHR RES, V9, P239; KANE JM, 1987, PSYCHOPHARMACOLOGY 3, P1103; KEEPERS GA, 1983, ARCH GEN PSYCHIAT, V40, P1113; KENDLER KS, 1993, SCHIZOPHRENIA BULL, V19, P261, DOI 10.1093/schbul/19.2.261; KINON BJ, 1993, PSYCHOPHARMACOL BULL, V29, P309; KIRCH DG, 1993, SCHIZOPHRENIA BULL, V19, P355, DOI 10.1093/schbul/19.2.355; Kissling W., 1991, GUIDELINES NEUROLEPT; Klein DF, 1969, DIAGNOSIS DRUG TREAT; LEVINSON DF, 1990, ARCH GEN PSYCHIAT, V47, P761; LIEBERMAN JA, 1987, PSYCHOPHARMACOLOGY, V91, P415, DOI 10.1007/BF00216006; LIEBERMAN JA, 1990, ARCH GEN PSYCHIAT, V47, P945; MALLYA AR, 1992, J CLIN PSYCHIAT, V53, P395; MARDER SR, 1994, AM J PSYCHIAT, V151, P825; MARDER SR, 1984, ARCH GEN PSYCHIAT, V41, P1025; MARDER SR, 1987, ARCH GEN PSYCHIAT, V44, P518; MCCREADIE RG, 1977, BRIT J PSYCHIAT, V131, P310, DOI 10.1192/bjp.131.3.310; MELTZER HY, 1995, AM J PSYCHIAT, V152, P183; MELTZER HY, 1993, PSYCHIAT CLIN N AM, V16, P365; MENZA MA, 1989, BIOL PSYCHIAT, V26, P842, DOI 10.1016/0006-3223(89)90124-8; Muller-Spahn F, 1992, Clin Neuropharmacol, V15 Suppl 1 Pt A, p90A; NEBORSKY R, 1981, ARCH GEN PSYCHIAT, V38, P195; NORDSTROM AL, 1993, BIOL PSYCHIAT, V33, P227, DOI 10.1016/0006-3223(93)90288-O; PATO CN, 1989, PSYCHOPHARMACOL BULL, V25, P263; PIETZCKER A, 1993, J PSYCHIAT RES, V27, P321, DOI 10.1016/0022-3956(93)90059-B; POST RM, 1990, J CLIN PSYCHIAT, V51, P9; PRUSOFF BA, 1979, ARCH GEN PSYCHIAT, V36, P569; QUITKIN F, 1975, ARCH GEN PSYCHIAT, V32, P1276; REARDON GT, 1989, AM J PSYCHIAT, V146, P726; REMINGTON G, 1993, J CLIN PSYCHOPHARM, V13, P41; RIFKIN A, 1978, ARCH GEN PSYCHIAT, V35, P483; RIFKIN A, 1991, ARCH GEN PSYCHIAT, V48, P166; SALZMAN C, 1991, J CLIN PSYCHIAT, V52, P177; SCHOFFERMAN J, 1993, CLIN J PAIN, V9, P260, DOI 10.1097/00002508-199312000-00007; SCHULZ SC, 1990, PROG PSYCH, V27, P109; SEEMAN P, 1976, NATURE, V261, P717, DOI 10.1038/261717a0; SEEMAN P, 1990, FASEB J, V4, P2737, DOI 10.1096/fasebj.4.10.2197154; SEEMAN P, 1992, NEUROPSYCHOPHARMACOL, V7, P261; SIMHANDL C, 1992, J PSYCHIATR NEUROSCI, V17, P1; SIRIS SG, 1978, ARCH GEN PSYCHIAT, V35, P1368; SIRIS SG, 1987, ARCH GEN PSYCHIAT, V44, P533; SIRIS SG, 1989, AM J PSYCHIAT, V146, P1495; SMALL JG, 1975, AM J PSYCHIAT, V132, P1315; VANPUTTEN T, 1990, ARCH GEN PSYCHIAT, V47, P754; VOLAVKA J, 1992, ARCH GEN PSYCHIAT, V49, P354; WOLKIN A, 1989, AM J PSYCHIAT, V146, P905; WOLKOWITZ OM, 1988, ARCH GEN PSYCHIAT, V45, P664; WOLKOWITZ OM, 1991, AM J PSYCHIAT, V148, P714; WONG DF, 1987, SCIENCE, V235, P623; WONG DF, 1986, SCIENCE, V234, P1558, DOI 10.1126/science.2878495; 1992, TARDIVE DYSKINESIA T	101	279	286	0	8	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JAN 4	1996	334	1					34	41		10.1056/NEJM199601043340109	http://dx.doi.org/10.1056/NEJM199601043340109			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	TM482	7494570				2022-12-28	WOS:A1996TM48200009
J	McDonnell, WM; Askari, FK				McDonnell, WM; Askari, FK			Molecular medicine - DNA vaccines	NEW ENGLAND JOURNAL OF MEDICINE			English	Article									UNIV MICHIGAN,SCH MED,DEPT INTERNAL MED,DIV GASTROENTEROL,ANN ARBOR,MI	University of Michigan System; University of Michigan	McDonnell, WM (corresponding author), VET AFFAIRS MED CTR,111D INTERNAL MED,2115 FULLER RD,ANN ARBOR,MI 48105, USA.							CEASE KB, 1994, ANNU REV IMMUNOL, V12, P923, DOI 10.1146/annurev.iy.12.040194.004423; DONNELLY JJ, 1995, NAT MED, V1, P583, DOI 10.1038/nm0695-583; FYNAN EF, 1995, INT J IMMUNOPHARMACO, V17, P79, DOI 10.1016/0192-0561(94)00090-B; GRAHAM BS, 1993, J INFECT DIS, V167, P533, DOI 10.1093/infdis/167.3.533; NABEL GJ, 1994, COLD SPRING HARB SYM, V59, P699, DOI 10.1101/SQB.1994.059.01.081; ULMER JB, 1993, SCIENCE, V259, P1745, DOI 10.1126/science.8456302; VITIELLO A, 1995, J CLIN INVEST, V95, P341, DOI 10.1172/JCI117662; WOLFF JA, 1990, SCIENCE, V247, P1465, DOI 10.1126/science.1690918	8	163	194	0	5	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JAN 4	1996	334	1					42	45		10.1056/NEJM199601043340110	http://dx.doi.org/10.1056/NEJM199601043340110			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TM482	7494571				2022-12-28	WOS:A1996TM48200010
J	Pate, MA				Pate, MA			Peak of the season	ANNALS OF INTERNAL MEDICINE			English	Editorial Material											Pate, MA (corresponding author), HOWARD UNIV HOSP, DEPT INTERNAL MED, 2041 GEORGIA AVE NW, WASHINGTON, DC 20060 USA.								0	0	0	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JAN 1	1996	124	1	1				69	69		10.7326/0003-4819-124-1_Part_1-199601010-00013	http://dx.doi.org/10.7326/0003-4819-124-1_Part_1-199601010-00013			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TL943	7503482				2022-12-28	WOS:A1996TL94300013
J	Mangano, DT; Goldman, L				Mangano, DT; Goldman, L			Current concepts - Preoperative assessment of patients with known or suspected coronary disease	NEW ENGLAND JOURNAL OF MEDICINE			English	Review							PERIPHERAL VASCULAR-SURGERY; PERIOPERATIVE MYOCARDIAL-INFARCTION; MAJOR CARDIAC EVENTS; NONCARDIAC SURGERY; ARTERY DISEASE; RISK STRATIFICATION; SURGICAL-PROCEDURES; ISCHEMIA; PREDICTION; COMPLICATIONS		UNIV CALIF SAN FRANCISCO, DEPT MED, SAN FRANCISCO, CA 94143 USA; MCSPI RES GRP, SAN FRANCISCO, CA USA; UNIV CALIF SAN FRANCISCO, DEPT ANESTHESIOL, SAN FRANCISCO, CA 94143 USA; VET AFFAIRS MED CTR, SAN FRANCISCO, CA 94121 USA	University of California System; University of California San Francisco; University of California System; University of California San Francisco; US Department of Veterans Affairs; Veterans Health Administration (VHA)								ABRAHAM SA, 1991, PROG CARDIOVASC DIS, V34, P205, DOI 10.1016/0033-0620(91)90014-D; ANDREWS TC, 1994, J VASC MED BIOL, V5, P8; ASHTON CM, 1993, ANN INTERN MED, V118, P504, DOI 10.7326/0003-4819-118-7-199304010-00004; BARON JF, 1994, NEW ENGL J MED, V330, P663, DOI 10.1056/NEJM199403103301002; BOUCHER CA, 1985, NEW ENGL J MED, V312, P389, DOI 10.1056/NEJM198502143120701; BROWN KA, 1993, J AM COLL CARDIOL, V21, P325, DOI 10.1016/0735-1097(93)90670-V; BRY JDL, 1994, J VASC SURG, V19, P112, DOI 10.1016/S0741-5214(94)70126-1; CARLINER NH, 1985, AM J CARDIOL, V56, P51, DOI 10.1016/0002-9149(85)90565-X; CUTLER BS, 1987, J VASC SURG, V5, P91, DOI 10.1067/mva.1987.avs0050091; CUTLER BS, 1981, AM J SURG, V141, P501, DOI 10.1016/0002-9610(81)90148-3; DETSKY AS, 1986, ARCH INTERN MED, V146, P2131, DOI 10.1001/archinte.146.11.2131; DETSKY AS, 1986, J GEN INTERN MED, V1, P211, DOI 10.1007/BF02596184; EAGLE KA, 1989, ANN INTERN MED, V110, P859, DOI 10.7326/0003-4819-110-11-859; EISENBERG MJ, 1992, JAMA-J AM MED ASSOC, V268, P210, DOI 10.1001/jama.268.2.210; FOSTER ED, 1986, ANN THORAC SURG, V41, P42, DOI 10.1016/S0003-4975(10)64494-3; GERSON MC, 1985, ANN INTERN MED, V103, P832, DOI 10.7326/0003-4819-103-6-832; GERSON MC, 1990, AM J MED, V88, P101, DOI 10.1016/0002-9343(90)90456-N; GOLDEN MA, 1990, ANN SURG, V212, P415, DOI 10.1097/00000658-199010000-00004; GOLDMAN L, 1994, NEW ENGL J MED, V330, P707, DOI 10.1056/NEJM199403103301010; Goldman L, 1987, J Cardiothorac Anesth, V1, P237, DOI 10.1016/S0888-6296(87)80011-X; GOLDMAN L, 1977, NEW ENGL J MED, V297, P845, DOI 10.1056/NEJM197710202971601; HENDEL RC, 1992, AM J CARDIOL, V70, P1243, DOI 10.1016/0002-9149(92)90756-O; HOLLENBERG M, 1992, JAMA-J AM MED ASSOC, V268, P205, DOI 10.1001/jama.268.2.205; JEFFREY CC, 1983, ANESTHESIOLOGY, V58, P462, DOI 10.1097/00000542-198305000-00013; KAZMERS A, 1988, J VASC SURG, V8, P307, DOI 10.1067/mva.1988.avs0080307; LANDESBERG G, 1993, LANCET, V341, P715, DOI 10.1016/0140-6736(93)90486-Z; LANGAN EM, 1993, J VASC SURG, V18, P905, DOI 10.1016/0741-5214(93)90544-V; LARSEN SF, 1987, EUR HEART J, V8, P179, DOI 10.1093/oxfordjournals.eurheartj.a062246; LEPPO JA, 1995, AM J CARDIOL, V75, pD42; LETTE J, 1992, AM J CARDIOL, V69, P1553, DOI 10.1016/0002-9149(92)90702-Z; LONDON MJ, 1990, ANESTHESIOLOGY, V73, P644, DOI 10.1097/00000542-199010000-00010; MANGANO DT, 1991, J AM COLL CARDIOL, V17, P851, DOI 10.1016/0735-1097(91)90864-6; MANGANO DT, 1990, NEW ENGL J MED, V323, P1781, DOI 10.1056/NEJM199012273232601; MANGANO DT, 1990, ANESTHESIOLOGY, V72, P153, DOI 10.1097/00000542-199001000-00025; MANGANO DT, 1991, J AM COLL CARDIOL, V17, P843, DOI 10.1016/0735-1097(91)90863-5; MANGANO DT, 1992, JAMA-J AM MED ASSOC, V268, P233, DOI 10.1001/jama.268.2.233; MANGANO DT, 1991, CIRCULATION, V84, P493, DOI 10.1161/01.CIR.84.2.493; MASSIE BM, 1993, CIRCULATION, V87, P1752, DOI 10.1161/01.CIR.87.5.1752; MCFALLS EO, 1993, J AM COLL CARDIOL, V21, P1347, DOI 10.1016/0735-1097(93)90307-M; MCPHAIL N, 1988, J VASC SURG, V7, P60, DOI 10.1067/mva.1988.avs0070060; MICHEL LA, 1990, J THORAC CARDIOV SUR, V100, P595; OUYANG P, 1989, AM J CARDIOL, V64, P1113, DOI 10.1016/0002-9149(89)90862-X; PASTERNACK PF, 1984, J VASC SURG, V1, P320, DOI 10.1067/mva.1984.avs0010320; PASTERNACK PF, 1989, J VASC SURG, V10, P617, DOI 10.1067/mva.1989.15572; POLDERMANS D, 1995, J AM COLL CARDIOL, V26, P648, DOI 10.1016/0735-1097(95)00240-5; RABY KE, 1992, JAMA-J AM MED ASSOC, V268, P222, DOI 10.1001/jama.268.2.222; RABY KE, 1989, NEW ENGL J MED, V321, P1296, DOI 10.1056/NEJM198911093211904; RIHAL CS, 1995, CIRCULATION, V91, P46, DOI 10.1161/01.CIR.91.1.46; SHAH KB, 1990, ANESTH ANALG, V70, P240; TISCHLER MD, 1991, AM J CARDIOL, V68, P593, DOI 10.1016/0002-9149(91)90349-P; WHITE GH, 1988, AM J SURG, V156, P103, DOI 10.1016/S0002-9610(88)80365-9; WONG T, 1992, ANN INTERN MED, V116, P743, DOI 10.7326/0003-4819-116-9-743; ZELDIN RA, 1984, CAN J SURG, V27, P402; 1990, GLOBAL ESTIMATES HLT; 1989, DHHS PHS891232 PUBL, P6	55	296	308	0	3	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	DEC 28	1995	333	26					1750	1756		10.1056/NEJM199512283332607	http://dx.doi.org/10.1056/NEJM199512283332607			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TM169	7491140				2022-12-28	WOS:A1995TM16900007
J	SANDERCOCK, P				SANDERCOCK, P			THROMBOLYTIC THERAPY FOR ACUTE ISCHEMIC STROKE - PROMISING, PERILOUS, OR UNPROVED	LANCET			English	Editorial Material											SANDERCOCK, P (corresponding author), WESTERN GEN HOSP,NEUROSCI TRIALS UNIT,EDINBURGH EH4 2XU,MIDLOTHIAN,SCOTLAND.		sandercock, peter/GQI-3167-2022	sandercock, peter/0000-0001-8484-0135				BATH PMW, 1995, BRIT MED J, V311, P139, DOI 10.1136/bmj.311.6998.139; COUNSELL C, 1995, STROKE MODULE COCHRA; DONNAN GA, 1995, LANCET, V345, P578; Fibrinolytic 'Therapy Trialists' (FTT) Collaborative Group, 1994, LANCET, V343, P311; HACKE W, 1995, JAMA-J AM MED ASSOC, V274, P1017, DOI 10.1001/jama.274.13.1017; HOMMEL M, 1995, LANCET, V345, P57, DOI 10.1016/S0140-6736(95)91179-0; PETO R, 1995, J CLIN EPIDEMIOL, V48, P23, DOI 10.1016/0895-4356(94)00150-O; SOLOMON NA, 1994, STROKE, V25, P1721, DOI 10.1161/01.STR.25.9.1721; WARDLAW J, 1995, STROKE MODULE COCHRA	9	14	16	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	DEC 9	1995	346	8989					1504	1505		10.1016/S0140-6736(95)92044-7	http://dx.doi.org/10.1016/S0140-6736(95)92044-7			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TJ291	7491040				2022-12-28	WOS:A1995TJ29100003
J	JACKSON, R; BEAGLEHOLE, R				JACKSON, R; BEAGLEHOLE, R			EVIDENCE-BASED MANAGEMENT OF DYSLIPIDEMIA	LANCET			English	Editorial Material							RISK; DYSLIPIDEMIA				JACKSON, R (corresponding author), UNIV AUCKLAND, FAC MED & HLTH SCI, DEPT COMMUNITY HLTH, AUCKLAND, NEW ZEALAND.			Jackson, Rod/0000-0001-5914-6934				ANDERSON KM, 1991, CIRCULATION, V83, P356, DOI 10.1161/01.CIR.83.1.356; BEARD K, 1992, BMJ-BRIT MED J, V304, P412, DOI 10.1136/bmj.304.6824.412; FRICK MH, 1987, NEW ENGL J MED, V317, P1237, DOI 10.1056/NEJM198711123172001; JACKSON R, 1993, BRIT MED J, V307, P107, DOI 10.1136/bmj.307.6896.107; KRISTIANSEN IS, 1991, BRIT MED J, V302, P1119, DOI 10.1136/bmj.302.6785.1119; LAW MR, 1994, BMJ-BRIT MED J, V308, P367, DOI 10.1136/bmj.308.6925.367; LAW MR, 1994, BRIT MED J, V308, P373, DOI 10.1136/bmj.308.6925.373; MANN JI, 1993, NEW ZEAL MED J, V106, P133; PEDERSEN TR, 1994, LANCET, V344, P1383; PYORALA K, 1994, EUR HEART J, V15, P1300; ROSE G, 1985, INT J EPIDEMIOL, V14, P32, DOI 10.1093/ije/14.1.32; SMITH GD, 1993, BMJ-BRIT MED J, V306, P1367, DOI 10.1136/bmj.306.6889.1367	12	28	29	2	4	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	DEC 2	1995	346	8988					1440	1442		10.1016/S0140-6736(95)92466-3	http://dx.doi.org/10.1016/S0140-6736(95)92466-3			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TH156	7490985				2022-12-28	WOS:A1995TH15600003
J	SNOW, TP; WITT, AN				SNOW, TP; WITT, AN			THE INTERSTELLAR CARBON BUDGET AND THE ROLE OF CARBON IN DUST AND LARGE MOLECULES	SCIENCE			English	Article							AROMATIC HYDROCARBON MOLECULES; HYDROGENATED AMORPHOUS-CARBON; B-TYPE STARS; CHEMICAL EVOLUTION; GALACTIC DISK; SOLAR NEIGHBORHOOD; ORION NEBULA; ELEMENTAL ABUNDANCES; EXTINCTION CURVE; ZETA-OPHIUCHI	Published data on stellar composition show that carbon in the sun is substantially more abundant than in other stars. A carbon abundance of 225 carbon atoms per 10(6) hydrogen atoms is representative of galactic stars, whereas Published values for the sun range from 350 to 470 carbon atoms per 10(6) hydrogen atoms. Other elements are also present in enhanced quantities in the solar system, consistent with suggestions that a supernova event was closely associated with the formation of the solar system. The overabundance of carbon in the solar system has many important implications, including new constraints on nucleosynthesis models for supernovae and substantial modification of the so-called ''cosmic'' composition normally adopted in discussions of galactic and interstellar abundances. A reduction in the galactic carbon budget, as suggested by the stellar composition data, strongly constrains the quantity of carbon that is available for the formation of interstellar dust, and some dust models now appear implausible because they require more carbon than is available.	UNIV TOLEDO,RITTER OBSERV,TOLEDO,OH 43606	University System of Ohio; University of Toledo	SNOW, TP (corresponding author), UNIV COLORADO,CTR ASTROPHYS & SPACE ASTRON,BOULDER,CO 80309, USA.		Witt, Adolf N./AAX-6976-2021					AANNESTAD PA, 1995, ASTROPHYS J, V443, P653, DOI 10.1086/175557; ADAMSON AJ, 1990, MON NOT R ASTRON SOC, V243, P400; ADELMAN SJ, 1993, PUBL ASTRON SOC PAC, V105, P327, DOI 10.1086/133158; ALLAMANDOLA LJ, 1989, ASTROPHYS J SUPPL S, V71, P733, DOI 10.1086/191396; ALLAMANDOLA LJ, 1985, ASTROPHYS J, V290, pL25, DOI 10.1086/184435; AMARI S, 1995, ASTROPHYS J, V447, pL147, DOI 10.1086/309573; ANDERS E, 1993, METEORITICS, V28, P490, DOI 10.1111/j.1945-5100.1993.tb00274.x; ANDERS E, 1989, GEOCHIM COSMOCHIM AC, V53, P197, DOI 10.1016/0016-7037(89)90286-X; BALDWIN JA, 1991, ASTROPHYS J, V374, P580, DOI 10.1086/170146; BOESGAARD AM, 1989, ASTROPHYS J, V336, P798, DOI 10.1086/167050; BOHLIN RC, 1978, ASTROPHYS J, V224, P132, DOI 10.1086/156357; BUCHMANN L, 1993, PHYS REV LETT, V70, P726, DOI 10.1103/PhysRevLett.70.726; BUSOLETTI E, 1987, APJ, V321, pL87; CAMERON AGW, 1995, ASTROPHYS J, V447, pL53, DOI 10.1086/309554; CAMERON AGW, 1973, SPACE SCI REV, V15, P121, DOI 10.1007/BF00172440; CARDELLI JA, 1993, ASTROPHYS J, V402, pL17, DOI 10.1086/186689; CARDELLI JA, 1991, ASTROPHYS J, V377, pL57, DOI 10.1086/186116; CARDELLI JA, IN PRESS ASTROPHYS J; CARIGI L, 1994, ASTROPHYS J, V424, P181, DOI 10.1086/173881; CARLBERG RG, 1985, ASTROPHYS J, V294, P674, DOI 10.1086/163337; CHYBA C, 1992, NATURE, V355, P125, DOI 10.1038/355125a0; CUNHA K, 1994, ASTROPHYS J, V426, P170, DOI 10.1086/174053; DESERT FX, 1990, ASTRON ASTROPHYS, V237, P215; Draine B, 1989, INTERSTELLAR DUST, P313; DRAINE BT, 1984, ASTROPHYS J, V285, P89, DOI 10.1086/162480; DULEY WW, 1990, ASTROPHYS J, V351, pL49, DOI 10.1086/185677; DULEY WW, 1987, MON NOT R ASTRON SOC, V229, P203, DOI 10.1093/mnras/229.2.203; DULEY WW, 1985, MON NOT R ASTRON SOC, V215, P259, DOI 10.1093/mnras/215.2.259; DULEY WW, 1989, MON NOT R ASTRON SOC, V236, P709, DOI 10.1093/mnras/236.4.709; DULEY WW, 1995, DIFFUSE INTERSTELLAR, V359; EDVARDSSON B, 1993, ASTRON ASTROPHYS, V275, P101; FANG Z, 1993, PHYS REV A, V48, P1114, DOI 10.1103/PhysRevA.48.1114; FOING BH, 1994, NATURE, V369, P296, DOI 10.1038/369296a0; FURTON DG, 1993, ASTROPHYS J, V415, pL51, DOI 10.1086/187030; GIES DR, 1992, ASTROPHYS J, V387, P673, DOI 10.1086/171116; GREVESSE N, 1991, ASTRON ASTROPHYS, V242, P488; GREVESSE N, 1992, INFRARED SOLAR PHYSI, P539; Grevesse N., 1993, ORIGIN EVOLUTION ELE, P15; HOBBS LM, 1982, ASTROPHYS J, V252, pL21, DOI 10.1086/183711; HOLWEGER H, 1974, SOL PHYS, V39, P19, DOI 10.1007/BF00154968; HONG SS, 1980, ASTRON ASTROPHYS, V88, P194; JENKINS EB, 1979, ASTROPHYS J, V231, P55, DOI 10.1086/157163; JENKINS EB, 1983, ASTROPHYS J, V270, P88, DOI 10.1086/161100; JOBLIN C, 1992, ASTROPHYS J, V393, pL79, DOI 10.1086/186456; JONES AP, 1990, MON NOT R ASTRON SOC, V247, P305; KILIAN J, 1994, ASTRON ASTROPHYS, V284, P437; KILIAN J, 1992, ASTRON ASTROPHYS, V262, P171; KILIANMONTENBRU.J, 1994, ASTRON ASTROPHYS, V291, P757; LAMBERT DL, 1978, MON NOT R ASTRON SOC, V182, P249, DOI 10.1093/mnras/182.2.249; LEGER A, 1995, ASTRON ASTROPHYS, V293, pL53; LENNON DJ, 1985, ASTROPHYS J, V294, P200, DOI 10.1086/163287; LUCK RE, 1994, ASTROPHYS J SUPPL S, V91, P309, DOI 10.1086/191940; MALINIE G, 1993, ASTROPHYS J, V413, P633, DOI 10.1086/173032; MATHIS JS, 1977, ASTROPHYS J, V217, P425, DOI 10.1086/155591; MATHIS JS, 1989, ASTROPHYS J, V341, P808, DOI 10.1086/167538; MATTEUCCI F, 1983, ASTRON ASTROPHYS, V123, P121; MEYER DM, 1994, ASTROPHYS J, V437, pL59, DOI 10.1086/187682; MORTON DC, 1975, ASTROPHYS J, V197, P85, DOI 10.1086/153490; OLIVE KA, 1982, ASTROPHYS J, V257, P276, DOI 10.1086/159986; OTT U, 1993, NATURE, V364, P25, DOI 10.1038/364025a0; PAGEL BEJ, 1989, EVOLUTIONARY PHENOMENA IN GALAXIES, P201; PAGEL BEJ, 1975, MON NOT R ASTRON SOC, V172, P13, DOI 10.1093/mnras/172.1.13; PAPOULAR R, 1993, ASTRON ASTROPHYS, V270, pL5; PEIMBERT M, 1993, ASTROPHYS J, V414, P626, DOI 10.1086/173108; PENDLETON YJ, 1994, ASTROPHYS J, V437, P683, DOI 10.1086/175031; PUGET JL, 1989, ANNU REV ASTRON ASTR, V27, P161; REEVES H, 1978, PROTOSTARS PLANETS, P399; ROLLESTON WRJ, 1994, ASTRON ASTROPHYS, V284, P72; ROY JR, 1995, ASTRON ASTROPHYS, V294, P432; RUBIN RH, 1991, ASTROPHYS J, V374, P564, DOI 10.1086/170145; RUBIN RH, 1993, ASTROPHYS J, V413, P242, DOI 10.1086/172992; SALAMA F, 1992, ASTROPHYS J, V395, P301, DOI 10.1086/171652; SALAMA F, 1992, NATURE, V358, P42, DOI 10.1038/358042a0; SANCISI R, 1974, GALACTIC RADIO ASTRO, P115; SCHUSTER WJ, 1989, ASTRON ASTROPHYS, V222, P69; SEARLE L, 1972, ASTROPHYS J, V173, P25, DOI 10.1086/151398; Snow T., UNPUB; SNOW TP, 1976, ASTROPHYS J, V204, P759, DOI 10.1086/154223; SNOW TP, IN PRESS ASTROPHYS J; SOFIA UJ, 1994, ASTROPHYS J, V430, P650, DOI 10.1086/174438; SORRELL WH, 1990, MON NOT R ASTRON SOC, V243, P570; Tielens A. G. G. M., 1995, DIFFUSE INTERSTELLAR; Tielens A.G.G.M., 1987, INTERSTELLAR PROCESS, P397; TINSLEY BM, 1980, FUNDAM COSMIC PHYS, V5, P587; TOMKIN J, 1995, ASTRON J, V109, P2204, DOI 10.1086/117446; TWAROG BA, 1980, ASTROPHYS J, V242, P242, DOI 10.1086/158460; TWAROG BA, 1982, ASTROPHYS J, V261, P636, DOI 10.1086/160375; WELTY DE, 1986, PUBL ASTRON SOC PAC, V98, P857, DOI 10.1086/131834; WHITTET DCB, 1989, MON NOT R ASTRON SOC, V241, P707, DOI 10.1093/mnras/241.4.707; WHITTET DCB, 1984, MON NOT R ASTRON SOC, V210, P479, DOI 10.1093/mnras/210.2.479; Williams, 1993, DUST CHEM ASTRONOMY, P9; ZHAO Z, 1993, PHYS REV LETT, V70, P2066, DOI 10.1103/PhysRevLett.70.2066; [No title captured]	94	164	164	0	13	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	DEC 1	1995	270	5241					1455	1460		10.1126/science.270.5241.1455	http://dx.doi.org/10.1126/science.270.5241.1455			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TH375	7491489				2022-12-28	WOS:A1995TH37500028
J	FRANCIS, CM; CARUANA, L; KEARNEY, P; LOVE, M; SUTHERLAND, GR; STARKEY, IR; SHAW, TRD; MCMURRAY, JJV				FRANCIS, CM; CARUANA, L; KEARNEY, P; LOVE, M; SUTHERLAND, GR; STARKEY, IR; SHAW, TRD; MCMURRAY, JJV			OPEN ACCESS ECHOCARDIOGRAPHY IN MANAGEMENT OF HEART-FAILURE IN THE COMMUNITY	BRITISH MEDICAL JOURNAL			English	Article							GASTROSCOPY	Objective-To assess the value of an open access echocardiography service. Design-Study of new open access service for general practitioners, who were invited to refer who patients taking diuretics for suspected heart failure, untreated patients with symptoms of possible heart failure, and asymptomatic patients with risk factors for left ventricular systolic dysfunction. Setting-Regional cardiology centre. Subjects-259 consecutive patients. Main outcome measure-Presence or absence of left ventricular systolic dysfunction and consequent changes in clinical management. Results-119 treated patients, 99 untreated patients, and nine asymptomatic patients were referred over five months. 32 were considered to be inappropriately referred. Among the treated patients, 31 had impaired left ventricular systolic function and five had valvular disease; angiotensin converting enzyme inhibitors were recommended for 34 of these patients, In addition, 53 were thought not to need diuretics. Eight untreated patients had impaired systolic function and six valvular disease. Conclusions-The service was well used by general practitioners and led to advice to change management in more than two thirds of patients.	WESTERN GEN HOSP,DEPT CARDIOL,EDINBURGH EH4 2XU,MIDLOTHIAN,SCOTLAND	University of Edinburgh			mcmurray, John/B-2467-2013	mcmurray, John/0000-0002-6317-3975				ALBIN G, 1990, AM J CARDIOL, V65, P1031, DOI 10.1016/0002-9149(90)91009-U; BRAMBLE MG, 1993, GUT, V34, P422, DOI 10.1136/gut.34.3.422; CHOY AMJ, 1994, BRIT HEART J, V72, P16; CLARKE KW, 1994, BRIT HEART J, V71, P584; DARGIE HJ, 1994, BMJ-BRIT MED J, V308, P321, DOI 10.1136/bmj.308.6924.321; DEJONGE JW, 1994, BMJ-BRIT MED J, V308, P511, DOI 10.1136/bmj.308.6927.511; GASSCH WH, 1994, JAMA-J AM MED ASSOC, V271, P1276; Hart W, 1993, BR J MED EC, V6, P91; KERRIGAN DD, 1990, BRIT MED J, V300, P374, DOI 10.1136/bmj.300.6721.374; MCCLEMENTS BM, 1994, BRIT HEART J, V71, P531; PFEFFER MA, 1992, NEW ENGL J MED, V327, P669, DOI 10.1056/NEJM199209033271001; REMES J, 1991, EUR HEART J, V12, P315, DOI 10.1093/oxfordjournals.eurheartj.a059896; SUTTON MS, 1994, CIRCULATION, V89, P68, DOI 10.1161/01.CIR.89.1.68; THOMAS JD, 1991, CIRCULATION, V84, P977, DOI 10.1161/01.CIR.84.3.977; Vuille C., 1994, PRINCIPLES PRACTICE, P575; WHEELDON NM, 1993, Q J MED, V86, P17; ZERMANSKY A, 1993, BRIT MED J, V306, P1750, DOI 10.1136/bmj.306.6894.1750-b; 1991, NEW ENGL J MED, V325, P293; 1994, BRIT HEART J, V72, P303; 1992, NEW ENGL J MED, V327, P685	20	136	136	0	10	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAR 11	1995	310	6980					634	636		10.1136/bmj.310.6980.634	http://dx.doi.org/10.1136/bmj.310.6980.634			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QL984	7503841	Green Published			2022-12-28	WOS:A1995QL98400019
J	IOST, I; DREYFUS, M				IOST, I; DREYFUS, M			MESSENGER-RNAS CAN BE STABILIZED BY DEAD-BOX PROTEINS	NATURE			English	Article							BACTERIOPHAGE-T7 RNA-POLYMERASE; ESCHERICHIA-COLI; MESSENGER-RNA; LACZ GENE; TRANSLATION; TRANSCRIPTION; INITIATION; EXPRESSION; HELICASE; DEGRADATION	EUBACTERIAL messenger RNAs are synthesized and translated simultaneously; moreover the speed of ribosomes usually matches that of RNA polymerase(1,2). We report here that when in Escherichia coli the host RNA polymerase is replaced by the eightfold faster bacteriophage T7 enzyme for the transcription of the lacZ gene, the beta-galactosidase yield per transcript is depressed 100-fold. But the overexpression of DEAD-box proteins(3) greatly improves this low yield by stabilizing the corresponding transcripts. More generally, it stabilizes inefficiently translated E. coli mRNAs. Ribosome-free mRNA regions, such as those lying behind the fast T7 enzyme or between successive ribosomes on inefficiently translated transcripts, are often unstable(4) and we propose that DEAD-box proteins protect them from endonucleases. These results pinpoint the importance of transcription-translation synchronization for mRNA stability, and reveal an undocumented property of DEAD-box RNA helicases. These proteins have been implicated in a variety of processes involving RNA(5) but not mRNA stability.	ECOLE NORMALE SUPER, CNRS D1302, GENET MOLEC LAB, F-75230 PARIS 05, FRANCE	UDICE-French Research Universities; PSL Research University Paris; Ecole Normale Superieure (ENS)			Iost, Isabelle/M-7149-2014	Iost, Isabelle/0000-0001-9061-4177				BECHHOFER DH, 1987, P NATL ACAD SCI USA, V84, P498, DOI 10.1073/pnas.84.2.498; CARPOUSIS AJ, 1994, CELL, V76, P889, DOI 10.1016/0092-8674(94)90363-8; CHAPON C, 1982, EMBO J, V1, P369, DOI 10.1002/j.1460-2075.1982.tb01176.x; CHEVRIERMILLER M, 1990, NUCLEIC ACIDS RES, V18, P5787, DOI 10.1093/nar/18.19.5787; CORMACK RS, 1992, J MOL BIOL, V228, P1078, DOI 10.1016/0022-2836(92)90316-C; FORD MJ, 1988, NATURE, V332, P736, DOI 10.1038/332736a0; IGGO R, 1990, NUCLEIC ACIDS RES, V18, P5413, DOI 10.1093/nar/18.18.5413; IOST I, 1992, J BACTERIOL, V174, P619, DOI 10.1128/jb.174.2.619-622.1992; JACQUET M, 1971, J MOL BIOL, V60, P453, DOI 10.1016/0022-2836(71)90181-1; KALMAN M, 1991, NEW BIOL, V3, P886; LESAGE P, 1992, J MOL BIOL, V228, P366, DOI 10.1016/0022-2836(92)90827-7; LINDER P, 1989, NATURE, V337, P121, DOI 10.1038/337121a0; LOPEZ PJ, 1994, NUCLEIC ACIDS RES, V22, P1186, DOI 10.1093/nar/22.7.1186; MACDONALD LE, 1993, J MOL BIOL, V232, P1030, DOI 10.1006/jmbi.1993.1458; MILLER OL, 1970, SCIENCE, V169, P392, DOI 10.1126/science.169.3943.392; NILSSON G, 1987, P NATL ACAD SCI USA, V84, P4890, DOI 10.1073/pnas.84.14.4890; NISHI K, 1988, NATURE, V336, P496, DOI 10.1038/336496a0; PAUSE A, 1993, MOL CELL BIOL, V13, P6789, DOI 10.1128/MCB.13.11.6789; Petersen C, 1993, CONTROL MESSENGER RN, P117; PLUMBRIDGE JA, 1983, J MOL BIOL, V167, P227, DOI 10.1016/S0022-2836(83)80333-7; Putzer Harald, 1995, P293; SCHMID SR, 1992, MOL MICROBIOL, V6, P283, DOI 10.1111/j.1365-2958.1992.tb01470.x; SPRINGER M, 1985, J MOL BIOL, V185, P93, DOI 10.1016/0022-2836(85)90185-8; STUDIER FW, 1986, J MOL BIOL, V189, P113, DOI 10.1016/0022-2836(86)90385-2; STUEBER D, 1982, EMBO J, V1, P1399, DOI 10.1002/j.1460-2075.1982.tb01329.x; TABOR S, 1985, P NATL ACAD SCI USA, V82, P1074, DOI 10.1073/pnas.82.4.1074; TOONE WM, 1991, J BACTERIOL, V173, P3291, DOI 10.1128/jb.173.11.3291-3302.1991; YARCHUK O, 1992, J MOL BIOL, V226, P581, DOI 10.1016/0022-2836(92)90617-S; YARCHUK O, 1991, BIOCHIMIE, V73, P1533, DOI 10.1016/0300-9084(91)90188-7	29	107	122	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	NOV 10	1994	372	6502					193	196		10.1038/372193a0	http://dx.doi.org/10.1038/372193a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PQ688	7526223				2022-12-28	WOS:A1994PQ68800060
J	MILAN, D; GRIFFITH, J; SU, M; PRICE, ER; MCKEON, F				MILAN, D; GRIFFITH, J; SU, M; PRICE, ER; MCKEON, F			THE LATCH REGION OF CALCINEURIN-B IS INVOLVED IN BOTH IMMUNOSUPPRESSANT-IMMUNOPHILIN COMPLEX DOCKING AND PHOSPHATASE ACTIVATION	CELL			English	Article							LIGHT CHAIN KINASE; CYCLOSPORINE-A; BINDING-PROTEIN; CYCLOPHILIN-B; CALMODULIN; TARGET; INHIBITION; SEQUENCE; SUBUNIT; DOMAIN	The immunosuppressants cyclosporin A and FK506, when complexed with their intracellular receptors, prevent T cell activation by directly binding to the phosphatase calcineurin. We have used molecular modeling and mutagenesis to identify sites on calcineurin important for this interaction. We have created calcineurins that are resistant to both cyclosporin A and FK506 by mutating specific residues in CnB, a calcium-binding protein that regulates the catalytic subunit, CnA. Significantly, on a model of CnB, these mutations map to the latch region, an element of tertiary structure that forms when CnB binds CnA. In addition, we show that this latch region plays an important role in activating the catalytic subunit CnA. These results suggest a molecular mechanism for suppression of calcineurin by cyclosporin A and FK506 involving their binding to the same region of CnB used for allosterically activating CnA.	HARVARD UNIV,SCH MED,DEPT CELL BIOL,BOSTON,MA 02115; VERTEX PHARMACEUT,CAMBRIDGE,MA 02139	Harvard University; Harvard Medical School; Vertex Pharmaceuticals								ALDAPE RA, 1992, J BIOL CHEM, V267, P16029; ANGLISTER J, 1994, BIOCHEMISTRY-US, V33, P3540, DOI 10.1021/bi00178a010; Ausubel FM., 1987, CURRENT PROTOCOLS MO, DOI 10.1002/mrd.1080010210; BABU YS, 1988, J MOL BIOL, V204, P191, DOI 10.1016/0022-2836(88)90608-0; BARBATO G, 1992, BIOCHEMISTRY-US, V31, P5269, DOI 10.1021/bi00138a005; BLUMENTHAL DK, 1986, J BIOL CHEM, V261, P8140; BLUMENTHAL DK, 1982, BIOCHEMISTRY-US, V21, P2386, DOI 10.1021/bi00539a017; CHATTOPADHYAYA R, 1992, J MOL BIOL, V228, P1177, DOI 10.1016/0022-2836(92)90324-D; CLIPSTONE NA, 1992, NATURE, V357, P695, DOI 10.1038/357695a0; COHEN P, 1989, J BIOL CHEM, V264, P21435; EMMEL EA, 1989, SCIENCE, V246, P1617, DOI 10.1126/science.2595372; FLANAGAN WM, 1991, NATURE, V352, P803, DOI 10.1038/352803a0; FRANTZ B, 1994, EMBO J, V13, P861, DOI 10.1002/j.1460-2075.1994.tb06329.x; FRIEDMAN J, 1991, CELL, V66, P799, DOI 10.1016/0092-8674(91)90123-G; FRUMAN DA, 1992, P NATL ACAD SCI USA, V89, P3686, DOI 10.1073/pnas.89.9.3686; GEORGE SE, 1990, J BIOL CHEM, V265, P9228; GUERINI D, 1989, P NATL ACAD SCI USA, V86, P9183, DOI 10.1073/pnas.86.23.9183; GUERINI D, 1989, DNA-J MOLEC CELL BIO, V8, P675, DOI 10.1089/dna.1.1989.8.675; HADDY A, 1992, FEBS LETT, V314, P37, DOI 10.1016/0014-5793(92)81456-V; HEALD R, 1993, CELL, V74, P463, DOI 10.1016/0092-8674(93)80048-J; HUBBARD MJ, 1989, BIOCHEMISTRY-US, V28, P1868, DOI 10.1021/bi00430a066; ITO A, 1989, BIOCHEM BIOPH RES CO, V163, P1492, DOI 10.1016/0006-291X(89)91148-0; JAIN J, 1992, NATURE, V356, P801, DOI 10.1038/356801a0; KAELIN WG, 1992, CELL, V70, P351, DOI 10.1016/0092-8674(92)90108-O; KLEE CB, 1988, MOL ASPECTS CELL REG, V5, P225; LI W, 1993, J BIOL CHEM, V268, P14040; LIU J, 1991, CELL, V66, P807, DOI 10.1016/0092-8674(91)90124-H; LIU J, 1992, BIOCHEMISTRY-US, V31, P3896, DOI 10.1021/bi00131a002; MCCAFFREY PG, 1993, J BIOL CHEM, V268, P3747; MEADOR WE, 1992, SCIENCE, V257, P1251, DOI 10.1126/science.1519061; MOORE JM, 1991, NATURE, V351, P248, DOI 10.1038/351248a0; OKEEFE SJ, 1992, NATURE, V357, P692, DOI 10.1038/357692a0; ONEIL KT, 1990, TRENDS BIOCHEM SCI, V15, P59, DOI 10.1016/0968-0004(90)90177-D; PERRINO BA, 1992, J BIOL CHEM, V267, P15965; PFLUGL G, 1993, NATURE, V361, P91, DOI 10.1038/361091a0; PRICE ER, 1991, P NATL ACAD SCI USA, V88, P1903, DOI 10.1073/pnas.88.5.1903; SCHREIBER SL, 1992, CELL, V70, P365, DOI 10.1016/0092-8674(92)90158-9; SPERA S, 1991, Journal of Biomolecular NMR, V1, P155, DOI 10.1007/BF01877227; SWANSON SKH, 1992, P NATL ACAD SCI USA, V89, P3741, DOI 10.1073/pnas.89.9.3741; THERIAULT Y, 1993, NATURE, V361, P88, DOI 10.1038/361088a0; VANBERKUM MFA, 1991, J BIOL CHEM, V266, P21488; VANDUYNE GD, 1991, SCIENCE, V252, P839, DOI 10.1126/science.1709302; WELLS JA, 1990, BIOCHEMISTRY-US, V29, P8517; ZOLLER MJ, 1984, DNA-J MOLEC CELL BIO, V3, P479, DOI 10.1089/dna.1.1984.3.479	44	102	104	0	3	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	NOV 4	1994	79	3					437	447		10.1016/0092-8674(94)90253-4	http://dx.doi.org/10.1016/0092-8674(94)90253-4			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	PQ488	7525078				2022-12-28	WOS:A1994PQ48800007
J	SEIWERT, SD; STUART, K				SEIWERT, SD; STUART, K			RNA EDITING - TRANSFER OF GENETIC INFORMATION FROM GRNA TO PRECURSOR MESSENGER-RNA IN-VITRO	SCIENCE			English	Article							AUG INITIATION CODONS; MESSENGER-RNA; TRYPANOSOMA-BRUCEI; KINETOPLASTID MITOCHONDRIA; B TRANSCRIPTS; INVITRO; MOLECULES; NUCLEOTIDES; URIDINES; SEQUENCE	RNA editing in the mitochondrion of Trypanosoma brucei extensively alters the adenosine triphosphate synthase (ATPase) subunit 6 precursor messenger RNA (pre-mRNA) by addition of 447 uridines and removal of 28 uridines. in vivo, the guide RNA gA6[14] is thought to specify the deletion of two uridines from the editing site closest to the 3' end. in this study, an in vitro system was developed that accurately removed uridines from this editing site in synthetic ATPase 6 pre-mRNA when gA6[14] and ATP were added. Mutations in both the guide RNA and the pre-mRNA editing site suggest that base-pairing interactions control the number of uridines deleted in vitro. Thus, guide RNAs are required for RNA editing and for the transfer of genetic information to pre-mRNAs.	SEATTLE BIOMED RES INST,SEATTLE,WA 98109; YALE UNIV,DEPT MOLEC BIOPHYS & BIOCHEM,NEW HAVEN,CT 06536; UNIV WASHINGTON,DEPT PATHOBIOL,SEATTLE,WA 98195	Center for Infectious Disease Research; Yale University; University of Washington; University of Washington Seattle					NIGMS NIH HHS [GM 42188] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABRAHAM JM, 1988, CELL, V55, P267, DOI 10.1016/0092-8674(88)90049-9; AUGUSTIN S, 1990, NATURE, V343, P383, DOI 10.1038/343383a0; BAKALARA N, 1989, J BIOL CHEM, V264, P18679; BENNE R, 1986, CELL, V46, P819, DOI 10.1016/0092-8674(86)90063-2; BENNE R, 1993, ALTERATION PROTEIN C; BHAT GJ, 1990, CELL, V61, P885, DOI 10.1016/0092-8674(90)90199-O; BLUM B, 1991, CELL, V65, P543, DOI 10.1016/0092-8674(91)90087-F; BLUM B, 1990, CELL, V60, P189, DOI 10.1016/0092-8674(90)90735-W; BLUM B, 1992, P NATL ACAD SCI USA, V89, P11944, DOI 10.1073/pnas.89.24.11944; CECH TR, 1991, CELL, V64, P667, DOI 10.1016/0092-8674(91)90494-J; DECKER CJ, 1990, CELL, V61, P1001, DOI 10.1016/0092-8674(90)90065-M; DRISCOLL DM, 1989, CELL, V58, P519, DOI 10.1016/0092-8674(89)90432-7; FEAGIN JE, 1987, CELL, V49, P337, DOI 10.1016/0092-8674(87)90286-8; FEAGIN JE, 1988, P NATL ACAD SCI USA, V85, P539, DOI 10.1073/pnas.85.2.539; FEAGIN JE, 1988, CELL, V53, P413, DOI 10.1016/0092-8674(88)90161-4; GORINGER HU, 1994, P NATL ACAD SCI USA, V91, P1776, DOI 10.1073/pnas.91.5.1776; HAJDUK SL, 1993, FASEB J, V7, P54, DOI 10.1096/fasebj.7.1.8422975; HARDY SF, 1984, NATURE, V308, P375, DOI 10.1038/308375a0; HARRIS M, 1992, MOL CELL BIOL, V12, P2591, DOI 10.1128/MCB.12.6.2591; HARRIS ME, 1992, CELL, V68, P1091, DOI 10.1016/0092-8674(92)90080-V; HARRIS ME, 1990, J BIOL CHEM, V265, P11368; HERNANDEZ N, 1983, CELL, V35, P89, DOI 10.1016/0092-8674(83)90211-8; KOSLOWSKY DJ, 1991, CELL, V67, P537, DOI 10.1016/0092-8674(91)90528-7; KOSLOWSKY DJ, 1992, NATURE, V356, P807, DOI 10.1038/356807a0; KOSLOWSKY DJ, 1992, MOL CELL BIOL, V12, P2043, DOI 10.1128/MCB.12.5.2043; KOSLOWSKY DJ, 1990, CELL, V62, P901, DOI 10.1016/0092-8674(90)90265-G; LANDWEBER LF, 1994, P NATL ACAD SCI USA, V91, P918, DOI 10.1073/pnas.91.3.918; Maniatis T., 1982, MOL CLONING; MASLOV DA, 1992, CELL, V70, P459, DOI 10.1016/0092-8674(92)90170-H; MASLOV DA, 1994, NATURE, V368, P345, DOI 10.1038/368345a0; PERIS M, 1994, EMBO J, V13, P1664, DOI 10.1002/j.1460-2075.1994.tb06430.x; POLLARD VW, 1992, EMBO J, V11, P4429, DOI 10.1002/j.1460-2075.1992.tb05543.x; READ LK, 1992, NUCLEIC ACIDS RES, V20, P2341, DOI 10.1093/nar/20.9.2341; READ LK, 1994, MOL CELL BIOL, V14, P2629, DOI 10.1128/MCB.14.4.2629; SEIWERT S, UNPUB; SHAW JM, 1988, CELL, V53, P401, DOI 10.1016/0092-8674(88)90160-2; SHU HH, 1994, NUCLEIC ACIDS RES, V22, P1696, DOI 10.1093/nar/22.9.1696; SIMPSON L, 1994, SCIENCE, V264, P1870, DOI 10.1126/science.8009214; STUART K, 1991, ANNU REV MICROBIOL, V45, P327, DOI 10.1146/annurev.mi.45.100191.001551; WOODSON SA, 1989, CELL, V57, P335, DOI 10.1016/0092-8674(89)90971-9; ZAUG AJ, 1984, SCIENCE, V224, P574, DOI 10.1126/science.6200938	41	131	133	0	5	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	OCT 7	1994	266	5182					114	117		10.1126/science.7524149	http://dx.doi.org/10.1126/science.7524149			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PK582	7524149				2022-12-28	WOS:A1994PK58200036
J	BRAM, RJ; CRABTREE, GR				BRAM, RJ; CRABTREE, GR			CALCIUM SIGNALING IN T-CELLS STIMULATED BY A CYCLOPHILIN B-BINDING PROTEIN	NATURE			English	Article							CYCLOSPORINE-A; ANTIGEN RECEPTOR; TYROSINE KINASE; LYMPHOCYTES-T; ACTIVATION; CALCINEURIN; IDENTIFICATION; TRANSDUCTION; EXPRESSION; PREDICTION	THE immunosuppressant drug cyclosporin A blocks a calcium-dependent signal from the T-cell receptor (TCR) that normally leads to T-cell activation(1-3). When bound to cyclophilin, cyclosporin A binds and inactivates the key signalling intermediate calcineurin(4-6). To identify potential cellular homologues of cyclosporin A that might regulate calcium signalling, we have cloned human genes encoding cyclophilin B-binding-proteins using the yeast two-hybrid system(7,8). One gene product, when overexpressed in Jurkat T cells, specifically induced transcription from the interleukin-2 enhancer, by activating the T-cell-specific transcription factors NF-AT and NF-IL2A. This protein, termed calcium-signal modulating cyclophilin ligand (CAML), acts downstream of the TCR and upstream of calcineurin by causing an influx of calcium. CAML appears to be a new participant in the calcium-signal transduction pathway, implicating cyclophilin B in calcium signalling, even in the absence of cyclosporin.	ST JUDE CHILDRENS RES HOSP, DEPT HEMATOL ONCOL, MEMPHIS, TN 38105 USA; UNIV TENNESSEE, DEPT PEDIAT, MEMPHIS, TN 38105 USA; STANFORD UNIV, HOWARD HUGHES MED INST, STANFORD, CA 94305 USA; STANFORD UNIV, DEPT PATHOL, STANFORD, CA 94305 USA	St Jude Children's Research Hospital; University of Tennessee System; University of Tennessee Health Science Center; Howard Hughes Medical Institute; Stanford University; Stanford University	BRAM, RJ (corresponding author), ST JUDE CHILDRENS RES HOSP, DEPT EXPTL ONCOL, 332 N LAUDERDALE ST, MEMPHIS, TN 38105 USA.							ARBER S, 1992, J CELL BIOL, V116, P113, DOI 10.1083/jcb.116.1.113; BOREL JF, 1976, AGENTS ACTIONS, V6, P468, DOI 10.1007/BF01973261; BRAM RJ, 1993, MOL CELL BIOL, V13, P4760, DOI 10.1128/MCB.13.8.4760; CHIEN CT, 1991, P NATL ACAD SCI USA, V88, P9578, DOI 10.1073/pnas.88.21.9578; CHOU PY, 1974, BIOCHEMISTRY-US, V13, P222, DOI 10.1021/bi00699a002; CLIPSTONE NA, 1992, NATURE, V357, P695, DOI 10.1038/357695a0; CLIPSTONE NA, 1993, ANN NY ACAD SCI, V696, P20; DURAND DB, 1988, MOL CELL BIOL, V8, P1715, DOI 10.1128/MCB.8.4.1715; DURFEE T, 1993, GENE DEV, V7, P555, DOI 10.1101/gad.7.4.555; EMMEL EA, 1989, SCIENCE, V246, P1617, DOI 10.1126/science.2595372; FIELDS S, 1989, NATURE, V340, P245, DOI 10.1038/340245a0; GIBRAT JF, 1987, J MOL BIOL, V198, P425, DOI 10.1016/0022-2836(87)90292-0; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; HUBBARD MJ, 1989, BIOCHEMISTRY-US, V28, P1868, DOI 10.1021/bi00430a066; June C H, 1990, Methods Cell Biol, V33, P37; KARTTUNEN J, 1991, P NATL ACAD SCI USA, V88, P3972, DOI 10.1073/pnas.88.9.3972; KAY JE, 1983, IMMUNOLOGY, V50, P441; KOZAK M, 1984, NATURE, V308, P241, DOI 10.1038/308241a0; KYPTA RM, 1988, EMBO J, V7, P3837, DOI 10.1002/j.1460-2075.1988.tb03269.x; LIU J, 1991, CELL, V66, P807, DOI 10.1016/0092-8674(91)90124-H; MATTILA PS, 1990, EMBO J, V9, P4425, DOI 10.1002/j.1460-2075.1990.tb07893.x; OKEEFE SJ, 1992, NATURE, V357, P692, DOI 10.1038/357692a0; RABINOVITCH PS, 1986, J IMMUNOL, V137, P952; SAMUELSON LE, 1990, P NATL ACAD SCI USA, V87, P4358; SIPOS L, 1993, EUR J BIOCHEM, V213, P1333, DOI 10.1111/j.1432-1033.1993.tb17885.x; STRAUS DB, 1992, CELL, V70, P585, DOI 10.1016/0092-8674(92)90428-F; TAKEBE Y, 1988, MOL CELL BIOL, V8, P466, DOI 10.1128/MCB.8.1.466; TWAMLEYSTEIN GM, 1993, P NATL ACAD SCI USA, V90, P7696, DOI 10.1073/pnas.90.16.7696; ULLMAN KS, 1991, SCIENCE, V254, P558, DOI 10.1126/science.1683003; VERWEIJ CL, 1990, J BIOL CHEM, V265, P15788	30	146	160	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	SEP 22	1994	371	6495					355	358		10.1038/371355a0	http://dx.doi.org/10.1038/371355a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PH254	7522304				2022-12-28	WOS:A1994PH25400059
J	PONZETTO, C; BARDELLI, A; ZHEN, Z; MAINA, F; DALLAZONCA, P; GIORDANO, S; GRAZIANI, A; PANAYOTOU, G; COMOGLIO, PM				PONZETTO, C; BARDELLI, A; ZHEN, Z; MAINA, F; DALLAZONCA, P; GIORDANO, S; GRAZIANI, A; PANAYOTOU, G; COMOGLIO, PM			A MULTIFUNCTIONAL DOCKING SITE MEDIATES SIGNALING AND TRANSFORMATION BY THE HEPATOCYTE GROWTH-FACTOR SCATTER FACTOR-RECEPTOR FAMILY	CELL			English	Article							PHOSPHOLIPASE-C-GAMMA; FACTOR SCATTER FACTOR; MET HGF RECEPTOR; TYROSINE KINASE; PHOSPHATIDYLINOSITOL 3-KINASE; PDGF RECEPTOR; SH2 DOMAINS; CELL-LINE; AUTOPHOSPHORYLATION; IDENTIFICATION	Signaling by tyrosine kinase receptors is mediated by selective interactions between individual Src homology 2 (SH2) domains of cytoplasmic effecters and specific phosphotyrosine residues in the activated receptor. Here, we report the existence in the hepatocyte growth factor/scatter factor (HGF/SF) receptor of a multifunctional docking site made of the tandemly arranged degenerate sequence YVH/NV. Phosphorylation of this site mediates intermediate- to high-affinity interactions with multiple SH2-containing signal transducers, including phosphatidylinositol 3-kinase, phospholipase C gamma, pp60(c-src), and the GRB-2-Sos complex. Mutation of the two tyrosines results in loss of biological function, as shown by abrogation of the transforming activity in the oncogenic counterpart of the receptor. The same bidentate motif is conserved in the evolutionarily related receptors Sea and Ron, suggesting that in all members of the HGF/SF receptor family, signal transduction is channeled through a multifunctional binding site.	LUDWIG INST CANC RES, LONDON W1P 8BT, ENGLAND	Ludwig Institute for Cancer Research	PONZETTO, C (corresponding author), UNIV TURIN, SCH MED, DEPT BIOCHEM SCI & ONCOL, I-10126 TURIN, ITALY.		graziani, andrea/B-2554-2009; Graziani, Andrea/AAB-6301-2022; Maina, Flavio/J-9962-2019; Giordano, Silvia/J-9858-2018; BARDELLI, Alberto/J-9721-2018	graziani, andrea/0000-0002-6302-2317; Graziani, Andrea/0000-0002-6302-2317; Maina, Flavio/0000-0001-6100-4695; Giordano, Silvia/0000-0003-1854-1086; BARDELLI, Alberto/0000-0003-1647-5070; Comoglio, Paolo/0000-0002-7056-5328	Fondazione Telethon Funding Source: Custom	Fondazione Telethon(Fondazione Telethon)		BARDELLI A, 1992, ONCOGENE, V7, P1973; BHARGAVA M, 1992, CELL GROWTH DIFFER, V3, P11; BOTTARO DP, 1991, SCIENCE, V251, P802, DOI 10.1126/science.1846706; BUSSOLINO F, 1992, J CELL BIOL, V119, P629, DOI 10.1083/jcb.119.3.629; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; COMOGLIO PM, 1993, HEPATOCYTE GROWTH FA, P131; COOPER CS, 1984, NATURE, V311, P29, DOI 10.1038/311029a0; COURTNEIDGE SA, 1993, EMBO J, V12, P943, DOI 10.1002/j.1460-2075.1993.tb05735.x; DIRENZO MF, 1991, ONCOGENE, V6, P1997; DIRENZO MF, 1992, ONCOGENE, V7, P2549; ECK MJ, 1993, NATURE, V362, P87, DOI 10.1038/362087a0; EGAN SE, 1993, NATURE, V365, P781, DOI 10.1038/365781a0; FANTL WJ, 1992, CELL, V69, P413, DOI 10.1016/0092-8674(92)90444-H; FELDER S, 1993, MOL CELL BIOL, V13, P1449, DOI 10.1128/MCB.13.3.1449; FERRACINI R, 1991, J BIOL CHEM, V266, P19558; GHERARDI E, 1991, CANCER CELL-MON REV, V3, P227; GIORDANO S, 1993, P NATL ACAD SCI USA, V90, P649, DOI 10.1073/pnas.90.2.649; GIORDANO S, 1989, NATURE, V339, P155, DOI 10.1038/339155a0; GONZATTIHACES M, 1988, P NATL ACAD SCI USA, V85, P21, DOI 10.1073/pnas.85.1.21; GRAZIANI A, 1991, J BIOL CHEM, V266, P22087; GRAZIANI A, 1993, J BIOL CHEM, V268, P9165; HUFF JL, 1993, P NATL ACAD SCI USA, V90, P6140, DOI 10.1073/pnas.90.13.6140; KASHISHIAN A, 1992, EMBO J, V11, P1373, DOI 10.1002/j.1460-2075.1992.tb05182.x; KAZLAUSKAS A, 1992, MOL CELL BIOL, V12, P2534, DOI 10.1128/MCB.12.6.2534; KIM HK, 1991, CELL, V65, P435, DOI 10.1016/0092-8674(91)90461-7; KOCH CA, 1991, SCIENCE, V252, P668, DOI 10.1126/science.1708916; KYPTA RM, 1990, CELL, V62, P481, DOI 10.1016/0092-8674(90)90013-5; LONGATI P, 1994, ONCOGENE, V9, P49; Matsumoto K, 1993, EXS, V65, P225; MORI S, 1993, EMBO J, V12, P2257, DOI 10.1002/j.1460-2075.1993.tb05879.x; NALDINI L, 1991, MOL CELL BIOL, V11, P1793, DOI 10.1128/MCB.11.4.1793; NALDINI L, 1991, ONCOGENE, V6, P501; NISHIMURA R, 1993, MOL CELL BIOL, V13, P6889, DOI 10.1128/MCB.13.11.6889; PANAYOTOU G, 1993, MOL CELL BIOL, V13, P3567, DOI 10.1128/MCB.13.6.3567; PARK M, 1986, CELL, V45, P895, DOI 10.1016/0092-8674(86)90564-7; PAWSON T, 1993, CURR BIOL, V3, P434, DOI 10.1016/0960-9822(93)90350-W; PELECH SL, 1992, SCIENCE, V257, P1355, DOI 10.1126/science.1382311; PENDERGAST AM, 1993, CELL, V75, P175, DOI 10.1016/S0092-8674(05)80094-7; PONZETTO C, 1993, MOL CELL BIOL, V13, P4600, DOI 10.1128/MCB.13.8.4600; PONZETTO C, 1991, ONCOGENE, V6, P553; PRAT M, 1991, MOL CELL BIOL, V11, P5954, DOI 10.1128/MCB.11.12.5954; RODRIGUES GA, 1993, MOL CELL BIOL, V13, P6711, DOI 10.1128/MCB.13.11.6711; RONG S, 1992, MOL CELL BIOL, V12, P5152, DOI 10.1128/MCB.12.11.5152; RONNSTRAND L, 1992, EMBO J, V11, P3911, DOI 10.1002/j.1460-2075.1992.tb05484.x; RONSIN C, 1993, ONCOGENE, V8, P1195; ROTIN D, 1992, EMBO J, V11, P559, DOI 10.1002/j.1460-2075.1992.tb05087.x; SONNENBERG E, 1993, HEPATOCYTE GROWTH FA, P381; STERN CD, 1990, DEVELOPMENT, V110, P1271; VALIUS M, 1993, MOL CELL BIOL, V13, P133, DOI 10.1128/MCB.13.1.133; VILLAMORUZZI E, 1993, J BIOL CHEM, V268, P18176; WAKSMAN G, 1993, CELL, V72, P779, DOI 10.1016/0092-8674(93)90405-F; WAKSMAN G, 1992, NATURE, V358, P646, DOI 10.1038/358646a0; WEIDNER KM, 1990, J CELL BIOL, V111, P2097, DOI 10.1083/jcb.111.5.2097; WEIDNER KM, 1993, J CELL BIOL, V121, P145, DOI 10.1083/jcb.121.1.145; ZHOU SY, 1993, CELL, V72, P767, DOI 10.1016/0092-8674(93)90404-E	55	899	942	0	35	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	APR 22	1994	77	2					261	271		10.1016/0092-8674(94)90318-2	http://dx.doi.org/10.1016/0092-8674(94)90318-2			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	NH634	7513258				2022-12-28	WOS:A1994NH63400011
J	MONTAGUE, PR; GANCAYCO, CD; WINN, MJ; MARCHASE, RB; FRIEDLANDER, MJ				MONTAGUE, PR; GANCAYCO, CD; WINN, MJ; MARCHASE, RB; FRIEDLANDER, MJ			ROLE OF NO PRODUCTION IN NMDA RECEPTOR-MEDIATED NEUROTRANSMITTER RELEASE IN CEREBRAL-CORTEX	SCIENCE			English	Article							LONG-TERM POTENTIATION; NITRIC-OXIDE SYNTHASE; D-ASPARTATE RECEPTORS; GLUTAMATE NEUROTOXICITY; NEURONAL MESSENGER; NERVOUS-SYSTEM; INTERCELLULAR MESSENGER; NORADRENALINE RELEASE; VISUAL-CORTEX; RAT-BRAIN	L-Glutamate and norepinephrine are examples of a major excitatory neurotransmitter and a neuromodulator in the cerebral cortex, respectively. Little is known of how chemical signaling between the anatomically distinct chemical pathways occurs. Specific activation of the N-methyl-D-aspartate (NMDA) class of glutamate receptor in synaptosomal preparations from guinea pig cerebral cortex caused release of both of these chemicals, and this release was blocked by agents that inhibit nitric oxide (NO) production or remove NO from the extracellular space. Furthermore, neurotransmitter release correlated with cortical NO production after NMDA receptor stimulation. These results suggest that NO production and its extracellular movement may be links in the pathway from NMDA receptor activation to changes in chemical signaling in surrounding synaptic terminals in the cerebral cortex.	UNIV ALABAMA, NEUROBIOL RES CTR, BIRMINGHAM, AL 35294 USA; UNIV ALABAMA, DEPT PHARMACOL, BIRMINGHAM, AL 35294 USA	University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham					NEI NIH HHS [EY05116, EY06714] Funding Source: Medline	NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		BEAR MF, 1990, J NEUROSCI, V10, P909; BECKMAN JS, 1990, P NATL ACAD SCI USA, V87, P1620, DOI 10.1073/pnas.87.4.1620; BELLAN JA, 1993, EUR J PHARMACOL, V234, P273, DOI 10.1016/0014-2999(93)90964-J; BETTACHE N, 1993, BIOPHYS J, V64, pA190; BOHME GA, 1991, EUR J PHARMACOL, V199, P379, DOI 10.1016/0014-2999(91)90505-K; BREDT DS, 1990, NATURE, V347, P768, DOI 10.1038/347768a0; BREDT DS, 1992, NEURON, V8, P3, DOI 10.1016/0896-6273(92)90104-L; CHOI DW, 1988, NEURON, V1, P623, DOI 10.1016/0896-6273(88)90162-6; CHOI DW, 1988, J NEUROSCI, V8, P185; CHOI DW, 1990, J NEUROSCI, V10, P2493; CLINE HT, 1987, P NATL ACAD SCI USA, V84, P4342, DOI 10.1073/pnas.84.12.4342; COLLINGRIDGE GL, 1983, J PHYSIOL-LONDON, V334, P33, DOI 10.1113/jphysiol.1983.sp014478; DAWSON TM, 1992, ANN NEUROL, V32, P297, DOI 10.1002/ana.410320302; DAWSON VL, 1993, J NEUROSCI, V13, P2651; DAWSON VL, 1991, P NATL ACAD SCI USA, V88, P6368, DOI 10.1073/pnas.88.14.6368; DWYER MA, 1991, BIOCHEM BIOPH RES CO, V176, P1136, DOI 10.1016/0006-291X(91)90403-T; ERRINGTON ML, 1987, NEUROSCIENCE, V20, P279, DOI 10.1016/0306-4522(87)90019-4; FARACI FM, 1993, CIRC RES, V72, P476, DOI 10.1161/01.RES.72.2.476; FARACI FM, 1990, AM J PHYSIOL, V259, pH1216, DOI 10.1152/ajpheart.1990.259.4.H1216; FEELISCH M, 1987, EUR J PHARMACOL, V139, P19, DOI 10.1016/0014-2999(87)90493-6; FERKANY JW, 1982, NATURE, V298, P757, DOI 10.1038/298757a0; FINK K, 1990, EUR J PHARMACOL, V185, P115, DOI 10.1016/0014-2999(90)90219-V; FREGNAC Y, 1994, IN PRESS J NEUROPHYS, V71, P146; FRIEDLANDER MJ, 1993, PROG BRAIN RES, V95, P207, DOI 10.1016/S0079-6123(08)60370-2; FURCHGOTT RF, 1980, NATURE, V288, P373, DOI 10.1038/288373a0; FURCHGOTT RF, 1989, FASEB J, V3, P2007, DOI 10.1096/fasebj.3.9.2545495; GALLY JA, 1990, P NATL ACAD SCI USA, V87, P3547, DOI 10.1073/pnas.87.9.3547; GARTHWAITE J, 1988, NATURE, V336, P385, DOI 10.1038/336385a0; GARTHWAITE J, 1989, EUR J PHARM-MOLEC PH, V172, P413, DOI 10.1016/0922-4106(89)90023-0; GARTHWAITE J, 1991, TRENDS NEUROSCI, V14, P60, DOI 10.1016/0166-2236(91)90022-M; GORDON B, 1988, PROG NEUROBIOL, V30, P171, DOI 10.1016/0301-0082(88)90005-6; HALEY JE, 1992, NEURON, V8, P211, DOI 10.1016/0896-6273(92)90288-O; HARRIS EW, 1984, BRAIN RES, V323, P132, DOI 10.1016/0006-8993(84)90275-0; IADECOLA C, 1993, TRENDS NEUROSCI, V16, P206, DOI 10.1016/0166-2236(93)90156-G; IZUMI Y, 1992, SCIENCE, V257, P1273, DOI 10.1126/science.1519065; KOVACH AGB, 1992, J PHYSIOL-LONDON, V449, P183, DOI 10.1113/jphysiol.1992.sp019081; LADECOLA C, 1993, BRAIN RES, V606, P148; LIPTON SA, 1993, NATURE, V364, P626, DOI 10.1038/364626a0; MANZONI O, 1993, J NEUROCHEM, V61, P368, DOI 10.1111/j.1471-4159.1993.tb03580.x; MANZONI O, 1992, NEURON, V8, P653, DOI 10.1016/0896-6273(92)90087-T; Montague PR, 1991, CEREB CORTEX, V1, P199, DOI 10.1093/cercor/1.3.199; MOORE PK, 1993, BRIT J PHARMACOL, V108, P296, DOI 10.1111/j.1476-5381.1993.tb12798.x; MUSLEH WY, 1993, SYNAPSE, V13, P370, DOI 10.1002/syn.890130409; NICHOLS RA, 1989, J NEUROCHEM, V52, P521, DOI 10.1111/j.1471-4159.1989.tb09151.x; ODELL TJ, 1991, P NATL ACAD SCI USA, V88, P11285, DOI 10.1073/pnas.88.24.11285; RADI R, 1991, J BIOL CHEM, V266, P4244; REGIDOR J, 1993, NEUROREPORT, V4, P112, DOI 10.1097/00001756-199301000-00030; SCHARFMAN HE, 1990, P NATL ACAD SCI USA, V87, P4548, DOI 10.1073/pnas.87.12.4548; SCHUMAN EM, 1991, SCIENCE, V254, P1503, DOI 10.1126/science.1720572; SHULZ D, 1992, J NEUROSCI, V12, P1301; SNYDER SH, 1992, SCIENCE, V257, P494, DOI 10.1126/science.1353273; SNYDER SH, 1991, TRENDS PHARMACOL SCI, V12, P125, DOI 10.1016/0165-6147(91)90526-X; STAMLER JS, 1992, SCIENCE, V258, P1898, DOI 10.1126/science.1281928; STEVENS CF, 1993, NATURE, V364, P147, DOI 10.1038/364147a0; SUTOR B, 1989, J NEUROPHYSIOL, V61, P621, DOI 10.1152/jn.1989.61.3.621; THOMSON AM, 1986, NEUROSCIENCE, V17, P37, DOI 10.1016/0306-4522(86)90223-X; THOMSON AM, 1986, J PHYSIOL-LONDON, V370, P531, DOI 10.1113/jphysiol.1986.sp015949; TSUMOTO T, 1987, NATURE, V327, P513, DOI 10.1038/327513a0; VALTSCHANOFF JG, 1993, J COMP NEUROL, V331, P111, DOI 10.1002/cne.903310107; VERMA A, 1993, SCIENCE, V259, P381, DOI 10.1126/science.7678352; VINCENT SR, 1992, TRENDS NEUROSCI, V15, P108, DOI 10.1016/0166-2236(92)90021-Y; VINCENT SR, 1992, NEUROSCIENCE, V46, P755, DOI 10.1016/0306-4522(92)90184-4; WANG JKT, 1992, J NEUROCHEM, V58, P204, DOI 10.1111/j.1471-4159.1992.tb09297.x; WILLIAMS JH, 1993, SEMIN NEUROSCI, V5, P149, DOI 10.1016/S1044-5765(05)80048-X; WINN MJ, 1991, J CARDIOVASC PHARM, V18, P68, DOI 10.1097/00005344-199107000-00010; WINN MJ, 1992, J PHARMACOL TOXICOL, V28, P49, DOI 10.1016/1056-8719(92)90065-9; WU WT, 1993, NEUROSCI LETT, V153, P121, DOI 10.1016/0304-3940(93)90303-3; ZHOU M, 1993, SCIENCE, V260, P1946	68	466	473	0	6	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	FEB 18	1994	263	5149					973	977		10.1126/science.7508638	http://dx.doi.org/10.1126/science.7508638			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	MX165	7508638				2022-12-28	WOS:A1994MX16500038
J	HUANG, MX; CHALFIE, M				HUANG, MX; CHALFIE, M			GENE INTERACTIONS AFFECTING MECHANOSENSORY TRANSDUCTION IN CAENORHABDITIS-ELEGANS	NATURE			English	Article							SODIUM-CHANNEL; EXPRESSION; NEURONS; PROTEIN	GENETIC screening has identified a group of mec (mechanosensory) genes that are required for the function of a set of six touch-receptor neurons in the nematode Caenorhabditis elegans1,2. Such genes potentially encode components of the mechanosensory apparatus. We have cloned one of these genes, mec-10, which is a member of the degenerin gene family (genes such as mec-4 and deg-1 (refs 3, 4) that can be mutated to cause neurodegeneration). Because components of an amiloride-sensitive sodium channel (alpha, beta and gammarENaC) from rat6-8 share considerable sequence similarity with the C. elegans genes, it is likely that degenerins may function as channel proteins. Here we show that two degenerin homologues (mec-4 and mec-10) are expressed in the same cells, although each provides a unique function. Based on genetic data of mutations affecting mec-10-induced degeneration, we propose that the products of three genes (mec-4, mec-10 and mec-6) form a complex needed for mechanosensation, and that several other mec genes may be important in regulating the putative channel complex.			HUANG, MX (corresponding author), COLUMBIA UNIV,DEPT BIOL SCI,1012 FAIRCHILD CTR,NEW YORK,NY 10027, USA.							BARBRY P, 1990, P NATL ACAD SCI USA, V87, P7347, DOI 10.1073/pnas.87.19.7347; BENOS DJ, 1987, J BIOL CHEM, V262, P10613; CANESSA CM, 1994, NATURE, V367, P463, DOI 10.1038/367463a0; CANESSA CM, 1993, NATURE, V361, P467, DOI 10.1038/361467a0; CHALFIE M, 1990, NATURE, V345, P410, DOI 10.1038/345410a0; CHALFIE M, 1981, DEV BIOL, V82, P358, DOI 10.1016/0012-1606(81)90459-0; CHALFIE M, 1989, SCIENCE, V243, P1027, DOI 10.1126/science.2646709; CHALFIE M, 1993, NATURE, V361, P504, DOI 10.1038/361504a0; DRISCOLL M, 1991, NATURE, V349, P588, DOI 10.1038/349588a0; FIRE A, 1990, GENE, V93, P189, DOI 10.1016/0378-1119(90)90224-F; FIRE A, 1986, EMBO J, V5, P2673, DOI 10.1002/j.1460-2075.1986.tb04550.x; HONG KS, 1994, NATURE, V367, P470, DOI 10.1038/367470a0; KAPLAN JM, 1993, P NATL ACAD SCI USA, V90, P2227, DOI 10.1073/pnas.90.6.2227; LINGUEGLIA E, 1993, FEBS LETT, V318, P95, DOI 10.1016/0014-5793(93)81336-X; MITANI S, 1993, DEVELOPMENT, V119, P373; PALOZZOLO MJ, 1990, GENE, V88, P25; PEARSON WR, 1988, P NATL ACAD SCI USA, V85, P2444, DOI 10.1073/pnas.85.8.2444; SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875; Sambrook J, 1989, MOL CLONING LABORATO; SAVAGE C, 1989, GENE DEV, V3, P870, DOI 10.1101/gad.3.6.870; STAUB O, 1992, J CELL BIOL, V119, P1497, DOI 10.1083/jcb.119.6.1497; SULSTON J, 1988, CAENORHABDITIS ELEGA; WAY JC, 1989, GENE DEV, V3, P1823, DOI 10.1101/gad.3.12a.1823; XUE D, 1993, SCIENCE, V261, P1324, DOI 10.1126/science.8103239	24	337	362	0	18	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	FEB 3	1994	367	6462					467	470		10.1038/367467a0	http://dx.doi.org/10.1038/367467a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	MU679	7509039				2022-12-28	WOS:A1994MU67900056
J	Wald, A; Zeh, J; Barnum, G; Davis, LG; Corey, L				Wald, A; Zeh, J; Barnum, G; Davis, LG; Corey, L			Suppression of subclinical shedding of herpes simplex virus type 2 with acyclovir	ANNALS OF INTERNAL MEDICINE			English	Article							RECURRENT GENITAL HERPES; ORAL ACYCLOVIR; TRANSMISSION; INFECTION; LESIONS; WOMEN; ACQUISITION; PARTNER; THERAPY; TRIAL	Objective: To assess the effect of the antiviral drug acyclovir on the frequency of subclinical shedding of herpes simplex virus (HSV) in the genital tract. Design: A double-blind, placebo-controlled, crossover clinical trial. Setting: A university-based virology research clinic. Patients: 34 women with herpes simplex virus type 2 (HSV-2) antibody only and genital herpes of less than 2 years' duration. Intervention: Participants were randomly assigned to receive either acyclovir, 400 mg twice daily for 70 days, followed by a 14-day washout period, and then placebo for 70 days, or the study medications in the reverse order. Measurements: Women collected daily genital swabs of the vulvar, cervicovaginal, and perianal areas for HSV culture, maintained a diary of genital lesions, and were examined at the time of recurrences. Results: In an intent-to-treat analysis of the initial treatment period, 15 of the 17 women who received placebo and 3 of the 17 women who received acyclovir had at least 1 day of subclinical shedding (P < 0.001). Among the participants who received placebo, subclinical shedding occurred on 64 of 928 (6.9%) days compared with 3 of 1057 (0.3%) days among the participants who received acyclovir (P < 0.001). The relative risk for subclinical shedding was 0.09 (95% CI, 0.03 to 0.35) for the women who received acyclovir compared with the women who received placebo. In a paired analysis of 26 women who completed both arms of the study, acyclovir therapy was associated with a decrease in the frequency of subclinical shedding; subclinical shedding occurred on 83 of 1439 (5.8%) days with placebo, and on 6 of 1611 (0.37%) days with acyclovir (P < 0.001)-a 94% reduction. The frequency of subclinical shedding was reduced at all anatomic sites and in all patients. Conclusions: Daily therapy with oral acyclovir suppresses subclinical shedding of HSV-2 in the genital tract, suggesting that studies to evaluate the use of acyclovir in preventing HSV-2 transmission are warranted.	BURROUGHS WELLCOME CO, RES TRIANGLE PK, NC 27709 USA	Burroughs Wellcome Fund	Wald, A (corresponding author), UNIV WASHINGTON, DIV VIROL, ROOM 9301, 1200 12TH AVE S, SEATTLE, WA 98144 USA.		Corey, Lawrence/AAE-1796-2020; Wald, Anna/B-6272-2012	Corey, Lawrence/0000-0002-2179-2436; Wald, Anna/0000-0003-3486-6438	NIAID NIH HHS [AI-30731] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [P01AI030731] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		[Anonymous], 1993, MMWR Recomm Rep, V42, P1; ASHLEY RL, 1988, J CLIN MICROBIOL, V26, P662, DOI 10.1128/JCM.26.4.662-667.1988; BARTON SE, 1987, GENITOURIN MED, V63, P102; BENEDETTI J, 1994, ANN INTERN MED, V121, P847, DOI 10.7326/0003-4819-121-11-199412010-00004; Bowman C A, 1990, Int J STD AIDS, V1, P174; BROCK BV, 1990, JAMA-J AM MED ASSOC, V263, P418, DOI 10.1001/jama.263.3.418; BROWN ZA, 1991, NEW ENGL J MED, V324, P1247, DOI 10.1056/NEJM199105023241804; BRYSON Y, 1993, J INFECT DIS, V167, P942, DOI 10.1093/infdis/167.4.942; COLLINS P, 1993, J MED VIROL, P58, DOI 10.1002/jmv.1890410512; CONE RW, 1994, JAMA-J AM MED ASSOC, V272, P792, DOI 10.1001/jama.272.10.792; DOUGLAS JM, 1984, NEW ENGL J MED, V310, P1551, DOI 10.1056/NEJM198406143102402; FIFE K, 1994, J INFECT DIS, P169; GOLDBERG LH, 1993, ARCH DERMATOL, V129, P582, DOI 10.1001/archderm.129.5.582; HADDAD J, 1993, OBSTET GYNECOL, V82, P102; KAPLOWITZ LG, 1991, JAMA-J AM MED ASSOC, V265, P747, DOI 10.1001/jama.265.6.747; KOELLE DM, 1992, ANN INTERN MED, V116, P433, DOI 10.7326/0003-4819-116-6-433; LAFFERTY WE, 1987, J CLIN MICROBIOL, V25, P323, DOI 10.1128/JCM.25.2.323-326.1987; LANGENBERG A, 1988, J CLIN MICROBIOL, V26, P1772, DOI 10.1128/JCM.26.9.1772-1774.1988; LANGENBERG A, 1989, ANN INTERN MED, V110, P882, DOI 10.7326/0003-4819-110-11-882; MCLAREN C, 1983, ANTIVIR RES, V3, P223, DOI 10.1016/0166-3542(83)90001-3; MERTZ GJ, 1988, J INFECT DIS, V157, P1169, DOI 10.1093/infdis/157.6.1169; MERTZ GJ, 1992, ANN INTERN MED, V116, P197, DOI 10.7326/0003-4819-116-3-197; MINDEL A, 1988, LANCET, V1, P926; MOORE DE, 1989, JAMA-J AM MED ASSOC, V261, P3441, DOI 10.1001/jama.261.23.3441; NILSEN AE, 1982, LANCET, V2, P571; REICHMAN RC, 1984, JAMA-J AM MED ASSOC, V251, P2103, DOI 10.1001/jama.251.16.2103; ROONEY JF, 1986, NEW ENGL J MED, V314, P1561, DOI 10.1056/NEJM198606123142407; SACKS SL, 1988, SEX TRANSM DIS, V15, P58, DOI 10.1097/00007435-198801000-00013; SIBRACK CD, 1982, J INFECT DIS, V146, P673, DOI 10.1093/infdis/146.5.673; STRAUS SE, 1989, SEX TRANSM DIS, V16, P107; STRAUS SE, 1984, NEW ENGL J MED, V310, P1545, DOI 10.1056/NEJM198406143102401; STRAUS SE, 1994, LANCET, V343, P1460, DOI 10.1016/S0140-6736(94)92581-X; SWANSON JM, 1990, PUBLIC HEALTH NURS, V7, P96, DOI 10.1111/j.1525-1446.1990.tb00618.x; WALD A, 1995, NEW ENGL J MED, V333, P770, DOI 10.1056/NEJM199509213331205; WOODS JR, 1989, ANN INTERN MED, V110, P560, DOI 10.7326/0003-4819-110-7-560	35	210	215	0	3	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JAN 1	1996	124	1	1				8	15		10.7326/0003-4819-124-1_Part_1-199601010-00002	http://dx.doi.org/10.7326/0003-4819-124-1_Part_1-199601010-00002			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TL943	7503497				2022-12-28	WOS:A1996TL94300002
J	SENEFF, MG; WAGNER, DP; WAGNER, RP; ZIMMERMAN, JE; KNAUS, WA				SENEFF, MG; WAGNER, DP; WAGNER, RP; ZIMMERMAN, JE; KNAUS, WA			HOSPITAL AND 1-YEAR SURVIVAL OF PATIENTS ADMITTED TO INTENSIVE-CARE UNITS WITH ACUTE EXACERBATION OF CHRONIC OBSTRUCTIVE PULMONARY-DISEASE	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							ACUTE RESPIRATORY-FAILURE; LONG-TERM PROGNOSIS; MECHANICAL VENTILATION; LUNG-DISEASE; COPD; MORTALITY; DETERMINANTS; INSUFFICIENCY; MANAGEMENT; PREDICTORS	Objective.-To describe outcomes and identify variables associated with hospital and 1-year survival for patients admitted to an intensive care unit (ICU) with an acute exacerbation of chronic obstructive pulmonary disease (COPD). Design.-Prospective, multicenter, inception cohort study. Setting.-Forty-two ICUs at 40 US hospitals. Patients.-A total of 362 admissions for COPD exacerbation selected from the Acute Physiology and Chronic Health Evaluation (APACHE) III database of 17 440 ICU admissions. Measurements and Results.-Hospital mortality for the 362 admissions was 24%, For the 167 patients aged 65 years or older, mortality was 30% at hospital discharge, 41% at 90 days, 47% at 180 days, and 59% at 1 year, Median survival for all patients was 224 days, and median survival for the patients who died within 1 year was 30.5 days, On multiple regression analysis, variables associated with hospital mortality included age, severity of respiratory and nonrespiratory organ system dysfunction, and hospital length of stay before ICU admission, Development of nonrespiratory organ system dysfunction was the major predictor of hospital mortality (60% of total explanatory power) and 180-day outcomes (54% of explanatory power), Respiratory physiological variables (respiratory rate, serum pH, PaCO2, PaO2, and alveolar-arterial difference in partial pressure of oxygen [PAO(2)-PaO2]) indicative of advanced dysfunction were more strongly associated with 180-day mortality rates (22% of explanatory power) than hospital death rates (4% of explanatory power), After controlling for severity of illness, mechanical ventilation at ICU admission was not associated with either hospital mortality or subsequent survival. Conclusions.-Patients with COPD admitted to an ICU for an acute exacerbation have a substantial hospital mortality (24%), For patients aged 65 years or older, mortality doubles in 1 year from 30% to 59%, Hospital and longer-term mortality is closely associated with development of nonrespiratory organ system dysfunction; severity of the underlying respiratory function substantially influences mortality following hospital discharge, The need for mechanical ventilation at ICU admission did not influence either short- or long-term outcomes, Physicians should be aware of these relationships when making treatment decisions or evaluating new therapies.	GEORGE WASHINGTON UNIV, MED CTR, DEPT MED, DIV PULM, WASHINGTON, DC 20037 USA	George Washington University	SENEFF, MG (corresponding author), GEORGE WASHINGTON UNIV, MED CTR, DEPT ANESTHESIOL, ICU RES UNIT, 901 23RD ST NW, WASHINGTON, DC 20037 USA.		Knaus, William/AAX-2138-2020		AHRQ HHS [HS07137] Funding Source: Medline	AHRQ HHS(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality)		ANTHONISEN NR, 1986, AM REV RESPIR DIS, V133, P14, DOI 10.1164/arrd.1986.133.1.14; ASMUNDSSON T, 1969, ANN INTERN MED, V70, P471, DOI 10.7326/0003-4819-70-3-471; BEAL AL, 1994, JAMA-J AM MED ASSOC, V271, P226, DOI 10.1001/jama.271.3.226; BONE RC, 1981, MED CLIN N AM, V65, P563, DOI 10.1016/S0025-7125(16)31514-0; BROCHARD L, 1990, NEW ENGL J MED, V323, P1523, DOI 10.1056/NEJM199011293232204; BURK RH, 1973, ARCH INTERN MED, V132, P865, DOI 10.1001/archinte.132.6.865; BURROWS B, 1969, AM REV RESPIR DIS, V99, P865; CORRADO A, 1992, CHEST, V101, P692, DOI 10.1378/chest.101.3.692; CURTIS JR, 1994, CLIN CHEST MED, V15, P481; DAMIANO AM, 1992, J CLIN EPIDEMIOL, V45, P93, DOI 10.1016/0895-4356(92)90001-4; DRAGSTED L, 1989, CRIT CARE MED, V17, P418, DOI 10.1097/00003246-198905000-00008; FUSO L, 1995, AM J MED, V98, P272, DOI 10.1016/S0002-9343(99)80374-X; GRACEY DR, 1995, CHEST, V107, P494, DOI 10.1378/chest.107.2.494; HEUSER MD, 1992, ARCH INTERN MED, V152, P1683, DOI 10.1001/archinte.152.8.1683; HIGGINS MW, 1989, CHEST, V96, pS328; HODGKIN JE, 1990, CLIN CHEST MED, V11, P555; JEFFREY AA, 1992, THORAX, V47, P34, DOI 10.1136/thx.47.1.34; JESSEN O, 1967, LANCET, V2, P9; KAELIN RM, 1987, CHEST, V92, P971, DOI 10.1378/chest.92.6.971; KANNER RE, 1983, AM J MED, V74, P249, DOI 10.1016/0002-9343(83)90623-X; KATZ S, 1963, JAMA-J AM MED ASSOC, V185, P914, DOI 10.1001/jama.1963.03060120024016; KETTEL LJ, 1971, J AMER MED ASSOC, V217, P1503, DOI 10.1001/jama.217.11.1503; KNAUS W A, 1989, American Review of Respiratory Disease, V140, pS8; KNAUS WA, 1993, ANN INTERN MED, V118, P753, DOI 10.7326/0003-4819-118-10-199305150-00001; KNAUS WA, 1991, CHEST, V100, P1619, DOI 10.1378/chest.100.6.1619; LUDWIGS UG, 1991, J INTERN MED, V229, P117, DOI 10.1111/j.1365-2796.1991.tb00318.x; MARTIN TR, 1982, CHEST, V82, P310, DOI 10.1378/chest.82.3.310; MENZIES R, 1989, CHEST, V95, P398, DOI 10.1378/chest.95.2.398; MOSER KM, 1973, JAMA-J AM MED ASSOC, V225, P705; PORTIER F, 1992, CHEST, V101, P204, DOI 10.1378/chest.101.1.204; POSTMA DS, 1979, AM REV RESPIR DIS, V119, P357; RIEVES RD, 1993, CHEST, V104, P854, DOI 10.1378/chest.104.3.854; ROGERS RM, 1989, AM REV RESPIR DIS, V140, P869, DOI 10.1164/ajrccm/140.4.869; SAINT S, 1995, JAMA-J AM MED ASSOC, V273, P957, DOI 10.1001/jama.273.12.957; SCHEINHORN DJ, 1994, CHEST, V105, P534, DOI 10.1378/chest.105.2.534; SCHMIDT GA, 1989, JAMA-J AM MED ASSOC, V261, P3444, DOI 10.1001/jama.261.23.3444; SHACHOR Y, 1989, ISRAEL J MED SCI, V25, P617; SLUITER HJ, 1972, AM REV RESPIR DIS, V105, P932; STAUFFER JL, 1993, CHEST, V104, P1222, DOI 10.1378/chest.104.4.1222; THURLBECK WM, 1990, CLIN CHEST MED, V11, P389; TRAVER GA, 1979, AM REV RESPIR DIS, V119, P895; VITACCA M, 1993, INTENS CARE MED, V19, P450, DOI 10.1007/BF01711086; WAGNER DP, 1986, ARCH INTERN MED, V146, P1389, DOI 10.1001/archinte.146.7.1389; WARREN PM, 1980, LANCET, V1, P467; WEISS SM, 1994, CRIT CARE CLIN, V10, P197, DOI 10.1016/S0749-0704(18)30156-8; WYSOCKI M, 1995, CHEST, V107, P761, DOI 10.1378/chest.107.3.761; 1991, STATISTICAL ABSTRACT	47	405	422	1	14	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	DEC 20	1995	274	23					1852	1857		10.1001/jama.274.23.1852	http://dx.doi.org/10.1001/jama.274.23.1852			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TK147	7500534				2022-12-28	WOS:A1995TK14700026
J	BRUSA, R; ZIMMERMANN, F; KOH, DS; FELDMEYER, D; GASS, P; SEEBURG, PH; SPRENGEL, R				BRUSA, R; ZIMMERMANN, F; KOH, DS; FELDMEYER, D; GASS, P; SEEBURG, PH; SPRENGEL, R			EARLY-ONSET EPILEPSY AND POSTNATAL LETHALITY ASSOCIATED WITH AN EDITING-DEFICIENT GLUR-B ALLELE IN MICE	SCIENCE			English	Article							RECEPTOR CHANNELS; DIFFERENTIAL EXPRESSION; ION FLOW; GENE; SUBUNITS; NEURONS; PERMEABILITY; HIPPOCAMPUS; SWITCH; FAMILY	The arginine residue at position 586 of the GluR-B subunit renders heteromeric alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionate (AMPA)-sensitive glutamate receptor channels impermeable to calcium. The codon for this arginine is introduced at the precursor messenger RNA (pre-mRNA) stage by site-selective adenosine editing of a glutamine codon. Heterozygous mice engineered by gene targeting to harbor an editing-incompetent GluR-B allele synthesized unedited GluR-B subunits and, in principal neurons and interneurons, expressed AMPA receptors with increased calcium permeability. These mice developed seizures and died by 3 weeks of age, showing that GluR-B pre-mRNA editing is essential for brain function.	MAX PLANCK INST MED RES, ZELLPHYSIOL ABT, D-69120 HEIDELBERG, GERMANY; UNIV HEIDELBERG, INST NEUROPATHOL, D-69120 HEIDELBERG, GERMANY	Max Planck Society; Ruprecht Karls University Heidelberg	BRUSA, R (corresponding author), UNIV HEIDELBERG, CTR MOLEC BIOL, MOLEC NEUROENDOCRINOL LAB, NEUENHEIMER FELD 282, D-69120 HEIDELBERG, GERMANY.		Feldmeyer, Dirk/H-5940-2013	Feldmeyer, Dirk/0000-0002-1716-8972				BECK E, 1982, GENE, V19, P327, DOI 10.1016/0378-1119(82)90023-3; BECK KD, 1995, NEURON, V14, P717, DOI 10.1016/0896-6273(95)90216-3; BURNASHEV N, 1992, NEURON, V8, P189, DOI 10.1016/0896-6273(92)90120-3; BURNASHEV N, 1995, J PHYSIOL-LONDON, V485, P403, DOI 10.1113/jphysiol.1995.sp020738; DISTREY BD, 1970, HISTOLOGICAL LABORAT; GALLIN WJ, 1995, CURR OPIN NEUROBIOL, V5, P367, DOI 10.1016/0959-4388(95)80050-6; GASS P, 1992, NEUROSCIENCE, V48, P315, DOI 10.1016/0306-4522(92)90493-L; GEIGER JRP, 1995, NEURON, V15, P193, DOI 10.1016/0896-6273(95)90076-4; GU H, 1993, CELL, V73, P1155, DOI 10.1016/0092-8674(93)90644-6; Hauser W, 1990, EPILEPSY FREQUENCY C; HESTRIN S, 1993, NEURON, V11, P1083, DOI 10.1016/0896-6273(93)90221-C; HIGUCHI M, 1993, CELL, V75, P1361, DOI 10.1016/0092-8674(93)90622-W; HOLLMANN M, 1991, SCIENCE, V252, P851, DOI 10.1126/science.1709304; HOLLMANN M, 1994, ANNU REV NEUROSCI, V17, P31, DOI 10.1146/annurev.ne.17.030194.000335; HUME RI, 1991, SCIENCE, V253, P1028, DOI 10.1126/science.1653450; ISHII T, 1993, J BIOL CHEM, V268, P2836; JONAS P, 1994, NEURON, V12, P1281, DOI 10.1016/0896-6273(94)90444-8; Jonas Peter, 1994, Current Opinion in Neurobiology, V4, P366, DOI 10.1016/0959-4388(94)90098-1; KEINANEN K, 1990, SCIENCE, V249, P556, DOI 10.1126/science.2166337; KOH DS, 1995, J PHYSIOL-LONDON, V485, P383, DOI 10.1113/jphysiol.1995.sp020737; KOHLER M, 1994, J BIOL CHEM, V269, P17367; LAMBOLEZ B, 1992, NEURON, V9, P247, DOI 10.1016/0896-6273(92)90164-9; LEWIS CA, 1979, J PHYSIOL-LONDON, V286, P417, DOI 10.1113/jphysiol.1979.sp012629; LOMELI H, 1994, SCIENCE, V266, P1709, DOI 10.1126/science.7992055; MAYER ML, 1987, J PHYSIOL-LONDON, V394, P501, DOI 10.1113/jphysiol.1987.sp016883; MCNAMARA JO, 1994, J NEUROSCI, V14, P3413; MELCHER T, 1995, J BIOL CHEM, V270, P8566, DOI 10.1074/jbc.270.15.8566; MONYER H, 1994, NEURON, V12, P529, DOI 10.1016/0896-6273(94)90210-0; MORGAN JI, 1991, ANNU REV NEUROSCI, V14, P421, DOI 10.1146/annurev.ne.14.030191.002225; NADLER JV, 1981, LIFE SCI, V29, P2031; NAGY A, 1993, P NATL ACAD SCI USA, V90, P8424, DOI 10.1073/pnas.90.18.8424; Nakajima S, 1991, Hippocampus, V1, P67, DOI 10.1002/hipo.450010107; RACINE RJ, 1972, ELECTROEN CLIN NEURO, V32, P281, DOI 10.1016/0013-4694(72)90177-0; RUETER SM, 1995, SCIENCE, V267, P1491, DOI 10.1126/science.7878468; SAKIMURA K, 1990, FEBS LETT, V272, P73, DOI 10.1016/0014-5793(90)80452-O; SATHER W, 1992, J PHYSIOL-LONDON, V450, P643, DOI 10.1113/jphysiol.1992.sp019148; SOMMER B, 1991, CELL, V67, P11, DOI 10.1016/0092-8674(91)90568-J; SOMMER B, 1990, SCIENCE, V249, P1580, DOI 10.1126/science.1699275; STERNBERG N, 1986, J MOL BIOL, V187, P197, DOI 10.1016/0022-2836(86)90228-7; STUART GJ, 1993, PFLUG ARCH EUR J PHY, V423, P511, DOI 10.1007/BF00374949; VERDOORN TA, 1991, SCIENCE, V252, P1715, DOI 10.1126/science.1710829; WATANABE M, 1992, NEUROREPORT, V3, P1138, DOI 10.1097/00001756-199212000-00027; WISDEN W, 1990, NEURON, V4, P603, DOI 10.1016/0896-6273(90)90118-Y; YANG JH, 1995, NATURE, V374, P77, DOI 10.1038/374077a0	44	458	472	0	15	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	DEC 8	1995	270	5242					1677	1680		10.1126/science.270.5242.1677	http://dx.doi.org/10.1126/science.270.5242.1677			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TJ293	7502080				2022-12-28	WOS:A1995TJ29300052
J	YIN, H; WANG, MD; SVOBODA, K; LANDICK, R; BLOCK, SM; GELLES, J				YIN, H; WANG, MD; SVOBODA, K; LANDICK, R; BLOCK, SM; GELLES, J			TRANSCRIPTION AGAINST AN APPLIED FORCE	SCIENCE			English	Article							RNA-POLYMERASE; ESCHERICHIA-COLI; SINGLE MOLECULES; DNA; TEMPLATE	The force produced by a single molecule of Escherichia coli RNA polymerase during transcription was measured optically. Polymerase immobilized on a surface was used to transcribe a DNA template attached to a polystyrene bead 0.5 micrometer in diameter. The bead position was measured by interferometry while a force opposing translocation of the polymerase along the DNA was applied with an optical trap. At saturating nucleoside triphosphate concentrations, polymerase molecules stalled reversibly at a mean applied force estimated to be 14 piconewtons. This force is substantially larger than those measured for the cytoskeletal motors kinesin and myosin and exceeds mechanical loads that are estimated to oppose transcriptional elongation in vivo. The data are consistent with efficient conversion of the free energy liberated by RNA synthesis into mechanical work.	BRANDEIS UNIV, DEPT BIOCHEM, BIOPHYS PROGRAM, WALTHAM, MA 02254 USA; BRANDEIS UNIV, CTR COMPLEX SYST, WALTHAM, MA 02254 USA; PRINCETON UNIV, DEPT MOLEC BIOL, PRINCETON, NJ 08544 USA; PRINCETON UNIV, PRINCETON MAT INST, PRINCETON, NJ 08544 USA; AT&T BELL LABS, DEPT BIOL COMPUTAT, MURRAY HILL, NJ 07974 USA; UNIV WISCONSIN, DEPT BACTERIOL, MADISON, WI 53706 USA	Brandeis University; Brandeis University; Princeton University; Princeton University; AT&T; Nokia Corporation; Nokia Bell Labs; University of Wisconsin System; University of Wisconsin Madison								BLOCK SM, 1995, TRENDS CELL BIOL, V5, P169, DOI 10.1016/S0962-8924(00)88982-5; BORUKHOV S, 1993, CELL, V72, P459, DOI 10.1016/0092-8674(93)90121-6; BUSTAMANTE C, 1994, SCIENCE, V265, P1599, DOI 10.1126/science.8079175; CHAMBERLIN M, 1963, J MOL BIOL, V7, P334, DOI 10.1016/S0022-2836(63)80028-5; Chamberlin M.J., 1994, HARVEY LECT, V88, P1; CHAN CL, 1994, TRANSCRIPTION MECHAN, P297; COOK DN, 1992, P NATL ACAD SCI USA, V89, P10603, DOI 10.1073/pnas.89.22.10603; COOK DN, 1994, NUCL ACIDS MOL BIOL, V8, P133; COOK PR, 1994, BIOESSAYS, V16, P425, DOI 10.1002/bies.950160611; ERIE DA, 1993, SCIENCE, V262, P867, DOI 10.1126/science.8235608; ERIE DA, 1992, ANNU REV BIOPH BIOM, V21, P379, DOI 10.1146/annurev.bb.21.060192.002115; FINER JT, 1994, NATURE, V368, P113, DOI 10.1038/368113a0; FINER JT, 1995, BIOPHYS J, V68, pS291; HUNT AJ, 1994, BIOPHYS J, V67, P766, DOI 10.1016/S0006-3495(94)80537-5; ISHIJIMA A, 1994, BIOCHEM BIOPH RES CO, V199, P1057, DOI 10.1006/bbrc.1994.1336; KABATA H, 1993, SCIENCE, V262, P1561, DOI 10.1126/science.8248804; KRUMMEL B, 1992, J MOL BIOL, V225, P221, DOI 10.1016/0022-2836(92)90917-9; KRUMMEL B, 1992, J MOL BIOL, V225, P239, DOI 10.1016/0022-2836(92)90918-A; LIU LF, 1987, P NATL ACAD SCI USA, V84, P7024, DOI 10.1073/pnas.84.20.7024; MIYATA H, 1995, BIOPHYS J, V68, pS286; NUDLER E, 1995, CELL, V81, P351, DOI 10.1016/0092-8674(95)90388-7; NUDLER E, 1994, SCIENCE, V265, P793, DOI 10.1126/science.8047884; SCHAFER DA, 1991, NATURE, V352, P444, DOI 10.1038/352444a0; SMITH SB, 1992, SCIENCE, V258, P1122, DOI 10.1126/science.1439819; SVOBODA K, 1994, ANNU REV BIOPH BIOM, V23, P247, DOI 10.1146/annurev.bb.23.060194.001335; SVOBODA K, 1993, NATURE, V365, P721, DOI 10.1038/365721a0; SVOBODA K, 1994, CELL, V77, P773, DOI 10.1016/0092-8674(94)90060-4; WANG DG, 1995, CELL, V81, P341, DOI 10.1016/0092-8674(95)90387-9; WANG JC, 1992, TRANSCRIPTIONAL REGU, P1253; WU HY, 1988, CELL, V53, P433, DOI 10.1016/0092-8674(88)90163-8; YAGER TD, 1987, ESCHERICHIA COLI SAL, V2, P1241; YIN H, 1994, BIOPHYS J, V67, P2468, DOI 10.1016/S0006-3495(94)80735-0	32	466	491	0	48	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	DEC 8	1995	270	5242					1653	1657		10.1126/science.270.5242.1653	http://dx.doi.org/10.1126/science.270.5242.1653			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TJ293	7502073				2022-12-28	WOS:A1995TJ29300045
J	MURPHY, DJ; SELLERS, S; MACKENZIE, IZ; YUDKIN, PL; JOHNSON, AM				MURPHY, DJ; SELLERS, S; MACKENZIE, IZ; YUDKIN, PL; JOHNSON, AM			CASE-CONTROL STUDY OF ANTENATAL AND INTRAPARTUM RISK-FACTORS FOR CEREBRAL-PALSY IN VERY PRETERM SINGLETON BABIES	LANCET			English	Article							GERMINAL MATRIX HEMORRHAGE; LOW-BIRTH-WEIGHT; MATERNAL TOXEMIA; INFANTS; DELIVERY; CHORIOAMNIONITIS; INFECTION; NEWBORN; EVENTS; LABOR	The increase in survival of very preterm babies during the 1980s was accompanied by a sharp increase in the rate of cerebral palsy in this group. The relation between antenatal and intrapartum factors and cerebral palsy in such babies has not been well defined. To identify adverse and protective antenatal and intrapartum factors we undertook a case-control study of 59 very preterm babies who developed cerebral palsy, identified from a population-based register, and 234 randomly selected controls. The frequency of cerebral palsy decreased with increasing gestational age and birthweight. Antenatal complications occurred in 215 (73%) of the women with preterm deliveries. Factors associated with an increased risk of cerebral palsy after adjustment for gestational age were chorioamnionitis (odds ratio 4.2 [95% CI 1.4-12.0]) rupture of membranes (2.3 [1.2-4.2]), and infection (2.3 [1.2-4.5]). Pre-eclampsia was associated with a reduced risk of cerebral palsy (0.4 [0.2-0.9]), as was delivery without labour (0.3 [0.2-0.7]). There was no increased risk of cerebral palsy with intrauterine growth retardation (1.0 [0.9-1.1]). The effect of rigorous management of adverse antenatal factors on the frequency of cerebral palsy in very preterm babies should be tested in randomised controlled trials.	RADCLIFFE INFIRM,NATL PERINATAL EPIDEMIOL UNIT,OXFORD OX2 6HE,ENGLAND; JOHN RADCLIFFE NHS TRUST,NUFFIELD DEPT OBSTET & GYNAECOL,OXFORD,ENGLAND	Radcliffe Infirmary; University of Oxford				Murphy, Deirdre/0000-0001-6074-6718				AMON E, 1987, AM J OBSTET GYNECOL, V156, P1143, DOI 10.1016/0002-9378(87)90128-1; BERNAL AL, 1989, BRIT J OBSTET GYNAEC, V96, P1133, DOI 10.1111/j.1471-0528.1989.tb03187.x; BLAIR E, 1990, AM J OBSTET GYNECOL, V162, P229, DOI 10.1016/0002-9378(90)90856-3; CHENG LC, 1992, BRIT J OBSTET GYNAEC, V99, P817, DOI 10.1111/j.1471-0528.1992.tb14413.x; GAFFNEY G, 1994, BRIT MED J, V308, P743, DOI 10.1136/bmj.308.6931.743; HILLIER SL, 1988, NEW ENGL J MED, V319, P972, DOI 10.1056/NEJM198810133191503; JOHNSON A, 1989, COMMUNITY MED, V11, P352; KITCHEN W, 1985, OBSTET GYNECOL, V66, P149; KUBAN KCK, 1992, J CHILD NEUROL, V7, P70, DOI 10.1177/088307389200700113; LEVITON A, 1988, OBSTET GYNECOL, V72, P571; LEVITON A, 1990, EARLY HUM DEV, V24, P1, DOI 10.1016/0378-3782(90)90002-Z; LEVITON A, 1993, DEV MED CHILD NEUROL, V35, P549; MACDONALD D, 1985, AM J OBSTET GYNECOL, V152, P524, DOI 10.1016/0002-9378(85)90619-2; MCGUIRE W, 1994, NATURE, V371, P508, DOI 10.1038/371508a0; NELSON KB, 1985, JAMA-J AM MED ASSOC, V254, P1473, DOI 10.1001/jama.254.11.1473; NELSON KB, 1986, NEW ENGL J MED, V315, P81, DOI 10.1056/NEJM198607103150202; NELSON KB, 1995, PEDIATRICS, V95, P263; O'Shea M, 1992, Paediatr Perinat Epidemiol, V6, P352, DOI 10.1111/j.1365-3016.1992.tb00775.x; OSHEA TM, 1991, PEDIATRICS; PETTERSON B, 1993, BRIT MED J, V307, P1239, DOI 10.1136/bmj.307.6914.1239; PHAROAH POD, 1990, ARCH DIS CHILD, V65, P602, DOI 10.1136/adc.65.6.602; PINTOMARTIN JA, 1995, PEDIATRICS, V95, P249; ROMERO R, 1989, AM J OBSTET GYNECOL, V161, P336, DOI 10.1016/0002-9378(89)90515-2; SINHA SK, 1990, ARCH DIS CHILD-FETAL, V65, P1017, DOI 10.1136/adc.65.10_Spec_No.1017; TORFS CP, 1990, J PEDIATR-US, V116, P615, DOI 10.1016/S0022-3476(05)81615-4; TROUNCE JQ, 1988, ARCH DIS CHILD, V63, P17, DOI 10.1136/adc.63.1.17; VOHR B, 1992, J PEDIATR-US, V121, P280, DOI 10.1016/S0022-3476(05)81204-1; WEINDLING AM, 1985, BRIT J OBSTET GYNAEC, V92, P1218, DOI 10.1111/j.1471-0528.1985.tb04865.x; YU VYH, 1984, BRIT J OBSTET GYNAEC, V91, P633, DOI 10.1111/j.1471-0528.1984.tb04822.x; 1995, LANCET, V345, P1455	30	331	337	1	5	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	DEC 2	1995	346	8988					1449	1454		10.1016/S0140-6736(95)92471-X	http://dx.doi.org/10.1016/S0140-6736(95)92471-X			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TH156	7490990				2022-12-28	WOS:A1995TH15600008
J	MCKENZIE, K; VANOS, J; FAHY, T; JONES, P; HARVEY, I; TOONE, B; MURRAY, R				MCKENZIE, K; VANOS, J; FAHY, T; JONES, P; HARVEY, I; TOONE, B; MURRAY, R			PSYCHOSIS WITH GOOD PROGNOSIS IN AFRO-CARIBBEAN PEOPLE NOW LIVING IN THE UNITED-KINGDOM	BMJ-BRITISH MEDICAL JOURNAL			English	Article							SCHIZOPHRENIA	Objectives-To compare the course and outcome of psychotic illness in a group of Afro-Caribbean patients resident in the United Kingdom and a group of white British patients. Design-Cohort study of consecutive admissions followed up for four years. Subjects-113 patients with psychotic illness of recent onset admitted to two south London hospitals. Main outcome measures-Course of illness, history of self harm, social disability, treatment received, and hospital use adjusted for socio-economic origin. Results-The Afro-Caribbean group spent more time in a recovered state during the follow up period (adjusted odds ratio 5.0; 95% confidence interval 1.7 to 14.5), were less likely to have had a continuous illness (0.3; 0.1 to 0.8), were less at risk of self harm (0.2; 0.1 to 0.8), and were less likely to have been prescribed antidepressant treatment (0.3; 0.1 to 0.9). There were no differences in hospital use, but the Afro-Caribbean group had more involuntary admissions (8.9; 2.1 to 35.6) and more imprisonments over the follow up period (9.2; 1.6 to 52.3). Conclusions-Afro-Caribbean patients in the United Kingdom have a better outcome after psychiatric illness than do white people. The combination of high incidence and more benign course of illness of psychotic illness in this group may be due, at least in part, to a greater exposure to precipitants in the social environment.	UNIV LONDON KINGS COLL HOSP, DEPT PSYCHOL MED, LONDON SE5 8AF, ENGLAND; INST PSYCHIAT, LONDON SE5 8AF, ENGLAND; MAUDSLEY HOSP & INST PSYCHIAT, BRIXTON COMMUNITY CARE PROJECT, LONDON SE5 8AZ, ENGLAND; TOWERS HOSP, LEICESTER LE5 0TD, LEICS, ENGLAND	King's College Hospital NHS Foundation Trust; King's College Hospital; University of London; King's College London; University of London; King's College London; South London & Maudsley NHS Trust; University of London; King's College London			van Os, Jim/C-2113-2014; Vasconcelos, Ana Carolina Souza de/GXW-3453-2022; van Os, Jim/I-9496-2012; van Os, Jim/V-8884-2019; murray, robin/F-8658-2012	van Os, Jim/0000-0002-7245-1586; van Os, Jim/0000-0002-7245-1586; Jones, Peter Brian/0000-0002-0387-880X; murray, robin/0000-0003-0829-0519; mckenzie, kwame/0000-0001-6419-8130				BIRCHWOOD M, 1992, BRIT J PSYCHIAT, V161, P783, DOI 10.1192/bjp.161.6.783; BURKE AW, 1976, BRIT J PSYCHIAT, V129, P261, DOI 10.1192/bjp.129.3.261; COOPER B, 1961, BRIT J PREV SOC MED, V15, P17; Fernando S., 1988, RACE CULTURE PSYCHIA; HAMILTON M, 1960, J NEUROL NEUROSUR PS, V23, P56, DOI 10.1136/jnnp.23.1.56; JABLENSKY A, 1980, ACTA PSYCHIAT SCAND, V62, P152, DOI 10.1111/j.1600-0447.1980.tb07687.x; KEHMING L, 1988, SCHIZOPHR B, V14, P555; LAGER AC, 1985, PSYCHIAT RES, V16, P27, DOI 10.1016/0165-1781(85)90025-3; LITTLEWOOD R, 1981, PSYCHOL MED, V11, P303, DOI 10.1017/S0033291700052120; MCGLASHAN TH, 1988, SCHIZOPHRENIA BULL, V14, P569, DOI 10.1093/schbul/14.4.569; MCGOVERN D, 1994, SOC PSYCH PSYCH EPID, V29, P8; MCGUFFIN P, 1991, ARCH GEN PSYCHIAT, V48, P764; MERRILL J, 1987, BRIT J PSYCHIAT, V150, P765, DOI 10.1192/bjp.150.6.765; RALEIGH V, 1982, HLTH TRENDS, V24, P91; SPIZER R, 1978, ARCH GEN PSYCHIAT, V35, P773; STRAUSS JS, 1978, SCHIZOPHRENIA BULL, V4, P56, DOI 10.1093/schbul/4.1.56; SUGARMAN PA, 1992, SOC PSYCH PSYCH EPID, V27, P102, DOI 10.1007/BF00788513; VAILLANT GE, 1964, ARCH GEN PSYCHIAT, V11, P509; VANOS J, 1994, PSYCHOL MED, V24, P503, DOI 10.1017/S003329170002746X; VANOS J, IN PRESS PSYCHOL MED; VANOS J, IN PRESS BR J PSYCHI; Wing J. K. C., 1974, MEASUREMENT CLASSIFI; 1992, WHO COORDINATED MULT	23	82	82	0	2	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	NOV 18	1995	311	7016					1325	1328		10.1136/bmj.311.7016.1325	http://dx.doi.org/10.1136/bmj.311.7016.1325			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	TF901	7496280	Green Published			2022-12-28	WOS:A1995TF90100017
J	PHILIPSON, LH				PHILIPSON, LH			UPDATE - ATP-SENSITIVE K+ CHANNELS - PARADIGM LOST, PARADIGM REGAINED	SCIENCE			English	Editorial Material									UNIV CHICAGO,COMM CELL PHYSIOL,CHICAGO,IL 60637	University of Chicago	PHILIPSON, LH (corresponding author), UNIV CHICAGO,DEPT MED,CHICAGO,IL 60637, USA.							AGUILARBRYAN L, 1995, SCIENCE, V268, P423, DOI 10.1126/science.7716547; HIGGINS CF, 1995, CELL, V82, P693, DOI 10.1016/0092-8674(95)90465-4; INAGAKI N, 1995, SCIENCE, V270, P1166, DOI 10.1126/science.270.5239.1166; KOFUJI P, 1995, P NATL ACAD SCI USA, V92, P6542, DOI 10.1073/pnas.92.14.6542; KRAPIVINSKY G, 1995, NATURE, V374, P135, DOI 10.1038/374135a0; KUBO Y, 1993, NATURE, V364, P802, DOI 10.1038/364802a0; PHILIPSON LH, 1995, SCIENCE, V268, P372, DOI 10.1126/science.7716539; SALKOFF L, 1995, NEURON, V15, P489, DOI 10.1016/0896-6273(95)90137-X; THOMAS PM, 1995, SCIENCE, V268, P426, DOI 10.1126/science.7716548	9	12	14	0	0	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	NOV 17	1995	270	5239					1159	1159		10.1126/science.270.5239.1159	http://dx.doi.org/10.1126/science.270.5239.1159			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TE905	7502039				2022-12-28	WOS:A1995TE90500044
J	CASEY, ATH; OBRIEN, M; KUMAR, V; HAYWARD, RD; CROCKARD, HA				CASEY, ATH; OBRIEN, M; KUMAR, V; HAYWARD, RD; CROCKARD, HA			LESSON OF THE WEEK - DONT TWIST MY CHILDS HEAD OFF - IATROGENIC CERVICAL DISLOCATION	BRITISH MEDICAL JOURNAL			English	Article							SPINE		UCL NATL HOSP NEUROL & NEUROSURG, LONDON WC1N 3BG, ENGLAND; HOSP SICK CHILDREN, LONDON WC1N 3JH, ENGLAND	University of London; University College London; UCL Medical School; University College London Hospitals NHS Foundation Trust; University of London; University College London; Great Ormond Street Hospital for Children NHS Foundation Trust								Coutts MB, 1934, ARCH SURG-CHICAGO, V29, P297, DOI 10.1001/archsurg.1934.01180020129007; CRISCO JJ, 1991, J BIOMECH, V24, P607, DOI 10.1016/0021-9290(91)90293-V; FIELDING JW, 1977, J BONE JOINT SURG AM, V59, P37, DOI 10.2106/00004623-197759010-00005; HUDGINS PA, 1989, CLIN NEUROSURG, V37, P571; KRATIMENOS GP, 1993, BRIT J NEUROSURG, V7, P129, DOI 10.3109/02688699309103469	5	11	11	0	0	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	NOV 4	1995	311	7014					1212	1213		10.1136/bmj.311.7014.1212	http://dx.doi.org/10.1136/bmj.311.7014.1212			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TD768	7488905	Green Published			2022-12-28	WOS:A1995TD76800029
J	AARON, BL; ROCKOFF, SD				AARON, BL; ROCKOFF, SD			THE ATTEMPTED ASSASSINATION OF PRESIDENT REAGAN - MEDICAL IMPLICATIONS AND HISTORICAL-PERSPECTIVE	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article								In 1981, President Ronald Reagan became the first incumbent president of the United States to survive being struck by a would-be assassin's bullet. Had President Reagan not survived, the history of this country and the world most certainly would have been changed. This report is the only first-hand account of the details of his medical care and complications following the assassination attempt, an event that emphasizes the vulnerability of presidents to would-be assassins and the importance of readily available expert medical care and facilities to their survival.	GEORGE WASHINGTON UNIV,MED CTR,DEPT SURG,WASHINGTON,DC 20037; GEORGE WASHINGTON UNIV,MED CTR,DEPT RADIOL,WASHINGTON,DC 20037	George Washington University; George Washington University								Abrams Herbert L., 1992, PRESIDENT HAS BEEN S; Barrett L. I., 1983, GAMBLING HIST; BEAHRS OH, 1994, J AM COLL SURGEONS, V178, P86; BLOCK AJ, 1993, CHEST, V104, P989, DOI 10.1378/chest.104.4.989b; GILBERT RE, 1992, MORTAL PRESIDENCY; Post Jerrold M., 1993, ILLNESS STRIKES LEAD; REAGAN N, 1989, MY TURN, P1; Reagan Ronald, 1990, AM LIFE; REGAN DT, 1988, RECORD; SMITH H, 1988, POWER GAME; WEINBERGER C, 1991, FIGHTING PEACE	11	11	10	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	DEC 7	1994	272	21					1689	1693		10.1001/jama.272.21.1689	http://dx.doi.org/10.1001/jama.272.21.1689			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PU759	7526010				2022-12-28	WOS:A1994PU75900029
J	AIELLO, LP; AVERY, RL; ARRIGG, PG; KEYT, BA; JAMPEL, HD; SHAH, ST; PASQUALE, LR; THIEME, H; IWAMOTO, MA; PARK, JE; NGUYEN, HV; AIELLO, LM; FERRARA, N; KING, GL				AIELLO, LP; AVERY, RL; ARRIGG, PG; KEYT, BA; JAMPEL, HD; SHAH, ST; PASQUALE, LR; THIEME, H; IWAMOTO, MA; PARK, JE; NGUYEN, HV; AIELLO, LM; FERRARA, N; KING, GL			VASCULAR ENDOTHELIAL GROWTH-FACTOR IN OCULAR FLUID OF PATIENTS WITH DIABETIC-RETINOPATHY AND OTHER RETINAL DISORDERS	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							PIGMENT EPITHELIAL-CELLS; PERMEABILITY FACTOR; ANGIOGENESIS; NEOVASCULARIZATION; SECRETION; INSULIN; INVIVO	Background. Retinal ischemia induces intraocular neovascularization, which often leads to glaucoma, vitreous hemorrhage, and retinal detachment, presumably by stimulating the release of angiogenic molecules. Vascular endothelial growth factor (VEGF) is an endothelial-cell-specific angiogenic factor whose production is increased by hypoxia. Methods. We measured the concentration of VEGF in 210 specimens of ocular fluid obtained from 164 patients undergoing intraocular surgery, using both radioimmunoassays and radioreceptor assays. Vitreous proliferative potential was measured with in vitro assays of the growth of retinal endothelial cells and with VEGF-neutralizing antibody. Results. VEGF was detected in 69 of 136 ocular-fluid samples from patients with diabetic retinopathy, 29 of 38 samples from patients with neovascularization of the iris, and 3 of 4 samples from patients with ischemic occlusion of the central retinal vein, as compared with 2 of 31 samples from patients with no neovascular disorders (P<0.001, P<0.001, and P = 0.006, respectively). The mean (+/-SD) VEGF concentration in 70 samples of ocular fluid from patients with active proliferative diabetic retinopathy (3.6+/-6.3 ng per milliliter) was higher than that in 25 samples from patients with nonproliferative diabetic retinopathy (0.1+/-0.1 ng per milliliter, P = 0.008), 41 samples from patients with quiescent proliferative diabetic retinopathy (0.2+/-0.6 ng per milliliter, P<0.001), or 31 samples from nondiabetic patients (0.1+/-0.2 ng per milliliter, P = 0.003). Concentrations of VEGF in vitreous fluid (8.8+/-9.9 ng per milliliter) were higher than those in aqueous fluid (5.6+/-8.6 ng per milliliter, P = 0.033) in all 10 pairs of samples obtained simultaneously from the same patient; VEGF concentrations in vitreous fluid declined after successful laser photocoagulation. VEGF stimulated the growth of retinal endothelial cells in vitro, as did vitreous fluid containing measurable VEGF. Stimulation was inhibited by VEGF-neutralizing antibodies. Conclusions. Our data suggest that VEGF plays a major part in mediating active intraocular neovascularization in patients with ischemic retinal diseases, such as diabetic retinopathy and retinal-vein occlusion.	JOSLIN DIABET CTR,DIV RES,BOSTON,MA 02215; BRIGHAM & WOMENS HOSP,DEPT MED,BOSTON,MA 02115; BRIGHAM & WOMENS HOSP,DEPT OPHTHALMOL,BOSTON,MA; HARVARD UNIV,SCH MED,BOSTON,MA; UNIV CALIF SANTA BARBARA,NEUROSCI RES INST,SANTA BARBARA,CA 93106; GENENTECH INC,SAN FRANCISCO,CA; JOHNS HOPKINS UNIV HOSP,WILMER OPHTHALMOL INST,DEPT OPHTHALMOL,BALTIMORE,MD	Harvard University; Joslin Diabetes Center, Inc.; Harvard University; Brigham & Women's Hospital; Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School; University of California System; University of California Santa Barbara; Roche Holding; Genentech; Johns Hopkins University; Johns Hopkins Medicine	AIELLO, LP (corresponding author), JOSLIN DIABET CTR,BEETHAM EYE INST,DEPT OPHTHALMOL,1 JOSLIN PL,BOSTON,MA 02215, USA.		CLIHON, Residencia Medica/K-4896-2013	CLIHON, Residencia Medica/0000-0001-6734-2513	NEI NIH HHS [EY05110] Funding Source: Medline; NIDCR NIH HHS [DERC36836-08] Funding Source: Medline	NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		ADAMIS AP, 1993, BIOCHEM BIOPH RES CO, V193, P631, DOI 10.1006/bbrc.1993.1671; ADAMIS AP, 1993, INVEST OPHTH VIS SCI, V34, P1440; AIELLO LP, 1994, INVEST OPHTH VIS SCI, V35, P1868; [Anonymous], 1976, AM J OPHTHALMOL, V81, P383; BLANKENSHIP GW, 1991, OPHTHALMOLOGY, V98, P125; BROWN GC, 1988, INT OPHTHALMOL, V11, P239, DOI 10.1007/BF00131023; BROWN GC, 1989, RETINA, V2, P547; CAPON DJ, 1989, NATURE, V337, P525, DOI 10.1038/337525a0; DEVRIES C, 1992, SCIENCE, V255, P989, DOI 10.1126/science.1312256; FERRARA N, 1992, ENDOCR REV, V13, P18, DOI 10.1210/er.13.1.18; GLASER BM, 1980, J CELL BIOL, V84, P298, DOI 10.1083/jcb.84.2.298; HANNEKEN A, 1991, ARCH OPHTHALMOL-CHIC, V109, P1005, DOI 10.1001/archopht.1991.01080070117048; HAYREH SS, 1983, OPHTHALMOLOGY, V90, P488; HOUCK KA, 1992, J BIOL CHEM, V267, P26031; JAKEMAN LB, 1992, J CLIN INVEST, V89, P244, DOI 10.1172/JCI115568; Kim KJ, 1992, GROWTH FACTORS, V7, P53, DOI 10.3109/08977199209023937; KIM KJ, 1993, NATURE, V362, P841, DOI 10.1038/362841a0; KING GL, 1985, J CLIN INVEST, V75, P1028, DOI 10.1172/JCI111764; MALECAZE F, 1993, INVEST OPHTH VIS SCI, V34, P1039; MEYERSCHWICKERATH R, 1993, J CLIN INVEST, V92, P2620, DOI 10.1172/JCI116877; Michaelson I.C., 1948, T OPHTHALMOL SOC, V68, P137; MUTHUKRISHNAN L, 1991, J CELL PHYSIOL, V148, P1, DOI 10.1002/jcp.1041480102; PARK JE, 1994, J BIOL CHEM, V269, P25646; PATZ A, 1980, INVEST OPHTH VIS SCI, V19, P1133; PEPPER MS, 1992, BIOCHEM BIOPH RES CO, V189, P824, DOI 10.1016/0006-291X(92)92277-5; PLATE KH, 1992, NATURE, V359, P845, DOI 10.1038/359845a0; PLOUET J, 1993, INVEST OPHTH VIS SCI, V34, P900; RAND LI, 1981, AM J MED, V70, P595, DOI 10.1016/0002-9343(81)90581-7; SENGER DR, 1983, SCIENCE, V219, P983, DOI 10.1126/science.6823562; SENGER DR, 1986, CANCER RES, V46, P5629; SHIMA D, 1993, INVEST OPHTH VIS SCI, V34, P900; SHWEIKI D, 1992, NATURE, V359, P843, DOI 10.1038/359843a0; SIVALINGAM A, 1990, ARCH OPHTHALMOL-CHIC, V108, P869, DOI 10.1001/archopht.1990.01070080113046; THIEME H, IN PRESS DIABETES; TISCHER E, 1991, J BIOL CHEM, V266, P11947; VLODAVSKY I, 1987, P NATL ACAD SCI USA, V84, P2292, DOI 10.1073/pnas.84.8.2292; WHITE P, 1960, DIABETES, V9, P345, DOI 10.2337/diab.9.5.345; 1991, OPHTHALMOLOGY S, V98, P741	38	3001	3216	4	147	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	DEC 1	1994	331	22					1480	1487		10.1056/NEJM199412013312203	http://dx.doi.org/10.1056/NEJM199412013312203			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PU866	7526212				2022-12-28	WOS:A1994PU86600003
J	NIGHTINGALE, SL				NIGHTINGALE, SL			FDA PROPOSES TO REQUIRE FINANCIAL DISCLOSURE BY CLINICAL INVESTIGATORS	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material											NIGHTINGALE, SL (corresponding author), US FDA,OFF HLTH AFFAIRS,PARKLAWN BLDG,5600 FISHERS LN,ROCKVILLE,MD 20857, USA.							1994, FED REGISTER, V59, P48708	1	3	3	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 19	1994	272	15					1160	1160		10.1001/jama.272.15.1160	http://dx.doi.org/10.1001/jama.272.15.1160			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PL212	7523738				2022-12-28	WOS:A1994PL21200009
J	VALEGARD, K; MURRAY, JB; STOCKLEY, PG; STONEHOUSE, NJ; LILJAS, L				VALEGARD, K; MURRAY, JB; STOCKLEY, PG; STONEHOUSE, NJ; LILJAS, L			CRYSTAL-STRUCTURE OF AN BACTERIOPHAGE-RNA COAT PROTEIN-OPERATOR COMPLEX	NATURE			English	Article							TURNIP CRINKLE VIRUS; BINDING SITE; RESOLUTION; SYNTHETASE; OLIGORIBONUCLEOTIDES; RECOGNITION; MECHANISM; MS2	THE RNA bacteriophage MS2 is a convenient model system for the study-of protein-RNA interactions, The MS2 coat protein achieves control of two distinct processes-sequence-specific RNA encapsidation and repression of replicase translation-by binding to an RNA stem-loop structure of 19 nucleotides containing the initiation codon of the replicase gene. The binding of a coat protein diner to this hairpin shuts off synthesis of the viral replicase(1), switching the viral replication cycle to virion assembly rather than continued replication. The operator fragment alone can trigger self-assembly of the phage capsid at low protein concentrations and a complex of about 90 RNA operator fragments per protein capsid has been described(2). We report here the crystal structure at 3.0 Angstrom resolution of a complex between recombinant MS2 capsids and the 19-nucleotide RNA fragment. It is the first example of a structure at this resolution for a sequence-specific protein-RNA complex apart from the transfer RNA synthetase complexes(3-5). The structure shows sequence-specific interactions between conserved residues on the protein and RNA bases essential for binding.	UNIV LEEDS, DEPT GENET, LEEDS LS2 9JT, W YORKSHIRE, ENGLAND	University of Leeds	VALEGARD, K (corresponding author), UPPSALA UNIV, DEPT MOLEC BIOL, BOX 590, S-75124 UPPSALA, SWEDEN.			Stonehouse, Nicola/0000-0003-1146-5519; Stockley, Peter/0000-0002-1360-2751	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		ABADZAPATERO C, 1980, NATURE, V286, P33, DOI 10.1038/286033a0; BECKETT D, 1988, J MOL BIOL, V204, P939, DOI 10.1016/0022-2836(88)90053-8; BECKETT D, 1988, J MOL BIOL, V204, P927, DOI 10.1016/0022-2836(88)90052-6; BRUNGER AT, 1992, NATURE, V355, P472, DOI 10.1038/355472a0; BRUNGER AT, 1990, XPLOR MANUAL; CAVARELLI J, 1993, NATURE, V362, P181, DOI 10.1038/362181a0; GOLMOHAMMADI R, 1993, J MOL BIOL, V234, P620, DOI 10.1006/jmbi.1993.1616; HARRISON SC, 1978, NATURE, V276, P368, DOI 10.1038/276368a0; HOGLE JM, 1986, J MOL BIOL, V191, P625, DOI 10.1016/0022-2836(86)90450-X; HOSUR MV, 1987, PROTEINS, V2, P167, DOI 10.1002/prot.340020302; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; JONES TA, 1992, CCP4 STUDY WEEKEND 1, P91; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LIDDINGTON RC, 1991, NATURE, V354, P278, DOI 10.1038/354278a0; LIM F, 1994, J BIOL CHEM, V269, P9006; MASTICO RA, 1993, J GEN VIROL, V74, P541, DOI 10.1099/0022-1317-74-4-541; MURRAY JB, 1994, ANAL BIOCHEM, V218, P177, DOI 10.1006/abio.1994.1157; PEABODY DS, 1993, EMBO J, V12, P595, DOI 10.1002/j.1460-2075.1993.tb05691.x; PEABODY DS, 1989, NUCLEIC ACIDS RES, V17, P6017, DOI 10.1093/nar/17.15.6017; ROMANIUK PJ, 1987, BIOCHEMISTRY-US, V26, P1563, DOI 10.1021/bi00380a011; ROULD MA, 1991, NATURE, V352, P213, DOI 10.1038/352213a0; RUFF M, 1991, SCIENCE, V252, P1682, DOI 10.1126/science.2047877; SORGER PK, 1986, J MOL BIOL, V191, P639, DOI 10.1016/0022-2836(86)90451-1; STOCKLEY PG, 1993, BIOCHEM SOC T, V21, P627, DOI 10.1042/bst0210627; TALBOT SJ, 1990, NUCLEIC ACIDS RES, V18, P3521, DOI 10.1093/nar/18.12.3521; USMAN N, 1987, J AM CHEM SOC, V109, P7845, DOI 10.1021/ja00259a037; VALEGARD K, 1990, NATURE, V345, P36, DOI 10.1038/345036a0; WITHERELL GW, 1991, PROG NUCLEIC ACID RE, V40, P185	28	328	332	1	28	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	OCT 13	1994	371	6498					623	626		10.1038/371623a0	http://dx.doi.org/10.1038/371623a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PL559	7523953				2022-12-28	WOS:A1994PL55900057
J	PRESTON, GM; SMITH, BL; ZEIDEL, ML; MOULDS, JJ; AGRE, P				PRESTON, GM; SMITH, BL; ZEIDEL, ML; MOULDS, JJ; AGRE, P			MUTATIONS IN AQUAPORIN-1 IN PHENOTYPICALLY NORMAL HUMANS WITHOUT FUNCTIONAL CHIP WATER CHANNELS	SCIENCE			English	Article							INTEGRAL MEMBRANE-PROTEIN; XENOPUS OOCYTES; RAT-KIDNEY; LOCALIZATION; EXPRESSION; FAMILY; GENE; ERYTHROCYTES; ORGANIZATION; APPEARANCE	The gene aquaporin-1 encodes channel-forming integral protein (CHIP), a member of a large family of water transporters found throughout nature. Three rare individuals were identified who do not express CHIP-associated Colton blood group antigens and whose red cells exhibit low osmotic water permeabilities. Genomic DNA analyses demonstrated that two individuals were homozygous for different nonsense mutations (exon deletion or frameshift), and the third had a missense mutation encoding a nonfunctioning CHIP molecule. Surprisingly, none of the three suffers any apparent clinical consequence, which raises questions about the physiologicai importance of CHIP and implies that other mechanisms may compensate for its absence.	JOHNS HOPKINS UNIV,SCH MED,DEPT BIOL CHEM,BALTIMORE,MD 21205; JOHNS HOPKINS UNIV,SCH MED,DEPT MED,BALTIMORE,MD 21205; UNIV PITTSBURGH,SCH MED,DEPT MED,PITTSBURGH,PA 15213; GAMMA BIOL,HOUSTON,TX 77092	Johns Hopkins University; Johns Hopkins University; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh					NHLBI NIH HHS [HL48268, HL33991] Funding Source: Medline; NIDDK NIH HHS [DK32753] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL048268, R01HL033991, R37HL048268] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R37DK032753, R01DK032753] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AGRE P, 1994, J CLIN INVEST, V94, P1050, DOI 10.1172/JCI117419; AGRE P, 1993, AM J PHYSIOL, V265, pF463; BENNETT V, 1983, METHOD ENZYMOL, V96, P313; BONDY C, 1993, P NATL ACAD SCI USA, V90, P4500, DOI 10.1073/pnas.90.10.4500; BROWN D, 1993, EUR J CELL BIOL, V61, P264; CHRISPEELS MJ, 1994, J CELL BIOCH SA, V18, P80; DEEN PMT, 1994, SCIENCE, V264, P92, DOI 10.1126/science.8140421; DENKER BM, 1988, J BIOL CHEM, V263, P15634; ENGEL A, 1994, CURR OPIN STRUC BIOL, V4, P545, DOI 10.1016/S0959-440X(94)90217-8; Finkelstein A., 1987, WATER MOVEMENT LIPID; FOLKESSON HG, 1994, P NATL ACAD SCI USA, V91, P4970, DOI 10.1073/pnas.91.11.4970; FUSHIMI K, 1993, NATURE, V361, P549, DOI 10.1038/361549a0; HARRIS HW, 1991, J CLIN INVEST, V88, P1, DOI 10.1172/JCI115263; KNEPPER MA, 1994, P NATL ACAD SCI USA, V91, P6255, DOI 10.1073/pnas.91.14.6255; LACEY PA, 1987, TRANSFUSION, V27, P268, DOI 10.1046/j.1537-2995.1987.27387235637.x; MOON C, 1993, J BIOL CHEM, V268, P15772; NIELSEN S, 1993, P NATL ACAD SCI USA, V90, P7275, DOI 10.1073/pnas.90.15.7275; NIELSEN S, 1993, J CELL BIOL, V120, P371, DOI 10.1083/jcb.120.2.371; OPPERMAN CH, 1994, SCIENCE, V263, P221, DOI 10.1126/science.263.5144.221; PRESTON GM, 1992, SCIENCE, V256, P385, DOI 10.1126/science.256.5055.385; PRESTON GM, 1993, J BIOL CHEM, V268, P17; PRESTON GM, 1991, P NATL ACAD SCI USA, V88, P11110, DOI 10.1073/pnas.88.24.11110; RAO Y, 1990, NATURE, V345, P163, DOI 10.1038/345163a0; REIZER J, 1993, CRIT REV BIOCHEM MOL, V28, P235, DOI 10.3109/10409239309086796; ROBERTS SK, IN PRESS P NATL ACAD; SABOLIC I, 1992, AM J PHYSIOL, V263, pC1225, DOI 10.1152/ajpcell.1992.263.6.C1225; SMITH BL, 1993, J CLIN INVEST, V92, P2035, DOI 10.1172/JCI116798; SMITH BL, 1994, J CLIN INVEST, V94, P1043, DOI 10.1172/JCI117418; SMITH BL, 1991, J BIOL CHEM, V266, P6407; VANOS CH, IN PRESS BIOCH BIOPH; VERKMAN AS, 1992, ANNU REV PHYSIOL, V54, P97, DOI 10.1146/annurev.physiol.54.1.97; WALL DA, 1989, J MEMBRANE BIOL, V107, P189, DOI 10.1007/BF01871724; ZAMPIGHI GA, 1989, J CELL BIOL, V108, P2255, DOI 10.1083/jcb.108.6.2255; ZEIDEL ML, 1992, BIOCHEMISTRY-US, V31, P7436, DOI 10.1021/bi00148a002	34	251	257	1	15	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	SEP 9	1994	265	5178					1585	1587		10.1126/science.7521540	http://dx.doi.org/10.1126/science.7521540			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PF336	7521540				2022-12-28	WOS:A1994PF33600037
J	FUCHS, HJ; BOROWITZ, DS; CHRISTIANSEN, DH; MORRIS, EM; NASH, ML; RAMSEY, BW; ROSENSTEIN, BJ; SMITH, AL; WOHL, ME				FUCHS, HJ; BOROWITZ, DS; CHRISTIANSEN, DH; MORRIS, EM; NASH, ML; RAMSEY, BW; ROSENSTEIN, BJ; SMITH, AL; WOHL, ME			EFFECT OF AEROSOLIZED RECOMBINANT HUMAN DNASE ON EXACERBATIONS OF RESPIRATORY SYMPTOMS AND ON PULMONARY-FUNCTION IN PATIENTS WITH CYSTIC-FIBROSIS	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							HUMAN DEOXYRIBONUCLEASE; COST-ANALYSIS; EFFICACY; SPUTUM; SAFETY	Background. Respiratory disease in patients with cystic fibrosis is characterized by airway obstruction caused by the accumulation of thick, purulent secretions, which results in recurrent, symptomatic exacerbations. The viscoelasticity of the secretions can be reduced in vitro by recombinant human deoxyribonuclease (rhDNase), a bioengineered copy of the human enzyme. Methods. We performed a randomized, double-blind, placebo-controlled study to determine the effects of once-daily and twice-daily administration of rhDNase on exacerbations of respiratory symptoms requiring parenteral antibiotics and on pulmonary function. A total of 968 adults and children with cystic fibrosis were treated for 24 weeks as outpatients. Results. One or more exacerbations occurred in 27 percent of the patients given placebo, 22 percent of those treated with rhDNase once daily, and 19 percent of those treated with rhDNase twice daily. As compared with placebo, the administration of rhDNase once daily and twice daily reduced the age-adjusted risk of respiratory exacerbations by 28 percent (P = 0.04) and 37 percent (P<0.01), respectively. The administration of rhDNase once daily and twice daily improved forced expiratory volume in one second during the study by a mean (+/-SD) of 5.8+/-0.7 and 5.6+/-0.7 percent, respectively. None of the patients had anaphylaxis. Voice alteration and laryngitis were more frequent in the rhDNase-treated patients than in those receiving placebo but were rarely severe and resolved within 21 days of onset. Conclusions. In patients with cystic fibrosis, the administration of rhDNase reduced but did not eliminate exacerbations of respiratory symptoms, resulted in slight improvement in pulmonary function, and was well tolerated.	CHILDRENS HOSP BUFFALO, BUFFALO, NY USA; GH BESSELAAR ASSOCIATES, PRINCETON, NJ USA; CHILDRENS HOSP & MED CTR, SEATTLE, WA 98105 USA; JOHNS HOPKINS UNIV, BALTIMORE, MD USA; CHILDRENS HOSP, BOSTON, MA 02115 USA	Seattle Children's Hospital; Johns Hopkins University; Harvard University; Boston Children's Hospital	FUCHS, HJ (corresponding author), GENENTECH INC, DEPT MED AFFAIRS, 460 POINT SAN BRUNO BLVD, San Francisco, CA 94080 USA.		Smith, Adam/GPS-8322-2022					AITKEN ML, 1992, JAMA-J AM MED ASSOC, V267, P1947, DOI 10.1001/jama.267.14.1947; [Anonymous], 1991, AM REV RESPIR DIS, V144, P1202, DOI 10.1164/ajrccm/144.5.1202; [Anonymous], 1987, Am Rev Respir Dis, V136, P1285; Baptist A J, 1987, Top Health Care Financ, V13, P32; BOAT TF, 1988, TXB RESP MED, V1, P1126; CHAMBERLAIN TM, 1988, AM J HOSP PHARM, V45, P2341, DOI 10.1093/ajhp/45.11.2341; CHERNICK WS, 1959, PEDIATRICS, V24, P739; COLLINS FS, 1992, SCIENCE, V256, P774, DOI 10.1126/science.1375392; CONN RB, 1985, JAMA-J AM MED ASSOC, V253, P1586, DOI 10.1001/jama.253.11.1586; COX DR, 1972, J R STAT SOC B, V34, P187; FITZSIMMONS SC, 1993, J PEDIATR-US, V122, P1, DOI 10.1016/S0022-3476(05)83478-X; Gift A G, 1989, Rehabil Nurs, V14, P323; HUBBARD RC, 1992, NEW ENGL J MED, V326, P812, DOI 10.1056/NEJM199203193261207; KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868; KNOWLES MR, 1990, NEW ENGL J MED, V322, P1189, DOI 10.1056/NEJM199004263221704; KNUDSON RJ, 1983, AM REV RESPIR DIS, V127, P725; LIAO TH, 1992, J BIOL CHEM, V267, P7957; LIAO TH, 1973, J BIOL CHEM, V248, P1489; MCPHERSON C, 1990, AM J DIS CHILD, V144, P1311; RAMSEY BW, 1993, AM REV RESPIR DIS, V148, P145, DOI 10.1164/ajrccm/148.1.145; RANASINHA C, 1993, LANCET, V342, P199, DOI 10.1016/0140-6736(93)92297-7; SAYWELL RM, 1989, J HEART TRANSPLANT, V8, P244; SCHAFERMEYER KW, 1992, J RES PHARM EC, V4, P3; SHAK S, 1990, P NATL ACAD SCI USA, V87, P9188, DOI 10.1073/pnas.87.23.9188; SINICROPI D, 1991, PEDIATR PULM S, V6, P300; SMITH AL, 1988, J PEDIATR-US, V112, P547, DOI 10.1016/S0022-3476(88)80165-3; WANNER A, 1980, AM REV RESPIR DIS, V122, P79, DOI 10.1164/arrd.1980.122.5P2.79; White JC, 1958, RHEOL ACTA, V1, P96; WILMOTT RW, 1990, AM REV RESPIR DIS, V142, P365, DOI 10.1164/ajrccm/142.2.365; 1992, 1992 RED BOOK; 1989, ICD 9 CM INT CLASSIF, V3; 1986, LENGTH STAY BY DIAGN; 1982, FED REGISTER, V47, P43296	33	1106	1157	0	38	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	SEP 8	1994	331	10					637	642		10.1056/NEJM199409083311003	http://dx.doi.org/10.1056/NEJM199409083311003			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PE382	7503821	Bronze			2022-12-28	WOS:A1994PE38200003
J	LAFAILLE, JJ; NAGASHIMA, K; KATSUKI, M; TONEGAWA, S				LAFAILLE, JJ; NAGASHIMA, K; KATSUKI, M; TONEGAWA, S			HIGH-INCIDENCE OF SPONTANEOUS AUTOIMMUNE ENCEPHALOMYELITIS IN IMMUNODEFICIENT ANTIMYELIN BASIC-PROTEIN T-CELL RECEPTOR TRANSGENIC MICE	CELL			English	Article							EXPERIMENTAL ALLERGIC ENCEPHALOMYELITIS; NONOBESE DIABETIC MICE; GLUTAMIC-ACID DECARBOXYLASE; MULTIPLE-SCLEROSIS; LESION DEVELOPMENT; LYMPHOCYTE-T; CLASS-II; DISEASE; EXPRESSION; INDUCTION	We have generated TCR transgenic mice (T/R(+)) specific for myelin basic protein (MBP) and crossed them to RAG-1-deficient mice to obtain mice (T/R(-)) that have T cells expressing the transgenic TCR but no other lymphocytes. Both T/R(+) and T/R(-) mice carry, in the lymph nodes and spleen, large numbers of the potentially encephalitogenic CD4(+) anti-MBP T cells. These cells respond to MBP in vitro but show no signs of activation in vivo. Nevertheless, similar to 14% of H-2(u) T/R(+) and 100% of H-2(u) T/R(-) mice developed spontaneous experimental autoimmune encephalomyelitis (EAE) within 12 months. These data indicate that EAE can be mediated by CD4(+) anti-MBP T cells in the absence of any other lymphocytes and that nontransgenic lymphocytes that are present in T/R(+) but absent in T/R(-) mice have a protective effect. The data also suggest that spontaneous EAE may be triggered by an in situ activation of CD4(+) anti-MBP cells in the nervous system.	KYUSHU UNIV,MED INST BIOREGULAT,FUKUOKA 812,JAPAN	Kyushu University	LAFAILLE, JJ (corresponding author), MIT,HOWARD HUGHES MED INST,DEPT BIOL,CTR CANC RES,CAMBRIDGE,MA 02139, USA.							AHARONI R, 1993, EUR J IMMUNOL, V23, P17, DOI 10.1002/eji.1830230105; BARON JL, 1993, J EXP MED, V177, P57, DOI 10.1084/jem.177.1.57; BERNARD CCA, 1992, CURR OPIN IMMUNOL, V4, P760, DOI 10.1016/0952-7915(92)90058-M; BOTTAZZO GF, 1983, LANCET, V2, P1115; BROCKE S, 1993, NATURE, V365, P642, DOI 10.1038/365642a0; BURMESTER GR, 1987, J CLIN INVEST, V80, P595, DOI 10.1172/JCI113111; DAY MJ, 1992, J EXP MED, V175, P655, DOI 10.1084/jem.175.3.655; EISENBARTH GS, 1986, NEW ENGL J MED, V314, P1360; ELLERMAN KE, 1988, NATURE, V331, P265, DOI 10.1038/331265a0; FFRENCHCONSTANT C, 1994, LANCET, V343, P271, DOI 10.1016/S0140-6736(94)91118-5; FRITZ RB, 1983, J IMMUNOL, V130, P191; GAUR A, 1993, SCIENCE, V259, P91, DOI 10.1126/science.8418501; GOVERMAN J, 1993, CELL, V72, P551, DOI 10.1016/0092-8674(93)90074-Z; HARRIS ED, 1990, NEW ENGL J MED, V322, P1277, DOI 10.1056/nejm199005033221805; HONEYMAN MC, 1993, J EXP MED, V177, P535, DOI 10.1084/jem.177.2.535; HVAS J, 1993, J NEUROIMMUNOL, V46, P225, DOI 10.1016/0165-5728(93)90253-U; JEWTOUKOFF V, 1989, P NATL ACAD SCI USA, V86, P2824, DOI 10.1073/pnas.86.8.2824; JIANG H, 1992, SCIENCE, V256, P1213, DOI 10.1126/science.256.5060.1213; KARPUS WJ, 1992, EUR J IMMUNOL, V22, P1757, DOI 10.1002/eji.1830220714; KATZ JD, 1993, CELL, V74, P1089, DOI 10.1016/0092-8674(93)90730-E; KAUFMAN DL, 1993, NATURE, V366, P69, DOI 10.1038/366069a0; KENNEDY MK, 1992, J IMMUNOL, V149, P2496; KOH DR, 1992, SCIENCE, V256, P1210, DOI 10.1126/science.256.5060.1210; KUMAR V, 1993, J EXP MED, V178, P909, DOI 10.1084/jem.178.3.909; LEHMANN PV, 1992, NATURE, V358, P155, DOI 10.1038/358155a0; LININGTON C, 1993, EUR J IMMUNOL, V23, P1364, DOI 10.1002/eji.1830230627; MARRACK P, 1990, SCIENCE, V248, P705, DOI 10.1126/science.2185544; MILLER A, 1992, P NATL ACAD SCI USA, V89, P421, DOI 10.1073/pnas.89.1.421; MOMBAERTS P, 1992, CELL, V68, P69; OLDSTONE MBA, 1987, CELL, V50, P819, DOI 10.1016/0092-8674(87)90507-1; Olerup O., 1990, TISSUE ANTIGENS, V38, P1; OTA K, 1990, NATURE, V346, P183, DOI 10.1038/346183a0; PADOVAN E, 1993, SCIENCE, V262, P422, DOI 10.1126/science.8211163; PATERSON PY, 1976, TXB IMMUNOPATHOLOGY, P179; PERRY LL, 1991, J NEUROIMMUNOL, V33, P7, DOI 10.1016/0165-5728(91)90029-7; PODOLIN PL, 1993, J EXP MED, V178, P793, DOI 10.1084/jem.178.3.793; RACKE MK, 1991, J IMMUNOL, V146, P3012; RAINE CS, 1991, NEUROPATH APPL NEURO, V17, P265, DOI 10.1111/j.1365-2990.1991.tb00724.x; SCOTT B, 1994, IMMUNITY, V1, P73, DOI 10.1016/1074-7613(94)90011-6; SEDGWICK JD, 1986, J NEUROIMMUNOL, V13, P217, DOI 10.1016/0165-5728(86)90066-4; SHA WC, 1988, NATURE, V335, P271, DOI 10.1038/335271a0; SHIMONKEVITZ R, 1993, P NATL ACAD SCI USA, V90, P923, DOI 10.1073/pnas.90.3.923; SINGER SM, 1993, P NATL ACAD SCI USA, V90, P9566, DOI 10.1073/pnas.90.20.9566; SINHA AA, 1990, SCIENCE, V248, P1380, DOI 10.1126/science.1972595; STUART JM, 1988, FASEB J, V2, P2950, DOI 10.1096/fasebj.2.14.3053308; SUN D, 1988, EUR J IMMUNOL, V18, P1993, DOI 10.1002/eji.1830181219; TABIRA T, 1987, LAB INVEST, V56, P518; TISCH R, 1993, NATURE, V366, P72, DOI 10.1038/366072a0; TODD JA, 1988, SCIENCE, V240, P1003, DOI 10.1126/science.3368786; TRAUGOTT U, 1987, J NEUROIMMUNOL, V16, P283, DOI 10.1016/0165-5728(87)90082-8; ZAMVIL SS, 1990, ANNU REV IMMUNOL, V8, P579, DOI 10.1146/annurev.iy.08.040190.003051; ZHANG JW, 1993, SCIENCE, V261, P1451, DOI 10.1126/science.7690157	52	459	469	0	5	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	AUG 12	1994	78	3					399	408		10.1016/0092-8674(94)90419-7	http://dx.doi.org/10.1016/0092-8674(94)90419-7			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	PC405	7520367				2022-12-28	WOS:A1994PC40500007
J	TAKAHASHI, T; TANAKA, M; BRANNAN, CI; JENKINS, NA; COPELAND, NG; SUDA, T; NAGATA, S				TAKAHASHI, T; TANAKA, M; BRANNAN, CI; JENKINS, NA; COPELAND, NG; SUDA, T; NAGATA, S			GENERALIZED LYMPHOPROLIFERATIVE DISEASE IN MICE, CAUSED BY A POINT MUTATION IN THE FAS LIGAND	CELL			English	Article							TUMOR-NECROSIS-FACTOR; T-CELL RECEPTOR; GENETIC-LINKAGE MAP; SYSTEMIC AUTOIMMUNITY; NEGATIVE SELECTION; CLONAL ELIMINATION; MOUSE GENOME; FACTOR-ALPHA; LPR; ANTIGEN	Mice homozygous for lpr (lymphoproliferation) or gld (generalized lymphoproliferative disease) develop lymphadenopathy and suffer from autoimmune disease. The lpr mice have a mutation in a cell-surface protein, Fas, that mediates apoptosis. Fas ligand (FasL) is a tumor necrosis factor (TNF)-related type II membrane protein and binds to Fas. Here, mouse Fasl gene was isolated and localized to the gld region of mouse chromosome 1. Activated splenocytes from gld mice express Fasl mRNA. However, FasL in gld mice carries a point mutation in the C-terminal region, which is highly conserved among members of the TNF family. The recombinant gld FasL expressed in COS cells could not induce apoptosis in cells expressing Fas. These results indicate that lpr and gld are mutations in Fas and Fasl, respectively, and suggest important roles of the Fas system in development of T cells as well as cytotoxic T lymphocyte-mediated cytotoxicity.	NCI FREDERICK CANC RES & DEV CTR,ADV BIOSCI LABS,BASIC RES PROGRAM,MAMMALIAN GENET LAB,FREDERICK,MD 21702	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	TAKAHASHI, T (corresponding author), OSAKA BIOSCI INST,6-2-4 FURUEDAI,SUITA,OSAKA 565,JAPAN.		Nagata, Shigekazu/AAG-3203-2019	Nagata, Shigekazu/0000-0001-9758-8426	OFFICE OF THE DIRECTOR, NCI [N01CO074101] Funding Source: NIH RePORTER; NCI NIH HHS [N01-CO-74101] Funding Source: Medline	OFFICE OF THE DIRECTOR, NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ADACHI M, 1993, P NATL ACAD SCI USA, V90, P1756, DOI 10.1073/pnas.90.5.1756; ALLEN RD, 1990, J EXP MED, V172, P1367, DOI 10.1084/jem.172.5.1367; ANDREWS BS, 1978, J EXP MED, V148, P1198, DOI 10.1084/jem.148.5.1198; BLACKMAN M, 1990, SCIENCE, V248, P1335, DOI 10.1126/science.1972592; BROWNING JL, 1993, CELL, V72, P847, DOI 10.1016/0092-8674(93)90574-A; COHEN PL, 1991, ANNU REV IMMUNOL, V9, P243, DOI 10.1146/annurev.iy.09.040191.001331; COPELAND NG, 1991, TRENDS GENET, V7, P113, DOI 10.1016/0168-9525(91)90455-Y; DAVIDSON WF, 1985, P NATL ACAD SCI USA, V82, P1219, DOI 10.1073/pnas.82.4.1219; DRAPPA J, 1993, P NATL ACAD SCI USA, V90, P10340, DOI 10.1073/pnas.90.21.10340; ECK MJ, 1989, J BIOL CHEM, V264, P17595; EGERTON M, 1990, P NATL ACAD SCI USA, V87, P2579, DOI 10.1073/pnas.87.7.2579; FUKUNAGA R, 1990, CELL, V61, P341, DOI 10.1016/0092-8674(90)90814-U; GASE K, 1990, IMMUNOLOGY, V77, P368; GIESE T, 1992, J IMMUNOL, V149, P3097; Green EL, 1981, GENETICS PROBABILITY, P77; HANG LM, 1984, J IMMUNOL, V132, P1809; HERRON LR, 1993, J IMMUNOL, V151, P3450; ITOH N, 1991, CELL, V66, P233, DOI 10.1016/0092-8674(91)90614-5; JENKINS NA, 1982, J VIROL, V43, P26, DOI 10.1128/JVI.43.1.26-36.1982; JONES EY, 1989, NATURE, V338, P225, DOI 10.1038/338225a0; JONES LA, 1990, SCIENCE, V250, P1726, DOI 10.1126/science.2125368; KABELITZ D, 1993, IMMUNOL TODAY, V14, P338, DOI 10.1016/0167-5699(93)90231-9; KAWABE Y, 1991, NATURE, V349, P245, DOI 10.1038/349245a0; KLAS C, 1993, INT IMMUNOL, V5, P625, DOI 10.1093/intimm/5.6.625; KOTZIN BL, 1988, J EXP MED, V168, P2221, DOI 10.1084/jem.168.6.2221; MATSUMOTO K, 1991, J EXP MED, V173, P127, DOI 10.1084/jem.173.1.127; MIZUSHIMA S, 1990, NUCLEIC ACIDS RES, V18, P5322, DOI 10.1093/nar/18.17.5322; MOUNTZ JD, 1986, J IMMUNOL, V137, P1029; MURPHY KM, 1990, SCIENCE, V250, P1720, DOI 10.1126/science.2125367; NAGATA S, 1994, IN PRESS ADV IMMUNOL; NEDWIN GE, 1985, NUCLEIC ACIDS RES, V13, P6361, DOI 10.1093/nar/13.17.6361; OGASAWARA J, 1993, NATURE, V364, P806, DOI 10.1038/364806a0; OWENSCHAUB LB, 1992, CELL IMMUNOL, V140, P197, DOI 10.1016/0008-8749(92)90187-T; PADGETT RA, 1986, ANNU REV BIOCHEM, V55, P1119, DOI 10.1146/annurev.bi.55.070186.005351; RAMSDELL F, 1990, SCIENCE, V248, P1342, DOI 10.1126/science.1972593; ROSE NR, 1993, IMMUNOL TODAY, V14, P426, DOI 10.1016/0167-5699(93)90244-F; ROTHS JB, 1984, J EXP MED, V159, P1, DOI 10.1084/jem.159.1.1; ROUVIER E, 1993, J EXP MED, V177, P195, DOI 10.1084/jem.177.1.195; RUSSELL JH, 1993, P NATL ACAD SCI USA, V90, P4409, DOI 10.1073/pnas.90.10.4409; RUSSELL JH, 1991, P NATL ACAD SCI USA, V88, P2151, DOI 10.1073/pnas.88.6.2151; RUSSELL JH, 1993, EUR J IMMUNOL, V23, P2379, DOI 10.1002/eji.1830230951; SCOLLAY RG, 1980, EUR J IMMUNOL, V10, P210, DOI 10.1002/eji.1830100310; SCOTT DE, 1993, J IMMUNOL, V150, P664; SIDMAN CL, 1992, EUR J IMMUNOL, V22, P499, DOI 10.1002/eji.1830220231; SINGH G, 1991, P NATL ACAD SCI USA, V88, P10706, DOI 10.1073/pnas.88.23.10706; SIRACUSA LD, 1991, GENOMICS, V10, P313, DOI 10.1016/0888-7543(91)90314-5; SMITH RA, 1987, J BIOL CHEM, V262, P6951; SOBEL ES, 1991, J EXP MED, V173, P1441, DOI 10.1084/jem.173.6.1441; SUDA T, 1993, CELL, V75, P1169, DOI 10.1016/0092-8674(93)90326-L; SUDA T, 1994, IN PRESS J EXP MED; TRAUTH BC, 1989, SCIENCE, V245, P301, DOI 10.1126/science.2787530; VANEWIJK W, 1991, ANNU REV IMMUNOL, V9, P591, DOI 10.1146/annurev.iy.09.040191.003111; VANOSTADE X, 1991, EMBO J, V10, P827, DOI 10.1002/j.1460-2075.1991.tb08015.x; VIGNAUX F, 1994, IN PRESS EUR J IMMUN; VONBOEHMER H, 1988, ANNU REV IMMUNOL, V6, P309, DOI 10.1146/annurev.iy.06.040188.001521; WATANABE T, 1991, BIOCHEM GENET, V29, P325, DOI 10.1007/BF00554140; WATANABEFUKUNAGA R, 1992, J IMMUNOL, V148, P1274; WATANABEFUKUNAGA R, 1992, NATURE, V356, P314, DOI 10.1038/356314a0; WATSON ML, 1992, MAMM GENOME, V2, P158, DOI 10.1007/BF00302874; WEBB S, 1990, CELL, V63, P1249, DOI 10.1016/0092-8674(90)90420-J; YAMAGISHI J, 1990, PROTEIN ENG, V3, P713, DOI 10.1093/protein/3.8.713; ZHOU T, 1993, J IMMUNOL, V150, P3651; [No title captured]	63	1445	1497	0	25	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	MAR 25	1994	76	6					969	976		10.1016/0092-8674(94)90375-1	http://dx.doi.org/10.1016/0092-8674(94)90375-1			8	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	ND246	7511063				2022-12-28	WOS:A1994ND24600004
J	FOTSIS, T; ZHANG, YM; PEPPER, MS; ADLERCREUTZ, H; MONTESANO, R; NAWROTH, PP; SCHWEIGERER, L				FOTSIS, T; ZHANG, YM; PEPPER, MS; ADLERCREUTZ, H; MONTESANO, R; NAWROTH, PP; SCHWEIGERER, L			THE ENDOGENOUS ESTROGEN METABOLITE 2-METHOXYOESTRADIOL INHIBITS ANGIOGENESIS AND SUPPRESSES TUMOR-GROWTH	NATURE			English	Article							METASTASIS; CELLS	THE formation of new blood vessels (angiogenesis) is critical for the growth of tumours(1-3) and is; a dominant feature in various angiogenic diseases such as diabetic retinopathy, arthritis, haemangiomas and psoriasis(4). Recognition of the potential therapeutic benefits of controlling pathological angiogenesis has led to a search for angiogenesis inhibitors. Here we report that 2-methoxyoestradiol, an endogenous oestrogen metabolite of previously unknown function, is a potent inhibitor of endothelial cell proliferation and migration as well as angiogenesis in vitro. Moreover, when administered orally in mice, it strongly inhibits the neovascularization of solid tumours and suppresses their growth. Unlike the angiostatic steroids of corticoid structure(5), it does not require the co-administration of heparin or sulphated cyclodextrins for activity. Thus, 2-methoxyoestradiol is the first steroid to have high antiangiogenic activity by itself. Our results suggest that this compound may have therapeutic potential in cancer and other angiogenic diseases.	UNIV HEIDELBERG,DEPT MED & PATHOL,D-69120 HEIDELBERG,GERMANY; UNIV GENEVA,MED CTR,INST HISTOL & EMBRYOL,DEPT MORPHOL,CH-1121 GENEVA 4,SWITZERLAND; UNIV HELSINKI,MEILAHTI HOSP,DEPT CLIN CHEM,SF-00290 HELSINKI,FINLAND	Ruprecht Karls University Heidelberg; University of Geneva; University of Helsinki; Helsinki University Central Hospital	FOTSIS, T (corresponding author), UNIV HEIDELBERG,CHILDRENS UNIV HOSP,DEPT ONCOL & HAEMATOL,INF 150,D-69120 HEIDELBERG,GERMANY.		Pepper, Michael S./M-6143-2014	Pepper, Michael S./0000-0001-6406-2380				BLOOD CH, 1990, BIOCHIM BIOPHYS ACTA, V1032, P89, DOI 10.1016/0304-419X(90)90014-R; CRUM R, 1985, SCIENCE, V230, P1375, DOI 10.1126/science.2416056; DAMATO RJ, IN PRESS P NATN ACAD; EZEKOWITZ A, 1991, BRIT J HAEMATOL, V79, P67, DOI 10.1111/j.1365-2141.1991.tb08123.x; FOLKMAN J, 1989, NATURE, V339, P58, DOI 10.1038/339058a0; FOTSIS T, 1993, P NATL ACAD SCI USA, V90, P2690, DOI 10.1073/pnas.90.7.2690; KLAGSBRUN M, 1990, PEPTIDE GROWTH FACTO, V2, P549; MACLUSKY NJ, 1983, CATECHOL ESTROGENS, P151; MAHADEVAN V, 1991, EUR J CANCER, V27, P679, DOI 10.1016/0277-5379(91)90163-8; MONTESANO R, 1986, P NATL ACAD SCI USA, V83, P7297, DOI 10.1073/pnas.83.19.7297; PEPPER MS, 1992, BIOCHEM BIOPH RES CO, V189, P824, DOI 10.1016/0006-291X(92)92277-5; SCHWEIGERER L, 1992, EUR J CLIN INVEST, V22, P260, DOI 10.1111/j.1365-2362.1992.tb01460.x; SEEGERS JC, 1989, J STEROID BIOCHEM, V32, P797, DOI 10.1016/0022-4731(89)90455-X; TAKAMIYA Y, 1993, J NEUROSURG, V78, P470, DOI 10.3171/jns.1993.78.3.0470; WHITE CW, 1989, NEW ENGL J MED, V320, P1197, DOI 10.1056/NEJM198905043201807	15	660	743	1	37	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	MAR 17	1994	368	6468					237	239		10.1038/368237a0	http://dx.doi.org/10.1038/368237a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	NA870	7511798				2022-12-28	WOS:A1994NA87000053
J	SUKHAREV, SI; BLOUNT, P; MARTINAC, B; BLATTNER, FR; KUNG, C				SUKHAREV, SI; BLOUNT, P; MARTINAC, B; BLATTNER, FR; KUNG, C			A LARGE-CONDUCTANCE MECHANOSENSITIVE CHANNEL IN E. COLI ENCODED BY MSCL ALONE	NATURE			English	Article							ESCHERICHIA-COLI; ION CHANNELS; TRANSPORT; GENE	ALL cellular organisms respond to vibration, touch, gravity or changes in osmolarity, although the molecules on which such mechanosensations depend are unknown. Candidates include certain channels that gate in response to membrane stretch(1,2). Patch-clamp experiments with Escherichia coli envelope have revealed a mechanosensitive channel with very large conductance (MscL) and one with a smaller conductance (MscS)(3-6) which may be important in osmoregulation. Here we have solubilized and fractionated the envelope, reconstituted the MscL activity in vitro, and traced it to a small protein, whose gene, mscL, we then cloned. Insertional disruption of mscL removes the channel activity, whereas reexpression of mscL borne on an expression plasmid restores it. MscL-channel activities were observed in material from a cell-free expression system with mscL as the only template. The mscL nucleotide sequence predicts a unique protein of only 136 amino acids, with a highly hydrophobic core and very different from porins or other known proteins.	UNIV WISCONSIN,MOLEC BIOL LAB,MADISON,WI 53706; UNIV WISCONSIN,DEPT GENET,MADISON,WI 53706	University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison			Martinac, Boris/A-7178-2018	Martinac, Boris/0000-0001-8422-7082; Sukharev, Sergei/0000-0002-4807-9665				BERRIER C, 1992, EUR J BIOCHEM, V206, P559, DOI 10.1111/j.1432-1033.1992.tb16960.x; BLACHLYDYSON E, 1990, SCIENCE, V247, P1233, DOI 10.1126/science.1690454; BRITTEN RJ, 1962, BACTERIOL REV, V26, P292, DOI 10.1128/MMBR.26.3.292-335.1962; COWAN SW, 1992, NATURE, V358, P727, DOI 10.1038/358727a0; DANIELS DL, 1987, NATURE, V325, P831, DOI 10.1038/325831a0; DELCOUR AH, 1989, BIOPHYS J, V56, P631, DOI 10.1016/S0006-3495(89)82710-9; EPSTEIN W, 1986, FEMS MICROBIOL LETT, V39, P73; HAMANN A, 1987, J BACTERIOL, V169, P3138, DOI 10.1128/jb.169.7.3138-3145.1987; Jackson M.B., 1993, THERMODYNAMICS MEMBR, P327; MARTINAC B, 1990, NATURE, V348, P261, DOI 10.1038/348261a0; MARTINAC B, 1987, P NATL ACAD SCI USA, V84, P2297, DOI 10.1073/pnas.84.8.2297; SACHS F, 1992, SENSORY TRANSDUCTION, P241; SUKHAREV SI, 1993, BIOPHYS J, V65, P177, DOI 10.1016/S0006-3495(93)81044-0	13	568	590	3	60	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	MAR 17	1994	368	6468					265	268		10.1038/368265a0	http://dx.doi.org/10.1038/368265a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	NA870	7511799				2022-12-28	WOS:A1994NA87000062
J	SAKO, D; CHANG, XJ; BARONE, KM; VACHINO, G; WHITE, HM; SHAW, G; VELDMAN, GM; BEAN, KM; AHERN, TJ; FURIE, B; CUMMING, DA; LARSEN, GR				SAKO, D; CHANG, XJ; BARONE, KM; VACHINO, G; WHITE, HM; SHAW, G; VELDMAN, GM; BEAN, KM; AHERN, TJ; FURIE, B; CUMMING, DA; LARSEN, GR			EXPRESSION CLONING OF A FUNCTIONAL GLYCOPROTEIN LIGAND FOR P-SELECTIN	CELL			English	Article							GRANULE MEMBRANE-PROTEIN; PLASMA-MEMBRANE; ADHESION; GMP-140; NEUTROPHILS; PLATELETS; CELLS; CARBOHYDRATE; SEQUENCE; RECEPTOR	The initial adhesive interactions between circulating leukocytes and endothelia are mediated, in part, by P-selectin. We now report the expression cloning of a functional ligand for P-selectin from an HL-60 cDNA library. The predicted amino acid sequence reveals a novel mucin-like transmembrane protein. Significant binding of transfected COS cells to P-selectin requires coexpression of both the protein ligand and a fucosyltransferase. This binding is calcium dependent and can be inhibited by a neutralizing monoclonal antibody to P-selectin. Cotransfected COS cells express the ligand as a homodimer of 220 kd. A soluble ligand construct, when coexpressed with fucosyltransferase in COS cells, also mediates P-selectin binding and is immunocrossreactive with the major HL-60 glycoprotein that specifically binds P-selectin.	TUFTS UNIV NEW ENGLAND MED CTR,CTR HEMOSTASIS & THROMBOSIS RES,DIV HEMATOL & ONCOL,BOSTON,MA 02111; TUFTS UNIV,SCH MED,DEPT MED,BOSTON,MA 02111	Tufts Medical Center; Tufts University	SAKO, D (corresponding author), SMALL MOLEC DRUG DISCOVERY GRP,INST GENET,87 CAMBRIDGE PK DR,CAMBRIDGE,MA 02140, USA.			Vachino, Gloria/0000-0002-9193-9990				ARUFFO A, 1987, P NATL ACAD SCI USA, V84, P8573, DOI 10.1073/pnas.84.23.8573; BERMAN CL, 1986, J CLIN INVEST, V78, P130, DOI 10.1172/JCI112542; BEVILACQUA MP, 1987, P NATL ACAD SCI USA, V84, P9238, DOI 10.1073/pnas.84.24.9238; BONTHRON DT, 1986, NATURE, V324, P270, DOI 10.1038/324270a0; BRENAN M, 1984, J IMMUNOL METHODS, V74, P31, DOI 10.1016/0022-1759(84)90364-8; CARLSSON SR, 1986, J BIOL CHEM, V261, P2779; CAWTHON RM, 1990, GENOMICS, V7, P555, DOI 10.1016/0888-7543(90)90199-5; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; DORNER AJ, 1990, METHOD ENZYMOL, V185, P577; GROBER JS, 1993, J CLIN INVEST, V91, P2609, DOI 10.1172/JCI116500; HAMBURGER SA, 1990, BLOOD, V75, P550; HIRT B, 1967, J MOL BIOL, V26, P365, DOI 10.1016/0022-2836(67)90307-5; HOPP TP, 1981, P NATL ACAD SCI-BIOL, V78, P3824, DOI 10.1073/pnas.78.6.3824; Huttner WB, 1988, MODERN CELL BIOL, V6, P97; KAUFMAN RJ, 1991, NUCLEIC ACIDS RES, V19, P4485, DOI 10.1093/nar/19.16.4485; KUKOWSKALATALLO JF, 1990, GENE DEV, V4, P1288, DOI 10.1101/gad.4.8.1288; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LARSEN E, 1989, CELL, V59, P305, DOI 10.1016/0092-8674(89)90292-4; LARSEN E, 1990, CELL, V63, P467, DOI 10.1016/0092-8674(90)90443-I; LARSEN GR, 1992, J BIOL CHEM, V267, P11104; LASKY LA, 1989, CELL, V56, P1045, DOI 10.1016/0092-8674(89)90637-5; LASKY LA, 1992, CELL, V69, P927, DOI 10.1016/0092-8674(92)90612-G; LAWRENCE MB, 1991, CELL, V65, P859, DOI 10.1016/0092-8674(91)90393-D; LEVINOVITZ A, 1993, J CELL BIOL, V121, P449, DOI 10.1083/jcb.121.2.449; LOWE JB, 1990, CELL, V63, P475, DOI 10.1016/0092-8674(90)90444-J; LUTZFREYERMUTH C, 1990, P NATL ACAD SCI USA, V87, P6393, DOI 10.1073/pnas.87.16.6393; MAEMURA K, 1992, J BIOL CHEM, V267, P24379; MOORE KL, 1991, J CELL BIOL, V112, P491, DOI 10.1083/jcb.112.3.491; MOORE KL, 1992, J CELL BIOL, V118, P445, DOI 10.1083/jcb.118.2.445; MULLIGAN MS, 1992, J CLIN INVEST, V90, P1600, DOI 10.1172/JCI116029; NORGARD KE, 1993, J BIOL CHEM, V268, P12764; PALABRICA T, 1992, NATURE, V359, P848, DOI 10.1038/359848a0; PICKER LJ, 1991, CELL, V66, P921, DOI 10.1016/0092-8674(91)90438-5; POLLEY MJ, 1991, P NATL ACAD SCI USA, V88, P6224, DOI 10.1073/pnas.88.14.6224; Rehemtulla Alnawaz, 1992, Current Opinion in Biotechnology, V3, P560, DOI 10.1016/0958-1669(92)90086-X; Sambrook J, 1989, MOL CLONING LABORATO; STENBERG PE, 1985, J CELL BIOL, V101, P880, DOI 10.1083/jcb.101.3.880; VARKI A, 1992, Current Opinion in Cell Biology, V4, P257, DOI 10.1016/0955-0674(92)90041-A; WELLER A, 1992, J BIOL CHEM, V267, P15176; WEYRICH AS, 1993, J CLIN INVEST, V91, P2620, DOI 10.1172/JCI116501; [No title captured]	41	659	698	2	19	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	DEC 17	1993	75	6					1179	1186		10.1016/0092-8674(93)90327-M	http://dx.doi.org/10.1016/0092-8674(93)90327-M			8	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	MM893	7505206				2022-12-28	WOS:A1993MM89300016
J	SEAGROATT, V				SEAGROATT, V			MORTALITY AFTER PROSTATECTOMY - SELECTION AND SURGICAL APPROACH	LANCET			English	Article							BENIGN PROSTATIC HYPERPLASIA; REOPERATION; HYPERTROPHY; RESECTION; PROGRAM	Observational studies have found higher long-term mortality after transurethral prostatectomy (TURP) than after open prostatectomy (OP) and that this difference remained after statistical adjustment for comorbidity. This higher mortality has been attributed to the transurethral procedure itself. This association is reassessed here. Time-sequenced hospital and death records were analysed for 13 815 men undergoing prostatectomy (not for cancer) during the years 1963-85. TURP had a lower 30-day case-fatality rate than had OP, a similar 90-day rate, but TURP had a higher one-year rate. By inference, any excess mortality after TURP must begin shortly after the first postoperative month. However, plotting mortality expressed as SMRs, for the three years after operation showed no increase in long-term mortality after TURP, nor was there any concomitant increase in one-year death rates after prostatectomy as TURP replaced OP. Long-term mortality after TURP was close to that expected from background population rates: after SMR for TURP, for the second and third postoperative years, was 100 (95% CI 93-107). In contrast, long-term mortality after OP was lower than expected from population rates with a corresponding SMR of 79 (95% CI 71-88). The apparent excess in long-term mortality after TURP is unlikely to be caused by the operation itself. It is more likely to reflect relatively low long-term mortality in OP patients as a consequence of OP patients having been relatively fitter than those having TURP.			SEAGROATT, V (corresponding author), UNIV OXFORD,DEPT PUBL HLTH & PRIMARY CARE,HLTH CARE EPIDEMIOL UNIT,OLD RD,OXFORD OX3 7LF,ENGLAND.							ANDERSEN TF, 1990, MED CARE, V28, P870, DOI 10.1097/00005650-199010000-00002; Breslow N. E., 1987, STATISTICAL METHODS, VII; COLEMAN M, 1986, INT J EPIDEMIOL, V15, P134, DOI 10.1093/ije/15.1.134; CONCATO J, 1992, JAMA-J AM MED ASSOC, V267, P1077, DOI 10.1001/jama.267.8.1077; DONOVAN JL, 1994, EPIDEMIOLOGICALLY BA, V2, P140; GOLDACRE MJ, 1988, BRIT MED J, V296, P583, DOI 10.1136/bmj.296.6621.583; GREENFIELD S, 1989, NEW ENGL J MED, V320, P1142, DOI 10.1056/NEJM198904273201710; Iezzoni L I, 1990, Int J Technol Assess Health Care, V6, P272; JENKINS BJ, 1992, BRIT J UROL, V69, P372, DOI 10.1111/j.1464-410X.1992.tb15561.x; KIRBY RS, 1994, BRIT MED J, V309, P716, DOI 10.1136/bmj.309.6956.716; MCPHERSON K, 1989, BRIT MED J, V299, P740, DOI 10.1136/bmj.299.6701.740; MEBUST WK, 1994, CAMPBELLS UROLOGY, P2900; NEAL DE, 1990, BRIT J UROL, V66, P449, DOI 10.1111/j.1464-410X.1990.tb14986.x; ROOS LL, 1991, J CLIN EPIDEMIOL, V44, P881, DOI 10.1016/0895-4356(91)90050-J; ROOS NP, 1989, NEW ENGL J MED, V320, P1120, DOI 10.1056/NEJM198904273201705; SEAGROATT V, 1994, BRIT MED J, V309, P361, DOI 10.1136/bmj.309.6951.361; SIDNEY S, 1992, MED CARE, V30, P117, DOI 10.1097/00005650-199202000-00003; STUTZMAN RE, 1994, CAMPBELLS UROLOGY, P285; 1975, CLASSIFICATION SURGI; 1992, LANCET, V340, P944	20	25	25	1	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	DEC 9	1995	346	8989					1521	1524		10.1016/S0140-6736(95)92052-8	http://dx.doi.org/10.1016/S0140-6736(95)92052-8			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TJ291	7491047				2022-12-28	WOS:A1995TJ29100011
J	BARLOW, DP				BARLOW, DP			GAMETIC IMPRINTING IN MAMMALS	SCIENCE			English	Article							DNA METHYLATION; MOUSE; SUGGESTS; GENE	Embryonic development in mammals is distinct from that in other vertebrates because it depends on a small number of imprinted genes that are specifically expressed from either the maternal or paternal genome. Why mammals are uniquely dependent on sexual reproduction and how this dependency is dictated at a molecular level are questions that have been intensively investigated during the past 2 years. Gene inactivation experiments have confirmed predictions that imprinted genes regulate embryonic and placental growth and that DNA methylation is part of the imprinting mechanism. Despite these considerable achievements, the reason why imprinted hemizygosity is used as a mechanism to regulate the intrauterine growth of mammalian embryos remains elusive.			BARLOW, DP (corresponding author), INST MOLEC PATHOL,DR BOHR GASSE 7,A-1030 VIENNA,AUSTRIA.							ARIEL M, 1995, NAT GENET, V9, P312, DOI 10.1038/ng0395-312; BARLOW DP, 1993, SCIENCE, V260, P309, DOI 10.1126/science.8469984; BARTOLOMEI MS, 1993, GENE DEV, V7, P1663, DOI 10.1101/gad.7.9.1663; BEARD C, 1995, GENE DEV, V9, P2325, DOI 10.1101/gad.9.19.2325; Beechey C. V., 1993, Mouse Genome, V91, P102; BRANDEIS M, 1993, BIOESSAYS, V15, P709, DOI 10.1002/bies.950151103; BRANDON EP, 1995, CURR BIOL, V5, P625, DOI 10.1016/S0960-9822(95)00127-8; BUITING K, 1995, NAT GENET, V9, P395, DOI 10.1038/ng0495-395; CHAILLET JR, 1995, GENE DEV, V9, P1177, DOI 10.1101/gad.9.10.1177; CROSS SH, 1995, CURR OPIN GENET DEV, V5, P309, DOI 10.1016/0959-437X(95)80044-1; Driscoll D J, 1994, Mol Genet Med, V4, P37; EFSTRATIADIS A, 1994, CURR OPIN GENET DEV, V4, P265, DOI 10.1016/S0959-437X(05)80054-1; GIDDINGS SJ, 1994, NAT GENET, V6, P310, DOI 10.1038/ng0394-310; Green MC., 1989, GENETIC VARIANTS STR, P12; GUILLEMOT F, 1994, NAT GENET, V9, P235; HATADA I, 1995, NAT GENET, V11, P204, DOI 10.1038/ng1095-204; Hogan B, 1994, MANIPULATING MOUSE E; JINNO Y, 1994, NAT GENET, V6, P305, DOI 10.1038/ng0394-305; KALSCHEUER VM, 1993, NAT GENET, V5, P74, DOI 10.1038/ng0993-74; KANEKOISHINO T, 1995, NAT GENET, V11, P52, DOI 10.1038/ng0995-52; KAWAME H, 1995, HUM MOL GENET, V4, P2287, DOI 10.1093/hmg/4.12.2287; KAY GF, 1993, CELL, V72, P171, DOI 10.1016/0092-8674(93)90658-D; KREIDBERG JA, 1993, CELL, V74, P679, DOI 10.1016/0092-8674(93)90515-R; LATHAM KE, 1994, GENE DEV, V8, P290, DOI 10.1101/gad.8.3.290; LEE JE, 1993, MOL REPROD DEV, V35, P382, DOI 10.1002/mrd.1080350411; LEIGHTON PA, 1995, NATURE, V375, P34, DOI 10.1038/375034a0; LERCHNER W, UNPUB; LI E, 1993, NATURE, V366, P362, DOI 10.1038/366362a0; MANDEL JL, 1993, NAT GENET, V4, P8, DOI 10.1038/ng0593-8; MCGRATH J, 1984, CELL, V37, P179, DOI 10.1016/0092-8674(84)90313-1; MOORE T, 1991, TRENDS GENET, V7, P45, DOI 10.1016/0168-9525(91)90230-N; NEUMANN B, 1995, NAT GENET, V9, P12, DOI 10.1038/ng0195-12; NICHOLLS RD, 1994, AM J HUM GENET, V54, P733; PALDI A, 1995, CURR BIOL, V5, P1030, DOI 10.1016/S0960-9822(95)00207-7; PFEIFER K, 1994, GENE DEV, V8, P1867, DOI 10.1101/gad.8.16.1867; PIRROTTA V, 1995, CURR OPIN GENET DEV, V5, P466, DOI 10.1016/0959-437X(95)90050-Q; RAINIER S, 1994, JNCI-J NATL CANCER I, V86, P753, DOI 10.1093/jnci/86.10.753; RAZIN A, 1994, CELL, V77, P473, DOI 10.1016/0092-8674(94)90208-9; SMRZKA OW, 1995, HUM MOL GENET, V4, P1945, DOI 10.1093/hmg/4.10.1945; STOGER R, 1993, CELL, V73, P61, DOI 10.1016/0092-8674(93)90160-R; SURANI MAH, 1984, NATURE, V308, P548, DOI 10.1038/308548a0; TREMBLAY KD, 1995, NAT GENET, V9, P407, DOI 10.1038/ng0495-407; VARMUZA S, 1994, TRENDS GENET, V10, P118, DOI 10.1016/0168-9525(94)90212-7; VILLAR AJ, 1994, NAT GENET, V8, P373, DOI 10.1038/ng1294-373; VU TH, 1994, NATURE, V371, P714, DOI 10.1038/371714a0; WANG ZQ, 1994, NATURE, V372, P464, DOI 10.1038/372464a0; WEVRICK R, 1994, HUM MOL GENET, V3, P1877, DOI 10.1093/hmg/3.10.1877; XU YQ, 1993, BIOCHEM BIOPH RES CO, V197, P747, DOI 10.1006/bbrc.1993.2542; ZUCOTTI M, 1995, NAT GENET, V9, P316	49	382	405	0	9	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	DEC 8	1995	270	5242					1610	1613		10.1126/science.270.5242.1610	http://dx.doi.org/10.1126/science.270.5242.1610			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TJ293	7502071				2022-12-28	WOS:A1995TJ29300033
J	DELEON, M; WANG, Y; JONES, L; PEREZREYES, E; WEI, XY; SOONG, TW; SNUTCH, TP; YUE, DT				DELEON, M; WANG, Y; JONES, L; PEREZREYES, E; WEI, XY; SOONG, TW; SNUTCH, TP; YUE, DT			ESSENTIAL CA2+-BINDING MOTIF FOR CA2+-SENSITIVE INACTIVATION OF L-TYPE CA2+ CHANNELS	SCIENCE			English	Article							CALCIUM-DEPENDENT INACTIVATION; FUNCTIONAL EXPRESSION; ALPHA-1 SUBUNIT; BETA-SUBUNIT; BINDING; NEURONS; CLONING; PHOSPHORYLATION; BRAIN; CELLS	Intracellular calcium (Ca2+) inhibits the opening of L-type (alpha(1C)) Ca2+ channels, providing physiological control of Ca2+ entry into a wide variety of cells. A structural determinant of this Ca2+-sensitive inactivation was revealed by chimeric Ca2+ channels derived from parental alpha(1C) and alpha(1E) channels, the latter of which is a neuronal channel lacking Ca2+ inactivation. A consensus Ca2+-binding motif (an EF hand), located on the alpha(1C) subunit, was required for Ca2+ inactivation. Donation of the alpha(1C) EF-hand region to the alpha(1E) channel conferred the Ca2+-inactivating phenotype. These results strongly suggest that Ca2+ binding to the alpha(1C) subunit initiates Ca2+ inactivation.	JOHNS HOPKINS UNIV,SCH MED,DEPT BIOMED ENGN,PROGRAM MOLEC & CELLULAR SYST PHYSIOL,BALTIMORE,MD 21205; LOYOLA UNIV,DEPT PHYSIOL,MAYWOOD,IL 60153; MED COLL GEORGIA,INST MOLEC MED & GENET,AUGUSTA,GA 30912; UNIV BRITISH COLUMBIA,BIOTECHNOL LAB,VANCOUVER,BC V6T 1Z3,CANADA	Johns Hopkins University; Loyola University Chicago; University System of Georgia; Augusta University; University of British Columbia			Snutch, Terrance P/L-3464-2019	Snutch, Terrance P/0000-0001-5182-1296; Soong, Tuck Wah/0000-0002-0876-0325				ARMSTRONG CM, 1974, J GEN PHYSIOL, V63, P533, DOI 10.1085/jgp.63.5.533; ARMSTRONG DL, 1989, TRENDS NEUROSCI, V12, P117, DOI 10.1016/0166-2236(89)90168-9; BABITCH J, 1990, NATURE, V346, P321, DOI 10.1038/346321b0; BREHM P, 1978, SCIENCE, V202, P1203, DOI 10.1126/science.103199; BRODIN P, 1990, J BIOL CHEM, V265, P11125; CHAD JE, 1986, J PHYSIOL-LONDON, V378, P31, DOI 10.1113/jphysiol.1986.sp016206; DHALLAN RS, 1990, NATURE, V347, P184, DOI 10.1038/347184a0; DUBEL SJ, 1992, P NATL ACAD SCI USA, V89, P5058, DOI 10.1073/pnas.89.11.5058; GUTNICK MJ, 1989, J PHYSIOL-LONDON, V412, P197, DOI 10.1113/jphysiol.1989.sp017611; HAACK JA, 1994, BIOPHYS J, V66, P1051, DOI 10.1016/S0006-3495(94)80886-0; IMREDY JP, 1992, NEURON, V9, P197, DOI 10.1016/0896-6273(92)90159-B; IMREDY JP, 1994, NEURON, V12, P1301, DOI 10.1016/0896-6273(94)90446-4; KAWASAKI H, 1994, PROTEIN PROFILE, V1, P343; KRETSINGER RH, 1972, NATURE-NEW BIOL, V240, P85, DOI 10.1038/newbio240085a0; LINSE S, 1991, J BIOL CHEM, V266, P8050; LINSE S, 1995, ADV SEC MESS PHOSPH, V30, P89; NOBLE D, 1979, INITIATION HEARTBEAT, P1; PEREZREYES E, 1992, J BIOL CHEM, V267, P1792; PLANT TD, 1988, J PHYSIOL-LONDON, V404, P731, DOI 10.1113/jphysiol.1988.sp017316; RAGSDALE DS, 1994, SCIENCE, V265, P1724, DOI 10.1126/science.8085162; Reuter H, 1973, Prog Biophys Mol Biol, V26, P1, DOI 10.1016/0079-6107(73)90016-3; SATHER WA, 1993, NEURON, V11, P291, DOI 10.1016/0896-6273(93)90185-T; SCHERUBL H, 1993, AM J PHYSIOL, V264, pE354, DOI 10.1152/ajpendo.1993.264.3.E354; SEINO S, 1992, P NATL ACAD SCI USA, V89, P584, DOI 10.1073/pnas.89.2.584; SHAM JSK, 1995, P NATL ACAD SCI USA, V92, P121, DOI 10.1073/pnas.92.1.121; SHENG M, 1990, NEURON, V4, P571, DOI 10.1016/0896-6273(90)90115-V; SHERMAN A, 1990, BIOPHYS J, V58, P985, DOI 10.1016/S0006-3495(90)82443-7; SOONG TW, 1993, SCIENCE, V260, P1133, DOI 10.1126/science.8388125; STARR TVB, 1991, P NATL ACAD SCI USA, V88, P5621, DOI 10.1073/pnas.88.13.5621; STRYNADKA NCJ, 1989, ANNU REV BIOCHEM, V58, P951, DOI 10.1146/annurev.bi.58.070189.004511; WANG Q, 1995, CELL, V80, P1; WEI XY, 1994, J BIOL CHEM, V269, P1635; WEI XY, 1991, J BIOL CHEM, V266, P21943; WELLING A, 1993, CIRC RES, V73, P974, DOI 10.1161/01.RES.73.5.974; WILLIAMS ME, 1992, SCIENCE, V257, P389, DOI 10.1126/science.1321501; YOSHIDA A, 1992, FEBS LETT, V309, P343, DOI 10.1016/0014-5793(92)80804-P; YUE DT, 1990, P NATL ACAD SCI USA, V87, P753, DOI 10.1073/pnas.87.2.753; YUE DT, 1990, SCIENCE, V250, P1735, DOI 10.1126/science.2176745	38	226	227	0	4	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	DEC 1	1995	270	5241					1502	1506		10.1126/science.270.5241.1502	http://dx.doi.org/10.1126/science.270.5241.1502			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TH375	7491499				2022-12-28	WOS:A1995TH37500042
J	LYDALL, D; WEINERT, T				LYDALL, D; WEINERT, T			YEAST CHECKPOINT GENES IN DNA-DAMAGE PROCESSING - IMPLICATIONS FOR REPAIR AND ARREST	SCIENCE			English	Article							EXONUCLEASE ACTIVE-SITE; SCHIZOSACCHAROMYCES-POMBE; SACCHAROMYCES-CEREVISIAE; TYROSINE PHOSPHORYLATION; REPLICATION; MITOSIS; POLYMERASES; P34CDC28; PROTEIN; MUTANTS	Yeast checkpoint control genes were found to affect processing of DNA damage as well as cell cycle arrest. An assay that measures DNA damage processing in vivo showed that the checkpoint genes RAD17, RAD24, and MEC3 activated an exonuclease that degrades DNA. The degradation is probably a direct consequence of checkpoint protein function, because RAD17 encodes a putative 3'-5' DNA exonuclease. Another checkpoint gene, RAD9, had a different role: It inhibited the degradation by RA17, RAD24, and MEC3. A model of how processing of DNA damage may be linked to both DNA repair and cell cycle arrest is proposed.			LYDALL, D (corresponding author), UNIV ARIZONA,DEPT MOLEC & CELLULAR BIOL,TUCSON,AZ 85721, USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM045276] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM 45276-01] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALKHODAIRY F, 1992, EMBO J, V11, P1343, DOI 10.1002/j.1460-2075.1992.tb05179.x; ALLEN JB, 1994, GENE DEV, V8, P2401, DOI 10.1101/gad.8.20.2401; AMON A, 1992, NATURE, V355, P368, DOI 10.1038/355368a0; BERNAD A, 1989, CELL, V59, P219, DOI 10.1016/0092-8674(89)90883-0; BLANCO L, 1992, GENE, V112, P139, DOI 10.1016/0378-1119(92)90316-H; ENOCH T, 1990, CELL, V60, P665, DOI 10.1016/0092-8674(90)90669-6; ENOCH T, 1992, GENE DEV, V6, P2035, DOI 10.1101/gad.6.11.2035; GARVIK B, 1995, MOL CELL BIOL, V15, P6128; HOLLIDAY R, 1976, GENET RES, V27, P413, DOI 10.1017/S0016672300016621; KASTAN MB, 1991, CANCER RES, V51, P6304; KUERBITZ SJ, 1992, P NATL ACAD SCI USA, V689, P7491; LI R, 1994, NATURE, V371, P534, DOI 10.1038/371534a0; LYDALL D, UNPUB; NASIM A, 1975, GENETICS, V79, P573; NAVAS TA, 1995, CELL, V80, P29, DOI 10.1016/0092-8674(95)90448-4; NOWAK R, 1995, SCIENCE, V268, P1700, DOI 10.1126/science.7792589; ONEL K, 1995, MOL CELL BIOL, V15, P5329; ONEL K, UNPUB; RILES L, 1993, GENETICS, V134, P81; ROWLEY R, 1992, EMBO J, V11, P1335, DOI 10.1002/j.1460-2075.1992.tb05178.x; SANDELL LL, 1993, CELL, V75, P729, DOI 10.1016/0092-8674(93)90493-A; SASSANFAR M, 1990, J MOL BIOL, V212, P79, DOI 10.1016/0022-2836(90)90306-7; SAVITSKY K, 1995, SCIENCE, V268, P1749, DOI 10.1126/science.7792600; SORGER PK, 1992, NATURE, V355, P365, DOI 10.1038/355365a0; THELEN MP, 1994, J BIOL CHEM, V269, P747; WEINERT TA, 1988, SCIENCE, V241, P317, DOI 10.1126/science.3291120; WEINERT TA, 1993, GENETICS, V134, P63; WEINERT TA, 1994, GENE DEV, V8, P652, DOI 10.1101/gad.8.6.652; WITKIN EM, 1991, BIOCHIMIE, V73, P133, DOI 10.1016/0300-9084(91)90196-8	29	352	356	0	4	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	DEC 1	1995	270	5241					1488	1491		10.1126/science.270.5241.1488	http://dx.doi.org/10.1126/science.270.5241.1488			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TH375	7491494				2022-12-28	WOS:A1995TH37500037
J	GROSHEIDE, PM; KLOKMANHOUWELING, JM; CONYNVANSPAENDONCK, MAE; VERBRUGGE, HP; LATUPERISA, R; MAZEL, JA; LEMS, AA; YPMA, TD; GERARDS, LJ; AARTS, GJ; BOLSCHER, DJA; DUFFELS, GJJ; KOPPENAAL, A; ENGEL, B; VANDERVOORN, JG; KOSTER, EH; VANDERSTEUR, JB				GROSHEIDE, PM; KLOKMANHOUWELING, JM; CONYNVANSPAENDONCK, MAE; VERBRUGGE, HP; LATUPERISA, R; MAZEL, JA; LEMS, AA; YPMA, TD; GERARDS, LJ; AARTS, GJ; BOLSCHER, DJA; DUFFELS, GJJ; KOPPENAAL, A; ENGEL, B; VANDERVOORN, JG; KOSTER, EH; VANDERSTEUR, JB			PROGRAM FOR PREVENTING PERINATAL HEPATITIS-B INFECTION THROUGH SCREENING OF PREGNANT-WOMEN AND IMMUNIZATION OF INFANTS OF INFECTED MOTHERS IN THE NETHERLANDS, 1989-92	BMJ-BRITISH MEDICAL JOURNAL			English	Article							PASSIVE-ACTIVE IMMUNIZATION; ANTIGEN-CARRIER MOTHERS; VACCINATION PROGRAM; SURFACE-ANTIGEN; IMMUNE GLOBULIN; VIRUS-INFECTION; TRANSMISSION	Objectives-To launch a programme for the prevention of perinatal infection with hepatitis B in the Netherlands. Design-Routine antenatal screening and intervention programme. Setting-Community antenatal programme, the Netherlands. Subjects-Infants of mothers who were carriers of hepatitis B detected by routine screening. Interventions-Infants of infected mothers received hepatitis B immunoglobulin at birth and four doses of hepatitis B vaccine in conjunction with routine immunisation at 3, 4, 5, and 11 months of age. Main outcome measures-Results of screening and immunisation from 1989-92. Results-The coverage of screening increased from 46% in 1989 to 84% in 1992. Hepatitis B surface antigen was detected in 2145 women (0.44%). The coverage of postnatal immunoprophylaxis in 1645 neonates born to mothers who were carriers of hepatitis B was 85% (1398); in 3% (42) there was a delay in administration of immunoglobulin of over 24 hours. In 1991, 96% (537), 95% (532), 94% (525), and 87% (489) of the infants received the first, second, third, and fourth dose of vaccine, respectively. There was considerable variation in the timing of vaccination; 17% (258) of the infants received their first dose more than two weeks late. Of the 59% (583) of infants who received the fourth dose more than two weeks beyond target age, 14% (141) also received their first dose too late. Conclusions-A prevention programme for perinatal hepatitis B in an area of low prevalence, when incorporated into existing health care, is feasible and achieves satisfactory coverage rates. Intensive follow up is needed to improve adherence to the immunisation schedule.	NATL INST PUBL HLTH & ENVIRONM PROTECT, DEPT INFECT DIS & EPIDEMIOL, 3720 BA BILTHOVEN, NETHERLANDS; MUNICIPAL PUBL HLTH SERV, HAARLEM, NETHERLANDS; NETHERLANDS RED CROSS, BLOOD TRANSFUS SERV, CENT LAB, AMSTERDAM, NETHERLANDS	Netherlands National Institute for Public Health & the Environment								BEASLEY RP, 1983, HEPATOLOGY, V3, P135; BEASLEY RP, 1983, LANCET, V2, P1099; CHEN D-S, 1987, Journal of the American Medical Association, V257, P2597, DOI 10.1001/jama.257.19.2597; GROSHEIDE PM, 1993, AM J DIS CHILD, V147, P1316, DOI 10.1001/archpedi.1993.02160360058019; GROSHEIDE PM, IN PRESS BMJ; HENNING KJ, 1992, AM J PUBLIC HEALTH, V82, P885, DOI 10.2105/AJPH.82.6.885; INSKIP HM, 1991, INT J EPIDEMIOL, V20, P764, DOI 10.1093/ije/20.3.764; JONAS MM, 1990, AM J GASTROENTEROL, V85, P277; MAZEL JA, 1984, BRIT MED J, V288, P513, DOI 10.1136/bmj.288.6416.513; NIU MT, 1992, AM J DIS CHILD, V146, P793, DOI 10.1001/archpedi.1992.02160190025012; SCHALM SW, 1989, PEDIATRICS, V83, P1041; STEVENS CE, 1985, JAMA-J AM MED ASSOC, V253, P1740, DOI 10.1001/jama.253.12.1740; STROFFOLINI T, 1989, VACCINE, V7, P152, DOI 10.1016/0264-410X(89)90056-X; VERBRUGGE HP, 1990, PEDIATRICS, V86, P1060; WEST DJ, 1993, VACCINE, V11, pS21, DOI 10.1016/0264-410X(93)90154-P	15	18	19	0	0	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	NOV 4	1995	311	7014					1200	1202		10.1136/bmj.311.7014.1200	http://dx.doi.org/10.1136/bmj.311.7014.1200			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TD768	7488896	Green Published			2022-12-28	WOS:A1995TD76800020
J	KAGI, D; VIGNAUX, F; LEDERMANN, B; BURKI, K; DEPRAETERE, V; NAGATA, S; HENGARTNER, H; GOLSTEIN, P				KAGI, D; VIGNAUX, F; LEDERMANN, B; BURKI, K; DEPRAETERE, V; NAGATA, S; HENGARTNER, H; GOLSTEIN, P			FAS AND PERFORIN PATHWAYS AS MAJOR MECHANISMS OF T-CELL-MEDIATED CYTOTOXICITY	SCIENCE			English	Article							TUMOR-NECROSIS-FACTOR; MONOCLONAL-ANTIBODY; TARGET-CELLS; MICE; APOPTOSIS; LYSIS; LYMPHOCYTES; LYMPHOMA; ANTIGEN; DEFECTS	Two molecular mechanisms of T cell-mediated cytotoxicity, one perforin-based, the other Fas-based, have been demonstrated. To determine the extent of their contribution to T cell-mediated cytotoxicity, a range of effector cells from normal control or perforin-deficient mice were tested against a panel of target cells with various levels of Fas expression. All cytotoxicity observed was due to either of these mechanisms, and no third mechanism was detected. Thus, the perforin- and Fas-based mechanisms may account for all T cell-mediated cytotoxicity in short-term in vitro assays.	CNRS MARSEILLE LUMINY,INSERM,CTR IMMUNOL,F-13288 MARSEILLE 9,FRANCE; UNIV ZURICH,INST EXPTL IMMUNOL,DEPT PATHOL,CH-8091 ZURICH,SWITZERLAND; SANDOZ PHARMA LTD,PRECLIN RES,CH-4002 BASEL,SWITZERLAND; OSAKA BIOSCI INST,SUITA,OSAKA 565,JAPAN	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Aix-Marseille Universite; University of Zurich; Novartis; Sandoz			Golstein, Pierre/A-4954-2014; Nagata, Shigekazu/AAG-3203-2019	Golstein, Pierre/0000-0003-1750-3483; Nagata, Shigekazu/0000-0001-9758-8426				BERKE G, 1972, J EXP MED, V135, P1334, DOI 10.1084/jem.135.6.1334; Berke G, 1980, Prog Allergy, V27, P69; BERKE G, 1989, FUNDAMENTAL IMMUNOLO, P735; Cerottini J C, 1974, Adv Immunol, V18, P67, DOI 10.1016/S0065-2776(08)60308-9; CONZELMANN A, 1982, NATURE, V298, P170, DOI 10.1038/298170a0; DOHERTY PC, 1978, J EXP MED, V148, P534, DOI 10.1084/jem.148.2.534; DUKE RC, 1991, APOPTOSIS MOL BASIS, P209; Golstein P, 1977, Contemp Top Immunobiol, V7, P273; GOLSTEIN P, IN PRESS APOPTOSIS I; HENKART PA, 1985, ANNU REV IMMUNOL, V3, P31, DOI 10.1146/annurev.iy.03.040185.000335; Henney C S, 1977, Contemp Top Immunobiol, V7, P245; HEUSEL JW, 1994, CELL, V76, P977, DOI 10.1016/0092-8674(94)90376-X; KAGI D, 1994, NATURE, V369, P31, DOI 10.1038/369031a0; LJUNGGREN HG, 1989, J IMMUNOL, V142, P2911; Martz E, 1977, Contemp Top Immunobiol, V7, P301; OGASAWARA J, 1993, NATURE, V364, P806, DOI 10.1038/364806a0; Perlmann P, 1969, Adv Immunol, V11, P117, DOI 10.1016/S0065-2776(08)60479-4; PIRCHER H, 1990, NATURE, V346, P629, DOI 10.1038/346629a0; PODACK ER, 1985, IMMUNOL TODAY, V6, P21, DOI 10.1016/0167-5699(85)90164-1; ROUVIER E, 1993, J EXP MED, V177, P195, DOI 10.1084/jem.177.1.195; SHI LF, 1992, J EXP MED, V176, P1521, DOI 10.1084/jem.176.6.1521; SHIVER JW, 1992, CELL, V71, P315, DOI 10.1016/0092-8674(92)90359-K; SITKOVSKY MV, 1993, CYTOTOXIC CELLS; SUDA T, 1993, CELL, V75, P1169, DOI 10.1016/0092-8674(93)90326-L; TRAUTH BC, 1989, SCIENCE, V245, P301, DOI 10.1126/science.2787530; TSCHOPP J, 1990, ANNU REV IMMUNOL, V8, P279, DOI 10.1146/annurev.immunol.8.1.279; VIGNAUX F, 1994, EUR J IMMUNOL, V24, P923, DOI 10.1002/eji.1830240421; VIGNAUX F, UNPUB; WATANABEFUKUNAGA R, 1992, NATURE, V356, P314, DOI 10.1038/356314a0; YONEHARA S, 1989, J EXP MED, V169, P1747, DOI 10.1084/jem.169.5.1747; YOUNG JDE, 1989, PHYSIOL REV, V69, P250, DOI 10.1152/physrev.1989.69.1.250	31	1436	1478	2	30	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUL 22	1994	265	5171					528	530		10.1126/science.7518614	http://dx.doi.org/10.1126/science.7518614			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	NY216	7518614				2022-12-28	WOS:A1994NY21600031
J	CONNELL, GJ; YARUS, M				CONNELL, GJ; YARUS, M			RNAS WITH DUAL-SPECIFICITY AND DUAL RNAS WITH SIMILAR SPECIFICITY	SCIENCE			English	Article							RIBOSOMAL-RNA; TETRAHYMENA; POLYMERASE; SUBSTRATE; STABILITY; ACID; DNA	The biological role of RNA is delimited by its possible reactions, which can be explored by selection. A comparison of selected RNAs that bind one ligand with those that bind two related ligands suggests that a single nucleotide substitution can expand binding specificity. An RNA site with dual (joint) specificity has adenine and cytosine bases whose pK(a)'s appear shifted upward, thereby mimicking an efficient general acid-base catalyst. The joint site also contains two conserved, looped arginine-coding triplets implicated in arginine site formation. Two selected joint RNAs are identical in some regions and distinct in others. The distinct regions, like some peptides, seem to function similarly without being similar in primary structure.	UNIV COLORADO, DEPT MOLEC CELLULAR & DEV BIOL, BOULDER, CO 80309 USA	University of Colorado System; University of Colorado Boulder			Yarus, Michael/Q-9813-2019					ALTMAN S, 1986, BIOCHEMISTRY-US, V25, P1205, DOI 10.1021/bi00354a002; BASS BL, 1984, NATURE, V308, P820, DOI 10.1038/308820a0; CALNAN BJ, 1991, SCIENCE, V252, P1167, DOI 10.1126/science.252.5009.1167; CHEONG CJ, 1990, NATURE, V346, P680, DOI 10.1038/346680a0; CONNELL GJ, 1993, BIOCHEMISTRY-US, V32, P5497, DOI 10.1021/bi00072a002; CONNELL GJ, UNPUB; FREIER SM, 1986, P NATL ACAD SCI USA, V83, P9373, DOI 10.1073/pnas.83.24.9373; HARTLEY BS, 1974, S SOC GEN MICROBIOL, V24, P151; HENDLER S, 1970, BIOCHEMISTRY-US, V9, P4141, DOI 10.1021/bi00823a017; HEUS HA, 1991, SCIENCE, V253, P191, DOI 10.1126/science.1712983; HUNTER WN, 1986, NATURE, V320, P552, DOI 10.1038/320552a0; INOUE T, 1985, P NATL ACAD SCI USA, V82, P648, DOI 10.1073/pnas.82.3.648; KAO TH, 1980, P NATL ACAD SCI-BIOL, V77, P3360, DOI 10.1073/pnas.77.6.3360; LEGAULT P, UNPUB; MADHANI HD, 1992, CELL, V71, P803, DOI 10.1016/0092-8674(92)90556-R; MAJERFELD I, 1994, NAT STRUCT BIOL, V1, P287, DOI 10.1038/nsb0594-287; MILLIGAN JF, 1989, METHOD ENZYMOL, V180, P51; PFEUFFER T, 1975, J BIOL CHEM, V250, P867; SASSANFAR M, 1993, NATURE, V364, P550, DOI 10.1038/364550a0; TOPAL MD, 1976, NATURE, V263, P285, DOI 10.1038/263285a0; TUERK C, 1990, SCIENCE, V249, P505, DOI 10.1126/science.2200121; WEINER AM, 1993, CELL, V72, P161, DOI 10.1016/0092-8674(93)90654-9; YARUS M, 1988, SCIENCE, V240, P1751, DOI 10.1126/science.3381099; Yarus M., 1993, RNA WORLD, P205; ZUKER M, 1989, SCIENCE, V244, P48, DOI 10.1126/science.2468181	25	104	116	0	5	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAY 20	1994	264	5162					1137	1141		10.1126/science.7513905	http://dx.doi.org/10.1126/science.7513905			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	NM146	7513905				2022-12-28	WOS:A1994NM14600030
J	ERNFORS, P; LEE, KF; KUCERA, J; JAENISCH, R				ERNFORS, P; LEE, KF; KUCERA, J; JAENISCH, R			LACK OF NEUROTROPHIN-3 LEADS TO DEFICIENCIES IN THE PERIPHERAL NERVOUS-SYSTEM AND LOSS OF LIMB PROPRIOCEPTIVE AFFERENTS	CELL			English	Article							DORSAL-ROOT GANGLIA; EXPRESSING MESSENGER-RNA; GROWTH-FACTOR FAMILY; SENSORY NEURONS; MOLECULAR-CLONING; BRAIN; RAT; SURVIVAL; BDNF; RECEPTORS	Neurotrophin-3-deficient (NT-3-deficient) mice were generated by gene targeting. Mutant mice displayed severe movement defects of the limbs, and most died shortly after birth. Substantial portions of peripheral sensory and sympathetic neurons were lost while motor neurons were not affected. Significantly, spinal proprioceptive afferents and their peripheral sense organs (muscle spindles and Golgi tendon organs) were completely absent in homozygous mutant mice. This correlated with a loss of parvalbumin and carbonic anhydrase-positive neurons in the dorsal root ganglion. No gross abnormalities were seen in Pacinian corpuscles, cutaneous afferents containing substance P and calcitonin gene-related peptide, and deep nerve fibers in the joint capsule and tendon. Importantly, the number of muscle spindles in heterozygous mutant mice was half of that in control mice, indicating that NT-3 is present at limiting concentrations in the embryo.	MIT,DEPT BIOL,CAMBRIDGE,MA 02142; BOSTON UNIV,SCH MED,DEPT NEUROL,BOSTON,MA 02118	Massachusetts Institute of Technology (MIT); Boston University	ERNFORS, P (corresponding author), WHITEHEAD INST BIOMED RES,9 CAMBRIDGE CTR,CAMBRIDGE,MA 02142, USA.				NATIONAL CANCER INSTITUTE [R35CA044339] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS025796] Funding Source: NIH RePORTER; NCI NIH HHS [5-R35-CA44339] Funding Source: Medline; NINDS NIH HHS [5-R01-NS25796] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ARENAS E, 1994, NATURE, V367, P368, DOI 10.1038/367368a0; ARUMAE U, 1993, J CELL BIOL, V122, P1053, DOI 10.1083/jcb.122.5.1053; AVILA MA, 1993, DEV BIOL, V159, P266, DOI 10.1006/dbio.1993.1239; BARDE YA, 1989, NEURON, V2, P1525, DOI 10.1016/0896-6273(89)90040-8; BARDE YA, 1982, EMBO J, V1, P549, DOI 10.1002/j.1460-2075.1982.tb01207.x; BARRES BA, 1994, NATURE, V367, P371, DOI 10.1038/367371a0; BERKEMEIER LR, 1991, NEURON, V7, P857, DOI 10.1016/0896-6273(91)90287-A; BIRREN SJ, 1993, DEVELOPMENT, V119, P597; BUCHMAN VL, 1993, DEVELOPMENT, V118, P989; CARR PA, 1989, BRAIN RES, V497, P163, DOI 10.1016/0006-8993(89)90983-9; CARR PA, 1993, BRAIN RES BULL, V30, P209, DOI 10.1016/0361-9230(93)90246-8; CARR PA, 1989, NEUROSCIENCE, V33, P363, DOI 10.1016/0306-4522(89)90216-9; DAVIES AM, 1986, J NEUROSCI, V6, P1897; DECHANT G, 1993, J NEUROSCI, V13, P2610, DOI 10.1523/JNEUROSCI.13-06-02610.1993; DICICCOBLOOM E, 1993, NEURON, V11, P1101, DOI 10.1016/0896-6273(93)90223-E; ERNFORS P, 1994, NATURE, V368, P147, DOI 10.1038/368147a0; ERNFORS P, 1992, EUR J NEUROSCI, V4, P1140, DOI 10.1111/j.1460-9568.1992.tb00141.x; ERNFORS P, 1990, P NATL ACAD SCI USA, V87, P5454, DOI 10.1073/pnas.87.14.5454; ERNFORS P, 1990, NEURON, V5, P511, DOI 10.1016/0896-6273(90)90090-3; ERNFORS P, 1991, EUR J NEUROSCI, V3, P953, DOI 10.1111/j.1460-9568.1991.tb00031.x; ERNFORS P, 1994, IN PRESS PROG BRAIN; GRIFFIN JW, 1990, ANN NEUROL, V27, P304, DOI 10.1002/ana.410270313; HALLBOOK F, 1991, NEURON, V6, P1; HENDERSON CE, 1993, NATURE, V363, P213; HOHN A, 1990, NATURE, V344, P339, DOI 10.1038/344339a0; HORYLEE F, 1993, P NATL ACAD SCI USA, V90, P2613, DOI 10.1073/pnas.90.7.2613; IBANEZ CF, 1993, DEVELOPMENT, V117, P1345; IP NY, 1992, P NATL ACAD SCI USA, V89, P3060, DOI 10.1073/pnas.89.7.3060; JONES KR, 1990, P NATL ACAD SCI USA, V87, P8060, DOI 10.1073/pnas.87.20.8060; KAISHO Y, 1990, FEBS LETT, V266, P187, DOI 10.1016/0014-5793(90)81536-W; KALCHEIM C, 1992, P NATL ACAD SCI USA, V89, P1661, DOI 10.1073/pnas.89.5.1661; KOLIATSOS VE, 1993, NEURON, V10, P359, DOI 10.1016/0896-6273(93)90326-M; KRINKE G, 1978, ACTA NEUROPATHOL, V43, P213; KRINKE G, 1980, NEUROTOXICOLOGY, V2, P13; KUCERA J, 1990, DEVELOPMENT, V110, P483; KUCERA J, 1992, ANAT EMBRYOL, V186, P301; LEE KF, 1994, IN PRESS DEVELOPMENT; LEIBROCK J, 1989, NATURE, V341, P149, DOI 10.1038/341149a0; LEVIMONTALCINI R, 1987, SCIENCE, V237, P1154, DOI 10.1126/science.3306916; LI E, 1992, CELL, V69, P915, DOI 10.1016/0092-8674(92)90611-F; LINDSAY RM, 1985, DEV BIOL, V112, P319, DOI 10.1016/0012-1606(85)90402-6; MAISONPIERRE PC, 1990, SCIENCE, V247, P1446, DOI 10.1126/science.2321006; MAISONPIERRE PC, 1990, NEURON, V5, P501, DOI 10.1016/0896-6273(90)90089-X; MAYEUX V, 1991, DEV BRAIN RES, V71, P201; MU XJ, 1993, J NEUROSCI, V13, P4029; PIRVOLA U, 1992, P NATL ACAD SCI USA, V89, P9915, DOI 10.1073/pnas.89.20.9915; Ranson SW, 1931, J COMP NEUROL, V52, P341, DOI 10.1002/cne.900520206; RITTER AM, 1991, NATURE, V350, P500, DOI 10.1038/350500a0; ROSENTHAL A, 1990, NEURON, V4, P767, DOI 10.1016/0896-6273(90)90203-R; RUIT KG, 1992, NEURON, V8, P573, DOI 10.1016/0896-6273(92)90284-K; SCHECTERSON LC, 1992, NEURON, V9, P449, DOI 10.1016/0896-6273(92)90183-E; SCHNELL L, 1994, NATURE, V367, P170, DOI 10.1038/367170a0; SENDTNER M, 1992, NATURE, V360, P757, DOI 10.1038/360757a0; SMITH BE, 1992, NEUROL CLIN, V10, P735, DOI 10.1016/S0733-8619(18)30206-8; STERMAN AB, 1980, ANN NEUROL, V7, P354, DOI 10.1002/ana.410070413; THOENEN H, 1980, PHYSIOL REV, V60, P1284, DOI 10.1152/physrev.1980.60.4.1284; WIESENDANGER M, 1964, ACTA PHYSIOL SCAND, V62, P160, DOI 10.1111/j.1748-1716.1964.tb03964.x; WOOD JN, 1981, BIOSCIENCE REP, V1, P263, DOI 10.1007/BF01114913; ZELENA J, 1957, J EMBRYOL EXP MORPH, V5, P283	59	608	619	0	7	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	MAY 20	1994	77	4					503	512		10.1016/0092-8674(94)90213-5	http://dx.doi.org/10.1016/0092-8674(94)90213-5			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	NM832	7514502				2022-12-28	WOS:A1994NM83200006
J	NIETO, MA; SARGENT, MG; WILKINSON, DG; COOKE, J				NIETO, MA; SARGENT, MG; WILKINSON, DG; COOKE, J			CONTROL OF CELL BEHAVIOR DURING VERTEBRATE DEVELOPMENT BY SLUG, A ZINC-FINGER GENE	SCIENCE			English	Article							NEURAL CREST; ADHESION; ANTIBODIES; CADHERIN; ENCODES	Slug, a vertebrate gene encoding a zinc finger protein of the Snail family, is expressed in the neural crest and in mesodermal cells emigrating from the primitive streak. Early chick embryos were incubated with antisense oligonucleotides to chick Slug. These oligonucleotides specifically inhibit the normal change in cell behavior that occurs at the two sites in the emerging body plan in which the gene is expressed. This change, which is the transition from epithelial to mesenchymal character, occurs at the formation of mesoderm during gastrulation and on emigration of the neural crest from the neural tube.	NATL INST MED RES,LONDON NW7 1AA,ENGLAND; CSIC,INST CAJAL,E-28002 MADRID,SPAIN	MRC National Institute for Medical Research; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Instituto Cajal (IC)			Nieto, M. Angela/A-6531-2008	Nieto, M. Angela/0000-0002-3538-840X; Wilkinson, David/0000-0001-6757-7080				BASLER K, 1993, CELL, V73, P687, DOI 10.1016/0092-8674(93)90249-P; Bellairs R., 1987, P123; BOULAY JL, 1987, NATURE, V330, P395, DOI 10.1038/330395a0; BRONNERFRASER M, 1992, DEV BIOL, V153, P291, DOI 10.1016/0012-1606(92)90114-V; BURDSAL CA, 1993, DEVELOPMENT, V118, P829; COOKE J, UNPUB; DAMICOMARTEL A, 1983, AM J ANAT, V166, P445, DOI 10.1002/aja.1001660406; DARRIBERE T, 1988, DEV BIOL, V126, P182, DOI 10.1016/0012-1606(88)90252-7; HAMBURGER V, 1951, J MORPHOL, V88, P49, DOI 10.1002/jmor.1050880104; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; LALLIER T, 1993, SCIENCE, V259, P692, DOI 10.1126/science.8430321; Le Douarin N, 1973, Dev Biol, V30, P217, DOI 10.1016/0012-1606(73)90061-4; Le Douarin N.M., 1982, NEURAL CREST; LELIEVRE C, 1975, J EMBRYOL EXP MORPH, V31, P125; NEW DAT, 1955, J EMBRYOL EXP MORPH, V3, P326; NIETO MA, 1992, DEVELOPMENT, V116, P227; SARGENT MG, 1990, DEVELOPMENT, V109, P963; SCHOENWOLF GC, 1990, DEVELOPMENT, V109, P243; SECHRIST J, 1993, DEVELOPMENT, V118, P691; SERBEDZIJA G, 1989, DEVELOPMENT, V106, P806; TAKEICHI M, 1991, SCIENCE, V251, P1451, DOI 10.1126/science.2006419; TUCKER GC, 1984, CELL DIFFER DEV, V14, P223, DOI 10.1016/0045-6039(84)90049-6; VINCENT M, 1984, DEV BIOL, V103, P468, DOI 10.1016/0012-1606(84)90334-8; WHITELEY M, 1992, MECH DEVELOP, V36, P117, DOI 10.1016/0925-4773(92)90063-P; WILKINSON DG, 1993, METHOD ENZYMOL, V225, P361; ZON G, 1991, OLIGONUCLEOTIDES ANA, P87	26	617	631	0	27	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAY 6	1994	264	5160					835	839		10.1126/science.7513443	http://dx.doi.org/10.1126/science.7513443			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	NJ949	7513443				2022-12-28	WOS:A1994NJ94900031
J	IWASHIMA, M; IRVING, BA; VANOERS, NSC; CHAN, AC; WEISS, A				IWASHIMA, M; IRVING, BA; VANOERS, NSC; CHAN, AC; WEISS, A			SEQUENTIAL INTERACTIONS OF THE TCR WITH 2 DISTINCT CYTOPLASMIC TYROSINE KINASES	SCIENCE			English	Article							CELL ANTIGEN RECEPTOR; T-CELL; SIGNAL TRANSDUCTION; ZETA-CHAIN; ACTIVATION; CD4; PHOSPHORYLATION; P56LCK; COMPLEX; DOMAIN	The T cell antigen receptor (TCR) initiates signals by interacting with cytoplasmic protein tyrosine kinases (PTKs) through a 17-residue sequence motif [called the antigen recognition activation motif (ARAM)] that is contained in the TCRzeta and CD3 chains. TCR stimulation induces the tyrosine phosphorylation of several cellular substrates, including the ARAMs. Lck kinase activity is required for phosphorylation of two conserved tyrosine residues in an ARAM. This phosphorylation leads to the recruitment of a second cytoplasmic PTK, ZAP-70, through both of the ZAP-70 Src homology 2 domains and its phosphorylation. Thus, TCR signal transduction is initiated by the sequential interaction of two PTKs with TCR ARAMs.	UNIV CALIF SAN FRANCISCO, HOWARD HUGHES MED INST, SAN FRANCISCO, CA 94143 USA; UNIV CALIF SAN FRANCISCO, DEPT MED, SAN FRANCISCO, CA 94143 USA; UNIV CALIF SAN FRANCISCO, DEPT MICROBIOL & IMMUNOL, SAN FRANCISCO, CA 94143 USA	Howard Hughes Medical Institute; University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco					NIAMS NIH HHS [AR-20684] Funding Source: Medline; NIGMS NIH HHS [GM39553] Funding Source: Medline; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [P60AR020684] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM039553] Funding Source: NIH RePORTER	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		APPLEBY MW, 1992, CELL, V70, P751, DOI 10.1016/0092-8674(92)90309-Z; BARBER EK, 1989, P NATL ACAD SCI USA, V86, P3277, DOI 10.1073/pnas.86.9.3277; CHAN AC, 1991, P NATL ACAD SCI USA, V88, P9166, DOI 10.1073/pnas.88.20.9166; CHAN AC, 1992, CELL, V71, P649, DOI 10.1016/0092-8674(92)90598-7; ECK MJ, 1993, NATURE, V362, P87, DOI 10.1038/362087a0; FIELD J, 1988, MOL CELL BIOL, V8, P2159, DOI 10.1128/MCB.8.5.2159; GAUEN LKT, 1992, MOL CELL BIOL, V12, P5438, DOI 10.1128/MCB.12.12.5438; GLAICHENHAUS N, 1991, CELL, V64, P511, DOI 10.1016/0092-8674(91)90235-Q; GOLDSMITH MA, 1987, P NATL ACAD SCI USA, V84, P6879, DOI 10.1073/pnas.84.19.6879; HALL CG, 1993, SCIENCE, V261, P915, DOI 10.1126/science.8346442; HUTCHCROFT JE, 1992, P NATL ACAD SCI USA, V89, P9107, DOI 10.1073/pnas.89.19.9107; HUTCHCROFT JE, 1991, J BIOL CHEM, V266, P14846; IRVING BA, 1991, CELL, V64, P891, DOI 10.1016/0092-8674(91)90314-O; IRVING BA, 1993, J EXP MED, V177, P1093, DOI 10.1084/jem.177.4.1093; Iwashima M., UNPUB; Iwashima M., 1992, PROG IMMUNOL, V8, P205; JANEWAY CA, 1992, ANNU REV IMMUNOL, V10, P645, DOI 10.1146/annurev.immunol.10.1.645; JUNE CH, 1990, J IMMUNOL, V144, P1591; JUNE CH, 1990, P NATL ACAD SCI USA, V87, P7722, DOI 10.1073/pnas.87.19.7722; KARNITZ L, 1992, MOL CELL BIOL, V12, P4521, DOI 10.1128/MCB.12.10.4521; KOLANUS W, 1993, CELL, V74, P171, DOI 10.1016/0092-8674(93)90304-9; Ledbetter J A, 1990, Semin Immunol, V2, P99; LETOURNEUR F, 1992, SCIENCE, V255, P79, DOI 10.1126/science.1532456; MARTH JD, 1985, CELL, V43, P393, DOI 10.1016/0092-8674(85)90169-2; MUSTELIN T, 1990, SCIENCE, V247, P1584, DOI 10.1126/science.2138816; ORLOFF DG, 1989, J BIOL CHEM, V264, P14812; QIAN DP, 1993, J BIOL CHEM, V268, P4488; RETH M, 1989, NATURE, V338, P383, DOI 10.1038/338383b0; ROMEO C, 1992, CELL, V68, P889, DOI 10.1016/0092-8674(92)90032-8; ROMEO C, 1991, CELL, V64, P1037, DOI 10.1016/0092-8674(91)90327-U; ROTIN D, 1992, EMBO J, V11, P559, DOI 10.1002/j.1460-2075.1992.tb05087.x; RUDD CE, 1988, P NATL ACAD SCI USA, V85, P5190, DOI 10.1073/pnas.85.14.5190; SAMELSON LE, 1992, J BIOL CHEM, V267, P24913; SAMELSON LE, 1990, P NATL ACAD SCI USA, V87, P4358, DOI 10.1073/pnas.87.11.4358; SAROSI GA, 1992, INT IMMUNOL, V4, P1211, DOI 10.1093/intimm/4.11.1211; STEIN PL, 1992, CELL, V70, P741, DOI 10.1016/0092-8674(92)90308-Y; STRAUS DB, 1992, CELL, V70, P585, DOI 10.1016/0092-8674(92)90428-F; TANIGUCHI T, 1991, J BIOL CHEM, V266, P15790; TURNER JM, 1990, CELL, V60, P755, DOI 10.1016/0092-8674(90)90090-2; VEILLETTE A, 1988, CELL, V55, P301, DOI 10.1016/0092-8674(88)90053-0; WANGE RL, 1992, J BIOL CHEM, V267, P11685; WANGE RL, 1993, J BIOL CHEM, V268, P19797; WEGENER AMK, 1992, CELL, V68, P83, DOI 10.1016/0092-8674(92)90208-T; WEISS A, 1991, ANNU REV GENET, V25, P487, DOI 10.1146/annurev.ge.25.120191.002415; WEISS A, 1993, CELL, V73, P209, DOI 10.1016/0092-8674(93)90221-B; WEISS A, 1984, J EXP MED, V160, P1284, DOI 10.1084/jem.160.5.1284; XU H, 1993, CELL, V74, P633, DOI 10.1016/0092-8674(93)90511-N	47	668	679	0	10	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	FEB 25	1994	263	5150					1136	1139		10.1126/science.7509083	http://dx.doi.org/10.1126/science.7509083			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	MX759	7509083				2022-12-28	WOS:A1994MX75900032
J	Salerno, SM; Landry, FJ; Schick, JD; Schoomaker, EB				Salerno, SM; Landry, FJ; Schick, JD; Schoomaker, EB			The effect of multiple neuroimaging studies on classification, treatment, and outcome of acute ischemic stroke	ANNALS OF INTERNAL MEDICINE			English	Article							RESONANCE; INFARCTION	Objective: To examine the effect of serial neuroimaging studies on the diagnosis, therapy, and outcome of patients with acute stroke. Design: Retrospective case series. Setting: Tertiary care teaching hospital. Patients: 206 adult patients (mean age +/- SD, 66.0 +/- 10.8 years) hospitalized with a diagnosis of acute stroke between 1990 and 1993. Measurements: Strokes were retrospectively assigned to five categories (large-vessel, small-vessel, cardioembolic, other, or unknown) using standardized criteria based on the history, physical examination, ancillary test results, and first computed tomographic (CT) or magnetic resonance imaging (MRI) study of the head. Strokes were reclassified after the results of further neuroimaging studies, if any, were reviewed. The type and timing of therapy and the patient outcome at hospital discharge were documented. Results: The additional studies changed stroke classification in only 20.0% of the 140 patients who had two or more neuroimaging studies. All classification changes were from the unknown cause category to a category with a specific cause. In most patients receiving treatment (93.2%), therapy began before an additional CT or MRI study was obtained. In patients who had one neuroimaging study, 70.1% went home, 24.0% went to a skilled nursing facility, and 5.9% died; the corresponding percentages in persons who had multiple studies were 73.3%, 24.4%, and 2.2% (P > 0.1). Conclusions: Serial neuroimaging studies did not alter the classification of strokes for which an initial diagnosis had already been made. However, they were useful in determining the cause of strokes initially classified as having an unknown cause. Therapy was almost always begun immediately after the first CT or MRI study was obtained. Outcome at hospital discharge was not significantly related to the number of neuroimaging studies obtained.	MADIGAN ARMY MED CTR, DEPT MED, TACOMA, WA 98431 USA	Madigan Army Medical Center								ADAMS HP, 1993, STROKE, V24, P35, DOI 10.1161/01.STR.24.1.35; BRYAN RN, 1991, AM J NEURORADIOL, V12, P611; DIXON AK, 1991, BRIT MED J, V302, P79, DOI 10.1136/bmj.302.6768.79; HOMMEL M, 1990, STROKE, V21, P546, DOI 10.1161/01.STR.21.4.546; KENT DL, 1994, ANN INTERN MED, V120, P856, DOI 10.7326/0003-4819-120-10-199405150-00007; KERTESZ A, 1987, NEUROLOGY, V37, P1580, DOI 10.1212/WNL.37.10.1580; MATCHAR DB, 1994, ANN INTERN MED, V121, P41, DOI 10.7326/0003-4819-121-1-199407010-00008; SHUAIB A, 1992, NEUROLOGY, V42, P816, DOI 10.1212/WNL.42.4.816; TEASDALE GM, 1989, BRIT MED J, V299, P349, DOI 10.1136/bmj.299.6695.349; WALL SD, 1982, AM J ROENTGENOL, V138, P307, DOI 10.2214/ajr.138.2.307	10	8	8	0	1	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JAN 1	1996	124	1	1				21	26		10.7326/0003-4819-124-1_Part_1-199601010-00004	http://dx.doi.org/10.7326/0003-4819-124-1_Part_1-199601010-00004			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TL943	7503473				2022-12-28	WOS:A1996TL94300004
J	VLADECK, BC				VLADECK, BC			A PROFILE OF THE MEDICAID PROGRAM	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article											VLADECK, BC (corresponding author), US HLTH CARE FINANCING ADM,BALTIMORE,MD 21207, USA.								0	1	1	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	DEC 20	1995	274	23					1826	1826						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TK147	7500518				2022-12-28	WOS:A1995TK14700004
J	WRAY, GM; COAKLEY, JH				WRAY, GM; COAKLEY, JH			SEVERE SEPTIC SHOCK UNRESPONSIVE TO NORADRENALINE	LANCET			English	Note							ANGIOTENSIN		HOMERTON HOSP,INTENS CARE UNIT,LONDON E9 6SR,ENGLAND									DOUGLAS WW, 1985, PHARMACOL BASIS THER, P639; HEALY DP, 1985, ENDOCRINOLOGY, V116, P1221, DOI 10.1210/endo-116-3-1221; MANGER WM, 1976, J CLIN PHARMACOL, V16, P129, DOI 10.1002/j.1552-4604.1976.tb02394.x; REGOLI D, 1974, PHARMACOL REV, V26, P69; THOMAS VL, 1991, CRIT CARE MED, V19, P1084, DOI 10.1097/00003246-199108000-00020	5	51	61	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	DEC 16	1995	346	8990					1604	1604		10.1016/S0140-6736(95)91933-3	http://dx.doi.org/10.1016/S0140-6736(95)91933-3			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TK481	7500755				2022-12-28	WOS:A1995TK48100014
J	VOGEL, A; RODRIGUEZ, C; WARNKEN, W; BELMONTE, JCI				VOGEL, A; RODRIGUEZ, C; WARNKEN, W; BELMONTE, JCI			DORSAL CELL FATE SPECIFIED BY CHICK LMX1 DURING VERTEBRATE LIMB DEVELOPMENT	NATURE			English	Article							APICAL ECTODERMAL RIDGE; BUD; EMBRYO; DROSOPHILA; MESODERM; GENE	THE positional cues that govern the fate of cells along the dorsoventral axis of the developing vertebrate limb are established in the mesoderm before outgrowth of limb buds. In Drosophila, a LIM/homeodomain gene, apterous, expressed in the dorsal compartment of the wing disc, specifies dorsal cell fate(1,2). Here we report the isolation of a vertebrate LIM-homeodomain containing gene, Chick Lmx1 (C-Lmx1). Transcripts for C-Lmx1 are detected in the presumptive dorsal limb mesoderm and are restricted thereafter to the dorsal mesoderm of the developing chick bud. C-Lmx1 expression is regulated by the overlying ectoderm where Wnt7a messenger RNA is localized(3). Wnt7a, required for normal development of the dorsoventral axis in mouse limbs(4), can induce ectopic expression of C-Lmx1 in ventral mesoderm, Misexpression of C-Lmx1 during limb outgrowth causes ventral to dorsal transformations of limb mesoderm, We propose that C-Lmx1 specifies dorsal cell fate during chick limb development.			VOGEL, A (corresponding author), SALK INST BIOL STUDIES, GENE EXPRESS LAB, 10010 N TORREY PINES RD, LA JOLLA, CA 92037 USA.							COHEN B, 1992, GENE DEV, V6, P715, DOI 10.1101/gad.6.5.715; DEALY CN, 1993, MECH DEVELOP, V43, P175, DOI 10.1016/0925-4773(93)90034-U; DHOUAILLY D, 1972, DEV BIOL, V28, P162, DOI 10.1016/0012-1606(72)90134-0; DIAZBENJUMEA FJ, 1993, CELL, V75, P741, DOI 10.1016/0092-8674(93)90494-B; DUBOULE D, 1994, TRENDS GENET, V10, P358, DOI 10.1016/0168-9525(94)90132-5; Duboule D, 1991, CURR OPIN GENET DEV, V1, P211, DOI 10.1016/S0959-437X(05)80072-3; GERMAN MS, 1992, GENE DEV, V6, P2165, DOI 10.1101/gad.6.11.2165; Hamburger V, 1938, J EXP ZOOL, V77, P379, DOI 10.1002/jez.1400770304; HAMBURGER V, 1951, J MORPHOL, V88, P49, DOI 10.1002/jmor.1050880104; IZPISUABELMONTE JC, 1993, CELL, V74, P645, DOI 10.1016/0092-8674(93)90512-O; KIENY M, 1960, J EMBRYOL EXP MORPH, V8, P457; KLINGENSMITH J, 1994, DEV BIOL, V166, P396, DOI 10.1006/dbio.1994.1325; LOGAN C, 1992, DEV GENET, V13, P345, DOI 10.1002/dvg.1020130505; MACCABE JA, 1974, DEV BIOL, V39, P69, DOI 10.1016/S0012-1606(74)80009-6; MCCABE JA, 1973, DEV BIOL, V31, P323, DOI 10.1016/0012-1606(73)90269-8; MORGAN BA, 1992, NATURE, V358, P236, DOI 10.1038/358236a0; NISWANDER L, 1993, CELL, V75, P579, DOI 10.1016/0092-8674(93)90391-3; PARR BA, 1995, NATURE, V374, P350, DOI 10.1038/374350a0; PAUTOU MP, 1973, CR ACAD SCI D NAT, V277, P1225; SAUNDERS JW, 1976, DEV BIOL, V50, P16, DOI 10.1016/0012-1606(76)90063-4; SAUNDERS JW, 1974, DEV BIOL, V38, P41, DOI 10.1016/0012-1606(74)90257-7; TICKLE C, 1995, CURR OPIN GENET DEV, V5, P478, DOI 10.1016/0959-437X(95)90052-I; YANG YZ, 1995, CELL, V80, P939, DOI 10.1016/0092-8674(95)90297-X	23	248	252	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	DEC 14	1995	378	6558					716	720		10.1038/378716a0	http://dx.doi.org/10.1038/378716a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TK379	7501017				2022-12-28	WOS:A1995TK37900052
J	HORTON, R				HORTON, R			MAST-I - AGREEING TO DISAGREE	LANCET			English	Editorial Material																		HORTON R, 1995, LANCET, V346, P3, DOI 10.1016/S0140-6736(95)92644-5	1	13	13	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	DEC 9	1995	346	8989					1504	1504		10.1016/S0140-6736(95)92043-9	http://dx.doi.org/10.1016/S0140-6736(95)92043-9			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TJ291	7491039				2022-12-28	WOS:A1995TJ29100002
J	CHONG, L; VANSTEENSEL, B; BROCCOLI, D; ERDJUMENTBROMAGE, H; HANISH, J; TEMPST, P; DELANGE, T				CHONG, L; VANSTEENSEL, B; BROCCOLI, D; ERDJUMENTBROMAGE, H; HANISH, J; TEMPST, P; DELANGE, T			A HUMAN TELOMERIC PROTEIN	SCIENCE			English	Article							SACCHAROMYCES-CEREVISIAE; BINDING-PROTEIN; DNA-BINDING; RAP1; CENTROMERE; YEAST; IDENTIFICATION; VARIABILITY; STABILITY; REPEATS	Telomeres are multifunctional elements that shield chromosome ends from degradation and end-to-end fusions, prevent activation of DNA damage checkpoints, and modulate the maintenance of telomeric DNA by telomerase. A major protein component of human telomeres has been identified and cloned. This factor, TRF, contains one Myb-type DNA-binding repeat and an amino-terminal acidic domain. Immunofluorescent labeling shows that TRF specifically colocalizes with telomeric DNA in human interphase cells and is located at chromosome ends during metaphase. The presence of TRF along the telomeric TTAGGG repeat army demonstrates that human telomeres form a specialized nucleoprotein complex.	ROCKEFELLER UNIV, CELL BIOL & GENET LAB, NEW YORK, NY 10021 USA; MEM SLOAN KETTERING CANC CTR, PROGRAM MOLEC BIOL, NEW YORK, NY 10021 USA	Rockefeller University; Memorial Sloan Kettering Cancer Center			de Lange, Titia/B-8263-2011	de Lange, Titia/0000-0002-9267-367X; Erdjument-Bromage, Hediye/0000-0003-0224-3594	NCI NIH HHS [P30 CA08748-29] Funding Source: Medline; NIGMS NIH HHS [GM49046] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA008748] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM049046, R37GM049046] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALLSHIRE RC, 1988, NATURE, V332, P656, DOI 10.1038/332656a0; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; BARANOWSKIJ N, 1994, EMBO J, V13, P5383, DOI 10.1002/j.1460-2075.1994.tb06873.x; BAUERLE PA, 1988, CELL, V53, P211; Broccoli D., UNPUB; Chong L. S., UNPUB; COMPTON DA, 1991, J CELL BIOL, V112, P1083, DOI 10.1083/jcb.112.6.1083; CONRAD MN, 1990, CELL, V63, P739, DOI 10.1016/0092-8674(90)90140-A; COOKE HJ, 1986, COLD SPRING HARB SYM, V51, P213, DOI 10.1101/SQB.1986.051.01.026; COUNTER CM, 1994, P NATL ACAD SCI USA, V91, P2900, DOI 10.1073/pnas.91.8.2900; COUNTER CM, 1992, EMBO J, V11, P1921, DOI 10.1002/j.1460-2075.1992.tb05245.x; COUNTER CM, 1994, J VIROL, V68, P3410, DOI 10.1128/JVI.68.5.3410-3414.1994; DELANGE T, 1990, MOL CELL BIOL, V10, P518, DOI 10.1128/MCB.10.2.518; DELANGE T, 1992, EMBO J, V11, P717, DOI 10.1002/j.1460-2075.1992.tb05104.x; DELANGE T, 1995, TELOMERES, P265; DELANGE T, UNPUB; DELANGE T, IN PRESS SEMIN CELL; DELMAS V, 1993, P NATL ACAD SCI USA, V90, P2414, DOI 10.1073/pnas.90.6.2414; DOHONY KF, 1993, CELL, V73, P761; EARNSHAW WC, 1987, J CELL BIOL, V104, P817, DOI 10.1083/jcb.104.4.817; ELICONE C, 1994, J CHROMATOGR A, V676, P121, DOI 10.1016/0021-9673(94)00089-1; ERDJUMENTBROMAGE H, 1994, PROTEIN SCI, V3, P2435, DOI 10.1002/pro.5560031227; FANG G, 1995, TELOMERES, P69; FENG JL, 1995, SCIENCE, V269, P1236, DOI 10.1126/science.7544491; GABRIELSEN OS, 1991, SCIENCE, V253, P1140, DOI 10.1126/science.1887237; HAHN S, 1993, CELL, V72, P481, DOI 10.1016/0092-8674(93)90064-W; HANISH JP, 1994, P NATL ACAD SCI USA, V91, P8861, DOI 10.1073/pnas.91.19.8861; HARLEY CB, 1990, NATURE, V345, P458, DOI 10.1038/345458a0; HARLEY CB, 1995, TELOMERES, P247; HASTIE ND, 1989, TRENDS GENET, V5, P326, DOI 10.1016/0168-9525(89)90137-6; HASTIE ND, 1990, NATURE, V346, P866, DOI 10.1038/346866a0; KAUFMAN PD, 1995, CELL, V81, P1105, DOI 10.1016/S0092-8674(05)80015-7; KIM NW, 1994, SCIENCE, V266, P2011, DOI 10.1126/science.7605428; KIPLING D, 1990, NATURE, V347, P400, DOI 10.1038/347400a0; KLEIN F, 1992, J CELL BIOL, V117, P935, DOI 10.1083/jcb.117.5.935; KLINGELHUTZ AJ, 1994, MOL CELL BIOL, V14, P961, DOI 10.1128/MCB.14.2.961; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; KYRION G, 1993, GENE DEV, V7, P1146, DOI 10.1101/gad.7.7a.1146; KYRION G, 1992, MOL CELL BIOL, V12, P5159, DOI 10.1128/MCB.12.11.5159; LECHNER J, 1991, CELL, V64, P717, DOI 10.1016/0092-8674(91)90501-O; LECHNER J, 1994, EMBO J, V13, P5203, DOI 10.1002/j.1460-2075.1994.tb06851.x; LEJNINE S, 1995, P NATL ACAD SCI USA, V92, P2393, DOI 10.1073/pnas.92.6.2393; LUSTIG AJ, 1990, SCIENCE, V250, P549, DOI 10.1126/science.2237406; MCEACHERN MJ, 1995, NATURE, V376, P403, DOI 10.1038/376403a0; OGATA K, 1994, CELL, V79, P639, DOI 10.1016/0092-8674(94)90549-5; Rhodes D., COMMUNICATION; ROBBINS J, 1991, CELL, V64, P615, DOI 10.1016/0092-8674(91)90245-T; SAIKUMAR P, 1990, P NATL ACAD SCI USA, V87, P8452, DOI 10.1073/pnas.87.21.8452; SHORE D, 1994, TRENDS GENET, V10, P408, DOI 10.1016/0168-9525(94)90058-2; SIBON OCM, 1994, HISTOCHEMISTRY, V101, P223, DOI 10.1007/BF00269548; STARLING JA, 1990, NUCLEIC ACIDS RES, V18, P6881, DOI 10.1093/nar/18.23.6881; STILLMAN B, COMMUNICATION; SUSSEL L, 1991, P NATL ACAD SCI USA, V88, P7749, DOI 10.1073/pnas.88.17.7749; Tempst Paul, 1994, Methods (Orlando), V6, P248, DOI 10.1006/meth.1994.1027; TOMMERUP H, 1994, MOL CELL BIOL, V14, P5777, DOI 10.1128/MCB.14.9.5777; VANSTEENSEL B, UNPUB; ZAKIAN VA, 1995, TELOMERES, P107; ZHONG Z, 1992, MOL CELL BIOL, V12, P4834, DOI 10.1128/MCB.12.11.4834	58	615	663	0	18	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	DEC 8	1995	270	5242					1663	1667		10.1126/science.270.5242.1663	http://dx.doi.org/10.1126/science.270.5242.1663			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TJ293	7502076				2022-12-28	WOS:A1995TJ29300048
J	VICKREY, BG; HAYS, RD; RAUSCH, R; ENGEL, J; VISSCHER, BR; ARY, CM; ROGERS, WH; BROOK, RH				VICKREY, BG; HAYS, RD; RAUSCH, R; ENGEL, J; VISSCHER, BR; ARY, CM; ROGERS, WH; BROOK, RH			OUTCOMES IN 248 PATIENTS WHO HAD DIAGNOSTIC EVALUATIONS FOR EPILEPSY SURGERY	LANCET			English	Article							MEDICAL-TREATMENT; SEIZURES	Surgery for intractable epilepsy is a widely used treatment that is not readily assessed by randomised trials. We evaluated the impact of epilepsy surgery on seizures, medication use, employment, and the quality of life in 248 adults and adolescents consecutively referred to one medical centre between 1974 and 1990. Outcomes were determined through self-administered questionnaire and medical record review for 202 surgery and 46 non-surgery patients whose treatment was usually determined by the presence or absence of an epileptogenic focus. Surgery and non-surgery patients differed at baseline only in median monthly seizure frequency (surgery lower than non-surgery). After adjustment for baseline covariates, surgery patients at follow-up had greater decline in average monthly seizure frequency (-11.9 vs -1.5; difference -10.4, 95% CI -20.5, -0.3) and took fewer antiepileptic medications (average number 1.4 vs 2.0; difference -0.67, 95% CI -0.94, -0.40). Although quality-of-life scores were higher (p<0.05) with surgery on 5 of 11 scales that were administered only at follow-up, there were no significant differences in employment status or prospectively assessed quality of life. Relative to a non-surgery group, patients treated surgically had better seizure control with less antiepileptic medication. The impact of epilepsy surgery on quality of life and employment needs to be assessed in larger prospective studies.	UNIV CALIF LOS ANGELES, DEPT PSYCHIAT, LOS ANGELES, CA 90095 USA; UNIV CALIF LOS ANGELES, DEPT PSYCHIAT, LOS ANGELES, CA 90095 USA; UNIV CALIF LOS ANGELES, DEPT ANAT & CELL BIOL, LOS ANGELES, CA 90095 USA; UNIV CALIF LOS ANGELES, DEPT EPIDEMIOL, LOS ANGELES, CA 90095 USA; UNIV CALIF LOS ANGELES, DEPT MED, LOS ANGELES, CA 90095 USA; UNIV CALIF LOS ANGELES, DEPT HLTH SERV, LOS ANGELES, CA 90095 USA; RAND CORP, DEPT SOCIAL POLICY, SANTA MONICA, CA 90406 USA; TUFTS UNIV NEW ENGLAND MED CTR, BOSTON, MA 02111 USA	University of California System; University of California Los Angeles; University of California System; University of California Los Angeles; University of California System; University of California Los Angeles; University of California System; University of California Los Angeles; University of California System; University of California Los Angeles; University of California System; University of California Los Angeles; RAND Corporation; Tufts Medical Center	VICKREY, BG (corresponding author), UNIV CALIF LOS ANGELES, DEPT NEUROL, C-128 RNRC, 710 WESTWOOD PLAZA, LOS ANGELES, CA 90095 USA.		Hays, Ronald/D-5629-2013	Hays, Ronald/0000-0001-6697-907X	PHS HHS [N501669-02, H506856-01, N531277] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [U54NS081764] Funding Source: NIH RePORTER	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		AFIFI AA, 1984, COMPUTER AIDED MULTI, P61; BAKER GA, 1993, EPILEPSY RES, V16, P65, DOI 10.1016/0920-1211(93)90041-5; BERG AT, 1994, SCIENCE, V264, P757; BRENNAN P, 1994, BRIT MED J, V309, P727, DOI 10.1136/bmj.309.6956.727; CRONBACH L, 1951, PSYCHOMETRIKA, V8, P297; Dasheiff R M, 1994, Seizure, V3, P197, DOI 10.1016/S1059-1311(05)80189-X; ENGEL J, 1981, ANN NEUROL, V9, P215, DOI 10.1002/ana.410090303; ENGEL J, 1991, PRINCIPLES NEUROSURG, P319; Engel Jerome Jr., 1993, P23; GULDVOG B, 1991, EPILEPSIA, V32, P477, DOI 10.1111/j.1528-1157.1991.tb04680.x; GULDVOG B, 1991, EPILEPSIA, V32, P375, DOI 10.1111/j.1528-1157.1991.tb04666.x; HALL WH, 1990, JAMA-J AM MED ASSOC, V264, P729; KATZ MM, 1963, PSYCHOL REP, V13, P503, DOI 10.2466/pr0.1963.13.2.503; KAZIS LE, 1989, MED CARE, V27, pS178, DOI 10.1097/00005650-198903001-00015; KLENERMAN P, 1993, J NEUROL NEUROSUR PS, V56, P149, DOI 10.1136/jnnp.56.2.149; MANN HB, 1947, ANN MATH STAT, V18, P50, DOI 10.1214/aoms/1177730491; Nunnally J. C., 1978, PSYCHOMETRIC THEORY, V2nd; RAUSCH R, 1982, EPILEPSIA, V23, P191, DOI 10.1111/j.1528-1157.1982.tb05067.x; SCHOENBAUM SC, 1993, JAMA-J AM MED ASSOC, V269, P794, DOI 10.1001/jama.269.6.794; SUTHERLING WW, 1990, NEUROLOGY, V40, P87, DOI 10.1212/WNL.40.1.87; VICKREY BG, 1995, ANN NEUROL, V37, P158, DOI 10.1002/ana.410370205; VICKREY BG, 1992, MED CARE, V30, P299, DOI 10.1097/00005650-199204000-00002; WAGNER AK, 1995, QUAL LIFE RES, V4, P115, DOI 10.1007/BF01833606; 1988, SAS STAT USERS GUIDE	24	162	164	0	2	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	DEC 2	1995	346	8988					1445	1449		10.1016/S0140-6736(95)92470-1	http://dx.doi.org/10.1016/S0140-6736(95)92470-1			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TH156	7490989				2022-12-28	WOS:A1995TH15600007
J	JEON, YH; NEGISHI, T; SHIRAKAWA, M; YAMAZAKI, T; FUJITA, N; ISHIHAMA, A; KYOGOKU, Y				JEON, YH; NEGISHI, T; SHIRAKAWA, M; YAMAZAKI, T; FUJITA, N; ISHIHAMA, A; KYOGOKU, Y			SOLUTION STRUCTURE OF THE ACTIVATOR CONTACT DOMAIN OF THE RNA-POLYMERASE ALPHA-SUBUNIT	SCIENCE			English	Article							DNA-BINDING DOMAIN; TRANSCRIPTION ACTIVATION; FUNCTIONAL MAP; PROTEINS; RECOGNITION; OCT-1	The structure of the carboxyl-terminal domain of the Escherichia coli RNA polymerase oc subunit (alpha CTD), which is regarded as the contact site for transcription activator proteins and for the promoter UP element, was determined by nuclear magnetic resonance spectroscopy, Its compact structure of four helices and two long arms enclosing its hydrophobic core shows a folding topology distinct from those of other DNA-binding proteins, The UP element binding site was found on the surface comprising helix 1, the amino-terminal end of helix 4, and the preceding loop, Mutation experiments indicated that the contact sites for transcription activator proteins are also on the same surface.	OSAKA UNIV,INST PROT RES,SUITA,OSAKA 565,JAPAN; NATL INST GENET,DEPT MOLEC GENET,MISHIMA,SHIZUOKA 411,JAPAN; NARA INST SCI & TECHNOL,GRAD SCH BIOSCI,NARA 63001,JAPAN	Osaka University; Research Organization of Information & Systems (ROIS); National Institute of Genetics (NIG) - Japan; Nara Institute of Science & Technology			Jeon, Young Ho/F-4483-2011					ASSAMUNT N, 1993, CELL, V73, P193, DOI 10.1016/0092-8674(93)90171-L; Bax A., 1993, NMR PROTEINS, P33; BLATTER EE, 1994, CELL, V78, P889, DOI 10.1016/S0092-8674(94)90682-3; BOWIE JU, 1991, SCIENCE, V253, P164, DOI 10.1126/science.1853201; BRUNGER AT, 1992, VERSION 3 1; Burgess RR, 1976, RNA POLYMERASE, P69; BUSBY S, 1994, CELL, V79, P743, DOI 10.1016/0092-8674(94)90063-9; CARSON M, 1991, J APPL CRYSTALLOGR, V24, P946; DEKKER N, 1993, NATURE, V362, P852, DOI 10.1038/362852a0; EBRIGHT RH, 1995, CURR OPIN GENET DEV, V5, P197, DOI 10.1016/0959-437X(95)80008-5; HARRISON SC, 1990, ANNU REV BIOCHEM, V59, P933, DOI 10.1146/annurev.bi.59.070190.004441; HELLMAN J, 1988, ANNU REV BIOCHEM, V57, P839; IGARASHI K, 1991, P NATL ACAD SCI USA, V88, P8958, DOI 10.1073/pnas.88.20.8958; IGARASHI K, 1991, CELL, V65, P1015, DOI 10.1016/0092-8674(91)90553-B; ISHIHAMA A, 1993, J BACTERIOL, V175, P2483, DOI 10.1128/JB.175.9.2483-2489.1993; ISHIHAMA A, 1992, MOL MICROBIOL, V6, P3283, DOI 10.1111/j.1365-2958.1992.tb02196.x; ISHIHAMA A, 1988, TRENDS GENET, V4, P282, DOI 10.1016/0168-9525(88)90170-9; KAY LE, 1990, J MAGN RESON, V86, P110, DOI 10.1016/0022-2364(90)90215-U; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; Kyogoku Y, 1995, METHOD ENZYMOL, V261, P524; MAJUMDAR A, 1993, J BIOMOL NMR, V3, P387; MATSUO Y, 1994, PROTEIN SCI, V3, P2055, DOI 10.1002/pro.5560031118; MURAKAMI K, UNPUB; NEGISHI T, 1995, J MOL BIOL, V248, P723, DOI 10.1006/jmbi.1995.0254; NILGES M, 1988, FEBS LETT, V229, P317, DOI 10.1016/0014-5793(88)81148-7; ROSS W, 1993, SCIENCE, V262, P1407, DOI 10.1126/science.8248780; TANG H, 1994, GENE DEV, V8, P3058, DOI 10.1101/gad.8.24.3058; TAO K, IN PRESS J BACTERIOL; ZOU C, 1992, MOL MICROBIOL, V6, P2599, DOI 10.1111/j.1365-2958.1992.tb01437.x	29	153	156	1	5	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	DEC 1	1995	270	5241					1495	1497		10.1126/science.270.5241.1495	http://dx.doi.org/10.1126/science.270.5241.1495			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TH375	7491496				2022-12-28	WOS:A1995TH37500039
J	GLASZIOU, PP; IRWIG, LM				GLASZIOU, PP; IRWIG, LM			AN EVIDENCE BASED APPROACH TO INDIVIDUALIZING TREATMENT	BMJ-BRITISH MEDICAL JOURNAL			English	Article								To which groups of patients can the results of clinical trials be applied? This question is often inappropriately answered by reference to the trial entry criteria. Instead, the benefit and harm (adverse events, discomfort of treatment, etc) of treatment could be assessed separately for individual patients. Patients at greatest risk of a disease will have the greatest net benefit as benefit to patients usually increases with risk while harm remains comparatively fixed. To assess net benefit, the relative risks should come from (a meta-analysis of) randomised trials; the risk in individual patients should come from multivariate risk equations derived from cohort studies. However, before making firm conclusions, the assumptions of fixed adverse effects and constant reduction in relative risk need to be checked.	UNIV SYDNEY, DEPT PUBL HLTH & COMMUNITY MED, SYDNEY, NSW 2006, AUSTRALIA	University of Sydney	GLASZIOU, PP (corresponding author), MED SCH HERSTON, DEPT SOCIAL & PREVENT MED, HERSTON, QLD 4006, AUSTRALIA.		Glasziou, Paul/A-7832-2008	Glasziou, Paul/0000-0001-7564-073X				ANDERSON DC, 1992, ANN INTERN MED, V116, P1, DOI 10.7326/0003-4819-116-1-1; ANDERSON DC, 1992, ANN INTERN MED, V116, P6; [Anonymous], 1988, LANCET, V2, P349; BOISSEL JP, 1993, J CARDIOVASC PHARM, V22, P356, DOI 10.1097/00005344-199309000-00003; DAVEYSMITH G, 1994, BRIT MED J, V308, P72; DICKERSIN K, 1992, EPIDEMIOL REV, V14, P154, DOI 10.1093/oxfordjournals.epirev.a036084; FIHN SD, 1993, ANN INTERN MED, V118, P511, DOI 10.7326/0003-4819-118-7-199304010-00005; GLASZIOU PP, 1994, MED J AUSTRALIA, V161, P532, DOI 10.5694/j.1326-5377.1994.tb127596.x; GREENLAND S, 1987, EPIDEMIOL REV, V9, P1; KASSIRER JP, 1981, NEW ENGL J MED, V305, P1465, DOI 10.1056/NEJM198112103052409; LANDEFELD CS, 1993, AM J MED, V95, P315, DOI 10.1016/0002-9343(93)90285-W; LAUPACIS A, 1988, NEW ENGL J MED, V318, P1728, DOI 10.1056/NEJM198806303182605; LAUPACIS A, 1994, JAMA-J AM MED ASSOC, V272, P234, DOI 10.1001/jama.272.3.234; LUBSEN J, 1989, CONTROL CLIN TRIALS, V10, pS151; MACLURE M, 1993, EPIDEMIOL REV, V15, P328, DOI 10.1093/oxfordjournals.epirev.a036124; MCINTOSH M, 1995, 4 HARV MED SCH TECHN, P1; PAUKER SG, 1980, NEW ENGL J MED, V302, P1109, DOI 10.1056/NEJM198005153022003; SACKETT DL, 1981, CAN MED ASSOC J, V124, P1156; Singer D E, 1993, Ann Epidemiol, V3, P563; 1993, LANCET, V342, P1255	20	262	266	0	5	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	NOV 18	1995	311	7016					1356	1359		10.1136/bmj.311.7016.1356	http://dx.doi.org/10.1136/bmj.311.7016.1356			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TF901	7496291	Green Published			2022-12-28	WOS:A1995TF90100030
J	INAGAKI, N; GONOI, T; CLEMENT, JP; NAMBA, N; INAZAWA, J; GONZALEZ, G; AGUILARBRYAN, L; SEINO, S; BRYAN, J				INAGAKI, N; GONOI, T; CLEMENT, JP; NAMBA, N; INAZAWA, J; GONZALEZ, G; AGUILARBRYAN, L; SEINO, S; BRYAN, J			RECONSTITUTION OF I-KATP - AN INWARD RECTIFIER SUBUNIT PLUS THE SULFONYLUREA RECEPTOR	SCIENCE			English	Article							SENSITIVE K+ CHANNELS; PANCREATIC BETA-CELLS; REGULATED POTASSIUM CHANNEL; FUNCTIONAL EXPRESSION; INTRACELLULAR ATP; B-CELLS; DIAZOXIDE; CLONING	A member of the inwardly rectifying potassium channel family was cloned here. The channel, called BIR (Kir6.2), was expressed in large amounts in rat pancreatic islets and glucose-responsive insulin-secreting cell lines. Coexpression with the sulfonylurea receptor SUR reconstituted an inwardly rectifying potassium conductance of 76 picosiemens that was sensitive to adenosine triphosphate (ATP) (I-KATP) and was inhibited by sulfonylureas and activated by diazoxide. The data indicate that these pancreatic beta cell potassium channels are a complex composed of at least two subunits-BIR, a member of the inward rectifier potassium channel family, and SUR, a member of the ATP-binding cassette superfamily. Gene mapping data show that these two potassium channel subunit genes are clustered on human chromosome 11 at position 11p15.1.	CHIBA UNIV,SCH MED,CTR BIOMED SCI,DIV MOLEC MED,CHUO KU,CHIBA 260,JAPAN; CHIBA UNIV,PATHOGEN FUNGI & MICROBIAL TOXICOSES RES CTR,CHUO KU,CHIBA 260,JAPAN; BAYLOR COLL MED,DEPT CELL BIOL,HOUSTON,TX 77030; BAYLOR COLL MED,DEPT MED,HOUSTON,TX 77030; KYOTO PREFECTURAL UNIV MED,DEPT HYG,KAMIKYO KU,KYOTO 602,JAPAN	Chiba University; Chiba University; Baylor College of Medicine; Baylor College of Medicine; Kyoto Prefectural University of Medicine			gonoi, tohru/AAC-5181-2021; , gonoi/GRS-0648-2022	gonoi, tohru/0000-0003-3655-7911; , gonoi/0000-0003-3655-7911; Inagaki, Nobuya/0000-0001-8261-2593	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK044311] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK44311] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AGUILARBRYAN L, 1995, SCIENCE, V268, P423, DOI 10.1126/science.7716547; ASHCROFT FM, 1988, ANNU REV NEUROSCI, V11, P97, DOI 10.1146/annurev.neuro.11.1.97; ASHCROFT SJH, 1992, BIOCHIM BIOPHYS ACTA, V1175, P45, DOI 10.1016/0167-4889(92)90008-Y; ASHFORD MLJ, 1994, NATURE, V370, P456, DOI 10.1038/370456a0; CHANDY KG, 1993, TRENDS PHARMACOL SCI, V14, P434, DOI 10.1016/0165-6147(93)90181-I; COOK DL, 1988, DIABETES, V37, P495, DOI 10.2337/diabetes.37.5.495; COOK DL, 1984, NATURE, V311, P271, DOI 10.1038/311271a0; DASCAL N, 1993, P NATL ACAD SCI USA, V90, P10235, DOI 10.1073/pnas.90.21.10235; FINDLAY I, 1985, J MEMBRANE BIOL, V88, P165, DOI 10.1007/BF01868430; GONOI T, UNPUB; HO K, 1993, NATURE, V362, P31, DOI 10.1038/362031a0; INAGAKI N, 1994, P NATL ACAD SCI USA, V91, P2679, DOI 10.1073/pnas.91.7.2679; INAGAKI N, 1995, J BIOL CHEM, V270, P5691, DOI 10.1074/jbc.270.11.5691; INAGAKI N, UNPUB; INAZAWA J, 1993, GENOMICS, V17, P153, DOI 10.1006/geno.1993.1297; JAN LY, 1994, NATURE, V371, P119, DOI 10.1038/371119a0; KERR ID, 1995, NATURE, V372, P112; KRAPIVINSKY G, 1995, NATURE, V374, P135, DOI 10.1038/374135a0; KUBO Y, 1993, NATURE, V362, P127, DOI 10.1038/362127a0; KUBO Y, 1993, NATURE, V364, P802, DOI 10.1038/364802a0; LU Z, 1994, NATURE, V371, P243, DOI 10.1038/371243a0; MISLER S, 1986, P NATL ACAD SCI USA, V83, P7119, DOI 10.1073/pnas.83.18.7119; NAMBA N, UNPUB; NOMA A, 1983, NATURE, V305, P147, DOI 10.1038/305147a0; RAJAN AS, 1993, J BIOL CHEM, V268, P15221; RORSMAN P, 1985, PFLUG ARCH EUR J PHY, V405, P305, DOI 10.1007/BF00595682; STANFIELD PR, 1994, J PHYSIOL-LONDON, V478, P1; STURGESS NC, 1988, BRIT J PHARMACOL, V95, P83, DOI 10.1111/j.1476-5381.1988.tb16551.x; SUTCLIFFE MJ, 1994, NATURE, V369, P616, DOI 10.1038/369616b0; THOMAS PM, 1995, SCIENCE, V268, P426, DOI 10.1126/science.7716548; TRUBE G, 1986, PFLUG ARCH EUR J PHY, V407, P493, DOI 10.1007/BF00657506; TSUURA Y, 1992, DIABETES, V42, P861; WIBLE BA, 1994, NATURE, V371, P246, DOI 10.1038/371246a0; WIBRAND F, 1992, P NATL ACAD SCI USA, V89, P5133, DOI 10.1073/pnas.89.11.5133; YAMASHITA H, 1992, ANAL SCI, V8, P251, DOI 10.2116/analsci.8.251	35	1494	1554	1	40	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	NOV 17	1995	270	5239					1166	1170		10.1126/science.270.5239.1166	http://dx.doi.org/10.1126/science.270.5239.1166			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TE905	7502040				2022-12-28	WOS:A1995TE90500046
J	SAJJAD, A; CAREY, PA; ARNOLD, IR; SMITH, SR				SAJJAD, A; CAREY, PA; ARNOLD, IR; SMITH, SR			LESSON OF THE WEEK - INFECTED RIGHT ATRIAL THROMBUS PRESENTING AS PULMONARY-EMBOLISM COMPLICATING CENTRAL VENOUS CANNULATION	BRITISH MEDICAL JOURNAL			English	Article									HORTON GEN HOSP NHS TRUST,BANBURY OX16 9AL,OXON,ENGLAND; JOHN RADCLIFFE HOSP,OXFORD OX3 9DU,ENGLAND	University of Oxford								ARNOLD IR, 1994, INT J CARDIOL, V43, P101, DOI 10.1016/0167-5273(94)90100-7; COHEN GI, 1992, AM J CARDIOL, V70, P925, DOI 10.1016/0002-9149(92)90740-P	2	5	5	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	NOV 11	1995	311	7015					1288	1288		10.1136/bmj.311.7015.1288	http://dx.doi.org/10.1136/bmj.311.7015.1288			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TE859	7496241	Green Published			2022-12-28	WOS:A1995TE85900031
J	ARAKI, E; LIPES, MA; PATTI, ME; BRUNING, JC; HAAG, B; JOHNSON, RS; KAHN, CR				ARAKI, E; LIPES, MA; PATTI, ME; BRUNING, JC; HAAG, B; JOHNSON, RS; KAHN, CR			ALTERNATIVE PATHWAY OF INSULIN SIGNALING IN MICE WITH TARGETED DISRUPTION OF THE IRS-1 GENE	NATURE			English	Article							GROWTH FACTOR-I; STIMULATES TYROSINE PHOSPHORYLATION; RECEPTOR SUBSTRATE-1; PHOSPHATIDYLINOSITOL 3-KINASE; HEMATOPOIETIC-CELLS; SIGNALING PATHWAYS; PROTEIN; MUSCLE; TRANSMISSION; EXPRESSION	THE principal substrate for the insulin and insulin-like growth factor-1 (IGF-1) receptors is the cytoplasmic protein insulin-receptor substrate-1 (IRS-1/pp185)(1-7). After tyrosine phosphorylation at several sites, IRS-1 binds to and activates phosphatidylinositol-3'-OH kinase (PI(3)K)(8-11) and several other proteins containing SH2 (Src-homology 2) domains(12-14). To elucidate the role of IRS-1 in insulin/IGF-1 action, we created IRS-1-deficient mice by targeted gene mutation. These mice had no IRS-1 and shelved no evidence IRS-1 phosphorylation or IRS-1-associated PI(3)K activity. They also had a 50 per cent reduction in intrauterine growth, impaired glucose tolerance, and a decrease in insulin/IGF-1-stimulated glucose uptake in vivo and in vitro. The residual insulin/ IGF-1 action correlated with the appearance of a new tyrosine-phosphorylated protein (IRS-2) which binds to PI(3)K, but is slightly larger than and immunologically distinct from IRS-1. Our results provide evidence for IRS-1-dependent and IRS-1-independent pathways of insulin/IGF-1 signalling and for the existence of an alternative substrate of these receptor kinases.	JOSLIN DIABET CTR,DIV RES,BOSTON,MA 02215; HARVARD UNIV,SCH MED,DEPT MED,BOSTON,MA 02215	Harvard University; Joslin Diabetes Center, Inc.; Harvard University; Harvard Medical School			Kahn, Ronald/AAY-2435-2021; Johnson, Randall/AAM-1189-2021	Kahn, Ronald/0000-0002-7583-9228; Johnson, Randall/0000-0002-4084-6639				ARAKI E, 1993, DIABETES, V42, P1041, DOI 10.2337/diabetes.42.7.1041; ARAKI E, 1994, BBA-MOL CELL RES, V1221, P353, DOI 10.1016/0167-4889(94)90261-5; BEGUINOT F, 1989, ENDOCRINOLOGY, V125, P1599, DOI 10.1210/endo-125-3-1599; CHUANG LM, 1993, MOL CELL BIOL, V13, P6653, DOI 10.1128/MCB.13.11.6653; FOLLI F, 1992, J BIOL CHEM, V267, P22171; GIORGETTI S, 1993, J BIOL CHEM, V268, P7358; KEEGAN AD, 1994, CELL, V76, P811, DOI 10.1016/0092-8674(94)90356-5; KELLER SR, 1991, J BIOL CHEM, V266, P12817; KOVACINA KS, 1993, BIOCHEM BIOPH RES CO, V192, P1303, DOI 10.1006/bbrc.1993.1558; KUHNE MR, 1993, J BIOL CHEM, V268, P11479; LIPES MA, 1993, SCIENCE, V259, P1165, DOI 10.1126/science.8267690; LIU JP, 1993, CELL, V75, P59, DOI 10.1016/0092-8674(93)90679-K; MIRALPEIX M, 1992, BIOCHEMISTRY-US, V31, P9031, DOI 10.1021/bi00152a046; MYERS MG, 1993, ENDOCRINOLOGY, V132, P1421, DOI 10.1210/en.132.4.1421; PAPAIOANNOU V, 1993, GENE TARGETING PRACT; ROSE DW, 1994, P NATL ACAD SCI USA, V91, P797, DOI 10.1073/pnas.91.2.797; RUDERMAN NB, 1990, P NATL ACAD SCI USA, V87, P1411, DOI 10.1073/pnas.87.4.1411; SAAD MJA, 1992, J CLIN INVEST, V90, P1839, DOI 10.1172/JCI116060; SHEPHERD PR, 1993, J BIOL CHEM, V269, P22232; SKOLNIK EY, 1993, SCIENCE, V260, P1953, DOI 10.1126/science.8316835; SUN XJ, 1991, NATURE, V352, P73, DOI 10.1038/352073a0; SUN XJ, 1992, J BIOL CHEM, V267, P22662; SUNG CK, 1994, J BIOL CHEM, V269, P12503; TAMEMOTO H, 1994, NATURE, V372, P182, DOI 10.1038/372182a0; VANHORN DJ, 1994, J BIOL CHEM, V269, P29; WANG LM, 1993, SCIENCE, V261, P1591, DOI 10.1126/science.8372354; WANG LM, 1993, P NATL ACAD SCI USA, V90, P4032, DOI 10.1073/pnas.90.9.4032; WATERS SB, 1993, J BIOL CHEM, V268, P22231; WHITE MF, 1985, NATURE, V318, P183, DOI 10.1038/318183a0; WHITE MF, 1994, J BIOL CHEM, V269, P1; WHITE MF, 1988, CELL, V54, P641, DOI 10.1016/S0092-8674(88)80008-4	31	1049	1072	1	45	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	NOV 10	1994	372	6502					186	190		10.1038/372186a0	http://dx.doi.org/10.1038/372186a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PQ688	7526222				2022-12-28	WOS:A1994PQ68800058
J	GRUBB, BR; PICKLES, RJ; YE, H; YANKASKAS, JR; VICK, RN; ENGELHARDT, JF; WILSON, JM; JOHNSON, LG; BOUCHER, RC				GRUBB, BR; PICKLES, RJ; YE, H; YANKASKAS, JR; VICK, RN; ENGELHARDT, JF; WILSON, JM; JOHNSON, LG; BOUCHER, RC			INEFFICIENT GENE-TRANSFER BY ADENOVIRUS VECTOR TO CYSTIC-FIBROSIS AIRWAY EPITHELIA OF MICE AND HUMANS	NATURE			English	Article							ION-TRANSPORT DEFECT; CHLORIDE TRANSPORT; TRANSGENIC MICE; EXPRESSION; THERAPY; INVIVO; MODEL; CFTR	THE success of adenoviral vectors for gene therapy of lung disease in cystic fibrosis (CF) depends on efficient transfer of the complementary DNA encoding the correct version of the cystic fibrosis transmembrane regulator (CFTR) to the affected columnar epithelial cells lining the airways of the lung. Pre-clinical studies in vitro suggest that low doses of adenovirus vectors carrying this CFTR cDNA fan correct defective Cl- transport in cultured human CF airway epithelia(1). Here He use mice carrying the disrupted CF gene(2) to test the efficacy of this transfer system in vivo. We find that even repeated high doses can only partially (50%) correct the CF defect in Cl- transport in vivo and do not correct the Na+ transport defect at all. We investigated this discrepancy between the in vivo and in vitro transfer efficiency using CF mouse and human samples, and found that it reflects a difference in the susceptibility to adenovirus-5 transduction of the epithelial cell types dosed in vivo (columnar) and in vitro (basal-cell-like). These studies indicate that more efficient adenoviral gene-transfer vectors and/or refinement of dosing strategies are needed for therapy of CF lung disease.	UNIV PENN,INST HUMAN GENE THERAPY,PHILADELPHIA,PA 19104	University of Pennsylvania	GRUBB, BR (corresponding author), UNIV N CAROLINA,CTR CF PULM RES & TREATMENT,CHAPEL HILL,NC 27599, USA.		Wilson, James M/F-9220-2011	Wilson, James M/0000-0002-9630-3131; Engelhardt, John/0000-0003-2389-9277	NIDDK NIH HHS [R01 DK047967] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK047967] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ALTON EWFW, 1993, NAT GENET, V5, P135, DOI 10.1038/ng1093-135; BOAT TF, 1974, AM REV RESPIR DIS, V110, P428; BOUCHER RC, 1994, HUM GENE THER, V5, P615, DOI 10.1089/hum.1994.5.5-615; BOUT A, 1994, HUM GENE THER, V5, P3, DOI 10.1089/hum.1994.5.1-3; CLARKE LL, 1992, SCIENCE, V257, P1125, DOI 10.1126/science.257.5073.1125; CUTTING GR, 1992, NAT GENET, V2, P4, DOI 10.1038/ng0992-4; DOMINEY AM, 1993, CELL GROWTH DIFFER, V4, P1071; ENGELHARDT JF, 1992, NAT GENET, V2, P240, DOI 10.1038/ng1192-240; ENGELHARDT JF, 1993, HUM GENE THER, V4, P759, DOI 10.1089/hum.1993.4.6-759; ENGELHARDT JF, 1993, NAT GENET, V4, P27, DOI 10.1038/ng0593-27; GROSS EA, 1982, J ANAT, V135, P83; GRUBB B, 1994, AM J PHYSIOL, V268, pC1478; HARKEMA JR, 1991, LUNG BIOL HLTH DIS, V0055, P00003; HYDE SC, 1993, NATURE, V362, P250, DOI 10.1038/362250a0; JOHNSON LG, 1992, NAT GENET, V2, P21, DOI 10.1038/ng0992-21; KNOWLES M, 1981, NEW ENGL J MED, V305, P1489, DOI 10.1056/NEJM198112173052502; KNOWLES M, 1983, J CLIN INVEST, V71, P1410, DOI 10.1172/JCI110894; KNOWLES MR, 1981, AM REV RESPIR DIS, V124, P484; MASTRANGELI A, 1993, J CLIN INVEST, V91, P225, DOI 10.1172/JCI116175; SHIMIZU T, 1992, AM J RESP CELL MOL, V7, P30, DOI 10.1165/ajrcmb/7.1.30; SIMON RH, 1993, HUM GENE THER, V4, P771, DOI 10.1089/hum.1993.4.6-771; SNOUWAERT JN, 1992, SCIENCE, V257, P1083, DOI 10.1126/science.257.5073.1083; WILSON JM, 1994, HUM GENE THER, V5, P501, DOI 10.1089/hum.1994.5.4-501; YANG YP, 1994, NAT GENET, V7, P362, DOI 10.1038/ng0794-362; YANKASKAS JR, 1985, AM REV RESPIR DIS, V132, P1281; ZABNER J, 1993, CELL, V75, P207, DOI 10.1016/0092-8674(93)80063-K; ZABNER J, 1994, HUM GENE THER, V5, P585, DOI 10.1089/hum.1994.5.5-585; ZABNER J, 1994, NAT GENET, V6, P75, DOI 10.1038/ng0194-75	28	317	331	0	6	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	OCT 27	1994	371	6500					802	806		10.1038/371802a0	http://dx.doi.org/10.1038/371802a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PP018	7523956				2022-12-28	WOS:A1994PP01800061
J	BRAKE, AJ; WAGENBACH, MJ; JULIUS, D				BRAKE, AJ; WAGENBACH, MJ; JULIUS, D			NEW STRUCTURAL MOTIF FOR LIGAND-GATED ION CHANNELS DEFINED BY AN IONOTROPIC ATP RECEPTOR	NATURE			English	Article							PHEOCHROMOCYTOMA CELLS; FUNCTIONAL EXPRESSION; MAMMALIAN NEURONS; POTASSIUM CHANNEL; NERVOUS-SYSTEM; SMOOTH-MUSCLE; PC12 CELLS; CURRENTS; CONDUCTANCE; CALCIUM	THE adenosine-5'-triphosphate (ATP) molecule is an extracellular messenger in neural and non-neural tissues, where it activates several cell-surface-receptor subtypes, including G-protein-coupled receptors and ligand-gated ion channels(1). ATP-gated channels (termed P-2X receptors) have been characterized on smooth muscle cells and autonomic and sensory neurons, where they mediate membrane depolarization and, in some cases, Ca2+ entry(2). P-2X receptors are functionally heterogeneous, but resemble acetylcholine- and serotonin-gated channels with respect to ion selectivity and kinetic parameters of channel gating. We report here that despite such close functional similarities, the deduced sequence of a cloned P-2X receptor predicts an unusual subunit structure resembling voltage-insensitive cation channels. Thus, the P-2X receptor provides a striking example of convergent evolution, whereby proteins have been fashioned with similar functional properties from subunits having very different structural characteristics. There is sequence similarity between the ATP receptor and RP-2, a gene activated in thymocytes undergoing programmed cell. death(3). RP-2 may encode a receptor for ATP or another metabolite released during apoptosis.	UNIV CALIF SAN FRANCISCO,SILVIO CONTE CTR NEUROSCI RES,CELL BIOL PROGRAM & NEUROSCI,SAN FRANCISCO,CA 94143	University of California System; University of California San Francisco	BRAKE, AJ (corresponding author), UNIV CALIF SAN FRANCISCO,DEPT PHARMACOL,SAN FRANCISCO,CA 94143, USA.							BEAN BP, 1992, TRENDS PHARMACOL SCI, V13, P87, DOI 10.1016/0165-6147(92)90032-2; BENHAM CD, 1987, NATURE, V328, P275, DOI 10.1038/328275a0; BURNSTOCK G, 1990, ANN NY ACAD SCI, V603, P1; CANESSA CM, 1994, NATURE, V367, P463, DOI 10.1038/367463a0; CLOUES R, 1993, PFLUG ARCH EUR J PHY, V424, P152, DOI 10.1007/BF00374606; EDWARDS FA, 1992, NATURE, V359, P144, DOI 10.1038/359144a0; EVANS RJ, 1992, NATURE, V357, P503, DOI 10.1038/357503a0; FIEBER LA, 1991, J PHYSIOL-LONDON, V434, P239, DOI 10.1113/jphysiol.1991.sp018467; FRIEL DD, 1990, PFLUG ARCH EUR J PHY, V415, P651, DOI 10.1007/BF02584001; FRIEL DD, 1988, J PHYSIOL-LONDON, V401, P361, DOI 10.1113/jphysiol.1988.sp017167; HO K, 1993, NATURE, V362, P31, DOI 10.1038/362031a0; HONG KS, 1994, NATURE, V367, P470, DOI 10.1038/367470a0; HUANG MX, 1994, NATURE, V367, P467, DOI 10.1038/367467a0; KUBO Y, 1993, NATURE, V362, P127, DOI 10.1038/362127a0; LI CY, 1993, P NATL ACAD SCI USA, V90, P8264, DOI 10.1073/pnas.90.17.8264; LI M, 1994, CURR BIOL, V4, P110, DOI 10.1016/S0960-9822(94)00026-6; MAJID MA, 1992, BIOCHIM BIOPHYS ACTA, V1136, P283, DOI 10.1016/0167-4889(92)90118-U; MARICQ AV, 1991, SCIENCE, V254, P432, DOI 10.1126/science.1718042; NAKAZAWA K, 1991, PFLUG ARCH EUR J PHY, V418, P214, DOI 10.1007/BF00370517; NAKAZAWA K, 1993, J GEN PHYSIOL, V101, P377, DOI 10.1085/jgp.101.3.377; NAKAZAWA K, 1990, NEUROSCI LETT, V119, P5, DOI 10.1016/0304-3940(90)90741-Q; NAKAZAWA K, 1990, J PHYSIOL-LONDON, V428, P257, DOI 10.1113/jphysiol.1990.sp018211; OWENS GP, 1991, MOL CELL BIOL, V11, P4177, DOI 10.1128/MCB.11.8.4177; SARASTE M, 1990, TRENDS BIOCHEM SCI, V15, P430, DOI 10.1016/0968-0004(90)90281-F; SILINSKY EM, 1992, BRIT J PHARMACOL, V106, P762, DOI 10.1111/j.1476-5381.1992.tb14408.x; SUZUKI M, 1994, NATURE, V367, P642, DOI 10.1038/367642a0; TECOTT LH, 1993, P NATL ACAD SCI USA, V90, P1430, DOI 10.1073/pnas.90.4.1430; THOMAS SA, 1990, J GEN PHYSIOL, V95, P569, DOI 10.1085/jgp.95.4.569; UNWIN N, 1993, CELL, V72, P31, DOI 10.1016/S0092-8674(05)80026-1	29	842	862	0	23	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	OCT 6	1994	371	6497					519	523		10.1038/371519a0	http://dx.doi.org/10.1038/371519a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PK589	7523952				2022-12-28	WOS:A1994PK58900057
J	HUANG, ZH; HUANG, PL; PANAHIAN, N; DALKARA, T; FISHMAN, MC; MOSKOWITZ, MA				HUANG, ZH; HUANG, PL; PANAHIAN, N; DALKARA, T; FISHMAN, MC; MOSKOWITZ, MA			EFFECTS OF CEREBRAL-ISCHEMIA IN MICE DEFICIENT IN NEURONAL NITRIC-OXIDE SYNTHASE	SCIENCE			English	Article							L-ARGININE; GUANYLATE-CYCLASE; ARTERY OCCLUSION; BRAIN; STIMULATION; MECHANISMS	The proposal that nitric oxide (NO) or its reactant products mediate toxicity in brain remains controversial in part because of the use of nonselective agents that block NO formation in neuronal, glial, and vascular compartments. In mutant mice deficient in neuronal NO synthase (NOS) activity, infarct volumes decreased significantly 24 and 72 hours after middle cerebral artery occlusion, and the neurological deficits were less than those in normal mice. This result could not be accounted for by differences in blood flow or vascular anatomy. However, infarct size in the mutant became larger after endothelial NOS inhibition by nitro-L-arginine administration. Hence, neuronal NO production appears to exacerbate acute ischemic injury, whereas vascular NO protects after middle cerebral artery occlusion. The data emphasize the importance of developing selective inhibitors of the neuronal isoform.	MASSACHUSETTS GEN HOSP,STROKE RES LAB,BOSTON,MA 02129; HARVARD UNIV,SCH MED,NEUROSURG SERV,BOSTON,MA 02139; HARVARD UNIV,SCH MED,DEPT NEUROL,BOSTON,MA 02129; HARVARD UNIV,MASSACHUSETTS GEN HOSP,SCH MED,CARDIOVASC RES CTR,DEPT MED,BOSTON,MA 02129	Harvard University; Massachusetts General Hospital; Harvard University; Harvard Medical School; Harvard University; Harvard Medical School; Harvard University; Harvard Medical School; Massachusetts General Hospital			Moskowitz, Michael A/D-9916-2011	Dalkara, Turgay/0000-0003-3943-7819	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [P01NS010828, P50NS010828] Funding Source: NIH RePORTER; NINDS NIH HHS [NS2636, NS10828] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		BECKMAN JS, 1990, P NATL ACAD SCI USA, V87, P1620, DOI 10.1073/pnas.87.4.1620; BEDERSON JB, 1986, STROKE, V17, P472, DOI 10.1161/01.STR.17.3.472; CHAN PH, 1994, BRAIN PATHOL, V4, P59; CHOI DW, 1993, P NATL ACAD SCI USA, V90, P9741, DOI 10.1073/pnas.90.21.9741; DALKARA T, 1994, AM J PHYSIOL, V267, pH678, DOI 10.1152/ajpheart.1994.267.2.H678; DALKARA T, 1994, BRAIN PATHOL, V4, P49; DALKARA T, UNPUB; DAWSON TM, 1992, ANN NEUROL, V32, P297, DOI 10.1002/ana.410320302; DAWSON VL, 1993, J NEUROSCI, V13, P2651; DINERMAN JL, 1994, P NATL ACAD SCI USA, V91, P4214, DOI 10.1073/pnas.91.10.4214; HUANG PL, 1993, CELL, V75, P1273, DOI 10.1016/0092-8674(93)90615-W; HUANG Z, UNPUB; IADECOLA C, 1994, J CEREBR BLOOD F MET, V14, P175, DOI 10.1038/jcbfm.1994.25; IRIKURA K, 1994, AM J PHYSIOL, V267, pH837, DOI 10.1152/ajpheart.1994.267.2.H837; KADER A, 1993, STROKE, V24, P1709, DOI 10.1161/01.STR.24.11.1709; KATSUKI S, 1977, J CYCLIC NUCL PROT, V3, P23; KNOWLES RG, 1989, P NATL ACAD SCI USA, V86, P5159, DOI 10.1073/pnas.86.13.5159; LIPTON SA, 1993, NATURE, V364, P626, DOI 10.1038/364626a0; MALINSKI T, 1993, J CEREBR BLOOD F MET, V13, P355, DOI 10.1038/jcbfm.1993.48; MONCADA S, 1991, PHARMACOL REV, V43, P109; MORIKAWA E, 1992, AM J PHYSIOL, V263, pH1632, DOI 10.1152/ajpheart.1992.263.5.H1632; MORIKAWA E, 1992, BRIT J PHARMACOL, V107, P905, DOI 10.1111/j.1476-5381.1992.tb13382.x; MORIKAWA E, 1994, STROKE, V25, P429, DOI 10.1161/01.STR.25.2.429; MOSKOWITZ MA, UNPUB; ODELL TJ, 1994, SCIENCE, V265, P542, DOI 10.1126/science.7518615; PANAHIAN N, UNPUB; STAMLER JS, 1992, P NATL ACAD SCI USA, V89, P444, DOI 10.1073/pnas.89.1.444; STAMLER JS, 1992, SCIENCE, V258, P1898, DOI 10.1126/science.1281928; WARD R, 1990, J ANAT, V173, P87; WINK DA, 1993, P NATL ACAD SCI USA, V90, P9813, DOI 10.1073/pnas.90.21.9813; YANG GY, 1994, STROKE, V25, P165, DOI 10.1161/01.STR.25.1.165; YOSHIDA T, 1994, J CEREBR BLOOD F MET, V14, P924, DOI 10.1038/jcbfm.1994.123; ZHANG J, 1992, P NATL ACAD SCI USA, V89, P9382, DOI 10.1073/pnas.89.20.9382	33	1397	1469	1	34	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	SEP 23	1994	265	5180					1883	1885		10.1126/science.7522345	http://dx.doi.org/10.1126/science.7522345			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PH258	7522345				2022-12-28	WOS:A1994PH25800038
J	RABINOVICH, NR; MCINNES, P; KLEIN, DL; HALL, BF				RABINOVICH, NR; MCINNES, P; KLEIN, DL; HALL, BF			VACCINE TECHNOLOGIES - VIEW TO THE FUTURE	SCIENCE			English	Article							ANTIGEN PEPTIDE; IMMUNE-RESPONSES; MOUSE MUSCLE; VIRUS; DNA; IMMUNIZATION; ADJUVANT	The development of vaccines to prevent infectious diseases has been one of the most important contributions of biomedical science. Recent advances in the basic sciences are now fueling the development of a new generation of vaccines that will be based on rational design approaches. Two factors are making this possible: an improved understanding of the microbial factors required for virulence and the nature of the immune response to infection. The status of new vaccine technologies is summarized here.			RABINOVICH, NR (corresponding author), NIAID,DIV MICROBIOL & INFECT DIS,BETHESDA,MD 20892, USA.							ALLISON AC, 1992, VACCINES NEW APPROAC, P431; ALONSO MJ, 1993, PHARMACEUT RES, V10, P945, DOI 10.1023/A:1018942118148; ANDINO R, 1984, SCIENCE, V265, P1448; ANDRE F, 1993, MAR WHO M DTP VACC C; CHAI SK, 1992, J IMMUNOL, V149, P2385; COONEY EL, 1991, LANCET, V337, P567, DOI 10.1016/0140-6736(91)91636-9; DERTZBAUGH MT, 1993, INFECT IMMUN, V61, P48, DOI 10.1128/IAI.61.1.48-55.1993; DOUGLAS RG, 1993, J INFECT DIS, V168, P269, DOI 10.1093/infdis/168.2.269; ELDRIDGE JH, 1989, ADV EXP MED BIOL, V251, P192; FYNAN EF, 1993, P NATL ACAD SCI USA, V90, P11478, DOI 10.1073/pnas.90.24.11478; GERMAIN RN, 1993, ANNU REV IMMUNOL, V11, P403, DOI 10.1146/annurev.immunol.11.1.403; GOLDENTHAL KL, 1993, AIDS RES HUM RETROV, V9, pS47; GOULDFOGERITE S, 1994, MAY M CHILDR VACC IN; HUNTER R, 1991, VACCINE, V9, P250, DOI 10.1016/0264-410X(91)90108-I; KENSIL CR, 1991, J AM VET MED ASSOC, V199, P1423; La Montagne J R, 1994, Int J Technol Assess Health Care, V10, P7; LEES A, IN PRESS VACCINE; LOUTAN L, 1994, LANCET, V343, P322, DOI 10.1016/S0140-6736(94)91162-2; LU YA, 1991, MOL IMMUNOL, V28, P623; MILLER MD, 1992, J EXP MED, V176, P1739, DOI 10.1084/jem.176.6.1739; MOREIN B, 1984, NATURE, V308, P457, DOI 10.1038/308457a0; MORRIS W, 1994, VACCINE, V12, P5, DOI 10.1016/0264-410X(94)90003-5; NARDELLI B, 1993, IMMUNOLOGY, V79, P355; PERKUS ME, 1985, SCIENCE, V229, P981, DOI 10.1126/science.2992092; Ramachandran S, 1994, Int J Technol Assess Health Care, V10, P193; RICKMAN LS, 1991, LANCET, V337, P998, DOI 10.1016/0140-6736(91)92659-P; SCHOOLNIK GK, 1992, RECOMBINANT DNA VACC, pR11; SCOTT P, 1991, J IMMUNOL, V147, P3149; SIBER GR, 1994, SCIENCE, V265, P1385, DOI 10.1126/science.8073278; Stein K E, 1994, Int J Technol Assess Health Care, V10, P167; TANG DC, 1992, NATURE, V356, P152, DOI 10.1038/356152a0; TARGAGLIA J, 1993, AIDS RES REV, P362; WANG B, 1993, DNA CELL BIOL, V12, P799, DOI 10.1089/dna.1993.12.799; WOLFF JA, 1990, SCIENCE, V247, P1465, DOI 10.1126/science.1690918; Wolff Jon A., 1992, Human Molecular Genetics, V1, P363, DOI 10.1093/hmg/1.6.363; 1993, PAHOHDPHDRRDVHMPEP11	36	77	95	0	6	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	SEP 2	1994	265	5177					1401	1404		10.1126/science.7521064	http://dx.doi.org/10.1126/science.7521064			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PE733	7521064				2022-12-28	WOS:A1994PE73300036
J	LORSCH, JR; SZOSTAK, JW				LORSCH, JR; SZOSTAK, JW			IN-VITRO EVOLUTION OF NEW RIBOZYMES WITH POLYNUCLEOTIDE KINASE-ACTIVITY	NATURE			English	Article							STRANDED-DNA MOLECULES; INVITRO SELECTION; RNA ENZYME; CLEAVAGE; RECOGNITION; TETRAHYMENA; POLYMERASE; CATALYSIS; SEQUENCE; LIGANDS	We have isolated a large number of polynucleotide kinase ribozymes from a pool of RNA molecules consisting of an ATP-binding domain flanked by regions of random sequence. Different classes of kinases catalyse the transfer of the gamma-thiophosphate of ATP-gamma S to the 5'-hydroxyl or to internal 2'-hydroxyls. An engineered version of one class is able to catalyse the transfer of thiophosphate from ATP-gamma S to the 5'-hydroxyl of an exogenous oligoribonucleotide substrate with multiple turnover, thus acting as a true enzyme.	HARVARD UNIV, DEPT BIOCHEM & MOLEC BIOL, CAMBRIDGE, MA 02138 USA; HARVARD UNIV, SCH MED, DEPT GENET, BOSTON, MA 02115 USA	Harvard University; Harvard University; Harvard Medical School	LORSCH, JR (corresponding author), MASSACHUSETTS GEN HOSP, DEPT MOLEC BIOL, BOSTON, MA 02114 USA.			Lorsch, Jon/0000-0002-4521-4999				BARTEL DP, 1991, CELL, V67, P529, DOI 10.1016/0092-8674(91)90527-6; BARTEL DP, 1993, SCIENCE, V261, P1411, DOI 10.1126/science.7690155; BASS BL, 1984, NATURE, V308, P820, DOI 10.1038/308820a0; BEAUDRY AA, 1992, SCIENCE, V257, P635, DOI 10.1126/science.1496376; BOCK LC, 1992, NATURE, V355, P564, DOI 10.1038/355564a0; BRESLOW R, 1968, J AM CHEM SOC, V90, P7376, DOI 10.1021/ja01028a054; Cadwell R C, 1992, PCR Methods Appl, V2, P28, DOI 10.1101/gr.2.1.28; CHOWRIRA BM, 1991, NATURE, V354, P320, DOI 10.1038/354320a0; CONNELL GJ, 1993, BIOCHEMISTRY-US, V32, P5497, DOI 10.1021/bi00072a002; DAHM SC, 1993, BIOCHEMISTRY-US, V32, P13040, DOI 10.1021/bi00211a013; DOMDEY H, 1979, ANAL BIOCHEM, V98, P346, DOI 10.1016/0003-2697(79)90152-0; ECKSTEIN F, 1985, ANNU REV BIOCHEM, V54, P367, DOI 10.1146/annurev.bi.54.070185.002055; ELLINGTON AD, 1992, NATURE, V355, P850, DOI 10.1038/355850a0; ELLINGTON AD, 1990, NATURE, V346, P818, DOI 10.1038/346818a0; FAMULOK M, 1992, J AM CHEM SOC, V114, P3990, DOI 10.1021/ja00036a065; FAMULOK M, 1994, J AM CHEM SOC, V116, P1698, DOI 10.1021/ja00084a010; Fersht A., 1985, ENZYME STRUCTURE MEC; GILBERT W, 1986, NATURE, V319, P618, DOI 10.1038/319618a0; GREEN R, 1992, SCIENCE, V258, P1910, DOI 10.1126/science.1470913; GUERRIERTAKADA C, 1983, CELL, V35, P849, DOI 10.1016/0092-8674(83)90117-4; HERSCHLAG D, 1991, BIOCHEMISTRY-US, V30, P4844, DOI 10.1021/bi00234a003; JENISON RD, 1994, SCIENCE, V263, P1425, DOI 10.1126/science.7510417; KONARSKA M, 1981, NATURE, V293, P112, DOI 10.1038/293112a0; LEHMAN N, 1993, NATURE, V361, P182, DOI 10.1038/361182a0; LILLEHAUG JR, 1975, BIOCHEMISTRY-US, V14, P1221, DOI 10.1021/bi00677a020; LORSCH JR, 1994, BIOCHEMISTRY-US, V33, P973, DOI 10.1021/bi00170a016; MILLIGAN JF, 1989, METHOD ENZYMOL, V180, P51; PAN T, 1992, BIOCHEMISTRY-US, V31, P3887, DOI 10.1021/bi00131a001; PERROTTA AT, 1992, BIOCHEMISTRY-US, V31, P16, DOI 10.1021/bi00116a004; PRUDENT JR, 1994, SCIENCE, V264, P1924; PYLE AM, 1994, BIOCHEMISTRY-US, V33, P2716, DOI 10.1021/bi00175a047; RAMIREZ F, 1980, J ORG CHEM, V45, P4748, DOI 10.1021/jo01311a038; Richardson C.C., 1981, ENZYMES A, V14, P299, DOI DOI 10.1016/S1874-6047(08)60342-X; SASSANFAR M, 1993, NATURE, V364, P550, DOI 10.1038/364550a0; TSAI DE, 1992, P NATL ACAD SCI USA, V89, P8864, DOI 10.1073/pnas.89.19.8864; TUERK C, 1990, SCIENCE, V249, P505, DOI 10.1126/science.2200121; WESTAWAY SK, 1993, J BIOL CHEM, V268, P2435; ZAUG AJ, 1986, BIOCHEMISTRY-US, V25, P4478, DOI 10.1021/bi00364a002; ZIMMERMAN SB, 1981, ENZYMES, V14, P315	39	218	243	0	20	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	SEP 1	1994	371	6492					31	36		10.1038/371031a0	http://dx.doi.org/10.1038/371031a0			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PE381	7521014				2022-12-28	WOS:A1994PE38100041
J	KOZAL, MJ; KROODSMA, K; WINTERS, MA; SHAFER, RW; EFRON, B; KATZENSTEIN, DA; MERIGAN, TC				KOZAL, MJ; KROODSMA, K; WINTERS, MA; SHAFER, RW; EFRON, B; KATZENSTEIN, DA; MERIGAN, TC			DIDANOSINE RESISTANCE IN HIV-INFECTED PATIENTS SWITCHED FROM ZIDOVUDINE TO DIDANOSINE MONOTHERAPY	ANNALS OF INTERNAL MEDICINE			English	Article						HUMAN IMMUNODEFICIENCY VIRUS; DRUG RESISTANCE; ZIDOVUDINE; DIDANOSINE; ANTIGENS, CD4	HUMAN-IMMUNODEFICIENCY-VIRUS; SYNCYTIUM-INDUCING PHENOTYPE; POLYMERASE CHAIN-REACTION; HIGH-LEVEL RESISTANCE; REVERSE-TRANSCRIPTASE; REDUCED SENSITIVITY; TYPE-1; MUTATIONS; AZT; RNA	Objective: To determine the frequency and pattern of development of specific drug resistance mutations for human immunodeficiency virus (HIV) reverse transcriptase in patients switched from zidovudine to didanosine therapy and to examine the relation of the didanosine resistance mutation at codon 74 of the HIV reverse-transcriptase gene to CD4(+) T-cell changes and virus burden. Design: Retrospective analysis of all patients enrolled at Stanford University in protocols where patients were switched from zidovudine to didanosine monotherapy. Setting: A university hospital. Patients: 64 patients infected with HIV who were switched from zidovudine to didanosine monotherapy. Patients had the acquired immunodeficiency syndrome (AIDS), AIDS-related complex, or were asymptomatic (mean [+/-SD] starting CD4(+) T-cell count of 129 +/- 88 cells/mm(3)). Measurements: Serial serum specimens were tested for the didanosine resistance mutation at codon 74 of the HIV reverse-transcriptase gene and for a zidovudine resistance mutation at codon 215 using selective polymerase chain reactions (PCR). Serum HIV RNA levels were determined by quantitative PCR. CD4(+) T-cell counts were determined at serial time points. Results: By 24 weeks of didanosine therapy, the proportion of patients with the didanosine resistance mutation at codon 74 increased from 0% to 56% (36 of 64). In contrast, the proportion of patients with the zidovudine resistance mutation at codon 215 decreased from 84% at the start to 59% after 24 weeks of didanosine therapy (a 25% decrease, 95% lower CI, 15%; P < 0.0001). Patients who developed the codon 74 mutation had a greater decrease in CD4(+) T cells after the development of the mutation than did patients without the mutation (P < 0.001). In addition, after 24 weeks of didanosine, patients who developed the codon 74 mutation had a greater serum HIV RNA burden than patients who remained wild type (did not have the mutation) at codon 74 (225 000 compared with 82 400 HIV RNA copies/mL serum; P = 0.01). Conclusions: Among patients infected with HIV who had advanced disease and were switched from zidovudine to didanosine therapy, more than one half developed the didanosine resistance mutation at codon 74 by 24 weeks of didanosine therapy. Patients who developed the codon 74 mutation had a greater decline in CD4(+) T cells after the development of the mutation and had a greater serum virus burden than did patients without the codon 74 mutation.			KOZAL, MJ (corresponding author), STANFORD UNIV, MED CTR, DIV INFECT DIS, ROOM S-156, STANFORD, CA 94305 USA.		Merigan, Thomas/AGQ-7464-2022	Kozal, Michael/0000-0002-3100-8254; , Michael/0000-0002-7719-7396; katzenstein, david/0000-0002-8593-4560	NIAID NIH HHS [AI-27762, AI-27666] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [P30AI027762, U01AI027666] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BOUCHER CAB, 1992, J INFECT DIS, V165, P105, DOI 10.1093/infdis/165.1.105; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DAQUILA RT, 1993, 1ST NAT C HUM RETR R; DAVEY RT, 1993, P NATL ACAD SCI USA, V90, P5608, DOI 10.1073/pnas.90.12.5608; ERON JJ, 1993, ANTIMICROB AGENTS CH, V37, P1480, DOI 10.1128/AAC.37.7.1480; GU ZX, 1992, J VIROL, V66, P7128, DOI 10.1128/JVI.66.12.7128-7135.1992; JAPOUR AJ, 1991, P NATL ACAD SCI USA, V88, P3092, DOI 10.1073/pnas.88.8.3092; KAHN JO, 1992, NEW ENGL J MED, V327, P581, DOI 10.1056/NEJM199208273270901; KAPPES JC, 1992, 8 INT C AIDS AMST; KATZENSTEIN DA, 1994, J INFECT DIS, V169, P416, DOI 10.1093/infdis/169.2.416; KELLAM P, 1992, P NATL ACAD SCI USA, V89, P1934, DOI 10.1073/pnas.89.5.1934; KOOT M, 1993, ANN INTERN MED, V118, P681, DOI 10.7326/0003-4819-118-9-199305010-00004; KOOT M, 1992, AIDS, V6, P49, DOI 10.1097/00002030-199201000-00006; KOZAL MJ, 1993, J INFECT DIS, V167, P526, DOI 10.1093/infdis/167.3.526; LARDER BA, 1989, SCIENCE, V243, P1731, DOI 10.1126/science.2467383; LARDER BA, 1991, AIDS, V5, P137, DOI 10.1097/00002030-199102000-00002; LARDER BA, 1989, SCIENCE, V246, P1155, DOI 10.1126/science.2479983; Larder Brendan A., 1993, P527; MAYERS DL, 1993, 1ST NAT C HUM RETR R; MONTANER JSG, 1993, AIDS, V7, P189, DOI 10.1097/00002030-199302000-00006; REICHMAN RC, 1993, ANTIVIR RES, V20, P267, DOI 10.1016/0166-3542(93)90071-P; RICHMAN DD, 1991, J INFECT DIS, V164, P1075, DOI 10.1093/infdis/164.6.1075; RICHMAN DD, 1990, J ACQ IMMUN DEF SYND, V3, P743; RICHMAN DD, 1993, ANTIMICROB AGENTS CH, V37, P1207, DOI 10.1128/AAC.37.6.1207; RICHMAN DD, 1992, 8 INT C AIDS AMST, P3576; SHAFER RW, 1994, J INFECT DIS, V169, P722, DOI 10.1093/infdis/169.4.722; SHIRASAKA T, 1993, P NATL ACAD SCI USA, V90, P562, DOI 10.1073/pnas.90.2.562; STCLAIR MH, 1993, J ACQ IMMUN DEF SYND, V6, P891; STCLAIR MH, 1991, SCIENCE, V253, P1557, DOI 10.1126/science.1716788; TERSMETTE M, 1989, LANCET, V1, P983; TISDALE M, 1993, P NATL ACAD SCI USA, V90, P5653, DOI 10.1073/pnas.90.12.5653; TUDORWILLIAMS G, 1992, LANCET, V339, P15, DOI 10.1016/0140-6736(92)90140-X; Winters M A, 1992, PCR Methods Appl, V1, P257; WINTERS MA, 1993, J CLIN MICROBIOL, V31, P2960, DOI 10.1128/JCM.31.11.2960-2966.1993	34	60	61	0	2	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	AUG 15	1994	121	4					263	268		10.7326/0003-4819-121-4-199408150-00005	http://dx.doi.org/10.7326/0003-4819-121-4-199408150-00005			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PB102	7518658				2022-12-28	WOS:A1994PB10200005
J	HOFFMAN, DM; OSULLIVAN, AJ; BAXTER, RC; HO, KKY				HOFFMAN, DM; OSULLIVAN, AJ; BAXTER, RC; HO, KKY			DIAGNOSIS OF GROWTH-HORMONE DEFICIENCY IN ADULTS	LANCET			English	Article							BINDING-PROTEIN; SOMATOMEDIN-C; RADIOIMMUNOASSAY; AGE; MEN; GH; SECRETION; PROFILES; PLASMA	There is no consensus as to the most appropriate method of diagnosing growth-hormone (GH) deficiency in adults. We have evaluated the relative diagnostic merits of measuring peak GH response to insulin-induced hypoglycaemia (insulin tolerance test), mean 24 h GH concentration derived from 20 min sampling, serum insulin-like growth factor I (IGF-I) concentrations, and serum IGF binding protein 3 (IGFBP-3) concentrations. These tests were undertaken in 23 patients considered GH deficient from extensive organic pituitary disease, and in 35 sex-matched normal subjects of similar age and body-mass index. Hypopituitary subjects had significantly lower stimulated peak GH, mean 24 h GH, IGF-I, and IGFBP-3 concentrations than normal subjects. The ranges of stimulated peak GH responses were clearly separated between the hypopituitary (<0.2-3.1 ng/mL) and normal (5.3-42.5 ng/mL) groups, but mean 24 h GH, IGF-I, and IGFBP-3 concentrations overlapped. Mean 24 h GH concentrations were below assay sensitivity in 80% of hypopituitary subjects and 16% of normal subjects. 70% and 72%, respectively, of the IGF-I and IGFBP-3 values in hypopituitary subjects were within the range for normal subjects. We conclude that GH deficiency in adults is most reliably identified by stimulatory testing, and that IGF-I and IGFBP-3 are poor diagnostic tests of adult GH deficiency.	ST VINCENTS HOSP,GARVAN INST MED RES,DARLINGHURST,NSW 2010,AUSTRALIA; ROYAL PRINCE ALFRED HOSP,SYDNEY,AUSTRALIA	Garvan Institute of Medical Research; St Vincents Hospital Sydney; University of Sydney			Ho, Ken/AAA-7428-2019; Ho, Ken KY/E-5832-2011; Baxter, Robert C/F-3927-2012	Ho, Ken/0000-0002-2508-9588; Baxter, Robert C/0000-0001-5061-2142				BARKAN AL, 1988, J CLIN ENDOCR METAB, V67, P69, DOI 10.1210/jcem-67-1-69; BAXTER RC, 1982, CLIN CHEM, V28, P488; BAXTER RC, 1993, TRENDS ENDOCRIN MET, V4, P91, DOI 10.1016/1043-2760(93)90085-S; BAXTER RC, 1986, J CLIN INVEST, V78, P1504, DOI 10.1172/JCI112742; BENGTSSON BA, 1993, J CLIN ENDOCR METAB, V76, P309, DOI 10.1210/jc.76.2.309; BLUM WF, 1993, J CLIN ENDOCR METAB, V76, P1610, DOI 10.1210/jc.76.6.1610; BLUM WF, 1990, J CLIN ENDOCR METAB, V70, P1292, DOI 10.1210/jcem-70-5-1292; CUNEO RC, 1991, J APPL PHYSIOL, V70, P695, DOI 10.1152/jappl.1991.70.2.695; GREENWOO.FC, 1966, J CLIN INVEST, V45, P429, DOI 10.1172/JCI105357; HINTZ RL, 1993, GROWTH HORMONE REPLA, P157; HO KKY, IN PRESS CLIN ENDOCR; HO KY, 1989, CLIN ENDOCRINOL, V30, P335, DOI 10.1111/j.1365-2265.1989.tb00431.x; HO KY, 1987, J CLIN ENDOCR METAB, V64, P51, DOI 10.1210/jcem-64-1-51; IRANMANESH A, 1991, J CLIN ENDOCR METAB, V73, P1081, DOI 10.1210/jcem-73-5-1081; JORGENSEN JOL, 1989, LANCET, V1, P1221; LANDON J, 1966, J CLIN INVEST, V45, P437, DOI 10.1172/JCI105358; LAUGHLIN GA, 1993, 75TH P ANN M END SOC; RUDMAN D, 1990, NEW ENGL J MED, V323, P1, DOI 10.1056/NEJM199007053230101; SAINI S, 1991, CLIN ENDOCRINOL, V34, P455, DOI 10.1111/j.1365-2265.1991.tb00325.x; SALOMON F, 1989, NEW ENGL J MED, V321, P1797, DOI 10.1056/NEJM198912283212605; VELDHUIS JD, 1991, J CLIN ENDOCR METAB, V72, P51, DOI 10.1210/jcem-72-1-51; VERMEULEN A, 1987, J CLIN ENDOCR METAB, V64, P884, DOI 10.1210/jcem-64-5-884; ZADIK Z, 1985, J CLIN ENDOCR METAB, V60, P513, DOI 10.1210/jcem-60-3-513	23	418	423	0	6	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	APR 30	1994	343	8905					1064	1068		10.1016/S0140-6736(94)90181-3	http://dx.doi.org/10.1016/S0140-6736(94)90181-3			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NJ694	7512681				2022-12-28	WOS:A1994NJ69400009
J	CLINTON, JJ				CLINTON, JJ			BENIGN PROSTATIC HYPERPLASIA (BPH) - DIAGNOSIS AND TREATMENT	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material											CLINTON, JJ (corresponding author), AGCY HLTH CARE POLICY & RES,POB 8547,SILVER SPRING,MD 20907, USA.								0	3	3	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	APR 20	1994	271	15					1151	1151		10.1001/jama.271.15.1151	http://dx.doi.org/10.1001/jama.271.15.1151			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NF207	7512166				2022-12-28	WOS:A1994NF20700006
J	FIRST, LR; PALFREY, JS				FIRST, LR; PALFREY, JS			CURRENT CONCEPTS - THE INFANT OR YOUNG-CHILD WITH DEVELOPMENTAL DELAY	NEW ENGLAND JOURNAL OF MEDICINE			English	Review							LANGUAGE MILESTONE SCALE; SCREENING-TESTS; BIRTH; INTERVENTION; DIAGNOSIS; DENVER		CHILDRENS HOSP,PEDIAT GRP ASSOCIATES PROGRAM,BOSTON,MA; CHILDRENS HOSP,DIV GEN PEDIAT,BOSTON,MA	Harvard University; Boston Children's Hospital; Harvard University; Boston Children's Hospital	FIRST, LR (corresponding author), HARVARD UNIV,SCH MED,DEPT PEDIAT,BOSTON,MA 02115, USA.							BENNETT FC, 1991, PEDIATR CLIN N AM, V38, P1513; Berrueta-Clement J. R., 1984, MONOGRAPHS HIGH SCOP, V8; BLACKMAN JA, 1991, PEDIATR CLIN N AM, V38, P1497; BLASCO PA, 1991, PEDIATR CLIN N AM, V38, P1425; BRICKER D, 1989, INFANT MONITORING SY; COPLAN J, 1990, PEDIATRICS, V86, P963; Coplan J., 1983, ELM SCALE EARLY LANG; DIXON SD, 1989, J PEDIATR-US, V115, P770, DOI 10.1016/S0022-3476(89)80661-4; DOBOS AE, 1992, AJDC, V146, P484; DRILLIEN CM, 1988, DEV MED CHILD NEUROL, V30, P294; Dunn L.M., 2007, PEABODY PICTURE VOCA; DWORKIN PH, 1989, PEDIATRICS, V84, P1000; FRANKENBURG WK, 1992, PEDIATRICS, V89, P91; FRANKENBURG WK, 1990, BATTELLE DEV INVENTO, V2; GLASCOE FP, 1990, PEDIATRICS, V86, P547; GLASCOE FP, 1992, PEDIATRICS, V89, P1221; ILLINGWORTH RS, 1978, TXB PEDIATRICS; Ireton H. R., 1987, PRESCHOOL DEV INVENT; Ireton H. R., 1980, MINNESOTA INFANT DEV; IRETON HR, 1988, EARLY CHILD DEV INVE; KONSTANTAREAS MM, 1991, PSYCHIATR CLIN N AM, V14, P1; MANDELLCZUDNOWS.C, 1983, DIAL R; MEISELS SJ, 1989, PEDIATRICS, V83, P578; MEISELS SJ, 1992, SCREENING ASSESSMENT; Menyuk P., 1986, OTITIS MEDIA CHILD D, P83; Newborg J., 1984, BATTELLE DEV INVENTO; PALFREY JS, 1981, J PEDIATR-US, V98, P1006, DOI 10.1016/S0022-3476(81)80619-1; PALFREY JS, 1987, J PEDIATR-US, V111, P651, DOI 10.1016/S0022-3476(87)80238-X; PALFREY JS, 1992, DEV BEHAV PEDIAT, P782; PHILLIPS S, 1992, PRIMARY PEDIATRIC CA, P678; RAPIN I, 1991, PEDIATRICS, V87, P751; SAIGAL S, 1990, J PEDIATR-US, V116, P409, DOI 10.1016/S0022-3476(05)82835-5; Sameroff A, 1975, REV CHILD DEV RES, P187; SCHMITT B, 1991, DEV MED CHILD NEUROL, V33, P535; SHALOWITZ MU, 1990, DIFFICULT DIAGNOSIS, P3; SHONKOFF JP, 1987, PEDIATRICS, V80, P650; Simeonsson RJ, 1992, PRIMARY PEDIAT CARE, P867; Sparrow S.S., 2005, VINELAND 2 ADAPTIVE; THOMPSON MGG, 1990, DIFFICULT DIAGNOSIS, P15; WALKER D, 1989, PEDIATRICS, V83, P284; ZUCKERMAN B, 1991, PEDIATR CLIN N AM, V38, P1387; ZUCKERMAN B, 1986, ADV PERINATOLOGY, V5, P125; [No title captured]	43	108	109	0	5	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	FEB 17	1994	330	7					478	483		10.1056/NEJM199402173300708	http://dx.doi.org/10.1056/NEJM199402173300708			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MW480	7507219				2022-12-28	WOS:A1994MW48000008
J	UMEMORI, H; SATO, S; YAGI, T; AIZAWA, S; YAMAMOTO, T				UMEMORI, H; SATO, S; YAGI, T; AIZAWA, S; YAMAMOTO, T			INITIAL EVENTS OF MYELINATION INVOLVE FYN TYROSINE KINASE SIGNALING	NATURE			English	Article							CELL ANTIGEN RECEPTOR; SRC PROTEIN; TERMINAL REGION; GLYCOPROTEIN; ASSOCIATION; FAMILY; ADHESION; BRAIN; EXPRESSION; EFFICIENT	MYELIN is the lipoprotein multimembrane that functions as an insulator preventing the flow of ion currents across the axonal membrane and facilitating the conduction of nerve impulses. It is synthesized by oligodendrocytes in the central nervous system at about the time of birth in mammals1. During the initial stages of myelination, several proteins are phosphorylated on tyrosine. Among these proteins, we identified Fyn tyrosine kinase, one of the non-receptor-type tyrosine kinases of the Src family. Here we report that Fyn tyrosine kinase is activated during the initial stages of myelination and that it is associated with the large myelin-associated glycoprotein (MAG), an adhesion molecule that has been implicated in myelinogenesis2. The Fyn-large MAG association requires amino-terminal domains of Fyn that include SH2 and SH3 (Src homology domains 2 and 3). Crosslinking of large MAG with antibody induces a rapid increase in the specific activity of Fyn kinase. These results indicate that Fyn participates in the initial events of myelination as a signalling molecule downstream of large MAG; indeed, we find that fyn-deficient mice exhibit impaired myelination.	UNIV TOKYO,INST MED SCI,DEPT ONCOL,4-6-1 SHIROKANEDAI,MINATO KU,TOKYO 108,JAPAN; NIIGATA UNIV,BRAIN RES INST,DEPT NEUROL,NIIGATA 951,JAPAN; INST PHYS & CHEM RES,TSUKUBA LIFE SCI CTR,MOLEC ONCOL LAB,TSUKUBA,IBARAKI 305,JAPAN	University of Tokyo; Niigata University; RIKEN			Messier, Claude/A-2322-2008	Messier, Claude/0000-0002-4791-1763; Umemori, Hisashi/0000-0001-7198-2062				Cooper J.A, 1990, PEPT PROT PHOSPH, P85; DUNCAN ID, 1990, MYELINATION DYSMYELI; EDWARDS AM, 1988, MOL CELL BIOL, V8, P2655, DOI 10.1128/MCB.8.6.2655; EISEMAN E, 1992, NATURE, V355, P78; FUJITA N, 1989, BIOCHEM BIOPH RES CO, V165, P1162, DOI 10.1016/0006-291X(89)92724-1; FUJITA N, 1990, J NEUROCHEM, V55, P1056, DOI 10.1111/j.1471-4159.1990.tb04596.x; GRANT SGN, 1992, SCIENCE, V258, P1903, DOI 10.1126/science.1361685; HATAKEYAMA M, 1991, SCIENCE, V252, P1523, DOI 10.1126/science.2047859; JOHNSON PW, 1989, NEURON, V3, P377, DOI 10.1016/0896-6273(89)90262-6; KOCH CA, 1991, SCIENCE, V252, P668, DOI 10.1126/science.1708916; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; LEMKE G, 1988, NEURON, V1, P535, DOI 10.1016/0896-6273(88)90103-1; NORTON WT, 1973, J NEUROCHEM, V21, P749, DOI 10.1111/j.1471-4159.1973.tb07519.x; OKADA M, 1991, J BIOL CHEM, V266, P24249; PARSONS SJ, 1986, J VIROL, V59, P755, DOI 10.1128/JVI.59.3.755-758.1986; POLTORAK M, 1987, J CELL BIOL, V105, P1893, DOI 10.1083/jcb.105.4.1893; SALZER JL, 1987, J CELL BIOL, V104, P957, DOI 10.1083/jcb.104.4.957; SAMELSON LE, 1990, P NATL ACAD SCI USA, V87, P4358, DOI 10.1073/pnas.87.11.4358; SEMBA K, 1986, P NATL ACAD SCI USA, V83, P5459, DOI 10.1073/pnas.83.15.5459; STERNBERGER NH, 1979, P NATL ACAD SCI USA, V76, P1510, DOI 10.1073/pnas.76.3.1510; SUDOL M, 1993, NEUROCHEM INT, V22, P369, DOI 10.1016/0197-0186(93)90019-2; SUKEGAWA J, 1990, ONCOGENE, V5, P611; TAKEBE Y, 1988, MOL CELL BIOL, V8, P466, DOI 10.1128/MCB.8.1.466; TANAKA A, 1987, MOL CELL BIOL, V7, P1978, DOI 10.1128/MCB.7.5.1978; TURNER JM, 1990, CELL, V60, P755, DOI 10.1016/0092-8674(90)90090-2; UMEMORI H, 1992, MOL BRAIN RES, V16, P303, DOI 10.1016/0169-328X(92)90239-8; VEILLETTE A, 1988, CELL, V55, P301, DOI 10.1016/0092-8674(88)90053-0; YAGI T, 1993, NATURE, V366, P742, DOI 10.1038/366742a0; YAMANASHI Y, 1991, SCIENCE, V251, P192, DOI 10.1126/science.1702903; YAMANASHI Y, 1992, P NATL ACAD SCI USA, V89, P1118, DOI 10.1073/pnas.89.3.1118	30	342	349	0	5	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	FEB 10	1994	367	6463					572	576		10.1038/367572a0	http://dx.doi.org/10.1038/367572a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	MV863	7509042				2022-12-28	WOS:A1994MV86300063
J	RASSOULZADEGAN, M; PAQUISFLUCKLINGER, V; BERTINO, B; SAGE, J; JASIN, M; MIYAGAWA, K; VANHEYNINGEN, V; BESMER, P; CUZIN, F				RASSOULZADEGAN, M; PAQUISFLUCKLINGER, V; BERTINO, B; SAGE, J; JASIN, M; MIYAGAWA, K; VANHEYNINGEN, V; BESMER, P; CUZIN, F			TRANSMEIOTIC DIFFERENTIATION OF MALE GERM-CELLS IN CULTURE	CELL			English	Article							SEMINIFEROUS EPITHELIAL CYCLE; CYTOMETRIC DNA ANALYSIS; TUMOR GENE WT1; SERTOLI-CELL; TRANSGENIC MICE; MESSENGER-RNA; C-KIT; FLOW-CYTOMETRY; EXPRESSION; MOUSE	A cell culture system that supports the differentiation of male germ cells through meiosis is described. It takes advantage of the properties of a cell line, 15P-1, established from testicular cells of transgenic mice that express the large T protein of polyoma virus in the seminiferous epithelium. This line exhibits features characteristic of Sertoli cells, including transcription of the Wilms' tumor (WT1) and Steel genes. Cells of the 15P-1 type support the meiotic and postmeiotic differentiation in cocultures of diploid premeiotic germ cells into haploid spermatids expressing the protamine (Prm-1) gene. When cocultured with P-15-1 cells, testicular cells explanted from immature 9-day-old animals, before the onset of the first meiosis, generated tetrads of haploid cells with the morphology of round spermatids and initiated protamine transcription.	SLOAN KETTERING INST CANC RES, NEW YORK, NY 10021 USA; WESTERN GEN HOSP, MRC, HUMAN GENET UNIT, EDINBURGH EH4 2X4, SCOTLAND	Memorial Sloan Kettering Cancer Center; University of Edinburgh	RASSOULZADEGAN, M (corresponding author), UNIV NICE, INSERM, U273, F-06108 NICE 2, FRANCE.		VAN HEYNINGEN, Veronica/GYE-0531-2022; Rassoulzadegan, Minoo/O-7939-2016; van Heyningen, Veronica/B-8039-2008	van Heyningen, Veronica/0000-0003-0359-0141	Medical Research Council [MC_U127527199] Funding Source: Medline; MRC [MC_U127527199] Funding Source: UKRI	Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))		BAUER TW, 1990, AM J CLIN PATHOL, V93, P322, DOI 10.1093/ajcp/93.3.322; BRAUN RE, 1989, GENE DEV, V3, P793, DOI 10.1101/gad.3.6.793; BUCKLER AJ, 1991, MOL CELL BIOL, V11, P1707, DOI 10.1128/MCB.11.3.1707; CASTELLON E, 1989, MOL CELL ENDOCRINOL, V64, P169, DOI 10.1016/0303-7207(89)90143-3; CELI FS, 1993, NUCLEIC ACIDS RES, V21, P1047, DOI 10.1093/nar/21.4.1047; DJAKIEW D, 1988, BIOL REPROD, V39, P1193, DOI 10.1095/biolreprod39.5.1193; ERICKSONLAWRENCE M, 1991, MOL ENDOCRINOL, V5, P1789, DOI 10.1210/mend-5-12-1789; Fritz I. B., 1990, Biology of mammalian germ cell mutagenesis.., P19; GILLILAND G, 1990, P NATL ACAD SCI USA, V87, P2725, DOI 10.1073/pnas.87.7.2725; GOETZ P, 1984, J CELL SCI, V65, P249; HOFMANN MC, 1992, EXP CELL RES, V201, P417, DOI 10.1016/0014-4827(92)90291-F; JASIN M, 1992, P NATL ACAD SCI USA, V89, P10681, DOI 10.1073/pnas.89.22.10681; JEGOU B, 1991, ANN NY ACAD SCI, V637, P340; KLEENE KC, 1985, BIOCHEMISTRY-US, V24, P719, DOI 10.1021/bi00324a027; KUO MS, 1986, CARBOHYD RES, V156, P173, DOI 10.1016/S0008-6215(00)90109-5; LACROIX M, 1981, BIOL REPROD, V25, P143, DOI 10.1095/biolreprod25.1.143; LEMAGUERESSE B, 1988, J ENDOCRINOL, V118, pR13, DOI 10.1677/joe.0.118R013; Leonard Davis G., 1986, BASIC METHODS MOL BI; MANOVA K, 1990, DEVELOPMENT, V110, P1057; MATHER JP, 1980, BIOL REPROD, V23, P243, DOI 10.1095/biolreprod23.1.243; MURTI JR, 1992, MOL CELL BIOL, V12, P2545, DOI 10.1128/MCB.12.6.2545; NISHIKAWA S, 1991, EMBO J, V10, P2111, DOI 10.1002/j.1460-2075.1991.tb07744.x; PAQUISFLUCKLINGER V, 1993, ONCOGENE, V8, P2087; PARVINEN M, 1986, INT REV CYTOL, V104, P115, DOI 10.1016/S0074-7696(08)61925-7; PELLETIER J, 1991, GENE DEV, V5, P1345, DOI 10.1101/gad.5.8.1345; PESCHON JJ, 1987, P NATL ACAD SCI USA, V84, P5316, DOI 10.1073/pnas.84.15.5316; ROSSI P, 1991, BIOCHEM BIOPH RES CO, V176, P910, DOI 10.1016/S0006-291X(05)80272-4; Russell L. D., 1990, HISTOLOGICAL HISTOPA; RUSSELL LD, 1983, AM J ANAT, V167, P181, DOI 10.1002/aja.1001670204; SHULDINER AR, 1991, P NATL ACAD SCI USA, V88, P7679, DOI 10.1073/pnas.88.17.7679; SKINNER MK, 1985, P NATL ACAD SCI USA, V82, P114, DOI 10.1073/pnas.82.1.114; STALLARD BJ, 1990, MOL ENDOCRINOL, V4, P393, DOI 10.1210/mend-4-3-393; Steinberger A, 1975, Methods Enzymol, V39, P283; TOKUDA N, 1992, J UROLOGY, V147, P278, DOI 10.1016/S0022-5347(17)37213-0; TOPPARI J, 1985, J ANDROL, V6, P325; VINDELOV LL, 1990, CYTOMETRY, V11, P753, DOI 10.1002/cyto.990110702	36	140	145	0	3	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	DEC 3	1993	75	5					997	1006		10.1016/0092-8674(93)90543-Y	http://dx.doi.org/10.1016/0092-8674(93)90543-Y			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	MK966	7504588				2022-12-28	WOS:A1993MK96600019
J	JICK, H; JICK, SS; GUREWICH, V; MYERS, MW; VASILAKIS, C				JICK, H; JICK, SS; GUREWICH, V; MYERS, MW; VASILAKIS, C			RISK OF IDIOPATHIC CARDIOVASCULAR DEATH AND NONFATAL VENOUS THROMBOEMBOLISM IN WOMEN USING ORAL-CONTRACEPTIVES WITH DIFFERING PROGESTAGEN COMPONENTS	LANCET			English	Article							VASCULAR-DISEASE	Concern about the risks of cardiovascular illness in women using combined oral contraceptives (OC) containing the progestagens desogestrel and gestodene prompted two studies of data from the UK General Practice Research Database. We compared the risks of certain cardiovascular illnesses in otherwise healthy women exposed to one of three OCs containing <35 mu g oestrogen plus levonorgestrel, desogestrel, or gestodene. In the first study, based on some 470 general practices, there were 15 cases of unexpected idiopathic cardiovascular death among 303 470 women who were current users of one of the study OCs. The estimated incidence rates were 8/184 536 (4.3 per 100 000) woman-years at risk for users of combined OCs containing levonorgestrel, 2/135 567 (1.5 per 100 000) for desogestrel users, and 5/105 201 (4.8 per 100 000) for gestodene users. The relative risk (RR) estimates were 0.4 (95% CI 0.1-2.1) and 1.4 (CI 0.5-4.5) for desogestrel and gestodene, respectively, compared with levonorgestrel. In the second study, derived from some 370 general practices, there were 80 cases of nonfatal venous thromboembolism (VTE) in a cohort of 238 130 otherwise healthy women. The incidence rates of VTE per 100 000 woman-years at risk were 16.1 for levonorgestrel users, 29.3 for desogestrel, and 28.1 for gestodene. The adjusted RR estimates from the cohort analysis were 1.9 (1.1-3.2) and 1.8 (1.0-3.2) for desogestrel and gestodene users, respectively, compared with users of levonorgestrel. In a nested case-control analysis the adjusted matched RR estimates were 2.2 (1.1-4.4) and 2.1 (1.0-4.4) for desogestrel and gestodene users, respectively, compared with users of levonorgestrel. The excess risk for nonfatal VTE associated with the new generation of combined OCs containing low-dose oestrogen and the progestagens desogestrel or gestodene compared with levonorgestrel is estimated to be 16 per 100 000 woman-years.	HARVARD UNIV,DEACONESS HOSP,SCH MED,VASC RES LAB,CAMBRIDGE,MA 02138; HARVARD UNIV,SCH MED,DEPT MED,CAMBRIDGE,MA 02138	Harvard University; Harvard University	JICK, H (corresponding author), BOSTON UNIV,MED CTR,BOSTON COLLABORAT DRUG SURVEILLANCE PROGRAM,11 MUZZEY ST,LEXINGTON,MA 02173, USA.			Jick, Hershel/0000-0003-4270-5992; Jick, Susan/0000-0002-2215-1067				JICK H, 1991, BRIT MED J, V302, P766, DOI 10.1136/bmj.302.6779.766; Jick H., 1992, PHARMACOEPIDEM DR S, V1, P347, DOI DOI 10.1002/PDS.2630010607; JICK SS, 1995, BRIT MED J, V310, P215, DOI 10.1136/bmj.310.6974.215; PORTER JB, 1985, OBSTET GYNECOL, V66, P1; PORTER JB, 1982, OBSTET GYNECOL, V59, P299; RODRIGUEZ LAG, 1994, LANCET, V343, P769, DOI 10.1016/S0140-6736(94)91843-0; SPEROFF L, 1993, OBSTET GYNECOL, V81, P1034; Van Staa TP, 1994, PHARMACOEPIDEM DR S, V3, P15, DOI DOI 10.1002/PDS.2630030106; VANDERVANGE N, 1988, CONTEMP OBSTET GYNEC, P317; 1995, LANCET, V346, P1582	10	623	631	0	19	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	DEC 16	1995	346	8990					1589	1593		10.1016/S0140-6736(95)91928-7	http://dx.doi.org/10.1016/S0140-6736(95)91928-7			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TK481	7500750	hybrid			2022-12-28	WOS:A1995TK48100009
J	WHITTAKER, M; WILSONKUBALEK, EM; SMITH, JE; FAUST, L; MILLIGAN, RA; SWEENEY, HL				WHITTAKER, M; WILSONKUBALEK, EM; SMITH, JE; FAUST, L; MILLIGAN, RA; SWEENEY, HL			A 35-ANGSTROM MOVEMENT OF SMOOTH-MUSCLE MYOSIN ON ADP RELEASE	NATURE			English	Article							CROSS-BRIDGE KINETICS; ACTOMYOSIN ATPASE; LIGHT CHAIN; CONTRACTION; ACTIN; FIBERS; PHOTOLYSIS; LOCATION; COMPLEX; BINDING	MYOSIN II crossbridges interact with F-actin producing power-strokes of around 100 Angstrom (refs 1, 2), during which the products of ATP hydrolysis are released(3,5). This has been postulated to involve an articulation of the myosin head (S1) on actin, or substantial conformational changes in S1 itself(6-8). Small movements of the regulatory light chain have been detected (see, for example, refs 9, 10), but most data suggest that the bulk of S1 does not move on actin during crossbridge cyclings(8,11). Here we present three-dimensional maps of S1-decorated F-actin in the presence and absence of MgADP. The myosin motor domain is similar in both states but there are major orientational differences in the chain-binding domain, This domain acts as a rigid level arm pivoting about the end of the motor domain and swinging similar to 23 degrees, resulting in a similar to 35-Angstrom step. Small, nucleotide-mediated conformational changes in the motor domain(14-16) may thus be converted by the light-chain domain into large movement steps.	Scripps Res Inst, DEPT CELL BIOL, LA JOLLA, CA 92037 USA; UNIV PENN, SCH MED, DEPT PHYSIOL, PHILADELPHIA, PA 19104 USA	Scripps Research Institute; University of Pennsylvania			Sweeney, H Lee/F-1862-2010					BRENNER B, 1987, ANNU REV PHYSIOL, V49, P655; DANTZIG JA, 1985, J GEN PHYSIOL, V86, P305, DOI 10.1085/jgp.86.3.305; DANTZIG JA, 1991, J PHYSIOL-LONDON, V432, P639, DOI 10.1113/jphysiol.1991.sp018405; FINER JT, 1994, NATURE, V368, P113, DOI 10.1038/368113a0; FISHER AJ, 1995, BIOCHEMISTRY-US, V34, P8960, DOI 10.1021/bi00028a004; FISHER AJ, 1995, BIOPHYS J, V68, pS19; GEEVES MA, 1991, BIOCHEM J, V274, P1; GOLDMAN YE, 1987, ANNU REV PHYSIOL, V49, P637, DOI 10.1146/annurev.ph.49.030187.003225; HAMBLY B, 1992, BIOPHYS J, V63, P1306, DOI 10.1016/S0006-3495(92)81717-4; HELPER DJ, 1988, J BIOL CHEM, V263, P15748; HOPP TP, 1988, BIOTECHNOLOGY, V6, P1205; HUXLEY AF, 1971, NATURE, V233, P533, DOI 10.1038/233533a0; HUXLEY HE, 1985, J MUSCLE RES CELL M, V6, P153, DOI 10.1007/BF00713057; HUXLEY HE, 1969, SCIENCE, V164, P1356, DOI 10.1126/science.164.3886.1356; IRVING M, 1995, NATURE, V375, P688, DOI 10.1038/375688a0; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; MILLIGAN RA, 1987, J CELL BIOL, V105, P29, DOI 10.1083/jcb.105.1.29; MILLIGAN RA, 1990, NATURE, V348, P217, DOI 10.1038/348217a0; MILLIGAN RA, IN PRESS P NATN ACAD; NISHIYE E, 1993, J PHYSIOL-LONDON, V460, P247, DOI 10.1113/jphysiol.1993.sp019470; RAYMENT I, 1993, SCIENCE, V261, P58, DOI 10.1126/science.8316858; RAYMENT I, 1993, SCIENCE, V261, P50, DOI 10.1126/science.8316857; RAYMENT I, 1995, P NATL ACAD SCI USA, V92, P3864, DOI 10.1073/pnas.92.9.3864; REEDY MK, 1965, NATURE, V207, P1276, DOI 10.1038/2071276a0; SMITH CA, 1995, BIOCHEMISTRY-US, V34, P8973, DOI 10.1021/bi00028a005; SPUDICH JA, 1971, J BIOL CHEM, V246, P4866; SWEENEY HL, 1994, J BIOL CHEM, V269, P1603; SWEENEY HL, IN PRESS BIOPHYS J; THOMAS DD, 1987, ANNU REV PHYSIOL, V49, P691, DOI 10.1146/annurev.ph.49.030187.003355; WHITTAKER M, 1995, ULTRAMICROSCOPY, V58, P245, DOI 10.1016/0304-3991(95)00057-8; [No title captured]	32	341	342	0	16	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	DEC 14	1995	378	6558					748	751		10.1038/378748a0	http://dx.doi.org/10.1038/378748a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TK379	7501026				2022-12-28	WOS:A1995TK37900061
J	OBRIEN, LA; GRISSO, JA; MAISLIN, G; LAPANN, K; KROTKI, KP; GRECO, PJ; SIEGERT, EA; EVANS, LK				OBRIEN, LA; GRISSO, JA; MAISLIN, G; LAPANN, K; KROTKI, KP; GRECO, PJ; SIEGERT, EA; EVANS, LK			NURSING-HOME RESIDENTS PREFERENCES FOR LIFE-SUSTAINING TREATMENTS	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							CARDIOPULMONARY-RESUSCITATION; DECISIONS; CARE	Objectives.-To determine life-sustaining treatment preferences among nursing home residents, whether information regarding cardiopulmonary resuscitation (CPR) affected these preferences, and with whom treatment preferences had been discussed, and to identify factors associated with CPR preferences. Design.-In-person survey. Setting.-Forty-nine randomly selected nursing homes. Subjects.-Four hundred twenty-one randomly selected nursing home residents capable of making decisions. Main Outcome Measures.-Preferences regarding CPR, hospitalization, and enteral tube feedings, and individual factors associated with CPR preferences. Results.-Of 1458 randomly selected nursing home residents assessed for the ability to participate in the study, 552 residents (38%) were eligible to participate and 421 agreed to be interviewed. Sixty percent of participants able to participate in the decision reported that they would elect CPR, 89% would choose hospitalization if seriously ill, and 33% would elect enteral tube feedings a no longer able to eat because of permanent brain damage. Individual factors associated with preferences for CPR included the following: African-American ethnicity, high self-reported physical mobility, belief that most important medical care decisions should be made by the doctor, moderate-to-severe impairment in daily decision-making skills, and not having a spouse. Fourteen percent changed their preference from preferring CPR to not preferring CPR after receiving additional information about CPR procedures. Twelve percent reported having discussed preferences with health care providers, and 31% discussed preferences with family members. Conclusions-More than half of nursing home residents capable of making decisions preferred the use of CPR. Few had discussed their preferences with health care providers. Individual preferences should be assessed when considering the use of life-sustaining treatments.	UNIV PENN,SCH NURSING,PHILADELPHIA,PA 19104; TEMPLE UNIV,INST SURVEY RES,PHILADELPHIA,PA 19122; CASE WESTERN RESERVE UNIV,SCH MED,CLEVELAND,OH; UNIV MED & DENT NEW JERSEY,ROBERT WOOD JOHNSON MED SCH,CAMDEN,NJ 08103	University of Pennsylvania; Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University; Case Western Reserve University; Rutgers State University New Brunswick; Rutgers State University Medical Center	OBRIEN, LA (corresponding author), UNIV PENN,SCH MED,CTR CLIN EPIDEMIOL & BIOSTAT,DIV GEN INTERNAL MED,PHILADELPHIA,PA 19104, USA.		Maislin, Greg/S-5322-2019		AHRQ HHS [1-R01-HS-06815] Funding Source: Medline	AHRQ HHS(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality)		CHARLSON ME, 1987, J CHRON DIS, V40, P373, DOI 10.1016/0021-9681(87)90171-8; DANIS M, 1991, NEW ENGL J MED, V324, P882, DOI 10.1056/NEJM199103283241304; FILLENBAUM GG, 1980, J AM GERIATR SOC, V28, P381, DOI 10.1111/j.1532-5415.1980.tb01103.x; GERETY MB, 1993, J AM GERIATR SOC, V41, P953, DOI 10.1111/j.1532-5415.1993.tb06761.x; GRISSO JA, 1994, NEW ENGL J MED, V330, P1555, DOI 10.1056/NEJM199406023302202; Hosmer D., 2000, APPL LOGISTIC REGRES, V2; HUNT SM, 1985, J ROY COLL GEN PRACT, V35, P185; JONSEN AR, 1986, CLIN ETHICS PRACTICA, P52; KISH L, 1965, SURVEY SAMPLING, P230; KOENIG HG, 1992, INT J PSYCHIAT MED, V22, P183, DOI 10.2190/M1F5-F40P-C4KD-YPA3; LO B, 1986, ARCH INTERN MED, V146, P1613, DOI 10.1001/archinte.146.8.1613; MURPHY DJ, 1994, NEW ENGL J MED, V330, P545, DOI 10.1056/NEJM199402243300807; OUSLANDER JG, 1989, ARCH INTERN MED, V149, P1367, DOI 10.1001/archinte.149.6.1367; PFEIFFER E, 1975, J AM GERIATR SOC, V25, P433; SACHS GA, 1992, J AM GERIATR SOC, V42, P269; SCHONWETTER RS, 1991, J AM GERIATR SOC, V39, P372, DOI 10.1111/j.1532-5415.1991.tb02902.x; SHADLEN F, 1990, J AM GERIATR SOC, V38, pA55; SHMERLING RH, 1988, J GEN INTERN MED, V3, P317, DOI 10.1007/BF02595786; SINGER PA, 1991, HASTINGS CTR REP S2, V21, P1; TENO J, 1991, CLIN RES, V39, pA632; UHLMANN RF, 1988, J GERONTOL, V43, pM115, DOI 10.1093/geronj/43.5.M115; 1993, SUDAAN VERSION 6 33; 1990, SAS P200 I INC TECHN, P194	23	134	135	0	3	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	DEC 13	1995	274	22					1775	1779		10.1001/jama.274.22.1775	http://dx.doi.org/10.1001/jama.274.22.1775			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	TJ225	7500508				2022-12-28	WOS:A1995TJ22500027
J	SCHOUTEN, EJ; BORGDORFF, MW				SCHOUTEN, EJ; BORGDORFF, MW			INCREASED MORTALITY AMONG DUTCH DEVELOPMENT WORKERS	BRITISH MEDICAL JOURNAL			English	Article									ROYAL TROP INST,1092 AD AMSTERDAM,NETHERLANDS		SCHOUTEN, EJ (corresponding author), HEALTHNET INT,1017 MB AMSTERDAM,NETHERLANDS.							FRAME JD, 1992, AM J TROP MED HYG, V46, P686, DOI 10.4269/ajtmh.1992.46.686; HARGARTEN SW, 1985, JAMA-J AM MED ASSOC, V10, P1326; Houweling H, 1991, Int J STD AIDS, V2, P252; KUNST AE, 1994, AM J PUBLIC HEALTH, V84, P932, DOI 10.2105/AJPH.84.6.932; 1975, INT CLASSIFICATION D	5	7	7	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	NOV 18	1995	311	7016					1343	1344		10.1136/bmj.311.7016.1343	http://dx.doi.org/10.1136/bmj.311.7016.1343			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	TF901	7496285	Green Published			2022-12-28	WOS:A1995TF90100023
J	RYDER, B; CAMPBELL, H				RYDER, B; CAMPBELL, H			NATURAL FAMILY-PLANNING IN THE 1990S	LANCET			English	Editorial Material							OVULATION; SYMPTOMS; EFFICACY		PWLL COCH UCHAF,CARDIFF CF3 9XE,S GLAM,WALES		RYDER, B (corresponding author), CITY HOSP NHS TRUST,DEPT ENDOCRINOL,DUDLEY RD,BIRMINGHAM B18 7QH,ENGLAND.							[Anonymous], 1981, FERTIL STERIL, V36, P591; [Anonymous], 1987, FERTIL STERIL, V47, P765; BARBER MD, 1993, BRIT MED J, V307, P1003, DOI 10.1136/bmj.307.6910.1003-b; BILLINGS EL, 1972, LANCET, V1, P282, DOI 10.1016/s0140-6736(72)90291-7; BILLINGS JJ, 1993, BRIT MED J, V307, P1357, DOI 10.1136/bmj.307.6915.1357-b; CLUBB EM, 1990, NATURAL FAMILY PLANN, P130; CRANE SF, 1993, BRIT MED J, V307, P1004, DOI 10.1136/bmj.307.6910.1004-c; DEPARES J, 1986, BRIT MED J, V292, P1562, DOI 10.1136/bmj.292.6535.1562; DIXON P, 1995, RISING PRICE LOVE; DORAIRAJ K, 1991, AM J OBSTET GYNECOL, V165, P2066, DOI 10.1016/S0002-9378(11)90584-5; FRANKHERRMANN P, 1991, AM J OBSTET GYNECOL, V165, P2052, DOI 10.1016/S0002-9378(11)90580-8; Ghosh AK, 1982, J OBSTET GYNAECOL, V32, P443; GRAY RH, 1993, J BIOSOC SCI, V25, P249, DOI 10.1017/S0021932000020538; JARVIS G, 1993, BRIT MED J, V307, P1358, DOI 10.1136/bmj.307.6915.1358-b; JEWELL A, 1993, BRIT MED J, V307, P1004; LAING JE, 1984, STUD FAMILY PLANN, V15, P49, DOI 10.2307/1966046; LIEZAOLA MA, 1994, J GYNCOL OBSTET BIOL, V23, P359; MILLS A, 1984, CLIN OBSTET GYNAECOL, V11, P641; NORMAN C, 1993, BRIT MED J, V307, P1359, DOI 10.1136/bmj.307.6915.1359-a; ODEBLAD E, 1989, MUCUS PATTERNS FERTI, P85; Odeblad E., 1994, B NATURAL FAMILY PLA, V21, P3; POOLE J, 1994, LANCET, V344, P679, DOI 10.1016/S0140-6736(94)92109-1; Prospective European multi-center study of natural family planning (1989-1992): interim results, 1993, ADV CONTRACEPT, V9, P269; RYDER REJ, 1993, BRIT MED J, V307, P723, DOI 10.1136/bmj.307.6906.723; RYDER REJ, 1993, BRIT MED J, V307, P1360, DOI 10.1136/bmj.307.6915.1360-c; THAPA S, 1990, STUD FAMILY PLANN, V21, P327, DOI 10.2307/1966921; VERKUYL DAA, 1993, LANCET, V342, P473, DOI 10.1016/0140-6736(93)91597-F; VESSEY M, 1982, LANCET, V1, P841; WILSON MBH, 1993, BRIT MED J, V307, P1357, DOI 10.1136/bmj.307.6915.1357-c; ZHANG DW, 1993, REPROD CONTRACEPTION, V13, P194; 1981, FERTIL STERIL, V36, P152; 1983, FERTIL STERIL, V40, P773; 1984, FERTIL STERIL, V41, P593	33	11	11	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	JUL 22	1995	346	8969					233	234						2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	RK419	7503859				2022-12-28	WOS:A1995RK41900016
J	EVANS, JA; MARRIAGE, SC; WALTERS, MDS; LEVIN, M				EVANS, JA; MARRIAGE, SC; WALTERS, MDS; LEVIN, M			UNSUSPECTED HIV-INFECTION PRESENTING IN FIRST YEAR OF LIFE	BRITISH MEDICAL JOURNAL			English	Article											EVANS, JA (corresponding author), ST MARYS HOSP,SCH MED,DEPT PAEDIAT,LONDON W2 1PG,ENGLAND.			Levin, Michael/0000-0003-2767-6919				CONNOR EM, 1994, NEW ENGL J MED, V331, P1173, DOI 10.1056/NEJM199411033311801; DUNN DT, 1992, LANCET, V340, P585, DOI 10.1016/0140-6736(92)92115-V; Holland F J, 1994, J Med Screen, V1, P176; RIGAUD M, 1994, J PEDIATR-US, V125, P476, DOI 10.1016/S0022-3476(05)83301-3; 1994, LANCET, V343, P1464	5	6	6	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAY 13	1995	310	6989					1235	1236		10.1136/bmj.310.6989.1235	http://dx.doi.org/10.1136/bmj.310.6989.1235			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QY877	7503850	Green Published			2022-12-28	WOS:A1995QY87700019
J	JAIN, A; JAIN, S; GANT, V				JAIN, A; JAIN, S; GANT, V			SHOULD PATIENTS POSITIVE FOR HIV-INFECTION RECEIVE PNEUMOCOCCAL VACCINE	BRITISH MEDICAL JOURNAL			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; AIDS-RELATED COMPLEX; IMMUNE-DEFICIENCY SYNDROME; STREPTOCOCCUS-PNEUMONIAE; CAPSULAR POLYSACCHARIDES; HIGH-RISK; ANTIBODY; BACTEREMIA; EFFICACY; SUBCLASS	Pneumococcal vaccination effectively reduces the incidence of invasive pneumococcal disease in normal subjects. Such invasive pneumococcal disease is 100 times more common in patients with HIV infection than in healthy people, so it seems logical to target this group of patients for vaccination. Few clinics routinely vaccinate patients positive for HIV, despite Department of Health guidelines. This is because of uncertainty about the vaccine's efficacy in HIV disease. There are many reasons to suspect that the vaccine will fail to protect these patients, including the fact that antibodies alone may not be sufficient protection against all serogroups of Pneumococcus and the vaccine works in healthy people but not immunocompromised subjects. Vaccination of HIV positive patients may not be indicated, at least for the time being. The cost of vaccinating such patients in the absence of data showing efficacy may well be less than the cost of a necessarily large and lengthy trial. But the truth must be sought to end current indecision.	UNITED MED & DENT SCH GUYS & ST THOMASS HOSP,DIV INFECT,LONDON SE1 7EH,ENGLAND	University of London; King's College London								AMMANN AJ, 1984, JAMA-J AM MED ASSOC, V251, P1447, DOI 10.1001/jama.251.11.1447; BENDER BS, 1985, J INFECT DIS, V152, P409, DOI 10.1093/infdis/152.2.409; BREMARDOURY C, 1986, PROGR IMMUNODEFICIEN, V2, P235; CHIRURGI VA, 1990, SOUTHERN MED J, V83, P895, DOI 10.1097/00007611-199008000-00012; DOUGLAS RM, 1986, AM J DIS CHILD, V140, P1183, DOI 10.1001/archpedi.1986.02140250109044; ELLIS M, 1988, J INFECT DIS, V158, P1268, DOI 10.1093/infdis/158.6.1268; GILLESPIE SH, 1989, J MED MICROBIOL, V28, P237, DOI 10.1099/00222615-28-4-237; GLASER JB, 1991, J INFECT DIS, V164, P761, DOI 10.1093/infdis/164.4.761; GRAY BM, 1986, PEDIATR INFECT DIS J, V5, P201, DOI 10.1097/00006454-198603000-00009; HAMILOS DL, 1992, ANN ALLERGY, V68, P472; HANSMAN D, EPIDEMIOL INFECT, V101, P411; JANOFF EN, 1988, J INFECT DIS, V158, P983, DOI 10.1093/infdis/158.5.983; JANOFF EN, 1992, ANN INTERN MED, V117, P314, DOI 10.7326/0003-4819-117-4-314; KLEIN RS, 1989, J INFECT DIS, V160, P826, DOI 10.1093/infdis/160.5.826; KROON FP, 1994, AIDS, V8, P469, DOI 10.1097/00002030-199404000-00008; LACEY RW, 1973, BRIT MED J, V4, P165, DOI 10.1136/bmj.4.5885.165-b; MUSHER DM, 1986, J INFECT DIS, V154, P245, DOI 10.1093/infdis/154.2.245; PARKIN JM, 1989, AIDS, V3, P37, DOI 10.1097/00002030-198903010-00008; PINCHING AJ, 1991, CLIN EXP IMMUNOL, V84, P181; POS O, 1992, CLIN EXP IMMUNOL, V88, P23; REDD SC, 1990, J INFECT DIS, V162, P1012, DOI 10.1093/infdis/162.5.1012; RODRIGUEZBARRAD.MC, 1992, J INFECT DIS, V165, P553; ROSE DN, 1993, AM J MED, V94, P160, DOI 10.1016/0002-9343(93)90178-R; ROSE DN, 1993, AM J MED, V94, P161; SALISBURY D, 1992, IMMUNISATION INFECT, P100; SAUNDERS P, 1994, BRIT MED J, V308, P2, DOI 10.1136/bmj.308.6920.2; SCHAPIRO ED, 1991, NEW ENGL J MED, V325, P1453; SCHATZ DA, 1987, CLIN EXP IMMUNOL, V70, P449; SHAPIRO ED, 1984, ANN INTERN MED, V101, P325, DOI 10.7326/0003-4819-101-3-325; SIMBERKOFF MS, 1984, AM REV RESPIR DIS, V130, P1174; SIMBERKOFF MS, 1986, NEW ENGL J MED, V315, P1318, DOI 10.1056/NEJM198611203152104; SIMS RV, 1988, ANN INTERN MED, V108, P653, DOI 10.7326/0003-4819-108-5-653; UNSWORTH DJ, 1993, GENITOURIN MED, V69, P373; WEBSTER ADB, 1984, BRIT MED J, V288, P1864, DOI 10.1136/bmj.288.6434.1864; 1989, MMWR-MORBID MORTAL W, V38, P64; 1993, TIDSSKR LAAGEFOREN, V113, P2010	36	21	21	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	APR 22	1995	310	6986					1060	1062		10.1136/bmj.310.6986.1060	http://dx.doi.org/10.1136/bmj.310.6986.1060			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QV313	7503844	Green Published			2022-12-28	WOS:A1995QV31300026
J	LOEWENSTEIN, JI				LOEWENSTEIN, JI			VISUAL HALLUCINATIONS IN PATIENTS WITH CHOROIDAL NEOVASCULARIZATION	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Letter							SYMPTOMS				LOEWENSTEIN, JI (corresponding author), HARVARD UNIV,SCH MED,BOSTON,MA, USA.							BROWN GC, 1992, ARCH OPHTHALMOL-CHIC, V110, P1251, DOI 10.1001/archopht.1992.01080210069027; FINE AM, 1986, ARCH OPHTHALMOL-CHIC, V104, P513; LESSELL SL, 1992, DUANES CLIN OPHTHALM, V2, P17	3	5	5	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 20	1994	272	3					243	243		10.1001/jama.272.3.243	http://dx.doi.org/10.1001/jama.272.3.243			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	NW185	7517460				2022-12-28	WOS:A1994NW18500033
J	COX, AL; SKIPPER, J; CHEN, Y; HENDERSON, RA; DARROW, TL; SHABANOWITZ, J; ENGELHARD, VH; HUNT, DF; SLINGLUFF, CL				COX, AL; SKIPPER, J; CHEN, Y; HENDERSON, RA; DARROW, TL; SHABANOWITZ, J; ENGELHARD, VH; HUNT, DF; SLINGLUFF, CL			IDENTIFICATION OF A PEPTIDE RECOGNIZED BY 5 MELANOMA-SPECIFIC HUMAN CYTOTOXIC T-CELL LINES	SCIENCE			English	Article							TUMOR-INFILTRATING LYMPHOCYTES; AUTOLOGOUS MELANOMA; HLA-A; ANTIGENS; EXPRESSION; RESPONSES; MOLECULE; CLONES; ALLELE; INTERLEUKIN-2	Of several thousand peptides presented by the major histocompatibility molecule HLA-A2.1, at least nine are recognized by melanoma-specific cytotoxic T lymphocytes (CTLs). Tandem mass spectrometry was used to identify and to sequence one of these peptide epitopes. Melanoma-specific CTLs had an exceptionally high affinity for this nine-residue peptide, which reconstituted an epitope for CTL lines from each of five different melanoma patients tested. Recognition by multiple CTL lines suggests that this may be a promising candidate for use in peptide-based melanoma vaccines.	UNIV VIRGINIA,HLTH SCI CTR,DEPT SURG,CHARLOTTESVILLE,VA 22908; UNIV VIRGINIA,DEPT CHEM,CHARLOTTESVILLE,VA 22908; UNIV VIRGINIA,DEPT MICROBIOL,CHARLOTTESVILLE,VA 22908; UNIV VIRGINIA,BEIRNE CARTER CTR IMMUNOL RES,CHARLOTTESVILLE,VA 22908; DUKE UNIV,DEPT SURG,DURHAM,NC 27710; UNIV VIRGINIA,DEPT PATHOL,CHARLOTTESVILLE,VA 22908	University of Virginia; University of Virginia; University of Virginia; University of Virginia; Duke University; University of Virginia			Hunt, Donald F/I-6936-2012	Hunt, Donald F/0000-0003-2815-6368; Cox, Andrea/0000-0002-9331-2462; Engelhard, Victor/0000-0002-1741-0925	NCI NIH HHS [CA57653] Funding Source: Medline; NIAID NIH HHS [AI33993] Funding Source: Medline; NIGMS NIH HHS [GM37537] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA057653, R29CA057653] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R37AI033993, R01AI033993] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM037537] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ANICHINI A, 1993, J EXP MED, V177, P989, DOI 10.1084/jem.177.4.989; BEDNAREK MA, 1991, J IMMUNOL, V147, P4047; BERTOLETTI A, 1993, J VIROL, V67, P2376, DOI 10.1128/JVI.67.4.2376-2380.1993; BRICHARD V, 1993, J EXP MED, V178, P489, DOI 10.1084/jem.178.2.489; CHEN QY, 1992, INT J CANCER, V51, P218, DOI 10.1002/ijc.2910510209; CHEN Y, IN PRESS J IMMUNOL; COULIE PG, 1992, INT J CANCER, V50, P289, DOI 10.1002/ijc.2910500220; CROWLEY NJ, 1991, J IMMUNOL, V146, P1692; DARROW TL, 1989, J IMMUNOL, V142, P3329; ENGELHARD VH, UNPUB; Everson TC, 1966, SPONTANEOUS REGRESSI; FALK K, 1991, J EXP MED, V174, P425, DOI 10.1084/jem.174.2.425; FALK K, 1991, NATURE, V351, P290, DOI 10.1038/351290a0; HAYASHI Y, 1992, CANCER IMMUNOL IMMUN, V34, P419, DOI 10.1007/BF01741754; HENDERSON RA, 1993, P NATL ACAD SCI USA, V90, P10275, DOI 10.1073/pnas.90.21.10275; HENDERSON RA, 1992, SCIENCE, V255, P1264, DOI 10.1126/science.1546329; HERIN M, 1987, INT J CANCER, V39, P390, DOI 10.1002/ijc.2910390320; HOM SS, 1991, J IMMUNOTHER, V10, P153; HUCZKO EL, 1993, J IMMUNOL, V151, P2572; HUNT DF, 1992, SCIENCE, V255, P1261, DOI 10.1126/science.1546328; IOANNIDES CG, 1991, J IMMUNOL, V146, P1700; IOANNIDES CG, 1993, SCAND J IMMUNOL, V37, P413, DOI 10.1111/j.1365-3083.1993.tb03312.x; KAWAKAMI Y, 1992, J IMMUNOL, V148, P638; KRADIN RL, 1989, LANCET, V1, P577; KWON BS, 1991, P NATL ACAD SCI USA, V88, P9228, DOI 10.1073/pnas.88.20.9228; KWON BS, 1987, MOL BIOL MED, V4, P339; MITCHELL MS, 1993, ANN NY ACAD SCI, V690, P153; MUUL LM, 1987, J IMMUNOL, V138, P989; PEOPLES GE, 1993, SURGERY, V114, P227; ROSENBERG SA, 1988, NEW ENGL J MED, V319, P1676, DOI 10.1056/NEJM198812223192527; RUPPERT J, 1993, CELL, V74, P929, DOI 10.1016/0092-8674(93)90472-3; SALTER RD, 1985, IMMUNOGENETICS, V21, P235, DOI 10.1007/BF00375376; SLINGLUFF CL, 1988, J NATL CANCER I, V80, P1016, DOI 10.1093/jnci/80.13.1016; SLINGLUFF CL, 1993, J IMMUNOL, V150, P2955; SLINGLUFF CL, IN PRESS CANCER RES; STORKUS WJ, 1993, J IMMUNOL, V151, P3719; STOVIN SF, 1986, J IMMUNOL, V137, P3042; TOPALIAN SL, 1992, J IMMUNOTHER, V12, P203, DOI 10.1097/00002371-199210000-00013; TOWNSEND A, 1989, ANNU REV IMMUNOL, V7, P601, DOI 10.1146/annurev.iy.07.040189.003125; UDAKA K, 1992, CELL, V69, P989, DOI 10.1016/0092-8674(92)90617-L; UTZ U, 1992, J IMMUNOL, V149, P214; VANBLEEK GM, 1990, NATURE, V348, P213; VOSE BM, 1982, NATURE, V296, P359, DOI 10.1038/296359a0; WOLFEL T, 1993, INT J CANCER, V55, P237, DOI 10.1002/ijc.2910550212; WOLFEL T, IN PRESS EUR J IMMUN; YASUMURA S, 1993, CANCER RES, V53, P1461	46	792	853	1	20	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	APR 29	1994	264	5159					716	719		10.1126/science.7513441	http://dx.doi.org/10.1126/science.7513441			4	Multidisciplinary Sciences	Index Chemicus (IC); Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	NH713	7513441				2022-12-28	WOS:A1994NH71300036
J	SAWYERS, CL; MCLAUGHLIN, J; GOGA, A; HAVLIK, M; WITTE, O				SAWYERS, CL; MCLAUGHLIN, J; GOGA, A; HAVLIK, M; WITTE, O			THE NUCLEAR TYROSINE KINASE C-ABL NEGATIVELY REGULATES CELL-GROWTH	CELL			English	Article							PHILADELPHIA-CHROMOSOME; PROTO-ONCOGENE; CANCER-CELLS; GENE-PRODUCT; B-CELL; BCR; TRANSFORMATION; SUPPRESSION; MICE; MUTATIONS	c-Abl is a tyrosine kinase localized primarily in the nucleus. Previous assays for abl function rely on cellular transformation by abl mutants, which are cytoplasmic. Using a conditional overexpression strategy, we have developed a functional assay for c-abl. Overexpression of c-abl inhibits growth by causing cell cycle arrest. Growth suppression requires tyrosine kinase activity, nuclear localization, and an intact SH2 domain. Overexpression of dominant negative c-abl disrupts cell cycle control and enhances transformation by tyrosine kinases, G proteins, and transcription factor oncogenes. These findings suggest that c-abl acts as a negative regulator of cell growth. This growth suppressive activity is functionally similar to that of tumor suppressor genes such as p53 and Rb.	UNIV CALIF LOS ANGELES, DEPT MICROBIOL & MOLEC GENET, LOS ANGELES, CA 90024 USA; UNIV CALIF LOS ANGELES, INST MOLEC BIOL, LOS ANGELES, CA 90024 USA; UNIV CALIF LOS ANGELES, HOWARD HUGHES MED INST, LOS ANGELES, CA 90024 USA	University of California System; University of California Los Angeles; University of California System; University of California Los Angeles; Howard Hughes Medical Institute; University of California System; University of California Los Angeles	SAWYERS, CL (corresponding author), UNIV CALIF LOS ANGELES, DEPT MED, DIV HEMATOL ONCOL, LOS ANGELES, CA 90024 USA.		Sawyers, Charles/G-5327-2016					BALKWILL F, 1978, NATURE, V274, P798, DOI 10.1038/274798a0; BEN-NERIAH Y, 1986, CELL, V44, P577, DOI 10.1016/0092-8674(86)90267-9; BONGARZONE I, 1993, MOL CELL BIOL, V13, P358, DOI 10.1128/MCB.13.1.358; BRUNET LJ, 1988, MOL CELL BIOL, V8, P4799, DOI 10.1128/MCB.8.11.4799; CICCHETTI P, 1992, SCIENCE, V257, P803, DOI 10.1126/science.1379745; DELSAL G, 1992, CELL, V70, P595, DOI 10.1016/0092-8674(92)90429-G; DIKSTEIN R, 1992, CELL, V69, P751, DOI 10.1016/0092-8674(92)90287-M; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; DUBRIDGE RB, 1987, MOL CELL BIOL, V7, P379, DOI 10.1128/MCB.7.1.379; FINLAY CA, 1989, CELL, V57, P1083, DOI 10.1016/0092-8674(89)90045-7; GERTLER FB, 1989, CELL, V58, P103, DOI 10.1016/0092-8674(89)90407-8; GERTLER FB, 1993, GENE DEV, V7, P441, DOI 10.1101/gad.7.3.441; GIBBS CS, 1991, J BIOL CHEM, V266, P8923; GOGA A, 1993, MOL CELL BIOL, V13, P4967, DOI 10.1128/MCB.13.8.4967; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; HARTWELL L, 1992, CELL, V71, P543, DOI 10.1016/0092-8674(92)90586-2; HENKEMEYER M, 1990, CELL, V63, P949, DOI 10.1016/0092-8674(90)90498-4; HENKEMEYER MJ, 1987, CELL, V51, P821, DOI 10.1016/0092-8674(87)90105-X; HERSKOWITZ I, 1987, NATURE, V329, P219, DOI 10.1038/329219a0; HUANG HJS, 1988, SCIENCE, V242, P1563, DOI 10.1126/science.3201247; JACKSON P, 1989, EMBO J, V8, P449, DOI 10.1002/j.1460-2075.1989.tb03397.x; KIPREOS ET, 1990, SCIENCE, V248, P217, DOI 10.1126/science.2183353; KIPREOS ET, 1992, SCIENCE, V256, P382, DOI 10.1126/science.256.5055.382; KRUH GD, 1990, P NATL ACAD SCI USA, V87, P5802, DOI 10.1073/pnas.87.15.5802; KURZROCK R, 1988, NEW ENGL J MED, V319, P990; LAIHO M, 1990, CELL, V62, P175, DOI 10.1016/0092-8674(90)90251-9; LEVIN SD, 1993, EMBO J, V12, P1671, DOI 10.1002/j.1460-2075.1993.tb05812.x; LEVINE AJ, 1993, ANNU REV BIOCHEM, V62, P623, DOI 10.1146/annurev.bi.62.070193.003203; LIN D, 1992, P NATL ACAD SCI USA, V89, P9210, DOI 10.1073/pnas.89.19.9210; LUGO TG, 1990, SCIENCE, V247, P1079, DOI 10.1126/science.2408149; MAYER BJ, 1992, MOL CELL BIOL, V12, P609, DOI 10.1128/MCB.12.2.609; MAYER BJ, 1991, P NATL ACAD SCI USA, V88, P627, DOI 10.1073/pnas.88.2.627; MCGOWAN CH, 1993, EMBO J, V12, P75, DOI 10.1002/j.1460-2075.1993.tb05633.x; MCLAUGHLIN J, 1987, P NATL ACAD SCI USA, V84, P6558, DOI 10.1073/pnas.84.18.6558; MOLINA TJ, 1992, NATURE, V357, P161, DOI 10.1038/357161a0; MULLER AJ, 1991, MOL CELL BIOL, V11, P1785, DOI 10.1128/MCB.11.4.1785; MULLIGAN LM, 1993, NATURE, V363, P458, DOI 10.1038/363458a0; OVERDUIN M, 1992, CELL, V70, P697, DOI 10.1016/0092-8674(92)90437-H; PENDERGAST AM, 1991, P NATL ACAD SCI USA, V88, P5927, DOI 10.1073/pnas.88.13.5927; PENDERGAST AM, 1993, MOL CELL BIOL, V13, P1728, DOI 10.1128/MCB.13.3.1728; PHILIPSON L, 1991, J CELL BIOCHEM, V46, P95, DOI 10.1002/jcb.240460202; REITH AD, 1993, ONCOGENE, V8, P45; RENSHAW MW, 1992, EMBO J, V11, P3941, DOI 10.1002/j.1460-2075.1992.tb05488.x; ROSENBERG N, 1988, ADV VIRUS RES, V35, P39; SAWYERS CL, 1992, CELL, V70, P901, DOI 10.1016/0092-8674(92)90241-4; SAWYERS CL, 1992, CANCER SURV, V15, P37; SCHWARTZBERG PL, 1991, CELL, V65, P1165, DOI 10.1016/0092-8674(91)90012-N; SHTLVELMAN E, 1986, CELL, V47, P277; SORRENTINO V, 1990, NATURE, V345, P813, DOI 10.1038/345813a0; TYBULEWICZ VLJ, 1991, CELL, V65, P1153, DOI 10.1016/0092-8674(91)90011-M; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; VANETTEN RA, 1989, CELL, V58, P669, DOI 10.1016/0092-8674(89)90102-5; WELCH PJ, 1993, CELL, V75, P779, DOI 10.1016/0092-8674(93)90497-E; YANG Z, 1987, MOL CELL BIOL, V7, P3923, DOI 10.1128/MCB.7.11.3923; YU G, 1989, J BIOL CHEM, V264, P10276; ZIEGLER SF, 1981, CELL, V27, P477, DOI 10.1016/0092-8674(81)90389-5	56	247	255	0	9	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	APR 8	1994	77	1					121	131		10.1016/0092-8674(94)90240-2	http://dx.doi.org/10.1016/0092-8674(94)90240-2			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	NF211	7512450				2022-12-28	WOS:A1994NF21100015
J	BRANCH, DW; MITCHELL, MD; MILLER, E; PALINSKI, W; WITZTUM, JL				BRANCH, DW; MITCHELL, MD; MILLER, E; PALINSKI, W; WITZTUM, JL			PREECLAMPSIA AND SERUM ANTIBODIES TO OXIDIZED LOW-DENSITY-LIPOPROTEIN	LANCET			English	Note							PREGNANCY; PREECLAMPSIA	Oxidised low-density lipoprotein (Ox-LDL) has been associated with arterial foam-cell formation, and autoantibodies to Ox-LDL are present in human serum. Lipid peroxidation is enhanced in pre-eclampsia. We assessed whether the titre of IgG autoantibody to an epitope of Ox-LDL, malondialdehyde-conjugated low-density lipoprotein (MDA-LDL), was increased in the sera of pre-eclamptic patients. 16 such patients had significantly higher mean titres of autoantibodies to MDA-LDL than healthy pregnant women (p = 0.028). In a multiple regression model, pre-eclamptic patients still had a significantly higher mean titre (p = 0.048). Enhanced lipid peroxidation may be involved in the foam-cell formation of decidua and in the pathogenesis of pre-eclampsia.	UNIV CALIF SAN DIEGO, DEPT MED, DIV ENDOCRINOL & METAB, SAN DIEGO, CA 92103 USA	University of California System; University of California San Diego	BRANCH, DW (corresponding author), UNIV UTAH, HLTH SCI CTR, DEPT OBSTET & GYNECOL, ROOM 2B200 MED CTR, 50 N MED DR, SALT LAKE CITY, UT 84132 USA.		Palinski, Wulf/AAW-8032-2021; Mitchell, Murray/A-8639-2010	Mitchell, Murray/0000-0002-6167-7176; Palinski, Wulf/0000-0002-5113-0169	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P50HL014197] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL14197] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		HUBEL CA, 1989, AM J OBSTET GYNECOL, V161, P1025, DOI 10.1016/0002-9378(89)90778-3; ISHIHARA M, 1978, CLIN CHIM ACTA, V84, P1; MASEKI M, 1981, CLIN CHIM ACTA, V115, P155; POTTER JM, 1979, AM J OBSTET GYNECOL, V133, P165, DOI 10.1016/0002-9378(79)90469-1; SALONEN JT, 1992, LANCET, V339, P883, DOI 10.1016/0140-6736(92)90926-T; SHEPPARD BL, 1981, BRIT J OBSTET GYNAEC, V88, P695, DOI 10.1111/j.1471-0528.1981.tb01268.x; WANG YP, 1991, AM J OBSTET GYNECOL, V165, P1695, DOI 10.1016/0002-9378(91)90017-L; WICKINS D, 1988, ANN CLIN BIOCHEM, V18, P158; WITZTUM JL, 1993, BRIT HEART J, V69, pS12	9	133	136	0	2	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	MAR 12	1994	343	8898					645	646		10.1016/S0140-6736(94)92639-5	http://dx.doi.org/10.1016/S0140-6736(94)92639-5			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NA093	7509433	Green Submitted			2022-12-28	WOS:A1994NA09300012
J	TSARFATY, I; RONG, S; RESAU, JH; SHEN, RL; DASILVA, PP; VANDEWOUDE, GF				TSARFATY, I; RONG, S; RESAU, JH; SHEN, RL; DASILVA, PP; VANDEWOUDE, GF			THE MET PROTOONCOGENE MESENCHYMAL TO EPITHELIAL-CELL CONVERSION	SCIENCE			English	Article							HEPATOCYTE GROWTH-FACTOR; SCATTER FACTOR; LIVER-REGENERATION; FACTOR HGF; C-MET; PROTOONCOGENE; VIMENTIN; CYTOKERATINS; EXPRESSION; RECEPTOR	Coexpression of the human Met receptor and its ligand, hepatocyte growth factor/scatter factor (HGF/SF), in NIH 3T3 fibroblasts causes the cells to become tumorigenic in nude mice. The resultant tumors display lumen-like morphology, contain carcinoma-like focal areas with intercellular junctions resembling desmosomes, and coexpress epithelial (cytokeratin) and mesenchymal (vimentin) cytoskeletal markers. The tumor cells also display enhanced expression of desmosomal and tight-junction proteins. The apparent mesenchymal to epithelial conversion of the tumor cells mimics the conversion that occurs during embryonic kidney development, suggesting that Met-HGF/SF signaling plays a role in this process as well as in tumors that express both epithelial and mesenchymal markers.	NCI,FREDERICK CANC RES & DEV CTR,ABL BASIC RES PROGRAM,POB B,FREDERICK,MD 21702; NCI,DIV CANC BIOL DIAG & CTR,INTRAMURAL RES PROGRAM,MATH BIOL LAB,MEMBRANE BIOL SECT,FREDERICK,MD 21702	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)			Shen, Rulong/E-4079-2011	Tsarfaty, Ilan/0000-0002-5230-7093	OFFICE OF THE DIRECTOR, NCI [N01CO074101] Funding Source: NIH RePORTER; NCI NIH HHS [N01-CO-74101] Funding Source: Medline	OFFICE OF THE DIRECTOR, NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BACALLAO R, 1989, AM J PHYSIOL, V257, P913; BHARGAVA M, 1992, CELL GROWTH DIFFER, V3, P11; BOTTARO DP, 1991, SCIENCE, V251, P802, DOI 10.1126/science.1846706; CHEJFEC G, 1991, ULTRASTRUCT PATHOL, V15, P131, DOI 10.3109/01913129109016231; CITI S, 1993, J CELL BIOL, V121, P485, DOI 10.1083/jcb.121.3.485; DOMAGALA W, 1990, AM J PATHOL, V137, P1059; EKBLOM P, 1989, FASEB J, V3, P2141, DOI 10.1096/fasebj.3.10.2666230; GIORDANO S, 1993, P NATL ACAD SCI USA, V90, P649, DOI 10.1073/pnas.90.2.649; GONZATTIHACES M, 1988, P NATL ACAD SCI USA, V85, P21, DOI 10.1073/pnas.85.1.21; GOULD VE, 1990, AM J PATHOL, V137, P1143; GRONE HJ, 1987, AM J PATHOL, V129, P1; GUMBINER BM, 1992, CELL, V69, P385, DOI 10.1016/0092-8674(92)90440-N; IYER A, 1990, CELL GROWTH DIFFER, V1, P87; KINOSHITA T, 1991, BIOCHEM BIOPH RES CO, V177, P330, DOI 10.1016/0006-291X(91)91987-N; MICHALOPOULOS GK, 1990, FASEB J, V4, P176, DOI 10.1096/fasebj.4.2.2404819; MOLL R, 1982, CELL, V31, P11, DOI 10.1016/0092-8674(82)90400-7; MONTESANO R, 1991, CELL, V66, P697, DOI 10.1016/0092-8674(91)90115-F; NAKAMURA T, 1989, SEIKAGAKU, V61, P1243; NALDINI L, 1991, ONCOGENE, V6, P501; PARK M, 1987, P NATL ACAD SCI USA, V84, P6379, DOI 10.1073/pnas.84.18.6379; RONG S, 1993, CANCER RES, V53, P5355; RONG S, 1993, CELL GROWTH DIFFER, V4, P563; RONG S, 1992, MOL CELL BIOL, V12, P5152, DOI 10.1128/MCB.12.11.5152; ROSEN EM, 1991, CELL GROWTH DIFFER, V2, P603; STOKER M, 1987, NATURE, V327, P239, DOI 10.1038/327239a0; TROYANOVSKY SM, 1993, CELL, V72, P561, DOI 10.1016/0092-8674(93)90075-2; TSARFATY I, 1992, SCIENCE, V257, P1258, DOI 10.1126/science.1387731; TSARFATY I, UNPUB; WARD JM, 1992, AM J PATHOL, V141, P955	29	198	210	0	4	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JAN 7	1994	263	5143					98	101		10.1126/science.7505952	http://dx.doi.org/10.1126/science.7505952			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	MQ301	7505952				2022-12-28	WOS:A1994MQ30100040
J	MOORE, PB				MOORE, PB			MOLECULAR MIMICRY IN PROTEIN-SYNTHESIS	SCIENCE			English	Editorial Material							ELONGATION; TU		YALE UNIV,DEPT BIOCHEM & MOLEC BIOPHYS,NEW HAVEN,CT 06520	Yale University	MOORE, PB (corresponding author), YALE UNIV,DEPT CHEM,NEW HAVEN,CT 06520, USA.							AEVARSSON A, 1994, EMBO J, V13, P3669, DOI 10.1002/j.1460-2075.1994.tb06676.x; BERCHTOLD H, 1993, NATURE, V365, P126, DOI 10.1038/365126a0; CZWORKOWSKI J, 1994, EMBO J, V13, P3661, DOI 10.1002/j.1460-2075.1994.tb06675.x; KAZIRO Y, 1978, BIOCHIM BIOPHYS ACTA, V505, P95, DOI 10.1016/0304-4173(78)90009-5; KJELDGAARD M, 1992, J MOL BIOL, V223, P721, DOI 10.1016/0022-2836(92)90986-T; KJELDGAARD M, 1993, STRUCTURE, V1, P35, DOI 10.1016/0969-2126(93)90007-4; NISSEN P, 1995, SCIENCE, V270, P1464, DOI 10.1126/science.270.5241.1464; NOLLER HF, 1991, ANNU REV BIOCHEM, V60, P191, DOI 10.1146/annurev.biochem.60.1.191; SPIRIN AS, 1985, PROG NUCLEIC ACID RE, V32, P75, DOI 10.1016/S0079-6603(08)60346-3	9	19	19	0	0	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	DEC 1	1995	270	5241					1453	1454		10.1126/science.270.5241.1453	http://dx.doi.org/10.1126/science.270.5241.1453			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TH375	7491488				2022-12-28	WOS:A1995TH37500026
J	STREILEIN, JW				STREILEIN, JW			UNRAVELING IMMUNE PRIVILEGE	SCIENCE			English	Editorial Material							ANTERIOR-CHAMBER; DEVIATION; SUPPRESSION; INDUCTION; ANTIGENS; PROTEIN; MICE; EYE				STREILEIN, JW (corresponding author), HARVARD UNIV,SCH MED,SCHEPENS EYE RES INST,BOSTON,MA 02114, USA.							BELLGRAU D, 1995, NATURE, V377, P630, DOI 10.1038/377630a0; BORA NS, 1993, INVEST OPHTH VIS SCI, V34, P3579; GRIFFITH TS, 1995, SCIENCE, V270, P1189, DOI 10.1126/science.270.5239.1189; HARA Y, 1992, J IMMUNOL, V148, P1685; KAPLAN HJ, 1977, J IMMUNOL, V118, P809; KAPLAN HJ, 1974, NATURE, V251, P553, DOI 10.1038/251553a0; KHAW PT, 1992, INVEST OPHTH VIS SCI, V33, P3302; MCLEISH W, 1989, REG IMMUNOL, V2, P235; MEDAWAR PB, 1948, BRIT J EXP PATHOL, V29, P58; NEAVES WB, 1979, TRANSPLANTATION, V27, P127, DOI 10.1097/00007890-197902000-00011; NIEDERKORN JY, 1983, J IMMUNOL, V131, P2670; SANO Y, IN PRESS INVEST OPHT; SHIMADA K, 1970, INVEST OPHTHALMOL, V9, P304; SPENCER SC, 1987, TRANSPLANTATION, V44, P141, DOI 10.1097/00007890-198707000-00028; STREILEIN JW, 1980, J EXP MED, V152, P1121, DOI 10.1084/jem.152.4.1121; STREILEIN JW, 1993, CURR OPIN IMMUNOL, V5, P428, DOI 10.1016/0952-7915(93)90064-Y; TAFURI A, 1995, SCIENCE, V270, P630, DOI 10.1126/science.270.5236.630; TAYLOR AW, 1994, J IMMUNOL, V153, P1080; WILBANKS GA, 1991, J IMMUNOL, V146, P2610	19	235	244	0	8	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	NOV 17	1995	270	5239					1158	1159		10.1126/science.270.5239.1158	http://dx.doi.org/10.1126/science.270.5239.1158			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TE905	7502038				2022-12-28	WOS:A1995TE90500043
J	MILLMAN, A				MILLMAN, A			ABC OF MEDICAL COMPUTING - KEEPING YOUR COMPUTER HEALTHY AND LEGAL	BRITISH MEDICAL JOURNAL			English	Article											MILLMAN, A (corresponding author), GLOUCESTERSHIRE ROYAL HOSP,GLOUCESTER,ENGLAND.								0	2	2	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	NOV 11	1995	311	7015					1289	1293		10.1136/bmj.311.7015.1289	http://dx.doi.org/10.1136/bmj.311.7015.1289			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TE859	7496242	Green Published			2022-12-28	WOS:A1995TE85900032
J	BINKLEY, PF; EATON, GM; NUNZIATA, E; KHOT, U; CODY, RJ				BINKLEY, PF; EATON, GM; NUNZIATA, E; KHOT, U; CODY, RJ			HEART-RATE ALTERNANS	ANNALS OF INTERNAL MEDICINE			English	Article							FAILURE				BINKLEY, PF (corresponding author), OHIO STATE UNIV, MED CTR, DIV CARDIOL, 6TH FLOOR MEANS HALL, 1654 UPHAM DR, COLUMBUS, OH 43210 USA.							BINKLEY PF, 1991, J AM COLL CARDIOL, V18, P464, DOI 10.1016/0735-1097(91)90602-6; ECKBERG DL, 1971, NEW ENGL J MED, V285, P877, DOI 10.1056/NEJM197110142851602; FRANKLIN GF, 1991, FEEDBACK CONTROL DYN, P111; Lewis T, 1911, Q J MED, V4, P141; SAUL JP, 1988, AM J CARDIOL, V61, P1292, DOI 10.1016/0002-9149(88)91172-1; SURAWICZ B, 1992, J AM COLL CARDIOL, V20, P483, DOI 10.1016/0735-1097(92)90122-4	6	18	19	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JAN 15	1995	122	2					115	117		10.7326/0003-4819-122-2-199501150-00007	http://dx.doi.org/10.7326/0003-4819-122-2-199501150-00007			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QC059	7503828				2022-12-28	WOS:A1995QC05900007
J	CREININ, MD; VITTINGHOFF, E				CREININ, MD; VITTINGHOFF, E			METHOTREXATE AND MISOPROSTOL VS MISOPROSTOL ALONE FOR EARLY ABORTION - A RANDOMIZED CONTROLLED TRIAL	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							EARLY-PREGNANCY; DOSE METHOTREXATE; ILLEGAL ABORTION; MIFEPRISTONE; TERMINATION; INDUCTION; CYTOTEC; BRAZIL	Objective.-To compare the safety and efficacy of early abortion by administration of methotrexate and misoprostol vs administration of misoprostol alone. Design.-Randomized controlled trial. Setting.--San Francisco (Calif) General Hospital. Patients.-Pregnant women at 56 days' gestation or less seeking elective abortion. Sixty-three women volunteered for the trial; 61 completed the study and are included in-the analysis. Intervention.-Intramuscular administration of 50 mg of methotrexate per square meter of body surface area followed 3 days later by vaginal administration of 800 mu g of misoprostol (group 1) or the same dose of misoprostol given alone (group 2). The misoprostol dose was repeated 24 hours later if abortion had not occurred. Main Outcome Measures.-Successful abortion, duration of vaginal bleeding, side effects, and change in beta-human chorionic gonadotropin (beta-hCG) level. An abortion;was considered successful if the pregnancy ended without requiring a surgical procedure. Results.-Complete abortion occurred in 28 (90%) of 31 patients in group 1 and 14 (47%) of 30 patients in group 2 (P<.001). Seventeen (61%) of the 28 women in group 1 who aborted did so the same day as misoprostol administration; vaginal bleeding lasted a mean (+/-SD) of 10 (+/-4) days, and beta-hCG level was less than or equal to 10 IU/L by a mean of 31 (+/-6) days after methotrexate administration. The 11 other women in group 1 who aborted did so after a mean delay of 29 (+/-11) days; vaginal bleeding lasted 7 (+/-4) days, and beta-hCG level was less than or equal to 10 IU/L by a mean of 24 (+/-11) days after the abortion. There were three treatment failures in group 1: two ongoing pregnancies (6%) and one incomplete abortion (3%). For the 14 women with successful abortions in group 2, vaginal bleeding lasted a mean of 10 (+/-6) days and beta-hCG level was less than or equal to 10 IU/L by a mean of 39 (+/-18) days after the misoprostol. There were 16 treatment failures in group 2: eight ongoing pregnancies (27%), and eight incomplete abortions (27%). Methotrexate side effects were minimal. Misoprostol side effects were diarrhea in 18% and nausea and vomiting in 5%. Conclusions.-Methotrexate and vaginal misoprostol are more effective than misoprostol alone. Both drugs are available throughout the United States, and both drugs are inexpensive. This combination may offer an alternative to the use of antiprogestin and prostaglandin for medical abortion.	UNIV CALIF SAN FRANCISCO, SAN FRANCISCO GEN HOSP, DEPT OBSTET GYNECOL & REPROD SCI, SAN FRANCISCO, CA USA	San Francisco General Hospital Medical Center; University of California System; University of California San Francisco			Creinin, Mitchell/AAH-3488-2020	Creinin, Mitchell/0000-0001-5967-8180				AVRECH OM, 1991, FERTIL STERIL, V56, P385; BARBOSA RM, 1993, STUD FAMILY PLANN, V24, P236, DOI 10.2307/2939191; BECKER RA, 1988, NEWE S LANGUAGE; BROWNER WS, 1988, DESIGNING CLIN RES E, P139; BUGALHO A, 1993, STUD FAMILY PLANN, V24, P319, DOI 10.2307/2939225; CAMERON IT, 1988, ACTA ENDOCRINOL-COP, V118, P161, DOI 10.1530/acta.0.1180161; COELHO HLL, 1993, LANCET, V341, P1261, DOI 10.1016/0140-6736(93)91157-H; COSTA SH, 1993, LANCET, V341, P1258, DOI 10.1016/0140-6736(93)91156-G; CREININ MD, 1993, CONTRACEPTION, V48, P339, DOI 10.1016/0010-7824(93)90079-M; CREININ MD, 1993, CONTRACEPTION, V48, P519, DOI 10.1016/0010-7824(93)90114-M; DARAB DJ, 1987, TERATOLOGY, V36, P77, DOI 10.1002/tera.1420360111; FONSECA W, 1991, LANCET, V338, P56, DOI 10.1016/0140-6736(91)90046-R; GOLDSTEIN SR, 1991, AM J OBSTET GYNECOL, V165, P497, DOI 10.1016/0002-9378(91)90274-U; GONZALEZ CH, 1993, AM J MED GENET, V47, P59, DOI 10.1002/ajmg.1320470113; KOZLOWSKI RD, 1990, AM J MED, V88, P589, DOI 10.1016/0002-9343(90)90522-F; LAHTEENMAKI P, 1978, CLIN ENDOCRINOL, V9, P101, DOI 10.1111/j.1365-2265.1978.tb02188.x; LEWIS JH, 1985, AM J GASTROENTEROL, V80, P743; Marcisz C, 1992, Pol Tyg Lek, V47, P733; MARRS RP, 1979, AM J OBSTET GYNECOL, V135, P731, DOI 10.1016/0002-9378(79)90383-1; NORMAN JE, 1991, LANCET, V338, P1233, DOI 10.1016/0140-6736(91)92102-8; OBRIEN PC, 1979, BIOMETRICS, V35, P549, DOI 10.2307/2530245; PEYRON R, 1993, NEW ENGL J MED, V328, P1509, DOI 10.1056/NEJM199305273282101; ROSS GT, 1976, CANCER, V37, P1043, DOI 10.1002/1097-0142(197602)37:2+<1043::AID-CNCR2820370809>3.0.CO;2-N; SCHIFF E, 1992, FERTIL STERIL, V57, P688; STOVALL TG, 1993, AM J OBSTET GYNECOL, V168, P1759, DOI 10.1016/0002-9378(93)90687-E; THONG KJ, 1992, BRIT J OBSTET GYNAEC, V99, P1004, DOI 10.1111/j.1471-0528.1992.tb13707.x	26	88	89	0	6	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 19	1994	272	15					1190	1195		10.1001/jama.272.15.1190	http://dx.doi.org/10.1001/jama.272.15.1190			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PL212	7523739				2022-12-28	WOS:A1994PL21200033
J	GRAFF, JM; THIES, RS; SONG, JJ; CELESTE, AJ; MELTON, DA				GRAFF, JM; THIES, RS; SONG, JJ; CELESTE, AJ; MELTON, DA			STUDIES WITH A XENOPUS BMP RECEPTOR SUGGEST THAT VENTRAL MESODERM-INDUCING SIGNALS OVERRIDE DORSAL SIGNALS IN-VIVO	CELL			English	Article							SERINE THREONINE KINASE; BONE MORPHOGENETIC PROTEIN-4; TRANSFORMING GROWTH-FACTOR; EARLY AMPHIBIAN EMBRYOS; DAUER LARVA DEVELOPMENT; TGF-BETA; ACTIVIN RECEPTOR; INOSITOL PHOSPHATES; EXPRESSION CLONING; MESSENGER-RNAS	We report the isolation of a Xenopus BMP receptor that is expressed maternally in the appropriate location to play a role in mesoderm induction. This receptor binds both BMP-2 and BMP-4 with high affinity. A truncated form of this BMP receptor specifically blocks BMP-4 signaling. Expression of this truncated BMP receptor during embryogenesis converts ventral mesoderm to dorsal mesoderm. Contrary to the popularly held view that ventral is the ground state for all mesoderm, our results suggest that formation of ventral mesoderm requires an active signal and that, in the absence of this ventral signal, dorsal mesoderm is formed.	GENET INST INC,CAMBRIDGE,MA 02140		GRAFF, JM (corresponding author), HARVARD UNIV,DEPT BIOCHEM & MOLEC BIOL,CAMBRIDGE,MA 02138, USA.		Young, Richard A/F-6495-2012	Young, Richard A/0000-0001-8855-8647				ALTABA AR, 1989, NATURE, V341, P33; ALTABA ARI, 1991, DEV GROWTH DIFFER, V33, P651; ALTABA ARI, 1992, DEVELOPMENT, V115, P67; AMAYA E, 1991, CELL, V66, P257, DOI 10.1016/0092-8674(91)90616-7; ASASHIMA M, 1990, ROUX ARCH DEV BIOL, V198, P330, DOI 10.1007/BF00383771; ATTISANO L, 1992, CELL, V68, P97, DOI 10.1016/0092-8674(92)90209-U; ATTISANO L, 1993, CELL, V75, P671, DOI 10.1016/0092-8674(93)90488-C; BANVILLE D, 1985, NUCLEIC ACIDS RES, V13, P5407, DOI 10.1093/nar/13.15.5407; BERRIDGE MJ, 1989, NATURE, V341, P197, DOI 10.1038/341197a0; BERRIDGE MJ, 1989, CELL, V59, P411, DOI 10.1016/0092-8674(89)90026-3; BUSA WB, 1989, DEV BIOL, V132, P315, DOI 10.1016/0012-1606(89)90228-5; CHO KWY, 1991, CELL, V67, P1111, DOI 10.1016/0092-8674(91)90288-A; CHRISTIAN JL, 1991, DEVELOPMENT, V111, P1045; DALE L, 1993, EMBO J, V12, P4471, DOI 10.1002/j.1460-2075.1993.tb06136.x; DALE L, 1985, J EMBRYOL EXP MORPH, V89, P289; DALE L, 1987, DEVELOPMENT, V100, P279; DALE L, 1992, DEVELOPMENT, V115, P573; EBNER R, 1993, SCIENCE, V262, P900, DOI 10.1126/science.8235612; EBNER R, 1993, SCIENCE, V260, P1344, DOI 10.1126/science.8388127; ESTEVEZ M, 1993, NATURE, V365, P644, DOI 10.1038/365644a0; FROLIK CA, 1984, J BIOL CHEM, V259, P995; GEORGI LL, 1990, CELL, V61, P635, DOI 10.1016/0092-8674(90)90475-T; HELNKOFF S, 1987, METHOD ENZYMOL, V154, P156; HEMMATIBRIVANLOU A, 1992, DEV DYNAM, V194, P1, DOI 10.1002/aja.1001940102; HEMMATIBRIVANLOU A, 1990, DEVELOPMENT, V110, P325; HEMMATIBRIVANLOU A, 1994, CELL, V77, P273, DOI 10.1016/0092-8674(94)90319-0; HEMMATIBRIVANLOU A, 1992, NATURE, V359, P609, DOI 10.1038/359609a0; JONES CM, 1992, DEVELOPMENT, V115, P639; KAO KR, 1986, NATURE, V322, P371, DOI 10.1038/322371a0; KAO KR, 1988, DEV BIOL, V127, P64, DOI 10.1016/0012-1606(88)90189-3; KIMELMAN D, 1992, DEVELOPMENT, V116, P1; KINGSLEY DM, 1994, GENE DEV, V8, P133, DOI 10.1101/gad.8.2.133; KINTNER CR, 1987, DEVELOPMENT, V99, P311; KLEIN PS, 1994, ENDOCR REV, V15, P326, DOI 10.1210/er.15.3.326; KOSTER M, 1991, MECH DEVELOP, V33, P191, DOI 10.1016/0925-4773(91)90027-4; KRIEG PA, 1989, DEV BIOL, V133, P93, DOI 10.1016/0012-1606(89)90300-X; KRIEG PA, 1984, NUCLEIC ACIDS RES, V12, P7057, DOI 10.1093/nar/12.18.7057; KRIEG PA, 1987, METHOD ENZYMOL, V155, P397; LIN HY, 1992, CELL, V68, P775, DOI 10.1016/0092-8674(92)90152-3; MASLANSKI JA, 1992, SCIENCE, V256, P243, DOI 10.1126/science.1314424; MASSAGUE J, 1987, METHOD ENZYMOL, V146, P174; MATHEWS LS, 1992, SCIENCE, V255, P1702, DOI 10.1126/science.1313188; MATHEWS LS, 1991, CELL, V65, P973, DOI 10.1016/0092-8674(91)90549-E; MOHUN TJ, 1984, NATURE, V311, P716, DOI 10.1038/311716a0; NIEUWKOOP P D, 1969, Wilhelm Roux' Archiv fuer Entwicklungsmechanik der Organismen, V162, P341, DOI 10.1007/BF00578701; Nieuwkoop P.D., 1967, NORMAL TABLE XENOPUS; NISHIMATSU S, 1992, BIOCHEM BIOPH RES CO, V186, P1487, DOI 10.1016/S0006-291X(05)81574-8; REBAGLIATI MR, 1985, CELL, V42, P769, DOI 10.1016/0092-8674(85)90273-9; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHARF SR, 1983, DEV BIOL, V99, P75, DOI 10.1016/0012-1606(83)90255-5; SIVE HL, 1993, GENE DEV, V7, P1, DOI 10.1101/gad.7.1.1; SLACK JMW, 1992, DEVELOPMENT, V114, P285; SLACK JMW, 1994, CURR BIOL, V4, P116, DOI 10.1016/S0960-9822(94)00027-8; SMITH JC, 1987, DEVELOPMENT, V99, P3; SMITH JC, 1991, CELL, V67, P79, DOI 10.1016/0092-8674(91)90573-H; SMITH JC, 1989, DEVELOPMENT, V105, P665; SMITH WC, 1991, CELL, V67, P753, DOI 10.1016/0092-8674(91)90070-F; TENDIJKE P, 1993, ONCOGENE, V8, P2879; THIES RS, 1992, ENDOCRINOLOGY, V130, P1319; THOMSEN G, 1990, CELL, V63, P485, DOI 10.1016/0092-8674(90)90445-K; THOMSEN GH, 1993, CELL, V74, P433, DOI 10.1016/0092-8674(93)80045-G; VONDASSOW G, 1993, GENE DEV, V7, P355, DOI 10.1101/gad.7.3.355; WHITMAN M, 1992, NATURE, V357, P252, DOI 10.1038/357252a0; WILSON P, 1991, DEVELOPMENT, V112, P289; WILSON P, 1994, IN PRESS CURR BIOL; WOZNEY JM, 1988, SCIENCE, V242, P1528, DOI 10.1126/science.3201241	66	436	445	0	6	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	OCT 7	1994	79	1					169	179		10.1016/0092-8674(94)90409-X	http://dx.doi.org/10.1016/0092-8674(94)90409-X			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	PK585	7522972				2022-12-28	WOS:A1994PK58500017
J	ARAFAH, BM				ARAFAH, BM			DECREASED LEVOTHYROXINE REQUIREMENT IN WOMEN WITH HYPOTHYROIDISM DURING ANDROGEN THERAPY FOR BREAST-CANCER	ANNALS OF INTERNAL MEDICINE			English	Article						BREAST NEOPLASMS; HYPOTHYROIDISM; LEVOTHYROXINE; ANDROGENS; FLUOHOMESTERONE	THYROXINE-BINDING GLOBULIN; NORMAL MEN; ESTROGEN	Objective: To determine the effects of androgen administration on measures of thyroid function and thyroid hormone replacement doses in women with breast cancer. Design: Consecutive patients with metastatic, hormone-dependent breast cancer who were eligible for androgen treatment. Interventions: Androgen therapy (fluoxymesterone, 10 mg orally twice daily) was continued for as long as it was effective in controlling tumor growth. Patients: 7 patients with no known thyroid disease and 4 others receiving long-term treatment for hypothyroidism. Measurements: Serum levels of total and free thyroxine (T-4), thyroid-stimulating hormone (TSH), and T-4-binding globulin were determined before and every 4 weeks after androgen therapy was initiated. Results: Within 4 weeks of androgen administration to the seven patients without thyroid disease, serum levels of total T-4 and T-4-binding globulin decreased (P < 0.001), whereas the calculated free thyroxine index and measured free hormone levels remained unchanged. Six to 12 weeks after androgen therapy was discontinued, all seven patients remained clinically euthyroid, and serum levels returned to baseline values. In contrast, clinical hyperthyroidism developed shortly after androgen was administered to four patients who received long-term thyroid hormone replacement therapy. Within 4 weeks of treatment, the serum free T-4 level increased in each of the four patients, whereas the TSH level decreased. Thyroid hormone doses had to be reduced by 25% to 50% to maintain euthyroidism. Conclusions: The study documents the reversible effects of androgens on thyroid hormone levels and indicates the need to reduce thyroid replacement doses in women during androgen therapy. Monitoring thyroid hormone levels in patients receiving replacement therapy and perhaps in those with autonomous thyroid function is necessary after androgen therapy.			ARAFAH, BM (corresponding author), UNIV CLEVELAND HOSP, DIV CLIN & MOLEC ENDOCRINOL, 11100 EUCLID AVE, ROOM 3128 LAKESIDE, CLEVELAND, OH 44106 USA.							AIN KB, 1987, J CLIN ENDOCR METAB, V65, P689, DOI 10.1210/jcem-65-4-689; BRAVERMA.LE, 1968, J CLIN ENDOCR METAB, V28, P831, DOI 10.1210/jcem-28-6-831; BRAVERMAN LE, 1967, J CLIN ENDOCR METAB, V27, P389, DOI 10.1210/jcem-27-3-389; CAMPBELL MJ, 1989, BRIT MED J, P71; FEDERMAN DD, 1958, J CLIN INVEST, V37, P1024, DOI 10.1172/JCI103683; FELDMAN EB, 1960, J CLIN ENDOCR METAB, V20, P842, DOI 10.1210/jcem-20-6-842; KIRSCHNE.MA, 1972, ACTA ENDOCRINOL-COP, V70, P342, DOI 10.1530/acta.0.0700342; MANDEL SJ, 1990, NEW ENGL J MED, V323, P91, DOI 10.1056/NEJM199007123230204; MANDEL SJ, 1993, ANN INTERN MED, V119, P492, DOI 10.7326/0003-4819-119-6-199309150-00009; MANNI A, 1981, CANCER, V48, P2507, DOI 10.1002/1097-0142(19811201)48:11<2507::AID-CNCR2820481127>3.0.CO;2-E; MORLEY JE, 1981, J CLIN ENDOCR METAB, V52, P173, DOI 10.1210/jcem-52-2-173; REFETOFF S, 1976, J CLIN INVEST, V57, P485, DOI 10.1172/JCI108301; Robbins J, 1978, Recent Prog Horm Res, V34, P477; TORMEY DC, 1983, ANN INTERN MED, V98, P139, DOI 10.7326/0003-4819-98-2-139; UTIGER RD, 1990, NEW ENGL J MED, V323, P126; WILSON JD, 1988, ENDOCR REV, V9, P181, DOI 10.1210/edrv-9-2-181	16	33	34	0	1	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	AUG 15	1994	121	4					247	251		10.7326/0003-4819-121-4-199408150-00002	http://dx.doi.org/10.7326/0003-4819-121-4-199408150-00002			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PB102	7518657				2022-12-28	WOS:A1994PB10200002
J	MAYOR, S; ROTHBERG, KG; MAXFIELD, FR				MAYOR, S; ROTHBERG, KG; MAXFIELD, FR			SEQUESTRATION OF GPI-ANCHORED PROTEINS IN CAVEOLAE TRIGGERED BY CROSS-LINKING	SCIENCE			English	Article							FOLATE-BINDING-PROTEIN; GLYCOSYL-PHOSPHATIDYLINOSITOL; CELL-SURFACE; MEMBRANE-PROTEINS; MOLECULES; 5'-NUCLEOTIDASE; RECEPTOR	Glycosyl-phosphatidylinositol (GPI)-anchored proteins have been reported to reside in clusters collected over small membrane invaginations called caveolae. The detection of different GPI-anchored proteins with fluorescently labeled monoclonal antibodies showed that these proteins are not constitutively concentrated in caveolae; they enter these structures independently after cross-linking with polyclonal secondary antibodies. Analysis of the cell surface distribution of the GPI-anchored folate receptor by electron microscopy confirms these observations. Thus, multimerization of GPI-anchored proteins regulates their sequestration in caveolae, but in the absence of agents that promote clustering they are diffusely distributed over the plasma membrane.	COLUMBIA UNIV,COLL PHYS & SURG,DEPT PATHOL,NEW YORK,NY 10032; UNIV TEXAS,SW MED CTR,DEPT CELL BIOL & NEUROSCI,DALLAS,TX 75235	Columbia University; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas			Maxfield, Fred/A-1718-2011; Maxfield, Fred/M-6747-2019; Eckhardt, Erik/G-1567-2010	Maxfield, Fred/0000-0003-4396-8866; 	NIDDK NIH HHS [DK27083] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK027083, R37DK027083] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ANDERSON RGW, 1992, SCIENCE, V255, P410, DOI 10.1126/science.1310359; Anderson Richard G., 1993, Trends in Cell Biology, V3, P69, DOI 10.1016/0962-8924(93)90065-9; BRETSCHER MS, 1980, P NATL ACAD SCI-BIOL, V77, P4156, DOI 10.1073/pnas.77.7.4156; BROWN D, 1993, CURR OPIN IMMUNOL, V5, P349, DOI 10.1016/0952-7915(93)90052-T; CONEY LR, 1991, CANCER RES, V51, P6125; CROSS GAM, 1990, ANNU REV CELL BIOL, V6, P1, DOI 10.1146/annurev.cb.06.110190.000245; DAVITZ MA, 1986, J EXP MED, V163, P1150, DOI 10.1084/jem.163.5.1150; DUPREE P, 1993, EMBO J, V12, P1597, DOI 10.1002/j.1460-2075.1993.tb05804.x; ENGLUND PT, 1993, ANNU REV BIOCHEM, V62, P121, DOI 10.1146/annurev.bi.62.070193.001005; FERGUSON MAJ, 1994, PARASITOL TODAY, V10, P48, DOI 10.1016/0169-4758(94)90392-1; FIELD MC, 1992, LIPID MODIFICATION P, P83; FUJIMOTO T, 1992, J CELL BIOL, V119, P1507, DOI 10.1083/jcb.119.6.1507; FUJIMOTO T, 1993, J CELL BIOL, V120, P1147, DOI 10.1083/jcb.120.5.1147; GRIFFITHS G, 1989, J CELL BIOL, V109, P2703, DOI 10.1083/jcb.109.6.2703; HUANG AJ, 1993, J CELL BIOL, V120, P1371, DOI 10.1083/jcb.120.6.1371; KELLER GA, 1992, EMBO J, V11, P863, DOI 10.1002/j.1460-2075.1992.tb05124.x; KELLY RB, 1985, SCIENCE, V230, P25, DOI 10.1126/science.2994224; LACEY SW, 1989, J CLIN INVEST, V84, P715, DOI 10.1172/JCI114220; LOW MG, 1989, BIOCHIM BIOPHYS ACTA, V988, P427, DOI 10.1016/0304-4157(89)90014-2; MAYOR S, 1993, J CELL BIOL, V121, P1257, DOI 10.1083/jcb.121.6.1257; ROBINSON PJ, 1991, IMMUNOL TODAY, V12, P35, DOI 10.1016/0167-5699(91)90110-F; ROTHBERG KG, 1992, CELL, V68, P673, DOI 10.1016/0092-8674(92)90143-Z; ROTHBERG KG, 1990, J CELL BIOL, V111, P2931, DOI 10.1083/jcb.111.6.2931; ROTHBERG KG, 1990, J CELL BIOL, V110, P627; SARGIACOMO M, 1993, J CELL BIOL, V122, P789, DOI 10.1083/jcb.122.4.789; SIMONS K, 1990, CELL, V62, P207, DOI 10.1016/0092-8674(90)90357-K; STEFANOVA I, 1991, SCIENCE, V254, P1016, DOI 10.1126/science.1719635; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; Van Deurs Bo, 1993, Trends in Cell Biology, V3, P249; VANDENBOSCH RA, 1988, EMBO J, V7, P3345, DOI 10.1002/j.1460-2075.1988.tb03206.x; WIDNELL CC, 1982, CELL, V28, P61, DOI 10.1016/0092-8674(82)90375-0; XU XX, 1991, J BIOL CHEM, V266, P17040; YING YS, 1992, COLD SPRING HARB SYM, V57, P593, DOI 10.1101/SQB.1992.057.01.065	33	449	454	0	10	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUN 24	1994	264	5167					1948	1951		10.1126/science.7516582	http://dx.doi.org/10.1126/science.7516582			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	NT847	7516582				2022-12-28	WOS:A1994NT84700050
J	WANG, YT; SALTER, MW				WANG, YT; SALTER, MW			REGULATION OF NMDA RECEPTORS BY TYROSINE KINASES AND PHOSPHATASES	NATURE			English	Article							LONG-TERM POTENTIATION; EXCITATORY AMINO-ACIDS; PHOSPHORYLATION; ACTIVATION; INHIBITOR; NEURONS; CELLS	PROTEIN-TYROSINE kinases (PTKs) and protein-tyrosine phosphatases (PTPs) are key enzymes in signal-transduction pathways for a wide range of cellular processes(1,2). PTKs and PTPs are highly expressed in the central nervous system(3), which is consistent with the importance of tyrosine phosphorylation in neuronal function(4-6). Protein phosphorylation is known to be involved in the regulation of neurotransmitter receptors(7,8), but the effects of tyrosine phosphorylation on neurotransmitter receptor function in the central nervous system are unknown. Here we present evidence that in mammalian central neurons tyrosine phosphorylation regulates the function of the NMDA (N-methyl-D-aspartate) receptor, a subtype of excitatory amino-acid receptor(9,10). NMDA-receptor-mediated whole-cell currents and intracellular Ca2+ responses are depressed by inhibition of PTKs. Conversely, NMDA currents are potentiated by intracellular application of the well characterized PTK pp60(c-src). NMDA currents are also potentiated by intracellular administration of an inhibitor of PTPs. Protein-tyrosine phosphorylation is a new mechanism for regulating NMDA receptors and may be important in neuronal development, plasticity and toxicity.	HOSP SICK CHILDREN,DIV NEUROSCI,TORONTO M5G 1X8,ON,CANADA; UNIV TORONTO,DEPT PHYSIOL,TORONTO M5S 1A8,ON,CANADA	University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); University of Toronto			Wang, Yu Tian/J-8255-2015; Wang, Yu Tian/A-4729-2008					AKIYAMA T, 1987, J BIOL CHEM, V262, P5592; BADING H, 1991, SCIENCE, V253, P912, DOI 10.1126/science.1715095; BRICKELL P M, 1992, Critical Reviews in Oncogenesis, V3, P401; CATARSI S, 1993, NATURE, V363, P353, DOI 10.1038/363353a0; CHIBA T, 1993, NATURE, V362, P646, DOI 10.1038/362646a0; FISCHER EH, 1991, SCIENCE, V253, P401, DOI 10.1126/science.1650499; GASIC GP, 1992, ANNU REV PHYSIOL, V54, P507, DOI 10.1146/annurev.physiol.54.1.507; GRANT SGN, 1992, SCIENCE, V258, P1903, DOI 10.1126/science.1361685; HORN R, 1988, J GEN PHYSIOL, V92, P145, DOI 10.1085/jgp.92.2.145; HUNTER T, 1985, ANNU REV BIOCHEM, V54, P897, DOI 10.1146/annurev.biochem.54.1.897; JOHNSON JW, 1987, NATURE, V325, P529, DOI 10.1038/325529a0; MAYER ML, 1987, PROG NEUROBIOL, V28, P197, DOI 10.1016/0301-0082(87)90011-6; MAYER ML, 1984, J PHYSIOL-LONDON, V354, P29, DOI 10.1113/jphysiol.1984.sp015360; ODELL TJ, 1991, NATURE, V353, P558, DOI 10.1038/353558a0; ONODA T, 1989, J NAT PROD, V52, P1252, DOI 10.1021/np50066a009; PAN MG, 1992, SCIENCE, V256, P1215, DOI 10.1126/science.256.5060.1215; RAYMOND LA, 1993, TRENDS NEUROSCI, V16, P147, DOI 10.1016/0166-2236(93)90123-4; SALTER MW, 1994, J NEUROSCI, V14, P1563, DOI 10.1523/JNEUROSCI.14-03-01563.1994; SCHLESSINGER J, 1992, NEURON, V9, P383, DOI 10.1016/0896-6273(92)90177-F; SWARUP G, 1982, BIOCHEM BIOPH RES CO, V107, P1104, DOI 10.1016/0006-291X(82)90635-0; WAGER KR, 1991, CURR OPIN NEUROBIOL, V1, P65; WALAAS SI, 1991, PHARMACOL REV, V43, P299; WANG LY, 1991, SCIENCE, V253, P1132, DOI 10.1126/science.1653455; ZACHARY I, 1991, P NATL ACAD SCI USA, V88, P4577, DOI 10.1073/pnas.88.11.4577	24	624	648	2	17	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	MAY 19	1994	369	6477					233	235		10.1038/369233a0	http://dx.doi.org/10.1038/369233a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	NM067	7514272				2022-12-28	WOS:A1994NM06700056
J	CARPOUSIS, AJ; VANHOUWE, G; EHRETSMANN, C; KRISCH, HM				CARPOUSIS, AJ; VANHOUWE, G; EHRETSMANN, C; KRISCH, HM			COPURIFICATION OF ESCHERICHIA-COLI RNASE-E AND PNPASE - EVIDENCE FOR A SPECIFIC ASSOCIATION BETWEEN 2 ENZYMES IMPORTANT IN RNA PROCESSING AND DEGRADATION	CELL			English	Article							BACTERIOPHAGE-T4 MESSENGER-RNA; SODIUM DODECYL-SULFATE; ESCHERICHIA-COLI; POLYNUCLEOTIDE PHOSPHORYLASE; NUCLEOTIDE-SEQUENCE; RIBONUCLEASE-E; RIBOSOMAL-RNA; AMS GENE; PROTEIN; DECAY	Ribonuclease E (RNAase E) was isolated in a complex that also contained polynucleotide phosphorylase (PNPase). Besides copurification, evidence for an association of these enzymes comes from sedimentation and immunoprecipitation experiments. Highly purified RNAase E correctly processed E. coli 5S ribosomal RNA, bacteriophage T4 gene 32 mRNA and E. coli ompA mRNA at sites known to depend on the rne gene for cleavage in vivo. The difference between previous smaller estimates of the size of RNAase E and that reported here apparently is due to the sensitivity of the enzyme to proteolysis during purification. The discovery of a specific association between RNAase E and PNPase raises the intriguing possibility that these enzymes act cooperatively in the processing and degradation of RNA.	CNRS,MICROBIOL & GENET MOLEC LAB,F-31062 TOULOUSE,FRANCE	Centre National de la Recherche Scientifique (CNRS)	CARPOUSIS, AJ (corresponding author), UNIV GENEVA,DEPT MOLEC BIOL,CH-1211 GENEVA 4,SWITZERLAND.		Carpousis, Agamemnon/S-2098-2019	Carpousis, Agamemnon/0000-0002-1774-2102				AMANN E, 1985, GENE, V40, P183, DOI 10.1016/0378-1119(85)90041-1; BABITZKE P, 1991, P NATL ACAD SCI USA, V88, P1, DOI 10.1073/pnas.88.1.1; CARPOUSIS AJ, 1989, MOL GEN GENET, V219, P39, DOI 10.1007/BF00261155; CASAREGOLA S, 1992, J MOL BIOL, V228, P30, DOI 10.1016/0022-2836(92)90489-7; CHAUHAN AK, 1991, NUCLEIC ACIDS RES, V19, P125, DOI 10.1093/nar/19.1.125; CLAVERIEMARTIN F, 1991, J BIOL CHEM, V266, P2843; CLEVELAND DW, 1977, J BIOL CHEM, V252, P1102; CORMACK RS, 1992, J MOL BIOL, V228, P1078, DOI 10.1016/0022-2836(92)90316-C; DEUTSCHER MP, 1991, P NATL ACAD SCI USA, V88, P3277, DOI 10.1073/pnas.88.8.3277; DONOVAN WP, 1986, P NATL ACAD SCI USA, V83, P120, DOI 10.1073/pnas.83.1.120; EHRETSMANN CP, 1992, GENE DEV, V6, P149, DOI 10.1101/gad.6.1.149; EHRETSMANN CP, 1992, FASEB J, V6, P3186, DOI 10.1096/fasebj.6.13.1397840; FREUDL R, 1985, EMBO J, V4, P3593, DOI 10.1002/j.1460-2075.1985.tb04122.x; GEORGELLIS D, 1992, J BACTERIOL, V174, P5382, DOI 10.1128/JB.174.16.5382-5390.1992; GHORA BK, 1978, CELL, V15, P1055, DOI 10.1016/0092-8674(78)90289-1; HAGER DA, 1980, ANAL BIOCHEM, V109, P76, DOI 10.1016/0003-2697(80)90013-5; LOAYZA D, 1991, MOL MICROBIOL, V5, P715, DOI 10.1111/j.1365-2958.1991.tb00742.x; LUNDBERG U, 1990, EMBO J, V9, P2731, DOI 10.1002/j.1460-2075.1990.tb07460.x; MCLAREN RS, 1991, J MOL BIOL, V221, P81, DOI 10.1016/0022-2836(91)90806-H; MELEFORS O, 1991, MOL MICROBIOL, V5, P857, DOI 10.1111/j.1365-2958.1991.tb00759.x; MICZAK A, 1991, MOL MICROBIOL, V5, P1801, DOI 10.1111/j.1365-2958.1991.tb01929.x; MISRA TK, 1979, J BIOL CHEM, V254, P1154; MISRA TK, 1980, J BACTERIOL, V142, P359, DOI 10.1128/JB.142.1.359-361.1980; MUDD EA, 1990, GENE DEV, V4, P873, DOI 10.1101/gad.4.5.873; MUDD EA, 1990, MOL MICROBIOL, V4, P2127, DOI 10.1111/j.1365-2958.1990.tb00574.x; MUDD EA, 1993, MOL MICROBIOL, V9, P557, DOI 10.1111/j.1365-2958.1993.tb01716.x; ONO M, 1979, J MOL BIOL, V129, P343, DOI 10.1016/0022-2836(79)90500-X; PEDERSEN C, 1992, MOL MICROBIOL, V6, P277; PORTIER C, 1975, EUR J BIOCHEM, V55, P573, DOI 10.1111/j.1432-1033.1975.tb02194.x; REGNIER P, 1987, J BIOL CHEM, V262, P63; ROY MK, 1983, EUR J BIOCHEM, V131, P119, DOI 10.1111/j.1432-1033.1983.tb07238.x; SOHLBERG B, 1993, P NATL ACAD SCI USA, V90, P277, DOI 10.1073/pnas.90.1.277	32	381	382	0	11	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	MAR 11	1994	76	5					889	900		10.1016/0092-8674(94)90363-8	http://dx.doi.org/10.1016/0092-8674(94)90363-8			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	NA890	7510217				2022-12-28	WOS:A1994NA89000014
J	EPSTEIN, JI; WALSH, PC; CARMICHAEL, M; BRENDLER, CB				EPSTEIN, JI; WALSH, PC; CARMICHAEL, M; BRENDLER, CB			PATHOLOGICAL AND CLINICAL FINDINGS TO PREDICT TUMOR EXTENT OF NONPALPABLE (STAGE-T1C) PROSTATE-CANCER	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							DIGITAL RECTAL EXAMINATION; TRANSRECTAL ULTRASOUND; ANTIGEN; ADENOCARCINOMA; VOLUME; DIFFERENTIATION; PROGNOSIS; DISEASE	Objectives.-We examined preoperative clinical and pathologic parameters in men with clinical stage T1c disease who underwent radical prostatectomy and correlated these findings with the pathologic extent of disease in the surgical specimen in an attempt to identify a subset of patients with potentially biologically insignificant tumor who might be followed up without immediate treatment. Design and Patients.-A case series of 157 consecutive men who underwent radical prostatectomy for clinical stage T1c disease compared with 64 similarly treated clinical stage T1a cancers (incidental minimal cancers found on transurethral resection of prostate) and 439 clinical stage T2 (palpable) cancers. Main Outcome Measures.-Pathologic stage, grade, and margins; tumor volume; and tumor location. Results.-Sixteen percent of tumors were insignificant (<0.2 cm3 and confined to the prostate, with a Gleason score <7); 10% were minimal (0.2 to 0.5 cm3 and confined to the prostate, with a Gleason score <7); 37% were moderate (>0.5 cm3 or capsular penetration, with a Gleason score <7); and 37% were advanced (capsular penetration, with a Gleason score greater-than-or-equal-to 7 or positive margins, seminal vesicles, or lymph nodes). These findings are intermediate between those found in clinical stage T1a and stage T2 disease. The following parameters were not predictive of tumor extent: age, reason for evaluation, method of detection, and transrectal ultrasound. The best model predicting insignificant tumor was prostate-specific antigen (PSA) density less than 0.1 ng/mL per gram and no adverse pathologic findings on needle biopsy, or PSA density of 0.1 to 0.15 ng/mL per gram, with a low- to intermediate-grade cancer smaller than 3 mm found in only one needle biopsy core specimen. The positive predictive value of the model was 95%, with a negative predictive value of 66%. We accurately predicted 73% of cases with insignificant tumor. Conclusions.-Eighty-four percent of nonpalpable prostate cancers diagnosed by screening techniques are significant tumors and warrant definitive therapy. However, 16% are insignificant. Serum PSA level, PSA density, and needle biopsy pathologic findings are accurate predictors of tumor extent. lt may be reasonable to follow up some patients whose tumors are most likely insignificant with serial PSA measurements and repeated biopsies.	JOHNS HOPKINS UNIV HOSP,JAMES BUCHANAN BRADY UROL INST,BALTIMORE,MD 21205; JOHNS HOPKINS UNIV,SCH MED,DEPT PATHOL,BALTIMORE,MD 21205; JOHNS HOPKINS UNIV,SCH MED,DEPT UROL,BALTIMORE,MD 21205	Johns Hopkins University; Johns Hopkins Medicine; Johns Hopkins University; Johns Hopkins University								BASTACKY SS, 1991, J UROLOGY, V145, P1003, DOI 10.1016/S0022-5347(17)38513-0; BENSON MC, 1992, J UROLOGY, V147, P815, DOI 10.1016/S0022-5347(17)37393-7; BENSON MC, 1992, J UROLOGY, V147, P817, DOI 10.1016/S0022-5347(17)37394-9; CARTER HB, 1992, JAMA-J AM MED ASSOC, V267, P2215, DOI 10.1001/jama.267.16.2215; CARTER HB, 1989, J UROLOGY, V142, P1008, DOI 10.1016/S0022-5347(17)38971-1; CATALONA WJ, 1991, NEW ENGL J MED, V324, P1156, DOI 10.1056/NEJM199104253241702; COONER WH, 1990, J UROLOGY, V143, P1146, DOI 10.1016/S0022-5347(17)40211-4; EPSTEIN JI, 1993, CANCER-AM CANCER SOC, V71, P3582, DOI 10.1002/1097-0142(19930601)71:11<3582::AID-CNCR2820711120>3.0.CO;2-Y; EPSTEIN JI, 1986, J UROLOGY, V136, P837, DOI 10.1016/S0022-5347(17)45097-X; EPSTEIN JI, 1993, J UROLOGY, V149, P1478, DOI 10.1016/S0022-5347(17)36421-2; EPSTEIN JI, 1993, J UROLOGY, V150, P135, DOI 10.1016/S0022-5347(17)35415-0; GLEASON DF, 1974, J UROLOGY, V111, P58, DOI 10.1016/S0022-5347(17)59889-4; LABRIE F, 1992, J UROLOGY, V147, P846, DOI 10.1016/S0022-5347(17)37402-5; LARSEN MP, 1991, J UROLOGY, V146, P1059, DOI 10.1016/S0022-5347(17)38000-X; MCNEAL JE, 1990, CANCER, V66, P1225, DOI 10.1002/1097-0142(19900915)66:6<1225::AID-CNCR2820660624>3.0.CO;2-X; OESTERLING JE, 1991, J UROLOGY, V145, P907, DOI 10.1016/S0022-5347(17)38491-4; PALKEN M, 1991, J UROLOGY, V145, P86, DOI 10.1016/S0022-5347(17)38254-X; PARTIN AW, 1989, J UROLOGY, V141, P341, DOI 10.1016/S0022-5347(17)40761-0; PARTIN AW, 1990, J UROLOGY, V143, P747, DOI 10.1016/S0022-5347(17)40079-6; Stamey TA, 1992, CAMPBELLS UROLOGY, P1200; STORMONT TJ, 1993, UROLOGY, V41, P3, DOI 10.1016/0090-4295(93)90233-Z; TERRIS MK, 1992, J UROLOGY, V148, P829, DOI 10.1016/S0022-5347(17)36735-6; WHITMORE WF, 1990, UROL CLIN N AM, V17, P689	23	1462	1496	0	30	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	FEB 2	1994	271	5					368	374		10.1001/jama.271.5.368	http://dx.doi.org/10.1001/jama.271.5.368			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MR983	7506797				2022-12-28	WOS:A1994MR98300032
J	SAKS, ME; SAMPSON, JR; ABELSON, JN				SAKS, ME; SAMPSON, JR; ABELSON, JN			THE TRANSFER-RNA IDENTITY PROBLEM - A SEARCH FOR RULES	SCIENCE			English	Article							GLUTAMINYL-TRANSFER RNA; PHENYLALANINE TRANSFER-RNA; FORMYLMETHIONINE TRANSFER-RNA; INITIATOR TRANSFER-RNA; SUPPRESSOR TRANSFER-RNAS; TYROSINE TRANSFER-RNA; YEAST TRANSFER RNAASP; ANTICODON LOOP; DISCRIMINATOR BASE; ACCEPTOR IDENTITY	Correct recognition of transfer RNAs (tRNAs) by aminoacyl-tRNA synthetases is central to the maintenance of translational fidelity. The hypothesis that synthetases recognize anticodon nucleotides was proposed in 1964 and had considerable experimental support by the mid-1970s. Nevertheless, the idea was not widely accepted until relatively recently in part because the methodologies initially available for examining tRNA recognition proved hampering for adequately testing alternative hypotheses. Implementation of new technologies has led to a reasonably complete picture of how tRNAs are recognized. The anticodon is indeed important for 17 of the 20 Escherichia coli isoaccepting groups. For many of the isoaccepting groups, the acceptor stem or position 73 (or both) is important as well.			SAKS, ME (corresponding author), CALTECH, DIV BIOL, PASADENA, CA 91125 USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM048560] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM 48560] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABELSON JN, 1970, J MOL BIOL, V47, P15, DOI 10.1016/0022-2836(70)90398-0; ASAHARA H, 1993, J MOL BIOL, V231, P219, DOI 10.1006/jmbi.1993.1277; BARE LA, 1986, BIOCHEMISTRY-US, V25, P5825, DOI 10.1021/bi00367a072; BEHLEN LS, 1990, BIOCHEMISTRY-US, V29, P2515, DOI 10.1021/bi00462a013; BIOU V, IN PRESS SCIENCE; BRUCE AG, 1982, BIOCHEMISTRY-US, V21, P855, DOI 10.1021/bi00534a007; BRUCE AG, 1982, BIOCHEMISTRY-US, V21, P3921, DOI 10.1021/bi00260a003; BUECHTER DD, 1993, BIOCHEMISTRY-US, V32, P5267, DOI 10.1021/bi00070a039; CARTER CW, 1993, ANNU REV BIOCHEM, V62, P715, DOI 10.1146/annurev.bi.62.070193.003435; CAVARELLI J, 1993, NATURE, V362, P181, DOI 10.1038/362181a0; Chambers R W, 1971, Prog Nucleic Acid Res Mol Biol, V11, P489, DOI 10.1016/S0079-6603(08)60336-0; CHAPEVILLE F, 1962, P NATL ACAD SCI USA, V48, P1086, DOI 10.1073/pnas.48.6.1086; CHATTAPADHYAY R, 1990, BIOCHEMISTRY-US, V29, P4263, DOI 10.1021/bi00470a001; CRICK FHC, 1960, NUCLEIC ACIDS, V3, P400; CROTHERS DM, 1972, P NATL ACAD SCI USA, V69, P3063, DOI 10.1073/pnas.69.10.3063; DREHER TW, 1984, NATURE, V311, P171, DOI 10.1038/311171a0; Ebel J P, 1979, TRANSFER RNA STRUCTU, P325; EBEL JP, 1973, BIOCHIMIE, V55, P547, DOI 10.1016/S0300-9084(73)80415-8; ENGELHARDT WA, 1966, CURRENT ASPECTS BIOC, P213; ERIANI G, 1990, NATURE, V347, P203, DOI 10.1038/347203a0; FRANCKLYN C, 1989, NATURE, V337, P478, DOI 10.1038/337478a0; FRANCKLYN C, 1992, SCIENCE, V255, P1121, DOI 10.1126/science.1546312; FRANCKLYN C, 1990, P NATL ACAD SCI USA, V87, P8655, DOI 10.1073/pnas.87.21.8655; FRUGIER M, 1992, P NATL ACAD SCI USA, V89, P3990, DOI 10.1073/pnas.89.9.3990; GHOSH G, 1991, BIOCHEMISTRY-US, V30, P11767, DOI 10.1021/bi00115a005; GHOSH G, 1990, BIOCHEMISTRY-US, V29, P2220, DOI 10.1021/bi00461a003; GIEGE R, 1990, BIOCHIMIE, V72, P453, DOI 10.1016/0300-9084(90)90069-S; GIEGE R, 1993, PROG NUCLEIC ACID RE, V45, P129, DOI 10.1016/S0079-6603(08)60869-7; GODDARD JP, 1977, PROG BIOPHYS MOL BIO, V32, P233; GUMPORT RI, 1981, GENE AMPLIFICATION A, V2, P314; HALL KB, 1989, BIOCHEMISTRY-US, V28, P5794, DOI 10.1021/bi00440a014; HASEGAWA T, 1992, BIOCHEM BIOPH RES CO, V184, P478, DOI 10.1016/0006-291X(92)91219-G; HASEGAWA T, 1989, BIOCHEM BIOPH RES CO, V163, P1534, DOI 10.1016/0006-291X(89)91154-6; HAYASE Y, 1992, EMBO J, V11, P4159, DOI 10.1002/j.1460-2075.1992.tb05509.x; HIMENO H, 1989, NUCLEIC ACIDS RES, V17, P7855, DOI 10.1093/nar/17.19.7855; HIMENO H, 1990, NUCLEIC ACIDS RES, V18, P6815, DOI 10.1093/nar/18.23.6815; HIMENO H, 1991, NUCLEIC ACIDS RES, V19, P6379, DOI 10.1093/nar/19.23.6379; HO YS, 1987, P NATL ACAD SCI USA, V84, P2185, DOI 10.1073/pnas.84.8.2185; HOAGLAND MB, 1957, BIOCHIM BIOPHYS ACTA, V24, P215, DOI 10.1016/0006-3002(57)90175-0; HOAGLAND MB, 1958, J BIOL CHEM, V231, P241; HOLLEY RW, 1965, SCIENCE, V147, P1462, DOI 10.1126/science.147.3664.1462; HOOPER ML, 1972, FEBS LETT, V22, P149, DOI 10.1016/0014-5793(72)80241-2; HOU YM, 1989, BIOCHEMISTRY-US, V28, P4942, DOI 10.1021/bi00438a005; HOU YM, 1989, BIOCHEMISTRY-US, V28, P6800, DOI 10.1021/bi00443a003; HOU YM, 1993, P NATL ACAD SCI USA, V90, P6776, DOI 10.1073/pnas.90.14.6776; HOU YM, 1988, NATURE, V333, P140, DOI 10.1038/333140a0; IMURA N, 1969, P NATL ACAD SCI USA, V62, P1203, DOI 10.1073/pnas.62.4.1203; IMURA N, 1969, NATURE, V222, P1147, DOI 10.1038/2221147a0; JAHN M, 1991, NATURE, V352, P258, DOI 10.1038/352258a0; KHORANA HG, 1966, COLD SPRING HARB SYM, V31, P39, DOI 10.1101/SQB.1966.031.01.010; KIM HY, 1993, BIOCHEMISTRY-US, V32, P10506, DOI 10.1021/bi00090a029; Kim S-H, 1979, TRANSFER RNA STRUCTU, P83; KIM SH, 1974, SCIENCE, V185, P435, DOI 10.1126/science.185.4149.435; KISSELEV LL, 1974, ADV ENZYMOL RAMB, V40, P141; KISSELEV LL, 1985, PROG NUCLEIC ACID RE, V32, P237, DOI 10.1016/S0079-6603(08)60350-5; KLEINA LG, 1990, J MOL BIOL, V213, P705, DOI 10.1016/S0022-2836(05)80257-8; KOMATSOULIS GA, 1993, BIOCHEMISTRY-US, V32, P7435, DOI 10.1021/bi00080a014; KOMINE Y, 1990, J MOL BIOL, V212, P579, DOI 10.1016/0022-2836(90)90224-A; LADNER JE, 1975, P NATL ACAD SCI USA, V72, P4414, DOI 10.1073/pnas.72.11.4414; LEON O, 1987, BIOCHEMISTRY-US, V26, P5416, DOI 10.1021/bi00391a030; LI SH, 1993, J BIOL CHEM, V268, P18335; Loftfield R B, 1972, Prog Nucleic Acid Res Mol Biol, V12, P87; MARTINIS SA, 1992, P NATL ACAD SCI USA, V89, P65, DOI 10.1073/pnas.89.1.65; MCCLAIN WH, 1987, J MOL BIOL, V194, P635, DOI 10.1016/0022-2836(87)90240-3; MCCLAIN WH, 1990, P NATL ACAD SCI USA, V87, P9260, DOI 10.1073/pnas.87.23.9260; MCCLAIN WH, 1991, P NATL ACAD SCI USA, V88, P6147, DOI 10.1073/pnas.88.14.6147; MCCLAIN WH, 1988, SCIENCE, V240, P793, DOI 10.1126/science.2452483; MCCLAIN WH, 1988, SCIENCE, V241, P1804, DOI 10.1126/science.2459773; MCCLAIN WH, 1991, P NATL ACAD SCI USA, V88, P9272, DOI 10.1073/pnas.88.20.9272; MCCLAIN WH, 1988, J MOL BIOL, V202, P697, DOI 10.1016/0022-2836(88)90551-7; MEINNEL T, 1993, J MOL BIOL, V229, P26, DOI 10.1006/jmbi.1993.1005; MEINNEL T, 1991, P NATL ACAD SCI USA, V88, P291, DOI 10.1073/pnas.88.1.291; MELLOT P, 1989, J MOL BIOL, V208, P429, DOI 10.1016/0022-2836(89)90507-X; MURAMATSU T, 1988, NATURE, V336, P179, DOI 10.1038/336179a0; MUSIERFORSYTH K, 1991, SCIENCE, V253, P784, DOI 10.1126/science.1876835; NAMEKI N, 1992, BIOCHEM BIOPH RES CO, V189, P856, DOI 10.1016/0006-291X(92)92282-3; NAZARENKO IA, 1992, NUCLEIC ACIDS RES, V20, P475, DOI 10.1093/nar/20.3.475; NIRENBERG M, 1961, P NATL ACAD SCI USA, V47, P1588, DOI 10.1073/pnas.47.10.1588; NORMANLY J, 1986, NATURE, V321, P213, DOI 10.1038/321213a0; NORMANLY J, 1992, P NATL ACAD SCI USA, V89, P5680, DOI 10.1073/pnas.89.12.5680; NORMANLY J, 1990, J MOL BIOL, V213, P719, DOI 10.1016/S0022-2836(05)80258-X; NORMANLY J, 1986, P NATL ACAD SCI USA, V83, P6548, DOI 10.1073/pnas.83.17.6548; OHTSUKA E, 1981, P NATL ACAD SCI-BIOL, V78, P5493, DOI 10.1073/pnas.78.9.5493; OZEKI H, 1980, TRANSFER RNA BIOL AS, P341; PAK M, 1992, BIOCHEMISTRY-US, V31, P3303, DOI 10.1021/bi00128a001; PALLANCK L, 1992, J BIOL CHEM, V267, P7221; PALLANCK L, 1991, P NATL ACAD SCI USA, V88, P3872, DOI 10.1073/pnas.88.9.3872; PALLANCK L, 1992, FASEB J, V6, pA360; PALLANCK L, UNPUB; PALLANCK L, 1992, TRANSFER RNA PROTEIN, P279; PERONA JJ, 1991, P NATL ACAD SCI USA, V88, P2903, DOI 10.1073/pnas.88.7.2903; PERRET V, 1992, J MOL BIOL, V226, P323, DOI 10.1016/0022-2836(92)90950-O; PETERSON ET, 1993, EMBO J, V12, P2959, DOI 10.1002/j.1460-2075.1993.tb05958.x; PETERSON ET, 1992, BIOCHEMISTRY-US, V31, P10380, DOI 10.1021/bi00157a028; PRATHER NE, 1984, J MOL BIOL, V172, P177, DOI 10.1016/S0022-2836(84)80036-4; PREISS J, 1959, P NATL ACAD SCI USA, V45, P319, DOI 10.1073/pnas.45.3.319; PUTZ J, 1991, SCIENCE, V252, P1696, DOI 10.1126/science.2047878; RICH A, 1977, NUCLEIC ACIDS RES, V4, P1649, DOI 10.1093/nar/4.5.1649; ROBERTUS JD, 1974, NATURE, V250, P546, DOI 10.1038/250546a0; Rogers M J, 1990, Prog Nucleic Acid Res Mol Biol, V39, P185, DOI 10.1016/S0079-6603(08)60627-3; ROGERS MJ, 1988, P NATL ACAD SCI USA, V85, P6627, DOI 10.1073/pnas.85.18.6627; ROGERS MJ, 1992, P NATL ACAD SCI USA, V89, P3463, DOI 10.1073/pnas.89.8.3463; ROULD MA, 1989, SCIENCE, V246, P1135, DOI 10.1126/science.2479982; ROULD MA, 1991, NATURE, V352, P213, DOI 10.1038/352213a0; RUDINGER J, 1992, NUCLEIC ACIDS RES, V20, P1865, DOI 10.1093/nar/20.8.1865; RUFF M, 1991, SCIENCE, V252, P1682, DOI 10.1126/science.2047877; Saks M., UNPUB; SAMPSON JR, 1993, NUCLEIC ACIDS RES, V21, P4467, DOI 10.1093/nar/21.19.4467; SAMPSON JR, 1990, BIOCHEMISTRY-US, V29, P2523, DOI 10.1021/bi00462a014; SAMPSON JR, 1989, SCIENCE, V243, P1363; SAMPSON JR, 1988, P NATL ACAD SCI USA, V85, P1033, DOI 10.1073/pnas.85.4.1033; SAMUELSSON T, 1988, J BIOL CHEM, V263, P13692; Sarkar A K, 1979, Methods Enzymol, V59, P156; SCHIMMEL P, 1993, P NATL ACAD SCI USA, V90, P8763, DOI 10.1073/pnas.90.19.8763; SCHIMMEL PR, 1977, ACCOUNTS CHEM RES, V10, P411, DOI 10.1021/ar50119a005; SCHIMMEL PR, 1979, ANNU REV BIOCHEM, V48, P601, DOI 10.1146/annurev.bi.48.070179.003125; SCHULMAN LH, 1972, P NATL ACAD SCI USA, V69, P3594, DOI 10.1073/pnas.69.12.3594; SCHULMAN LH, 1968, P NATL ACAD SCI USA, V61, P308, DOI 10.1073/pnas.61.1.308; SCHULMAN LH, 1989, SCIENCE, V246, P1595, DOI 10.1126/science.2688091; SCHULMAN LH, 1985, BIOCHEMISTRY-US, V24, P7309, DOI 10.1021/bi00346a043; SCHULMAN LH, 1991, PROG NUCLEIC ACID RE, V41, P23; SCHULMAN LH, 1983, P NATL ACAD SCI-BIOL, V80, P6755, DOI 10.1073/pnas.80.22.6755; SCHULMAN LH, 1983, NUCLEIC ACIDS RES, V11, P1439, DOI 10.1093/nar/11.5.1439; SCHULMAN LH, 1988, SCIENCE, V242, P765, DOI 10.1126/science.3055296; SCHULMAN LH, 1977, BIOCHEMISTRY-US, V16, P4256, DOI 10.1021/bi00638a020; SCHULMAN LH, 1990, NUCLEIC ACIDS RES, V18, P285, DOI 10.1093/nar/18.2.285; SCHULMAN LH, 1976, BIOCHEMISTRY-US, V15, P5769, DOI 10.1021/bi00671a013; SCHULMAN LH, 1988, SCIENCE, V240, P1591, DOI 10.1126/science.2454505; SEONG BL, 1987, P NATL ACAD SCI USA, V84, P8859, DOI 10.1073/pnas.84.24.8859; SEONG BL, 1987, P NATL ACAD SCI USA, V84, P334, DOI 10.1073/pnas.84.2.334; SHI JP, 1990, BIOCHEMISTRY-US, V29, P3621, DOI 10.1021/bi00467a005; SHIMIZU M, 1992, J MOL EVOL, V35, P436; SHIMURA Y, 1972, FEBS LETT, V22, P144, DOI 10.1016/0014-5793(72)80240-0; Shimura Y, 1973, Adv Biophys, V4, P191; Soll D., 1974, ENZYMES, V10, P489; SPRINZL M, 1991, NUCLEIC ACIDS RES, V19, P2127, DOI 10.1093/nar/19.suppl.2127; SQUIRES C, 1971, NATURE-NEW BIOL, V233, P274, DOI 10.1038/newbio233274a0; STERN L, 1977, J BIOL CHEM, V252, P6403; SUNDHARA.G, 1968, P NATL ACAD SCI USA, V61, P693, DOI 10.1073/pnas.61.2.693; SWANSON R, 1988, SCIENCE, V242, P1548, DOI 10.1126/science.3144042; SYLVERS LA, 1993, BIOCHEMISTRY-US, V32, P3836, DOI 10.1021/bi00066a002; TAMURA K, 1991, BIOCHEM BIOPH RES CO, V177, P619, DOI 10.1016/0006-291X(91)91833-X; Tamura K, 1991, J Mol Recognit, V4, P129, DOI 10.1002/jmr.300040404; TAMURA K, 1992, NUCLEIC ACIDS RES, V20, P2335, DOI 10.1093/nar/20.9.2335; TUERK C, 1990, SCIENCE, V249, P505, DOI 10.1126/science.2200121; VARSHNEY U, 1991, J BIOL CHEM, V266, P24712; VARSHNEY U, 1991, J BIOL CHEM, V266, P18018; XUE H, 1993, J BIOL CHEM, V268, P9316; YANIV M, 1974, J MOL BIOL, V86, P245, DOI 10.1016/0022-2836(74)90016-3; YARUS M, 1972, NATURE-NEW BIOL, V239, P106, DOI 10.1038/newbio239106a0; YARUS M, 1977, NUCLEIC ACID PROTEIN, P391; ZELWER C, 1982, J MOL BIOL, V155, P63, DOI 10.1016/0022-2836(82)90492-2	152	150	153	1	15	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JAN 14	1994	263	5144					191	197		10.1126/science.7506844	http://dx.doi.org/10.1126/science.7506844			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	MQ879	7506844				2022-12-28	WOS:A1994MQ87900023
J	BIRGE, RB; HANAFUSA, H				BIRGE, RB; HANAFUSA, H			CLOSING IN ON SH2 SPECIFICITY	SCIENCE			English	Editorial Material							SIGNAL TRANSDUCTION; DOMAIN; PROTEIN; IRS-1				BIRGE, RB (corresponding author), ROCKEFELLER UNIV, MOLEC ONCOL LAB, NEW YORK, NY 10021 USA.							BACKER JM, 1992, EMBO J, V11, P3469, DOI 10.1002/j.1460-2075.1992.tb05426.x; BARSAGI D, 1993, CELL, V74, P83, DOI 10.1016/0092-8674(93)90296-3; BOOKER GW, 1992, NATURE, V358, P684, DOI 10.1038/358684a0; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; CARPENTER CL, 1993, J BIOL CHEM, V268, P9478; CHOU MMC, UNPUB; CICCHETTI P, 1992, SCIENCE, V257, P803, DOI 10.1126/science.1379745; ECK MJ, 1993, NATURE, V362, P87, DOI 10.1038/362087a0; EGAN SE, 1993, NATURE, V363, P45, DOI 10.1038/363045a0; ESCOBEDO JA, 1991, MOL CELL BIOL, V11, P1125, DOI 10.1128/MCB.11.2.1125; FANTL WJ, 1992, CELL, V69, P413, DOI 10.1016/0092-8674(92)90444-H; FELLER S, UNPUB; KASHISHIAN A, 1993, OMOL CELL BIOL, V4, P49; LI N, 1993, NATURE, V363, P85, DOI 10.1038/363085a0; LIU XQ, 1993, MOL CELL BIOL, V13, P5225, DOI 10.1128/MCB.13.9.5225; Mayer Bruce J., 1993, Trends in Cell Biology, V3, P8, DOI 10.1016/0962-8924(93)90194-6; MORI S, 1993, EMBO J, V12, P2257, DOI 10.1002/j.1460-2075.1993.tb05879.x; OVERDUIN M, 1992, CELL, V70, P697, DOI 10.1016/0092-8674(92)90437-H; PANAYOTOU G, 1993, MOL CELL BIOL, V13, P3567, DOI 10.1128/MCB.13.6.3567; PAWSON T, 1992, CELL, V71, P359, DOI 10.1016/0092-8674(92)90504-6; REN R, COMMUNICATION; REN RB, 1993, SCIENCE, V259, P1157, DOI 10.1126/science.8438166; ROUSSEL RR, 1991, P NATL ACAD SCI USA, V88, P10696, DOI 10.1073/pnas.88.23.10696; ROZAKISADCOCK M, 1993, NATURE, V363, P83, DOI 10.1038/363083a0; SUN XJ, 1991, NATURE, V352, P73, DOI 10.1038/352073a0; TANAKA M, COMMUNICATION; WAKSMAN G, 1993, CELL, V72, P779, DOI 10.1016/0092-8674(93)90405-F; WAKSMAN G, 1992, NATURE, V358, P646, DOI 10.1038/358646a0; WENG ZG, 1993, J BIOL CHEM, V268, P14956; ZHOU SY, 1993, CELL, V72, P767, DOI 10.1016/0092-8674(93)90404-E	30	87	90	0	3	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	DEC 3	1993	262	5139					1522	1523		10.1126/science.7504323	http://dx.doi.org/10.1126/science.7504323			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	MK329	7504323				2022-12-28	WOS:A1993MK32900027
J	Murakami, S; Mizobuchi, M; Nakashiro, Y; Doi, T; Hato, N; Yanagihara, N				Murakami, S; Mizobuchi, M; Nakashiro, Y; Doi, T; Hato, N; Yanagihara, N			Bell palsy and herpes simplex virus: Identification of viral DNA in endoneurial fluid and muscle	ANNALS OF INTERNAL MEDICINE			English	Note							POLYMERASE CHAIN-REACTION; VARICELLA-ZOSTER VIRUS; CEREBROSPINAL-FLUID; NERVOUS-SYSTEM; GENE	Objective: To determine whether herpes simplex virus type 1 (HSV-1) causes Bell palsy. Design: Prospective study. Setting: University inpatient service. Patients: 14 patients with Bell palsy, 9 patients with the Ramsay-Hunt syndrome, and 12 other controls. Measurements: Viral genomes of HSV-1, varicella-zoster virus, and Epstein-Barr virus were analyzed in clinical samples of facial nerve endoneurial fluid and posterior auricular muscle using polymerase chain reaction (PCR) followed by hybridization with Southern blot analysis. Results: Herpes simplex virus type 1 genomes were detected in 11 of 14 patients (79%) with Bell palsy but not in patients with the Ramsay-Hunt syndrome or in other controls. The nucleotide sequences of the PCR fragments were identical to those of the HSV-1 genome. Conclusions: Herpes simplex virus type 1 is the major etiologic agent in Bell palsy.	EHIME UNIV, SCH MED, DEPT NEUROPSYCHIAT, SHIGENOBU, EHIME 79102, JAPAN	Ehime University	Murakami, S (corresponding author), EHIME UNIV, SCH MED, DEPT OTOLARYNGOL, SHIGENOBU, EHIME 79102, JAPAN.							ABRAMSKY O, 1975, J NEUROL SCI, V26, P13, DOI 10.1016/0022-510X(75)90109-4; ADOUR KK, 1975, JAMA-J AM MED ASSOC, V233, P527, DOI 10.1001/jama.233.6.527; Aitken RS, 1933, LANCET, V1, P19; AURELIUS E, 1991, LANCET, V337, P189, DOI 10.1016/0140-6736(91)92155-U; BURGESS RC, 1994, ANN OTO RHINOL LARYN, V103, P775, DOI 10.1177/000348949410301006; CARTON CA, 1953, J NEUROSURG, V10, P463, DOI 10.3171/jns.1953.10.5.0463; CINQUE P, 1993, LANCET, V342, P398, DOI 10.1016/0140-6736(93)92814-A; DEVRIESE PP, 1974, ACTA OTO-LARYNGOL, V77, P108, DOI 10.3109/00016487409124605; DOWBENKO DJ, 1984, J VIROL, V52, P154, DOI 10.1128/JVI.52.1.154-163.1984; FURUTA Y, 1992, J INFECT DIS, V166, P1157, DOI 10.1093/infdis/166.5.1157; GILDEN DH, 1992, J INFECT DIS, V166, pS30, DOI 10.1093/infdis/166.Supplement_1.S30; HADAR T, 1983, J MED VIROL, V12, P237, DOI 10.1002/jmv.1890120403; LISTON SL, 1989, LARYNGOSCOPE, V99, P23; MCCORMICK DP, 1972, LANCET, V1, P937; MIZOBUCHI M, 1991, MOL ENDOCRINOL, V5, P476, DOI 10.1210/mend-5-4-476; PALVA T, 1978, ACTA OTO-LARYNGOL, V86, P269, DOI 10.3109/00016487809124746; SARTORETTISCHEFER S, 1994, AM J NEURORADIOL, V15, P479; SPRUANCE SL, 1994, ANN INTERN MED, V120, P1045, DOI 10.7326/0003-4819-120-12-199406150-00013; TAKASU T, 1992, ACTA OTO-LARYNGOL, V112, P1004, DOI 10.3109/00016489209137502; TOWNSEND JJ, 1986, J NEUROPATH EXP NEUR, V45, P419, DOI 10.1097/00005072-198607000-00004	20	456	474	0	7	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JAN 1	1996	124	1	1				27	30		10.7326/0003-4819-124-1_Part_1-199601010-00005	http://dx.doi.org/10.7326/0003-4819-124-1_Part_1-199601010-00005			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TL943	7503474				2022-12-28	WOS:A1996TL94300005
J	PLUTA, AF; MACKAY, AM; AINSZTEIN, AM; GOLDBERG, IG; EARNSHAW, WC				PLUTA, AF; MACKAY, AM; AINSZTEIN, AM; GOLDBERG, IG; EARNSHAW, WC			CENTROMERE - HUB OF CHROMOSOMAL ACTIVITIES	SCIENCE			English	Article							YEAST SCHIZOSACCHAROMYCES-POMBE; SACCHAROMYCES-CEREVISIAE; CELL-CYCLE; BUDDING YEAST; FISSION YEAST; 3-DIMENSIONAL RECONSTRUCTION; FUNCTIONAL-ANALYSIS; BINDING-PROTEIN; AUTOIMMUNE SERA; SATELLITE DNA	Centromeres are the structures that direct eukaryotic chromosome segregation In mitosis and meiosis. There are two major classes of centromeres. Point centromeres, found in the budding yeasts, are compact loci whose constituent proteins are now beginning to yield to biochemical analysis. Regional centromeres, best described in the fission yeast Schizosaccharomyces pombe, encompass many kilobases of DNA and are packaged into heterochromatin. Their associated proteins are as yet poorly understood. In addition to providing the site for microtubule attachment, centromeres also have an important role in checkpoint regulation during mitosis.	JOHNS HOPKINS UNIV,SCH MED,DEPT CELL BIOL & ANAT,BALTIMORE,MD 21205	Johns Hopkins University			Goldberg, Ilya/H-5307-2011; Earnshaw, William/AAY-7438-2020	Goldberg, Ilya/0000-0001-8514-6110; Earnshaw, William/0000-0002-7191-0621	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM035212] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM35212] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALBERTSON DG, 1982, CHROMOSOMA, V86, P409, DOI 10.1007/BF00292267; ALLSHIRE RC, 1994, CELL, V76, P157, DOI 10.1016/0092-8674(94)90180-5; ALLSHIRE RC, 1995, GENE DEV, V9, P218, DOI 10.1101/gad.9.2.218; BAKER RE, 1989, J BIOL CHEM, V264, P10843; BAUM M, 1994, MOL BIOL CELL, V5, P747, DOI 10.1091/mbc.5.7.747; BERNAT RL, 1990, J CELL BIOL, V111, P1519, DOI 10.1083/jcb.111.4.1519; BISCHOFF FR, 1990, P NATL ACAD SCI USA, V87, P8617, DOI 10.1073/pnas.87.21.8617; BLOOM KS, 1982, CELL, V29, P305, DOI 10.1016/0092-8674(82)90147-7; BRAM RJ, 1987, MOL CELL BIOL, V7, P403, DOI 10.1128/MCB.7.1.403; BROWN KE, 1994, HUM MOL GENET, V3, P1227, DOI 10.1093/hmg/3.8.1227; BROWN MT, 1993, J CELL BIOL, V123, P387, DOI 10.1083/jcb.123.2.387; BROWN MT, 1995, GENE, V160, P111, DOI 10.1016/0378-1119(95)00163-Z; CAI MJ, 1990, CELL, V61, P437, DOI 10.1016/0092-8674(90)90525-J; CAMPBELL MS, 1995, J CELL BIOL, V129, P1195, DOI 10.1083/jcb.129.5.1195; CASLANO CA, 1993, J CELL SCI, V106, P1045; CHIKASHIGE Y, 1989, CELL, V57, P739, DOI 10.1016/0092-8674(89)90789-7; CLARKE L, 1990, TRENDS GENET, V6, P150, DOI 10.1016/0168-9525(90)90149-Z; CONNELLY C, UNPUB; COOKE C, UNPUB; COOKE CA, 1990, J CELL BIOL, V110, P1475, DOI 10.1083/jcb.110.5.1475; COOKE CA, 1993, J CELL BIOL, V120, P1083, DOI 10.1083/jcb.120.5.1083; DIETZ R, 1958, CHROMOSOMA, V9, P359; DING R, 1993, J CELL BIOL, V120, P141, DOI 10.1083/jcb.120.1.141; DOHENY KF, 1993, CELL, V73, P761, DOI 10.1016/0092-8674(93)90255-O; EARNSHAW W C, 1992, Current Opinion in Cell Biology, V4, P86, DOI 10.1016/0955-0674(92)90063-I; EARNSHAW WC, 1991, J CELL SCI, V98, P443; EARNSHAW WC, 1985, CHROMOSOMA, V91, P313, DOI 10.1007/BF00328227; EARNSHAW WC, 1991, COLD SH Q B, V56, P675; EARNSHAW WC, 1990, CHROMOSOMA, V100, P139; EKWALL K, 1995, SCIENCE, V269, P1429, DOI 10.1126/science.7660126; FERGUSON M, 1992, CHROMOSOMA, V101, P557, DOI 10.1007/BF00660315; FISHEL B, 1988, MOL CELL BIOL, V8, P754, DOI 10.1128/MCB.8.2.754; FITZGERALDHAYES M, 1982, CELL, V29, P235, DOI 10.1016/0092-8674(82)90108-8; FOE VE, 1985, J CELL BIOL, V100, P1623, DOI 10.1083/jcb.100.5.1623; FOURNIER P, 1993, P NATL ACAD SCI USA, V90, P4912, DOI 10.1073/pnas.90.11.4912; FUNABIKI H, 1993, J CELL BIOL, V121, P961, DOI 10.1083/jcb.121.5.961; GOH PY, 1993, J CELL BIOL, V121, P503, DOI 10.1083/jcb.121.3.503; GOLDBERG IB, UNPUB; GORBSKY GJ, 1995, TRENDS CELL BIOL, V5, P143, DOI 10.1016/S0962-8924(00)88968-0; GORBSKY GJ, 1993, J CELL BIOL, V122, P1311, DOI 10.1083/jcb.122.6.1311; HAAF T, 1992, CELL, V70, P1; HEGEMANN JH, 1993, BIOESSAYS, V15, P451, DOI 10.1002/bies.950150704; HEUS JJ, 1990, CURR GENET, V18, P517, DOI 10.1007/BF00327022; HILL A, 1987, MOL CELL BIOL, V7, P2397, DOI 10.1128/MCB.7.7.2397; HUBERMAN JA, 1986, CHROMOSOMA, V94, P162, DOI 10.1007/BF00288490; JAMES TC, 1986, MOL CELL BIOL, V6, P3862, DOI 10.1128/MCB.6.11.3862; JANEVSKI J, 1995, EXP CELL RES, V217, P227, DOI 10.1006/excr.1995.1082; JIANG WD, 1993, J CELL BIOL, V121, P513, DOI 10.1083/jcb.121.3.513; JIANG WD, 1993, MOL CELL BIOL, V13, P4884, DOI 10.1128/MCB.13.8.4884; KIPLING D, 1995, MOL CELL BIOL, V15, P4009; LARIN Z, 1994, HUM MOL GENET, V3, P689, DOI 10.1093/hmg/3.5.689; LECHNER J, 1991, CELL, V64, P717, DOI 10.1016/0092-8674(91)90501-O; LECHNER J, 1994, EMBO J, V13, P5203, DOI 10.1002/j.1460-2075.1994.tb06851.x; LEGER I, 1994, CYTOMETRY, V16, P313, DOI 10.1002/cyto.990160405; LIXX, 1995, NATURE, V373, P630; LORENTZ A, 1994, GENE, V143, P139, DOI 10.1016/0378-1119(94)90619-X; MANUELIDIS L, 1988, CHROMOSOMA, V96, P397, DOI 10.1007/BF00303033; MARSCHALL LG, 1995, J CELL BIOL, V128, P445, DOI 10.1083/jcb.128.4.445; MASUMOTO H, 1989, EXP CELL RES, V181, P181, DOI 10.1016/0014-4827(89)90192-4; MASUMOTO H, 1989, J CELL BIOL, V109, P1963, DOI 10.1083/jcb.109.5.1963; MASUMOTO H, 1993, NATO ASI SERIES H, V72, P31; MCINTOSH JR, 1991, COLD SH Q B, V56, P613; MEIER UT, 1994, J CELL BIOL, V127, P1505, DOI 10.1083/jcb.127.6.1505; MELLOR J, 1990, EMBO J, V8, P4017; MELUH PB, 1995, MOL BIOL CELL, V6, P793, DOI 10.1091/mbc.6.7.793; MIDDLETON K, 1994, P NATL ACAD SCI USA, V91, P7212, DOI 10.1073/pnas.91.15.7212; MOROI Y, 1981, J CELL BIOL, V90, P254, DOI 10.1083/jcb.90.1.254; MURPHY TD, 1995, CELL, V82, P599, DOI 10.1016/0092-8674(95)90032-2; NICKLAS RB, 1969, J CELL BIOL, V43, P40, DOI 10.1083/jcb.43.1.40; NICKLAS RB, 1995, J CELL BIOL, V130, P929, DOI 10.1083/jcb.130.4.929; Nicol L, 1994, CHROMOSOME RES, V2, P245, DOI 10.1007/BF01553325; OCHS RL, 1992, EXP CELL RES, V200, P339, DOI 10.1016/0014-4827(92)90181-7; PARK PC, 1992, EXP CELL RES, V203, P222, DOI 10.1016/0014-4827(92)90058-G; PARO R, 1991, P NATL ACAD SCI USA, V88, P263, DOI 10.1073/pnas.88.1.263; PETERSON JB, 1976, J CELL SCI, V22, P219; PLUTA AF, 1991, J EXP MED, V174, P1239; RATTNER JB, 1993, CELL MOTIL CYTOSKEL, V26, P214, DOI 10.1002/cm.970260305; RATTNER JB, 1991, BIOESSAYS, V13, P51, DOI 10.1002/bies.950130202; RIEDER CL, 1995, J CELL BIOL, V130, P941, DOI 10.1083/jcb.130.4.941; SAITOH H, 1992, CELL, V70, P115, DOI 10.1016/0092-8674(92)90538-N; SAUNDERS MJ, 1990, MOL CELL BIOL, V10, P5721, DOI 10.1128/MCB.10.11.5721; SCHULMAN I, 1991, ANNU REV CELL BIOL, V7, P311, DOI 10.1146/annurev.cellbio.7.1.311; SIMERLY C, 1990, J CELL BIOL, V111, P1491, DOI 10.1083/jcb.111.4.1491; SLUDER G, 1994, J CELL BIOL, V126, P189, DOI 10.1083/jcb.126.1.189; SORGER PK, 1994, J CELL BIOL, V127, P995, DOI 10.1083/jcb.127.4.995; SPENCER F, 1992, P NATL ACAD SCI USA, V89, P8908, DOI 10.1073/pnas.89.19.8908; STEINER NC, 1994, CELL, V79, P865, DOI 10.1016/0092-8674(94)90075-2; STEINER NC, 1993, MOL CELL BIOL, V13, P4578, DOI 10.1128/MCB.13.8.4578; STOLER S, 1995, GENE DEV, V9, P573, DOI 10.1101/gad.9.5.573; STRUNNIKOV AV, 1995, J CELL BIOL, V128, P749, DOI 10.1083/jcb.128.5.749; SULLIVAN KF, 1994, J CELL BIOL, V127, P581, DOI 10.1083/jcb.127.3.581; TAN EM, 1988, CLIN IMMUNOL IMMUNOP, V47, P121, DOI 10.1016/0090-1229(88)90066-9; TOMKIEL J, 1994, J CELL BIOL, V125, P531, DOI 10.1083/jcb.125.3.531; TYLERSMITH C, 1993, CURR OPIN GENET DEV, V3, P390, DOI 10.1016/0959-437X(93)90110-B; WEVRICK R, 1989, P NATL ACAD SCI USA, V86, P9394, DOI 10.1073/pnas.86.23.9394; WORDEMAN L, 1995, J CELL BIOL, V128, P95, DOI 10.1083/jcb.128.1.95; WORDEMAN L, 1991, J CELL BIOL, V114, P285, DOI 10.1083/jcb.114.2.285; ZHU XL, 1995, MOL CELL BIOL, V15, P5017; ZIRKLE RE, 1970, J CELL BIOL, V47, P235	99	299	309	0	14	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	DEC 8	1995	270	5242					1591	1594		10.1126/science.270.5242.1591	http://dx.doi.org/10.1126/science.270.5242.1591			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TJ293	7502067				2022-12-28	WOS:A1995TJ29300029
J	FRIEDLANDER, M; BROOKS, PC; SHAFFER, RW; KINCAID, CM; VARNER, JA; CHERESH, DA				FRIEDLANDER, M; BROOKS, PC; SHAFFER, RW; KINCAID, CM; VARNER, JA; CHERESH, DA			DEFINITION OF 2 ANGIOGENIC PATHWAYS BY DISTINCT ALPHA(V) INTEGRINS	SCIENCE			English	Article							EXTRACELLULAR-MATRIX; ENDOTHELIAL-CELLS; MECHANISMS; FIBRINOGEN	Angiogenesis depends on cytokines and vascular cell adhesion events, Two cytokine-dependent pathways of angiogenesis were shown to exist and were defined by their dependency on distinct vascular cell integrins. In vivo angiogenesis in corneal or chorioallantoic membrane models induced by basic fibroblast growth factor or by tumor necrosis factor-alpha depended on alpha(V) beta(3), whereas angiogenesis initiated by vascular endothelial growth factor, transforming growth factor-alpha, or phorbol ester depended on alpha(V) beta(5). Antibody to each integrin selectively blocked one of these pathways, and a cyclic peptide antagonist of both integrins blocked angiogenesis stimulated by each cytokine tested. These pathways are further distinguished by their sensitivity to calphostin C, an inhibitor of protein kinase C that blocked angiogenesis potentiated by alpha(V) beta(5) but not by alpha(V) beta(3).	Scripps Res Inst, DEPT IMMUNOL, LA JOLLA, CA 92037 USA; Scripps Res Inst, DEPT VASC BIOL, LA JOLLA, CA 92037 USA; UNIV CALIF SAN DIEGO, DEPT MED, LA JOLLA, CA 92093 USA	Scripps Research Institute; Scripps Research Institute; University of California System; University of California San Diego	FRIEDLANDER, M (corresponding author), Scripps Res Inst, DEPT CELL BIOL, ROBERT MEALEY LAB STUDY MASCULAR DEGENERAT, LA JOLLA, CA 92037 USA.			Varner, Judith/0000-0002-9251-0600				AIELLO LP, 1994, NEW ENGL J MED, V331, P1480, DOI 10.1056/NEJM199412013312203; BROOKS PC, 1994, SCIENCE, V264, P569, DOI 10.1126/science.7512751; BROOKS PC, 1994, CELL, V79, P1157, DOI 10.1016/0092-8674(94)90007-8; BROOKS PM, UNPUB; CHERESH DA, 1989, CELL, V58, P945, DOI 10.1016/0092-8674(89)90946-X; CHERESH DA, 1987, P NATL ACAD SCI USA, V84, P6471, DOI 10.1073/pnas.84.18.6471; DAMATO RJ, 1994, P NATL ACAD SCI USA, V91, P4082, DOI 10.1073/pnas.91.9.4082; DAMORE PA, 1994, INVEST OPHTH VIS SCI, V35, P3974; DAMORE PA, 1987, ANNU REV PHYSIOL, V49, P453; DRAKE CJ, 1995, J CELL SCI, V108, P2655; ENENSTEIN J, 1994, J INVEST DERMATOL, V103, P381, DOI 10.1111/1523-1747.ep12395390; FOLKMAN J, 1992, J BIOL CHEM, V267, P10931; FOLKMAN J, 1995, NAT MED, V1, P27, DOI 10.1038/nm0195-27; FRIEDLANDER M, 1995, SEP RET SOC M SANT F; INGBER DE, 1989, J CELL BIOL, V109, P317, DOI 10.1083/jcb.109.1.317; KLEMKE RL, 1994, J CELL BIOL, V127, P859, DOI 10.1083/jcb.127.3.859; LEAVESLEY DI, 1993, J CELL BIOL, V121, P163, DOI 10.1083/jcb.121.1.163; MEREDITH JE, 1993, MOL BIOL CELL, V4, P953, DOI 10.1091/mbc.4.9.953; MILLER JW, 1994, AM J PATHOL, V145, P574; PFAFF M, 1994, J BIOL CHEM, V269, P20233; SHAFFER R, IN PRESS NATO ASI MO; WEINSTATSASLOW D, 1994, FASEB J, V8, P401, DOI 10.1096/fasebj.8.6.7513289	22	1139	1256	1	35	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	DEC 1	1995	270	5241					1500	1502		10.1126/science.270.5241.1500	http://dx.doi.org/10.1126/science.270.5241.1500			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TH375	7491498				2022-12-28	WOS:A1995TH37500041
J	RICE, WG; SUPKO, JG; MALSPEIS, L; BUCKHEIT, RW; CLANTON, D; BU, M; GRAHAM, L; SCHAEFFER, CA; TURPIN, JA; DOMAGALA, J; GOGLIOTTI, R; BADER, JP; HALLIDAY, SM; COREN, L; SOWDER, RC; ARTHUR, LO; HENDERSON, LE				RICE, WG; SUPKO, JG; MALSPEIS, L; BUCKHEIT, RW; CLANTON, D; BU, M; GRAHAM, L; SCHAEFFER, CA; TURPIN, JA; DOMAGALA, J; GOGLIOTTI, R; BADER, JP; HALLIDAY, SM; COREN, L; SOWDER, RC; ARTHUR, LO; HENDERSON, LE			INHIBITORS OF HIV NUCLEOCAPSID PROTEIN ZINC FINGERS AS CANDIDATES FOR THE TREATMENT OF AIDS	SCIENCE			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; REVERSE-TRANSCRIPTASE; TYPE-1; RETROVIRUSES; INFECTIVITY; SEQUENCES; CLONE; RNA	Strategies for the treatment of human immunodeficiency virus-type 1 (HIV-1) infection must contend with the obstacle of drug resistance. HIV-1 nucleocapsid protein zinc fingers are prime antiviral targets because they are mutationally into lerant and are required both for acute infection and virion assembly. Nontoxic disulfide-substituted benzamides were identified that attack the zinc fingers, inactivate cell-free virions, inhibit acute and chronic infections, and exhibit broad antiretroviral activity. The compounds were highly synergistic with other antiviral agents, and resistant mutants have not been detected. Zinc finger-reactive compounds may offer an anti-HIV strategy that restricts drug-resistance development.	NCI,DIV CANC TREATMENT,PHARMACEUT CHEM LAB,DEV THERAPEUT PROGRAM,FREDERICK,MD 21701; SO RES INST FREDERICK RES CTR,VIROL RES GRP,FREDERICK,MD 21701; NCI,FREDERICK CANC RES & DEV CTR,PRI DYNCORP,ANTI AIDS VIRUS DRUG SCREENING LAB,FREDERICK,MD 21702; WARNER LAMBERT PARKE DAVIS,PARKE DAVIS PHARMACEUT RES DIV,DEPT CHEM,ANN ARBOR,MI 48105; NCI,DIV CANC TREATMENT,DEV THERAPEUT PROGRAM,ANTIVIRAL EVALUAT BRANCH,BETHESDA,MD 20892; NCI,FREDERICK CANC RES & DEV CTR,PRI DYNCORP,AIDS VACCINE PROGRAM,FREDERICK,MD 21702	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick; Pfizer; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick	RICE, WG (corresponding author), NCI,FREDERICK CANC RES & DEV CTR,PRI DYNCORP,ANTIVIRAL DRUG MECHANISMS LAB,FREDERICK,MD 21702, USA.							ALDOVINI A, 1990, J VIROL, V64, P1920, DOI 10.1128/JVI.64.5.1920-1926.1990; BERG JM, 1986, SCIENCE, V232, P485, DOI 10.1126/science.2421409; BESS JW, 1992, J VIROL, V66, P840, DOI 10.1128/JVI.66.2.840-847.1992; BUCKHEIT RW, 1995, ANTIVIR RES, V26, P117, DOI 10.1016/0166-3542(94)00069-K; BUCKHEIT RW, 1994, ANTIVIR RES, V25, P43, DOI 10.1016/0166-3542(94)90092-2; BUCKHEIT RW, 1993, ANTIVIR RES, V21, P247, DOI 10.1016/0166-3542(93)90031-D; CHANCE MR, 1992, P NATL ACAD SCI USA, V89, P10124; CLOUSE KA, 1989, J IMMUNOL, V142, P431; COFFIN JM, 1995, SCIENCE, V267, P483, DOI 10.1126/science.7824947; CUSHMAN M, 1994, J MED CHEM, V37, P3040, DOI 10.1021/jm00045a008; FOLKS TM, 1988, J IMMUNOL, V140, P1117; GIBALDI M, 1982, PHARMACOKINETICS, P410; GORELICK RJ, 1993, J VIROL, V67, P4027, DOI 10.1128/JVI.67.7.4027-4036.1993; GORELICK RJ, 1990, J VIROL, V64, P3207, DOI 10.1128/JVI.64.7.3207-3211.1990; HART GJ, 1992, ANTIMICROB AGENTS CH, V36, P1688, DOI 10.1128/AAC.36.8.1688; HENDERSON LE, 1992, J VIROL, V66, P1856, DOI 10.1128/JVI.66.4.1856-1865.1992; KAGEYAMA S, 1994, ANTIMICROB AGENTS CH, V38, P1107, DOI 10.1128/AAC.38.5.1107; Mellors J. W., 1995, International Antiviral News, V3, P8; PELISKA JA, 1994, BIOCHEMISTRY-US, V33, P13817, DOI 10.1021/bi00250a036; PRICHARD MN, 1990, ANTIVIR RES, V14, P181, DOI 10.1016/0166-3542(90)90001-N; Rice W. G., 1995, International Antiviral News, V3, P87; RICE WG, 1993, P NATL ACAD SCI USA, V90, P9721, DOI 10.1073/pnas.90.20.9721; RICE WG, 1993, NATURE, V361, P473, DOI 10.1038/361473a0; RICE WG, 1995, ANTIVIR RES, V26, pA235; RICE WG, UNPUB; South T L, 1990, Adv Inorg Biochem, V8, P199; SOUTH TL, 1990, BIOCHEM PHARMACOL, V40, P123, DOI 10.1016/0006-2952(90)90187-P; STAAL FTJ, 1993, AIDS RES HUM RETROV, V9, P4299; SUMMERS MF, 1992, PROTEIN SCI, V1, P563, DOI 10.1002/pro.5560010502; WEISLOW OS, 1989, JNCI-J NATL CANCER I, V81, P577, DOI 10.1093/jnci/81.8.577	30	234	280	0	13	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	NOV 17	1995	270	5239					1194	1197		10.1126/science.270.5239.1194	http://dx.doi.org/10.1126/science.270.5239.1194			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TE905	7502043				2022-12-28	WOS:A1995TE90500055
J	BLUMBERGS, PC; SCOTT, G; MANAVIS, J; WAINWRIGHT, H; SIMPSON, DA; MCLEAN, AJ				BLUMBERGS, PC; SCOTT, G; MANAVIS, J; WAINWRIGHT, H; SIMPSON, DA; MCLEAN, AJ			STAINING OF AMYLOID PRECURSOR PROTEIN TO STUDY AXONAL DAMAGE IN MILD HEAD-INJURY	LANCET			English	Note							DEGENERATION	The most common definition of cerebral concussion is that of a transient loss of neurological function without macroscopic or microscopic abnormality in the brain. However, some patients have persistent symptoms and subtle neuropsychological deficits, particularly affecting memory. We have studied five patients aged 59-89 years who sustained mild concussive head injury and died of other causes (2-99 days post-injury). Immunostaining with an antibody to amyloid precursor protein, a marker oi fast axonal transport, showed multifocal axonal injury in all five. All had axonal damage in the fornices, which are important in memory function.	UNIV ADELAIDE,NHMRC RD ACCID RES UNIT,ADELAIDE,SA,AUSTRALIA	University of Adelaide	BLUMBERGS, PC (corresponding author), INST MED & VET SCI,NEUROPATHOL LAB,POB 14,ADELAIDE,SA 5001,AUSTRALIA.							Amaral D. G., 1987, HDB PHYSL NERVOUS SY, P211; GALE SD, 1993, BRAIN RES BULL, V32, P345, DOI 10.1016/0361-9230(93)90198-K; GENTLEMAN SM, 1993, NEUROSCI LETT, V160, P139, DOI 10.1016/0304-3940(93)90398-5; GRONWALL D, 1974, LANCET, V2, P605; JANE JA, 1985, J NEUROSURG, V62, P96, DOI 10.3171/jns.1985.62.1.0096; KOO EH, 1990, P NATL ACAD SCI USA, V87, P1561, DOI 10.1073/pnas.87.4.1561; LEVIN HS, 1987, J NEUROSURG, V66, P234, DOI 10.3171/jns.1987.66.2.0234; OMMAYA AK, 1974, BRAIN, V97, P633, DOI 10.1093/brain/97.1.633; OPPENHEI.DR, 1968, J NEUROL NEUROSUR PS, V31, P299, DOI 10.1136/jnnp.31.4.299; RYAN GA, 1994, J TRAUMA, V36, P469	10	360	368	0	15	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	OCT 15	1994	344	8929					1055	1056		10.1016/S0140-6736(94)91712-4	http://dx.doi.org/10.1016/S0140-6736(94)91712-4			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PL852	7523810				2022-12-28	WOS:A1994PL85200012
J	SABATINI, DM; ERDJUMENTBROMAGE, H; LUI, M; TEMPST, P; SNYDER, SH				SABATINI, DM; ERDJUMENTBROMAGE, H; LUI, M; TEMPST, P; SNYDER, SH			RAFT1 - A MAMMALIAN PROTEIN THAT BINDS TO FKBP12 IN A RAPAMYCIN-DEPENDENT FASHION AND IS HOMOLOGOUS TO YEAST TORS	CELL			English	Article							PEPTIDYL-PROLYL ISOMERASE; CALCIUM-RELEASE CHANNEL; CYCLOSPORINE-A; SIGNAL-TRANSDUCTION; PHOSPHATIDYLINOSITOL KINASE; SACCHAROMYCES-CEREVISIAE; IMMUNOSUPPRESSANT FK506; FK-506-BINDING PROTEIN; MOLECULAR-CLONING; SEQUENCE-ANALYSIS	The immunosuppressants rapamycin and FK506 bind to the same intracellular protein, the immunophilin FKBP12. The FKBP12-FK506 complex interacts with and inhibits the Ca2+-activated protein phosphatase calcineurin. The target of the FKBP12-rapamycin complex has not yet been identified. We report that a protein complex containing 245 kDa and 35 kDa components, designated rapamycin and FKBP12 targets 1 and 2 (RAFT1 and RAFT2), interacts with FKBP12 in a rapamycin-dependent manner. Sequences (330 amino acids total) of tryptic peptides derived from the 245 kDa RAFT1 reveal striking homologies to the yeast TOR gene products, which were originally identified by mutations that confer rapamycin resistance in yeast. A RAFT1 cDNA was obtained and found to encode a 289 kDa protein (2549 amino acids) that is 43% and 39% identical to TOR2 and TOR1, respectively. We propose that RAFT1 is the direct target of FKBP12-rapamycin and a mammalian homolog of the TOR proteins.	MEM SLOAN KETTERING CANC CTR, PROGRAM MOLEC BIOL, NEW YORK, NY 10021 USA	Memorial Sloan Kettering Cancer Center	SABATINI, DM (corresponding author), JOHNS HOPKINS UNIV, SCH MED, DEPT NEUROSCI, BALTIMORE, MD 21205 USA.			/0000-0002-1446-7256; Erdjument-Bromage, Hediye/0000-0003-0224-3594	NATIONAL INSTITUTE ON DRUG ABUSE [P50DA000266] Funding Source: NIH RePORTER; NIDA NIH HHS [DA-00074, DA-00266] Funding Source: Medline; NIGMS NIH HHS [GM-07309] Funding Source: Medline	NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission); NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALBERS MW, 1993, J BIOL CHEM, V268, P22825; ALTIN JG, 1991, J BIOL CHEM, V266, P5401; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; AUGER KR, 1989, CELL, V57, P167, DOI 10.1016/0092-8674(89)90182-7; BALLA T, 1994, MOL BIOL CELL, V5, P17, DOI 10.1091/mbc.5.1.17; BIERER BE, 1990, SCIENCE, V250, P556, DOI 10.1126/science.1700475; BIERER BE, 1990, P NATL ACAD SCI USA, V87, P9231, DOI 10.1073/pnas.87.23.9231; BLANAR MA, 1992, NATURE, V256, P1014; BOREL JF, 1986, PROG ALLERGY, V38, P9; CAFFERKEY R, 1993, MOL CELL BIOL, V13, P6012, DOI 10.1128/MCB.13.10.6012; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; CARPENTER CL, 1990, J BIOL CHEM, V265, P19704; CHUNG J, 1992, CELL, V69, P1227, DOI 10.1016/0092-8674(92)90643-Q; DUMONT FJ, 1990, J IMMUNOL, V144, P251; ELICONE C, 1994, IN PRESS J CHROMATOG, V676; ERDJUMENTBROMAG.H, 1993, TECHNIQUES PROTEIN C, V4, P419; FLANAGAN WM, 1991, NATURE, V352, P803, DOI 10.1038/352803a0; FRUMAN DA, 1994, FASEB J, V8, P391, DOI 10.1096/fasebj.8.6.7513288; GEROMANOS S, 1994, TECHNIQUES PROTEIN C, V5, P143; GOULD SJ, 1989, P NATL ACAD SCI USA, V86, P1934, DOI 10.1073/pnas.86.6.1934; HANDSCHUMACHER RE, 1984, SCIENCE, V226, P544, DOI 10.1126/science.6238408; HARDING MW, 1989, NATURE, V341, P758, DOI 10.1038/341758a0; HEITMAN J, 1991, P NATL ACAD SCI USA, V88, P1948, DOI 10.1073/pnas.88.5.1948; HEITMAN J, 1992, NEW BIOL, V4, P448; HEITMAN J, 1991, SCIENCE, V253, P905, DOI 10.1126/science.1715094; HELLIWELL SB, 1994, MOL BIOL CELL, V5, P105, DOI 10.1091/mbc.5.1.105; JAYARAMAN T, 1993, J BIOL CHEM, V268, P25385; JAYARAMAN T, 1992, J BIOL CHEM, V267, P9474; JIN YJ, 1992, J BIOL CHEM, V267, P10942; KINO T, 1987, J ANTIBIOT, V40, P1249, DOI 10.7164/antibiotics.40.1249; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; KRONKE M, 1984, P NATL ACAD SCI-BIOL, V81, P5214, DOI 10.1073/pnas.81.16.5214; KUNZ J, 1993, TRENDS BIOCHEM SCI, V18, P334, DOI 10.1016/0968-0004(93)90069-Y; KUNZ J, 1993, CELL, V73, P585, DOI 10.1016/0092-8674(93)90144-F; KUO CJ, 1992, NATURE, V358, P70, DOI 10.1038/358070a0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LI M, 1992, SCIENCE, V257, P1225, DOI 10.1126/science.1519059; LIU J, 1991, CELL, V66, P807, DOI 10.1016/0092-8674(91)90124-H; LIU J, 1993, TRENDS PHARMACOL SCI, V14, P182, DOI 10.1016/0165-6147(93)90206-Y; MARTEL RR, 1977, CAN J PHYSIOL PHARM, V55, P48, DOI 10.1139/y77-007; McCombie W R, 1992, DNA Seq, V2, P289, DOI 10.3109/10425179209030961; MORICE WG, 1993, J BIOL CHEM, V268, P22737; Sambrook J, 1989, MOL CLONING LABORATO; SCHREIBER SL, 1991, SCIENCE, V251, P283, DOI 10.1126/science.1702904; SIEKIERKA JJ, 1989, NATURE, V341, P755, DOI 10.1038/341755a0; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; SMITH LM, 1986, NATURE, V321, P674, DOI 10.1038/321674a0; STANDAERT RF, 1990, NATURE, V346, P671, DOI 10.1038/346671a0; STEINER JP, 1992, NATURE, V358, P584, DOI 10.1038/358584a0; TEMPST P, 1989, ANAL BIOCHEM, V183, P290, DOI 10.1016/0003-2697(89)90482-X; TEMPST P, 1990, ELECTROPHORESIS, V11, P537, DOI 10.1002/elps.1150110704; TIMERMAN AP, 1993, J BIOL CHEM, V268, P22992; TROPSCHUG M, 1989, NATURE, V342, P953, DOI 10.1038/342953a0; WHITMAN M, 1988, NATURE, V332, P644, DOI 10.1038/332644a0	54	1183	1250	3	54	CELL PRESS	CAMBRIDGE	600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JUL 15	1994	78	1					35	43		10.1016/0092-8674(94)90570-3	http://dx.doi.org/10.1016/0092-8674(94)90570-3			9	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	NX328	7518356				2022-12-28	WOS:A1994NX32800006
J	DELASALLE, H; HANAU, D; FRICKER, D; URLACHER, A; KELLY, A; SALAMERO, J; POWIS, SH; DONATO, L; BAUSINGER, H; LAFORET, M; JERAS, M; SPEHNER, D; BIEBER, T; FALKENRODT, A; CAZENAVE, JP; TROWSDALE, J; TONGIO, MM				DELASALLE, H; HANAU, D; FRICKER, D; URLACHER, A; KELLY, A; SALAMERO, J; POWIS, SH; DONATO, L; BAUSINGER, H; LAFORET, M; JERAS, M; SPEHNER, D; BIEBER, T; FALKENRODT, A; CAZENAVE, JP; TROWSDALE, J; TONGIO, MM			HOMOZYGOUS HUMAN TAP PEPTIDE TRANSPORTER MUTATION IN HLA CLASS-I DEFICIENCY	SCIENCE			English	Article							MAJOR HISTOCOMPATIBILITY COMPLEX; PRIMERS PCR-SSP; T-CELLS; COMBINED IMMUNODEFICIENCY; DEFECTIVE EXPRESSION; ANTIGEN PRESENTATION; BARE LYMPHOCYTE; SURFACE; REGION; MICE	Human lymphocyte antigen (HLA) class I proteins of the major histocompatibility complex are largely dependent for expression on small peptides supplied to them by transporter associated with antigen processing (TAP) protein. An inherited human deficiency in the TAP transporter was identified in two siblings suffering from recurrent respiratory bacterial infections. The expression on the cell surface of class I proteins was very low, whereas that of CD1a was normal, and the cytotoxicity of natural killer cells was affected. In addition, CD8(+) alpha beta T cells were present in low but significant numbers and were cytotoxic in the most severely affected sibling, who also showed an increase in CD4(+)CD8(+) T cells and gamma delta T cells.	IMPERIAL CANC RES FUND,LONDON WC2A 3PX,ENGLAND; INST CURIE,INSERM,U255,F-75231 PARIS,FRANCE; UNIV STRASBOURG,HOP HAUTEPIERRE,SERV PEDIAT,F-67098 STRASBOURG,FRANCE; UNIV STRASBOURG 1,INSERM,U74,F-67085 STRASBOURG,FRANCE; UNIV STRASBOURG 1,SYNTHELABO,FAC MED,COMMUN LAB,F-67085 STRASBOURG,FRANCE; CTR REG TRANSFUS SANGUINE,HEMATOL NORMALE & PATHOL LAB,F-67085 STRASBOURG,FRANCE; CTR REG TRANSFUS SANGUINE,INSERM,U311,F-67085 STRASBOURG,FRANCE	Cancer Research UK; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie; CHU Strasbourg; UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg; Sanofi-Aventis; Sanofi France; UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg	DELASALLE, H (corresponding author), CTR REG TRANSFUS SANGUINE,HISTOCOMPATIBIL LAB,F-67085 STRASBOURG,FRANCE.		Cazenave, Jean-Pierre/AAE-2935-2019; De La Salle, Henri/H-9353-2016	De La Salle, Henri/0000-0001-5136-0776; salamero, jean/0000-0002-2610-5826				APASOV S, 1993, P NATL ACAD SCI USA, V90, P2837, DOI 10.1073/pnas.90.7.2837; BAHRAM S, 1991, P NATL ACAD SCI USA, V88, P10094, DOI 10.1073/pnas.88.22.10094; BECK S, 1992, J MOL BIOL, V228, P433, DOI 10.1016/0022-2836(92)90832-5; BERGER AE, 1982, HYBRIDOMA, V1, P87, DOI 10.1089/hyb.1.1982.1.87; BIEBER T, 1989, J INVEST DERMATOL, V93, P215, DOI 10.1111/1523-1747.ep12277574; BIRON CA, 1989, NEW ENGL J MED, V320, P1731, DOI 10.1056/NEJM198906293202605; BIRON CA, 1988, NAT IMMUN CELL GROW, V7, P47; BROWNING MJ, 1993, P NATL ACAD SCI USA, V90, P2842, DOI 10.1073/pnas.90.7.2842; DELASALLE H, UNPUB; DIBRINO M, 1993, P NATL ACAD SCI USA, V90, P1508, DOI 10.1073/pnas.90.4.1508; DOHERTY PC, 1993, CURR OPIN IMMUNOL, V5, P479, DOI 10.1016/0952-7915(93)90026-O; FURUKAWA S, 1992, BLOOD, V80, P3253; GLAS R, 1994, J EXP MED, V179, P661, DOI 10.1084/jem.179.2.661; GLYNNE R, 1993, EUR J IMMUNOL, V23, P860, DOI 10.1002/eji.1830230414; GROH V, 1989, J EXP MED, V169, P1277, DOI 10.1084/jem.169.4.1277; HAMMOND SA, 1993, NATURE, V364, P158, DOI 10.1038/364158a0; HANNET I, 1992, IMMUNOL TODAY, V13, P215, DOI 10.1016/0167-5699(92)90157-3; HEEMELS MT, 1993, CURR BIOL, V3, P380, DOI 10.1016/0960-9822(93)90208-6; KELLY A, 1991, NATURE, V353, P667, DOI 10.1038/353667a0; KELLY A, 1992, NATURE, V355, P641, DOI 10.1038/355641a0; Kimura A., 1991, HLA 1991 P 11 INT HI, VVolume 1, P397; LAMOUSESMITH E, 1993, J IMMUNOL, V151, P6283; LJUNGGREN HG, 1990, NATURE, V346, P476, DOI 10.1038/346476a0; MAEDA H, 1985, IMMUNOGENETICS, V21, P549, DOI 10.1007/BF00395879; MARCADET A, 1985, NEW ENGL J MED, V312, P1287, DOI 10.1056/NEJM198505163122004; MONACO JJ, 1992, IMMUNOL TODAY, V13, P173, DOI 10.1016/0167-5699(92)90122-N; MURPHY GF, 1983, BRIT J DERMATOL, V108, P423, DOI 10.1111/j.1365-2133.1983.tb04594.x; NEEFJES JJ, 1986, HUM IMMUNOL, V16, P169, DOI 10.1016/0198-8859(86)90046-7; NEEFJES JJ, 1993, SCIENCE, V261, P769, DOI 10.1126/science.8342042; OLERUP O, 1993, TISSUE ANTIGENS, V41, P119, DOI 10.1111/j.1399-0039.1993.tb01991.x; OTTEN GR, 1992, J IMMUNOL, V148, P3723; PAYNE R, 1983, HUM IMMUNOL, V6, P219, DOI 10.1016/0198-8859(83)90095-2; PFEIFER JD, 1993, NATURE, V361, P359, DOI 10.1038/361359a0; PORCELLI S, 1992, NATURE, V360, P593, DOI 10.1038/360593a0; POWIS SH, 1992, P NATL ACAD SCI USA, V89, P1463, DOI 10.1073/pnas.89.4.1463; RAULET DH, 1994, ADV IMMUNOL, V55, P381; RITTIG MG, 1994, INT ARCH ALLERGY IMM, V103, P4, DOI 10.1159/000236598; ROCK KL, 1991, P NATL ACAD SCI USA, V88, P4200, DOI 10.1073/pnas.88.10.4200; SALA P, 1993, BLOOD, V82, P1546; SCHUURMAN RKB, 1979, CLIN IMMUNOL IMMUNOP, V14, P418, DOI 10.1016/0090-1229(79)90094-1; SEAMAN WE, 1981, J CLIN INVEST, V67, P1324, DOI 10.1172/JCI110161; SHEPHERD JC, 1993, CELL, V74, P577, DOI 10.1016/0092-8674(93)80058-M; SUGIYAMA Y, 1986, CHEST, V89, P398, DOI 10.1378/chest.89.3.398; Sugiyama Y, 1989, Nihon Kyobu Shikkan Gakkai Zasshi, V27, P980; TERASAKI PI, 1964, NATURE, V204, P998, DOI 10.1038/204998b0; TIERCY JM, 1991, TRANSPLANTATION, V51, P1110, DOI 10.1097/00007890-199105000-00034; TONGIO MM, UNPUB; TOURAINE JL, 1978, J PEDIATR-US, V93, P47, DOI 10.1016/S0022-3476(78)80598-8; TOWNSEND A, 1989, NATURE, V340, P443, DOI 10.1038/340443a0; VANKAER L, 1992, CELL, V71, P1205, DOI 10.1016/S0092-8674(05)80068-6; VARDAL F, 1986, TISSUE ANTIGENS, V28, P301; ZETTERQUIST H, 1992, HUM IMMUNOL, V34, P64, DOI 10.1016/0198-8859(92)90086-3; ZIJILSTA M, 1992, J EXP MED, V175, P885; 1980, TISSUE ANTIGENS, V16, P335	54	252	255	0	13	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUL 8	1994	265	5169					237	241		10.1126/science.7517574	http://dx.doi.org/10.1126/science.7517574			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	NV957	7517574				2022-12-28	WOS:A1994NV95700038
J	WIGLEY, FM; WISE, RA; SEIBOLD, JR; MCCLOSKEY, DA; KUJALA, G; MEDSGER, TA; STEEN, VD; VARGA, J; JIMENEZ, S; MAYES, M; CLEMENTS, PJ; WEINER, SR; PORTER, J; ELLMAN, M; WISE, C; KAUFMAN, LD; WILLIAMS, J; DOLE, W				WIGLEY, FM; WISE, RA; SEIBOLD, JR; MCCLOSKEY, DA; KUJALA, G; MEDSGER, TA; STEEN, VD; VARGA, J; JIMENEZ, S; MAYES, M; CLEMENTS, PJ; WEINER, SR; PORTER, J; ELLMAN, M; WISE, C; KAUFMAN, LD; WILLIAMS, J; DOLE, W			INTRAVENOUS ILOPROST INFUSION IN PATIENTS WITH RAYNAUD PHENOMENON SECONDARY TO SYSTEMIC-SCLEROSIS - A MULTICENTER, PLACEBO-CONTROLLED, DOUBLE-BLIND-STUDY	ANNALS OF INTERNAL MEDICINE			English	Article							PROSTACYCLIN INFUSION; BETA-THROMBOGLOBULIN; SCLERODERMA; NIFEDIPINE; TRIAL; ANALOG	Objective: To evaluate the efficacy and safety of iloprost, a prostacyclin analog, administered intravenously in patients with Raynaud phenomenon secondary to systemic sclerosis. Design: Multicenter, randomized, parallel placebo-controlled, double-blind study. Setting: University medical centers. Patients: 131 patients with systemic sclerosis (101 women, 30 men) ages 20 to 79 years. Intervention: Patients were randomly assigned to receive one of two parallel treatments of five daily sequential, 6-hour intravenous infusions of iloprost (0.5 to 2.0 ng/kg per min) or to receive a similar volume of placebo. Measurements: Frequency of Raynaud attacks, Raynaud severity score, physician's overall rating of treatment effect, and digital cutaneous lesion healing. Results: Of the 131 patients enrolled, 126 completed the 5-day infusion and 114 (87%) completed at least 6 weeks of follow-up. Sixty-four patients were randomly assigned to receive iloprost and 67 patients, to receive placebo. The mean weekly number of Raynaud attacks decreased 39.1% with iloprost and 22.2% with placebo (P = 0.005). In addition, the moan percentage of improvement in a global Raynaud severity score during the entire 9-week follow-up was greater in patients given iloprost (34.8%) than in those receiving placebo (19.7%) (P = 0.011). The physician's overall rating of, treatment effect showed greater improvement with iloprost than with placebo at week 6 (52.4% compared with 27.4%; P = 0.008) and week 9 (60.9% compared with 26.9%; P < 0.001). At week 3, 14.6% more patients receiving iloprost had 50% or more lesions heal compared with those given placebo (95% CI, 0.9% to 30%). During the infusion, 59 (92%) of the patients receiving iloprost had one or more side effects compared with 38 (57%) of the patients receiving placebo. Conclusion: iloprost is effective for the short-term palliation of severe Raynaud phenomenon in patients with systemic sclerosis.	UNIV CALIF LOS ANGELES, SAN FERNANDO VALLEY PROGRAM, GRANADA HILLS, CA USA; UMDNJ, ROBERT WOOD JOHNSON MED SCH, NEW BRUNSWICK, NJ 08903 USA; W VIRGINIA UNIV, MORGANTOWN, WV 26506 USA; UNIV PITTSBURGH, DEPT MED, PITTSBURGH, PA 15260 USA; THOMAS JEFFERSON UNIV, PHILADELPHIA, PA 19107 USA; WAYNE STATE UNIV, DETROIT, MI 48202 USA; UNIV CALIF LOS ANGELES, SCH MED, DEPT MED, LOS ANGELES, CA 90024 USA; UNIV OREGON, EUGENE, OR 97403 USA; UNIV CHICAGO, CHICAGO, IL 60637 USA; WAKE FOREST UNIV, BOWMAN GRAY SCH MED, WINSTON SALEM, NC 27103 USA; SUNY STONY BROOK, DIV ALLERGY & RHEUMATOL, STONY BROOK, NY 11794 USA; BERLEX LABS INC, WAYNE, NJ 07470 USA	University of California System; University of California Los Angeles; Rutgers State University New Brunswick; Rutgers State University Medical Center; West Virginia University; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Jefferson University; Wayne State University; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of Oregon; University of Chicago; Wake Forest University; Wake Forest Baptist Medical Center; State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook	WIGLEY, FM (corresponding author), JOHNS HOPKINS UNIV, SCH MED, DIV MOLEC & CLIN RHEUMATOL, 1830 E MONUMENT ST, SUITE 7500, BALTIMORE, MD 21205 USA.		Varga, John/AAK-6472-2021	Jimenez, Sergio/0000-0001-5213-1203; Wise, Robert/0000-0002-8353-2349				[Anonymous], 1980, ARTHRITIS RHEUM, V23, P581, DOI 10.1002/art.1780230510; BELCH JJF, 1983, LANCET, V1, P313; BELCH JJF, 1981, THROMB HAEMOSTASIS, V45, P255; BELLUCCI S, 1986, SCAND J RHEUMATOL, V15, P392, DOI 10.3109/03009748609098210; COFFMAN JD, 1989, AM J MED, V87, P264; CORBIN DOC, 1986, EUR HEART J, V7, P165, DOI 10.1093/oxfordjournals.eurheartj.a062040; DOWD PM, 1982, BRIT J DERMATOL, V106, P81, DOI 10.1111/j.1365-2133.1982.tb00905.x; FISHER CA, 1987, J LAB CLIN MED, V109, P184; FRIES JF, 1980, ARTHRITIS RHEUM, V23, P137, DOI 10.1002/art.1780230202; FRIES JF, 1982, J RHEUMATOL, V9, P789; HINDERLING PH, 1992, CLIN PHARMACOL THER, V51, P133; KAHALEH MB, 1982, ANN INTERN MED, V96, P610, DOI 10.7326/0003-4819-96-5-610; KAHAN A, 1983, EUR HEART J, V4, P123, DOI 10.1093/eurheartj/4.suppl_C.123; KELLER J, 1985, ARCH DERMATOL RES, V277, P323, DOI 10.1007/BF00509089; KYLE MV, 1992, J RHEUMATOL, V19, P1403; MCHUGH NJ, 1988, ANN RHEUM DIS, V47, P43, DOI 10.1136/ard.47.1.43; NORTON WL, 1970, ANN INTERN MED, V73, P317, DOI 10.7326/0003-4819-73-2-317; Poole J L, 1991, Arthritis Care Res, V4, P27, DOI 10.1002/art.1790040106; RADEMAKER M, 1987, POSTGRAD MED J, V63, P617, DOI 10.1136/pgmj.63.742.617; RADEMAKER M, 1989, BRIT MED J, V298, P561, DOI 10.1136/bmj.298.6673.561; REILLY IAG, 1986, BRIT MED J, V292, P1037, DOI 10.1136/bmj.292.6527.1037; RODEHEFFER RJ, 1983, NEW ENGL J MED, V308, P880, DOI 10.1056/NEJM198304143081507; RODNAN GP, 1980, MEDICINE, V59, P393, DOI 10.1097/00005792-198011000-00001; SEIBOLD JR, 1985, J RHEUMATOL, V12, P99; TORLEY HI, 1991, ANN RHEUM DIS, V50, P800, DOI 10.1136/ard.50.11.800; WATSON HR, 1991, ANN RHEUM DIS, V50, P359, DOI 10.1136/ard.50.6.359; WIGLEY FM, 1987, J RHEUMATOL, V14, P751; WIGLEY FM, 1992, J RHEUMATOL, V19, P1407; YARDUMIAN DA, 1988, BRIT J RHEUMATOL, V27, P220; YLITALO P, 1984, BIOMED BIOCHIM ACTA, V43, pS399	30	294	307	0	6	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	FEB 1	1994	120	3					199	206		10.7326/0003-4819-120-3-199402010-00004	http://dx.doi.org/10.7326/0003-4819-120-3-199402010-00004			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MU303	7506013				2022-12-28	WOS:A1994MU30300004
J	MCLEAN, A				MCLEAN, A			REGULATION WITH RANTES	LANCET			English	Editorial Material							FAMILY				MCLEAN, A (corresponding author), JOHN RADCLIFFE HOSP,NUFFIELD DEPT SURG,OXFORD OX3 9DU,ENGLAND.							AKBAR AN, 1990, CLIN EXP IMMUNOL, V81, P225; CERRETTI DP, 1993, MOL IMMUNOL, V30, P359; GAO JL, 1993, J EXP MED, V177, P1421, DOI 10.1084/jem.177.5.1421; GIMBRONE MA, 1989, SCIENCE, V246, P1601, DOI 10.1126/science.2688092; HARADA A, 1993, INT IMMUNOL, V5, P681, DOI 10.1093/intimm/5.6.681; HEEGER P, 1992, KIDNEY INT, V41, P220, DOI 10.1038/ki.1992.31; HORUK R, 1993, SCIENCE, V261, P1182, DOI 10.1126/science.7689250; MILLER MD, 1992, CRIT REV IMMUNOL, V12, P17; NEOTE K, 1993, CELL, V72, P415, DOI 10.1016/0092-8674(93)90118-A; OPPENHEIM JJ, 1991, ANNU REV IMMUNOL, V9, P617, DOI 10.1146/annurev.iy.09.040191.003153; SCHALL TJ, 1990, NATURE, V347, P669, DOI 10.1038/347669a0; WEBB LMC, 1993, P NATL ACAD SCI USA, V90, P7158, DOI 10.1073/pnas.90.15.7158	12	16	17	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JAN 22	1994	343	8891					189	190		10.1016/S0140-6736(94)90985-7	http://dx.doi.org/10.1016/S0140-6736(94)90985-7			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MT332	7507195				2022-12-28	WOS:A1994MT33200004
J	PATTISON, J; NELSON, PJ; HUIE, P; VONLEUTTICHAU, I; FARSHID, G; SIBLEY, RK; KRENSKY, AM				PATTISON, J; NELSON, PJ; HUIE, P; VONLEUTTICHAU, I; FARSHID, G; SIBLEY, RK; KRENSKY, AM			RANTES CHEMOKINE EXPRESSION IN CELL-MEDIATED TRANSPLANT REJECTION OF THE KIDNEY	LANCET			English	Note							MONOCLONAL-ANTIBODIES; FAMILY	RANTES (regulated upon activation, normal T cell expressed and secreted) is a chemotactic cytokine (a chemokine) for memory T lymphocytes, monocytes, and eosinophils. RANTES expression was studied in renal allograft biopsy specimens. Although RANTES was not expressed in samples,taken one hour after transplantation, or in native renal biopsy specimens from patients with cyclosporin nephrotoxicity, it was expressed during cell-mediated transplant rejection. RANTES mRNA was detected in infiltrating mononuclear cells and renal tubular epithelium, and RANTES protein was localised to mononuclear cells, tubular epithelium, and vascular endothelium. This suggests RANTES has a role in allograft rejection.	STANFORD UNIV,MED CTR,DEPT PATHOL,STANFORD,CA 94305	Stanford University	PATTISON, J (corresponding author), STANFORD UNIV,MED CTR,DEPT PEDIAT,STANFORD,CA 94305, USA.		Krensky, Alan/F-7956-2011					BISHOP GA, 1986, KIDNEY INT, V29, P708, DOI 10.1038/ki.1986.56; CHLEQDESCHAMPS CM, 1993, BLOOD, V81, P293; HEEGER P, 1992, KIDNEY INT, V41, P220, DOI 10.1038/ki.1992.31; MCCAUGHAN GW, 1990, HEPATOLOGY, V12, P1305, DOI 10.1002/hep.1840120610; OPPENHEIM JJ, 1991, ANNU REV IMMUNOL, V9, P617, DOI 10.1146/annurev.iy.09.040191.003153; RATHANASWAMI P, 1993, J BIOL CHEM, V268, P5834; ROT A, 1993, EUR J IMMUNOL, V23, P303, DOI 10.1002/eji.1830230150; SCHALL TJ, 1990, NATURE, V347, P669, DOI 10.1038/347669a0; SCHALL TJ, 1988, J IMMUNOL, V141, P1018; TAUB DD, 1993, SCIENCE, V260, P355, DOI 10.1126/science.7682337	10	255	267	0	4	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JAN 22	1994	343	8891					209	211		10.1016/S0140-6736(94)90992-X	http://dx.doi.org/10.1016/S0140-6736(94)90992-X			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MT332	7507196				2022-12-28	WOS:A1994MT33200011
J	Vakil, NB; Schwartz, SM; Buggy, BP; Brummitt, CF; Kherellah, M; Letzer, DM; Gilson, IH; Jones, PG				Vakil, NB; Schwartz, SM; Buggy, BP; Brummitt, CF; Kherellah, M; Letzer, DM; Gilson, IH; Jones, PG			Biliary cryptosporidiosis in HIV-infected people after the waterborne outbreak of cryptosporidiosis in Milwaukee	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							ACQUIRED-IMMUNODEFICIENCY-SYNDROME; SCLEROSING CHOLANGITIS; CHOLANGIOPATHY; VIRUS; SPECTRUM; DISEASE	Background. In March 1993, the municipal water supply in Milwaukee became contaminated with cruptosporidium and a widespread outbreak of cryptosporidiosis occurred. Methods. We retrospectively studied the relations among the clinical presentation, CD4 count, and survival in a group of 82 patients infected with the human immunodeficiency virus (HIV) in whom cryptosporidiosis developed during the outbreak. Infection was documented by the finding of cryptosporidium in stool. Results. There was a sharp increase in the number of HIV-infected patients with cryptosporidiosis after the period of water contamination. Four of 24 patients with biliary symptoms (17 percent) and 30 of 58 without biliary symptoms (52 percent) were alive one year after the outbreak (P = 0.003). Twenty-one of the patients with biliary symptoms had CD4 counts less than or equal to 50 per cubic millimeter, as compared with 36 of 57 patients without biliary symptoms (88 percent vs. 63 percent, P = 0.03). The CD4 count was not available for one patient in the latter group, Within one year, 41 of the patients with CD4 counts less than or equal to 50 per cubic millimeter had died, as compared with 6 of those with higher counts (72 percent vs. 25 percent, P < 0.001). After adjustment for the CD4 count, independent predictors of death were older age and the presence of nausea and vomiting. Conclusions, When HIV-infected patients are exposed to cryptosporidium, those with CD4 counts less than or equal to 50 per cubic millimeter are at increased risk for biliary symptoms and for death within one year after the infection. (C) 1996, Massachusetts Medical Society.	MED COLL WISCONSIN,MILWAUKEE,WI 53226	Medical College of Wisconsin	Vakil, NB (corresponding author), UNIV WISCONSIN,SCH MED,SINAI SAMARITAN MED CTR,DEPT MED,MILWAUKEE CAMPUS,945 N 12TH ST,RM A 324,MILWAUKEE,WI 53233, USA.							ARMITAGE P, 1987, STATISTICAL METHODS; BENATOR DA, 1994, ANN INTERN MED, V121, P663, DOI 10.7326/0003-4819-121-9-199411010-00006; BENHAMOU Y, 1993, DIGEST DIS SCI, V38, P1113, DOI 10.1007/BF01295729; BERKELMAN RL, 1994, SCIENCE, V264, P368, DOI 10.1126/science.8153621; BOUCHE H, 1993, J HEPATOL, V17, P34, DOI 10.1016/S0168-8278(05)80518-5; CELLO JP, 1989, AM J MED, V86, P539, DOI 10.1016/0002-9343(89)90381-1; CHAN MF, 1992, HEPATOLOGY, V16, pA127; COX DR, 1972, J R STAT SOC B, V34, P187; FLANIGAN T, 1992, ANN INTERN MED, V116, P840, DOI 10.7326/0003-4819-116-10-840; FORBES A, 1993, GUT, V34, P116, DOI 10.1136/gut.34.1.116; GODWIN TA, 1991, HUM PATHOL, V22, P1215, DOI 10.1016/0046-8177(91)90103-V; HAYES EB, 1989, NEW ENGL J MED, V320, P1372, DOI 10.1056/NEJM198905253202103; KAVIN H, 1986, ANN INTERN MED, V104, P53, DOI 10.7326/0003-4819-104-1-53; MACKENZIE WR, 1994, NEW ENGL J MED, V331, P161, DOI 10.1056/NEJM199407213310304; MARGULIS SJ, 1986, ANN INTERN MED, V105, P207, DOI 10.7326/0003-4819-105-2-207; PETERSEN C, 1992, CLIN INFECT DIS, V15, P903, DOI 10.1093/clind/15.6.903; PITLIK SD, 1983, ARCH INTERN MED, V143, P2269, DOI 10.1001/archinte.143.12.2269; POL S, 1993, NEW ENGL J MED, V328, P95, DOI 10.1056/NEJM199301143280204; RICHARDSON AJ, 1991, EPIDEMIOL INFECT, V107, P485, DOI 10.1017/S0950268800049189; SCHNEIDERMAN DJ, 1987, ANN INTERN MED, V106, P546, DOI 10.7326/0003-4819-106-4-546; SOAVE R, 1984, ANN INTERN MED, V100, P504, DOI 10.7326/0003-4819-100-4-504; WHITE AC, 1994, J INFECT DIS, V170, P419, DOI 10.1093/infdis/170.2.419	22	109	117	1	10	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JAN 4	1996	334	1					19	23		10.1056/NEJM199601043340104	http://dx.doi.org/10.1056/NEJM199601043340104			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TM482	7494565				2022-12-28	WOS:A1996TM48200004
J	Folkman, J				Folkman, J			Seminars in medicine of the Beth Israel Hospital, Boston - Clinical applications of research on angiogenesis	NEW ENGLAND JOURNAL OF MEDICINE			English	Review							ENDOTHELIAL GROWTH-FACTOR; TUMOR ANGIOGENESIS; INTERFERON ALFA-2A; THERAPY; INHIBITION		HARVARD UNIV,SCH MED,DEPT CELL BIOL,BOSTON,MA	Harvard University; Harvard Medical School	Folkman, J (corresponding author), CHILDRENS HOSP,DEPT SURG,HUNNEWELL 103,300 LONGWOOD AVE,BOSTON,MA 02115, USA.							AIELLO LP, 1994, NEW ENGL J MED, V331, P1480, DOI 10.1056/NEJM199412013312203; BACHARACHBUHLES M, 1994, J INVEST DERMATOL, V103, P263; Beattie G. J., 1994, ANN ONCOL, V5, p72a; BROOKS PC, 1994, SCIENCE, V264, P569, DOI 10.1126/science.7512751; CLAPP C, 1993, ENDOCRINOLOGY, V133, P1292, DOI 10.1210/en.133.3.1292; DAMATO RJ, 1994, P NATL ACAD SCI USA, V91, P4082, DOI 10.1073/pnas.91.9.4082; DAMERON KM, 1994, SCIENCE, V265, P1582, DOI 10.1126/science.7521539; DENEKAMP J, 1993, BRIT J RADIOL, V66, P181, DOI 10.1259/0007-1285-66-783-181; Drummond A. H., 1995, Proceedings of the American Association for Cancer Research Annual Meeting, V36, P100; DVORAK HF, 1995, AM J PATHOL, V146, P1029; EZEKOWITZ RAB, 1994, NEW ENGL J MED, V330, P300; EZEKOWITZ RAB, 1992, NEW ENGL J MED, V326, P1456, DOI 10.1056/NEJM199205283262203; EZEKOWITZ RAB, 1995, NEW ENGL J MED, V333, P595; FOLKMAN J, 1971, NEW ENGL J MED, V285, P1182; FOLKMAN J, 1995, NAT MED, V1, P27, DOI 10.1038/nm0195-27; FOLKMAN J, 1994, J CLIN ONCOL, V12, P441, DOI 10.1200/JCO.1994.12.3.441; FOLKMAN J, 1991, ANN SURG, V214, P414, DOI 10.1097/00000658-199110000-00006; FOLKMAN J, 1992, STEROID HORMONES AND UTERINE BLEEDING, P143; FOLKMAN J, 1993, CANCER MED, V1, P153; Folkman J, 1995, MOL BASIS CANC, P206; GUERIN C, 1992, BIOCHEM BIOPH RES CO, V188, P740, DOI 10.1016/0006-291X(92)91118-A; HANNEKEN A, 1994, P NATL ACAD SCI USA, V91, P9170, DOI 10.1073/pnas.91.19.9170; HOLMGREN L, 1995, NAT MED, V1, P149, DOI 10.1038/nm0295-149; HULL MA, 1994, GASTROENTEROLOGY, V106, pA97; INGBER D, 1990, NATURE, V348, P555, DOI 10.1038/348555a0; JACKSON D, 1994, SCIENCE, V266, P1581, DOI 10.1126/science.7527157; JAFFE EA, 1987, HUM PATHOL, V18, P234, DOI 10.1016/S0046-8177(87)80005-9; KAHN J, 1993, P AN M AM SOC CLIN, V12, P50; KOHN EC, 1995, P NATL ACAD SCI USA, V92, P1307, DOI 10.1073/pnas.92.5.1307; LI VW, 1994, LANCET, V344, P82, DOI 10.1016/S0140-6736(94)91280-7; MILLER JW, 1994, AM J PATHOL, V145, P574; NGUYEN M, 1994, J NATL CANCER I, V86, P356, DOI 10.1093/jnci/86.5.356; NICKOLOFF BJ, 1994, AM J PATHOL, V144, P820; OBRIEN ER, 1994, AM J PATHOL, V145, P883; OREILLY MS, 1994, CELL, V79, P315, DOI 10.1016/0092-8674(94)90200-3; PAULUS HE, 1995, ANN INTERN MED, V122, P147, DOI 10.7326/0003-4819-122-2-199501150-00012; PEACOCK DJ, 1992, J EXP MED, V175, P1135, DOI 10.1084/jem.175.4.1135; PEPPER MS, 1992, BIOCHEM BIOPH RES CO, V189, P824, DOI 10.1016/0006-291X(92)92277-5; RAK JW, 1995, ANTI-CANCER DRUG, V6, P3, DOI 10.1097/00001813-199502000-00001; SHWEIKI D, 1992, NATURE, V359, P843, DOI 10.1038/359843a0; SINGH RK, 1995, P NATL ACAD SCI USA, V92, P4562, DOI 10.1073/pnas.92.10.4562; STAVRI GT, 1995, FEBS LETT, V358, P311, DOI 10.1016/0014-5793(94)01458-D; TEICHER BA, 1994, INT J CANCER, V57, P920, DOI 10.1002/ijc.2910570624; TULPULE A, 1994, BLOOD, V84, pA248; VOEST EE, 1995, J NATL CANCER I, V87, P581, DOI 10.1093/jnci/87.8.581; VUKANOVIC J, 1993, CANCER RES, V53, P1833; WEIDNER N, 1995, AM J PATHOL, V147, P9; WEIDNER N, 1991, NEW ENGL J MED, V324, P1, DOI 10.1056/NEJM199101033240101; WEINSTATSASLOW DL, 1994, CANCER RES, V54, P6504; WHITE CW, 1989, NEW ENGL J MED, V320, P1197, DOI 10.1056/NEJM198905043201807; WOLFE MM, 1994, GASTROENTEROLOGY, V106, pA212; Young AE, 1988, VASCULAR BIRTHMARKS, P24	52	1997	2218	0	38	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	DEC 28	1995	333	26					1757	1763		10.1056/NEJM199512283332608	http://dx.doi.org/10.1056/NEJM199512283332608			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TM169	7491141				2022-12-28	WOS:A1995TM16900008
J	MAX, MB; DONOVAN, M; MIASKOWSKI, CA; WARD, SE; GORDON, D; BOOKBINDER, M; CLEELAND, CS; COYLE, N; KISS, M; THALER, HT; JANJAN, N; WEINSTEIN, S; EDWARDS, T				MAX, MB; DONOVAN, M; MIASKOWSKI, CA; WARD, SE; GORDON, D; BOOKBINDER, M; CLEELAND, CS; COYLE, N; KISS, M; THALER, HT; JANJAN, N; WEINSTEIN, S; EDWARDS, T			QUALITY IMPROVEMENT GUIDELINES FOR THE TREATMENT OF ACUTE PAIN AND CANCER PAIN	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							MEDICAL-STUDENTS; ATTITUDES; PATIENT; MANAGEMENT; CARE; UNDERTREATMENT; INPATIENTS; KNOWLEDGE; EDUCATION; CHILDREN	Objective.-To develop quality improvement (QI) guidelines and programs to improve treatment outcomes for patients with acute pain and cancer pain. Participants.-Twenty-four members of the American Pain Society (APS) participated in preparing the statement, including 15 nurses (oncology, general medical-surgical nursing, pediatrics, and QI research), seven physicians (clinical pharmacology, neurology, anesthesiology, radiation oncology, and physiatry), one psychologist, and one statistician. Participants were self-selected from the 3000 members of the APS, which supported the process and held annual open committee meetings and scientific symposia beginning in 1988. Evidence.-MEDLINE was searched (1980 to 1995) to identify all articles on pain assessment, treatment of acute pain or cancer pain, and QI or education related to pain. Consensus Process.-Following panel discussions, one member (M.B.M.) prepared successive drafts and circulated them to the panel and APS membership for comments. After publication of a prototype version in 1991, 14 panelists carried out formal studies of implementation of the guidelines at three medical centers. This article was prepared based on this research, a new literature review, and suggestions from 50 pain clinicians and researchers. Conclusions.-Quality improvement programs to improve treatment of acute pain and cancer pain should include five key elements: (1) Assuring that a report of unrelieved pain raises a ''red flag'' that attracts clinicians' attention; (2) making information about analgesics convenient where orders are written; (3) promising patients responsive analgesic care and urging them to communicate pain; (4) implementing policies and safeguards for the use of modem analgesic technologies, and (5) coordinating and assessing implementation of these measures. Several short-term studies suggest that this QI approach may improve patient satisfaction and facilitate recognition of institutional obstacles to optimal pain treatment, but it is not a panacea for undertreated pain. By making the magnitude of the problem apparent and committing the institution to change, pain treatment QI programs can provide a foundation for a multifaceted approach that includes education of clinicians and patients, design of informational tools to minimize errors in prescribing, and improved coordination of the process of assessing and treating pain.	NIDR, NEUROBIOL & ANESTHESIOL BRANCH, BETHESDA, MD 20892 USA; KAISER SUNNYSIDE MED CTR, DEPT NURSING, CLACKAMAS, OR USA; UNIV CALIF SAN FRANCISCO, DEPT PHYSIOL NURSING, SAN FRANCISCO, CA 94143 USA; UNIV WISCONSIN, SCH NURSING, PAIN RES GRP, MADISON, NJ USA; UNIV WISCONSIN, CTR COMPREHENS CARE, MADISON, NJ USA; UNIV WISCONSIN, DEPT NURSING, MADISON, NJ USA; MEM SLOAN KETTERING CANC CTR, DEPT NURSING, NEW YORK, NY 10021 USA; UNIV WISCONSIN, DEPT NEUROL, PAIN RES GRP, MADISON, WI 53706 USA; MEM SLOAN KETTERING CANC CTR, DEPT NEUROL, NEW YORK, NY 10021 USA; MEM SLOAN KETTERING CANC CTR, DEPT EPIDEMIOL & BIOSTAT, NEW YORK, NY 10021 USA; UNIV TEXAS, MD ANDERSON CANC CTR, DEPT RADIOTHERAPY, HOUSTON, TX USA; UNIV TEXAS, MD ANDERSON CANC CTR, DEPT NEUROONCOL, HOUSTON, TX USA; UNIV WASHINGTON, HARBORVIEW MED CTR, DEPT ANESTHESIOL, SEATTLE, WA 98104 USA; AMER PAIN SOC, GLENVIEW, IL 60025 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Dental & Craniofacial Research (NIDCR); Kaiser Permanente; University of California System; University of California San Francisco; University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison; Memorial Sloan Kettering Cancer Center; University of Wisconsin System; University of Wisconsin Madison; Memorial Sloan Kettering Cancer Center; Memorial Sloan Kettering Cancer Center; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; Harborview Medical Center; University of Washington; University of Washington Seattle								[Anonymous], 1992, J Clin Oncol, V10, P1976; ATCHISON NE, 1991, PAIN, V47, P41, DOI 10.1016/0304-3959(91)90009-M; AU E, 1994, J CLIN ONCOL, V12, P2751, DOI 10.1200/JCO.1994.12.12.2751; BERWICK DM, 1991, CURING HLTH CARE; BOND MR, 1991, 6TH P WORLD C PAIN, P185; BOOKBINDER M, IN PRESS J PAIN SYMP; Bookbinder M., 1995, CANC PAIN MANAGEMENT, P321; CARR DB, 1992, AHCPR920032 US PHS A; CHARAP AD, 1978, MT SINAI J MED, V45, P561; CLEELAND CS, 1994, NEW ENGL J MED, V330, P592, DOI 10.1056/NEJM199403033300902; CLEELAND CS, 1991, ADV PAIN RES THER, V18, P631; COOPER JR, 1992, JAMA-J AM MED ASSOC, V268, P1306, DOI 10.1001/jama.268.10.1306; DAR R, 1992, J PAIN SYMPTOM MANAG, V7, P87, DOI 10.1016/0885-3924(92)90119-3; DAUT RL, 1982, CANCER-AM CANCER SOC, V50, P1913, DOI 10.1002/1097-0142(19821101)50:9<1913::AID-CNCR2820500944>3.0.CO;2-R; DAUT RL, 1983, PAIN, V17, P197, DOI 10.1016/0304-3959(83)90143-4; DEMING WE, 1986, GUT CRISIS; Dietrick-Gallagher M, 1994, J Nurs Care Qual, V9, P30; DONABEDIAN A, 1990, J OCCUP ENVIRON MED, V32, P1167, DOI 10.1097/00043764-199012000-00008; DONOVAN M, 1987, PAIN, V30, P69, DOI 10.1016/0304-3959(87)90084-4; Doyle D., 1993, OXFORD TXB PALLIATIV; Edwards W T, 1990, J Pain Symptom Manage, V5, pS24; ENGLEHARDT HT, 1989, DRUG TREATMENT CANCE, V11, P71; FERRELL BR, 1994, J PAIN SYMPTOM MANAG, V9, P221, DOI 10.1016/0885-3924(94)90099-X; FERRELL BR, 1991, CANCER NURS, V14, P289; FERRELL BR, 1994, CANCER, V74, P2139, DOI 10.1002/1097-0142(19941001)74:7+<2139::AID-CNCR2820741722>3.0.CO;2-C; FOLEY KM, 1995, J CLIN ONCOL, V13, P2149, DOI 10.1200/JCO.1995.13.9.2149; FRIEDRICHS JB, 1995, NURS CLIN N AM, V30, P143; GRECO PJ, 1993, NEW ENGL J MED, V329, P1271, DOI 10.1056/NEJM199310213291714; GROSSMAN SA, 1985, J MED EDUC, V60, P552; GROSSMAN SA, 1991, J PAIN SYMPTOM MANAG, V6, P53, DOI 10.1016/0885-3924(91)90518-9; GROSSMAN SA, 1989, J HOPKINSONCOLOGY CT; HODES R, 1989, DRUG TREATMENT CANCE, V11, P91; JACOX A, 1994, US PHS AHCPR940592 A; JOHNSTON ME, 1994, ANN INTERN MED, V120, P135, DOI 10.7326/0003-4819-120-2-199401150-00007; JORANSON DE, 1994, J PAIN SYMPTOM MANAG, V9, P244, DOI 10.1016/0885-3924(94)90101-5; KRITCHEVSKY SB, 1991, JAMA-J AM MED ASSOC, V266, P1817, DOI 10.1001/jama.266.13.1817; LEAPE LL, 1995, JAMA-J AM MED ASSOC, V274, P35, DOI 10.1001/jama.1995.03530010049034; MARKS RM, 1973, ANN INTERN MED, V78, P173, DOI 10.7326/0003-4819-78-2-173; MAX MB, 1990, ANN INTERN MED, V113, P885, DOI 10.7326/0003-4819-113-11-885; MCGIVNEY WT, 1984, JAMA-J AM MED ASSOC, V251, P1182; MIASKOWISKI C, 1994, 7TH P WORLD C PAIN S, P75; MIASKOWSKI C, 1994, J PAIN SYMPTOM MANAG, V9, P5, DOI 10.1016/0885-3924(94)90140-6; Montaigne M., 2008, ESEJE; Morgan J. P., 1989, ADV PAIN RES THER, V11, P181; PORTENOY RK, 1994, QUAL LIFE RES, V3, P183, DOI 10.1007/BF00435383; READY LB, 1995, ANESTHESIOLOGY, V82, P1071; RIMER B, 1987, PATIENT EDUC COUNS, V10, P267, DOI 10.1016/0738-3991(87)90128-5; SCHECHTER NL, 1989, PEDIATR CLIN N AM, V36, P781; Schmidt K, 1994, J Pediatr Oncol Nurs, V11, P4, DOI 10.1177/104345429401100103; SENGSTAKEN EA, 1994, CLIN J PAIN, V10, P303, DOI 10.1097/00002508-199412000-00010; SERLIN RC, 1995, PAIN, V61, P277, DOI 10.1016/0304-3959(94)00178-H; Sheidler V R, 1992, Oncol Nurs Forum, V19, P1531; SRIWATANAKUL K, 1983, JAMA-J AM MED ASSOC, V250, P926, DOI 10.1001/jama.250.7.926; TODD KH, 1993, JAMA-J AM MED ASSOC, V269, P1537, DOI 10.1001/jama.269.12.1537; VONROENN JH, 1993, ANN INTERN MED, V119, P121, DOI 10.7326/0003-4819-119-2-199307150-00005; VORTHERMS R, 1992, RES NURS HEALTH, V15, P459, DOI 10.1002/nur.4770150608; WANZER SH, 1989, NEW ENGL J MED, V320, P844, DOI 10.1056/NEJM198903303201306; WARD SE, 1993, PAIN, V52, P319, DOI 10.1016/0304-3959(93)90165-L; WARD SE, 1994, PAIN, V56, P299, DOI 10.1016/0304-3959(94)90168-6; WARD SE, IN PRESS PAIN; Ware J E Jr, 1983, Eval Program Plann, V6, P247, DOI 10.1016/0149-7189(83)90005-8; WARE JE, 1988, MED CARE, V26, P393, DOI 10.1097/00005650-198804000-00008; WEIS OF, 1983, ANESTH ANALG, V62, P70; Weissman D E, 1991, Wis Med J, V90, P671; WEISSMAN DE, 1993, J PAIN SYMPTOM MANAG, V8, P29, DOI 10.1016/0885-3924(93)90117-E; WILSON JF, 1992, PAIN, V50, P251, DOI 10.1016/0304-3959(92)90028-A; 1992, PRINCIPLES ANALGESIC	67	577	589	0	26	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	DEC 20	1995	274	23					1874	1880		10.1001/jama.1995.03530230060032	http://dx.doi.org/10.1001/jama.1995.03530230060032			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	TK147	7500539				2022-12-28	WOS:A1995TK14700031
J	PROCTOR, MH				PROCTOR, MH			HUMAN-RIGHTS VIOLATIONS AMONG BHUTANESE REFUGEES	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article											PROCTOR, MH (corresponding author), BOSTON UNIV,SCH MED,PREVENT MED & EPIDEMIOL SECT,88 E NEWTON ST,BOSTON,MA 02118, USA.							BARAL LR, 1993, J CTR NEPAL ASIAN ST, V20, P197; BHANDARI BP, 1994, HIMAL            MAR, P31; BHUTAN, CITED INDIRECTLY; BHUTAN, 1994, AMNESTY INT REP  AUG, P1; Browne Thomas, 1716, CHRISTIAN MORALS; DHAKAL DNS, 1994, BHUTAN MOVEMENT EX 3, pCH1; DIXIT JN, 1994, HIMAL            JUL, P15; DIXIT KM, 1994, HIMAL            JUL, P22; DIXIT KM, 1994, HIMAL            MAR, P19; MARFIN AA, 1994, JAMA-J AM MED ASSOC, V272, P377, DOI 10.1001/jama.272.5.377; TSERING LD, CITED INDIRECTLY; 1992, BHUTAN IRON PATH DEM; 1993, SO BHUTAN PROBLEM TH; 1995, BHUTAU REV, V3, P4; 1993, BHUTAN SHANGRILA HUM	15	0	0	0	5	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	DEC 20	1995	274	23					1891	1892						2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TK147	7500541				2022-12-28	WOS:A1995TK14700033
J	HORTON, R				HORTON, R			REVISING THE RESEARCH RECORD	LANCET			English	Editorial Material							FRAUDULENT											CHILVERS CED, 1990, LANCET, V336, P1186; EVERED D, 1995, LANCET, V345, P1661; EZEKOWITZ A, 1995, NEW ENGL J MED, V333, P595, DOI 10.1056/NEJM199508313330913; FORBES CD, 1994, SCOT MED J, P139; FRIEDMAN PJ, 1990, JAMA-J AM MED ASSOC, V263, P1416; HAMMERSCHMIDT DE, 1994, J LAB CLIN MED, V123, P795; HAMMERSCHMIDT DE, 1994, J LAB CLIN MED, V123, P792; HORTON R, 1995, LANCET, V346, P1504, DOI 10.1016/S0140-6736(95)92043-9; JACKSON G, 1995, BRIT J CLIN PRACT, V49, P115; LOCK S, 1995, BRIT MED J, V310, P1547, DOI 10.1136/bmj.310.6994.1547; MISHKIN B, 1995, SCIENCE, V270, P927, DOI 10.1126/science.270.5238.927; SHARP DW, 1991, INVEST RADIOL, V26, P586, DOI 10.1097/00004424-199106000-00016; SNODGRASS GL, 1992, B MED LIBR ASSOC, V80, P328; WHITELY WP, 1994, JAMA-J AM MED ASSOC, V272, P170, DOI 10.1001/jama.272.2.170; 1995, INTEGRITY MISCONDUCT; 1994, UNPUB BIOMEDICAL J	16	12	12	1	5	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	DEC 16	1995	346	8990					1610	1611		10.1016/S0140-6736(95)91935-X	http://dx.doi.org/10.1016/S0140-6736(95)91935-X			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TK481	7500757				2022-12-28	WOS:A1995TK48100016
J	RENAUD, JP; ROCHEL, N; RUFF, M; VIVAT, V; CHAMBON, P; GRONEMEYER, H; MORAS, D				RENAUD, JP; ROCHEL, N; RUFF, M; VIVAT, V; CHAMBON, P; GRONEMEYER, H; MORAS, D			CRYSTAL-STRUCTURE OF THE RAR-GAMMA LIGAND-BINDING DOMAIN BOUND TO ALL-TRANS-RETINOIC ACID	NATURE			English	Article							NUCLEAR RECEPTOR; IDENTIFICATION; ACTIVATION; DNA	The 2.0-Angstrom crystal structure of the ligand-binding domain (LED) of the human retinoic acid receptor (RAR)-gamma bound to all-trans retinoic acid reveals the ligand-binding interactions and suggests an electrostatic guidance mechanism. The overall fold is similar to that of the human RXR-alpha apo-LBD, except for the carboxy-terminal part which folds back towards the LED core, contributing to the hydrophobic ligand pocket and 'sealing' its entry site. We propose a 'mouse trap' mechanism whereby a ligand-induced conformational transition repositions the amphipathic alpha-helix of the AF-2 activating domain and forms a transcriptionally active receptor.	UNIV STRASBOURG 1,COLL FRANCE,CNRS,INSERM,INST GENET & BIOL MOLEC & CELLULAIRE,F-67404 ILLKIRCH GRAFFENS,FRANCE	Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; PSL Research University Paris; College de France; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg			Gronemeyer, Hinrich/G-6240-2011; Gronemeyer, Hinrich/AAH-5575-2019; Gronemeyer, Hinrich/H-7002-2016; Renaud, Jean-Paul/AAM-4879-2020; Rochel, Natacha/A-5718-2016; ruff, marc/J-3011-2013	Gronemeyer, Hinrich/0000-0001-9454-2449; Gronemeyer, Hinrich/0000-0001-9454-2449; Gronemeyer, Hinrich/0000-0001-9454-2449; Renaud, Jean-Paul/0000-0001-9180-5426; Rochel, Natacha/0000-0002-3573-5889; ruff, marc/0000-0001-5451-6377				ALLENBY G, 1994, J BIOL CHEM, V269, P16689; [Anonymous], 1994, ACTA CRYSTALLOGR D, V50, P760; BARETTINO D, 1994, EMBO J, V13, P3039, DOI 10.1002/j.1460-2075.1994.tb06603.x; BAUR EV, IN PRESS EMBO J; BOURGUET W, 1995, NATURE, V375, P377, DOI 10.1038/375377a0; BRAND N, 1988, NATURE, V332, P850, DOI 10.1038/332850a0; BRUNGER AT, 1992, NATURE, V355, P472, DOI 10.1038/355472a0; BRUNGER AT, 1992, X PLOR VERSION 3 1; CAVAILLES V, 1994, P NATL ACAD SCI USA, V91, P10009, DOI 10.1073/pnas.91.21.10009; CAVAILLES V, 1995, EMBO J, V14, P3741, DOI 10.1002/j.1460-2075.1995.tb00044.x; Chambon Pierre, 1994, Seminars in Cell Biology, V5, P115, DOI 10.1006/scel.1994.1015; CHEN JY, 1995, EMBO J, V14, P1187, DOI 10.1002/j.1460-2075.1995.tb07102.x; DANIELIAN PS, 1992, EMBO J, V11, P1025, DOI 10.1002/j.1460-2075.1992.tb05141.x; DURAND B, 1994, EMBO J, V13, P5370, DOI 10.1002/j.1460-2075.1994.tb06872.x; GIGUERE V, 1994, ENDOCR REV, V15, P61, DOI 10.1210/er.15.1.61; GIGUERE V, 1987, NATURE, V330, P624, DOI 10.1038/330624a0; GLASS CK, 1994, ENDOCR REV, V15, P391, DOI 10.1210/er.15.3.391; GRONEMEYER H, 1995, NATURE, V375, P190, DOI 10.1038/375190a0; HALACHMI S, 1994, SCIENCE, V264, P1455, DOI 10.1126/science.8197458; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; JOSEPH D, 1990, SCIENCE, V249, P1425, DOI 10.1126/science.2402636; KABSCH W, 1988, J APPL CRYSTALLOGR, V21, P916, DOI 10.1107/S0021889888007903; KLEYWEGT GJ, 1994, STRUCTURE, V2, P1241, DOI 10.1016/S0969-2126(94)00125-1; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; KRUST A, 1989, P NATL ACAD SCI USA, V86, P5310, DOI 10.1073/pnas.86.14.5310; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; LAUDET V, 1992, EMBO J, V11, P1003, DOI 10.1002/j.1460-2075.1992.tb05139.x; LEDOUARIN B, 1995, EMBO J, V14, P2020, DOI 10.1002/j.1460-2075.1995.tb07194.x; LEE JW, 1995, NATURE, V374, P91, DOI 10.1038/374091a0; LEID M, 1994, J BIOL CHEM, V269, P14175; LEID M, 1992, TRENDS BIOCHEM SCI, V17, P427, DOI 10.1016/0968-0004(92)90014-Z; LEID M, 1992, CELL, V68, P377, DOI 10.1016/0092-8674(92)90478-U; LENG XH, 1995, MOL CELL BIOL, V15, P255, DOI 10.1128/MCB.15.1.255; LUISI BF, 1991, NATURE, V352, P497, DOI 10.1038/352497a0; Mangelsdorf David J., 1994, P319; MANGELSDORF DJ, 1990, NATURE, V345, P224, DOI 10.1038/345224a0; MERRITT EA, 1994, ACTA CRYSTALLOGR D, V50, P869, DOI 10.1107/S0907444994006396; NAGPAL S, 1993, EMBO J, V12, P2349, DOI 10.1002/j.1460-2075.1993.tb05889.x; NEWCOMER ME, 1993, STRUCTURE, V1, P7, DOI 10.1016/0969-2126(93)90004-Z; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; OSTROWSKI J, 1995, P NATL ACAD SCI USA, V92, P1812, DOI 10.1073/pnas.92.6.1812; PETKOVICH M, 1987, NATURE, V330, P444, DOI 10.1038/330444a0; PFAHL M, 1993, ENDOCR REV, V14, P651, DOI 10.1210/er.14.5.651; RASTINEJAD F, 1995, NATURE, V375, P203, DOI 10.1038/375203a0; SCHWABE JWR, 1993, CELL, V75, P567, DOI 10.1016/0092-8674(93)90390-C; TAIRIS N, 1994, J BIOL CHEM, V269, P19516; TATE BF, 1995, J BIOL CHEM, V270, P20258, DOI 10.1074/jbc.270.35.20258; WURTZ JM, IN PRESS NATURE STRU; ZENKE M, 1990, CELL, V61, P1035, DOI 10.1016/0092-8674(90)90068-P	49	987	1003	4	44	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	DEC 14	1995	378	6558					681	689		10.1038/378681a0	http://dx.doi.org/10.1038/378681a0			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TK379	7501014				2022-12-28	WOS:A1995TK37900042
J	AYANIAN, JZ; GUADAGNOLI, E; CLEARY, PD				AYANIAN, JZ; GUADAGNOLI, E; CLEARY, PD			PHYSICAL AND PSYCHOSOCIAL FUNCTIONING OF WOMEN AND MEN AFTER CORONARY-ARTERY BYPASS-SURGERY	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							LONG-TERM; MYOCARDIAL-INFARCTION; OPERATIVE MORTALITY; HEART-DISEASE; GENDER BIAS; SURVIVAL; OUTCOMES; CASS; SEX; SELECTION	Objective.-To assess whether physical and psychosocial functioning differs between women and men after coronary artery bypass surgery. Design.-Observational cohort study. Setting.-Major teaching hospital. Patients.-A total of 454 consecutive patients who received coronary artery bypass surgery from June 1989 through March 1990. Main Outcome Measures.-Nurse reviewers collected data on the severity of coronary artery disease and coexisting illnesses from medical records. A mailed survey measuring instrumental activities of daily living (IADLs), social activities, mental health, and vitality was completed by 306 (70.2%) of 436 patients who were alive 6 months after surgery. Functioning on each scale was adjusted for age, marital status, education, severity of angina, recent myocardial infarction, congestive heart failure, and coexisting illnesses at the time of surgery. Results.-Before surgery, women were much more likely than men to have had class IV angina (50.9% vs 30.4%), a recent myocardial infarction (32.1% vs 18.0%), and congestive heart failure (34.0% vs 17.6%) (all P<.002). On a range from 0 (severe impairment) to 100 (no impairment), adjusted postoperative functioning was equivalent for women and men in IADLs (86.7 vs 89.1), social activities (95.2 vs 95.3), mental health (72.6 vs 76.0), and vitality (58.1 vs 62.5) (all P>.20). Women reported similar or greater adjusted improvements than men for IDALs (27.2 vs 19.6, P=.08), social activities (20.8 vs 8.0, P=.002), mental health (11.2 vs 5.7, P=.05), and vitality (22.2 vs 12.9, P=.04). Conclusions.-Women were more severely ill than men at the time of coronary artery bypass surgery, but women and men reported similar physical and psychosocial functioning 6 months after surgery. These findings demonstrate important functional benefits of this procedure among both women and men.	BRIGHAM & WOMENS HOSP,DEPT MED,DIV GEN MED,HLTH SERV & POLICY RES SECT,BOSTON,MA 02115	Harvard University; Brigham & Women's Hospital	AYANIAN, JZ (corresponding author), HARVARD UNIV,SCH MED,25 SHATTUCK ST,PARCEL B,1ST FLOOR,BOSTON,MA 02115, USA.		Cleary, Paul/AAF-7048-2019		AHRQ HHS [HS06341] Funding Source: Medline	AHRQ HHS(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality)		ADLER DS, 1986, AM J CARDIOL, V58, P195, DOI 10.1016/0002-9149(86)90046-9; ALLEN JK, 1990, AM J CARDIOL, V65, P921; Ayanian J. Z., 1995, JGIM, V10, P60; AYANIAN JZ, 1991, NEW ENGL J MED, V325, P221, DOI 10.1056/NEJM199107253250401; BICKELL NA, 1992, ANN INTERN MED, V116, P791, DOI 10.7326/0003-4819-116-10-791; CLEARY PD, 1991, JAMA-J AM MED ASSOC, V266, P73, DOI 10.1001/jama.266.1.73; CLEARY PD, 1991, CONTROL CLIN TRIALS, V12, pS189, DOI 10.1016/S0197-2456(05)80023-6; DOUGLAS JS, 1981, CIRCULATION, V64, P11; EAKER ED, 1989, AM HEART J, V117, P71, DOI 10.1016/0002-8703(89)90658-3; FISHER LD, 1982, J THORAC CARDIOV SUR, V84, P334; GUADAGNOLI E, 1992, AM J CARDIOL, V70, P60, DOI 10.1016/0002-9149(92)91390-P; GUADAGNOLI E, 1995, MED CARE, V33, P106, DOI 10.1097/00005650-199501000-00009; GUYATT GH, 1993, ANN INTERN MED, V118, P622, DOI 10.7326/0003-4819-118-8-199304150-00009; HANNAN EL, 1992, AM HEART J, V123, P866, DOI 10.1016/0002-8703(92)90689-S; JENKINS CD, 1988, JAMA-J AM MED ASSOC, V250, P782; JETTE AM, 1986, J GEN INTERN MED, V1, P143, DOI 10.1007/BF02602324; KENNEDY JW, 1981, CIRCULATION, V63, P793, DOI 10.1161/01.CIR.63.4.793; KHAN SS, 1990, ANN INTERN MED, V112, P561, DOI 10.7326/0003-4819-112-8-561; KOSTIS JB, 1994, CIRCULATION, V90, P1715, DOI 10.1161/01.CIR.90.4.1715; KRUMHOLZ HM, 1992, ANN INTERN MED, V116, P785, DOI 10.7326/0003-4819-116-10-785; LOOP FD, 1983, J AM COLL CARDIOL, V1, P383, DOI 10.1016/S0735-1097(83)80064-3; MAGNI G, 1987, ARCH INTERN MED, V147, P473, DOI 10.1001/archinte.147.3.473; NEASE RF, 1995, JAMA-J AM MED ASSOC, V273, P1185, DOI 10.1001/jama.273.15.1185; OCONNOR GT, 1991, JAMA-J AM MED ASSOC, V266, P803, DOI 10.1001/jama.266.6.803; PARSONNET V, 1989, CIRCULATION, V79, P3; PASSAMANI E, 1985, NEW ENGL J MED, V312, P1665, DOI 10.1056/NEJM198506273122603; RANKIN SH, 1990, HEART LUNG, V19, P481; SHAW PJ, 1987, Q J MED, V239, P259; STEINGART RM, 1991, NEW ENGL J MED, V325, P226, DOI 10.1056/NEJM199107253250402; TOBIN JN, 1987, ANN INTERN MED, V107, P19, DOI 10.7326/0003-4819-107-1-19; UDVARHELYI IS, 1992, JAMA-J AM MED ASSOC, V268, P2530, DOI 10.1001/jama.268.18.2530; WARE JE, 1992, MED CARE, V30, P473, DOI 10.1097/00005650-199206000-00002; WILSON IB, 1995, JAMA-J AM MED ASSOC, V273, P59, DOI 10.1001/jama.273.1.59; 1983, CIRCULATION, V68, P951; 1983, CIRCULATION, V68, P939	35	45	47	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	DEC 13	1995	274	22					1767	1770		10.1001/jama.274.22.1767	http://dx.doi.org/10.1001/jama.274.22.1767			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TJ225	7500506				2022-12-28	WOS:A1995TJ22500025
J	NISSEN, P; KJELDGAARD, M; THIRUP, S; POLEKHINA, G; RESHETNIKOVA, L; CLARK, BFC; NYBORG, J				NISSEN, P; KJELDGAARD, M; THIRUP, S; POLEKHINA, G; RESHETNIKOVA, L; CLARK, BFC; NYBORG, J			CRYSTAL-STRUCTURE OF THE TERNARY COMPLEX OF PHE-TRNA(PHE), EF-TU, AND A GTP ANALOG	SCIENCE			English	Article							ELONGATION-FACTOR-TU; AMINOACYL-TRANSFER-RNA; PHENYLALANINE TRANSFER-RNA; ESCHERICHIA-COLI; CRYSTALLOGRAPHIC REFINEMENT; BINDING-SITE; PROTEIN; YEAST; RESOLUTION; RIBOSOME	The structure of the ternary complex consisting of yeast phenylalanyl-transfer RNA (Phe-tRNA(Phe)), Thermus aquaticus elongation factor Tu (EF-Tu), and the guanosine triphosphate (GTP) analog GDPNP was determined by x-ray crystallography at 2.7 angstrom resolution. The ternary complex participates in placing the amino acids in their correct order when messenger RNA is translated into a protein sequence on the ribosome. The EF-Tu-GDPNP component binds to one side of the acceptor helix of Phe-tRNA(Phe) involving all three domains of EF-Tu. Binding sites for the phenylalanylated CCA end and the phosphorylated 5' end are located at domain interfaces, whereas the T stem interacts with the surface of the beta-barrel domain 3. The binding involves many conserved residues in EF-Tu. The overall shape of the ternary complex is similar to that of the translocation factor, EF-G-GDP, and this suggests a novel mechanism involving ''molecular mimicry'' in the translational apparatus.	AARHUS UNIV, INST CHEM, DEPT BIOSTRUCT CHEM, DK-8000 AARHUS C, DENMARK; RUSSIAN ACAD SCI, VA ENGELHARDT MOLEC BIOL INST, MOSCOW 117984, RUSSIA	Aarhus University; Russian Academy of Sciences; Engelhardt Institute of Molecular Biology, RAS			Nissen, Poul/D-5774-2014	Thirup, Soren/0000-0002-0061-7137; Nissen, Poul/0000-0003-0948-6628				Abrahams Jan Pieter, 1992, Spectroscopy (Amsterdam), V10, P1; AEVARSSON A, 1994, EMBO J, V13, P3669, DOI 10.1002/j.1460-2075.1994.tb06676.x; AMOR JC, 1994, NATURE, V372, P704, DOI 10.1038/372704a0; ANDERSEN C, 1994, EUR J BIOCHEM, V220, P739, DOI 10.1111/j.1432-1033.1994.tb18674.x; ANTONSSON B, 1984, EUR J BIOCHEM, V141, P483, DOI 10.1111/j.1432-1033.1984.tb08218.x; ANTONSSON B, 1986, BIOCHEMISTRY-US, V25, P3655, DOI 10.1021/bi00360a027; BAIROCH A, 1994, NUCLEIC ACIDS RES, V22, P3578; BASAVAPPA R, 1991, EMBO J, V10, P3105, DOI 10.1002/j.1460-2075.1991.tb07864.x; BERCHTOLD H, 1993, NATURE, V365, P126, DOI 10.1038/365126a0; BOURNE HR, 1991, NATURE, V349, P117, DOI 10.1038/349117a0; BRUNGER AT, 1989, ACTA CRYSTALLOGR A, V45, P50, DOI 10.1107/S0108767388009195; CANTOR CR, 1979, TRANSFER RNA STRUCTU, P363; Clark Brian F. C., 1995, P423; COLEMAN DE, 1994, SCIENCE, V265, P1405, DOI 10.1126/science.8073283; COTTRELLE P, 1985, J BIOL CHEM, V260, P3090; CZWORKOWSKI J, 1994, EMBO J, V13, P3661, DOI 10.1002/j.1460-2075.1994.tb06675.x; DELARUE M, 1993, BIOESSAYS, V15, P675, DOI 10.1002/bies.950151007; DINCBAS V, 1995, FEBS LETT, V357, P19, DOI 10.1016/0014-5793(94)01318-U; DOUDNA JA, 1995, P NATL ACAD SCI USA, V92, P2355, DOI 10.1073/pnas.92.6.2355; EHRENBERG M, 1990, J MOL BIOL, V211, P739, DOI 10.1016/0022-2836(90)90074-V; ENGH RA, 1991, ACTA CRYSTALLOGR A, V47, P392, DOI 10.1107/S0108767391001071; FAULHAMMER HG, 1987, FEBS LETT, V217, P203, DOI 10.1016/0014-5793(87)80664-6; FORSTER C, 1994, P NATL ACAD SCI USA, V91, P4254, DOI 10.1073/pnas.91.10.4254; FORSTER C, 1993, BIOCHIMIE, V75, P1159, DOI 10.1016/0300-9084(93)90015-K; GIRSHOVICH AS, 1981, FEBS LETT, V130, P54, DOI 10.1016/0014-5793(81)80664-3; GIRSHOVICH AS, 1986, FEBS LETT, V197, P192, DOI 10.1016/0014-5793(86)80325-8; GRENTZMANN G, 1994, P NATL ACAD SCI USA, V91, P5848, DOI 10.1073/pnas.91.13.5848; HAUSNER TP, 1987, BIOCHIMIE, V69, P911, DOI 10.1016/0300-9084(87)90225-2; JACK A, 1976, J MOL BIOL, V108, P619, DOI 10.1016/S0022-2836(76)80109-X; JONAK J, 1994, FEBS LETT, V343, P94, DOI 10.1016/0014-5793(94)80614-4; JONAK J, 1984, EUR J BIOCHEM, V144, P295, DOI 10.1111/j.1432-1033.1984.tb08463.x; JONES MD, 1980, EUR J BIOCHEM, V108, P507, DOI 10.1111/j.1432-1033.1980.tb04748.x; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KIESEWETTER S, 1990, NUCLEIC ACIDS RES, V18, P4677, DOI 10.1093/nar/18.16.4677; KIM SH, 1974, SCIENCE, V185, P435, DOI 10.1126/science.185.4149.435; KINZY TG, 1992, J BIOL CHEM, V267, P1623; KJELDGAARD M, 1992, J MOL BIOL, V223, P721, DOI 10.1016/0022-2836(92)90986-T; KJELDGAARD M, 1993, STRUCTURE, V1, P35, DOI 10.1016/0969-2126(93)90007-4; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LAMBRIGHT DG, 1994, NATURE, V369, P621, DOI 10.1038/369621a0; LANGER JA, 1986, J MOL BIOL, V187, P617, DOI 10.1016/0022-2836(86)90339-6; LEBERMAN R, 1995, FEBS LETT, V358, P71, DOI 10.1016/0014-5793(94)01398-K; LIM V, 1992, NUCLEIC ACIDS RES, V20, P2627, DOI 10.1093/nar/20.11.2627; LOUIE A, 1984, J BIOL CHEM, V259, P5010; METZBOUTIGUE MH, 1989, FEBS LETT, V245, P194, DOI 10.1016/0014-5793(89)80220-0; MOAZED D, 1989, NATURE, V342, P142, DOI 10.1038/342142a0; MOAZED D, 1988, NATURE, V334, P362, DOI 10.1038/334362a0; MOL CD, 1995, CELL, V82, P701, DOI 10.1016/0092-8674(95)90467-0; MURZIN AG, 1995, NAT STRUCT BIOL, V2, P25, DOI 10.1038/nsb0195-25; NASSAR M, 1995, NATURE, V375, P554, DOI 10.1038/375554a0; NAVAZA J, 1994, ACTA CRYSTALLOGR A, V50, P157, DOI 10.1107/S0108767393007597; NIERHAUS KH, 1993, TRANSLATIONAL APPARATUS, P263; NISSEN P, 1994, FEBS LETT, V356, P165, DOI 10.1016/0014-5793(94)01254-7; NOEL JP, 1993, NATURE, V366, P654, DOI 10.1038/366654a0; OSTERBERG R, 1981, EUR J BIOCHEM, V117, P155; OTT G, 1990, BIOCHIM BIOPHYS ACTA, V1050, P222, DOI 10.1016/0167-4781(90)90170-7; OTWINOWSKI Z, 1993, CCP4 STUDY WEEKEND D; PAI EF, 1990, EMBO J, V9, P2351, DOI 10.1002/j.1460-2075.1990.tb07409.x; PINGOUD A, 1982, J BIOL CHEM, V257, P1261; ROBERTUS JD, 1974, NATURE, V250, P546, DOI 10.1038/250546a0; RODNINA MV, 1995, P NATL ACAD SCI USA, V92, P1945, DOI 10.1073/pnas.92.6.1945; SAVVA R, 1995, NAT STRUCT BIOL, V2, P752, DOI 10.1038/nsb0995-752; SCHEFFZEK K, 1995, NATURE, V374, P378, DOI 10.1038/374378a0; SCOBLE J, 1994, BIOCHIMIE, V76, P59, DOI 10.1016/0300-9084(94)90063-9; SHULMAN RG, 1974, J MOL BIOL, V90, P601, DOI 10.1016/0022-2836(74)90237-X; SPURIO R, 1993, TRANSLATIONAL APPARATUS, P241; STOUTEN PFW, 1993, FEBS LETT, V320, P1, DOI 10.1016/0014-5793(93)81644-F; THIRUP S, 1990, PROTEINS, V7, P291, DOI 10.1002/prot.340070310; TONG L, 1991, J MOL BIOL, V217, P503, DOI 10.1016/0022-2836(91)90753-S; TRONRUD DE, 1992, ACTA CRYSTALLOGR A, V48, P912, DOI 10.1107/S0108767392005415; VANNOORT JM, 1985, P NATL ACAD SCI USA, V82, P3212, DOI 10.1073/pnas.82.10.3212; VANNOORT JM, 1984, P NATL ACAD SCI-BIOL, V81, P3969; VOSS RH, 1992, EUR J BIOCHEM, V207, P839, DOI 10.1111/j.1432-1033.1992.tb17115.x; WEIJLAND A, 1994, TRENDS BIOCHEM SCI, V19, P188, DOI 10.1016/0968-0004(94)90018-3; WIKMAN FP, 1982, EMBO J, V1, P1095, DOI 10.1002/j.1460-2075.1982.tb01302.x; Yarus Michael, 1995, P443; 1979, CCP4 DAR LAB	77	787	803	1	52	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	DEC 1	1995	270	5241					1464	1472		10.1126/science.270.5241.1464	http://dx.doi.org/10.1126/science.270.5241.1464			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TH375	7491491				2022-12-28	WOS:A1995TH37500030
J	TAYLOR, MFJ; SHEN, Y; KREITMAN, ME				TAYLOR, MFJ; SHEN, Y; KREITMAN, ME			A POPULATION GENETIC TEST OF SELECTION AT THE MOLECULAR-LEVEL	SCIENCE			English	Article							INSECTICIDE RESISTANCE; HELIOTHIS-VIRESCENS; DROSOPHILA-MELANOGASTER; TOBACCO BUDWORM; LEPIDOPTERA; NOCTUIDAE; POLYMORPHISMS; PATTERNS; LOCUS	The role of natural selection in molecular evolution has been inferred primarily by rejection of null hypotheses based on neutral theory, rather than by acceptance of specific predictions based on selection. In this report, a population genetic lest of a specific prediction for selection on DNA polymorphism is presented. Pyrethroid insecticide use constitutes an experiment for which form of selection and molecular target (voltage-gated sodium channels) are both known. As predicted, differential pyrethroid selection on tobacco budworm populations generated significant geographic heterogeneity in sodium channel marker allele frequencies, compared with arbitrary loci.	UNIV CHICAGO,DEPT ECOL & EVOLUT,CHICAGO,IL 60637	University of Chicago	TAYLOR, MFJ (corresponding author), UNIV ARIZONA,CTR INSECT SCI,DEPT ENTOMOL,TUCSON,AZ 85721, USA.							BERRY A, 1993, GENETICS, V134, P869; CHRISTIANSEN FB, 1974, GENETICS, V77, P765; FFRENCHCONSTANT RH, 1993, P NATL ACAD SCI USA, V90, P1957, DOI 10.1073/pnas.90.5.1957; HANZLIK TN, 1989, J BIOL CHEM, V264, P12419; HARSHMAN LG, 1994, INSECT BIOCHEM MOLEC, V24, P671, DOI 10.1016/0965-1748(94)90054-X; HEAD RB, 1990, P BELTWIDE COTTON PR, P157; KARL SA, 1992, SCIENCE, V256, P100, DOI 10.1126/science.1348870; KING EG, 1990, P BELTWIDE COTTON C, P140; KORMAN AK, 1993, ANN ENTOMOL SOC AM, V86, P182, DOI 10.1093/aesa/86.2.182; KREITMAN M, 1991, GENETICS, V127, P565; LESSA EP, 1993, MOL ECOL, V2, P119, DOI 10.1111/j.1365-294X.1993.tb00006.x; LEWONTIN RC, 1973, GENETICS, V74, P175; MCCAFFERY AR, 1991, SOUTHWEST ENTOMOL S, V15, P143; MYERS RM, 1987, METHOD ENZYMOL, V155, P501; NARAHASHI T, 1986, NEUROPHARMACOLOGY PE, P37; NEI M, 1983, ANN HUM GENET, V47, P253, DOI 10.1111/j.1469-1809.1983.tb00993.x; NEI M, 1975, GENETICS, V80, P395; NEUNZIG HH, 1963, J ECON ENTOMOL, V56, P135, DOI 10.1093/jee/56.2.135; PLAPP FW, 1990, J ECON ENTOMOL, V83, P335, DOI 10.1093/jee/83.2.335; RAYMOND M, 1991, NATURE, V350, P151, DOI 10.1038/350151a0; ROBERTSON A, 1975, GENETICS, V80, P396; ROEHRDANZ RL, 1994, ANN ENTOMOL SOC AM, V87, P856, DOI 10.1093/aesa/87.6.856; ROSENHEIM JA, 1986, J ECON ENTOMOL, V79, P1161, DOI 10.1093/jee/79.5.1161; SATTELLE DB, 1988, ADV INSECT PHYSL, V20, P145; SOKAL R, 1981, BIOMETRY, pCH18; STADELBACHER E A, 1972, Environmental Entomology, V1, P318; STAETZ CA, 1985, J ECON ENTOMOL, V78, P505, DOI 10.1093/jee/78.3.505; TABASHNIK BE, 1987, J ECON ENTOMOL, V80, P1091, DOI 10.1093/jee/80.6.1091; TAYLOR MFJ, 1993, INSECT BIOCHEM MOLEC, V23, P763, DOI 10.1016/0965-1748(93)90064-Y	29	62	65	0	15	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	DEC 1	1995	270	5241					1497	1499		10.1126/science.270.5241.1497	http://dx.doi.org/10.1126/science.270.5241.1497			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TH375	7491497				2022-12-28	WOS:A1995TH37500040
J	MEISTER, M; LAGNADO, L; BAYLOR, DA				MEISTER, M; LAGNADO, L; BAYLOR, DA			CONCERTED SIGNALING BY RETINAL GANGLION-CELLS	SCIENCE			English	Article							ROD OUTER SEGMENTS; TIGER SALAMANDER; X-CELL; Y-CELL; GOLDFISH; NEURONS; NOISE; INPUTS	To analyze the rules that govern communication between eye and brain, visual responses were recorded from an intact salamander retina. Parallel observation of many retinal ganglion cells with a microelectrode array showed that nearby neurons often fired synchronously, with spike delays of less than 10 milliseconds. The frequency of such synchronous spikes exceeded the correlation expected from a shared visual stimulus up to 20-fold. Synchronous firing persisted under a variety of visual stimuli and accounted for the majority of action potentials recorded. Analysis of receptive fields showed that concerted spikes encoded information not carried by individual cells; they may represent symbols in a multineuronal code for vision.	STANFORD UNIV,SCH MED,DEPT NEUROBIOL,STANFORD,CA 94305	Stanford University	MEISTER, M (corresponding author), HARVARD UNIV,DEPT MOLEC & CELLULAR BIOL,16 DIVIN AVE,CAMBRIDGE,MA 02138, USA.			Meister, Markus/0000-0003-2136-6506	NEI NIH HHS [EY01543, EY05750, EY10020] Funding Source: Medline; NATIONAL EYE INSTITUTE [R01EY001543, R01EY010020, R37EY001543] Funding Source: NIH RePORTER	NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		AHO AC, 1988, NATURE, V334, P348, DOI 10.1038/334348a0; ARNETT D, 1981, J PHYSIOL-LONDON, V317, P29, DOI 10.1113/jphysiol.1981.sp013812; ARNETT DW, 1978, EXP BRAIN RES, V32, P49; Aticky JJ, 2011, NETWORK-COMP NEURAL, V22, P4, DOI [10.1088/0954-898X/3/2/009, 10.3109/0954898X.2011.638888]; Barlow H B, 1971, Vision Res, VSuppl 3, P87; Barlow H. B., 1961, SENS COMMUN, P217, DOI DOI 10.7551/MITPRESS/9780262518420.003.0013; BAYLOR DA, 1979, J PHYSIOL-LONDON, V288, P589; BAYLOR DA, 1980, J PHYSIOL-LONDON, V309, P591, DOI 10.1113/jphysiol.1980.sp013529; BUCHSBAUM G, 1983, PROC R SOC SER B-BIO, V220, P89, DOI 10.1098/rspb.1983.0090; FIELD DJ, 1987, J OPT SOC AM A, V4, P2379, DOI 10.1364/JOSAA.4.002379; GHOSE GM, 1994, J NEUROPHYSIOL, V71, P330, DOI 10.1152/jn.1994.71.1.330; GINSBURG KS, 1984, J PHYSIOL-LONDON, V351, P433, DOI 10.1113/jphysiol.1984.sp015254; GLICKMAN RD, 1982, BRAIN RES, V234, P81, DOI 10.1016/0006-8993(82)90474-7; GUILOFF GD, 1992, VISION RES, V32, P2023, DOI 10.1016/0042-6989(92)90063-O; JOHNSEN JA, 1983, J PHYSIOL-LONDON, V345, P439, DOI 10.1113/jphysiol.1983.sp014987; MAPLE BR, 1994, VISION RES, V34, P2357, DOI 10.1016/0042-6989(94)90281-X; MASLAND RH, 1984, PROC R SOC SER B-BIO, V223, P121, DOI 10.1098/rspb.1984.0086; MASTRONARDE DN, 1983, J NEUROPHYSIOL, V49, P303, DOI 10.1152/jn.1983.49.2.303; MASTRONARDE DN, 1983, J NEUROPHYSIOL, V49, P325, DOI 10.1152/jn.1983.49.2.325; MASTRONARDE DN, 1983, J NEUROPHYSIOL, V49, P350, DOI 10.1152/jn.1983.49.2.350; MEISTER M, 1994, J NEUROSCI METH, V51, P95, DOI 10.1016/0165-0270(94)90030-2; MEISTER M, IN PRESS P NATL ACAD; MILLAR T, 1985, NEUROSCI LETT, V61, P311, DOI 10.1016/0304-3940(85)90482-3; MOORE GP, 1970, BIOPHYS J, V10, P876, DOI 10.1016/S0006-3495(70)86341-X; SAKAI HM, 1990, J NEUROPHYSIOL, V63, P105, DOI 10.1152/jn.1990.63.1.105; SCHNITZER MJ, UNPUB; VANEY DI, 1994, PROG RETIN EYE RES, V13, P301, DOI 10.1016/1350-9462(94)90014-0; WERBLIN F, 1988, VISUAL NEUROSCI, V1, P317, DOI 10.1017/S0952523800001978; WUNK DF, 1979, J GEN PHYSIOL, V73, P265, DOI 10.1085/jgp.73.3.265	29	286	292	1	15	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	NOV 17	1995	270	5239					1207	1210		10.1126/science.270.5239.1207	http://dx.doi.org/10.1126/science.270.5239.1207			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TE905	7502047				2022-12-28	WOS:A1995TE90500059
J	LANGFORD, EJ; BROWN, AS; WAINWRIGHT, RJ; DEBELDER, AJ; THOMAS, MR; SMITH, REA; RADOMSKI, MW; MARTIN, JF; MONCADA, S				LANGFORD, EJ; BROWN, AS; WAINWRIGHT, RJ; DEBELDER, AJ; THOMAS, MR; SMITH, REA; RADOMSKI, MW; MARTIN, JF; MONCADA, S			INHIBITION OF PLATELET ACTIVITY BY S-NITROSOGLUTATHIONE DURING CORONARY ANGIOPLASTY	LANCET			English	Article							SMOOTH-MUSCLE CELLS; NITRIC-OXIDE; VASCULAR ENDOTHELIUM; FOLLOW-UP; ACTIVATION; PROSTACYCLIN; RESTENOSIS; ADHESION; PROLIFERATION; DIPYRIDAMOLE	Platelet activation is associated with acute vessel occlusion and chronic restenosis after percutaneous transluminal coronary angioplasty (PTCA), Organic nitrates, which act by releasing the vasodilator and anti-platelet agent nitric oxide (NO), have a predominantly vasodilator action and cause hypotension at doses required to inhibit platelet activation. S-nitrosoglutathione (GSNO) is an NO donor with a preferential action on platelets. We investigated platelet activation in patients undergoing PTCA and the effect of GSNO. Blood was sampled from the coronary sinus to measure platelet surface expression of P-selectin and glycoprotein IIb/IIIa as indices of platelet activation. In 7 control patients, PTCA caused a rise in platelet surface expression of P-selectin and glycoprotein IIb/IIIa, which was maximal 5 minutes after PTCA, indicating increased platelet activation despite treatment with aspirin, glyceryl trinitrate, and heparin. 6 patients received an intracoronary infusion of GSNO, starting 10 min before PTCA. GSNO significantly inhibited the PTCA-induced increase in platelet surface expression of P-selectin and glycoprotein IIb/IIIa without altering blood pressure. These findings show that platelets are activated following PTCA and that GSNO can prevent this activation.	UNIV LONDON KINGS COLL,SCH MED & DENT,DEPT MED,LONDON SE5 9PJ,ENGLAND; UNIV LONDON KINGS COLL HOSP,DEPT CARDIOL,LONDON,ENGLAND; WELLCOME RES LABS,BECKENHAM BR3 3BS,KENT,ENGLAND	University of London; King's College London; King's College Hospital NHS Foundation Trust; King's College Hospital; University of London; King's College London; GlaxoSmithKline; Wellcome Research Laboratories			Radomski, Marek W/C-5195-2014					BARNATHAN ES, 1987, CIRCULATION, V76, P125, DOI 10.1161/01.CIR.76.1.125; CAHILL MR, 1993, BRIT J HAEMATOL, V84, P527, DOI 10.1111/j.1365-2141.1993.tb03112.x; CASSCELLS W, 1992, CIRCULATION, V86, P723, DOI 10.1161/01.CIR.86.3.723; DEBELDER AJ, 1994, CARDIOVASC RES, V28, P691; DEFEYTER PJ, 1991, CIRCULATION, V83, P927, DOI 10.1161/01.CIR.83.3.927; FERNS GAA, 1991, SCIENCE, V253, P1129, DOI 10.1126/science.1653454; FINGERLE J, 1989, P NATL ACAD SCI USA, V86, P8412, DOI 10.1073/pnas.86.21.8412; FITZGERALD DJ, 1984, CIRCULATION, V70, P297, DOI 10.1161/01.CIR.70.2.297; GARG UC, 1989, J CLIN INVEST, V83, P1774, DOI 10.1172/JCI114081; GERSHLICK AH, 1994, BRIT HEART J, V71, P7; GROVES PH, 1993, CIRCULATION, V87, P590, DOI 10.1161/01.CIR.87.2.590; GRUENTZIG AR, 1987, NEW ENGL J MED, V316, P1127, DOI 10.1056/NEJM198704303161805; HIGGS EA, 1978, PROSTAGLANDINS, V16, P17, DOI 10.1016/0090-6980(78)90197-1; KOWALUK EA, 1990, J PHARMACOL EXP THER, V255, P1256; LAM JYT, 1988, CIRCULATION, V78, P712, DOI 10.1161/01.CIR.78.3.712; MABIN TA, 1985, J AM COLL CARDIOL, V5, P198, DOI 10.1016/S0735-1097(85)80037-1; MARTIN JF, 1991, LANCET, V338, P1409, DOI 10.1016/0140-6736(91)92719-I; MCEWAN J, 1993, BRIT HEART J, V70, P1; RADOMSKI MW, 1990, P NATL ACAD SCI USA, V87, P5193, DOI 10.1073/pnas.87.13.5193; RADOMSKI MW, 1987, LANCET, V2, P1057, DOI 10.1016/S0140-6736(87)91481-4; RADOMSKI MW, 1987, BRIT J PHARMACOL, V92, P639, DOI 10.1111/j.1476-5381.1987.tb11367.x; RADOMSKI MW, 1992, BRIT J PHARMACOL, V107, P745, DOI 10.1111/j.1476-5381.1992.tb14517.x; SALVEMINI D, 1992, P NATL ACAD SCI USA, V89, P982, DOI 10.1073/pnas.89.3.982; SCHARF RE, 1992, ARTERIOSCLER THROMB, V12, P1475, DOI 10.1161/01.ATV.12.12.1475; SCHWARTZ L, 1988, NEW ENGL J MED, V318, P1714, DOI 10.1056/NEJM198806303182603; SHATTIL SJ, 1987, BLOOD, V70, P307; SMYTH DW, 1993, EUR J CLIN INVEST, V23, P361, DOI 10.1111/j.1365-2362.1993.tb02037.x; 1993, LANCET, V341, P573; 1994, J AM COLL CARDIOL, V23, pA59	29	183	196	0	14	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	NOV 26	1994	344	8935					1458	1460		10.1016/S0140-6736(94)90287-9	http://dx.doi.org/10.1016/S0140-6736(94)90287-9			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PT995	7526102				2022-12-28	WOS:A1994PT99500006
J	FENG, SB; CHEN, JK; YU, HT; SIMON, JA; SCHREIBER, SL				FENG, SB; CHEN, JK; YU, HT; SIMON, JA; SCHREIBER, SL			2 BINDING ORIENTATIONS FOR PEPTIDES TO THE SRC SH3 DOMAIN - DEVELOPMENT OF A GENERAL-MODEL FOR SH3-LIGAND INTERACTIONS	SCIENCE			English	Article							MULTIPLE QUANTUM COHERENCE; NMR-SPECTROSCOPY; C-SRC; PROTEIN; IDENTIFICATION; MAGNETIZATION; DELETIONS; RECEPTOR; SPECTRA; SITE	Solution structures of two Src homology 3 (SH3) domain-ligand complexes have been determined by nuclear magnetic resonance. Each complex consists of the SH3 domain and a nine-residue proline-rich peptide selected from a large library of ligands prepared by combinatorial synthesis. The bound ligands adopt a left-handed polyproline type II (PPII) helix, although the amino to carboxyl directionalities of their helices are opposite. The peptide orientation is determined by a salt bridge formed by the terminal arginine residues of the ligands and the conserved aspartate-99 of the SH3 domain. Residues at positions 3, 4, 6, and 7 of both peptides also intercalate into the ligand-binding site; however, the respective proline and nonproline residues show exchanged binding positions in the two complexes. These structural results led to a model for the interactions of SH3 domains with proline-rich peptides that can be used to predict critical residues in complexes of unknown structure. The model was used to identify correctly both the binding orientation and the contact and noncontact residues of a peptide derived from the nucleotide exchange factor Sos in association with the amino-terminal SH3 domain of the adaptor protein Grb2.	HARVARD UNIV, HOWARD HUGHES MED INST, DEPT CHEM, CAMBRIDGE, MA 02138 USA	Harvard University; Howard Hughes Medical Institute			Chen, James/G-9972-2011	Chen, James/0000-0002-9220-8436; Yu, Hongtao/0000-0002-8861-049X	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM044993] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM44993] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ADZHUBEI AA, 1993, J MOL BIOL, V229, P472, DOI 10.1006/jmbi.1993.1047; BARFOD ET, 1993, J BIOL CHEM, V268, P26059; BAX A, 1985, J MAGN RESON, V65, P355, DOI 10.1016/0022-2364(85)90018-6; BAX A, 1990, J MAGN RESON, V88, P425, DOI 10.1016/0022-2364(90)90202-K; BAX A, 1983, J AM CHEM SOC, V105, P7188, DOI 10.1021/ja00362a038; BROOKS BR, 1983, J COMPUT CHEM, V4, P187, DOI 10.1002/jcc.540040211; BRUNGER AT, 1988, X PLOR MANUAL; BRUNGER T, 1992, X PLOR MANUAL V 3 1; CHEN JK, 1994, BIOORG MED CHEM LETT, V4, P1755, DOI 10.1016/S0960-894X(00)80375-3; CHEN JK, 1993, J AM CHEM SOC, V115, P12591, DOI 10.1021/ja00079a051; CHENG GH, 1994, P NATL ACAD SCI USA, V91, P8152, DOI 10.1073/pnas.91.17.8152; CICCHETTI P, 1992, SCIENCE, V257, P803, DOI 10.1126/science.1379745; FINAN P, 1994, J BIOL CHEM, V269, P13752; FUMAGALLI S, 1994, NATURE, V368, P871, DOI 10.1038/368871a0; GOUT I, 1993, CELL, V75, P25, DOI 10.1016/0092-8674(93)90676-H; IKURA M, 1992, J AM CHEM SOC, V114, P2433, DOI 10.1021/ja00033a019; KAPELLER R, 1994, J BIOL CHEM, V269, P1927; KATO JY, 1986, MOL CELL BIOL, V6, P4155, DOI 10.1128/MCB.6.12.4155; KAY LE, 1990, J MAGN RESON, V86, P110, DOI 10.1016/0022-2364(90)90215-U; KOCH CA, 1991, SCIENCE, V252, P668, DOI 10.1126/science.1708916; LIM WA, 1994, NAT STRUCT BIOL, V1, P221, DOI 10.1038/nsb0494-221; LIU XQ, 1993, MOL CELL BIOL, V13, P5225, DOI 10.1128/MCB.13.9.5225; MACURA S, 1981, J MAGN RESON, V43, P259, DOI 10.1016/0022-2364(81)90037-8; MARION D, 1989, BIOCHEMISTRY-US, V28, P6150, DOI 10.1021/bi00441a004; MICHNICK SW, 1991, SCIENCE, V252, P836, DOI 10.1126/science.1709301; MULLER N, 1986, J AM CHEM SOC, V108, P6482, DOI 10.1021/ja00281a006; MUSACCHIO A, 1994, NAT STRUCT BIOL, V1, P546, DOI 10.1038/nsb0894-546; MUSACCHIO A, 1992, FEBS LETT, V307, P55, DOI 10.1016/0014-5793(92)80901-R; NEMETH SP, 1989, MOL CELL BIOL, V9, P1109, DOI 10.1128/MCB.9.3.1109; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; PATERSON Y, 1990, SCIENCE, V249, P755, DOI 10.1126/science.1697101; PAWSON T, 1993, CURR BIOL, V3, P434, DOI 10.1016/0960-9822(93)90350-W; PAWSON T, 1992, CELL, V71, P359, DOI 10.1016/0092-8674(92)90504-6; PIANTINI U, 1982, J AM CHEM SOC, V104, P6800, DOI 10.1021/ja00388a062; PLEIMAN CM, 1994, SCIENCE, V263, P1609, DOI 10.1126/science.8128248; Potts W M, 1988, Oncogene Res, V3, P343; REIF K, 1994, J BIOL CHEM, V269, P14081; REN RB, 1993, SCIENCE, V259, P1157, DOI 10.1126/science.8438166; RICKLES RJ, 1994, EMBO J, V13, P5598, DOI 10.1002/j.1460-2075.1994.tb06897.x; ROZAKISADCOCK M, 1993, NATURE, V363, P83, DOI 10.1038/363083a0; SARKAR G, 1990, BIOTECHNIQUES, V8, P404; SEIDELDUGAN C, 1992, MOL CELL BIOL, V12, P1835, DOI 10.1128/MCB.12.4.1835; SUDOL M, 1994, ONCOGENE, V9, P2145; SUMIMOTO H, 1994, P NATL ACAD SCI USA, V91, P5345, DOI 10.1073/pnas.91.12.5345; TANAKA S, 1994, P NATL ACAD SCI USA, V91, P3443, DOI 10.1073/pnas.91.8.3443; TAYLOR SJ, 1994, NATURE, V368, P867, DOI 10.1038/368867a0; VIGUERA AR, 1994, BIOCHEMISTRY-US, V33, P2142, DOI 10.1021/bi00174a022; WENG ZG, 1993, J BIOL CHEM, V268, P14956; YU HT, 1992, SCIENCE, V258, P1665, DOI 10.1126/science.1280858; YU HT, 1994, CELL, V76, P933, DOI 10.1016/0092-8674(94)90367-0; ZUIDERWEG ERP, 1989, BIOCHEMISTRY-US, V28, P2387, DOI 10.1021/bi00432a008	51	753	776	1	15	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	NOV 18	1994	266	5188					1241	1247		10.1126/science.7526465	http://dx.doi.org/10.1126/science.7526465			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PT132	7526465				2022-12-28	WOS:A1994PT13200054
J	DANSKA, JS; PFLUMIO, F; WILLIAMS, CJ; HUNER, O; DICK, JE; GUIDOS, CJ				DANSKA, JS; PFLUMIO, F; WILLIAMS, CJ; HUNER, O; DICK, JE; GUIDOS, CJ			RESCUE OF T-CELL-SPECIFIC V(D)J RECOMBINATION IN SCID MICE BY DNA-DAMAGING AGENTS	SCIENCE			English	Article							ANTIGEN RECEPTOR GENES; STRAND BREAK REPAIR; PRE-B CELLS; COMBINED IMMUNODEFICIENCY MICE; COMBINED IMMUNE-DEFICIENCY; LIGHT CHAIN GENES; BETA-CHAIN; THYMOCYTE DEVELOPMENT; JUNCTIONAL SEQUENCES; MOUSE THYMOCYTES	Assembly of antigen receptor V (variable), D (diversity), and J (joining) gene segments requires lymphocyte-specific genes and ubiquitous DNA repair activities. Severe combined immunodeficient (SCID) mice are defective in general double-strand (ds) DNA break repair and V(D)J coding joint formation, resulting in arrested lymphocyte development. A single treatment of newborn SCID mice with DNA-damaging agents restored functional, diverse, T cell receptor beta chain coding joints, as well as development and expansion oi thymocytes expressing both CD4 and CD8 coreceptors, but did not promote B cell development. Thymic lymphoma developed in all mice treated with DNA-damaging agents, suggesting an Interrelation between V(D)J recombination, dsDNA break repair, and lymphomagenesis.	HOSP SICK CHILDREN, RES INST, DIV IMMUNOL & CANC, TORONTO M5G 1X8, ON, CANADA; UNIV TORONTO, DEPT IMMUNOL, TORONTO, ON, CANADA; HOSP SICK CHILDREN, RES INST, DEPT GENET, TORONTO M5G 1X8, ON, CANADA; UNIV TORONTO, DEPT MOLEC & MED GENET, TORONTO, ON, CANADA; UNIV TORONTO, DEPT IMMUNOL, TORONTO, ON, CANADA	University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); University of Toronto; University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); University of Toronto; University of Toronto	DANSKA, JS (corresponding author), HOSP SICK CHILDREN, RES INST, DIV SURG RES, TORONTO M5G 1X8, ON, CANADA.		Pflumio, Francoise/E-2074-2017	Pflumio, Francoise/0000-0001-8995-596X; Dick, John/0000-0002-9527-8317				BARRY TS, 1991, J EXP MED, V173, P167, DOI 10.1084/jem.173.1.167; BIEDERMANN KA, 1991, P NATL ACAD SCI USA, V88, P1394, DOI 10.1073/pnas.88.4.1394; BLACKWELL TK, 1989, EMBO J, V8, P735, DOI 10.1002/j.1460-2075.1989.tb03433.x; Chabner B., 1990, CANC CHEMOTHERAPY PR, P341; CLARKE AR, 1993, NATURE, V362, P849, DOI 10.1038/362849a0; CLEARY ML, 1991, CELL, V66, P619, DOI 10.1016/0092-8674(91)90105-8; DANSKA JS, 1990, J EXP MED, V172, P27, DOI 10.1084/jem.172.1.27; DANSKA JS, UNPUB; DISNEY JE, 1992, CYTOGENET CELL GENET, V59, P39, DOI 10.1159/000133196; EHLICH A, 1993, CELL, V72, P695, DOI 10.1016/0092-8674(93)90398-A; FERRIER P, 1990, J EXP MED, V171, P1909, DOI 10.1084/jem.171.6.1909; FULOP GM, 1990, NATURE, V347, P479, DOI 10.1038/347479a0; GILFILLAN S, 1993, SCIENCE, V261, P1175, DOI 10.1126/science.8356452; GROETTRUP M, 1993, CELL, V75, P283, DOI 10.1016/0092-8674(93)80070-U; GUIDOS CJ, 1990, J EXP MED, V172, P835, DOI 10.1084/jem.172.3.835; GUIDOS CJ, 1989, P NATL ACAD SCI USA, V86, P7542, DOI 10.1073/pnas.86.19.7542; HABU S, 1987, EUR J IMMUNOL, V17, P1467, DOI 10.1002/eji.1830171013; HARDY RR, 1989, CURR TOP MICROBIOL, V152, P19; HARRINGTON J, 1992, MOL CELL BIOL, V12, P4758, DOI 10.1128/MCB.12.10.4758; HENDRICKSON EA, 1991, P NATL ACAD SCI USA, V88, P4061, DOI 10.1073/pnas.88.10.4061; HENDRICKSON EA, 1990, MOL CELL BIOL, V10, P5397, DOI 10.1128/MCB.10.10.5397; KAPLAN HS, 1952, J NATL CANCER I, V13, P185; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; KASTAN MB, 1991, CANCER RES, V51, P6304; KIENKER LJ, 1991, J EXP MED, V174, P769, DOI 10.1084/jem.174.4.769; KISHI H, 1991, EMBO J, V10, P93, DOI 10.1002/j.1460-2075.1991.tb07924.x; KITAMURA D, 1992, CELL, V69, P823, DOI 10.1016/0092-8674(92)90293-L; KOMORI T, 1993, SCIENCE, V261, P1171, DOI 10.1126/science.8356451; KOTLOFF DB, 1993, INT IMMUNOL, V5, P383, DOI 10.1093/intimm/5.4.383; KOTLOFF DB, 1993, J EXP MED, V178, P1981, DOI 10.1084/jem.178.6.1981; KUERBITZ SJ, 1992, P NATL ACAD SCI USA, V89, P7491, DOI 10.1073/pnas.89.16.7491; LAFAILLE JJ, 1989, CELL, V59, P859, DOI 10.1016/0092-8674(89)90609-0; LEVELT CN, 1993, J EXP MED, V178, P1867, DOI 10.1084/jem.178.6.1867; LIEBER MR, 1988, CELL, V55, P7, DOI 10.1016/0092-8674(88)90004-9; LIEBERMAN M, 1992, J EXP MED, V176, P399, DOI 10.1084/jem.176.2.399; LOWE SW, 1993, NATURE, V362, P847, DOI 10.1038/362847a0; LYNCH F, 1993, INT IMMUNOL, V5, P991, DOI 10.1093/intimm/5.8.991; MACDONALD HR, 1988, EUR J IMMUNOL, V18, P519, DOI 10.1002/eji.1830180405; MALLICK CA, 1993, CELL, V73, P513, DOI 10.1016/0092-8674(93)90138-G; MALYNN BA, 1988, CELL, V54, P453, DOI 10.1016/0092-8674(88)90066-9; MOMBAERTS P, 1992, NATURE, V360, P225, DOI 10.1038/360225a0; MOMBAERTS P, 1992, CELL, V68, P869, DOI 10.1016/0092-8674(92)90030-G; MURPHY WJ, 1994, J IMMUNOL, V153, P1004; NIKOLICZUGIC J, 1988, P NATL ACAD SCI USA, V85, P8633, DOI 10.1073/pnas.85.22.8633; PEARSE M, 1989, P NATL ACAD SCI USA, V86, P1614, DOI 10.1073/pnas.86.5.1614; PENNYCOOK JL, 1993, J EXP MED, V178, P1007, DOI 10.1084/jem.178.3.1007; PERGOLA F, 1993, MOL CELL BIOL, V13, P3464, DOI 10.1128/MCB.13.6.3464; PETRINI JHJ, 1990, P NATL ACAD SCI USA, V87, P3450, DOI 10.1073/pnas.87.9.3450; PFLUMIO F, 1993, INT IMMUNOL, V5, P1509, DOI 10.1093/intimm/5.12.1509; PFLUMIO F, UNPUB; PHILPOTT KL, 1992, SCIENCE, V256, P1448, DOI 10.1126/science.1604321; RAULET DH, 1985, NATURE, V314, P101, DOI 10.1038/314101a0; ROEHM N, 1984, CELL, V38, P577, DOI 10.1016/0092-8674(84)90512-9; ROTH DB, 1992, CELL, V70, P983, DOI 10.1016/0092-8674(92)90248-B; SCHATZ DG, 1992, ANNU REV IMMUNOL, V10, P359, DOI 10.1146/annurev.iy.10.040192.002043; SCHULER W, 1991, EUR J IMMUNOL, V21, P589, DOI 10.1002/eji.1830210309; SCHULER W, 1988, EMBO J, V7, P2019, DOI 10.1002/j.1460-2075.1988.tb03041.x; SCHULER W, 1986, CELL, V46, P963, DOI 10.1016/0092-8674(86)90695-1; SHINKAI Y, 1993, SCIENCE, V259, P822, DOI 10.1126/science.8430336; SHORES EW, 1993, J IMMUNOL, V150, P1263; SHORES EW, 1990, EUR J IMMUNOL, V20, P69, DOI 10.1002/eji.1830200111; SNODGRASS HR, 1985, NATURE, V313, P592, DOI 10.1038/313592a0; STRASSER A, 1994, NATURE, V368, P457, DOI 10.1038/368457a0; TACCIOLI GE, 1993, SCIENCE, V260, P207, DOI 10.1126/science.8469973; VONBOEHMER H, 1994, CELL, V76, P219, DOI 10.1016/0092-8674(94)90330-1; WILSON RK, 1988, IMMUNOL REV, V101, P149, DOI 10.1111/j.1600-065X.1988.tb00736.x; [No title captured]	68	114	114	0	3	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	OCT 21	1994	266	5184					450	455		10.1126/science.7524150	http://dx.doi.org/10.1126/science.7524150			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PN272	7524150				2022-12-28	WOS:A1994PN27200039
J	NIGHTINGALE, SL				NIGHTINGALE, SL			REPORTS OF SKIN INJURIES FOLLOWING HIGH X-RAY DOSE INTERVENTIONAL PROCEDURES	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material											NIGHTINGALE, SL (corresponding author), US FDA,OFF HLTH AFFAIRS,PARKLAWN BLDG,5600 FISHERS LN,ROCKVILLE,MD 20857, USA.							1994, JAMA-J AM MED ASSOC, V5, P71	1	3	3	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 19	1994	272	15					1160	1160		10.1001/jama.272.15.1160	http://dx.doi.org/10.1001/jama.272.15.1160			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PL212	7523738				2022-12-28	WOS:A1994PL21200007
J	ROOT, MJ; MACKINNON, R				ROOT, MJ; MACKINNON, R			2 IDENTICAL NONINTERACTING SITES IN AN ION-CHANNEL REVEALED BY PROTON-TRANSFER	SCIENCE			English	Article							INDUCED CURRENT FLUCTUATIONS; OLFACTORY RECEPTOR NEURONS; NUCLEOTIDE-GATED CHANNEL; CALCIUM CHANNELS; CRYSTAL-STRUCTURE; ACTIVATED CHANNEL; DIVALENT-CATIONS; 2.0-A RESOLUTION; K+ CHANNELS; PERMEATION	The functional consequences of single proton transfers occurring in the pore of a cyclic nucleotide-gated channel were observed with patch recording techniques. These results led to three conclusions about the chemical nature of ion binding sites in the conduction pathway: The channel contains two identical titratable sites, even though there are more than two (probably four) identical subunits; the sites are formed by glutamate residues that have a pK(a) (where K-a is the acid constant) of 7.6; and protonation of one site does not perturb the pK(a) of the other. These properties point to an unusual arrangement of carboxyl side-chain residues in the pore of a cation channel.	HARVARD UNIV, SCH MED, BIOPHYS PROGRAM, BOSTON, MA 02115 USA	Harvard University; Harvard Medical School	ROOT, MJ (corresponding author), HARVARD UNIV, SCH MED, DEPT NEUROBIOL, BOSTON, MA 02115 USA.				NIGMS NIH HHS [GM47400, 5 T32 GM083113] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM047400, R01GM083113] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ARMSTRONG CM, 1991, ANN NY ACAD SCI, V635, P18, DOI 10.1111/j.1749-6632.1991.tb36477.x; Bell R.P., 1973, PROTON CHEM; Caldin E. F., 1975, PROTON TRANSFER REAC; Caspar D L, 1990, Adv Biophys, V26, P157, DOI 10.1016/0065-227X(90)90011-H; CHEN TY, 1994, NATURE, V368, P545, DOI 10.1038/368545a0; COLAMARTINO G, 1991, J PHYSIOL-LONDON, V440, P189, DOI 10.1113/jphysiol.1991.sp018703; COLLYER CA, 1990, J MOL BIOL, V211, P617, DOI 10.1016/0022-2836(90)90269-R; EISMANN E, 1994, P NATL ACAD SCI USA, V91, P1109, DOI 10.1073/pnas.91.3.1109; Fersht A., 1985, ENZYME STRUCTURE MEC; GOULDING EH, 1992, NEURON, V8, P45, DOI 10.1016/0896-6273(92)90107-O; HEGINBOTHAM L, 1992, SCIENCE, V258, P1152, DOI 10.1126/science.1279807; HERZBERG O, 1988, J MOL BIOL, V203, P761, DOI 10.1016/0022-2836(88)90208-2; Jencks W. P., 1987, CATALYSIS CHEM ENZYM; KAUPP UB, 1992, ANNU REV PHYSIOL, V54, P153; KIM MS, 1993, FEBS LETT, V318, P145, DOI 10.1016/0014-5793(93)80009-J; KOHLER HH, 1979, J THEOR BIOL, V79, P381, DOI 10.1016/0022-5193(79)90354-0; KRAMER RH, 1992, NEURON, V9, P897, DOI 10.1016/0896-6273(92)90242-6; MACKINNON R, 1988, NEURON, V1, P997, DOI 10.1016/0896-6273(88)90156-0; MANGANI S, 1992, J MOL BIOL, V223, P573, DOI 10.1016/0022-2836(92)90671-6; MIKALA G, 1993, FEBS LETT, V335, P265, DOI 10.1016/0014-5793(93)80743-E; PENTZ L, 1967, J AM CHEM SOC, V89, P6931, DOI 10.1021/ja01002a022; PIETROBON D, 1989, J GEN PHYSIOL, V94, P1, DOI 10.1085/jgp.94.1.1; PRODHOM B, 1989, J GEN PHYSIOL, V94, P23, DOI 10.1085/jgp.94.1.23; ROOT MJ, 1993, NEURON, V11, P459, DOI 10.1016/0896-6273(93)90150-P; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SAWYER L, 1982, NATURE, V295, P79, DOI 10.1038/295079a0; SCHUMAKER MF, 1990, BIOPHYS J, V58, P975, DOI 10.1016/S0006-3495(90)82442-5; SIELECKI AR, 1979, J MOL BIOL, V134, P781, DOI 10.1016/0022-2836(79)90486-8; TSIEN RW, 1987, ANNU REV BIOPHYS BIO, V16, P265; TYERMAN SD, 1992, BIOPHYS J, V61, P736, DOI 10.1016/S0006-3495(92)81878-7; YANG J, 1993, NATURE, V366, P158, DOI 10.1038/366158a0; YAU KW, 1989, ANNU REV NEUROSCI, V12, P289, DOI 10.1146/annurev.ne.12.030189.001445; ZUFALL F, 1993, J NEUROPHYSIOL, V69, P1758, DOI 10.1152/jn.1993.69.5.1758	33	139	143	0	13	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	SEP 23	1994	265	5180					1852	1856		10.1126/science.7522344	http://dx.doi.org/10.1126/science.7522344			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PH258	7522344				2022-12-28	WOS:A1994PH25800029
J	SHARKEY, J; BUTCHER, SP				SHARKEY, J; BUTCHER, SP			IMMUNOPHILINS MEDIATE THE NEUROPROTECTIVE EFFECTS OF FK506 IN FOCAL CEREBRAL-ISCHEMIA	NATURE			English	Article							CALCINEURIN PHOSPHATASE-ACTIVITY; CYCLOSPORINE-A; NITRIC-OXIDE; IMMUNOSUPPRESSANT FK506; GLUTAMATE NEUROTOXICITY; LYMPHOCYTES-T; BRAIN; COMPLEXES; ISCHEMIA; RAPAMYCIN	THE immunosuppressive action of the drug FK506 involves inhibition of calcineurin in T-lymphocytes by a complex of FK506 and an FK506 binding protein, FKBP 12(1,2), a member of the immunophilin protein family(3,4). The functional role of brain immunophilins is, however, unclear(5,6). We show here that FK506 is a powerful neuroprotective agent in an in vivo model of focal cerebral ischaemia when administered up to 60 min post-occlusion. The minimum effective neuroprotective dose is comparable with the immunosuppressant dose in humans(7), suggesting. that FK506 may have clinical potential for the treatment of stroke. Although the related immunosuppressants rapamycin and cyclosporin failed to reduce brain damage, the finding that rapamycin pretreatment blocked the effect of FK506 confirms a role for immunophilins in the neuroprotective mechanism.			SHARKEY, J (corresponding author), UNIV EDINBURGH,FUJISAWA INST NEUROSCI,DEPT PHARMACOL,EDINBURGH EH8 9JZ,MIDLOTHIAN,SCOTLAND.			Sharkey, John/0000-0001-8288-1857				ARMSTRONG DL, 1989, TRENDS NEUROSCI, V12, P117, DOI 10.1016/0166-2236(89)90168-9; ASAMI M, 1993, BIOCHEM BIOPH RES CO, V192, P1388, DOI 10.1006/bbrc.1993.1570; BEGLEY DJ, 1990, J NEUROCHEM, V55, P1222, DOI 10.1111/j.1471-4159.1990.tb03128.x; BIERER BE, 1990, P NATL ACAD SCI USA, V87, P9231, DOI 10.1073/pnas.87.23.9231; CHOI DW, 1992, SCIENCE, V258, P241, DOI 10.1126/science.1357748; CHOI DW, 1988, TRENDS NEUROSCI, V11, P465, DOI 10.1016/0166-2236(88)90200-7; CLIPSTONE NA, 1992, NATURE, V357, P695, DOI 10.1038/357695a0; DAWSON TM, 1993, P NATL ACAD SCI USA, V90, P9808, DOI 10.1073/pnas.90.21.9808; DAWSON VL, 1991, P NATL ACAD SCI USA, V88, P6368, DOI 10.1073/pnas.88.14.6368; DUMONT FJ, 1990, J IMMUNOL, V144, P1418; FRUMAN DA, 1992, P NATL ACAD SCI USA, V89, P3686, DOI 10.1073/pnas.89.9.3686; FUNG J, 1991, TRANSPLANT P, V23, P2977; HARDING MW, 1989, NATURE, V341, P758, DOI 10.1038/341758a0; KUNO T, 1992, J NEUROCHEM, V58, P1643, DOI 10.1111/j.1471-4159.1992.tb10036.x; LIPTON SA, 1993, NATURE, V364, P626, DOI 10.1038/364626a0; LIU J, 1991, CELL, V66, P807, DOI 10.1016/0092-8674(91)90124-H; LIU J, 1993, TRENDS PHARMACOL SCI, V14, P182, DOI 10.1016/0165-6147(93)90206-Y; LIU J, 1992, BIOCHEMISTRY-US, V31, P3896, DOI 10.1021/bi00131a002; MAKAI H, 1993, J BIOCH, V113, P292; NAGASAWA H, 1989, STROKE, V20, P150; NISHINAKA Y, 1993, J CARDIOVASC PHARM, V21, P448, DOI 10.1097/00005344-199303000-00015; PARK CK, 1989, ANN NEUROL, V20, P150; SCHNEIBER SL, 1991, SCIENCE, V251, P283; SHARKEY J, 1993, J CEREBR BLOOD F MET, V13, P865, DOI 10.1038/jcbfm.1993.108; SHARKEY J, IN PRESS J AUTONOM T; SHIGA Y, 1992, BRAIN RES, V595, P145, DOI 10.1016/0006-8993(92)91465-Q; SLEKULERKA JJ, 1989, NATURE, V341, P755; STANDAERT RF, 1990, NATURE, V346, P671, DOI 10.1038/346671a0; STEINER JP, 1992, NATURE, V358, P584, DOI 10.1038/358584a0	29	436	469	0	15	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	SEP 22	1994	371	6495					336	339		10.1038/371336a0	http://dx.doi.org/10.1038/371336a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PH254	7522303				2022-12-28	WOS:A1994PH25400053
J	BOLOTINA, VM; NAJIBI, S; PALACINO, JJ; PAGANO, PJ; COHEN, RA				BOLOTINA, VM; NAJIBI, S; PALACINO, JJ; PAGANO, PJ; COHEN, RA			NITRIC-OXIDE DIRECTLY ACTIVATES CALCIUM-DEPENDENT POTASSIUM CHANNELS IN VASCULAR SMOOTH-MUSCLE	NATURE			English	Article							K+ CHANNELS; SKELETAL-MUSCLE; RELAXING FACTOR; ENDOTHELIUM; CELLS; RELAXATION; TONE	NITRIC oxide is the major endothelium-derived relaxing factor (EDRF)(1-3), and it is thought to relax smooth muscle cells by stimulation of guanylate cyclase, accumulation of its product cyclic GMP, and cGMP-dependent modification of several intracellular processes(4-5), including activation of potassium channels through cGMP-dependent protein kinase(6,7). Here we present evidence that both exogenous nitric oxide and native EDRF can directly activate single Ca2+-dependent K+ channels (K-Ca(+)) in cell-free membrane patches without requiring cGMP. Under conditions when guanylate cyclase was inhibited by methylene blue, considerable relaxation of rabbit aorta to nitric oxide persisted which was blocked by charybdotoxin, a specific inhibitor of K-Ca(+) channels. These studies demonstrate a novel direct action of nitric oxide on K-Ca(+) channels.			BOLOTINA, VM (corresponding author), BOSTON UNIV,MED CTR,ROBERT DAWSON EVANS DEPT CLIN RES,VASC BIOL UNIT,BOSTON,MA 02118, USA.		Pagano, Patrick/GYO-2619-2022	/0000-0002-1070-6408; Bolotina, Victoria/0000-0001-5862-181X				BARRETT JN, 1982, J PHYSIOL-LONDON, V331, P211, DOI 10.1113/jphysiol.1982.sp014370; BENHAM CD, 1986, J PHYSIOL-LONDON, V371, P45, DOI 10.1113/jphysiol.1986.sp015961; BOLOTINA V, 1989, PFLUG ARCH EUR J PHY, V415, P262, DOI 10.1007/BF00370875; BRAYDEN JE, 1992, SCIENCE, V256, P532, DOI 10.1126/science.1373909; COWAN CL, 1993, J PHARMACOL EXP THER, V266, P1482; GRIFFITH TM, 1984, NATURE, V308, P645, DOI 10.1038/308645a0; HAMILL OP, 1981, PFLUG ARCH EUR J PHY, V391, P85, DOI 10.1007/BF00656997; KNOWLES RG, 1992, TRENDS BIOCHEM SCI, V17, P399, DOI 10.1016/0968-0004(92)90008-W; KRIPPEITDREWS P, 1992, J CARDIOVASC PHARM, V20, pS72, DOI 10.1097/00005344-199204002-00022; LEI SZ, 1992, NEURON, V8, P1087, DOI 10.1016/0896-6273(92)90130-6; LINCOLN TM, 1991, BLOOD VESSELS, V28, P129; LINCOLN TM, 1993, FASEB J, V7, P328, DOI 10.1096/fasebj.7.2.7680013; LIPTON SA, 1993, NATURE, V364, P626, DOI 10.1038/364626a0; MALINSKI T, 1993, BIOCHEM BIOPH RES CO, V193, P1076, DOI 10.1006/bbrc.1993.1735; MILLER C, 1985, NATURE, V313, P316, DOI 10.1038/313316a0; MONCADA S, 1988, BIOCHEM PHARMACOL, V37, P2495, DOI 10.1016/0006-2952(88)90236-5; NAJIBI S, 1994, AM J PHYSL, V266; PALMER RMJ, 1987, NATURE, V327, P524, DOI 10.1038/327524a0; ROBERTSON BE, 1993, AM J PHYSIOL, V265, pC299; SINGER JJ, 1987, PFLUG ARCH EUR J PHY, V408, P98, DOI 10.1007/BF00581337; STAMLER JS, 1992, P NATL ACAD SCI USA, V89, P444, DOI 10.1073/pnas.89.1.444; STAMLER JS, 1992, SCIENCE, V258, P1898, DOI 10.1126/science.1281928; TAHA Z, 1992, BIOCHEM BIOPH RES CO, V188, P734, DOI 10.1016/0006-291X(92)91117-9; TANIGUCHI J, 1993, PFLUG ARCH EUR J PHY, V423, P167, DOI 10.1007/BF00374390; TARE M, 1990, NATURE, V346, P69, DOI 10.1038/346069a0; TORO L, 1991, J BIOENERG BIOMEMBR, V23, P561, DOI 10.1007/BF00785811; WHITE RE, 1993, NATURE, V361, P263, DOI 10.1038/361263a0; WOLIN MS, 1990, J PHARMACOL EXP THER, V254, P872	28	1445	1481	1	42	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	APR 28	1994	368	6474					850	853		10.1038/368850a0	http://dx.doi.org/10.1038/368850a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	NH717	7512692				2022-12-28	WOS:A1994NH71700070
J	SAITOH, Y; LAEMMLI, UK				SAITOH, Y; LAEMMLI, UK			METAPHASE CHROMOSOME STRUCTURE - BANDS ARISE FROM A DIFFERENTIAL FOLDING PATH OF THE HIGHLY AT-RICH SCAFFOLD	CELL			English	Article							DNA TOPOISOMERASE-II; INDIAN MUNTJAC; MITOTIC CHROMOSOMES; ATTACHMENT SITES; HISTONE H-1; REGIONS; CONDENSATION; PROTEINS; BINDING; ORDER	Using the highly AT-specific fluorchrome daunomycin, a longitudinal optical signal called AT queue, thought to arise from a line-up of the highly AT-rich scaffold-associated regions (SARs) by the scaffolding, was identified in native chromosomes. Fluorescence banding is proposed to result from a differential folding path of the AT queue during its progression from telomere to telomere. The AT queue is tightly coiled or folded in a Q band, the resulting transverse striations across the chromatid, which also represent Giemsa subbands, generating a bright AT-rich signal over the Q region. The R bands, in contrast, contain a more central (unfolded) AT queue, yielding an AT-dull signal over the R regions. The AT queue is identified by immunofluorescence against topoisomerase II (topo II) and HMG-I/Y as the scaffold of native chromosomes; the fluorescence signal from both proteins is akin to a detailed Q-type banding pattern. Native chromosomes appear assembled according to the loop-scaffold model.	UNIV GENEVA,DEPT MOLEC BIOL,CH-1211 GENEVA 4,SWITZERLAND	University of Geneva	SAITOH, Y (corresponding author), UNIV GENEVA,DEPT BIOCHEM,30 QUAI ERNEST ANSRMET,CH-1211 GENEVA 4,SWITZERLAND.			Galora De Mora, Raul Pavlov/0000-0001-8342-9782				ADACHI Y, 1989, EMBO J, V8, P3997, DOI 10.1002/j.1460-2075.1989.tb08582.x; ADACHI Y, 1991, CELL, V64, P137, DOI 10.1016/0092-8674(91)90215-K; BERNARDI G, 1988, J MOL EVOL, V28, P7, DOI 10.1007/BF02143493; BODE J, 1992, SCIENCE, V255, P195, DOI 10.1126/science.1553545; COMINGS DE, 1971, EXP CELL RES, V67, P441, DOI 10.1016/0014-4827(71)90430-7; COMINGS DE, 1976, CHROMOSOMA, V56, P199, DOI 10.1007/BF00293185; COMINGS DE, 1978, ANNU REV GENET, V12, P25, DOI 10.1146/annurev.ge.12.120178.000325; CRAIG JM, 1993, BIOESSAYS, V15, P349, DOI 10.1002/bies.950150510; DELATOUR EB, 1988, CELL, V55, P937, DOI 10.1016/0092-8674(88)90239-5; DISNEY JE, 1989, J CELL BIOL, V109, P1975, DOI 10.1083/jcb.109.5.1975; EARNSHAW WC, 1985, J CELL BIOL, V100, P1716, DOI 10.1083/jcb.100.5.1716; EARNSHAW WC, 1983, J CELL BIOL, V96, P84, DOI 10.1083/jcb.96.1.84; ERICSSON C, 1990, CELL, V60, P73, DOI 10.1016/0092-8674(90)90717-S; GARRARD WT, 1990, NUCL ACIDS MOL BIOL, P163; GASSER SM, 1987, TRENDS GENET, V3, P16, DOI 10.1016/0168-9525(87)90156-9; GASSER SM, 1986, J MOL BIOL, V188, P613, DOI 10.1016/S0022-2836(86)80010-9; HOLM C, 1985, CELL, V41, P553, DOI 10.1016/S0092-8674(85)80028-3; HOLMQUIST G, 1982, CELL, V31, P121, DOI 10.1016/0092-8674(82)90411-1; HOLMQUIST GP, 1992, AM J HUM GENET, V51, P17; HOMBERGER HP, 1989, CHROMOSOMA, V98, P99, DOI 10.1007/BF00291044; IZAURRALDE E, 1989, J MOL BIOL, V210, P573, DOI 10.1016/0022-2836(89)90133-2; JEPPESEN P, 1993, CELL, V74, P281, DOI 10.1016/0092-8674(93)90419-Q; JOHNSTON FP, 1978, CHROMOSOMA, V68, P115, DOI 10.1007/BF00287144; KAS E, 1989, J MOL BIOL, V210, P587, DOI 10.1016/0022-2836(89)90134-4; KAS E, 1993, EMBO J, V12, P115, DOI 10.1002/j.1460-2075.1993.tb05637.x; KEREM BS, 1984, CELL, V38, P493, DOI 10.1016/0092-8674(84)90504-X; KORENBERG JR, 1978, P NATL ACAD SCI USA, V75, P3382, DOI 10.1073/pnas.75.7.3382; LAEMMLI UK, 1977, COLD SPRING HARB SYM, V42, P351; Laemmli UK, 1992, CURR OPIN GENET DEV, V2, P275, DOI 10.1016/S0959-437X(05)80285-0; LEWIS CD, 1982, CELL, V29, P171, DOI 10.1016/0092-8674(82)90101-5; MARSDEN MPF, 1979, CELL, V17, P849, DOI 10.1016/0092-8674(79)90325-8; MIRKOVITCH J, 1984, CELL, V39, P223, DOI 10.1016/0092-8674(84)90208-3; MULLER W, 1975, EUR J BIOCHEM, V54, P385, DOI 10.1111/j.1432-1033.1975.tb04149.x; PARDUE ML, 1975, J CELL BIOL, V64, P251, DOI 10.1083/jcb.64.1.251; PAULSON JR, 1977, CELL, V12, P817, DOI 10.1016/0092-8674(77)90280-X; RATTNER JB, 1985, CELL, V42, P291, DOI 10.1016/S0092-8674(85)80124-0; REEVES R, 1990, J BIOL CHEM, V265, P8573; REEVES R, 1992, Current Opinion in Cell Biology, V4, P413, DOI 10.1016/0955-0674(92)90006-X; ROCA J, 1992, CELL, V71, P833, DOI 10.1016/0092-8674(92)90558-T; ROTH MB, 1987, J CELL BIOL, V105, P1047, DOI 10.1083/jcb.105.3.1047; SAITOH Y, 1984, IN PRESS COLD SPRING, V85; Sambrook J, 1989, MOL CLONING LABORATO; SCHWEIZER D, 1981, HUM GENET, V57, P1; SCHWEIZER D, 1976, CHROMOSOMA, V58, P307, DOI 10.1007/BF00292840; SEN P, 1985, CYTOGENET CELL GENET, V39, P145, DOI 10.1159/000132124; SOLOMON MJ, 1986, P NATL ACAD SCI USA, V83, P1276, DOI 10.1073/pnas.83.5.1276; SPERRY AO, 1989, P NATL ACAD SCI USA, V86, P5497, DOI 10.1073/pnas.86.14.5497; Sumner A. T, 1990, CHROMOSOME BANDING; UEMURA T, 1984, EMBO J, V3, P1737, DOI 10.1002/j.1460-2075.1984.tb02040.x; ZHAO K, 1993, EMBO J, V12, P3237, DOI 10.1002/j.1460-2075.1993.tb05993.x	50	323	344	0	14	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	FEB 25	1994	76	4					609	622		10.1016/0092-8674(94)90502-9	http://dx.doi.org/10.1016/0092-8674(94)90502-9			14	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	MZ285	7510215				2022-12-28	WOS:A1994MZ28500005
J	GRAVES, BJ; CROWTHER, RL; CHANDRAN, C; RUMBERGER, JM; LI, S; HUANG, KS; PRESKY, DH; FAMILLETTI, PC; WOLITZKY, BA; BURNS, DK				GRAVES, BJ; CROWTHER, RL; CHANDRAN, C; RUMBERGER, JM; LI, S; HUANG, KS; PRESKY, DH; FAMILLETTI, PC; WOLITZKY, BA; BURNS, DK			INSIGHT INTO E-SELECTIN LIGAND INTERACTION FROM THE CRYSTAL-STRUCTURE AND MUTAGENESIS OF THE LEC EGF DOMAINS	NATURE			English	Article							LEUKOCYTE-ADHESION MOLECULE-1; GROWTH FACTOR-ALPHA; MANNOSE-BINDING PROTEIN; NODE HOMING RECEPTOR; CARBOHYDRATE-RECOGNITION; EVOLUTIONARY CONSERVATION; FUNCTIONAL INTERACTIONS; NMR-SPECTROSCOPY; CELL-ADHESION; P-SELECTIN	The three-dimensional structure of the ligand-binding region of human E-selectin has been determined at 2.0 angstrom resolution. The structure reveals limited contact between the two domains and a coordination of Ca2+ not predicted from other C-type lectins. Structure/function analysis indicates a defined region and specific amino-acid side chains that may be involved in ligand binding. These features of the E-selectin/ligand interaction have important implications for understanding the recruitment of leukocytes to sites of inflammation.			GRAVES, BJ (corresponding author), HOFFMANN LA ROCHE INC,ROCHE RES CTR,NUTLEY,NJ 07110, USA.							BARON M, 1992, PROTEIN SCI, V1, P81; BECKERANDRE M, 1992, EUR J BIOCHEM, V206, P401, DOI 10.1111/j.1432-1033.1992.tb16940.x; BEVILACQUA MP, 1993, ANNU REV IMMUNOL, V11, P767, DOI 10.1146/annurev.iy.11.040193.004003; BEVILACQUA MP, 1987, P NATL ACAD SCI USA, V84, P9238, DOI 10.1073/pnas.84.24.9238; BEVILACQUA MP, 1989, SCIENCE, V243, P1160, DOI 10.1126/science.2466335; BEZOUSKA K, 1991, J BIOL CHEM, V266, P11604; BOWEN BR, 1990, J CELL BIOL, V110, P147, DOI 10.1083/jcb.110.1.147; BRUNGER AT, 1992, NATURE, V355, P472, DOI 10.1038/355472a0; BRUNGER AT, 1987, SCIENCE, V235, P458, DOI 10.1126/science.235.4787.458; BUTCHER EC, 1991, CELL, V67, P1033, DOI 10.1016/0092-8674(91)90279-8; BVALL GE, 1992, J AM CHEM SOC, V114, P5449; DEFREES SA, 1993, J AM CHEM SOC, V115, P7549, DOI 10.1021/ja00069a083; ERBE DV, 1992, J CELL BIOL, V119, P215, DOI 10.1083/jcb.119.1.215; ERBE DV, 1993, J CELL BIOL, V120, P1227, DOI 10.1083/jcb.120.5.1227; FOXALL C, 1992, J CELL BIOL, V117, P895, DOI 10.1083/jcb.117.4.895; HARVEY TS, 1991, EUR J BIOCHEM, V198, P555, DOI 10.1111/j.1432-1033.1991.tb16050.x; HESSION C, 1990, P NATL ACAD SCI USA, V87, P1673, DOI 10.1073/pnas.87.5.1673; HOLLENBAUGH D, 1993, BIOCHEMISTRY-US, V32, P2960, DOI 10.1021/bi00063a006; HOMMEL U, 1992, J MOL BIOL, V227, P271, DOI 10.1016/0022-2836(92)90697-I; HUNTER CA, 1991, J MOL BIOL, V218, P837, DOI 10.1016/0022-2836(91)90271-7; JOHNSTON GI, 1989, CELL, V56, P1033, DOI 10.1016/0092-8674(89)90636-3; JONES TA, 1978, J APPL CRYSTALLOGR, V11, P268, DOI 10.1107/S0021889878013308; KABSCH W, 1983, BIOPOLYMERS, V22, P2577, DOI 10.1002/bip.360221211; KLINE TP, 1990, BIOCHEMISTRY-US, V29, P7805, DOI 10.1021/bi00486a005; KOHDA D, 1989, BIOCHEMISTRY-US, V28, P953, DOI 10.1021/bi00429a005; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; LARIGAN JD, 1992, DNA CELL BIOL, V11, P149, DOI 10.1089/dna.1992.11.149; LASKY LA, 1989, CELL, V56, P1045, DOI 10.1016/0092-8674(89)90637-5; LASKY LA, 1992, SCIENCE, V258, P964, DOI 10.1126/science.1439808; LASKY LA, 1992, CELL, V69, P927, DOI 10.1016/0092-8674(92)90612-G; LEVINOVITZ A, 1993, J CELL BIOL, V121, P449, DOI 10.1083/jcb.121.2.449; LI SH, IN PRESS J BIOL CHEM; LIN YC, 1992, J AM CHEM SOC, V114, P5452, DOI 10.1021/ja00039a082; MILLER KE, 1992, BIOCHEMISTRY-US, V31, P6703, DOI 10.1021/bi00144a009; MIZUSHIMA S, 1990, NUCLEIC ACIDS RES, V18, P5322, DOI 10.1093/nar/18.17.5322; MONTELIONE GT, 1992, BIOCHEMISTRY-US, V31, P236, DOI 10.1021/bi00116a033; MOORE KL, 1992, J CELL BIOL, V118, P445, DOI 10.1083/jcb.118.2.445; NORGARD KE, 1993, J BIOL CHEM, V268, P12764; PADMANABHAN K, 1993, J MOL BIOL, V232, P947, DOI 10.1006/jmbi.1993.1441; PIGOTT R, 1991, J IMMUNOL, V147, P130; QUESENBERRY MS, 1992, J BIOL CHEM, V267, P10831; SCALLON BJ, 1992, BIO-TECHNOL, V10, P550, DOI 10.1038/nbt0592-550; SELANDERSUNNERHAGEN M, 1992, J BIOL CHEM, V267, P19642; SIEGELMAN MH, 1989, P NATL ACAD SCI USA, V86, P5562, DOI 10.1073/pnas.86.14.5562; SIEGELMAN MH, 1989, SCIENCE, V243, P1165, DOI 10.1126/science.2646713; STRUBEL NA, 1993, BIOCHEM BIOPH RES CO, V192, P338, DOI 10.1006/bbrc.1993.1420; WALZ G, 1990, SCIENCE, V250, P1132, DOI 10.1126/science.1701275; WEIS WI, 1991, SCIENCE, V254, P1608, DOI 10.1126/science.1721241; WEIS WI, 1992, NATURE, V360, P127, DOI 10.1038/360127a0; WELLER A, 1992, J BIOL CHEM, V267, P15176; WORMALD MR, 1991, BIOCHEM BIOPH RES CO, V180, P1214, DOI 10.1016/S0006-291X(05)81325-7; 1992, SYBYL MOL MODELING S	52	403	418	0	10	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	FEB 10	1994	367	6463					532	538		10.1038/367532a0	http://dx.doi.org/10.1038/367532a0			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	MV863	7509040				2022-12-28	WOS:A1994MV86300050
J	JACOBS, RE; FRASER, SE				JACOBS, RE; FRASER, SE			MAGNETIC-RESONANCE MICROSCOPY OF EMBRYONIC-CELL LINEAGES AND MOVEMENTS	SCIENCE			English	Article							NEMATODE CAENORHABDITIS-ELEGANS; XENOPUS-LAEVIS; NMR MICROSCOPY; INTRACELLULAR INJECTION; MOUSE EMBRYOS; FATE MAP; RESOLUTION; RETINA; RETROVIRUS; BLASTOMERE	Key events in vertebrate embryogenesis are difficult to observe in many species. High-resolution magnetic resonance imaging was used to follow cell movements and lineages in developing frog embryos. A single cell was injected at the 16-cell stage with a contrast agent, based on the gadolinium chelate gadolinium-diethylenetriamine pentaacetic acid-dextran. The labeled progeny cells could be followed uniquely in three-dimensional magnetic resonance images, acquired from the embryo over several days. The results show that external ectodermal and internal mesodermal tissues extend at different rates during amphibian gastrulation and neurulation.			JACOBS, RE (corresponding author), CALTECH,BECKMAN INST 13974,DIV BIOL,PASADENA,CA 91125, USA.		Fraser, Scott/Y-3406-2019	Fraser, Scott/0000-0002-5377-0223	NICHD NIH HHS [HD 25390] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD025390] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		AGUAYO JB, 1986, NATURE, V322, P190, DOI 10.1038/322190a0; AHN CB, 1989, MED PHYS, V16, P22, DOI 10.1118/1.596393; AKERS RM, 1986, SCIENCE, V231, P613, DOI 10.1126/science.3945801; BALAKIER H, 1982, DEV BIOL, V90, P352, DOI 10.1016/0012-1606(82)90384-0; BEHLING RW, 1989, NATURE, V341, P321, DOI 10.1038/341321a0; BRONNERFRASER M, 1988, NATURE, V335, P161, DOI 10.1038/335161a0; CALLAGHAN PT, 1988, J MAGN RESON, V78, P1, DOI 10.1016/0022-2364(88)90151-5; CALLAGHAN PT, 1991, PRINCIPLES NUCLEAR M; CAMERON RA, 1987, GENE DEV, V1, P75, DOI 10.1101/gad.1.1.75; CHO ZH, 1988, MED PHYS, V15, P815, DOI 10.1118/1.596287; CONNER WE, 1988, EXPERIENTIA, V44, P11, DOI 10.1007/BF01960223; DALE L, 1987, DEVELOPMENT, V99, P527; EAGLESON GW, 1990, J NEUROBIOL, V21, P427, DOI 10.1002/neu.480210305; ECCLES CD, 1986, J MAGN RESON, V68, P393, DOI 10.1016/0022-2364(86)90261-1; EFFMANN EL, 1988, TERATOLOGY, V38, P59, DOI 10.1002/tera.1420380109; GIBBY WA, 1989, INVEST RADIOL, V24, P302, DOI 10.1097/00004424-198904000-00009; GIMLICH RL, 1985, DEV BIOL, V109, P509, DOI 10.1016/0012-1606(85)90476-2; GLOVER P, 1989, 8TH ANN M SOC MAGN R, P285; GREENWALD IS, 1983, CELL, V34, P435, DOI 10.1016/0092-8674(83)90377-X; HEDGECOCK EM, 1985, TRENDS NEUROSCI, V8, P288, DOI 10.1016/0166-2236(85)90104-3; HOLT CE, 1988, NEURON, V1, P15, DOI 10.1016/0896-6273(88)90205-X; JACKSON GE, 1990, MAGNET RESON MED, V16, P57, DOI 10.1002/mrm.1910160107; JACOBS RR, COMMUNICATION; JENNER CF, 1988, NATURE, V336, P399, DOI 10.1038/336399a0; JOHNSON GA, 1986, J MAGN RESON, V68, P129, DOI 10.1016/0022-2364(86)90322-7; KELLER R, 1991, GASTRULATION MOVEMEN; KELLER RE, 1985, NEW SERIES, V31; KIMBLE J, 1979, DEV BIOL, V70, P396, DOI 10.1016/0012-1606(79)90035-6; KIMMEL CB, 1986, SCIENCE, V231, P365, DOI 10.1126/science.231.4736.365; KUHN W, 1990, ANGEW CHEM INT EDIT, V29, P1, DOI 10.1002/anie.199000013; LAUFFER RB, 1987, CHEM REV, V87, P901, DOI 10.1021/cr00081a003; LEE DH, 1991, J CAN ASSOC RADIOL, V42, P6; MAKI JH, 1988, J MAGN RESON, V80, P482, DOI 10.1016/0022-2364(88)90243-0; Mansfield P., 1982, NMR IMAGING BIOMEDIC; Mathews WW., 1986, ATLAS DESCRIPTIVE EM; MOODY SA, 1987, DEV BIOL, V119, P560, DOI 10.1016/0012-1606(87)90059-5; MOONEN CTW, 1990, SCIENCE, V250, P53, DOI 10.1126/science.2218514; PRICE J, 1987, P NATL ACAD SCI USA, V84, P156, DOI 10.1073/pnas.84.1.156; SANES JR, 1986, EMBO J, V5, P3133, DOI 10.1002/j.1460-2075.1986.tb04620.x; SLACK JMW, 1992, DEVELOPMENT, V114, P285; STEHLING MK, 1991, SCIENCE, V254, P43, DOI 10.1126/science.1925560; SULSTON JE, 1977, DEV BIOL, V56, P110, DOI 10.1016/0012-1606(77)90158-0; SULSTON JE, 1983, DEV BIOL, V100, P64, DOI 10.1016/0012-1606(83)90201-4; TURNER DL, 1987, NATURE, V328, P131, DOI 10.1038/328131a0; WANG SC, 1990, RADIOLOGY, V175, P483, DOI 10.1148/radiology.175.2.1691513; WEISBLAT DA, 1980, SCIENCE, V209, P1538, DOI 10.1126/science.6159680; WEISBLAT DA, 1978, SCIENCE, V202, P1295, DOI 10.1126/science.725606; WETTS R, 1988, SCIENCE, V239, P1142, DOI 10.1126/science.2449732; WETTS R, 1989, DEVELOPMENT, V105, P9; WILSON PA, 1989, DEVELOPMENT, V105, P155; ZHOU X, 1989, 8TH ANN M SOC MAGN R, P286; [No title captured]	52	144	158	0	10	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	FEB 4	1994	263	5147					681	684		10.1126/science.7508143	http://dx.doi.org/10.1126/science.7508143			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	MU964	7508143				2022-12-28	WOS:A1994MU96400049
J	LINGUEGLIA, E; CHAMPIGNY, G; LAZDUNSKI, M; BARBRY, P				LINGUEGLIA, E; CHAMPIGNY, G; LAZDUNSKI, M; BARBRY, P			CLONING OF THE AMILORIDE-SENSITIVE FMRFAMIDE PEPTIDE-GATED SODIUM-CHANNEL	NATURE			English	Article							CAENORHABDITIS-ELEGANS; RECEPTOR; BRAIN; NEURODEGENERATION; EXPRESSION	THE peptide Phe-Met-Arg-Phe-NH2 (FMRFamide) and structurally related peptides are present both in invertebrate and vertebrate nervous systems(1,2). Although they constitute a major class of invertebrate peptide neurotransmitters(3), the molecular structure of their receptors has not yet been identified, In neurons of the snail Helix aspersa(4), as well as in Aplysia bursting(5) and motor(6) neurons, FMRFamide induces a fast excitatory depolarizing response due to direct activation of an amiloride-sensitive Na+ channel(4). We have now isolated a complementary DNA from Helix nervous tissue; when expressed in Xenopus oocytes, it encodes an FMRF-amide-activated Na+ channel (FaNaCh) that can be blocked by amiloride. The corresponding protein shares a very low sequence identity with the previously cloned epithelial Na+ channel subunits(7-12) and Caenorhabditis elegans degenerins(13-15), but it displays the same overall structural organization. To our knowledge, this is the first characterization of a peptide-gated ionotropic receptor.	CNRS,INST PHARMACOL MOLEC & CELLULAIRE,F-06560 VALBONNE,FRANCE	Centre National de la Recherche Scientifique (CNRS)			LINGUEGLIA, Eric/F-5509-2013; Barbry, Pascal/O-5021-2016	LINGUEGLIA, Eric/0000-0003-3902-3405; Barbry, Pascal/0000-0001-9632-6483				BELKIN KJ, 1993, J NEUROSCI, V13, P5139, DOI 10.1523/JNEUROSCI.13-12-05139.1993; BETZ H, 1990, NEURON, V5, P383, DOI 10.1016/0896-6273(90)90077-S; BRAKE AJ, 1994, NATURE, V371, P519, DOI 10.1038/371519a0; CANESSA CM, 1994, NATURE, V367, P463, DOI 10.1038/367463a0; CANESSA CM, 1993, NATURE, V361, P467, DOI 10.1038/361467a0; CHALFIE M, 1990, NATURE, V345, P410, DOI 10.1038/345410a0; COTTRELL GA, 1993, COMP MOL NEUROBIOL, V63, P279; DRISCOLL M, 1991, NATURE, V349, P588, DOI 10.1038/349588a0; GALZI JL, 1992, NATURE, V359, P500, DOI 10.1038/359500a0; GALZI JL, 1991, ANNU REV PHARMACOL, V31, P37, DOI 10.1146/annurev.pa.31.040191.000345; GARCIAANOVEROS J, 1995, CURR BIOL, V5, P441, DOI 10.1016/S0960-9822(95)00085-6; GARTY H, 1994, FASEB J, V8, P523; GREEN KA, 1994, PFLUG ARCH EUR J PHY, V428, P232, DOI 10.1007/BF00724502; GREENBERG MJ, 1992, PROG BRAIN RES, V92, P25, DOI 10.1016/S0079-6123(08)61162-0; HONG KS, 1994, NATURE, V367, P470, DOI 10.1038/367470a0; HUANG MX, 1994, NATURE, V367, P467, DOI 10.1038/367467a0; LI XJ, 1994, P NATL ACAD SCI USA, V91, P1814, DOI 10.1073/pnas.91.5.1814; LINGUEGLIA E, 1993, FEBS LETT, V318, P95, DOI 10.1016/0014-5793(93)81336-X; LINGUEGLIA E, 1994, J BIOL CHEM, V269, P13736; MARICQ AV, 1991, SCIENCE, V254, P432, DOI 10.1126/science.1718042; PALMER LG, 1992, ANNU REV PHYSIOL, V54, P51, DOI 10.1146/annurev.ph.54.030192.000411; PRICE DA, 1977, SCIENCE, V197, P670, DOI 10.1126/science.877582; RAFFA RB, 1988, PEPTIDES, V9, P915, DOI 10.1016/0196-9781(88)90141-6; RENARD S, 1994, J BIOL CHEM, V269, P12981; RUBEN P, 1986, J NEUROSCI, V6, P252; VALERA S, 1994, NATURE, V371, P516, DOI 10.1038/371516a0; VOILLEY N, 1995, GENOMICS, V28, P560, DOI 10.1006/geno.1995.1188; VOILLEY N, 1994, P NATL ACAD SCI USA, V91, P247, DOI 10.1073/pnas.91.1.247; WALDMANN R, 1995, J BIOL CHEM, V270, P11735, DOI 10.1074/jbc.270.20.11735; YANG HYT, 1985, P NATL ACAD SCI USA, V82, P7757, DOI 10.1073/pnas.82.22.7757	30	339	345	0	13	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	DEC 14	1995	378	6558					730	733		10.1038/378730a0	http://dx.doi.org/10.1038/378730a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TK379	7501021				2022-12-28	WOS:A1995TK37900056
J	BRADY, HR; SINGER, GG				BRADY, HR; SINGER, GG			ACUTE-RENAL-FAILURE	LANCET			English	Review							ATRIAL-NATRIURETIC-PEPTIDE; ACUTE TUBULAR-NECROSIS; MANNITOL; PREVENTION; NEPHROTOXICITY; FUROSEMIDE; DILTIAZEM; DIURESIS; DIALYSIS; TRIAL		BROCKTON W ROXBURY DEPT VET AFAIRS MED CTR,MED SERV,RENAL SECT,BOSTON,MA; HARVARD UNIV,BRIGHAM & WOMENS HOSP,SCH MED,DEPT MED,DIV RENAL,BOSTON,MA 02115	Harvard University; Brigham & Women's Hospital; Harvard Medical School								BAIRD RJ, 1963, CAN MED ASSOC J, V89, P705; BARRY KG, 1961, NEW ENGL J MED, V264, P967, DOI 10.1056/NEJM196105112641902; BEALL AC, 1963, ARCH SURG-CHICAGO, V86, P34, DOI 10.1001/archsurg.1963.01310070036005; BERMAN LB, 1964, ARCH SURG-CHICAGO, V88, P239; BOZKURT F, 1987, TRANSPLANT P, V19, P4192; BRADY HR, KIDNEY, P1200; BRADY HR, 1994, HARRISONS PRINCIPLES, P1264; BROWN CB, 1986, CLIN NEPHROL, V15, P90; CACOUB P, 1988, CLIN NEPHROL, V29, P215; CANTAROVICH F, 1973, BMJ-BRIT MED J, V4, P449, DOI 10.1136/bmj.4.5890.449; CONGER JD, 1990, SEMIN DIALYSIS, V3, P146, DOI 10.1111/j.1525-139X.1990.tb00031.x; CONGER JD, 1975, J TRAUMA, V15, P1056, DOI 10.1097/00005373-197512000-00003; CONGER JD, 1971, PRESENT CONCEPTS, V4, P739; DAWSON JL, 1965, BRIT MED J, V1, P82, DOI 10.1136/bmj.1.5427.82; DENTON MD, IN PRESS KIDNEY INT; DERAY G, 1989, EUR J CLIN PHARMACOL, V37, P337, DOI 10.1007/BF00558496; DUGGAN KA, 1985, CLIN NEPHROL, V24, P289; FISCHER RP, 1966, SURG GYNECOL OBSTETR, V123, P1019; GILLUM DM, 1986, CLIN NEPHROL, V25, P249; GOTZ R, 1990, MINER ELECTROL METAB, V16, P34; GRINO JM, 1987, TRANSPLANT P, V19, P4140; GUBERN JM, 1988, SURGERY, V103, P39; HAKIM RM, 1994, NEW ENGL J MED, V331, P1338, DOI 10.1056/NEJM199411173312003; HAKIM RM, 1993, KIDNEY INT, V44, P484, DOI 10.1038/ki.1993.272; HAYES DM, 1977, CANCER, V39, P1372, DOI 10.1002/1097-0142(197704)39:4<1372::AID-CNCR2820390404>3.0.CO;2-J; KAHN DR, 1965, SURGERY, V57, P676; KJELLSTRAND CM, 1972, NEPHRON, V9, P337, DOI 10.1159/000180167; KLEINKNECHT D, 1976, NEPHRON, V17, P51, DOI 10.1159/000180710; LAZARUS JM, 1993, ACUTE RENAL FAILURE; LUCAS CE, 1977, SURGERY, V82, P314; LUMLERTGUL D, 1989, Renal Failure, V11, P201, DOI 10.3109/08860228909054932; MEHTA RL, 1994, SEMIN NEPHROL, V14, P64; MENTZER SJ, 1985, ARCH SURG-CHICAGO, V120, P907; NUUTINEN LS, 1978, J CARDIOVASC SURG, V19, P471; OLIVERO JJ, 1975, BRIT MED J, V1, P550, DOI 10.1136/bmj.1.5957.550; PARFREY PS, 1989, NEW ENGL J MED, V320, P143, DOI 10.1056/NEJM198901193200303; PRINS JM, 1993, LANCET, V341, P335, DOI 10.1016/0140-6736(93)90137-6; RAHMAN SN, 1994, KIDNEY INT, V45, P1731, DOI 10.1038/ki.1994.225; REUBI FC, 1974, KIDNEY INT, V5, P106, DOI 10.1038/ki.1974.14; REUBI FC, 1976, KIDNEY INT, V10, pS131; SCHIFFL H, 1994, LANCET, V344, P570, DOI 10.1016/S0140-6736(94)91964-X; SMITH L L, 1963, Surg Forum, V14, P103; SOLOMON R, 1994, NEW ENGL J MED, V331, P1416, DOI 10.1056/NEJM199411243312104; STONE AM, 1971, ANN SURG, V174, P1, DOI 10.1097/00000658-197107010-00001; TESCHAN PE, 1960, ANN INTERN MED, V53, P992, DOI 10.7326/0003-4819-53-5-992; TURNEY JH, 1990, Q J MED, V74, P1956; Untura A, 1979, Rev Med Chir Soc Med Nat Iasi, V83, P249; VANVALENBERG PLJ, 1987, TRANSPLANTATION, V44, P784, DOI 10.1097/00007890-198712000-00012; VINCENTI F, 1978, PROSTAGLANDINS, V15, P463, DOI 10.1016/0090-6980(78)90130-2; WAGNER K, 1987, AM J NEPHROL, V7, P287, DOI 10.1159/000167487	50	150	156	0	4	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	DEC 9	1995	346	8989					1533	1540		10.1016/S0140-6736(95)92057-9	http://dx.doi.org/10.1016/S0140-6736(95)92057-9			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TJ291	7491052				2022-12-28	WOS:A1995TJ29100016
J	ESCHWEGE, P; DUMAS, F; BLANCHET, P; LEMAIRE, V; BENOIT, G; JARDIN, A; LACOUR, B; LORIC, S				ESCHWEGE, P; DUMAS, F; BLANCHET, P; LEMAIRE, V; BENOIT, G; JARDIN, A; LACOUR, B; LORIC, S			HEMATOGENOUS DISSEMINATION OF PROSTATIC EPITHELIAL-CELLS DURING RADICAL PROSTATECTOMY	LANCET			English	Note							CANCER	Radical prostatectomy is one treatment for organ-confined prostatic adenocarcinoma. Dissemination of malignant prostatic cells after radical prostatectomy could be partly due to prostate manipulation during dissection. We confirmed by assay of prostate-specific membrane antigen by reverse-transcription nested PCR that prostate manipulation seeded prostatic epithelial cells in the general circulation in 12 of 14 consecutive patients operated on for organ-confined prostate adenocarcinoma. Our results suggest that surgeons should approach radical prostatectomy with care to avoid seeding from the prostate gland. Antiandrogen therapy might reduce the haematogenous spread of prostatic cells during radical prostatectomy.	HOP NECKER ENFANTS MALAD,BIOCHEM LAB A,PARIS,FRANCE	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Necker-Enfants Malades - APHP; UDICE-French Research Universities; Universite Paris Cite	ESCHWEGE, P (corresponding author), HOP BICETRE,SERV UROL,F-94270 LE KREMLIN BICETR,FRANCE.							DODDS PR, 1981, J UROLOGY, V126, P753, DOI 10.1016/S0022-5347(17)54735-7; FAIR WR, 1995, APR P AM UR ASS LA S, V153; HANKS GE, 1991, INT J RADIAT ONCOL, V21, P1099, DOI 10.1016/0360-3016(91)90757-U; ISRAELI RS, 1994, CANCER RES, V54, P6306; KASSABIAN VS, 1993, J UROLOGY, V150, P1169, DOI 10.1016/S0022-5347(17)35716-6; KATZ AE, 1994, UROLOGY, V43, P765, DOI 10.1016/0090-4295(94)90132-5; MAREEL M, 1993, CRIT REV ONCOGENESIS, V5, P559; MORENO JG, 1992, CANCER RES, V52, P6110; PAULSON DF, 1990, J UROLOGY, V144, P1180, DOI 10.1016/S0022-5347(17)39686-6	9	189	194	0	5	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	DEC 9	1995	346	8989					1528	1530		10.1016/S0140-6736(95)92054-4	http://dx.doi.org/10.1016/S0140-6736(95)92054-4			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TJ291	7491049				2022-12-28	WOS:A1995TJ29100013
J	GAETJE, R; KOTZIAN, S; HERRMANN, G; BAUMANN, R; STARZINSKIPOWITZ, A				GAETJE, R; KOTZIAN, S; HERRMANN, G; BAUMANN, R; STARZINSKIPOWITZ, A			INVASIVENESS OF ENDOMETRIOTIC CELLS IN-VITRO	LANCET			English	Note								The pathogenesis of endometriosis is not known. The currently favoured theory is that viable endometrial cells, shed from the endometrium into the pelvic cavity by retrograde menstruation, reattach and invade other tissues. We used a collagen gel invasion assay to assess invasive potential of endometriotic cells. The invasion indices of cells from peritoneal endometriotic lesions and a metastatic bladder carcinoma cell line (EJ28) were similar (2.2-15.6 vs 8.4-11.6) whereas cells from normal endometrium and non-metastatic carcinoma cells (RT112) were non-invasive (indices <1). Invasiveness of endometriotic cells might contribute to the pathogenesis of endometriosis.	UNIV FRANKFURT,D-60054 FRANKFURT,GERMANY; UNIV FRANKFURT KLINIKUM,ZENTRUM FRAUENHEILKUNDE & GEBURTSCHILFE,W-6000 FRANKFURT,GERMANY; UNIV FRANKFURT KLINIKUM,ZENTRUM SENCKENBERG PATHOL,W-6000 FRANKFURT,GERMANY	Goethe University Frankfurt; Goethe University Frankfurt; Goethe University Frankfurt Hospital; Goethe University Frankfurt; Goethe University Frankfurt Hospital								BATTISTA G, 1991, OBSTET GYNECOL SURV, V46, P374; FRIXEN UH, 1991, J CELL BIOL, V113, P173, DOI 10.1083/jcb.113.1.173; GLDMANN MB, 1990, CURRENT CONCEPTS END, P15; HANEY AF, 1990, CURRENT CONCEPTS END, P1; HULSKEN J, 1994, CURR OPIN CELL BIOL, V6, P711, DOI 10.1016/0955-0674(94)90098-1; LANFRANCONE L, 1994, CURR OPIN GENET DEV, V4, P109, DOI 10.1016/0959-437X(94)90099-X; MACKINNON WB, 1992, INVAS METAST, V12, P241; OSTEEN KG, 1989, FERTIL STERIL, V52, P965; RAMEY JW, 1993, FERTIL STERIL, V60, P1	9	126	137	1	6	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	DEC 2	1995	346	8988					1463	1464		10.1016/S0140-6736(95)92474-4	http://dx.doi.org/10.1016/S0140-6736(95)92474-4			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TH156	7490993				2022-12-28	WOS:A1995TH15600011
J	JOHNSON, TL; CHAMBERLIN, MJ				JOHNSON, TL; CHAMBERLIN, MJ			COMPLEXES OF YEAST RNA-POLYMERASE-II AND RNA ARE SUBSTRATES FAR TFIIS-INDUCED RNA CLEAVAGE	CELL			English	Article							TRANSCRIPTION ELONGATION-FACTOR; RHO-INDEPENDENT TERMINATORS; ESCHERICHIA-COLI; INFLUENZA-VIRUS; FACTOR-SII; INVITRO; ENZYME; DNA	In the absence of DNA, purified yeast RNA polymerase II can bind RNA to form a binary complex. RNA in such RNA-RNA polymerase complexes undergoes reactions previously thought to be unique to nascent RNA in ternary complexes with DNA, including TFIIS-dependent cleavage and elongation by 3'-terminal addition of NMP from NTP. Both of these reactions are inhibited by alpha-amanitin. Hence, by several criteria the RNA in binary complexes is bound to the polymerase in a manner quite similar to that in ternary complexes in which the catalytic site for nucleotide addition is positioned at or near the 3'-OH terminus of the RNA. These findings are consistent with a model for the RNA polymerase ternary complete in which the RNA is bound at the 3' terminus through two protein-binding sites located up to 10 nt apart.			JOHNSON, TL (corresponding author), UNIV CALIF BERKELEY,DIV BIOCHEM & MOLEC BIOL,BERKELEY,CA 94720, USA.				NIGMS NIH HHS [GM34963] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALTMANN CR, 1994, P NATL ACAD SCI USA, V91, P3784, DOI 10.1073/pnas.91.9.3784; ARNDT KM, 1988, J MOL BIOL, V202, P271, DOI 10.1016/0022-2836(88)90457-3; BORUKHOV S, 1992, P NATL ACAD SCI USA, V89, P8899, DOI 10.1073/pnas.89.19.8899; BORUKHOV S, 1993, CELL, V72, P459, DOI 10.1016/0092-8674(93)90121-6; BREMER H, 1966, J MOL BIOL, V16, P94, DOI 10.1016/S0022-2836(66)80265-6; BUSBY S, 1981, EUR J BIOCHEM, V118, P443, DOI 10.1111/j.1432-1033.1981.tb05540.x; CHAMBERLIN M, 1994, IN PRESS HARVEY LECT; CHAN CL, 1994, TRANSCRIPTION MECHAN, P297; CHRISTIE KR, 1994, J BIOL CHEM, V269, P936; FOX CF, 1965, J BIOL CHEM, V240, P2101; GONZALEZ N, 1977, ARCH BIOCHEM BIOPHYS, V182, P404, DOI 10.1016/0003-9861(77)90521-5; GU WG, 1993, J BIOL CHEM, V268, P25604; HONDA A, 1988, J BIOCHEM-TOKYO, V104, P1021, DOI 10.1093/oxfordjournals.jbchem.a122569; ISHIHAMA A, 1986, J BIOL CHEM, V261, P417; IZBAN MG, 1992, GENE DEV, V6, P1342, DOI 10.1101/gad.6.7.1342; IZBAN MG, 1993, J BIOL CHEM, V268, P12874; IZBAN MG, 1993, J BIOL CHEM, V268, P12864; KANE CM, 1993, TRANSCRIPTION MECH R, P279; KASSAVETIS GA, 1993, SCIENCE, V259, P944, DOI 10.1126/science.7679800; KERPPOLA TK, 1991, FASEB J, V5, P2833, DOI 10.1096/fasebj.5.13.1916107; KRAKOW JS, 1970, COLD SPRING HARB SYM, V35, P73, DOI 10.1101/SQB.1970.035.01.013; KURMMEL B, 1992, J MOL BIOL, V225, P221; LIU B, 1993, NATURE, V366, P33, DOI 10.1038/366033a0; MELTON DA, 1984, NUCLEIC ACIDS RES, V12, P7035, DOI 10.1093/nar/12.18.7035; MILLIGAN JF, 1987, NUCLEIC ACIDS RES, V15, P8783, DOI 10.1093/nar/15.21.8783; PLOTCH SJ, 1981, CELL, V23, P847, DOI 10.1016/0092-8674(81)90449-9; REINES D, 1992, J BIOL CHEM, V267, P15516; REINES D, 1989, J BIOL CHEM, V264, P10799; REINES D, 1993, P NATL ACAD SCI USA, V90, P1917, DOI 10.1073/pnas.90.5.1917; REYNOLDS R, 1992, J MOL BIOL, V224, P31, DOI 10.1016/0022-2836(92)90574-4; RICE GA, 1993, NUCLEIC ACIDS RES, V21, P113, DOI 10.1093/nar/21.1.113; ROSENBERG M, 1976, P NATL ACAD SCI USA, V73, P717, DOI 10.1073/pnas.73.3.717; SPENCER CA, 1990, ONCOGENE, V5, P777; STEVENS A, 1969, J BIOL CHEM, V244, P425; SURRATT CK, 1991, P NATL ACAD SCI USA, V88, P7983, DOI 10.1073/pnas.88.18.7983; WANG DG, 1993, P NATL ACAD SCI USA, V90, P843, DOI 10.1073/pnas.90.3.843; WEISSMAN.C, 1967, P NATL ACAD SCI USA, V57, P1870, DOI 10.1073/pnas.57.6.1870; WEIST DK, 1992, J BIOL CHEM, V267, P7733; YAGER TD, 1991, BIOCHEMISTRY-US, V30, P1097, DOI 10.1021/bi00218a032; YAGER TD, 1987, ESCHERICHIA COLI SAL, P1241	40	68	69	0	3	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	APR 22	1994	77	2					217	224		10.1016/0092-8674(94)90314-X	http://dx.doi.org/10.1016/0092-8674(94)90314-X			8	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	NH634	7513257				2022-12-28	WOS:A1994NH63400007
J	CRITCHFIELD, JM; RACKE, MK; ZUNIGAPFLUCKER, JC; CANNELLA, B; RAINE, CS; GOVERMAN, J; LENARDO, MJ				CRITCHFIELD, JM; RACKE, MK; ZUNIGAPFLUCKER, JC; CANNELLA, B; RAINE, CS; GOVERMAN, J; LENARDO, MJ			T-CELL DELETION IN HIGH ANTIGEN DOSE THERAPY OF AUTOIMMUNE ENCEPHALOMYELITIS	SCIENCE			English	Article							EXPERIMENTAL ALLERGIC ENCEPHALOMYELITIS; MYELIN BASIC-PROTEIN; LYMPHOCYTES-T; CLONAL ANERGY; INVITRO; INTERLEUKIN-2; TOLERANCE; SUPPRESSION; ACTIVATION; RECEPTOR	Encounters with antigen can stimulate T cells to become activated and proliferate, become nonresponsive to antigen, or to die. T cell death was shown to be a physiological response to interleukin-2-stimulated cell cycling and T cell receptor reengagement at high antigen doses. This feedback regulatory mechanism attenuates the immune response by deleting a portion of newly dividing, antigen-reactive T cells. This mechanism deleted autoreactive T cells and abrogated the clinical and pathological signs of autoimmune encephalomyelitis in mice after repetitive administration of myelin basic protein.	NIAID,IMMUNOL LAB,BETHESDA,MD 20892; NINCDS,NEUROIMMUNOL BRANCH,BETHESDA,MD 20892; YESHIVA UNIV ALBERT EINSTEIN COLL MED,DEPT PATHOL,DIV NEUROPATHOL,BRONX,NY 10461; UNIV WASHINGTON,SCH MED,DEPT MOLEC BIOTECHNOL,SEATTLE,WA 98195	National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); National Institutes of Health (NIH) - USA; NIH National Institute of Neurological Disorders & Stroke (NINDS); Yeshiva University; Albert Einstein College of Medicine; University of Washington; University of Washington Seattle			Zuniga-Pflucker, Juan C/H-1295-2012	Zuniga-Pflucker, Juan Carlos/0000-0003-2538-3178; Goverman, Joan/0000-0002-7361-9424				ALVORD EC, 1965, ANN NY ACAD SCI, V122, P333; BELL RB, 1993, J IMMUNOL, V150, P4085; BEVERLY B, 1992, INT IMMUNOL, V4, P661, DOI 10.1093/intimm/4.6.661; BOEHME SA, 1993, LEUKEMIA, V7, P545; BOEHME SA, 1903, EUR J IMMUNOL, V23, P152; BYERS VS, 1967, J EXP MED, V125, P307; CEREDIG R, 1986, EUR J IMMUNOL, V16, P30, DOI 10.1002/eji.1830160107; CLAYTON JP, 1989, J EXP MED, V169, P1681, DOI 10.1084/jem.169.5.1681; Cohen I R, 1993, Int Rev Immunol, V9, P243, DOI 10.3109/08830189309051209; COTRAN RS, 1988, J IMMUNOL, V140, P1883; CRITCHFIELD JM, UNPUB; EINSTEIN ER, 1968, IMMUNOCHEMISTRY, V5, P567, DOI 10.1016/0019-2791(68)90092-X; FELTON LD, 1949, J IMMUNOL, V61, P107; GAUR A, 1992, SCIENCE, V258, P1491, DOI 10.1126/science.1279812; GOVERMAN J, 1993, CELL, V72, P551, DOI 10.1016/0092-8674(93)90074-Z; HECHT TT, 1983, J IMMUNOL, V131, P1049; JONES LA, 1990, SCIENCE, V250, P1726, DOI 10.1126/science.2125368; KANG SM, 1992, SCIENCE, V256, P1452, DOI 10.1126/science.1604322; KANG SM, 1992, SCIENCE, V257, P1134, DOI 10.1126/science.257.5073.1134; KAUFMAN DL, 1993, NATURE, V366, P69, DOI 10.1038/366069a0; KAWABE Y, 1991, NATURE, V349, P245, DOI 10.1038/349245a0; KYBURZ D, IN PRESS EUR J IMMUN; LENARDO MJ, 1991, NATURE, V353, P858, DOI 10.1038/353858a0; LEVINE S, 1968, SCIENCE, V161, P1155, DOI 10.1126/science.161.3846.1155; LIDER O, 1989, J IMMUNOL, V142, P748; LIU Y, 1990, Journal of Experimental Medicine, V172, P1735, DOI 10.1084/jem.172.6.1735; LUPIN C, 1988, J EXP MED, V167, P752; MACDONALD HR, 1974, J EXP MED, V140, P718, DOI 10.1084/jem.140.3.718; MALEK TR, 1984, J IMMUNOL, V133, P1976; MATIS LA, 1983, P NATL ACAD SCI-BIOL, V80, P6019, DOI 10.1073/pnas.80.19.6019; Miller S D, 1992, Int Rev Immunol, V9, P203, DOI 10.3109/08830189209061791; MITCHISON NA, 1964, PROC R SOC SER B-BIO, V161, P275, DOI 10.1098/rspb.1964.0093; MOSKOPHIDIS D, 1993, NATURE, V362, P758, DOI 10.1038/362758a0; MOSMANN TR, 1986, J IMMUNOL, V136, P2348; MULE JJ, 1990, BIOL THERAPY CANCER, P142; OHARA J, 1985, NATURE, V315, P333, DOI 10.1038/315333a0; OTTEN G, 1986, EUR J IMMUNOL, V16, P217, DOI 10.1002/eji.1830160302; PETTINELLI CB, 1981, J IMMUNOL, V127, P1420; RACKE MK, 1991, J IMMUNOL, V146, P3012; RADVANYI LG, 1993, J IMMUNOL, V150, P5704; RAINE CS, 1978, SCIENCE, V201, P445, DOI 10.1126/science.78524; RAZVI ES, 1993, J VIROL, V67, P5754, DOI 10.1128/JVI.67.10.5754-5765.1993; ROCHA B, 1991, SCIENCE, V251, P1255; RUSSELL JH, 1991, P NATL ACAD SCI USA, V88, P2151, DOI 10.1073/pnas.88.6.2151; RUSSELL JH, 1993, EUR J IMMUNOL, V23, P2379, DOI 10.1002/eji.1830230951; SCHWARTZ RH, 1989, CELL, V57, P1073, DOI 10.1016/0092-8674(89)90044-5; SCHWARTZ RH, 1990, SCIENCE, V248, P1349, DOI 10.1126/science.2113314; SERCARZ E., 1959, NATURE, V184, P1080, DOI 10.1038/1841080a0; SU MWC, 1993, J IMMUNOL, V151, P658; SU XM, 1991, J NEUROIMMUNOL, V34, P181; SUZUKI G, 1988, J IMMUNOL, V140, P1359; TALMAGE DW, 1956, J INFECT DIS, V98, P293, DOI 10.1093/infdis/98.3.293; UCKER DS, 1992, J IMMUNOL, V149, P1583; URBAN JL, 1988, CELL, V54, P577, DOI 10.1016/0092-8674(88)90079-7; VONBOEHMER H, 1993, NATURE, V362, P696, DOI 10.1038/362696a0; WALDEN PR, 1990, P NATL ACAD SCI USA, V87, P9015, DOI 10.1073/pnas.87.22.9015; WANG R, 1993, J IMMUNOL, V150, P3832; WEBB S, 1990, CELL, V63, P1249, DOI 10.1016/0092-8674(90)90420-J; WESSELBORG O, 1993, J IMMUNOL, V150, P4338; WHITACRE CC, 1991, J IMMUNOL, V147, P2155; WRAITH DC, 1989, CELL, V59, P247, DOI 10.1016/0092-8674(89)90287-0; ZAMVIL SS, 1990, ANNU REV IMMUNOL, V8, P579, DOI 10.1146/annurev.iy.08.040190.003051	62	495	512	1	8	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	FEB 25	1994	263	5150					1139	1143		10.1126/science.7509084	http://dx.doi.org/10.1126/science.7509084			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	MX759	7509084				2022-12-28	WOS:A1994MX75900033
J	LAPIDOT, T; SIRARD, C; VORMOOR, J; MURDOCH, B; HOANG, T; CACERESCORTES, J; MINDEN, M; PATERSON, B; CALIGIURI, MA; DICK, JE				LAPIDOT, T; SIRARD, C; VORMOOR, J; MURDOCH, B; HOANG, T; CACERESCORTES, J; MINDEN, M; PATERSON, B; CALIGIURI, MA; DICK, JE			A CELL INITIATING HUMAN ACUTE MYELOID-LEUKEMIA AFTER TRANSPLANTATION INTO SCID MICE	NATURE			English	Article							IMMUNE-DEFICIENT MICE; BONE-MARROW; PROGENITOR CELLS; LEUKEMIA; HEMATOPOIESIS; DIFFERENTIATION; CULTURE; GROWTH; MOUSE	MOST human acute myeloid leukaemia (AML) cells have limited proliferative capacity, suggesting that the leukaemic clone may be maintained. by a rare population of stem cells(1-5). This putative leukaemic stem cell has not been characterized because the available in vitro assays can only detect progenitors with limited proliferative and replating potential(4-7). We have now identified an AML-initiating cell by transplantation into severe combined immune-deficient (SCID) mice. These cells homed to the bone marrow and proliferated extensively in response to in vivo cytokine treatment, resulting in a pattern of dissemination and leukaemic cell morphology similar to that seen in the original patients. Limiting dilution analysis showed that the frequency of these leukaemia-initiating cells in the peripheral blood of AML patients was one engraftment unit in 250,000 cells. We fractionated AML cells on the basis of cell-surface-marker expression and found that the leukaemia-initiating cells that could engraft SCID mice to produce large numbers of colony-forming progenitors were CD34(+) CD38(-); however, the CD34(+) CD38(+) and CD34(-) fractions contained no cells with these properties. This in vivo model replicates many aspects of human AML and defines a new leukaemia-initiating cell which is less mature than colony-forming cells.	UNIV TORONTO, HOSP SICK CHILDREN, RES INST, DEPT GENET, TORONTO M5G 1X8, ON, CANADA; UNIV TORONTO, DEPT MOLEC & MED GENET, TORONTO M5G 1X8, ON, CANADA; CLIN RES INST MONTREAL, MONTREAL H2W 1R7, PQ, CANADA; PRINCESS MARGARET HOSP, DEPT MED, TORONTO M4X 1K9, ON, CANADA; PRINCESS MARGARET HOSP, DEPT ONCOL PATHOL, TORONTO M4X 1K9, ON, CANADA; ROSWELL PK CANC INST, DEPT MED, BUFFALO, NY 14263 USA	University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); University of Toronto; Institut de Recherche Clinique de Montreal (IRCM); Universite de Montreal; University of Toronto; University Toronto Affiliates; University Health Network Toronto; Princess Margaret Cancer Centre; University of Toronto; University Toronto Affiliates; University Health Network Toronto; Princess Margaret Cancer Centre; Roswell Park Cancer Institute			Vormoor, Josef/GPS-7248-2022; Lapidot, Tsvee/A-1812-2010	Vormoor, Josef/0000-0002-1825-1890; Dick, John/0000-0002-9527-8317				BENNETT JM, 1976, BRIT J HAEMATOL, V33, P451, DOI 10.1111/j.1365-2141.1976.tb03563.x; BRADY G, 1990, Methods in Molecular and Cellular Biology, V2, P17; CESANO A, 1992, ONCOGENE, V7, P827; CIVIN CI, 1984, J IMMUNOL, V133, P157; COULOMBEL L, 1985, J CLIN INVEST, V75, P961, DOI 10.1172/JCI111797; DELORD C, 1991, EXP HEMATOL, V19, P991; DICK JE, 1991, IMMUNOL REV, V124, P25, DOI 10.1111/j.1600-065X.1991.tb00614.x; FEARON ER, 1986, NEW ENGL J MED, V315, P15, DOI 10.1056/NEJM198607033150103; GRIER HE, 1993, HEMATOLOGY INFANCY C, P1288; GRIFFIN JD, 1986, BLOOD, V68, P1185; KAMELREID S, 1991, BLOOD, V78, P2973; KAMELREID S, 1988, SCIENCE, V242, P1706, DOI 10.1126/science.2904703; KAMELREID S, 1989, SCIENCE, V246, P1597, DOI 10.1126/science.2595371; KEINANEN M, 1988, NEW ENGL J MED, V318, P1153, DOI 10.1056/NEJM198805053181803; LAPIDOT T, 1992, SCIENCE, V255, P1137, DOI 10.1126/science.1372131; LOWENBERG B, 1993, BLOOD, V81, P281; MCCULLOCH EA, 1982, J CELL PHYSIOL, P103; PORTER EH, 1963, BRIT J CANCER, V17, P583, DOI 10.1038/bjc.1963.78; SAWYERS CL, 1992, BLOOD, V79, P2089, DOI 10.1182/blood.V79.8.2089.bloodjournal7982089; SAWYERS CL, 1991, CELL, V64, P337, DOI 10.1016/0092-8674(91)90643-D; SCHIRO R, 1990, BLUT, V61, P267, DOI 10.1007/BF01732875; TERSTAPPEN LWMM, 1991, BLOOD, V77, P1218; TERSTAPPEN LWMM, 1992, LEUKEMIA, V6, P993; WAYE JS, 1986, MOL CELL BIOL, V6, P3156, DOI 10.1128/MCB.6.9.3156	24	3379	3663	14	240	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	FEB 17	1994	367	6464					645	648		10.1038/367645a0	http://dx.doi.org/10.1038/367645a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	MW688	7509044				2022-12-28	WOS:A1994MW68800054
J	SHUAL, K; ZIEMIECKI, A; WILKS, AF; HARPUR, AG; SADOWSKI, HB; GILMAN, MZ; DARNELL, JE				SHUAL, K; ZIEMIECKI, A; WILKS, AF; HARPUR, AG; SADOWSKI, HB; GILMAN, MZ; DARNELL, JE			POLYPEPTIDE SIGNALING TO THE NUCLEUS THROUGH TYROSINE PHOSPHORYLATION OF JAK AND STAT PROTEINS	NATURE			English	Article								BINDING of interferons IFN-alpha and IFN-gamma to their cell surface receptors promptly induces tyrosine phosphorylation of latent cytoplasmic transcriptional activators1-4 (or Stat proteins, for signal transducers and activators of transcription). Interferon-alpha activates both Stat91 (M(r) 91,000; ref. 1) and Stat113 (M(r) 113,000; ref. 2) whereas IFN-gamma activates only Stat91 (refs 3, 4). The activated proteins then move into the nucleus and directly activate genes induced by IFN-alpha and IFN-gamma. Somatic cell genetics experiments have demonstrated a requirement for tyrosine kinase-2 (Tyk2) in the IFN-alpha response pathway5 and for Jak2 (ref. 6), a kinase with similar sequence7, in the IFN-gamma response pathway. Here we investigate the tyrosine phosphorylation events on Stat and Jak proteins after treatment of cells with IFNs alpha and gamma and with epidermal growth factor (EGF). Stat91 is phosphorylated on Tyr 701 after cells are treated with IFN-alpha and EGF, as it was after treatment with IFN-gamma (ref. 8). We find that Jak1 also becomes phosphorylated on tyrosine after cells are treated with these same three ligands, although each ligand is shown to activate at least one other different kinase. Jak1 may therefore be the enzyme that phosphorylates Tyr 701 in Stat91.	UNIV BERN, INST CLIN & EXPTL CANC RES, CH-3004 BERN, SWITZERLAND; ROYAL MELBOURNE HOSP, LUDWIG INST CANC RES, PARKVILLE, VIC 3050, AUSTRALIA; COLD SPRING HARBOR LAB, COLD SPRING HARBOR, NY 11724 USA	University of Bern; Ludwig Institute for Cancer Research; Royal Melbourne Hospital; Cold Spring Harbor Laboratory	SHUAL, K (corresponding author), ROCKEFELLER UNIV, MOLEC CELL BIOL LAB, 1230 YORK AVE, NEW YORK, NY 10021 USA.		Wilks, Andrew F/R-5542-2019	Wilks, Andrew F/0000-0002-8554-2399				ARGETSINGER LS, 1993, CELL, V74, P237, DOI 10.1016/0092-8674(93)90415-M; BOYLE WJ, 1991, METHOD ENZYMOL, V201, P110; DECKER T, 1991, EMBO J, V10, P927, DOI 10.1002/j.1460-2075.1991.tb08026.x; FU XY, 1992, P NATL ACAD SCI USA, V89, P7840, DOI 10.1073/pnas.89.16.7840; FU XY, 1992, CELL, V70, P323, DOI 10.1016/0092-8674(92)90106-M; HAYES TE, 1987, P NATL ACAD SCI USA, V84, P1272, DOI 10.1073/pnas.84.5.1272; HOWARD OMZ, 1992, ONCOGENE, V7, P895; KANNO Y, 1993, MOL CELL BIOL, V13, P3951, DOI 10.1128/MCB.13.7.3951; KAWASAKI E, 1990, PRC PROTOCOLS GUIDE, P119; KHAN KD, 1993, P NATL ACAD SCI USA, V90, P6806, DOI 10.1073/pnas.90.14.6806; KOCH CA, 1991, SCIENCE, V252, P668, DOI 10.1126/science.1708916; MCKENDRY R, 1991, P NATL ACAD SCI USA, V88, P11455, DOI 10.1073/pnas.88.24.11455; MULLER M, 1993, NATURE, V366, P129, DOI 10.1038/366129a0; MULLER M, 1993, EMBO J, V12, P4221, DOI 10.1002/j.1460-2075.1993.tb06106.x; OVERDUIN M, 1992, CELL, V70, P697, DOI 10.1016/0092-8674(92)90437-H; PEARSE RN, 1993, P NATL ACAD SCI USA, V90, P4314, DOI 10.1073/pnas.90.9.4314; PELLEGRINI S, 1989, MOL CELL BIOL, V9, P4605, DOI 10.1128/MCB.9.11.4605; SADOWSKI HB, 1993, Z NATURE, V372, P79; SCHINDLER C, 1992, SCIENCE, V257, P809, DOI 10.1126/science.1496401; SHUAI K, 1993, SCIENCE, V261, P1744, DOI 10.1126/science.7690989; SILVENNOINEN O, 1993, P NATL ACAD SCI USA, V90, P8429, DOI 10.1073/pnas.90.18.8429; VELAZQUEZ L, 1992, CELL, V70, P313, DOI 10.1016/0092-8674(92)90105-L; WAGNER BJ, 1990, EMBO J, V9, P4477, DOI 10.1002/j.1460-2075.1990.tb07898.x; WAKSMAN G, 1992, NATURE, V358, P646, DOI 10.1038/358646a0; WATING D, 1993, NATURE, V366, P166; WILKS AF, 1991, MOL CELL BIOL, V11, P2057, DOI 10.1128/MCB.11.4.2057; WITTHUHN BA, 1993, CELL, V74, P227, DOI 10.1016/0092-8674(93)90414-L	28	451	461	0	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	DEC 9	1993	366	6455					580	583		10.1038/366580a0	http://dx.doi.org/10.1038/366580a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ML218	7504784				2022-12-28	WOS:A1993ML21800074
J	HOCKENBERY, DM; OLTVAI, ZN; YIN, XM; MILLIMAN, CL; KORSMEYER, SJ				HOCKENBERY, DM; OLTVAI, ZN; YIN, XM; MILLIMAN, CL; KORSMEYER, SJ			BCL-2 FUNCTIONS IN AN ANTIOXIDANT PATHWAY TO PREVENT APOPTOSIS	CELL			English	Article							PROGRAMMED CELL-DEATH; MOUSE EPIDERMAL-CELLS; OXIDATIVE STRESS; CAENORHABDITIS-ELEGANS; SUPEROXIDE-DISMUTASE; LIPID-PEROXIDATION; MEMBRANE PROTEIN; OXIDANT STRESS; PARINARIC ACID; CIS-FOS	Bcl-2 inhibits most types of apoptotic cell death, implying a common mechanism of lethality. Bcl-2 is localized to intracellular sites of oxygen free radical generation including mitochondria, endoplasmic reticula, and nuclear membranes. Antioxidants that scavenge peroxides, N-acetylcysteine and glutathione peroxidase, countered apoptotic death, while manganese superoxide dismutase did not. Bcl-2 protected cells from H2O2- and menadione-induced oxidative deaths. Bcl-2 did not prevent the cyanide-resistant oxidative burst generated by menadione. Two model systems of apoptosis showed no increment in cyanide-resistant respiration, and generation of endogenous peroxides continued at an inherent rate that was unaltered by Bcl-2. Following an apoptotic signal, cells sustained progressive lipid peroxidation. Overexpression of Bcl-2 functioned suppress lipid peroxidation completely. We propose a model in which Bcl-2 regulates an antioxidant pathway at sites of free radical generation.	WASHINGTON UNIV, SCH MED, DEPT MED, ST LOUIS, MO 63110 USA; WASHINGTON UNIV, SCH MED, DEPT PATHOL, ST LOUIS, MO 63110 USA; FRED HUTCHINSON CANC RES CTR, DIV CLIN RES, SEATTLE, WA 98104 USA	Washington University (WUSTL); Washington University (WUSTL); Fred Hutchinson Cancer Center	HOCKENBERY, DM (corresponding author), WASHINGTON UNIV, SCH MED, HOWARD HUGHES MED INST, ST LOUIS, MO 63110 USA.				PHS HHS [49712-05] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		ABATE C, 1990, SCIENCE, V249, P1157, DOI 10.1126/science.2118682; ABRAMS JM, 1993, DEVELOPMENT, V117, P29; AMSTAD P, 1991, BIOCHEMISTRY-US, V30, P9305, DOI 10.1021/bi00102a024; APPLEGATE LA, 1991, CANCER RES, V51, P974; BASS DA, 1983, J IMMUNOL, V130, P1910; BLOK J, 1986, MECHANISMS DNA DAMAG, P75; BOISSY RE, 1989, CYTOMETRY, V10, P779, DOI 10.1002/cyto.990100616; BOVERIS A, 1973, BIOCHEM J, V134, P707, DOI 10.1042/bj1340707; CATHCART R, 1983, ANAL BIOCHEM, V134, P111, DOI 10.1016/0003-2697(83)90270-1; CHENLEVY Z, 1989, MOL CELL BIOL, V9, P701, DOI 10.1128/MCB.9.2.701; CRAWFORD D, 1988, ONCOGENE, V3, P27; CROSS AR, 1991, BIOCHIM BIOPHYS ACTA, V1057, P281, DOI 10.1016/S0005-2728(05)80140-9; DEWEY DL, 1960, NATURE, V186, P780, DOI 10.1038/186780a0; ELLIS HM, 1986, CELL, V44, P817, DOI 10.1016/0092-8674(86)90004-8; ERNSTER L, 1986, CHEM SCRIPTA, V26, P525; Flohe L., 1982, FREE RADICAL BIO MED, V5, P223; FORMAN HJ, 1982, FREE RADICAL BIO MED, V5, P65; Gutteridge J M, 1986, Free Radic Res Commun, V1, P173, DOI 10.3109/10715768609083149; HALLIWELL B, 1984, BIOCHEM J, V219, P1, DOI 10.1042/bj2190001; HALLIWELL B, 1986, ARCH BIOCHEM BIOPHYS, V246, P501, DOI 10.1016/0003-9861(86)90305-X; Halliwell B, 1989, FREE RADICALS BIOL M, VUK; HARLOW E, 1988, ANTIBODIES LABORATOR; HEDLEY D, 1992, CYTOMETRY, V13, P686, DOI 10.1002/cyto.990130704; HENGARTNER MO, 1992, NATURE, V356, P494, DOI 10.1038/356494a0; HIROSE K, 1993, FASEB J, V7, P361, DOI 10.1096/fasebj.7.2.8440412; HOCKENBERY D, 1990, NATURE, V348, P334, DOI 10.1038/348334a0; HOCKENBERY DM, 1991, P NATL ACAD SCI USA, V88, P6961, DOI 10.1073/pnas.88.16.6961; HOLBROOK NJ, 1991, NEW BIOL, V3, P825; JACOBSON MD, 1993, NATURE, V361, P365, DOI 10.1038/361365a0; KERR JFR, 1972, BRIT J CANCER, V26, P239, DOI 10.1038/bjc.1972.33; KORSMEYER SJ, 1992, BLOOD, V80, P879; KUYPERS FA, 1987, BIOCHIM BIOPHYS ACTA, V921, P266, DOI 10.1016/0005-2760(87)90027-0; LEBRUN DP, 1993, AM J PATHOL, V142, P743; MCCONKEY DJ, 1988, TOXICOL LETT, V42, P123, DOI 10.1016/0378-4274(88)90069-0; MCCONKEY DJ, 1989, FASEB J, V3, P1843, DOI 10.1096/fasebj.3.7.2497041; MCCORD JM, 1978, FEBS LETT, V86, P139, DOI 10.1016/0014-5793(78)80116-1; MCDONNELL TJ, 1989, CELL, V57, P79, DOI 10.1016/0092-8674(89)90174-8; MEISTER A, 1983, ANNU REV BIOCHEM, V52, P711, DOI 10.1146/annurev.bi.52.070183.003431; MIYASHITA T, 1993, BLOOD, V81, P151; MONAGHAN P, 1992, J HISTOCHEM CYTOCHEM, V40, P1819, DOI 10.1177/40.12.1453000; NGUYEN M, 1993, IN PRESS J BIOL CHEM; NUNEZ G, 1990, J IMMUNOL, V144, P3602; OBERLEY LW, 1985, HDB METHODS OXYGEN R, P219; OLTVAI ZN, 1993, CELL, V74, P609, DOI 10.1016/0092-8674(93)90509-O; POGNONEC P, 1992, J BIOL CHEM, V267, P24563; ROSEN DR, 1993, NATURE, V362, P59, DOI 10.1038/362059a0; SCHRECK R, 1991, EMBO J, V10, P2247, DOI 10.1002/j.1460-2075.1991.tb07761.x; SENTMAN CL, 1991, CELL, V67, P879, DOI 10.1016/0092-8674(91)90361-2; SETO M, 1988, EMBO J, V7, P123, DOI 10.1002/j.1460-2075.1988.tb02791.x; SHIBANUMA M, 1988, ONCOGENE, V3, P17; SMEYNE RJ, 1993, NATURE, V363, P166, DOI 10.1038/363166a0; STRASSER A, 1991, CELL, V67, P889, DOI 10.1016/0092-8674(91)90362-3; SULSTON JE, 1977, DEV BIOL, V56, P110, DOI 10.1016/0012-1606(77)90158-0; THOR H, 1982, J BIOL CHEM, V257, P2419; TSUJIMOTO Y, 1989, ONCOGENE, V4, P1331; TSUJIMOTO Y, 1986, P NATL ACAD SCI USA, V83, P5214, DOI 10.1073/pnas.83.14.5214; UCKUN FM, 1992, P NATL ACAD SCI USA, V89, P9005, DOI 10.1073/pnas.89.19.9005; VAUX DL, 1988, NATURE, V335, P440, DOI 10.1038/335440a0; VEIS DJ, 1993, CELL, V75, P229, DOI 10.1016/0092-8674(93)80065-M; WALTON MI, 1993, CANCER RES, V53, P1853; WEISIGER RA, 1973, J BIOL CHEM, V248, P4793; WONG GHW, 1989, CELL, V58, P923, DOI 10.1016/0092-8674(89)90944-6; Wyllie A H, 1980, Int Rev Cytol, V68, P251; WYLLIE AH, 1980, NATURE, V284, P555, DOI 10.1038/284555a0; ZACHARCHUK CM, 1990, J IMMUNOL, V145, P4037; ZEHAVA CL, 1990, J BIOL CHEM, V265, P4929; ZHONG LT, 1993, P NATL ACAD SCI USA, V90, P4533, DOI 10.1073/pnas.90.10.4533	67	3305	3471	6	218	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	OCT 22	1993	75	2					241	251		10.1016/0092-8674(93)80066-N	http://dx.doi.org/10.1016/0092-8674(93)80066-N			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	MD885	7503812				2022-12-28	WOS:A1993MD88500006
J	McGuire, WP; Hoskins, WJ; Brady, MF; Kucera, PR; Partridge, EE; Look, KY; ClarkePearson, DL; Davidson, M				McGuire, WP; Hoskins, WJ; Brady, MF; Kucera, PR; Partridge, EE; Look, KY; ClarkePearson, DL; Davidson, M			Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							RANDOMIZED TRIAL; COMBINATION CHEMOTHERAPY; FOLLOW-UP; CARCINOMA; TAXOL; DOXORUBICIN	Background. Chemotherapy combinations that include an alkylating agent and a platinum coordination complex have high response rates in women with advanced ovarian cancer. Such combinations provide longterm control of disease in few patients, however. We compared two combinations, cisplatin and cyclophosphamide and cisplatin and paclitaxel, in women with ovarian cancer. Methods. We randomly assigned 410 women with advanced ovarian cancer and residual masses larger than 1 cm after initial surgery to receive cisplatin (75 mg per square meter of body-surface area) with either cyclophosphamide (750 mg per square meter) or paclitaxel (135 mg per square meter over a period of 24 hours). Results. Three hundred eighty-six women met all the eligibility criteria. Known prognostic factors were similar in the two treatment groups. Alopecia, neutropenia, fever, and allergic reactions were reported more frequently in the cisplatin-paclitaxel group. Among 216 women with measurable disease, 73 percent in the cisplatin-paclitaxel group responded to therapy, as compared with 60 percent in the cisplatin-cyclophosphamide group (P=0.01), The frequency of surgically verified complete response was similar in the two groups, Progression-free survival was significantly longer (P<0.001) in the cisplatin-paclitaxel group than in the cisplatin-cyclophosphamide group (median, 18 vs, 13 months), Survival was also significantly longer (P<0.001) in the cisplatin-paclitaxel group (median, 38 vs. 24 months). Conclusions. Incorporating paclitaxel into first-line therapy improves the duration of progression-free survival and of overall survival in women with incompletely resected stage III and stage IV ovarian cancer. (C) 1996, Massachusetts Medical Society.	EMORY UNIV, DEPT MED, ATLANTA, GA 30322 USA; MEM SLOAN KETTERING CANC CTR, DEPT SURG, GYNECOL SERV, NEW YORK, NY 10021 USA; CORNELL UNIV, COLL MED, DEPT OBSTET & GYNECOL, NEW YORK, NY USA; ROSWELL PK CANC INST, GYNECOL ONCOL GRP STAT OFF, BUFFALO, NY USA; OREGON HLTH SCI UNIV, DEPT OBSTET & GYNECOL, DIV GYNECOL ONCOL, PORTLAND, OR USA; UNIV ALABAMA, DEPT OBSTET & GYNECOL, DIV GYNECOL ONCOL, BIRMINGHAM, AL USA; INDIANA UNIV, SCH MED, DIV OBSTET & GYNECOL, INDIANAPOLIS, IN USA; DUKE UNIV, SCH MED, DEPT OBSTET & GYNECOL, DIV GYNECOL ONCOL, DURHAM, NC USA; WALTER REED ARMY MED CTR, DEPT PATHOL & AREA LAB SCI, WASHINGTON, DC 20307 USA	Emory University; Memorial Sloan Kettering Cancer Center; Cornell University; Roswell Park Cancer Institute; Oregon Health & Science University; University of Alabama System; University of Alabama Birmingham; Indiana University System; Indiana University-Purdue University Indianapolis; Duke University; United States Department of Defense; United States Army; Walter Reed National Military Medical Center					NATIONAL CANCER INSTITUTE [U10CA027469, U10CA037517] Funding Source: NIH RePORTER; NCI NIH HHS [CA 37517, CA 27469] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Agresti A., 1990, CATEGORICAL DATA ANA, pXV; [Anonymous], 1979, WHO HDB REPORTING RE; BLESSING JA, 1990, CHEMOTHERAPY GYNECOL, P63; BOOKMAN MA, IN PRESS J CLIN ONCO; COX DR, 1972, J R STAT SOC B, V34, P187; EISENHAUER EA, 1994, J CLIN ONCOL, V12, P2654, DOI 10.1200/JCO.1994.12.12.2654; KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868; KRUSKAL WH, 1952, J AM STAT ASSOC, V47, P583, DOI 10.1080/01621459.1952.10483441; LIEBMANN JE, 1993, BRIT J CANCER, V68, P1104, DOI 10.1038/bjc.1993.488; MANGIONI C, 1992, GYNECOL ONCOL, V45, P115; MANTEL NATHAN, 1966, CANCERCHEMOTHERAP REP, V50, P163; MCGUIRE WP, 1989, ANN INTERN MED, V111, P273, DOI 10.7326/0003-4819-111-4-273; MCGUIRE WP, 1995, J CLIN ONCOL, V13, P1589, DOI 10.1200/JCO.1995.13.7.1589; MCGUIRE WP, 1993, GYNECOL ONCOL, V51, P78, DOI 10.1006/gyno.1993.1250; NEIJT JP, 1984, LANCET, V2, P594; OMURA G, 1986, CANCER, V57, P1725, DOI 10.1002/1097-0142(19860501)57:9<1725::AID-CNCR2820570903>3.0.CO;2-J; OMURA GA, 1991, J CLIN ONCOL, V9, P1138, DOI 10.1200/JCO.1991.9.7.1138; ROWINSKY EK, 1991, J CLIN ONCOL, V9, P1692, DOI 10.1200/JCO.1991.9.9.1692; ROWINSKY EK, 1991, J CLIN ONCOL, V9, P1704, DOI 10.1200/JCO.1991.9.9.1704; ROWINSKY EK, 1995, NEW ENGL J MED, V332, P1004, DOI 10.1056/NEJM199504133321507; STEWART LA, 1991, BRIT MED J, V303, P884; SUTTON GP, 1989, J CLIN ONCOL, V7, P223, DOI 10.1200/JCO.1989.7.2.223; THIGPEN JT, 1989, SEMIN ONCOL, V16, P58; THIGPEN JT, 1994, J CLIN ONCOL, V12, P1748, DOI 10.1200/JCO.1994.12.9.1748; Williams C J, 1992, Semin Oncol, V19, P120; WILLIAMS CJ, 1985, J CLIN ONCOL, V3, P1455, DOI 10.1200/JCO.1985.3.11.1455	26	2477	2541	2	157	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JAN 4	1996	334	1					1	6		10.1056/NEJM199601043340101	http://dx.doi.org/10.1056/NEJM199601043340101			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TM482	7494563				2022-12-28	WOS:A1996TM48200001
J	BARKERCUMMINGS, C; MCCLELLAN, W; SOUCIE, JM; KRISHER, J				BARKERCUMMINGS, C; MCCLELLAN, W; SOUCIE, JM; KRISHER, J			ETHNIC-DIFFERENCES IN THE USE OF PERITONEAL-DIALYSIS AS INITIAL TREATMENT FOR END-STAGE RENAL-DISEASE	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							QUALITY-OF-LIFE; RACIAL-DIFFERENCES; UNITED-STATES; RACE; TRANSPLANTATION; ACCESS; BLACK; EXPERIENCE; CANDIDATES; AMERICANS	Objective.-To evaluate the influence of ethnicity on the use of peritoneal dialysis (PD) as initial treatment for end-stage renal disease (ESRD) after controlling for other patient characteristics. Design.-Inception cohort analysis of incident ESRD patients. Patients.-All African-American and white patients (N=10726) who began treatment for ESRD at dialysis centers in North Carolina, South Carolina, and Georgia and reported to ESRD Network 6 between January 1, 1989, and December 31, 1991. Main Outcome Measure.-Odds ratios (ORs) of the association between ethnicity and PD as initial treatment modality. Results.-African-American patients were 56% less likely than whites to use PD (OR, 0.44; 95% confidence interval [CI], 0.40 to 0.49). This difference persisted (OR, 0.45; 95% CI, 0.38 to 0.52) after multivariable adjustment for age, education, social support, home ownership, functional status, albumin level, hypertension, history of myocardial infarction, peripheral neuropathy, and comorbid diabetes. Conclusions.-Ethnic differences in initial PD use cannot be explained by many demographic, socioeconomic, and comorbid factors associated with the use of PD as initial treatment for ESRD.	EMORY UNIV,ROLLINS SCH PUBL HLTH,CTR CLIN EVALUAT SCI,ATLANTA,GA 30322; EMORY UNIV,ROLLINS SCH PUBL HLTH,DEPT EPIDEMIOL,ATLANTA,GA 30322; EMORY UNIV,SCH MED,DIV RENAL,ATLANTA,GA 30322; SE KIDNEY COUNCIL,ESRD NETWORK 6,RALEIGH,NC	Emory University; Rollins School Public Health; Emory University; Rollins School Public Health; Emory University								BLENDON RJ, 1989, JAMA-J AM MED ASSOC, V261, P278, DOI 10.1001/jama.261.2.278; BROGAN D, 1988, NEW ENGL J MED, V319, P55; BUTKUS DE, 1992, NEW ENGL J MED, V327, P840, DOI 10.1056/NEJM199209173271203; CHURCHILL DN, 1993, KIDNEY INT, V43, pS16; Dean A. G., 1990, EPI INFO VERSION 5 W; Dixon W. J., 1990, BMDP STATISTICAL SOF; EGGERS PW, 1988, NEW ENGL J MED, V318, P223, DOI 10.1056/NEJM198801283180406; EVANS RW, 1985, NEW ENGL J MED, V312, P553, DOI 10.1056/NEJM198502283120905; FOX MP, 1993, AM J KIDNEY DIS, V22, P32, DOI 10.1016/0272-6386(93)70179-3; GUTMAN RA, 1981, NEW ENGL J MED, V304, P309, DOI 10.1056/NEJM198102053040601; HELD PJ, 1988, ARCH INTERN MED, V148, P2594, DOI 10.1001/archinte.148.12.2594; HELD PJ, 1994, KIDNEY INT, V45, P1163, DOI 10.1038/ki.1994.154; HILL CE, 1988, COMMUNITY HLTH SYSTE, P60; Hosmer D., 2000, APPL LOGISTIC REGRES, V2; JACKSON FLC, 1993, AM J KIDNEY DIS, V21, P10, DOI 10.1016/0272-6386(93)70070-F; JOHNSON PA, 1993, ANN INTERN MED, V118, P593, DOI 10.7326/0003-4819-118-8-199304150-00004; KASISKE BL, 1991, NEW ENGL J MED, V324, P302, DOI 10.1056/NEJM199101313240505; KJELLSTRAND CM, 1988, ARCH INTERN MED, V148, P1305; Kleinbaum DG, 1982, EPIDEMIOLOGIC RES PR; LEVINSON R, 1986, SOC PSYCHOL QUART, V49, P330, DOI 10.2307/2786772; LEVY DR, 1985, PEDIATRICS, V75, P639; MAIORCA R, 1993, KIDNEY INT, V43, pS4; MCCLELLAN WM, 1991, J CLIN EPIDEMIOL, V44, P83, DOI 10.1016/0895-4356(91)90204-M; NISSENSON AR, 1986, AM J KIDNEY DIS, V7, P229, DOI 10.1016/S0272-6386(86)80009-9; NOLPH KD, 1990, CONTEMP ISS NEPHROL, P127; OSBORNE NG, 1992, JAMA-J AM MED ASSOC, V267, P275, DOI 10.1001/jama.267.2.275; Rosenstock I.M., 1990, HLTH BEHAV HLTH ED T, P39; ROTELLAR C, 1991, AM J KIDNEY DIS, V17, P158, DOI 10.1016/S0272-6386(12)81122-X; Rothman K, 1986, MODERN EPIDEMIOLOGY; SANFILIPPO FP, 1992, JAMA-J AM MED ASSOC, V267, P247, DOI 10.1001/jama.267.2.247; SIMMONS RG, 1990, AM J KIDNEY DIS, V15, P201, DOI 10.1016/S0272-6386(12)80763-3; SNOW LF, 1974, ANN INTERN MED, V81, P82, DOI 10.7326/0003-4819-81-1-82; SOUCIE JM, 1992, AM J KIDNEY DIS, V19, P414, DOI 10.1016/S0272-6386(12)80947-4; WENNEKER MB, 1989, JAMA-J AM MED ASSOC, V261, P253, DOI 10.1001/jama.261.2.253; YERGAN J, 1987, MED CARE, V25, P592, DOI 10.1097/00005650-198707000-00003; 1992, AM J KIDNEY DIS S2, V20, P20; 1990, JAMA-J AM MED ASSOC, V263, P2344; 1992, AM J KIDNEY DIS S2, V20, P68; 1988, SAS PROCEDURES GUIDE; 1992, USRDS1992 NIH NAT I	40	41	41	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	DEC 20	1995	274	23					1858	1862						5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TK147	7500535				2022-12-28	WOS:A1995TK14700027
J	PERILLO, NL; PACE, KE; SEILHAMER, JJ; BAUM, LG				PERILLO, NL; PACE, KE; SEILHAMER, JJ; BAUM, LG			APOPTOSIS OF T-CELLS MEDIATED BY GALECTIN-1	NATURE			English	Article							GALACTOSIDE-BINDING-PROTEIN; DEATH; ADHESION; IDENTIFICATION; GLYCOSYLATION; BIOSYNTHESIS; GALAPTIN; CD45	GALECTIN-1, a member of the family of beta-galactoside binding proteins(1), has growth regulatory and immunomodulatory activities(2-4). We report here that galectin-1, expressed by stromal cells in human thymus and lymph nodes(5,6), is present at sites of cell death by apoptosis during normal T-cell development and maturation, Galectin-1 induced apoptosis of activated human T cells and human T leukaemia cell lines. Resting T cells also bound galectin-1, but did not undergo apoptosis. Human endothelial cells that expressed galectin-1 induced apoptosis of bound T cells. Galectin-1-induced apoptosis required expression of CD45, and was decreased when N-glycan elongation was blocked by treatment of the cells by swainsonine(7), whereas inhibition of O-glycan elongation(8) potentiated the apoptotic effect of galectin-1. Induction of apoptosis by an endogenous mammalian lectin represents a new mechanism for regulating the immune response.	UNIV CALIF LOS ANGELES, DEPT PATHOL & LAB MED, LOS ANGELES, CA 90095 USA; INCYTE PHARMACEUT INC, PALO ALTO, CA 94304 USA	University of California System; University of California Los Angeles; Incyte								ALLEN HJ, 1990, J CELL BIOCHEM, V43, P43, DOI 10.1002/jcb.240430105; BARONDES SH, 1994, CELL, V76, P597, DOI 10.1016/0092-8674(94)90498-7; BARONDES SH, 1994, J BIOL CHEM, V269, P20807; BAUM LG, 1995, GLYCOCONJUGATE J, V12, P63, DOI 10.1007/BF00731870; BAUM LG, 1995, J EXP MED, V181, P877, DOI 10.1084/jem.181.3.877; BEZOUSKA K, 1994, NATURE, V372, P150, DOI 10.1038/372150a0; BOURNE Y, 1994, NAT STRUCT BIOL, V1, P863, DOI 10.1038/nsb1294-863; CHO MJ, 1995, J BIOL CHEM, V270, P5207, DOI 10.1074/jbc.270.10.5207; Colin Hughes R., 1992, CURR OPIN STRUC BIOL, V2, P687, DOI 10.1016/0959-440X(92)90202-I; COOPER DNW, 1991, J CELL BIOL, V115, P1437, DOI 10.1083/jcb.115.5.1437; DUVALL E, 1986, IMMUNOL TODAY, V7, P115, DOI 10.1016/0167-5699(86)90152-0; ELBEIN AD, 1987, ANNU REV BIOCHEM, V56, P497, DOI 10.1146/annurev.biochem.56.1.497; GAVRIELI Y, 1992, J CELL BIOL, V119, P493, DOI 10.1083/jcb.119.3.493; GOLDSTONE SD, 1991, BIOCHEM BIOPH RES CO, V178, P746, DOI 10.1016/0006-291X(91)90171-3; HARRISON FL, 1980, FEBS LETT, V122, P157, DOI 10.1016/0014-5793(80)80428-5; HIRABAYASHI J, 1993, GLYCOBIOLOGY, V3, P297, DOI 10.1093/glycob/3.4.297; KORETZKY GA, 1990, NATURE, V346, P66, DOI 10.1038/346066a0; KUAN SF, 1989, J BIOL CHEM, V264, P19271; LEE RT, 1990, J BIOL CHEM, V265, P7864; LEVI G, 1983, EUR J IMMUNOL, V13, P500, DOI 10.1002/eji.1830130613; LIAO DI, 1994, P NATL ACAD SCI USA, V91, P1428, DOI 10.1073/pnas.91.4.1428; OFFNER H, 1990, J NEUROIMMUNOL, V28, P177, DOI 10.1016/0165-5728(90)90032-I; ONG CJ, 1994, J IMMUNOL, V152, P3793; PULIDO R, 1990, EUR J IMMUNOL, V20, P2667, DOI 10.1002/eji.1830201221; QUN Z, 1993, ARCH BIOCHEM BIOPHYS, V300, P6, DOI 10.1006/abbi.1993.1002; SU X, 1995, IMMUNITY, V2, P353, DOI 10.1016/1074-7613(95)90143-4; TELFORD WG, 1992, CYTOMETRY, V13, P137, DOI 10.1002/cyto.990130205; TRAUTH BC, 1994, SCIENCE, V245, P150; WELLS V, 1991, CELL, V64, P91, DOI 10.1016/0092-8674(91)90211-G; WESSELBORG S, 1993, J IMMUNOL, V150, P4338	30	904	932	2	45	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	DEC 14	1995	378	6558					736	739		10.1038/378736a0	http://dx.doi.org/10.1038/378736a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TK379	7501023				2022-12-28	WOS:A1995TK37900058
J	MARINER, WK				MARINER, WK			RESEARCH IN EMERGENCY CARE WITHOUT CONSENT - NEW PROPOSED FDA RULES	LANCET			English	Editorial Material									BOSTON UNIV,SCH PUBL HLTH,BOSTON,MA 02215	Boston University	MARINER, WK (corresponding author), BOSTON UNIV,SCH MED,DEPT HLTH LAW,BOSTON,MA 02118, USA.			Mariner, Wendy/0000-0001-5176-5917				ABRAMSON NS, 1990, ANN EMERG MED, V19, P781, DOI 10.1016/S0196-0644(05)81703-2; [Anonymous], 1979, BELMONT REPORT ETHIC; 1995, REPORT PUBLIC FORUM; 1994, COALITION C ACUTE RE; 1995, FED REGISTER, V60, P49086	5	5	5	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	DEC 9	1995	346	8989					1505	1506		10.1016/S0140-6736(95)92045-5	http://dx.doi.org/10.1016/S0140-6736(95)92045-5			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TJ291	7491041				2022-12-28	WOS:A1995TJ29100004
J	NELLES, J; HARDING, T				NELLES, J; HARDING, T			PREVENTING HIV TRANSMISSION IN PRISON - A TALE OF MEDICAL DISOBEDIENCE AND SWISS PRAGMATISM	LANCET			English	Editorial Material									INST UNIV MED LEGALE,GENEVA,SWITZERLAND	University of Geneva	NELLES, J (corresponding author), UNIV BERN,PSYCHIAT KLIN,BERN,SWITZERLAND.							[Anonymous], 1991, Lancet, V337, P647; CONINX R, 1995, LANCET, V346, P1238, DOI 10.1016/S0140-6736(95)92952-5; CROFTS N, 1995, BRIT MED J, V310, P285, DOI 10.1136/bmj.310.6975.285; MARTIN V, 1994, TUBERCLE LUNG DIS, V75, P49, DOI 10.1016/0962-8479(94)90102-3; NELLES J, 1995, DROGEN HIV PRAVENTIO; POWER KG, 1992, BRIT J ADDICT, V87, P35; SCHALLER S, 1995, MED SOC PREVEN, V40, P298; TAYLOR A, 1995, BRIT MED J, V310, P289, DOI 10.1136/bmj.310.6975.289; Turnbull P. J., 1991, PRISON HIV AIDS RISK; VALWAY SE, 1994, AM J EPIDEMIOL, V140, P113, DOI 10.1093/oxfordjournals.aje.a117222; 1990, HIV DISEASE CORRECTI; 1993, WHO GUIDELINES HIV I	12	27	27	0	2	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	DEC 9	1995	346	8989					1507	1508		10.1016/S0140-6736(95)92047-1	http://dx.doi.org/10.1016/S0140-6736(95)92047-1			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TJ291	7491043				2022-12-28	WOS:A1995TJ29100006
J	MEIRE, HB; DARZI, A; LEE, N				MEIRE, HB; DARZI, A; LEE, N			ABC OF MEDICAL COMPUTING - DIGITAL IMAGING	BRITISH MEDICAL JOURNAL			English	Article																			0	2	2	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	NOV 4	1995	311	7014					1218	1221		10.1136/bmj.311.7014.1218	http://dx.doi.org/10.1136/bmj.311.7014.1218			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TD768	7488908	Green Published			2022-12-28	WOS:A1995TD76800032
J	JACKSON, D; VOLPERT, OV; BOUCK, N; LINZER, DIH				JACKSON, D; VOLPERT, OV; BOUCK, N; LINZER, DIH			STIMULATION AND INHIBITION OF ANGIOGENESIS BY PLACENTAL PROLIFERIN AND PROLIFERIN-RELATED PROTEIN	SCIENCE			English	Article							MOUSE PLACENTA; MESSENGER-RNA; GIANT-CELLS; PROLACTIN; FAMILY; EXPRESSION; GENE; DIFFERENTIATION; MEMBER; SITE	In many mammalian species, the placenta is the site of synthesis of proteins in the prolactin and growth hormone family. Analysis of two such proteins, proliferin (PLF) and proliferin-related protein (PRP), revealed that they are potent regulators of angiogenesis; PLF stimulated and PRP inhibited endothelial cell migration in cell culture and neovascularization in vivo. The mouse placenta secretes an angiogenic activity during the middle of pregnancy that corresponds primarily to PLF, but later in gestation releases a factor that inhibits angiogenesis, which was identified as PRP. Incubation of placental tissue with PLF led to the specific binding of this hormone to capillary endothelial cells. Thus PLF and PRP may regulate the initiation and then the cessation of placental neovascularization.	NORTHWESTERN UNIV, DEPT BIOCHEM MOLEC BIOL & CELL BIOL, EVANSTON, IL 60208 USA; NORTHWESTERN UNIV, SCH MED, DEPT MICROBIOL IMMUNOL, CHICAGO, IL 60611 USA; NORTHWESTERN UNIV, SCH MED, RH LURIE CANC CTR, CHICAGO, IL 60611 USA	Northwestern University; Northwestern University; Northwestern University; Robert H. Lurie Comprehensive Cancer Center				Volpert, Olga/0000-0003-1381-5543	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD024518, R01HD029962] Funding Source: NIH RePORTER; NCI NIH HHS [CA52750] Funding Source: Medline; NICHD NIH HHS [HD24518, HD29962] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		CARNEY EW, 1993, MOL REPROD DEV, V34, P357, DOI 10.1002/mrd.1080340403; CLAPP C, 1992, ENDOCRINOLOGY, V130, P1380, DOI 10.1210/en.130.3.1380; COFFIN JD, 1991, DEV BIOL, V148, P51, DOI 10.1016/0012-1606(91)90316-U; COLOSI P, 1988, MOL ENDOCRINOL, V2, P579, DOI 10.1210/mend-2-6-579; HORSEMAN N, COMMUNICATION; JACKSON DJC, UNPUB; LEE SJ, 1988, ENDOCRINOLOGY, V122, P1761, DOI 10.1210/endo-122-5-1761; LEE SJ, 1988, J BIOL CHEM, V263, P3521; LINZER DIH, 1985, EMBO J, V4, P1419, DOI 10.1002/j.1460-2075.1985.tb03796.x; LINZER DIH, 1985, P NATL ACAD SCI USA, V82, P4356, DOI 10.1073/pnas.82.13.4356; LINZER DIH, 1984, P NATL ACAD SCI-BIOL, V81, P4255, DOI 10.1073/pnas.81.14.4255; LINZER DIH, 1983, P NATL ACAD SCI-BIOL, V80, P4271, DOI 10.1073/pnas.80.14.4271; LOPEZ MF, 1993, ENDOCR J, V1, P513; MORDACQ JC, 1989, GENE DEV, V3, P760, DOI 10.1101/gad.3.6.760; MUSCAT GEO, 1991, MOL ENDOCRINOL, V5, P802, DOI 10.1210/mend-5-6-802; NILSENHAMILTON M, 1980, CELL, V20, P19, DOI 10.1016/0092-8674(80)90230-5; POLVERINI PJ, 1991, METHOD ENZYMOL, V198, P440; RAMSEY EM, 1982, PLACENTA; RASTINEJAD F, 1989, CELL, V56, P345, DOI 10.1016/0092-8674(89)90238-9; SOARES MJ, 1991, ENDOCR REV, V12, P402, DOI 10.1210/edrv-12-4-402; TOLSMA SS, 1993, J CELL BIOL, V122, P497, DOI 10.1083/jcb.122.2.497; WILDER EL, 1989, MOL CELL BIOL, V9, P430, DOI 10.1128/MCB.9.2.430	22	194	200	0	4	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	DEC 2	1994	266	5190					1581	1584		10.1126/science.7527157	http://dx.doi.org/10.1126/science.7527157			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PV015	7527157				2022-12-28	WOS:A1994PV01500050
J	VALERA, S; HUSSY, N; EVANS, RJ; ADAMI, N; NORTH, RA; SURPRENANT, A; BUELL, G				VALERA, S; HUSSY, N; EVANS, RJ; ADAMI, N; NORTH, RA; SURPRENANT, A; BUELL, G			NEW CLASS OF LIGAND-GATED ION-CHANNEL DEFINED BY P-2X RECEPTOR FOR EXTRACELLULAR ATP	NATURE			English	Article							PROGRAMMED CELL-DEATH; FUNCTIONAL EXPRESSION; POTASSIUM CHANNEL; TRANSMISSION	EXTRACELLULAR ATP exerts its effects through P-2 purinoceptors(1): these are ligand-gated ion channels (P-2X)(2,3) or G-protein-coupled receptors (P-2Y, P-2U)(4). ATP at P-2X receptors mediates synaptic transmission between neurons(5-7) and from neurons to smooth muscle(1), being responsible, for example, for sympathetic vasoconstriction in small arteries and arterioles(8,9) We have now cloned a complementary DNA encoding the P-2X receptor from rat vas deferens and expressed it in Xenopus oocytes and mammalian cells. ATP activates a cation-selective ion channel with relatively high calcium permeability. Structural predictions suggest that the protein (399 amino acids long) is mostly extracellular and contains only two transmembrane domains plus a pore-forming motif which resembles that of potassium channels. The P-2X receptor thus defines a new family of ligand-gated ion channels.			VALERA, S (corresponding author), GLAXO INST MOLEC BIOL SA,14 CHEMIN AUIX,PLAN OUATES,CH-1228 GENEVA,SWITZERLAND.		North, Richard/GQA-6156-2022					ABBRACHIO MP, IN PRESS PHARM THERA; ADAMS DJ, 1980, J GEN PHYSIOL, V75, P493, DOI 10.1085/jgp.75.5.493; ASHFORD MLJ, 1994, NATURE, V370, P456, DOI 10.1038/370456a0; BARNARD EA, 1994, TRENDS PHARMACOL SCI, V15, P67, DOI 10.1016/0165-6147(94)90280-1; BARNARD EA, 1992, TRENDS BIOCHEM SCI, V17, P368, DOI 10.1016/0968-0004(92)90002-Q; Bean B P, 1990, Ion Channels, V2, P169; BEAN BP, 1992, TRENDS PHARMACOL SCI, V13, P87, DOI 10.1016/0165-6147(92)90032-2; BENHAM CD, 1987, NATURE, V328, P275, DOI 10.1038/328275a0; BO XN, 1992, J BIOL CHEM, V267, P17581; BURNSTOCK G, 1988, TRENDS PHARMACOL SCI, V9, P116, DOI 10.1016/0165-6147(88)90185-X; BURNSTOCK G, 1990, ANN NY ACAD SCI, V603, P1; CANESSA CM, 1994, NATURE, V367, P463, DOI 10.1038/367463a0; CHALFIE M, 1993, NATURE, V361, P504, DOI 10.1038/361504a0; DURELL SR, 1992, BIOPHYS J, V62, P238, DOI 10.1016/S0006-3495(92)81809-X; EDWARDS FA, 1992, NATURE, V359, P144, DOI 10.1038/359144a0; EVANS RJ, 1992, BRIT J PHARMACOL, V106, P242, DOI 10.1111/j.1476-5381.1992.tb14323.x; EVANS RJ, 1992, NATURE, V357, P503, DOI 10.1038/357503a0; FELGNER PL, 1987, P NATL ACAD SCI USA, V84, P7413, DOI 10.1073/pnas.84.21.7413; HENIKOFF S, 1987, METHOD ENZYMOL, V155, P156; KUBO Y, 1993, NATURE, V362, P127, DOI 10.1038/362127a0; KUBO Y, 1993, NATURE, V364, P802, DOI 10.1038/364802a0; NORTH RA, IN PRESS HDB RECEPTO, V2; OWENS GP, 1991, MOL CELL BIOL, V11, P4177, DOI 10.1128/MCB.11.8.4177; SCHAERENWIEMERS N, 1993, HISTOCHEMISTRY, V100, P431, DOI 10.1007/BF00267823; SILINSKY EM, 1992, BRIT J PHARMACOL, V106, P762, DOI 10.1111/j.1476-5381.1992.tb14408.x; SPRANZI E, 1993, BLOOD, V82, P1578; WALKER JE, 1982, EMBO J, V1, P945, DOI 10.1002/j.1460-2075.1982.tb01276.x; ZHENG LM, 1991, J CELL BIOL, V112, P279, DOI 10.1083/jcb.112.2.279; ZIGANSHIN AU, 1994, BRIT J PHARMACOL, V111, P923, DOI 10.1111/j.1476-5381.1994.tb14827.x; ZOETEWEIJ JP, 1992, BIOCHEM J, V288, P207, DOI 10.1042/bj2880207	30	886	908	1	20	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	OCT 6	1994	371	6497					516	519		10.1038/371516a0	http://dx.doi.org/10.1038/371516a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PK589	7523951				2022-12-28	WOS:A1994PK58900056
J	MACPHERSON, AJS; BJARNASON, I				MACPHERSON, AJS; BJARNASON, I			COLONOCYTES IN BARRETTS METAPLASIA	LANCET			English	Editorial Material							ULCERATIVE-COLITIS				MACPHERSON, AJS (corresponding author), UNIV LONDON KINGS COLL,SCH MED,DEPT MED,LONDON,ENGLAND.							DAS KM, 1990, GASTROENTEROLOGY, V98, P464, DOI 10.1016/0016-5085(90)90839-S; DAS KM, 1994, ANN INTERN MED, V120, P753, DOI 10.7326/0003-4819-120-9-199405010-00006; DAS KM, 1993, J IMMUNOL, V150, P2487; HALSTENSEN TS, 1993, GUT, V34, P650, DOI 10.1136/gut.34.5.650; PAULL A, 1976, NEW ENGL J MED, V295, P476, DOI 10.1056/NEJM197608262950904	5	2	2	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	OCT 1	1994	344	8927					903	904		10.1016/S0140-6736(94)92264-0	http://dx.doi.org/10.1016/S0140-6736(94)92264-0			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PJ287	7523804				2022-12-28	WOS:A1994PJ28700005
J	MARLETTA, MA				MARLETTA, MA			NITRIC-OXIDE SYNTHASE - ASPECTS CONCERNING STRUCTURE AND CATALYSIS	CELL			English	Review							HYDROXY-L-ARGININE; MOLECULAR-CLONING; HEME; PURIFICATION; OXIDATION; SEQUENCE; CELLS		UNIV MICHIGAN,SCH MED,DEPT BIOL CHEM,ANN ARBOR,MI 48109	University of Michigan System; University of Michigan	MARLETTA, MA (corresponding author), UNIV MICHIGAN,COLL PHARM,INTERDEPT PROGRAM MED CHEM,ANN ARBOR,MI 48109, USA.							ABUSOUD HM, 1993, P NATL ACAD SCI USA, V90, P10769, DOI 10.1073/pnas.90.22.10769; BREDT DS, 1991, NATURE, V351, P714, DOI 10.1038/351714a0; BUSCONI L, 1993, J BIOL CHEM, V268, P8410; GELLER DA, 1993, P NATL ACAD SCI USA, V90, P3491, DOI 10.1073/pnas.90.8.3491; KORTH HG, 1994, J BIOL CHEM, V269, P17776; LAMAS S, 1992, P NATL ACAD SCI USA, V89, P6348, DOI 10.1073/pnas.89.14.6348; LOWENSTEIN CJ, 1992, CELL, V70, P705, DOI 10.1016/0092-8674(92)90301-R; MARLETTA MA, 1994, J MED CHEM, V37, P1899, DOI 10.1021/jm00039a001; MARLETTA MA, 1993, J BIOL CHEM, V268, P12231; MCMILLAN K, 1992, P NATL ACAD SCI USA, V89, P11141, DOI 10.1073/pnas.89.23.11141; NARHI LO, 1986, J BIOL CHEM, V261, P7160; NATHAN C, 1992, FASEB J, V6, P3051, DOI 10.1096/fasebj.6.12.1381691; NATHAN C, 1994, J BIOL CHEM, V269, P13725; NELSON DR, 1993, DNA CELL BIOL, V12, P1, DOI 10.1089/dna.1993.12.1; POLLOCK JS, 1991, P NATL ACAD SCI USA, V88, P10480, DOI 10.1073/pnas.88.23.10480; POULOS TL, 1987, J MOL BIOL, V195, P687, DOI 10.1016/0022-2836(87)90190-2; PUFAHL RA, 1993, BIOCHEM BIOPH RES CO, V193, P963, DOI 10.1006/bbrc.1993.1719; PUFAHL RA, 1992, BIOCHEMISTRY-US, V31, P6822, DOI 10.1021/bi00144a024; RENAUD JP, 1993, BIOCHEM BIOPH RES CO, V192, P53, DOI 10.1006/bbrc.1993.1380; RENGASAMY A, 1993, MOL PHARMACOL, V44, P124; ROGERS NE, 1992, BIOCHEM BIOPH RES CO, V189, P242, DOI 10.1016/0006-291X(92)91550-A; SHERMAN PA, 1993, BIOCHEMISTRY-US, V32, P11600, DOI 10.1021/bi00094a017; SHETA EA, 1994, J BIOL CHEM, V269, P15147; STUEHR DJ, 1991, J BIOL CHEM, V266, P6259; WHITE KA, 1992, BIOCHEMISTRY-US, V31, P6627, DOI 10.1021/bi00144a001; WHITE KA, 1993, HDB EXPT PHARM, V105, P719	26	719	747	0	19	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	SEP 23	1994	78	6					927	930		10.1016/0092-8674(94)90268-2	http://dx.doi.org/10.1016/0092-8674(94)90268-2			4	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	PJ294	7522970	Green Published			2022-12-28	WOS:A1994PJ29400004
J	KIRBY, RS				KIRBY, RS			ARE THE DAYS OF TRANSURETHRAL RESECTION OF PROSTATE FOR BENIGN PROSTATIC HYPERPLASIA NUMBERED - UROLOGISTS MUST GRASP THE FUTURE .3.	BRITISH MEDICAL JOURNAL			English	Article							OBSTRUCTION; FINASTERIDE				KIRBY, RS (corresponding author), ST BARTHOLOMEWS HOSP,LONDON EC1,ENGLAND.							GORMLEY GJ, 1992, NEW ENGL J MED, V327, P1185, DOI 10.1056/NEJM199210223271701; KIRBY RS, 1987, BRIT J UROL, V60, P136, DOI 10.1111/j.1464-410X.1987.tb04950.x; KIRBY RS, 1993, EUR UROL, V24, P20; LEPOR H, 1992, J UROLOGY, V148, P1467, DOI 10.1016/S0022-5347(17)36941-0; LEPOR H, 1991, Journal of Urology, V145, p362A; NEAL DE, 1989, BRIT MED J, V299, P762, DOI 10.1136/bmj.299.6702.762; Ng J., 1993, Journal of Urology, V149, p449A; NORRIS JP, 1993, J UROLOGY, V150, P1612, DOI 10.1016/S0022-5347(17)35857-3; OGDEN CW, 1993, LANCET, V341, P14, DOI 10.1016/0140-6736(93)92482-9; WENNBERG JE, 1987, JAMA-J AM MED ASSOC, V257, P933, DOI 10.1001/jama.257.7.933	10	8	8	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	SEP 17	1994	309	6956					716	717		10.1136/bmj.309.6956.716	http://dx.doi.org/10.1136/bmj.309.6956.716			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PH407	7524872	Green Published			2022-12-28	WOS:A1994PH40700022
J	KRAHN, MD; MAHONEY, JE; ECKMAN, MH; TRACHTENBERG, J; PAUKER, SG; DETSKY, AS				KRAHN, MD; MAHONEY, JE; ECKMAN, MH; TRACHTENBERG, J; PAUKER, SG; DETSKY, AS			SCREENING FOR PROSTATE-CANCER - A DECISION-ANALYTIC VIEW	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							RADICAL RETROPUBIC PROSTATECTOMY; TERM FOLLOW-UP; STAGE-A ADENOCARCINOMA; DEFINITIVE RADIOTHERAPY; PELVIC LYMPHADENECTOMY; EXPECTANT MANAGEMENT; DETECTION-PROJECT; NATURAL COURSE; CARCINOMA; COMPLICATIONS	Objective.-To determine the clinical and economic effects of screening for prostate cancer with prostate-specific antigen (PSA), transrectal ultrasound (TRUS), and digital rectal examination (DRE). Design.-Decision analytic cost-utility analysis comparing four screening strategies with a strategy of not screening. We assumed that the cancer detection rate and stage distribution were predicted by each combination of tests and that localized cancer was treated with radical prostatectomy. For each strategy, we calculated life expectancy, quality-adjusted life expectancy (QALE), and cost-utility ratios for unselected and high-prevalence populations. Data.-Probabilities and rates for clinical events were gathered from published data. We assessed utilities by the time-trade-off method using urologists, radiation oncologists, and internists as subjects. The Clinical Cost Manager at the New England Medical Center provided cost data. Results.-ln unselected men between the ages of 50 and 70 years, screening with PSA or TRUS prolonged unadjusted life expectancy but diminished QALE. Screening with DRE alone yielded no reduction in mortality at any age. All programs increased costs. Results were sensitive only to assumptions about the efficacy of treatment. In high-prevalence populations, screening produced a similar pattern: gains in unadjusted life expectancy, losses in QALE, and increased costs. Conclusions.-Our analysis does not support using PSA, TRUS, or DRE to screen asymptomatic men for prostatic cancer. Screening may result in poorer health outcomes and will increase costs dramatically. Assessment of comorbidity, risk attitude, and valuation of sexual function may identify individuals who will benefit from screening, but selecting high-prevalence populations will not improve the benefit of screening.	UNIV TORONTO, DEPT MED, TORONTO, ON, CANADA; UNIV TORONTO, DEPT CLIN BIOCHEM, TORONTO, ON, CANADA; UNIV TORONTO, DEPT HLTH ADM, TORONTO M5S 1A1, ON, CANADA; UNIV TORONTO, DEPT UROL, TORONTO, ON, CANADA; TORONTO HOSP, CTR PROSTATE, TORONTO M5T 2S8, ON, CANADA; WELLESLEY COLL HOSP, TORONTO M4Y 1J3, ON, CANADA; TUFTS UNIV NEW ENGLAND MED CTR, DEPT MED, DIV CLIN DECIS MAKING, BOSTON, MA 02111 USA; TUFTS UNIV, SCH MED, BOSTON, MA 02111 USA	University of Toronto; University of Toronto; University of Toronto; University of Toronto; University of Toronto; University Toronto Affiliates; University Health Network Toronto; University of Toronto; University Toronto Affiliates; Saint Michaels Hospital Toronto; Tufts Medical Center; Tufts University	KRAHN, MD (corresponding author), TORONTO HOSP, CLIN EPIDEMIOL UNIT, EN G-248, 200 ELIZABETH ST, TORONTO M5G 2C4, ON, CANADA.			Krahn, Murray/0000-0001-5836-397X				ADOLFSSON J, 1991, J UROLOGY, V146, P96, DOI 10.1016/S0022-5347(17)37722-4; ADOLFSSON J, 1990, BRIT J UROL, V65, P611, DOI 10.1111/j.1464-410X.1990.tb14829.x; BABAIAN RJ, 1992, CANCER, V69, P1195; BAGSHAW MA, 1990, UROL CLIN N AM, V17, P787; BECK JR, 1983, MED DECIS MAKING, V3, P419, DOI 10.1177/0272989X8300300403; BLACK WC, 1993, NEW ENGL J MED, V328, P1237, DOI 10.1056/NEJM199304293281706; BLUTE ML, 1989, J UROLOGY, V142, P1262, DOI 10.1016/S0022-5347(17)39051-1; BLUTE ML, 1986, J UROLOGY, V136, P840, DOI 10.1016/S0022-5347(17)45098-1; BORING CC, 1992, CA-CANCER J CLIN, V42, P19, DOI 10.3322/canjclin.42.1.19; BOWERSOX J, 1992, J NATL CANCER I, V84, P1857, DOI 10.1093/jnci/84.24.1857; Burks D A, 1992, Henry Ford Hosp Med J, V40, P89; BYAR DP, 1981, UROLOGY, V17, P7; CANTRELL BB, 1981, J UROLOGY, V125, P516, DOI 10.1016/S0022-5347(17)55092-2; CATALONA WJ, 1991, NEW ENGL J MED, V324, P1156, DOI 10.1056/NEJM199104253241702; CATALONA WJ, 1993, JAMA-J AM MED ASSOC, V270, P948, DOI 10.1001/jama.270.8.948; CHODAK GW, 1994, NEW ENGL J MED, V330, P242, DOI 10.1056/NEJM199401273300403; COWEN ME, 1994, J CLIN EPIDEMIOL, V47, P3, DOI 10.1016/0895-4356(94)90029-9; DAVIES AH, 1990, EUR UROL, V18, P117; DAYAL HH, 1982, J CHRON DIS, V35, P553, DOI 10.1016/0021-9681(82)90074-1; DETSKY AS, 1990, ANN INTERN MED, V113, P147, DOI 10.7326/0003-4819-113-2-147; DORR VJ, 1993, ARCH INTERN MED, V153, P2529, DOI 10.1001/archinte.153.22.2529; EDDY DM, 1983, CANCER, V51, P2440, DOI 10.1002/1097-0142(19830615)51:12+<2440::AID-CNCR2820511309>3.0.CO;2-M; EPSTEIN JI, 1986, J UROLOGY, V136, P837, DOI 10.1016/S0022-5347(17)45097-X; FINCHAM SM, 1990, PROSTATE, V17, P189, DOI 10.1002/pros.2990170303; FLEMING C, 1993, JAMA-J AM MED ASSOC, V269, P2650, DOI 10.1001/jama.269.20.2650; FORMAN JD, 1986, INT J RADIAT ONCOL, V12, P185, DOI 10.1016/0360-3016(86)90092-1; FOWLER FJ, 1993, UROLOGY, V42, P622, DOI 10.1016/0090-4295(93)90524-E; FOWLER JE, 1985, UROLOGY, V24, P243; GIBBONS R P, 1988, NCI (National Cancer Institute) Monographs, P123; GIBBONS RP, 1984, J UROLOGY, V131, P73, DOI 10.1016/S0022-5347(17)50210-4; GIBBONS RP, 1989, J UROLOGY, V141, P564, DOI 10.1016/S0022-5347(17)40895-0; GONZALEZ EF, 1992, 14TH ANN M SOC MED D; GREEN CJ, 1993, PROSTATE SPECIFIC AN; HANKS GE, 1991, ACTA ONCOL, V30, P231, DOI 10.3109/02841869109092359; IGEL TC, 1987, J UROLOGY, V137, P1189, DOI 10.1016/S0022-5347(17)44445-4; Jewett H J, 1975, Urol Clin North Am, V2, P105; JOHANSSON JE, 1992, JAMA-J AM MED ASSOC, V267, P2191, DOI 10.1001/jama.267.16.2191; KINSEY AC, 1948, SEXUAL BEHAV HUMAN M, P218; KRAHN M, 1993, MED CARE, V31, P403, DOI 10.1097/00005650-199305000-00003; KRAMER BS, 1993, ANN INTERN MED, V119, P914, DOI 10.7326/0003-4819-119-9-199311010-00009; LABRIE F, 1993, CLIN INVEST MED, V16, P425; LABRIE F, 1992, J UROLOGY, V147, P846, DOI 10.1016/S0022-5347(17)37402-5; LANGE PH, 1987, J UROLOGY, V138, P348, DOI 10.1016/S0022-5347(17)43143-0; LAUPACIS A, 1993, CAN MED ASSOC J, V148, P927; LAWRENCE RS, 1992, SCREENING PROSTATE C, P1; LEANDRI P, 1992, J UROLOGY, V147, P883, DOI 10.1016/S0022-5347(17)37412-8; LEPOR H, 1989, J UROLOGY, V141, P82, DOI 10.1016/S0022-5347(17)40596-9; LEPOR H, 1988, NATL CANCER I MONOGR, V7, P117; LOWE BA, 1988, J UROLOGY, V140, P1345, DOI 10.1016/S0022-5347(17)42040-4; LUYAO GL, 1993, JAMA-J AM MED ASSOC, V269, P2633, DOI 10.1001/jama.269.20.2633; MEBANE C, 1990, J NATL MED ASSOC, V82, P782; METTLIN C, 1991, CANCER, V67, P2949, DOI 10.1002/1097-0142(19910615)67:12<2949::AID-CNCR2820671202>3.0.CO;2-X; MIDDLETON AW, 1987, J UROLOGY, V138, P1185, DOI 10.1016/S0022-5347(17)43544-0; MIDDLETON RG, 1990, UROL CLIN N AM, V17, P779; MIDDLETON RG, 1986, J UROLOGY, V136, P422, DOI 10.1016/S0022-5347(17)44890-7; MILLER AB, 1989, WORLD J SURG, V13, P79, DOI 10.1007/BF01671158; MORTON RA, 1991, J UROLOGY, V145, P1197, DOI 10.1016/S0022-5347(17)38574-9; NEWLING D, 1992, PROSTATE S4, V19, P139; OPTENBERG SA, 1990, UROL CLIN N AM, V17, P719; PATTERSON DE, 1984, UROLOGY, V23, P243, DOI 10.1016/S0090-4295(84)90038-4; PAULSON DF, 1990, J UROLOGY, V144, P1180, DOI 10.1016/S0022-5347(17)39686-6; PILEPICH M V, 1988, NCI (National Cancer Institute) Monographs, P61; PILEPICH MV, 1981, INT J RADIAT ONCOL, V7, P1341, DOI 10.1016/0360-3016(81)90029-8; RITCHIE AWS, 1989, BRIT J UROL, V64, P511, DOI 10.1111/j.1464-410X.1989.tb05289.x; ROOS LL, 1990, JAMA-J AM MED ASSOC, V263, P2453, DOI 10.1001/jama.263.18.2453; ROOS NP, 1987, J UROLOGY, V137, P1184, DOI 10.1016/S0022-5347(17)44442-9; SCHELLHAMMER PF, 1990, UROL CLIN N AM, V17, P835; SCHUMAN LM, 1980, PREV MED, V9, P630, DOI 10.1016/0091-7435(80)90035-3; SINGER PA, 1991, J CLIN ONCOL, V9, P328, DOI 10.1200/JCO.1991.9.2.328; SPITZ MR, 1991, J UROLOGY, V146, P1305, DOI 10.1016/S0022-5347(17)38074-6; STEINBERG GD, 1990, PROSTATE, V17, P337, DOI 10.1002/pros.2990170409; STEINECK G, 1991, SCAND J UROL NEPHROL, P121; STEINER MS, 1991, J UROLOGY, V145, P512, DOI 10.1016/S0022-5347(17)38382-9; WALSH PC, 1992, J UROLOGY, V147, P853, DOI 10.1016/S0022-5347(17)37404-9; WALSH PC, 1987, CANCER, V60, P526, DOI 10.1002/1097-0142(19870801)60:3+<526::AID-CNCR2820601515>3.0.CO;2-9; WALSH PC, 1982, J UROLOGY, V128, P492, DOI 10.1016/S0022-5347(17)53012-8; Weinstein MC, 1980, CLIN DECISION ANAL; WENNBERG JE, 1987, JAMA-J AM MED ASSOC, V257, P933, DOI 10.1001/jama.257.7.933; WHITMORE WF, 1991, CANCER, V67, P1091, DOI 10.1002/1097-0142(19910215)67:4<1091::AID-CNCR2820670437>3.0.CO;2-J; ZHANG G, 1991, J UROLOGY, V146, P99, DOI 10.1016/S0022-5347(17)37723-6; ZINCKE H, 1991, J UROLOGY, V146, P1053, DOI 10.1016/S0022-5347(17)37999-5; 1989, GUIDE CLIN PREVENTIV, P63; 1991, CAN MED ASSOC J, V145, P413	83	321	323	0	20	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	SEP 14	1994	272	10					773	780		10.1001/jama.272.10.773	http://dx.doi.org/10.1001/jama.272.10.773			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PF188	7521400				2022-12-28	WOS:A1994PF18800025
J	BROWN, SC; THOMSON, SA; VEAL, JM; DAVIS, DG				BROWN, SC; THOMSON, SA; VEAL, JM; DAVIS, DG			NMR SOLUTION STRUCTURE OF A PEPTIDE NUCLEIC-ACID COMPLEXED WITH RNA	SCIENCE			English	Article							DNA; PNA; SPECTROSCOPY; INHIBITION; ANTISENSE; PROTEINS; OLIGONUCLEOTIDES; MACROMOLECULES; POLYAMIDE; EFFICIENT	Peptide nucleic acids (PNA) incorporating nucleic acid bases into an achiral polyamide backbone bind to DNA in a sequence-dependent manner. The structure of a PNA-ribonucleic acid (RNA) complex was determined with nuclear magnetic resonance methods. A hexameric PNA formed a 1:1 complex with a complementary RNA that is an antiparallel, right-handed double helix with Watson-Crick base pairing similar to the ''A'' form structure of RNA duplexes. The achiral PNA backbone assumed a distinct conformation upon binding that differed from previously proposed models and provides a basis for further structure-based design of antisense agents.			BROWN, SC (corresponding author), GLAXO INC,RES INST,RES TRIANGLE PK,NC 27709, USA.							ALMARSSON O, 1993, P NATL ACAD SCI USA, V90, P7518, DOI 10.1073/pnas.90.16.7518; ALMARSSON O, 1993, P NATL ACAD SCI USA, V90, P9542, DOI 10.1073/pnas.90.20.9542; BAX A, 1985, J MAGN RESON, V65, P355, DOI 10.1016/0022-2364(85)90018-6; BAX A, 1983, J MAGN RESON, V55, P81; BAX A, 1989, METHOD ENZYMOL, V176, P164; Brunger A.T., 1992, X PLOR VERSION 3 1 M; BUCHARDT O, 1993, TRENDS BIOTECHNOL, V11, P384, DOI 10.1016/0167-7799(93)90097-S; CHANDRASEKARAN R, 1989, LANDOLTBORNSTEIN NUC, V7, P55; COHEN JS, 1989, OLIGODEOXYNUCLEOTIDE; EGHOLM M, 1993, NATURE, V365, P566, DOI 10.1038/365566a0; EGHOLM M, 1992, J AM CHEM SOC, V114, P1895, DOI 10.1021/ja00031a062; EGHOLM M, 1992, J AM CHEM SOC, V114, P114; FEHRENTZ JA, 1983, SYNTHESIS-STUTTGART, P676; HANVEY JC, 1992, SCIENCE, V258, P1481, DOI 10.1126/science.1279811; JONES AS, 1973, TETRAHEDRON, V29, P2293, DOI 10.1016/S0040-4020(01)93352-6; KELLOGG GW, 1992, J MAGN RESON, V98, P176, DOI 10.1016/0022-2364(92)90122-N; KUMAR A, 1980, BIOCHEM BIOPH RES CO, V95, P1, DOI 10.1016/0006-291X(80)90695-6; MILLIGAN JF, 1993, J MED CHEM, V36, P1923, DOI 10.1021/jm00066a001; NIELSEN PE, 1991, SCIENCE, V254, P1497, DOI 10.1126/science.1962210; NIELSEN PE, 1993, NUCLEIC ACIDS RES, V21, P197, DOI 10.1093/nar/21.2.197; OTTING G, 1986, J MAGN RESON, V70, P500, DOI 10.1016/0022-2364(86)90144-7; PEFFER NJ, 1993, P NATL ACAD SCI USA, V90, P10648, DOI 10.1073/pnas.90.22.10648; PINES O, 1986, TRENDS GENET, P284; SKLENAR V, 1987, J MAGN RESON, V75, P352, DOI 10.1016/0022-2364(87)90041-2; STEIN CA, 1993, SCIENCE, V261, P1004, DOI 10.1126/science.8351515; STEPHENSON ML, 1978, P NATL ACAD SCI USA, V75, P285, DOI 10.1073/pnas.75.1.285; Thomson S., UNPUB; UHLMANN E, 1990, CHEM REV, V90, P544; VARANI G, 1991, Q REV BIOPHYS, V24, P479, DOI 10.1017/S0033583500003875; WAGNER G, 1983, BIOCHEM BIOPH RES CO, V113, P854, DOI 10.1016/0006-291X(83)91077-X; WEINER SJ, 1986, J COMPUT CHEM, V7, P230, DOI 10.1002/jcc.540070216; Wuthrich K., 1986, NMR PROTEINS NUCL AC; ZAMECNIK PC, 1978, P NATL ACAD SCI USA, V75, P280, DOI 10.1073/pnas.75.1.280; ZYDOWSKY TM, 1988, J ORG CHEM, V53, P5607, DOI 10.1021/jo00259a003	34	215	232	1	24	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	AUG 5	1994	265	5173					777	780		10.1126/science.7519361	http://dx.doi.org/10.1126/science.7519361			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PA372	7519361				2022-12-28	WOS:A1994PA37200032
J	DISANTO, JP; MARKIEWICZ, S; GAUCHAT, JF; BONNEFOY, JY; FISCHER, A; DESAINTBASILE, G				DISANTO, JP; MARKIEWICZ, S; GAUCHAT, JF; BONNEFOY, JY; FISCHER, A; DESAINTBASILE, G			PRENATAL-DIAGNOSIS OF X-LINKED HYPER-IGM SYNDROME	NEW ENGLAND JOURNAL OF MEDICINE			English	Note							HUMAN T-CELLS; HYPERIMMUNOGLOBULINEMIA-M; CLOSE LINKAGE; LIGAND; CD40; IMMUNODEFICIENCY; ACTIVATION; RECEPTOR; LOCUS; FORM		GLAXO INST MOLEC BIOL,GENEVA,SWITZERLAND	GlaxoSmithKline	DISANTO, JP (corresponding author), HOP NECKER ENFANTS MALAD,INSERM,U132,149 RUE SEVRES,F-75743 PARIS 15,FRANCE.		Di Santo, James P/M-4298-2014; de Saint Basile, Genevieve/G-9731-2017	Di Santo, James P/0000-0002-7146-1862; de Saint Basile, Genevieve/0000-0002-1913-5269				ALLEN RC, 1993, SCIENCE, V259, P990, DOI 10.1126/science.7679801; ARMITAGE RJ, 1992, NATURE, V357, P80, DOI 10.1038/357080a0; ARUFFO A, 1993, CELL, V72, P291, DOI 10.1016/0092-8674(93)90668-G; DESAINTBASILE G, 1987, P NATL ACAD SCI USA, V84, P7576; DISANTO JP, 1993, NATURE, V361, P541, DOI 10.1038/361541a0; GAUCHAT JF, 1993, FEBS LETT, V315, P259, DOI 10.1016/0014-5793(93)81175-Y; GRAF D, 1992, EUR J IMMUNOL, V22, P3191, DOI 10.1002/eji.1830221226; HENDRIKS RW, 1990, EUR J IMMUNOL, V20, P2603, DOI 10.1002/eji.1830201212; HOLLENBAUGH D, 1992, EMBO J, V11, P4313, DOI 10.1002/j.1460-2075.1992.tb05530.x; KORTHAUER U, 1993, NATURE, V361, P539, DOI 10.1038/361539a0; LANE P, 1992, EUR J IMMUNOL, V22, P2573, DOI 10.1002/eji.1830221016; MENSINK EJBM, 1987, HUM GENET, V76, P96; NOELLE RJ, 1992, IMMUNOL TODAY, V13, P431, DOI 10.1016/0167-5699(92)90068-I; NOTARANGELO L D, 1992, Immunodeficiency Reviews, V3, P101; PADAYACHEE M, 1992, GENOMICS, V14, P551, DOI 10.1016/S0888-7543(05)80270-8; PEAKMAN DC, 1977, J MED GENET, V14, P37, DOI 10.1136/jmg.14.1.37; ROSEN FS, 1961, PEDIATRICS, V28, P182; WEBER JL, 1989, AM J HUM GENET, V44, P388; 1992, IMMUNODEFIC REV, V3, P195	19	38	39	0	0	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	APR 7	1994	330	14					969	973		10.1056/NEJM199404073301404	http://dx.doi.org/10.1056/NEJM199404073301404			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ND793	7510042				2022-12-28	WOS:A1994ND79300004
J	CHENG, JH; ZHOU, T; LIU, CD; SHAPIRO, JP; BRAUER, MJ; KIEFER, MC; BARR, PJ; MOUNTZ, JD				CHENG, JH; ZHOU, T; LIU, CD; SHAPIRO, JP; BRAUER, MJ; KIEFER, MC; BARR, PJ; MOUNTZ, JD			PROTECTION FROM FAS-MEDIATED APOPTOSIS BY A SOLUBLE FORM OF THE FAS MOLECULE	SCIENCE			English	Article							TUMOR-NECROSIS-FACTOR; CELL-SURFACE ANTIGEN; RECEPTOR SUPERFAMILY; DNA FRAGMENTATION; CLONING; EXPRESSION; DEATH; CDNA; MICE	Fas is an apoptosis-signaling receptor molecule on the surface of a number of cell types. Molecular cloning and nucleotide sequence analysis revealed a human Fas messenger RNA variant capable of encoding a soluble Fas molecule lacking the transmembrane domain because of the deletion of an exon encoding this region. The expression of soluble Fas was confirmed by flow cytometry and immunocytochemical analysis. Supernatants from cells transfected with the variant messenger RNA blocked apoptosis induced by the antibody to Fas. Levels of soluble Fas were elevated in patients with systemic lupus erythematosus, and mice injected with soluble Fas displayed autoimmune features.	UNIV ALABAMA,BIRMINGHAM,AL 35294; VET ADM MED CTR,BIRMINGHAM,AL 35294; LXR BIOTECHNOL INC,RICHMOND,CA 94804	University of Alabama System; University of Alabama Birmingham; US Department of Veterans Affairs; Veterans Health Administration (VHA)					NIAID NIH HHS [P50 AI23694] Funding Source: Medline; NIAMS NIH HHS [P60 AR20614, P01 AR03555] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [P50AI023694] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [P60AR020614, P01AR003555] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		ADACHI M, 1993, P NATL ACAD SCI USA, V90, P1756, DOI 10.1073/pnas.90.5.1756; FERNANDEZBOTRAN R, 1991, FASEB J, V5, P2567, DOI 10.1096/fasebj.5.11.1868981; FRIZZERA G, 1989, LEUKEMIA, V3, P1; GAVRIELI Y, 1992, J CELL BIOL, V119, P493, DOI 10.1083/jcb.119.3.493; GOODWIN RG, 1990, CELL, V60, P941, DOI 10.1016/0092-8674(90)90342-C; GOODWIN RG, 1993, CELL, V73, P447, DOI 10.1016/0092-8674(93)90133-B; ITOH N, 1993, J BIOL CHEM, V268, P10932; ITOH N, 1991, CELL, V66, P233, DOI 10.1016/0092-8674(91)90614-5; JOSIMOVICALASEV.O, 1988, EUR J IMMUNOL, V18, P855; KLINMAN DM, 1986, J EXP MED, V163, P1292, DOI 10.1084/jem.163.5.1292; KROWKA J, UNPUB; MOSLEY B, 1989, CELL, V59, P335, DOI 10.1016/0092-8674(89)90295-X; OEHM A, 1992, J BIOL CHEM, V267, P10709; OHSAKA A, 1992, J CANCER, V69, P1259; OWENSCHAUB LB, 1992, CELL IMMUNOL, V140, P197, DOI 10.1016/0008-8749(92)90187-T; SCHALL TJ, 1990, CELL, V61, P361, DOI 10.1016/0092-8674(90)90816-W; TAKASHI S, 1993, CELL, V75, P1169; TAN EM, 1982, ARTHRITIS RHEUM, V25, P1277; WALLACE DJ, 1992, NEW ENGL J MED, V327, P1029; WATANABEFUKUNAGA R, 1992, J IMMUNOL, V148, P1274; WATANABEFUKUNAGA R, 1992, NATURE, V356, P314, DOI 10.1038/356314a0; WATSON ML, 1992, J EXP MED, V176, P1645, DOI 10.1084/jem.176.6.1645; WU JG, 1993, J EXP MED, V178, P461, DOI 10.1084/jem.178.2.461	23	1064	1172	1	31	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAR 25	1994	263	5154					1759	1762		10.1126/science.7510905	http://dx.doi.org/10.1126/science.7510905			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	NC040	7510905				2022-12-28	WOS:A1994NC04000035
J	BERG, EL; MCEVOY, LM; BERLIN, C; BARGATZE, RF; BUTCHER, EC				BERG, EL; MCEVOY, LM; BERLIN, C; BARGATZE, RF; BUTCHER, EC			L-SELECTIN-MEDIATED LYMPHOCYTE ROLLING ON MADCAM-1	NATURE			English	Article							ENDOTHELIAL CELL RECOGNITION; NODE HOMING RECEPTOR; VASCULAR ADDRESSIN; LIGAND; MOLECULE; IDENTIFICATION; MIGRATION; ADHESION; VENULES; SPECIFICITY	THE L-selectin, a cell surface C-type lectin, directs lymphocyte traffic to lymph nodes1, and contributes to lymphocyte homing to Peyer's patches2,3 and to leukocyte interactions with inflamed venules4,5. Here we report that the mucosal vascular addressin MAdCAM-1, a mucosal endothelial adhesion molecule with immunoglobulin- and mucin-like domains6, is a facultative ligand for L-selectin. MAdCAM-1 isolated from mesenteric lymph nodes, but not from cultured endothelioma cells, bears N-glycanase-resistant sialic acid-containing carbohydrate which supports adhesion of L-selectin-transfected lymphoid cells under shear. Interacting lymphoid cells display a 'rolling' behaviour similar to the selectin-dependent rolling of neutrophils observed in inflamed venules. MAdCAM-1 is also a ligand for the lymphocyte integrin homing receptor for Peyer's patches, alpha4beta7 (ref. 7), and may be uniquely adapted to support both selectin-mediated lymphocyte rolling and integrin-mediated adhesion and arrest in vivo.	STANFORD UNIV,DEPT PATHOL,IMMUNOL & VASC BIOL LAB,STANFORD,CA 94305; VET ADM MED CTR,FOOTHILL RES CTR,CTR MOLEC BIOL & MED,PALO ALTO,CA 94304	Stanford University; US Department of Veterans Affairs; Veterans Health Administration (VHA)			Berg, Ellen/D-9076-2014; Berg, Ellen/T-8827-2019	Berg, Ellen/0000-0001-5149-6665; 				BARGATZE RF, 1990, J CELL BIOCHEM, V42, P219, DOI 10.1002/jcb.240420405; BAUMHUETER S, 1993, SCIENCE, V262, P436, DOI 10.1126/science.7692600; BERG E L, 1991, P111; BERG EL, 1992, BIOCHEM BIOPH RES CO, V184, P1048, DOI 10.1016/0006-291X(92)90697-J; BERG EL, 1991, J CELL BIOL, V114, P343, DOI 10.1083/jcb.114.2.343; BERLIN C, 1993, CELL, V74, P185, DOI 10.1016/0092-8674(93)90305-A; BJERKNES M, 1986, SCIENCE, V231, P402, DOI 10.1126/science.3941903; BRISKIN MJ, 1993, NATURE, V363, P461, DOI 10.1038/363461a0; BRUSTEIN M, 1992, J EXP MED, V176, P1415, DOI 10.1084/jem.176.5.1415; BUTCHER EC, 1980, EUR J IMMUNOL, V10, P556, DOI 10.1002/eji.1830100713; BUTCHER EC, 1991, CELL, V67, P1033, DOI 10.1016/0092-8674(91)90279-8; GALLATIN WM, 1983, NATURE, V304, P30, DOI 10.1038/304030a0; HAMANN A, 1991, EUR J IMMUNOL, V21, P2925, DOI 10.1002/eji.1830211205; HOLTZMANN B, 1989, CELL, V56, P37; IMAI Y, 1991, J CELL BIOL, V113, P1213, DOI 10.1083/jcb.113.5.1213; ISSEKUTZ TB, 1991, J IMMUNOL, V147, P4178; KISHIMOTO TK, 1990, P NATL ACAD SCI USA, V87, P2244, DOI 10.1073/pnas.87.6.2244; LASKY LA, 1992, CELL, V69, P927, DOI 10.1016/0092-8674(92)90612-G; LAWRENCE MB, 1991, CELL, V65, P859, DOI 10.1016/0092-8674(91)90393-D; LEWINSOHN DM, 1987, J IMMUNOL, V138, P4313; NAKACHE M, 1988, NATURE, V304, P32; PERRY MA, 1991, J CLIN INVEST, V87, P1798, DOI 10.1172/JCI115200; PICKER LJ, 1989, J CELL BIOL, V109, P927, DOI 10.1083/jcb.109.2.927; SHIMIZU Y, 1992, IMMUNOL TODAY, V13, P106, DOI 10.1016/0167-5699(92)90151-V; SIMMONS DL, 1992, J IMMUNOL, V148, P267; STREETER PR, 1988, J CELL BIOL, V107, P1853, DOI 10.1083/jcb.107.5.1853; STREETER PR, 1988, NATURE, V331, P41, DOI 10.1038/331041a0; UMEMOTO J, 1977, J BIOL CHEM, V252, P8609; VONANDRIAN UH, 1992, AM J PHYSIOL, V263, pH1034, DOI 10.1152/ajpheart.1992.263.4.H1034; WATSON SR, 1990, J CELL BIOL, V110, P2221, DOI 10.1083/jcb.110.6.2221	30	487	502	0	5	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	DEC 16	1993	366	6456					695	698		10.1038/366695a0	http://dx.doi.org/10.1038/366695a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	MM265	7505053				2022-12-28	WOS:A1993MM26500072
J	Lim, PO; MacFadyen, RJ; Clarkson, PBM; MacDonald, TM				Lim, PO; MacFadyen, RJ; Clarkson, PBM; MacDonald, TM			Impaired exercise tolerance in hypertensive patients	ANNALS OF INTERNAL MEDICINE			English	Review							LEFT-VENTRICULAR HYPERTROPHY; BLOOD-PRESSURE RESPONSE; WHITE COAT HYPERTENSION; CONGESTIVE-HEART-FAILURE; TERM DIURETIC THERAPY; SYSTEMIC HYPERTENSION; BORDERLINE HYPERTENSION; ANTIHYPERTENSIVE AGENTS; PROGNOSTIC-SIGNIFICANCE; CORONARY CIRCULATION	Purpose: To review information on exercise testing in hypertensive patients and persons at risk for developing hypertension and to determine whether this type of investigation is valuable for diagnosis, prognosis, or assessment of the effect of therapy. Data Sources: A MEDLINE search of English-language articles published between 1985 and 1995 and reviews of the bibliographies of textbooks. Study Selection: Primary research articles on exercise testing in patients with hypertension, with an emphasis on methods, diagnosis, prognosis, and assessment of drug therapy. Data Extraction: Study design and quality were assessed, with particular attention paid to methods and aims. Relevant data on hemodynamic responses in hypertensive patients and persons at risk for developing hypertension and correlations to end-organ damage, mortality, and exercise tolerance were analyzed. Data Synthesis: The exercise capacity of hypertensive patients was found to be reduced by as much as 30% compared with age-matched controls. This exercise impairment increases with age and end-organ damage, and its origin can be traced back to adolescence. Total peripheral resistance also progressively increases. These changes are caused by functional and structural involvement of the cardiovascular system. Diastolic dysfunction of the heart is a prominent factor in this exercise limitation. The blood pressure responses to exercise have prognostic value for the future development of hypertension, end-organ damage, and death. The adequacy of antihypertensive treatment should therefore be evaluated in terms of normalizing these stress-related blood pressure responses. Conclusion: Exercise testing is a simple procedure that has great potential for assessing hypertensive patients. More research is necessary, however, to determine whether controlling blood pressure during exercise is beneficial.			Lim, PO (corresponding author), UNIV DUNDEE, NINEWELLS HOSP & MED SCH, DEPT CLIN PHARMACOL, DUNDEE DD1 9SY, SCOTLAND.			MacDonald, Thomas/0000-0001-5189-6669				AGOSTONI P, 1992, CHEST, V101, P1591, DOI 10.1378/chest.101.6.1591; AHLAWAT S, 1991, INT J CARDIOL, V33, P385, DOI 10.1016/0167-5273(91)90067-Y; AJAYI AAL, 1993, J HYPERTENS, V11, P99, DOI 10.1097/00004872-199301000-00014; AKHRAS F, 1991, LANCET, V337, P899, DOI 10.1016/0140-6736(91)90216-C; ALCAZAR JM, 1990, AM J CARDIOL, V65, pH51, DOI 10.1016/0002-9149(90)90343-Y; ALEXANDER JK, 1964, AM J CARDIOL, V14, P860, DOI 10.1016/0002-9149(64)90014-1; ALLEMANN Y, 1992, J HYPERTENS, V10, P1257, DOI 10.1097/00004872-199210000-00021; AMERY A, 1967, CIRCULATION, V36, P231, DOI 10.1161/01.CIR.36.2.231; [Anonymous], 1987, PEDIATRICS, V79, P1; Antony I, 1993, J AM COLL CARDIOL, V22, P514, DOI 10.1016/0735-1097(93)90058-9; ARRIGHI JA, 1994, CIRCULATION, V90, P213, DOI 10.1161/01.CIR.90.1.213; ATKINS JM, 1977, AM J CARDIOL, V39, P802, DOI 10.1016/S0002-9149(77)80030-1; BALOGUN MO, 1988, INT J CARDIOL, V21, P293, DOI 10.1016/0167-5273(88)90106-4; BENBASSAT J, 1986, ARCH INTERN MED, V146, P2053, DOI 10.1001/archinte.146.10.2053; BIANCHETTI MG, 1986, KIDNEY INT, V29, P882, DOI 10.1038/ki.1986.81; BOND V, 1994, J HYPERTENS, V12, P285; BOND V, 1993, BRIT J SPORT MED, V27, P107, DOI 10.1136/bjsm.27.2.107; BREISCH EA, 1980, CARDIOVASC RES, V14, P469, DOI 10.1093/cvr/14.8.469; BRILLA CG, 1991, CIRC RES, V69, P107, DOI 10.1161/01.RES.69.1.107; BUCHFUHRER MJ, 1983, J APPL PHYSIOL, V55, P1558, DOI 10.1152/jappl.1983.55.5.1558; CARDILLO C, 1993, HYPERTENSION, V21, P836, DOI 10.1161/01.HYP.21.6.836; CHAKKO S, 1990, AM J CARDIOL, V65, P1117, DOI 10.1016/0002-9149(90)90324-T; CLARK AL, 1994, BRIT HEART J, V71, P162; CLARKSON P, 1994, Q J MED, V87, P143; COCA A, 1994, J HYPERTENS, V12, pS13; COLLINS R, 1990, LANCET, V335, P827, DOI 10.1016/0140-6736(90)90944-Z; CRUICKSHANK JM, 1992, J HUM HYPERTENS, V6, P85; CUOCOLO A, 1990, CIRCULATION, V81, P978, DOI 10.1161/01.CIR.81.3.978; DAHLOF B, 1992, CARDIOLOGY, V81, P307, DOI 10.1159/000175821; DAHLOF B, 1992, AM J HYPERTENS, V5, P95, DOI 10.1093/ajh/5.2.95; DAVIDOFF R, 1982, AVIAT SPACE ENVIR MD, V53, P591; DAVIES SW, 1992, EUR HEART J, V13, P749, DOI 10.1093/oxfordjournals.eurheartj.a060251; DENGEL DR, 1994, HYPERTENSION, V23, P320, DOI 10.1161/01.HYP.23.3.320; DEVEREUX RB, 1983, AM J CARDIOL, V51, P171, DOI 10.1016/S0002-9149(83)80031-9; DEVEREUX RB, 1983, CIRCULATION, V68, P470, DOI 10.1161/01.CIR.68.3.470; DLIN RA, 1983, AM HEART J, V106, P316, DOI 10.1016/0002-8703(83)90198-9; DOUGHERTY AH, 1984, AM J CARDIOL, V54, P778, DOI 10.1016/S0002-9149(84)80207-6; ELBORN JS, 1990, EUR HEART J, V11, P75, DOI 10.1093/oxfordjournals.eurheartj.a059596; ENDRE T, 1994, J HYPERTENS, V12, P81; EPSTEIN SE, 1969, AM J CARDIOL, V23, P572, DOI 10.1016/0002-9149(69)90011-3; FAGARD R, 1991, HYPERTENSION, V17, P574, DOI 10.1161/01.HYP.17.4.574; FAGARD R, 1991, J HUM HYPERTENS, V5, P69; FAGARD R, 1988, J HYPERTENS, V6, P859, DOI 10.1097/00004872-198811000-00003; FERLINZ J, 1980, CIRCULATION, V61, P156, DOI 10.1161/01.CIR.61.1.156; FILIPOVSKY J, 1992, HYPERTENSION, V20, P333, DOI 10.1161/01.HYP.20.3.333; FOUAD FM, 1980, CLIN SCI, V59, pS411, DOI 10.1042/cs059411s; FROELICHER VF, 1994, MANUAL EXERCISE TEST; FROHLICH ED, 1992, NEW ENGL J MED, V327, P998, DOI 10.1056/NEJM199210013271406; FURUYAMA M, 1962, TOHOKU J EXP MED, V76, P388, DOI 10.1620/tjem.76.388; GARCIAGREGORY JA, 1984, CLIN CARDIOL, V7, P315, DOI 10.1002/clc.4960070511; GIACONI S, 1989, J NUCL MED ALLIED S, V33, P26; GIACONI S, 1989, HYPERTENSION, V14, P22, DOI 10.1161/01.HYP.14.1.22; GILLUM RF, 1981, AM HEART J, V102, P728, DOI 10.1016/0002-8703(81)90098-3; GOODMAN JM, 1992, CAN J CARDIOL, V8, P363; GOSSE P, 1986, J HYPERTENS, V4, pS297; GOTTDIENER JS, 1990, ANN INTERN MED, V112, P161, DOI 10.7326/0003-4819-112-3-161; GOULD BA, 1985, BRIT HEART J, V53, P611; GRANT S, 1993, BR HEART J P, V71, P267; GROSSMAN E, 1994, J HUM HYPERTENS, V8, P417; GUAZZI M, 1979, AM J CARDIOL, V44, P1007, DOI 10.1016/0002-9149(79)90236-4; GUYTON AC, 1983, HYPERTENSION MECHANI, P25; HABIB GB, 1992, AM HEART J, V124, P1313, DOI 10.1016/0002-8703(92)90417-T; HANRATH P, 1983, AM J CARDIOL, V52, P544, DOI 10.1016/0002-9149(83)90023-1; HANSEN HS, 1989, J HYPERTENS, V7, pS41, DOI 10.1097/00004872-198902001-00012; HIRSCH GL, 1985, J APPL PHYSIOL, V58, P1975, DOI 10.1152/jappl.1985.58.6.1975; HITTINGER L, 1990, CIRC RES, V66, P329, DOI 10.1161/01.RES.66.2.329; HOLLAND WW, 1964, BRIT MED J, V2, P1241, DOI 10.1136/bmj.2.5419.1241; INOUYE I, 1984, AM J CARDIOL, V53, P120, DOI 10.1016/0002-9149(84)90695-7; JULIUS S, 1968, CIRCULATION, V38, P282, DOI 10.1161/01.CIR.38.2.282; JULIUS S, 1967, CIRCULATION, V36, P222, DOI 10.1161/01.CIR.36.2.222; JULIUS S, 1990, HYPERTENSION, V16, P617, DOI 10.1161/01.HYP.16.6.617; JULIUS S, 1992, CLIN EXP HYPERTENS A, V14, P45, DOI 10.3109/10641969209036170; JULIUS S, 1975, CIRC RES, V36, P199, DOI 10.1161/01.RES.36.6.199; JULIUS S, 1971, CIRCULATION, V43, P382, DOI 10.1161/01.CIR.43.3.382; KAPUKU GK, 1993, AM HEART J, V125, P1710, DOI 10.1016/0002-8703(93)90763-Y; KITZMAN DW, 1991, J AM COLL CARDIOL, V17, P1065, DOI 10.1016/0735-1097(91)90832-T; KNUTSEN KM, 1991, J HUM HYPERTENS, V5, P149; KUO LC, 1987, AM J CARDIOL, V59, P1174, DOI 10.1016/0002-9149(87)90870-8; KUSAKA M, 1989, J HYPERTENS, V7, pS59, DOI 10.1097/00004872-198909007-00014; KUWAJIMA I, 1993, HYPERTENSION, V22, P826, DOI 10.1161/01.HYP.22.6.826; LAUER MS, 1992, ANN INTERN MED, V116, P203, DOI 10.7326/0003-4819-116-3-203; LEVY BI, 1988, CIRC RES, V63, P227, DOI 10.1161/01.RES.63.1.227; LIEBSON PR, 1995, CIRCULATION, V91, P698, DOI 10.1161/01.CIR.91.3.698; LIGHTFOOT JT, 1989, MED SCI SPORT EXER, V21, P698; LIPKIN DP, 1986, BRIT HEART J, V55, P439; Lund-Johansen P, 1983, J Hypertens, V1, P159, DOI 10.1097/00004872-198308000-00008; Lund-Johansen P., 1984, J HYPERTENSION S2, V2, pS49; LUNDJOHANSEN P, 1989, J HYPERTENS, V7, pS52, DOI 10.1097/00004872-198900076-00023; LUNDJOHANSEN P, 1983, AM J MED, V75, P24, DOI 10.1016/0002-9343(83)90133-X; LUNDJOHANSEN P, 1970, ACTA MED SCAND, V187, P509; LUNDJOHANSEN P, 1983, EUR HEART J, V4, P1; LUNDJOHANSEN P, 1980, CLIN SCI, V59, pS343, DOI 10.1042/cs059343s; LUNDJOHANSEN P, 1986, BRIT J CLIN PHARMACO, V21, pS45, DOI 10.1111/j.1365-2125.1986.tb02853.x; LUNDJOHANSEN P, 1984, ACTA MED SCAND, P109; LUNDJOHANSEN P, 1975, POSTGRAD MED, P45; LUNDJOHANSEN P, 1974, ACTA MED SCAND, V195, P111; LUNDJOHANSEN P, 1967, ACTA MED SCAND S482, V183, P1; MACMAHON S, 1990, LANCET, V335, P765, DOI 10.1016/0140-6736(90)90878-9; MAGRINI F, 1987, CIRCULATION, V75, P168; MAHONEY LT, 1988, HYPERTENSION, V12, P206, DOI 10.1161/01.HYP.12.2.206; MAKENE WJ, 1976, CARDIOVASCULAR DISEA, P275; MANCIA G, 1983, LANCET, V2, P695; McArdle WD, 1986, EXERCISE PHYSL ENERG; MESSERLI FH, 1981, CIRCULATION, V64, P760, DOI 10.1161/01.CIR.64.4.760; MILLER DD, 1987, AM J CARDIOL, V59, P409, DOI 10.1016/0002-9149(87)90946-5; MISSAULT L, 1992, J HUM HYPERTENS, V6, P151; MODESTI PA, 1993, ANGIOLOGY, V43, P908; MOLINEUX D, 1988, J HYPERTENS, V6, P361; MONTAIN SJ, 1988, HYPERTENSION, V12, P479, DOI 10.1161/01.HYP.12.5.479; MOREIRA ED, 1992, HYPERTENSION, V19, P198, DOI 10.1161/01.HYP.19.2_Suppl.II198; MUNDAL R, 1994, HYPERTENSION, V24, P56, DOI 10.1161/01.HYP.24.1.56; MYERS J, 1992, CHEST, V101, pS236; MYERS J, 1990, J APPL PHYSIOL, V68, P404, DOI 10.1152/jappl.1990.68.1.404; MYERS J, 1991, J AM COLL CARDIOL, V17, P1334, DOI 10.1016/S0735-1097(10)80144-5; NATHWANI D, 1985, AM HEART J, V109, P386, DOI 10.1016/0002-8703(85)90622-2; NIEDERBERGER M, 1974, BRIT HEART J, V36, P377; NIELSEN JR, 1989, J HYPERTENS, V7, P377, DOI 10.1097/00004872-198905000-00005; OGUNNOWO PO, 1986, T ROY SOC TROP MED H, V80, P923, DOI 10.1016/0035-9203(86)90260-9; PALATINI P, 1994, CLIN SCI, V87, P275, DOI 10.1042/cs0870275; PAPADEMETRIOU V, 1989, AM J HYPERTENS, V2, P114, DOI 10.1093/ajh/2.2.114; PERLOFF D, 1991, J HYPERTENS, V9, pS31; PERLOFF D, 1990, J HYPERTENS, V8, pS105; PINSKY DJ, 1986, CIRCULATION S2, V80, P426; POLONIA J, 1992, EUR HEART J, V13, P30, DOI 10.1093/eurheartj/13.suppl_A.30; POOL PE, 1985, AM J CARDIOL, V56, pH86, DOI 10.1016/0002-9149(85)90550-8; POULEUR H, 1990, EUR HEART J, V11, P30, DOI 10.1093/eurheartj/11.suppl_C.30; PRASAD N, 1995, J HYPERTENS, V13, P291; RAFTERY EB, 1968, CARDIOVASC RES, V2, P210, DOI 10.1093/cvr/2.2.210; RAMES LK, 1978, PEDIATRICS, V61, P245; REN JF, 1985, J AM COLL CARDIOL, V5, P1224, DOI 10.1016/S0735-1097(85)80029-2; ROSTAND SG, 1989, NEW ENGL J MED, V320, P684, DOI 10.1056/NEJM198903163201102; RUDDY TD, 1986, CLIN RES, V34, pA485; SAFAR ME, 1985, CLIN SCI, V69, P497, DOI 10.1042/cs0690497; SCHMIEDER RE, 1990, AM J HYPERTENS, V3, P281, DOI 10.1093/ajh/3.4.281; SETARO JF, 1990, AM J CARDIOL, V66, P981, DOI 10.1016/0002-9149(90)90937-V; SHEPS DS, 1979, AM J CARDIOL, V43, P708, DOI 10.1016/0002-9149(79)90067-5; SIDERY MB, 1994, J ROY COLL PHYS LOND, V28, P19; SIEGEL WC, 1990, HYPERTENSION, V16, P140, DOI 10.1161/01.HYP.16.2.140; SILKE B, 1991, BR J CLIN PHARM, V33, pP540; SLEIGHT P, 1984, AM J MED, V76, P3, DOI 10.1016/0002-9343(84)90877-5; SMITH DHG, 1992, AM J CARDIOL, V69, P225, DOI 10.1016/0002-9149(92)91309-R; SMOKLER PE, 1973, CIRCULATION, V48, P346, DOI 10.1161/01.CIR.48.2.346; SOLOMON SA, 1991, BRIT MED J, V303, P1100, DOI 10.1136/bmj.303.6810.1100; STEGEMANN J, 1981, PHYSL BASES WORK SPO; STRAUER BE, 1990, AM J CARDIOL, V65, pG34; SULLIVAN M, 1984, CHEST, V86, P375, DOI 10.1378/chest.86.3.375; SULLIVAN MJ, 1990, CIRCULATION, V81, P518, DOI 10.1161/01.CIR.81.2.518; SUNG BH, 1990, AM J CARDIOL, V65, P909, DOI 10.1016/0002-9149(90)91435-9; SVENSSON A, 1984, ACTA MED SCAND, P51; TARAZI RC, 1976, CIRC RES, V38, P73, DOI 10.1161/01.RES.38.6.73; TARAZI RC, 1972, AM J CARDIOL, V29, P633, DOI 10.1016/0002-9149(72)90164-6; TOMTEN SE, 1994, AM J HYPERTENS, V7, P603, DOI 10.1093/ajh/7.7.603; TUBAU JF, 1989, HYPERTENSION, V14, P1; TUCK ML, 1986, AM HEART J, V112, P877, DOI 10.1016/0002-8703(86)90497-7; VANZWIETEN PA, 1980, BRIT J CLIN PHARMACO, V10, pS13; VIRTANEN K, 1982, EUR J CLIN PHARMACOL, V21, P275, DOI 10.1007/BF00637613; WATT G, 1986, J HYPERTENS, V4, P1, DOI 10.1097/00004872-198602000-00001; WEBER KT, 1991, CIRCULATION, V83, P1849, DOI 10.1161/01.CIR.83.6.1849; WEBER KT, 1994, J HUM HYPERTENS, V8, P665; WHEELDON NM, 1994, EUR HEART J, V15, P1689, DOI 10.1093/oxfordjournals.eurheartj.a060453; WHEELDON NM, 1993, Q J MED, V86, P17; WHITE WB, 1992, LEFT VENTRICULAR HYP, P31; WICKS JR, 1978, CIRCULATION, V57, P1066, DOI 10.1161/01.CIR.57.6.1066; WIDGREN BR, 1992, J HYPERTENS, V10, P459, DOI 10.1097/00004872-199205000-00009; WILSON MF, 1990, AM J CARDIOL, V66, P731, DOI 10.1016/0002-9149(90)91139-W; WILSON NV, 1981, PREV MED, V10, P62, DOI 10.1016/0091-7435(81)90006-2; ZAHKA KG, 1981, HYPERTENSION, V3, P664, DOI 10.1161/01.HYP.3.6.664; 1964, VITAL HLTH STATIS 11, V4	168	102	103	0	2	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JAN 1	1996	124	1	1				41	55		10.7326/0003-4819-124-1_Part_1-199601010-00008	http://dx.doi.org/10.7326/0003-4819-124-1_Part_1-199601010-00008			15	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TL943	7503477				2022-12-28	WOS:A1996TL94300008
J	JADAD, AR; BROWMAN, GP				JADAD, AR; BROWMAN, GP			THE WHO ANALGESIC LADDER FOR CANCER PAIN MANAGEMENT - STEPPING UP THE QUALITY OF ITS EVALUATION	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Review							WORLD-HEALTH-ORGANIZATION; DEMONSTRATION PROJECTS; RELIEF-PROGRAM; VALIDATION; GUIDELINES	Objective.-To perform a systematic review of studies evaluating the effectiveness of the World Health Organization (WHO) analgesic ladder as an intervention for cancer pain management. Data Sources.-Systematic search of MEDLINE from 1982 to 1995, hand search of textbooks and meeting proceedings, reference lists, and direct contact with authors. Study Selection.-Studies of any methodological design were included if they evaluated patients with cancer pain treated according to the WHO analgesic ladder and if the studies provided enough information to estimate the proportion of patients who achieved adequate analgesia with the use of the ladder. The strength of the evidence provided by each study was assessed separately by both authors using current concepts. Data Extraction.-from the hard copy of each study report, the first author's name, publication year, study design, number of dropouts per study, and proportion of patients with adequate analgesia in each study were extracted. Data Synthesis.-Eight studies purporting to evaluate the effectiveness of the WHO ladder were included in the review. Meta-analysis was not performed because the studies were case series with no control groups. The studies had other limitations: none provided information on the conditions in which pain was assessed; two were retrospective; one had short follow-up periods; three had high withdrawal rates; and one had variable follow-up periods, Analgesia was adequate in 69% to 100% of patients analyzed in the studies. Conclusions.-The studies available provide valuable information on the course of cancer pain and its treatment. However, the evidence they provide is insufficient to estimate confidently the effectiveness of the WHO analgesic ladder for the management of cancer pain. Until results from carefully designed controlled trials are available, it would be inappropriate to judge the performance of clinicians programs, and institutions or to design policies based on such evidence.			JADAD, AR (corresponding author), MCMASTER UNIV, DEPT CLIN EPIDEMIOL & BIOSTAT, 1200 MAIN ST W, HAMILTON, ON L8N 3Z5, CANADA.							BONICA JJ, 1990, MANAGEMENT PAIN, P400; BROWMAN GP, 1995, J CLIN ONCOL, V13, P502, DOI 10.1200/JCO.1995.13.2.502; CHERNY NI, 1994, TXB PAIN, P1437; CLEELAND C, 1991, CANCER, V67, P823, DOI 10.1002/1097-0142(19910201)67:3+<823::AID-CNCR2820671412>3.0.CO;2-S; CLEELAND CS, 1994, NEW ENGL J MED, V330, P592, DOI 10.1056/NEJM199403033300902; CLEELAND CS, 1990, ADV PAIN RES THER, V16, P465; CLEELAND CS, 1993, J PAIN SYMPTOM MANAG, V8, P361, DOI 10.1016/0885-3924(93)90053-X; COOK DJ, 1992, CHEST, V102, pS305; FOLEY KM, 1985, NEW ENGL J MED, V313, P84, DOI 10.1056/NEJM198507113130205; FOLEY KM, 1990, ADV PAIN RES THERAPY; GOISIS A, 1989, TUMORI, V75, P470, DOI 10.1177/030089168907500513; GROND S, 1991, J PAIN SYMPTOM MANAG, V6, P411, DOI 10.1016/0885-3924(91)90039-7; GROND S, 1993, ANN OTO RHINOL LARYN, V102, P342, DOI 10.1177/000348949310200504; HANKS GW, 1992, LANCET, V339, P1031; JACOX A, 1994, AHCPR940592 US DEP H; JADAD AR, 1994, THESIS U OXFORD OXFO; JAGOX A, 1994, NEW ENGL J MED, V330, P651, DOI 10.1056/NEJM199403033300926; Loeser J., 1990, MANAGEMENT PAIN, P2040; MCCAFFERY M, 1992, CANCER-AM CANCER SOC, V70, P1438, DOI 10.1002/1097-0142(19920901)70:3+<1438::AID-CNCR2820701536>3.0.CO;2-W; Melzack R, 1994, TXB PAIN; PATT RB, 1993, CANCER PAIN; RAPPAZ O, 1985, THER UMSCH, V42, P843; SACKETT DL, 1989, CHEST, V95, pS2, DOI 10.1378/chest.95.2.2S; SCHNEIDER M, 1994, CHIRURG, V65, P551; Schug S A, 1990, J Pain Symptom Manage, V5, P27, DOI 10.1016/S0885-3924(05)80006-5; Siguan SS, 1992, PHILLIPPINE J SURG S, V47, P173; STJERNSWARD J, 1990, ADV PAIN RES THER, V16, P7; STJERNSWARD J, 1993, J PAIN SYMPTOM MANAG, V8, P340, DOI 10.1016/0885-3924(93)90050-6; SWERDLOW M, 1982, WORLD HEALTH FORUM, V3, P325; TAKEDA F, 1990, ADV PAIN RES THER, V16, P475; Takeda F., 1986, PAIN CLINIC, V1, P83; Twycross RG, 1994, PAIN RELIEF ADV CANC; VENTAFRIDDA V, 1990, ADV PAIN RES THER, V16, P451; VENTAFRIDDA V, 1987, CANCER, V59, P850, DOI 10.1002/1097-0142(19870215)59:4<850::AID-CNCR2820590432>3.0.CO;2-1; VONROENN JH, 1993, ANN INTERN MED, V119, P121, DOI 10.7326/0003-4819-119-2-199307150-00005; Walker V A, 1988, J Pain Symptom Manage, V3, P145, DOI 10.1016/0885-3924(88)90160-1; WENK R, 1991, J PAIN SYMPTOM MANAG, V6, P40, DOI 10.1016/0885-3924(91)90070-K; ZECH DFJ, 1995, PAIN, V63, P65, DOI 10.1016/0304-3959(95)00017-M; 1990, WHO TECHNICAL REPORT, V804; 1986, CANCER PAIN RELIEF	40	295	298	0	15	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	DEC 20	1995	274	23					1870	1873		10.1001/jama.274.23.1870	http://dx.doi.org/10.1001/jama.274.23.1870			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TK147	7500538				2022-12-28	WOS:A1995TK14700030
J	LAUNER, LJ; MASAKI, K; PETROVITCH, H; FOLEY, D; HAVLIK, RJ				LAUNER, LJ; MASAKI, K; PETROVITCH, H; FOLEY, D; HAVLIK, RJ			THE ASSOCIATION BETWEEN MIDLIFE BLOOD-PRESSURE LEVELS AND LATE-LIFE COGNITIVE FUNCTION - THE HONOLULU-ASIA AGING STUDY	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							CORONARY HEART-DISEASE; WHITE MATTER LESIONS; MINI-MENTAL STATE; JAPANESE MEN; HYPERTENSION; STROKE; HAWAII; CALIFORNIA; MORTALITY; DEMENTIA	Objective.-To assess the long-term relationship of midlife blood pressure levels to late-life cognitive function. Design.-The 4678 surviving cohort members of the prospective Honolulu Heart Program (baseline, 1965-1968) were examined a fourth time in 1991 through 1993 and given a cognitive test. Participants.-The subjects were 3735 Japanese-American men living in Hawaii in the community or in institutions, with an average age of 78 years at the fourth examination. Main Outcome Measures.-Cognitive function, measured by the 100-point Cognitive Abilities Screening Instrument (CASI), was categorized into good (reference: a CASI score of 92 to 100), intermediate (<92 to 82), and poor (<82). Midlife systolic blood pressure (SEP) and diastolic blood pressure (DBP) values were measured in 1965, 1968, and 1971. A respondent was classified into the following categories if two of three measurements fell into the following groups: for SEP, <110, 110 to 139, 140 to 159, and greater than or equal to 160 mm Hg; and for DBP, <80, 80 to 89, 90 to 94, and greater than or equal to 95 mm Hg. Results.-When we controlled for age and education, the risk for intermediate and poor cognitive function increased progressively with increasing level of midlife SEP category (P for trend <.03 and <.001, respectively). for every 10-mm Hg increase in SEP there was an increase in risk for intermediate cognitive function of 7% (95% confidence interval [C], 3% to 11%) and for poor cognitive function of 9% (95% CI, 3% to 16%). Adjustment for prevalent stroke, coronary heart disease, and subclinical atherosclerosis reduced the strength of the relationship between midlife SEP and poor cognitive function to 5% (95% CI, 0% to 12%). The level of cognitive function was not associated with midlife DBP. Conclusions.-Midlife SEP is a significant predictor of reduced cognitive function in later life. Early control of SEP levels may reduce the risk for cognitive impairment in old age.	ERASMUS UNIV ROTTERDAM,SCH MED,DEPT EPIDEMIOL & BIOSTAT,BILTHOVEN,NETHERLANDS; UNIV HAWAII,DEPT MED,HONOLULU,HI; KUAKINI MED CTR,HONOLULU,HI 96817; NIA,EPIDEMIOL DEMOG & BIOMETRY PROGRAM,BETHESDA,MD 20892	Erasmus University Rotterdam; University of Hawaii System; National Institutes of Health (NIH) - USA; NIH National Institute on Aging (NIA)	LAUNER, LJ (corresponding author), NATL INST PUBL HLTH & ENVIRONM PROTECT,POB 1,3720 BA BILTHOVEN,NETHERLANDS.				NHLBI NIH HHS [N01-HR-02901] Funding Source: Medline; NIA NIH HHS [N01-AG-4-2149] Funding Source: Medline; NATIONAL INSTITUTE ON AGING [N01AG042149] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		APPLEGATE WB, 1989, ANN INTERN MED, V110, P901, DOI 10.7326/0003-4819-110-11-901; BOTS ML, 1993, LANCET, V341, P1232, DOI 10.1016/0140-6736(93)91144-B; BOTS ML, 1991, EPIDEMIOL REV, V13, P294, DOI 10.1093/oxfordjournals.epirev.a036073; BRETELER MMB, 1994, STROKE, V25, P1109, DOI 10.1161/01.STR.25.6.1109; COLSHER PL, 1991, EPIDEMIOL REV, V13, P1; ELIAS MF, 1993, AM J EPIDEMIOL, V138, P353, DOI 10.1093/oxfordjournals.aje.a116868; ELIAS MF, 1989, J GERONTOL, V44, pP25, DOI 10.1093/geronj/44.1.P25; ERKINJUNTTI T, 1993, CEREBROVASC DIS, V3, P3, DOI 10.1159/000108661; FARACI FM, 1990, CIRC RES, V66, P8, DOI 10.1161/01.RES.66.1.8; FARMER ME, 1987, AM J EPIDEMIOL, V126, P1103, DOI 10.1093/oxfordjournals.aje.a114749; FOLSTEIN MF, 1975, J PSYCHIAT RES, V12, P189, DOI 10.1016/0022-3956(75)90026-6; FUMTA A, 1991, STROKE, V22, P442; GRAVES AB, 1993, ALZHEIMERS DIS ADV C, P113; Hasegawa K., 1983, AGING EIGHTIES, P207; HAVLIK RJ, 1992, NESTLE NUTR WORKSHOP, P7; KANNEL WB, 1985, HDB BIOL AGING, P859; KANNEL WB, 1976, STROKE, V4, P327; MACMAHON S, 1990, LANCET, V335, P765, DOI 10.1016/0140-6736(90)90878-9; MILLER VT, 1983, ARCH NEUROL-CHICAGO, V40, P129, DOI 10.1001/archneur.1983.04050030023002; NAG S, 1984, ACTA NEUROPATHOL, V62, P178, DOI 10.1007/BF00691850; REED D, 1994, STROKE, V25, P60, DOI 10.1161/01.STR.25.1.60; SALERNO JA, 1992, HYPERTENSION, V20, P340, DOI 10.1161/01.HYP.20.3.340; SANDS LP, 1992, J GERONTOL, V47, pP81, DOI 10.1093/geronj/47.2.P81; SCHERR PA, 1991, AM J EPIDEMIOL, V134, P1303, DOI 10.1093/oxfordjournals.aje.a116033; SIU AL, 1991, ANN INTERN MED, V115, P122, DOI 10.7326/0003-4819-115-2-122; STAMLER J, 1987, NEW PERSPECTIVES CAR, P13; STARR JM, 1993, J AM GERIATR SOC, V41, P753, DOI 10.1111/j.1532-5415.1993.tb07466.x; SYME SL, 1975, AM J EPIDEMIOL, V102, P477, DOI 10.1093/oxfordjournals.aje.a112185; TATAMICHI TK, 1994, J NEUROL NEUROSUR PS, V57, P202; Teng E L, 1994, Int Psychogeriatr, V6, P45, DOI 10.1017/S1041610294001602; TENG EL, 1987, J CLIN PSYCHIAT, V48, P314; VANSWIETEN JC, 1991, ANN NEUROL, V30, P825, DOI 10.1002/ana.410300612; VOGT MT, 1992, J CLIN EPIDEMIOL, V45, P529, DOI 10.1016/0895-4356(92)90102-S; WALLACE RB, 1985, J CHRON DIS, V38, P475, DOI 10.1016/0021-9681(85)90031-1; WHITE LR, 1992, CURR SCI INDIA, V63, P456; WILKIE F, 1971, SCIENCE, V172, P959, DOI 10.1126/science.172.3986.959; WILKIE F L, 1976, Experimental Aging Research, V2, P3; WINKELSTEIN W, 1975, AM J EPIDEMIOL, V102, P502, DOI 10.1093/oxfordjournals.aje.a112188; WITTEMAN JCM, 1994, LANCET, V343, P504, DOI 10.1016/S0140-6736(94)91459-1; WORTH RM, 1975, AM J EPIDEMIOL, V102, P481, DOI 10.1093/oxfordjournals.aje.a112186; YANO K, 1983, J CHRON DIS, V36, P569, DOI 10.1016/0021-9681(83)90145-5; 1987, DIAGNOSTIC STATISTIC; 1993, SAS STAT USERS GUIDE	43	700	729	1	38	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	DEC 20	1995	274	23					1846	1851		10.1001/jama.274.23.1846	http://dx.doi.org/10.1001/jama.274.23.1846			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	TK147	7500533				2022-12-28	WOS:A1995TK14700025
J	BEURSKENS, AJ; DEVET, HC; KOKE, AJ; LINDEMAN, E; REGTOP, W; VANDERHEIJDEN, GJ; KNIPSCHILD, PG				BEURSKENS, AJ; DEVET, HC; KOKE, AJ; LINDEMAN, E; REGTOP, W; VANDERHEIJDEN, GJ; KNIPSCHILD, PG			EFFICACY OF TRACTION FOR NONSPECIFIC LOW-BACK-PAIN - A RANDOMIZED CLINICAL-TRIAL	LANCET			English	Article							DISABILITY	Previous trials to assess the efficacy of lumbar traction for back pain have been methodologically flawed. To avoid these shortcomings, we conducted a randomised controlled trial in which high-dose traction was compared with sham traction. The sham traction was given with a specially developed brace that tightens in the back during traction. To the patient, the experience is that of traction. The patients and outcome assessor were blinded for the assigned treatment. 151 patients with at least six weeks of non-specific low back pain were randomised. Intention to treat analysis showed no differences between the groups on all outcome measures (patients' global perceived effect, severity of main complaints, functional status and pain); all 95% confidence intervals included the valve zero. The number of withdrawals from treatment, loss to follow-up, and protocol deviations was low. Consequently, the per-protocol analysis showed results similar to the intention to treat analysis. Subgroup analyses did not show any group for which traction might seem promising. Our data do not support the claim that traction is effective for patients with low back pain.	UNIV LIMBURG HOSP,DEPT PHYSIOTHERAPY,MAASTRICHT,NETHERLANDS; UNIV LIMBURG HOSP,DEPT REHABIL MED,MAASTRICHT,NETHERLANDS; HOGESCH HEERLEN,DEPT PHYSIOTHERAPY,HEERLEN,NETHERLANDS	Maastricht University; Maastricht University Medical Centre (MUMC); Maastricht University; Maastricht University Medical Centre (MUMC)	BEURSKENS, AJ (corresponding author), UNIV LIMBURG,DEPT EPIDEMIOL,POB 616,6200 MD MAASTRICHT,NETHERLANDS.			de Vet, Henrica/0000-0002-5454-2804				BECKERMAN H, 1993, BRIT J GEN PRACT, V43, P73; BEURSKENS AJHM, 1995, J MANIP PHYSIOL THER, V18, P141; BRIDGER RS, 1990, SPINE, V156, P522; COLACHIS SC, 1969, ARCH PHYS MED REHAB, V44, P251; DEYO RA, 1993, SPINE, V18, P2153, DOI 10.1097/00007632-199311000-00002; DEYO RA, 1983, SPINE, V11, P28; EIE N, 1962, J OSLO CITY HOSP, V12, P4; FRYMOYER JW, 1988, NEW ENGL J MED, V318, P291, DOI 10.1056/NEJM198802043180506; JUDOVICH B, 1957, AM J SURG, V93, P282; JUDOVICH BD, 1955, JAMA-J AM MED ASSOC, V1596, P549; KELSEY JL, 1980, SPINE, V5, P133, DOI 10.1097/00007632-198003000-00007; KIENLE GS, 1995, THESIS FREIEN U BERL; Mathews J A, 1972, Physiotherapy, V58, P64; MATHEWS JA, 1968, ANN PHYS MED, V97, P275; Norusis M.J., 1992, SPSS WINDOWS BASE SY; ONEL D, 1989, SPINE, V141, P82; ROLAND M, 1983, SPINE, V8, P141, DOI 10.1097/00007632-198303000-00004; SAUNDERS HD, 1983, CLIN ORTHOP RELAT R, V179, P31; Spitzer WO, 1987, SPINE, V12, P1, DOI DOI 10.1097/00007632-198701000-00001; SWEZEY RL, 1983, SEMIN ARTHRITIS RHEU, V12, P322, DOI 10.1016/0049-0172(83)90013-6; VANDERHEIJDEN GJM, 1995, PHYSIOTHERAPY, V81, P29; VANDERHEIJDEN GJMG, 1995, PHYS THER, V75, P93, DOI 10.1093/ptj/75.2.93; Yates D A, 1972, Physiotherapy, V58, P55	23	53	53	0	9	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	DEC 16	1995	346	8990					1596	1600		10.1016/S0140-6736(95)91930-9	http://dx.doi.org/10.1016/S0140-6736(95)91930-9			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TK481	7500752	Bronze			2022-12-28	WOS:A1995TK48100011
J	FARLEY, TMM; MEIRIK, O; CHANG, CL; MARMOT, MG; POULTER, NR				FARLEY, TMM; MEIRIK, O; CHANG, CL; MARMOT, MG; POULTER, NR			EFFECT OF DIFFERENT PROGESTAGENS IN LOW ESTROGEN ORAL-CONTRACEPTIVES ON VENOUS THROMBOEMBOLIC DISEASE	LANCET			English	Article							CARDIOVASCULAR-DISEASE; PROSTATE-CANCER; LEVONORGESTREL; VASECTOMY; STEROIDS; SAFETY	A multinational hospital-based case-control study of the risk of venous thromboembolic disease associated with combined oral contraceptives (OCs) done in 1989-93 prompted a separate inquiry comparing the risk of venous thromboembolism (VTE) associated with low oestrogen (<35 mu g ethinyloestradiol) OCs containing levonorgestrel with risks in low oestrogen preparations containing the third-generation progestagens desogestrel or gestodene. This analysis of data from 9 countries, involved 769 cases and 1979 age matched hospital centre, 246 community controls general practice. 137 cases and 203 controls were current users of levonorgestrel (odds ratio [OR with 95% confidence interval] 3.5 [2.6-4.7]), with non-users as the reference; 28 controls were current users of [4.9-17.0]), and 36 cases and 28 controls were current users of gestodene (9.1 [4.9-16.7]). The ratios of these risks, compared with levonorgestrel, were 2.6 (1.4-4.8) for both products separately, Risk estimates adjusted for body mass index (BMI) were 3.4, 7.3, and 10.2 for levonorgestrel, desogestrel, and gestodene, respectively, compared with non-users, and 2.2 and 3.0 for desogestrel and gestodene, respectively, compared with levonorgestrel. 48 (68%) cases and 48 (86%) controls exposed to desogestrel or gestodene were from the UK (Oxford region). In this centre risk estimates compared with non-users, adjusted for BMI were 2.6, 5.3, and 5.7 for levonorgestrel, desogestrel, and gestodene, respectively. Current users of low oestrogen dose combined OCs containing desogestrel or gestodene appear to be at higher risk of VTE than users of combined OCs containing levonorgestrel. The possibility that these unexpected results on a secondary study objective are due to chance, bias, or residual confounding cannot be excluded entirely and the results need to be confirmed by independent studies. They are at variance with the apparently more favourable metabolic effects of the newer progestagens. Whether the new progestagens are associated with lower risk of arterial disease (stroke and myocardial infarction) must be evaluated further.	WHO,SPECIAL PROGRAMME RES DEV & RES TRAINING HUMAN RE,WORLD BANK,CH-1211 GENEVA 27,SWITZERLAND	The World Bank; World Health Organization			Marmot, M G/Y-3920-2019	Marmot, M G/0000-0002-2431-6419				[Anonymous], 1995, LANCET, V346, P1575; BOTTIGER LE, 1980, LANCET, V1, P1097; BRESLOW NE, 1980, STATISTICAL METHODS; DARNEY PD, 1995, AM J MED, V98, pS104, DOI 10.1016/S0002-9343(99)80067-9; DIEBEN TOM, 1994, CONTRACEPTION, V50, P373, DOI 10.1016/0010-7824(94)90024-8; GERSTMAN BB, 1991, AM J EPIDEMIOL, V131, P32; GUESS HA, 1990, AM J EPIDEMIOL, V132, P1062, DOI 10.1093/oxfordjournals.aje.a115748; HELMRICH SP, 1987, OBSTET GYNECOL, V69, P91; HIRJI KF, 1988, BIOMETRICS, V44, P803, DOI 10.2307/2531592; INMAN WHW, 1970, BMJ-BRIT MED J, V2, P203, DOI 10.1136/bmj.2.5703.203; JONES EE, 1995, AM J MED, V98, pS116, DOI 10.1016/S0002-9343(99)80069-2; MALDONADO G, 1993, AM J EPIDEMIOL, V138, P923, DOI 10.1093/oxfordjournals.aje.a116813; MEADE TW, 1980, BRIT MED J, V280, P1157, DOI 10.1136/bmj.280.6224.1157; Newton JR, 1995, HUM REPROD UPDATE, V1, P231; NEWTON JR, 1994, OBSTET GYNECOL, V14, pS1; ROBINSON GE, 1994, BRIT J OBSTET GYNAEC, V101, P1036, DOI 10.1111/j.1471-0528.1994.tb13578.x; ROSENBERG L, 1990, AM J EPIDEMIOL, V132, P1051, DOI 10.1093/oxfordjournals.aje.a115746; Schlesselman JJ, 1982, CASE CONTROL STUDIES; SHAABAN MM, 1984, CONTRACEPTION, V30, P421, DOI 10.1016/0010-7824(84)90034-9; SHENFIELD GM, 1991, CLIN PHARMACOKINET, V20, P15, DOI 10.2165/00003088-199120010-00002; SINGH K, 1990, Advances in Contraception, V6, P23, DOI 10.1007/BF01849484; SPEROFF L, 1993, OBSTET GYNECOL, V81, P1034; STADEL BV, 1981, NEW ENGL J MED, V305, P612, DOI 10.1056/NEJM198109103051104; STADEL BV, 1981, NEW ENGL J MED, V305, P672, DOI 10.1056/NEJM198109173051205; STANCZYK FZ, 1990, CONTRACEPTION, V42, P67, DOI 10.1016/0010-7824(90)90093-B; STUBBLEFIELD PG, 1993, AM J OBSTET GYNECOL, V168, P1047, DOI 10.1016/0002-9378(93)90336-H; Thorogood M., 1993, PHARMACOEPIDEMIOL DR, V2, P3; VANDERVANGE N, 1988, CONT OBSTETRICS GYNA, P315; 1988, POPUL REP A, P1; IN PRESS J CLIN EPID; 1989, MORTALITY STATIS DH5, V16	31	462	468	0	9	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	DEC 16	1995	346	8990					1582	1588						7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TK481	7500749				2022-12-28	WOS:A1995TK48100008
J	WEISS, N				WEISS, N			3RD-GENERATION ORAL-CONTRACEPTIVES - HOW RISKY	LANCET			English	Editorial Material							VENOUS THROMBOEMBOLISM; PROGESTOGENS; ESTROGEN; DISEASE				WEISS, N (corresponding author), UNIV WASHINGTON,DEPT EPIDEMIOL,SEATTLE,WA 98195, USA.							GERSTMAN BB, 1990, INT J EPIDEMIOL, V19, P931, DOI 10.1093/ije/19.4.931; HELMRICH SP, 1987, OBSTET GYNECOL, V69, P91; KAY CR, 1982, AM J OBSTET GYNECOL, V142, P762; MEADE TW, 1980, BRIT MED J, V280, P1157, DOI 10.1136/bmj.280.6224.1157; SPEROFF L, 1993, OBSTET GYNECOL, V81, P1034; STADEL BV, 1981, NEW ENGL J MED, V305, P672, DOI 10.1056/NEJM198109173051205; VANDENBROUCKE JP, 1994, LANCET, V344, P1453, DOI 10.1016/S0140-6736(94)90286-0; VESSEY M, 1986, BRIT MED J, V292, P526, DOI 10.1136/bmj.292.6519.526	8	30	30	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	DEC 16	1995	346	8990					1570	1570		10.1016/S0140-6736(95)91921-X	http://dx.doi.org/10.1016/S0140-6736(95)91921-X			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TK481	7500743				2022-12-28	WOS:A1995TK48100002
J	MEISSNER, RS; REBEK, J; DEMENDOZA, J				MEISSNER, RS; REBEK, J; DEMENDOZA, J			AUTOENCAPSULATION THROUGH INTERMOLECULAR FORCES - A SYNTHETIC SELF-ASSEMBLING SPHERICAL COMPLEX	SCIENCE			English	Article								The synthesis and characterization of a system for the study of molecular recognition phenomena are described. The system involves a tetraurea molecule that is capable of assembly into various associated states through hydrogen bonding. In organic solvents, the dynamic transition between a low-ordered (aggregate) state and a highly ordered dimeric assembly can be induced by the introduction of smaller molecules of appropriate size and shape. These smaller molecules, such as benzene, adamantanes, and ferrocenes, act as guests that occupy the pseudospherical capsule formed by the dimeric host, Among various guests, those that best fill the cavity and offer chemical complementarity to the host are preferentially encapsulated.	MIT,DEPT CHEM,CAMBRIDGE,MA 02139; UNIV AUTONOMA MADRID,DEPT QUIM,E-28049 MADRID,SPAIN	Massachusetts Institute of Technology (MIT); Autonomous University of Madrid								[Anonymous], 1992, INTERMOLECULAR SURFA; BAXTER P, 1993, ANGEW CHEM INT EDIT, V32, P69, DOI 10.1002/anie.199300691; BEERLI R, 1995, TETRAHEDRON LETT, V36, P1813, DOI 10.1016/0040-4039(95)00150-B; BONARLAW RP, 1993, TETRAHEDRON LETT, V34, P1677, DOI 10.1016/0040-4039(93)85039-Y; BRANDA N, 1994, SCIENCE, V263, P1267, DOI 10.1126/science.8122107; CARPINO LA, 1963, J AM CHEM SOC, V85, P2144, DOI 10.1021/ja00897a024; CRAM DJ, 1992, NATURE, V356, P29, DOI 10.1038/356029a0; CRAM DJ, 1993, J AM CHEM SOC, V115, P10111, DOI 10.1021/ja00075a029; DUGAS H, 1989, BIOORG CHEM, P20; FUJITA M, 1995, J AM CHEM SOC, V117, P1649, DOI 10.1021/ja00110a026; GHADIRI MR, 1993, NATURE, V366, P324, DOI 10.1038/366324a0; GHADIRI MR, 1995, ANGEW CHEM INT EDIT, V34, P93, DOI 10.1002/anie.199500931; MATHIAS JP, 1994, J AM CHEM SOC, V116, P4326, DOI 10.1021/ja00089a022; MATTIAS JP, 1994, J AM CHEM SOC, V116, P1725; MOHAMADI F, 1990, J COMPUT CHEM, V11, P440, DOI 10.1002/jcc.540110405; SETO CT, 1991, J AM CHEM SOC, V113, P712, DOI 10.1021/ja00002a071; SIMARD M, 1991, J AM CHEM SOC, P4696; WYLER R, 1993, ANGEW CHEM INT EDIT, V32, P1699, DOI 10.1002/anie.199316991; YANG J, 1993, J AM CHEM SOC, V115, P5314, DOI 10.1021/ja00065a061	19	201	201	1	40	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	DEC 1	1995	270	5241					1485	1488		10.1126/science.270.5241.1485	http://dx.doi.org/10.1126/science.270.5241.1485			4	Multidisciplinary Sciences	Index Chemicus (IC); Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TH375	7491493				2022-12-28	WOS:A1995TH37500036
J	IMPALLOMENI, M; GALLETLY, NP; WORT, SJ; STARR, JM; ROGERS, TR				IMPALLOMENI, M; GALLETLY, NP; WORT, SJ; STARR, JM; ROGERS, TR			INCREASED RISK OF DIARRHEA CAUSED BY CLOSTRIDIUM-DIFFICILE IN ELDERLY PATIENTS RECEIVING CEFOTAXIME	BRITISH MEDICAL JOURNAL			English	Article									ROYAL POSTGRAD MED SCH,DEPT INFECT DIS & BACTERIOL,LONDON W12 0NN,ENGLAND	Imperial College London	IMPALLOMENI, M (corresponding author), HAMMERSMITH HOSP,ROYAL POSTGRAD MED SCH,DEPT MED,DIV GERIATR MED,LONDON W12 0HS,ENGLAND.		Starr, John/C-8951-2011	Rogers, Thomas/0000-0003-4336-7729				GOLLEDGE CL, 1989, J ANTIMICROB CHEMOTH, V23, P929, DOI 10.1093/jac/23.6.929; GREEN ST, 1985, ULSTER MED J, V54, P80; PEAR SM, 1994, ANN INTERN MED, V120, P272, DOI 10.7326/0003-4819-120-4-199402150-00003; 1994, CLOSTRIDIUM DIFFICIL; 1993, BR J HOSP MED, V49, P346	5	86	88	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	NOV 18	1995	311	7016					1345	1346		10.1136/bmj.311.7016.1345	http://dx.doi.org/10.1136/bmj.311.7016.1345			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TF901	7496287	Green Published			2022-12-28	WOS:A1995TF90100025
J	KLONOFFCOHEN, H; EDELSTEIN, SL				KLONOFFCOHEN, H; EDELSTEIN, SL			BED SHARING AND THE SUDDEN-INFANT-DEATH-SYNDROME	BMJ-BRITISH MEDICAL JOURNAL			English	Article							HONG-KONG; SLEEP	Objective-To determine whether infants who died of the sudden infant death syndrome routinely shared their parents' bed more commonly than control infants. Design-Case-control study. Setting-Southern California. Subjects-200 white, African-American, Latin American, and Asian infants who died and 200 living controls, matched by birth hospital, date of birth, sex, and race. Main outcome measures-Routine bedding (for example, crib, cradle), day and night time sleeping arrangement (for example, alone or sharing a bed); for cases only, sleeping arrangement at death. Differences in bed sharing practices among races. Results-Of the infants who died of the syndrome, 45 (22.4%) were sharing a bed. Daytime bed sharing was more common in African-American (P<0.001) and Latin American families (P < 0.001) than in white families. The overall adjusted odds ratio for the syndrome and routine bed sharing in the daytime was 1 38 (95% confidence interval 0.59 to 3.22) and for night was 1.21 (0.59 to 2.48). These odds ratios were adjusted for routine sleep position, passive smoking, breast feeding, intercom use, infant birth weight, medical conditions at birth, and maternal age and education. There was no interaction between bed sharing and passive smoking or alcohol use by either parent. Conclusions-Although there was a significant difference between bed sharing among African-American and Latin American parents compared with white parents, there was no significant relation between routine bed sharing and the sudden infant death syndrome.	GEORGE WASHINGTON UNIV, CTR BIOSTAT, ROCKVILLE, MD 20852 USA	George Washington University	KLONOFFCOHEN, H (corresponding author), UNIV CALIF SAN DIEGO, DEPT FAMILY & PREVENT MED, DIV EPIDEMIOL, LA JOLLA, CA 92037 USA.							BOURNE AJ, 1994, BRIT MED J, V308, P537, DOI 10.1136/bmj.308.6927.537c; CARPENTER RG, 1972, SUDDEN UNEXPECTED DE, P7; DAVIES DP, 1985, LANCET, V2, P1346; FAROOQI I, 1994, BMJ-BRIT MED J, V308, P204, DOI 10.1136/bmj.308.6922.204b; GUNTHEROTH WG, 1989, CRIB DEATH SUDDEN IN; HOPPENBROUWERS T, 1982, SLEEP, V5, P131; KONNER M, 1987, ROLE CLTURE DEV DISO; LEE NNY, 1989, BRIT MED J, V298, P721, DOI 10.1136/bmj.298.6675.721; LUKE JL, 1978, J FORENSIC SCI, V23, P379; MCKENNA JJ, 1993, ACTA PAEDIATR, V82, P31, DOI 10.1111/j.1651-2227.1993.tb12871.x; MCKENNA JJ, 1990, AM J PHYS ANTHROPOL, V83, P331, DOI 10.1002/ajpa.1330830307; MITCHELL EA, 1991, NEW ZEAL MED J, V104, P71; MITCHELL EA, 1993, SLEEP, V16, P387; MITCHELL EA, 1993, BMJ-BRIT MED J, V306, P13, DOI 10.1136/bmj.306.6869.13; Mitchell EA, 1992, J PAEDIAT CHILD HL S, V28, P3; MOSKO S, 1993, J BEHAV MED, V16, P589, DOI 10.1007/BF00844721; SCRAGG R, 1993, BMJ-BRIT MED J, V307, P1312, DOI 10.1136/bmj.307.6915.1312; TASAKI H, 1992, J PAEDIATRIC ASS JAP, P364; 1989, MONTHLY VITAL STATIS; 1990, SAS USERS GUIDE STAT; 1993, EGRET EPIDEMIOLOGICA	21	56	56	0	2	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	NOV 11	1995	311	7015					1269	1272		10.1136/bmj.311.7015.1269	http://dx.doi.org/10.1136/bmj.311.7015.1269			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TE859	7496236	Green Published			2022-12-28	WOS:A1995TE85900021
J	VUORI, K; RUOSLAHTI, E				VUORI, K; RUOSLAHTI, E			ASSOCIATION OF INSULIN-RECEPTOR SUBSTRATE-1 WITH INTEGRINS	SCIENCE			English	Article							EPIDERMAL GROWTH-FACTOR; CARCINOMA-CELLS; ADHESION RECEPTORS; VITRONECTIN; TYROSINE	Insulin stimulation was found to promote association of the alpha(v) beta(3) integrin (a vitronectin receptor) with insulin receptor substrate-1 (IRS-1), an intracellular protein that mediates insulin signaling by binding other signaling molecules, including growth factor receptor-bound protein 2 (Grb2) and phosphatidylinositol-3' kinase. Insulin-treated cells expressing the alpha(v) beta(3) integrin showed 2.5 times more DNA synthesis when plated on vitronectin than on other substrates, whereas cells expressing another vitronectin receptor, alpha(v) beta(5), did not show this difference. The association between integrin and IRS-1 may be a mechanism for the synergistic action of growth factor and extracellular matrix receptors.	LA JOLLA CANC RES FDN, CANC RES CTR, LA JOLLA, CA 92037 USA	Sanford Burnham Prebys Medical Discovery Institute					NATIONAL CANCER INSTITUTE [P01CA028896, P30CA030199, R35CA042507] Funding Source: NIH RePORTER; NCI NIH HHS [CA 28896, CA 30199, CA 42507] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BARTFELD NS, 1993, J BIOL CHEM, V268, P17270; BOCKUS BJ, 1984, EXP CELL RES, V153, P186, DOI 10.1016/0014-4827(84)90460-9; CHERESH DA, 1989, CELL, V57, P59, DOI 10.1016/0092-8674(89)90172-4; DEJANA E, 1988, J CELL BIOL, V107, P1215, DOI 10.1083/jcb.107.3.1215; FRISCH SM, 1994, J CELL BIOL, V124, P619, DOI 10.1083/jcb.124.4.619; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; JULIANO RL, 1993, J CELL BIOL, V120, P577, DOI 10.1083/jcb.120.3.577; KADOWAKI T, 1986, J BIOL CHEM, V261, P6141; Keller Susanne R., 1994, Trends in Cell Biology, V4, P115, DOI 10.1016/0962-8924(94)90065-5; LEAVESLEY DI, 1992, J CELL BIOL, V117, P1101, DOI 10.1083/jcb.117.5.1101; LILIEN LE, 1990, J CELL BIOL, V111, P635; MCCLAIN DA, 1987, J BIOL CHEM, V262, P14663; MEREDITH JE, 1993, MOL BIOL CELL, V4, P953, DOI 10.1091/mbc.4.9.953; PYTELA R, 1987, METHOD ENZYMOL, V144, P475; ROSE DW, 1994, P NATL ACAD SCI USA, V91, P797, DOI 10.1073/pnas.91.2.797; RUOSLAHTI E, 1991, J CLIN INVEST, V87, P1, DOI 10.1172/JCI114957; RUOSLAHTI E, 1994, CELL, V77, P477, DOI 10.1016/0092-8674(94)90209-7; RUOSLAHTI E, 1987, SCIENCE, V238, P491, DOI 10.1126/science.2821619; Schaller Michael D., 1993, Trends in Cell Biology, V3, P258, DOI 10.1016/0962-8924(93)90053-4; SCHLESSINGER J, 1981, EXP CELL RES, V134, P273, DOI 10.1016/0014-4827(81)90426-2; SCHUBERT D, 1991, J CELL BIOL, V114, P841, DOI 10.1083/jcb.114.4.841; STOKER M, 1968, INT J CANCER, V3, P683, DOI 10.1002/ijc.2910030517; STRACKE ML, 1988, BIOCHEM BIOPH RES CO, V153, P1076, DOI 10.1016/S0006-291X(88)81338-X; VUORI K, UNPUB; WAYNER EA, 1991, J CELL BIOL, V113, P919, DOI 10.1083/jcb.113.4.919; WHITE MF, 1994, J BIOL CHEM, V269, P1	26	344	348	0	12	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	DEC 2	1994	266	5190					1576	1578		10.1126/science.7527156	http://dx.doi.org/10.1126/science.7527156			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PV015	7527156				2022-12-28	WOS:A1994PV01500048
J	PALLER, AS; SYDER, AJ; CHAN, YM; HUTTON, E; TADINI, G; FUCHS, E; YU, QC				PALLER, AS; SYDER, AJ; CHAN, YM; HUTTON, E; TADINI, G; FUCHS, E; YU, QC			GENETIC AND CLINICAL MOSAICISM IN A TYPE OF EPIDERMAL NEVUS	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							EPIDERMOLYSIS-BULLOSA SIMPLEX; KERATIN EXPRESSION; POINT MUTATIONS; ALPHA-SUBUNIT; HYPERKERATOSIS; SKIN; MICE; DIFFERENTIATION; ABNORMALITIES; ERYTHRODERMA	Background. Many skin disorders are characterized by a mosaic pattern, often with alternating stripes of affected and unaffected skin that follow the lines of Blaschko. These nonrandom patterns may be caused by a postzygotic mutation during embryogenesis. We studied the genetic basis of one such disorder, epidermal nevus of the epidermolytic hyperkeratotic type. Epidermolytic hyperkeratosis is an autosomal dominant blistering skin disease arising from mutations in the genes for keratin (K) 1 and 10. The offspring of patients with epidermal nevi may have generalized epidermolytic hyperkeratosis. Methods. We studied the K1 and K10 genes in blood and in the keratinocytes and fibroblasts of lesional and nonlesional skin from three patients with epidermal nevi and four of their offspring with epidermolytic hyperkeratosis. Results. In the patients with epidermal nevi, point mutations in 50 percent of the K10 alleles of epidermal cells were found in keratinocytes from lesional skin; no mutations were detected in normal skin. This mutation was-absent or underrepresented in blood and skin fibroblasts. In the offspring with epidermolytic hyperkeratosis, the same mutations as those in the parents were found in 50 percent of the K10 alleles from all cell types examined. Conclusions. Epidermal nevus of the epidermolytic hyperkeratotic type is a mosaic genetic disorder of suprabasal keratin. The correlation of mutations in the K10 gene with lesional skin and the correlation of the normal gene with normal skin provide evidence that genetic mosaicism can cause clinical mosaicism.	NORTHWESTERN UNIV, SCH MED, DEPT PEDIAT, CHICAGO, IL 60611 USA; NORTHWESTERN UNIV, SCH MED, DEPT DERMATOL, CHICAGO, IL 60611 USA; UNIV CHICAGO, HOWARD HUGHES MED INST, DEPT MOLEC GENET & CELL BIOL, CHICAGO, IL 60637 USA; UNIV MILAN, DEPT DERMATOL, MILAN, ITALY	Northwestern University; Northwestern University; Howard Hughes Medical Institute; University of Chicago; University of Milan			Fuchs, Elaine/G-1565-2016	Paller, Amy/0000-0001-6187-6549	NIAMS NIH HHS [AR01811, R01-AR27883] Funding Source: Medline; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR027883, K08AR001811] Funding Source: NIH RePORTER	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		ALBERS K, 1989, J CELL BIOL, V108, P1477, DOI 10.1083/jcb.108.4.1477; ANTONLAMPRECHT I, 1983, J INVEST DERMATOL, V81, pS149, DOI 10.1111/1523-1747.ep12540961; BARKER LP, 1953, AMA ARCH DERM SYPH, V67, P443, DOI 10.1001/archderm.1953.01540050007002; BLASCHKO A, 1901, VERHANDLUNGEN DTSCH; BONAFE JL, 1987, ANN DERMATOL VENER, V114, P916; BONIFAS JM, 1991, SCIENCE, V254, P1202, DOI 10.1126/science.1720261; CHENG J, 1992, CELL, V70, P811, DOI 10.1016/0092-8674(92)90314-3; CHIPEV CC, 1994, AM J HUM GENET, V54, P179; CHIPEV CC, 1992, CELL, V70, P821, DOI 10.1016/0092-8674(92)90315-4; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; COMPTON JG, 1992, NAT GENET, V1, P301, DOI 10.1038/ng0792-301; COULOMBE PA, 1990, J CELL BIOL, V111, P3049, DOI 10.1083/jcb.111.6.3049; COULOMBE PA, 1991, CELL, V66, P1301, DOI 10.1016/0092-8674(91)90051-Y; FUCHS E, 1994, J CELL BIOL, V125, P511, DOI 10.1083/jcb.125.3.511; FUCHS E, 1992, CELL, V69, P899, DOI 10.1016/0092-8674(92)90607-E; FUCHS E, 1992, P NATL ACAD SCI USA, V89, P6906, DOI 10.1073/pnas.89.15.6906; HAPPLE R, 1990, HAUTARZT, V41, P117; HAPPLE R, 1993, ARCH DERMATOL, V129, P1460, DOI 10.1001/archderm.129.11.1460; HAPPLE R, 1985, HUM GENET, V70, P200; LANE EB, 1992, NATURE, V356, P244, DOI 10.1038/356244a0; LETAI A, 1993, P NATL ACAD SCI USA, V90, P3197, DOI 10.1073/pnas.90.8.3197; LORETTE G, 1984, ANN DERMATOL VENER, V111, P858; MALCHOFF CD, 1994, J CLIN ENDOCR METAB, V78, P803, DOI 10.1210/jc.78.3.803; MCLEAN WHI, 1994, J INVEST DERMATOL, V102, P24, DOI 10.1111/1523-1747.ep12371726; NAZZARO V, 1990, BRIT J DERMATOL, V122, P417, DOI 10.1111/j.1365-2133.1990.tb08292.x; RHEINWALD JG, 1975, CELL, V6, P331, DOI 10.1016/S0092-8674(75)80001-8; RIEGER E, 1994, BRIT J DERMATOL, V130, P215, DOI 10.1111/j.1365-2133.1994.tb02903.x; ROTHNAGEL JA, 1993, HUM MOL GENET, V2, P2147, DOI 10.1093/hmg/2.12.2147; ROTHNAGEL JA, 1992, SCIENCE, V257, P1128, DOI 10.1126/science.257.5073.1128; ROTHNAGEL JA, 1994, J INVEST DERMATOL, V102, P13, DOI 10.1111/1523-1747.ep12371723; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHWINDINGER WF, 1992, P NATL ACAD SCI USA, V89, P5152, DOI 10.1073/pnas.89.11.5152; STOLER A, 1988, J CELL BIOL, V107, P427, DOI 10.1083/jcb.107.2.427; SYDER AJ, 1994, J CLIN INVEST, V93, P1533, DOI 10.1172/JCI117132; VASSAR R, 1991, CELL, V64, P365, DOI 10.1016/0092-8674(91)90645-F; WEINSTEIN LS, 1990, P NATL ACAD SCI USA, V87, P8287, DOI 10.1073/pnas.87.21.8287; YANG JM, 1994, J INVEST DERMATOL, V102, P17, DOI 10.1111/1523-1747.ep12371725; [No title captured]	38	208	213	0	4	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	NOV 24	1994	331	21					1408	1415		10.1056/NEJM199411243312103	http://dx.doi.org/10.1056/NEJM199411243312103			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PU533	7526210	Bronze			2022-12-28	WOS:A1994PU53300003
J	SHORES, EW; HUANG, K; TRAN, T; LEE, E; GRINBERG, A; LOVE, PE				SHORES, EW; HUANG, K; TRAN, T; LEE, E; GRINBERG, A; LOVE, PE			ROLE OF TCR ZETA-CHAIN IN T-CELL DEVELOPMENT AND SELECTION	SCIENCE			English	Article							ANTIGEN RECEPTOR; TRANSGENIC MICE; ACTIVATION; EXPRESSION; COMPLEX; THYMOCYTES; LACKING; DOMAIN; RAG-1; TAIL	Signals mediated by the T cell receptor (TCR) are required for thymocyte maturation and selection. To examine the role of TCR zeta chain signals in development, TCR expression was restored in zeta-deficient mice with transgenic zeta chains that partially or completely lacked sequences required for signal transduction. The zeta chain played a role in thymic development by promoting TCR surface expression, but zeta-mediated signals were not essential because TCRs that contained signaling-deficient zeta chains promoted T cell maturation and transduced signals associated with thymic selection.	NICHHD, MAMMALIAN GENES & DEV LAB, BETHESDA, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)	SHORES, EW (corresponding author), US FDA, CTR BIOL, DIV HEMATOL PROD, BETHESDA, MD 20892 USA.							BORGULYA P, 1992, CELL, V69, P529, DOI 10.1016/0092-8674(92)90453-J; BRANDLE D, 1994, EUR J IMMUNOL, V24, P145, DOI 10.1002/eji.1830240122; BRANDLE D, 1992, P NATL ACAD SCI USA, V89, P9529, DOI 10.1073/pnas.89.20.9529; CLEVERS H, 1988, ANNU REV IMMUNOL, V6, P629, DOI 10.1146/annurev.iy.06.040188.003213; EXLEY M, 1994, J BIOL CHEM, V269, P15140; FOWLKES BJ, 1989, ADV IMMUNOL, V44, P207; FRANK SJ, 1990, SCIENCE, V249, P174, DOI 10.1126/science.2371564; GREAVES DR, 1989, CELL, V56, P979, DOI 10.1016/0092-8674(89)90631-4; IRVING BA, 1991, CELL, V64, P891, DOI 10.1016/0092-8674(91)90314-O; IRVING BA, 1993, J EXP MED, V177, P1093, DOI 10.1084/jem.177.4.1093; KLAUSNER RD, 1990, ANNU REV CELL BIOL, V6, P403, DOI 10.1146/annurev.cb.06.110190.002155; LETOURNEUR F, 1992, SCIENCE, V255, P79, DOI 10.1126/science.1532456; LIU CP, 1993, EMBO J, V12, P4863, DOI 10.1002/j.1460-2075.1993.tb06176.x; LOVE PE, 1994, J EXP MED, V179, P1485, DOI 10.1084/jem.179.5.1485; LOVE PE, 1993, SCIENCE, V261, P918, DOI 10.1126/science.7688481; MALISSEN M, 1993, EMBO J, V12, P4347, DOI 10.1002/j.1460-2075.1993.tb06119.x; NAKAYAMA T, 1989, NATURE, V341, P651, DOI 10.1038/341651a0; OHNO H, 1993, EMBO J, V12, P4357, DOI 10.1002/j.1460-2075.1993.tb06120.x; ORLOFF DG, 1990, NATURE, V347, P189, DOI 10.1038/347189a0; RETH M, 1989, NATURE, V338, P383, DOI 10.1038/338383b0; ROMEO C, 1992, CELL, V68, P889, DOI 10.1016/0092-8674(92)90032-8; SAMELSON LE, 1992, J BIOL CHEM, V267, P24913; SHA WC, 1988, NATURE, V336, P73, DOI 10.1038/336073a0; SHORES EW, UNPUB; SWAT W, 1993, EUR J IMMUNOL, V23, P739, DOI 10.1002/eji.1830230326; TEH HS, 1988, NATURE, V335, P229, DOI 10.1038/335229a0; TESTI R, 1989, J IMMUNOL, V143, P1123; THOMPSON JA, 1987, BIOCHEMISTRY-US, V26, P743, DOI 10.1021/bi00377a014; TURKA LA, 1991, SCIENCE, V253, P778, DOI 10.1126/science.1831564; UNKELESS JC, 1979, J EXP MED, V150, P580, DOI 10.1084/jem.150.3.580; VONBOEHMER H, 1994, CELL, V76, P219, DOI 10.1016/0092-8674(94)90330-1; WEGENER AMK, 1992, CELL, V68, P83, DOI 10.1016/0092-8674(92)90208-T; WEISS A, 1994, CELL, V76, P263, DOI 10.1016/0092-8674(94)90334-4	33	129	130	0	3	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	NOV 11	1994	266	5187					1047	1050		10.1126/science.7526464	http://dx.doi.org/10.1126/science.7526464			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PQ924	7526464				2022-12-28	WOS:A1994PQ92400046
J	BUSUTTIL, RW; MCDIARMID, S; KLINTMALM, GB; GOLDSTEIN, R; MILLER, CM; SCHWARTZ, M; SHAW, BW; ROBERTS, JP; HEBERT, MF; ESQUIVEL, CO; NAKAZATO, P; WIESNER, RH; KROM, RAF; KALAYOGLU, M; DALESSANDRO, AM; MARSH, JW; PETERS, MG; BURDICK, J; KLEIN, A; LEWIS, WD; JENKINS, R; THISTLETHWAITE, JR; EMOND, JC; JUSKO, WJ; DAMBROSIO, R; BUELL, D; FITZSIMMONS, WE				BUSUTTIL, RW; MCDIARMID, S; KLINTMALM, GB; GOLDSTEIN, R; MILLER, CM; SCHWARTZ, M; SHAW, BW; ROBERTS, JP; HEBERT, MF; ESQUIVEL, CO; NAKAZATO, P; WIESNER, RH; KROM, RAF; KALAYOGLU, M; DALESSANDRO, AM; MARSH, JW; PETERS, MG; BURDICK, J; KLEIN, A; LEWIS, WD; JENKINS, R; THISTLETHWAITE, JR; EMOND, JC; JUSKO, WJ; DAMBROSIO, R; BUELL, D; FITZSIMMONS, WE			A COMPARISON OF TACROLIMUS (FK-506) AND CYCLOSPORINE FOR IMMUNOSUPPRESSION IN LIVER-TRANSPLANTATION	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							FK-506 IMMUNOSUPPRESSION; RESCUE IMMUNOSUPPRESSION; CARDIAC TRANSPLANTATION; ALLOGRAFT SURVIVAL; CLINICAL-TRIAL; FK506; STREPTOMYCES; EXPERIENCE; INVITRO; RATS	Background. Tacrolimus (FK 506), a macrolide compound isolated from a bacterium, is a potent immunosuppressant with activity in solid-organ transplants. Most immunosuppressive regimens for liver transplantation are based on cyclosporine. Methods. We conducted an open-label, randomized, multicenter trial to compare the efficacy and safety of tacrolimus-based and cyclosporine-based immunosuppressive regimens for patients receiving a first liver transplant. A total of 478 adults and 51 children (less than or equal to 12 years of age) were randomly assigned at the time of transplantation to receive tacrolimus (n = 263) or cyclosporine (n = 266) and were followed for one year. The primary end points were patient and graft survival at one year. The secondary end points were the incidence of acute rejection, corticosteroid-resistant rejection, and refractory rejection (continued rejection after two courses of corticosteroids and an intervening course of muromonab-CD3). Results. According to Kaplan-Meier analysis, actuarial patient-survival rates at day 360 were 88 percent for both the tacrolimus and cyclosporine groups (P = 0.85; 95 percent confidence interval for the difference, -5.4 to 6.6 percent), and graft-survival rates were 82 percent and 79 percent, respectively (P = 0.55; 95 percent confidence interval for the difference, -4.8 to 9.7 percent). Acute rejection occurred in 154 patients in the tacrolimus group and 173 patients in the cyclosporine group (P<0.002), corticosteroid-resistant rejection occurred in 43 and 82 patients, respectively (P<0.001), and refractory rejection occurred in 6 and 32 patients, respectively (P<0.001). Tacrolimus was associated with a higher incidence of adverse events requiring withdrawal from the study, primarily nephrotoxicity and neurotoxicity; 37 patients in the tacrolimus group and 13 in the cyclosporine group discontinued the study because of adverse events (P<0.001). Conclusions. After one year, immunosuppressive regimens based on tacrolimus and cyclosporine were comparable in terms of patient and graft survival. Tacrolimus was associated with significantly fewer episodes of acute, corticosteroid-resistant, or refractory rejection, but substantially more adverse events requiring discontinuation of the drug.	BAYLOR UNIV, MED CTR, DALLAS, TX 75246 USA; UNIV CALIF LOS ANGELES, LOS ANGELES, CA USA; MT SINAI MED CTR, NEW YORK, NY 10029 USA; UNIV NEBRASKA, OMAHA, NE 68182 USA; UNIV CALIF SAN FRANCISCO, SAN FRANCISCO, CA USA; CALIF PACIFIC MED CTR, SAN FRANCISCO, CA USA; MAYO CLIN & MAYO FDN, ROCHESTER, MN 55905 USA; UNIV WISCONSIN, MADISON, WI USA; WASHINGTON UNIV, SCH MED, ST LOUIS, MO USA; JOHNS HOPKINS UNIV HOSP, BALTIMORE, MD USA; NEW ENGLAND DEACONESS HOSP, BOSTON, MA USA; UNIV CHICAGO, CHICAGO, IL 60637 USA; SUNY COLL BUFFALO, BUFFALO, NY USA; FUJISAWA USA, DEERFIELD, IL USA	Baylor University; Baylor University Medical Center; University of California System; University of California Los Angeles; Icahn School of Medicine at Mount Sinai; University of Nebraska System; University of California System; University of California San Francisco; California Pacific Medical Center; Mayo Clinic; University of Wisconsin System; University of Wisconsin Madison; Washington University (WUSTL); Johns Hopkins University; Johns Hopkins Medicine; University of Chicago; State University of New York (SUNY) System; Buffalo State College			Jusko, William J/G-4885-2015; Marsh, Wallis/C-6796-2013	Marsh, Wallis/0000-0002-8143-9511				[Anonymous], 1994, Lancet, V344, P423; ARMITAGE JM, 1991, TRANSPLANT P, V23, P3058; ARMITAGE JM, 1991, TRANSPLANT P, V23, P3054; CHENWOAN M, 1991, TRANSPLANT P, V23, P2941; Conover W. J., 1980, PRACTICAL NONPARAMET, P278; FUNG J, 1991, TRANSPLANT P, V23, P2977; FUNG JJ, 1990, TRANSPLANT P, V22, P6; FUNG JJ, 1991, TRANSPLANT P, V23, P3105; GORDON RD, 1991, TRANSPLANT P, V23, P1393; GOTO T, 1991, TRANSPL P, V23, P2713; ISAI H, 1990, TRANSPLANT P, V22, P2125; JENSEN CWB, 1991, TRANSPLANT P, V23, P3075; JIANG H, 1991, TRANSPLANT P, V23, P540; JIANG H, 1991, TRANSPLANT P, V23, P2933; JUSKO WJ, 1991, TRANSPLANT P, V23, P2732; KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868; KAWAUCHI M, 1991, TRANSPLANT P, V23, P2970; KINO T, 1987, J ANTIBIOT, V40, P1256, DOI 10.7164/antibiotics.40.1256; KINO T, 1987, J ANTIBIOT, V40, P1249, DOI 10.7164/antibiotics.40.1249; MCCAULEY J, 1991, TRANSPLANT P, V23, P3143; MYERS BD, 1986, KIDNEY INT, V30, P964, DOI 10.1038/ki.1986.280; OCHIAI T, 1987, TRANSPLANTATION, V44, P729, DOI 10.1097/00007890-198712000-00001; OCHIAI T, 1987, TRANSPLANT P, V19, P1284; OCHIAI T, 1987, TRANSPLANT P, V19, P53; POWELLJACKSON P, 1987, LIVER TRANSPLANT, P253; ROLLES K, 1989, ORGAN TRANSPLANTATIO, P201; SHAPIRO R, 1991, TRANSPLANT P, V23, P3065; SIGAL NH, 1991, TRANSPLANT P, V23, P1; STARZL TE, 1984, HEPATOLOGY, V4, pS47, DOI 10.1002/hep.1840040714; STARZL TE, 1989, NEW ENGL J MED, V321, P1014, DOI 10.1056/NEJM198910123211505; STARZL TE, 1989, NEW ENGL J MED, V321, P1092, DOI 10.1056/NEJM198910193211606; STARZL TE, 1986, HEPATIC TRANSPLANTAT, P3; TAKAYA S, 1991, TRANSPLANT P, V23, P3026; TAUXE WN, 1991, TRANSPLANT P, V23, P3146; TSUCHIMOTO S, 1989, TRANSPLANT P, V21, P1064; TZAKIS AG, 1991, TRANSPL P, V23, P3010; UEMOTO S, 1991, TRANSPLANT P, V23, P3007; VENKATARAMANAN R, 1991, TRANSPLANT P, V23, P931; WHITE DJG, 1987, LIVER TRANSPLANT, P305; YAMAGUCHI Y, 1991, TRANSPLANT P, V23, P3111; 1993, UNOS UPDATE, V9, P9	41	703	707	2	26	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	OCT 27	1994	331	17					1110	1115						6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PN065	7523946				2022-12-28	WOS:A1994PN06500002
J	CHENG, HJ; FLANAGAN, JG				CHENG, HJ; FLANAGAN, JG			IDENTIFICATION AND CLONING OF ELF-1, A DEVELOPMENTALLY EXPRESSED LIGAND FOR THE MEK4 AND SEK RECEPTOR TYROSINE KINASES	CELL			English	Article							GROWTH-FACTOR; KIT LIGAND; W-LOCUS; PROTO-ONCOGENE; SI-LOCUS; MOUSE; ENCODES; GENE; TRANSMEMBRANE; MUTANT	Mek4 and Sek are tyrosine kinases with expression patterns in the mouse embryo that suggest important functions in early development. However, like all Eph family kinases, both were identified as orphan receptors without known ligands. We show that Mek4 and Sek soluble receptor-alkaline phosphatase fusion proteins can be used in a procedure termed RAP in situ to identify regions of ligand expression in the mouse embryo. Based on this spatial information, a cDNA expression library was prepared, and was screened with the fusion proteins to identify Eph ligand family-1 (ELF-1). In cell lines and embryos, ELF-1 is membrane bound by a phosphatidylinositol tail, a feature that may account for unique biological functions. Its sequence is homologous with B61, a ligand for the Eck kinase, defining a family of related ligands. The expression domains of ELF-1, Mek4 and Sek indicate potential roles in embryonic patterning.			CHENG, HJ (corresponding author), HARVARD UNIV,SCH MED,DEPT CELL BIOL,BOSTON,MA 02115, USA.		Cheng, Hwai-Jong/AAY-5067-2021; Flanagan, John/AAM-2995-2020	Cheng, Hwai-Jong/0000-0003-0647-0567; 	NICHD NIH HHS [HD29417] Funding Source: Medline; NIDDK NIH HHS [DK45580] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD029417, R37HD029417] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK045580] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AMAYA E, 1991, CELL, V66, P257, DOI 10.1016/0092-8674(91)90616-7; ANDRES AC, 1994, ONCOGENE, V9, P1461; ARUFFO A, 1990, CELL, V61, P1303, DOI 10.1016/0092-8674(90)90694-A; BARTLEY TD, 1994, NATURE, V368, P558, DOI 10.1038/368558a0; BECKER N, 1994, MECH DEVELOP, V47, P3, DOI 10.1016/0925-4773(94)90091-4; BERNFIELD M, 1992, ANNU REV CELL BIOL, V8, P365, DOI 10.1146/annurev.cb.08.110192.002053; BRANNAN CI, 1991, P NATL ACAD SCI USA, V88, P4671, DOI 10.1073/pnas.88.11.4671; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; CHABOT B, 1988, NATURE, V335, P88, DOI 10.1038/335088a0; COPELAND NG, 1990, CELL, V63, P175, DOI 10.1016/0092-8674(90)90298-S; FANTL WJ, 1993, ANNU REV BIOCHEM, V62, P453, DOI 10.1146/annurev.bi.62.070193.002321; FERGUSON MAJ, 1988, ANNU REV BIOCHEM, V57, P285; FLANAGAN JG, 1991, CELL, V64, P1025, DOI 10.1016/0092-8674(91)90326-T; FLANAGAN JG, 1990, CELL, V63, P185, DOI 10.1016/0092-8674(90)90299-T; GEISSLER EN, 1988, CELL, V55, P185, DOI 10.1016/0092-8674(88)90020-7; GILARDIHEBENSTREIT P, 1992, ONCOGENE, V7, P2499; HENKEMEYER M, 1994, ONCOGENE, V9, P1001; HOLZMAN LB, 1990, MOL CELL BIOL, V10, P5830, DOI 10.1128/MCB.10.11.5830; HUANG E, 1990, CELL, V63, P225, DOI 10.1016/0092-8674(90)90303-V; JESSELL TM, 1992, CELL, V68, P257, DOI 10.1016/0092-8674(92)90469-S; KRUMLAUF R, 1993, TRENDS GENET, V9, P106, DOI 10.1016/0168-9525(93)90203-T; LYMAN SD, 1993, CELL, V75, P1157, DOI 10.1016/0092-8674(93)90325-K; MAISONPIERRE PC, 1993, ONCOGENE, V8, P3277; MASSAGUE J, 1993, ANNU REV BIOCHEM, V62, P515, DOI 10.1146/annurev.bi.62.070193.002503; NIETO MA, 1992, DEVELOPMENT, V116, P1137; RUIZ JC, 1994, MECH DEVELOP, V46, P87; SAJJADI FG, 1991, NEW BIOL, V3, P769; SCHLESSINGER J, 1992, NEURON, V9, P383, DOI 10.1016/0896-6273(92)90177-F; SHILO BZ, 1992, FASEB J, V6, P2915, DOI 10.1096/fasebj.6.11.1322852; SNIDER WD, 1994, CELL, V77, P627, DOI 10.1016/0092-8674(94)90048-5; TABIN CJ, 1991, CELL, V66, P199, DOI 10.1016/0092-8674(91)90612-3; TUZI NL, 1994, BRIT J CANCER, V69, P417, DOI 10.1038/bjc.1994.77; WICKS IP, 1992, P NATL ACAD SCI USA, V89, P1611, DOI 10.1073/pnas.89.5.1611; WILKINSON DG, 1992, IN SITU HYBRIDIZATIO, P75; XU QL, 1994, DEVELOPMENT, V120, P287; ZHOU R, 1994, J NEUROSCI RES, V37, P129, DOI 10.1002/jnr.490370117; ZIPURSKY SL, 1992, COLD SPRING HARB SYM, V57, P381, DOI 10.1101/SQB.1992.057.01.043; ZSEBO KM, 1990, CELL, V63, P213, DOI 10.1016/0092-8674(90)90302-U	38	254	278	0	6	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	OCT 7	1994	79	1					157	168		10.1016/0092-8674(94)90408-1	http://dx.doi.org/10.1016/0092-8674(94)90408-1			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	PK585	7522971				2022-12-28	WOS:A1994PK58500016
J	WILLBOLD, D; ROSINARBESFELD, R; STICHT, H; FRANK, R; ROSCH, P				WILLBOLD, D; ROSINARBESFELD, R; STICHT, H; FRANK, R; ROSCH, P			STRUCTURE OF THE EQUINE INFECTIOUS-ANEMIA VIRUS TAT PROTEIN	SCIENCE			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; TRANSACTIVATION RESPONSE RNA; HIV-1 TAT; CIRCULAR-DICHROISM; LENTIVIRUS TAT; SEQUENCE; PEPTIDES; BINDING; REGION; RECOGNITION	Trans-activator (Tat) proteins regulate the transcription of lentiviral DNA in the host cell genome. These RNA binding proteins participate in the life cycle of all known lentiviruses, such as the human immunodeficiency viruses (HIV) or the equine infectious anemia virus (EIAV). The consensus RNA binding motifs [the trans-activation responsive element (TAR)] of HIV-1 as well as EIAV Tat proteins are well characterized. The structure of the 75-amino acid EIAV Tat protein in solution was determined by two- and three-dimensional nuclear magnetic resonance methods and molecular dynamics calculations. The protein structure exhibits a well-defined hydrophobic core of 15 amino acids that serves as a scaffold for two flexible domains corresponding to the NH2- and COOH-terminal regions. The core region is a strictly conserved sequence region among the known Tat proteins. The structural data can be used to explain several of the observed features of Tat proteins.	UNIV BAYREUTH,LEHRSTUHL BIOPOLYMERE,D-95440 BAYREUTH,GERMANY; UNIV BAYREUTH,BAYREUTHER INST MAKROMOLEK FORSCH,D-95440 BAYREUTH,GERMANY; TEL AVIV UNIV,SACKLER FAC MED,DEPT HUMAN MICROBIOL,IL-69978 TEL AVIV,ISRAEL; ZENTRUM MOLEK BIOL HEIDELBERG,D-69120 HEIDELBERG,GERMANY	University of Bayreuth; University of Bayreuth; Tel Aviv University; Sackler Faculty of Medicine; Ruprecht Karls University Heidelberg			Willbold, Dieter/A-6280-2013; Rösch, Paul/I-5445-2014	Willbold, Dieter/0000-0002-0065-7366; Rösch, Paul/0000-0003-3330-2446; Sticht, Heinrich/0000-0001-5644-045X				BRUNGER AT, 1993, X PLOR 3 1; CALNAN BJ, 1991, GENE DEV, V5, P201, DOI 10.1101/gad.5.2.201; CARROLL R, 1991, J VIROL, V65, P3460, DOI 10.1128/JVI.65.7.3460-3467.1991; CARROLL R, 1992, J VIROL, V66, P2000, DOI 10.1128/JVI.66.4.2000-2007.1992; CHURCHER MJ, 1993, J MOL BIOL, V230, P90, DOI 10.1006/jmbi.1993.1128; CORDINGLEY MG, 1990, P NATL ACAD SCI USA, V87, P8985, DOI 10.1073/pnas.87.22.8985; DERSE D, 1991, J VIROL, V65, P7012, DOI 10.1128/JVI.65.12.7012-7015.1991; DERSE D, 1992, VIROLOGY, V194, P530; DORN P, 1990, J VIROL, V64, P1616, DOI 10.1128/JVI.64.4.1616-1624.1990; GAIT MJ, 1993, TRENDS BIOCHEM SCI, V18, P255, DOI 10.1016/0968-0004(93)90176-N; HERRMANN F, UNPUB; HIGGINS DG, 1992, COMPUT APPL BIOSCI, V8, P189; HOFFMAN DW, 1993, BIOCHEMISTRY-US, V32, P1096, DOI 10.1021/bi00055a015; KASHANSHI F, 1993, NATURE, V267, P295; LAUGHON A, 1991, BIOCHEMISTRY-US, V30, P11357, DOI 10.1021/bi00112a001; LORET EP, 1991, BIOCHEMISTRY-US, V30, P6013, DOI 10.1021/bi00238a027; LORET EP, 1992, P NATL ACAD SCI USA, V89, P9734, DOI 10.1073/pnas.89.20.9734; NOIMAN S, 1991, VIROLOGY, V184, P521, DOI 10.1016/0042-6822(91)90422-8; PATAK D, 1992, CURR OPIN STRUCT BIO, V2, P115; PUGLISI JD, 1992, SCIENCE, V257, P76, DOI 10.1126/science.1621097; RAINER L, 1985, NATURE, V313, P277; RICE AP, 1990, J VIROL, V64, P6018, DOI 10.1128/JVI.64.12.6018-6026.1990; SLICE LW, 1992, BIOCHEMISTRY-US, V31, P12062, DOI 10.1021/bi00163a014; SPIRE B, 1989, GENE, V81, P275, DOI 10.1016/0378-1119(89)90188-1; STICHT H, 1993, EUR J BIOCHEM, V218, P973, DOI 10.1111/j.1432-1033.1993.tb18455.x; WEEKS KM, 1991, CELL, V66, P577, DOI 10.1016/0092-8674(81)90020-9; WEEKS KM, 1990, SCIENCE, V249, P1281, DOI 10.1126/science.2205002; WILLBOLD D, 1993, BIOCHEMISTRY-US, V32, P8439, DOI 10.1021/bi00084a008; Wuthrich K., 1986, NMR PROTEINS NUCL AC	29	44	45	0	4	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUN 10	1994	264	5165					1584	1587		10.1126/science.7515512	http://dx.doi.org/10.1126/science.7515512			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	NQ285	7515512				2022-12-28	WOS:A1994NQ28500034
J	LIEBERMAN, DN; MODY, I				LIEBERMAN, DN; MODY, I			REGULATION OF NMDA CHANNEL FUNCTION BY ENDOGENOUS CA2+-DEPENDENT PHOSPHATASE	NATURE			English	Article							D-ASPARTATE RECEPTORS; OKADAIC ACID; PROTEIN PHOSPHATASE; CENTRAL NEURONS; RAT-BRAIN; CALCINEURIN; ACTIVATION; GLUTAMATE; DEPHOSPHORYLATION; HIPPOCAMPUS	PROTEIN kinases modulate the activity of several ligand-gated ion channels(1), including the NMDA (N-methyl-D-aspartate)(2) subtype of glutamate receptor. Although phosphorylation and dephosphorylation of glutamate receptors may participate in several lasting physiological and pathological alterations of neuronal excitability(3-7), the physiological control of this cycle for NMDA channels has not yet been established. Using cell-attached recordings in acutely dissociated adult rat dentate gyrus granule cells, we now demonstrate that inhibitors of an endogenous serine/threonine phosphatase prolong the duration of single NMDA channel openings, bursts, clusters and superclusters. Okadaic acid, a non-selective phosphatase inhibitor, prolongs channel openings only at a concentration that inhibits the Ca2+/calmodulin-dependent phosphatase 2B (calcineurin)(8), and is ineffective when Ca2+ entry through NMDA channels is prevented. Furthermore, FK506, an inhibitor of calcineurin(9,10), mimics the effects of okadaic acid. Thus in adult neurons, calcineurin, activated by calcium entry through native NMDA channels, shortens the duration of channel openings. Simulated synaptic currents(11) were enhanced after phosphatase inhibition, which is consistent with the importance of phosphorylation of the NMDA-receptor complex in the short- and longterm control of neuronal excitability.	UNIV TEXAS,SW MED CTR,DEPT ANESTESIOL & PAIN MANAGEMENT,DALLAS,TX 75235; STANFORD UNIV,SCH MED,GRAD PROGRAM NEUROSCI,STANFORD,CA 94305	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; Stanford University								ABDULGHANI M, 1991, P NATL ACAD SCI USA, V88, P1803, DOI 10.1073/pnas.88.5.1803; BIALOJAN C, 1988, BIOCHEM J, V256, P283, DOI 10.1042/bj2560283; BLISS TVP, 1993, NATURE, V361, P31, DOI 10.1038/361031a0; CHEN L, 1992, NATURE, V356, P521, DOI 10.1038/356521a0; CLIPSTONE NA, 1992, NATURE, V357, P695, DOI 10.1038/357695a0; CREPEL V, 1993, J NEUROPHYSIOL, V69, P1774, DOI 10.1152/jn.1993.69.5.1774; EDMONDS B, 1992, P ROY SOC B-BIOL SCI, V250, P279, DOI 10.1098/rspb.1992.0160; FIGUROV A, 1993, EUR J NEUROSCI, V5, P1035, DOI 10.1111/j.1460-9568.1993.tb00956.x; GIBB AJ, 1992, J PHYSIOL-LONDON, V456, P143, DOI 10.1113/jphysiol.1992.sp019331; GOTO S, 1985, J NEUROCHEM, V45, P276, DOI 10.1111/j.1471-4159.1985.tb05504.x; HALPAIN S, 1990, NEURON, V5, P237, DOI 10.1016/0896-6273(90)90161-8; HAYSTEAD TAJ, 1989, NATURE, V337, P78, DOI 10.1038/337078a0; KLEE CB, 1988, ADV ENZYMOL RAMB, V61, P149; KOHR G, 1993, J NEUROSCI, V13, P3612; LEGENDRE P, 1993, J NEUROSCI, V13, P674; LESTER RAJ, 1992, J NEUROSCI, V12, P635; LIU J, 1991, CELL, V66, P807, DOI 10.1016/0092-8674(91)90124-H; MACDONALD JF, 1989, J PHYSIOL-LONDON, V414, P17, DOI 10.1113/jphysiol.1989.sp017674; MAYER ML, 1987, J PHYSIOL-LONDON, V394, P501, DOI 10.1113/jphysiol.1987.sp016883; MORIOKA M, 1992, J NEUROCHEM, V58, P1798, DOI 10.1111/j.1471-4159.1992.tb10056.x; MULKEY RM, 1993, SCIENCE, V261, P1051, DOI 10.1126/science.8394601; NOWAK L, 1984, NATURE, V307, P462, DOI 10.1038/307462a0; POLLI JW, 1991, DEV BRAIN RES, V63, P105, DOI 10.1016/0165-3806(91)90071-P; RAYMOND LA, 1993, TRENDS NEUROSCI, V16, P147, DOI 10.1016/0166-2236(93)90123-4; ROSENMUND C, 1993, NEURON, V10, P805, DOI 10.1016/0896-6273(93)90197-Y; SAH P, 1989, SCIENCE, V246, P815, DOI 10.1126/science.2573153; SCHNEGGENBURGER R, 1993, NEURON, V11, P133, DOI 10.1016/0896-6273(93)90277-X; STEINER JP, 1992, NATURE, V358, P584, DOI 10.1038/358584a0; TINGLEY WG, 1993, NATURE, V364, P70, DOI 10.1038/364070a0; WATANABE M, 1992, NEUROREPORT, V3, P1138, DOI 10.1097/00001756-199212000-00027	30	425	435	0	4	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	MAY 19	1994	369	6477					235	239		10.1038/369235a0	http://dx.doi.org/10.1038/369235a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	NM067	7514273				2022-12-28	WOS:A1994NM06700057
J	JENSEN, RT; FRAKER, DL				JENSEN, RT; FRAKER, DL			ZOLLINGER-ELLISON SYNDROME - ADVANCES IN TREATMENT OF GASTRIC HYPERSECRETION AND THE GASTRINOMA	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							MULTIPLE ENDOCRINE NEOPLASIA; DUODENAL GASTRINOMAS; HELICOBACTER-PYLORI; COLORECTAL-CANCER; TYPE-1; TUMORS; LOCALIZATION; MANAGEMENT; OMEPRAZOLE; HYPERGASTRINEMIA		NCI, SURG METAB SECT, BETHESDA, MD USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	JENSEN, RT (corresponding author), NIDDKD, DIGEST DIS BRANCH, BLDG 10, ROOM 9C-103, BETHESDA, MD 20892 USA.							ARNOLD R, 1993, WORLD J SURG, V17, P511, DOI 10.1007/BF01655111; BARDRAM L, 1990, GASTROENTEROLOGY, V98, P1420, DOI 10.1016/0016-5085(90)91071-D; BENYA RV, IN PRESS AM J MED; BISMUTH A, IN PRESS FRONTIERS G; CADIOT G, 1993, GASTROENTEROLOGY, V105, P579, DOI 10.1016/0016-5085(93)90736-V; CHIANG HCV, 1990, GASTROENTEROLOGY, V99, P1565, DOI 10.1016/0016-5085(90)90459-E; CREUTZFELDT W, 1988, DIGESTION, V39, P61, DOI 10.1159/000199609; DELCORE R, 1989, SURGERY, V106, P1094; DELCORE R, 1992, SURGERY, V112, P1016; DOPPMAN JL, 1991, RADIOLOGY, V178, P237, DOI 10.1148/radiology.178.1.1984311; DOPPMAN JL, 1992, NEW ENGL J MED, V326, P1770, DOI 10.1056/NEJM199206253262609; EKMAN L, 1985, SCAND J GASTROENTERO, V20, P53, DOI 10.3109/00365528509095819; ELLISON EC, 1987, AM J MED, V82, P17, DOI 10.1016/0002-9343(87)90423-2; ELLISON EH, 1964, ANN SURG, V160, P512, DOI 10.1097/00000658-196409000-00013; FICH A, 1991, DIGEST DIS SCI, V36, P10, DOI 10.1007/BF01300079; FISHBEYN VA, 1993, ANN INTERN MED, V119, P199, DOI 10.7326/0003-4819-119-3-199308010-00004; FRUCHT H, 1989, ANN INTERN MED, V111, P713, DOI 10.7326/0003-4819-111-9-713; FRUCHT H, 1991, DIGEST DIS SCI, V36, P394, DOI 10.1007/BF01298865; GREGORY RA, 1960, LANCET, V1, P1045; HIRSCHOWITZ BI, 1988, GASTROENTEROLOGY, V94, pA188; HOWARD TJ, 1990, ANN SURG, V211, P9, DOI 10.1097/00000658-199001000-00002; IMAMURA M, 1993, WORLD J SURG, V17, P433, DOI 10.1007/BF01655100; JANSEN JBMJ, 1990, GASTROENTEROLOGY, V99, P621, DOI 10.1016/0016-5085(90)90946-X; JENSEN RT, 1993, GASTRIN, P373; JENSEN RT, 1993, ALIMENT PHARM THER, V7, P41; JENSEN RT, 1992, REG PEP LETT, V4, P31; Jensen RT, 1993, GASTROINTESTINAL DIS, P1695; JENSEN RT, IN PRESS YALE J BIOL; JENSEN RT, 1992, STOMACH, P341; JENSENRT, 1993, PANCREAS BIOL PATHOB, P931; KLOPPEL G, 1988, PATHOL RES PRACT, V183, P155; LAMBERTS R, 1993, GASTROENTEROLOGY, V104, P1356, DOI 10.1016/0016-5085(93)90344-C; LAMBERTS SWJ, 1990, NEW ENGL J MED, V323, P1246, DOI 10.1056/NEJM199011013231805; LEHY T, 1992, GUT, V33, P1275, DOI 10.1136/gut.33.9.1275; LLOYD-DAVIES K A, 1988, Alimentary Pharmacology and Therapeutics, V2, P13; Maton PN, 1991, PEPTIC ULCER DISEASE, P213; MET DC, 1992, GASTROENTEROLOGY, V103, P1498; METZ DC, 1993, GASTROENTEROLOGY, V105, P799, DOI 10.1016/0016-5085(93)90898-M; METZ DC, 1993, ALIMENT PHARM THERAP, V7, P247; METZ DC, 1993, WORLD J SURG, V17, P468, DOI 10.1007/BF01655106; METZ DC, 1993, ALIMENT PHARM THERAP, V7, P597; MOERTEL CG, 1992, NEW ENGL J MED, V326, P563; NORTON JA, 1991, WORLD J SURG, V15, P151, DOI 10.1007/BF01658992; NORTON JA, 1992, ANN SURG, V215, P8, DOI 10.1097/00000658-199201000-00012; NORTON JA, 1993, CANCER PRINCIPLES PR, P1333; PIPELEERSMARICHAL M, 1990, NEW ENGL J MED, V322, P723, DOI 10.1056/NEJM199003153221103; PISEGNA JR, 1993, GASTROENTEROLOGY, V105, P1179, DOI 10.1016/0016-5085(93)90965-F; PISEGNA JR, 1993, DIGEST DIS SCI, V38, P1318, DOI 10.1007/BF01296084; PISEGNA JR, 1992, GASTROENTEROLOGY, V102, P767, DOI 10.1016/0016-5085(92)90157-T; RINDI G, 1993, GASTROENTEROLOGY, V104, P994, DOI 10.1016/0016-5085(93)90266-F; ROSCH T, 1992, NEW ENGL J MED, V326, P1721, DOI 10.1056/NEJM199206253262601; SAEED ZA, 1991, DIGEST DIS SCI, V36, P15, DOI 10.1007/BF01300080; SHEPHERD JJ, 1991, ARCH SURG-CHICAGO, V126, P935; SHEPHERD JJ, 1993, ARCH SURG-CHICAGO, V128, P1133; SMITH JP, 1989, DIGEST DIS SCI, V34, P171, DOI 10.1007/BF01536047; SOBHANI I, 1993, GASTROENTEROLOGY, V105, P22; SOLCIA E, 1990, AM J SURG PATHOL, V14, P503, DOI 10.1097/00000478-199006000-00001; STABILE BE, 1985, AM J SURG, V49, P144; STADIL F, 1993, WORLD J SURG, V117, P433; SUGG SL, 1993, ANN SURG, V218, P138, DOI 10.1097/00000658-199308000-00004; SUZUKI H, 1989, DIS COLON RECTUM, V32, P449; THOM AK, 1991, SURGERY, V110, P1086; THOM AK, 1992, SURGERY, V112, P1002; VINAYEK R, 1993, DIGEST DIS SCI, V38, P1857, DOI 10.1007/BF01296110; Wilder RM, 1927, J AMER MED ASSOC, V89, P348, DOI 10.1001/jama.1927.02690050014007; WONG K, 1991, GUT, V32, P1352, DOI 10.1136/gut.32.11.1352; YAPP R, 1992, DIGEST DIS SCI, V37, P481, DOI 10.1007/BF01307566; ZOLLINGER RM, 1955, ANN SURG, V142, P709, DOI 10.1097/00000658-195510000-00015	68	33	33	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAY 11	1994	271	18					1429	1435		10.1001/jama.271.18.1429	http://dx.doi.org/10.1001/jama.271.18.1429			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NJ693	7513768				2022-12-28	WOS:A1994NJ69300031
J	FUMAGALLI, S; TOTTY, NF; HSUAN, JJ; COURTNEIDGE, SA				FUMAGALLI, S; TOTTY, NF; HSUAN, JJ; COURTNEIDGE, SA			A TARGET FOR SRC IN MITOSIS	NATURE			English	Article							TYROSINE KINASES; GROWTH-FACTOR; SIGNAL TRANSDUCTION; C-SRC; PROTEIN; PHOSPHORYLATION; ACTIVATION; GAP; IDENTIFICATION; ASSOCIATION	THE activity of the c-Src protein is increased during cell-cycle stage G1 in fibroblasts stimulated with certain growth factors(1-4), and at the G2/M transition(5), but little is known about Src substrates in these circumstances. In contrast, cells transformed with activated Src contain many tyrosine-phosphorylated proteins. We compared the phosphotyrosine content of growing and mitotically arrested Src-transformed cells. We report here that although phosphorylation of most proteins was unchanged during mitosis, phosphorylation of one of about 68K was greatly enhanced. The p68. was physically associated with activated c-Src, and it bound to the SH3 domain of c-Src in vitro. Tyrosine-phosphorylated p68 was also present in mitotic extracts of normal cells, suggesting that its phosphorylation was not just a consequence of transformation; Purification and microsequencing of p68 showed that it was related to the previously described GAP-associated protein p62 (ref. 6).	EUROPEAN MOLEC BIOL LAB,D-69012 HEIDELBERG,GERMANY; LUDWIG INST CANC RES,MIDDLESEX BRANCH,LONDON W1P 8BT,ENGLAND	European Molecular Biology Laboratory (EMBL); Ludwig Institute for Cancer Research			FUMAGALLI, Stefano/C-2914-2019; Hsuan, Justin/C-8825-2009	Hsuan, Justin/0000-0001-6083-7564; Fumagalli, Stefano/0000-0001-5832-8680				BAGRODIA S, 1991, NATURE, V349, P172, DOI 10.1038/349172a0; CHACKALAPARAMPIL I, 1988, CELL, V52, P801, DOI 10.1016/0092-8674(88)90422-9; CICCHETTI P, 1992, SCIENCE, V257, P803, DOI 10.1126/science.1379745; COURTNEIDGE SA, 1993, EMBO J, V12, P943, DOI 10.1002/j.1460-2075.1993.tb05735.x; COURTNEIDGE SA, 1983, NATURE, V303, P435, DOI 10.1038/303435a0; ELLIS C, 1990, NATURE, V343, P377, DOI 10.1038/343377a0; FERRARI S, 1992, P NATL ACAD SCI USA, V89, P7282, DOI 10.1073/pnas.89.15.7282; GOULD KL, 1988, MOL CELL BIOL, V8, P3345, DOI 10.1128/MCB.8.8.3345; GOUT I, 1993, CELL, V75, P25, DOI 10.1016/0092-8674(93)90676-H; KANNER SB, 1990, P NATL ACAD SCI USA, V87, P3328, DOI 10.1073/pnas.87.9.3328; KREMER NE, 1991, J CELL BIOL, V115, P809, DOI 10.1083/jcb.115.3.809; KYPTA RM, 1990, CELL, V62, P481, DOI 10.1016/0092-8674(90)90013-5; LI N, 1993, NATURE, V363, P85, DOI 10.1038/363085a0; MORAN MF, 1990, P NATL ACAD SCI USA, V87, P8622, DOI 10.1073/pnas.87.21.8622; OLIVIER JP, 1993, CELL, V73, P179, DOI 10.1016/0092-8674(93)90170-U; PAWSON T, 1993, CURR BIOL, V3, P434, DOI 10.1016/0960-9822(93)90350-W; RALSTON R, 1985, P NATL ACAD SCI USA, V82, P7845, DOI 10.1073/pnas.82.23.7845; REN RB, 1993, SCIENCE, V259, P1157, DOI 10.1126/science.8438166; REYNOLDS AB, 1992, ONCOGENE, V7, P2439; ROZAKISADCOCK M, 1992, NATURE, V360, P689, DOI 10.1038/360689a0; SCHALLER MD, 1992, P NATL ACAD SCI USA, V89, P5192, DOI 10.1073/pnas.89.11.5192; TOTTY NF, 1992, PROTEIN SCI, V1, P1215, DOI 10.1002/pro.5560010914; WONG G, 1992, CELL, V69, P551, DOI 10.1016/0092-8674(92)90455-L; WU H, 1991, MOL CELL BIOL, V11, P5113, DOI 10.1128/MCB.11.10.5113	24	336	347	0	2	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	APR 28	1994	368	6474					871	874		10.1038/368871a0	http://dx.doi.org/10.1038/368871a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	NH717	7512695				2022-12-28	WOS:A1994NH71700076
J	HADDOW, JE; PALOMAKI, GE; KNIGHT, GJ; CUNNINGHAM, GC; LUSTIG, LS; BOYD, PA				HADDOW, JE; PALOMAKI, GE; KNIGHT, GJ; CUNNINGHAM, GC; LUSTIG, LS; BOYD, PA			REDUCING THE NEED FOR AMNIOCENTESIS IN WOMEN 35 YEARS OF AGE OR OLDER WITH SERUM MARKERS FOR SCREENING	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							MATERNAL SERUM; ALPHA-FETOPROTEIN; DOWNS-SYNDROME; UNCONJUGATED ESTRIOL; CHORIONIC-GONADOTROPIN; ABNORMALITIES; PREGNANCIES; DIAGNOSIS; WEIGHT; TRIAL	Background. As maternal age advances, the risk of fetal Down's syndrome increases. Pregnant women 35 years of age or older are routinely offered amniocentesis because of this risk. Recently, maternal serum markers have been reported to be useful in screening for Down's syndrome, primarily in younger women. We therefore investigated whether offering amniocentesis only to selected women 35 years of age or older who were identified by screening measurements in serum might prove a useful alternative to the current practice. Methods. We studied 5385 women with singleton pregnancies who were 35 years of age or older and were undergoing routine amniocentesis. Along with information about the pregnancy, we obtained a serum sample for measurement of alpha-fetoprotein, unconjugated estriol, and human chorionic gonadotropin. Individual estimates of the risk of Down's syndrome in the fetus were calculated for each pregnancy before the karyotype was known. Results. If amniocentesis had been reserved for the women calculated to have a risk greater than 1 in 200 of having a fetus with Down's syndrome, 48 of the 54 cases of Down's syndrome (89 percent) would have been identified; 25 percent of the unaffected pregnancies would also have been identified as being at high risk for Down's syndrome (false positives). Seven of 15 fetuses (47 percent) with other trisomies, 11 of 25 (44 percent) with sex aneuploidy, and 1 of 9 (11 percent) with miscellaneous chromosomal abnormalities would also have been detected. In practice, such screening would have made 75 percent of the amniocenteses unnecessary, along with a proportion of the amniocentesis-associated fetal losses. If the cutoff for the risk of Down's syndrome were set higher than 1 in 200, both the rate of detection and the false positive rate would be lower. Conversely, these rates would be higher if the cutoff were set lower. Conclusions. Prenatal screening of serum to generate individual estimates of the risk of Down's syndrome in the fetus can provide a basis for decision making in the cases of women 35 years of age or older, as it does in younger pregnant women, and is an alternative to current testing practices.	CALIF PUBL HLTH FDN,BERKELEY,CA; CALIF DEPT HLTH SERV,GENET DIS BRANCH,BERKELEY,CA 94704	California Department of Health Care Services	HADDOW, JE (corresponding author), FDN BLOOD RES,SCARBOROUGH,ME 04074, USA.				PHS HHS [MCJ-237014-02-2] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		BOGART MH, 1987, PRENATAL DIAG, V7, P623, DOI 10.1002/pd.1970070904; CANICK JA, 1988, BRIT J OBSTET GYNAEC, V95, P330, DOI 10.1111/j.1471-0528.1988.tb06601.x; CANICK JA, 1990, J CLIN IMMUNOASSAY, V13, P30; CHENG EY, 1993, OBSTET GYNECOL, V81, P72; CRANDALL BF, 1983, CLIN CHEM, V29, P531; CUCKLE HS, 1984, LANCET, V1, P926; DIMAIO MS, 1987, NEW ENGL J MED, V317, P342, DOI 10.1056/NEJM198708063170603; GREENE MF, 1988, LANCET, V2, P345; HADDOW JE, 1992, NEW ENGL J MED, V327, P588, DOI 10.1056/NEJM199208273270902; HOLMESSIEDLE M, 1987, PRENAT DIAGN, V77, P239; HOOK EB, 1983, JAMA-J AM MED ASSOC, V249, P2034, DOI 10.1001/jama.249.15.2034; HOOK EB, 1981, TRISOMY, V21, P3; KNIGHT GJ, 1987, METHODS CLIN CHEM, P459; MERKATZ IR, 1984, AM J OBSTET GYNECOL, V148, P886, DOI 10.1016/0002-9378(84)90530-1; PALOMAKI GE, 1992, PRENATAL DIAG, V12, P925, DOI 10.1002/pd.1970121112; PALOMAKI GE, 1990, AM J HUM GENET, V47, pA282; PHILLIPS OP, 1992, OBSTET GYNECOL, V80, P353; ROBINSON A, 1989, AM J MED GENET, V34, P552, DOI 10.1002/ajmg.1320340420; ROBINSON A, 1992, GENETIC DISORDERS FE, P211; TABOR A, 1986, LANCET, V1, P1287; WALD NJ, 1988, BRIT MED J, V297, P1029; WALD NJ, 1992, BRIT J OBSTET GYNAEC, V99, P144, DOI 10.1111/j.1471-0528.1992.tb14474.x; WALD NJ, 1988, BRIT MED J, V297, P883, DOI 10.1136/bmj.297.6653.883; WALD NJ, 1992, BMJ-BRIT MED J, V305, P391, DOI 10.1136/bmj.305.6850.391; WALD NJ, 1993, PRENATAL DIAG, V13, P1149, DOI 10.1002/pd.1970131211; WARBURTON D, 1991, AM J HUM GENET, V49, P995; 1989, AM J OBSTET GYNECOL, V160, P575; 1976, JAMA-J AM MED ASSOC, V236, P1471; 1990, DHHS PHS901100 PUBL, P89	29	155	159	0	3	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	APR 21	1994	330	16					1114	1118		10.1056/NEJM199404213301603	http://dx.doi.org/10.1056/NEJM199404213301603			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NF699	7510852				2022-12-28	WOS:A1994NF69900003
J	AKIRA, S; NISHIO, Y; INOUE, M; WANG, XJ; WEI, S; MATSUSAKA, T; YOSHIDA, K; SUDO, T; NARUTO, M; KISHIMOTO, T				AKIRA, S; NISHIO, Y; INOUE, M; WANG, XJ; WEI, S; MATSUSAKA, T; YOSHIDA, K; SUDO, T; NARUTO, M; KISHIMOTO, T			MOLECULAR-CLONING OF APRF, A NOVEL IFN-STIMULATED GENE FACTOR-3 P91-RELATED TRANSCRIPTION FACTOR INVOLVED IN THE GP130-MEDIATED SIGNALING PATHWAY	CELL			English	Article							RAT ALPHA-2-MACROGLOBULIN GENE; ACUTE-PHASE RESPONSE; INTERFERON-ALPHA; NUCLEAR-PROTEIN; INTERLEUKIN-6; GP130; IL-6; TRANSDUCER; EXPRESSION; RECEPTOR	Acute-phase response factor (APRF) is a transcription factor that binds to the interleukin-6 (IL-6)-responsive elements identified in the promoters of various acute-phase protein genes. We report here the purification and cloning of APRF. APRF exhibits a 52.5% overall homology at the amino acid level with p91, a component of the interferon (IFN) stimulated gene factor 3 complexes. The cloned APRF protein is tyrosine phosphorylated and translocated into the nucleus in response to IL-6, but not in response to IFN-gamma. Tyrosine phosphorylation was also observed in response to other cytokines, such as leukemia inhibitory factor, oncostatin M, and ciliary neurotrophic factor, whose receptors share the IL-6 receptor signal transducer gp130. In contrast, we observed that p91. is not tyrosine phosphorylated in response to IL-6. These results suggest that this novel p91-related protein may play a major role in the gpl30-mediated signaling pathway and that selective activation of p91-related factors may explain the diversity of cellular responses to different cytokines.	TORAY INDUSTRIES LTD, BASIC RES LABS, KAMAKURA, KANAGAWA 248, JAPAN; TORAY INDUSTRIES LTD, TORAY RES CTR, KAMAKURA, KANAGAWA 248, JAPAN; OSAKA UNIV, SCH MED, DEPT MED 3, SUITA, OSAKA 565, JAPAN	Toray Industries, Inc.; Toray Industries, Inc.; Toray Research Center, Inc.; Osaka University	AKIRA, S (corresponding author), OSAKA UNIV, INST MOLEC & CELLULAR BIOL, 1-3 YAMADA OKA, SUITA, OSAKA 565, JAPAN.		Akira, Shizuo/C-3134-2009; Kishimoto, Tadamitsu/C-8470-2009					AKIRA S, 1990, EMBO J, V9, P1897, DOI 10.1002/j.1460-2075.1990.tb08316.x; AKIRA S, 1992, IMMUNOL REV, V127, P25, DOI 10.1111/j.1600-065X.1992.tb01407.x; ARGETSINGER LS, 1993, CELL, V74, P237, DOI 10.1016/0092-8674(93)90415-M; BAUMANN H, 1989, ANN NY ACAD SCI, V557, P280; BONNI A, 1993, SCIENCE, V262, P1575, DOI 10.1126/science.7504325; DAVIS S, 1993, SCIENCE, V260, P1805, DOI 10.1126/science.8390097; FOWLKES DM, 1984, P NATL ACAD SCI-BIOL, V81, P2313, DOI 10.1073/pnas.81.8.2313; FU XY, 1992, CELL, V70, P323, DOI 10.1016/0092-8674(92)90106-M; FU XY, 1990, P NATL ACAD SCI USA, V87, P8555, DOI 10.1073/pnas.87.21.8555; FU XY, 1993, CELL, V74, P1135, DOI 10.1016/0092-8674(93)90734-8; GEARING DP, 1992, SCIENCE, V255, P1434, DOI 10.1126/science.1542794; HATTORI M, 1990, P NATL ACAD SCI USA, V87, P2364, DOI 10.1073/pnas.87.6.2364; HIBI M, 1990, CELL, V63, P1149, DOI 10.1016/0092-8674(90)90411-7; HOCKE GM, 1992, MOL CELL BIOL, V12, P2282, DOI 10.1128/MCB.12.5.2282; IP NY, 1992, CELL, V69, P1121, DOI 10.1016/0092-8674(92)90634-O; ITO T, 1989, NUCLEIC ACIDS RES, V17, P9425, DOI 10.1093/nar/17.22.9425; KESSLER DS, 1990, GENE DEV, V4, P1753, DOI 10.1101/gad.4.10.1753; KINOSHITA S, 1992, P NATL ACAD SCI USA, V89, P1473, DOI 10.1073/pnas.89.4.1473; KISHIMOTO T, 1994, CELL, V76, P253, DOI 10.1016/0092-8674(94)90333-6; KOJ A, 1985, ACUTE PHASE RESPONSE; KOTANIDES H, 1993, SCIENCE, V262, P1265, DOI 10.1126/science.7694370; KUNZ D, 1989, NUCLEIC ACIDS RES, V17, P1121, DOI 10.1093/nar/17.3.1121; KUSHNER I, 1982, ANN NY ACAD SCI, V389, P39, DOI 10.1111/j.1749-6632.1982.tb22124.x; LARNER AC, 1993, SCIENCE, V261, P1730, DOI 10.1126/science.8378773; LUTTICKEN C, 1994, SCIENCE, V263, P89, DOI 10.1126/science.8272872; MANN EA, 1991, J BIOL CHEM, V266, P16931; MULLER M, 1993, NATURE, V366, P129, DOI 10.1038/366129a0; MURAKAMI M, 1993, SCIENCE, V260, P1808, DOI 10.1126/science.8511589; NAKAJIMA T, 1993, P NATL ACAD SCI USA, V90, P2207, DOI 10.1073/pnas.90.6.2207; NARAZAKI M, 1994, IN PRESS P NATL ACAD; OLIVIERO S, 1989, EMBO J, V8, P1145, DOI 10.1002/j.1460-2075.1989.tb03485.x; POLI V, 1990, CELL, V63, P643, DOI 10.1016/0092-8674(90)90459-R; POLI V, 1989, P NATL ACAD SCI USA, V86, P8202, DOI 10.1073/pnas.86.21.8202; RUFFJAMISON S, 1993, SCIENCE, V261, P1733, DOI 10.1126/science.8378774; SADOWSKI HB, 1993, SCIENCE, V261, P1739, DOI 10.1126/science.8397445; SCHINDLER C, 1992, P NATL ACAD SCI USA, V89, P7836, DOI 10.1073/pnas.89.16.7836; SCHINDLER C, 1992, SCIENCE, V257, P809, DOI 10.1126/science.1496401; SHUAI K, 1993, SCIENCE, V261, P1744, DOI 10.1126/science.7690989; SILVENNOINEN O, 1993, P NATL ACAD SCI USA, V90, P8429, DOI 10.1073/pnas.90.18.8429; SILVENNOINEN O, 1993, SCIENCE, V261, P1736, DOI 10.1126/science.8378775; STAHL N, 1994, SCIENCE, V263, P92, DOI 10.1126/science.8272873; TAGA T, 1989, CELL, V58, P573, DOI 10.1016/0092-8674(89)90438-8; TAGA T, 1992, P NATL ACAD SCI USA, V89, P10998, DOI 10.1073/pnas.89.22.10998; VELAZQUEZ L, 1992, CELL, V70, P313, DOI 10.1016/0092-8674(92)90105-L; WATLING D, 1993, NATURE, V366, P166, DOI 10.1038/366166a0; WEGENKA UM, 1993, MOL CELL BIOL, V13, P276, DOI 10.1128/MCB.13.1.276; WITTHUHN BA, 1993, CELL, V74, P227, DOI 10.1016/0092-8674(93)90414-L; YIN TG, 1993, J IMMUNOL, V151, P2555; ZHONG Z, 1994, IN PRESS SCIENCE; ZHONG Z, 1994, IN PRESS P NATL ACAD	50	886	913	3	26	CELL PRESS	CAMBRIDGE	600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA	0092-8674			CELL	Cell	APR 8	1994	77	1					63	71		10.1016/0092-8674(94)90235-6	http://dx.doi.org/10.1016/0092-8674(94)90235-6			9	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	NF211	7512451				2022-12-28	WOS:A1994NF21100010
J	BODMER, H; VIVILLE, S; BENOIST, C; MATHIS, D				BODMER, H; VIVILLE, S; BENOIST, C; MATHIS, D			DIVERSITY OF ENDOGENOUS EPITOPES BOUND TO MHC CLASS-II MOLECULES LIMITED BY INVARIANT CHAIN	SCIENCE			English	Article							MYELIN BASIC-PROTEIN; T-CELL DETERMINANTS; HLA-DR MOLECULES; ANTIGEN PRESENTATION; PEPTIDE BINDING; SURFACE EXPRESSION; INFLUENZA-VIRUS; COMPLEX; PH; DISTINCT	The invariant chain (li) binds nascent major histocompatibility complex (MHC) class II molecules, blocking peptide binding until the complex dissociates in the endosomes. This may serve to differentiate the MHC class I and II antigen presentation pathways and enable class II molecules to efficiently bind peptides in the endosomes. This hypothesis was addressed by probing spleen cells from a combination of knock-out and transgenic mice with a large panel of T cell hybridomas. The li molecule blocked the presentation of a range of endogenously synthesized epitopes, but some epitopes actually required li. Thus, the influence of li on presentation does not follow simple rules. In addition, mice expressing li were not tolerant to epitopes unmasked in its absence, a finding with possible implications for autoimmunity.	INST CHIM BIOL,CNRS,GENET MOLEC EUCARYOTES,F-67000 STRASBOURG,FRANCE; INST CHIM BIOL,INSERM,UNITE BIOL MOLEC 184,F-67000 STRASBOURG,FRANCE	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg				Viville, Stephane/0000-0002-5088-3003				BAKKE O, 1990, CELL, V63, P707, DOI 10.1016/0092-8674(90)90137-4; BIKOFF EK, 1993, J EXP MED, V177, P1699, DOI 10.1084/jem.177.6.1699; BIKOFF EK, 1992, J IMMUNOL, V149, P1; BODMER H, UNPUB; BRODSKY FM, 1991, ANNU REV IMMUNOL, V9, P707; BROOKS A, 1991, P NATL ACAD SCI USA, V88, P3290, DOI 10.1073/pnas.88.8.3290; BROOKS AG, 1993, J IMMUNOL, V150, P3690; CALINLAURENS V, 1992, INT IMMUNOL, V4, P1113, DOI 10.1093/intimm/4.10.1113; CRESSWELL P, 1992, CURR OPIN IMMUNOL, V4, P87, DOI 10.1016/0952-7915(92)90131-W; EISENLOHR LC, 1989, J EXP MED, V169, P921, DOI 10.1084/jem.169.3.921; HARDING CV, 1991, P NATL ACAD SCI USA, V88, P2740, DOI 10.1073/pnas.88.7.2740; HUMBERT M, 1993, EUR J IMMUNOL, V23, P3167, DOI 10.1002/eji.1830231219; JENSEN PE, 1991, J EXP MED, V174, P1111, DOI 10.1084/jem.174.5.1111; KONO DH, 1988, J EXP MED, V168, P213, DOI 10.1084/jem.168.1.213; KOUSKOFF V, IN PRESS METHODS IMM; LAMB CA, 1991, P NATL ACAD SCI USA, V88, P5998, DOI 10.1073/pnas.88.14.5998; LEHMANN PV, 1993, IMMUNOL TODAY, V14, P203, DOI 10.1016/0167-5699(93)90163-F; LOSS GE, 1993, J EXP MED, V178, P73, DOI 10.1084/jem.178.1.73; LOTTEAU V, 1990, NATURE, V348, P600, DOI 10.1038/348600a0; MALNATI MS, 1992, NATURE, V357, P702, DOI 10.1038/357702a0; MOMBURG F, 1988, CLIN EXP IMMUNOL, V72, P367; MOMBURG F, 1986, J IMMUNOL, V136, P940; MOORE MJ, 1993, CELL BIOCH C S, V17, P70; MORENO J, 1991, J IMMUNOL, V147, P3306; MOURITSEN S, 1992, J IMMUNOL, V148, P1438; MURPHY DB, 1992, J IMMUNOL, V148, P3483; NEEFJES JJ, 1992, EMBO J, V11, P411, DOI 10.1002/j.1460-2075.1992.tb05069.x; NUCHTERN JG, 1990, NATURE, V343, P74, DOI 10.1038/343074a0; PURE E, 1990, J EXP MED, V172, P1459, DOI 10.1084/jem.172.5.1459; ROCHE PA, 1990, NATURE, V345, P615, DOI 10.1038/345615a0; ROCHE PA, 1991, P NATL ACAD SCI USA, V88, P3150, DOI 10.1073/pnas.88.8.3150; ROCHE PA, 1992, EMBO J, V11, P2841, DOI 10.1002/j.1460-2075.1992.tb05351.x; ROSENBERG AH, 1987, GENE, V56, P125, DOI 10.1016/0378-1119(87)90165-X; SAKAI K, 1988, P NATL ACAD SCI USA, V85, P8608, DOI 10.1073/pnas.85.22.8608; SETTE A, 1992, J IMMUNOL, V148, P844; TAKAHASHI N, 1985, CELL, V42, P139, DOI 10.1016/S0092-8674(85)80109-4; TEYTON L, 1990, NATURE, V348, P39, DOI 10.1038/348039a0; VIDAL K, 1993, J IMMUNOL, V151, P4642; VIDARD L, 1992, J IMMUNOL, V149, P498; VIVILLE S, 1993, CELL, V72, P635, DOI 10.1016/0092-8674(93)90081-Z; YAO XR, 1988, LEUKEMIA RES, V12, P787, DOI 10.1016/0145-2126(88)90030-6	41	112	112	0	4	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAR 4	1994	263	5151					1284	1286		10.1126/science.7510069	http://dx.doi.org/10.1126/science.7510069			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	MY570	7510069				2022-12-28	WOS:A1994MY57000038
J	RITTMASTER, RS				RITTMASTER, RS			FINASTERIDE	NEW ENGLAND JOURNAL OF MEDICINE			English	Review							BENIGN PROSTATIC HYPERPLASIA; 5-ALPHA-REDUCTASE INHIBITOR FINASTERIDE; HUMAN STEROID 5-ALPHA-REDUCTASE; ANDROGEN RECEPTOR; MALE PSEUDOHERMAPHRODITES; EXTERNAL GENITALIA; HORMONE AGONIST; NORMAL MEN; DEFICIENCY; TESTOSTERONE				RITTMASTER, RS (corresponding author), DALHOUSIE UNIV, DEPT MED, RM 809, GERARD HALL, 5303 MORRIS ST, HALIFAX B3J 1B6, NS, CANADA.							ANDERSON CA, 1990, TERATOLOGY, V42, P483, DOI 10.1002/tera.1420420505; ANDERSSON S, 1990, P NATL ACAD SCI USA, V87, P3640, DOI 10.1073/pnas.87.10.3640; ANDERSSON S, 1989, J BIOL CHEM, V264, P16249; ANDERSSON S, 1991, NATURE, V354, P159, DOI 10.1038/354159a0; BALL AJ, 1981, BRIT J UROL, V53, P613, DOI 10.1111/j.1464-410X.1981.tb03273.x; BERRY SJ, 1984, J UROLOGY, V132, P474, DOI 10.1016/S0022-5347(17)49698-4; BRANDT M, 1990, J STEROID BIOCHEM, V37, P575, DOI 10.1016/0960-0760(90)90403-8; CARLIN JR, 1992, DRUG METAB DISPOS, V20, P148; CLARK RL, 1990, TERATOLOGY, V42, P91, DOI 10.1002/tera.1420420111; CRAWFORD ED, 1989, NEW ENGL J MED, V321, P419, DOI 10.1056/NEJM198908173210702; DESCHEPPER PJ, 1991, STEROIDS, V56, P469, DOI 10.1016/0039-128X(91)90003-E; DIANI AR, 1992, J CLIN ENDOCR METAB, V74, P345, DOI 10.1210/jc.74.2.345; FORTI G, 1989, J CLIN ENDOCR METAB, V68, P461, DOI 10.1210/jcem-68-2-461; GABRILOVE JL, 1989, J CLIN ENDOCR METAB, V69, P629, DOI 10.1210/jcem-69-3-629; GELLER J, 1989, PROSTATE, P95; GELLER J, 1990, J CLIN ENDOCR METAB, V71, P1552, DOI 10.1210/jcem-71-6-1552; GORMLEY GJ, 1991, UROL CLIN N AM, V18, P93; GORMLEY GJ, 1992, NEW ENGL J MED, V327, P1185, DOI 10.1056/NEJM199210223271701; GORMLEY GJ, 1990, J CLIN ENDOCR METAB, V70, P1136, DOI 10.1210/jcem-70-4-1136; GRIFFIN JE, 1989, METABOLIC BASIS INHE, V2, P1919; GRINO PB, 1990, ENDOCRINOLOGY, V126, P1165, DOI 10.1210/endo-126-2-1165; GUESS HA, 1993, PROSTATE, V22, P31, DOI 10.1002/pros.2990220105; HALD T, 1989, PROSTATE, P69; Hamilton JB, 1942, AM J ANAT, V71, P451, DOI 10.1002/aja.1000710306; HARRIS G, 1992, P NATL ACAD SCI USA, V89, P10787, DOI 10.1073/pnas.89.22.10787; Huggins C, 1940, J UROLOGY, V43, P705, DOI 10.1016/S0022-5347(17)71453-X; IMPERATOMCGINLEY J, 1993, J CLIN ENDOCR METAB, V76, P524, DOI 10.1210/jc.76.2.524; IMPERATOMCGINLEY J, 1992, ENDOCRINOLOGY, V131, P1149, DOI 10.1210/en.131.3.1149; IMPERATOMCGINLEY J, 1992, J CLIN ENDOCR METAB, V75, P1022, DOI 10.1210/jc.75.4.1022; IMPERATOMCGINLEY J, 1990, J CLIN ENDOCR METAB, V70, P777, DOI 10.1210/jcem-70-3-777; IMPERATOMCGINLEY J, 1991, CLIN ENDOCRINOL, V34, P293, DOI 10.1111/j.1365-2265.1991.tb03769.x; ISAACS JT, 1989, PROSTATE, P33; ITAMI S, 1991, J INVEST DERMATOL, V96, P57, DOI 10.1111/1523-1747.ep12514729; JENKINS EP, 1992, J CLIN INVEST, V89, P293, DOI 10.1172/JCI115574; JENKINS EP, 1991, GENOMICS, V11, P1102, DOI 10.1016/0888-7543(91)90038-G; JOHNSON L, 1986, J CLIN ENDOCR METAB, V63, P1091, DOI 10.1210/jcem-63-5-1091; KAUFMAN M, 1983, J STEROID BIOCHEM, V18, P121, DOI 10.1016/0022-4731(83)90077-8; LANGE PH, 1992, NEW ENGL J MED, V327, P1234, DOI 10.1056/NEJM199210223271709; LONGCOPE C, 1986, CLIN ENDOCRINOL META, V15, P213, DOI 10.1016/S0300-595X(86)80021-4; MATZKIN H, 1992, CLIN ENDOCRINOL, V37, P432, DOI 10.1111/j.1365-2265.1992.tb02355.x; MCCONNELL JD, 1992, J CLIN ENDOCR METAB, V74, P505, DOI 10.1210/jc.74.3.505; METCALF BW, 1989, TRENDS PHARMACOL SCI, V10, P491, DOI 10.1016/0165-6147(89)90048-5; MOCELLINI AI, 1993, PROSTATE, V22, P291; MOORE RJ, 1976, J BIOL CHEM, V251, P5895; NIGHTINGALE SL, 1992, JAMA-J AM MED ASSOC, V268, P1390; NORMAN RW, 1993, J UROLOGY, V150, P1736, DOI 10.1016/S0022-5347(17)35882-2; OHTAWA M, 1991, EUR J DRUG METAB PH, V16, P15, DOI 10.1007/BF03189869; PETERS CA, 1987, NEW ENGL J MED, V317, P599, DOI 10.1056/NEJM198709033171004; PRESTI JC, 1992, J UROLOGY, V148, P1201, DOI 10.1016/S0022-5347(17)36860-X; RASMUSSON GH, 1986, J MED CHEM, V29, P2298, DOI 10.1021/jm00161a028; RITTMASTER R, IN PRESS J ANDROL; RITTMASTER RS, 1992, J CLIN ENDOCR METAB, V75, P484, DOI 10.1210/jc.75.2.484; RITTMASTER RS, 1991, MOL ENDOCRINOL, V5, P1023, DOI 10.1210/mend-5-7-1023; RITTMASTER RS, 1989, J ANDROL, V10, P259; RITTMASTER RS, 1991, TERRA S ANDROGENS AN, P48; SHECKTER CB, 1989, J CLIN ENDOCR METAB, V68, P397, DOI 10.1210/jcem-68-2-397; STAMEY TA, 1989, J UROLOGY, V141, P1070; STONER E, 1992, J UROLOGY, V147, P1298, DOI 10.1016/S0022-5347(17)37547-X; STONER E, 1990, J STEROID BIOCHEM, V37, P375, DOI 10.1016/0960-0760(90)90487-6; STONER E, 1992, 1992 P FOOD DRUG ADM, P354; TAMMELA TLJ, 1993, J UROLOGY, V149, P342, DOI 10.1016/S0022-5347(17)36077-9; THIBOUTOT DM, 1992, J INVEST DERMATOL, V98, P581; THIGPEN AE, 1992, NEW ENGL J MED, V327, P1216, DOI 10.1056/NEJM199210223271706; THIGPEN AE, 1992, J CLIN INVEST, V90, P799, DOI 10.1172/JCI115954; VERMEULEN A, 1989, PROSTATE, V14, P45, DOI 10.1002/pros.2990140106; WEIS KA, 1993, PROSTATE, V22, P325, DOI 10.1002/pros.2990220407; WILBERT DM, 1983, J CLIN ENDOCR METAB, V56, P113, DOI 10.1210/jcem-56-1-113; WILSON JD, 1980, AM J MED, V68, P745, DOI 10.1016/0002-9343(80)90267-3; 1993, PROSCAR PRODUCT MONO	69	244	251	4	16	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JAN 13	1994	330	2					120	125						6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MQ670	7505051				2022-12-28	WOS:A1994MQ67000008
J	HAMID, Q; SPRINGALL, DR; RIVEROSMORENO, V; CHANEZ, P; HOWARTH, P; REDINGTON, A; BOUSQUET, J; GODARD, P; HOLGATE, S; POLAK, JM				HAMID, Q; SPRINGALL, DR; RIVEROSMORENO, V; CHANEZ, P; HOWARTH, P; REDINGTON, A; BOUSQUET, J; GODARD, P; HOLGATE, S; POLAK, JM			INDUCTION OF NITRIC-OXIDE SYNTHASE IN ASTHMA	LANCET			English	Article							NECROSIS-FACTOR-ALPHA; MAST-CELLS; BRONCHIAL HYPERRESPONSIVENESS; PULMONARY VASODILATOR; GUINEA-PIGS; L-ARGININE; EXPRESSION; MACROPHAGES; EOSINOPHILS; EPITHELIUM	Nitric oxide (NO) is a mediator of vasodilatation and bronchodilatation synthesised from L-arginine by the enzyme NO synthase, which is either constitutive or induced by lipopolysaccharides and/or cytokines. The presence and function of NO synthase in normal or diseased lung is not yet clear. Asthma is characterised by bronchial hyperresponsiveness, epithelial damage, inflammation, and increased cytokine production. To investigate the presence of NO synthase in asthma, we immunostained bronchial biopsies from non-steroid-treated people with asthma and non-asthmatic controls with specific polyvalent antisera to purified inducible NO synthase and to a selected peptide sequence of the same enzyme. Immunoreactivity was seen in the epithelium and some inflammatory cells in 22 of 23 biopsies from people with asthma, but in only 2 of 20 controls. To assess the relation of cytokines to NO synthase induction, bronchial epithelial cells in culture were stimulated with tumour necrosis factor (TNFalpha). Inducible enzyme immunoreactivity was found only in the treated cells. The existence of inducible NO synthase in human lungs suggests that increased production of NO, probably induced by cytokines, may be relevant to the pathology of asthma.	ROYAL POSTGRAD MED SCH,DEPT HISTOCHEM,DU CANE RD,LONDON W12 0NN,ENGLAND; WELLCOME RES LABS,BECKENHAM BR3 3BS,KENT,ENGLAND; NATL HEART & LUNG INST,LONDON,ENGLAND; HOP ARNAUD VILLENEUVE,SERV MALAD RESP,F-34059 MONTPELLIER,FRANCE; SOUTHAMPTON GEN HOSP,DEPT MED,IMMUNOPHARMACOL GRP,SOUTHAMPTON SO9 4XY,HANTS,ENGLAND	Imperial College London; GlaxoSmithKline; Wellcome Research Laboratories; Imperial College London; Universite de Montpellier; CHU de Montpellier; University of Southampton				Howarth, Peter/0000-0003-0619-7927; chanez, pascal/0000-0003-4059-0917				BELVISI MG, 1992, EUR J PHARMACOL, V210, P221, DOI 10.1016/0014-2999(92)90676-U; BRADLEY BL, 1991, J ALLERGY CLIN IMMUN, V88, P661, DOI 10.1016/0091-6749(91)90160-P; BREDT DS, 1990, NATURE, V347, P768, DOI 10.1038/347768a0; CRAWLEY DE, 1992, J APPL PHYSIOL, V72, P1425, DOI 10.1152/jappl.1992.72.4.1425; CROMWELL O, 1992, IMMUNOLOGY, V77, P330; CURRAN RD, 1989, J EXP MED, V170, P1769, DOI 10.1084/jem.170.5.1769; DJUKANOVIC R, 1990, AM REV RESPIR DIS, V142, P863, DOI 10.1164/ajrccm/142.4.863; DUPUY PM, 1992, J CLIN INVEST, V90, P421, DOI 10.1172/JCI115877; FORSTERMANN U, 1991, BIOCHEM PHARMACOL, V42, P1849, DOI 10.1016/0006-2952(91)90581-O; FROSTELL C, 1991, CIRCULATION, V83, P2038, DOI 10.1161/01.CIR.83.6.2038; GELLER DA, 1993, P NATL ACAD SCI USA, V90, P3491, DOI 10.1073/pnas.90.8.3491; GUSTAFSSON LE, 1991, BIOCHEM BIOPH RES CO, V181, P852, DOI 10.1016/0006-291X(91)91268-H; HAMID Q, 1991, J CLIN INVEST, V87, P1541, DOI 10.1172/JCI115166; KIPS JC, 1992, AM REV RESPIR DIS, V145, P332, DOI 10.1164/ajrccm/145.2_Pt_1.332; KNOWLES RG, 1990, BIOCHEM BIOPH RES CO, V172, P1042, DOI 10.1016/0006-291X(90)91551-3; LUNDGREN R, 1988, EUR RESPIR J, V1, P883; LYONS CR, 1992, J BIOL CHEM, V267, P6370; MASON DY, 1985, TECH IMMUNOCYTOCHEM, V3, P25; MONCADA S, 1991, PHARMACOL REV, V43, P109; MONTEFORT S, 1992, CLIN EXP ALLERGY, V22, P511, DOI 10.1111/j.1365-2222.1992.tb00159.x; MULLIGAN MS, 1991, P NATL ACAD SCI USA, V88, P6338, DOI 10.1073/pnas.88.14.6338; OGUCHI S, 1992, FEBS LETT, V308, P22, DOI 10.1016/0014-5793(92)81041-J; PEPKEZABA J, 1991, LANCET, V338, P1173, DOI 10.1016/0140-6736(91)92033-X; RIVEROSMORENO V, 1993, IN PRESS EUR J BIOCH; ROCHE WR, 1989, LANCET, V1, P520; SPRINGALL DR, 1991, LANCET, V337, P697, DOI 10.1016/0140-6736(91)90279-X; SPRINGALL DR, 1992, HISTOCHEMISTRY, V98, P259, DOI 10.1007/BF00271040; STUEHR DJ, 1989, J EXP MED, V169, P1011, DOI 10.1084/jem.169.3.1011; STUEHR DJ, 1989, J EXP MED, V169, P1543, DOI 10.1084/jem.169.5.1543; WALSH LJ, 1991, P NATL ACAD SCI USA, V88, P4220, DOI 10.1073/pnas.88.10.4220; YING S, 1991, Clinical and Experimental Allergy, V21, P745, DOI 10.1111/j.1365-2222.1991.tb03205.x	31	719	740	0	9	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	DEC 18	1993	342	8886-7					1510	1513		10.1016/S0140-6736(05)80083-2	http://dx.doi.org/10.1016/S0140-6736(05)80083-2			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MM402	7504773				2022-12-28	WOS:A1993MM40200010
J	ARIDOR, M; RAJMILEVICH, G; BEAVEN, MA; SAGIEISENBERG, R				ARIDOR, M; RAJMILEVICH, G; BEAVEN, MA; SAGIEISENBERG, R			ACTIVATION OF EXOCYTOSIS BY THE HETEROTRIMERIC-G PROTEIN-G(I3)	SCIENCE			English	Article							RAT MAST-CELLS; GTP-BINDING PROTEINS; SYNTHETIC PEPTIDES; ALPHA-SUBUNIT; SUBSTANCE-P; MASTOPARAN; IDENTIFICATION; NUCLEOTIDE; SECRETION; MEMBRANES	Secretagogues of rat peritoneal mast cells, such as mastoparan and compound 48/80, induce mast cell exocytosis by activating directly the guanosine triphosphate-binding proteins that are required for exocytosis. The introduction of a synthetic peptide that corresponds to the carboxyl-terminal end sequence of Galpha(i3) into the cells specifically blocked this secretion. Similar results were obtained when antibodies to this peptide were introduced. The Galpha(i3) was located in both the Golgi and the plasma membrane, but only the latter source of Galpha(i3) appeared to be essential for secretion. These results indicate that Galpha(i3) functions to control regulated exocytosis in mast cells.	NHLBI,CHEM PHARMACOL LAB,BLDG 10,ROOM 8H108,BETHESDA,MD 20892; WEIZMANN INST SCI,DEPT CHEM IMMUNOL,IL-76100 REHOVOT,ISRAEL	National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI); Weizmann Institute of Science								ARIDOR M, 1990, J CELL BIOL, V111, P2885, DOI 10.1083/jcb.111.6.2885; ARIDOR M, 1990, J CELL BIOL, V111, P909, DOI 10.1083/jcb.111.3.909; ARIDOR M, UNPUB; BARSAGI D, 1988, ONCOGENE, V3, P463; BUEB JL, 1990, MOL PHARMACOL, V38, P816; CERIONE RA, 1988, J BIOL CHEM, V262, P14683; COCKCROFT S, 1979, NATURE, V279, P541, DOI 10.1038/279541a0; COCKCROFT S, 1987, J CELL BIOL, V105, P2745, DOI 10.1083/jcb.105.6.2745; DONALDSON JG, 1991, SCIENCE, V254, P1197, DOI 10.1126/science.1957170; FERNANDEZ JM, 1984, NATURE, V312, P453, DOI 10.1038/312453a0; GIERSCHIK P, 1989, J BIOL CHEM, V264, P21470; GOMPERTS BD, 1990, ANNU REV PHYSIOL, V52, P591; HAMM HE, 1988, SCIENCE, V241, P832, DOI 10.1126/science.3136547; HIGASHIJIMA T, 1988, J BIOL CHEM, V263, P6491; HIGASHIJIMA T, 1990, J BIOL CHEM, V265, P14176; HOWELL TW, 1987, J CELL BIOL, V105, P191, DOI 10.1083/jcb.105.1.191; KAHN RA, 1991, J BIOL CHEM, V266, P15595; LILLIE THW, 1992, BIOCHEM J, V288, P181, DOI 10.1042/bj2880181; MOUSLI M, 1990, FEBS LETT, V259, P260, DOI 10.1016/0014-5793(90)80023-C; MOUSLI M, 1990, IMMUNOL LETT, V25, P355, DOI 10.1016/0165-2478(90)90207-7; OBERHAUSER AF, 1992, NATURE, V360, P270, DOI 10.1038/360270a0; ORTNER MJ, 1981, BIOCHEM PHARMACOL, V30, P283, DOI 10.1016/0006-2952(81)90055-1; PALM D, 1990, FEBS LETT, V261, P294, DOI 10.1016/0014-5793(90)80575-4; PLUTNER H, 1990, EMBO J, V9, P2375, DOI 10.1002/j.1460-2075.1990.tb07412.x; SIMONDS WF, 1989, P NATL ACAD SCI USA, V86, P7809, DOI 10.1073/pnas.86.20.7809; STOW JL, 1991, J CELL BIOL, V114, P113; TRAUB LM, 1991, J BIOL CHEM, V266, P24642	27	230	236	0	3	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	DEC 3	1993	262	5139					1569	1572		10.1126/science.7504324	http://dx.doi.org/10.1126/science.7504324			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	MK329	7504324				2022-12-28	WOS:A1993MK32900040
J	Zignego, AL; Ferri, C; Giannini, C; Monti, M; LaCivita, L; Careccia, G; Longombardo, G; Lombardini, F; Bombardieri, S; Gentilini, P				Zignego, AL; Ferri, C; Giannini, C; Monti, M; LaCivita, L; Careccia, G; Longombardo, G; Lombardini, F; Bombardieri, S; Gentilini, P			Hepatitis C virus genotype analysis in patients with type II mixed cryoglobulinemia	ANNALS OF INTERNAL MEDICINE			English	Note							POLYMERASE CHAIN-REACTION; INTERFERON-ALPHA; LIVER-DISEASE; ANTIBODIES; INFECTION; CELLS	Objective: To investigate the possible role of HCV variants in the pathogenesis of mixed cryoglobulinemia. Setting: Medical service (rheumatology and hepatology units) of urban, university-affiliate teaching hospitals. Design: Analysis of vira I genotypes in a cohort of patients with hepatitis C virus (HCV) infection and mixed cryoglobulinemia. Patients: 90 unselected HCV-positive (anti-HCV antibody-positive and HCV RNA-positive) patients consecutively recruited at routine ambulatory visits: 29 with and 61 without (control group) mixed cryoglobulinemia. Measurements: Clinical and histologic data; HCV RNA detection in serum and peripheral blood mononuclear cells by polymerase chain reaction (PCR); HCV genotype determination by two methods based on genotype specific primer PCR and genotype-specific probe hybridization, respectively. Results: Persistent aminotransferase increases were found in 55% of patients with mixed cryoglobulinemia. Peripheral blood mononuclear cells were infected in 80% of cases. In serum samples, HCV genotype 2a/III was detected with a higher prevalence in patients with mixed cryoglobulinemia than in controls (41% compared with 15%). The overall prevalence of genotype 2a/III in mixed cryoglobulinemia increased to 52% when findings in peripheral blood mononuclear cells were also considered. Among patients with mixed cryoglobulinemia, this genotype was more frequent in those without clinical and biochemical signs of liver disease (85%) or with serum autoantibodies (75%). Conclusions: Mixed cryoglobulinemia may be related, at least in part, to the HCV genotype infecting the host.	IST PATOL MED 1, PISA, ITALY		Zignego, AL (corresponding author), UNIV FLORENCE, IST MED INTERNA, V MORGAGNI 85, I-50134 FLORENCE, ITALY.		Zignego, Anna Linda/AAL-8205-2021					BUNN CC, 1982, J CLIN LAB IMMUNOL, V8, P13; FERRI C, 1994, J INTERN MED, V236, P31, DOI 10.1111/j.1365-2796.1994.tb01116.x; FERRI C, 1994, EUR J CLIN INVEST, V24, P781, DOI 10.1111/j.1365-2362.1994.tb01077.x; FERRI C, 1993, BLOOD, V82, P3701; FERRI C, 1993, BLOOD, V81, P1132; FERRI C, 1991, ARTHRITIS RHEUM, V34, P1606; GIANNINI C, 1995, J HEPATOL, V23, P246, DOI 10.1016/S0168-8278(95)80002-6; GOREVIC PD, 1991, SEMIN HEMATOL, V28, P79; KWOK S, 1989, NATURE, V339, P237, DOI 10.1038/339237a0; LENZI M, 1991, LANCET, V338, P277, DOI 10.1016/0140-6736(91)90418-O; MANNS MP, 1989, J CLIN INVEST, V83, P1066, DOI 10.1172/JCI113949; MICHITAKA K, 1994, GASTROENTEROLOGY, V106, P1603, DOI 10.1016/0016-5085(94)90417-0; OKAMOTO H, 1992, J GEN VIROL, V73, P673, DOI 10.1099/0022-1317-73-3-673; PASCUAL M, 1990, J INFECT DIS, V162, P569, DOI 10.1093/infdis/162.2.569; POZZATO G, 1991, LANCET, V338, P509, DOI 10.1016/0140-6736(91)90578-D; TAKADA N, 1992, J HEPATOL, V14, P35, DOI 10.1016/0168-8278(92)90128-C; YOSHIOKA K, 1992, HEPATOLOGY, V16, P293, DOI 10.1002/hep.1840160203; ZIGNEGO AL, 1992, J HEPATOL, V15, P382, DOI 10.1016/0168-8278(92)90073-X; ZIGNEGO AL, 1995, J MED VIROL, V47, P58, DOI 10.1002/jmv.1890470112; ZIGNEGO AL, 1994, HEPATOLOGY, V19, P577, DOI 10.1002/hep.1840190306	20	166	170	0	3	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JAN 1	1996	124	1	1				31	34		10.7326/0003-4819-124-1_Part_1-199601010-00006	http://dx.doi.org/10.7326/0003-4819-124-1_Part_1-199601010-00006			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TL943	7503475				2022-12-28	WOS:A1996TL94300006
J	Boyle, PJ; Kempers, SF; OConnor, AM; Nagy, RJ				Boyle, PJ; Kempers, SF; OConnor, AM; Nagy, RJ			Brain glucose uptake and unawareness of hypoglycemia in patients with insulin-dependent diabetes mellitus	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							GLYCEMIC THRESHOLDS; SUBSEQUENT HYPOGLYCEMIA; AUTONOMIC FAILURE; SYMPTOMS; RESPONSES; NEUROENDOCRINE; METABOLISM; TRANSPORT; BARRIER; IDDM	Background. In patients with insulin-dependent diabetes mellitus (IDDM) whose treatment results in nearly normal mean plasma glucose concentrations, an unawareness of hypoglycemia can develop, and such patients are at increased risk for seizures and coma. We tested the hypothesis that during hypoglycemia, these patients would have normal glucose uptake in the brain and that consequently no sympathoadrenal activation would begin, resulting in an unawareness of hypoglycemia. Methods. We measured glucose uptake in the brain at plasma glucose concentrations of 105 and 54 mg per deciliter (5.8 and 3.0 mmol per liter) in 24 patients with IDDM, stratified into three groups according to their glycosylated hemoglobin values (mean [+/-SD] values, 7.2 +/- 0.5, 8.5 +/- 0.4, and 10.2 +/- 1.3 percent) and compared the values for brain glucose uptake with those measured in 15 normal subjects at plasma glucose concentrations of 85 and 55 mg per deciliter (4.2 and 3.1 mmol per liter). We also recorded the subjects' hypoglycemic-symptom scores and measured their plasma concentrations of counterregulatory hormones. Results. There was no significant change in the uptake of glucose in the brain (calculated as the uptake during hypoglycemia minus the uptake during normoglycemia) among the patients with IDDM who had the lowest glycosylated hemoglobin values (+0.6 +/- 2.0, mg [3.3 +/- 11.1 mu mol] per 100 g of brain tissue per minute, P = 0.39). Conversely, glucose uptake in the brain fell in both the group with intermediate values (a decrease of 1.3 +/- 1.0 mg [7.2 +/- 5.6 mu mol] per 100 g per minute, P = 0.009) and the group with the highest values (a decrease of 1.8 +/- 1.6 mg [10.0 +/- 9.0, mu mol] per 100 g per minute, P = 0.01), as it did in the normal subjects (a decrease of 1.6 +/- 1.8 mg [9.0 +/- 10.1 mu mol] per 100 g per minute, P = 0.003). The responses of plasma epinephrine and pancreatic polypeptide and the frequency of symptoms of hypoglycemia were lowest in the group with the lowest glycosylated hemoglobin values. Conclusions. During hypoglycemia, patients with IDDM who have nearly normal glycosylated hemoglobin values have normal glucose uptake in the brain, which preserves cerebral metabolism, reduces the responses of counter-regulatory hormones, and causes an unawareness of hypoglycemia.			Boyle, PJ (corresponding author), UNIV NEW MEXICO, DEPT MED, DIV ENDOCRINOL & METAB, 5ACC, 2211 LOMAS NE, ALBUQUERQUE, NM 87131 USA.				NCRR NIH HHS [5 M01 RR00997-19,20] Funding Source: Medline; NINDS NIH HHS [1 R29 NS29972-01A1] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR000997] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R29NS029972] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		AMIEL SA, 1988, DIABETES, V37, P901, DOI 10.2337/diabetes.37.7.901; BOADO RJ, 1993, J NEUROCHEM, V60, P2290, DOI 10.1111/j.1471-4159.1993.tb03516.x; BORG WP, 1994, J CLIN INVEST, V93, P1677, DOI 10.1172/JCI117150; BORG WP, 1994, DIABETES, V43, pA142; BOYLE PJ, 1994, P NATL ACAD SCI USA, V91, P9352, DOI 10.1073/pnas.91.20.9352; BOYLE PJ, 1994, J CLIN INVEST, V93, P529, DOI 10.1172/JCI117003; BOYLE PJ, 1988, NEW ENGL J MED, V318, P1487, DOI 10.1056/NEJM198806093182302; CRANSTON I, 1994, LANCET, V344, P283, DOI 10.1016/S0140-6736(94)91336-6; CRYER PE, 1992, DIABETES, V41, P255, DOI 10.2337/diabetes.41.3.255; CRYER PE, 1985, ANN INTERN MED, V103, P284, DOI 10.7326/0003-4819-103-2-284; DAGOGOJACK S, 1994, DIABETES, V43, P1426, DOI 10.2337/diabetes.43.12.1426; DAGOGOJACK SE, 1993, J CLIN INVEST, V91, P819, DOI 10.1172/JCI116302; DCCT Res Grp, 1991, AM J MED, V90, P450, DOI 10.1016/0002-9343(91)80085-Z; ENSINCK J, 1983, HDB EXPT PHARM, V66, P203; FANELLI CG, 1993, DIABETES, V42, P1683, DOI 10.2337/diabetes.42.11.1683; FRIZZELL RT, 1993, DIABETES, V42, P1253, DOI 10.2337/diabetes.42.9.1253; GERICH JE, 1991, ENDOCR REV, V12, P356, DOI 10.1210/edrv-12-4-356; GINGERICH RL, 1978, DIABETES, V27, P96, DOI 10.2337/diabetes.27.2.96; GOETTING MG, 1990, CRIT CARE MED, V18, P1220, DOI 10.1097/00003246-199011000-00006; GUTNIAK M, 1990, AM J PHYSIOL, V258, pE805, DOI 10.1152/ajpendo.1990.258.5.E805; HELLER SR, 1991, DIABETES, V40, P223, DOI 10.2337/diabetes.40.2.223; KETY SS, 1948, J CLIN INVEST, V27, P476, DOI 10.1172/JCI101994; KORANYI L, 1991, Molecular and Cellular Neuroscience, V2, P244, DOI 10.1016/1044-7431(91)90051-O; KUZUYA H, 1977, DIABETES, V26, P22, DOI 10.2337/diabetes.26.1.22; MCCALL AL, 1982, P NATL ACAD SCI-BIOL, V79, P5406, DOI 10.1073/pnas.79.17.5406; MCCALL AL, 1986, AM J PHYSIOL, V251, pE442, DOI 10.1152/ajpendo.1986.251.4.E442; PARDRIDGE WM, 1990, J BIOL CHEM, V265, P18035; PARDRIDGE WM, 1983, PHYSIOL REV, V63, P1481, DOI 10.1152/physrev.1983.63.4.1481; SCHWARTZ NS, 1987, J CLIN INVEST, V79, P777, DOI 10.1172/JCI112884; SHAH SD, 1985, J LAB CLIN MED, V106, P624; SHAMOON H, 1993, NEW ENGL J MED, V329, P977, DOI 10.1056/nejm199309303291401; SVENDSEN PA, 1982, DIABETOLOGIA, V23, P403; TAKAKURA Y, 1991, BIOCHIM BIOPHYS ACTA, V1070, P1, DOI 10.1016/0005-2736(91)90139-Y; TOWLER DA, 1993, DIABETES, V42, P1791, DOI 10.2337/diabetes.42.12.1791	34	192	194	0	3	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	DEC 28	1995	333	26					1726	1731		10.1056/NEJM199512283332602	http://dx.doi.org/10.1056/NEJM199512283332602			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TM169	7491135				2022-12-28	WOS:A1995TM16900002
J	Hauth, JC; Goldenberg, RL; Andrews, WW; DuBard, MB; Copper, RL				Hauth, JC; Goldenberg, RL; Andrews, WW; DuBard, MB; Copper, RL			Reduced incidence of preterm delivery with metronidazole and erythromycin in women with bacterial vaginosis	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							AMNIOTIC-FLUID INFECTION; PLACEBO-CONTROLLED TRIAL; NONSPECIFIC VAGINITIS; CHLAMYDIA-TRACHOMATIS; INTACT MEMBRANES; PREMATURE LABOR; RISK-FACTORS; GRAM STAIN; BIRTH; ASSOCIATION	Background. Pregnant women with bacterial vaginosis may be at increased risk for preterm delivery, We investigated whether treatment with metronidazole and erythromycin during the second trimester would low er the incidence of delivery before 37 weeks' gestation. Methods. In 624 pregnant women at risk for delivering prematurely, vaginal and cervical cultures and other laboratory tests for bacterial vaginosis were performed at a mean of 22.9 weeks' gestation. We then performed a 2:1 double-blind randomization to treatment with metronidazole and erythromycin (433 women) or placebo (191 women). After treatment, the vaginal and cervical tests were repeated and a second course of treatment was given to women who had bacterial vaginosis at that time (a mean of 27.6 weeks' gestation). Results. A total of 178 women (29 percent) delivered infants at less than 37 weeks' gestation. Eight women were lost to follow-up, In the remaining population, 110 of the 426 women assigned to metronidazole and erythromycin (26 percent) delivered prematurely, as compared with 68 of the 190 assigned to placebo (36 percent, P = 0.01). However, the association between the study treatment and lower rates of prematurity was observed only among the 258 women who had bacterial vaginosis (rate of preterm delivery, 31 percent with treatment vs. 49 percent with placebo; P = 0.006). Of the 358 women who did not have bacterial vaginosis when initially examined, 22 percent of those assigned to metronidazole and erythromycin and 25 percent of those assigned to placebo delivered prematurely (P = 0.55). The lower rate of preterm delivery among the women with bacterial vaginosis who were assigned to the study treatment was observed both in women at risk because of previous preterm delivery (preterm delivery in the treatment group, 39 percent; and in the placebo group, 57 percent; P = 0.02) and in women who weighed less than 50 kg before pregnancy (preterm delivery in the treatment group, 14 percent; and in the placebo group, 33 percent; P = 0.04). Conclusions. Treatment with metronidazole and erythromycin reduced rates of premature delivery in women with bacterial vaginosis and an increased risk for preterm delivery.			Hauth, JC (corresponding author), UNIV ALABAMA, DEPT OBSTET & GYNECOL, 618 S 20TH ST, BIRMINGHAM, AL 35233 USA.				PHS HHS [282-92-0055] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		AMSEL R, 1983, AM J MED, V74, P14, DOI 10.1016/0002-9343(83)91112-9; BOBITT JR, 1981, AM J OBSTET GYNECOL, V140, P947, DOI 10.1016/0002-9378(81)90090-9; BRAND JM, 1986, OBSTET GYNECOL, V68, P682; BRIGGS GG, 1990, DRUGS PREGNANCY LACT, P430; BURTIN P, 1995, AM J OBSTET GYNECOL, V172, P525, DOI 10.1016/0002-9378(95)90567-7; Cassell G., 1993, American Journal of Obstetrics and Gynecology, V168, P425; Cassell G., 1993, American Journal of Obstetrics and Gynecology, V168, P424; ESCHENBACH DA, 1991, AM J OBSTET GYNECOL, V164, P734, DOI 10.1016/0002-9378(91)90506-M; ESCHENBACH DA, 1983, SCAND J INFECT DIS, P73; Goldenberg R., 1995, American Journal of Obstetrics and Gynecology, V172, P303, DOI 10.1016/0002-9378(95)90842-0; GORBACH SL, 1976, J CLIN INVEST, V57, P478, DOI 10.1172/JCI108300; GRAVETT MG, 1986, OBSTET GYNECOL, V67, P229, DOI 10.1097/00006250-198602000-00013; GRAVETT MG, 1986, JAMA-J AM MED ASSOC, V256, P1899; HILLIER SL, 1988, NEW ENGL J MED, V319, P972, DOI 10.1056/NEJM198810133191503; HOLST E, 1994, J CLIN MICROBIOL, V32, P176, DOI 10.1128/JCM.32.1.176-186.1994; KORN AP, 1995, OBSTET GYNECOL, V85, P387, DOI 10.1016/0029-7844(94)00400-8; KROHN MA, 1991, J INFECT DIS, V164, P88, DOI 10.1093/infdis/164.1.88; KURKI T, 1992, OBSTET GYNECOL, V80, P173; LUGOMIRO VI, 1992, JAMA-J AM MED ASSOC, V268, P92, DOI 10.1001/jama.268.1.92; MALOUF M, 1981, OBSTET GYNECOL, V57, P711; MARTIUS J, 1988, OBSTET GYNECOL, V71, P89; MCCORMACK WM, 1987, OBSTET GYNECOL, V69, P202; MCDONALD HM, 1992, BRIT J OBSTET GYNAEC, V99, P190, DOI 10.1111/j.1471-0528.1992.tb14497.x; MCDONALD HM, 1994, OBSTET GYNECOL, V84, P343; MCGREGOR JA, 1986, AM J OBSTET GYNECOL, V154, P98, DOI 10.1016/0002-9378(86)90401-1; Meis P., 1995, American Journal of Obstetrics and Gynecology, V172, P410; MILLER JM, 1980, AM J OBSTET GYNECOL, V136, P796, DOI 10.1016/0002-9378(80)90458-5; MORALES WJ, 1994, AM J OBSTET GYNECOL, V171, P345, DOI 10.1016/S0002-9378(94)70033-8; PHEIFER TA, 1978, NEW ENGL J MED, V298, P1429, DOI 10.1056/NEJM197806292982601; PHILLIPS KD, 1976, J CLIN PATHOL, V29, P428, DOI 10.1136/jcp.29.5.428; PIPER JM, 1993, OBSTET GYNECOL, V82, P348; RIDUAN JM, 1993, AM J OBSTET GYNECOL, V169, P175, DOI 10.1016/0002-9378(93)90157-E; ROMERO R, 1993, AM J OBSTET GYNECOL, V169, P764, DOI 10.1016/0002-9378(93)90003-2; Rosner B., 2010, FUNDAMENTALS BIOSTAT; SPIEGEL CA, 1980, NEW ENGL J MED, V303, P601, DOI 10.1056/NEJM198009113031102; SPIEGEL CA, 1983, SCAND J INFECT DIS, P41; SPIEGEL CA, 1983, J CLIN MICROBIOL, V18, P170, DOI 10.1128/JCM.18.1.170-177.1983; THOMASON JL, 1992, AM J OBSTET GYNECOL, V167, P16, DOI 10.1016/S0002-9378(11)91617-2; WAHBEH CJ, 1984, AM J OBSTET GYNECOL, V148, P739, DOI 10.1016/0002-9378(84)90558-1; WATTS DH, 1992, OBSTET GYNECOL, V79, P351; WEN SW, 1990, AM J OBSTET GYNECOL, V162, P213; 1985, MMWR-MORBID M      S, V34, pS75	42	450	465	0	9	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	DEC 28	1995	333	26					1732	1736		10.1056/NEJM199512283332603	http://dx.doi.org/10.1056/NEJM199512283332603			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TM169	7491136				2022-12-28	WOS:A1995TM16900003
J	CARRERA, MRA; ASHLEY, JA; PARSONS, LH; WIRSCHING, P; KOOB, GF; JANDA, KD				CARRERA, MRA; ASHLEY, JA; PARSONS, LH; WIRSCHING, P; KOOB, GF; JANDA, KD			SUPPRESSION OF PSYCHOACTIVE EFFECTS OF COCAINE BY ACTIVE IMMUNIZATION	NATURE			English	Article							AMPHETAMINE; APOMORPHINE; METABOLISM; SEROTONIN; MORPHINE; NEURONS; HUMANS; MICE; RATS	COCAINE is a powerfully addictive substance and new strategies are needed to treat its abuse. Generating an active immunization(1,2) to cocaine offers a means of blocking the actions of the drug by preventing it from entering the central nervous system, and should have fewer side effects than treatments based on manipulation of central neurotransmitter function. The design and preparation of a cocaine immunogen requires special regard for the stability of cocaine both free and as a haptenic determinant. Immunochemistry and a well defined behavioural model were brought together to address the problem of inactivation of the psychostimulant actions of cocaine. We report here that active immunization with a new, stable cocaine conjugate suppressed locomotor activity and stereotyped behaviour in rats induced by cocaine but not by amphetamine, Moreover, following acute injection of cocaine, levels of cocaine in the striatum and cerebellum of the immunized animals were lower than those of control animals, These results suggest that immunopharmacotherapy may be a promising means by which to explore new treatments for cocaine abuse.	SCRIPPS RES INST, DEPT MOLEC BIOL, LA JOLLA, CA 92037 USA; Scripps Res Inst, DEPT NEUROPHARMACOL, LA JOLLA, CA 92037 USA; Scripps Res Inst, DEPT CHEM, LA JOLLA, CA 92037 USA	Scripps Research Institute; Scripps Research Institute; Scripps Research Institute								BAGASRA O, 1992, IMMUNOPHARMACOLOGY, V23, P173, DOI 10.1016/0162-3109(92)90023-6; BENUCK M, 1987, J PHARMACOL EXP THER, V243, P144; BERKOWITZ B, 1972, SCIENCE, V178, P1290, DOI 10.1126/science.178.4067.1290; CUNNINGHAM KA, 1990, NEUROPSYCHOPHARMACOL, V3, P41; EISEN HN, 1964, METHOD MED RES, P106; FISCHMAN MW, 1983, PHARMACOL BIOCHEM BE, V18, P123, DOI 10.1016/0091-3057(83)90261-7; FRAY PJ, 1980, PSYCHOPHARMACOLOGY, V69, P253, DOI 10.1007/BF00433091; GALLACHER G, 1994, IMMUNOPHARMACOLOGY, V27, P79, DOI 10.1016/0162-3109(94)90009-4; GARRETT ER, 1983, J PHARM SCI, V72, P258, DOI 10.1002/jps.2600720314; GOLD LH, 1988, PHARMACOL BIOCHEM BE, V29, P645, DOI 10.1016/0091-3057(88)90034-2; HILL JH, 1973, CLIN EXP IMMUNOL, V15, P213; JAVAID JI, 1978, SCIENCE, V202, P227, DOI 10.1126/science.694530; KELLY PH, 1975, BRAIN RES, V94, P507, DOI 10.1016/0006-8993(75)90233-4; KELLY PH, 1976, EUR J PHARMACOL, V40, P45, DOI 10.1016/0014-2999(76)90352-6; KULLBACK S, 1968, INFORMATION THEORY S; LANDRY DW, 1993, SCIENCE, V259, P1899, DOI 10.1126/science.8456315; LYON M, 1975, CURRENT DEV PSYCHOPH, V2, P89; MATSUBARA K, 1984, FORENSIC SCI INT, V26, P169, DOI 10.1016/0379-0738(84)90215-9; MINDEN P, 1967, HDB EXPT IMMUNOLOGY, P463; MISRA AL, 1976, RES COMMUN CHEM PATH, V13, P579; RITZ MC, 1987, SCIENCE, V237, P1219, DOI 10.1126/science.2820058; ROBBINS TW, 1977, HDB PSYCHOPHARMACOLO, V7, P37; SPECTOR S, 1973, PHARMACOL REV, V25, P281; Steward M.W., 1983, ANTIBODY AFFINITY TH; STEWART DJ, 1979, CLIN PHARMACOL THER, V25, P464; Taussig M J, 1973, Curr Top Microbiol Immunol, V60, P125	26	170	180	1	13	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	DEC 14	1995	378	6558					727	730		10.1038/378727a0	http://dx.doi.org/10.1038/378727a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TK379	7501020				2022-12-28	WOS:A1995TK37900055
J	LI, M; SENDTNER, M; SMITH, A				LI, M; SENDTNER, M; SMITH, A			ESSENTIAL FUNCTION OF LIF RECEPTOR IN MOTOR-NEURONS	NATURE			English	Article							LEUKEMIA-INHIBITORY FACTOR; IL-6 SIGNAL TRANSDUCER; EMBRYONIC MOTONEURONS; CNTF RECEPTOR; ONCOSTATIN-M; STEM-CELLS; SURVIVAL; RAT; DEGENERATION; EXPRESSION	DEVELOPMENT and maintenance of the mammalian nervous system is dependent upon neurotrophic cytokines. One class of neurotrophic factor acts through receptor complexes involving the low-affinity leukaemia inhibitory factor receptor subunit (LIF-R)(1-3). Members of this family of cytokines, such as ciliary neurotrophic factor (CNTF) and leukaemia inhibitory factor (LIF), have profound effects on the survival and maintenance of motor neurons(4-10). Recently it was reported that mice lacking LIF-R die shortly after birth(11) unlike mice lacking CNTF or LIF which are viable. Here we describe histopathological analyses of lifr mutants that reveal a loss >35% of facial motor neurons, 40% of spinal motor neurons and 50% of neurons in the nucleus ambiguus. These findings point to the existence of a ligand for LIF-R that is required for the normal development of motor neurons in both brainstem nuclei and spinal cord.	UNIV EDINBURGH,CTR GENOME RES,EDINBURGH EH9 3JQ,MIDLOTHIAN,SCOTLAND; UNIV WURZBURG,DEPT NEUROL,CLIN RES UNIT NEUROREGENERAT,D-97080 WURZBURG,GERMANY	University of Edinburgh; University of Wurzburg			Sendtner, Michael/M-8137-2014; Sendtner, Michael/J-1542-2012; Li, Meng/I-6941-2013	Sendtner, Michael/0000-0002-4737-2974; Sendtner, Michael/0000-0002-4737-2974; Smith, Austin/0000-0002-3029-4682				ARAKAWA Y, 1990, J NEUROSCI, V10, P3507; BEDDINGTON RSP, 1989, DEVELOPMENT, V106, P37; DAVIS S, 1993, SCIENCE, V260, P1805, DOI 10.1126/science.8390097; ELLENBERGER HH, 1990, J COMP NEUROL, V294, P202, DOI 10.1002/cne.902940205; ESCARY JL, 1993, NATURE, V363, P361, DOI 10.1038/363361a0; GEARING DP, 1992, SCIENCE, V255, P1434, DOI 10.1126/science.1542794; GEARING DP, 1991, EMBO J, V10, P2839, DOI 10.1002/j.1460-2075.1991.tb07833.x; HUGHES RA, 1993, J NEUROSCI RES, V36, P663, DOI 10.1002/jnr.490360607; IP NY, 1993, NEURON, V10, P89, DOI 10.1016/0896-6273(93)90245-M; MARTINOU JC, 1992, NEURON, V8, P737, DOI 10.1016/0896-6273(92)90094-T; MASU Y, 1993, NATURE, V365, P27, DOI 10.1038/365027a0; MOUNTFORD P, 1994, P NATL ACAD SCI USA, V91, P4303, DOI 10.1073/pnas.91.10.4303; MOUNTFORD PS, 1995, TRENDS GENET, V11, P179, DOI 10.1016/S0168-9525(00)89040-X; PATON JFR, 1994, PFLUG ARCH EUR J PHY, V428, P250, DOI 10.1007/BF00724504; PENNICA D, 1995, J BIOL CHEM, V270, P10915, DOI 10.1074/jbc.270.18.10915; RICHARDS LJ, 1992, J NEUROSCI RES, V33, P476, DOI 10.1002/jnr.490330314; ROSE TM, 1991, P NATL ACAD SCI USA, V88, P8641, DOI 10.1073/pnas.88.19.8641; SENDTNER M, 1990, NATURE, V345, P440, DOI 10.1038/345440a0; SKARNES WC, 1992, GENE DEV, V6, P903, DOI 10.1101/gad.6.6.903; Smith AG., 1991, J TISSUE CULT METHOD, V13, P89, DOI [10.1007/BF01666137, DOI 10.1007/BF01666137, 10.1007/bf01666137]; SMITH JC, 1990, J NEUROPHYSIOL, V64, P1149, DOI 10.1152/jn.1990.64.4.1149; STAHL N, 1994, J NEUROBIOL, V25, P1454, DOI 10.1002/neu.480251111; STEWART CL, 1992, NATURE, V359, P76, DOI 10.1038/359076a0; WARE CB, 1995, DEVELOPMENT, V121, P1283; WILKINSON DG, 1992, IN SITU HYBRIDIZATIO; ZURN AD, 1994, DEV BIOL, V163, P309, DOI 10.1006/dbio.1994.1150	26	263	268	0	4	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	DEC 14	1995	378	6558					724	727		10.1038/378724a0	http://dx.doi.org/10.1038/378724a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TK379	7501019	Green Submitted			2022-12-28	WOS:A1995TK37900054
J	STEITZ, JA; TYCOWSKI, KT				STEITZ, JA; TYCOWSKI, KT			SMALL RNA CHAPERONES FOR RIBOSOME BIOGENESIS	SCIENCE			English	Editorial Material							DEPLETION				STEITZ, JA (corresponding author), YALE UNIV,SCH MED,DEPT BIOCHEM & MOLEC BIOPHYS,HOWARD HUGHES MED INST,NEW HAVEN,CT 06536, USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM026154, R01GM026154] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM26154] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BACHELLERIE JP, 1995, TRENDS BIOCHEM SCI, V20, P261, DOI 10.1016/S0968-0004(00)89039-8; BELTRAME M, 1995, EMBO J, V14, P4350, DOI 10.1002/j.1460-2075.1995.tb00109.x; BRAM RJ, 1980, CELL, V19, P393, DOI 10.1016/0092-8674(80)90513-9; HUGHES JMX, 1991, EMBO J, V10, P4231, DOI 10.1002/j.1460-2075.1991.tb05001.x; KISS T, 1995, GENE DEV, V9, P1411, DOI 10.1101/gad.9.11.1411; LI HV, 1990, MOL CELL BIOL, V10, P1145, DOI 10.1128/MCB.10.3.1145; LIANG WQ, 1995, GENE DEV, V9, P2433, DOI 10.1101/gad.9.19.2433; MAXWELL ES, 1995, ANNU REV BIOCHEM, V35, P897; MILLER OL, 1969, SCIENCE, V164, P955, DOI 10.1126/science.164.3882.955; MORRISSEY JP, 1995, TRENDS BIOCHEM SCI, V20, P78, DOI 10.1016/S0968-0004(00)88962-8; MOUGEY EB, 1993, GENE DEV, V7, P1609, DOI 10.1101/gad.7.8.1609; PECULIS BA, 1993, CELL, V73, P1233, DOI 10.1016/0092-8674(93)90651-6; RIMOLDI OJ, 1993, MOL CELL BIOL, V13, P4382, DOI 10.1128/MCB.13.7.4382; SOLLNERWEBB B, IN PRESS RIBOSOMAL R; TYCOWSKI KT, 1994, SCIENCE, V266, P1558, DOI 10.1126/science.7985025; TYCOWSKI KT, UNPUB	16	67	68	0	2	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	DEC 8	1995	270	5242					1626	1627		10.1126/science.270.5242.1626	http://dx.doi.org/10.1126/science.270.5242.1626			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TJ293	7502072				2022-12-28	WOS:A1995TJ29300035
J	MALANE, MS; LAUDE, TA; CHEN, CK; FIKRIG, S				MALANE, MS; LAUDE, TA; CHEN, CK; FIKRIG, S			AN HIV-1-POSITIVE CHILD WITH FEVER AND A SCALP NODULE	LANCET			English	Note									SUNY HLTH SCI CTR,DEPT PEDIAT,BROOKLYN,NY 11203; SUNY HLTH SCI CTR,DEPT PATHOL,BROOKLYN,NY 11203	State University of New York (SUNY) System; State University of New York (SUNY) Downstate Medical Center; State University of New York (SUNY) System; State University of New York (SUNY) Downstate Medical Center	MALANE, MS (corresponding author), SUNY HLTH SCI CTR,DEPT DERMATOL,450 CLARKSON AVE,BOX 46,BROOKLYN,NY 11203, USA.							ADAL KA, 1994, NEW ENGL J MED, V330, P1509, DOI 10.1056/NEJM199405263302108; KOEHLER JE, 1993, CLIN INFECT DIS, V17, P612, DOI 10.1093/clinids/17.4.612; PAUL MA, 1994, PEDIATR DERMATOL, V11, P338, DOI 10.1111/j.1525-1470.1994.tb00101.x; SLATER LN, 1995, PRINCIPLES PRACTICE, P1741; STOLER MH, 1983, AM J CLIN PATHOL, V80, P714, DOI 10.1093/ajcp/80.5.714	5	6	6	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	DEC 2	1995	346	8988					1466	1466		10.1016/S0140-6736(95)92476-0	http://dx.doi.org/10.1016/S0140-6736(95)92476-0			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TH156	7490995				2022-12-28	WOS:A1995TH15600013
J	PARKES, C; WALD, NJ; MURPHY, P; GEORGE, L; WATT, HC; KIRBY, R; KNEKT, P; HELZLSOUER, KJ; TUOMILEHTO, J				PARKES, C; WALD, NJ; MURPHY, P; GEORGE, L; WATT, HC; KIRBY, R; KNEKT, P; HELZLSOUER, KJ; TUOMILEHTO, J			PROSPECTIVE OBSERVATIONAL STUDY TO ASSESS VALUE OF PROSTATE-SPECIFIC ANTIGEN AS SCREENING-TEST FOR PROSTATE-CANCER	BMJ-BRITISH MEDICAL JOURNAL			English	Article							SERUM VITAMIN-E; RISK; SELENIUM; MEN	Objective-To evaluate measurement of serum prostate specific antigen as a potential screening test for future clinical prostate cancer among healthy men. Design-Nested case-control study with stored serum samples collected from 49261 men with follow up using national death and cancer registration systems. Subjects-265 asymptomatic men who subsequently developed clinical prostate cancer and 1055 controls matched for age, study centre, and duration of storage of samples. Main outcome measures-Distribution of concentrations of the antigen in men who developed prostate cancer and in controls. Results-Prostate specific antigen concentrations were significantly higher in men who subsequently developed prostate cancer than in controls. In the first three years after blood collection the median concentration was 23 times greater in cases than in controls of the same age at the same centre (that is, 23 multiples of the median). A smaller difference persisted thereafter; 4.0 multiples of the median 3-6 years after blood collection, 3.6 6-10 years, and 1.8 after 10 years. In the first three years the proportion of men who developed prostate cancer and had raised levels of the antigen (greater than or equal to 12 multiples of the median) (detection rate or sensitivity) was 81% (95% confidence interval 54% to 96%). The proportion of men who did not develop prostate cancer but had levels this high (false positive rate) was only 0.5%. Conclusion-Prostate specific antigen measurement is a highly discriminatory screening test for prostate cancer among healthy men. In the general population, 60-74 year old men who had greater than or equal to 12 times the normal median level would have about a 50% chance of developing clinical prostate cancer in the next three years. Measurement of this antigen is a good enough screening test to justify a randomised controlled trial to determine any reduction in mortality from prostate cancer.	UNIV LONDON ST BARTHOLOMEWS HOSP & MED COLL, WOLFSON INST PREVENT MED, LONDON EC1M 6BQ, ENGLAND; UNIV LONDON ST BARTHOLOMEWS HOSP & MED COLL, DEPT UROL, LONDON EC1A 7BE, ENGLAND; NATL PUBL HLTH INST, DEPT HLTH & DISABIL, HELSINKI, FINLAND; SOCIAL INSURANCE INST, RES & DEV UNIT, HELSINKI, FINLAND; JOHNS HOPKINS UNIV, SCH HYG & PUBL HLTH, DEPT EPIDEMIOL, TRAINING CTR PUBL HLTH RES, BALTIMORE, MD 21742 USA; NATL PUBL HLTH INST, DEPT EPIDEMIOL & HLTH PROMOT, HELSINKI, FINLAND	University of London; Queen Mary University London; University of London; Queen Mary University London; Finland National Institute for Health & Welfare; Johns Hopkins University; Finland National Institute for Health & Welfare			Wald, Nicholas/AAY-8924-2021; Wald, Nicholas/AAY-2814-2021					AXTELL LM, 1976, US DHEW5 REP; BRESLOW N, 1977, INT J CANCER, V20, P680, DOI 10.1002/ijc.2910200506; CARTER HB, 1992, JAMA-J AM MED ASSOC, V267, P2215, DOI 10.1001/jama.267.16.2215; CATALONA WJ, 1991, NEW ENGL J MED, V324, P1156, DOI 10.1056/NEJM199104253241702; CHODAK GW, 1994, NEW ENGL J MED, V330, P242, DOI 10.1056/NEJM199401273300403; FRANKS LM, 1954, J PATHOL BACTERIOL, V68, P603, DOI 10.1002/path.1700680233; GANN PH, 1995, JAMA-J AM MED ASSOC, V273, P289, DOI 10.1001/jama.273.4.289; HELZLSOUER KJ, 1989, CANCER RES, V49, P6144; HELZLSOUER KJ, 1992, CANCER EPIDEM BIOMAR, V1, P537; JOHANSSON JE, 1992, JAMA-J AM MED ASSOC, V267, P2191, DOI 10.1001/jama.267.16.2191; KABALIN JN, 1989, J UROLOGY, V141, P1091, DOI 10.1016/S0022-5347(17)41178-5; KILLIAN CS, 1990, CANCER INVEST, V8, P27, DOI 10.3109/07357909009017544; KNEKT P, 1988, INT J CANCER, V42, P846, DOI 10.1002/ijc.2910420609; OESTERLING JE, 1993, JAMA-J AM MED ASSOC, V270, P860, DOI 10.1001/jama.270.7.860; PALKEN M, 1990, J UROLOGY, V143, P1155, DOI 10.1016/S0022-5347(17)40213-8; PUSKA P, 1979, BRIT MED J, V2, P1173, DOI 10.1136/bmj.2.6199.1173; STAMEY TA, 1989, J UROLOGY, V141, P1070; STENMAN UH, 1994, LANCET, V344, P1594, DOI 10.1016/S0140-6736(94)90405-7; WALD NJ, 1987, BRIT J CANCER, V56, P69, DOI 10.1038/bjc.1987.156; WHITTEMORE AS, 1995, J NATL CANCER I, V87, P354, DOI 10.1093/jnci/87.5.354; 1994, CANCER STATISTICS RE; 1990, 3813BE HYBR EUR CAT; 1993, MORTALITY STATIS DH2	23	54	54	0	2	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	NOV 18	1995	311	7016					1340	1343		10.1136/bmj.311.7016.1340	http://dx.doi.org/10.1136/bmj.311.7016.1340			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TF901	7496284	Green Published			2022-12-28	WOS:A1995TF90100022
J	DENNING, DW; EVANS, EGV; KIBBLER, CC; RICHARDSON, MD; ROBERTS, MM; ROGERS, TR; WARNOCK, DW; WARREN, RE				DENNING, DW; EVANS, EGV; KIBBLER, CC; RICHARDSON, MD; ROBERTS, MM; ROGERS, TR; WARNOCK, DW; WARREN, RE			FORTNIGHTLY REVIEW - FUNGAL NAIL DISEASE - A GUIDE TO GOOD PRACTICE (REPORT OF A WORKING GROUP OF THE BRITISH-SOCIETY-FOR-MEDICAL-MYCOLOGY)	BMJ-BRITISH MEDICAL JOURNAL			English	Article							DERMATOPHYTE ONYCHOMYCOSIS; DERMATOMYCOSES; INFECTIONS	The term onychomycosis refers to fungal infection of the nails whether this is a primary event or a secondary infection of a previously diseased or traumatised nail. Infection may be due to dermatophyte (ringworm, tinea unguium), yeast, or other non-dermatophyte (mould) species, and the clinical appearance may indicate the nature of the offending organism. In paronychia chronic infection of the nail fold is most often coused by Candida species, but bacterial infection with Gram negative species such as Pseudomonas may coexist. Acute paronychia (whitlow) due to staphylococcal infection may also occur, and the presence of these bacterial infections will influence management. Invasion of the nail plate by Candida species may occur in the presence of paronychia, immune deficiency state (including chronic mucocutaneous candidiasis), Raynaud's disease, or endocrine disorders. This paper reviews the clinical features of onychomycosis and the differential diagnosis of nail dystrophy, gives the reasons for appropriate mycological investigation, and discusses guidelines for appropriate treatment on the basis of laboratory findings and particular clinical situations.	UNIV SALFORD, HOPE HOSP, DEPT DERMATOL, SALFORD M6 8MD, LANCS, ENGLAND; N MANCHESTER GRP HOSP, DEPT INFECT DIS & TROP MED, MONSALL UNIT, MANCHESTER M8 5RB, LANCS, ENGLAND; UNIV LEEDS, DEPT MICROBIOL, PUBL HLTH LAB SERV, MYCOL REFERENCE LAB, LEEDS LS2 9JT, W YORKSHIRE, ENGLAND; ROYAL FREE HOSP, DEPT MED MICROBIOL, LONDON, ENGLAND; UNIV GLASGOW, DEPT DERMATOL, REG MYCOL REFERENCE LAB, GLASGOW G12 8QQ, LANARK, SCOTLAND; ROYAL POSTGRAD MED SCH, DEPT INFECT DIS & BACTERIOL, LONDON, ENGLAND; PUBL HLTH LAB, PUBL HLTH LAB SERV, MYCOL REFERENCE LAB, BRISTOL, AVON, ENGLAND; ROYAL SHREWSBURY HOSP, PUBL HLTH LAB, SHREWSBURY, ENGLAND	University of Salford; University of Leeds; University of London; University College London; Royal Free London NHS Foundation Trust; UCL Medical School; University of Glasgow; Imperial College London			Denning, David/AAC-6931-2019	Denning, David/0000-0001-5626-2251; Rogers, Thomas/0000-0003-4336-7729; Richardson, Malcolm/0000-0001-5672-9552				ALTERAS I, 1971, MYKOSEN, V16, P227; ANDRE J, 1987, INT J DERMATOL, V26, P481, DOI 10.1111/j.1365-4362.1987.tb02287.x; CLAYTON YM, 1992, CLIN EXP DERMATOL, V17, P37, DOI 10.1111/j.1365-2230.1992.tb00276.x; DAVIES RR, 1967, BMJ-BRIT MED J, V3, P464, DOI 10.1136/bmj.3.5563.464; ENGLISH MP, 1959, BMJ-BRIT MED J, V1, P1442, DOI 10.1136/bmj.1.5135.1442; ENGLISH MP, 1967, BMJ-BRIT MED J, V3, P136, DOI 10.1136/bmj.3.5558.136; GANOR S, 1975, BRIT J DERMATOL, V92, P685, DOI 10.1111/j.1365-2133.1975.tb03150.x; GENTLES JC, 1973, BMJ-BRIT MED J, V3, P260, DOI 10.1136/bmj.3.5874.260; GOODFIELD MJD, 1992, BRIT MED J, V304, P1151, DOI 10.1136/bmj.304.6835.1151; HANEKE E, 1991, SEMIN DERMATOL, V10, P41; HOWELL SA, 1988, MICROBIOL ECOL HLTH, V1, P31; JEVONS S, 1985, TROSYL TIOCONAZOLE P, P122; NOLTING S, 1994, BRIT J DERMATOL, V130, P16, DOI 10.1111/j.1365-2133.1994.tb06088.x; ROBERTS DT, 1992, BRIT J DERMATOL, V126, P23, DOI 10.1111/j.1365-2133.1992.tb00005.x; WALSHE MM, 1966, BRIT J DERMATOL, V78, P198, DOI 10.1111/j.1365-2133.1966.tb12205.x; WHITE MI, 1982, CLIN EXP DERMATOL, V7, P273, DOI 10.1111/j.1365-2230.1982.tb02427.x; WILLIAMS HC, 1993, BRIT J DERMATOL, V129, P101, DOI 10.1111/j.1365-2133.1993.tb03510.x; ZAIAS N, 1969, ARCH DERMATOL, V99, P567, DOI 10.1001/archderm.99.5.567; ZAUG M, 1992, CLIN EXP DERMATOL, V17, P61, DOI 10.1111/j.1365-2230.1992.tb00281.x	19	41	42	0	3	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	NOV 11	1995	311	7015					1277	1281		10.1136/bmj.311.7015.1277	http://dx.doi.org/10.1136/bmj.311.7015.1277			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TE859	7496239	Green Published			2022-12-28	WOS:A1995TE85900026
J	BJORO, K; FROLAND, SS; YUN, ZB; SAMDAL, HH; HAALAND, T				BJORO, K; FROLAND, SS; YUN, ZB; SAMDAL, HH; HAALAND, T			HEPATITIS-C INFECTION IN PATIENTS WITH PRIMARY HYPOGAMMAGLOBULINEMIA AFTER TREATMENT WITH CONTAMINATED IMMUNE GLOBULIN	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							NON-B-HEPATITIS; NON-A-HEPATITIS; INTRAVENOUS GAMMA-GLOBULIN; ALPHA-INTERFERON THERAPY; VIRUS HCV RNA; BLOOD-DONORS; IMMUNOGLOBULIN; SERUM; DEFICIENCY; GENOTYPES	Background. In Scandinavia many patients with primary hypogammaglobulinemia contracted non-A, non-B hepatitis after intravenous treatment with an immune globulin product that was later found to contain a non-A, non-B hepatitis virus. Methods. We studied the prevalence and clinical course of hepatitis C virus (HCV) infection in a group of 55 Norwegian patients with primary hypogammaglobulinemia and investigated its association with the use of contaminated immune globulin. We used the polymerase chain reaction to detect HCV RNA and performed HCV genotyping. We also analyzed the responses to treatment with interferon. Results. Of 20 patients who received the contaminated immune globulin, 17 were seropositive for HCV RNA, In addition, 1 of 35 patients not exposed to the contaminated immune globulin was HCV RNA-positive. HCV genotype V was found in all 12 patients for whom genotyping was performed, but 8 patients also had genotype II or III, or both. All HCV RNA-positive patients had abnormal results on biochemical liver tests. All liver-biopsy specimens (from 15 patients) were abnormal, with portal inflammation, bile-duct damage, and focal necrosis. In six patients there was cirrhosis. Two patients died of liver failure. In 4 of the 10 patients treated with interferon there were complete, though transient, biochemical responses, but the follow-up biopsy specimens showed evidence of histologic progression. The poorest responses to interferon were among the patients with multiple HCV genotypes. All but one patient remained positive for HCV RNA. Conclusions. In patients with primary hypogammaglobulinemia there was a high rate of HCV infection after treatment with contaminated immune globulin. In these immunocompromised patients HCV infection has a severe and rapidly progressive course, and responses to interferon are poor.	NATL HOSP NORWAY, DEPT MED A, HEPATOL & GASTROENTEROL SECT, N-0027 OSLO, NORWAY; NATL HOSP NORWAY, DEPT PATHOL, N-0027 OSLO, NORWAY; NATL INST PUBL HLTH, DEPT VIROL, OSLO, NORWAY; KAROLINSKA INST, HUDDINGE HOSP, INST CLIN VIROL, S-10401 STOCKHOLM, SWEDEN	University of Oslo; National Hospital Norway; University of Oslo; National Hospital Norway; Karolinska Institutet	BJORO, K (corresponding author), NATL HOSP NORWAY, DEPT MED A, CLIN IMMUNOL & INFECT DIS SECT, N-0027 OSLO, NORWAY.							ALTER HJ, 1992, VIRAL HEPATITIS LIVE, P396; AUKRUST P, 1992, CLIN EXP IMMUNOL, V89, P211; BJORKANDER J, 1988, AM J MED, V84, P107, DOI 10.1016/0002-9343(88)90016-2; CHEMELLO L, 1994, NEW ENGL J MED, V330, P143, DOI 10.1056/NEJM199401133300215; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CUNNINGHAMRUNDLES C, 1989, J CLIN IMMUNOL, V9, P22, DOI 10.1007/BF00917124; DUSHEIKO G, 1994, HEPATOLOGY, V19, P13, DOI 10.1016/0270-9139(94)90046-9; FORBES A, 1993, GUT, V34, P116, DOI 10.1136/gut.34.1.116; GARSON JA, 1991, LANCET, V338, P1466, DOI 10.1016/0140-6736(91)92775-W; GEROLAMI V, 1993, J INFECT DIS, V168, P1328, DOI 10.1093/infdis/168.5.1328; HAGIWARA H, 1992, HEPATOLOGY, V15, P37, DOI 10.1002/hep.1840150108; IWARSON S, 1987, SERODIAGN IMMUNOTHER, V1, P261; KWOK S, 1989, NATURE, V339, P237, DOI 10.1038/339237a0; LANE RS, 1983, LANCET, V2, P974; LEVER AML, 1984, LANCET, V2, P1062; NORDOY I, 1994, SCAND J GASTROENTERO, V29, P77, DOI 10.3109/00365529409090441; OKAMOTO H, 1993, J GEN VIROL, V74, P2385, DOI 10.1099/0022-1317-74-11-2385; REINHERZ EL, 1979, NEW ENGL J MED, V301, P1018, DOI 10.1056/NEJM197911083011902; SEEFF LB, 1992, NEW ENGL J MED, V327, P1906, DOI 10.1056/NEJM199212313272703; SHINDO M, 1991, ANN INTERN MED, V115, P700, DOI 10.7326/0003-4819-115-9-700; SIMMONDS P, 1993, J GEN VIROL, V74, P2391, DOI 10.1099/0022-1317-74-11-2391; SKAUG K, 1993, VOX SANG, V64, P215, DOI 10.1111/j.1423-0410.1993.tb03058.x; SPICKETT GP, 1991, LANCET, V337, P281, DOI 10.1016/0140-6736(91)90882-P; THOMSON BJ, 1987, LANCET, V1, P539; TINE F, 1991, J HEPATOL, V13, P192, DOI 10.1016/0168-8278(91)90814-R; WEBSTER ADB, 1988, IMMUNOL INVEST, V17, P93, DOI 10.3109/08820138809055722; WEBSTER ADB, 1986, LANCET, V1, P322; WEILAND O, 1986, LANCET, V1, P976; WILLIAMS PE, 1989, VOX SANG, V57, P15, DOI 10.1111/j.1423-0410.1989.tb04977.x; YEI S, 1992, TRANSFUSION, V32, P824, DOI 10.1046/j.1537-2995.1992.32993110753.x; YUN ZB, 1993, J MED VIROL, V39, P57, DOI 10.1002/jmv.1890390111; 1989, IMMUNODEFIC REV, V1, P173	32	336	340	0	5	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	DEC 15	1994	331	24					1607	1611		10.1056/NEJM199412153312402	http://dx.doi.org/10.1056/NEJM199412153312402			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PW446	7526215				2022-12-28	WOS:A1994PW44600002
J	MUTIMER, DJ; HARRISON, RF; ODONNELL, KB; SHAW, J; MARTIN, BAB; ATRAH, H; ALA, FA; SKIDMORE, S; HUBSCHER, SG; NEUBERGER, JM; ELIAS, E				MUTIMER, DJ; HARRISON, RF; ODONNELL, KB; SHAW, J; MARTIN, BAB; ATRAH, H; ALA, FA; SKIDMORE, S; HUBSCHER, SG; NEUBERGER, JM; ELIAS, E			HEPATITIS-C IN ASYMPTOMATIC BRITISH BLOOD-DONORS WITH INDETERMINATE SEROPOSITIVITY	BRITISH MEDICAL JOURNAL			English	Article							VIRUS		UNIV BIRMINGHAM,DEPT PATHOL,BIRMINGHAM,ENGLAND; UNIV BIRMINGHAM,DEPT INFECT,BIRMINGHAM,ENGLAND; W MIDLANDS REG HLTH AUTHOR,BLOOD TRANSFUS SERV,BIRMINGHAM,W MIDLANDS,ENGLAND; REG VIROL LABS,E BIRMINGHAM,ENGLAND	University of Birmingham; University of Birmingham	MUTIMER, DJ (corresponding author), QUEEN ELIZABETH HOSP,LIVER UNIT,BIRMINGHAM B15 2TH,W MIDLANDS,ENGLAND.		Neuberger, James/ABG-3010-2020					CHEMELLO L, 1993, HEPATOLOGY, V17, P179, DOI 10.1002/hep.1840170203; FOLLETT EAC, 1992, LANCET, V339, P928, DOI 10.1016/0140-6736(92)90964-5; IRVING WL, 1994, BRIT MED J, V308, P695, DOI 10.1136/bmj.308.6930.695; SCHEUER PJ, 1992, HEPATOLOGY, V15, P567, DOI 10.1002/hep.1840150402; SERFATY L, 1993, HEPATOLOGY, V17, P183, DOI 10.1002/hep.1840170204	5	9	9	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	OCT 1	1994	309	6958					847	848		10.1136/bmj.309.6958.847	http://dx.doi.org/10.1136/bmj.309.6958.847			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PK501	7524875	Green Published			2022-12-28	WOS:A1994PK50100023
J	BENSIMON, A; SIMON, A; CHIFFAUDEL, A; CROQUETTE, V; HESLOT, F; BENSIMON, D				BENSIMON, A; SIMON, A; CHIFFAUDEL, A; CROQUETTE, V; HESLOT, F; BENSIMON, D			ALIGNMENT AND SENSITIVE DETECTION OF DNA BY A MOVING INTERFACE	SCIENCE			English	Article							NUCLEIC-ACIDS; GEL-ELECTROPHORESIS; MAGNETIC BEADS; MOLECULES; HYBRIDIZATION; MICROSCOPY; ASSEMBLIES	In a process called ''molecular combing,'' DNA molecules attached at one end to a solid surface were extended and aligned by a receding air-water interface and left to dry on the surface. Molecular combing was observed to extend the length of the bacteriophage lambda DNA molecule to 21.5 +/- 0.5 micrometers (unextended length, 16.2 micrometers). With the combing process, it was possible to (i) extend a chromosomal Escherichia coli DNA fragment (10(6) base pairs) and (ii) detect a minute quantity of DNA (10(3) molecules). These results open the way for a faster physical mapping of the genome and for the detection of small quantities of target DNA from a population of molecules.	ECOLE NORMALE SUPER,PHYS STAT LAB,F-75005 PARIS,FRANCE; ECOLE NORMALE SUPER,PHYS MAT CONDENSEE LAB,F-75005 PARIS,FRANCE	UDICE-French Research Universities; PSL Research University Paris; Ecole Normale Superieure (ENS); UDICE-French Research Universities; PSL Research University Paris; Ecole Normale Superieure (ENS)	BENSIMON, A (corresponding author), INST PASTEUR,F-75015 PARIS,FRANCE.		Bensimon, David/E-7768-2015; heslot, françois/AAF-9406-2021	Bensimon, David/0000-0003-1971-9907; Croquette, Vincent/0000-0003-1400-0039				BENSIMON D, UNPUB; BRZOSKA JB, 1992, NATURE, V360, P719, DOI 10.1038/360719a0; BUSTAMANTE C, 1993, CURR OPIN STRUC BIOL, V3, P363, DOI 10.1016/S0959-440X(05)80107-1; CHU S, 1991, SCIENCE, V253, P861, DOI 10.1126/science.253.5022.861; DICKERSON RE, 1983, COLD SPRING HARB SYM, V47, P13; GUESDON JL, 1992, J IMMUNOL METHODS, V150, P33, DOI 10.1016/0022-1759(92)90063-Y; HOUSEAL TW, 1989, BIOPHYS J, V56, P507, DOI 10.1016/S0006-3495(89)82697-9; INNIS MA, 1990, PCR PROTOCOLS; ISRAELACHVILI JN, 1985, INTERMOLECULAR SURFA, P24; KABATA H, 1993, SCIENCE, V262, P1561, DOI 10.1126/science.8248804; LABROUSSE H, 1982, J IMMUNOL METHODS, V48, P133, DOI 10.1016/0022-1759(82)90188-0; LANGDALE JA, 1985, GENE, V36, P201, DOI 10.1016/0378-1119(85)90175-1; LICHTER P, 1990, SCIENCE, V247, P64, DOI 10.1126/science.2294592; LUND V, 1988, NUCLEIC ACIDS RES, V16, P10861, DOI 10.1093/nar/16.22.10861; NETZER L, 1983, J AM CHEM SOC, V105, P674, DOI 10.1021/ja00341a087; PARRA I, 1993, NAT GENET, V5, P17, DOI 10.1038/ng0993-17; PERKINS TT, 1994, SCIENCE, V264, P819, DOI 10.1126/science.8171335; PERKINS TT, 1994, SCIENCE, V264, P822, DOI 10.1126/science.8171336; SAIKI RK, 1985, SCIENCE, V230, P1350, DOI 10.1126/science.2999980; SCHWARTZ DC, 1993, SCIENCE, V262, P110, DOI 10.1126/science.8211116; SCHWARTZ DC, 1989, NATURE, V338, P520, DOI 10.1038/338520a0; SMITH SB, 1992, SCIENCE, V258, P1122, DOI 10.1126/science.1439819; SMITH SB, 1989, SCIENCE, V243, P203, DOI 10.1126/science.2911733; VOLKMUTH WD, 1992, NATURE, V358, P600, DOI 10.1038/358600a0; Yanagida M, 1983, Cold Spring Harb Symp Quant Biol, V47 Pt 1, P177; YANAGIDA M, 1986, APPLICATIONS FLUORES, P321; ZIMMERMANN RM, 1994, NUCLEIC ACIDS RES, V22, P492, DOI 10.1093/nar/22.3.492	27	691	767	2	134	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	SEP 30	1994	265	5181					2096	2098		10.1126/science.7522347	http://dx.doi.org/10.1126/science.7522347			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PJ912	7522347				2022-12-28	WOS:A1994PJ91200031
J	MARENGERE, LEM; ZHOU, SY; GISH, GD; SCHALLER, MD; PARSONS, JT; STERN, MJ; CANTLEY, LC; PAWSON, T				MARENGERE, LEM; ZHOU, SY; GISH, GD; SCHALLER, MD; PARSONS, JT; STERN, MJ; CANTLEY, LC; PAWSON, T			SH2 DOMAIN SPECIFICITY AND ACTIVITY MODIFIED BY A SINGLE RESIDUE	NATURE			English	Article							TYROSINE-PHOSPHORYLATED PEPTIDES; AFFINITY PHOSPHOTYROSYL PEPTIDE; GROWTH-FACTOR RECEPTORS; SIGNALING GENE SEM-5; TRANSFORMING PROTEIN; SRC; BINDING; GRB2; TRANSDUCTION; RECOGNITION	MANY intracellular targets of protein-tyrosine kinases possess Src homology 2 (SH2) domains that directly recognize phosphotyrosine-containing sites on autophosphorylated growth factor receptors and cytoplasmic proteins, and thereby mediate the activation of biochemical signalling pathways(1-7) SH2 domains possess relatively well conserved residues that form the phosphotyrosine-binding pocket(8-11), and more variable residues that are implicated in determining binding specificity by recognition of the three amino acids carboxy-terminal to phosphotyrosine (the +1 to +3 positions)(5,7,12,13). One such residue, occupying the EF1 position of the +3-binding pocket, is a Thr in the SH2 domain of the Src tyrosine kinase(12), but is predicted to be a Trp in the SH2 domain of the Sem-5/drk/Grb2 adaptor protein(5). Here eve report that changing this residue in the Src SH2 domain from Thr to Trp switches its selectivity to resemble that of the Sem-5-/drk/Grb2 SH2 domain. Furthermore, this mutant Src SH2 domain effectively substitutes for the SH2 domain of the Sem-5 protein in activation of the Ras pathway in vivo. These results identify a residue that can modify SH2 selectivity, and indicate that the biological activity of an SH2 domain correlates with its binding specificity.	UNIV TORONTO, DEPT MOLEC & MED GENET, TORONTO M5S 1A8, ON, CANADA; HARVARD UNIV, SCH MED, DEPT CELL BIOL, BOSTON, MA 02115 USA; BETH ISRAEL HOSP, DEPT MED, BOSTON, MA 02115 USA; UNIV VIRGINIA, DEPT MICROBIOL, CHARLOTTESVILLE, VA 22908 USA; UNIV VIRGINIA, CTR CANC, CHARLOTTESVILLE, VA 22908 USA; YALE UNIV, BOYER CTR MOLEC MED, NEW HAVEN, CT 06536 USA	University of Toronto; Harvard University; Harvard Medical School; Harvard University; Beth Israel Deaconess Medical Center; University of Virginia; University of Virginia; Yale University	MARENGERE, LEM (corresponding author), MT SINAI HOSP, SAMUEL LUNENFELD RES INST, DIV MOLEC & DEV BIOL, 600 UNIV AVE, TORONTO M5G 1X5, ON, CANADA.		Pawson, Tony J/E-4578-2013; Cantley, Lewis C/D-1800-2014; Gish, Gerald D/C-7228-2017	Cantley, Lewis C/0000-0002-1298-7653; 				ANDERSON D, 1990, SCIENCE, V250, P979, DOI 10.1126/science.2173144; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; CLARK SG, 1992, NATURE, V356, P340, DOI 10.1038/356340a0; COBB BS, 1984, MOL CELL BIOL, V14, P1147; ECK MJ, 1993, NATURE, V362, P87, DOI 10.1038/362087a0; FANTL WJ, 1992, CELL, V69, P413, DOI 10.1016/0092-8674(92)90444-H; FELDER S, 1993, MOL CELL BIOL, V13, P1449, DOI 10.1128/MCB.13.3.1449; HANKS SK, 1992, P NATL ACAD SCI USA, V89, P8487, DOI 10.1073/pnas.89.18.8487; KOCH CA, 1991, SCIENCE, V252, P668, DOI 10.1126/science.1708916; LI N, 1993, NATURE, V363, P85, DOI 10.1038/363085a0; LOWENSTEIN EJ, 1992, CELL, V70, P431, DOI 10.1016/0092-8674(92)90167-B; MARENGERE LEM, 1992, J BIOL CHEM, V267, P22779; MATSUDA M, 1990, SCIENCE, V248, P1537, DOI 10.1126/science.1694307; MAYER BJ, 1991, P NATL ACAD SCI USA, V88, P627, DOI 10.1073/pnas.88.2.627; OLIVIER JP, 1993, CELL, V73, P179, DOI 10.1016/0092-8674(93)90170-U; PASCAL SM, 1994, CELL, V77, P461, DOI 10.1016/0092-8674(94)90160-0; PAWSON T, 1992, CELL, V71, P359, DOI 10.1016/0092-8674(92)90504-6; PAWSON T, 1993, J CURR BIOL, V4, P434; PELICCI G, 1992, CELL, V70, P93, DOI 10.1016/0092-8674(92)90536-L; PENDERGAST AM, 1993, CELL, V75, P175, DOI 10.1016/S0092-8674(05)80094-7; PUIL L, 1994, EMBO J, V764, P773; ROZAKISADCOCK M, 1993, NATURE, V363, P83, DOI 10.1038/363083a0; ROZAKISADCOCK M, 1992, NATURE, V360, P689, DOI 10.1038/360689a0; SCHALLER MD, 1994, MOL CELL BIOL, V14, P1680, DOI 10.1128/MCB.14.3.1680; SCHALLER MD, 1992, P NATL ACAD SCI USA, V89, P5192, DOI 10.1073/pnas.89.11.5192; SIMON MA, 1993, CELL, V73, P169, DOI 10.1016/0092-8674(93)90169-Q; SONGYANG Z, 1994, MOL CELL BIOL, V14, P2777, DOI 10.1128/MCB.14.4.2777; STERN MJ, 1993, MOL BIOL CELL, V4, P1175, DOI 10.1091/mbc.4.11.1175; WAKSMAN G, 1993, CELL, V72, P779, DOI 10.1016/0092-8674(93)90405-F; WAKSMAN G, 1992, NATURE, V358, P646, DOI 10.1038/358646a0; ZHOU SY, 1993, CELL, V72, P767, DOI 10.1016/0092-8674(93)90404-E	31	172	182	0	12	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JUN 9	1994	369	6480					502	505		10.1038/369502a0	http://dx.doi.org/10.1038/369502a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	NQ286	7515480	Green Submitted			2022-12-28	WOS:A1994NQ28600062
J	KUPFER, A; AESCHLIMANN, C; WERMUTH, B; CERNY, T				KUPFER, A; AESCHLIMANN, C; WERMUTH, B; CERNY, T			PROPHYLAXIS AND REVERSAL OF IFOSFAMIDE ENCEPHALOPATHY WITH METHYLENE-BLUE	LANCET			English	Note								The antineoplastic ifosfamide produces dose-dependent signs of neurotoxicity. After ifosfamide overdose in a patient, we found excessive urinary excretion of glutaric acid and sarcosine, which is compatible with glutaric aciduria type II, a defect in mitochondrial fatty acid oxidation that results from defective electron transfer to flavoproteins. We therefore used the electron-accepting drug methylene-blue as an antidote for ifosfamide encephalopathy. In one patient, ifosfamide neurotoxicity was rapidly reversed by methylene-blue 50 mg intravenously. In another patient with previous episodes of ifosfamide encephalopathy, methylene-blue was administered orally prophylactically. No symptoms of neurotoxicity were noted.	UNIV BERN,INSELSPITAL,DEPT CLIN CHEM,BERN,SWITZERLAND; UNIV HOSP BERNE,DEPT MED ONCOL,BERN,SWITZERLAND	University of Bern; University Hospital of Bern; University of Bern; University Hospital of Bern	KUPFER, A (corresponding author), UNIV BERN,DEPT CLIN PHARMACOL,MURTENSTR 35,CH-3010 BERN,SWITZERLAND.							BHAT HK, 1991, TOXICOL LETT, V59, P203, DOI 10.1016/0378-4274(91)90073-F; CERNY T, 1992, ANN ONCOL, V3, P679, DOI 10.1093/oxfordjournals.annonc.a058317; GOODMAN SI, 1989, METABOLIC BASIS INHE, V1, P915; HARPEY JP, 1986, LANCET, V1, P391; KUPFER A, 1990, LANCET, V335, P1461, DOI 10.1016/0140-6736(90)91487-U; KUPFER A, 1990, N-S ARCH PHARMACOL S, V342, pR20; PETERS RA, 1952, PROC R SOC SER B-BIO, V139, P143, DOI 10.1098/rspb.1952.0001; SOOD C, 1993, BIOCHEM PHARMACOL, V46, P1621, DOI 10.1016/0006-2952(93)90332-Q; WOLFF SN, 1990, SEMIN ONCOL, V17, P2	9	138	138	0	9	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAR 26	1994	343	8900					763	764		10.1016/S0140-6736(94)91839-2	http://dx.doi.org/10.1016/S0140-6736(94)91839-2			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NC351	7510815				2022-12-28	WOS:A1994NC35100011
J	HUANG, PL; DAWSON, TM; BREDT, DS; SNYDER, SH; FISHMAN, MC				HUANG, PL; DAWSON, TM; BREDT, DS; SNYDER, SH; FISHMAN, MC			TARGETED DISRUPTION OF THE NEURONAL NITRIC-OXIDE SYNTHASE GENE	CELL			English	Article							LONG-TERM POTENTIATION; HYPERTROPHIC PYLORIC-STENOSIS; RAT ANOCOCCYGEUS MUSCLE; MONOMETHYL-L-ARGININE; NADPH-DIAPHORASE; GLYCERALDEHYDE-3-PHOSPHATE DEHYDROGENASE; HUNTINGTONS-DISEASE; ADP-RIBOSYLATION; STRIATAL NEURONS; PENILE ERECTION	By homologous recombination, we have generated mice that lack the neuronal nitric oxide synthase (NOS) gene. Neuronal NOS expression and NADPH-diaphorase (NDP) staining are absent in the mutant mice. Very low level residual catalytic activity suggests that other enzymes in the brain may generate nitric oxide. The neurons normally expressing NOS appear intact, and the mutant NOS mice are viable, fertile, and without evident histopathological abnormalities in the central nervous system. The most evident effect of disrupting the neuronal NOS gene is the development of grossly enlarged stomachs, with hypertrophy of the pyloric sphincter and the circular muscle layer. This phenotype resembles the human disorder infantile pyloric stenosis, in which gastric outlet obstruction is associated with the lack of NDP neurons in the pylorus.	JOHNS HOPKINS UNIV, SCH MED, DEPT NEUROSCI, BALTIMORE, MD 21205 USA; JOHNS HOPKINS UNIV, SCH MED, DEPT PHARMACOL & MOLEC SCI, BALTIMORE, MD 21205 USA; JOHNS HOPKINS UNIV, SCH MED, DEPT PSYCHIAT & BEHAV SCI, BALTIMORE, MD 21205 USA; JOHNS HOPKINS UNIV, SCH MED, DEPT NEUROL, BALTIMORE, MD 21205 USA	Johns Hopkins University; Johns Hopkins University; Johns Hopkins University; Johns Hopkins University	HUANG, PL (corresponding author), MASSACHUSETTS GEN HOSP, CARDIOVASC RES CTR, BOSTON, MA 02129 USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [K08HL002792] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF MENTAL HEALTH [R01MH018501, R37MH018501] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [K08NS001578] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL-02792-02] Funding Source: Medline; NIMH NIH HHS [MH-18501] Funding Source: Medline; NINDS NIH HHS [CIDA NS-01578] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		BEAL MF, 1986, NATURE, V321, P168, DOI 10.1038/321168a0; BOECKXSTAENS GE, 1991, BRIT J PHARMACOL, V102, P434, DOI 10.1111/j.1476-5381.1991.tb12191.x; BOHME GA, 1991, EUR J PHARMACOL, V199, P379, DOI 10.1016/0014-2999(91)90505-K; BREDT DS, 1989, P NATL ACAD SCI USA, V86, P9030, DOI 10.1073/pnas.86.22.9030; BREDT DS, 1990, NATURE, V347, P768, DOI 10.1038/347768a0; BREDT DS, 1991, NEURON, V7, P615, DOI 10.1016/0896-6273(91)90374-9; BREDT DS, 1990, P NATL ACAD SCI USA, V87, P682, DOI 10.1073/pnas.87.2.682; BREDT DS, 1991, NATURE, V351, P714, DOI 10.1038/351714a0; BRESLOW MJ, 1987, AM J PHYSIOL, V252, pH521, DOI 10.1152/ajpheart.1987.252.3.H521; BRESLOW MJ, 1992, EUR J PHARMACOL, V87, P682; BULT H, 1990, NATURE, V345, P3469; BURNETT AL, 1992, SCIENCE, V257, P401, DOI 10.1126/science.1378650; DAWSON TM, 1992, ANN NEUROL, V32, P297, DOI 10.1002/ana.410320302; DAWSON TM, 1991, P NATL ACAD SCI USA, V88, P7797, DOI 10.1073/pnas.88.17.7797; DAWSON VL, 1993, J NEUROSCI, V13, P2651; DESAI KM, 1991, NATURE, V351, P477, DOI 10.1038/351477a0; DICKIE BGM, 1992, NEUROSCI LETT, V138, P145, DOI 10.1016/0304-3940(92)90492-P; DIMMELER S, 1992, J BIOL CHEM, V267, P16771; EDELMAN GM, 1992, P NATL ACAD SCI USA, V89, P11651, DOI 10.1073/pnas.89.24.11651; FARACI FM, 1992, PHARMACOL THERAPEUT, V56, P1, DOI 10.1016/0163-7258(92)90035-X; FERRANTE RJ, 1985, SCIENCE, V230, P561, DOI 10.1126/science.2931802; FURCHGOTT RF, 1989, FASEB J, V3, P2007, DOI 10.1096/fasebj.3.9.2545495; GALLY JA, 1990, P NATL ACAD SCI USA, V87, P3547, DOI 10.1073/pnas.87.9.3547; GARTHWAITE J, 1991, TRENDS NEUROSCI, V14, P60, DOI 10.1016/0166-2236(91)90022-M; GHOSH A, 1992, SCIENCE, V255, P1441, DOI 10.1126/science.1542795; GIBSON A, 1990, BRIT J PHARMACOL, V99, P602, DOI 10.1111/j.1476-5381.1990.tb12976.x; GILLESPIE JS, 1989, BRIT J PHARMACOL, V98, P1080, DOI 10.1111/j.1476-5381.1989.tb12650.x; HALEY JE, 1992, NEURON, V8, P211, DOI 10.1016/0896-6273(92)90288-O; HANBAUER I, 1992, NEUROREPORT, V3, P409, DOI 10.1097/00001756-199205000-00008; HIBBS JB, 1988, BIOCHEM BIOPH RES CO, V157, P87, DOI 10.1016/S0006-291X(88)80015-9; HIRSCH DP, 1993, IN PRESS CURR BIOL; HOPE BT, 1991, P NATL ACAD SCI USA, V88, P2811, DOI 10.1073/pnas.88.7.2811; IADECOLA C, 1993, TRENDS NEUROSCI, V16, P206, DOI 10.1016/0166-2236(93)90156-G; IGNARRO LJ, 1989, FASEB J, V3, P31, DOI 10.1096/fasebj.3.1.2642868; KOH JY, 1986, SCIENCE, V234, P73, DOI 10.1126/science.2875522; KOTS AY, 1992, FEBS LETT, V300, P9, DOI 10.1016/0014-5793(92)80153-8; LE E, 1992, CELL, V69, P915; LI CG, 1990, EUR J PHARMACOL, V191, P303; LONART G, 1992, EUR J PHARMACOL, V220, P271, DOI 10.1016/0014-2999(92)90759-W; LOWENSTEIN CJ, 1992, CELL, V70, P705, DOI 10.1016/0092-8674(92)90301-R; MARLETTA MA, 1993, J BIOL CHEM, V268, P12231; MARLETTA MA, 1989, TRENDS BIOCHEM SCI, V14, P88; MCDONALD LJ, 1993, P NATL ACAD SCI USA, V90, P6238, DOI 10.1073/pnas.90.13.6238; MONCADA S, 1991, PHARMACOL REV, V43, P109; NATHAN C, 1992, FASEB J, V6, P3051, DOI 10.1096/fasebj.6.12.1381691; NOZAKI K, 1993, J CEREBR BLOOD F MET, V13, P70, DOI 10.1038/jcbfm.1993.9; ODELL TJ, 1991, P NATL ACAD SCI USA, V88, P11285, DOI 10.1073/pnas.88.24.11285; POLAK JM, 1981, LANCET, V2, P217; PRADO R, 1992, STROKE, V23, P1118, DOI 10.1161/01.STR.23.8.1118; RAJFER J, 1992, NEW ENGL J MED, V326, P90, DOI 10.1056/NEJM199201093260203; RAMAGOPAL MV, 1989, EUR J PHARMACOL, V174, P297, DOI 10.1016/0014-2999(89)90325-7; SCHUMAN EM, 1991, SCIENCE, V254, P1503, DOI 10.1126/science.1720572; SHIBUKI K, 1991, NATURE, V349, P326, DOI 10.1038/349326a0; SNYDER SH, 1992, SCIENCE, V257, P494, DOI 10.1126/science.1353273; SPICER RD, 1982, BRIT J SURG, V69, P128, DOI 10.1002/bjs.1800690304; STAMLER JS, 1992, P NATL ACAD SCI USA, V89, P444, DOI 10.1073/pnas.89.1.444; STEVENS CF, 1993, NATURE, V364, P147, DOI 10.1038/364147a0; THOMAS E, 1961, HISTOCHEMISTRY, V2, P266, DOI 10.1007/BF00736504; THOMAS E., 1964, ACTA NEUROPATHOL, V3, P238; TODA N, 1990, BIOCHEM BIOPH RES CO, V170, P308, DOI 10.1016/0006-291X(90)91275-W; TOTTRUP A, 1991, AM J PHYSIOL, V260, pG385, DOI 10.1152/ajpgi.1991.260.3.G385; TYBULEWICZ VLJ, 1991, CELL, V65, P1153, DOI 10.1016/0092-8674(91)90011-M; UEMURA Y, 1990, ANN NEUROL, V27, P620, DOI 10.1002/ana.410270606; VANDERWINDEN JM, 1992, NEW ENGL J MED, V327, P511, DOI 10.1056/NEJM199208203270802; VINCENT SR, 1983, J COMP NEUROL, V217, P252, DOI 10.1002/cne.902170303; WHITTLE BJR, 1992, ANN NY ACAD SCI, V664, P126, DOI 10.1111/j.1749-6632.1992.tb39755.x; WILCOX CS, 1992, P NATL ACAD SCI USA, V89, P11993, DOI 10.1073/pnas.89.24.11993; WILLIS EA, 1983, LIFE SCI, V33, P383, DOI 10.1016/S0024-3205(83)80013-7; ZHANG J, 1992, P NATL ACAD SCI USA, V89, P9382, DOI 10.1073/pnas.89.20.9382; ZHU XZ, 1992, J NEUROCHEM, V59, P932, DOI 10.1111/j.1471-4159.1992.tb08332.x; ZHUO M, 1993, SCIENCE, V260, P1946, DOI 10.1126/science.8100368	71	1133	1155	1	14	CELL PRESS	CAMBRIDGE	600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA	0092-8674			CELL	Cell	DEC 31	1993	75	7					1273	1286		10.1016/0092-8674(93)90615-W	http://dx.doi.org/10.1016/0092-8674(93)90615-W			14	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	MP869	7505721				2022-12-28	WOS:A1993MP86900007
J	Hillier, SL; Nugent, RP; Eschenbach, DA; Krohn, MA; Gibbs, RS; Martin, DH; Cotch, MF; Edelman, R; Pastorek, JG; Rao, AV; McNellis, D; Regan, JA; Carey, JC; Klebanoff, MA				Hillier, SL; Nugent, RP; Eschenbach, DA; Krohn, MA; Gibbs, RS; Martin, DH; Cotch, MF; Edelman, R; Pastorek, JG; Rao, AV; McNellis, D; Regan, JA; Carey, JC; Klebanoff, MA			Association between bacterial vaginosis and preterm delivery of a low-birth-weight infant	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							AMNIOTIC-FLUID INFECTION; CHLAMYDIA-TRACHOMATIS; GESTATIONAL-AGE; PREGNANT-WOMEN; VAGINAL FLORA; GRAM STAIN; LABOR; PREMATURITY	Background. Bacterial vaginosis is believed to be a risk factor for preterm delivery. We undertook a study of the association between bacterial vaginosis and the preterm delivery of infants with low birth weight after accounting for other known risk factors. Methods. In this cohort study, we enrolled 10,397 pregnant women from seven medical centers who had no known medical risk factors for preterm delivery. At 23 to 26 weeks' gestation, bacterial vaginosis was determined to be present or absent on the basis of the vaginal pH and the results of Gram's staining. The principal outcome variable was the delivery at less than 37 weeks' gestation of an infant with a birth weight below 2500 g. Results. Bacterial vaginosis was detected in 16 percent of the 10,397 women. The women with bacterial vaginosis were more likely to be unmarried, to be black, to have low incomes, and to have previously delivered low-birth-weight infants. In a multivariate analysis, the presence of bacterial vaginosis was related to preterm delivery of a low-birth-weight infant (odds ratio, 1.4; 95 percent confidence interval to 1.8). Other risk factors that were significantly associated with such a delivery in this population were the previous delivery of a low-birthweight infant (odds ratio, 6.2; 95 percent confidence interval, 4.6 to 8.4), the loss of an earlier pregnancy (odds ratio, 1.7, 1.3 to 2.2), primigravidity (odds ratio, 1.6; 1.1 to 1.9), smoking (odds ratio, 1.4, 1.1 to 1.7); and black race (odds ratio, 1.4; 1.1 to 1.7). Among women with bacterial vaginosis, the highest risk of preterm delivery of a low-birth-weight infant was found among those with both vaginal bacteroides and Mycoplasma hominis (odds ratio, 2.1; 95 percent confidence interval, 1.5 to 3.0). Conclusions. Bacterial vaginosis was associated with the preterm delivery of low-birth-weight infants independently of other recognized risk factors.	UNIV WASHINGTON, SEATTLE, WA 98195 USA; NICHHD, BETHESDA, MD 20892 USA; UNIV TEXAS SAN ANTONIO, SAN ANTONIO, TX 78285 USA; LOUISIANA STATE UNIV, NEW ORLEANS, LA USA; NIAID, BETHESDA, MD 20892 USA; RES TRIANGLE INST, RES TRIANGLE PK, NC 27709 USA; COLUMBIA UNIV, NEW YORK, NY USA; UNIV OKLAHOMA, OKLAHOMA CITY, OK USA	University of Washington; University of Washington Seattle; National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD); University of Texas System; University of Texas at San Antonio (UTSA); Louisiana State University System; National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); Research Triangle Institute; Columbia University; University of Oklahoma System; University of Oklahoma Health Sciences Center				Nugent, Rachel/0000-0001-6421-9077; Cotch, Mary Frances/0000-0002-2046-4350	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI042532, R56AI042532] Funding Source: NIH RePORTER; Intramural NIH HHS [Z99 EY999999] Funding Source: Medline; NIAID NIH HHS [AI-4-2532] Funding Source: Medline; NICHD NIH HHS [HD-3-2836, HD-3-2832] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); Intramural NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		ARMITAGE P, 1980, STATISTICAL METHODS, P135; BURTIN P, 1995, AM J OBSTET GYNECOL, V172, P525, DOI 10.1016/0002-9378(95)90567-7; CAMPBELL S, 1985, OBSTET GYNECOL, V65, P613; ESCHENBACH DA, 1991, AM J OBSTET GYNECOL, V164, P734, DOI 10.1016/0002-9378(91)90506-M; GRAVETT MG, 1986, OBSTET GYNECOL, V67, P229, DOI 10.1097/00006250-198602000-00013; GRAVETT MG, 1986, JAMA-J AM MED ASSOC, V256, P1899; HAY PE, 1994, BRIT MED J, V308, P295, DOI 10.1136/bmj.308.6924.295; HILLIER SL, 1993, CLIN INFECT DIS, V16, pS273, DOI 10.1093/clinids/16.Supplement_4.S273; HILLIER SL, 1995, CLIN INFECT DIS, V20, pS276, DOI 10.1093/clinids/20.Supplement_2.S276; HILLIER SL, 1992, AM J OBSTET GYNECOL, V166, P938, DOI 10.1016/0002-9378(92)91368-K; HILLIER SL, 1988, NEW ENGL J MED, V319, P972, DOI 10.1056/NEJM198810133191503; HOLST E, 1994, J CLIN MICROBIOL, V32, P176, DOI 10.1128/JCM.32.1.176-186.1994; KROHN MA, 1991, J INFECT DIS, V164, P88, DOI 10.1093/infdis/164.1.88; KURKI T, 1992, OBSTET GYNECOL, V80, P173; MARTIUS J, 1988, OBSTET GYNECOL, V71, P89; MCDONALD HM, 1991, BRIT J OBSTET GYNAEC, V98, P427, DOI 10.1111/j.1471-0528.1991.tb10335.x; MCDONALD HM, 1994, OBSTET GYNECOL, V84, P343; MCGREGOR JA, 1994, AM J OBSTET GYNECOL, V170, P1048, DOI 10.1016/S0002-9378(94)70098-2; MINKOFF H, 1984, AM J OBSTET GYNECOL, V150, P965, DOI 10.1016/0002-9378(84)90392-2; NUGENT RP, 1991, J CLIN MICROBIOL, V29, P297, DOI 10.1128/JCM.29.2.297-301.1991; PLATZCHRISTENSEN JJ, 1993, AM J OBSTET GYNECOL, V169, P1161, DOI 10.1016/0002-9378(93)90274-M; RIDUAN JM, 1993, AM J OBSTET GYNECOL, V169, P175, DOI 10.1016/0002-9378(93)90157-E; ROBBIE MO, 1983, AM J OBSTET GYNECOL, V145, P865, DOI 10.1016/0002-9378(83)90693-2; SILVER HM, 1989, AM J OBSTET GYNECOL, V161, P808, DOI 10.1016/0002-9378(89)90406-7; WATTS DH, 1992, OBSTET GYNECOL, V79, P351; WOOLF B, 1955, ANN HUM GENET, V19, P251, DOI 10.1111/j.1469-1809.1955.tb01348.x; 1994, MMWR-MORBID MORTAL W, V43, P335; [No title captured]; 1993, MMWR-MORBID MORTAL W, V42, P926	29	986	1035	1	30	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	DEC 28	1995	333	26					1737	1742		10.1056/NEJM199512283332604	http://dx.doi.org/10.1056/NEJM199512283332604			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TM169	7491137	Bronze			2022-12-28	WOS:A1995TM16900004
J	Wilensky, GR				Wilensky, GR			The score on Medicare reform - Minus the hype and hyperbole	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material											Wilensky, GR (corresponding author), PROJECT HOPE,BETHESDA,MD 20814, USA.								0	5	5	0	0	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	DEC 28	1995	333	26					1774	1777		10.1056/NEJM199512283332612	http://dx.doi.org/10.1056/NEJM199512283332612			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TM169	7491145				2022-12-28	WOS:A1995TM16900012
J	WALDRON, HA				WALDRON, HA			LITTLE ARROWS	LANCET			English	Editorial Material											WALDRON, HA (corresponding author), ST MARYS HOSP,DEPT OCCUPAT HLTH,PRAED ST,LONDON W2 1NY,ENGLAND.								0	3	3	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	DEC 2	1995	346	8988					1475	1475		10.1016/S0140-6736(95)92479-5	http://dx.doi.org/10.1016/S0140-6736(95)92479-5			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TH156	7490998				2022-12-28	WOS:A1995TH15600016
J	BARRETTCONNOR, E; GOODMANGRUEN, D				BARRETTCONNOR, E; GOODMANGRUEN, D			PROSPECTIVE-STUDY OF ENDOGENOUS SEX-HORMONES AND FATAL CARDIOVASCULAR-DISEASE IN POSTMENOPAUSAL WOMEN	BRITISH MEDICAL JOURNAL			English	Article							CORONARY HEART-DISEASE; STEROIDS; THERAPY; HEALTH; PLASMA	Objectives-To examine the association between androstenedione, total and bioavailable testosterone, oestrone, and total and bioavailable oestradiol concentrations and the risk of death from cardiovascular and ischaemic heart disease. Design-19 year old population based prospective study with 99.9% follow up. Setting-Rancho Bernardo, California. Subjects-651 postmenopausal women, none taking oestrogen. Main outcome measures-Concentrations of plasma sex hormones measured by radioimmunoassay in an endocrinology research laboratory. Cardiovascular and ischaemic heart disease deaths assessed by death certificate; 85% of 30% sample validated by record review. Results-Age adjusted concentrations of sex hormones did not differ significantly in women with and without a history of heart disease at baseline and did not predict cardiovascular death or death from ischaemic heart disease. Most 95% confidence intervals for the age adjusted relative risk of cardiovascular death or death from ischaemic heart disease were narrow, and all included one. Endogenous oestrogen concentrations were not associated with significantly more favourable risk factors for heart disease, and testosterone was not associated with less favourable risk factors. Conclusion-These prospective data do not support a causal or preventive role for endogenous oestrogens or androgens and cardiovascular mortality in older women.			BARRETTCONNOR, E (corresponding author), UNIV CALIF SAN DIEGO,DEPT FAMILY & PREVENT MED,LA JOLLA,CA 92093, USA.				NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK031801] Funding Source: NIH RePORTER; NIDDK NIH HHS [2RO1 DK31 801-0942] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ANDERSON DC, 1976, STEROIDS, V28, P179, DOI 10.1016/0039-128X(76)90108-2; BUSH TL, 1990, P S MENOPAUSE, P211; CAULEY JA, 1994, ARTERIOSCLER THROMB, V14, P14, DOI 10.1161/01.ATV.14.1.14; CAULEY JA, 1989, AM J EPIDEMIOL, V129, P1120, DOI 10.1093/oxfordjournals.aje.a115234; CAULEY JA, 1991, AM J EPIDEMIOL, V133, P50, DOI 10.1093/oxfordjournals.aje.a115801; CAULEY JA, 1991, AM J EPIDEMIOL, V132, P884; COX DR, 1972, J R STAT SOC B, V34, P187; MELDRUM DR, 1981, OBSTET GYNECOL, V57, P624; STAMPFER MJ, 1991, NEW ENGL J MED, V325, P756, DOI 10.1056/NEJM199109123251102; STAMPFER MJ, 1991, PREV MED, V20, P47, DOI 10.1016/0091-7435(91)90006-P; TRACY R, 1976, J CHRON DIS, V19, P1245; TREMBLAY RR, 1974, CONTRACEPTION, V10, P599, DOI 10.1016/0010-7824(74)90099-7; TUNSTALLPEDOE H, 1991, BMJ-BRIT MED J, V303, P701, DOI 10.1136/bmj.303.6804.701; VERMEULEN A, 1979, CLIN ENDOCRINOL, V9, P59; WINGARD DL, 1984, ANNU REV PUBL HEALTH, V5, P433, DOI 10.1146/annurev.pu.05.050184.002245; ZUMOFF B, 1982, ARTERIOSCLEROSIS, V2, P58, DOI 10.1161/01.ATV.2.1.58; 1985, SAS USERS GUIDE	17	138	145	0	3	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	NOV 4	1995	311	7014					1193	1196		10.1136/bmj.311.7014.1193	http://dx.doi.org/10.1136/bmj.311.7014.1193			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TD768	7488894	Green Published			2022-12-28	WOS:A1995TD76800017
J	SURENDER, R; BRADLOW, J; COULTER, A; DOLL, H; BROWN, SS				SURENDER, R; BRADLOW, J; COULTER, A; DOLL, H; BROWN, SS			PROSPECTIVE-STUDY OF TRENDS IN REFERRAL PATTERNS IN FUNDHOLDING AND NON-FUNDHOLDING PRACTICES IN THE OXFORD REGION, 1990-4	BRITISH MEDICAL JOURNAL			English	Article								Objective-To compare outpatient referral patterns in fundholding and non-fundholding practices before and after the NHS reforms in April 1991. Design-Prospective collection of data on general practitioners' referrals to specialist outpatient clinics between June 1990 and January 1994 and detailed comparisons of three phases-October 1990 to March 1991 (phase 1), October 1991 to March 1992 (phase 2), and October 1993 to January 1994 (phase 3). Setting-10 first wave fundholding practices and six non-fundholding practices in the Oxford region. Subjects-Patients referred to consultant outpatient clinics. Results-NHS referral rates increased in fundholding practices in phase 2 and phase 3 of the study by 8.1/1000 patients a year (95% confidence interval 5.7 to 10.5), an increase of 7.5% from phase 1 (107.3/1000) to phase 3 (115.4/1000). Non-fundholders' rates increased significantly, by 25.3/1000 patients (22.5-28.1), an increase of 26.6% from phase 1 (95.0/1000) to phase 3 (120.3/1000). The fundholders' referral rates to private clinics decreased by 8.8%, whereas those from non-fundholding practices increased by 12.2%. The proportion of referrals going outside district boundaries did not change significantly. Three of the four practices entering the third and fourth wave of fundholding increased their referral rates significantly in the year before becoming fundholders. Conclusions-No evidence existed that budgetary pressures caused first wave fundholders to reduce referral rates, although the method of budget allocation may have encouraged general practitioners to inflate their referral rates in the preparatory year. Despite investment in new practice based facilities, no evidence yet exists that fundholding encourages a shift away from specialist care.	KINGS FUND DEV CTR,LONDON W1M 0AN,ENGLAND; UNIV OXFORD,RADCLIFFE INFIRM,DEPT PUBL HLTH & PRIMARY CARE,HLTH SERV RES UNIT,OXFORD OX2 6HE,ENGLAND; UNIV OXFORD,DEPT PUBL HLTH & PRIMARY CARE,HLTH CARE EPIDEMIOL UNIT,OXFORD OX3 7LF,ENGLAND	Radcliffe Infirmary; University of Oxford; University of Oxford			Coulter, Angela/N-6998-2019	Coulter, Angela/0000-0002-6308-8375				BRADLOW J, 1992, PATTERNS REFERRAL; COULTER A, 1993, BRIT MED J, V306, P433, DOI 10.1136/bmj.306.6875.433; COULTER A, IN PRESS EUR J PUBLI; GARDINER M, 1990, BMJ; GLENNERSTER H, 1994, IMPLEMENTING GP FUND; Roland M, 1992, HOSPITAL REFERRALS; SHELDON TA, 1994, BRIT MED J, V309, P1059, DOI 10.1136/bmj.309.6961.1059	7	45	45	0	2	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	NOV 4	1995	311	7014					1205	1208		10.1136/bmj.311.7014.1205	http://dx.doi.org/10.1136/bmj.311.7014.1205			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TD768	7488902	Green Published			2022-12-28	WOS:A1995TD76800026
J	HIGHSMITH, WE; BURCH, LH; ZHOU, ZQ; OLSEN, JC; BOAT, TE; SPOCK, A; GORVOY, JD; QUITTELL, L; FRIEDMAN, KJ; SILVERMAN, LM; BOUCHER, RC; KNOWLES, MR				HIGHSMITH, WE; BURCH, LH; ZHOU, ZQ; OLSEN, JC; BOAT, TE; SPOCK, A; GORVOY, JD; QUITTELL, L; FRIEDMAN, KJ; SILVERMAN, LM; BOUCHER, RC; KNOWLES, MR			A NOVEL MUTATION IN THE CYSTIC-FIBROSIS GENE IN PATIENTS WITH PULMONARY-DISEASE BUT NORMAL SWEAT CHLORIDE CONCENTRATIONS	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							CONDUCTANCE REGULATOR GENE; POLYMERASE CHAIN-REACTION; ION PERMEABILITY; SUBJECTS INVIVO; MESSENGER-RNA; CFTR; GLANDS; ACTIN; DNA	Background. Many patients with chronic pulmonary disease similar to that seen in cystic fibrosis have normal (or nondiagnostic) sweat chloride values. It has been difficult to make the diagnosis of cystic fibrosis in these patients because no associated mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene has been identified. Methods. We evaluated 23 patients with pulmonary disease characteristic of cystic fibrosis but with sweat chloride concentrations in the normal range. Mutations in the CFTR gene were sought by direct sequencing of polymerase chain reaction-amplified nasal epithelial messenger RNA and by testing the functioning of affected epithelium. Results. A cytidine phosphate guanosine dinucleotide C-to-T point mutation in intron 19 of the CFTR gene, termed 3849+10 kb C to TI was identified in 13 patients from eight unrelated families. This mutation was found in patients from three different ethnic groups with three different extended haplotypes. The mutation leads to the creation of a partially active splice site in intron 19 and to the insertion into most CFTR transcripts of a new 84-base-pair ''exon,'' containing an in-frame stop codon, between exons 19 and 20. Normally spliced transcripts were also detected at a level approximately 8 percent of that found in normal subjects. This mutation is associated with abnormal nasal epithelial and sweat acinar epithelial function. Conclusions. We have identified a point mutation in intron 19 of CFTR and abnormal epithelial function in patients who have cystic fibrosis-like lung disease but normal sweat chloride values. The identification of this mutation indicates that this syndrome is a form of cystic fibrosis. Screening for the mutation should prove diagnostically useful in this population of patients.	UNIV N CAROLINA, DEPT MED, DIV PULM DIS, CHAPEL HILL, NC 27599 USA; APPL TECHNOL GENET CORP, MALVERN, PA USA; UNIV N CAROLINA, DIV MOLEC PATHOL, CHAPEL HILL, NC USA; CHILDRENS HOSP, MED CTR, CINCINNATI, OH USA; DUKE UNIV, DEPT PEDIAT, DURHAM, NC 27706 USA; LONG ISL JEWISH MED CTR, SCHNEIDER CHILDRENS HOSP, NEW HYDE PK, NY 11042 USA; COLUMBIA PRESBYTERIAN MED CTR, DIV PEDIAT PULM, NEW YORK, NY USA	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill; Cincinnati Children's Hospital Medical Center; Duke University; Northwell Health; North Shore University Hospital; Steven & Alexandra Cohen Children's Medical Center of New York; Columbia University; NewYork-Presbyterian Hospital			Highsmith, William E/B-6175-2008		NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR000046] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL034322] Funding Source: NIH RePORTER; NCRR NIH HHS [RR000046] Funding Source: Medline; NHLBI NIH HHS [HL34322] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ABELIOVICH D, 1992, AM J HUM GENET, V51, P951; ANDERSON MP, 1991, SCIENCE, V253, P202, DOI 10.1126/science.1712984; AUGARTEN A, 1993, LANCET, V342, P25, DOI 10.1016/0140-6736(93)91885-P; BEAR CE, 1992, CELL, V68, P809, DOI 10.1016/0092-8674(92)90155-6; BEAUDET AL, 1988, NEW ENGL J MED, V318, P50; BIJMAN J, 1984, AM J PHYSIOL, V247, pC3, DOI 10.1152/ajpcell.1984.247.1.C3; Boat T.J., 1989, METABOLIC BASIS INHE, P2649; CHENG TC, 1984, P NATL ACAD SCI-BIOL, V81, P2821, DOI 10.1073/pnas.81.9.2821; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CHU CS, 1992, J CLIN INVEST, V90, P785, DOI 10.1172/JCI115952; COLLINS FS, 1992, SCIENCE, V256, P774, DOI 10.1126/science.1375392; COOPER DN, 1990, HUM GENET, V85, P55; DAVIS PB, 1983, AM REV RESPIR DIS, V128, P34, DOI 10.1164/arrd.1983.128.1.34; DAVIS PB, 1980, AM J MED, V69, P643, DOI 10.1016/0002-9343(80)90482-9; DORK T, 1992, HUM GENET, V88, P417, DOI 10.1007/BF00215676; ERBA HP, 1986, NUCLEIC ACIDS RES, V14, P5275, DOI 10.1093/nar/14.13.5275; FRIEDMAN KJ, 1991, CLIN CHEM, V37, P753; GIBSON LE, 1959, PEDIATRICS, V23, P545; GILBERT F, 1992, PEDIATR PULM S, V14, P240; GILBERT W, 1978, NATURE, V271, P501, DOI 10.1038/271501a0; GUNNING P, 1983, MOL CELL BIOL, V3, P787, DOI 10.1128/MCB.3.5.787; GYLLENSTEN UB, 1988, P NATL ACAD SCI USA, V85, P7652, DOI 10.1073/pnas.85.20.7652; KAZAZIAN HH, 1994, HUM MUTAT, V4, P167; KEREM BS, 1989, SCIENCE, V245, P1073, DOI 10.1126/science.2570460; KEREM E, 1990, NEW ENGL J MED, V323, P1517, DOI 10.1056/NEJM199011293232203; KNOWLES M, 1983, CLIN RES, V31, pA858; KNOWLES M, 1981, NEW ENGL J MED, V305, P1489, DOI 10.1056/NEJM198112173052502; KNOWLES M, 1983, J CLIN INVEST, V71, P1410, DOI 10.1172/JCI110894; KNOWLES MR, 1981, AM REV RESPIR DIS, V124, P484; QUINTON PM, 1983, NEW ENGL J MED, V308, P1185, DOI 10.1056/NEJM198305193082002; RIORDAN JR, 1989, SCIENCE, V245, P1437; SATO K, 1984, J CLIN INVEST, V73, P1763, DOI 10.1172/JCI111385; SATO K, 1988, J LAB CLIN MED, V111, P511; SHWACHMAN H, 1972, BIRTH DEFECTS ORGINA, P102; STERN RC, 1978, JAMA-J AM MED ASSOC, V239, P2676, DOI 10.1001/jama.239.25.2676; STRONG TV, 1991, NEW ENGL J MED, V325, P1630, DOI 10.1056/NEJM199112053252307; TRAPNELL BC, 1991, P NATL ACAD SCI USA, V88, P6565, DOI 10.1073/pnas.88.15.6565; WEATHERALL DJ, 1989, METABOLIC BASIS INHE, V2, P2281	38	344	351	0	5	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	OCT 13	1994	331	15					974	980		10.1056/NEJM199410133311503	http://dx.doi.org/10.1056/NEJM199410133311503			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PK504	7521937	Green Submitted			2022-12-28	WOS:A1994PK50400003
J	MAHER, DW; LIESCHKE, GJ; GREEN, M; BISHOP, J; STUARTHARRIS, R; WOLF, M; SHERIDAN, WP; KEFFORD, RF; CEBON, J; OLVER, I; MCKENDRICK, J; TONER, G; BRADSTOCK, K; LIESCHKE, M; CRUICKSHANK, S; TOMITA, DK; HOFFMAN, EW; FOX, RM; MORSTYN, G				MAHER, DW; LIESCHKE, GJ; GREEN, M; BISHOP, J; STUARTHARRIS, R; WOLF, M; SHERIDAN, WP; KEFFORD, RF; CEBON, J; OLVER, I; MCKENDRICK, J; TONER, G; BRADSTOCK, K; LIESCHKE, M; CRUICKSHANK, S; TOMITA, DK; HOFFMAN, EW; FOX, RM; MORSTYN, G			FILGRASTIM IN PATIENTS WITH CHEMOTHERAPY-INDUCED FEBRILE NEUTROPENIA - A DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL	ANNALS OF INTERNAL MEDICINE			English	Article						FILGRASTIM; NEUTROPENIA; FEVER; TOBRAMYCIN; PIPERACILLIN	COLONY-STIMULATING FACTOR; CELL LUNG-CANCER; GRANULOCYTOPENIC PATIENTS; EMPIRIC THERAPY; FEVER; LEUKOPENIA; INFECTION; DURATION	Objective: To determine if filgrastim (recombinant human methionyl granulocyte colony-stimulating factor) used in addition to standard inpatient antibiotic therapy accelerated recovery from infection associated with chemotherapy-induced neutropenia. Design: Randomized, double-blind, placebo-controlled trial. Setting: Hematology and oncology wards of four teaching hospitals. Patients: 218 patients with cancer who had fever (temperature >38.2 degrees C) and neutropenia (neutrophil count <1.0 x 10(9)/L) after chemotherapy. Intervention: Patients were randomly assigned to receive filgrastim (12 mu g/kg of body weight per day) (n = 109) or placebo (n = 107) beginning within 12 hours of empiric therapy with tobramycin and piperacillin. Patients received treatment and remained in the study until the neutrophil count was greater than 0.5 x 10(9)/L and until 4 days without fever (temperature <37.5 degrees C) had elapsed. Measurements: Days of neutropenia and fever and days in the study (hospitalization); time to resolution of fever and febrile neutropenia; and frequency of the use of alternative antibiotics. Results: Compared with placebo, filgrastim reduced the median number of days of neutropenia (3.0 compared with 4.0 days of a neutrophil count of <0.5 x 10(9)/L; P = 0.005) and the time to resolution of febrile neutropenia (5.0 compared with 6.0 days; P = 0.01) but not days of fever (3.0 days for both groups). The frequency of the use of alternative antibiotics was similar in the two groups (46% compared with 41%; P = 0.48). The median number of days patients were hospitalized while on study was the same (8.0 days; P = 0.09); however, filgrastim decreased the risk for prolonged hospitalization (>11 days, 4th quartile) by half (relative risk, 2.1 [95% CI, 1.1 to 4.1]; P = 0.02). In exploratory subset analyses, filgrastim appeared to provide the greatest benefit in patients with documented infection and in patients presenting with neutrophil counts of less than 0.1 x 10(9)/L. Conclusions: Filgrastim treatment used with antibiotics at the onset of febrile neutropenia in patients with cancer who have received chemotherapy accelerated neutrophil recovery and shortened the duration of febrile neutropenia.	ROYAL MELBOURNE HOSP, DEPT CLIN HAEMATOL & MED ONCOL, MELBOURNE, VIC 3050, AUSTRALIA; PETER MACCALLUM CANC INST, DEPT HAEMATOL & MED ONCOL, MELBOURNE, VIC 3000, AUSTRALIA; AUSTIN HOSP, LUDWIG AUSTIN ONCOL UNIT, HEIDELBERG, VIC 3084, AUSTRALIA; WESTMEAD HOSP, DEPT MED ONCOL, WESTMEAD, NSW 2145, AUSTRALIA; WESTMEAD HOSP, DEPT HAEMATOL, WESTMEAD, NSW 2145, AUSTRALIA; AMGEN INC, AMGEN CTR, THOUSAND OAKS, CA 91320 USA	Royal Melbourne Hospital; Peter Maccallum Cancer Center; Austin Research Institute; Florey Institute of Neuroscience & Mental Health; Ludwig Institute for Cancer Research; University of Sydney; University of Sydney; Amgen	MAHER, DW (corresponding author), ROYAL MELBOURNE HOSP, LUDWIG INST CANC RES, MELBOURNE TUMOUR BIOL BRANCH, MELBOURNE, VIC 3050, AUSTRALIA.		Olver, Ian/I-1518-2015; Toner, Guy C/G-1738-2011	Olver, Ian/0000-0001-5478-1576; Toner, Guy/0000-0001-9873-3592; Cebon, Jonathan/0000-0002-3898-950X; Lieschke, Graham/0000-0003-0325-798X; Kefford, Richard/0000-0001-9251-9229; Sheridan, William/0000-0001-8320-1323				BIESMA B, 1990, EUR J CANCER, V26, P932, DOI 10.1016/0277-5379(90)90613-X; BODEY GP, 1990, CANCER, V65, P9, DOI 10.1002/1097-0142(19900101)65:1<9::AID-CNCR2820650105>3.0.CO;2-C; BODEY GP, 1966, ANN INTERN MED, V64, P328, DOI 10.7326/0003-4819-64-2-328; BRONCHUD MH, 1987, BRIT J CANCER, V56, P809, DOI 10.1038/bjc.1987.295; CHABNER BA, 1989, CANCER PRINCIPLES PR, P349; COX DR, 1972, J R STAT SOC B, V34, P187; CRAWFORD J, 1991, NEW ENGL J MED, V325, P164, DOI 10.1056/NEJM199107183250305; CRAWFORD J, 1992, P AN M AM SOC CLIN, V11, P299; DEISSEROTH A, 1989, CANCER PRINCIPLES PR; GABRILOVE JL, 1988, NEW ENGL J MED, V318, P1414, DOI 10.1056/NEJM198806023182202; GERHARTZ HH, 1993, LEUKEMIA RES, V17, P175, DOI 10.1016/0145-2126(93)90063-Q; HOLLANDER M, 1973, NONPARAMETRIC STATIS; HUGHES WT, 1990, J INFECT DIS, V161, P381, DOI 10.1093/infdis/161.3.381; KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868; LIESCHKE GJ, 1992, NEW ENGL J MED, V327, P28; LYMAN GH, 1980, NEW ENGL J MED, V302, P257, DOI 10.1056/NEJM198001313020503; MANTEL N, 1963, J AM STAT ASSOC, V58, P690; MANTEL NATHAN, 1966, CANCERCHEMOTHERAP REP, V50, P163; Metcalf D, 1988, MOL CONTROL BLOOD CE; MILLER AB, 1981, CANCER, V47, P207, DOI 10.1002/1097-0142(19810101)47:1<207::AID-CNCR2820470134>3.0.CO;2-6; MORSTYN G, 1988, LANCET, V1, P667, DOI 10.1016/S0140-6736(88)91475-4; MORSTYN G, 1989, J CLIN ONCOL, V7, P1554, DOI 10.1200/JCO.1989.7.10.1554; OBRIEN PC, 1979, BIOMETRICS, V35, P549, DOI 10.2307/2530245; PIZZO PA, 1979, AM J MED, V67, P194, DOI 10.1016/0002-9343(79)90390-5; PIZZO PA, 1982, AM J MED, V72, P101, DOI 10.1016/0002-9343(82)90594-0; ROLSTON KVI, 1992, ARCH INTERN MED, V152, P283, DOI 10.1001/archinte.152.2.283; SCHIMPFF S, 1971, NEW ENGL J MED, V284, P1061, DOI 10.1056/NEJM197105132841904; SCHIMPFF SC, 1974, J INFECT DIS, V130, pS24, DOI 10.1093/infdis/130.Supplement.S24; SICKLES EA, 1975, ARCH INTERN MED, V135, P715, DOI 10.1001/archinte.135.5.715; SOUZA LM, 1986, SCIENCE, V232, P61, DOI 10.1126/science.2420009; TRILLETLENOIR V, 1993, EUR J CANCER, V29A, P319, DOI 10.1016/0959-8049(93)90376-Q; WINSTON DJ, 1982, ANN INTERN MED, V97, P509, DOI 10.7326/0003-4819-97-4-509; 1990, BMDP STATISTICAL SOF; 1992, SAS PROCEDURES GUIDE	34	171	172	0	1	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	OCT 1	1994	121	7					492	501		10.7326/0003-4819-121-7-199410010-00004	http://dx.doi.org/10.7326/0003-4819-121-7-199410010-00004			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PJ102	7520676				2022-12-28	WOS:A1994PJ10200004
J	BISHOP, MC				BISHOP, MC			ALTERNATIVES ARE STILL UNPROVED	BRITISH MEDICAL JOURNAL			English	Article							BENIGN PROSTATIC HYPERTROPHY; PROSTATECTOMY; RESECTION				BISHOP, MC (corresponding author), CITY HOSP,NOTTINGHAM NG5 1PB,ENGLAND.							ABRAMS PH, 1979, J UROLOGY, V121, P640, DOI 10.1016/S0022-5347(17)56918-9; BALL AJ, 1981, BRIT J UROL, V53, P613, DOI 10.1111/j.1464-410X.1981.tb03273.x; BDESHA AS, 1993, BRIT MED J, V306, P1293, DOI 10.1136/bmj.306.6888.1293; DOLL HA, 1993, BRIT J UROL, V72, P322, DOI 10.1111/j.1464-410X.1993.tb00727.x; EVANS JWH, 1992, BMJ-BRIT MED J, V304, P666, DOI 10.1136/bmj.304.6828.666; MEBUST WK, 1989, J UROLOGY, V141, P243, DOI 10.1016/S0022-5347(17)40731-2; NEAL DE, 1990, BRIT J UROL, V66, P449, DOI 10.1111/j.1464-410X.1990.tb14986.x; ROOS NP, 1989, NEW ENGL J MED, V320, P1120, DOI 10.1056/NEJM198904273201705	8	3	3	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	SEP 17	1994	309	6956					717	718		10.1136/bmj.309.6956.717	http://dx.doi.org/10.1136/bmj.309.6956.717			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PH407	7524873	Green Published			2022-12-28	WOS:A1994PH40700023
J	CHEN, YH; KUCHROO, VK; INOBE, J; HAFLER, DA; WEINER, HL				CHEN, YH; KUCHROO, VK; INOBE, J; HAFLER, DA; WEINER, HL			REGULATORY T-CELL CLONES INDUCED BY ORAL TOLERANCE - SUPPRESSION OF AUTOIMMUNE ENCEPHALOMYELITIS	SCIENCE			English	Article							MYELIN BASIC-PROTEIN; GROWTH-FACTOR-BETA; DRIVEN BYSTANDER SUPPRESSION; IMMUNE-RESPONSES; TRANSGENIC MICE; EFFECTOR-CELLS; IGA PRODUCTION; LYMPHOCYTES; TOLERIZATION; ANTIGENS	Experimental autoimmune encephalomyelitis (EAE) is a cell-mediated autoimmune disease that serves as an animal model for multiple sclerosis. Oral administration of myelin basic protein (MBP) suppresses EAE by inducing peripheral tolerance. T cell clones were isolated from the mesenteric lymph nodes of SJL mice that had been orally tolerized to MBP. These clones were CD4(+) and were structurally identical to T helper cell type 1 (T(H)1) encephalitogenic CD4(+) clones in T cell receptor usage, major histocompatibility complex restriction, and epitope recognition. However, they produced transforming growth factor-beta with various amounts of interleukin-4 and interleukin-10 and suppressed EAE induced with either MBP or proteolipid protein. Thus, mucosally derived T(H)2-like clones induced by oral antigen can actively regulate immune responses in vivo and may represent a different subset of T cells.	HARVARD UNIV,BRIGHAM & WOMENS HOSP,SCH MED,DEPT MED,CTR NEUROL DIS,BOSTON,MA 02115	Harvard University; Brigham & Women's Hospital; Harvard Medical School			Chen, Youhai/AAJ-4031-2021		NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS030843, R29NS030843, R01NS029352, R37NS030843] Funding Source: NIH RePORTER; NIAMS NIH HHS [AR/A143220] Funding Source: Medline; NINDS NIH HHS [NS29352, NS30843] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ALSABBAGH A, IN PRESS EUR J IMMUN; CHASE MW, 1946, P SOC EXP BIOL MED, V61, P257; Chen Y, UNPUB; CHEN YH, 1994, J IMMUNOL, V152, P3; CHIN YH, 1992, J IMMUNOL, V148, P1106; COFFMAN RL, 1989, J EXP MED, V170, P1039, DOI 10.1084/jem.170.3.1039; FRIEDMAN R, 1994, P NATL ACAD SCI USA, V91, P6688; GERMAIN RN, 1981, SCAND J IMMUNOL, V13, P1, DOI 10.1111/j.1365-3083.1981.tb00104.x; GERSHON RK, 1970, IMMUNOLOGY, V18, P723; GOVERMAN J, 1993, CELL, V72, P551, DOI 10.1016/0092-8674(93)90074-Z; GREGERSON DS, 1993, J IMMUNOL, V151, P5751; JENKINS MK, 1990, J IMMUNOL, V144, P16; KARPUS WJ, 1992, EUR J IMMUNOL, V22, P1757, DOI 10.1002/eji.1830220714; KARPUS WJ, 1991, J IMMUNOL, V146, P1163; KENNEDY MK, 1992, J IMMUNOL, V149, P2496; KHOURY SJ, 1992, J EXP MED, V176, P1355, DOI 10.1084/jem.176.5.1355; KIM PH, 1990, J IMMUNOL, V144, P3411; LIDER O, 1989, J IMMUNOL, V142, P748; LIDER O, 1988, SCIENCE, V239, P181, DOI 10.1126/science.2447648; MARRACK P, 1990, SCIENCE, V248, P705, DOI 10.1126/science.2185544; MILLER A, 1991, J EXP MED, V174, P791, DOI 10.1084/jem.174.4.791; MILLER A, 1992, P NATL ACAD SCI USA, V89, P421, DOI 10.1073/pnas.89.1.421; MILLER A, 1993, J IMMUNOL, V151, P7307; MOWAT AM, 1987, IMMUNOL TODAY, V8, P93, DOI 10.1016/0167-5699(87)90853-X; Nossal G J, 1987, Int Rev Immunol, V2, P321, DOI 10.3109/08830188709044760; PRABHUDAS M, UNPUB; ROCHA B, 1991, SCIENCE, V251, P1225, DOI 10.1126/science.1900951; SALGAME P, 1991, P NATL ACAD SCI USA, V88, P2598, DOI 10.1073/pnas.88.6.2598; SALGAME P, 1991, SCIENCE, V254, P279, DOI 10.1126/science.1681588; SCHWARTZ RH, 1990, SCIENCE, V248, P1349, DOI 10.1126/science.2113314; SUN D, 1988, NATURE, V332, P843, DOI 10.1038/332843a0; TRENTHAM DE, 1993, SCIENCE, V261, P1727, DOI 10.1126/science.8378772; VONBOEHMER H, 1990, ANNU REV IMMUNOL, V8, P531, DOI 10.1146/annurev.iy.08.040190.002531; WEINER HL, 1993, SCIENCE, V259, P1321, DOI 10.1126/science.7680493; WEINER HL, 1994, ANNU REV IMMUNOL, V12, P809, DOI 10.1146/annurev.immunol.12.1.809; Wells HG, 1911, J INFECT DIS, V9, P147, DOI 10.1093/infdis/9.2.147; WHITACRE CC, 1991, J IMMUNOL, V147, P2155; WUCHERPFENNIG KW, 1994, J IMMUNOL, V152, P5581; YAMAMURA M, 1991, SCIENCE, V254, P5029	39	1643	1721	1	53	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	AUG 26	1994	265	5176					1237	1240		10.1126/science.7520605	http://dx.doi.org/10.1126/science.7520605			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PD422	7520605				2022-12-28	WOS:A1994PD42200039
J	HOU, S; HYLAND, L; RYAN, KW; PORTNER, A; DOHERTY, PC				HOU, S; HYLAND, L; RYAN, KW; PORTNER, A; DOHERTY, PC			VIRUS-SPECIFIC CD8+ T-CELL MEMORY DETERMINED BY CLONAL BURST SIZE	NATURE			English	Article							LYMPHOCYTIC CHORIOMENINGITIS VIRUS; SENDAI VIRUS; INVIVO; MICE; EXPRESSION; INFLUENZA; INFECTION; IMMUNITY; ANTIGEN; BETA	Although some viruses, particularly the herpes viruses, may never be eliminated from the body(1), others like influenza A, regularly reinfect humans and boost waning crossreactive CD8(+) T-cell immunity(2). Prolonged T-cell memory is found for viruses that are unlikely to be re-encountered and which do not persist in the host genome(3-5), indicating that CD8(+) T-cell memory might be independent dent of continued (or sporadic) antigenic exposure. A feature of virus-specific CD8(+) T-cell memory is that antigen-specific cytotoxic T-lymphocyte precursors (CTLp) are greatly increased and remain high throughout life. The idea that persistence of the inducing antigen is essential is based on experiments in which adoptively transferred CD8(+) memory T cells could not be detected for more than a few weeks in naive recipient mice without secondary challenge(6,7). Here we show that restimulation of such chimaeric mice with an inducing Sendai virus antigen increases the clonal burst size more than 7-fold within 8 days, making memory CTLp easier to detect in the longer term. We find that Sendai-virus-specific CTLp are maintained for >250 days in irradiated uninfected recipients, including reconstituted beta(2)-microglobulin(-/-) mice. To determine whether a source of viral peptide can persist after primary infection, we gave Sendai-virus-specific Thy1.1(+) memory spleen cells to naive mice that had been minimally depleted of Thy1.2(+) T cells, or to comparable recipients that had recovered from infection with Sendai virus or influenza virus. Although antibody against Sendai virus was never found in the naive recipients, Sendai-virus-specific CD8(+) memory T cells were maintained equally well in each case for >100 days after cell transfer. We find so evidence for persisting depots of viral protein that might feed into the endogenous processing pathway and maintain virus-specific CD8(+) T-cell memory.	ST JUDE CHILDRENS RES HOSP, DEPT VIROL & IMMUNOL, MEMPHIS, TN 38105 USA; ST JUDE CHILDRENS RES HOSP, DEPT MOLEC BIOL, MEMPHIS, TN 38105 USA	St Jude Children's Research Hospital; St Jude Children's Research Hospital			Doherty, Peter Charles/C-4185-2013	Doherty, Peter Charles/0000-0002-5028-3489				BEVERLEY PCL, 1990, IMMUNOL TODAY, V11, P203, DOI 10.1016/0167-5699(90)90083-L; BURTON GF, 1993, J IMMUNOL, V150, P31; CHAKRABARTI S, 1985, MOL CELL BIOL, V5, P3403, DOI 10.1128/MCB.5.12.3403; DEMKOWICZ WE, 1993, J VIROL, V67, P1538, DOI 10.1128/JVI.67.3.1538-1544.1993; DOHERTY PC, 1981, IMMUNOL REV, V58, P37, DOI 10.1111/j.1600-065X.1981.tb00349.x; DOHERTY PC, 1992, ANNU REV IMMUNOL, V10, P123; DOHERTY PC, 1988, CLIN IMMUNOL IMMUNOP, V47, P19, DOI 10.1016/0090-1229(88)90141-9; DOHERTY PC, 1989, IMMUNOLOGY, V66, P631; DOHERTY PC, 1994, STRATEGIES VACCINE D, P51; FINK PJ, 1988, ANNU REV IMMUNOL, V6, P115; FRASER JD, 1987, IMMUNOGENETICS, V26, P31, DOI 10.1007/BF00345451; GRAY D, 1991, J EXP MED, V174, P969, DOI 10.1084/jem.174.5.969; GRAY D, 1993, ANNU REV IMMUNOL, V11, P49, DOI 10.1146/annurev.immunol.11.1.49; HOU S, 1992, J IMMUNOL, V149, P1319; HOU S, 1993, J IMMUNOL, V150, P5494; KAST WM, 1991, P NATL ACAD SCI USA, V88, P2283, DOI 10.1073/pnas.88.6.2283; KING CC, 1990, J VIROL, V64, P5611, DOI 10.1128/JVI.64.11.5611-5616.1990; LAU LL, 1994, NATURE, V369, P648, DOI 10.1038/369648a0; MACKAY CR, 1993, ADV IMMUNOL, V53, P217, DOI 10.1016/S0065-2776(08)60501-5; MCMICHAEL AJ, 1983, LANCET, V2, P762; Moss D J, 1992, Semin Immunol, V4, P97; MULLBACHER A, 1994, J EXP MED, V179, P317, DOI 10.1084/jem.179.1.317; OEHEN S, 1992, J EXP MED, V176, P1273, DOI 10.1084/jem.176.5.1273; ROCHA B, 1989, EUR J IMMUNOL, V19, P905, DOI 10.1002/eji.1830190518; SEDGWICK JD, 1986, J IMMUNOL METHODS, V87, P37, DOI 10.1016/0022-1759(86)90341-8; SMITH GL, 1987, VIROLOGY, V160, P336, DOI 10.1016/0042-6822(87)90004-3; SPRENT J, 1993, CURR OPIN IMMUNOL, V5, P433, DOI 10.1016/0952-7915(93)90065-Z; ZIJLSTRA M, 1990, NATURE, V344, P742, DOI 10.1038/344742a0	28	465	475	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JUN 23	1994	369	6482					652	654		10.1038/369652a0	http://dx.doi.org/10.1038/369652a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	NT459	7516039				2022-12-28	WOS:A1994NT45900056
J	NELSON, BH; LORD, JD; GREENBERG, PD				NELSON, BH; LORD, JD; GREENBERG, PD			CYTOPLASMIC DOMAINS OF THE INTERLEUKIN-2 RECEPTOR BETA-CHAIN AND GAMMA-CHAIN MEDIATE THE SIGNAL FOR T-CELL PROLIFERATION	NATURE			English	Article							IL-2 RECEPTOR; TYROSINE KINASE; FUNCTIONAL COMPONENT; GM-CSF; TRANSDUCTION; ACTIVATION; BINDING; PHOSPHORYLATION; INVOLVEMENT; EXPRESSION	The interleukin-2 (IL-2R) consists of three distinct chains (alpha, beta, gamma) which bind IL-2 and generate a proliferative signal in T cells(1). To define the mechanism of receptor activation, chimaeric receptors were constructed from the intracellular region of either IL-2R beta or IL-2R gamma and the extracellular region of c-kit, a receptor tyrosine kinase that homodimerizes on binding stem cell factor (SCF)(2). We report here that binding of SCF to the beta-chain chimaera induced proliferation of the pro-B-cell line BA/F3, but not T cells. But in T cells expressing both the beta- and gamma-chain chimaeras, SCF induced proliferation and tyrosine phosphorylation characteristic of the native IL-2R signal. Chimaeric IL-2 receptor beta and gamma chains constructed with the heterodimeric extracellular regions of the granulocyte-macrophage colony stimulating factor receptor (GM-CSFR) also provided the IL-2R signal. Thus, heterodimerization of the cytoplasmic domains of n-2R beta and -gamma appears necessary and sufficient for signalling in T cells.	UNIV WASHINGTON,DEPT IMMUNOL,SEATTLE,WA 98195; UNIV WASHINGTON,DEPT MED,SEATTLE,WA 98195	University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle	NELSON, BH (corresponding author), FRED HUTCHINSON CANC RES CTR,1124 COLUMBIA ST M758,SEATTLE,WA 98104, USA.		Nelson, Brad H/K-2622-2014	Nelson, Brad/0000-0002-4445-5539				ARIMA N, 1992, J EXP MED, V176, P1265, DOI 10.1084/jem.176.5.1265; ASAO H, 1990, J EXP MED, V171, P637, DOI 10.1084/jem.171.3.637; ASAO H, 1993, P NATL ACAD SCI USA, V90, P4127, DOI 10.1073/pnas.90.9.4127; BECKMANN MP, 1990, J IMMUNOL, V144, P4212; BICHTHUY LT, 1987, J IMMUNOL, V139, P1550; CHIBA T, 1993, NATURE, V362, P646, DOI 10.1038/362646a0; DANDREA A, 1989, CELL, V58, P1023, DOI 10.1016/0092-8674(89)90499-6; GUNNING P, 1987, P NATL ACAD SCI USA, V84, P4831, DOI 10.1073/pnas.84.14.4831; HATAKEYAMA M, 1991, SCIENCE, V252, P1523, DOI 10.1126/science.2047859; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; HORAK ID, 1991, P NATL ACAD SCI USA, V88, P1996, DOI 10.1073/pnas.88.5.1996; KONDO M, 1993, SCIENCE, V262, P1874, DOI 10.1126/science.8266076; LEV S, 1992, J BIOL CHEM, V267, P15970; LINNEKIN D, 1992, J BIOL CHEM, V267, P23993; MOREAU JL, 1987, EUR J IMMUNOL, V17, P929, DOI 10.1002/eji.1830170706; MURAKAMI M, 1993, SCIENCE, V260, P1808, DOI 10.1126/science.8511589; NOGUCHI M, 1993, CELL, V73, P147, DOI 10.1016/0092-8674(93)90167-O; NOGUCHI M, 1993, SCIENCE, V262, P1877, DOI 10.1126/science.8266077; RUSSELL SM, 1993, SCIENCE, V262, P1880, DOI 10.1126/science.8266078; SAKAMAKI K, 1992, EMBO J, V11, P3541, DOI 10.1002/j.1460-2075.1992.tb05437.x; SHANAFELT AB, 1991, EMBO J, V10, P4105, DOI 10.1002/j.1460-2075.1991.tb04987.x; SIU G, 1992, MOL CELL BIOL, V12, P1592, DOI 10.1128/MCB.12.4.1592; SMITH KA, 1985, P NATL ACAD SCI USA, V82, P864, DOI 10.1073/pnas.82.3.864; STAHL N, 1993, CELL, V74, P587, DOI 10.1016/0092-8674(93)90506-L; SUGAMURA K, 1990, LYMPHOKINE RES, V9, P539; TAKESHITA T, 1992, SCIENCE, V257, P379, DOI 10.1126/science.1631559; TANIGUCHI T, 1993, CELL, V73, P5, DOI 10.1016/0092-8674(93)90152-G; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; WALDMANN TA, 1991, J BIOL CHEM, V266, P2681; ZIEGLER SF, 1991, NEW BIOL, V3, P1242	30	294	310	0	4	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	MAY 26	1994	369	6478					333	336		10.1038/369333a0	http://dx.doi.org/10.1038/369333a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	NN109	7514277				2022-12-28	WOS:A1994NN10900054
J	ECK, MJ; ATWELL, SK; SHOELSON, SE; HARRISON, SC				ECK, MJ; ATWELL, SK; SHOELSON, SE; HARRISON, SC			STRUCTURE OF THE REGULATORY DOMAINS OF THE SRC-FAMILY TYROSINE KINASE LCK	NATURE			English	Article							PROTEIN STRUCTURES; CRYSTAL-STRUCTURE; SH3 DOMAIN; IDENTIFICATION; P60C-SRC; BINDING	THE kinase p56(lck) (Lck) is a T-lymphocyte-specific member of the Src family of non-receptor tyrosine kinases(1). Members of the Src family each contain unique amino-terminal regions, followed by Src-homology domains SH3 and SH2, and a tyrosine kinase domain. SH3 and SH2 domains mediate critical protein interactions in many signal-transducing pathways(2). They are small, independently folded modules of about 60 and 100 residues, respectively, and they are often but not always found together in the same molecule. Like all nine Src-family kinases (reviewed in ref. 3), Lck is regulated by phosphorylation of a tyrosine in the short C-terminal tail of its catalytic domain(4). There is evidence that binding of the phosphorylated tail to the SH2 domain inhibits catalytic activity of the kinase domain(5,6) and that the SH3 and SH2 domains may act together to effect this regulation(7). Here we report the crystal structures for a fragment of Lck bearing its SH3 and SH2 domains, alone and in complex with a phosphotyrosyl peptide containing the sequence of the Lck C-terminal regulatory tail. The latter complex represents the regulatory apparatus of Lck. The SH3-SH2 fragment forms similar dimers in both crystals, and the tail peptide binds at the intermolecular SH3/SH2 contact. The two structures show how an SH3 domain might recognize a specific target and suggest how dimerization could play a role in regulating Src-family kinases.	CHILDRENS HOSP MED CTR, MOLEC MED LAB, BOSTON, MA 02115 USA; HARVARD UNIV, SCH MED, DEPT MICROBIOL & MOLEC GENET, BOSTON, MA 02115 USA; HARVARD UNIV, BRIGHAM & WOMENS HOSP,SCH MED,JOSLIN DIABET CTR, DIV RES, BOSTON, MA 02115 USA; HARVARD UNIV, DEPT BIOCHEM & MOLEC BIOL, CAMBRIDGE, MA 02138 USA	Harvard University; Boston Children's Hospital; Harvard University; Harvard Medical School; Harvard University; Brigham & Women's Hospital; Harvard Medical School; Joslin Diabetes Center, Inc.; Harvard University	ECK, MJ (corresponding author), CHILDRENS HOSP MED CTR, HOWARD HUGHES MED INST, 300 LONGWOOD AVE, BOSTON, MA 02115 USA.							ABRAHAM N, 1991, NATURE, V350, P62, DOI 10.1038/350062a0; BOOKER GW, 1992, NATURE, V358, P684, DOI 10.1038/358684a0; BOOKER GW, 1993, CELL, V73, P813, DOI 10.1016/0092-8674(93)90259-S; Brunger AT, 1992, X PLOR VERSION 3 0 S; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; CICCHETTI P, 1992, SCIENCE, V257, P803, DOI 10.1126/science.1379745; COOPER JA, 1993, CELL, V73, P1051, DOI 10.1016/0092-8674(93)90634-3; ECK MJ, 1993, NATURE, V362, P87, DOI 10.1038/362087a0; GRANDORI C, 1988, J CELL BIOL, V107, P2125, DOI 10.1083/jcb.107.6.2125; JANIN J, 1990, J BIOL CHEM, V265, P16027; JONES TA, 1989, CRYSTALLOGRAPHIC COM; JONES TA, 1992, MOL REPLACEMENT, P91; KABSCH W, 1988, J APPL CRYSTALLOGR, V21, P916, DOI 10.1107/S0021889888007903; KATO JY, 1986, MOL CELL BIOL, V6, P4155, DOI 10.1128/MCB.6.12.4155; KOCH CA, 1991, SCIENCE, V252, P668, DOI 10.1126/science.1708916; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LEE B, 1971, J MOL BIOL, V55, P379, DOI 10.1016/0022-2836(71)90324-X; MARTH JD, 1985, CELL, V43, P393, DOI 10.1016/0092-8674(85)90169-2; MUSACCHIO A, 1992, NATURE, V359, P851, DOI 10.1038/359851a0; NAVAZA J, 1992, AMORE NEW PACKAGE MO; OVERDUIN M, 1992, CELL, V70, P697, DOI 10.1016/0092-8674(92)90437-H; PICCIONE E, 1993, BIOCHEMISTRY-US, V32, P3197, DOI 10.1021/bi00064a001; Potts W M, 1988, Oncogene Res, V3, P343; PRASAD KVS, 1993, MOL CELL BIOL, V13, P7708, DOI 10.1128/MCB.13.12.7708; ROUSSEL RR, 1991, P NATL ACAD SCI USA, V88, P10696, DOI 10.1073/pnas.88.23.10696; SUPERTIFURGA G, 1993, EMBO J, V12, P2625, DOI 10.1002/j.1460-2075.1993.tb05923.x; WAKSMAN G, 1993, CELL, V72, P779, DOI 10.1016/0092-8674(93)90405-F; WAKSMAN G, 1992, NATURE, V358, P646, DOI 10.1038/358646a0; YU HT, 1992, SCIENCE, V258, P1665, DOI 10.1126/science.1280858; ZHOU SY, 1993, CELL, V72, P767, DOI 10.1016/0092-8674(93)90404-E	30	263	268	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	APR 21	1994	368	6473					764	769		10.1038/368764a0	http://dx.doi.org/10.1038/368764a0			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	NG553	7512222				2022-12-28	WOS:A1994NG55300065
J	AMIN, J; WEISS, DS				AMIN, J; WEISS, DS			GABA(A) RECEPTOR NEEDS 2 HOMOLOGOUS DOMAINS OF THE BETA-SUBUNIT FOR ACTIVATION BY GABA BUT NOT BY PENTOBARBITAL	NATURE			English	Article							NICOTINIC ACETYLCHOLINE-RECEPTOR; GLYCINE RECEPTOR; ALPHA-SUBUNIT; BINDING-SITE; ION CHANNELS; AMINO-ACIDS; A RECEPTORS; AGONIST; RAT; NEURONS	THE predominant inhibitory neurotrasmitter of the brain, GABA (gamma-antinobutyric acid), activates chloride-selective ion pores integral to the receptor complex. Subunits comprising the presumed hetero-pentameric GABA channel have been cloned1-4, but little information is available on the domains important for activation. Rat wild-type or mutated alpha1-, beta2- and gamma2-subunits (designated alpha, beta and gamma) were coexpressed in Xenopus oocytes and examined electrophysiologically. We report here the identification of two separate and homologous domains of the beta-subunit, each of which contributes a tyrosine and threonine essential for activation by GABA. Conservative substitution of each of these four amino acids dramatically decreased GABA channel sensitivity to activation by GABA and the GABA agonist muscimol. These substitutions, however, did not impair activation by the barbiturate pentobarbital, indicating these two different classes of agonists activate GABA channels through distinct mechanisms. We also present evidence suggesting that the two identified domains of the beta-subunit contribute a major component of the GABA receptor.	UNIV S FLORIDA,COLL MED,DEPT PHYSIOL & BIOPHYS,12901 BRUCE B DOWNS BLVD,TAMPA,FL 33612; UNIV S FLORIDA,COLL MED,INST BIOMOLEC SCI,TAMPA,FL 33612	State University System of Florida; University of South Florida; State University System of Florida; University of South Florida			Amin, Jahanshah/I-7174-2012					BARKER JL, 1978, J PHYSIOL-LONDON, V280, P355, DOI 10.1113/jphysiol.1978.sp012388; BrõndÚn CI., 1991, INTRO PROTEIN STRUCT; CASALOTTI SO, 1986, J BIOL CHEM, V261, P5013; COLQUHOUN D, 1988, J PHYSIOL-LONDON, V395, P131, DOI 10.1113/jphysiol.1988.sp016912; COLQUHOUN D, 1981, PROC R SOC SER B-BIO, V211, P205, DOI 10.1098/rspb.1981.0003; COLQUHOUN D, 1986, ION CHANNELS NEURAL; CRAWFORD JL, 1973, P NATL ACAD SCI USA, V70, P538, DOI 10.1073/pnas.70.2.538; DELCASTILLO J, 1957, PROC R SOC SER B-BIO, V146, P369; DENG L, 1986, BIOCHEM BIOPH RES CO, V138, P1308, DOI 10.1016/S0006-291X(86)80425-9; DENNIS M, 1988, BIOCHEMISTRY-US, V27, P2346, DOI 10.1021/bi00407a016; FRIEDA S, 1990, P R SOC B, V241, P207; GALZI JL, 1991, FEBS LETT, V294, P198, DOI 10.1016/0014-5793(91)80668-S; GALZI JL, 1991, ANNU REV PHARMACOL, V31, P37, DOI 10.1146/annurev.pa.31.040191.000345; KHRESTCHATISKY M, 1989, NEURON, V3, P745, DOI 10.1016/0896-6273(89)90243-2; LEVITAN ES, 1988, NEURON, V1, P773, DOI 10.1016/0896-6273(88)90125-0; LOLAIT SJ, 1989, FEBS LETT, V246, P145, DOI 10.1016/0014-5793(89)80271-6; NEWLAND CF, 1991, J PHYSIOL-LONDON, V432, P203, DOI 10.1113/jphysiol.1991.sp018382; NICOLL RA, 1980, BRAIN RES, V191, P225, DOI 10.1016/0006-8993(80)90325-X; NICOLL RA, 1975, NATURE, V258, P625, DOI 10.1038/258625a0; OLEARY ME, 1992, J BIOL CHEM, V267, P8360; PRITCHETT DB, 1989, NATURE, V338, P582, DOI 10.1038/338582a0; SAIKI RK, 1988, SCIENCE, V239, P481; Sakmann B, 1983, J Neural Transm Suppl, V18, P83; SCHMIEDEN V, 1992, EMBO J, V11, P2025, DOI 10.1002/j.1460-2075.1992.tb05259.x; SCHOFIELD PR, 1987, NATURE, V328, P221, DOI 10.1038/328221a0; SCHULZ DW, 1981, BRAIN RES, V209, P177, DOI 10.1016/0006-8993(81)91179-3; SHIVERS BD, 1989, NEURON, V3, P327, DOI 10.1016/0896-6273(89)90257-2; SIGEL E, 1992, EMBO J, V11, P2017, DOI 10.1002/j.1460-2075.1992.tb05258.x; SIGEL E, 1990, NEURON, V5, P703, DOI 10.1016/0896-6273(90)90224-4; TOMASELLI GF, 1991, BIOPHYS J, V60, P721, DOI 10.1016/S0006-3495(91)82102-6; TWYMAN RE, 1990, J PHYSIOL-LONDON, V423, P193, DOI 10.1113/jphysiol.1990.sp018018; VANDENBERG RJ, 1992, NEURON, V9, P491, DOI 10.1016/0896-6273(92)90186-H; VERDOORN TA, 1990, NEURON, V4, P919, DOI 10.1016/0896-6273(90)90145-6; WEISS DS, 1989, J NEUROSCI, V9, P1314	34	384	386	0	3	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	DEC 9	1993	366	6455					565	569		10.1038/366565a0	http://dx.doi.org/10.1038/366565a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ML218	7504783				2022-12-28	WOS:A1993ML21800070
J	NAYLOR, CD; SYKORA, K; JAGLAL, SB; JEFFERSON, S; BEANLANDS, DS; BICKERTON, LM; CHISHOLM, R; LOZON, J; GOLDBACH, M; KAMINSKI, V; MCKENZIE, N; MONAGHAN, BJ; MORGAN, CD; PYM, J; SCULLY, H; SHRAGGE, BW; SWAN, J				NAYLOR, CD; SYKORA, K; JAGLAL, SB; JEFFERSON, S; BEANLANDS, DS; BICKERTON, LM; CHISHOLM, R; LOZON, J; GOLDBACH, M; KAMINSKI, V; MCKENZIE, N; MONAGHAN, BJ; MORGAN, CD; PYM, J; SCULLY, H; SHRAGGE, BW; SWAN, J			WAITING FOR CORONARY-ARTERY BYPASS-SURGERY - POPULATION-BASED STUDY OF 8517 CONSECUTIVE PATIENTS IN ONTARIO, CANADA	LANCET			English	Article							OPEN-HEART-SURGERY; REVASCULARIZATION PROCEDURES; EARLY MORTALITY; RISK-FACTORS; CONSEQUENCES; PRIORITY; ACCESS; CARE	Deaths and delays in queues for coronary surgery in Canada have been highlighted by American interest groups opposed to ''socialised medicine''. Since 1991 all nine cardiac surgery centres in Ontario register and follow patients after acceptance for surgery. We examined the experience of 8517 consecutive patients leaving the registry from October 1991 to July 1993. Individual acuity scores were determined based on symptoms, angiographic findings, left ventricular function, and, where available, non-invasive tests of ischaemic jeopardy. Planned surgery was declined or deferred for 3.2% of registrants. While in the queue, 31 (0.4%) patients died and three had surgery indefinitely deferred after a nonfatal myocardial infarction. Among 8213 patients receiving surgery, the median wait was 17 days (inter-quartile range [IQR]: 4, 51), ranging from one day (IQR 0:4) for patients needing very urgent surgery (acuity score 2-3) to 42 days (IQR: 18, 77) for those rated low priority (acuity score 6-7). In a multivariate analysis, the most important determinant of waiting time was symptom status (p<0.001), followed by anatomy (p<0.001). Age did not alter waiting time; depending on statistical methods, female sex was either not significant or independently approximately 11% relative delay controlling for significant clinical factors or the multifactorial acuity scores, waiting times clearly varied (p<0.001) among hospitals. We conclude that, during 1991-93, patients queuing for coronary surgery in Ontario rarely suffered critical events or extreme delays, and individual variation in waiting times primarily reflected clinical acuity. Nonetheless, symptoms provoked by very modest exertion were commonplace in the queue, and waiting times did vary inequitably among hospitals.	ST MICHAELS HOSP,TORONTO,ON M5B 1W8,CANADA; UNIV OTTAWA,INST HEART,OTTAWA,ON K1N 6N5,CANADA; VICTORIA HOSP,LONDON,ON N6A 4G5,CANADA; SUNNYBROOK HLTH SCI CTR,TORONTO,ON M4N 3M5,CANADA; SUDBURY MEM HOSP,SUDBURY,ON,CANADA; UNIV WESTERN ONTARIO HOSP,LONDON,ON N6A 5A5,CANADA; W PK HOSP,TORONTO,ON,CANADA; KINGSTON GEN HOSP,KINGSTON,ON K7L 2V7,CANADA; TORONTO HOSP,TORONTO,ON M5T 2S8,CANADA; HAMILTON GEN HOSP,HAMILTON,ON,CANADA; CENTENARY HLTH CTR,SCARBOROUGH,ON,CANADA; INST CLIN EVALUAT SCI ONTARIO,TORONTO,ON,CANADA; UNIV TORONTO,CLIN EPIDEMIOL & HLTH CARE PROGRAM,SUNNYBROOK UNIT,TORONTO,ON,CANADA; UNIV TORONTO,DEPT MED,TORONTO,ON M5S 1A1,CANADA; UNIV TORONTO,DEPT SURG,TORONTO,ON M5S 1A1,CANADA; ADULT CARDIAC CARE NETWORK ONTARIO,CENT OFF,TORONTO,ON,CANADA	University of Toronto; University Toronto Affiliates; Saint Michaels Hospital Toronto; University of Ottawa; University of Ottawa Heart Institute; University of Victoria; Western University (University of Western Ontario); University of Toronto; Sunnybrook Research Institute; University Toronto Affiliates; Sunnybrook Health Science Center; University of Ottawa; Western University (University of Western Ontario); Queens University - Canada; University of Toronto; University Toronto Affiliates; University Health Network Toronto; McMaster University; University of Toronto; University of Toronto; Sunnybrook Research Institute; University Toronto Affiliates; Sunnybrook Health Science Center; University of Toronto; University of Toronto				Jaglal, Susan/0000-0002-2930-1443				BARNES JA, 1990, WALL STREET J   1212, pA16; BINDMAN AB, 1991, JAMA-J AM MED ASSOC, V266, P1091, DOI 10.1001/jama.266.8.1091; CAMPEAU L, 1976, CIRCULATION, V54, P522, DOI 10.1161/circ.54.3.947585; CARRIER M, 1993, CAN MED ASSOC J, V149, P1117; DUPUIS G, 1990, Clinical and Investigative Medicine, V13, pC35; FITZPATRICK MA, 1992, NEW ZEAL MED J, V105, P145; HANNAN EL, 1990, JAMA-J AM MED ASSOC, V264, P2768, DOI 10.1001/jama.264.21.2768; KATZ SJ, 1991, JAMA-J AM MED ASSOC, V266, P1108, DOI 10.1001/jama.266.8.1108; LLEWELLYNTHOMAS HA, 1992, MED DECIS MAKING, V12, P337; MARBER M, 1991, BRIT MED J, V302, P1189, DOI 10.1136/bmj.302.6786.1189; MULGAN R, 1990, NEW ZEAL MED J, V103, P371; NAYLOR CD, 1991, CAN J CARDIOL, V7, P207; NAYLOR CD, 1990, LANCET, V335, P1070, DOI 10.1016/0140-6736(90)92640-4; NAYLOR CD, 1993, CAN MED ASSOC J, V149, P955; NAYLOR CD, 1993, SOC SCI MED, V37, P61, DOI 10.1016/0277-9536(93)90318-X; OCONNOR GT, 1991, JAMA-J AM MED ASSOC, V266, P803, DOI 10.1001/jama.266.6.803; PIEPER B, 1985, HEART LUNG, V14, P40; RACHLIS MM, 1991, IATROGENICS, V1, P103; SULLIVAN P, 1990, CAN MED ASSOC J, V142, P50; SUTTORP MJ, 1990, LANCET, V336, P310, DOI 10.1016/0140-6736(90)91843-Y; SUTTORP MJ, 1992, EUR HEART J, V13, P238, DOI 10.1093/oxfordjournals.eurheartj.a060153; UGNAT AM, 1994, PATTERNS HLTH CARE O, P88; WEISSMAN JS, 1991, ANN INTERN MED, V114, P325, DOI 10.7326/0003-4819-114-4-325; YUSUF S, 1994, LANCET, V344, P563, DOI 10.1016/S0140-6736(94)91963-1	24	95	96	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	DEC 16	1995	346	8990					1605	1609		10.1016/S0140-6736(95)91934-1	http://dx.doi.org/10.1016/S0140-6736(95)91934-1			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TK481	7500756				2022-12-28	WOS:A1995TK48100015
J	MCKIM, KS; HAWLEY, RS				MCKIM, KS; HAWLEY, RS			CHROMOSOMAL CONTROL OF MEIOTIC CELL-DIVISION	SCIENCE			English	Article							KINESIN-LIKE PROTEIN; CAENORHABDITIS-ELEGANS; SPINDLE FORMATION; CYCLE CHECKPOINTS; MICROTUBULE; KINETOCHORES; CENTROMERE; MITOSIS; CENTROSOMES; SEGREGATION	Chromosomes have multiple roles both in controlling the cell assembly and structure of the spindle and in determining chromosomal position on the spindle in many meiotic cells and in some types of mitotic cells. Moreover, functionally significant chromosome-microtubule interactions are not limited to the kinetochore but are also mediated by proteins localized along the arms of chromosomes. Finally, chromosomes also play a crucial role in control of the cell cycle.	UNIV CALIF DAVIS,DEPT GENET,MOLEC & CELLULAR BIOL SECT,DAVIS,CA 95616	University of California System; University of California Davis				Hawley, R. Scott/0000-0002-6478-0494				AFSHAR K, 1995, CELL, V81, P129, DOI 10.1016/0092-8674(95)90377-1; ALBERTSON DG, 1982, CHROMOSOMA, V86, P409, DOI 10.1007/BF00292267; Albertson DG, 1993, CHROMOSOME RES, V1, P15, DOI 10.1007/BF00710603; AULT JG, 1989, CHROMOSOMA, V98, P33, DOI 10.1007/BF00293332; BAKER SM, 1995, CELL, V82, P309, DOI 10.1016/0092-8674(95)90318-6; BISHOP DK, 1992, CELL, V69, P439, DOI 10.1016/0092-8674(92)90446-J; BLOOM K, 1993, CELL, V73, P621, DOI 10.1016/0092-8674(93)90242-I; BRINKLEY BR, 1988, NATURE, V336, P251, DOI 10.1038/336251a0; BROWN W, 1995, TRENDS GENET, V11, P337, DOI 10.1016/S0168-9525(00)89100-3; BURGOYNE PS, 1992, CELL, V71, P391, DOI 10.1016/0092-8674(92)90509-B; CAMPBELL MS, 1995, J CELL BIOL, V129, P1195, DOI 10.1083/jcb.129.5.1195; CHURCH K, 1986, J CELL BIOL, V103, P2765, DOI 10.1083/jcb.103.6.2765; DEBOER P, 1989, FERTILITY CHROMOSOME; DERNBERG A, UNPUB; Dietz R, 1966, HEREDITY S, V19, P161; EARNSHAW WC, 1991, J CELL SCI, V99, P1; EARNSHAW WC, 1991, COLD SH Q B, V56, P675; FULLER MT, 1995, CELL, V81, P6; GORBSKY GJ, 1993, J CELL BIOL, V122, P1311, DOI 10.1083/jcb.122.6.1311; HARTWELL LH, 1989, SCIENCE, V246, P629, DOI 10.1126/science.2683079; HATSUMI M, 1992, J CELL SCI, V101, P547; HODGKIN J, 1980, GENETICS, V96, P649; HODGKIN J, 1979, GENETICS, V91, P67; HUGHESSCHRADER S, 1948, CHROMOSOMA, V3, P258; HUNT P, IN PRESS HUM MOL GEN; HYMAN AA, 1991, NATURE, V351, P206, DOI 10.1038/351206a0; JANG J, UNPUB; JANG JK, 1995, SCIENCE, V268, P1917, DOI 10.1126/science.7604267; KARSENTI E, 1984, J CELL BIOL, V98, P1730, DOI 10.1083/jcb.98.5.1730; Lindsley D.L., 1992, GENOME DROSOPHILA ME, Veighth; LINDSLEY DL, 1958, GENETICS, V43, P790; LIXX, 1995, NATURE, V373, P630; MCINTOSH JR, 1991, COLD SH Q B, V56, P613; MCINTOSH JR, 1991, J CELL BIOL, V115, P577, DOI 10.1083/jcb.115.3.577; MCKIM KS, 1993, NATURE, V362, P364, DOI 10.1038/362364a0; MCKIM KS, UNPUB; MILLER OL, 1963, GENETICS, V48, P1445; MURRAY AW, 1992, NATURE, V359, P599, DOI 10.1038/359599a0; NICKLAS RB, 1977, PHILOS T ROY SOC B, V277, P267, DOI 10.1098/rstb.1977.0017; NICKLAS RB, 1995, J CELL BIOL, V130, P929, DOI 10.1083/jcb.130.4.929; NICKLAS RB, 1994, J CELL BIOL, V126, P1241, DOI 10.1083/jcb.126.5.1241; NICKLAS RB, 1967, CHROMOSOMA, V21, P1, DOI 10.1007/BF00330544; NICKLAS RB, 1974, GENETICS, V78, P205; NICKLAS RB, 1992, J CELL SCI, V102, P681; NICKLAS RB, 1988, CHROMOSOME STRUCTURE, P53; OSTERGREN G, 1951, HEREDITAS, V37, P85; RHODES MM, 1952, HETEROSIS, P66; RIEDER CL, 1994, J CELL BIOL, V127, P1301, DOI 10.1083/jcb.127.5.1301; RIEDER CL, 1990, J CELL BIOL, V110, P81, DOI 10.1083/jcb.110.1.81; RIEDER CL, 1994, J CELL BIOL, V124, P223, DOI 10.1083/jcb.124.3.223; RIEDER CL, 1995, J CELL BIOL, V130, P941, DOI 10.1083/jcb.130.4.941; RIEDER CL, 1993, CHROMOSOME SEGREGATI, P183; Rieder CL, 1991, CURR OPIN CELL BIOL, V3, P59, DOI 10.1016/0955-0674(91)90166-V; RING D, 1982, J CELL BIOL, V94, P549, DOI 10.1083/jcb.94.3.549; SANDLER L, 1954, GENETICS, V39, P365; SAWIN KE, 1991, J CELL BIOL, V112, P925, DOI 10.1083/jcb.112.5.925; SCHATTEN G, 1985, P NATL ACAD SCI USA, V82, P4152, DOI 10.1073/pnas.82.12.4152; SEARS ER, 1952, CHROMOSOMA, V4, P535, DOI 10.1007/BF00325789; SIMCHEN G, 1993, BIOESSAYS, V15, P1, DOI 10.1002/bies.950150102; SKIBBENS RV, 1995, J CELL SCI, V108, P2537; SLUDER G, 1994, J CELL BIOL, V126, P189, DOI 10.1083/jcb.126.1.189; SLUDER G, 1986, J CELL BIOL, V103, P1873, DOI 10.1083/jcb.103.5.1873; SLUDER G, 1985, J CELL BIOL, V100, P897, DOI 10.1083/jcb.100.3.897; SPENCER F, 1992, P NATL ACAD SCI USA, V89, P8908, DOI 10.1073/pnas.89.19.8908; STEFFEN W, 1986, J CELL BIOL, V102, P1679, DOI 10.1083/jcb.102.5.1679; SYM M, 1993, CELL, V72, P365, DOI 10.1016/0092-8674(93)90114-6; SYM M, 1994, CELL, V79, P283, DOI 10.1016/0092-8674(94)90197-X; THEURKAUF WE, 1992, J CELL BIOL, V116, P1167, DOI 10.1083/jcb.116.5.1167; THEURKAUF WE, COMMUNICATION; TOMKIEL J, 1994, J CELL BIOL, V12, P531; VERMOS I, 1995, CELL, V81, P117; WATERS JC, 1993, J CELL BIOL, V122, P361, DOI 10.1083/jcb.122.2.361; WEINERT T, 1993, SEMIN CANCER BIOL, V4, P129; White M. J. D, 1973, ANIMAL CYTOLOGY EVOL; ZHANG DH, 1995, J CELL BIOL, V129, P1287, DOI 10.1083/jcb.129.5.1287; ZHANG P, 1990, CELL, V62, P1053, DOI 10.1016/0092-8674(90)90383-P	76	144	145	0	5	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	DEC 8	1995	270	5242					1595	1601		10.1126/science.270.5242.1595	http://dx.doi.org/10.1126/science.270.5242.1595			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TJ293	7502068				2022-12-28	WOS:A1995TJ29300030
J	CUNNINGHAM, S; FLECK, BW; ELTON, RA; MCINTOSH, N				CUNNINGHAM, S; FLECK, BW; ELTON, RA; MCINTOSH, N			TRANSCUTANEOUS OXYGEN LEVELS IN RETINOPATHY OF PREMATURITY	LANCET			English	Note							TENSION	Retinopathy of prematurity (ROP) is a potentially blinding disease of preterm infants. 21 days of computer-recorded transcutaneous oxygen (TcPO2) data were compared in 31 infants with stage 3 or greater ROP and 38 infants with no ROP or stage 1 or 2. In a multiple logistic regression adjusted for significant perinatal factors (birthweight, gestation, and intraventricular haemorrhage), babies with stage 3 or higher ROP showed an increased variability of TcPO2 in week 1 (p<0.01) and 2 (p=0.012) but not week 3. Variability of TcPO, in the first 2 weeks of life is a significant predictor of severe ROP.	UNIV EDINBURGH, PRINCESS ALEXANDRA EYE PAVIL, EDINBURGH, MIDLOTHIAN, SCOTLAND; UNIV EDINBURGH, MED STAT UNIT, EDINBURGH, MIDLOTHIAN, SCOTLAND	University of Edinburgh; University of Edinburgh	CUNNINGHAM, S (corresponding author), UNIV EDINBURGH, DEPT CHILD LIFE & HLTH, 20 SYLVAN PL, EDINBURGH, MIDLOTHIAN, SCOTLAND.			Cunningham, Steve/0000-0001-7342-251X				ASHTON N, 1954, BRIT J OPHTHALMOL, V38, P433, DOI 10.1136/bjo.38.7.433; CUNNINGHAM S, 1994, INT J CLIN MONIT COM, V11, P211, DOI 10.1007/BF01139872; FLYNN JT, 1992, NEW ENGL J MED, V326, P1050, DOI 10.1056/NEJM199204163261603; KRETZER FL, 1988, ARCH DIS CHILD-FETAL, V63, P1151, DOI 10.1136/adc.63.10_Spec_No.1151; PEABODY JL, 1978, ACTA ANAESTH SCAND, P76; PENN JS, 1995, INVEST OPHTH VIS SCI, V36, P2063; SAITO Y, 1993, GRAEF ARCH CLIN EXP, V231, P151, DOI 10.1007/BF00920938; SHWEIKI D, 1992, NATURE, V359, P843, DOI 10.1038/359843a0; Watts John L., 1992, P617; 1990, ARCH OPHTHALMOL-CHIC, V108, P195	10	123	125	0	2	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	DEC 2	1995	346	8988					1464	1465		10.1016/S0140-6736(95)92475-2	http://dx.doi.org/10.1016/S0140-6736(95)92475-2			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TH156	7490994				2022-12-28	WOS:A1995TH15600012
J	STEVENS, MCG; HOCKLEY, AD; SPOONER, D; WALSH, AR				STEVENS, MCG; HOCKLEY, AD; SPOONER, D; WALSH, AR			TREATMENT FOR CHILDREN WITH BRAIN-TUMORS	BRITISH MEDICAL JOURNAL			English	Article								The overall survival for children with malignant brain tumours has not greatly improved in recent years, so that apparently innovative treatments may seem attractive, especially in cases with a poor prognosis. Problems associated with treating such children include balancing the need to provide optimum treatment for individual patients with the need to properly evaluate advances in treatment in clinical trials and determining who should be responsible for decisions about funding such treatments. Treatment abroad is rarely justified when judged on the basis of whether the treatment is available in Britain (or European Community) and whether there is accepted evidence for its clinical benefit. However, referral to specialist paediatric centres is essential. The range of daily experience in such centres allows an educated choice between established and new treatments. Close collaboration these centres is essential for clinical trials.			STEVENS, MCG (corresponding author), BIRMINGHAM CHILDRENS HOSP NHS TRUST,LADYWOOD MIDDLEWAY,BIRMINGHAM B16 8ET,W MIDLANDS,ENGLAND.			Stevens, Michael/0000-0001-6466-551X				LUKENS JN, 1994, CANCER-AM CANCER SOC, V74, P2710, DOI 10.1002/1097-0142(19941101)74:9+<2710::AID-CNCR2820741821>3.0.CO;2-G; MAGRATH I, 1995, LANCET, V345, P601, DOI 10.1016/S0140-6736(95)90516-2; SMYTH JF, 1994, BRIT MED J, V309, P457, DOI 10.1136/bmj.309.6952.457; STILLER CA, 1988, ARCH DIS CHILD, V63, P23, DOI 10.1136/adc.63.1.23; STILLER CA, 1994, BRIT MED J, V309, P1612, DOI 10.1136/bmj.309.6969.1612; 1993, SAFE NEUROSURGERY MA; 1992, ASSESSING EFFECTS HL; [No title captured]	8	7	7	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	NOV 4	1995	311	7014					1213	1214		10.1136/bmj.311.7014.1213	http://dx.doi.org/10.1136/bmj.311.7014.1213			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TD768	7488906	Green Published			2022-12-28	WOS:A1995TD76800030
J	HOLTON, JB; LEONARD, JV				HOLTON, JB; LEONARD, JV			CLOUDS STILL GATHERING OVER GALACTOSEMIA	LANCET			English	Editorial Material							URIDINE-DIPHOSPHATE GALACTOSE; DEFICIENCY		INST CHILD HLTH,LONDON CTR PAEDIAT ENDOCRINOL & METAB,METAB UNIT,LONDON,ENGLAND	University of London; University College London	HOLTON, JB (corresponding author), UNIV BRISTOL,DEPT CHILD HLTH,BRISTOL BS8 1TH,AVON,ENGLAND.							ALLEN JT, 1980, LANCET, V1, P603; BAKKER HD, 1993, INT PEDIATR, V8, P135; Elsas LJ, 1993, INT PEDIATR, V8, P101; HOLTON JB, 1993, J PEDIATR-US, V123, P1009, DOI 10.1016/S0022-3476(05)80404-4; HOLTON JB, 1994, 32ND ANN S SOC STUD; JACOBS C, 1988, PRENAT DIAGN, V8, P641; KAUFMAN FR, 1994, J PEDIATR-US, V125, P225, DOI 10.1016/S0022-3476(94)70197-0; KEEVILL NJ, 1994, J INHERIT METAB DIS, V17, P23, DOI 10.1007/BF00735392; MATTISON DR, 1993, GALACTOSEMIA NEW FRO, P109; NG WG, 1989, J INHERIT METAB DIS, V12, P257, DOI 10.1007/BF01799215; ORNSTEIN KS, 1992, PEDIATR RES, V31, P508, DOI 10.1203/00006450-199205000-00020; SCHWEITZER S, 1993, EUR J PEDIATR, V152, P36, DOI 10.1007/BF02072514; Segal S, 1989, METABOLIC BASIS INHE, P453; SEGAL S, 1993, INT PEDIATR, V8, P125; Waggoner D. D., 1993, INT PEDIAT, V8, P97; WAGGONER DD, 1990, J INHERIT METAB DIS, V13, P802, DOI 10.1007/BF01800204; 1984, LANCET, V2, P1379	17	17	17	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	NOV 5	1994	344	8932					1242	1243		10.1016/S0140-6736(94)90745-5	http://dx.doi.org/10.1016/S0140-6736(94)90745-5			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PP701	7526095				2022-12-28	WOS:A1994PP70100003
J	TAKESHIMA, H; IINO, M; TAKEKURA, H; NISHI, M; KUNO, J; MINOWA, O; TAKANO, H; NODA, T				TAKESHIMA, H; IINO, M; TAKEKURA, H; NISHI, M; KUNO, J; MINOWA, O; TAKANO, H; NODA, T			EXCITATION-CONTRACTION UNCOUPLING AND MUSCULAR DEGENERATION IN MICE LACKING FUNCTIONAL SKELETAL-MUSCLE RYANODINE-RECEPTOR GENE	NATURE			English	Article							CALCIUM RELEASE CHANNEL; SARCOPLASMIC-RETICULUM; CA-2+ RELEASE; MOLECULAR-CLONING; TARGETED MUTATION; MYOGENIN GENE; DNA; CDNA; INACTIVATION; EXPRESSION	CONTRACTION of skeletal muscle is triggered by the release of Ca2+ from the sarcoplasmic reticulum (SR) after depolarization of transverse tubules(1,2). The ryanodine receptor exists as a 'foot' protein in the junctional gap between the sarcoplasmic reticulum and the transverse tubule in skeletal muscle, and is proposed to function as a calcium-release channel during excitation-contraction (E-C) coupling(3-6). Previous complementary DNA-cloning studies have defined three distinct subtypes of the ryanodine receptor in mammalian tissues, namely skeletal muscle, cardiac and brain types(7-12). We report here mice with a targeted mutation in the skeletal muscle ryanodine receptor gene. Mice homozygous for the mutation die perinatally with gross abnormalities of the skeletal muscle. The contractile response to electrical stimulation under physiological conditions is totally abolished in the mutant muscle, although ryanodine receptors other than the skeletal-muscle type seem to exist because the response to caffeine is retained. Our results show that the skeletal muscle ryanodine receptor is essential for both muscular maturation and E-C coupling, and also imply that the function of the skeletal muscle ryanodine receptor during E-C coupling cannot be substituted by other subtypes of the receptor.	INT INST ADV STUDIES,KYOTO 604,JAPAN; UNIV TOKYO,FAC MED,DEPT PHARMACOL,BUNKYO KU,TOKYO 113,JAPAN; NATL INST FITNESS & SPORTS,DEPT PHYSIOL,KANOYA,KAGOSHIMA 89123,JAPAN; JAPANESE FDN CANC RES,INST CANC,DEPT CELL BIOL,TOSHIMA KU,TOKYO 170,JAPAN	University of Tokyo; National Institute Fitness & Sports Kanoya; Japanese Foundation for Cancer Research			Tuluc, Petronel/C-2527-2011; Minowa, Osamu/AAM-1238-2020; Noda, Tetsuo/B-1667-2016	Takeshima, Hiroshi/0000-0003-4525-3725				BEAM KG, 1986, NATURE, V320, P168, DOI 10.1038/320168a0; BLOCK BA, 1988, J CELL BIOL, V107, P2587, DOI 10.1083/jcb.107.6.2587; BRAUN T, 1992, CELL, V71, P369, DOI 10.1016/0092-8674(92)90507-9; CHAUDHARI N, 1992, J BIOL CHEM, V267, P25636; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; ENDO M, 1977, PHYSIOL REV, V57, P71, DOI 10.1152/physrev.1977.57.1.71; FLEISCHER S, 1989, ANNU REV BIOPHYS BIO, V18, P333, DOI 10.1146/annurev.bb.18.060189.002001; GLIANNINI G, 1992, SCIENCE, V257, P91; GLUECKSOHNWAELS.S, 1963, SCIENCE, V142, P1269, DOI 10.1126/science.142.3597.1269; HAKAMATA Y, 1992, FEBS LETT, V312, P229, DOI 10.1016/0014-5793(92)80941-9; HASTY P, 1993, NATURE, V364, P501, DOI 10.1038/364501a0; KLAUS MM, 1983, DEV BIOL, V99, P152, DOI 10.1016/0012-1606(83)90262-2; LAI FA, 1988, NATURE, V331, P315, DOI 10.1038/331315a0; LI E, 1992, CELL, V69, P915, DOI 10.1016/0092-8674(92)90611-F; MANSOUR AP, 1990, CELL, V62, P1073; MARTONOSI AN, 1984, PHYSIOL REV, V64, P1240, DOI 10.1152/physrev.1984.64.4.1240; MCPHERSON PS, 1993, J BIOL CHEM, V268, P13765; MISHINA M, 1986, NATURE, V321, P406, DOI 10.1038/321406a0; NABESHIMA Y, 1993, NATURE, V364, P532, DOI 10.1038/364532a0; NAKAI J, 1990, FEBS LETT, V271, P169, DOI 10.1016/0014-5793(90)80399-4; NUMA S, 1990, COLD SPRING HARB SYM, V40, P1; OTSU K, 1990, J BIOL CHEM, V265, P13472; PAI AC, 1965, DEV BIOL, V11, P82, DOI 10.1016/0012-1606(65)90038-2; PAI AC, 1965, DEV BIOL, V11, P93, DOI 10.1016/0012-1606(65)90039-4; RIOS E, 1987, NATURE, V325, P717, DOI 10.1038/325717a0; RUDNICKI MA, 1992, CELL, V71, P383, DOI 10.1016/0092-8674(92)90508-A; SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875; SAITO A, 1986, J CELL BIOL, V103, P741; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SOUTHERN EM, 1979, METHOD ENZYMOL, V88, P152; TAKESHIMA H, 1989, NATURE, V339, P439, DOI 10.1038/339439a0; TAKESHIMA H, 1993, FEBS LETT, V322, P105, DOI 10.1016/0014-5793(93)81547-D; TANABE T, 1988, NATURE, V336, P134, DOI 10.1038/336134a0; ZORZATO F, 1990, J BIOL CHEM, V265, P2244	34	329	337	0	13	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JUN 16	1994	369	6481					556	559		10.1038/369556a0	http://dx.doi.org/10.1038/369556a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	NR294	7515481				2022-12-28	WOS:A1994NR29400048
J	BASTION, Y; REYES, F; BOSLY, A; GISSELBRECHT, C; YVER, A; GILLES, E; MARAL, J; COIFFIER, B				BASTION, Y; REYES, F; BOSLY, A; GISSELBRECHT, C; YVER, A; GILLES, E; MARAL, J; COIFFIER, B			POSSIBLE TOXICITY WITH THE ASSOCIATION OF G-CSF AND BLEOMYCIN	LANCET			English	Letter									CHU HENRI MONDOR,SERV HEMATOL,GELA,F-94010 CRETEIL,FRANCE; CLIN UNIV MONT GODINE,GELA,B-5180 YVOIR,BELGIUM; CHUGAI RHONE POULENC,F-92165 ANTONY,FRANCE; ROCHE PROD LTD,NEUILLY SUR SEINE,FRANCE; AMGEN INC,PARIS,FRANCE	Assistance Publique Hopitaux Paris (APHP); Universite Paris-Est-Creteil-Val-de-Marne (UPEC); Hopital Universitaire Henri-Mondor - APHP; Universite Catholique Louvain; Universite Catholique Louvain Hospital; Chugai Pharmaceutical Co., Ltd.; Roche Holding	BASTION, Y (corresponding author), CTR HOSP LYON SUD,SERV HEMATOL,GELA,F-69495 PIERRE BENITE,FRANCE.							BASTION Y, 1993, BLOOD, V82, pA143; COIFFIER B, 1991, J CLIN ONCOL, V9, P211, DOI 10.1200/JCO.1991.9.2.211; COIFFIER B, 1989, J CLIN ONCOL, V7, P1018, DOI 10.1200/JCO.1989.7.8.1018; GISSELBRECHT C, 1993, P AN M AM SOC CLIN, V12, P363; MATTHEWS JH, 1993, LANCET, V342, P988, DOI 10.1016/0140-6736(93)92033-P	5	28	28	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAY 14	1994	343	8907					1221	1222		10.1016/S0140-6736(94)92426-0	http://dx.doi.org/10.1016/S0140-6736(94)92426-0			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NL175	7513778				2022-12-28	WOS:A1994NL17500033
J	PARAZZINI, F; BORTOLUS, R; CHATENOUD, L; RESTELLI, S; BENEDETTO, C				PARAZZINI, F; BORTOLUS, R; CHATENOUD, L; RESTELLI, S; BENEDETTO, C			FOLLOW-UP OF CHILDREN IN THE ITALIAN STUDY OF ASPIRIN IN PREGNANCY	LANCET			English	Letter									UNIV TURIN,OSTETR GINECOL CLIN,TURIN,ITALY	University of Turin	PARAZZINI, F (corresponding author), IST RIC FARMACOL MARIO NEGRI,I-20157 MILAN,ITALY.		Bortolus, Renata/K-6396-2016; Chatenoud, Liliane/AAA-6377-2020	Bortolus, Renata/0000-0003-3857-4133; Chatenoud, Liliane/0000-0001-9599-8229; BENEDETTO, CHIARA/0000-0003-1514-4771; parazzini, fabio/0000-0001-5624-4854				[Anonymous], 1994, LANCET, P619; BRYANT GM, 1974, DEV MED CHILD NEUROL, V16, P475; SONNANDER K, 1987, DEV MED CHILD NEUROL, V29, P351; 1993, LANCET, V341, P396; 1985, PREVENZIONE NELLA ME	5	16	16	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAY 14	1994	343	8907					1235	1235		10.1016/S0140-6736(94)92452-X	http://dx.doi.org/10.1016/S0140-6736(94)92452-X			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NL175	7513779				2022-12-28	WOS:A1994NL17500061
J	JAGOX, A; CARR, DB; PAYNE, R				JAGOX, A; CARR, DB; PAYNE, R			NEW CLINICAL-PRACTICE GUIDELINES FOR THE MANAGEMENT OF PAIN IN PATIENTS WITH CANCER	NEW ENGLAND JOURNAL OF MEDICINE			English	Article									MASSACHUSETTS GEN HOSP,CTR PAIN,DEPT ANESTHESIA,BOSTON,MA 02114; JOHNS HOPKINS UNIV,SCH NURSING,BALTIMORE,MD 21205; MD ANDERSON CANC CTR,HOUSTON,TX 77030	Harvard University; Massachusetts General Hospital; Johns Hopkins University; University of Texas System; UTMD Anderson Cancer Center								ARCANGELI G, 1989, RADIOTHER ONCOL, V14, P95, DOI 10.1016/0167-8140(89)90053-4; CLEELAND CS, 1994, NEW ENGL J MED, V330, P592, DOI 10.1056/NEJM199403033300902; FERRANTE FM, 1990, PATIENT CONTROLLED A; Field MJ, 1990, CLIN PRACTICE GUIDEL; FOLEY KM, 1985, NEW ENGL J MED, V313, P84, DOI 10.1056/NEJM198507113130205; GALER BS, 1992, PAIN, V49, P87, DOI 10.1016/0304-3959(92)90192-E; GROSSMAN SA, 1991, J PAIN SYMPTOM MANAG, V6, P53, DOI 10.1016/0885-3924(91)90518-9; Jacox A, 1994, CLIN PRACTICE GUIDEL; JACOX AK, 1994, AHCPR940594 AG HLTH; JACOX AK, 1994, AHCPR940593 PUBL; JACOX AK, 1994, AHCPR940596 AG HLTH; JACOX AK, 1994, AHCPR940595 AG HLTH; KAIKO RF, 1983, ANN NEUROL, V13, P180, DOI 10.1002/ana.410130213; PATT RB, 1993, CANCER PAIN; VONROENN JH, 1993, ANN INTERN MED, V119, P121, DOI 10.7326/0003-4819-119-2-199307150-00005; 1986, CANCER PAIN RELIEF; 1994, CANCER FACTS FIGURES, P2	17	207	214	0	2	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	MAR 3	1994	330	9					651	655		10.1056/NEJM199403033300926	http://dx.doi.org/10.1056/NEJM199403033300926			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MY573	7508094	Bronze			2022-12-28	WOS:A1994MY57300037
J	GUSTAFSONBROWN, C; SAVIDGE, B; YANOFSKY, MF				GUSTAFSONBROWN, C; SAVIDGE, B; YANOFSKY, MF			REGULATION OF THE ARABIDOPSIS FLORAL HOMEOTIC GENE APETALA1	CELL			English	Article							FLOWER DEVELOPMENT; INFLORESCENCE DEVELOPMENT; TRANSCRIPTION FACTOR; DNA-BINDING; MADS-BOX; LEAFY; INTERACTS; DEFICIENS; THALIANA	The Arabidopsis floral homeotic gene APETALA1 (AP1) encodes a putative transcription factor that acts locally to specify the identity of the floral meristem and to determine sepal and petal development. RNA tissue in situ hybridization studies show that AP1 RNA accumulates uniformly throughout young floral primordia, but is absent from the inflorescence meristem. Later in development, AP1 RNA is excluded from cells that will give rise to the two inner whorls of organs. Here we show that AP1 expression is under the control of two negative regulators: the meristem identity gene TERMINAL FLOWER represses AP1 RNA accumulation in the inflorescence meristem, and the organ identity gene AGAMOUS prevents AP1 RNA accumulation in the two inner whorls of wild-type flowers. These and other data presented here lead to a revised model for the regulatory interactions among the genes specifying floral organ identity in Arabidopsis.	UNIV CALIF SAN DIEGO,CTR MOLEC GENET,LA JOLLA,CA 92093	University of California System; University of California San Diego	GUSTAFSONBROWN, C (corresponding author), UNIV CALIF SAN DIEGO,DEPT BIOL,LA JOLLA,CA 92093, USA.				NIGMS NIH HHS [GMO7313] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALVAREZ J, 1992, PLANT J, V2, P103, DOI 10.1111/j.1365-313X.1992.00103.x; BOWMAN JL, 1991, DEVELOPMENT, V112, P1; BOWMAN JL, 1992, DEVELOPMENT, V114, P599; BOWMAN JL, 1993, DEVELOPMENT, V119, P721; BOWMAN JL, 1989, PLANT CELL, V1, P37, DOI 10.1105/tpc.1.1.37; COEN ES, 1991, NATURE, V353, P31, DOI 10.1038/353031a0; DREWS GN, 1991, CELL, V65, P991, DOI 10.1016/0092-8674(91)90551-9; HAYES TE, 1988, GENE DEV, V2, P1713, DOI 10.1101/gad.2.12b.1713; HUALA E, 1992, PLANT CELL, V4, P901, DOI 10.1105/tpc.4.8.901; IRISH VF, 1990, PLANT CELL, V2, P741, DOI 10.1105/tpc.2.8.741; JACK T, 1992, CELL, V68, P683, DOI 10.1016/0092-8674(92)90144-2; MA H, 1991, GENE DEV, V5, P484, DOI 10.1101/gad.5.3.484; MANDEL MA, 1992, NATURE, V360, P273, DOI 10.1038/360273a0; NORMAN C, 1988, CELL, V55, P989, DOI 10.1016/0092-8674(88)90244-9; SCHULTZ EA, 1991, PLANT CELL, V3, P771, DOI 10.1105/tpc.3.8.771; SCHWARZSOMMER Z, 1992, EMBO J, V11, P251, DOI 10.1002/j.1460-2075.1992.tb05048.x; SCHWARZSOMMER Z, 1990, SCIENCE, V250, P931, DOI 10.1126/science.250.4983.931; SHANNON S, 1991, PLANT CELL, V3, P877, DOI 10.1105/tpc.3.9.877; SHANNON S, 1993, PLANT CELL, V5, P639, DOI 10.1105/tpc.5.6.639; SMYTH DR, 1990, PLANT CELL, V2, P755, DOI 10.1105/tpc.2.8.755; TROBNER W, 1992, EMBO J, V11, P4693, DOI 10.1002/j.1460-2075.1992.tb05574.x; WEIGEL D, 1993, SCIENCE, V261, P1723, DOI 10.1126/science.261.5129.1723; WEIGEL D, 1992, CELL, V69, P843, DOI 10.1016/0092-8674(92)90295-N; YANOFSKY MF, 1990, NATURE, V346, P35, DOI 10.1038/346035a0	24	320	344	1	48	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	JAN 14	1994	76	1					131	143		10.1016/0092-8674(94)90178-3	http://dx.doi.org/10.1016/0092-8674(94)90178-3			13	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	MR495	7506995				2022-12-28	WOS:A1994MR49500012
J	RASTINEJAD, F; CONBOY, MJ; RANDO, TA; BLAU, HM				RASTINEJAD, F; CONBOY, MJ; RANDO, TA; BLAU, HM			TUMOR SUPPRESSION BY RNA FROM THE 3' UNTRANSLATED REGION OF ALPHA-TROPOMYOSIN	CELL			English	Article							TRANSFORMED-CELLS; MOLECULAR-CLONING; EPITHELIAL-CELLS; GENE-EXPRESSION; PROTEIN-KINASE; GROWTH-FACTOR; CANCER-CELLS; BHK CELLS; RETINOBLASTOMA; ONCOGENE	NMU2, a nondifferentiating mutant myogenic cell line, gives rise to rhabdomyosarcomas in mice. We show that constitutive expression of RNA from 0.2 kb of the alpha-tropomyosin (Tm) 3' untranslated region (UTR), but not control 3'UTRs, suppresses anchorage-independent growth and tumor formation by NMU2 cells. When beta-galactosidase (beta-gal)-labeled cells were implanted into muscles of adult mouse hindlimbs, Tm 3'UTR expression suppressed the proliferation, invasion, and destruction of muscle tissues characteristic of NMU2. In the rare tumors that developed from Tm 3'UTR transfectants, RNA expression was extinguished. These results suggest that suppression of tumorigenicity is dependent on the continued expression of Tm transcripts lacking a coding region. We conclude that untranslated RNAs can function as regulators (riboregulators) that suppress tumor formation.			RASTINEJAD, F (corresponding author), STANFORD UNIV,MED CTR,SCH MED,DEPT MOLEC PHARMACOL,STANFORD,CA 94305, USA.				EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD020203] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [F32GM014588] Funding Source: NIH RePORTER; NICHD NIH HHS [HD 20203, HD 07249-11] Funding Source: Medline; NIGMS NIH HHS [GM 14588] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BAKER SJ, 1990, SCIENCE, V249, P912, DOI 10.1126/science.2144057; BEGLEY CG, 1989, P NATL ACAD SCI USA, V86, P10128, DOI 10.1073/pnas.86.24.10128; BLAU HM, 1983, CELL, V32, P1171, DOI 10.1016/0092-8674(83)90300-8; BOUCK N, 1982, MOL CELL BIOL, V2, P97, DOI 10.1128/MCB.2.2.97; BRANNAN CI, 1990, MOL CELL BIOL, V10, P28, DOI 10.1128/MCB.10.1.28; BROOK JD, 1992, CELL, V68, P799, DOI 10.1016/0092-8674(92)90154-5; CAVENEE WK, 1983, NATURE, V305, P779, DOI 10.1038/305779a0; CHAN D, 1989, P NATL ACAD SCI USA, V86, P2747, DOI 10.1073/pnas.86.8.2747; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CHO M, 1993, J CELL BIOL, V121, P795, DOI 10.1083/jcb.121.4.795; COOPER HL, 1985, MOL CELL BIOL, V5, P972, DOI 10.1128/MCB.5.5.972; COOPER HL, 1987, CANCER RES, V47, P4493; EIDEN MV, 1991, MOL CELL BIOL, V11, P5321, DOI 10.1128/MCB.11.10.5321; ENZINGER FM, 1988, SOFT TISSUE TUMORS, P448; FERNANDEZ JLR, 1992, J CELL BIOL, V119, P427, DOI 10.1083/jcb.119.2.427; FERNANDEZ JLR, 1993, J CELL BIOL, V122, P1285, DOI 10.1083/jcb.122.6.1285; FINLAY CA, 1989, CELL, V57, P1083, DOI 10.1016/0092-8674(89)90045-7; FOINTOURA BMA, 1992, MOL CELL BIOL, V12, P5145; FUKUI T, 1982, J BIOCHEM-TOKYO, V91, P331, DOI 10.1093/oxfordjournals.jbchem.a133692; GABBIANI G, 1976, AM J PATHOL, V83, P457; GERWIN BI, 1992, P NATL ACAD SCI USA, V89, P2759, DOI 10.1073/pnas.89.7.2759; GLUCK U, 1993, P NATL ACAD SCI USA, V90, P383, DOI 10.1073/pnas.90.2.383; GOOD DJ, 1990, P NATL ACAD SCI USA, V87, P6624, DOI 10.1073/pnas.87.17.6624; GRAHAM F, 1973, VIROLOGY, V52, P452; HARRIS H, 1985, J CELL SCI, V79, P83; HARRIS H, 1969, NATURE, V223, P363, DOI 10.1038/223363a0; HINDS PW, 1992, CELL, V70, P993, DOI 10.1016/0092-8674(92)90249-C; HITI AL, 1989, MOL CELL BIOL, V9, P4722, DOI 10.1128/MCB.9.11.4722; HUANG HJS, 1988, SCIENCE, V242, P1563, DOI 10.1126/science.3201247; HUGHES SM, 1992, CELL, V68, P659, DOI 10.1016/0092-8674(92)90142-Y; KIMCHI A, 1988, SCIENCE, V240, P196, DOI 10.1126/science.2895499; KINOSHITA S, 1992, P NATL ACAD SCI USA, V89, P1473, DOI 10.1073/pnas.89.4.1473; KNUDSON AG, 1971, P NATL ACAD SCI USA, V68, P820, DOI 10.1073/pnas.68.4.820; KOROMILAS AE, 1992, SCIENCE, V257, P1685, DOI 10.1126/science.1382315; LEAVITT J, 1982, CELL, V28, P259, DOI 10.1016/0092-8674(82)90344-0; LEAVITT J, 1985, NATURE, V316, P840, DOI 10.1038/316840a0; LEESMILLER JP, 1991, BIOESSAYS, V13, P429, DOI 10.1002/bies.950130902; LIN JJC, 1985, J CELL BIOL, V100, P692, DOI 10.1083/jcb.100.3.692; LIU DG, 1992, SCI CHINA SER B, V35, P822; LIU P, 1993, SCIENCE, V261, P1041, DOI 10.1126/science.8351518; MARTINZANCA D, 1986, COLD SPRING HARB SYM, V51, P983, DOI 10.1101/SQB.1986.051.01.112; MATSUMURA F, 1983, J BIOL CHEM, V258, P3954; MECHLER BM, 1985, EMBO J, V4, P1551, DOI 10.1002/j.1460-2075.1985.tb03816.x; Mintz B, 1981, Adv Cancer Res, V34, P211, DOI 10.1016/S0065-230X(08)60243-2; MOSMANN T, 1983, J IMMUNOL METHODS, V65, P55, DOI 10.1016/0022-1759(83)90303-4; NIGRO JM, 1992, MOL CELL BIOL, V12, P1357, DOI 10.1128/MCB.12.3.1357; OSKAM R, 1988, P NATL ACAD SCI USA, V85, P2964, DOI 10.1073/pnas.85.9.2964; PETERSON CA, 1990, CELL, V62, P493, DOI 10.1016/0092-8674(90)90014-6; PRASAD GL, 1993, P NATL ACAD SCI USA, V90, P7039, DOI 10.1073/pnas.90.15.7039; RASTINEJAD F, 1993, CELL, V72, P903, DOI 10.1016/0092-8674(93)90579-F; RASTINEJAD F, 1989, CELL, V56, P345, DOI 10.1016/0092-8674(89)90238-9; ROSENGARD AM, 1989, NATURE, V342, P177, DOI 10.1038/342177a0; SACHS L, 1981, BLOOD CELLS, V7, P31; Sachs L, 1984, Symp Fundam Cancer Res, V37, P341; SEED B, 1987, P NATL ACAD SCI USA, V84, P3365, DOI 10.1073/pnas.84.10.3365; SHIMOYAMA Y, 1992, CANCER RES, V52, P5770; VANDERIJN M, 1993, IN PRESS APPL IMMUNO; WEISSMAN BE, 1987, SCIENCE, V236, P175, DOI 10.1126/science.3031816; YAFFE D, 1977, NATURE, V270, P725, DOI 10.1038/270725a0; ZAJCHOWSKI DA, 1990, P NATL ACAD SCI USA, V87, P2314, DOI 10.1073/pnas.87.6.2314; ZELENETZ AD, 1993, GENE CHROMOSOME CANC, V6, P140, DOI 10.1002/gcc.2870060303	61	200	203	1	2	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	DEC 17	1993	75	6					1107	1117		10.1016/0092-8674(93)90320-P	http://dx.doi.org/10.1016/0092-8674(93)90320-P			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	MM893	7505203				2022-12-28	WOS:A1993MM89300009
J	Wang, XB; Zuckerman, B; Coffman, GA; Corwin, MJ				Wang, XB; Zuckerman, B; Coffman, GA; Corwin, MJ			Aggregation of low birth weight among whites and blacks in the United States	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							GESTATIONAL-AGE; FETAL GROWTH; DETERMINANTS; GENERATIONS; DURATION; RECORDS; RECALL	Background. Studies have shown that the birth weight of infants is correlated with the birth weights of their siblings and their mothers. We investigated whether the birth weights of mothers and index children were jointly associated with the risk of low birth weight in the siblings of the index children. Methods. We used data on the live-birth cohort of the 1988 National Maternal and Infant Health Survey, The analysis included 1691 white and 1461 black mothers, each of whom had two or more live-born, singleton children, Multiple logistic regression with generalized-estimation equations was used to assess the risk of low birth weight among an index child's siblings, Four groups were studied: that in which neither the mother nor the index child had low birth weight (group 1), that in which only the mother had low birth weight (group 2), that in which only the index child had low birth weight (group 3), and that in which both the mother and the index child had low birth weight (group 4). There was adjustment for other maternal and infant covariates. Results. In groups 1, 2, 3, and 4, respectively, 3.6, 8.3, 21.2, and 38.9 percent of white siblings had low birth weights, as compared with 8.0, 19.0, 31.1, and 57.1 percent of black siblings, When group 1 was used as the reference group, the adjusted odds ratios (and 95 percent confidence intervals) for low birth weight in groups 2, 3, and 4 were 2.5 (1.4 to 4.3), 6.8 (4.7 to 9.8), and 15.4 (9.2 to 25.5), respectively, among white siblings and 2.6 (1.8 to 3.8), 4.7 (3.5 to 6.4), and 13.9 (9.2 to 20.9) among black siblings. These associations were consistently found for birth weights below 1500 g and those ranging from 1500 to 2499 g in both races and after stratification for the mother's age, parity, education, cigarette-smoking status, and weight and height before pregnancy and the infant's sex. Conclusions. Although the possibility of selection and recall biases cannot be excluded with certainty, our data suggest a strong familial aggregation of low birth weight among both whites and blacks in the United States.	BOSTON UNIV,SCH PUBL HLTH,BOSTON,MA	Boston University	Wang, XB (corresponding author), BOSTON UNIV,SCH MED,DEPT PEDIAT,818 HARRISON AVE,BOSTON,MA 02118, USA.			Corwin, Michael/0000-0002-6591-209X; Zuckerman, Barry/0000-0002-0044-2592; Coffman, Gerald/0000-0002-0044-6219	PHS HHS [MCJ-259501] Funding Source: Medline; BHP HRSA HHS [HRSA 5 T32 PE10014] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service); BHP HRSA HHS		BEATY TH, 1988, GENET EPIDEMIOL, V5, P241, DOI 10.1002/gepi.1370050406; HACKMAN E, 1983, JAMA-J AM MED ASSOC, V250, P2016, DOI 10.1001/jama.250.15.2016; HOGAN MD, 1978, AM J EPIDEMIOL, V108, P60; KEMPE A, 1992, NEW ENGL J MED, V327, P969, DOI 10.1056/NEJM199210013271401; Khoury MJ, 1993, FUNDAMENTALS GENETIC, P164; KLEBANOFF MA, 1987, J PEDIATR-US, V111, P287, DOI 10.1016/S0022-3476(87)80089-6; KLEBANOFF MA, 1984, JAMA-J AM MED ASSOC, V252, P2423, DOI 10.1001/jama.252.17.2423; KLEBANOFF MA, 1986, AM J EPIDEMIOL, V124, P535; KLEIN J, 1989, MONOGRAPHS EPIDEMIOL, V14, P231; KOGAN MD, 1994, JAMA-J AM MED ASSOC, V271, P1340, DOI 10.1001/jama.271.17.1340; LIANG KY, 1986, BIOMETRIKA, V73, P13, DOI 10.1093/biomet/73.1.13; LITTLE RE, 1986, AM J PUBLIC HEALTH, V76, P1350, DOI 10.2105/AJPH.76.11.1350; MAGNUS P, 1993, ANN HUM BIOL, V20, P231, DOI 10.1080/03014469300002662; MCCORMICK MC, 1985, NEW ENGL J MED, V312, P82, DOI 10.1056/NEJM198501103120204; Morgenstern H, 1982, EPIDEMIOLOGIC RES PR, P403; PANETH N, 1994, AM J PUBLIC HEALTH, V84, P1372, DOI 10.2105/AJPH.84.9.1372; RAWLINGS JS, 1995, NEW ENGL J MED, V332, P69, DOI 10.1056/NEJM199501123320201; Robson E., 1978, HUMAN GROWTH, V1, P285; SANDERSON M, 1991, BIRTH-ISS PERINAT C, V18, P26, DOI 10.1111/j.1523-536X.1991.tb00050.x; SEIDMAN DS, 1987, BRIT J OBSTET GYNAEC, V94, P731, DOI 10.1111/j.1471-0528.1987.tb03717.x; TANNER JM, 1972, LANCET, V2, P193; TILLEY BC, 1985, AM J EPIDEMIOL, V121, P269, DOI 10.1093/oxfordjournals.aje.a113997; WEGMAN ME, 1989, PEDIATRICS, V84, P943; WEGMAN ME, 1990, PEDIATRICS, V85, P302; ZUCKERMAN B, 1989, NEW ENGL J MED, V320, P762, DOI 10.1056/NEJM198903233201203; [No title captured]	27	80	83	0	3	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	DEC 28	1995	333	26					1744	1749		10.1056/NEJM199512283332606	http://dx.doi.org/10.1056/NEJM199512283332606			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	TM169	7491139				2022-12-28	WOS:A1995TM16900006
J	GAGE, BF; CARDINALLI, AB; ALBERS, GW; OWENS, DK				GAGE, BF; CARDINALLI, AB; ALBERS, GW; OWENS, DK			COST-EFFECTIVENESS OF WARFARIN AND ASPIRIN FOR PROPHYLAXIS OF STROKE IN PATIENTS WITH NONVALVULAR ATRIAL-FIBRILLATION	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							ORAL ANTICOAGULANT-THERAPY; RISK-FACTORS; THROMBOEMBOLIC COMPLICATIONS; DECISION-ANALYSIS; PROTHROMBIN-TIME; ELDERLY PATIENTS; PREVENTION; FRAMINGHAM; CANCER; SURVIVAL	Objective.-To examine the cost-effectiveness of prescribing warfarin sodium in patients who have nonvalvular atrial fibrillation (NVAF) with or without additional stroke risk factors (a prior stroke or transient ischemic attack, diabetes, hypertension, or heart disease). Design.-Decision and cost-effectiveness analyses. The probabilities for stroke, hemorrhage, and death were obtained from published randomized controlled trials. The quality-of-life estimates were obtained by interviewing 74 patients with atrial fibrillation, Costs were estimated from literature review, phone survey, and Medicare reimbursement. Patients.-In the base case, the patients were 65 years of age and good candidates for warfarin therapy. Interventions.-Treatment with warfarin, aspirin, or no therapy in the decision analytic model. Main Outcome Measures.-Quality-adjusted survival and marginal cost-effectiveness of warfarin as compared with aspirin or no therapy. Results.-For patients with NVAF and additional risk factors for stroke, warfarin therapy led to a greater quality-adjusted survival and to cost savings. For patients with NVAF and one additional risk factor, warfarin therapy cost $8000 per quality-adjusted life-year saved. For 65-year-old patients with NVAF alone, warfarin cost about $370 000 per quality-adjusted life-year saved, as compared with aspirin therapy. However, for 75-year-old patients with NVAF alone, prescribing warfarin cost $110 000 per quality-adjusted life-year saved. For patients who were not prescribed warfarin, aspirin was preferred to no therapy on the basis of both quality-adjusted survival and cost in all patients, regardless of the number of risk factors present. Conclusions.-Treatment with warfarin is cost-effective in patients with NVAF and one or more additional risk factors for stroke, In 65-year-old patients with NVAF but no other risk factors for stroke, prescribing warfarin instead of aspirin would affect quality-adjusted survival minimally but increase costs significantly.	VET AFFAIRS PALO ALTO HLTH CARE SYST, PALO ALTO, CA USA; STANFORD UNIV, DEPT NEUROL & NEUROL SCI, STANFORD, CA 94305 USA; STANFORD UNIV, DEPT HLTH RES & POLICY, STANFORD, CA 94305 USA	US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Palo Alto Health Care System; Stanford University; Stanford University				Gage, Brian/0000-0002-4727-8742; Albers, Gregory/0000-0003-0263-4632				ALBERS GW, 1994, ARCH INTERN MED, V154, P1443, DOI 10.1001/archinte.154.13.1443; ALTMAN R, 1994, BMJ-BRIT MED J, V308, P81, DOI 10.1136/bmj.308.6921.81; ANDERSON DC, 1992, ANN INTERN MED, V116, P1, DOI 10.7326/0003-4819-116-1-1; ANDERSON DC, 1992, ANN INTERN MED, V116, P6; ARONOW WS, 1989, AM J CARDIOL, V63, P366, DOI 10.1016/0002-9149(89)90349-4; BARNETT HJM, 1995, NEW ENGL J MED, V332, P238, DOI 10.1056/NEJM199501263320408; BECK JR, 1981, MED DECIS MAKING, V1, P284; BECKER RC, 1995, ARCH INTERN MED, V155, P149, DOI 10.1001/archinte.155.2.149; BRAND FN, 1985, JAMA-J AM MED ASSOC, V254, P3449, DOI 10.1001/jama.254.24.3449; CABIN HS, 1990, AM J CARDIOL, V65, P1112, DOI 10.1016/0002-9149(90)90323-S; CAIRNS JA, 1995, JAMA-J AM MED ASSOC, V273, P965; CANDELISE L, 1991, STROKE, V22, P169, DOI 10.1161/01.STR.22.2.169; CARO JJ, 1993, LANCET, V341, P1381, DOI 10.1016/0140-6736(93)90950-L; CARTER GM, 1990, SERVICES COSTS VARY, P122; CONNOLLY SJ, 1991, J AM COLL CARDIOL, V18, P349, DOI 10.1016/0735-1097(91)90585-W; DENNIS MS, 1993, STROKE, V24, P796, DOI 10.1161/01.STR.24.6.796; DISCH DL, 1994, ANN INTERN MED, V120, P449, DOI 10.7326/0003-4819-120-6-199403150-00001; ECKMAN MH, 1993, NEW ENGL J MED, V329, P696, DOI 10.1056/NEJM199309023291005; ECKMAN MH, 1992, CHEST, V102, pS538, DOI 10.1378/chest.102.4_Supplement.538S; EDDY DM, 1989, ANN INTERN MED, V111, P389, DOI 10.7326/0003-4819-111-5-389; EDDY DM, 1990, ANN INTERN MED, V113, P214, DOI 10.7326/0003-4819-113-3-214; EZEKOWITZ MD, 1992, NEW ENGL J MED, V327, P1406, DOI 10.1056/NEJM199211123272002; FEINBERG WM, 1995, ARCH INTERN MED, V155, P469, DOI 10.1001/archinte.155.5.469; FIHN SD, 1993, ANN INTERN MED, V118, P511, DOI 10.7326/0003-4819-118-7-199304010-00005; FLEGEL KM, 1991, J CLIN EPIDEMIOL, V44, P551, DOI 10.1016/0895-4356(91)90219-Y; FLEGEL KM, 1989, STROKE, V20, P1000, DOI 10.1161/01.STR.20.8.1000; FRYBACK DG, 1993, MED DECIS MAKING, V13, P89, DOI 10.1177/0272989X9301300202; GAGE BF, 1993, MED DECIS MAKING, V13, P386; GOTTLIEB LK, 1994, ARCH INTERN MED, V154, P1945, DOI 10.1001/archinte.154.17.1945; GUSTAFSSON C, 1992, BRIT MED J, V305, P1457, DOI 10.1136/bmj.305.6867.1457; HART RG, 1994, STROKE, V25, P1337, DOI 10.1161/01.STR.25.7.1337; HARTUNIAN NS, 1980, AM J PUBLIC HEALTH, V70, P1249, DOI 10.2105/AJPH.70.12.1249; HYLEK EM, 1994, ANN INTERN MED, V120, P897, DOI 10.7326/0003-4819-120-11-199406010-00001; KISTLER JP, 1990, NEW ENGL J MED, V323, P1505; KOPECKY SL, 1987, NEW ENGL J MED, V317, P669, DOI 10.1056/NEJM198709103171104; KOUDSTAAL PJ, 1995, NEW ENGL J MED, V333, P5; KUTNER M, 1991, ARCH INTERN MED, V151, P1950, DOI 10.1001/archinte.151.10.1950; LANDEFELD CS, 1993, AM J MED, V95, P315, DOI 10.1016/0002-9343(93)90285-W; LANDEFELD CS, 1989, AM J MED, V87, P153; LAUPACIS A, 1994, ARCH INTERN MED, V154, P1449; LAUPACIS A, 1992, CHEST, V102, pS426, DOI 10.1378/chest.102.4_Supplement.426S; LITTENBERG B, 1990, ANN INTERN MED, V112, P192, DOI 10.7326/0003-4819-112-3-192; MATCHAR DB, 1994, ANN INTERN MED, V121, P54; MCBRIDE R, 1990, NEW ENGL J MED, V322, P863; MCBRIDE R, 1994, LANCET, V343, P687; MCBRIDE R, 1991, CIRCULATION, V84, P527, DOI 10.1161/01.CIR.84.2.527; MOULTON AW, 1991, AM J MED, V91, P156, DOI 10.1016/0002-9343(91)90008-L; NAGLIE IG, 1992, MED DECIS MAKING, V12, P239, DOI 10.1177/0272989X9201200401; NOLAN J, 1992, BRIT HEART J, V68, P544; PAUKER SG, 1987, NEW ENGL J MED, V316, P250, DOI 10.1056/NEJM198701293160505; PETERSEN P, 1990, ARCH INTERN MED, V150, P819, DOI 10.1001/archinte.150.4.819; PETERSEN P, 1989, LANCET, V1, P175; RAMSAY LE, 1993, LANCET, V341, P1376, DOI 10.1016/0140-6736(93)90945-D; RUSSEL LB, 1983, MED DECIS MAKING, V246, P892; SACCO RL, 1982, STROKE, V13, P290, DOI 10.1161/01.STR.13.3.290; SHERMAN DG, 1992, CHEST, V102, pS529, DOI 10.1378/chest.102.4_Supplement.529S; SINGER DE, 1992, AM HEART J, V124, P1567, DOI 10.1016/0002-8703(92)90074-6; SMURAWSKA LT, 1994, STROKE, V25, P1628, DOI 10.1161/01.STR.25.8.1628; SUMNER W, 1992, U TITER UTILITY ASSE; THORNGREN M, 1991, ACTA NEUROL SCAND, V84, P303, DOI 10.1111/j.1600-0404.1991.tb04959.x; TORRANCE GW, 1976, SOCIO ECON PLAN SCI, V10, P129, DOI 10.1016/0038-0121(76)90036-7; VANBERGEN PFMM, 1995, JAMA-J AM MED ASSOC, V273, P925, DOI 10.1001/jama.273.12.925; VANDERMEER FJM, 1993, ARCH INTERN MED, V153, P1557, DOI 10.1001/archinte.153.13.1557; WHITE HD, 1994, LANCET, V343, P683, DOI 10.1016/S0140-6736(94)91573-3; WOLF PA, 1978, NEUROLOGY, V28, P973, DOI 10.1212/WNL.28.10.973; YUAN Z, 1994, MED DECIS MAKING, V14, P444; 1993, LANCET, V342, P1255; 1992, STAT ABSTR US, P77; 1993, STROKE; 1991, ARCH INTERN MED, V151, P1944; 1991, MED DRUG HDB COMP CL; 1994, STROKE, V25, P541	72	279	280	0	6	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	DEC 20	1995	274	23					1839	1845		10.1001/jama.274.23.1839	http://dx.doi.org/10.1001/jama.274.23.1839			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TK147	7500532				2022-12-28	WOS:A1995TK14700024
J	COHEN, SI				COHEN, SI			OVERDIAGNOSIS OF SCHIZOPHRENIA - ROLE OF ALCOHOL AND DRUG MISUSE	LANCET			English	Editorial Material							PRECEDING 1ST ADMISSIONS; PSYCHOSIS											AZUONYE IO, 1992, PSYCHIATR B, V16, P311; COHEN SI, 1988, BRIT MED J, V297, P1270, DOI 10.1136/bmj.297.6658.1270-c; COHEN SI, 1994, BRIT J PSYCHIAT, V165, P410, DOI 10.1192/bjp.165.3.410; COHEN SI, 1995, J ROY SOC MED, V88, P73; COHEN SI, 1993, BRIT J PSYCHIAT, V163, P547; COHEN SI, 1992, PSYCHIATR B, V16, P513; COHEN SI, 1992, PSYCHIATRIC B, V16, P664; COOPER JE, 1972, MAUDSLEY MONOGRAPHS, V20; DUKE PJ, 1994, BRIT J PSYCHIAT, V164, P630, DOI 10.1192/bjp.164.5.630; EVA J, 1992, PSYCHIAT B, V16, P310; EVANS M, 1992, PSYCHIATR B, V16, P327; HUMPHREYS MS, 1992, BRIT J PSYCHIAT, V161, P501, DOI 10.1192/bjp.161.4.501; MARTINEZAREVALO MJ, 1994, BRIT J PSYCHIAT, V164, P679, DOI 10.1192/bjp.164.5.679; ROTTANBURG D, 1982, LANCET, V2, P1364; Sandford T, 1995, Nurs Stand, V9, P16; SCADDING G, 1993, BRIT J PSYCHIAT, V162, P237, DOI 10.1192/S0007125000180109; SMITH J, 1994, BRIT J PSYCHIAT, V165, P13, DOI 10.1192/bjp.165.1.13; VANPRAAG HM, 1992, BRIT J PSYCHIAT, V160, P266, DOI 10.1192/bjp.160.2.266; WILSON GT, 1988, BEHAV RES THER, V26, P369, DOI 10.1016/0005-7967(88)90070-8	19	12	11	0	2	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	DEC 9	1995	346	8989					1541	1542		10.1016/S0140-6736(95)92058-7	http://dx.doi.org/10.1016/S0140-6736(95)92058-7			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	TJ291	7491053				2022-12-28	WOS:A1995TJ29100017
J	TOGNONI, G; RONCAGLIONI, MC				TOGNONI, G; RONCAGLIONI, MC			DISSENT - AN ALTERNATIVE INTERPRETATION OF MAST-I	LANCET			English	Note											TOGNONI, G (corresponding author), MARIO NEGRI INST PHARMACOL RES,DEPT CARDIOVASC RES,VIA ERITREA 62,I-20157 MILAN,ITALY.		roncaglioni, maria carla/AAB-1875-2020	roncaglioni, maria carla/0000-0002-2029-7847				DONNAN GA, 1995, LANCET, V345, P578; HACKE W, 1995, JAMA-J AM MED ASSOC, V284, P1017; HOMMEL M, 1995, LANCET, V345, P57, DOI 10.1016/S0140-6736(95)91179-0	3	18	18	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	DEC 9	1995	346	8989					1515	1515		10.1016/S0140-6736(95)92050-1	http://dx.doi.org/10.1016/S0140-6736(95)92050-1			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TJ291	7491045				2022-12-28	WOS:A1995TJ29100009
J	DEVRIES, TPGM; HENNING, RH; HOGERZEIL, HV; BAPNA, JS; BERO, L; KAFLE, KK; MABADEJE, AFB; SANTOSO, B; SMITH, AJ				DEVRIES, TPGM; HENNING, RH; HOGERZEIL, HV; BAPNA, JS; BERO, L; KAFLE, KK; MABADEJE, AFB; SANTOSO, B; SMITH, AJ			IMPACT OF A SHORT-COURSE IN PHARMACOTHERAPY FOR UNDERGRADUATE MEDICAL-STUDENTS - AN INTERNATIONAL RANDOMIZED CONTROLLED-STUDY	LANCET			English	Article							PRESENTING CLINICAL-PHARMACOLOGY; THERAPEUTICS; CURRICULUM; SCHOOLS	Irrational prescribing is a habit which is difficult to cure. However, prevention is possible and for this reason the WHO Action Programme on Essential Drugs aims to improve the teaching of pharmacotherapy to medical students. The impact of a short problem-based training course in pharmacotherapy, using a WHO manual on the principles of rational prescribing, was measured in an international multi-centre controlled study of 219 undergraduate students in (Netherlands), Kathmandu (Nepal), Lagos Newcastle (Australia), New Delhi (India), San Francisco (USA), and Yogyakarta (Japan). The manual and the course presented the students, who were about to enter the clinical phase of their studies, with a normative model for pharmacotherapeutic reasoning in which they were taught to generate a ''standard'' pharmacotherapeutic approach to common disorders, resulting in a set of first-choice drugs called P(ersonal)-drugs. The students were then taught how to apply this set of P-drugs to specific patient problems on the symptomatic treatment of pain, using a six-step problem-solving routine. The impact of the course was measured by tests before training, immediately after, and six months later. After the course, students from the study group performed significantly better than controls in all patient problems presented (p<0.05). The students not only remembered how to solve old problems, but they could also apply their shills to new problems. Both retention and transfer effect were maintained at least six months after the training session in all seven medical schools. In view of the impossibiity of teaching students all basic knowledge on the thousands of drugs available, this approach seems to be an efficient way of teaching rational prescribing. However, the method should be accompanied by a change in teaching methods away from the habit of transferring knowledge about the drugs towards problem-based leaching of therapeutic reasoning.	WHO,ACT PROGRAMME ESSENTIAL DRUGS,CH-1211 GENEVA,SWITZERLAND; UNIV GRONINGEN,FAC MED,DEPT CLIN PHARMACOL,WHO,COLLABORATING CTR PHARMACOTHERAPY TEACHING TR,GRONINGEN,NETHERLANDS; MAULANA AZAD MED COLL,DEPT PHARMACOL,NEW DELHI,INDIA; UNIV CALIF SAN FRANCISCO,SCH MED,INST HLTH POLICY STUDIES,SAN FRANCISCO,CA 94143; TRIBHUVAN UNIV,TEACHING HOSP,DEPT CLIN PHARMACOL,KATMANDU,NEPAL; UNIV LAGOS,COLL MED,DEPT PHARMACOL,LAGOS,NIGERIA; GADJAH MADA UNIV,DEPT CLIN PHARMACOL,YOGYAKARTA,INDONESIA; MATER MISERICORDIAE HOSP,DISCIPLINE CLIN PHARMACOL,WARATAH,NSW 2298,AUSTRALIA	World Health Organization; University of Groningen; World Health Organization; Maulana Azad Medical College; University of California System; University of California San Francisco; Tribhuvan University; Institute of Medicine (IoM) - Nepal; University of Lagos; Gadjah Mada University			Henning, Robert H/AAY-5222-2020; Smith, Ashley/GZB-0298-2022	Henning, Robert/0000-0002-5135-4621				BRODY J, 1985, KNOWLEDGE OBJECTIVES; DEVRIES TPG, 1995, WHODAP951 DOC; DEVRIES TPGM, 1993, BRIT J CLIN PHARMACO, V35, P591; DEVRIES TPGM, 1993, BRIT J CLIN PHARMACO, V35, P587; DEVRIES TPGM, 1993, BRIT J CLIN PHARMACO, V35, P581; DeVries TPGM., 1994, GUIDE GOOD PRESCRIBI; ELLISON MJ, 1990, J CLIN PHARMACOL, V30, P489, DOI 10.1002/j.1552-4604.1990.tb03613.x; FELDMAN RD, 1987, J CLIN PHARMACOL, V27, P682, DOI 10.1002/j.1552-4604.1987.tb03088.x; FISHER JW, 1980, J MED EDUC, V55, P168; HERXHEIMER A, 1983, MED TEACH, V5, P16, DOI 10.3109/01421598309145614; HOGERZEIL HV, 1995, BRIT J CLIN PHARMACO, V39, P1; NIERENBERG DW, 1986, CLIN PHARMACOL THER, V40, P488, DOI 10.1038/clpt.1986.213; NIERENBERG DW, 1990, CLIN PHARMACOL THER, V48, P603, DOI 10.1038/clpt.1990.200; ORME M, 1990, EUR J CLIN PHARMACOL, V38, P101; SNELL BF, 1992, MED J AUSTRALIA, V156, P352, DOI 10.5694/j.1326-5377.1992.tb139797.x; VESTAL RE, 1992, J CLIN PHARMACOL, V32, P779, DOI 10.1002/j.1552-4604.1992.tb03884.x; WILLIAMS PB, 1990, J CLIN PHARMACOL, V30, P1065, DOI 10.1002/j.1552-4604.1990.tb01847.x	17	69	73	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	DEC 2	1995	346	8988					1454	1457		10.1016/S0140-6736(95)92472-8	http://dx.doi.org/10.1016/S0140-6736(95)92472-8			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TH156	7490991				2022-12-28	WOS:A1995TH15600009
J	OPPENHEIMER, BR; KULKARNI, SR; MATTHEWS, K; NAKAJIMA, T				OPPENHEIMER, BR; KULKARNI, SR; MATTHEWS, K; NAKAJIMA, T			INFRARED SPECTRUM OF THE COOL BROWN DWARF-GL-229B	SCIENCE			English	Article								Spectroscopic measurements of a cool brown dwarf, Gl 229B, reveal absorption features attributable to methane in the near infrared much like those of Jupiter, These features are not seen in any star. The presence of methane indicates that the surface temperature of Gl 229B is below 1000 kelvin. Features attributed to water vapor also indicate that Gl 229B is much cooler than any known star.	CALTECH,PALOMAR OBSERV 10524,PASADENA,CA 91125	California Institute of Technology				Oppenheimer, Rebecca/0000-0001-7130-7681				Allard F., 1995, Bottom of the Main Sequence - and Beyond. Proceedings of the ESO Workshop, P32; BURROWS A, 1993, REV MOD PHYS, V65, P301, DOI 10.1103/RevModPhys.65.301; DANIELSON RE, 1966, ASTROPHYS J, V143, P949, DOI 10.1086/148570; JONES HRA, 1994, MON NOT R ASTRON SOC, V267, P413, DOI 10.1093/mnras/267.2.413; KUMAR SS, 1963, ASTROPHYS J, V137, P1121, DOI 10.1086/147589; NAKAJIMA T, IN PRESS NATURE; Stevenson D.J., 1986, ASTROPHYSICS BROWN D, P218; STEVENSON DJ, 1991, ANNU REV ASTRON ASTR, V29, P163; Tsuji T., 1995, Bottom of the Main Sequence - and Beyond. Proceedings of the ESO Workshop, P45; Tsuji T., 1964, ANN TOKYO ASTRON OBS, V9, P1; ZUCKERMAN B, 1992, ASTROPHYS J, V386, P260, DOI 10.1086/171012	11	260	260	0	5	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	DEC 1	1995	270	5241					1478	1479		10.1126/science.270.5241.1478	http://dx.doi.org/10.1126/science.270.5241.1478			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TH375	7491492				2022-12-28	WOS:A1995TH37500033
J	WAGHORN, A; THOMPSON, J; MCKEE, M				WAGHORN, A; THOMPSON, J; MCKEE, M			ROUTINE SURGICAL FOLLOW-UP - DO SURGEONS AGREE	BRITISH MEDICAL JOURNAL			English	Article									HAMMERSMITH HOSP,ROYAL POSTGRAD MED SCH,LONDON W12 0NN,ENGLAND	Imperial College London	WAGHORN, A (corresponding author), UNIV LONDON LONDON SCH HYG & TROP MED,HLTH SERV RES UNIT,LONDON WC1E 7HT,ENGLAND.		McKee, Marc D/E-2187-2011; Mckee, Martin/E-6673-2018	McKee, Marc D/0000-0001-8349-965X; Mckee, Martin/0000-0002-0121-9683				CDU VF, 1995, J PUB HLTH MED, V16, P455; COCHRANE JPS, 1980, BRIT MED J, V280, P593, DOI 10.1136/bmj.280.6214.593; HAM C, 1994, BRIT MED J, V309, P1032, DOI 10.1136/bmj.309.6961.1032; LOUDON ISL, 1976, LANCET, V1, P736; McCormack T T, 1984, Health Trends, V16, P46; MORRIS S, 1992, POSTGRAD MED J, V68, P904, DOI 10.1136/pgmj.68.805.904	6	17	17	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	NOV 18	1995	311	7016					1344	1345		10.1136/bmj.311.7016.1344	http://dx.doi.org/10.1136/bmj.311.7016.1344			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TF901	7496286	Green Published			2022-12-28	WOS:A1995TF90100024
J	LEE, N; MILLMAN, A				LEE, N; MILLMAN, A			ABC OF MEDICAL COMPUTING - MANIPULATING AND ANALYZING DATA	BRITISH MEDICAL JOURNAL			English	Article									HILLINGDON HOSP,LONDON,ENGLAND; GLOUCESTERSHIRE ROYAL HOSP,GLOUCESTER,ENGLAND	Brunel University; Imperial College London; Gloucestershire Royal Hospital	LEE, N (corresponding author), WESTERN EYE HOSP,LONDON,ENGLAND.								0	2	2	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	SEP 2	1995	311	7005					614	617		10.1136/bmj.311.7005.614	http://dx.doi.org/10.1136/bmj.311.7005.614			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RT723	7503928	Green Published			2022-12-28	WOS:A1995RT72300023
J	GROSSMAN, ME				GROSSMAN, ME			PORPHYRIA-CUTANEA-TARDA	NEW ENGLAND JOURNAL OF MEDICINE			English	Note											GROSSMAN, ME (corresponding author), COLUMBIA PRESBYTERIAN MED CTR,NEW YORK,NY 10032, USA.								0	0	0	0	0	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	OCT 13	1994	331	15					988	988						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PK504	7521939				2022-12-28	WOS:A1994PK50400005
J	HACK, M; TAYLOR, HG; KLEIN, N; EIBEN, R; SCHATSCHNEIDER, C; MERCURIMINICH, N				HACK, M; TAYLOR, HG; KLEIN, N; EIBEN, R; SCHATSCHNEIDER, C; MERCURIMINICH, N			SCHOOL-AGE OUTCOMES IN CHILDREN WITH BIRTH WEIGHTS UNDER 750 G	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							INTRAVENTRICULAR HEMORRHAGE; COGNITIVE-ABILITIES; PREMATURE-INFANTS; PRETERM INFANTS; SURVIVAL; PERFORMANCE; PREDICTION; GROWTH; GRAMS	Background. Since the mid-1980s, increasing numbers of children with birth weights under 750 g have survived to school age. Methods. We matched a regional cohort of 68 surviving children born from 1982 through 1986 with birth weights under 750 g (mean, 670 g; gestational age, 25.7 weeks) with 65 children weighing 750 to 1499 g at birth and 61 children born at term. Growth, neurosensory status, and functioning at school age in the three groups were compared. Associations of biologic and social risk factors with major developmental outcomes were examined by means of logistic-regression analyses. Results. Children with birth weights under 750 g were inferior to both comparison groups in cognitive ability, psychomotor skills, and academic achievement. They had poorer social skills and adaptive behavior and more behavioral and attention problems. The mean (+/- SD) Mental Processing Composite score for the cohort was 87 +/- 15, as compared with 93 +/- 14 for children with birth weights of 750 to 1499 g and 100 +/- 13 for children born at term (P<0.001). The rates of mental retardation (IQ <70) in the three groups were 21, 8, and 2 percent, respectively; the rates of cerebral palsy were 9, 6, and 0 percent; and the rates of severe visual disability were 25, 5, and 2 percent. Major cerebral ultrasonographic abnormalities were associated with mental retardation (odds ratio, 5.4; 95 percent confidence interval, 1.8 to 15.8) and cerebral palsy (odds ratio, 15.2; 95 percent confidence interval, 3.0 to 77.4). Oxygen dependence at 36 weeks of corrected age was associated with mental retardation (odds ratio, 4.5; 95 percent confidence interval, 1.2 to 10.7) and severe visual disability (odds ratio, 4.3; 95 percent confidence interval, 1.3 to 14.2). Social disadvantage, though associated with several neuropsychological outcomes, was not associated with major developmental impairment. Conclusions. Children with birth weights under 750 g who survive represent a subgroup of very-low-birth-weight children who are at high risk for neurobehavioral dysfunction and poor school performance.	CASE WESTERN RESERVE UNIV, SCH MED, DEPT PEDIAT, CLEVELAND, OH 44106 USA; CASE WESTERN RESERVE UNIV, DEPT PSYCHOL, CLEVELAND, OH 44106 USA; CLEVELAND STATE UNIV, DEPT SPECIAL EDUC, CLEVELAND, OH 44115 USA	Case Western Reserve University; Case Western Reserve University; University System of Ohio; Cleveland State University					EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD026554, T32HD007176] Funding Source: NIH RePORTER; NICHD NIH HHS [R01 HD26554, HD07176] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		Achenbach T.M., 1991, MANUAL TEACHERS REPO; ACHENBACH TM, 1991, MANUAL CHILD BEHAVIO; Barkley R. A., 1998, ATTENTION DEFICIT HY, V2nd; BEERY KE, 1989, REVISED ADM SCORING; Bruininks R.H., 2005, BRUININKS OSERETSKY; Fienberg S.E., 1980, ANAL CROSS CLASSIFIE, V2nd ed.; FLETCHER JM, 1985, J EXP CHILD PSYCHOL, V40, P244, DOI 10.1016/0022-0965(85)90088-8; Gardner M.F., 1990, EXPRESSIVE ONE WORD; GARDNER R, 1979, OBJECTIVE DIAGNOSIS; GIBSON DL, 1990, PEDIATRICS, V86, P405; Gresham F.M., 1990, SOCIAL SKILLS RATING; GROSS RT, 1990, JAMA-J AM MED ASSOC, V263, P3035; HACK M, 1991, PEDIATRICS, V87, P587; HACK M, 1991, NEW ENGL J MED, V325, P231, DOI 10.1056/NEJM199107253250403; HACK M, 1989, NEW ENGL J MED, V321, P1642, DOI 10.1056/NEJM198912143212405; HAMILL PVV, 1979, AM J CLIN NUTR, V32, P607, DOI 10.1093/ajcn/32.3.607; HIRATA T, 1983, J PEDIATR-US, V102, P741, DOI 10.1016/S0022-3476(83)80250-9; HORBAR JD, 1993, PEDIATRICS, V92, P191; JOHNSON A, 1993, BRIT MED J, V306, P1715, DOI 10.1136/bmj.306.6894.1715; KAUFMAN AS, 1988, J CLIN CHILD PSYCHOL, V17, P359, DOI 10.1207/s15374424jccp1704_10; LINDGREN SD, 1984, PEDIATRIC ASSESSMENT; LIPPER EG, 1990, AM J OBSTET GYNECOL, V163, P146, DOI 10.1016/S0002-9378(11)90689-9; PAGE JM, 1993, PEDIATRICS, V92, P787; PALMER EA, 1993, ARCH OPHTHALMOL-CHIC, V111, P339; PAPILE LA, 1978, J PEDIATR-US, V92, P529, DOI 10.1016/S0022-3476(78)80282-0; Pendergast K, 1969, PHOTO ARTICULATION T; PHILIP AGS, 1989, PEDIATRICS, V84, P797; ROBERTSON CMT, 1992, PEDIATRICS, V89, P365; ROCHE AF, 1987, PEDIATRICS, V79, P706; ROTH SC, 1993, DEV MED CHILD NEUROL, V35, P755; ROURKE BP, 1977, J ABNORM CHILD PSYCH, V5, P9, DOI 10.1007/BF00915756; SAIGAL S, 1991, J PEDIATR-US, V118, P751, DOI 10.1016/S0022-3476(05)80043-5; Semel E, 1987, CELF R CLIN EVALUATI; SHENNAN AT, 1988, PEDIATRICS, V82, P527; Sparrow S.S., 2005, VINELAND 2 ADAPTIVE; TAYLOR HG, 1989, APPL PSYCHOLINGUIST, V10, P203, DOI 10.1017/S0142716400008523; TAYLOR HG, 1987, J PEDIATR PSYCHOL, V12, P395, DOI 10.1093/jpepsy/12.3.395; TAYLOR HG, 1992, ADV CHILD NEUROPSYCH, V1, P50; USHER R, 1969, J PEDIATR-US, V74, P901, DOI 10.1016/S0022-3476(69)80224-6; VOHR B, 1992, J PEDIATR-US, V121, P280, DOI 10.1016/S0022-3476(05)81204-1; Woodcock R.W., 1989, WOODCOCK JOHNSON TES	41	516	527	0	14	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	SEP 22	1994	331	12					753	759		10.1056/NEJM199409223311201	http://dx.doi.org/10.1056/NEJM199409223311201			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PG301	7520533				2022-12-28	WOS:A1994PG30100001
J	SHARP, PA				SHARP, PA			SPLIT GENES AND RNA SPLICING	CELL			English	Article							PRE-MESSENGER-RNA; LABELED POLYRIBOSOMAL RNA; BASE-PAIRING INTERACTION; NUCLEAR-RNA; RIBONUCLEOPROTEIN PARTICLE; TETRAHYMENA RIBOZYME; COMPLEX REQUIRES; SITE SELECTION; ADENYLIC ACID; HELA CELLS		MIT,CTR CANC RES,CAMBRIDGE,MA 02139	Massachusetts Institute of Technology (MIT)	SHARP, PA (corresponding author), MIT,DEPT BIOL,77 MASSACHUSETTS AVE,CAMBRIDGE,MA 02139, USA.							AGABIAN N, 1990, CELL, V61, P1157, DOI 10.1016/0092-8674(90)90674-4; BAKER BS, 1989, NATURE, V340, P521, DOI 10.1038/340521a0; BELL LR, 1988, CELL, V55, P1037, DOI 10.1016/0092-8674(88)90248-6; BENNE R, 1986, CELL, V46, P819, DOI 10.1016/0092-8674(86)90063-2; BERGET SM, 1977, P NATL ACAD SCI USA, V74, P3171, DOI 10.1073/pnas.74.8.3171; BEYER AL, 1988, GENE DEV, V2, P754, DOI 10.1101/gad.2.6.754; BLAKE CCF, 1978, NATURE, V273, P267, DOI 10.1038/273267a0; BORST P, 1986, ANNU REV BIOCHEM, V55, P701, DOI 10.1146/annurev.bi.55.070186.003413; BREATHNACH R, 1977, NATURE, V270, P314, DOI 10.1038/270314a0; BREATHNACH R, 1981, ANNU REV BIOCHEM, V50, P349, DOI 10.1146/annurev.bi.50.070181.002025; BRODY E, 1985, SCIENCE, V228, P963, DOI 10.1126/science.3890181; CARTER KC, 1993, SCIENCE, V259, P1330, DOI 10.1126/science.8446902; CECH TR, 1985, CELL, V43, P713; CHOW LT, 1977, CELL, V12, P1, DOI 10.1016/0092-8674(77)90180-5; COCQUERELLE C, 1992, EMBO J, V11, P1095, DOI 10.1002/j.1460-2075.1992.tb05148.x; DARNELL JE, 1971, P NATL ACAD SCI USA, V68, P1321, DOI 10.1073/pnas.68.6.1321; DARNELL JE, 1978, SCIENCE, V202, P1257, DOI 10.1126/science.364651; DARNELL JE, 1975, HARVEY LECT, V69, P1; DOOLITTLE WF, 1978, NATURE, V272, P581, DOI 10.1038/272581a0; EDMONDS M, 1971, P NATL ACAD SCI USA, V68, P1336, DOI 10.1073/pnas.68.6.1336; FAY FS, 1993, SCIENCE, V259, P1330; FINK GR, 1987, CELL, V49, P5, DOI 10.1016/0092-8674(87)90746-X; FRENDEWEY D, 1985, CELL, V42, P355, DOI 10.1016/S0092-8674(85)80131-8; FU XD, 1990, NATURE, V343, P437, DOI 10.1038/343437a0; FURUICHI Y, 1975, P NATL ACAD SCI USA, V72, P362, DOI 10.1073/pnas.72.1.362; GE H, 1990, CELL, V62, P25, DOI 10.1016/0092-8674(90)90236-8; GILBERT W, 1978, NATURE, V271, P501, DOI 10.1038/271501a0; GRABOWSKI PJ, 1984, CELL, V37, P415, DOI 10.1016/0092-8674(84)90372-6; GRABOWSKI PJ, 1985, CELL, V42, P345, DOI 10.1016/S0092-8674(85)80130-6; GREEN MR, 1983, CELL, V32, P681, DOI 10.1016/0092-8674(83)90054-5; GUTHRIE C, 1988, ANNU REV GENET, V22, P387, DOI 10.1146/annurev.ge.22.120188.002131; GUTHRIE C, 1991, SCIENCE, V253, P157, DOI 10.1126/science.1853200; HERNANDEZ N, 1983, CELL, V35, P89, DOI 10.1016/0092-8674(83)90211-8; HYNES RO, 1989, FIBRONECTIN; JAMISON SF, 1992, P NATL ACAD SCI USA, V89, P5482, DOI 10.1073/pnas.89.12.5482; JEFFREYS AJ, 1977, CELL, V12, P1097, DOI 10.1016/0092-8674(77)90172-6; KONARSKA MM, 1987, CELL, V49, P763, DOI 10.1016/0092-8674(87)90614-3; KONARSKA MM, 1985, NATURE, V313, P552, DOI 10.1038/313552a0; KRAINER AR, 1984, CELL, V36, P993, DOI 10.1016/0092-8674(84)90049-7; KRAINER AR, 1990, CELL, V62, P35, DOI 10.1016/0092-8674(90)90237-9; KRAUSE M, 1987, CELL, V49, P753, DOI 10.1016/0092-8674(87)90613-1; LEE SY, 1971, P NATL ACAD SCI USA, V68, P1331, DOI 10.1073/pnas.68.6.1331; LERNER MR, 1980, NATURE, V283, P220, DOI 10.1038/283220a0; LONBERG N, 1985, CELL, V40, P81, DOI 10.1016/0092-8674(85)90311-3; MADHANI HD, 1992, CELL, V71, P803, DOI 10.1016/0092-8674(92)90556-R; MCPHEETERS DS, 1992, CELL, V71, P819, DOI 10.1016/0092-8674(92)90557-S; MCSWIGGEN JA, 1989, SCIENCE, V244, P679, DOI 10.1126/science.2470150; MEHLIN H, 1992, CELL, V69, P605, DOI 10.1016/0092-8674(92)90224-Z; MICHAUD S, 1991, GENE DEV, V5, P2534, DOI 10.1101/gad.5.12b.2534; Moore M., 1993, RNA WORLD, P303; MOORE MJ, 1993, NATURE, V365, P364, DOI 10.1038/365364a0; MOORE MJ, 1992, SCIENCE, V256, P992, DOI 10.1126/science.1589782; NEWMAN AJ, 1992, CELL, V68, P743, DOI 10.1016/0092-8674(92)90149-7; NIGRO JM, 1991, CELL, V64, P607, DOI 10.1016/0092-8674(91)90244-S; NYMAN U, 1986, J CELL BIOL, V102, P137, DOI 10.1083/jcb.102.1.137; PADGETT RA, 1983, P NATL ACAD SCI-BIOL, V80, P5230, DOI 10.1073/pnas.80.17.5230; PADGETT RA, 1986, ANNU REV BIOCHEM, V55, P1119, DOI 10.1146/annurev.bi.55.070186.005351; PARKER R, 1987, CELL, V49, P229, DOI 10.1016/0092-8674(87)90564-2; PATEL RS, 1987, EMBO J, V6, P2565, DOI 10.1002/j.1460-2075.1987.tb02545.x; PEEBLES CL, 1986, CELL, V44, P213, DOI 10.1016/0092-8674(86)90755-5; PETTERSSON U, 1973, P NATL ACAD SCI USA, V70, P200, DOI 10.1073/pnas.70.1.200; PULOK R, 1993, GENE DEV, V7, P1885; RAJAGOPAL J, 1989, SCIENCE, V244, P692, DOI 10.1126/science.2470151; ROGERS J, 1980, P NATL ACAD SCI-BIOL, V77, P1877, DOI 10.1073/pnas.77.4.1877; ROSBASH M, 1981, CELL, V24, P679, DOI 10.1016/0092-8674(81)90094-5; ROTH MB, 1991, J CELL BIOL, V115, P587, DOI 10.1083/jcb.115.3.587; ROTH MB, 1990, J CELL BIOL, V111, P2217, DOI 10.1083/jcb.111.6.2217; ROTTMAN F, 1974, CELL, V3, P197, DOI 10.1016/0092-8674(74)90131-7; RUBY SW, 1991, TRENDS GENET, V7, P79; RUSKIN B, 1988, CELL, V52, P207, DOI 10.1016/0092-8674(88)90509-0; SAWA H, 1992, P NATL ACAD SCI USA, V89, P11269, DOI 10.1073/pnas.89.23.11269; SERAPHIN B, 1991, EMBO J, V10, P1209, DOI 10.1002/j.1460-2075.1991.tb08062.x; SOTNE EM, 1990, INTERVENING SEQUENCE; SPECTOR DL, 1993, ANNU REV CELL BIOL, V9, P265, DOI 10.1146/annurev.cellbio.9.1.265; Steitz J. A., 1988, STRUCTURE FUNCTION M, P115; SUH E, 1992, NUCLEIC ACIDS RES, V20, P6303, DOI 10.1093/nar/20.23.6303; TIAN M, 1992, SCIENCE, V256, P237, DOI 10.1126/science.1566072; TILGHMAN SM, 1978, P NATL ACAD SCI USA, V75, P725, DOI 10.1073/pnas.75.2.725; TONEGAWA S, 1978, P NATL ACAD SCI USA, V75, P1485, DOI 10.1073/pnas.75.3.1485; TREISMAN R, 1983, NATURE, V302, P591, DOI 10.1038/302591a0; VANDERVEEN R, 1986, CELL, V44, P225, DOI 10.1016/0092-8674(86)90756-7; VELLARD M, 1992, P NATL ACAD SCI USA, V89, P2511, DOI 10.1073/pnas.89.7.2511; WALLACE JC, 1983, P NATL ACAD SCI-BIOL, V80, P950, DOI 10.1073/pnas.80.4.950; WASSARMAN DA, 1992, SCIENCE, V257, P1918, DOI 10.1126/science.1411506; WEI CM, 1974, P NATL ACAD SCI USA, V71, P3014, DOI 10.1073/pnas.71.8.3014; XING YG, 1993, SCIENCE, V259, P1326, DOI 10.1126/science.8446901; ZEITLIN S, 1989, J CELL BIOL, V108, P765, DOI 10.1083/jcb.108.3.765	87	452	488	3	27	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	JUN 17	1994	77	6					805	815		10.1016/0092-8674(94)90130-9	http://dx.doi.org/10.1016/0092-8674(94)90130-9			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	NT331	7516265				2022-12-28	WOS:A1994NT33100006
J	MATTHEWS, DA; SMITH, WW; FERRE, RA; CONDON, B; BUDAHAZI, G; SISSON, W; VILLAFRANCA, JE; JANSON, CA; MCELROY, HE; GRIBSKOV, CL; WORLAND, S				MATTHEWS, DA; SMITH, WW; FERRE, RA; CONDON, B; BUDAHAZI, G; SISSON, W; VILLAFRANCA, JE; JANSON, CA; MCELROY, HE; GRIBSKOV, CL; WORLAND, S			STRUCTURE OF HUMAN RHINOVIRUS 3C PROTEASE REVEALS A TRYPSIN-LIKE POLYPEPTIDE FOLD, RNA-BINDING SITE, AND MEANS FOR CLEAVING PRECURSOR POLYPROTEIN	CELL			English	Article							SERINE PROTEASES; ESCHERICHIA-COLI; POLIOVIRUS RNA; VIRAL-RNA; DIRECTED MUTAGENESIS; CYSTEINE PROTEASES; PROTEINASE; CHYMOTRYPSIN; CLEAVAGE; CARBOXYLATE	The structure of human rhinovirus-14 3C protease (3C(pro)) has been determined at 2.3 Angstrom resolution and refined to an R factor of 0.22. This cysteine protease folds into two topologically equivalent six-stranded beta barrels and in this sense is similar to trypsin-like serine proteases. However, there are differences in the lengths and positioning of individual beta strands as well as in loops connecting elements of secondary structure. The catalytic residues Cys-146, His-40, and Glu-71 are positioned as in serine proteases, but the oxyanion hole is moved 1-1.2 Angstrom away. Residues that bind to the 5' noncoding region of rhinovirus genomic RNA are located on the opposite side of the molecule from the active site. Interactions between individual 3C(pro) molecules in the crystal lattice suggest a model for intermolecular proteolytic cleavage of the 3CD polyprotein.			MATTHEWS, DA (corresponding author), AGOURON PHARMACEUT, 3565 GEN ATOM COURT, SAN DIEGO, CA 92121 USA.		Grünberg, Katrien/M-9715-2015	Grünberg, Katrien/0000-0003-1164-4365; Worland, Stephen/0000-0001-8924-253X				ALMASSY RJ, 1986, NATURE, V323, P304, DOI 10.1038/323304a0; ANDINO R, 1990, CELL, V63, P369, DOI 10.1016/0092-8674(90)90170-J; ANDINO R, 1993, EMBO J, V12, P3587, DOI 10.1002/j.1460-2075.1993.tb06032.x; BAZAN JF, 1988, P NATL ACAD SCI USA, V85, P7872, DOI 10.1073/pnas.85.21.7872; BIRKTOFT JJ, 1972, J MOL BIOL, V68, P187, DOI 10.1016/0022-2836(72)90210-0; BROOKS BR, 1983, J COMPUT CHEM, V4, P187, DOI 10.1002/jcc.540040211; BRUNGER AT, 1987, SCIENCE, V235, P458, DOI 10.1126/science.235.4787.458; CHAMBERS JL, 1979, ACTA CRYSTALLOGR B, V35, P1861, DOI 10.1107/S0567740879007925; CHEAH KC, 1990, J BIOL CHEM, V265, P7180; CHOI HK, 1991, NATURE, V354, P37, DOI 10.1038/354037a0; CORDINGLEY MG, 1989, J VIROL, V63, P5037, DOI 10.1128/JVI.63.12.5037-5045.1989; CYBULSKI SM, 1989, J AM CHEM SOC, V111, P23, DOI 10.1021/ja00183a004; DEWALT PG, 1987, J VIROL, V61, P2162, DOI 10.1128/JVI.61.7.2162-2170.1987; FUJINAGA M, 1985, J MOL BIOL, V184, P479, DOI 10.1016/0022-2836(85)90296-7; GANDOUR RD, 1981, BIOORG CHEM, V10, P169, DOI 10.1016/0045-2068(81)90020-1; GANDOUR RD, 1990, J AM CHEM SOC, V112, P7816, DOI 10.1021/ja00177a064; GORBALENYA AE, 1989, FEBS LETT, V243, P103, DOI 10.1016/0014-5793(89)80109-7; GORBALENYA AE, 1986, FEBS LETT, V194, P253, DOI 10.1016/0014-5793(86)80095-3; HAMMERLE T, 1992, J VIROL, V66, P6028; HANECAK R, 1984, CELL, V37, P1063, DOI 10.1016/0092-8674(84)90441-0; HARRIS KS, 1992, J VIROL, V66, P7481, DOI 10.1128/JVI.66.12.7481-7489.1992; HIGAKI JN, 1989, BIOCHEMISTRY-US, V28, P9256, DOI 10.1021/bi00450a004; IVANOFF LA, 1986, P NATL ACAD SCI USA, V83, P5392, DOI 10.1073/pnas.83.15.5392; KAY J, 1990, BIOCHIM BIOPHYS ACTA, V1048, P1, DOI 10.1016/0167-4781(90)90015-T; KEAN KM, 1988, VIROLOGY, V163, P330, DOI 10.1016/0042-6822(88)90273-5; KRAUSSLICH HG, 1988, ANNU REV BIOCHEM, V57, P701, DOI 10.1146/annurev.bi.57.070188.003413; LAWSON MA, 1990, CURR TOP MICROBIOL, V161, P49; LAWSON MA, 1992, VIROLOGY, V191, P309, DOI 10.1016/0042-6822(92)90193-S; LAWSON MA, 1991, P NATL ACAD SCI USA, V88, P9919, DOI 10.1073/pnas.88.22.9919; LEONG LEC, 1993, J BIOL CHEM, V268, P25735; LONG AC, 1989, FEBS LETT, V258, P75, DOI 10.1016/0014-5793(89)81619-9; NEET KE, 1966, P NATL ACAD SCI USA, V56, P1606, DOI 10.1073/pnas.56.5.1606; NIENABER VL, 1993, BIOCHEMISTRY-US, V32, P11469, DOI 10.1021/bi00094a001; POLGAR L, 1966, J AM CHEM SOC, V88, P3153, DOI 10.1021/ja00965a060; RAO ST, 1973, J MOL BIOL, V76, P241, DOI 10.1016/0022-2836(73)90388-4; SEMLER BL, 1983, VIROLOGY, V126, P624, DOI 10.1016/S0042-6822(83)80018-X; SMITH SO, 1989, SCIENCE, V244, P961, DOI 10.1126/science.2499045; STANWAY G, 1984, NUCLEIC ACIDS RES, V12, P7859, DOI 10.1093/nar/12.20.7859; TERWILLIGER TC, 1983, ACTA CRYSTALLOGR A, V39, P813, DOI 10.1107/S0108767383001592; TONG L, 1990, ACTA CRYSTALLOGR A, V46, P783, DOI 10.1107/S0108767390005530; TSUNOGAE Y, 1986, J BIOCHEM-TOKYO, V100, P1637, DOI 10.1093/oxfordjournals.jbchem.a121872; WANG BC, 1985, METHOD ENZYMOL, V115, P90; WARSHEL A, 1989, BIOCHEMISTRY-US, V28, P3629, DOI 10.1021/bi00435a001	43	269	280	0	23	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JUN 3	1994	77	5					761	771		10.1016/0092-8674(94)90059-0	http://dx.doi.org/10.1016/0092-8674(94)90059-0			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	NQ123	7515772				2022-12-28	WOS:A1994NQ12300015
J	JENISON, RD; GILL, SC; PARDI, A; POLISKY, B				JENISON, RD; GILL, SC; PARDI, A; POLISKY, B			HIGH-RESOLUTION MOLECULAR DISCRIMINATION BY RNA	SCIENCE			English	Article							STRANDED-DNA MOLECULES; THEOPHYLLINE; SELECTION; INVITRO; RECOGNITION; IMMUNOASSAY; POLYMERASE; LIGANDS; BIND	Species of RNA that bind with high affinity and specificity to the bronchodilator theophylline were identified by selection from an oligonucleotide library. One RNA molecule binds to theophylline with a dissociation constant K-d of 0.1 mu M. This binding affinity is 10,000-fold greater than the RNA molecule's affinity for caffeine, which differs from theophylline only by a methyl group at nitrogen atom N-7. Analysis by nuclear magnetic resonance indicates that this RNA molecule undergoes a significant change in its conformation or dynamics upon theophylline binding. Binding studies of compounds chemically related to theophylline have revealed structural features required for the observed binding specificity. These results demonstrate the ability of RNA molecules to exhibit an extremely high degree of ligand recognition and discrimination.	NEXAGEN INC,BOULDER,CO 80301; UNIV COLORADO,DEPT CHEM & BIOCHEM,BOULDER,CO 80309	University of Colorado System; University of Colorado Boulder					NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI033098] Funding Source: NIH RePORTER; NCRR NIH HHS [RR03283] Funding Source: Medline; NIAID NIH HHS [AI33098, AI01051] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ANTONI G, 1983, ANAL BIOCHEM, V129, P60, DOI 10.1016/0003-2697(83)90052-0; BARTEL DP, 1991, CELL, V67, P529, DOI 10.1016/0092-8674(91)90527-6; BOCK LC, 1992, NATURE, V355, P564, DOI 10.1038/355564a0; BROUSSARD LA, 1981, CLIN CHEM, V27, P1931; CONNELL GJ, 1993, BIOCHEMISTRY-US, V32, P5497, DOI 10.1021/bi00072a002; ELLINGTON AD, 1992, NATURE, V355, P850, DOI 10.1038/355850a0; ELLINGTON AD, 1990, NATURE, V346, P818, DOI 10.1038/346818a0; FAMULOK M, 1992, J AM CHEM SOC, V114, P3990, DOI 10.1021/ja00036a065; GILL SC, 1991, J MOL BIOL, V220, P307, DOI 10.1016/0022-2836(91)90015-X; HENDELES L, 1983, PHARMACOTHERAPY, V3, P2; JELLINEK D, 1993, P NATL ACAD SCI USA, V90, P11227, DOI 10.1073/pnas.90.23.11227; JOLLEY ME, 1981, CLIN CHEM, V27, P1575; PLATEAU P, 1982, J AM CHEM SOC, V104, P731; PONCELET SM, 1990, J IMMUNOASSAY, V11, P77, DOI 10.1080/01971529008053259; REINECKE T, 1986, ANN EMERG MED, V15, P147, DOI 10.1016/S0196-0644(86)80009-9; SASSANFAR M, 1993, NATURE, V364, P550, DOI 10.1038/364550a0; SCHNEIDER D, 1992, J MOL BIOL, V228, P862, DOI 10.1016/0022-2836(92)90870-P; SKIENAR V, 1990, NATURE, V345, P836; TUERK C, 1992, P NATL ACAD SCI USA, V89, P6988, DOI 10.1073/pnas.89.15.6988; TUERK C, 1990, SCIENCE, V249, P505, DOI 10.1126/science.2200121; TUERK C, IN PRESS GENE; VANDEVEN FJM, 1988, EUR J BIOCHEM, V178, P1; VARANI G, 1991, Q REV BIOPHYS, V24, P479, DOI 10.1017/S0033583500003875	23	860	933	7	208	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAR 11	1994	263	5152					1425	1429		10.1126/science.7510417	http://dx.doi.org/10.1126/science.7510417			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	MZ927	7510417				2022-12-28	WOS:A1994MZ92700028
J	DEROUX, GI; CHELALA, C				DEROUX, GI; CHELALA, C			VIOLENCE IN THE AMERICA	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Letter									UNIV VALLE,PROGRAMA SALUD & VIOLENCIA,CALI,COLOMBIA	Universidad del Valle								ATEHORTUA AL, 1992, IVOLENCIA JUVENIL CA; BARNEY AG, 1993, DATOS AGREGADOS VIOL; FRANKS F, 1990, CRYO-LETT, V11, P1; Yunes J, 1993, Bull Pan Am Health Organ, V27, P154; 1990, HLTH CONDITIONS AM, V1, P210; 1993, INFORMES VARIOS SOBR	6	2	2	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAR 9	1994	271	10					727	727		10.1001/jama.271.10.727	http://dx.doi.org/10.1001/jama.271.10.727			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MY288	7509417				2022-12-28	WOS:A1994MY28800001
J	WOODHOUSE, PR; KHAW, KT; PLUMMER, M; FOLEY, A; MEADE, TW				WOODHOUSE, PR; KHAW, KT; PLUMMER, M; FOLEY, A; MEADE, TW			SEASONAL-VARIATIONS OF PLASMA-FIBRINOGEN AND FACTOR-VII ACTIVITY IN THE ELDERLY - WINTER INFECTIONS AND DEATH FROM CARDIOVASCULAR-DISEASE	LANCET			English	Article							ISCHEMIC HEART-DISEASE; RISK-FACTORS; MYOCARDIAL-INFARCTION; HEMOSTATIC VARIABLES; HYPERLIPEMIA	There are approximately 20 000 excess deaths from cardiovascular disease each winter in England and Wales, The reasons for the excess have not been fully elucidated. For one year, we studied 96 men and women aged 65-74 living in their own homes in order to examine seasonal variation in plasma fibrinogen and factor VII clotting activity (fVIIc), and to investigate relationships with infection and other cardiovascular-disease risk factors. Both fibrinogen and FVIIc plasma values were greater in winter with estimated winter-summer differences (confidence intervals) of 0.13 (0.05-0.20) g/L for fibrinogen and 4.2 (1.2-7.1)% of standard for FVIIc. These differences could account for 15% and 9% increases in ischaemic heart disease risk in winter respectively. After adjustment for confounding by season, fibrinogen was strongly related to neutrophil count (p<0.0001), C-reactive protein (p<0.0001), alpha 1-antichymotrypsin (p<0.0001), and self-reported cough (p<0.0001) and coryza (p=0.0004), but not to ambient temperature. Therefore, we suggest that seasonal variation in fibrinogen might be induced by winter respiratory infections via activation of the acute phase response. Seasonal variations in the cardiovascular risk factors fibrinogen and FVIIc provide further possible explanations for the marked seasonal variation in death from ischaemic heart disease and stroke in the elderly.	UNIV CAMBRIDGE, CLIN GERONTOL UNIT, CAMBRIDGE, CAMBS, ENGLAND; INST PUBL HLTH, MRC, BIOSTAT UNIT, CAMBRIDGE, CAMBS, ENGLAND; WOLFSON INST PREVENT MED, MRC, EPIDEMIOL & MED CARE UNIT, LONDON, ENGLAND	University of Cambridge; MRC Biostatistics Unit; University of Cambridge; University of London; Queen Mary University London				Plummer, Martyn/0000-0001-5130-6497				AKIRA S, 1992, IMMUNOL REV, V127, P25, DOI 10.1111/j.1600-065X.1992.tb01407.x; BAINTON D, 1978, INT J EPIDEMIOL, V7, P231, DOI 10.1093/ije/7.3.231; BRENNAN PJ, 1982, BMJ-BRIT MED J, V285, P919, DOI 10.1136/bmj.285.6346.919; CHOOI CC, 1989, THROMB RES, V53, P493, DOI 10.1016/0049-3848(89)90204-1; CLAUSS A., 1957, ACTA HAEMATOL, V17, P237; COOK NS, 1990, TRENDS PHARMACOL SCI, V11, P444, DOI 10.1016/0165-6147(90)90125-R; Curwen M., 1991, HLTH TRENDS, V22, P169; DURRINGTON PN, 1990, SCAND J CLIN LAB INV, V50, P86, DOI 10.3109/00365519009091092; ELKELES RS, 1980, BRIT MED J, V281, P973, DOI 10.1136/bmj.281.6246.973; FOLSOM AR, 1991, ATHEROSCLEROSIS, V91, P191, DOI 10.1016/0021-9150(91)90167-2; GORDON DJ, 1988, J CLIN EPIDEMIOL, V41, P679, DOI 10.1016/0895-4356(88)90120-5; ISO H, 1989, AM J EPIDEMIOL, V130, P925, DOI 10.1093/oxfordjournals.aje.a115425; KANNEL WB, 1992, JAMA-J AM MED ASSOC, V267, P1253, DOI 10.1001/jama.267.9.1253; KANNEL WB, 1987, JAMA-J AM MED ASSOC, V258, P1183, DOI 10.1001/jama.258.9.1183; MARCKMANN P, 1990, ATHEROSCLEROSIS, V80, P227, DOI 10.1016/0021-9150(90)90030-M; MEADE TW, 1987, LANCET, V2, P986; MEADE TW, 1979, BMJ-BRIT MED J, V1, P153, DOI 10.1136/bmj.1.6157.153; MEADE TW, 1986, LANCET, V2, P533, DOI 10.1016/S0140-6736(86)90111-X; MILLER GJ, 1991, LANCET, V338, P1079, DOI 10.1016/0140-6736(91)91936-O; MILLER GJ, 1985, BRIT J HAEMATOL, V59, P249, DOI 10.1111/j.1365-2141.1985.tb02991.x; NASKI MC, 1991, J BIOL CHEM, V266, P13003; PRICE CP, 1987, J IMMUNOL METHODS, V99, P205, DOI 10.1016/0022-1759(87)90129-3; QIZILBASH N, 1991, BRIT MED J, V303, P605, DOI 10.1136/bmj.303.6803.605; RAO CR, 1973, LINEAR STATISTICAL I, P418; SPODICK DH, 1984, AM J CARDIOL, V53, P481, DOI 10.1016/0002-9149(84)90016-X; STOUT RW, 1991, LANCET, V338, P9, DOI 10.1016/0140-6736(91)90004-9; SYRJANEN J, 1988, BRIT MED J, V296, P1156, DOI 10.1136/bmj.296.6630.1156; WILHELMSEN L, 1984, NEW ENGL J MED, V311, P501, DOI 10.1056/NEJM198408233110804; WOODHOUSE PR, 1993, J HYPERTENS, V11, P1267; WOODHOUSE PR, 1993, AGE AGEING, V22, P273, DOI 10.1093/ageing/22.4.273; ZEGER SL, 1986, BIOMETRICS, V42, P121, DOI 10.2307/2531248	31	463	479	0	10	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	FEB 19	1994	343	8895					435	439		10.1016/S0140-6736(94)92689-1	http://dx.doi.org/10.1016/S0140-6736(94)92689-1			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MW690	7508540				2022-12-28	WOS:A1994MW69000007
J	Andreotti, F; Pasceri, V; Hackett, DR; Davies, GJ; Haider, AW; Maseri, A				Andreotti, F; Pasceri, V; Hackett, DR; Davies, GJ; Haider, AW; Maseri, A			Preinfarction angina as a predictor of more rapid coronary thrombolysis in patients with acute myocardial infarction	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							PLASMINOGEN-ACTIVATOR; ANTECEDENT ANGINA; PECTORIS; THERAPY; STREPTOKINASE; THROMBOSIS; OCCLUSION; ARTERY; PREVENTION; MORTALITY	Background. When a myocardial infarction is preceded by angina, the infarct tends to be smaller than when there is no preinfarction angina. Prompt re canalization of the occluded infarct-related artery is crucial in limiting the size of the infarct. We prospectively studied the relation among preinfarction unstable angina, the speed of coronary reperfusion, and the size of the infarct in patients with acute myocardial infarction receiving thrombolytic therapy. Methods. We compared 14 patients who had unstable angina during the week before myocardial infarction with 9 patients who had no preinfarction angina. Coronary arteriograms were obtained at base line and 15, 35, 55, and 90 minutes and 24 hours after the start of thrombolytic therapy, The size of the infarct was estimated on the basis of creatine kinase and creatine kinase MB levels, which were measured every 4 hours during the first 24 hours. Results. Complete reperfusion (a flow of grade 3 according to the Thrombolysis in Myocardial Infarction classification) was achieved at 35 minutes in 64 percent of the patients with preinfarction angina but in none of those without preinfarction angina (P = 0.006); at 55 minutes in 86 percent and 38 percent, respectively (P = 0.05); and at 90 minutes in 86 percent and 50 percent, respectively (P = 0.14). The mean (+/-SD) time to reperfusion was 27+/-16 minutes in the group with preinfarction angina and 48+/-17 minutes in the group without preinfarction angina (P = 0.04); the peak creatine kinase levels were 1118+/-783 and 2395+/-1615 U per liter, respectively (P = 0.03); the peak creatine kinase MB levels were 102+/-67 and 251+/-186 U per liter, respectively (P = 0.009); and the 24-hour integrated creatine kinase MB levels were 1716+/-1171 and 4267+/-3252 U . liter(-1). 24 hours, respectively (P = 0.009). The time to reperfusion was positively correlated with the indexes of infarct size (r greater than or equal to 0.53, P less than or equal to 0.02). Conclusions. In patients with acute myocardial infarction preceded by unstable angina, as compared with those without preinfarction angina, thrombolytic therapy resulted in more rapid reperfusion and smaller infarcts. Earlier myocardial reperfusion may thus account for the smaller infarct size in patients with preinfarction angina. (C) 1996, Massachusetts Medical Society.	HAMMERSMITH HOSP, ROYAL POSTGRAD MED SCH, LONDON, ENGLAND	Imperial College London	Andreotti, F (corresponding author), CATHOLIC UNIV, INST CARDIOL, LARGO A GEMELLI 8, I-00168 ROME, ITALY.		Andreotti, Felicita/A-9962-2019	Andreotti, Felicita/0000-0002-1456-6430				BARBASH GI, 1992, J AM COLL CARDIOL, V20, P36, DOI 10.1016/0735-1097(92)90134-9; BEEBE DP, 1987, THROMB RES, V47, P123, DOI 10.1016/0049-3848(87)90249-0; BRAUNWALD E, 1995, CIRCULATION, V91, P1604, DOI 10.1161/01.CIR.91.5.1604; BRAUNWALD E, 1982, CIRCULATION, V66, P1146, DOI 10.1161/01.CIR.66.6.1146; CLAUSS A., 1957, ACTA HAEMATOL, V17, P237; COLLEN D, 1990, ANN INTERN MED, V112, P529, DOI 10.7326/0003-4819-112-7-529; Cox DR, 1974, THEORETICAL STATISTI; DAVIES GJ, 1984, NEW ENGL J MED, V311, P1488, DOI 10.1056/NEJM198412063112306; DAVIES MJ, 1984, NEW ENGL J MED, V310, P1137, DOI 10.1056/NEJM198405033101801; DEWOOD MA, 1980, NEW ENGL J MED, V303, P897, DOI 10.1056/NEJM198010163031601; FALK E, 1985, CIRCULATION, V71, P699, DOI 10.1161/01.CIR.71.4.699; FOX KAA, 1985, CIRCULATION, V72, P1346, DOI 10.1161/01.CIR.72.6.1346; FUJITA M, 1987, BRIT HEART J, V57, P139; GRANDE P, 1982, CIRCULATION, V65, P756, DOI 10.1161/01.CIR.65.4.756; HACKETT D, 1987, NEW ENGL J MED, V317, P1055, DOI 10.1056/NEJM198710223171704; HARPER RW, 1979, AM HEART J, V97, P178, DOI 10.1016/0002-8703(79)90353-3; INGERSLEV J, 1987, SCAND J CLIN LAB INV, V47, P143; JANG IK, 1989, CIRCULATION, V79, P920, DOI 10.1161/01.CIR.79.4.920; KAGEN L, 1977, AM J MED, V62, P86, DOI 10.1016/0002-9343(77)90353-9; KARAGOUNIS L, 1992, J AM COLL CARDIOL, V19, P1, DOI 10.1016/0735-1097(92)90043-M; KHAN MI, 1990, AM J CARDIOL, V65, P1051, DOI 10.1016/0002-9149(90)90313-P; KLONER RA, 1995, CIRCULATION, V91, P37, DOI 10.1161/01.CIR.91.1.37; KLONER RA, 1994, J AM COLL CARDIOL, V24, P1133, DOI 10.1016/0735-1097(94)90880-X; KUNITADA S, 1992, BLOOD, V79, P1420; LINCOFF AM, 1993, CIRCULATION, V87, P1792; LIUZZO G, 1994, NEW ENGL J MED, V331, P417, DOI 10.1056/NEJM199408183310701; LOSCALZO J, 1990, ARTERIOSCLEROSIS, V10, P240, DOI 10.1161/01.ATV.10.2.240; MATSUDA Y, 1984, AM HEART J, V108, P955, DOI 10.1016/0002-8703(84)90460-5; MULLER DWM, 1990, AM HEART J, V119, P224, DOI 10.1016/S0002-8703(05)80008-0; OTTANI F, 1995, CIRCULATION, V91, P291, DOI 10.1161/01.CIR.91.2.291; PASCERI V, 1995, AM J CARDIOL, V75, P224, DOI 10.1016/0002-9149(95)80024-M; PASSAMANI E, 1985, NEW ENGL J MED, V312, P932; PIERARD LA, 1988, AM J CARDIOL, V61, P984, DOI 10.1016/0002-9149(88)90111-7; Ridker, 1994, J Thromb Thrombolysis, V1, P35, DOI 10.1007/BF01061993; ROSS AM, 1993, NEW ENGL J MED, V329, P1615; RUOCCO NA, 1992, J AM COLL CARDIOL, V20, P1445, DOI 10.1016/0735-1097(92)90435-P; SALAZAR AE, 1961, CIRC RES, V9, P1351, DOI 10.1161/01.RES.9.6.1351; VANLOON BJP, 1992, THROMB HAEMOSTASIS, V67, P101; VOGT A, 1993, J AM COLL CARDIOL, V21, P1391, DOI 10.1016/0735-1097(93)90314-Q; WALKER AM, 1995, NEW ENGL J MED, V332, P1091, DOI 10.1056/NEJM199504203321609	40	204	212	0	2	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JAN 4	1996	334	1					7	12		10.1056/NEJM199601043340102	http://dx.doi.org/10.1056/NEJM199601043340102			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TM482	7494588				2022-12-28	WOS:A1996TM48200002
J	Genc, M; Mardh, PA				Genc, M; Mardh, PA			A cost-effectiveness analysis of screening and treatment for Chlamydia trachomatis infection in asymptomatic women	ANNALS OF INTERNAL MEDICINE			English	Article							PELVIC INFLAMMATORY DISEASE; ECONOMIC-EVALUATION; DECISION-ANALYSIS; ADOLESCENT MALES; SPECIMENS; ASSAY; RISK	Objective: To assess the cost-effectiveness of identifying and treating asymptomatic female carriers of Chlamydia trachomatis. Design: Cost-effectiveness analysis based on previously reported cohort analytic studies and average salaries and costs of medical care in Sweden. Setting: Women attending youth, family planning, and gynecology clinics. Participants: 1000 women and their male sex partners. Intervention: Screening with tissue cell culture, confirmed enzyme immunoassay, and DNA amplification as says based on either polymerase chain reaction or ligase chain reaction was compared with no screening (no treatment and no tracing of sexual contacts). The effect of antibiotic regimens on the outcome of the screening strategies was also evaluated. Results: When the prevalence of chlamydial infection exceeded 6%, screening of women with DNA amplification assay and treatment of positive patients with a single oral dose of azithromycin given under supervision in the clinic was the most cost-effective intervention strategy. At greater prevalences, screening with enzyme immunoassay also generated savings and improved the cure rates compared with no screening, but such screening was less cost-effective than screening with a DNA amplification assay. Compared with no intervention, tissue cell culture is cost-effective only when the prevalence of infection is greater than 14%. Compared with the azithromycin regimen, the standard 7-day, twice-daily doxycycline regimen resulted in significantly lower cure rates because of patients' poor compliance with this regimen. Conclusion: For asymptomatic female carriers of C. trachomatis, screening with a DNA amplification assay combined with the single-dose azithromycin treatment of positive patients is the most cost-effective strategy when the prevalence is 6%. When the prevalence is lower than 6%, the decision to choose a competing strategy depends on the physician's view of the value of preventing an illness caused by untreated chlamydial infection.			Genc, M (corresponding author), UPPSALA UNIV, CTR STD RES, INST CLIN BACTERIOL, BOX 552, S-75122 UPPSALA, SWEDEN.							BASS CA, 1993, J CLIN MICROBIOL, V31, P2648, DOI 10.1128/JCM.31.10.2648-2653.1993; CHERNESKY M, 1994, CHLAMYDIAL INFECTION, P333; ESTANY A, 1989, SEX TRANSM DIS, V16, P21, DOI 10.1097/00007435-198901000-00005; GENC M, 1993, JAMA-J AM MED ASSOC, V270, P2057, DOI 10.1001/jama.270.17.2057; GENC M, 1994, JAMA-J AM MED ASSOC, V271, P1741, DOI 10.1001/jama.1994.03510460033017; GENC M, 1991, CHLAMYDIAL INFECTION, P112; HADDIX A, 1994, CHLAMYDIAL INFECTION, P55; HELLBERG D, 1995, GENITOURIN MED, V71, P88; HILLIS SD, 1993, AM J OBSTET GYNECOL, V168, P1503, DOI 10.1016/S0002-9378(11)90790-X; HOOK EW, 1994, JAMA-J AM MED ASSOC, V272, P867, DOI 10.1001/jama.272.11.867; KATZ BP, 1988, SEX TRANSM DIS, V15, P11, DOI 10.1097/00007435-198801000-00003; LANGILLE DB, 1992, CAN J PUBLIC HEALTH, V83, P358; LEE HH, 1995, LANCET, V345, P213, DOI 10.1016/S0140-6736(95)90221-X; MAHONY JB, 1992, MOL CELL PROBE, V6, P381, DOI 10.1016/0890-8508(92)90031-R; MARTIN DH, 1992, NEW ENGL J MED, V327, P921, DOI 10.1056/NEJM199209243271304; MONCADA J, 1990, J CLIN MICROBIOL, V28, P1770, DOI 10.1128/JCM.28.8.1770-1773.1990; NETTLEMAN MD, 1988, JAMA-J AM MED ASSOC, V260, P207, DOI 10.1001/jama.260.2.207; PHILLIPS RS, 1987, ANN INTERN MED, V107, P188, DOI 10.7326/0003-4819-107-2-188; PIOT P, 1994, CHLAMYDIAL INFECTION, P7; QUINN TC, 1994, CHLAMYDIAL INFECTION, P21; RAMSTEDT K, 1991, SEX TRANSM DIS, V18, P205, DOI 10.1097/00007435-199110000-00002; RAMSTEDT K, 1991, INT J STD AIDS, V2, P428, DOI 10.1177/095646249100200607; RANDOLPH AG, 1990, AM J PUBLIC HEALTH, V80, P545, DOI 10.2105/AJPH.80.5.545; SCHACHTER J, 1994, J CLIN MICROBIOL, V32, P2540, DOI 10.1128/JCM.32.10.2540-2543.1994; TRACHTENBERG AI, 1988, OBSTET GYNECOL, V71, P101; WASHINGTON AE, 1987, JAMA-J AM MED ASSOC, V257, P2056, DOI 10.1001/jama.257.15.2056; WESTROM L, 1993, GENITOURIN MED, V69, P9; Whatley J D, 1991, Int J STD AIDS, V2, P248	28	113	113	0	5	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JAN 1	1996	124	1	1				1	7		10.7326/0003-4819-124-1_Part_1-199601010-00001	http://dx.doi.org/10.7326/0003-4819-124-1_Part_1-199601010-00001			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TL943	7503471				2022-12-28	WOS:A1996TL94300001
J	BONDY, S				BONDY, S			ALCOHOL AVAILABILITY AND ALCOHOLISM	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Letter							CONSUMPTION; STRIKE				BONDY, S (corresponding author), ADDICT RES FDN,TORONTO,ON M5S 2S1,CANADA.		Bondy, Susan J/C-6737-2014	Bondy, Susan J/0000-0002-6516-4159				BASS K, DEV LOCAL CONTROL AL; BLOSE JO, 1987, J STUD ALCOHOL, V48, P52, DOI 10.15288/jsa.1987.48.52; Bruun K., 1975, ALCOHOL CONTROL POLI; EDWARDS G, 1994, ALCOHOL POLICY PUBLI, pCH6; GODFREY C, 1988, APPL ECON, V20, P1541, DOI 10.1080/00036848800000085; GRUENEWALD PJ, 1993, ALCOHOL CLIN EXP RES, V17, P38, DOI 10.1111/j.1530-0277.1993.tb00723.x; GRUENEWALD PJ, 1993, NIAAA RES MONOGRAPH, V25, P59; HOLDER HD, 1987, CONTROL ISSUES ALCOH; HORVERAK O, 1983, BRIT J ADDICT, V78, P51; Lenke L., 1990, ALCOHOL CRIMINAL VIO; LESTER D, 1988, SOC PSYCH PSYCH EPID, V23, P202, DOI 10.1007/BF01794789; MAKELA K, 1980, J DRUG ISSUES, V10, P131; Mosher J. F., 1994, CONFRONTING SACRAMEN; MOSKOWITZ JM, 1989, J STUD ALCOHOL, V30, P54; OSTERBERG E, 1991, NATURAL EXPT DECREAS; OSTERBERG E, 1993, ALCOHOL HEALTH RES W, V17, P205; ROOM R, 1984, ANNU REV PUBL HEALTH, V5, P293, DOI 10.1146/annurev.pu.05.050184.001453; RUSH BR, 1986, J STUD ALCOHOL, V47, P1; SCHECHTER EJ, 1986, CONT DRUG PROBL, V15, P587; SCRIBNER RA, 1994, J STUD ALCOHOL, V55, P447, DOI 10.15288/jsa.1994.55.447; SKOG OJ, 1980, J DRUG ISSUES, V10, P71, DOI 10.1177/002204268001000105; SONENSHEIM RJ, 1993, BATTLE LIQUOR STORES; WATTS RK, 1983, ALCOHOL CLIN EXP RES, V7, P47, DOI 10.1111/j.1530-0277.1983.tb05410.x; WILKINSON JT, 1987, SOUTHERN ECON J, V54, P322, DOI 10.2307/1059317	24	2	2	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	DEC 20	1995	274	23					1832	1832		10.1001/jama.274.23.1832	http://dx.doi.org/10.1001/jama.274.23.1832			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	TK147	7500522				2022-12-28	WOS:A1995TK14700008
J	LIN, JC; LIN, SC; MAR, EC; PELLETT, PE; STAMEY, FR; STEWART, JA; SPIRA, TJ				LIN, JC; LIN, SC; MAR, EC; PELLETT, PE; STAMEY, FR; STEWART, JA; SPIRA, TJ			RETRACTED: IS KAPOSIS-SARCOMA-ASSOCIATED HERPESVIRUS DETECTABLE IN SEMEN OF HIV-INFECTED HOMOSEXUAL MEN (Retracted article. See vol. 351, pg. 1365, 1998)	LANCET			English	Note; Retracted Publication								We explored a possible route of transmission of Kaposi's sarcoma-associated herpes virus (KSHV) with nested and unnested PCR techniques. We looked for KSHV DNA sequences in semen of HIV-positive homosexual men and HIV-negative healthy semen donors. With unnested primers we found KSHV sequences in 21 of 33 (64%) homosexual men and in none of 30 healthy donors. With a nested PCR assay, 30 of 33 (91%) specimens from the homosexual men and 7 of 30 (23%) specimens from healthy donors had detectable KSHV sequences. Over 5 years of follow-up, 13 of 30 KSHV-positive homosexual men (43%) developed KS compared with none of the 3 KSHV-negative homosexual men.			LIN, JC (corresponding author), CTR DIS CONTROL & PREVENT, 1600 CLIFTON RD, MS-D10, ATLANTA, GA 30333 USA.			Pellett, Philip/0000-0002-8536-8343				AMBROZIAK JA, 1995, SCIENCE, V268, P582, DOI 10.1126/science.7725108; BERAL V, 1990, LANCET, V335, P123, DOI 10.1016/0140-6736(90)90001-L; CESARMAN E, 1995, NEW ENGL J MED, V332, P1186, DOI 10.1056/NEJM199505043321802; CHANG Y, 1994, SCIENCE, V266, P1865, DOI 10.1126/science.7997879; DUPIN N, 1995, LANCET, V345, P761, DOI 10.1016/S0140-6736(95)90642-8; HUANG YQ, 1995, LANCET, V345, P759, DOI 10.1016/S0140-6736(95)90641-X; LIN JC, 1993, BLOOD, V81, P3372; MOORE PS, 1995, NEW ENGL J MED, V332, P1181, DOI 10.1056/NEJM199505043321801; RADY PL, 1995, LANCET, V345, P1339, DOI 10.1016/S0140-6736(95)92538-4; SU IJ, 1995, LANCET, V345, P722, DOI 10.1016/S0140-6736(95)90893-5	10	104	107	0	10	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	DEC 16	1995	346	8990					1601	1602		10.1016/S0140-6736(95)91931-7	http://dx.doi.org/10.1016/S0140-6736(95)91931-7			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TK481	7500753				2022-12-28	WOS:A1995TK48100012
J	BECKMANN, H; CHEN, JL; OBRIEN, T; TJIAN, R				BECKMANN, H; CHEN, JL; OBRIEN, T; TJIAN, R			COACTIVATOR AND PROMOTER-SELECTIVE PROPERTIES OF RNA-POLYMERASE-I TAFS	SCIENCE			English	Article							TRANSCRIPTION FACTOR; BINDING	Human ribosomal RNA synthesis by RNA polymerase I requires the activator UBF and the promoter selectivity factor SL1, which consists of the TATA binding protein (TBP) and three associated subunits, TAF(I) 110, TAF(I)63, and TAF(I)48. Here it is shown that both TAF(I)110 and TAF(I)63 contact the promoter, whereas TAF(l)48 serves as a target for interaction with UBF and is required to form a transcriptionally active SL1 complex responsive to UBF in vitro. TAF(I)48 also alters the ability of TBP to interact with TATA box elements, and the resulting complex fails to support transcription by RNA polymerase II. Thus, TAF(I)48 may function both as a target to mediate UBF activation and as a class-specific promoter selectivity factor.	UNIV CALIF BERKELEY, DEPT MOLEC & CELL BIOL, BERKELEY, CA 94720 USA	University of California System; University of California Berkeley				O'Brien, Thomas/0000-0002-9161-8070				BECKMANN H, UNPUB; BELL SP, 1988, SCIENCE, V241, P1192, DOI 10.1126/science.3413483; BELL SP, 1990, GENE DEV, V4, P943, DOI 10.1101/gad.4.6.943; BURATOWSKI S, 1994, CELL, V77, P1, DOI 10.1016/0092-8674(94)90226-7; CHEN JL, 1994, CELL, V79, P93, DOI 10.1016/0092-8674(94)90403-0; CHIANG CM, 1995, SCIENCE, V267, P531, DOI 10.1126/science.7824954; COMAI L, 1994, SCIENCE, V266, P1966, DOI 10.1126/science.7801123; COMAI L, 1992, CELL, V68, P965, DOI 10.1016/0092-8674(92)90039-F; GOODRICH JA, 1993, CELL, V75, P519, DOI 10.1016/0092-8674(93)90386-5; GOODRICH LA, 1994, CURR OPIN CELL BIOL, V6, P403, DOI 10.1016/0955-0674(94)90033-7; GROSS CA, 1992, TRANSCRIPTIONAL REGU, P129; HA I, 1993, GENE DEV, V7, P1021, DOI 10.1101/gad.7.6.1021; HERNANDEZ N, 1993, GENE DEV, V7, P1291, DOI 10.1101/gad.7.7b.1291; HOEY T, 1993, CELL, V72, P247, DOI 10.1016/0092-8674(93)90664-C; JACQ X, 1994, CELL, V79, P107, DOI 10.1016/0092-8674(94)90404-9; KWON H, 1994, J BIOL CHEM, V269, P30140; LEARNED RM, 1986, CELL, V45, P847, DOI 10.1016/0092-8674(86)90559-3; MITCHELL PJ, 1989, SCIENCE, V245, P371, DOI 10.1126/science.2667136; OBRIEN T, 1995, GENE DEV, V9, P1098, DOI 10.1101/gad.9.9.1098; RADEBAUGH CA, 1994, MOL CELL BIOL, V14, P597, DOI 10.1128/MCB.14.1.597; RUDLOFF U, 1994, EMBO J, V13, P2611, DOI 10.1002/j.1460-2075.1994.tb06551.x; RUPPERT S, IN PRESS GENES DEV; SMALE S.T., 1994, TRANSCRIPTION MECHAN, P63; TANSEY WP, 1994, GENE DEV, V8, P2756, DOI 10.1101/gad.8.22.2756; THUT CJ, 1995, SCIENCE, V267, P100, DOI 10.1126/science.7809597; TJIAN R, 1994, CELL, V77, P5, DOI 10.1016/0092-8674(94)90227-5; VERRIJZER CP, 1995, CELL, V81, P1115, DOI 10.1016/S0092-8674(05)80016-9; YOKOMORI K, 1993, GENE DEV, V7, P2235, DOI 10.1101/gad.7.11.2235; ZAWEL L, 1993, PROG NUCLEIC ACID RE, V44, P67, DOI 10.1016/S0079-6603(08)60217-2; ZOMERDIJK JCBM, 1994, SCIENCE, V266, P2015, DOI 10.1126/science.7801130	30	82	85	0	7	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	DEC 1	1995	270	5241					1506	1509		10.1126/science.270.5241.1506	http://dx.doi.org/10.1126/science.270.5241.1506			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TH375	7491500				2022-12-28	WOS:A1995TH37500043
J	LEEUW, T; FOURESTLIEUVIN, A; WU, CL; CHENEVERT, J; CLARK, K; WHITEWAY, M; THOMAS, DY; LEBERER, E				LEEUW, T; FOURESTLIEUVIN, A; WU, CL; CHENEVERT, J; CLARK, K; WHITEWAY, M; THOMAS, DY; LEBERER, E			PHEROMONE RESPONSE IN YEAST - ASSOCIATION OF BEM1P WITH PROTEINS OF THE MAP KINASE CASCADE AND ACTIN	SCIENCE			English	Article							BUD SITE SELECTION; SACCHAROMYCES-CEREVISIAE; CELLULAR MORPHOGENESIS; GENE BEM1; GROWTH; POLARITY; DICTYOSTELIUM; POLARIZATION; INTERACTS; IDENTIFY	Haploid cells of the yeast Saccharomyces cerevisiae respond to mating pheromones with polarized growth toward the mating partner. This morphological response requires the function of the cell polarity establishment protein Bem1p. Immunochemical and two-hybrid protein interaction assays revealed that Bem1p interacts with two components of the pheromone-responsive mitogen-activated protein (MAP) kinase cascade, Ste20p and Ste5p, as well as with actin. Mutants of Bem1p that are associated with defective pheromone-induced polarized morphogenesis interacted with Ste5p and actin but not with Ste20p. Thus, the association of Bem1p with Ste20p and Ste5p may contribute to the conveyance of spatial information that regulates polarized rearrangement of the actin cytoskeleton during yeast mating.	NATL RES COUNCIL CANADA,BIOTECHNOL RES INST,EUKARYOT GENET GRP,MONTREAL,PQ H4P 2R2,CANADA; UNIV CALIF SAN FRANCISCO,DEPT BIOCHEM & BIOPHYS,SAN FRANCISCO,CA 94143	National Research Council Canada; University of California System; University of California San Francisco			Fourest-Lieuvin, Anne/AGA-6504-2022; Thomas, David/M-7661-2017	Fourest-Lieuvin, Anne/0000-0003-1325-6788; Thomas, David/0000-0002-8854-762X				ABEIJON C, 1989, P NATL ACAD SCI USA, V86, P6935, DOI 10.1073/pnas.86.18.6935; ADAMS AEM, 1990, J CELL BIOL, V111, P131, DOI 10.1083/jcb.111.1.131; BENDER A, 1991, MOL CELL BIOL, V11, P1295, DOI 10.1128/MCB.11.3.1295; BOWMAN BJ, 1979, J BIOL CHEM, V254, P2928; BRAY D, 1988, ANNU REV CELL BIOL, V4, P43, DOI 10.1146/annurev.cb.04.110188.000355; CHANT J, 1991, CELL, V65, P1213, DOI 10.1016/0092-8674(91)90016-R; CHANT J, 1995, CELL, V81, P1, DOI 10.1016/0092-8674(95)90363-1; CHANT J, 1991, CELL, V65, P1203, DOI 10.1016/0092-8674(91)90015-Q; CHENEVERT J, 1994, MOL BIOL CELL, V5, P1169, DOI 10.1091/mbc.5.11.1169; CHENEVERT J, 1992, NATURE, V356, P77, DOI 10.1038/356077a0; CHENEVERT J, 1994, GENETICS, V136, P1287; CHENEVERT J, UNPUB; CHIEN CT, 1991, P NATL ACAD SCI USA, V88, P9578, DOI 10.1073/pnas.88.21.9578; CHOI KY, 1994, CELL, V78, P499; COSO OA, 1995, CELL, V81, P1137, DOI 10.1016/S0092-8674(05)80018-2; DEVREOTES PN, 1988, ANNU REV CELL BIOL, V4, P649, DOI 10.1146/annurev.cb.04.110188.003245; DOWNEY GP, 1994, CURR OPIN IMMUNOL, V6, P113, DOI 10.1016/0952-7915(94)90042-6; FIELD C, 1980, J CELL BIOL, V86, P123, DOI 10.1083/jcb.86.1.123; FIELDS S, 1989, NATURE, V340, P245, DOI 10.1038/340245a0; GERISCH G, 1987, ANNU REV BIOCHEM, V56, P853, DOI 10.1146/annurev.biochem.56.1.853; HARLOW E, 1988, ANTIBODIES LABORATOR; HERSKOWITZ I, 1995, CELL, V80, P187, DOI 10.1016/0092-8674(95)90402-6; JOHNSON DI, 1990, J CELL BIOL, V111, P143, DOI 10.1083/jcb.111.1.143; KOZMA R, 1995, MOL CELL BIOL, V15, P1942; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEBERER E, 1993, MOL GEN GENET, V241, P241, DOI 10.1007/BF00284675; LEBERER E, 1992, EMBO J, V11, P4815, DOI 10.1002/j.1460-2075.1992.tb05587.x; LEBERER E, UNPUB; LEEUW T, UNPUB; MANSER E, 1994, NATURE, V367, P40, DOI 10.1038/367040a0; MARCUS S, 1994, P NATL ACAD SCI USA, V91, P7762, DOI 10.1073/pnas.91.16.7762; MINDEN A, 1995, CELL, V81, P1147, DOI 10.1016/S0092-8674(05)80019-4; NOBES CD, 1995, CELL, V81, P53, DOI 10.1016/0092-8674(95)90370-4; PARLATI F, 1995, J BIOL CHEM, V270, P244, DOI 10.1074/jbc.270.1.244; PETERSON J, 1994, J CELL BIOL, V127, P1395, DOI 10.1083/jcb.127.5.1395; PRINTEN JA, 1994, GENETICS, V138, P609; RAMER SW, 1993, P NATL ACAD SCI USA, V90, P452, DOI 10.1073/pnas.90.2.452; REID BJ, 1977, J CELL BIOL, V75, P355, DOI 10.1083/jcb.75.2.355; RIDLEY AJ, 1992, CELL, V70, P401, DOI 10.1016/0092-8674(92)90164-8; RIDLEY AJ, 1992, CELL, V70, P389, DOI 10.1016/0092-8674(92)90163-7; RODRIGUEZBOULAN E, 1989, SCIENCE, V245, P718, DOI 10.1126/science.2672330; Rose MD., 1990, METHODS YEAST GENETI; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SEGALL JE, 1993, P NATL ACAD SCI USA, V90, P8332, DOI 10.1073/pnas.90.18.8332; SIMON MN, 1995, NATURE, V376, P702, DOI 10.1038/376702a0; SIMONS K, 1985, ANNU REV CELL BIOL, V1, P243, DOI 10.1146/annurev.cb.01.110185.001331; SLOAT BF, 1978, SCIENCE, V200, P1171, DOI 10.1126/science.349694; SLOAT BF, 1981, J CELL BIOL, V89, P395, DOI 10.1083/jcb.89.3.395; VOJTEK AB, 1993, CELL, V74, P205, DOI 10.1016/0092-8674(93)90307-C; WHITEWAY MS, 1995, SCIENCE, V269, P1572, DOI 10.1126/science.7667635; WU CL, 1995, J BIOL CHEM, V270, P15984, DOI 10.1074/jbc.270.27.15984; ZIMAN M, 1993, MOL BIOL CELL, V4, P1307, DOI 10.1091/mbc.4.12.1307	52	178	178	0	8	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	NOV 17	1995	270	5239					1210	1213		10.1126/science.270.5239.1210	http://dx.doi.org/10.1126/science.270.5239.1210			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TE905	7502048				2022-12-28	WOS:A1995TE90500060
J	COX, C; MANN, J; SUTHERLAND, W; BALL, M				COX, C; MANN, J; SUTHERLAND, W; BALL, M			INDIVIDUAL VARIATION IN PLASMA-CHOLESTEROL RESPONSE TO DIETARY SATURATED FAT	BMJ-BRITISH MEDICAL JOURNAL			English	Article							DENSITY-LIPOPROTEIN CHOLESTEROL; CORONARY HEART-DISEASE; SERUM-CHOLESTEROL; GENETIC-VARIATION; LIPID TRANSFER; RESPONSIVENESS; POPULATION; MORTALITY	Objective-To determine the extent to which plasma lipid concentrations of individuals are consistently sensitive to changes in saturated fats; to examine whether groups that consistently have large or small responses can be defined; and to identify factors which predict response of lipids to dietary change. Design-A double crossover design in which two diets (S, providing 21% energy from saturated fat, and P, providing 10%) were followed for periods of six weeks in the sequence SPSP or PSPS. Setting-67 free living subjects, total cholesterol 5.5-7.9 mmol/l. Main outcome measures-Relation of cholesterol responses to repeated dietary changes and of potential predictors and cholesterol response. Results Similar average changes in cholesterol mask a wide range of individual responses. Response was not related to compliance. In all participants the change in cholesterol observed when the nature of dietary fat was changed on the two crossovers was correlated (r=0.31, P=0.01); the degree of correlation between the two sets of responses was greater in the 46 consistent responders than in the 21 variable responders (r=0.71 v r=0.21). Mean differences in cholesterol between diet S and diet P during the two crossovers were 1.16 (SD 0.35) mmo/l and 0.95 (0.26) mmol/l for consistent hyperresponders and 0.18 (0.26) mmol/l and 0.18 (0.25) mmol/l for consistent minimal responders. in consistent responders, changes in total cholesterol in response to increasing saturated fats correlated with baseline cholesteryl ester transfer activity (r=0.32, P=0.03); total cholesterol (r=0 37, P=0.01); triglycerides (r=0.30, P=0.04); and apolipoprotein B (r=0.54, P=0.01). Conclusions-There is a degree of consistency in cholesterol response to instructions to change dietary fat which is not explained by dietary compliance, and there are groups of consistent hyperresponders and minimal responders within population of hypercholesterolaemic individuals. Several factors predicting response have been identified. These results have relevance to dietary approaches aimed at reducing the Lipoprotein mediated risk of coronary heart disease.	UNIV OTAGO, DEPT HUMAN NUTR, DUNEDIN, NEW ZEALAND; UNIV OTAGO, DEPT MED, DUNEDIN, NEW ZEALAND	University of Otago; University of Otago			Ball, Madeleine J/J-6901-2012					Abbey M., 1991, NUTR METAB CARDIOVAS, V1, P10; ASSMANN G, 1983, CLIN CHEM, V29, P2026; BERG K, 1986, CLIN GENET, V30, P515; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; BRESLOW JL, 1988, PHYSIOL REV, V68, P85, DOI 10.1152/physrev.1988.68.1.85; CASTELLI WP, 1986, JAMA-J AM MED ASSOC, V256, P2835, DOI 10.1001/jama.256.20.2835; CHANNON KM, 1990, ATHEROSCLEROSIS, V80, P217, DOI 10.1016/0021-9150(90)90029-I; CLIFTON PM, 1990, ARTERIOSCLEROSIS, V10, P394, DOI 10.1161/01.ATV.10.3.394; CLIFTON PM, 1992, ARTERIOSCLER THROMB, V12, P955, DOI 10.1161/01.ATV.12.8.955; COBB MM, 1993, METABOLISM, V42, P7, DOI 10.1016/0026-0495(93)90164-J; EDINGTON J, 1987, BMJ-BRIT MED J, V294, P333, DOI 10.1136/bmj.294.6568.333; FOLCH J, 1957, J BIOL CHEM, V226, P497; FRIEDEWALD WT, 1972, CLIN CHEM, V18, P499; GROENER JEM, 1991, ATHEROSCLEROSIS, V87, P221, DOI 10.1016/0021-9150(91)90024-W; GRUNDY SM, 1988, AM J CLIN NUTR, V47, P822, DOI 10.1093/ajcn/47.5.822; HEGSTED DM, 1965, AM J CLIN NUTR, V17, P281; JACOBS DR, 1983, ARTERIOSCLEROSIS, V3, P349, DOI 10.1161/01.ATV.3.4.349; KATAN MB, 1988, J LIPID RES, V29, P883; KATAN MB, 1986, AM J EPIDEMIOL, V123, P221, DOI 10.1093/oxfordjournals.aje.a114231; KEYS A, 1965, METABOLIS, V14, P776, DOI 10.1016/0026-0495(65)90004-1; KEYS A, 1959, CIRCULATION, V19, P201, DOI 10.1161/01.CIR.19.2.201; KEYS A, 1957, LANCET, V2, P959; LERNER DJ, 1986, AM HEART J, V111, P383, DOI 10.1016/0002-8703(86)90155-9; LEWIS B, 1986, LANCET, V1, P956; MARTIN MJ, 1986, LANCET, V2, P933; MCGILL HC, 1979, AM J CLIN NUTR, V32, P2664, DOI 10.1093/ajcn/32.12.2664; MCNAMARA DJ, 1987, J CLIN INVEST, V79, P1729, DOI 10.1172/JCI113013; MIETTINEN TA, 1988, LANCET, V2, P1261, DOI 10.1016/S0140-6736(88)90862-8; MILLIGAN C, 1991, NZ FOOD COMPOSITION; SUTHERLAND WH, 1994, CLIN CHIM ACTA, V231, P29, DOI 10.1016/0009-8981(94)90251-8; TIKKANEN MJ, 1990, ARTERIOSCLEROSIS, V10, P285, DOI 10.1161/01.ATV.10.2.285; WARNICK GR, 1979, CLIN CHEM, V25, P279; XU CF, 1990, GENET EPIDEMIOL, V7, P261, DOI 10.1002/gepi.1370070405	33	37	37	0	5	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	NOV 11	1995	311	7015					1260	1264		10.1136/bmj.311.7015.1260	http://dx.doi.org/10.1136/bmj.311.7015.1260			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TE859	7496234	Green Published			2022-12-28	WOS:A1995TE85900019
J	ZEHNDER, D; HOIGNE, R; NEFTEL, KA; SIEBER, R				ZEHNDER, D; HOIGNE, R; NEFTEL, KA; SIEBER, R			PAINFUL DYSAESTHESIA WITH CIPROFLOXACIN	BRITISH MEDICAL JOURNAL			English	Letter													Zehnder, Daniel/B-2519-2010					AOUN M, 1992, LANCET, V340, P127, DOI 10.1016/0140-6736(92)90460-K; DAVIS H, 1989, ANN INTERN MED, V111, P1041, DOI 10.7326/0003-4819-111-12-1041; WOLFSON JS, 1991, AM J MED S6A, V91, P153	3	3	3	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	NOV 4	1995	311	7014					1204	1204		10.1136/bmj.311.7014.1204a	http://dx.doi.org/10.1136/bmj.311.7014.1204a			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TD768	7488901	Green Published			2022-12-28	WOS:A1995TD76800022
J	STENMAN, UH; HAKAMA, M; KNEKT, P; AROMAA, A; TEPPO, L; LEINONEN, J				STENMAN, UH; HAKAMA, M; KNEKT, P; AROMAA, A; TEPPO, L; LEINONEN, J			SERUM CONCENTRATIONS OF PROSTATE-SPECIFIC ANTIGEN AND ITS COMPLEX WITH ALPHA(1)-ANTICHYMOTRYPSIN BEFORE DIAGNOSIS OF PROSTATE-CANCER	LANCET			English	Article							SCREENING-TEST; ALPHA-1-ANTICHYMOTRYPSIN; ASSAY; MEN	Prostate cancer can be detected at an early, potentially curable stage by screening based on digital rectal examination and serum prostate specific antigen (PSA). The value of screening appears doubtful, based on high 10-year survival rates in selected cases of early prostate cancer, but this follow-up time may be insufficient. By linking the information on 21172 men who took part in a screening examination in Finland, 1968-73, with data from the Finnish Cancer Registry, 44 cases of prostate cancer diagnosed up to 1980 were identified. Serum samples from cancer cases and from 74 controls matched for age and time of sampling were assayed for PSA and its complex with alpha(1)-antichymotrypsin (PSA-ACT). With a cut-off for PSA of 2.5 mu g/L giving 92% specificity, 95% of the cancers developing within the first 5 years, and 52% developing in 6-10 years tested positive. As a potential screening test with a 5-year interval for men under 65, the sensitivity would be 92% and specificity 97%. The ratio of PSA-ACT to total PSA was lower in controls than in patients wih cancer. Using this ratio, we could eliminate half of the false-positive results in the range 2.5-25 mu g/L without loss of sensitivity. Cancer was typically diagnosed 5-10 years after PSA exceeded 2.5 mu g/L, and the median survival after diagnosis was 3.6 years. 10-year survivat after drawing the sample was 71% in cancer cases with a PSA concentration less than 4 mu g/L and 48% in those with higher concentrations. The corresponding figures at 15 years were 53% and 27%, and at 20 years 43% and 18%, respectively. These results suggest it is advisable to confine screening for prostate cancer to men with a life expectancy of clearly more than 10 years-ie, younger men, who have the greatest chance to benefit from early detection.	UNIV TAMPERE,DEPT PUBL HLTH,TAMPERE,FINLAND; SOCIAL INSURANCE INST,RES & DEV UNIT,HELSINKI,FINLAND; FINNISH CANC REGISTRY,HELSINKI,FINLAND	Tampere University; Finnish Cancer Registry	STENMAN, UH (corresponding author), HELSINKI UNIV HOSP,DEPT CLIN CHEM,HAARTMANINKATU 2,SF-00290 HELSINKI,FINLAND.							ADAMI HO, 1994, LANCET, V343, P958, DOI 10.1016/S0140-6736(94)90071-X; AUS G, 1994, J UROLOGY, V151, P278; BABAIAN RJ, 1990, J CLIN LAB ANAL, V4, P135, DOI 10.1002/jcla.1860040212; BRAWER MK, 1992, J UROLOGY, V147, P841, DOI 10.1016/S0022-5347(17)37401-3; CARTER HB, 1992, CANCER RES, V52, P3323; CATALONA WJ, 1991, NEW ENGL J MED, V324, P1156, DOI 10.1056/NEJM199104253241702; CHADWICK DJ, 1991, LANCET, V338, P613; CHODAK GW, 1994, NEW ENGL J MED, V330, P242, DOI 10.1056/NEJM199401273300403; CHRISTENSSON A, 1993, J UROLOGY, V150, P100, DOI 10.1016/S0022-5347(17)35408-3; COLBERG JW, 1993, J UROLOGY, V149, P507, DOI 10.1016/S0022-5347(17)36130-X; FELDMANN U, 1981, J CLIN CHEM CLIN BIO, V19, P121; FRANKS LM, 1954, J PATHOL BACTERIOL, V68, P603, DOI 10.1002/path.1700680233; KABALIN JN, 1989, J UROLOGY, V141, P1091, DOI 10.1016/S0022-5347(17)41178-5; KALBFLEISCH JD, 1980, STATISTICAL ANAL FAI; Knekt P, 1988, PUBLICATIONS SOCIAL, V83, P1; LABRIE F, 1993, CLIN INVEST MED, V16, P425; LABRIE F, 1992, J UROLOGY, V147, P846, DOI 10.1016/S0022-5347(17)37402-5; LEINONEN J, 1993, CLIN CHEM, V39, P2098; LILJA H, 1991, CLIN CHEM, V37, P1618; METTLIN C, 1993, CANCER, V72, P1050, DOI 10.1002/1097-0142(19930801)72:3+<1050::AID-CNCR2820721318>3.0.CO;2-J; METTLIN C, 1993, CANCER, V72, P1701, DOI 10.1002/1097-0142(19930901)72:5<1701::AID-CNCR2820720534>3.0.CO;2-E; MILLER AB, 1991, CANCER SCREENING, P289; OESTERLING JE, 1993, JAMA-J AM MED ASSOC, V269, P57; PARTIN AW, 1993, UROL CLIN N AM, V20, P713; SCHMID HP, 1993, EUR UROL, V2, P60; SCHRODER FH, 1993, BRIT MED J, V306, P407, DOI 10.1136/bmj.306.6875.407; STAMEY TA, 1987, NEW ENGL J MED, V317, P909, DOI 10.1056/NEJM198710083171501; STENMAN UH, 1991, CANCER RES, V51, P222; STENMAN UH, 1990, J NUCL MED ALLIED S3, V34, P249; TEPPO L, 1994, ACTA ONCOL, V33, P365, DOI 10.3109/02841869409098430; ZWEIG MH, 1993, CLIN CHEM, V39, P561	31	218	222	0	6	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	DEC 10	1994	344	8937					1594	1598		10.1016/S0140-6736(94)90405-7	http://dx.doi.org/10.1016/S0140-6736(94)90405-7			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PW051	7527116				2022-12-28	WOS:A1994PW05100008
J	BURTON, JL				BURTON, JL			KERATIN GENES AND EPIDERMOLYTIC HYPERKERATOSIS	LANCET			English	Editorial Material							ICHTHYOSIS BULLOSA; SIEMENS; DIFFERENTIATION				BURTON, JL (corresponding author), BRISTOL ROYAL INFIRM & GEN HOSP,DEPT DERMATOL,BRISTOL,AVON,ENGLAND.							CHENG J, 1992, CELL, V70, P811, DOI 10.1016/0092-8674(92)90314-3; COLLIN C, 1992, EXP CELL RES, V202, P132, DOI 10.1016/0014-4827(92)90412-2; KREMER H, 1994, J INVEST DERMATOL, V103, P286, DOI 10.1111/1523-1747.ep12394414; LANE EB, 1994, CURR OPIN GENET DEV, V4, P412, DOI 10.1016/0959-437X(94)90030-2; LEIGH IM, 1993, ARCH DERMATOL, V129, P1571, DOI 10.1001/archderm.129.12.1571; MCLEAN WHI, 1994, J INVEST DERMATOL, V103, P277, DOI 10.1111/1523-1747.ep12394307; MURDOCH ME, 1990, CLIN EXP DERMATOL, V15, P53, DOI 10.1111/j.1365-2230.1990.tb02021.x; REIS A, 1994, NAT GENET, V6, P174, DOI 10.1038/ng0294-174; ROTHNAGEL JA, 1994, NAT GENET, V7, P485, DOI 10.1038/ng0894-485; STEIJLEN PM, 1990, ARCH DERMATOL RES, V282, P1, DOI 10.1007/BF00505636; STEIJLEN PM, 1994, J INVEST DERMATOL, V103, P282, DOI 10.1111/1523-1747.ep12394335; TRAUPE H, 1986, J AM ACAD DERMATOL, V14, P1000, DOI 10.1016/S0190-9622(86)70123-0; VAKILZADEH F, 1991, BRIT J DERMATOL, V124, P191, DOI 10.1111/j.1365-2133.1991.tb00432.x; 1993, LANCET, V339, P29	14	5	5	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	OCT 22	1994	344	8930					1103	1104		10.1016/S0140-6736(94)90626-2	http://dx.doi.org/10.1016/S0140-6736(94)90626-2			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PN066	7523811				2022-12-28	WOS:A1994PN06600005
J	KLOC, M; ETKIN, LD				KLOC, M; ETKIN, LD			DELOCALIZATION OF VG1 MESSENGER-RNA FROM THE VEGETAL CORTEX IN XENOPUS-OOCYTES AFTER DESTRUCTION OF XLSIRT RNA	SCIENCE			English	Article							MATERNAL MESSENGER-RNA; CELL-FORMATION; LAEVIS; ABLATION; PROTEIN; EMBRYOS; NANOS; XLGV7; OSKAR; EGGS	The Xlsirts are a family of transcribed repeat sequence genes that do not code for protein. Xlsirt RNAs become localized to the vegetal cortex of Xenopus oocytes early in oogenesis, before the localization of the messenger RNA Vg1, which encodes a transforming growth factor-beta-like molecule involved in mesoderm formation, and coincident with the localization of Xcat2 transcripts, which encode a nanos-like molecule. Destruction of the localized Xlsirts by injection of antisense oligodeoxynucleotides into stage 4 oocytes resulted in the release of Vg1 transcripts but not Xcat2 transcripts from the vegetal cortex. Xlsirt RNAs, which may be a structural component of the vegetal cortex, are a crucial part of a genetic pathway necessary for the proper localization of Vg1 that leads to subsequent normal pattern formation.	UNIV TEXAS, MD ANDERSON CANC CTR, DEPT MOLEC GENET, HOUSTON, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center			Kloc, Malgorzata/AAF-6982-2020					DING D, 1993, BIOESSAYS, V15, P651, DOI 10.1002/bies.950151004; DUMONT JN, 1972, J MORPHOL, V136, P153, DOI 10.1002/jmor.1051360203; EPHRUSSI A, 1992, NATURE, V358, P387, DOI 10.1038/358387a0; HARLAND RM, 1991, METHOD CELL BIOL, V36, P685; King Jr Martin Luther, COMMUNICATION; KLOC M, 1989, DEVELOPMENT, V107, P899; KLOC M, 1993, SCIENCE, V262, P1712, DOI 10.1126/science.7505061; KLOC M, UNPUB; MILLER M, 1989, GENE DEV, V3, P572, DOI 10.1101/gad.3.4.572; MORGAN R, 1993, NUCLEIC ACIDS RES, V21, P4615, DOI 10.1093/nar/21.19.4615; MOSQUERA L, 1993, DEVELOPMENT, V117, P377; REBAGLIATI MR, 1985, CELL, V42, P769, DOI 10.1016/0092-8674(85)90273-9; SMITH JL, 1992, CELL, V70, P849, DOI 10.1016/0092-8674(92)90318-7; SMITH RC, 1990, DEVELOPMENT, V110, P769; THOMSEN GH, 1993, CELL, V74, P433, DOI 10.1016/0092-8674(93)80045-G; WEEKS DL, 1987, CELL, V51, P861, DOI 10.1016/0092-8674(87)90109-7; YISRAELI JK, 1990, DEVELOPMENT, V108, P289	17	128	131	0	3	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	AUG 19	1994	265	5175					1101	1103		10.1126/science.7520603	http://dx.doi.org/10.1126/science.7520603			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PC539	7520603				2022-12-28	WOS:A1994PC53900039
J	OPAL, SM; PALARDY, JE; MARRA, MN; FISHER, CJ; MCKELLIGON, BM; SCOTT, RW				OPAL, SM; PALARDY, JE; MARRA, MN; FISHER, CJ; MCKELLIGON, BM; SCOTT, RW			RELATIVE CONCENTRATIONS OF ENDOTOXIN-BINDING PROTEINS IN BODY-FLUIDS DURING INFECTION	LANCET			English	Article							PERMEABILITY-INCREASING PROTEIN; GRAM-NEGATIVE BACTERIA; LIPOPOLYSACCHARIDE; SEPSIS; DISEASE; MECHANISMS; LPS	Endotoxin initiates the systemic inflammatory response, haemodynamic changes, and multi-organ failure that may occur as a consequence of systemic gram-negative bacterial infection. The serum protein lipopolysaccharide-binding protein (LBP) binds to the lipid A component of bacterial endotoxin and facilitates its delivery to the CD14 antigen on the macrophage, where proinflammatory cytokines are released and a cascade of host mediators is initiated. The neutrophil granular protein bactericidal/permeability-increasing protein (BPI) competes with LBP for endotoxin binding and functions as a molecular antagonist of LBP-endotoxin interactions. We have measured concentrations of both proteins in body fluids from 49 consecutive patients. In 16 of 17 samples of fluid from closed-space infections, BPI was present in greater concentration than LBP (median BPI/LBP ratio 7.6 [95% CI 2.32-22.1]), The ratio of BPI and LBP was not significantly different from 1.0 in abdominal fluid from 10 patients with peritonitis (ratio 0.235 [0.18-0.47]), whereas the BPI/LBP ratio was low in 22 non-infected body fluids (0.01 [0.001-0.04]) and concentrations of both proteins approached those in normal human plasma. BPI concentrations were directly correlated with the quantity of neutrophils within clinical samples (r(s) = 0.81, p < 0.0001). Thus, within abscess cavities BPI is available in sufficient quantities for effective competition with LBP for endotoxin. BPI may attenuate the local inflammatory response and the systemic toxicity of endotoxin release during gram-negative infections.	BROWN UNIV,SCH MED,PAWTUCKET,RI; INCYTE PHARMACEUT,PALO ALTO,CA; CLEVELAND CLIN FDN,CLEVELAND,OH	Brown University; Incyte; Cleveland Clinic Foundation	OPAL, SM (corresponding author), MEM HOSP RHODE ISL,DIV INFECT DIS,111 BREWSTER ST,PAWTUCKET,RI 02860, USA.							BONE RC, 1991, ANN INTERN MED, V115, P457, DOI 10.7326/0003-4819-115-6-457; BRANDTZAEG P, 1989, J INFECT DIS, V159, P195, DOI 10.1093/infdis/159.2.195; CASEY LC, 1993, ANN INTERN MED, V119, P771, DOI 10.7326/0003-4819-119-8-199310150-00001; CROSS AS, 1993, J INFECT DIS, V167, P112, DOI 10.1093/infdis/167.1.112; FISHER CJ, 1994, CRIT CARE MED, V22, P553, DOI 10.1097/00003246-199404000-00008; GAZZANOSANTORO H, 1994, INFECT IMMUN, V62, P1185, DOI 10.1128/IAI.62.4.1185-1191.1994; GRAY PW, 1989, J BIOL CHEM, V264, P9595; HEUMANN D, 1993, J INFECT DIS, V167, P1351, DOI 10.1093/infdis/167.6.1351; HOESS A, 1993, EMBO J, V12, P3351, DOI 10.1002/j.1460-2075.1993.tb06008.x; MARRA MN, 1992, J IMMUNOL, V148, P532; MARRA MN, 1990, J IMMUNOL, V144, P622; MORRISON DC, 1987, ANNU REV MED, V38, P417, DOI 10.1146/annurev.me.38.020187.002221; OPAL SM, 1991, CLIN RES, V30, pA451; PARRILLO JE, 1993, NEW ENGL J MED, V328, P1471, DOI 10.1056/nejm199305203282008; RIVEAU GR, 1987, J CLIN MICROBIOL, V25, P889, DOI 10.1128/JCM.25.5.889-892.1987; SCHUMANN RR, 1990, SCIENCE, V249, P1429, DOI 10.1126/science.2402637; TOBIAS PS, 1988, J BIOL CHEM, V263, P13479; WEISS J, 1980, J CLIN INVEST, V65, P619, DOI 10.1172/JCI109707; WEISS J, 1992, J CLIN INVEST, V90, P1122, DOI 10.1172/JCI115930; WEISS J, 1978, J BIOL CHEM, V253, P2664; WILDE CG, IN PRESS J BIOL CHEM; WRIGHT SD, 1990, SCIENCE, V249, P1431, DOI 10.1126/science.1698311	22	77	78	0	2	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	AUG 13	1994	344	8920					429	431		10.1016/S0140-6736(94)91767-1	http://dx.doi.org/10.1016/S0140-6736(94)91767-1			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PB761	7520106				2022-12-28	WOS:A1994PB76100007
J	WANG, TW; DONAHOE, PK; ZERVOS, AS				WANG, TW; DONAHOE, PK; ZERVOS, AS			SPECIFIC INTERACTION OF TYPE-I RECEPTORS OF THE TGF-BETA FAMILY WITH THE IMMUNOPHILIN FKBP-12	SCIENCE			English	Article							TRANSMEMBRANE SERINE KINASE; GROWTH-FACTOR-BETA; PROTEIN-KINASE; THREONINE KINASE; ACTIVIN; COMPLEX; EXPRESSION; CLONING	Transforming growth factor-beta (TGF-beta) family members bind to receptors that consist of heteromeric serine-threonine kinase subunits (type I and type II). In a yeast genetic screen, the immunophilin FKBP-12, a target of the macrolides FK506 and rapamycin, interacted with the type I receptor for TGF-beta and with other type I receptors. Deletion, point mutation, and co-immunoprecipitation studies further demonstrated the specificity of the interaction. Excess FK506 competed with type I receptors for binding to FKBP-12, which suggests that these receptors share or overlap the macrolide binding site on FKBP-12, and therefore they may represent its natural ligand. The specific interaction between the type I receptors and FKBP-12 suggests that FKBP-12 may play a role in type I receptor-mediated signaling.	MASSACHUSETTS GEN HOSP,CUTANEOUS BIOL RES CTR,BOSTON,MA 02129; MASSACHUSETTS GEN HOSP,CUTANEOUS BIOL RES CTR,BOSTON,MA 02114; MASSACHUSETTS GEN HOSP,PEDIAT SURG RES LAB,BOSTON,MA 02114	Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital					EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [P30HD028138] Funding Source: NIH RePORTER; NATIONAL CANCER INSTITUTE [R01CA017393] Funding Source: NIH RePORTER; NCI NIH HHS [CA17393] Funding Source: Medline; NICHD NIH HHS [NICHD P-30 HD28138, NICHD P-32 HD07396] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		ATTISANO L, 1993, CELL, V75, P671, DOI 10.1016/0092-8674(93)90488-C; BASSING CH, 1994, SCIENCE, V263, P87, DOI 10.1126/science.8272871; CHEN RH, 1993, SCIENCE, V260, P1335, DOI 10.1126/science.8388126; EBNER R, 1993, SCIENCE, V262, P900, DOI 10.1126/science.8235612; FIELDS S, 1989, NATURE, V340, P245, DOI 10.1038/340245a0; FRAZEN P, 1993, CELL, V75, P681; GEORGI LL, 1990, CELL, V61, P635, DOI 10.1016/0092-8674(90)90475-T; GYURIS J, 1993, CELL, V75, P791, DOI 10.1016/0092-8674(93)90498-F; HE WW, 1993, DEV DYNAM, V196, P133, DOI 10.1002/aja.1001960207; Lin Herbert Y., 1993, Trends in Cell Biology, V3, P14, DOI 10.1016/0962-8924(93)90195-7; LIN HY, 1992, CELL, V68, P1; MATHEWS LS, 1991, CELL, V65, P973, DOI 10.1016/0092-8674(91)90549-E; MATSUZAKI K, 1993, J BIOL CHEM, V268, P12719; TENDIJKE P, 1994, SCIENCE, V264, P101, DOI 10.1126/science.8140412; TSUCHIDA K, 1993, P NATL ACAD SCI USA, V90, P11242, DOI 10.1073/pnas.90.23.11242; VANDUYNE GD, 1991, J AM CHEM SOC, V113, P7433, DOI 10.1021/ja00019a057; WANG TW, UNPUB; WITTENBERG C, 1988, CELL, V54, P1061, DOI 10.1016/0092-8674(88)90121-3; WRANA JL, 1992, CELL, V71, P1003, DOI 10.1016/0092-8674(92)90395-S; YAMAZAKI Y, 1993, DNA SEQUENCE, V3, P297; ZERVOS AS, 1993, CELL, V72, P223, DOI 10.1016/0092-8674(93)90662-A	21	308	336	1	6	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUL 29	1994	265	5172					674	676		10.1126/science.7518616	http://dx.doi.org/10.1126/science.7518616			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	NZ538	7518616				2022-12-28	WOS:A1994NZ53800037
J	ZUCKERMAN, J; CLEWLEY, G; GRIFFITHS, P; COCKCROFT, A				ZUCKERMAN, J; CLEWLEY, G; GRIFFITHS, P; COCKCROFT, A			PREVALENCE OF HEPATITIS-C ANTIBODIES IN CLINICAL HEALTH-CARE WORKERS	LANCET			English	Article							VIRUS-INFECTION; NEEDLESTICK INJURY; HCV; BLOOD; RISK	Health-care workers are known to be at risk from occupational transmission of blood-borne viruses, including hepatitis C. There may be serious implications following infection with hepatitis C including possible transmission to patients. We determined the prevalence of hepatitis C virus (HCV) antibodies among health-care workers at risk of occupational contact with blood and body fluids and among source patients in reported blood-exposure incidents. Anonymised stored blood samples from health-care workers immunised against hepatitis B virus since 1991 (n=1053) and blood samples from source patients in needlestick injuries (retrospective and prospective) since 1989 (n=373) were analysed. 3 (0.28%) of the serum samples from health-care workers were found to be anti-HCV-positive. 17 (8.5%) of 200 source patients tested retrospectively between January 1989 and January 1992, and 24 (13.9%) of 173 source patients tested prospectively between January 1992 and June 1993 were anti-HCV-positive. During the second period, 15 (10.6%) of 142 source patients tested for human immunodeficiency virus (HIV) were positive and 7 (3.8%) of 184 source patients tested for hepatitis B surface antigen were positive. 6 of 24 (25%) HCV-infected patients were diagnosed only after the incident; for hepatitis B, 2 (33%) of patients were diagnosed after the incident, and for HIV all patients were previously diagnosed. The seroprevalence of HCV among these health-care workers is no higher than that reported in blood donors. This suggests that there has not been significant occupational transmission of HCV to these health-care workers despite the high prevalence of HCV (often covert) among source patients in reported blood exposure in the same hospital.	ROYAL FREE NHS TRUST,OCCUPAT HLTH UNIT,LONDON,ENGLAND; ROYAL FREE NHS TRUST,DEPT VIROL,DIV COMMUNICABLE DIS,LONDON,ENGLAND; ROYAL FREE HOSP,SCH MED,LONDON,ENGLAND	University of London; University College London; University of London; University College London; University of London; University College London; Royal Free London NHS Foundation Trust; UCL Medical School								CARIANI E, 1991, LANCET, V337, P850, DOI 10.1016/0140-6736(91)92555-G; COCKCROFT A, 1990, BRIT J IND MED, V47, P199; DUSHEIKO GM, 1990, LANCET, V336, P503, DOI 10.1016/0140-6736(90)92049-N; GARSON JA, 1991, LANCET, V335, P1419; HERBERT AM, 1992, LANCET, V339, P304; JOCHEN ABB, 1992, LANCET, V339, P304, DOI 10.1016/0140-6736(92)91373-G; KIYOSAWA K, 1991, ANN INTERN MED, V115, P367, DOI 10.7326/0003-4819-115-5-367; KLEIN RS, 1991, LANCET, V338, P1539, DOI 10.1016/0140-6736(91)92369-D; MACLENNAN S, 1992, LANCET, V339, P131, DOI 10.1016/0140-6736(92)91048-D; MITSUI T, 1992, HEPATOLOGY, V16, P1109, DOI 10.1002/hep.1840160502; OAKLEY K, 1992, BRIT MED J, V304, P949, DOI 10.1136/bmj.304.6832.949; RYAN KE, 1994, BRIT MED J, V308, P696, DOI 10.1136/bmj.308.6930.696; SCHLIPKOTER U, 1990, SCAND J INFECT DIS, V22, P757, DOI 10.3109/00365549009027136; SEEFF LB, 1991, ANN INTERN MED, V115, P411, DOI 10.7326/0003-4819-115-5-411_1; VAGLIA A, 1990, LANCET, V336, P1315, DOI 10.1016/0140-6736(90)92997-V; WEST DJ, 1984, AM J MED SCI, V287, P26, DOI 10.1097/00000441-198403000-00006; 1988, MMWR-MORBID MORTAL W, V37, P377; 1993, COMMUNICAB DIS REP, V3, pR135	18	100	102	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUN 25	1994	343	8913					1618	1620		10.1016/S0140-6736(94)93064-3	http://dx.doi.org/10.1016/S0140-6736(94)93064-3			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NU354	7516460				2022-12-28	WOS:A1994NU35400017
J	MULKEY, RM; ENDO, S; SHENOLIKAR, S; MALENKA, RC				MULKEY, RM; ENDO, S; SHENOLIKAR, S; MALENKA, RC			INVOLVEMENT OF A CALCINEURIN/INHIBITOR-1 PHOSPHATASE CASCADE IN HIPPOCAMPAL LONG-TERM DEPRESSION	NATURE			English	Article							PROTEIN PHOSPHATASES; AREA CA1; PHOSPHORYLATION; IDENTIFICATION; MEMORY	LONG-TERM potentiation (LTP) is a synaptic mechanism thought to be involved in learning and memory(1). Long-term depression (LTD), an activity-dependent decrease in synaptic efficacy, may be an equally important mechanism which permits neural networks to store information more effectively(2,3). One form of LTD that has been observed in the hippocampus(4) requires activation of postsynaptic NMDA (N-methyl-D-aspartate) receptors(4,5), a change in postsynaptic calcium concentration(5), and activation of postsynaptic serine/threonine protein phosphatase 1 (PP1) or 2A (PP2A)(6). The mechanism by which PP1 or PP2A is regulated by synaptic activity is unclear because these protein phosphatases are not directly influenced by calcium concentration. LTD induction may require activation of a more complex protein phosphatase cascade consisting of the Ca2+/calmodulin-dependent protein phosphatase, calcineurin, its phosphoprotein substrate, inhibitor-1, and PP1(7,8). We tested this hypothesis using calcineurin inhibitors as well as different forms of inhibitor-1 loaded into postsynaptic cells. Our results suggest a signalling pathway in which calcineurin dephosphorylates and inactivates inhibitor-1. This in turn increases PP1 activity and contributes to the generation of LTD.	UNIV CALIF SAN FRANCISCO, DEPT PSYCHIAT, SAN FRANCISCO, CA 94143 USA; UNIV CALIF SAN FRANCISCO, DEPT PHYSIOL, SAN FRANCISCO, CA 94143 USA; DUKE UNIV, MED CTR, DEPT PHARMACOL, DURHAM, NC 27710 USA	University of California System; University of California San Francisco; University of California System; University of California San Francisco; Duke University								BLISS TVP, 1993, NATURE, V361, P31, DOI 10.1038/361031a0; COHEN P, 1988, PROC R SOC SER B-BIO, V234, P115, DOI 10.1098/rspb.1988.0040; Cohen P, 1988, CALMODULIN; DOSEMECI A, 1993, J NEUROCHEM, V61, P550; DUDEK SM, 1992, P NATL ACAD SCI USA, V89, P4363, DOI 10.1073/pnas.89.10.4363; GRATECOS D, 1974, BIOCHEM BIOPH RES CO, V58, P960, DOI 10.1016/S0006-291X(74)80237-8; HASHIMOTO Y, 1990, J BIOL CHEM, V265, P1924; KUNZ J, 1993, TRENDS BIOCHEM SCI, V18, P334, DOI 10.1016/0968-0004(93)90069-Y; LISMAN J, 1989, P NATL ACAD SCI USA, V86, P9574, DOI 10.1073/pnas.86.23.9574; MULKEY RM, 1992, NEURON, V9, P967, DOI 10.1016/0896-6273(92)90248-C; MULKEY RM, 1993, SCIENCE, V261, P1051, DOI 10.1126/science.8394601; SEJNOWSKI TJ, 1977, J MATH BIOL, V4, P303, DOI 10.1007/BF00275079; SHENOLIKAR S, 1984, METHOD ENZYMOL, V107, P102; SHENOLIKAR S, 1991, ADV SEC MESS PHOSPH, V23, P1; SHIELDS SM, 1985, J NEUROSCI, V5, P3414; Stemmer P, 1991, Curr Opin Neurobiol, V1, P53, DOI 10.1016/0959-4388(91)90010-5; Willshaw D, 1990, NEURAL COMPUT, V2, P85, DOI 10.1162/neco.1990.2.1.85	17	874	897	0	23	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JUN 9	1994	369	6480					486	488		10.1038/369486a0	http://dx.doi.org/10.1038/369486a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	NQ286	7515479				2022-12-28	WOS:A1994NQ28600057
J	BOWCOCK, AM; RUIZLINARES, A; TOMFOHRDE, J; MINCH, E; KIDD, JR; CAVALLISFORZA, LL				BOWCOCK, AM; RUIZLINARES, A; TOMFOHRDE, J; MINCH, E; KIDD, JR; CAVALLISFORZA, LL			HIGH-RESOLUTION OF HUMAN EVOLUTIONARY TREES WITH POLYMORPHIC MICROSATELLITES	NATURE			English	Article							MITOCHONDRIAL-DNA; POPULATIONS; PERSISTENCE; LOCI	GENETIC variation at hypervariable loci is being used extensively for linkage analysis1 and individual identification2, and may be useful for inter-population studies2-5. Here we show that polymorphic microsatellites (primarily CA repeats) allow trees of human individuals to be constructed that reflect their geographic origin with remarkable accuracy. This is achieved by the analysis of a large number of loci for each individual, in spite of the small variations in allele frequencies existing between populations6,7. Reliable evolutionary relationships could also be established in comparisons among human populations but not among great ape species, probably because of constraints on allele length variation. Among human populations, diversity of microsatellites is highest in Africa, which is in contrast to other nuclear markers and supports the hypothesis of an African origin for humans.	STANFORD UNIV, DEPT GENET, STANFORD, CA 94305 USA; YALE UNIV, SCH MED, DEPT GENET, NEW HAVEN, CT 06510 USA	Stanford University; Yale University	BOWCOCK, AM (corresponding author), UNIV TEXAS, SW MED CTR, DEPT PEDIAT, 5323 HARRY HINES BLVD, DALLAS, TX 75235 USA.		Klein, Richard G/B-5910-2009; Ruiz-Linares, Andres/AAR-1104-2021	Ruiz-Linares, Andres/0000-0001-8372-1011; Bowcock, Anne/0000-0001-8691-9090				BARBUJANI G, 1990, P NATL ACAD SCI USA, V87, P1816, DOI 10.1073/pnas.87.5.1816; BOWCOCK A, 1993, GENOMICS, V15, P376, DOI 10.1006/geno.1993.1071; Bowcock A M, 1991, Gene Geogr, V5, P151; BOWCOCK AM, 1991, P NATL ACAD SCI USA, V88, P839, DOI 10.1073/pnas.88.3.839; CANN RL, 1987, NATURE, V325, P31, DOI 10.1038/325031a0; CAVALLISFORZA LL, 1993, SCIENCE, V259, P639, DOI 10.1126/science.8430313; CAVALLISFORZA LL, 1988, P NATL ACAD SCI USA, V85, P6002, DOI 10.1073/pnas.85.16.6002; CAVALLISFORZA LL, 1967, EVOLUTION, V21, P550, DOI 10.1111/j.1558-5646.1967.tb03411.x; CAVALLISFORZA LL, IN PRESS HIST GEOGRA; CHAKRABORTY R, 1992, AM J HUM BIOL, V4, P387, DOI 10.1002/ajhb.1310040315; EDWARDS A, 1992, GENOMICS, V12, P241, DOI 10.1016/0888-7543(92)90371-X; Felsenstein J., 1993, PHYLIP PHYLOGENY INF; GILBERT DA, 1990, NATURE, V344, P764, DOI 10.1038/344764a0; HORAI S, 1993, MOL BIOL EVOL, V10, P23; Lewontin R.C., 1972, EVOL BIOL, P381, DOI [10.1007/978-1-4684-9063-3_14, DOI 10.1007/978-1-4684-9063-3_14]; MITTON JB, 1977, AM NAT, V111, P203, DOI 10.1086/283155; NEI M, 1993, MOL BIOL EVOL, V10, P927; NEI M, 1972, SCIENCE, V177, P434, DOI 10.1126/science.177.4047.434; Pena Sergio D. J., 1993, DNA FINGERPRINTING S; SAITOU N, 1987, MOL BIOL EVOL, V4, P406, DOI 10.1093/oxfordjournals.molbev.a040454; SMOUSE PE, 1982, AM NAT, V119, P445, DOI 10.1086/283925; TACHIDA H, 1992, GENETICS, V131, P471; TEMPLETON AR, 1993, AM ANTHROPOL, V95, P51, DOI 10.1525/aa.1993.95.1.02a00030; VIGILANT L, 1991, SCIENCE, V253, P1503, DOI 10.1126/science.1840702; WALSH JB, 1987, GENETICS, V115, P553; WEISSENBACH J, 1992, NATURE, V359, P794, DOI 10.1038/359794a0; ZEI G, 1993, ANN HUM GENET, V57, P123, DOI 10.1111/j.1469-1809.1993.tb00894.x; [No title captured]	28	1506	1559	2	119	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	MAR 31	1994	368	6470					455	457		10.1038/368455a0	http://dx.doi.org/10.1038/368455a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ND120	7510853				2022-12-28	WOS:A1994ND12000063
J	MONCADA, S; HIGGS, A				MONCADA, S; HIGGS, A			MECHANISMS OF DISEASE - THE L-ARGININE NITRIC-OXIDE PATHWAY	NEW ENGLAND JOURNAL OF MEDICINE			English	Review							LONG-TERM POTENTIATION; ENDOTHELIUM-DEPENDENT VASODILATION; NEURONAL NADPH DIAPHORASE; CAVERNOSUM SMOOTH-MUSCLE; CENTRAL-NERVOUS-SYSTEM; CORPUS CAVERNOSUM; INTERCELLULAR MESSENGER; TRANSDUCTION MECHANISM; INDUCED HYPOTENSION; GUANYLATE-CYCLASE				MONCADA, S (corresponding author), WELLCOME RES LABS, LANGLEY CT, S EDEN PK RD, BECKENHAM BR3 3BS, KENT, ENGLAND.							ALBINA JE, 1991, J IMMUNOL, V147, P144; BAYLIS C, 1992, J CLIN INVEST, V90, P278, DOI 10.1172/JCI115849; BECKMAN JS, 1990, P NATL ACAD SCI USA, V87, P1620, DOI 10.1073/pnas.87.4.1620; BELVISI MG, 1992, EUR J PHARMACOL, V210, P221, DOI 10.1016/0014-2999(92)90676-U; BOHME GA, 1991, EUR J PHARMACOL, V199, P379, DOI 10.1016/0014-2999(91)90505-K; BORLAND CDR, 1989, EUR RESPIR J, V2, P56; BREDT DS, 1990, NATURE, V347, P768, DOI 10.1038/347768a0; BREDT DS, 1991, NATURE, V351, P714, DOI 10.1038/351714a0; BREER H, 1993, TRENDS NEUROSCI, V16, P5, DOI 10.1016/0166-2236(93)90040-S; BUCKBERG GD, 1992, BIOL NITRIC OXIDE, V1, P52; BURLEIGH DE, 1992, GASTROENTEROLOGY, V102, P679, DOI 10.1016/0016-5085(92)90120-N; BURNETT AL, 1992, SCIENCE, V257, P401, DOI 10.1126/science.1378650; CACHOFEIRO V, 1992, HYPERTENSION, V19, P138, DOI 10.1161/01.HYP.19.2.138; CALVER A, 1992, J HYPERTENS, V10, P1025; CELERMAJER DS, 1992, LANCET, V340, P1111, DOI 10.1016/0140-6736(92)93147-F; CHAPMAN PF, 1992, NEUROREPORT, V3, P567, DOI 10.1097/00001756-199207000-00005; CHEN PY, 1991, J CLIN INVEST, V88, P1559, DOI 10.1172/JCI115467; CHO HJ, 1992, J EXP MED, V176, P599, DOI 10.1084/jem.176.2.599; COLLINGRIDGE GL, 1983, J PHYSIOL-LONDON, V334, P33, DOI 10.1113/jphysiol.1983.sp014478; COOKE JP, 1992, CURR OPIN CARDIOL, V7, P799, DOI 10.1097/00001573-199210000-00013; COX DA, 1989, CIRCULATION, V80, P458, DOI 10.1161/01.CIR.80.3.458; CREAGER MA, 1992, J CLIN INVEST, V90, P1248, DOI 10.1172/JCI115987; DAWSON TM, 1991, P NATL ACAD SCI USA, V88, P7797, DOI 10.1073/pnas.88.17.7797; DAWSON VL, 1991, P NATL ACAD SCI USA, V88, P6368, DOI 10.1073/pnas.88.14.6368; DEBELDER AJ, 1993, LANCET, V341, P84, DOI 10.1016/0140-6736(93)92559-C; DENIS M, 1991, J LEUKOCYTE BIOL, V49, P380, DOI 10.1002/jlb.49.4.380; DINHXUAN AT, 1991, NEW ENGL J MED, V324, P1539, DOI 10.1056/NEJM199105303242203; DREXLER H, 1991, LANCET, V338, P1546, DOI 10.1016/0140-6736(91)92372-9; DUARTE IDG, 1990, INT CONGR SER, V897, P165; FARRELL AJ, 1992, ANN RHEUM DIS, V51, P1219, DOI 10.1136/ard.51.11.1219; FEELISCH M, 1991, J CARDIOVASC PHARM, V17, pS25, DOI 10.1097/00005344-199117003-00006; FIONA SF, 1992, LIFE SCI, V51, P1277, DOI 10.1016/0024-3205(92)90017-J; FORSTERMANN U, 1986, J CARDIOVASC PHARM, V8, pS45; FORSTERMANN U, 1990, BIOCHEM BIOPH RES CO, V168, P727, DOI 10.1016/0006-291X(90)92382-A; FURCHGOTT RF, 1990, ACTA PHYSIOL SCAND, V139, P257, DOI 10.1111/j.1748-1716.1990.tb08923.x; FURCHGOTT RF, 1980, NATURE, V288, P373, DOI 10.1038/288373a0; GARG UC, 1989, J CLIN INVEST, V83, P1774, DOI 10.1172/JCI114081; GARTHWAITE J, 1988, NATURE, V336, P385, DOI 10.1038/336385a0; GARTHWAITE J, 1991, TRENDS NEUROSCI, V14, P60, DOI 10.1016/0166-2236(91)90022-M; GREEN LC, 1982, ANAL BIOCHEM, V126, P131, DOI 10.1016/0003-2697(82)90118-X; GUARNER C, 1993, HEPATOLOGY, V18, P1139; GUSTAFSSON LE, 1991, BIOCHEM BIOPH RES CO, V181, P852, DOI 10.1016/0006-291X(91)91268-H; HIBBS JB, 1990, NITRIC OXIDE L ARGIN, P6189; HOFFMAN RA, 1990, J IMMUNOL, V145, P2220; HOLMQUIST F, 1991, ACTA PHYSIOL SCAND, V141, P441, DOI 10.1111/j.1748-1716.1991.tb09103.x; HOPE BT, 1991, P NATL ACAD SCI USA, V88, P2811, DOI 10.1073/pnas.88.7.2811; HUNT NCA, 1992, J HEPATOL, V14, P146, DOI 10.1016/0168-8278(92)90150-N; IALENTI A, 1993, BRIT J PHARMACOL, V110, P701, DOI 10.1111/j.1476-5381.1993.tb13868.x; IALENTI A, 1992, EUR J PHARMACOL, V211, P177, DOI 10.1016/0014-2999(92)90526-A; IGNARRO LJ, 1991, BLOOD VESSELS, V28, P67; IGNARRO LJ, 1990, BIOCHEM BIOPH RES CO, V170, P843, DOI 10.1016/0006-291X(90)92168-Y; IGNARRO LJ, 1990, ANNU REV PHARMACOL, V30, P535, DOI 10.1146/annurev.pa.30.040190.002535; KELM M, 1992, BIOL NITRIC OXIDE, V1, P319; KIM N, 1991, J CLIN INVEST, V88, P112, DOI 10.1172/JCI115266; KIRK SJ, 1990, BIOCHEM BIOPH RES CO, V173, P660, DOI 10.1016/S0006-291X(05)80086-5; KNOWLES RG, 1989, P NATL ACAD SCI USA, V86, P5159, DOI 10.1073/pnas.86.13.5159; KUBES P, 1991, P NATL ACAD SCI USA, V88, P4651, DOI 10.1073/pnas.88.11.4651; LAMAS S, 1992, P NATL ACAD SCI USA, V89, P6348, DOI 10.1073/pnas.89.14.6348; LANGREHR JM, 1991, SURGERY, V110, P335; LEAF CD, 1990, INT CONGR SER, V897, P291; LEFER AM, 1992, BIOL NITRIC OXIDE, V1, P55; LEPOIVRE M, 1992, J BIOL CHEM, V267, P22994; LUSCHER TF, 1988, NEW ENGL J MED, V319, P462, DOI 10.1056/NEJM198808253190802; MARLETTA MA, 1989, TRENDS BIOCHEM SCI, V14, P488, DOI 10.1016/0968-0004(89)90181-3; MARLETTA MA, 1988, BIOCHEMISTRY-US, V27, P8706, DOI 10.1021/bi00424a003; MCVEIGH GE, 1992, BIOL NITRIC OXIDE, V1, P332; MEARIN F, 1993, EUR J CLIN INVEST, V23, P724, DOI 10.1111/j.1365-2362.1993.tb01292.x; MIDDLETON SJ, 1993, LANCET, V341, P465, DOI 10.1016/0140-6736(93)90211-X; MILLER MJS, 1993, J PHARMACOL EXP THER, V264, P11; MILLS CD, 1991, J IMMUNOL, V146, P2719; MOLLACE V, 1991, NEUROREPORT, V2, P269, DOI 10.1097/00001756-199105000-00014; MONCADA S, 1989, BIOCHEM PHARMACOL, V38, P1709, DOI 10.1016/0006-2952(89)90403-6; MONCADA S, 1992, ACTA PHYSIOL SCAND, V145, P201, DOI 10.1111/j.1748-1716.1992.tb09359.x; MOORE PK, 1991, BRIT J PHARMACOL, V102, P198, DOI 10.1111/j.1476-5381.1991.tb12153.x; MORLEY JE, 1991, LIFE SCI, V49, P707, DOI 10.1016/0024-3205(91)90102-H; MULLIGAN MS, 1991, P NATL ACAD SCI USA, V88, P6338, DOI 10.1073/pnas.88.14.6338; NAKAKI T, 1990, LANCET, V336, P696, DOI 10.1016/0140-6736(90)92196-O; NATHAN CF, 1991, CURR OPIN IMMUNOL, V3, P65, DOI 10.1016/0952-7915(91)90079-G; NOWICKI JP, 1991, EUR J PHARMACOL, V204, P339, DOI 10.1016/0014-2999(91)90862-K; NUSSLER AK, 1992, J EXP MED, V176, P261, DOI 10.1084/jem.176.1.261; OCHOA JB, 1991, ANN SURG, V214, P621, DOI 10.1097/00000658-199111000-00013; ODELL TJ, 1991, P NATL ACAD SCI USA, V88, P11285, DOI 10.1073/pnas.88.24.11285; OURY TD, 1992, P NATL ACAD SCI USA, V89, P9715, DOI 10.1073/pnas.89.20.9715; PALMER RMJ, 1992, BIOCHEM BIOPH RES CO, V188, P209, DOI 10.1016/0006-291X(92)92371-4; PALMER RMJ, 1988, NATURE, V333, P664, DOI 10.1038/333664a0; PANZA JA, 1990, NEW ENGL J MED, V323, P22, DOI 10.1056/NEJM199007053230105; PEPKEZABA J, 1991, LANCET, V338, P1173, DOI 10.1016/0140-6736(91)92033-X; PERSSON K, 1992, BRIT J PHARMACOL, V107, P178, DOI 10.1111/j.1476-5381.1992.tb14483.x; PETROS A, 1991, LANCET, V338, P1557, DOI 10.1016/0140-6736(91)92376-D; PETROS AJ, 1991, LANCET, V337, P1044, DOI 10.1016/0140-6736(91)92708-A; RADOMSKI MW, 1990, P NATL ACAD SCI USA, V87, P10043, DOI 10.1073/pnas.87.24.10043; RADOMSKI MW, 1991, CLIN RELEVANCE NITRI, P45; RAND MJ, 1992, CLIN EXP PHARMACOL P, V19, P147, DOI 10.1111/j.1440-1681.1992.tb00433.x; REES DD, 1990, BIOCHEM BIOPH RES CO, V173, P541, DOI 10.1016/S0006-291X(05)80068-3; ROSSAINT R, 1993, NEW ENGL J MED, V328, P399, DOI 10.1056/NEJM199302113280605; SALAZAR FJ, 1993, HYPERTENSION, V22, P49, DOI 10.1161/01.HYP.22.1.49; SALTER M, 1991, FEBS LETT, V291, P145, DOI 10.1016/0014-5793(91)81123-P; SCHMIDT HHW, 1991, BIOCHEM BIOPH RES CO, V181, P1372, DOI 10.1016/0006-291X(91)92090-7; SCHULZ R, 1992, BRIT J PHARMACOL, V105, P575, DOI 10.1111/j.1476-5381.1992.tb09021.x; SCHUMAN EM, 1991, SCIENCE, V254, P1503, DOI 10.1126/science.1720572; SHERMAN MP, 1991, J PROTOZOOL, V38, pS234; SHIBUKI K, 1991, NATURE, V349, P326, DOI 10.1038/349326a0; SINZINGER H, 1992, BRIT J CLIN PHARMACO, V33, P289, DOI 10.1111/j.1365-2125.1992.tb04037.x; SNYDER SH, 1992, SCI AM, V266, P68, DOI 10.1038/scientificamerican0592-68; SPRINGALL DR, 1992, HISTOCHEMISTRY, V98, P259, DOI 10.1007/BF00271040; STAMLER JS, 1992, P NATL ACAD SCI USA, V89, P444, DOI 10.1073/pnas.89.1.444; STUEHR DJ, 1985, P NATL ACAD SCI USA, V82, P7738, DOI 10.1073/pnas.82.22.7738; THOM SA, 1985, J HYPERTENS, V3, pS97; VALLANCE P, 1991, LANCET, V337, P776, DOI 10.1016/0140-6736(91)91384-7; Vallance P, 1993, New Horiz, V1, P77; VALLANCE P, 1992, LANCET, V339, P572; VANDERWINDEN JM, 1992, NEW ENGL J MED, V327, P511, DOI 10.1056/NEJM199208203270802; VANHOUTTE PM, 1989, HYPERTENSION, V13, P658, DOI 10.1161/01.HYP.13.6.658; VENTURINI CM, 1991, BIOCHEM BIOPH RES CO, V180, P920, DOI 10.1016/S0006-291X(05)81153-2; WALDMAN SA, 1988, J CARDIOVASC PHARM, V12, pS115; WRIGHT CE, 1992, CARDIOVASC RES, V26, P48, DOI 10.1093/cvr/26.1.48; XIE QW, 1992, SCIENCE, V256, P225, DOI 10.1126/science.1373522; YOSHIDA K, 1980, INT ARCH OCC ENV HEA, V46, P71, DOI 10.1007/BF00377461; ZIELASEK J, 1992, CELL IMMUNOL, V141, P111, DOI 10.1016/0008-8749(92)90131-8; 1882, DEUT MED WOCHENSCHR, V8, P553	120	5335	5507	2	270	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	DEC 30	1993	329	27					2002	2012						11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MN573	7504210				2022-12-28	WOS:A1993MN57300006
J	Gervais, DA; Whitman, GJ				Gervais, DA; Whitman, GJ			Ruptured abdominal aortic aneurysm	NEW ENGLAND JOURNAL OF MEDICINE			English	Article											Gervais, DA (corresponding author), MASSACHUSETTS GEN HOSP,BOSTON,MA 02114, USA.								0	1	1	0	0	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JAN 4	1996	334	1					27	27		10.1056/NEJM199601043340107	http://dx.doi.org/10.1056/NEJM199601043340107			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TM482	7494568				2022-12-28	WOS:A1996TM48200007
J	Kinlay, S; Leitch, JW; Neil, A; Chapman, BL; Hardy, DB; Fletcher, PJ				Kinlay, S; Leitch, JW; Neil, A; Chapman, BL; Hardy, DB; Fletcher, PJ			Cardiac event recorders yield more diagnoses and are more cost-effective than 48-hour holter monitoring in patients with palpitations - A controlled clinical trial	ANNALS OF INTERNAL MEDICINE			English	Article							ARRHYTHMIA; DOCUMENTATION	Objective: To compare the diagnostic yield and cost-effectiveness of transtelephonic event monitors with those of Hotter monitoring in patients with intermittent palpitations. Design: Randomized crossover trial. Setting: Diagnostic service of a teaching hospital and surrounding primary care practices. Patients: 43 patients with previously uninvestigated palpitations who were referred for Holter monitoring. Measurements: Patients were randomly allocated to receive an event monitor or 48-hour Holter monitor and then to receive the other device. Event monitors were used for 3 months or until two recordings were obtained while symptoms occurred. The main end point was an electrogram recorded during symptoms. The incremental cost-effectiveness of obtaining a diagnostic rhythm strip from event monitors was compared with that of Holter monitoring. Results: The mean (+/-SD) patient age was 45 +/- 19 years; 37 patients (88%) were women. Event monitors were twice as likely to provide a diagnostic rhythm strip electrocardiogram during symptoms as 48-hour Holter monitoring (29 patients [67%] and 15 patients [35%], respectively; P < 0.001). Event monitors detected 8 patients (19%) with clinically important arrhythmias (6 patients with supraventricular tachycardia and 2 with atrial fibrillation or flutter), whereas the Hotter monitors detected no significant arrhythmia (P < 0.005). With the event monitors, most patients transmitted an electrocardiogram recording by 6 weeks. Event monitors were dominant and therefore more cost-effective than 48-hour Holter monitoring, resulting in a cost savings of $213 for each additional diagnostic rhythm strip obtained during symptoms. Conclusions: Holter monitoring is a poor diagnostic test for intermittent palpitations. Event recorders provide better data and are more cost-effective.	UNIV NEWCASTLE, ROYAL NEWCASTLE HOSP, CTR CLIN EPIDEMIOL & BIOSTAT, NEWCASTLE, NSW 2300, AUSTRALIA	University of Newcastle	Kinlay, S (corresponding author), JOHN HUNTER HOSP, CARDIOVASC UNIT, LOCKED BAG 1, HUNTER MAIL CTR, NEWCASTLE, NSW 2310, AUSTRALIA.		Neil, Amanda Louise/K-1212-2019; Neil, Amanda/L-9052-2013	Neil, Amanda Louise/0000-0002-1344-6672; Neil, Amanda/0000-0002-1344-6672				CLAIR WK, 1993, CIRCULATION, V87, P1114, DOI 10.1161/01.CIR.87.4.1114; COLTON T, 1974, STAT MED, P171; DIMARCO JP, 1990, ANN INTERN MED, V113, P53, DOI 10.7326/0003-4819-113-1-53; GOLDSTEIN M, 1990, AM J DIS CHILD, V144, P178, DOI 10.1001/archpedi.1990.02150260058028; GRODMAN RS, 1979, AM HEART J, V98, P459, DOI 10.1016/0002-8703(79)90251-5; JUDSON P, 1979, AM HEART J, V97, P759, DOI 10.1016/0002-8703(79)90011-5; KLOOTWIJK P, 1986, INT J CARDIOL, V13, P155, DOI 10.1016/0167-5273(86)90140-3; LEITCH JW, 1991, AM J CARDIOL, V68, P964, DOI 10.1016/0002-9149(91)90420-P; REIFFEL JA, 1991, J ELECTROCARDIOL, V24, P165, DOI 10.1016/0022-0736(91)90007-9; SAFE AF, 1990, POSTGRAD MED J, V66, P110, DOI 10.1136/pgmj.66.772.110; SHEN WK, 1987, MAYO CLIN PROC, V62, P109, DOI 10.1016/S0025-6196(12)61878-3; THOMAS LE, 1984, BRIT MED J, V289, P1106, DOI 10.1136/bmj.289.6452.1106	12	152	154	1	8	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JAN 1	1996	124	1	1				16	20		10.7326/0003-4819-124-1_Part_1-199601010-00003	http://dx.doi.org/10.7326/0003-4819-124-1_Part_1-199601010-00003			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TL943	7503472				2022-12-28	WOS:A1996TL94300003
J	POULTER, NR; CHANG, CL; FARLEY, TMM; MEIRIK, O; MARMOT, MG; DEBERTRIBEIRO, M; MEDINA, E; ARTIGAS, J; HE, S; ZHONG, YH; ZHANG, DW; ZHAO, WJ; ROJAS, O; VESSEY, MP; HEINEMANN, L; DONNAN, S; HO, S; BARTFAI, G; KISJANTO, J; WILKS, R; AGWANDA, R; RUIZ, R; KOZUHNOVAK, M; DUSITSIN, N; VIRUTAMASEN, P; PHANTHUMCHINDA, K; KOETSAWANG, S; PIYAANANT, M; DEMIROVIC, J; BELKIC, K; MWANDILA, WS; MUTALE, CM; MATENGA, J; WILSON, A; PETITTI, D; HOLCK, S; LAWLEY, S; SMITH, S; SHIPLEY, M; OLSEN, J; THOROGOOD, M; KELAGHAN, J				POULTER, NR; CHANG, CL; FARLEY, TMM; MEIRIK, O; MARMOT, MG; DEBERTRIBEIRO, M; MEDINA, E; ARTIGAS, J; HE, S; ZHONG, YH; ZHANG, DW; ZHAO, WJ; ROJAS, O; VESSEY, MP; HEINEMANN, L; DONNAN, S; HO, S; BARTFAI, G; KISJANTO, J; WILKS, R; AGWANDA, R; RUIZ, R; KOZUHNOVAK, M; DUSITSIN, N; VIRUTAMASEN, P; PHANTHUMCHINDA, K; KOETSAWANG, S; PIYAANANT, M; DEMIROVIC, J; BELKIC, K; MWANDILA, WS; MUTALE, CM; MATENGA, J; WILSON, A; PETITTI, D; HOLCK, S; LAWLEY, S; SMITH, S; SHIPLEY, M; OLSEN, J; THOROGOOD, M; KELAGHAN, J			VENOUS THROMBOEMBOLIC DISEASE AND COMBINED ORAL-CONTRACEPTIVES - RESULTS OF INTERNATIONAL MULTICENTER CASE-CONTROL STUDY	LANCET			English	Article							NONFATAL VASCULAR-DISEASE; MU-G ETHINYLESTRADIOL; CARDIOVASCULAR-DISEASE; ETHINYL ESTRADIOL; SERUM LEVELS; 12 CYCLES; THROMBOSIS; WOMEN; FORMULATIONS; DESOGESTREL	The composition and use of oral contraceptives (OCs) have changed since their cardiovascular side-effects were established 20 years ago. This report describes the risk of idiopathic venous thromboembolic (VTE) events (deep vein thrombosis [DVT] and/or pulmonary embolism [PEI]) in association with current use of combined OCs among 1143 cases aged 20-44 and 2998 age-matched controls, as evaluated in a hospital-based, case-control study in 21 centres in Africa, Asia, Europe, and Latin America. OC use was associated with an increased risk of VTE in Europe (odds ratio 4.15 [95% CI 3.09-5.57]) and in non-European (''developing'') countries (3.25 [2.59-4.08]). Risk estimates were generally higher for DVT than for PE but no consistent trend by certainty of diagnosis (definite, probable, possible) was found. Increased risk was apparent within 4 months of starting OCs, was unaffected by duration of current episode of OC use, and had disappeared within 3 months of stopping OCs. Relative risk estimates of VTE associated with OC use were unaffected by age of user, by history of hypertension (excluding hypertension in pregnancy), or in any consistent way by smoking. However, in both groups of countries increased body mass index (BMI) was an independent risk factor for VTE, and OC-associated odds ratios were higher among those with a BMI above 25 kg/m(2) than among those with smaller BMIs. OC-associated risk estimates were high among women in Europe with a history of hypertension in pregnancy. Odds ratios associated with the use of OCs containing a third-generation progestagen observed with progestagens type) and second (norgestrel group) generation. Odds ratios associated with first and second generation progestagens tended to be lower, though not significantly, when used in combination with low (<50 mu g oestrogen) rather than higher oestrogen doses. This study confirms an association between OC use and VTE in Europe and the developing countries, although overall risk estimates associated with use were lower than demonstrated in most previous studies of non-fatal idiopathic VTE.	ESCOLA PAULISTA MED, SAO PAULO, BRAZIL; ESCUELA MED, VALPARAISO, CHILE; SHANGHAI INST PLANNED PARENTHOOD RES, SHANGHAI, PEOPLES R CHINA; UNIV VALLE, FAC SALUD, CALI, COLOMBIA; UNIV OXFORD, OXFORD, ENGLAND; ZENTRUM EPIDEMIOL & GESUNDHEITFORSCH, BERLIN, GERMANY; CHINESE UNIV HONG KONG, HONG KONG, HONG KONG; ALBERT SZENT GYORGYI MED UNIV, H-6701 SZEGED, HUNGARY; UNIV INDONESIA, FAC MED, JAKARTA, INDONESIA; UNIV W INDIES, TROP METAB RES UNIT, KINGSTON 7, JAMAICA; KENYA GOVT MED RES CTR, NAIROBI, KENYA; GRP INTERUNIV MEXICANO INVEST EPIDEMIOL SALUD REP, DURANGO, MEXICO; UNIV LJUBLJANA, INST PUBL HLTH, LJUBLJANA, SLOVENIA; CHULALONGKORN HOSP, BANGKOK, THAILAND; SIRIRAJ HOSP, SIRIRAJ FAMILY HLTH RES CTR, BANGKOK, THAILAND; UNIV BELGRADE, SCH MED, BELGRADE, YUGOSLAVIA; UNIV LUSAKA, TEACHING HOSP, LUSAKA, ZAMBIA; UNIV ZIMBABWE, HARARE, ZIMBABWE	Universidade Federal de Sao Paulo (UNIFESP); Universidad del Valle; University of Oxford; Chinese University of Hong Kong; Szeged University; University of Indonesia; University West Indies Mona Jamaica; Kenya Medical Research Institute; University of Ljubljana; Chulalongkorn University; Mahidol University; University of Belgrade; University of Zimbabwe			Marmot, M G/Y-3920-2019	Marmot, M G/0000-0002-2431-6419	Medical Research Council [G8802774] Funding Source: researchfish	Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission)		[Anonymous], 1973, Lancet, V1, P1399; [Anonymous], 1967, J R Coll Gen Pract, V13, P267; BOTTIGER LE, 1971, ACTA MED SCAND, V190, P455; Breslow N.E., 1980, STAT METHODS CANC RE, P192; FARLEY TMM, 1995, LANCET, V346, P1582; GERSTMAN BB, 1990, INT J EPIDEMIOL, V19, P931, DOI 10.1093/ije/19.4.931; GODSLAND IF, 1990, NEW ENGL J MED, V323, P1375, DOI 10.1056/NEJM199011153232003; GREENE GR, 1972, AM J PUBLIC HEALTH N, V62, P680, DOI 10.2105/AJPH.62.5.680; HELMRICH SP, 1987, OBSTET GYNECOL, V69, P91; HUMPEL M, 1990, AM J OBSTET GYNECOL, V163, P329; INMAN WHW, 1970, BMJ-BRIT MED J, V2, P203, DOI 10.1136/bmj.2.5703.203; JORDAN WM, 1961, LANCET, V2, P1146, DOI DOI 10.1016/S0140-6736(61)91061-3; KUHL H, 1988, CONTRACEPTION, V38, P381, DOI 10.1016/0010-7824(88)90110-2; KUHL H, 1988, CONTRACEPTION, V38, P477, DOI 10.1016/0010-7824(88)90088-1; KUHNZ W, 1990, HORM RES, V33, P40, DOI 10.1159/000181446; LAROSA JC, 1988, AM J OBSTET GYNECOL, V158, P1621, DOI 10.1016/0002-9378(88)90200-1; LAWSON DH, 1977, BRIT MED J, V2, P729, DOI 10.1136/bmj.2.6089.729; MAGUIRE MG, 1979, AM J EPIDEMIOL, V110, P188, DOI 10.1093/oxfordjournals.aje.a112803; MALDONADO G, 1993, AM J EPIDEMIOL, V138, P923, DOI 10.1093/oxfordjournals.aje.a116813; NICOLAIDES AN, 1995, THROMBOEMBOLISM, P193; PERLMAN JA, 1985, J CHRON DIS, V38, P857, DOI 10.1016/0021-9681(85)90110-9; PETITTI DB, 1978, AM J EPIDEMIOL, V108, P480, DOI 10.1093/oxfordjournals.aje.a112646; POLLER L, 1978, BRIT MED BULL, V34, P151, DOI 10.1093/oxfordjournals.bmb.a071485; PORTER JB, 1985, OBSTET GYNECOL, V66, P1; PORTER JB, 1982, OBSTET GYNECOL, V59, P299; POULOSE KP, 1970, BRIT MED J, V3, P67, DOI 10.1136/bmj.3.5714.67; RAMCHARAN S, 1981, NIH81564 CTR POP RES; REALINI JP, 1985, AM J OBSTET GYNECOL, V152, P729, DOI 10.1016/S0002-9378(85)80001-6; ROYAL COLLEGE OF GENERAL PRACTITIONERS' ORAL CONTRACEPTION STUDY, 1978, Journal of the Royal College of General Practitioners, V28, P393; SARTWELL PE, 1969, AM J EPIDEMIOL, V90, P365, DOI 10.1093/oxfordjournals.aje.a121082; STADEL BV, 1981, NEW ENGL J MED, V305, P612, DOI 10.1056/NEJM198109103051104; STADEL BV, 1981, NEW ENGL J MED, V305, P672, DOI 10.1056/NEJM198109173051205; STOLLEY PD, 1975, AM J EPIDEMIOL, V102, P197, DOI 10.1093/oxfordjournals.aje.a112148; THOROGOOD M, 1992, INT J EPIDEMIOL, V21, P48, DOI 10.1093/ije/21.1.48; THOROGOOD M, 1990, BRIT J FAMILY PLANNI, V0016; VESSEY M, 1986, BRIT MED J, V292, P526, DOI 10.1136/bmj.292.6519.526; VESSEY M P, 1980, British Journal of Family Planning, V6, P1; VESSEY MP, 1968, BMJ-BRIT MED J, V2, P199, DOI 10.1136/bmj.2.5599.199; VESSEY MP, 1970, BMJ-BRIT MED J, V3, P123, DOI 10.1136/bmj.3.5715.123; VESSEY MP, 1969, BRIT MED J, V2, P651, DOI 10.1136/bmj.2.5658.651; VESSEY MP, 1990, ORAL CONTRACEPTIVES, P121; VREIM CE, 1990, JAMA-J AM MED ASSOC, V263, P2753; WACHOLDER S, 1992, AM J EPIDEMIOL, V135, P1019, DOI 10.1093/oxfordjournals.aje.a116396; WELLS PS, 1995, LANCET, V345, P1326, DOI 10.1016/S0140-6736(95)92535-X; WESSLER S, 1976, JAMA-J AM MED ASSOC, V236, P2179, DOI 10.1001/jama.236.19.2179; 1991, EPIDEMIOLOGICAL GRAP; IN PRESS J EPIDEMIOL; IN PRESS J CLIN EPID	48	554	559	0	15	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	DEC 16	1995	346	8990					1575	1582						8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TK481	7500748				2022-12-28	WOS:A1995TK48100007
J	MELDOLESI, J				MELDOLESI, J			SURVIVAL OF ITALIAN BIOMEDICAL-RESEARCH	NATURE			English	Editorial Material											MELDOLESI, J (corresponding author), UNIV MILAN,DIBIT,SAN RAFFAELE INST,VIA OLGETTINA 60,I-20132 MILAN,ITALY.								0	0	0	0	1	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	DEC 14	1995	378	6558					659	660		10.1038/378659a0	http://dx.doi.org/10.1038/378659a0			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TK379	7501006				2022-12-28	WOS:A1995TK37900023
J	SHIOZAKI, K; RUSSELL, P				SHIOZAKI, K; RUSSELL, P			CELL-CYCLE CONTROL LINKED TO EXTRACELLULAR ENVIRONMENT BY MAP KINASE PATHWAY IN FISSION YEAST	NATURE			English	Article							SCHIZOSACCHAROMYCES-POMBE; TYROSINE PHOSPHORYLATION; PROTEIN PHOSPHATASE; MITOSIS	IN fission yeast the onset of mitosis is brought about by Cdc2/Cdc13 kinase, which is inhibited by the Wee1/Mik1 tyrosine kinases and activated by Cdc25 tyrosine phosphatase(1). This control network integrates many signals, including those that monitor DNA replication, DNA damage and cell size, We report here that a fission yeast MAP kinase pathway links the cell-cycle G(2)/M control with changes in the extracellular environment that affect cell physiology. Fission yeast spc1(-) mutants have a G(2) delay that is greatly exacerbated by growth in high osmolarity media and nutrient limitation. A lethal interaction of spc1 and cdc25 mutations shows that Spc1 promotes the onset of mitosis, Spc1 is a MAP kinase homologue that is activated by Wis1 kinase in response to osmotic stress and nutrient limitation, Spc1 is inactivated by Pyp1, a phosphatase previously identified as a mitotic inhibitor(2,3). Pyp1 dephosphorylates only tyrosine-173 of Spc1, unlike the dual-specificity phosphatases that have been shown to regulate other MAP kinases(4).	SCRIPPS RES INST, DEPT MOLEC BIOL, LA JOLLA, CA 92037 USA; Scripps Res Inst, DEPT CELL BIOL, LA JOLLA, CA 92037 USA	Scripps Research Institute; Scripps Research Institute			Shiozaki, Kazuhiro/K-3440-2019	Shiozaki, Kazuhiro/0000-0002-0395-5457				ALESSI DR, 1993, ONCOGENE, V8, P2015; ALESSI DR, 1995, CURR BIOL, V5, P283, DOI 10.1016/S0960-9822(95)00059-5; BOYLE WJ, 1991, METHOD ENZYMOL, V201, P110; BREWSTER JL, 1993, SCIENCE, V259, P1760, DOI 10.1126/science.7681220; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; DOI K, 1994, EMBO J, V13, P61, DOI 10.1002/j.1460-2075.1994.tb06235.x; Dunphy William G., 1994, Trends in Cell Biology, V4, P202; Errede B, 1993, CURR OPIN CELL BIOL, V5, P254, DOI 10.1016/0955-0674(93)90112-4; GOMEZ N, 1990, FEBS LETT, V271, P119, DOI 10.1016/0014-5793(90)80386-W; GUAN KL, 1991, ANAL BIOCHEM, V192, P262, DOI 10.1016/0003-2697(91)90534-Z; HAN J, 1994, SCIENCE, V265, P808, DOI 10.1126/science.7914033; HANNIG G, 1994, P NATL ACAD SCI USA, V91, P10084, DOI 10.1073/pnas.91.21.10084; LEE JC, 1994, NATURE, V372, P739, DOI 10.1038/372739a0; LUNDGREN K, 1991, CELL, V64, P1111, DOI 10.1016/0092-8674(91)90266-2; MAEDA T, 1994, NATURE, V369, P242, DOI 10.1038/369242a0; MARSHALL CJ, 1994, CURR OPIN GENET DEV, V4, P82, DOI 10.1016/0959-437X(94)90095-7; MAUNDRELL K, 1993, GENE, V123, P127, DOI 10.1016/0378-1119(93)90551-D; MILLAR JBA, 1992, EMBO J, V11, P4943, DOI 10.1002/j.1460-2075.1992.tb05601.x; MILLAR JBA, 1995, GENE DEV, V9, P2117, DOI 10.1101/gad.9.17.2117; MORENO S, 1991, METHOD ENZYMOL, V194, P795; NISHIDA E, 1993, TRENDS BIOCHEM SCI, V18, P128, DOI 10.1016/0968-0004(93)90019-J; OTTILIE S, 1992, MOL CELL BIOL, V12, P5571, DOI 10.1128/MCB.12.12.5571; ROUSE J, 1994, CELL, V78, P1027, DOI 10.1016/0092-8674(94)90277-1; SHIOZAKI K, 1995, EMBO J, V14, P492, DOI 10.1002/j.1460-2075.1995.tb07025.x; SHIOZAKI K, 1994, MOL CELL BIOL, V14, P3742, DOI 10.1128/MCB.14.6.3742; SUN H, 1993, CELL, V75, P487, DOI 10.1016/0092-8674(93)90383-2; WARBRICK E, 1991, EMBO J, V10, P4291, DOI 10.1002/j.1460-2075.1991.tb05007.x; WU L, 1993, NATURE, V363, P738, DOI 10.1038/363738a0; ZHENG CF, 1993, J BIOL CHEM, V268, P16116	29	392	398	0	13	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	DEC 14	1995	378	6558					739	743		10.1038/378739a0	http://dx.doi.org/10.1038/378739a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TK379	7501024				2022-12-28	WOS:A1995TK37900059
J	RIMELL, FL; THOME, A; STOOL, S; REILLY, JS; RIDER, G; STOOL, D; WILSON, CL				RIMELL, FL; THOME, A; STOOL, S; REILLY, JS; RIDER, G; STOOL, D; WILSON, CL			CHARACTERISTICS OF OBJECTS THAT CAUSE CHOKING IN CHILDREN	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							FOREIGN-BODIES; CHILDHOOD ASPHYXIATION; AIRWAY; BODY; INHALATION	Objective.-To characterize the types, shapes, and sizes of objects causing choking or asphyxiation in children and to compare these characteristics to current standards. Design.-To evaluate morbidity, retrospective 5-year medical record survey; to evaluate mortality, data reanalysis. Settings.-Pediatric hospital and consumer product testing laboratory. Patients.-All children (n=165) who underwent endoscopy for foreign body aspiration or ingestion at Children's Hospital of Pittsburgh (Pa) between 1989 and 1993 and children (n=449) whose deaths due to choking on man-made objects were recorded by the Consumer Product Safety Commission (CPSC) between 1972 and 1992. Main Outcome Measures.-Objects removed from children's aerodigestive tracts were characterized by location, procedure for removal, and type. Objects causing death were characterized by type, shape, and consistency. Three-dimensional objects that had caused asphyxiation were analyzed by computer-simulated models. Results.-Of the 165 children treated by endoscopy, 69% were 3 years of age or younger. Foreign bodies most often ingested or aspirated were food (in 36 children) and coins (in 60 children). Of 449 children whose deaths after aspirating foreign bodies were reported to the CPSC, 65% were younger than 3 years. Balloons caused 29% of deaths overall. Conforming objects such as balloons caused a significantly (P<.001) higher proportion of deaths in those aged 3 years or older (60%) vs those younger than 3 years (33%). Of the 101 objects causing deaths that we could analyze, 14 met current standards for use by children younger than 3 years. Conclusions.-Balloons pose a high risk of asphyxiation to children of any age. Changes in regulations regarding products intended for children's use might have prevented up to 14 (14%) of 101 deaths in this study.	CHILDRENS HOSP PITTSBURGH,DEPT PEDIAT OTOLARYNGOL,PITTSBURGH,PA 15213; ALFRED I DUPONT INST,DIV PEDIAT OTOLARYNGOL,WILMINGTON,DE; INCHCAPE TESTING SERV RISK ANAL & MANAGEMENT,MOONACHIE,NJ	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Nemours Alfred I. duPont Hospital for Children								AYTAC A, 1977, J THORAC CARDIOV SUR, V74, P145; BAKER SP, 1980, JAMA-J AM MED ASSOC, V244, P1343; Baker SP, 1992, THE INJURY FACT BOOK, V2nd; BINDER L, 1984, ANN EMERG MED, V13, P112, DOI 10.1016/S0196-0644(84)80573-9; BLAZER S, 1980, AM J DIS CHILD, V134, P68, DOI 10.1001/archpedi.1980.02130130050015; HARRIS CS, 1984, JAMA-J AM MED ASSOC, V251, P2231, DOI 10.1001/jama.251.17.2231; HAWKINS DB, 1990, ANN OTO RHINOL LARYN, V99, P935, DOI 10.1177/000348949009901201; Kenna M A, 1988, Pediatr Rev, V10, P25, DOI 10.1542/pir.10-1-25; KIM IG, 1973, LARYNGOSCOPE, V83, P347, DOI 10.1288/00005537-197303000-00004; MITTLEMAN RE, 1984, AM J FOREN MED PATH, V5, P201, DOI 10.1097/00000433-198409000-00003; MU LC, 1991, LARYNGOSCOPE, V101, P657; ODELOWO EOO, 1990, INT SURG, V75, P148; RIMELL FL, 1994, DEC SOC RISK AN ANN; WOLACH B, 1994, INT J PEDIATR OTORHI, V30, P1, DOI 10.1016/0165-5876(94)90045-0; 1995, MONTHLY VITAL STAT S, V40; 1979, METHOD IDENTIFYING T; 1994, VITAL HLTH STATISTIC	17	108	110	0	3	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	DEC 13	1995	274	22					1763	1766		10.1001/jama.274.22.1763	http://dx.doi.org/10.1001/jama.274.22.1763			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TJ225	7500505				2022-12-28	WOS:A1995TJ22500024
J	ZIMMER, KP; NAIM, HY; KOCH, HG; COLOMBO, JP; ROSSI, R; SCHMID, KW; DEUFEL, T; ULLRICH, K; HARMS, E				ZIMMER, KP; NAIM, HY; KOCH, HG; COLOMBO, JP; ROSSI, R; SCHMID, KW; DEUFEL, T; ULLRICH, K; HARMS, E			SURVIVAL AFTER EARLY TREATMENT FOR CARBAMYL-PHOSPHATE SYNTHETASE (CPS)-I DEFICIENCY ASSOCIATED WITH INCREASE OF INTRAMITOCHONDRIAL CPS-I	LANCET			English	Note							LIVER	The basis for the benefit of early treatment in urea-cycle defects might be an increase in intramitochondrial mutant enzyme in hepatocytes in the postnatal period. In two siblings with carbamyl phosphate synthetase I (CPS I) deficiency, immunoreactive CPS I was greatly reduced in the liver and no residual enzyme activity was detectable. The elder child died at age 4 days, before the diagnosis of CPS I deficiency was established, but in the younger child, age 9 months, treatment was initiated on the 2nd day of life when ammonia concentration was moderately increased, and she has survived. Intramitochondrial CPS I was substantially higher in this sibling than in-the elder sister. The different outcome in the younger patient was probably attributable to prompt treatment after early diagnosis.	UNIV MUNSTER,INST PATHOL,W-4400 MUNSTER,GERMANY; UNIV DUSSELDORF,INST MIKROBIOL,W-4000 DUSSELDORF,GERMANY; INSELSPITAL BERN,CHEM ZENT LAB,CH-3010 BERN,SWITZERLAND	University of Munster; Heinrich Heine University Dusseldorf; University of Bern; University Hospital of Bern	ZIMMER, KP (corresponding author), UNIV MUNSTER,KINDERKLIN,D-48149 MUNSTER,GERMANY.		Zimmer, Klaus-Peter/AAY-9261-2020; Zimmer, Klaus-Peter/AAY-9351-2020	Deufel, Thomas/0000-0003-4839-3117				BAIG MMA, 1992, PEDIATR RES, V31, P143, DOI 10.1203/00006450-199202000-00010; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; HOSHIDE R, 1993, J CLIN INVEST, V91, P1884, DOI 10.1172/JCI116405; LATHAM PS, 1984, HEPATOLOGY, V4, P404, DOI 10.1002/hep.1840040308; MAESTRI NE, 1991, J PEDIATR-US, V119, P923, DOI 10.1016/S0022-3476(05)83044-6; TUCHMAN M, 1989, PEDIATR RES, V26, P77, DOI 10.1203/00006450-198907000-00021; WONG LJC, 1994, ANN INTERN MED, V120, P216, DOI 10.7326/0003-4819-120-3-199402010-00007; ZIMMER KP, 1995, J INHERIT METAB DIS, V18, P356, DOI 10.1007/BF00710430; ZIMMER KP, 1995, EUR J CELL BIOL, V67, P73; ZIMMERMANN A, 1981, VIRCHOWS ARCH A, V393, P321, DOI 10.1007/BF00430832	10	5	5	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	DEC 9	1995	346	8989					1530	1531		10.1016/S0140-6736(95)92055-2	http://dx.doi.org/10.1016/S0140-6736(95)92055-2			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TJ291	7491050				2022-12-28	WOS:A1995TJ29100014
J	GOSSEN, M; PAK, DTS; HANSEN, SK; ACHARYA, JK; BOTCHAN, MR				GOSSEN, M; PAK, DTS; HANSEN, SK; ACHARYA, JK; BOTCHAN, MR			A DROSOPHILA HOMOLOG OF THE YEAST ORIGIN RECOGNITION COMPLEX	SCIENCE			English	Article							ELECTRON-MICROSCOPIC ANALYSIS; DNA-REPLICATION; MELANOGASTER; EMBRYOS	Genes from Drosophila melanogaster have been identified that encode proteins homologous to Orc2p and Orc5p of the Saccharomyces cerevisiae origin recognition complex (ORC). The abundance of the Drosophila Orc2p homolog DmORC2 is developmentally regulated and is greatest during the earliest stages of embryogenesis, concomitant with the highest rate of DNA replication. Fractionation of embryo nuclear extracts revealed that DmORC2 is found in a tightly associated complex with five additional polypeptides, much like the yeast ORC. These studies will enable direct testing of the initiator-based model of replication in a metazoan.	UNIV CALIF BERKELEY,DEPT MOLEC & CELL BIOL,DIV BIOCHEM & MOLEC BIOL,BERKELEY,CA 94720; UNIV CALIF BERKELEY,HOWARD HUGHES MED INST,DEPT MOLEC & CELL BIOL,BERKELEY,CA 94720; UNIV CALIF SAN DIEGO,HOWARD HUGHES MED INST,DEPT BIOL,LA JOLLA,CA 92093; UNIV CALIF SAN DIEGO,DEPT NEUROSCI,LA JOLLA,CA 92093	University of California System; University of California Berkeley; Howard Hughes Medical Institute; University of California System; University of California Berkeley; Howard Hughes Medical Institute; University of California System; University of California San Diego; University of California System; University of California San Diego			Gossen, Manfred/K-9602-2013	Gossen, Manfred/0000-0002-1761-4063; Acharya, Jairaj/0000-0001-7366-4228	NATIONAL CANCER INSTITUTE [R01CA030490, R37CA030490] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P30ES001896] Funding Source: NIH RePORTER; NCI NIH HHS [CA30490] Funding Source: Medline; NIEHS NIH HHS [ES-01896] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		BELL SP, 1993, SCIENCE, V262, P1844, DOI 10.1126/science.8266072; BELL SP, 1992, NATURE, V357, P128, DOI 10.1038/357128a0; BLUMENTH.AB, 1973, COLD SPRING HARB SYM, V38, P205, DOI 10.1101/SQB.1974.038.01.024; BROWN NH, 1988, J MOL BIOL, V203, P425, DOI 10.1016/0022-2836(88)90010-1; CHIANG CS, 1993, P NATL ACAD SCI USA, V90, P9105, DOI 10.1073/pnas.90.19.9105; EHRENHOFERMURRA.AE, 1995, SCIENCE, V270, P1671; FOE VE, 1993, DEV DROSOPHILA MELAN, V1, P149; FOSS M, 1993, SCIENCE, V262, P1838, DOI 10.1126/science.8266071; FOX CA, 1995, GENE DEV, V9, P911, DOI 10.1101/gad.9.8.911; HAMLIN JL, 1995, CURR OPIN GENET DEV, V5, P153, DOI 10.1016/0959-437X(95)80002-6; HANAHAN D, 1989, RECOMBINANT DNA METH, P267; HANSEN SB, UNPUB; HARLOW E, 1988, ANTIBODIES; HEBERLEIN U, 1988, NATURE, V331, P410, DOI 10.1038/331410a0; JACOB F, 1963, COLD SPRING HARB SYM, V28, P329, DOI 10.1101/SQB.1963.028.01.048; KAMAKAKA RT, 1994, MOL CELL BIOL, V14, P5114, DOI 10.1128/MCB.14.8.5114; KOONIN EV, 1993, NUCLEIC ACIDS RES, V21, P2541, DOI 10.1093/nar/21.11.2541; Kornberg A., 1992, DNA REPLICATION; LI JJ, 1993, SCIENCE, V262, P1870, DOI 10.1126/science.8266075; LIANG C, 1995, CELL, V81, P667, DOI 10.1016/0092-8674(95)90528-6; LOO S, 1995, MOL BIOL CELL, V6, P741, DOI 10.1091/mbc.6.6.741; MCKNIGHT SL, 1977, CELL, V12, P795, DOI 10.1016/0092-8674(77)90278-1; MICKLEM G, 1993, NATURE, V366, P87, DOI 10.1038/366087a0; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; ZAKIAN VA, 1976, J MOL BIOL, V108, P305, DOI 10.1016/S0022-2836(76)80123-4	25	125	131	0	3	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	DEC 8	1995	270	5242					1674	1677		10.1126/science.270.5242.1674	http://dx.doi.org/10.1126/science.270.5242.1674			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TJ293	7502079				2022-12-28	WOS:A1995TJ29300051
J	WILSON, RPH; BUCHAN, I; WALLEY, T				WILSON, RPH; BUCHAN, I; WALLEY, T			ALTERATIONS IN PRESCRIBING BY GENERAL-PRACTITIONER FUNDHOLDERS - AN OBSERVATIONAL STUDY	BRITISH MEDICAL JOURNAL			English	Article							COSTS	Objectives-To compare prescribing in general practices before and after they become fundholders to assess whether this affected prescribing patterns. Design-Analysis of prescribing data (PACT) for one year before and one year after practices become first, second, or third wave fundholders and comparison with practices that were not fundholders during any part of the study. Main outcome measures-Prescribing costs (net ingredient cost per prescribing unit), prescribing volume (items per 1000 prescribing units), net ingredient cost per item, and percentage of generic prescribing. Setting-Former Mersey Regional Health Authority. Subjects-100 fundholders (20 first wave, 31 second wave, 49 third wave) and 312 non-fundholders. Results-Prescribing costs and volume rose throughout the study in all groups. In all three fundholding waves the rate of increase of prescribing costs was significantly lower than for non-fundholders. Both cost per item and prescribing volume tended to decrease, the former probably because of a significant increase in generic prescribing: Fundholding and non-fundholding practices differed in several respects. Conclusion-Fundholding has altered practice prescribing patterns compared with those of non-fundholders, increasing generic prescribing and reducing the rate of increase of prescribing costs.	UNIV LIVERPOOL,DEPT THERAPEUT & PHARMACOL,LIVERPOOL L69 3BX,MERSEYSIDE,ENGLAND; UNIV LIVERPOOL,DEPT MED,LIVERPOOL L69 3BX,MERSEYSIDE,ENGLAND	University of Liverpool; University of Liverpool			Buchan, Iain E/H-5767-2013	Buchan, Iain E/0000-0003-3392-1650				BOGLE SM, 1994, BRIT MED J, V308, P637, DOI 10.1136/bmj.308.6929.637; BRADLOW J, 1993, BRIT MED J, V307, P1186, DOI 10.1136/bmj.307.6913.1186; BRITTEN N, 1995, BRIT MED J, V310, P1067, DOI 10.1136/bmj.310.6986.1067c; CHEW R, 1995, OHE COMPENDIUM HLTH; DOWELL JS, 1995, BRIT MED J, V310, P505, DOI 10.1136/bmj.310.6978.505; GILLIGAN JD, 1991, 54 ROYAL COLL GEN PR; GLENNERSTER H, 1994, EVALUATING NHS REFOR; KEELEY D, 1994, BRIT MED J, V308, P206, DOI 10.1136/bmj.308.6922.206c; LLOYD DCEF, 1995, BRIT MED J, V310, P165, DOI 10.1136/bmj.310.6973.165; MAXWELL M, 1993, BRIT MED J, V307, P1190, DOI 10.1136/bmj.307.6913.1190; ROBERTS SJ, 1993, BRIT MED J, V307, P485, DOI 10.1136/bmj.307.6902.485; SHINE C, 1995, BRIT MED J, V310, P1070, DOI 10.1136/bmj.310.6986.1070a; WALLEY T, 1995, PHARMACOECONOMICS, V7, P320, DOI 10.2165/00019053-199507040-00006; 1994, PRESCRIPTION IMPROVE; 1994, PRIORITY SETTING NHS; 1995, BRIEFING GP FUNDHOLD; [No title captured]	17	48	48	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	NOV 18	1995	311	7016					1347	1350		10.1136/bmj.311.7016.1347	http://dx.doi.org/10.1136/bmj.311.7016.1347			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TF901	7496289	Green Published			2022-12-28	WOS:A1995TF90100027
J	DOWSE, GK; GAREEBOO, H; ALBERTI, KGMM; ZIMMET, P; TUOMILEHTO, J; PURRAN, A; FAREED, D; CHITSON, P; COLLINS, VR; HEMRAJ, F				DOWSE, GK; GAREEBOO, H; ALBERTI, KGMM; ZIMMET, P; TUOMILEHTO, J; PURRAN, A; FAREED, D; CHITSON, P; COLLINS, VR; HEMRAJ, F			CHANGES IN POPULATION CHOLESTEROL CONCENTRATIONS AND OTHER CARDIOVASCULAR RISK FACTOR LEVELS AFTER 5 YEARS OF THE NONCOMMUNICABLE DISEASE INTERVENTION PROGRAM IN MAURITIUS	BRITISH MEDICAL JOURNAL			English	Article							IMPAIRED GLUCOSE-TOLERANCE; STANFORD 5-CITY PROJECT; CORONARY HEART-DISEASE; HYPERTENSION-CONTROL; CHINESE MAURITIANS; PLASMA-CHOLESTEROL; HEALTH EDUCATION; BLOOD-PRESSURE; PREVALENCE; NIDDM	Objective-To study changes in the prevalence of risk factors for cardiovascular disease after a five year population-wide intervention programme promoting a healthy lifestyle in a developing country. Design-Cross sectional cluster surveys in 1987 and 1992. Methodology included a two hour 75 g oral glucose tolerance test, measurement of body mass index, waist:hip ratio, basal Lipid concentrations, and blood pressure; and a lifestyle questionnaire. Setting-Mauritius, in the Indian Ocean. Subjects-All adults aged 25-74 years residing in geographically defined clusters. Main outcome measures-Age standardised prevalence of categorical disease and risk factor conditions and mean levels and frequency distributions of continuous variables. Results-Response rates were 86.2% (5080/5892) in 1987 and 89.5% (5162/5770) in 1992. Significant decreases were found in the prevalence of hypertension (15.0% to 12.1% in men and 12.4% to 10.9% in women); cigarette smoking (58.2% to 47.2% and 6.9% to 3.7% respectively); and heavy alcohol consumption (38.2% to 14.4% and 2 6% to 0.6% respectively). Moderate leisure physical activity increased from 16.9% to 22.1% in men and from 1.3% to 2.7% in women. Mean population serum total cholesterol concentration fell appreciably from 5.5 mmol/l to 4.7 mmol/l (P < 0.001). The prevalence of overweight or obesity increased, and the rates of glucose intolerance changed little. The population frequency distributions of blood pressure, serum lipid concentration, and a composite risk factor score shifted advantageously. Conclusions-Lifestyle intervention projects can be implemented and have positive effects in developing countries. A pronounced improvement in the population lipid profile in Mauritius was probably related to a change in the saturated fat content of a widely used cooking oil.	INT DIABET INST,MELBOURNE,VIC,AUSTRALIA; MINIST HLTH,PORT LOUIS,MAURITIUS; UNIV NEWCASTLE UPON TYNE,CTR HUMAN DIABET & METAB RES,NEWCASTLE TYNE,TYNE & WEAR,ENGLAND; NATL PUBL HLTH INST,DEPT EPIDEMIOL & HLTH PROMOT,HELSINKI,FINLAND; WHO,PORT LOUIS,MAURITIUS	Newcastle University - UK; Finland National Institute for Health & Welfare; World Health Organization			Zimmet, Paul/O-8486-2019	Zimmet, Paul/0000-0003-0627-0776	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK025446] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK-25446] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ALROOMI KA, 1989, AM J EPIDEMIOL, V129, P503, DOI 10.1093/oxfordjournals.aje.a115161; ARMITAGE P, 1987, STATISTICAL METHODS; BENNETT SA, 1994, MED J AUSTRALIA, V161, P519, DOI 10.5694/j.1326-5377.1994.tb127594.x; BONANOME A, 1988, NEW ENGL J MED, V318, P1244, DOI 10.1056/NEJM198805123181905; COLLINS VR, 1994, DIABETES CARE, V17, P288, DOI 10.2337/diacare.17.4.288; DOWSE GK, 1990, DIABETES, V39, P390, DOI 10.2337/diabetes.39.3.390; DOWSE GK, 1991, DIABETES CARE, V14, P271, DOI 10.2337/diacare.14.4.271; DOWSE GK, 1991, DIABETES CARE, V14, P968, DOI 10.2337/diacare.14.11.968; DOWSE GK, 1994, MED J AUSTRALIA, V160, P767, DOI 10.5694/j.1326-5377.1994.tb125945.x; EPSTEIN FH, 1989, INT J EPIDEMIOL, V18, pS203; FORTMANN SP, 1993, AM J EPIDEMIOL, V137, P1039, DOI 10.1093/oxfordjournals.aje.a116608; FORTMANN SP, 1990, AM J EPIDEMIOL, V132, P629, DOI 10.1093/oxfordjournals.aje.a115705; HARRIS MI, 1987, DIABETES, V36, P523, DOI 10.2337/diabetes.36.4.523; HIGGINS M, 1989, INT J EPIDEMIOL, V18, pS58; HODGE AM, 1994, INT J OBESITY, V18, P419; LI N, 1991, J HYPERTENS, V9, P859; MATTSON FH, 1985, J LIPID RES, V26, P194; NISSINEN A, 1988, AM J EPIDEMIOL, V127, P488, DOI 10.1093/oxfordjournals.aje.a114825; PUSKA P, 1985, ANNU REV PUBL HEALTH, V6, P147, DOI 10.1146/annurev.pu.06.050185.001051; ROSSOUW JE, 1993, INT J EPIDEMIOL, V22, P428, DOI 10.1093/ije/22.3.428; SHIGAN E N, 1988, World Health Statistics Quarterly, V41, P267; TUOMILEHTO J, 1986, ADDICT BEHAV, V11, P1, DOI 10.1016/0306-4603(86)90002-X; TUOMILEHTO J, 1993, J INTERN MED, V233, P187, DOI 10.1111/j.1365-2796.1993.tb00672.x; UEMURA K, 1988, World Health Statistics Quarterly, V41, P155; VARTIAINEN E, 1994, INT J EPIDEMIOL, V23, P495, DOI 10.1093/ije/23.3.495; WILHELMSEN L, 1989, INT J EPIDEMIOL, V18, pS101; ZIMMET PZ, 1991, AM J EPIDEMIOL, V134, P862, DOI 10.1093/oxfordjournals.aje.a116161; 1993, 1993 WORLD BANK DEV; 1988, WORLD HLTH STATISTIC; 1978, WHO TECHNICAL REPORT, V628; 1990, STATISTICAL PACKAGE	31	161	169	0	3	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	NOV 11	1995	311	7015					1255	1259		10.1136/bmj.311.7015.1255	http://dx.doi.org/10.1136/bmj.311.7015.1255			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TE859	7496233	Green Published			2022-12-28	WOS:A1995TE85900018
J	IMASHUKU, S; AKIYAMA, Y; NAKAJIMA, F; HIBI, S; OGUNI, T; KOIKE, M				IMASHUKU, S; AKIYAMA, Y; NAKAJIMA, F; HIBI, S; OGUNI, T; KOIKE, M			MULTILINEAGE RESPONSE TO G-CSF IN PEDIATRIC APLASTIC-ANEMIA	LANCET			English	Letter							COLONY-STIMULATING FACTOR; ANEMIA		KYOTO UNIV HOSP,DEPT PEDIAT,KYOTO,JAPAN; HIRAKATA CITY HOSP,DIV PEDIAT,HIRAKATA,OSAKA,JAPAN; WAKAYAMA MED COLL,DEPT PEDIAT,WAKAYAMA,JAPAN	Kyoto University; Wakayama Medical University	IMASHUKU, S (corresponding author), KYOTO PREFECTURAL UNIV MED,CHILDRENS RES HOSP,DIV PAEDIAT,KAMIKYO KU,KAWARAMACHI,KYOTO 602,JAPAN.							ASANO S, 1991, AM J PEDIAT HEMATOL, V13, P400; BERTRAND Y, 1991, BRIT J HAEMATOL, V79, P648, DOI 10.1111/j.1365-2141.1991.tb08096.x; KOJIMA S, 1991, BLOOD, V77, P937; MARSH, 1994, LANCET, V344, P172; SONODA Y, 1992, EUR J HAEMATOL, V48, P41; TAKAHASHI S, 1984, CHEM LETT, V1, P127	6	3	3	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	OCT 29	1994	344	8931					1236	1237		10.1016/S0140-6736(94)90556-8	http://dx.doi.org/10.1016/S0140-6736(94)90556-8			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PN803	7523817				2022-12-28	WOS:A1994PN80300059
J	NATHAN, C; XIE, QW				NATHAN, C; XIE, QW			NITRIC-OXIDE SYNTHASES - ROLES, TOLLS, AND CONTROLS	CELL			English	Review							PURIFICATION; MACROPHAGES; CALMODULIN				NATHAN, C (corresponding author), CORNELL UNIV,COLL MED,DEPT MED,BEATRICE & SAMUEL SEAVER LAB,NEW YORK,NY 10021, USA.				NATIONAL CANCER INSTITUTE [R01CA043610] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL051967] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R21AI034543, R01AI034543] Funding Source: NIH RePORTER; NCI NIH HHS [CA43610] Funding Source: Medline; NHLBI NIH HHS [HL51967] Funding Source: Medline; NIAID NIH HHS [AI34543] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ABUSOUD HM, 1993, P NATL ACAD SCI USA, V90, P10769, DOI 10.1073/pnas.90.22.10769; BAEK KJ, 1993, J BIOL CHEM, V268, P21120; BREDT DS, 1994, NEURON, V13, P301, DOI 10.1016/0896-6273(94)90348-4; BUKRINSKY MI, 1994, IN PRESS J EXP MED, V180; CALDERON HC, 1994, J EXP MED, V180, P945; CHO HJ, 1992, J EXP MED, V176, P599, DOI 10.1084/jem.176.2.599; DAWSON VL, 1993, P NATL ACAD SCI USA, V90, P3256, DOI 10.1073/pnas.90.8.3256; DEMARIA R, 1994, IN PRESS J EXP MED, V180; DINERMAN JL, 1994, P NATL ACAD SCI USA, V91, P4214, DOI 10.1073/pnas.91.10.4214; ELPHICK MR, 1993, BRAIN RES, V619, P344, DOI 10.1016/0006-8993(93)91632-3; GELPERIN A, 1994, NATURE, V369, P61, DOI 10.1038/369061a0; HEISS LN, 1994, P NATL ACAD SCI USA, V91, P267, DOI 10.1073/pnas.91.1.267; HU JR, 1993, NEUROREPORT, V4, P760, DOI 10.1097/00001756-199306000-00041; IMAI T, 1994, J CLIN INVEST, V93, P543, DOI 10.1172/JCI117005; KAMIJO R, 1994, SCIENCE, V263, P1612, DOI 10.1126/science.7510419; KUNZ D, 1994, P NATL ACAD SCI USA, V91, P5387, DOI 10.1073/pnas.91.12.5387; LEE KH, 1994, J BIOL CHEM, V269, P14371; MADISON DV, 1993, P NATL ACAD SCI USA, V90, P4329, DOI 10.1073/pnas.90.10.4329; MARTIN E, 1994, J EXP MED, V180, P977, DOI 10.1084/jem.180.3.977; MORRIS SM, 1994, AM J PHYSIOL, V266, pE829, DOI 10.1152/ajpendo.1994.266.6.E829; NATHAN C, 1992, FASEB J, V6, P3051, DOI 10.1096/fasebj.6.12.1381691; NATHAN C, 1994, J BIOL CHEM, V269, P13725; OSWALD IP, 1994, P NATL ACAD SCI USA, V91, P999, DOI 10.1073/pnas.91.3.999; PERRELLA JA, 1994, J BIOL CHEM, V269, P14595; SCHMIDT HHHW, 1991, P NATL ACAD SCI USA, V88, P365, DOI 10.1073/pnas.88.2.365; SESSA WC, 1994, CIRC RES, V74, P349, DOI 10.1161/01.RES.74.2.349; SLADEK SM, 1993, AM J OBSTET GYNECOL, V169, P1285, DOI 10.1016/0002-9378(93)90295-T; STUEHR DJ, 1985, P NATL ACAD SCI USA, V82, P7738, DOI 10.1073/pnas.82.22.7738; VERGE VMK, 1992, P NATL ACAD SCI USA, V89, P11617, DOI 10.1073/pnas.89.23.11617; WEINER CP, 1994, P NATL ACAD SCI USA, V91, P5212, DOI 10.1073/pnas.91.11.5212; WEISS G, 1994, J EXP MED, V180, P969, DOI 10.1084/jem.180.3.969; WERNERFELMAYER G, 1994, IN PRESS BIOCH J; ZHANG J, 1994, SCIENCE, V263, P687, DOI 10.1126/science.8080500	33	2620	2734	2	76	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	SEP 23	1994	78	6					915	918		10.1016/0092-8674(94)90266-6	http://dx.doi.org/10.1016/0092-8674(94)90266-6			4	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	PJ294	7522969				2022-12-28	WOS:A1994PJ29400002
J	BROOKS, PC; CLARK, RAF; CHERESH, DA				BROOKS, PC; CLARK, RAF; CHERESH, DA			REQUIREMENT OF VASCULAR INTEGRIN ALPHA(V)BETA(3) FOR ANGIOGENESIS	SCIENCE			English	Article							ARG-GLY-ASP; EXTRACELLULAR-MATRIX; BLOOD-VESSELS; EXPRESSION; ADHESION; CELLS; INHIBITION; ATTACHMENT; GROWTH; ALPHA	Angiogenesis depends on the adhesive interactions of vascular cells. The adhesion receptor integrin alpha(v) beta(3), was identified as a marker of angiogenic vascular tissue. Integrin alpha(v) beta(3), was expressed on blood vessels in human wound granulation tissue but not in normal skin, and it showed a fourfold increase in expression during angiogenesis on the chick chorioallantoic membrane. In the latter assay, a monoclonal antibody to alpha(v) beta(3), blocked angiogenesis induced by basic fibroblast growth factor, tumor necrosis factor-alpha, and human melanoma fragments but had no effect on preexisting vessels. These findings suggest that alpha(v) beta(3) may be a useful therapeutic target for diseases characterized by neovascularization.	Scripps Res Inst, DEPT IMMUNOL, LA JOLLA, CA 92037 USA; SUNY STONY BROOK, SCH MED, DEPT DERMATOL, STONY BROOK, NY 11794 USA	Scripps Research Institute; State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook					NATIONAL CANCER INSTITUTE [R01CA045726, R37CA050286, R01CA050286] Funding Source: NIH RePORTER; NCI NIH HHS [CA45726, CA50286] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ADAMS JC, 1990, CELL, V63, P425, DOI 10.1016/0092-8674(90)90175-E; AUERBACH R, 1975, INT J CANCER, V15, P241, DOI 10.1002/ijc.2910150209; AUSPRUNK DH, 1975, AM J PATHOL, V79, P597; BROOKS PC, 1993, J CELL BIOL, V122, P1351, DOI 10.1083/jcb.122.6.1351; BROOKS PM, UNPUB; BUCK CA, 1986, J CELL BIOL, V103, P2421, DOI 10.1083/jcb.103.6.2421; CHENG YF, 1989, J CELL PHYSIOL, V139, P275, DOI 10.1002/jcp.1041390209; CHERESH DA, 1987, P NATL ACAD SCI USA, V84, P6471, DOI 10.1073/pnas.84.18.6471; CLARK RAF, 1982, J EXP MED, V156, P646, DOI 10.1084/jem.156.2.646; DVORAK HF, 1986, NEW ENGL J MED, V315, P1650; ENENSTEIN J, 1992, EXP CELL RES, V203, P499, DOI 10.1016/0014-4827(92)90028-7; FELDINGHABERMANN B, 1992, J CLIN INVEST, V89, P2018, DOI 10.1172/JCI115811; Folkman J, 1992, Semin Cancer Biol, V3, P65; GLADSON CL, 1991, J CLIN INVEST, V88, P1924, DOI 10.1172/JCI115516; INGBER D, 1990, NATURE, V348, P555, DOI 10.1038/348555a0; INGBER D, 1991, J CELL BIOCHEM, V47, P236, DOI 10.1002/jcb.240470309; JANAT MF, 1992, J CELL PHYSIOL, V151, P588, DOI 10.1002/jcp.1041510319; KLIER G, UNPUB; LAWLER J, 1988, J CELL BIOL, V107, P2351, DOI 10.1083/jcb.107.6.2351; LEAVESLEY DI, 1993, J CELL BIOL, V121, P163, DOI 10.1083/jcb.121.1.163; LEIBOVICH SJ, 1987, NATURE, V329, P630, DOI 10.1038/329630a0; NGUYEN M, 1993, NATURE, V365, P267, DOI 10.1038/365267a0; SWERLICK RA, 1992, J INVEST DERMATOL, V99, P715, DOI 10.1111/1523-1747.ep12614207; WEIDNER N, 1992, JNCI-J NATL CANCER I, V84, P1875, DOI 10.1093/jnci/84.24.1875; WOODY JN, 1993, DEC COMM PROSP CELL; YAMAOKA M, 1993, CANCER RES, V53, P4262	26	2589	2751	3	173	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	APR 22	1994	264	5158					569	571		10.1126/science.7512751	http://dx.doi.org/10.1126/science.7512751			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	NH010	7512751				2022-12-28	WOS:A1994NH01000037
J	LIVINGSTON, MG				LIVINGSTON, MG			RISPERIDONE	LANCET			English	Note							SCHIZOPHRENIA; SEROTONIN-S2; RECEPTORS; DOPAMINE; SAFETY				LIVINGSTON, MG (corresponding author), UNIV GLASGOW,GARTNAVEL ROYAL HOSP,DEPT PSYCHOL MED,1055 GREAT WESTERN RD,GLASGOW G12 0XH,SCOTLAND.							BERSANI G, 1986, CURR THER RES CLIN E, V40, P492; BORISON RL, 1992, PSYCHOPHARMACOL BULL, V28, P213; CHOUINARD G, 1993, J CLIN PSYCHOPHARM, V13, P25; CLAUS A, 1992, ACTA PSYCHIAT SCAND, V85, P295, DOI 10.1111/j.1600-0447.1992.tb01473.x; COOPER JE, 1987, BRIT J PSYCHIAT, V151, P619, DOI 10.1192/bjp.151.5.619; DAVIES LM, 1990, PSYCHIATRIC B, V14, P522; DELAY J, 1952, Ann Med Psychol (Paris), V110, P267; GELDERS Y, 1986, CLIN NEUROPHARMACOL, V9, P325; HOYBERG OJ, IN PRESS ACTA PSYCHI; JANSSEN PAJ, 1988, J PHARMACOL EXP THER, V244, P685; KANE J, 1988, ARCH GEN PSYCHIAT, V45, P789; KAYE SR, 1980, SCHIZ B, V13, P261; KLIESER E, 1991, RISFRG9005 JANSS CLI; LEYSEN JE, 1988, J PHARMACOL EXP THER, V247, P661; MERTENS C, 1992, R64766JRD0005 JANSS; MESOTTEN F, 1989, PSYCHOPHARMACOLOGY, V99, P445, DOI 10.1007/BF00589890; Roose K, 1988, Acta Psychiatr Belg, V88, P233; SACH MR, 1992, R64766JRD0005 JANSS; SEEMAN P, 1987, SYNAPSE, V1, P133, DOI 10.1002/syn.890010203; SEEMAN P, 1990, ACTA PSYCHIAT SCAND, V82, P14, DOI 10.1111/j.1600-0447.1990.tb05280.x; SHIELDS J, 1978, SCHIZOPHRENIA NEW SY, P56; TATOSSIAN A, 1991, RISFRA9003 JANSS CLI; YASSA R, 1992, SCHIZOPHRENIA BULL, V18, P701, DOI 10.1093/schbul/18.4.701; 1987, BRIT J PSYCHIAT, V150, P340; 1987, DIAGNOSTIC STATISTIC; 1991, RISINT3 JANSS CLIN R; 1992, RISINT2 JANSS CLIN R	27	80	80	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	FEB 19	1994	343	8895					457	460		10.1016/S0140-6736(94)92696-4	http://dx.doi.org/10.1016/S0140-6736(94)92696-4			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MW690	7508541				2022-12-28	WOS:A1994MW69000014
J	GILLESPIE, DH; CUDDY, KK; KOLBE, T; MARKS, DI				GILLESPIE, DH; CUDDY, KK; KOLBE, T; MARKS, DI			DISSOLVE AND CAPTURE - A STRATEGY FOR ANALYZING MESSENGER-RNA IN BLOOD	NATURE			English	Article							THIOCYANATE; DNA		RNA LAB INC,EAGLE,PA 19480		GILLESPIE, DH (corresponding author), HAHNEMANN UNIV,DEPT NEOPLAST DIS,ROAD & VINE,PHILADELPHIA,PA 19102, USA.							CASEY J, 1977, NUCLEIC ACIDS RES, V4, P1539, DOI 10.1093/nar/4.5.1539; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CUDDY K, 1993, NUCLEIC ACIDS RES, V21, P2281, DOI 10.1093/nar/21.9.2281; CUDDY KK, 1993, IN PRESS NOV EDGW RE; SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875; Sambrook J., 1989, MOL CLONING; THOMPSON J, 1987, ANAL BIOCHEM, V163, P281, DOI 10.1016/0003-2697(87)90225-9; THOMPSON JD, 1992, BLOOD, V79, P1629; VOGELSTEIN B, 1977, BIOCHEM BIOPH RES CO, V75, P1127, DOI 10.1016/0006-291X(77)91500-5	9	9	9	0	1	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JAN 27	1994	367	6461					390	391		10.1038/367390a0	http://dx.doi.org/10.1038/367390a0			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	MT540	7509457				2022-12-28	WOS:A1994MT54000075
J	Gardner, P; Eickhoff, T; Poland, GA; Gross, P; Griffin, M; LaForce, M; Schaffner, W; Strikas, R				Gardner, P; Eickhoff, T; Poland, GA; Gross, P; Griffin, M; LaForce, M; Schaffner, W; Strikas, R			Adult immunizations	ANNALS OF INTERNAL MEDICINE			English	Article							ATTENUATED VARICELLA VACCINE; HEPATITIS-A VACCINE; HEALTHY-CHILDREN; UNITED-STATES; SALMONELLA-TYPHI; ZOSTER VIRUS; SUSCEPTIBILITY; INFECTIONS; SEROSURVEY; RECRUITS	New vaccines have been licensed for hepatitis A, varicella, and typhoid. This paper reviews these Vaccines and their recommended uses in adults. Special attention is given to a new national policy establishing age 50 years as a time for review of preventive health measures with emphasis on evaluating risk factors that indicate a need for pneumococcal vaccine and the initiation of annual influenza immunization.	UNIV COLORADO, HLTH SCI CTR, DIV INFECT DIS, DENVER, CO 80262 USA; MAYO CLIN & MAYO FDN, MAYO VACCINE RES GRP, DEPT MED & CLIN PHARMACOL, ROCHESTER, MN 55905 USA; HACKENSACK MED CTR, DEPT INTERNAL MED, HACKENSACK, NJ 07601 USA; VANDERBILT UNIV, SCH MED, DEPT MED, NASHVILLE, TN 37232 USA; UNIV ROCHESTER, GENESSEE HOSP, SCH MED & DENT, ROCHESTER, NY 14607 USA; VANDERBILT UNIV, SCH MED, DEPT PREVENT MED, DIV INFECT DIS, NASHVILLE, TN 37232 USA; CTR DIS CONTROL & PREVENT, NATL IMMUNIZATION PROGRAM, ATLANTA, GA 30333 USA	University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; Mayo Clinic; Hackensack University Medical Center; Vanderbilt University; University of Rochester; Vanderbilt University; Centers for Disease Control & Prevention - USA	Gardner, P (corresponding author), SUNY STONY BROOK, HLTH SCI CTR, SCH MED, STONY BROOK, NY 11794 USA.							ACHARYA IL, 1987, NEW ENGL J MED, V317, P1101, DOI 10.1056/NEJM198710293171801; AKRIVIADIS EA, 1989, ANN INTERN MED, V110, P838, DOI 10.7326/0003-4819-110-10-838; ALTER SJ, 1986, INFECT CONT HOSP EP, V7, P448, DOI 10.1017/S0195941700064936; Centers for Disease Control and Prevention (CDC), 1994, MMWR Morb Mortal Wkly Rep, V43, P1; FEDSON DS, 1994, JAMA-J AM MED ASSOC, V272, P1133, DOI 10.1001/jama.272.14.1133; Gershon A A, 1994, Clin Diagn Virol, V2, P271, DOI 10.1016/0928-0197(94)90051-5; GERSHON AA, 1988, J INFECT DIS, V158, P132, DOI 10.1093/infdis/158.1.132; GERSHON AA, 1989, NEW ENGL J MED, V320, P892, DOI 10.1056/NEJM198904063201403; GREEN MS, 1993, J INFECT DIS, V168, P740, DOI 10.1093/infdis/168.3.740; GROSS PA, 1995, ANN INTERN MED, V123, P518, DOI 10.7326/0003-4819-123-7-199510010-00008; HARRIS RE, 1965, OBSTET GYNECOL, V25, P734; HOPESIMPSON RE, 1965, P ROY SOC MED, V58, P9, DOI 10.1177/003591576505800106; INNIS BL, 1994, JAMA-J AM MED ASSOC, V271, P1328, DOI 10.1001/jama.271.17.1328; JILIG W, 1994, VACCINES, P583; KANE MA, 1992, VACCINE, V10, pS93, DOI 10.1016/0264-410X(92)90555-X; KELLEY PW, 1991, JAMA-J AM MED ASSOC, V266, P2724, DOI 10.1001/jama.266.19.2724; KLUGMAN KP, 1987, LANCET, V2, P1165; KUTER BJ, 1991, VACCINE, V9, P643, DOI 10.1016/0264-410X(91)90189-D; LEMON SM, 1994, INFECT AGENT DIS, V3, P38; MCMAHON BJ, 1994, 34TH INT C ANT AG CH, pH11; MORENS DM, 1980, ANN INTERN MED, V93, P414, DOI 10.7326/0003-4819-93-3-414; NICHOL KL, 1995, NEW ENGL J MED, V333, P889, DOI 10.1056/NEJM199510053331401; NICHOL KL, 1994, NEW ENGL J MED, V331, P778, DOI 10.1056/NEJM199409223311206; RYAN CA, 1989, REV INFECT DIS, V11, P1; SHAPIRO CN, 1992, VACCINE, V10, pS59, DOI 10.1016/0264-410X(92)90545-U; STRUEWING JP, 1993, AM J PUBLIC HEALTH, V83, P1717, DOI 10.2105/AJPH.83.12.1717; TSOLIA M, 1990, J PEDIATR-US, V116, P184, DOI 10.1016/S0022-3476(05)82872-0; USA Adult Vaccine Preventable Disease Br., 1995, Morbidity and Mortality Weekly Report, V44, P506; WAGNER G, 1993, VACCINE, V11, P1027, DOI 10.1016/0264-410X(93)90128-K; WEIBEL RE, 1984, NEW ENGL J MED, V310, P1409, DOI 10.1056/NEJM198405313102201; WERZBERGER A, 1992, NEW ENGL J MED, V327, P453, DOI 10.1056/NEJM199208133270702; WHITE CJ, 1991, PEDIATRICS, V87, P604; 1995, MMWR-MORBID MORTAL W, V44, P561; 1994, GUIDE ADULT IMMUNIZA	34	46	46	0	2	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JAN 1	1996	124	1	1				35	40		10.7326/0003-4819-124-1_Part_1-199601010-00007	http://dx.doi.org/10.7326/0003-4819-124-1_Part_1-199601010-00007			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TL943	7503476				2022-12-28	WOS:A1996TL94300007
J	AVORN, J; GURWITZ, JH; BOHN, RL; MOGUN, H; MONANE, M; WALKER, A				AVORN, J; GURWITZ, JH; BOHN, RL; MOGUN, H; MONANE, M; WALKER, A			INCREASED INCIDENCE OF LEVODOPA THERAPY FOLLOWING METOCLOPRAMIDE USE	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Note							DRUG	Objective.-To determine whether there is an increase in use of antiparkinsonian therapy in older persons taking metoclopramide hydrochloride. Design.-Case-control study. Setting.-New Jersey Medicaid program. Patients.-Medicaid enrollees aged 65 years and older. Cases were patients newly prescribed a levodopa-containing medication (n=1253); a secondary case group were patients newly prescribed an anticholinergic antiparkinsonian drug (n=2377). The control group consisted of 16 435 Medicaid enrollees older than 65 years who were not users of any antiparkinsonian therapy. Main Outcome Measures.-We used logistic regression to determine the odds ratio (OR) for the initiation of antiparkinsonian therapy in patients using metoclopramide relative to nonusers, after adjusting for age, sex, race, nursing home residence, exposure to antipsychotic medication, and days hospitalized. Results.-Metoclopramide users were three times more likely to begin use of a levodopa-containing medication compared with nonusers (OR=3.09; 95% confidence interval [CI], 2.25 to 4.26). Risk increased with increasing daily metoclopramide dose: the OR was 1.19 (95% CI, 0.50 to 2.81) for more than 0 to 10 mg per day, 3.33 (95% CI, 1.98 to 5.58) for more than 10 to 20 mg per day, and 5.25 (95% CI, 1.16 to 8.50) for more than 20 mg per day. The effect persisted after adjustment for demographic, health service utilization, and medication use variables. The OR for initiation of anticholinergic antiparkinsonian drugs was also elevated in metoclopramide users. Conclusion.-Metoclopramide use confers an increased risk for the initiation of treatment generally reserved for the management of idiopathic Parkinson's disease. Such polypharmacy may represent the misdiagnosis of Parkinson's disease in patients with drug-induced parkinsonian symptoms, which should be ruled out before starting dopaminergic therapy for this condition.	HARVARD UNIV,SCH MED,BOSTON,MA; HARVARD UNIV,SCH PUBL HLTH,DEPT EPIDEMIOL,BOSTON,MA 02115	Harvard University; Harvard Medical School; Harvard University; Harvard T.H. Chan School of Public Health	AVORN, J (corresponding author), BRIGHAM & WOMENS HOSP,DEPT MED,DIV GERONTOL,PROGRAM ANAL CLIN STRATEGIES,221 LONGWOOD AVE,BOSTON,MA 02115, USA.				NIA NIH HHS [AG09634] Funding Source: Medline; NATIONAL INSTITUTE ON AGING [R01AG009634] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Avorn J, 1993, J Glaucoma, V2, P158; AVORN J, 1990, JAMA-J AM MED ASSOC, V263, P1823, DOI 10.1001/jama.263.13.1823; AVORN J, 1995, AM J MED, V99, P48, DOI 10.1016/S0002-9343(99)80104-1; AVORN J, 1990, GERIATRIC MED; BERKOW R, 1992, MERCK MANUAL DIAGNOS, P1283; BRIGHT RA, 1989, J CLIN EPIDEMIOL, V42, P937, DOI 10.1016/0895-4356(89)90158-3; DURAZO FA, 1993, AM J GASTROENTEROL, V88, P1657; Gilman AG., 1990, J MED CHEM, V8th, DOI DOI 10.1021/acs.jmedchem.8b01308; GURWITZ JH, 1991, ANN INTERN MED, V114, P956, DOI 10.7326/0003-4819-114-11-956; GURWITZ JH, 1994, ARCH INTERN MED, V154, P97, DOI 10.1001/archinte.154.1.97; KALISH SC, 1995, J AM GERIATR SOC, V43, P967, DOI 10.1111/j.1532-5415.1995.tb05559.x; Koller W, 1987, Adv Neurol, V45, P317; MARTTILA RJ, 1976, ACTA NEUROL SCAND, V53, P81; MCEVOY GK, 1995, AHFS 95 DRUG INFORMA, P2042; SNAPE WJ, 1982, ANN INTERN MED, V96, P444, DOI 10.7326/0003-4819-96-4-444; 1993, MED LETT DRUGS THER, V35, P124	16	45	46	0	3	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	DEC 13	1995	274	22					1780	1782		10.1001/jama.274.22.1780	http://dx.doi.org/10.1001/jama.274.22.1780			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TJ225	7500509				2022-12-28	WOS:A1995TJ22500028
J	CLAYTON, EW; STEINBERG, KK; KHOURY, MJ; THOMSON, E; ANDREWS, L; KAHN, MJE; KOPELMAN, LM; WEISS, JO				CLAYTON, EW; STEINBERG, KK; KHOURY, MJ; THOMSON, E; ANDREWS, L; KAHN, MJE; KOPELMAN, LM; WEISS, JO			INFORMED CONSENT FOR GENETIC RESEARCH ON STORED TISSUE SAMPLES	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article								Objective.-To develop recommendations for obtaining adequate informed consent in the future when gathering tissue samples that may be used for genetic studies and defining the circumstances under which it is necessary to obtain further consent if tissue samples already in hand are to be used for such research. Participants.-Scientists, ethicists, lawyers, and consumers selected by the National Center for Human Genome Research and the Centers for Disease Control and Prevention to represent a wide array of opinions. Evidence.-Statutes, regulations, and cases and articles on law and ethics. Consensus Process.-Initial workshop, followed by circulation of several drafts of this document with opportunities for comment by workshop participants and others as well as smaller meetings involving participants with widely differing views. Conclusions.-Genetic research using stored tissue samples poses an array of benefits and risks to individuals, researchers, and society, As a result, the workshop participants conclude that (1) informed consent is required for all genetic research using linkable samples unless conditions for limitation or waiver are met; (2) informed consent is not required for genetic research using anonymous samples but may be considered if identifiers are to be removed from currently linkable samples; (3) institutional review boards could usefully review all protocols that propose to use samples for genetic research; and (4) further work regarding these issues is warranted.	VANDERBILT UNIV, DEPT PEDIAT, NASHVILLE, TN USA; VANDERBILT UNIV, SCH LAW, NASHVILLE, TN 37240 USA; CTR DIS CONTROL & PREVENT, BIRTH DEFECTS & GENET DIS BRANCH, MOLEC BIOL BRANCH, ATLANTA, GA 30341 USA; NATL CTR HUMAN GENOME RES, BETHESDA, MD USA; CHICAGO KENT COLL LAW, CHICAGO, IL USA; NATL BREAST CANC COALIT, WASHINGTON, DC USA; VIRGINIA BREAST CANC FDN, RICHMOND, VA USA; E CAROLINA UNIV, SCH MED, DEPT MED HUMANITIES, GREENVILLE, NC USA; ALLIANCE GENET SUPPORT GRP, CHEVY CHASE, MD USA	Vanderbilt University; Vanderbilt University; Centers for Disease Control & Prevention - USA; National Institutes of Health (NIH) - USA; NIH National Human Genome Research Institute (NHGRI); University of North Carolina; East Carolina University				Clayton, Ellen/0000-0002-0308-4110				ANDREWS L, 1987, MED GENETICS LEGAL F; ANDREWS LB, 1986, HASTINGS CTR REP OCT, P28; ANNAS GJ, 1995, GENETIC PRIVACY ACT; CAPRON AM, 1991, J CLIN EPIDEMIOL, V44, pS81; Clayton Ellen Wright, 1992, Houst Law Rev, V29, P85; CLAYTON EW, 1995, AM J MED GENET, V57, P630, DOI 10.1002/ajmg.1320570423; EARLEY CL, 1995, AM J HUM GENET, V57, P727; FEINLEIB M, 1991, J CLIN EPIDEMIOL, V44, pS73; HARPER PS, 1994, GENETIC COUNSELING P, P84; KOHRMAN A, 1995, PEDIATRICS, V95, P314; Last J M, 1991, Law Med Health Care, V19, P166, DOI 10.1111/j.1748-720X.1991.tb01811.x; LAST JM, 1991, J CLIN EPIDEMIOL, V44, pS95; LEVINE ROBERT J., 1988, ETHICS REGULATION CL, V2nd; MALONEY DM, 1984, PROTECTION HUMAN RES, P127; MCEWEN JE, 1994, ASSESSING GENETIC RI; PELIAS MZ, 1991, AM J MED GENET, V39, P347, DOI 10.1002/ajmg.1320390320; WEIR RF, 1995, IRB, V17, P1; WERTZ DC, 1994, JAMA-J AM MED ASSOC, V272, P875, DOI 10.1001/jama.272.11.875; WILFOND BS, 1995, AM J HUM GENET, V57, P1233; 1993, PROTECTING HUMAN RES	20	212	215	0	23	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	DEC 13	1995	274	22					1786	1792		10.1001/jama.274.22.1786	http://dx.doi.org/10.1001/jama.274.22.1786			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TJ225	7500511				2022-12-28	WOS:A1995TJ22500030
J	WARNOCK, DW; DELVES, HT; CAMPELL, CK; CROUDACE, IW; DAVEY, KG; JOHNSON, EM; SIENIAWSKA, C				WARNOCK, DW; DELVES, HT; CAMPELL, CK; CROUDACE, IW; DAVEY, KG; JOHNSON, EM; SIENIAWSKA, C			TOXIC GAS GENERATION FROM PLASTIC MATTRESSES AND SUDDEN-INFANT-DEATH-SYNDROME	LANCET			English	Article								Microbial generation of toxic gases from antimony, arsenic, or phosphorus in compounds used as fire retardants in cot mattresses has been proposed as a cause of sudden infant death. To test this hypothesis, 23 polyvinyl chloride mattress samples from cot death cases were incubated on malt agar plates until good microbial growth was obtained. Silver nitrate and mercuric chloride test papers were then inserted and the colour reactions recorded. The predominant organism, recovered from all mattresses tested, was not, as claimed in earlier work, the fungus Scopulariopsis brevicaulis, but a mix of common environmental Bacillus spp. Test paper colour changes occurred whenever bacterial growth was present, but these reactions also occurred in control tests in which no mattress material was present on the plates. Chemical and instrumental analyses of exposed test papers showed that the colour reactions were not due to deposits of antimony, arsenic, or phosphorus. Our findings do not support the hypothesis that toxic gases derived from antimony, arsenic, or phosphorus are a cause of sudden infant death. More sulphur was found in test papers exposed in plates containing bacterial growth than in those without such growth. This result suggests that the test paper reactions were due to the generation of sulphur-containing compounds during bacterial growth on the agar medium.	SOUTHAMPTON GEN HOSP,DEPT CLIN BIOCHEM,TRACE ELEMENT UNIT,SOUTHAMPTON SO9 4XY,HANTS,ENGLAND; UNIV SOUTHAMPTON,SOUTHAMPTON OCEANOG CTR,DEPT GEOL,SOUTHAMPTON,HANTS,ENGLAND	University of Southampton; NERC National Oceanography Centre; University of Southampton	WARNOCK, DW (corresponding author), PUBL HLTH LAB,PHLS MYCOL REFERENCE LAB,BRISTOL BS2 8EL,AVON,ENGLAND.		Croudace, Ian W/N-7018-2013	Croudace, Ian W/0000-0003-1547-5650				CULLEN WR, 1989, CHEM REV, V89, P713, DOI 10.1021/cr00094a002; GATES PN, 1995, LANCET, V345, P386, DOI 10.1016/S0140-6736(95)90372-0; KELLEY J, 1992, HUM EXP TOXICOL, V11, P247; MORTON FJ, 1963, 86 COMM MYC I MYC PA; ONIONS AHS, 1966, SCOPULARIOPSIS BREVI; RICHARDSON BA, 1994, J FORENSIC SCI SOC, V34, P199, DOI 10.1016/S0015-7368(94)72915-7; RICHARDSON BA, 1990, LANCET, V335, P670, DOI 10.1016/0140-6736(90)90463-F; TURNBULL PCB, 1990, TOPLEY WILSONS PRINC, V2, P187; 1991, SUDDEN INFANT DEATH	9	33	33	0	2	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	DEC 9	1995	346	8989					1516	1520		10.1016/S0140-6736(95)92051-X	http://dx.doi.org/10.1016/S0140-6736(95)92051-X			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TJ291	7491046				2022-12-28	WOS:A1995TJ29100010
J	WURTMAN, RJ; ZHDANOVA, I				WURTMAN, RJ; ZHDANOVA, I			IMPROVEMENT OF SLEEP QUALITY BY MELATONIN	LANCET			English	Letter											WURTMAN, RJ (corresponding author), MIT,DEPT BRAIN & COGNIT SCI,E25-618,CAMBRIDGE,MA 02142, USA.			Zhdanova, Irina/0000-0002-8401-9571				DOLLINS AB, 1994, P NATL ACAD SCI USA, V91, P1824, DOI 10.1073/pnas.91.5.1824; GARFINKEL, 1995, LANCET          0826, P541; ZHDANOVA IV, 1995, CLIN PHARMACOL THER, V57, P552, DOI 10.1016/0009-9236(95)90040-3	3	119	121	0	13	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	DEC 2	1995	346	8988					1491	1491		10.1016/S0140-6736(95)92509-0	http://dx.doi.org/10.1016/S0140-6736(95)92509-0			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TH156	7491013				2022-12-28	WOS:A1995TH15600048
J	KAULA, WM				KAULA, WM			VENUS RECONSIDERED	SCIENCE			English	Article							THERMAL EVOLUTION; PHASE-TRANSITION; MAGELLAN DATA; TECTONICS; MODEL; CONSTRAINTS; MANTLE; EARTH; WATER	The Magellan imagery shows that Venus has a crater abundance equivalent to a surface age of 300 million to 500 million years and a crater distribution close to random. Hence, the tectonics of Venus must be quiescent compared to those of Earth in the last few 100 million years. The main debate is whether the decline in tectonic activity on Venus is closer to monotonic or episodic, with enhanced tectonism and volcanism yet to come. The former hypothesis implies that most radioactive heat sources have been differentiated upward; the latter, that they have remained at depth. The low level of activity in the last few 100 million years inferred from imagery favors the monotonic hypothesis; some chemical evidence, particularly the low abundance of radiogenic argon, favors the episodic. A problem for both hypotheses is the rapid decline of thermal and tectonic activity some 300 million to 500 million years ago. The nature of the convective instabilities that caused the decline, and their propagation, are unclear.			KAULA, WM (corresponding author), UNIV CALIF LOS ANGELES, DEPT EARTH & SPACE SCI, LOS ANGELES, CA 90095 USA.							ARKANIHAMED J, 1994, J GEOPHYS RES-PLANET, V99, P2019, DOI 10.1029/93JE03172; ARKANIHAMED J, 1993, J GEOPHYS RES-PLANET, V98, P5309, DOI 10.1029/93JE00052; ARKANIHAMED J, 1993, PHYS EARTH PLANET IN, V76, P75, DOI 10.1016/0031-9201(93)90056-F; BAKER VR, 1992, J GEOPHYS RES-PLANET, V97, P13421, DOI 10.1029/92JE00927; BIRD GP, 1995, REV GEOPHYS S, V33, P379; BRACKETT RA, 1995, J GEOPHYS RES-PLANET, V100, P1553, DOI 10.1029/94JE02708; Burnham C. W., 1979, EVOLUTION IGNEOUS RO, P439, DOI DOI 10.2307/J.CTT13X1DKM.19; CARLSON RW, 1994, REV GEOPHYS, V32, P337, DOI 10.1029/94RG01874; FORSYTH DW, 1985, J GEOPHYS RES-SOLID, V90, P2623, DOI 10.1029/JB090iB14p12623; FREED AM, 1995, LUNAR PLANET SCI C, V26, P421; GREEN DH, 1973, EARTH PLANET SC LETT, V19, P37, DOI 10.1016/0012-821X(73)90176-3; GRIMM RE, 1988, J GEOPHYS RES-SOLID, V93, P11911, DOI 10.1029/JB093iB10p11911; GRIMM RE, 1994, J GEOPHYS RES-PLANET, V99, P23163, DOI 10.1029/94JE02196; HERRICK RR, 1994, GEOLOGY, V22, P703, DOI 10.1130/0091-7613(1994)022<0703:RHOV>2.3.CO;2; Herzog S. G., 1995, LUNAR PLANET SCI C, P591; IVANOV MA, 1993, GEOPHYS RES LETT, V20, P2579, DOI 10.1029/93GL02692; JULL MG, 1995, PHYS EARTH PLANET IN, V89, P163, DOI 10.1016/0031-9201(95)03015-O; KARATO SI, 1986, J GEOPHYS RES-SOLID, V91, P8151, DOI 10.1029/JB091iB08p08151; KARGEL JS, 1993, ICARUS, V103, P253, DOI 10.1006/icar.1993.1069; KAULA WM, 1993, GEOPHYS RES LETT, V20, P2583, DOI 10.1029/93GL03086; KAULA WM, 1981, GEOPHYS RES LETT, V8, P1187, DOI 10.1029/GL008i012p01187; KAULA WM, 1992, J GEOPHYS RES-PLANET, V97, P16085, DOI 10.1029/92JE01643; KAULA WM, 1990, SCIENCE, V247, P1191, DOI 10.1126/science.247.4947.1191; KAULA WM, UNPUB; KAULA WM, 1993, LUNAR PLANET SCI C, V24, P767; KIEFER WS, 1986, GEOPHYS RES LETT, V13, P14, DOI 10.1029/GL013i001p00014; KLOSE KB, 1992, J GEOPHYS RES-PLANET, V97, P16353, DOI 10.1029/92JE01865; KONOPLIV AS, UNPUB; LACHENBRUCH AH, 1970, J GEOPHYS RES, V75, P3291, DOI 10.1029/JB075i017p03291; LITHGOWBERTELLONI C, 1993, GEOPHYS RES LETT, V20, P375, DOI 10.1029/93GL00168; MACKWELL SJ, 1995, ROCK MECHANICS - PROCEEDINGS OF THE 35TH U.S. SYMPOSIUM, P207; NAMIKI N, 1994, SCIENCE, V265, P929, DOI 10.1126/science.265.5174.929; NAMIKI N, 1993, J GEOPHYS RES-PLANET, V98, P15025, DOI 10.1029/93JE01626; NAMIKI N, 1995, LUNAR PLANET SCI, V26, P1029; NIKOLAYEVA OV, 1995, LUNAR PLANET SCI C, V26, P1049; PARMENTIER EM, 1992, GEOPHYS RES LETT, V19, P2015, DOI 10.1029/92GL01862; PHILLIPS RJ, 1995, GEOPHYS RES LETT, V22, P1517, DOI 10.1029/95GL01412; PHILLIPS RJ, 1992, J GEOPHYS RES-PLANET, V97, P15923, DOI 10.1029/92JE01696; PHILLIPS RJ, 1994, ANNU REV EARTH PL SC, V22, P597, DOI 10.1146/annurev.ea.22.050194.003121; PHILLIPS RJ, 1991, SCIENCE, V252, P651, DOI 10.1126/science.252.5006.651; PHILLIPS RJ, 1990, J GEOPHYS RES-SOLID, V95, P1301, DOI 10.1029/JB095iB02p01301; PHILLIPS RJ, 1990, LUNAR PLANET SCI, V21, P1065; POLLACK JB, 1992, ICARUS, V51, P169; PRICE M, 1994, NATURE, V372, P756, DOI 10.1038/372756a0; SANDWELL DT, 1992, SCIENCE, V257, P766, DOI 10.1126/science.257.5071.766; SCHABER GG, 1992, J GEOPHYS RES-PLANET, V97, P13257, DOI 10.1029/92JE01246; SCHATZ JF, 1972, J GEOPHYS RES, V77, P6966, DOI 10.1029/JB077i035p06966; SOLOMON SC, 1993, LUNAR PLANET SCI, V24, P1331; STEVENSON DJ, 1983, ICARUS, V54, P466, DOI 10.1016/0019-1035(83)90241-5; STROM RG, 1994, J GEOPHYS RES-PLANET, V99, P10899, DOI 10.1029/94JE00388; SURKOV YA, 1987, J GEOPHYS RES-SOLID, V92, pE537, DOI 10.1029/JB092iB04p0E537; SURKOV YA, 1984, J GEOPHYS RES S, V89, pB383; TACKLEY PJ, 1993, NATURE, V361, P699, DOI 10.1038/361699a0; TURCOTTE DL, 1993, J GEOPHYS RES-PLANET, V98, P17061, DOI 10.1029/93JE01775; ZUBER MT, 1987, J GEOPHYS RES-SOLID, V92, pE541, DOI 10.1029/JB092iB04p0E541	55	28	28	0	7	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	DEC 1	1995	270	5241					1460	1464		10.1126/science.270.5241.1460	http://dx.doi.org/10.1126/science.270.5241.1460			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TH375	7491490				2022-12-28	WOS:A1995TH37500029
J	JUDGE, K				JUDGE, K			INCOME-DISTRIBUTION AND LIFE EXPECTANCY - A CRITICAL-APPRAISAL	BRITISH MEDICAL JOURNAL			English	Article							MORTALITY	In a series of papers published during the past decade Richard Wilkinson has advanced the view that income inequality is the key determinant of variations in average life expectancy at birth among developed countries. Yet a careful examination of the two sources of data on income distribution most often used by Wilkinson suggests that if they are analysed more appropriately they do not lend support to his claims. More recent data on income distribution is now available for several countries in the Organisation for Economic Development and Cooperation in the mid-1980s and for Great Britain from 1961 to 1991. The use of these data also casts doubt on the hypothesis that inequalities in the distribution of income are closely associated with variations in average life expectancy at birth among the richest nations of the world.			JUDGE, K (corresponding author), KINGS FUND POLICY INST,11-13 CAVENDISH SQ,LONDON W1M 0AN,ENGLAND.							BISHOP JA, 1991, ECONOMICA, V58, P461, DOI 10.2307/2554692; BISHOP JA, 1989, LIS26 WORK PAP; BUHMANN B, 1988, REV INCOME WEALTH, V34, P115; Evans R. G., 1994, WHY ARE SOME PEOPLE; FORSTER M, 1993, LIS100 WORK PAP; Goodman A., 1994, RICHER POORER CHANGI; LUNDBERG O, 1994, EUROPEAN SERIES, V54; MACKENBACH JP, 1994, J EPIDEMIOL COMMUN H, V48, P140, DOI 10.1136/jech.48.2.140; MATSAGANIS M, 1992, THESIS  BRISTOL BRIS; ODONNELL O, 1991, J HEALTH ECON, V10, P1, DOI 10.1016/0167-6296(91)90014-E; OHIGGINS M, 1990, ANAL POVERTY EUROPEA, P87; PANETH N, 1994, BRIT MED J, V310, P411; PAPPAS G, 1993, NEW ENGL J MED, V329, P103, DOI 10.1056/NEJM199307083290207; QUICK A, 1991, INCOME HLTH; SMEEDING TM, 1990, POVERTY INEQUALITY I, P1; Wilkinson R.G., 1994, PAYING INEQUALITY, P24; WILKINSON RG, 1990, SOCIOL HEALTH ILL, V12, P391, DOI 10.1111/1467-9566.ep11340405; WILKINSON RG, 1992, BRIT MED J, V304, P165, DOI 10.1136/bmj.304.6820.165; WILKINSON RG, 1986, CLASS HLTH RES LONGI, P88; WILKINSON RG, 1994, SOCIOLOGY HLTH ILLNE, V16, P2; WILKINSON RG, 1994, UNFAIR SHARES EFFECT; WILKINSON RG, 1993, HLTH WEALTH POVERTY, P6; WILKINSON RG, 1993, LOCATING HLTH SOCIOL, P7; 1993, SOCIAL INDICATORS DE; 1993, 1993 WORLD BANK DEV; 1994, SOCIAL JUSTICE STRAT; 1992, 1 DEP HLTH RES PAP	27	112	116	0	9	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	NOV 11	1995	311	7015					1282	1285		10.1136/bmj.311.7015.1282	http://dx.doi.org/10.1136/bmj.311.7015.1282			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	TE859	7496240	Green Published			2022-12-28	WOS:A1995TE85900028
J	KONSTAN, MW; BYARD, PJ; HOPPEL, CL; DAVIS, PB				KONSTAN, MW; BYARD, PJ; HOPPEL, CL; DAVIS, PB			EFFECT OF HIGH-DOSE IBUPROFEN IN PATIENTS WITH CYSTIC-FIBROSIS	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							ANTI-INFLAMMATORY AGENTS; ALTERNATE-DAY PREDNISONE; PSEUDOMONAS-AERUGINOSA; LEUKOCYTE MIGRATION; RESPONSES; INVITRO; INVIVO; DRUGS	Background. Since the inflammatory response to chronic infection contributes to lung destruction in patients with cystic fibrosis, we hypothesized that antiinflammatory therapy might slow the progression of lung disease. Methods. In a double-blind trial, 85 patients, 5 to 39 years of age, with mild lung disease (forced expiratory volume in one second [FEV(1)], greater than or equal to 60 percent of the predicted value) were randomly assigned to receive ibuprofen or placebo orally twice daily for four years. Doses were adjusted individually to achieve peak plasma concentrations of 50 to 100 mu g per milliliter. Changes in pulmonary function, the percentage of ideal body weight, the chest-radiograph score, and the frequency of hospitalization were assessed. Results. Patients randomly assigned to ibuprofen had a slower annual rate of change in FEV(1) than the patients assigned to placebo (mean [+/-SE] slope, -2.17+/-0.57 percent vs. -3.60+/-0.55 percent in the placebo group; weight) was better maintained in the former group (P = 0.02), Among the patients who took ibuprofen for four years and had at least a 70 percent rate of compliance, the annual rate of change in FEV(1) was even slower (-1.48+-0.69 percent vs. -3.57+/-0.65 percent in the placebo group, P=0.03), and this group of patients also had a significantly slower rate of decline in forced vital capacity, the percentage of ideal body weight, and the chest-radiograph score. There was no significant difference between the ibuprofen and placebo groups in the frequency of hospitalization. One patient was withdrawn from the study because of conjunctivitis, and one because of epistaxis related to ibuprofen. Conclusions. In patients with cystic fibrosis and mild lung disease, high-dose ibuprofen, taken consistently for four years, significantly slows the progression of the lung disease without serious adverse effects.	CASE WESTERN RESERVE UNIV,RAINBOW BABIES & CHILDRENS HOSP,SCH MED,DEPT MED,CLEVELAND,OH 44106; CASE WESTERN RESERVE UNIV,RAINBOW BABIES & CHILDRENS HOSP,SCH MED,DEPT PHARMACOL,CLEVELAND,OH 44106; VET AFFAIRS MED CTR,CLEVELAND,OH	Case Western Reserve University; Case Western Reserve University Hospital; University Hospitals of Cleveland; Rainbow Babies & Children's Hospital; Case Western Reserve University; Case Western Reserve University Hospital; University Hospitals of Cleveland; Rainbow Babies & Children's Hospital; US Department of Veterans Affairs; Veterans Health Administration (VHA); Case Western Reserve University; Louis Stokes Cleveland Veterans Affairs Medical Center	KONSTAN, MW (corresponding author), CASE WESTERN RESERVE UNIV,RAINBOW BABIES & CHILDRENS HOSP,SCH MED,DEPT PEDIAT,2101 ADELBERT RD,CLEVELAND,OH 44106, USA.			Konstan, Michael/0000-0002-0557-7277	NCRR NIH HHS [MO1 RR-00080] Funding Source: Medline; NIDDK NIH HHS [P30-DK27651] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR000080] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK027651] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		[Anonymous], 1987, Am Rev Respir Dis, V136, P1285; AUERBACH HS, 1985, LANCET, V2, P686; BRASFIELD D, 1979, PEDIATRICS, V63, P24; BROWN KA, 1977, ANN RHEUM DIS, V36, P239, DOI 10.1136/ard.36.3.239; DAVIS PB, 1994, NEW ENGL J MED, V331, P672, DOI 10.1056/NEJM199409083311011; FLYNN PJ, 1984, INFLAMMATION, V8, P33, DOI 10.1007/BF00918351; GASKIN K, 1982, J PEDIATR-US, V100, P857, DOI 10.1016/S0022-3476(82)80501-5; HIGGS GA, 1980, EUR J PHARMACOL, V66, P81, DOI 10.1016/0014-2999(80)90297-6; KAPLAN HB, 1984, BIOCHEM PHARMACOL, V33, P371, DOI 10.1016/0006-2952(84)90228-4; KEREM E, 1992, NEW ENGL J MED, V326, P1187, DOI 10.1056/NEJM199204303261804; KNUDSON RJ, 1983, AM REV RESPIR DIS, V127, P725; Konstan M.W., 1993, CYSTIC FIBROSIS, V64, P219; KONSTAN MW, 1994, AM J RESP CRIT CARE, V150, P448, DOI 10.1164/ajrccm.150.2.8049828; KONSTAN MW, 1991, J PEDIATR-US, V118, P956, DOI 10.1016/S0022-3476(05)82218-8; KONSTAN MW, 1990, AM REV RESPIR DIS, V141, P186, DOI 10.1164/ajrccm/141.1.186; KONSTAN MW, 1989, PEDIATR PULM, V4, P152; KRAEMER R, 1978, ACTA PAEDIATR SCAND, V67, P33, DOI 10.1111/j.1651-2227.1978.tb16273.x; MADERAZO EG, 1984, J PHARM SCI, V73, P1403, DOI 10.1002/jps.2600731020; MINKLER PE, 1988, J CHROMATOGR-BIOMED, V428, P388, DOI 10.1016/S0378-4347(00)83933-X; RINALDO JE, 1986, AM J MED SCI, V291, P29, DOI 10.1097/00000441-198601000-00007; ROSENSTEIN BJ, 1991, PEDIATRICS, V87, P245; SHIMANUKI T, 1985, INFLAMMATION, V9, P285, DOI 10.1007/BF00916277; SORDELLI DO, 1985, EUR J RESPIR DIS, V67, P118; SPISANI S, 1979, EXPERIENTIA, V35, P803, DOI 10.1007/BF01968260; VENEZIO FR, 1985, J INFECT DIS, V152, P690, DOI 10.1093/infdis/152.4.690; WAGENER JS, 1980, PERSPECTIVES CYSTIC, P236; 1990, AM J DIS CHILD, V144, P1311; 1988, PHYSICIANS DESK REFE, P2138	28	564	591	0	30	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	MAR 30	1995	332	13					848	854		10.1056/NEJM199503303321303	http://dx.doi.org/10.1056/NEJM199503303321303			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QP228	7503838				2022-12-28	WOS:A1995QP22800003
J	SLATIN, SL; QIU, XQ; JAKES, KS; FINKELSTEIN, A				SLATIN, SL; QIU, XQ; JAKES, KS; FINKELSTEIN, A			IDENTIFICATION OF A TRANSLOCATED PROTEIN SEGMENT IN A VOLTAGE-DEPENDENT CHANNEL	NATURE			English	Article							COLICIN-E1 ION CHANNEL; PLANAR LIPID BILAYERS; HELICAL HAIRPIN; MEMBRANE; TOPOGRAPHY	VOLTAGE-GATED channels undergo a conformational change in response to changes in transmembrane voltage. Here we use site-directed biotinylation to create conformation-sensitive sites on colicin Ia, a bacteriocidal protein that forms a voltage-sensitive membrane channel, which can be monitored by electrophysiological methods(1,2). We investigated a model of gating developed for the partly homologous colicin E1 that is based on the insertion of regions of the protein into the membrane in response to cis-positive voltages(3-6). Site-directed cysteine mutagenesis, followed by chemical modification, was used to attach a biotin molecule covalently to a series of unique sites on colicin Ia. The modified protein was incorporated into planar lipid membranes, where the introduced biotin moiety served as a site to bind the water-soluble protein streptavidin, added to one side of the membrane or the other. Our results show that colicin gating is associated with the translocation across the membrane of a segment of the protein of at least 31 amino acids.			SLATIN, SL (corresponding author), YESHIVA UNIV ALBERT EINSTEIN COLL MED,DEPT PHYSIOL & BIOPHYS,BRONX,NY 10461, USA.							ABRAMS CK, 1991, J GEN PHYSIOL, V98, P77, DOI 10.1085/jgp.98.1.77; BLOBEL G, 1975, J CELL BIOL, V67, P835, DOI 10.1083/jcb.67.3.835; CRAMER WA, 1990, MOL MICROBIOL, V4, P519, DOI 10.1111/j.1365-2958.1990.tb00619.x; CRONAN JE, 1990, J BIOL CHEM, V265, P10327; DUCHE D, 1994, J BIOL CHEM, V269, P6332; ENGELMAN DM, 1981, CELL, V23, P411, DOI 10.1016/0092-8674(81)90136-7; GREEN NM, 1971, BIOCHEM J, V125, P781, DOI 10.1042/bj1250781; LAKEY JH, 1993, J MOL BIOL, V230, P1055, DOI 10.1006/jmbi.1993.1218; MANKOVICH JA, 1986, J BACTERIOL, V168, P228, DOI 10.1128/jb.168.1.228-236.1986; MERRILL AR, 1990, BIOCHEMISTRY-US, V29, P8529, DOI 10.1021/bi00489a004; PALMER LR, 1994, J BIOL CHEM, V269, P4187; PARKER MW, 1989, NATURE, V337, P93, DOI 10.1038/337093a0; PATTUS F, 1990, EXPERIENTIA, V46, P180; QIU XQ, 1994, J BIOL CHEM, V269, P7483; SHIN YK, 1993, SCIENCE, V259, P960, DOI 10.1126/science.8382373; SLATIN SL, 1986, J MEMBRANE BIOL, V92, P247, DOI 10.1007/BF01869393; SLATIN SL, 1988, INT J BIOCHEM, V20, P737, DOI 10.1016/0020-711X(88)90058-4; SONG HY, 1991, J BACTERIOL, V173, P2927, DOI 10.1128/JB.173.9.2927-2934.1991; ZHANG YL, 1992, PROTEIN SCI, V1, P1666, DOI 10.1002/pro.5560011215	19	153	157	1	7	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	SEP 8	1994	371	6493					158	161		10.1038/371158a0	http://dx.doi.org/10.1038/371158a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PF191	7521016				2022-12-28	WOS:A1994PF19100064
J	WANG, H; LAMBOWITZ, AM				WANG, H; LAMBOWITZ, AM			THE MAURICEVILLE PLASMID REVERSE-TRANSCRIPTASE CAN INITIATE CDNA SYNTHESIS DE-NOVO AND MAY BE RELATED TO REVERSE-TRANSCRIPTASE AND DNA-POLYMERASE PROGENITOR	CELL			English	Article							RNA-LIKE STRUCTURES; MITOCHONDRIAL PLASMIDS; VIRUS RNA; 3' END; NEUROSPORA; ORIGIN; REPLICATION; EVOLUTION; SEQUENCE; ELEMENTS	We show that the reverse transcriptase (RT) encoded by the Mauriceville mitochondrial plasmid of Neurospora closely resembles viral RNA-dependent RNA polymerases in initiating cDNA synthesis opposite the penultimate C residue of a 3' tRNA-like structure and has the unprecedented ability for a DNA polymerase to initiate DNA synthesis at a specific site in a natural template without a primer. The Mauriceville plasmid enzyme can also use DNA or RNA primers in a manner suggesting how a primitive RT could have evolved from an RNA-dependent RNA polymerase into retroviral and other types of RTs. The characteristics of the Mauriceville plasmid RT suggest that it may be related to the progenitor of present-day RTs and DNA polymerases.	OHIO STATE UNIV,DEPT BIOCHEM,COLUMBUS,OH 43210; OHIO STATE UNIV,DEPT MED BIOCHEM,COLUMBUS,OH 43210; OHIO STATE UNIV,CTR BIOTECHNOL,COLUMBUS,OH 43210	University System of Ohio; Ohio State University; University System of Ohio; Ohio State University; University System of Ohio; Ohio State University	WANG, H (corresponding author), OHIO STATE UNIV,DEPT MOLEC GENET,COLUMBUS,OH 43210, USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM037949] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM37949] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AKINS RA, 1988, J MOL BIOL, V204, P1, DOI 10.1016/0022-2836(88)90594-3; AKINS RA, 1989, MOL CELL BIOL, V9, P678, DOI 10.1128/MCB.9.2.678; AKINS RA, 1986, CELL, V47, P505, DOI 10.1016/0092-8674(86)90615-X; BARAT C, 1989, EMBO J, V8, P3279, DOI 10.1002/j.1460-2075.1989.tb08488.x; BLACKBURN EH, 1991, NATURE, V350, P569, DOI 10.1038/350569a0; BLUMENTHAL T, 1979, ANNU REV BIOCHEM, V48, P525, DOI 10.1146/annurev.bi.48.070179.002521; BRUCE AG, 1978, NUCLEIC ACIDS RES, V5, P3665, DOI 10.1093/nar/5.10.3665; CLARK JM, 1988, NUCLEIC ACIDS RES, V16, P9677, DOI 10.1093/nar/16.20.9677; COLLINS RA, 1981, CELL, V24, P443, DOI 10.1016/0092-8674(81)90335-4; DARNELL JE, 1986, P NATL ACAD SCI USA, V83, P1271, DOI 10.1073/pnas.83.5.1271; Davis R.H., 1970, METHODS ENZYMOL, V17, P79, DOI [10.1016/0076-6879(71)17168-6, DOI 10.1016/0076-6879(71)17168-6]; Deininger PL, 1989, MOBILE DNA, P619; DELARUE M, 1990, PROTEIN ENG, V3, P461, DOI 10.1093/protein/3.6.461; Eickbush Thomas H., 1994, P121; FERAT JL, 1993, NATURE, V364, P358, DOI 10.1038/364358a0; GILBERT W, 1986, NATURE, V319, P618, DOI 10.1038/319618a0; GROSSHANS CA, 1991, NUCLEIC ACIDS RES, V19, P3875, DOI 10.1093/nar/19.14.3875; INOUYE M, 1991, ANNU REV MICROBIOL, V45, P163; KENNELL JC, 1993, CELL, V73, P133, DOI 10.1016/0092-8674(93)90166-N; KOHLSTAEDT LA, 1992, SCIENCE, V256, P1783, DOI 10.1126/science.1377403; Kornberg A., 1992, DNA REPLICATION; KUIPER MTR, 1988, CELL, V55, P693, DOI 10.1016/0092-8674(88)90228-0; KUIPER MTR, 1990, J BIOL CHEM, V265, P6936; Lambowitz A M, 1979, Methods Enzymol, V59, P421; LAMBOWITZ AM, 1993, ANNU REV BIOCHEM, V62, P587, DOI 10.1146/annurev.bi.62.070193.003103; LUAN DD, 1993, CELL, V72, P595, DOI 10.1016/0092-8674(93)90078-5; MAIZELS N, 1993, IN PRESS RNA WORLD; MANS RMW, 1991, EUR J BIOCHEM, V201, P303, DOI 10.1111/j.1432-1033.1991.tb16288.x; MILLER WA, 1986, J MOL BIOL, V187, P537, DOI 10.1016/0022-2836(86)90332-3; NARGANG FE, 1984, CELL, V38, P441, DOI 10.1016/0092-8674(84)90499-9; PANET A, 1975, P NATL ACAD SCI USA, V72, P2535, DOI 10.1073/pnas.72.7.2535; RAO ALN, 1989, P NATL ACAD SCI USA, V86, P5335, DOI 10.1073/pnas.86.14.5335; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SAVILLE BJ, 1990, CELL, V61, P685, DOI 10.1016/0092-8674(90)90480-3; TEMIN HM, 1989, NATURE, V339, P254, DOI 10.1038/339254a0; TEMIN HM, 1980, CELL, V21, P599, DOI 10.1016/0092-8674(80)90420-1; TEMIN HM, 1970, PERSPECT BIOL MED, V14, P11; TESSIER DC, 1986, ANAL BIOCHEM, V158, P171, DOI 10.1016/0003-2697(86)90606-8; VARMUS H, 1989, MOBILE DNA, P53; WANG GH, 1992, CELL, V71, P663, DOI 10.1016/0092-8674(92)90599-8; WANG H, 1992, MOL CELL BIOL, V12, P5131, DOI 10.1128/MCB.12.11.5131; WANG H, 1993, J BIOL CHEM, V268, P18951; WEINER AM, 1987, P NATL ACAD SCI USA, V84, P7383, DOI 10.1073/pnas.84.21.7383; WINTERSBERGER U, 1987, TRENDS GENET, V3, P198, DOI 10.1016/0168-9525(87)90233-2; XIONG Y, 1990, EMBO J, V9, P3353, DOI 10.1002/j.1460-2075.1990.tb07536.x	45	82	84	0	2	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	DEC 17	1993	75	6					1071	1081		10.1016/0092-8674(93)90317-J	http://dx.doi.org/10.1016/0092-8674(93)90317-J			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	MM893	7505202				2022-12-28	WOS:A1993MM89300006
J	KRISHNAN, SC; SHIVKUMAR, K; GARAN, H; RUSKIN, JN				KRISHNAN, SC; SHIVKUMAR, K; GARAN, H; RUSKIN, JN			INCREASED VULNERABILITY OF THE SUBENDOCARDIUM TO ISCHEMIC-INJURY - AN ELECTROPHYSIOLOGICAL EXPLANATION	LANCET			English	Note							MYOCARDIAL BLOOD-FLOW; CORONARY-ARTERY OCCLUSION; ISCHEMIC CELL-DEATH; INFARCT SIZE; VENTRICULAR WALL; COLLATERAL FLOW; DOG HEART; EPICARDIUM; PRESSURE; TENSION		HENRY FORD HOSP,DETROIT,MI 48202	Henry Ford Health System; Henry Ford Hospital	KRISHNAN, SC (corresponding author), MASSACHUSETTS GEN HOSP,DEPT MED,CARDIAC UNIT,BOSTON,MA 02114, USA.		Shivkumar, Kalyanam/AAI-1085-2019	Shivkumar, Kalyanam/0000-0002-4121-1766				ALLEN DG, 1989, J PHYSIOL-LONDON, V410, P297, DOI 10.1113/jphysiol.1989.sp017534; ANTZELEVITCH C, 1991, CIRC RES, V69, P1427, DOI 10.1161/01.RES.69.6.1427; AUCHAMPACH JA, 1991, J PHARMACOL EXP THER, V259, P961; CAMICI P, 1984, BASIC RES CARDIOL, V79, P454, DOI 10.1007/BF01908146; DIDIEGO JM, 1993, CIRCULATION, V88, P1177, DOI 10.1161/01.CIR.88.3.1177; DOWNAR E, 1977, CIRCULATION, V56, P217, DOI 10.1161/01.CIR.56.2.217; ENG C, 1987, J AM COLL CARDIOL, V9, P374, DOI 10.1016/S0735-1097(87)80391-1; FUKUNAMI M, 1987, Canadian Journal of Cardiology, V3, P94; GAMBLE WJ, 1974, CIRC RES, V34, P672, DOI 10.1161/01.RES.34.5.672; GETTES LS, 1992, HEART CARDIOVASCULAR, P2021; GOLDNER MG, 1971, J AMER MED ASSOC, V218, P1400, DOI 10.1001/jama.218.9.1400; GRIGGS DM, 1972, AM J PHYSIOL, V222, P705; HOMANS DC, 1988, CIRCULATION, V78, P1267, DOI 10.1161/01.CIR.78.5.1267; HORN H, 1950, AM HEART J, V40, P63, DOI 10.1016/0002-8703(50)90150-5; KIMURA S, 1986, CIRCULATION, V74, P401, DOI 10.1161/01.CIR.74.2.401; KIRK ES, 1964, AM J PHYSIOL, V207, P361, DOI 10.1152/ajplegacy.1964.207.2.361; KLEBER AG, 1984, J MOL CELL CARDIOL, V16, P389, DOI 10.1016/S0022-2828(84)80610-0; KRISHNAN SC, 1991, CIRC RES, V69, P277, DOI 10.1161/01.RES.69.2.277; Krishnan Subramaniam, 1993, Journal of the American College of Cardiology, V21, p220A; LANGER GA, 1987, WESTERN J MED, V146, P713; LEE JT, 1981, CIRCULATION, V64, P526, DOI 10.1161/01.CIR.64.3.526; LOWE JE, 1983, CIRCULATION, V68, P190, DOI 10.1161/01.CIR.68.1.190; MARQUIS RM, 1955, BRIT HEART J, V17, P373; MASTER AM, 1950, CIRCULATION, V1, P1302, DOI 10.1161/01.CIR.1.6.1302; NOMA A, 1983, NATURE, V305, P147, DOI 10.1038/305147a0; OPIE LH, 1993, CARDIOVASC DRUG THER, V7, P507, DOI 10.1007/BF00877615; PATH G, 1990, CIRC RES, V67, P660, DOI 10.1161/01.RES.67.3.660; REIMER KA, 1977, CIRCULATION, V56, P786, DOI 10.1161/01.CIR.56.5.786; RIVAS F, 1976, CIRC RES, V38, P439, DOI 10.1161/01.RES.38.5.439; RUBIO R, 1975, PROG CARDIOVASC DIS, V18, P105, DOI 10.1016/0033-0620(75)90001-8; RUFFY R, 1979, CIRC RES, V45, P764, DOI 10.1161/01.RES.45.6.764; SABBAH HN, 1982, AM J PHYSIOL, V242, pH240, DOI 10.1152/ajpheart.1982.242.2.H240; SEDEK G, 1986, BASIC RES CARDIOL, V81, P219; STEIN PD, 1980, AM J PHYSIOL, V238, pH625, DOI 10.1152/ajpheart.1980.238.5.H625; WEINTRAUB WS, 1981, CIRC RES, V48, P430, DOI 10.1161/01.RES.48.3.430; WEISS HR, 1978, CIRC RES, V42, P394, DOI 10.1161/01.RES.42.3.394; WETTWER E, 1994, CIRC RES, V75, P473, DOI 10.1161/01.RES.75.3.473; WHITE FC, 1981, BASIC RES CARDIOL, V76, P189, DOI 10.1007/BF01907957	38	4	4	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	DEC 16	1995	346	8990					1612	1614		10.1016/S0140-6736(95)91936-8	http://dx.doi.org/10.1016/S0140-6736(95)91936-8			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TK481	7500758	Bronze			2022-12-28	WOS:A1995TK48100017
J	GUYATT, GH; SACKETT, DL; SINCLAIR, JC; HAYWARD, R; COOK, DJ; COOK, RJ				GUYATT, GH; SACKETT, DL; SINCLAIR, JC; HAYWARD, R; COOK, DJ; COOK, RJ			USERS GUIDES TO THE MEDICAL LITERATURE .9. A METHOD FOR GRADING HEALTH-CARE RECOMMENDATIONS	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							CLINICAL-TRIALS		MCMASTER UNIV, FAC HLTH SCI, DEPT CLIN EPIDEMIOL & BIOSTAT, HAMILTON, ON L8N 3Z5, CANADA; MCMASTER UNIV, FAC HLTH SCI, DEPT PEDIAT, HAMILTON, ON L8N 3Z5, CANADA; UNIV OXFORD, NUFFIELD DEPT MED, CTR EVIDENCE BASED MED, OXFORD, ENGLAND; UNIV WATERLOO, FAC MATH, DEPT STAT & ACTUARIAL SCI, WATERLOO, ON N2L 3G1, CANADA	McMaster University; McMaster University; University of Oxford; University of Waterloo	GUYATT, GH (corresponding author), MCMASTER UNIV, FAC HLTH SCI,HLTH SCI CTR,DEPT MED,ROOM 2C12, 1200 MAIN ST W, HAMILTON, ON L8N 3Z5, CANADA.			Gerstein, Hertzel/0000-0001-8072-2836; Bass, Eric/0000-0001-9106-527X; Cook, Richard/0000-0002-1414-4908				ALTMAN DG, 1989, STATISTICS CONFIDENC, P83; ANTMAN EM, 1992, JAMA-J AM MED ASSOC, V268, P240, DOI 10.1001/jama.268.2.240; CHALMERS TC, 1983, NEW ENGL J MED, V309, P1358, DOI 10.1056/NEJM198312013092204; COOK DJ, 1994, NEW ENGL J MED, V330, P377, DOI 10.1056/NEJM199402103300601; COOK DJ, 1992, CHEST, V102, pS305; COOK DJ, IN PRESS JAMA; DIAMOND GA, 1993, ANN INTERN MED, V118, P455, DOI 10.7326/0003-4819-118-6-199303150-00010; DOBBS JH, 1986, ANN INTERN MED, V105, P803; GLASZIOU P, 1994, 2ND COCHR C HAM; Guyatt, 1993, ANN INTERN MED, V70, P225; GUYATT G, 1995, CAN MED ASSOC J, V152, P169; GUYATT GH, 1994, JAMA-J AM MED ASSOC, V271, P59, DOI 10.1001/jama.271.1.59; HAYWARD RSA, 1995, JAMA-J AM MED ASSOC, V274, P570, DOI 10.1001/jama.274.7.570; Hedges L, 1985, STATISTICAL METHODS; JACKSON R, 1993, BRIT MED J, V307, P107, DOI 10.1136/bmj.307.6896.107; JAESCHKE R, 1995, CAN MED ASSOC J, V152, P351; LABBE KA, 1987, ANN INTERN MED, V107, P224, DOI 10.7326/0003-4819-107-2-224; LAUPACIS A, 1988, NEW ENGL J MED, V318, P1728, DOI 10.1056/NEJM198806303182605; LUBSEN J, 1989, CONTROL CLIN TRIALS, V10, pS151; OXMAN AD, 1993, JAMA-J AM MED ASSOC, V270, P2093; OXMAN AD, 1992, ANN INTERN MED, V116, P78, DOI 10.7326/0003-4819-116-1-78; OXMAN AD, 1994, JAMA-J AM MED ASSOC, V272, P1367, DOI 10.1001/jama.272.17.1367; SACKETT DL, 1986, CHEST, V89, pS2, DOI 10.1378/chest.89.2_Supplement.2S; SACKS HS, 1983, ARCH INTERN MED, V143, P753, DOI 10.1001/archinte.143.4.753; SACKS HS, 1987, NEW ENGL J MED, V316, P450, DOI 10.1056/NEJM198702193160806; SINCLAIR JC, 1994, J CLIN EPIDEMIOL, V47, P881, DOI 10.1016/0895-4356(94)90191-0; SMITH GD, 1994, BMJ-BRIT MED J, V308, P72, DOI 10.1136/bmj.308.6921.72; TORRANCE GW, 1986, J HEALTH ECON, V5, P1, DOI 10.1016/0167-6296(86)90020-2; VIAL T, 1991, DRUG SAFETY, V6, P94, DOI 10.2165/00002018-199106020-00002; WILSON MC, 1995, JAMA-J AM MED ASSOC, V274, P1630, DOI 10.1001/jama.274.20.1630; WOOLF SH, 1990, J CLIN EPIDEMIOL, V43, P891, DOI 10.1016/0895-4356(90)90073-X; YUSUF S, 1991, JAMA-J AM MED ASSOC, V266, P93, DOI 10.1001/jama.266.1.93; 1993, JAMA-J AM MED ASSOC, V269, P2667; 1979, CAN MED ASS J, V121, P1193	34	605	617	0	35	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	DEC 13	1995	274	22					1800	1804		10.1001/jama.274.22.1800	http://dx.doi.org/10.1001/jama.274.22.1800			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TJ225	7500513				2022-12-28	WOS:A1995TJ22500032
J	OLIVER, RTD				OLIVER, RTD			DOES SURGERY DISSEMINATE OR ACCELERATE CANCER	LANCET			English	Editorial Material							CELLS		ROYAL LONDON HOSP,LONDON E1 1BB,ENGLAND	Barts Health NHS Trust; Royal London Hospital	OLIVER, RTD (corresponding author), ST BARTHOLOMEWS HOSP,COLL MED,DEPT MED ONCOL,LONDON,ENGLAND.							Alexander P, 1988, Adv Exp Med Biol, V233, P245; ECCLES SA, 1975, NATURE, V257, P52, DOI 10.1038/257052a0; FAIR W, 1995, J UROL S, V150, P652; FENTIMAN IS, 1994, LANCET, V344, P402, DOI 10.1016/S0140-6736(94)91428-1; GRIFFITHS JD, 1973, CANCER-AM CANCER SOC, V31, P226, DOI 10.1002/1097-0142(197301)31:1<226::AID-CNCR2820310130>3.0.CO;2-M; Iversen P, 1995, Scand J Urol Nephrol Suppl, V172, P65; JOYNES F, 1914, J EXP MED, V20, P404; LUYAO GL, 1994, LANCET, V343, P251, DOI 10.1016/S0140-6736(94)91109-6; OLIVER RTD, 1994, LANCET, V344, P471, DOI 10.1016/S0140-6736(94)91801-5; OLIVER RTD, 1995, EUR J CANCER, V6, P859; OLIVER RTD, 1991, CANCER SURV, V13, P173; SKIPPER D, 1989, INT J COLORECTAL DIS, V4, P172, DOI 10.1007/BF01649697	12	20	20	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	DEC 9	1995	346	8989					1506	1507		10.1016/S0140-6736(95)92046-3	http://dx.doi.org/10.1016/S0140-6736(95)92046-3			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TJ291	7491042				2022-12-28	WOS:A1995TJ29100005
J	MACARTHUR, A; MACARTHUR, C; WEEKS, S				MACARTHUR, A; MACARTHUR, C; WEEKS, S			EPIDURAL-ANESTHESIA AND LOW-BACK-PAIN AFTER DELIVERY - A PROSPECTIVE COHORT STUDY	BRITISH MEDICAL JOURNAL			English	Article							LONG-TERM BACKACHE; CHILDBIRTH	Objective-To determine whether epidural anaesthesia during labour and delivery is a risk factor for postpartum back pain. Design-Prospective cohort study with follow up at one day, seven days, and six weeks after delivery. Setting-Teaching hospital in Montreal. Subjects-329 women who delivered a live infant(s) during the study period, Exclusion criteria were back pain before pregnancy and delivery by elective caesarean section. Intervention-Epidural anaesthesia during labour and delivery. Main outcome measures and results-The primary outcome variable was development of postpartum low back pain, Back pain was quantified with self reports (yes/no), a pain score (numeric rating scale), and degree of interference with daily activities. Of the 329 women, 164 received epidural anaesthesia during labour and 165 did not. The incidence of low back pain in epidural v non-epidural group was 53% v 43% on day one; 21% v 23% on day seven; and 14% v 7% at six weeks, The relative risk for low back pain (epidural v non-epidural) adjusted for parity, delivery, ethnicity, and weight was 1.76 (95% confidence interval 1.06 to 2.92) on day one; 1.00 (0.54 to 1.86) on day seven; and 2.22 (0.89 to 5.53) at six weeks. There were no differences between the two groups in pain scores or the frequency of interference with daily activities. Similar results were obtained in the subgroup of women with low back pain of new onset-that is, those women with no back pain during their pregnancy, Conclusions-Postpartum low back pain was common but decreased considerably over the short term, The association between epidural anaesthesia and postpartum low back pain was inconsistent over time with a significantly increased risk of low back pain (epidural v non-epidural) noted only on the first day after delivery.	ROYAL VICTORIA HOSP,DEPT ANAESTHESIA,MONTREAL,PQ H3A 1A1,CANADA; MCGILL UNIV,DEPT EPIDEMIOL & BIOSTAT,MONTREAL,PQ,CANADA	McGill University; Royal Victoria Hospital; McGill University			MacArthur, Christine/ABA-8601-2021	MacArthur, Christine/0000-0003-0434-2158				Alexander J T, 1993, Neurosurg Clin N Am, V4, P153; BREEN TW, 1994, ANESTHESIOLOGY, V81, P29, DOI 10.1097/00000542-199407000-00006; FRYMOYER JW, 1988, NEW ENGL J MED, V318, P291, DOI 10.1056/NEJM198802043180506; GREEN LW, 1970, PUBLIC HEALTH REP, V85, P815, DOI 10.2307/4593972; Hosmer D.W., 1989, APPL LOGISTIC REGRES, P1; JENSEN MP, 1986, PAIN, V27, P117, DOI 10.1016/0304-3959(86)90228-9; KITZINGER S, 1987, SOME WOMENS EXPERIEN; KRAMER MS, 1988, CLIN EPIDEMIOLOGY BI, P165; MACARTHUR C, 1990, BRIT MED J, V301, P9, DOI 10.1136/bmj.301.6742.9; MIETTINEN O, 1976, AM J EPIDEMIOL, V103, P226, DOI 10.1093/oxfordjournals.aje.a112220; RUSSELL R, 1993, BRIT MED J, V306, P1299, DOI 10.1136/bmj.306.6888.1299	11	52	54	1	2	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	NOV 18	1995	311	7016					1336	1339		10.1136/bmj.311.7016.1336	http://dx.doi.org/10.1136/bmj.311.7016.1336			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TF901	7496283	Green Published			2022-12-28	WOS:A1995TF90100020
J	NIGHTINGALE, SL				NIGHTINGALE, SL			PSA TEST IS APPROVED FOR USE IN CONJUNCTION WITH DIGITAL RECTAL EXAMINATION AS AID IN PROSTATE-CANCER DETECTION	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material											NIGHTINGALE, SL (corresponding author), US FDA,OFF HLTH AFFAIRS,PARKLAWN BLDG,5600 FISHERS LN,ROCKVILLE,MD 20857, USA.								0	3	3	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 19	1994	272	15					1160	1160		10.1001/jama.272.15.1160	http://dx.doi.org/10.1001/jama.272.15.1160			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PL212	7523738				2022-12-28	WOS:A1994PL21200008
J	NILSSON, M; MALMGREN, H; SAMIOTAKI, M; KWIATKOWSKI, M; CHOWDHARY, BP; LANDEGREN, U				NILSSON, M; MALMGREN, H; SAMIOTAKI, M; KWIATKOWSKI, M; CHOWDHARY, BP; LANDEGREN, U			PADLOCK PROBES - CIRCULARIZING OLIGONUCLEOTIDES FOR LOCALIZED DNA DETECTION	SCIENCE			English	Article							ALPHA-SATELLITE DNA; LIGASE; HYBRIDIZATION; GENE	Nucleotide sequence information derived from DNA segments of the human and other genomes is accumulating rapidly. However, it frequently proves difficult to use such short DNA segments to identify clones in genomic libraries or fragments in blots of the whole genome or for in situ analysis of chromosomes. Oligonucleotide probes, consisting of two target-complementary segments, connected by a linker sequence, were designed. Upon recognition of the specific nucleic acid molecule the ends of the probes were joined through the action of a ligase, creating circular DNA molecules catenated to the target sequence. These probes thus provide highly specific detection with minimal background.	BIOMED CTR,DEPT MED GENET,BEIJER LAB,S-75123 UPPSALA,SWEDEN; SWEDISH UNIV AGR SCI,DEPT ANIM BREEDING & GENET,S-75007 UPPSALA,SWEDEN	Swedish University of Agricultural Sciences			Samiotaki, Martina/B-3851-2018; Landegren, Ulf D/A-8197-2019	Samiotaki, Martina/0000-0001-9952-0636; Nilsson, Mats/0000-0001-9985-0387				ALVES AM, 1988, NUCLEIC ACIDS RES, V16, P8723, DOI 10.1093/nar/16.17.8723; BALDINI A, 1990, AM J HUM GENET, V46, P784; BARANY F, 1991, P NATL ACAD SCI USA, V88, P189, DOI 10.1073/pnas.88.1.189; DOLINNAYA NG, 1993, NUCLEIC ACIDS RES, V21, P5403, DOI 10.1093/nar/21.23.5403; Higgins N P, 1979, Methods Enzymol, V68, P50; JASCHKE A, 1993, TETRAHEDRON LETT, V34, P301, DOI 10.1016/S0040-4039(00)60572-5; LANDEGREN U, 1988, SCIENCE, V241, P1077, DOI 10.1126/science.3413476; Maniatis T., 1982, MOL CLONING; MATERA AG, 1992, HUM MOL GENET, V1, P535, DOI 10.1093/hmg/1.7.535; Nilsson M., UNPUB; PINKEL D, 1988, P NATL ACAD SCI USA, V85, P9138, DOI 10.1073/pnas.85.23.9138; PRAKASH G, 1992, J AM CHEM SOC, V114, P3523, DOI 10.1021/ja00035a056; RIORDAN JR, 1989, SCIENCE, V245, P1066; SUND C, 1988, NUCLEOS NUCLEOT, V7, P655, DOI 10.1080/07328318808056303; WILLARD HF, 1987, TRENDS GENET, V3, P192, DOI 10.1016/0168-9525(87)90232-0; WU DY, 1989, GENE, V76, P245, DOI 10.1016/0378-1119(89)90165-0	16	548	712	9	130	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	SEP 30	1994	265	5181					2085	2088		10.1126/science.7522346	http://dx.doi.org/10.1126/science.7522346			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PJ912	7522346				2022-12-28	WOS:A1994PJ91200027
J	PRUKSAKORN, S; CURRIE, B; BRANDT, E; MARTIN, D; GALBRAITH, A; PHORNPHUTKUL, C; HUNSAKUNACHAI, S; MANMONTRI, A; GOOD, MF				PRUKSAKORN, S; CURRIE, B; BRANDT, E; MARTIN, D; GALBRAITH, A; PHORNPHUTKUL, C; HUNSAKUNACHAI, S; MANMONTRI, A; GOOD, MF			TOWARDS A VACCINE FOR RHEUMATIC-FEVER - IDENTIFICATION OF A CONSERVED TARGET EPITOPE ON M-PROTEIN OF GROUP-A STREPTOCOCCI	LANCET			English	Article							GROUP-A STREPTOCOCCI; NUCLEOTIDE-SEQUENCE; PROTECTIVE IMMUNOGENICITY; MUCOSAL COLONIZATION; SYNTHETIC PEPTIDE; HEART-DISEASE; TYPE-5; IMMUNIZATION; SPECIFICITY; FRAGMENT	Rheumatic fever and rheumatic heart disease remain very common in developing countries, and a vaccine to protect against these disorders would have a great impact on public health. A vaccine must target the M protein of group A streptococci (Streptococcus pyogenes), but until lately immunity was thought to be strain-specific and dependent on antibodies to the variable serotype-specific regions of the protein. Experiments in animals have suggested the conserved region of the M protein as a possible alternative target for protective antibodies. We constructed a 20-aminoacid peptide (peptide 145) within the conserved region of the carboxyl terminus of the protein. In mice the peptide induced serum antibodies that could opsonise reference type 5 streptococci. By enzyme-linked immunosorbent assay, positive responses to peptide 145 were obtained with serum from 77 (90%) of 86 Aboriginal subjects and 135 (81%) of 167 Thai subjects living in areas with high exposure to streptococci. Only 10 (14%) of 71 Caucasian subjects with low exposure to streptococci showed positive responses. There was no difference in the proportion positive between subjects with rheumatic heart disease and control groups (other or no heart disease). Antibodies to peptide 145 were able to opsonise isolates of streptococci from Aboriginal and Thai subjects with acute rheumatic fever as well as reference strains. This highly conserved part of the M protein may be a suitable target for vaccines to prevent steptococcal infections and their sequelae.	QUEENSLAND INST MED RES,MOLEC IMMUNOL LAB,BRISBANE,QLD 4029,AUSTRALIA; MENZIES SCH HLTH RES,CASUARINA,NT,AUSTRALIA; INST ENVIRONM SCI & RES LTD,WELLINGTON,NEW ZEALAND; PRINCE CHARLES HOSP,BRISBANE,QLD 4032,AUSTRALIA; CHIANG MAI UNIV,DEPT PEDIAT,CHIANG MAI 50000,THAILAND; CHIANG MAI UNIV,DEPT MED,CHIANG MAI 50000,THAILAND	QIMR Berghofer Medical Research Institute; Charles Darwin University; Menzies School of Health Research; Institute of Environmental Science & Research (ESR) - New Zealand; Prince Charles Hospital; Chiang Mai University; Chiang Mai University								BEACHEY EH, 1984, P NATL ACAD SCI-BIOL, V81, P2203, DOI 10.1073/pnas.81.7.2203; BEACHEY EH, 1981, NATURE, V292, P457, DOI 10.1038/292457a0; BEACHEY EH, 1986, J IMMUNOL, V136, P2287; BEACHEY EH, 1987, J EXP MED, V166, P647, DOI 10.1084/jem.166.3.647; BEACHEY EH, 1973, INFECT IMMUN, V8, P19, DOI 10.1128/IAI.8.1.19-24.1973; BEACHEY EH, 1988, VACCINE, V6, P192, DOI 10.1016/S0264-410X(88)80027-6; BEACHEY EH, 1979, J EXP MED, V150, P862, DOI 10.1084/jem.150.4.862; BESSEN D, 1990, J IMMUNOL, V145, P1251; BESSEN D, 1988, INFECT IMMUN, V56, P2666, DOI 10.1128/IAI.56.10.2666-2672.1988; BRENNAN RE, 1990, MED J AUSTRALIA, V153, P335, DOI 10.5694/j.1326-5377.1990.tb136942.x; COLIGAN JE, 1992, CURRENT PROTOCOLS IM, V2; CURRIE B, 1993, MED J AUSTRALIA, V153, P609; DALE JB, 1986, J EXP MED, V163, P1191, DOI 10.1084/jem.163.5.1191; DALE JB, 1983, J EXP MED, V158, P1727, DOI 10.1084/jem.158.5.1727; Devanesen D, 1986, HLTH INDICATORS NO T; HOLLINGSHEAD SK, 1986, J BIOL CHEM, V261, P1677; HOUGHTEN RA, 1985, P NATL ACAD SCI USA, V82, P5131, DOI 10.1073/pnas.82.15.5131; JOSE DG, 1969, AUST PAEDIATR J, V5, P209; LANCEFIELD RC, 1957, J EXP MED, V106, P525, DOI 10.1084/jem.106.4.525; MACDONALD KT, 1989, MED J AUSTRALIA, V150, P503, DOI 10.5694/j.1326-5377.1989.tb136596.x; MARTIN DR, 1983, NEW ZEAL MED J, V96, P298; MILLER L, 1988, J BIOL CHEM, V263, P5668; MOUW AR, 1988, J BACTERIOL, V170, P676, DOI 10.1128/jb.170.2.676-684.1988; PHORNPHUTKUL C, 1981, CHIANG MAI MED B, V23, P275; PRUKSAKORN S, 1992, J IMMUNOL, V149, P2729; PRUKSAKORN S, 1990, CHIANG MAI MED B, V29, P15; RELF WA, 1992, J CLIN MICROBIOL, V30, P3190, DOI 10.1128/JCM.30.12.3190-3194.1992; ROBINSON JH, 1992, IMMUNOL TODAY, V13, P362, DOI 10.1016/0167-5699(92)90173-5; Shulman ST, 1984, CIRCULATION, V69, p203A; VEASY LG, 1987, NEW ENGL J MED, V316, P421, DOI 10.1056/NEJM198702193160801; 1992, B WORLD HEALTH ORGAN, V70, P213	31	72	79	0	3	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	SEP 3	1994	344	8923					639	642		10.1016/S0140-6736(94)92083-4	http://dx.doi.org/10.1016/S0140-6736(94)92083-4			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PE386	7520963				2022-12-28	WOS:A1994PE38600008
J	WATANABE, Y; YAMAMOTO, M				WATANABE, Y; YAMAMOTO, M			S-POMBE-MEI2(+) ENCODES AN RNA-BINDING PROTEIN ESSENTIAL FOR PREMEIOTIC DNA-SYNTHESIS AND MEIOSIS-I, WHICH COOPERATES WITH A NOVEL RNA SPECIES MEIRNA	CELL			English	Article							YEAST SCHIZOSACCHAROMYCES-POMBE; FISSION YEAST; NUCLEAR RIBONUCLEOPROTEIN; GENE DISRUPTION; MESSENGER-RNAS; SEX-LETHAL; XIST GENE; DOMAIN; INITIATION; SEQUENCE	The molecular controls over meiosis are poorly understood compared with those over mitosis. Here, we show that S. pombe mei2, which is essential for the initiation of premeiotic DNA synthesis, encodes an RNA-binding protein. A temperature-sensitive mei2 mutant performs premeiotic DNA synthesis but does not undergo meiotic divisions, suggesting that Mei2 is required also for meiosis I. A novel, polyadenylated RNA species (meiRNA), which suppresses this temperature-sensitive defect if overexpressed, specifically binds to Mei2 both in vivo and in vitro. Cells without meiRNA perform premeiotic DNA synthesis but cannot undergo meiosis I. Mutations that apparently block the RNA binding ability of Mei2 inhibit premeiotic DNA synthesis. Mei2 is thus likely to couple with another RNA species to promote premeiotic DNA synthesis.			WATANABE, Y (corresponding author), UNIV TOKYO, SCH SCI, DEPT BIOCHEM & BIOPHYS, TOKYO 113, JAPAN.			Watanabe, Yoshinori/0000-0002-5488-4812				ADAM SA, 1986, MOL CELL BIOL, V6, P2932, DOI 10.1128/MCB.6.8.2932; AMREIN H, 1988, CELL, V55, P1025, DOI 10.1016/0092-8674(88)90247-4; BANDZIULIS RJ, 1989, GENE DEV, V3, P431, DOI 10.1101/gad.3.4.431; Baserga S., 1993, RNA WORLD, P359; BEACH D, 1982, MOL GEN GENET, V187, P326, DOI 10.1007/BF00331138; BEACH D, 1985, CURR GENET, V10, P297, DOI 10.1007/BF00365626; BELL LR, 1988, CELL, V55, P1037, DOI 10.1016/0092-8674(88)90248-6; BOSTOCK CJ, 1970, EXP CELL RES, V60, P16, DOI 10.1016/0014-4827(70)90484-2; BRESCH C, 1968, MOL GEN GENET, V102, P301, DOI 10.1007/BF00433721; BROCKDORFF N, 1992, CELL, V71, P515, DOI 10.1016/0092-8674(92)90519-I; BROWN CJ, 1992, CELL, V71, P527, DOI 10.1016/0092-8674(92)90520-M; EGEL R, 1974, EXP CELL RES, V88, P127, DOI 10.1016/0014-4827(74)90626-0; ENGEBRECHT J, 1991, CELL, V66, P1257, DOI 10.1016/0092-8674(91)90047-3; FOULKES NS, 1992, NATURE, V355, P80, DOI 10.1038/355080a0; FOULKES NS, 1993, NATURE, V362, P264, DOI 10.1038/362264a0; GRIMM C, 1988, MOL GEN GENET, V215, P81, DOI 10.1007/BF00331307; GUAN KL, 1991, ANAL BIOCHEM, V192, P262, DOI 10.1016/0003-2697(91)90534-Z; Gutz H., 1974, HDB GENETICS, V1, P395; HEDLEY ML, 1991, CELL, V65, P579, DOI 10.1016/0092-8674(91)90090-L; HENIKOFF S, 1984, GENE, V28, P351, DOI 10.1016/0378-1119(84)90153-7; HOFFMAN DW, 1991, P NATL ACAD SCI USA, V88, P2495, DOI 10.1073/pnas.88.6.2495; HOTTA Y, 1985, CELL, V40, P785, DOI 10.1016/0092-8674(85)90338-1; HOTTA Y, 1981, CELL, V27, P309, DOI 10.1016/0092-8674(81)90414-1; IINO Y, 1985, P NATL ACAD SCI USA, V82, P2447, DOI 10.1073/pnas.82.8.2447; IINO Y, 1985, MOL GEN GENET, V198, P416, DOI 10.1007/BF00332932; INOUE K, 1990, NATURE, V344, P461, DOI 10.1038/344461a0; ISSHIKI T, 1992, GENE DEV, V6, P2455, DOI 10.1101/gad.6.12b.2455; KENAN DJ, 1991, TRENDS BIOCHEM SCI, V16, P214, DOI 10.1016/0968-0004(91)90088-D; KISHIDA M, 1994, CURR GENET, V25, P497, DOI 10.1007/BF00351668; KOZAK M, 1980, CELL, V22, P7, DOI 10.1016/0092-8674(80)90148-8; KOZAK M, 1991, J BIOL CHEM, V266, P19867; KRAINER AR, 1991, CELL, V66, P383, DOI 10.1016/0092-8674(91)90627-B; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; MCLEOD M, 1987, EMBO J, V6, P729, DOI 10.1002/j.1460-2075.1987.tb04814.x; MCLEOD M, 1988, NATURE, V332, P509, DOI 10.1038/332509a0; MERRILL BM, 1988, J BIOL CHEM, V263, P3307; MORENO S, 1991, METHOD ENZYMOL, V194, P795; NAGAI K, 1990, NATURE, V348, P515, DOI 10.1038/348515a0; NIELSEN O, 1990, EMBO J, V9, P1401, DOI 10.1002/j.1460-2075.1990.tb08255.x; NURSE P, 1985, MOL GEN GENET, V198, P497, DOI 10.1007/BF00332946; OKAZAKI K, 1990, NUCLEIC ACIDS RES, V18, P6485, DOI 10.1093/nar/18.22.6485; QUERY CC, 1989, CELL, V57, P89, DOI 10.1016/0092-8674(89)90175-X; ROTHSTEIN RJ, 1983, METHOD ENZYMOL, V101, P202; SACHS AB, 1986, CELL, V45, P827, DOI 10.1016/0092-8674(86)90557-X; SALLES FJ, 1992, GENE DEV, V6, P1202, DOI 10.1101/gad.6.7.1202; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; Sherman F., 1986, METHODS YEAST GENETI; SHIMODA C, 1985, MOL GEN GENET, V200, P252, DOI 10.1007/BF00425432; Southern E, 1979, Methods Enzymol, V68, P152; SUGIMOTO A, 1991, GENE DEV, V5, P1990, DOI 10.1101/gad.5.11.1990; THEISSEN H, 1986, EMBO J, V5, P3209, DOI 10.1002/j.1460-2075.1986.tb04631.x; THOMAS PS, 1980, P NATL ACAD SCI-BIOL, V77, P5201, DOI 10.1073/pnas.77.9.5201; WATANABE Y, 1988, EMBO J, V7, P761, DOI 10.1002/j.1460-2075.1988.tb02873.x	54	203	208	3	9	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	AUG 12	1994	78	3					487	498		10.1016/0092-8674(94)90426-X	http://dx.doi.org/10.1016/0092-8674(94)90426-X			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	PC405	7520368				2022-12-28	WOS:A1994PC40500014
J	DONNELLY, SC; HASLETT, C; DRANSFIELD, I; ROBERTSON, CE; CARTER, DC; ROSS, JA; GRANT, IS; TEDDER, TF				DONNELLY, SC; HASLETT, C; DRANSFIELD, I; ROBERTSON, CE; CARTER, DC; ROSS, JA; GRANT, IS; TEDDER, TF			ROLE OF SELECTINS IN DEVELOPMENT OF ADULT-RESPIRATORY-DISTRESS-SYNDROME	LANCET			English	Article							LEUKOCYTE ADHESION MOLECULE-1; ENDOTHELIAL-CELLS; LUNG INJURY; SUPERNATANTS; NEUTROPHILS; RISK	The acute lung injury of adult respiratory distress syndrome (ARDS) is characterised by inflammatory cell accumulation and activation in the lung. Selectins are a family of adhesion molecules implicated in leucocyte-endothelial adhesion, whose receptors can exist in a cleaved, soluble form. We investigated whether circulating soluble selectin adhesion molecules, obtained from ARDS at-risk patients, were associated with subsequent ARDS development. 82 patients, at risk of ARDS, were enrolled from three well-defined groups (multiple trauma, pancreatitis, perforated bowel). Plasma samples were obtained on hospital presentation and soluble L, E, and P, selectins were quantified with a sandwich enzyme-linked immunosorbent assay (ELISA). 14 patients subsequently developed ARDS. Initial plasma soluble L-selectin (sL-selectin) levels were significantly lower in patients who progressed to ARDS compared to those who did not (p = 0.0001; 95% Cl for mean in ARDS patients as percent of that in non-ARDS patients, 27-61%). Moreover concentrations were lower than in 62 normal volunteers (range 0.37-6.55, median 1.83 mu g/mL, n = 62), suggesting that a selective reduction of sL-selectin correlates with susceptibility. In addition, a significant correlation was found between low values of sL-selectin and indices of subsequent lung injury including requirement for ventilation (p = 0.0001) and degree of respiratory failure (p = 0.0001). A significant correlation was also found between low values of sL-selectin and patient mortality(p = 0.002). These results elucidate the inflammatory cell endothelial interactions in the early stages of ARDS and may be of prognostic value.	UNIV EDINBURGH,RAYNE LAB,RESP MED UNIT,EDINBURGH EH8 9AG,MIDLOTHIAN,SCOTLAND; ROYAL INFIRM,DEPT ACCID & EMERGENCY,EDINBURGH,MIDLOTHIAN,SCOTLAND; UNIV EDINBURGH,ROYAL INFIRM,DEPT SURG,EDINBURGH,MIDLOTHIAN,SCOTLAND; WESTERN GEN HOSP,INTENS THERAPY UNIT,EDINBURGH,MIDLOTHIAN,SCOTLAND; HARVARD UNIV,SCH MED,DANA FARBER CANC INST,DIV TUMOR IMMUNOL,BOSTON,MA 02115; HARVARD UNIV,SCH MED,DEPT PATHOL,BOSTON,MA 02115	University of Edinburgh; Royal Infirmary of Edinburgh; Royal Infirmary of Edinburgh; University of Edinburgh; University of Edinburgh; Harvard University; Dana-Farber Cancer Institute; Harvard Medical School; Harvard University; Harvard Medical School				Donnelly, Seamas/0000-0001-7145-1843; Dransfield, Ian/0000-0001-5848-7059	NATIONAL CANCER INSTITUTE [R55CA054464, R01CA054464] Funding Source: NIH RePORTER; NCI NIH HHS [CA54464] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BEVILACQUA MP, 1987, P NATL ACAD SCI USA, V84, P9238, DOI 10.1073/pnas.84.24.9238; BOYD CR, 1987, J TRAUMA, V27, P370, DOI 10.1097/00005373-198704000-00005; BUTCHER EC, 1991, CELL, V67, P1033, DOI 10.1016/0092-8674(91)90279-8; CHRISTNER P, 1985, AM REV RESPIR DIS, V131, P690; DONNELLY SC, 1993, LANCET, V341, P643, DOI 10.1016/0140-6736(93)90416-E; DONNELLY SC, 1992, EUR RESPIR J, V5; ETZIONI A, 1992, NEW ENGL J MED, V327, P1789, DOI 10.1056/NEJM199212173272505; FOWLER AA, 1983, ANN INTERN MED, V98, P593, DOI 10.7326/0003-4819-98-5-593; GORIS RJA, 1985, ARCH SURG-CHICAGO, V120, P1109; GRIFFIN JD, 1990, J IMMUNOL, V145, P576; KATAYAMA M, 1992, J IMMUNOL METHODS, V153, P41, DOI 10.1016/0022-1759(92)90303-B; LASKY LA, 1989, CELL, V56, P1045, DOI 10.1016/0092-8674(89)90637-5; MACNAUGHTON PD, 1992, LANCET, V339, P469, DOI 10.1016/0140-6736(92)91068-J; MCEVER R, 1989, J CLIN INVEST, V112, P491; MILLER EJ, 1992, AM REV RESPIR DIS, V146, P427, DOI 10.1164/ajrccm/146.2.427; MULLIGAN MS, 1993, NATURE, V364, P149, DOI 10.1038/364149a0; MURRAY JF, 1988, AM REV RESPIR DIS, V138, P720, DOI 10.1164/ajrccm/138.3.720; NEWMAN W, 1993, J IMMUNOL, V150, P644; OSBORNE DH, 1981, BRIT J SURG, V68, P758, DOI 10.1002/bjs.1800681103; PARSONS PE, 1985, AM REV RESPIR DIS, V132, P490; PARSONS PE, 1989, AM REV RESPIR DIS, V140, P294, DOI 10.1164/ajrccm/140.2.294; PIGOTT R, 1992, BIOCHEM BIOPH RES CO, V187, P584, DOI 10.1016/0006-291X(92)91234-H; REPINE JE, 1992, LANCET, V339, P466, DOI 10.1016/0140-6736(92)91067-I; RINALDO JE, 1982, NEW ENGL J MED, V306, P900, DOI 10.1056/NEJM198204153061504; ROCKER GM, 1989, LANCET, V1, P120; SCHLEIFFENBAUM B, 1992, J CELL BIOL, V119, P229, DOI 10.1083/jcb.119.1.229; SPERTINI O, 1991, J IMMUNOL, V147, P2565; SPERTINI O, 1992, J IMMUNOL METHODS, V156, P115, DOI 10.1016/0022-1759(92)90017-N; WEILAND JE, 1986, AM REV RESPIR DIS, V133, P218	29	216	221	0	4	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUL 23	1994	344	8917					215	219		10.1016/S0140-6736(94)92995-5	http://dx.doi.org/10.1016/S0140-6736(94)92995-5			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NY060	7518025				2022-12-28	WOS:A1994NY06000007
J	ODELL, TJ; HUANG, PL; DAWSON, TM; DINERMAN, JL; SNYDER, SH; KANDEL, ER; FISHMAN, MC				ODELL, TJ; HUANG, PL; DAWSON, TM; DINERMAN, JL; SNYDER, SH; KANDEL, ER; FISHMAN, MC			ENDOTHELIAL NOS AND THE BLOCKADE OF LTP BY NOS INHIBITORS IN MICE LACKING NEURONAL NOS	SCIENCE			English	Article							LONG-TERM POTENTIATION; NITRIC-OXIDE SYNTHASE; PLATELET-ACTIVATING-FACTOR; HIPPOCAMPAL SLICES; INTERCELLULAR MESSENGER; RAT HIPPOCAMPUS; CARBON-MONOXIDE; ENHANCEMENT; STIMULATION; RELEASE	Long-term potentiation (LTP) is a persistent increase in synaptic strength implicated in certain forms of learning and memory. In the CA1 region of the hippocampus, LTP is thought to involve the release of one or more retrograde messengers from the postsynaptic cell that act on the presynaptic terminal to enhance transmitter release. One candidate retrograde messenger is the membrane-permeant gas nitric oxide (NO), which in the brain is released after activation of the neuronal-specific NO synthase isoform (nNOS). To assess the importance of NO in hippocampal synaptic plasticity, LTP was examined in mice where the gene encoding nNOS was disrupted by gene targeting. In nNOS(-) mice, LTP induced by weak intensity tetanic stimulation was normal except for a slight reduction in comparison to that in wild-type mice and was blocked by NOS inhibitors, just as it was in wild-type mice. Immunocytochemical studies indicate that in the nNOS(-) mice as in wild-type mice, the endothelial form of NOS (eNOS) is expressed in CA1 neurons. These findings suggest that eNOS, rather than nNOS, generates NO within the postsynaptic cell during LTP.	COLUMBIA UNIV,COLL PHYS & SURG,HOWARD HUGHES MED INST,NEW YORK,NY 10032; COLUMBIA UNIV,COLL PHYS & SURG,CTR NEUROBIOL & BEHAV,NEW YORK,NY 10032; MASSACHUSETTS GEN HOSP E,CARDIOVASC RES CTR,BOSTON,MA 02129; HARVARD UNIV,SCH MED,BOSTON,MA 02129; JOHNS HOPKINS UNIV,SCH MED,DEPT NEUROL,BALTIMORE,MD 21205; JOHNS HOPKINS UNIV,SCH MED,DEPT NEUROSCI,BALTIMORE,MD 21205; JOHNS HOPKINS UNIV,SCH MED,DEPT MED,DIV CARDIOL,BALTIMORE,MD 21205	Columbia University; Howard Hughes Medical Institute; Columbia University; Harvard University; Harvard Medical School; Johns Hopkins University; Johns Hopkins University; Johns Hopkins University					NATIONAL INSTITUTE OF MENTAL HEALTH [R01MH045923, R37MH045923] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON DRUG ABUSE [P50DA000266] Funding Source: NIH RePORTER; NIDA NIH HHS [DA-00074, DA-00266] Funding Source: Medline; NIMH NIH HHS [MH-45923] Funding Source: Medline	NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission); NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		ARAI A, 1992, EUR J NEUROSCI, V4, P411, DOI 10.1111/j.1460-9568.1992.tb00890.x; BEKKERS JM, 1990, NATURE, V346, P724, DOI 10.1038/346724a0; BLISS TVP, 1993, NATURE, V361, P31, DOI 10.1038/361031a0; BOHME GA, 1991, EUR J PHARMACOL, V199, P379, DOI 10.1016/0014-2999(91)90505-K; BON C, 1992, EUR J NEUROSCI, V4, P420, DOI 10.1111/j.1460-9568.1992.tb00891.x; BREDT DS, 1989, P NATL ACAD SCI USA, V86, P9030, DOI 10.1073/pnas.86.22.9030; BREDT DS, 1990, NATURE, V347, P768, DOI 10.1038/347768a0; BREDT DS, 1992, NEURON, V8, P3, DOI 10.1016/0896-6273(92)90104-L; BREDT DS, 1991, NEURON, V7, P615, DOI 10.1016/0896-6273(91)90374-9; BREDT DS, 1994, ANNU REV BIOCHEM, V63, P175, DOI 10.1146/annurev.bi.63.070194.001135; CHETKOVICH DM, 1993, NEUROREPORT, V4, P919, DOI 10.1097/00001756-199307000-00020; CLARK GD, 1992, NEURON, V9, P1211, DOI 10.1016/0896-6273(92)90078-R; DINERMAN JL, 1994, P NATL ACAD SCI USA, V91, P4214, DOI 10.1073/pnas.91.10.4214; EAST SJ, 1991, NEUROSCI LETT, V123, P17, DOI 10.1016/0304-3940(91)90147-L; FURTINE ES, 1993, BIOCHEMISTRY-US, V32, P8512; GALLY JA, 1990, P NATL ACAD SCI USA, V87, P3547, DOI 10.1073/pnas.87.9.3547; GARTHWAITE J, 1988, NATURE, V336, P385, DOI 10.1038/336385a0; GRANT SGN, 1992, SCIENCE, V258, P1903, DOI 10.1126/science.1361685; GRIBKOFF VK, 1992, J NEUROPHYSIOL, V68, P639, DOI 10.1152/jn.1992.68.2.639; HALEY JE, 1992, NEURON, V8, P211, DOI 10.1016/0896-6273(92)90288-O; HALEY JE, 1993, NEUROSCI LETT, V160, P85, DOI 10.1016/0304-3940(93)90919-C; HUANG PL, 1993, CELL, V75, P1273, DOI 10.1016/0092-8674(93)90615-W; IZUMI Y, 1992, SCIENCE, V257, P1273, DOI 10.1126/science.1519065; KATO K, 1994, NATURE, V367, P175, DOI 10.1038/367175a0; KNOWLES RG, 1994, BIOCHEM J, V298, P249, DOI 10.1042/bj2980249; KULLMANN DM, 1992, NATURE, V357, P240, DOI 10.1038/357240a0; LARKMAN A, 1992, NATURE, V360, P70, DOI 10.1038/360070a0; LARSON J, 1986, BRAIN RES, V368, P347, DOI 10.1016/0006-8993(86)90579-2; LUMRAGAN JT, 1993, NEUROSCIENCE, V57, P973, DOI 10.1016/0306-4522(93)90042-E; MALINOW R, 1990, NATURE, V346, P177, DOI 10.1038/346177a0; MONCADA S, 1993, NEW ENGL J MED, V329, P2002; MUSLEH WY, 1993, SYNAPSE, V13, P370, DOI 10.1002/syn.890130409; NATHAN C, 1992, FASEB J, V3, P31; ODELL TJ, 1991, P NATL ACAD SCI USA, V88, P11285, DOI 10.1073/pnas.88.24.11285; SCHMIDT HH, 1992, J HISTOCHEM CYTOCHEM, V90, P1439; SCHUMAN EM, 1991, SCIENCE, V254, P1503, DOI 10.1126/science.1720572; SCHUMAN EM, 1994, SCIENCE, V263, P532, DOI 10.1126/science.8290963; Schweizer F. E., 1993, Society for Neuroscience Abstracts, V19, P241; SHUMAN EM, 1993, SEMIN NEUROSCI, V5, P207; STEVENS CF, 1993, NATURE, V364, P147, DOI 10.1038/364147a0; VERMA A, 1993, SCIENCE, V259, P381, DOI 10.1126/science.7678352; WIERASZKO A, 1993, NEURON, V10, P553, DOI 10.1016/0896-6273(93)90342-O; WILLIAMS JH, 1993, SEMIN NEUROSCI, V5, P149, DOI 10.1016/S1044-5765(05)80048-X; WILLIAMS JH, 1993, NEURON, V11, P877, DOI 10.1016/0896-6273(93)90117-A; ZHUO M, 1993, SCIENCE, V260, P1946, DOI 10.1126/science.8100368	45	374	382	0	4	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUL 22	1994	265	5171					542	546		10.1126/science.7518615	http://dx.doi.org/10.1126/science.7518615			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	NY216	7518615				2022-12-28	WOS:A1994NY21600037
J	LI, CM; TROPAK, MB; GERLAI, R; CLAPOFF, S; ABRAMOWNEWERLY, W; TRAPP, B; PETERSON, A; RODER, J				LI, CM; TROPAK, MB; GERLAI, R; CLAPOFF, S; ABRAMOWNEWERLY, W; TRAPP, B; PETERSON, A; RODER, J			MYELINATION IN THE ABSENCE OF MYELIN-ASSOCIATED GLYCOPROTEIN	NATURE			English	Article							CELL-ADHESION MOLECULES; EMBRYONIC STEM-CELLS; SCHWANN-CELLS; PERIAXONAL SPACE; MICE; GENE; MAG; L1	THE hypothesis that myelin-associated glycoprotein (MAG) initiates myelin formation is based in part on observations that MAG has an adhesive role in interactions between oligodendrocytes and neurons(1). Furthermore, the over- or underexpression of MAG in transfected Schwann cells in vitro leads to accelerated myelination(2) or hypomyelination(3), respectively. Here we test this idea by creating a null mutation in the mag locus and deriving mice that are totally deficient in MAG expression at the RNA and protein level. In adult mutant animals the degree of myelination and its compaction are normal, whereas the organization of the periaxonal region is partially impaired. Mutant animals show a subtle intention tremor. Our findings do not support the widely held view that MAG is critical for myelin formation but rather indicate that MAG is necessary for maintenance of the cytoplasmic collar and periaxonal space of myelinated fibres.	UNIV TORONTO, DEPT MOLEC & MED GENET, TORONTO M5G 1X5, ON, CANADA; CLEVELAND CLIN FDN, DEPT NEUROSCI, CLEVELAND, OH 44195 USA; MCGILL UNIV, ROYAL VICTORIA HOSP, MONTREAL H3A 1A1, PQ, CANADA	University of Toronto; Cleveland Clinic Foundation; McGill University; Royal Victoria Hospital	LI, CM (corresponding author), MT SINAI HOSP, SAMUEL LUNENFELD RES INST, 600 UNIV AVE, TORONTO M5G 1X5, ON, CANADA.		Roder, John/G-6468-2013					ARQUINT M, 1987, P NATL ACAD SCI USA, V84, P600, DOI 10.1073/pnas.84.2.600; CAPECCHI MR, 1994, SCI AM, V270, P52, DOI 10.1038/scientificamerican0394-52; DULAC C, 1992, NEURON, V8, P323, DOI 10.1016/0896-6273(92)90298-R; EDWARDS AM, 1988, MOL CELL BIOL, V8, P2655, DOI 10.1128/MCB.8.6.2655; GERLAI R, 1993, BEHAV BRAIN RES, V55, P51, DOI 10.1016/0166-4328(93)90006-C; HIRANO A, 1983, PROG NEUROPATH, V5, P99; HUNTINGFORD F, 1984, STUDY ANIMAL BEHAVIO; JOHNSON PW, 1989, NEURON, V3, P377, DOI 10.1016/0896-6273(89)90262-6; Kirschner D., 1984, MYELIN, P51; LAI C, 1987, P NATL ACAD SCI USA, V84, P4337, DOI 10.1073/pnas.84.12.4337; MARTINI R, 1986, J CELL BIOL, V103, P2439, DOI 10.1083/jcb.103.6.2439; NAGY A, 1993, P NATL ACAD SCI USA, V90, P8424, DOI 10.1073/pnas.90.18.8424; OWENS GC, 1991, NEURON, V7, P565, DOI 10.1016/0896-6273(91)90369-B; OWENS GC, 1990, J CELL BIOL, V111, P1171, DOI 10.1083/jcb.111.3.1171; POLTORAK M, 1987, J CELL BIOL, V105, P1893, DOI 10.1083/jcb.105.4.1893; RIELE HT, 1992, P NATL ACAD SCI USA, V89, P5128, DOI 10.1073/pnas.89.11.5128; SALZER JL, 1987, J CELL BIOL, V104, P957, DOI 10.1083/jcb.104.4.957; SORIANO P, 1991, CELL, V64, P693, DOI 10.1016/0092-8674(91)90499-O; STERNBERGER NH, 1979, P NATL ACAD SCI USA, V76, P1510, DOI 10.1073/pnas.76.3.1510; TRAPP BD, 1982, J CELL BIOL, V92, P877, DOI 10.1083/jcb.92.3.877; TRAPP BD, 1984, J CELL BIOL, V98, P1272, DOI 10.1083/jcb.98.4.1272; TRAPP BD, 1984, J CELL BIOL, V99, P594, DOI 10.1083/jcb.99.2.594; TROPAK MB, 1988, MOL BRAIN RES, V4, P143, DOI 10.1016/0169-328X(88)90006-X; UMERMORI H, 1994, NATURE, V367, P572; VANDEURSEN J, 1992, NUCLEIC ACIDS RES, V20, P3815, DOI 10.1093/nar/20.15.3815; WOOD PM, 1990, J NEUROSCI, V10, P3635; WOOD SA, 1993, NATURE, V365, P87, DOI 10.1038/365025a0	27	308	310	0	2	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	0028-0836	1476-4687		NATURE	Nature	JUN 30	1994	369	6483					747	750		10.1038/369747a0	http://dx.doi.org/10.1038/369747a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	NU581	7516497				2022-12-28	WOS:A1994NU58100061
J	BONNI, A; FRANK, DA; SCHINDLER, C; GREENBERG, ME				BONNI, A; FRANK, DA; SCHINDLER, C; GREENBERG, ME			CHARACTERIZATION OF A PATHWAY FOR CILIARY NEUROTROPHIC FACTOR SIGNALING TO THE NUCLEUS	SCIENCE			English	Article							LEUKEMIA INHIBITORY FACTOR; PROTEIN-TYROSINE KINASES; C-FOS PROMOTER; TRANSCRIPTION FACTOR; CYTOPLASMIC ACTIVATION; BINDING PROTEIN; FACTOR PREVENTS; FACTOR RECEPTOR; MOTOR NEURONS; IFN-GAMMA	Components of a signaling pathway that couples the ciliary neurotrophic factor (CNTF) receptor to induction of transcription were identified. CNTF stimulated the tyrosine phosphorylation of p91, a protein implicated in interferon signaling pathways, and of two proteins that are distinct but related to p91. Tyrosine-phosphorylated p91 translocated to the nucleus, where p91 and p91-related proteins bound to a DNA sequence found in promoters of genes responsive to CNTF. This DNA sequence, when inserted upstream of a reporter gene, conferred a transcriptional response to CNTF. A pathway that transduces interferon signals may therefore have a more general function in the propagation of responses to certain neurotrophic factors.	HARVARD UNIV, SCH MED, PROGRAM NEUROSCI, BOSTON, MA 02115 USA; HARVARD UNIV, SCH MED, DEPT MICROBIOL & MOLEC GENET, BOSTON, MA 02115 USA; HARVARD UNIV, SCH MED, DANA FARBER CANC INST, BOSTON, MA 02115 USA; COLUMBIA UNIV, DEPT MED, NEW YORK, NY 10032 USA	Harvard University; Harvard Medical School; Harvard University; Harvard Medical School; Harvard University; Dana-Farber Cancer Institute; Harvard Medical School; Columbia University					NCI NIH HHS [R01 CA43855] Funding Source: Medline; NHLBI NIH HHS [HL21006-17] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA043855] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P50HL021006] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ARGETSINGER LS, 1993, CELL, V74, P237, DOI 10.1016/0092-8674(93)90415-M; BAZAN JF, 1990, P NATL ACAD SCI USA, V87, P6934, DOI 10.1073/pnas.87.18.6934; BERKOWITZ LA, 1989, MOL CELL BIOL, V9, P4272, DOI 10.1128/MCB.9.10.4272; BONNI A, UNPUB; BOYLE WJ, 1991, METHOD ENZYMOL, V201, P110; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CHURCH GM, 1984, P NATL ACAD SCI-BIOL, V81, P1991, DOI 10.1073/pnas.81.7.1991; CLEVELAND DW, 1977, J BIOL CHEM, V252, P1102; DAVIS S, 1993, SCIENCE, V260, P1805, DOI 10.1126/science.8390097; DAVIS S, 1991, SCIENCE, V253, P59, DOI 10.1126/science.1648265; Davis S, 1993, CURR OPIN CELL BIOL, V5, P281, DOI 10.1016/0955-0674(93)90117-9; DECKER T, 1991, EMBO J, V10, P927, DOI 10.1002/j.1460-2075.1991.tb08026.x; DENG HX, 1993, SCIENCE, V261, P1047, DOI 10.1126/science.8351519; DUBOIS RN, 1990, J BIOL CHEM, V265, P19185; FU XY, 1992, P NATL ACAD SCI USA, V89, P7840, DOI 10.1073/pnas.89.16.7840; GEARING DP, 1992, NEW BIOL, V4, P61; GEARING DP, 1992, SCIENCE, V255, P1434, DOI 10.1126/science.1542794; GEARING DP, 1991, EMBO J, V10, P2839, DOI 10.1002/j.1460-2075.1991.tb07833.x; HARPUR AG, 1992, ONCOGENE, V7, P1347; HIBI M, 1990, CELL, V63, P1149, DOI 10.1016/0092-8674(90)90411-7; Ip Nancy Y., 1992, Progress in Growth Factor Research, V4, P139, DOI 10.1016/0955-2235(92)90028-G; IP NY, 1992, CELL, V69, P1121, DOI 10.1016/0092-8674(92)90634-O; KISHIMOTO T, 1992, SCIENCE, V258, P593, DOI 10.1126/science.1411569; LARNER AC, 1993, IN PRESS SCIENCE, V261, P1730; LEVY D, 1990, New Biologist, V2, P923; LEVY DE, 1988, GENE DEV, V2, P383, DOI 10.1101/gad.2.4.383; LEVY DE, 1989, GENE DEV, V3, P1362, DOI 10.1101/gad.3.9.1362; LEW DJ, 1991, MOL CELL BIOL, V11, P182, DOI 10.1128/MCB.11.1.182; LORD KA, 1991, MOL CELL BIOL, V11, P4371, DOI 10.1128/MCB.11.9.4371; LOUIS JC, 1993, SCIENCE, V259, P689, DOI 10.1126/science.8430320; MASIAKOWSKI P, 1991, J NEUROCHEM, V57, P1003, DOI 10.1111/j.1471-4159.1991.tb08250.x; MASU Y, 1993, NATURE, V365, P27, DOI 10.1038/365027a0; MURAKAMI M, 1991, P NATL ACAD SCI USA, V88, P11349, DOI 10.1073/pnas.88.24.11349; MURAKAMI M, 1993, SCIENCE, V260, P1808, DOI 10.1126/science.8511589; NAKAJIMA K, 1991, MOL CELL BIOL, V11, P1409, DOI 10.1128/MCB.11.3.1409; Patterson P H, 1992, Curr Opin Neurobiol, V2, P94, DOI 10.1016/0959-4388(92)90169-L; PEARSE RN, 1993, P NATL ACAD SCI USA, V90, P4314, DOI 10.1073/pnas.90.9.4314; PINE R, IN PRESS TRENDS BIOC; ROSEN DR, 1993, NATURE, V362, P59, DOI 10.1038/362059a0; RUFFJAMISON S, 1993, SCIENCE, V261, P1733, DOI 10.1126/science.8378774; SADOWSKI HB, 1993, SCIENCE, V261, P1739, DOI 10.1126/science.8397445; SCHINDLER C, 1992, SCIENCE, V257, P809, DOI 10.1126/science.1496401; SENDTNER M, 1992, NATURE, V358, P502, DOI 10.1038/358502a0; SENDTNER M, 1990, NATURE, V345, P440, DOI 10.1038/345440a0; SHENG M, 1991, SCIENCE, V252, P1427, DOI 10.1126/science.1646483; SHENG M, 1990, NEURON, V4, P571, DOI 10.1016/0896-6273(90)90115-V; SILVENNOINEN O, 1993, SCIENCE, V261, P1736, DOI 10.1126/science.8378775; SQUINTO SP, 1990, NEURON, V5, P757, DOI 10.1016/0896-6273(90)90334-C; STAHL N, 1993, CELL, V74, P587, DOI 10.1016/0092-8674(93)90506-L; STAHL N, IN PRESS SCIENCE; TAGA T, 1989, CELL, V58, P573, DOI 10.1016/0092-8674(89)90438-8; VELAZQUEZ L, 1992, CELL, V70, P313, DOI 10.1016/0092-8674(92)90105-L; WAGNER BJ, 1990, EMBO J, V9, P4477, DOI 10.1002/j.1460-2075.1990.tb07898.x; WEGENKA UM, 1993, MOL CELL BIOL, V13, P276, DOI 10.1128/MCB.13.1.276; WILKS AF, 1991, MOL CELL BIOL, V11, P2057, DOI 10.1128/MCB.11.4.2057; WITTHUHN BA, 1993, CELL, V74, P227, DOI 10.1016/0092-8674(93)90414-L	57	179	182	0	5	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	DEC 3	1993	262	5139					1575	1579		10.1126/science.7504325	http://dx.doi.org/10.1126/science.7504325			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	MK329	7504325				2022-12-28	WOS:A1993MK32900042
J	Latchman, DS				Latchman, DS			Mechanisms of disease - Transcription-factor mutations and disease	NEW ENGLAND JOURNAL OF MEDICINE			English	Review							THYROID-HORMONE RECEPTOR; GENE; DOMAIN; CANCER; PIT-1; P53				Latchman, DS (corresponding author), UCL, SCH MED, DEPT MOLEC PATHOL, WINDEYER BLDG, CLEVELAND ST, LONDON W1P 6DB, ENGLAND.							ANDERSEN B, 1994, J BIOL CHEM, V269, P29335; BANIAHMAD A, 1992, P NATL ACAD SCI USA, V89, P10633, DOI 10.1073/pnas.89.22.10633; BANIAHMAD A, 1992, EMBO J, V11, P1015, DOI 10.1002/j.1460-2075.1992.tb05140.x; BERNS A, 1994, CURR BIOL, V4, P137, DOI 10.1016/S0960-9822(94)00031-X; BISHOP JM, 1987, SCIENCE, V235, P305, DOI 10.1126/science.3541204; Bourne HR, 1992, CURR OPIN GENET DEV, V2, P1, DOI 10.1016/S0959-437X(05)80313-2; CHOO Y, 1994, NATURE, V372, P642, DOI 10.1038/372642a0; CHOO Y, 1995, P NATL ACAD SCI USA, V92, P646; CHOO Y, 1994, P NATL ACAD SCI USA, V91, P11163, DOI 10.1073/pnas.91.23.11163; DEKOK YJM, 1995, SCIENCE, V267, P685, DOI 10.1126/science.7839145; DYCK JA, 1994, CELL, V76, P333, DOI 10.1016/0092-8674(94)90340-9; Forrest D, 1992, CURR OPIN GENET DEV, V2, P19, DOI 10.1016/S0959-437X(05)80316-8; FREDERICKS WJ, 1995, MOL CELL BIOL, V15, P1522; FRIEND S, 1994, SCIENCE, V265, P334, DOI 10.1126/science.8023155; GLASER T, 1992, NAT GENET, V2, P232, DOI 10.1038/ng1192-232; HANSON IM, 1994, NAT GENET, V6, P168, DOI 10.1038/ng0294-168; HASTIE ND, 1993, CURR OPIN GENET DEV, V3, P408, DOI 10.1016/0959-437X(93)90113-4; HATANO M, 1991, SCIENCE, V253, P79, DOI 10.1126/science.1676542; Hill Robert E., 1992, Current Opinion in Cell Biology, V4, P967, DOI 10.1016/0955-0674(92)90126-W; HUGHES MR, 1991, NUCLEAR HORMONE RECE, P321; KNUDSON AG, 1993, P NATL ACAD SCI USA, V90, P10914, DOI 10.1073/pnas.90.23.10914; LANE DP, 1992, NATURE, V358, P15, DOI 10.1038/358015a0; LATCHMAN D, 1995, GENE REGULATION EUKA; LATCHMAN DS, 1991, EUKARYOTIC TRANSCRIP; LIU J, 1991, CELL, V66, P807, DOI 10.1016/0092-8674(91)90124-H; MARX J, 1993, SCIENCE, V262, P1644, DOI 10.1126/science.8259506; MIYASHITA T, 1995, CELL, V80, P293; OLINER JD, 1993, NATURE, V362, P857, DOI 10.1038/362857a0; PAPAVASSILIOU AG, 1995, NEW ENGL J MED, V332, P45, DOI 10.1056/NEJM199501053320108; Parker MG, 1993, CURR OPIN CELL BIOL, V5, P499, DOI 10.1016/0955-0674(93)90016-J; PFAFFLE RW, 1992, SCIENCE, V257, P1118, DOI 10.1126/science.257.5073.1118; RABBITTS TH, 1994, NATURE, V372, P143, DOI 10.1038/372143a0; RADOVICK S, 1992, SCIENCE, V257, P1115, DOI 10.1126/science.257.5073.1115; SANYANUSIN P, 1995, NAT GENET, V9, P358, DOI 10.1038/ng0495-358; SAWYERS CL, 1994, CELL, V77, P171, DOI 10.1016/0092-8674(94)90307-7; SPENCER CA, 1991, ADV CANCER RES, V56, P1; TASSABEHJI M, 1992, NATURE, V355, P635, DOI 10.1038/355635a0; TON CCT, 1991, CELL, V67, P1059, DOI 10.1016/0092-8674(91)90284-6; VERRIJZER CP, 1993, BIOCHIM BIOPHYS ACTA, V1173, P1, DOI 10.1016/0167-4781(93)90237-8; WAGNER RW, 1994, NATURE, V372, P333, DOI 10.1038/372333a0; WAGNER S, 1991, NATURE, V352, P189, DOI 10.1038/352189a0; WEINBERG R, 1993, NEURON, V11, P191, DOI 10.1016/0896-6273(93)90177-S; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; ZANARIA E, 1994, NATURE, V372, P635, DOI 10.1038/372635a0	44	101	104	0	10	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JAN 4	1996	334	1					28	33		10.1056/NEJM199601043340108	http://dx.doi.org/10.1056/NEJM199601043340108			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TM482	7494569				2022-12-28	WOS:A1996TM48200008
J	Lackritz, EM; Satten, GA; AberleGrasse, J; Dodd, RY; Raimondi, VP; Janssen, RS; Lewis, WF; Notari, EP; Petersen, LR				Lackritz, EM; Satten, GA; AberleGrasse, J; Dodd, RY; Raimondi, VP; Janssen, RS; Lewis, WF; Notari, EP; Petersen, LR			Estimated risk of transmission of the human immunodeficiency virus by screened blood in the United States	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							ANTI-HIV; TRANSFUSION; INFECTION; DONORS; PREVALENCE; TYPE-1; SAFETY; TESTS	Background. In the United States, transmission of the human immunodeficiency virus (HIV) by blood transfusion occurs almost exclusively when a recently infected blood donor is infectious but before antibodies to HIV become detectable (during the ''window period''). We estimated the risk of HIV transmission caused by transfusion on the basis of the window period associated with the use of current, sensitive enzyme immunosorbent assays and recent data on HIV incidence among blood donors. Methods. We analyzed demographic and laboratory data on more than 4.1 million blood donations obtained in 1992 and 1993 in 19 regions served by the American National Red Cross, as well as the results of HIV-antibody tests of 4.9 million donations obtained in an additional 23 regions. Results. We estimated that, in the 19 study regions, 1 donation in every 360,000 (95 percent confidence interval, 210,000 to 1,140,000) was made during the window period. In addition, it is estimated that 1 in 2,600,000 donations was HIV-seropositive but was not identified as such because of an error in the laboratory. We estimated that 15 to 42 percent of window-period donations were discarded because they were seropositive on laboratory tests other than the HIV-antibody test. When these results were extrapolated to include the additional 23 Red Cross service regions, there was a risk of 1 case of HIV transmission for every 450,000 to 660,000 donations of screened blood. If the Red Cross centers are assumed to be representative of all U.S. blood centers, among the 12 million donations collected nationally each year an estimated 18 to 27 infectious donations are available for transfusion. Conclusions The estimated risk of transmitting HIV by the transfusion of screened blood is very small and nearly half that estimated previously, primarily because the sensitivity of enzyme immunosorbent assays has been improved.	CTR DIS CONTROL & PREVENT,DIV HIV AIDS PREVENT,STAT & DATA MANAGEMENT BRANCH,ATLANTA,GA 30333; AMER NATL RED CROSS,JEROME H HOLLAND LAB,ROCKVILLE,MD; ORKAND CORP,ATLANTA,GA	Centers for Disease Control & Prevention - USA; American Red Cross	Lackritz, EM (corresponding author), CTR DIS CONTROL & PREVENT,DIV HIV AIDS PREVENT,HIV SEROEPIDEMIOL BRANCH,MAILSTOP E-46,ATLANTA,GA 30333, USA.			Lackritz, Eve/0000-0002-5397-7291; Satten, Glen/0000-0001-7275-5371				BUSCH MP, 1991, NEW ENGL J MED, V325, P1, DOI 10.1056/NEJM199107043250101; BUSCH MP, 1995, TRANSFUSION, V35, P91, DOI 10.1046/j.1537-2995.1995.35295125745.x; BUSCH MP, 1995, 1995 NAT I HLTH CONS, P29; CARSON JL, 1992, AM J MED, V92, P45, DOI 10.1016/0002-9343(92)90014-3; COHEN ND, 1989, NEW ENGL J MED, V320, P1172, DOI 10.1056/NEJM198905043201803; COUROUCE AM, 1993, REV FR TRANSFUS HEM, V36, P327, DOI 10.1016/S1140-4639(05)80238-2; CUMMING PD, 1989, NEW ENGL J MED, V321, P941, DOI 10.1056/NEJM198910053211405; DOCK NL, 1991, ARCH INTERN MED, V151, P525, DOI 10.1001/archinte.151.3.525; DODD RY, 1994, BLOOD SUPPLY RISKS P, P1; DONAHUE JG, 1990, NEW ENGL J MED, V323, P1709; JACKSON JB, 1990, NEW ENGL J MED, V322, P217, DOI 10.1056/NEJM199001253220402; JOHNSON ES, 1994, TRANSFUSION, V34, P769, DOI 10.1046/j.1537-2995.1994.34994378277.x; KALBFLEISCH JD, 1989, TRANSFUSION, V29, P672, DOI 10.1046/j.1537-2995.1989.29890020437.x; KLEINMAN S, 1988, TRANSFUSION, V28, P499, DOI 10.1046/j.1537-2995.1988.28588337347.x; KLEINMAN S, 1990, ARCH PATHOL LAB MED, V114, P298; KLEINMAN SH, 1989, TRANSFUSION, V29, P572, DOI 10.1046/j.1537-2995.1989.29789369672.x; LINDEN JV, 1994, TRANSFUS MED REV, V8, P169, DOI 10.1016/S0887-7963(94)70109-7; LINDEN JV, 1994, TRANSFUSION, V34, P1016, DOI 10.1046/j.1537-2995.1994.341195065028.x; PETERSEN L, 1992, 8TH INT C AIDS 3RD S, V1; PETERSEN LR, 1994, TRANSFUSION, V34, P283, DOI 10.1046/j.1537-2995.1994.34494233574.x; ROBERTS CR, 1994, ARCH PATHOL LAB MED, V118, P1188; SCHALLA WO, 1995, 2ND NAT C HUM RETR R, P120; SELIK RM, 1994, AM J EPIDEMIOL, V140, P105, DOI 10.1093/oxfordjournals.aje.a117221; SURGENOR DM, 1990, NEW ENGL J MED, V322, P1646, DOI 10.1056/NEJM199006073222306; VAMVAKAS EC, 1994, TRANSFUSION, V34, P471, DOI 10.1046/j.1537-2995.1994.34694295060.x; WARD JW, 1988, NEW ENGL J MED, V318, P473, DOI 10.1056/NEJM198802253180803; YOUNG FE, 1990, TRANSFUSION, V30, P4, DOI 10.1046/j.1537-2995.1990.30190117628.x; 1994, NATIONAL HIV SEROSUR, V3	28	270	281	0	5	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	DEC 28	1995	333	26					1721	1725		10.1056/NEJM199512283332601	http://dx.doi.org/10.1056/NEJM199512283332601			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TM169	7491134				2022-12-28	WOS:A1995TM16900001
J	NEFF, JM; ANDERSON, G				NEFF, JM; ANDERSON, G			CARING FOR THE UNINSURED AND UNDERINSURED - PROTECTING CHILDREN WITH CHRONIC ILLNESS IN A COMPETITIVE MARKETPLACE	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							CAPITATION RATES	Health care for children with chronic illnesses is significantly more expensive than for the average child. Children with chronic illnesses are especially vulnerable in a competitive health care environment because of the higher ongoing cost associated with treating their illnesses and the inherent pressures to reduce services to manage within the capitated rate. To minimize the adverse impact a competitive market could have on these children, a ''carve-out'' for specific medical conditions is discussed. A capitation pricing system that reflects their higher costs is proposed, as well as a delivery system that is focused on their needs.	UNIV WASHINGTON,DEPT PEDIAT,SEATTLE,WA 98195; JOHNS HOPKINS MED INST,CTR HOSP FINANCE MANAGEMENT,BALTIMORE,MD 21205	University of Washington; University of Washington Seattle; Johns Hopkins University; Johns Hopkins Medicine	NEFF, JM (corresponding author), CHILDRENS HOSP & MED CTR,4800 SAND POINT WAY NE,POB 5371,SEATTLE,WA 98105, USA.							ACKERLOFF GA, 1970, Q J ECON, V84, P489; ANDERSON GF, 1990, INQUIRY-J HEALTH CAR, V27, P225; ARROW KJ, 1963, AM ECON REV, V53, P941; Ash A, 1989, Health Care Financ Rev, V10, P17; ATKINSON MA, 1994, NEW ENGL J MED, V331, P1428; BEHRMAN RE, 1992, NELSON TXB PAEDIAT, P1; BOYLE CA, 1994, PEDIATRICS, V93, P399; CONE TE, 1979, HIST AM PEDIATRICS, P159; ELSAS LJ, 1991, RUDOLPHS PEDIATRICS, P281; ELWOOD JM, 1992, EPIDEMIOLOGY CONTROL, P110; EPSTEIN A, 1995, NEW ENGL J MED, V333, P57, DOI 10.1056/NEJM199507063330114; Epstein A M, 1988, Health Care Financ Rev, V10, P51; FITZSIMMONS SC, 1993, J PEDIATR-US, V122, P1, DOI 10.1016/S0022-3476(05)83478-X; FOX HB, 1993, AM J DIS CHILD, V147, P546, DOI 10.1001/archpedi.1993.02160290052025; GILLUM RF, 1994, AM HEART J, V127, P919, DOI 10.1016/0002-8703(94)90562-2; Hahn J A, 1993, Paediatr Perinat Epidemiol, V7, P450, DOI 10.1111/j.1365-3016.1993.tb00426.x; HOWARD WT, 1924, PUBLIC HLTH ADM NATU; HOYER LW, 1994, NEW ENGL J MED, V330, P38, DOI 10.1056/NEJM199401063300108; HUGHES DC, 1995, PEDIATRICS, V95, P591; IANNACCONE ST, 1992, PEDIATR CLIN N AM, V39, P879; MCCLURE W, 1984, INQUIRY-J HEALTH CAR, V21, P205; NEWACHECK PW, 1994, J PEDIATR-US, V124, P40, DOI 10.1016/S0022-3476(94)70252-7; NEWACHECK PW, 1992, AM J PUBLIC HEALTH, V82, P364, DOI 10.2105/AJPH.82.3.364; Newhouse J P, 1989, Health Care Financ Rev, V10, P41; ROSS JA, 1994, EPIDEMIOL REV, V16, P243, DOI 10.1093/oxfordjournals.epirev.a036153; RUDOLPH AM, 1991, RUDOLPHS PEDIATRICS, P1; SAMANEK M, 1992, PEDIATR CARDIOL, V13, P152; Starfield B, 1985, EFFECTIVENESS MED CA; THOMAS JW, 1986, MED CARE, V24, P259, DOI 10.1097/00005650-198603000-00008; WARE JE, 1992, MED CARE, V30, P473, DOI 10.1097/00005650-199206000-00002; WEINER JP, 1991, MED CARE, V29, P452, DOI 10.1097/00005650-199105000-00006; 1992, CTR FUTURE CHILDREN, P102; 1987, NATIONAL MED EXPENDI, P37; 1994, ANN REPORT C 1994; 1992, VITAL HLTH STAT 10, V189; 1994, WASHINGTON HLTH SERV; 1995, MMWR-MORBID MORTAL W, V43, P952	37	88	88	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	DEC 20	1995	274	23					1866	1869		10.1001/jama.274.23.1866	http://dx.doi.org/10.1001/jama.274.23.1866			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	TK147	7500537				2022-12-28	WOS:A1995TK14700029
J	ACETI, A; MURA, MS; BABUDIERI, S; BACCIU, SA				ACETI, A; MURA, MS; BABUDIERI, S; BACCIU, SA			A YOUNG WOMAN WITH HEPATITIS AFTER A SORE THROAT	LANCET			English	Note											ACETI, A (corresponding author), UNIV SASSARI,INST INFECT DIS,VIA MANNO 54,I-07100 SASSARI,ITALY.		Babudieri, Sergio/C-7559-2011	BABUDIERI, SERGIO/0000-0001-7291-8687				FINKEL M, 1964, MIL MED, V129, P553; SCHOOLEY RT, 1995, PRINCIPLES PRACTICE, P1364; SHERLOCK S, 1993, DISEASES LIVER BILIA, P288; SHERLOCK S, 1993, DIS LIVER BILIARY SY, P299; VENTO S, 1991, LANCET, V337, P1183, DOI 10.1016/0140-6736(91)92858-Y	5	14	14	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	DEC 16	1995	346	8990					1603	1603		10.1016/S0140-6736(95)91932-5	http://dx.doi.org/10.1016/S0140-6736(95)91932-5			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TK481	7500754				2022-12-28	WOS:A1995TK48100013
J	BLOEMENKAMP, KWM; ROSENDAAL, FR; HELMERHORST, FM; BULLER, HR; VANDENBROUCKE, JP				BLOEMENKAMP, KWM; ROSENDAAL, FR; HELMERHORST, FM; BULLER, HR; VANDENBROUCKE, JP			ENHANCEMENT BY FACTOR-V LEIDEN MUTATION OF RISK OF DEEP-VEIN THROMBOSIS ASSOCIATED WITH ORAL-CONTRACEPTIVES CONTAINING 3RD-GENERATION PROGESTAGEN	LANCET			English	Article							THROMBOEMBOLIC DISEASE; VENOUS THROMBOSIS	Recent concern about the safety of combined oral contraceptives (OCs) with third-generation progestagens prompted an examination of data from a population-based case-control study (Leiden Thrombophilia Study). We compared the risk of deep-vein thrombosis (DVT) during use of the newest OCs, containing a third-generation progestagen, with the risk of ''older'' products. We also investigated the influence of family history of thrombosis, previous pregnancy, age, and the thrombogenic factor V Leiden mutation. We selected 126 women with DVT and 159 controls aged 15-49 (mean 34.9) and premenopausal found, as compared non-users, the highest adjusted relative risks to be that for an OC containing desogestrel and 30 mu g ethinyloestradiol (relative risk [RR] 8.7, 95% CI 3.9-19.3). We found lower relative risks for ail other types of OC, ranging from 2.2 to 3.8. In a direct comparison, users of the desogestrel-containing oral contraceptive had a 2.5-fold higher risk (95% CI 1.2-5.2) than users of all other OC types combined. The relative risk for the desogestrel-containing OC was similar among women with and without a family history--ie, preferential prescription because of family history cannot explain our findings. Nor could the excess risk be explained by previous pregnancy, and it was highest in the youngest age categories, where we would expect most new users. The age-adjusted RR for the desogestrel-containing contraceptive was 9.2 (3.9-21.4) among non-carriers of the factor V Leiden mutation and 6.0 (1.9-19.0) among carriers of the mutation. This latter risk is superimposed on the 8-fold increased risk of venous thrombosis for carriers of the factor V Leiden mutation. The risk of carriers using the desogestrel-containing OC as compared with noncarrier non-users will therefore be increased almost 50-fold. Use of low-dose OCs with a third-generation progestagen carries a higher risk of DVT than the previous generation of OCs. The absolute risk of DVT associated with these OCs seems to be especially high among carriers of the factor V Leiden mutation and among women with a family history of thrombosis. However, the higher risk associated with OC with a third-generation progestagen compared with previous generations was also present in women without factor V Leiden and with no family history.	LEIDEN UNIV HOSP,DEPT CLIN EPIDEMIOL,2300 RC LEIDEN,NETHERLANDS; LEIDEN UNIV HOSP,DEPT OBSTET GYNAECOL & REPROD MED,2300 RC LEIDEN,NETHERLANDS; LEIDEN UNIV HOSP,THROMBOSIS & HAEMOSTASIS RES CTR,2300 RC LEIDEN,NETHERLANDS; UNIV AMSTERDAM,ACAD MED CTR,CTR HEMOSTASIS THROMBOSIS ATHEROSCLEROSIS & INFLA,1105 AZ AMSTERDAM,NETHERLANDS	Leiden University; Leiden University Medical Center (LUMC); Leiden University; Leiden University Medical Center (LUMC); Leiden University; Leiden University Medical Center (LUMC); University of Amsterdam; Academic Medical Center Amsterdam			Rosendaal, Frits/Q-3842-2017; Vandenbroucke, Jan/AAM-3928-2020	Rosendaal, Frits/0000-0003-2558-7496; Vandenbroucke, Jan/0000-0001-5668-6716				BERTINA RM, 1994, NATURE, V369, P64, DOI 10.1038/369064a0; BOTTIGER LE, 1980, LANCET, V1, P1097; CARTER JC, 1994, PROGR CARDIOVASC DIS, V6, P423; FOTHERBY K, 1994, CONTRACEPTION, V49, P1, DOI 10.1016/0010-7824(94)90106-6; GERSTMAN BB, 1991, AM J EPIDEMIOL, V133, P32, DOI 10.1093/oxfordjournals.aje.a115799; INMAN WHW, 1970, BMJ-BRIT MED J, V2, P203, DOI 10.1136/bmj.2.5703.203; JANSSEN HF, 1987, SURGERY, V101, P205; KOSTER T, 1993, LANCET, V342, P1503, DOI 10.1016/S0140-6736(05)80081-9; LIDEGAARD O, 1993, BRIT MED J, V306, P956, DOI 10.1136/bmj.306.6883.956; ROBINSON GE, 1994, BRIT J OBSTET GYNAEC, V101, P1036, DOI 10.1111/j.1471-0528.1994.tb13578.x; SHAPIRO S, 1979, LANCET, V1, P743; SPEROFF L, 1993, OBSTET GYNECOL, V1, P1034; VANDENBROUCKE JP, 1994, LANCET, V344, P1453, DOI 10.1016/S0140-6736(94)90286-0; VESSEY M, 1986, BRIT MED J, V292, P526, DOI 10.1136/bmj.292.6519.526	14	535	541	0	7	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	DEC 16	1995	346	8990					1593	1596		10.1016/S0140-6736(95)91929-5	http://dx.doi.org/10.1016/S0140-6736(95)91929-5			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TK481	7500751	Bronze			2022-12-28	WOS:A1995TK48100010
J	PICKUP, J				PICKUP, J			WHERE SENSORS LEAD	LANCET			English	Editorial Material											PICKUP, J (corresponding author), UNITED MED & DENT SCH,GUYS HOSP,DIV CHEM PATHOL,LONDON SE1 9RT,ENGLAND.							ANDERSSON LI, 1995, P NATL ACAD SCI USA, V92, P4788, DOI 10.1073/pnas.92.11.4788; BALL P, 1994, NATURE, V371, P202, DOI 10.1038/371202a0; BELL TW, 1995, SCIENCE, V269, P671, DOI 10.1126/science.7624796; Czamik A. W., 1993, FLUORESCENT CHEMOSEN, P1; HEILMANN J, 1994, ANGEW CHEM INT EDIT, V33, P471, DOI 10.1002/anie.199404711; KRIZ D, 1995, ANAL CHEM, V67, P2142, DOI 10.1021/ac00109a037; LEHN JM, 1993, SCIENCE, V260, P1762, DOI 10.1126/science.8511582; NICHOLLS IA, 1995, TRENDS BIOTECHNOL, V13, P47, DOI 10.1016/S0167-7799(00)88904-0; PICKUP JC, 1993, LANCET, V342, P1068, DOI 10.1016/0140-6736(93)92059-3; SHEA KJ, 1995, TRENDS PHARMACOL SCI, V2, P166; Turner APF, 1987, BIOSENSORS FUNDAMENT; Vidyasankar Sundaresan, 1995, Current Opinion in Biotechnology, V6, P218, DOI 10.1016/0958-1669(95)80036-0; VLATAKIS G, 1993, NATURE, V361, P645, DOI 10.1038/361645a0	13	1	1	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	DEC 16	1995	346	8990					1572	1573		10.1016/S0140-6736(95)91924-4	http://dx.doi.org/10.1016/S0140-6736(95)91924-4			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TK481	7500746				2022-12-28	WOS:A1995TK48100005
J	GOSTIN, LO; LAZZARINI, Z				GOSTIN, LO; LAZZARINI, Z			CHILDHOOD IMMUNIZATION REGISTRIES - A NATIONAL REVIEW OF PUBLIC-HEALTH INFORMATION-SYSTEMS AND THE PROTECTION OF PRIVACY	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							UNITED-STATES; CHILDREN; COVERAGE; CARE		GEORGETOWN JOHNS HOPKINS UNIV PROGRAM LAW & PUBL,WASHINGTON,DC; GEORGETOWN JOHNS HOPKINS UNIV PROGRAM LAW & PUBL,BALTIMORE,MD; HARVARD UNIV,SCH PUBL HLTH,BOSTON,MA 02115	Johns Hopkins University; Johns Hopkins University; Harvard University; Harvard T.H. Chan School of Public Health								ATKINSON WL, 1992, ANNU REV MED, V43, P451, DOI 10.1146/annurev.med.43.1.451; BYRNE EB, 1970, J AMER MED ASSOC, V212, P770, DOI 10.1001/jama.212.5.770; CLAYTON EW, 1994, PEDIATRICS, V93, P369; CUTTS FT, 1992, JAMA-J AM MED ASSOC, V267, P1952, DOI 10.1001/jama.267.14.1952; CUTTS FT, 1992, ANNU REV PUBL HEALTH, V13, P385, DOI 10.1146/annurev.publhealth.13.1.385; FLINT SS, 1990, PEDIATRICS, V85, P567; FREED GL, 1993, NEW ENGL J MED, V329, P1957, DOI 10.1056/NEJM199312233292611; FREED GL, 1993, MILBANK Q, V71, P65, DOI 10.2307/3350275; GALE JL, 1994, JAMA-J AM MED ASSOC, V271, P37, DOI 10.1001/jama.271.1.37; GOLDSTEIN KP, 1993, JAMA-J AM MED ASSOC, V270, P2190, DOI 10.1001/jama.270.18.2190; Gostin L. O., 1995, CORNELL LAW REV, V80, P101; GOSTIN LO, 1993, JAMA-J AM MED ASSOC, V269, P2527; GOSTIN LO, 1993, JAMA-J AM MED ASSOC, V270, P2487; HEMENWAY D, 1994, ECON INQ, V32, P519, DOI 10.1111/j.1465-7295.1994.tb01348.x; HEROLD AH, 1993, J FAM PRACTICE, V36, P158; HINMAN AR, 1991, AM J DIS CHILD, V145, P559, DOI 10.1001/archpedi.1991.02160050085023; HINMAN AR, 1990, PEDIATRICS, V86, P1064; KLACHKO DM, 1989, J FAM PRACTICE, V29, P169; LINKINS RW, 1994, ARCH PEDIAT ADOL MED, V148, P908, DOI 10.1001/archpedi.1994.02170090022002; LITT JCB, 1993, MED J AUSTRALIA, V159, P542, DOI 10.5694/j.1326-5377.1993.tb138009.x; LOESER H, 1983, AM J PUBLIC HEALTH, V73, P1298, DOI 10.2105/AJPH.73.11.1298; MOORE P, 1994, JAMA-J AM MED ASSOC, V272, P297, DOI 10.1001/jama.272.4.297; Orenstein W A, 1990, J Health Care Poor Underserved, V1, P315; ORENSTEIN WA, 1994, PEDIATRICS, V94, P545; PELTOLA H, 1994, NEW ENGL J MED, V331, P1397, DOI 10.1056/NEJM199411243312101; Salsberry P J, 1993, J Community Health Nurs, V10, P213, DOI 10.1207/s15327655jchn1004_2; SATCHER D, 1994, PUBLIC HLTH REP, P593; SKOLNICK A, 1991, JAMA-J AM MED ASSOC, V265, P2453, DOI 10.1001/jama.265.19.2453; Stratton K.R., 1994, ADVERSE EVENTS ASS C; SZILAGYI PG, 1992, PEDIATRICS, V90, P871; SZILAGYI PG, 1993, PEDIATRICS, V91, P1; TOLLESTRUP K, 1991, AM J PREV MED, V7, P24, DOI 10.1016/S0749-3797(18)30961-9; WILLIAMS BC, 1990, PEDIATRICS S1, V115, P1052; WOOD DL, 1990, PEDIATRICS, V86, P666; YOUNG SA, 1980, AM J PUBLIC HEALTH, V70, P422, DOI 10.2105/AJPH.70.4.422; 1994, DEV NATIONAL CHILDHO; 1994, HLTH US 1993, P63; 1993, PREVENTIVE HLTH CARE; 1995, MMWR-MORBID MORTAL W, V44, P142; 1995, MMWR-MORBID MORTAL W, V44, P545; 1991, HLTH PEOPLE 2000 NAT; 1994, MMWR-MORBID MORTAL W, V43, P709; 1990, CHILDREN DEV 1990S U; 1994, MMWR-MORBID MORTAL W, V43, P57; 1992, JAMA-J AM MED ASSOC, V266, P1547; 1994, JAMA-J AM MED ASSOC, V271, P260; 1973, RECORDS COMPUTERS RI; 1995, PUBLICATION GAO PEMD, V9522; 1994, MMWR-MORBID MORTAL W, V43, P716; 1992, ACCESS CHILDHOOD IMM; 1995, MMWR-MORBID MORTAL W, V44, P149; 1993, JAMA-J AM MED ASSOC, V42, P378; 1995, ACIP RECOMMENDED IMM; 1994, MMWR-MORBID MORTAL W, V43, P718; 1992, STANDARDS PEDIATRIC; 1994, OVERCOMING BARRIERS; 1989, MMWR-MORBID MORTAL W, V38, P4; 1992, STATE AM CHILDREN; 1994, VACCINES CHILDREN CR	59	48	48	0	4	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	DEC 13	1995	274	22					1793	1799		10.1001/jama.274.22.1793	http://dx.doi.org/10.1001/jama.274.22.1793			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TJ225	7500512				2022-12-28	WOS:A1995TJ22500031
J	GAVIN, KA; HIDAKA, M; STILLMAN, B				GAVIN, KA; HIDAKA, M; STILLMAN, B			CONSERVED INITIATOR PROTEINS IN EUKARYOTES	SCIENCE			English	Article							ORIGIN RECOGNITION COMPLEX; DNA-REPLICATION; SACCHAROMYCES-CEREVISIAE; YEAST; GENES; START; EGGS	The origin recognition complex (ORC), a multisubunit protein identified in Saccharomyces cerevisiae, binds to chromosomal replicators and is required for the initiation of cellular DNA replication. complementary DNAs (cDNAs) encoding proteins related to the two largest subunits of ORC were cloned from various eukaryotes. The cDNAs encoding proteins related to S. cerevisiae Orc1p were cloned from the budding yeast Kluyveromyces lactis, the fission yeast Schizosaccharomyces pombe, and human cells. These proteins show similarity to regulators of the S and M phases of the cell cycle. Genetic analysis of orc1(+) from S. pombe reveals that it is essential for cell viability. The cDNAs encoding proteins related to S. cerevisiae Orc2p were cloned from Arabidopsis thaliana, Caenorhabditis elegans, and human cells. The human ORC-related proteins interact in vivo to form a complex. These studies suggest that ORC subunits are conserved and that the role of ORC is a general feature of eukaryotic DNA replication.	COLD SPRING HARBOR LAB, COLD SPRING HARBOR, NY 11724 USA; SUNY STONY BROOK, GENET PROGRAM, STONY BROOK, NY 11794 USA	Cold Spring Harbor Laboratory; State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook				Stillman, Bruce/0000-0002-9453-4091	NATIONAL CANCER INSTITUTE [P01CA013106] Funding Source: NIH RePORTER; NCI NIH HHS [CA13106] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; Baker T, 1991, DNA REPLICATION, V2; BELL SP, 1993, SCIENCE, V262, P1844, DOI 10.1126/science.8266072; BELL SP, 1995, CELL, V83, P563, DOI 10.1016/0092-8674(95)90096-9; BELL SP, 1992, NATURE, V357, P128, DOI 10.1038/357128a0; BLOW JJ, 1990, J CELL SCI, V95, P383; BUENO A, 1992, EMBO J, V11, P2167, DOI 10.1002/j.1460-2075.1992.tb05276.x; CALIGIURI M, 1993, CELL, V72, P607, DOI 10.1016/0092-8674(93)90079-6; Campbell JL, 1991, MOL CELLULAR BIOL YE, P41; DEPAMPHILIS ML, 1993, J BIOL CHEM, V268, P1; DIFFLEY JFX, 1992, NATURE, V357, P169, DOI 10.1038/357169a0; DIFFLEY JFX, 1994, CELL, V78, P303, DOI 10.1016/0092-8674(94)90299-2; EHRENHOFERMURRAY AE, 1995, SCIENCE, V270, P1671, DOI 10.1126/science.270.5242.1671; FIELD J, 1988, MOL CELL BIOL, V8, P2159, DOI 10.1128/MCB.8.5.2159; FOSS M, 1993, SCIENCE, V262, P1838, DOI 10.1126/science.8266071; FOX CA, 1995, GENE DEV, V9, P911, DOI 10.1101/gad.9.8.911; GAVIN KA, UNPUB; GOSSEN M, 1995, SCIENCE, V270, P1674, DOI 10.1126/science.270.5242.1674; HAMLIN JL, 1995, CURR OPIN GENET DEV, V5, P153, DOI 10.1016/0959-437X(95)80002-6; HARLAND RM, 1980, CELL, V21, P761, DOI 10.1016/0092-8674(80)90439-0; JACOB F, 1963, COLD SPRING HARB SYM, V28, P329, DOI 10.1101/SQB.1963.028.01.048; KELLY TJ, 1993, CELL, V74, P371, DOI 10.1016/0092-8674(93)90427-R; KOONIN EV, 1993, NUCLEIC ACIDS RES, V21, P2541, DOI 10.1093/nar/21.11.2541; LI JJ, 1993, SCIENCE, V262, P1870, DOI 10.1126/science.8266075; LIANG C, 1995, CELL, V81, P667, DOI 10.1016/0092-8674(95)90528-6; LOO S, 1995, MOL BIOL CELL, V6, P741, DOI 10.1091/mbc.6.6.741; MARAHRENS Y, 1992, SCIENCE, V255, P817, DOI 10.1126/science.1536007; MECHALI M, 1984, CELL, V38, P55, DOI 10.1016/0092-8674(84)90526-9; MICKLEM G, 1993, NATURE, V366, P87, DOI 10.1038/366087a0; MIZUKAMI T, 1993, CELL, V73, P121, DOI 10.1016/0092-8674(93)90165-M; MORENO S, 1991, METHOD ENZYMOL, V194, P795; PIATTI S, 1995, EMBO J, V14, P3788, DOI 10.1002/j.1460-2075.1995.tb00048.x; RAO H, 1994, MOL CELL BIOL, V14, P7643, DOI 10.1128/MCB.14.11.7643; RAO H, 1995, P NATL ACAD SCI USA, V92, P2224, DOI 10.1073/pnas.92.6.2224; ROWLEY A, 1994, BBA-GENE STRUCT EXPR, V1217, P239, DOI 10.1016/0167-4781(94)90283-6; ROWLEY A, 1995, EMBO J, V14, P2631, DOI 10.1002/j.1460-2075.1995.tb07261.x; SHORE D, 1984, EMBO J, V3, P2817, DOI 10.1002/j.1460-2075.1984.tb02214.x; SKOWRONSKI J, 1988, MOL CELL BIOL, V8, P1385, DOI 10.1128/MCB.8.4.1385; STARK MJR, 1989, YEAST, V5, P35, DOI 10.1002/yea.320050106; THEIS JF, 1994, MOL CELL BIOL, V14, P7652, DOI 10.1128/MCB.14.11.7652; WALKER SS, 1991, NUCLEIC ACIDS RES, V19, P6255, DOI 10.1093/nar/19.22.6255; WEIGEL D, 1992, CELL, V69, P843, DOI 10.1016/0092-8674(92)90295-N; WILSON AC, 1995, GENE DEV, V9, P2445, DOI 10.1101/gad.9.20.2445	43	205	216	0	1	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	DEC 8	1995	270	5242					1667	1671		10.1126/science.270.5242.1667	http://dx.doi.org/10.1126/science.270.5242.1667			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TJ293	7502077				2022-12-28	WOS:A1995TJ29300049
J	RUBIO, F; GASSMANN, W; SCHROEDER, JI				RUBIO, F; GASSMANN, W; SCHROEDER, JI			SODIUM-DRIVEN POTASSIUM UPTAKE BY THE PLANT POTASSIUM TRANSPORTER HKT1 AND MUTATIONS CONFERRING SALT TOLERANCE	SCIENCE			English	Article							SACCHAROMYCES-CEREVISIAE; CULTIVARS; MECHANISM; PROTEIN; MUTANT; YEAST	Sodium (Na+) at high millimolar concentrations in soils is toxic to most higher plants and severely reduces agricultural production worldwide. However, the molecular mechanisms for plant Na+ uptake remain unknown. Here, the wheat root high-affinity potassium (K+) uptake transporter HKT1 was shown to function as a high-affinity K+-Na+ cotransporter. High-affinity K+ uptake was activated by micromolar Na+ concentrations; moreover, high-affinity Na+ uptake was activated by K+ (half-activation constant, 2.8 mu M K+). However, at physiologically detrimental concentrations of Na+, K+ accumulation mediated by HKT1 was blocked and low-affinity Na+ uptake occurred (Michaelis constant, similar to 16 mM Na+), which correlated to Na+ toxicity in plants. Point mutations in the sixth putative transmembrane domain of HKT1 that increase Na+ tolerance were isolated with the use of yeast as a screening system. Na+ uptake and Na+ inhibition of K+ accumulation indicate a possible role for HKT1 in physiological Na+ toxicity in plants.					Rubio, Francisco/ABF-8662-2020; Rubio, Francisco/K-2854-2014	Rubio, Francisco/0000-0001-7640-9548; Rubio, Francisco/0000-0001-7640-9548; Schroeder, Julian/0000-0002-3283-5972; Gassmann, Walter/0000-0002-7527-0385				ANDERSON JA, 1992, P NATL ACAD SCI USA, V89, P3736, DOI 10.1073/pnas.89.9.3736; BARKLA BJ, 1991, P NATL ACAD SCI USA, V88, P11177, DOI 10.1073/pnas.88.24.11177; BORSTPAUWELS GWFH, 1981, BIOCHIM BIOPHYS ACTA, V650, P88, DOI 10.1016/0304-4157(81)90002-2; FAN TWM, 1989, P NATL ACAD SCI USA, V86, P9856, DOI 10.1073/pnas.86.24.9856; FLOWERS TJ, 1983, ENCY PLANT PHYSL B, V15, P651; GASSMANN W, UNPUB; GAXIOLA R, 1992, EMBO J, V11, P3157, DOI 10.1002/j.1460-2075.1992.tb05392.x; GREENWAY H, 1980, ANNU REV PLANT PHYS, V31, P149, DOI 10.1146/annurev.pp.31.060180.001053; LEYH TS, 1993, CRIT REV BIOCHEM MOL, V28, P515, DOI 10.3109/10409239309085137; MAATHUIS FJM, 1994, P NATL ACAD SCI USA, V91, P9272, DOI 10.1073/pnas.91.20.9272; MURGUIA JR, 1995, SCIENCE, V267, P232; RAINS DW, 1967, PLANT PHYSIOL, V42, P314, DOI 10.1104/pp.42.3.314; RAINS DW, 1965, SCIENCE, V148, P1611, DOI 10.1126/science.148.3677.1611; RAMOS J, 1985, ARCH MICROBIOL, V143, P88, DOI 10.1007/BF00414774; RAMOS J, 1986, EUR J BIOCHEM, V154, P307, DOI 10.1111/j.1432-1033.1986.tb09398.x; RODRIGUEZNAVARR.A, 1984, J BACTERIOL, V159, P940; RUBIO F, UNPUB; SCHACHTMAN DP, 1994, NATURE, V370, P655, DOI 10.1038/370655a0; SCHROEDER JI, 1994, ANNU REV BIOPH BIOM, V23, P441, DOI 10.1146/annurev.bb.23.060194.002301; SCHUBERT S, 1990, PLANT SOIL, V123, P205, DOI 10.1007/BF00011269; SERRANO R, 1985, PLASMA MEMBRANE ATPA; SIKORSKI RS, 1991, METHOD ENZYMOL, V194, P302; SMITH FA, 1989, J MEMBRANE BIOL, V108, P125, DOI 10.1007/BF01871024; SUSSMAN MR, 1994, ANNU REV PLANT PHYS, V45, P211, DOI 10.1146/annurev.pp.45.060194.001235; TARCZYNSKI MC, 1993, SCIENCE, V259, P508, DOI 10.1126/science.259.5094.508; WALKER NA, 1991, PLANTA, V185, P443, DOI 10.1007/BF00201070	26	476	536	7	85	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	DEC 8	1995	270	5242					1660	1663		10.1126/science.270.5242.1660	http://dx.doi.org/10.1126/science.270.5242.1660			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TJ293	7502075				2022-12-28	WOS:A1995TJ29300047
J	SAINSBURY, R				SAINSBURY, R			UPPER-LIMB DISEASE IN WOMEN TREATED FOR BREAST-CANCER	LANCET			English	Editorial Material											SAINSBURY, R (corresponding author), ROYAL INFIRM,HUDDERSFIELD,W YORKSHIRE,ENGLAND.							ADAM A, 1995, BRIT MED J, V311, P341, DOI 10.1136/bmj.311.7001.341; Janse A J, 1995, Eur J Surg Oncol, V21, P155, DOI 10.1016/S0748-7983(95)90270-8; TAYLOR PJ, 1995, BRIT J SURG, V82, P1089, DOI 10.1002/bjs.1800820827; 1995, MANAGEMENT ADVERSE E	4	4	4	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	DEC 2	1995	346	8988					1444	1444		10.1016/S0140-6736(95)92469-8	http://dx.doi.org/10.1016/S0140-6736(95)92469-8			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TH156	7490988				2022-12-28	WOS:A1995TH15600006
J	SPECKENS, AEM; VANHEMERT, AM; SPINHOVEN, P; HAWTON, KE; BOLK, JH; ROOIJMANS, HGM				SPECKENS, AEM; VANHEMERT, AM; SPINHOVEN, P; HAWTON, KE; BOLK, JH; ROOIJMANS, HGM			COGNITIVE-BEHAVIORAL THERAPY FOR MEDICALLY UNEXPLAINED PHYSICAL SYMPTOMS - A RANDOMIZED CONTROLLED TRIAL	BRITISH MEDICAL JOURNAL			English	Article								Objective-To examine the additional effect of cognitive behavioural therapy for patients with medically unexplained physical symptoms in comparison with optimised medical care; Design-Randomised controlled trial with follow up assessments six and 12 months after the baseline evaluation. Setting-General medical outpatient clinic in a university hospital. Subjects-An intervention group of 39 patients and a control group of 40 patients. Interventions-The intervention group received between six and 16 sessions of cognitive behavioural therapy. Therapeutic techniques used included identification and modification of dysfunctional automatic thoughts and behavioural experiments aimed at breaking the vicious cycles of the symptoms and their consequences. The control group received optimised medical care. Main outcome measures-The degree of change, frequency and intensity of the presenting symptoms, psychological distress, functional impairment, hypochondriacal beliefs and attitudes, and (at 12 months of follow up) number of visits to the general practitioner. Results-At six months of follow up the intervention group reported a higher recovery rate (odds ratio 0.40; 95% confidence interval 0.16 to 1.00), a lower mean intensity of the physical symptoms (difference -1.2; -2.0 to -0.3), and less impairment of sleep (odds ratio 0.38; 0.15 to 0.94) than the controls. After adjustment for coincidental baseline differences the intervention and control groups also differed with regard to frequency of the symptoms (0.32; 0.13 to 0.77), limitations in social (0.35; 0.14 to 0.85) and leisure (0.36; 0.14 to 0.93) activities, and illness behaviour (difference -2.5; -4.6 to -0.5). At It months of follow up the differences between the groups were largely maintained. Conclusion-Cognitive behavioural therapy seems to be a feasible and effective treatment in general medical patients with unexplained physical symptoms.	UNIV OXFORD,WARNEFORD HOSP,DEPT PSYCHIAT,OXFORD OX3 7JX,ENGLAND; UNIV LEIDEN HOSP,DEPT GEN INTERNAL MED,LEIDEN,NETHERLANDS	University of Oxford; Leiden University; Leiden University Medical Center (LUMC)	SPECKENS, AEM (corresponding author), LEIDEN UNIV HOSP,DEPT PSYCHIAT,B1-P,POSTBOX 9600,2300 RC LEIDEN,NETHERLANDS.		Speckens, Anne/H-8093-2014	Speckens, Anne/0000-0001-5266-1554				BERGNER M, 1981, MED CARE, V19, P787, DOI 10.1097/00005650-198108000-00001; DEBRUIN AF, 1992, TIJDSCHRIFT SOCIALE, V70, P160; Goldberg DP., 1972, DETECTION PSYCHIATRI; KELLNER R, 1987, J NERV MENT DIS, V175, P20, DOI 10.1097/00005053-198701000-00004; KOETER MWJ, 1991, MANUAL DUTCH VERSION; McCullagh P., 1989, GENERALIZED LINEAR M, DOI DOI 10.1007/978-1-4899-3242-6; PILOWSKY I, 1967, BRIT J PSYCHIAT, V113, P89, DOI 10.1192/bjp.113.494.89; Sackett DL, 1991, CLIN EPIDEMIOLOGY BA, V2nd; SALKOVSKIS PM, 1989, COGNITIVE BEHAVIOUR; SHARPE M, 1992, J PSYCHOSOM RES, V36, P515, DOI 10.1016/0022-3999(92)90037-3; SLOOFF CJ, 1983, TIJDSCHR PSYCHIAT, V25, P151; VANHEMERT AM, 1995, PSYCHOL MED, V25, P165, DOI 10.1017/S003329170002818X; VANHEMERT AM, 1993, PSYCHOL MED, V23, P167, DOI 10.1017/S0033291700038952; Wing J. K. C., 1974, MEASUREMENT CLASSIFI; ZIGMOND AS, 1983, ACTA PSYCHIAT SCAND, V67, P361, DOI 10.1111/j.1600-0447.1983.tb09716.x; 1993, STATA REFERENCE MANU, V3	16	222	224	1	23	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	NOV 18	1995	311	7016					1328	1332		10.1136/bmj.311.7016.1328	http://dx.doi.org/10.1136/bmj.311.7016.1328			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	TF901	7496281	Green Published			2022-12-28	WOS:A1995TF90100018
J	OREILLY, MS; HOLMGREN, L; SHING, Y; CHEN, C; ROSENTHAL, RA; MOSES, M; LANE, WS; CAO, YH; SAGE, EH; FOLKMAN, J				OREILLY, MS; HOLMGREN, L; SHING, Y; CHEN, C; ROSENTHAL, RA; MOSES, M; LANE, WS; CAO, YH; SAGE, EH; FOLKMAN, J			ANGIOSTATIN - A NOVEL ANGIOGENESIS INHIBITOR THAT MEDIATES THE SUPPRESSION OF METASTASES BY A LEWIS LUNG-CARCINOMA	CELL			English	Article							PRIMARY TUMOR REMOVAL; CONCOMITANT IMMUNITY; ENDOTHELIAL-CELLS; RESIDUAL TUMOR; GROWTH-FACTOR; PLASMINOGEN; RESISTANCE; BINDING; CANCER; MICE	The phenomenon of inhibition of tumor growth by tumor mass has been repeatedly studied, but without elucidation of a satisfactory mechanism. In our animal model, a primary tumor inhibits its remote metastases. After tumor removal, metastases neovascularize and grow. When the primary tumor is present, metastatic growth is suppressed by a circulating angiogenesis inhibitor. Serum and urine from tumor-bearing mice, but not from controls, specifically inhibit endothelial cell proliferation. The activity copurifies with a 38 kDa plasminogen fragment that we have sequenced and named angiostatin. A corresponding fragment of human plasminogen has similar activity. Systemic administration of angiostatin, but not intact plasminogen, potently blocks neovascularization and growth of metastases. We here show that the inhibition of metastases by a primary mouse tumor is mediated, at least in part, by angiostatin.	HARVARD UNIV,SCH MED,DEPT BIOL CELULAR,BOSTON,MA 02115; HARVARD UNIV,HARVARD MICROCHEM FACIL,CAMBRIDGE,MA 02138; UNIV WASHINGTON,DEPT BIOL STRUCT,SEATTLE,WA 98195	Harvard University; Harvard Medical School; Harvard University; University of Washington; University of Washington Seattle	OREILLY, MS (corresponding author), CHILDRENS HOSP,DEPT SURG,300 LONGWOOD AVE,BOSTON,MA 02115, USA.				NCI NIH HHS [P01-CA45548] Funding Source: Medline; NHLBI NIH HHS [HL40711] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA045548] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL040711] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Apolant, 1905, BERL KLIN WSCHR, V42, P871; BARRES BA, 1992, CELL, V70, P31, DOI 10.1016/0092-8674(92)90531-G; Bashford EF, 1907, P R SOC LOND B-CONTA, V79, P164, DOI 10.1098/rspb.1907.0014; BICHEL P, 1971, EUR J CANCER, V7, P349, DOI 10.1016/0014-2964(71)90079-X; BOK RA, 1985, BIOCHEMISTRY-US, V24, P3279, DOI 10.1021/bi00334a031; BONFIL RD, 1988, INT J CANCER, V41, P415, DOI 10.1002/ijc.2910410317; BRUNSCHW.A, 1965, ANN SURG, V162, P416, DOI 10.1097/00000658-196509000-00011; BURSCH W, 1990, CARCINOGENESIS, V11, P847, DOI 10.1093/carcin/11.5.847; CASTLE V, 1991, J CLIN INVEST, V87, P1883, DOI 10.1172/JCI115212; CLAPP C, 1993, ENDOCRINOLOGY, V133, P1292, DOI 10.1210/en.133.3.1292; CLARK WH, 1989, JNCI-J NATL CANCER I, V81, P1893, DOI 10.1093/jnci/81.24.1893; DEUTSCH DG, 1970, SCIENCE, V170, P1095, DOI 10.1126/science.170.3962.1095; DEWYS WD, 1972, CANCER RES, V32, P374; ELLEMAN CJ, 1977, J NATL CANCER I, V59, P925, DOI 10.1093/jnci/59.3.925; FIDLER IJ, 1991, BRIT MED BULL, V47, P157, DOI 10.1093/oxfordjournals.bmb.a072453; FISHER B, 1989, CANCER RES, V49, P1996; FISHER B, 1983, CANCER RES, V43, P1488; FOLKMAN J, 1979, P NATL ACAD SCI USA, V76, P5217, DOI 10.1073/pnas.76.10.5217; FOLKMAN J, 1971, NEW ENGL J MED, V285, P1182; FOLKMAN J, 1994, J CLIN ONCOL, V12, P441, DOI 10.1200/JCO.1994.12.3.441; GAVRIELI Y, 1992, J CELL BIOL, V119, P493, DOI 10.1083/jcb.119.3.493; GERSHON RK, 1967, NATURE, V213, P674, DOI 10.1038/213674a0; GOOD DJ, 1990, P NATL ACAD SCI USA, V87, P6624, DOI 10.1073/pnas.87.17.6624; GORELIK E, 1978, INT J CANCER, V21, P617, DOI 10.1002/ijc.2910210512; GORELIK E, 1981, INT J CANCER, V27, P847, DOI 10.1002/ijc.2910270618; GORELIK E, 1983, CANCER RES, V43, P138; GORELIK E, 1983, ADV CANCER RES, V39, P71, DOI 10.1016/S0065-230X(08)61033-7; GORELLK E, 1980, J NATL CANCER I, V65, P1257; GREENE HSN, 1960, CANCER RES, V20, P1094; GUNDUZ N, 1979, CANCER RES, V39, P3861; HIMMELE JC, 1986, J CANCER RES CLIN, V111, P160, DOI 10.1007/BF00400757; HOMANDBERG GA, 1985, AM J PATHOL, V120, P327; HORI A, 1991, CANCER RES, V51, P6180; HOWARD JM, 1963, SURG GYNECOL OBSTET, V117, P567; ICHINOSE A, 1992, BIOCHEMISTRY-US, V31, P3113, DOI 10.1021/bi00127a011; INGBER D, 1990, NATURE, V348, P555, DOI 10.1038/348555a0; IRUELAARISPE ML, 1991, P NATL ACAD SCI USA, V88, P5026, DOI 10.1073/pnas.88.11.5026; KIM KJ, 1993, NATURE, V362, P841, DOI 10.1038/362841a0; KOIKE A, 1963, CANCER, V16, P1065, DOI 10.1002/1097-0142(196308)16:8<1065::AID-CNCR2820160814>3.0.CO;2-O; LANE WS, 1991, J PROTEIN CHEM, V10, P151, DOI 10.1007/BF01024778; LANGE PH, 1980, CANCER-AM CANCER SOC, V45, P1498, DOI 10.1002/1097-0142(19800315)45:6<1498::AID-CNCR2820450633>3.0.CO;2-7; LAUSCH RN, 1969, INT J CANCER, V4, P226, DOI 10.1002/ijc.2910040213; LERCH PG, 1980, EUR J BIOCHEM, V107, P7, DOI 10.1111/j.1432-1033.1980.tb04617.x; MACHOVICH R, 1989, BIOCHEMISTRY-US, V28, P4517, DOI 10.1021/bi00436a059; Machovich R, 1990, Blood Coagul Fibrinolysis, V1, P273, DOI 10.1097/00001721-199008000-00004; Marie P., 1910, B ASS FR ETUD CANC, V3, P19; MILAS L, 1974, CANCER RES, V34, P61; MILLAUER B, 1994, NATURE, V367, P576, DOI 10.1038/367576a0; MOHR U, 1968, NATURE, V220, P138, DOI 10.1038/220138a0; MUTHUKKARUPPAN V, 1979, SCIENCE, V28, P1416; NAKAJIMA K, 1993, J NEUROCHEM, V61, P2155, DOI 10.1111/j.1471-4159.1993.tb07454.x; NGUYEN M, 1994, MICROVASC RES, V47, P31, DOI 10.1006/mvre.1994.1003; NICKOLOFF BJ, 1994, AM J PATHOL, V144, P820; O'Reilly Michael, 1993, Surgical Forum, V44, P474; OBESO J, 1990, LAB INVEST, V63, P259; PONTING CP, 1992, BLOOD COAGUL FIBRIN, V3, P605, DOI 10.1097/00001721-199210000-00012; PREHN RT, 1993, CANCER RES, V53, P3266; PREHN RT, 1991, CANCER RES, V51, P2; RASTINEJAD F, 1989, CELL, V56, P345, DOI 10.1016/0092-8674(89)90238-9; ROTHBARTH K, 1977, EUR J CANCER, V13, P1195, DOI 10.1016/0014-2964(77)90021-4; ROUNDS DE, 1970, CANCER RES, V30, P2847; RUGGIERO RA, 1985, BRIT J CANCER, V51, P37, DOI 10.1038/bjc.1985.6; RUGGIERO RA, 1990, CANCER RES, V50, P7159; SCHATTEN WE, 1958, CANCER, V11, P455, DOI 10.1002/1097-0142(195805/06)11:3<455::AID-CNCR2820110303>3.0.CO;2-3; SIMPSONHERREN L, 1976, CANCER TREAT REP, V60, P1749; SOTTRUPJENSEN L, 1978, PROGR CHEM FIBRINOLY, P191; SOUTHAM CM, 1961, CANCER, V14, P971, DOI 10.1002/1097-0142(196109/10)14:5<971::AID-CNCR2820140510>3.0.CO;2-O; SUGARBAKER EV, 1977, PROGR CANC RES THERA, P227; TOLSMA SS, 1993, J CELL BIOL, V122, P497, DOI 10.1083/jcb.122.2.497; Tyzzer EE, 1913, J MED RES, V28, P309; WARREN BA, 1977, PROGR CANC RES THERA, P185; WEISSBACH L, 1992, BIOCHEM BIOPH RES CO, V186, P1108, DOI 10.1016/0006-291X(92)90861-E; WOODRUFF M, 1990, CELLULAR VARIATION A; WOODRUFF M, 1980, INTERACTIONS CANCER; WYLLIE AH, 1993, BRIT J CANCER, V67, P205, DOI 10.1038/bjc.1993.40; YUHAS JM, 1974, CANCER RES, V34, P2005; [No title captured]	77	2837	3232	3	144	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	OCT 21	1994	79	2					315	328		10.1016/0092-8674(94)90200-3	http://dx.doi.org/10.1016/0092-8674(94)90200-3			14	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	PN630	7525077				2022-12-28	WOS:A1994PN63000015
J	DUCLOSVALLEE, JC; JOHANET, C; TRINCHET, JC; DENY, P; LAURENT, MF; DURON, F; VALENSI, P; WEIL, B; HOMBERG, JC; PATERON, D; BEAUGRAND, M				DUCLOSVALLEE, JC; JOHANET, C; TRINCHET, JC; DENY, P; LAURENT, MF; DURON, F; VALENSI, P; WEIL, B; HOMBERG, JC; PATERON, D; BEAUGRAND, M			HIGH PREVALENCE OF SERUM ANTIBODIES TO HEPATITIS-C VIRUS IN PATIENTS WITH HASHIMOTOS-THYROIDITIS	BRITISH MEDICAL JOURNAL			English	Article							DISEASE		HOP JEAN VERDIER,SERV HEPATOGASTROENTEROL,F-93140 BONDY,FRANCE; HOP ST ANTOINE,IMMUNOL LAB,F-75012 PARIS,FRANCE; HOP AVICENNE,SERV MICROBIOL,F-93000 BOBIGNY,FRANCE; HOP LA PITIE SALPETRIERE,NUCL MED SERV,F-75013 PARIS,FRANCE; HOP ST ANTOINE,SERV ENDOCRINOL,F-75012 PARIS,FRANCE; HOP JEAN VERDIER,SERV ENDOCRINOL,F-93140 BONDY,FRANCE; HOP COCHIN,CLIN IMMUNOL LAB,F-75014 PARIS,FRANCE	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Jean-Verdier - APHP; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Antoine - APHP; UDICE-French Research Universities; Sorbonne Universite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Avicenne - APHP; Universite Paris 13; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Pitie-Salpetriere - APHP; UDICE-French Research Universities; Sorbonne Universite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Antoine - APHP; UDICE-French Research Universities; Sorbonne Universite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Jean-Verdier - APHP; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Cochin - APHP; UDICE-French Research Universities; Universite Paris Cite			Deny, Paul/C-6099-2011					ALTER HJ, 1989, NEW ENGL J MED, V321, P1494, DOI 10.1056/NEJM198911303212202; CIAMPOLILLO A, 1989, LANCET, V1, P1096; ESTEBAN JI, 1992, PROGR LIVER DISEASE, P219; HADDAD J, 1992, LANCET, V339, P321, DOI 10.1016/0140-6736(92)91645-O; MANNS MP, 1993, PROGRESS IN HEPATOLOGY 93, P79	5	30	31	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	OCT 1	1994	309	6958					846	847		10.1136/bmj.309.6958.846	http://dx.doi.org/10.1136/bmj.309.6958.846			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PK501	7524874	Green Published			2022-12-28	WOS:A1994PK50100022
J	BILGRAMI, S; GREENBERG, BR				BILGRAMI, S; GREENBERG, BR			WHY SO MANY OPERATIONS FOR LOCALIZED PROSTATE-CANCER	LANCET			English	Editorial Material									VET AFFAIRS MED CTR,NEWINGTON,CT	US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Connecticut Healthcare System	BILGRAMI, S (corresponding author), UNIV CONNECTICUT,CTR HLTH,DIV HEMATOL ONCOL,FARMINGTON,CT, USA.							ADOLFSSON J, 1993, CANCER-AM CANCER SOC, V72, P310, DOI 10.1002/1097-0142(19930715)72:2<310::AID-CNCR2820720203>3.0.CO;2-T; BADALAMENT RA, 1991, DISEASE A MONTH, V37, P203; CHODAK GW, 1994, NEW ENGL J MED, V330, P242, DOI 10.1056/NEJM199401273300403; JOHANSSON JE, 1992, JAMA-J AM MED ASSOC, V267, P2191, DOI 10.1001/jama.267.16.2191; LUYAO GL, 1993, JAMA-J AM MED ASSOC, V269, P2633, DOI 10.1001/jama.269.20.2633; LUYAO GL, 1994, LANCET, V343, P251, DOI 10.1016/S0140-6736(94)91109-6; METTLIN C, 1994, UROLOGY, V43, P488, DOI 10.1016/0090-4295(94)90236-4; MOORE MJ, 1988, J CLIN ONCOL, V6, P1736, DOI 10.1200/JCO.1988.6.11.1736; PEZZINO G, 1994, J NATL CANCER I, V86, P1083, DOI 10.1093/jnci/86.14.1083	9	3	3	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	SEP 10	1994	344	8924					700	701		10.1016/S0140-6736(94)92202-0	http://dx.doi.org/10.1016/S0140-6736(94)92202-0			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PF187	7521501				2022-12-28	WOS:A1994PF18700004
J	DAMERON, KM; VOLPERT, OV; TAINSKY, MA; BOUCK, N				DAMERON, KM; VOLPERT, OV; TAINSKY, MA; BOUCK, N			CONTROL OF ANGIOGENESIS IN FIBROBLASTS BY P53 REGULATION OF THROMBOSPONDIN-1	SCIENCE			English	Article							TUMOR-SUPPRESSOR GENES; CANCER SYNDROME; WILD-TYPE; EXPRESSION; INHIBITOR; MUTANT; TRANSFORMATION; PROTEIN; FAMILY; CYCLE	As normal cells progress toward malignancy, they must switch to an angiogenic phenotype to attract the nourishing vasculature that they depend on for their growth. In cultured fibroblasts from Li-Fraumeni patients, this switch was found to coincide with loss of the wild-type allele of the p53 tumor suppressor gene and to be the result of reduced expression of thrombospondin-1 (TSP-1), a potent inhibitor of angiogenesis. Transfection assays revealed that p53 can stimulate the endogenous TSP-1 gene and positively regulate TSP-1 promoter sequences. These data indicate that, in fibroblasts, wild-type p53 inhibits angiogenesis through regulation of TSP-1 synthesis.	NORTHWESTERN UNIV, SCH MED, DEPT MICROBIOL IMMUNOL, CHICAGO, IL 60611 USA; NORTHWESTERN UNIV, SCH MED, RH LURIE CANC CTR, CHICAGO, IL 60611 USA; UNIV TEXAS, MD ANDERSON CANC CTR, DEPT TUMOR BIOL, HOUSTON, TX 77030 USA	Northwestern University; Northwestern University; Robert H. Lurie Comprehensive Cancer Center; University of Texas System; UTMD Anderson Cancer Center				Volpert, Olga/0000-0003-1381-5543; Tainsky, Michael/0000-0002-0261-831X	NCI NIH HHS [P01 CA34936, CA52750, CA64239] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA034936, R01CA064239] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ASCH AS, 1989, PROG HEMOST THROMB, V9, P157; BICKNELL R, 1991, EUR J CANCER, V27, P781, DOI 10.1016/0277-5379(91)90189-K; BISCHOFF FZ, 1990, CANCER RES, V50, P7979; BISCHOFF FZ, 1991, ONCOGENE, V6, P183; BLOOD CH, 1990, BIOCHIM BIOPHYS ACTA, V1032, P89, DOI 10.1016/0304-419X(90)90014-R; BORNSTEIN P, 1990, J BIOL CHEM, V265, P16691; BORNSTEIN P, 1992, FASEB J, V6, P3290, DOI 10.1096/fasebj.6.14.1426766; BOUCK N, 1990, CANCER CELL-MON REV, V2, P179; DAMERON KM, IN PRESS COLD SPRING; DAMERON KM, UNPUB; DONEHOWER LA, 1993, BIOCHIM BIOPHYS ACTA, V1155, P181, DOI 10.1016/0304-419X(93)90004-V; DONOVIEL DB, 1988, J BIOL CHEM, V263, P18590; FOLKMAN J, 1992, J BIOL CHEM, V267, P10931; Folkman J, 1992, Semin Cancer Biol, V3, P65; FOLKMAN J, 1992, PRINCESS TAKAMATSU S, V22, P339; Frazier WA, 1991, CURR OPIN CELL BIOL, V3, P792, DOI 10.1016/0955-0674(91)90052-Z; GANNON JV, 1991, NATURE, V349, P802; GOOD DJ, 1990, P NATL ACAD SCI USA, V87, P6624, DOI 10.1073/pnas.87.17.6624; HARVEY M, 1993, ONCOGENE, V8, P2457; HUNTER T, 1993, CELL, V75, P839, DOI 10.1016/0092-8674(93)90528-X; KERN SE, 1992, SCIENCE, V256, P827, DOI 10.1126/science.1589764; LABELL TL, 1992, GENOMICS, V12, P421, DOI 10.1016/0888-7543(92)90430-Z; MALKIN D, 1990, SCIENCE, V250, P1233, DOI 10.1126/science.1978757; MICHALOVITZ D, 1990, CELL, V62, P671, DOI 10.1016/0092-8674(90)90113-S; PIETENPOL JA, 1993, NATURE, V365, P17, DOI 10.1038/365017a0; POLVERINI PJ, 1991, METHOD ENZYMOL, V198, P440; RASTINEJAD F, 1989, CELL, V56, P345, DOI 10.1016/0092-8674(89)90238-9; SRIVASTAVA S, 1990, NATURE, V348, P747, DOI 10.1038/348747a0; TAINSKY MA, UNPUB; TOLSMA SS, 1993, J CELL BIOL, V122, P497, DOI 10.1083/jcb.122.2.497; TSO JY, 1985, NUCLEIC ACIDS RES, V13, P2485, DOI 10.1093/nar/13.7.2485; VIRBASIUS JV, 1991, MOL CELL BIOL, V11, P5631, DOI 10.1128/MCB.11.11.5631; YIN YX, 1992, CELL, V70, P937, DOI 10.1016/0092-8674(92)90244-7; ZAMBETTI GP, 1993, FASEB J, V7, P855, DOI 10.1096/fasebj.7.10.8344485	34	1259	1314	1	30	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	SEP 9	1994	265	5178					1582	1584		10.1126/science.7521539	http://dx.doi.org/10.1126/science.7521539			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PF336	7521539				2022-12-28	WOS:A1994PF33600036
J	ADAMI, HO; BARON, JA; ROTHMAN, KJ				ADAMI, HO; BARON, JA; ROTHMAN, KJ			ETHICS OF A PROSTATE-CANCER SCREENING TRIAL	LANCET			English	Article									HARVARD UNIV,SCH PUBL HLTH,DEPT EPIDEMIOL,BOSTON,MA 02115; BOSTON UNIV,SCH MED,SCH PUBL HLTH,DEPT EPIDEMIOL & BIOSTAT,BOSTON,MA 02118; DARTMOUTH COLL,HITCHCOCK MED CTR,DARTMOUTH MED SCH,DEPT MED,HANOVER,NH 03756	Harvard University; Harvard T.H. Chan School of Public Health; Boston University; Dartmouth College	ADAMI, HO (corresponding author), UNIV HOSP UPPSALA,CANC EPIDEMIOL UNIT,S-75185 UPPSALA,SWEDEN.			Rothman, Kenneth/0000-0003-2398-1705				BLACK WC, 1993, NEW ENGL J MED, V328, P1237, DOI 10.1056/NEJM199304293281706; CHODAK GW, 1994, NEW ENGL J MED, V330, P242, DOI 10.1056/NEJM199401273300403; COCHRANE AL, 1971, BRIT MED BULL, V27, P3, DOI 10.1093/oxfordjournals.bmb.a070810; DAVIS DL, 1994, JAMA-J AM MED ASSOC, V271, P152, DOI 10.1001/jama.271.2.152; Fleming C, 1993, JAMA, V269, P2650; FLETCHER SW, 1993, J NATL CANCER I, V85, P1644, DOI 10.1093/jnci/85.20.1644; FREEDMAN B, 1987, NEW ENGL J MED, V317, P141, DOI 10.1056/NEJM198707163170304; FRIED C, 1974, MED EXPT PERSONAL IN; GARNICK MB, 1993, ANN INTERN MED, V118, P804, DOI 10.7326/0003-4819-118-10-199305150-00008; GERBER GS, 1991, J NATL CANCER I, V83, P329, DOI 10.1093/jnci/83.5.329; GERBER GS, 1993, JAMA-J AM MED ASSOC, V269, P61, DOI 10.1001/jama.269.1.61; GOLDBLOOM R, 1991, CAN MED ASSOC J, V145, P413; HULKA BS, 1988, CANCER, V62, P1776, DOI 10.1002/1097-0142(19881015)62:1+<1776::AID-CNCR2820621314>3.0.CO;2-V; JOHANSSON JE, 1992, JAMA-J AM MED ASSOC, V267, P2191, DOI 10.1001/jama.267.16.2191; KRAMER BS, 1993, ANN INTERN MED, V119, P914, DOI 10.7326/0003-4819-119-9-199311010-00009; LANGE PH, 1993, JAMA-J AM MED ASSOC, V269, P95, DOI 10.1001/jama.269.1.95; LUJAO GL, 1994, LANCET, V343, P251; LUYAO GL, 1993, JAMA-J AM MED ASSOC, V269, P2633, DOI 10.1001/jama.269.20.2633; MILLER AB, 1991, CANCER SCREENING, P289; MILLER AB, 1986, IARC SCI PUBL, V76, P149; MORRISON AS, 1992, SCREENING CHRONIC DI; OESTERLING JE, 1992, JAMA-J AM MED ASSOC, V267, P2236, DOI 10.1001/jama.267.16.2236; PEETERS PHM, 1989, INT J EPIDEMIOL, V18, P295, DOI 10.1093/ije/18.2.295; TAGNON H, 1984, CANCER CLIN TRIALS M; Tulinius H, 1991, IARC Sci Publ, P253; WALD N, 1993, BRIT MED J, V306, P563, DOI 10.1136/bmj.306.6877.563; Wasson J H, 1993, Arch Fam Med, V2, P487, DOI 10.1001/archfami.2.5.487; WHITMORE WF, 1993, JAMA-J AM MED ASSOC, V269, P2676, DOI 10.1001/jama.269.20.2676; Wilson JMG, 1968, PRINCIPLES PRACTICE; 1964, RECOMMENDATIONS GUID; 1993, LANCET, V342, P901	31	68	68	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	APR 16	1994	343	8903					958	960		10.1016/S0140-6736(94)90071-X	http://dx.doi.org/10.1016/S0140-6736(94)90071-X			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NF700	7512680	hybrid			2022-12-28	WOS:A1994NF70000015
J	SHEPPARD, DN; OSTEDGAARD, LS; RICH, DP; WELSH, MJ				SHEPPARD, DN; OSTEDGAARD, LS; RICH, DP; WELSH, MJ			THE AMINO-TERMINAL PORTION OF CFTR FORMS A REGULATED CL- CHANNEL	CELL			English	Article							TRANSMEMBRANE CONDUCTANCE REGULATOR; CYSTIC-FIBROSIS GENE; NUCLEOTIDE-BINDING; CHLORIDE CHANNEL; ESCHERICHIA-COLI; R-DOMAIN; ATP; TRANSPORT; IDENTIFICATION; EXPRESSION	The cystic fibrosis transmembrane conductance regulator (CFTR) Cl- channel consists of two motifs (each containing a membrane-spanning domain [MSD] and a nucleotide-binding domain [NBD]) linked by an R domain. We tested the hypothesis that one MSD-NBD motif could form a Cl- channel. The amino-terminal portion of CFTR (D836X, which contains MSD1, NBD1, and the R domain) formed Cl- channels with conductive properties identical to those of CFTR. However, channel regulation differed. Although phosphorylation increased activity, channels opened without phosphorylation. MgATP stimulated D836X more potently than CFTR and may interact at more than one site. These data and migration of D836X on sucrose density gradients suggest that D836X may function as a multimer. Thus, the amino-terminal portion of CFTR contains all of the structures required to build a regulated Cl- channel.	UNIV IOWA,COLL MED,DEPT INTERNAL MED,IOWA CITY,IA 52242; UNIV IOWA,COLL MED,DEPT PHYSIOL & BIOPHYS,IOWA CITY,IA 52242	University of Iowa; University of Iowa	SHEPPARD, DN (corresponding author), UNIV IOWA,COLL MED,HOWARD HUGHES MED INST,IOWA CITY,IA 52242, USA.		Sheppard, David N/AAV-4187-2021	Sheppard, David N/0000-0001-5533-9130; Ostedgaard, Lynda/0000-0001-7717-3442; Welsh, Michael/0000-0002-1646-6206				AMES GF, 1990, FEMS MICROBIOL LETT, V75, P429, DOI 10.1016/S0168-6445(05)80008-7; ANDERSON MP, 1992, SCIENCE, V257, P1701, DOI 10.1126/science.1382316; ANDERSON MP, 1991, CELL, V67, P775, DOI 10.1016/0092-8674(91)90072-7; ANDERSON MP, 1991, SCIENCE, V253, P202, DOI 10.1126/science.1712984; CHANG XB, 1993, J BIOL CHEM, V268, P11304; CHENG SH, 1990, CELL, V63, P827, DOI 10.1016/0092-8674(90)90148-8; CHENG SH, 1991, CELL, V66, P1027, DOI 10.1016/0092-8674(91)90446-6; ELROYSTEIN O, 1989, P NATL ACAD SCI USA, V86, P6126, DOI 10.1073/pnas.86.16.6126; FELMLEE T, 1985, J BACTERIOL, V163, P94, DOI 10.1128/JB.163.1.94-105.1985; GREGORY RJ, 1990, NATURE, V347, P382, DOI 10.1038/347382a0; HAMILL OP, 1981, PFLUG ARCH EUR J PHY, V391, P85, DOI 10.1007/BF00656997; HAMOSH A, 1991, J CLIN INVEST, V88, P1880, DOI 10.1172/JCI115510; HARTMAN J, 1992, J BIOL CHEM, V267, P6455; Hille B., 1992, IONIC CHANNELS EXCIT; HYDE SC, 1990, NATURE, V346, P362, DOI 10.1038/346362a0; KAMIJO K, 1990, J BIOL CHEM, V265, P4534; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; MARSHALL J, 1994, IN PRESS J BIOL CHEM; RICH DP, 1991, SCIENCE, V253, P205, DOI 10.1126/science.1712985; RICH DP, 1993, J BIOL CHEM, V268, P20259; RIORDAN JR, 1989, SCIENCE, V245, P1066; RIORDAN JR, 1993, ANNU REV PHYSIOL, V55, P609, DOI 10.1146/annurev.ph.55.030193.003141; SHEPPARD DN, 1993, NATURE, V362, P160, DOI 10.1038/362160a0; SMIT LS, 1993, P NATL ACAD SCI USA, V90, P9963, DOI 10.1073/pnas.90.21.9963; TABCHARANI JA, 1993, NATURE, V366, P79, DOI 10.1038/366079a0; THOMAS PJ, 1991, SCIENCE, V251, P555, DOI 10.1126/science.1703660; TRAVIS SM, 1993, J BIOL CHEM, V268, P15336; VIDAUD M, 1990, HUM GENET, V85, P446, DOI 10.1007/BF02428305; WALKER JE, 1982, EMBO J, V1, P945, DOI 10.1002/j.1460-2075.1982.tb01276.x; WELSH MJ, 1992, NEURON, V8, P821, DOI 10.1016/0896-6273(92)90196-K; WHITE MB, 1991, GENOMICS, V11, P778, DOI 10.1016/0888-7543(91)90092-S; 1993, NEW ENGL J MED, V329, P1308	32	103	105	0	5	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	MAR 25	1994	76	6					1091	1098		10.1016/0092-8674(94)90385-9	http://dx.doi.org/10.1016/0092-8674(94)90385-9			8	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	ND246	7511062				2022-12-28	WOS:A1994ND24600014
J	LEE, HS; HUANG, SS; KAO, TH				LEE, HS; HUANG, SS; KAO, TH			S-PROTEINS CONTROL REJECTION OF INCOMPATIBLE POLLEN IN PETUNIA-INFLATA	NATURE			English	Article							SELF-INCOMPATIBILITY; NICOTIANA-ALATA; RIBONUCLEASE-ACTIVITY; ALLELES; EXPRESSION; HYBRIDA	FLOWERING plants have evolved various stratagems to prevent inbreeding and promote outcrosses1. One such mechanism, gametophytic self-incompatibility, provides a genetic barrier to self-fertilization, and in the simplest cases is controlled by the highly polymorphic S locus2. Growth of a pollen tube in the style is arrested when the S allele carried by the pollen matches one of the two S alleles carried by the pistil. Putative S allele proteins of the pistil have been identified in several solanaceous species based on their co-segregation with S alleles3-12, and they have been shown to be ribonucleases13-15. So far. there has been only correlative or indirect evidence for the claim that these S allele-associated proteins (S proteins) are involved in recognition and rejection of self pollen16,17. Here we show that inhibition of synthesis of S3 and S2 proteins in Petunia inflata plants of S2S3 genotype by the antisense S3 gene resulted in failure of the transgenic plants to reject S3 and S2 pollen. We further show that expression of the transgene encoding S3 protein in P. inflata plants of S1S2 genotype confers on the transgenic plants the ability to reject S3 pollen. The self-incompatibility behaviour of the pollen was not affected by the transgene in either set of experiments. Taken together, these findings provide direct in vivo evidence that S proteins control the self-incompatibility behaviour of the pistil.	PENN STATE UNIV,DEPT BIOCHEM & MOLEC BIOL,UNIV PK,PA 16802; PENN STATE UNIV,CTR GENE REGULAT,UNIV PK,PA 16802	Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University								AI YJ, 1991, MOL GEN GENET, V230, P353, DOI 10.1007/BF00280291; AI YJ, 1990, SEX PLANT REPROD, V3, P130, DOI 10.1007/BF00198857; ANDERSON MA, 1986, NATURE, V321, P38, DOI 10.1038/321038a0; BREDEMEIJER GMM, 1981, THEOR APPL GENET, V59, P185, DOI 10.1007/BF00264974; BROOTHAERTS W, 1991, SEX PLANT REPROD, V4, P258, DOI 10.1007/BF00200545; BROOTHAERTS WJ, 1989, PLANT MOL BIOL, V14, P93; CLARK KR, 1990, PLANT CELL, V2, P815, DOI 10.1105/tpc.2.8.815; COLEMAN CE, 1992, PLANT MOL BIOL, V18, P725, DOI 10.1007/BF00020014; De Nettancourt D., 1977, MONOGRAPHS THEORETIC, P28; FRANKEL R, 1977, MONOGRAPHS THEORETIC, P5; HORSCH RB, 1985, SCIENCE, V227, P1229, DOI 10.1126/science.227.4691.1229; IOERGER TR, 1991, SEX PLANT REPROD, V4, P81; KAMBOJ RK, 1986, THEOR APPL GENET, V71, P815, DOI 10.1007/BF00276423; KHEYRPOUR A, 1990, SEX PLANT REPROD, V3, P88, DOI 10.1007/BF00198851; KIRCH HH, 1989, THEOR APPL GENET, V78, P581, DOI 10.1007/BF00290845; LEE HS, 1992, PLANT MOL BIOL, V20, P1131, DOI 10.1007/BF00028899; LEWIS D, 1949, HEREDITY, V3, P339, DOI 10.1038/hdy.1949.25; LINSMAIER EM, 1965, PHYSIOL PLANTARUM, V18, P100, DOI 10.1111/j.1399-3054.1965.tb06874.x; MAU SL, 1986, PLANTA, V169, P184, DOI 10.1007/BF00392312; MCCLURE BA, 1989, NATURE, V342, P955, DOI 10.1038/342955a0; OELLER PW, 1991, SCIENCE, V254, P437, DOI 10.1126/science.1925603; SIMS TL, 1993, CRIT REV PLANT SCI, V12, P129, DOI 10.1080/07352689309382359; SINGH A, 1991, PLANT PHYSIOL, V96, P61, DOI 10.1104/pp.96.1.61; SINGH A, 1992, SEXUAL REPRODUCTION, P449; XU B, 1990, SEX PLANT REPROD, V3, P54, DOI 10.1007/BF00189952	25	333	375	2	47	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	FEB 10	1994	367	6463					560	563		10.1038/367560a0	http://dx.doi.org/10.1038/367560a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	MV863	7509041				2022-12-28	WOS:A1994MV86300059
J	PARKER, MW; BUCKLEY, JT; POSTMA, JPM; TUCKER, AD; LEONARD, K; PATTUS, F; TSERNOGLOU, D				PARKER, MW; BUCKLEY, JT; POSTMA, JPM; TUCKER, AD; LEONARD, K; PATTUS, F; TSERNOGLOU, D			STRUCTURE OF THE AEROMONAS TOXIN PROAEROLYSIN IN ITS WATER-SOLUBLE AND MEMBRANE-CHANNEL STATES	NATURE			English	Article							SITE-DIRECTED MUTAGENESIS; HOLE-FORMING TOXIN; AEROLYSIN; HYDROPHILA; OLIGOMERIZATION; HISTIDINES; MONOMER; VIRUS	AEROLYSIN is chiefly responsible for the pathogenicity of Aeromonas hydrophila, a bacterium associated with diarrhoeal diseases and deep wound infections1. Like many other microbial toxins, the protein changes in a multistep process from a completely water-soluble form to produce a transmembrane channel that destroys sensitive cells by breaking their permeability barriers2. Here we describe the structure of proaerolysin determined by X-ray crystallography at 2.8 angstrom resolution. The protoxin (M(r) 52,000) adopts a novel protein fold. Images of an aerolysin oligomer derived from electron microscopy have assisted in constructing a model of the membrane channel and have led to the proposal of a scheme to account for insertion of the protein into lipid bilayers to form ion channels.	UNIV VICTORIA,DEPT BIOCHEM & MOLEC BIOL,VICTORIA V8W 2Y2,BC,CANADA; EUROPEAN MOLEC BIOL LAB,W-6900 HEIDELBERG,GERMANY	University of Victoria; European Molecular Biology Laboratory (EMBL)	PARKER, MW (corresponding author), ST VINCENTS INST MED RES,41 VICTORIA PARADE,FITZROY,VIC 3065,AUSTRALIA.		Parker, Michael W/F-9069-2013	Parker, Michael W/0000-0002-3101-1138	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		ALTWEGG M, 1989, CRC CR REV MICROBIOL, V16, P253, DOI 10.3109/10408418909105478; ARGOS P, 1988, PROTEIN ENG, V2, P101, DOI 10.1093/protein/2.2.101; ARNOLD E, 1990, J MOL BIOL, V211, P763, DOI 10.1016/0022-2836(90)90076-X; BERNSTEIN FC, 1977, J MOL BIOL, V112, P535, DOI 10.1016/S0022-2836(77)80200-3; BHAKDI S, 1987, REV PHYSL BIOCH PHAR, V107, P148; COWAN SW, 1992, NATURE, V358, P727, DOI 10.1038/358727a0; FERRIN TE, 1988, J MOL GRAPHICS, V6, P13, DOI 10.1016/0263-7855(88)80054-7; GARLAND WJ, 1988, INFECT IMMUN, V56, P1249, DOI 10.1128/IAI.56.5.1249-1253.1988; GREEN MJ, 1990, BIOCHEMISTRY-US, V29, P2177, DOI 10.1021/bi00460a031; HENDRICKSON WA, 1980, COMPUTING CRYSTALLOG; JONES TA, 1978, J APPL CRYSTALLOGR, V11, P268, DOI 10.1107/S0021889878013308; KABSCH W, 1983, BIOPOLYMERS, V22, P2577, DOI 10.1002/bip.360221211; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; PARKER MW, 1990, TRENDS BIOCHEM SCI, V15, P126, DOI 10.1016/0968-0004(90)90205-P; TUCKER AD, 1990, J MOL BIOL, V212, P561, DOI 10.1016/0022-2836(90)90222-8; VANDERGOOT FG, 1992, BIOCHEMISTRY-US, V31, P8566, DOI 10.1021/bi00151a026; VANDERGOOT FG, 1993, J BIOL CHEM, V268, P18272; VANDERGOOT FG, 1993, BIOCHEMISTRY-US, V32, P2636, DOI 10.1021/bi00061a023; VANGUNSTEREN WF, 1988, PROTEIN ENG, V2, P5, DOI 10.1093/protein/2.1.5; VELLIEUX FMD, 1993, P NATL ACAD SCI USA, V90, P2355, DOI 10.1073/pnas.90.6.2355; WEISS MS, 1991, SCIENCE, V254, P1627, DOI 10.1126/science.1721242; WICKNER W, 1989, TRENDS BIOCHEM SCI, V14, P280, DOI 10.1016/0968-0004(89)90064-9; WILEY DC, 1987, ANNU REV BIOCHEM, V56, P365, DOI 10.1146/annurev.bi.56.070187.002053; WILMSEN HU, 1990, J MEMBRANE BIOL, V115, P71, DOI 10.1007/BF01869107; WILMSEN HU, 1992, EMBO J, V11, P2457, DOI 10.1002/j.1460-2075.1992.tb05310.x; WILMSEN HU, 1991, MOL MICROBIOL, V5, P2745, DOI 10.1111/j.1365-2958.1991.tb01983.x; 1979, CCP4 DAR LAB	27	367	376	2	57	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JAN 20	1994	367	6460					292	295		10.1038/367292a0	http://dx.doi.org/10.1038/367292a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	MR494	7510043				2022-12-28	WOS:A1994MR49400062
J	KLOC, M; SPOHR, G; ETKIN, LD				KLOC, M; SPOHR, G; ETKIN, LD			TRANSLOCATION OF REPETITIVE RNA SEQUENCES WITH THE GERM PLASM IN XENOPUS-OOCYTES	SCIENCE			English	Article							MATERNAL MESSENGER-RNA; DROSOPHILA EMBRYOS; ANIMAL DEVELOPMENT; CELL-FORMATION; XIST GENE; LOCALIZATION; LAEVIS; PATTERN; PRODUCT; NUCLEUS	Xlsirts are a family of interspersed repeat RNAs from Xenopus laevis that contain from 3 to 13 repeat units (each 79 to 81 nucleotides long) flanked by unique sequences. They are homologous to the mammalian Xist gene that is involved in X chromosome inactivation. Xlsirt RNA appears first in the mitochondrial cloud (Balbiani body) in stage 2 oocytes and is then translocated as island-like structures to the vegetal cortex at early stage 3 coincident with the localization of the germ plasm. Exogenous Xlsirt RNA injected into oocytes translocates to the location of the endogenous RNA at that particular stage. The Xlsirt RNA repeat sequences are required for translocation and can cause the translocation of heterologous unique RNAs to the vegetal cortex.	UNIV TEXAS, MD ANDERSON CANC CTR, DEPT MOLEC GENET, 1515 HOLCOMBE BLVD, HOUSTON, TX 77030 USA; UNIV GENEVA, DEPT CELL BIOL, CH-1211 GENEVA 4, SWITZERLAND	University of Texas System; UTMD Anderson Cancer Center; University of Geneva			Kloc, Malgorzata/AAF-6982-2020					BROCKDORFF N, 1992, CELL, V71, P515, DOI 10.1016/0092-8674(92)90519-I; BROWN CJ, 1992, CELL, V71, P527, DOI 10.1016/0092-8674(92)90520-M; ELLINGERZIEGELBAUER H, 1991, GENE DEV, V5, P94, DOI 10.1101/gad.5.1.94; EPHRUSSI A, 1992, NATURE, V358, P387, DOI 10.1038/358387a0; GERHART J, 1989, DEVELOPMENT S; GURDON JB, 1992, CELL, V68, P185, DOI 10.1016/0092-8674(92)90465-O; HEASMAN J, 1984, DEV BIOL, V105, P458, DOI 10.1016/0012-1606(84)90303-8; JAMRICH M, 1983, P NATL ACAD SCI-BIOL, V80, P3364, DOI 10.1073/pnas.80.11.3364; KLOC M, UNPUB; KRIEG PA, 1984, NUCLEIC ACIDS RES, V12, P7057, DOI 10.1093/nar/12.18.7057; MACDONALD PM, 1990, DEVELOPMENT, V110, P161; MACDONALD PM, 1988, NATURE, V336, P595, DOI 10.1038/336595a0; MAHOWALD AP, 1992, SCIENCE, V255, P1216, DOI 10.1126/science.1372132; MELTON DA, 1987, NATURE, V328, P80, DOI 10.1038/328080a0; MELTON DA, 1991, SCIENCE, V252, P234, DOI 10.1126/science.1672778; MILLER M, 1989, GENE DEV, V3, P572, DOI 10.1101/gad.3.4.572; MOSQUERA L, 1993, DEVELOPMENT, V117, P377; MOWRY KL, 1992, SCIENCE, V255, P991, DOI 10.1126/science.1546297; Nieuwkoop P.D., 1967, NORMAL TABLE XENOPUS; REITH W, 1982, EMBRYONIC DEV A, P139; SMITH JL, 1992, CELL, V70, P849, DOI 10.1016/0092-8674(92)90318-7; SMITH LD, 1975, MATERNAL EFFECTS DEV, P167; SPOHR G, 1983, MOL BIOL REP, V9, P33, DOI 10.1007/BF00777471; SPOHR G, 1981, J MOL BIOL, V151, P573, DOI 10.1016/0022-2836(81)90424-1; WEEKS DL, 1987, CELL, V51, P861, DOI 10.1016/0092-8674(87)90109-7; WYLIE CC, 1985, J EMBRYOL EXP MORPH, V89, P1	26	127	127	0	4	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	DEC 10	1993	262	5140					1712	1714		10.1126/science.7505061	http://dx.doi.org/10.1126/science.7505061			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ML220	7505061				2022-12-28	WOS:A1993ML22000035
J	McDonald, CJ				McDonald, CJ			Medical heuristics: The silent adjudicators of clinical practice	ANNALS OF INTERNAL MEDICINE			English	Editorial Material							ACUTE MYOCARDIAL-INFARCTION; DECISION-ANALYSIS; CONFIDENCE; MANAGEMENT; DISEASE; CANCER; RISK	Robust scientific conclusions are too sparse to inform fully most of the choices that physicians must make about tests and treatments. Instead, ad hoc rules of thumb, or ''heuristics,'' must guide them, and many of these are problematic. Physicians extrapolate from the small samples studied by clinical trials to general populations, but they do so inconsistently. Many physicians live by rules that dictate ''not treating the numbers,'' correcting abnormalities slowly, achieving diagnostic certainty, and operating now to avoid ''greater'' risk in the future. Yet in each case, historical trends or statistical realities suggest either doing the opposite or investing in more discriminating heuristics. The heuristics of medicine should be discussed, criticized, refined, and then taught. More uniform use of explicit and better heuristics could lead to less practice variation and more efficient medical care.	INDIANA UNIV, SCH MED, INDIANAPOLIS, IN USA	Indiana University System; Indiana University-Purdue University Indianapolis	McDonald, CJ (corresponding author), REGENSTRIEF INST HLTH CARE, 1001 W 10TH ST, INDIANAPOLIS, IN 46202 USA.				AHRQ HHS [HS 08750-02, HS 07719-013] Funding Source: Medline; NLM NIH HHS [N01-LM-4-3410] Funding Source: Medline; AGENCY FOR HEALTHCARE RESEARCH AND QUALITY [R01HS007719, U01HS008750] Funding Source: NIH RePORTER	AHRQ HHS(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality); NLM NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Library of Medicine (NLM)); AGENCY FOR HEALTHCARE RESEARCH AND QUALITY(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality)		AHLMARK G, 1976, EUR J CLIN PHARMACOL, V10, P77, DOI 10.1007/BF00609463; [Anonymous], 1970, JAMA, V213, P1143; [Anonymous], 1995, J Neurol Sci, V129, P76; [Anonymous], 1975, Br Med J, V3, P735; BAKKE OM, 1984, CLIN PHARMACOL THER, V35, P559, DOI 10.1038/clpt.1984.78; BARRY MJ, 1988, JAMA-J AM MED ASSOC, V259, P3010, DOI 10.1001/jama.259.20.3010; BERWICK DM, 1989, NEW ENGL J MED, V320, P53, DOI 10.1056/NEJM198901053200110; BRECHNER RJ, 1993, JAMA-J AM MED ASSOC, V270, P1714, DOI 10.1001/jama.270.14.1714; BURNUM JF, 1987, NEW ENGL J MED, V317, P1220, DOI 10.1056/NEJM198711053171910; CEBUL RD, 1986, JAMA-J AM MED ASSOC, V256, P3353, DOI 10.1001/jama.256.24.3353; COOK DJ, 1992, CHEST, V102, pS305; CORRE KA, 1988, ANN EMERG MED, V17, P145, DOI 10.1016/S0196-0644(88)80300-7; CRAVEN RB, 1975, ANN INTERN MED, V82, P628, DOI 10.7326/0003-4819-82-5-628; DALEN JE, 1995, CHEST, V108, pS225, DOI 10.1378/chest.108.4_Supplement.225S; DANTZKER DR, 1982, CHEST, V81, P495, DOI 10.1378/chest.81.4.495; EDDY DM, 1989, ANN INTERN MED, V111, P389, DOI 10.7326/0003-4819-111-5-389; EDDY DM, 1990, MED DECIS MAKING, V10, P15, DOI 10.1177/0272989X9001000104; Evans W O, 1988, Indiana Med, V81, P842; FLEMING C, 1993, JAMA-J AM MED ASSOC, V269, P2650, DOI 10.1001/jama.269.20.2650; FRISHMAN WH, 1984, NEW ENGL J MED, V310, P830; GOLDBLOOM R, 1988, CAN MED ASSOC J, V138, P618; GOODMAN LS, 1990, PHARMACOL BASIS THER, P58; GUYATT G, 1992, JAMA-J AM MED ASSOC, V268, P2420, DOI 10.1001/jama.1992.03490170092032; GUYATT GH, 1990, ANN INTERN MED, V112, P293, DOI 10.7326/0003-4819-112-4-293; JAESCHKE R, 1994, JAMA-J AM MED ASSOC, V271, P703, DOI 10.1001/jama.271.9.703; JOHNSON D, 1991, J ASTHMA, V28, P85, DOI 10.3109/02770909109082732; KELLER MB, 1988, PSYCHOPHARMACOL BULL, V24, P75; KELLER RB, 1990, J BONE JOINT SURG AM, V72A, P1286, DOI 10.2106/00004623-199072090-00002; KENT DL, 1994, ANN INTERN MED, V120, P856, DOI 10.7326/0003-4819-120-10-199405150-00007; KLECH H, 1982, CHEST, V82, P732, DOI 10.1378/chest.82.6.732; KNAPP DE, 1979, AM J HOSP PHARM, V36, P1334, DOI 10.1093/ajhp/36.10.1334; KORIAT A, 1980, J EXP PSYCHOL-HUM L, V6, P107, DOI 10.1037/0278-7393.6.2.107; LEE PM, 1989, BAYESIAN STATISTICS; LENAT DB, 1982, ARTIF INTELL, V19, P189, DOI 10.1016/0004-3702(82)90036-4; LENERT LA, 1993, CLIN PHARMACOL THER, V53, P285, DOI 10.1038/clpt.1993.23; LEWIS EJ, 1993, NEW ENGL J MED, V329, P1456, DOI 10.1056/NEJM199311113292004; MASERI A, 1991, NEW ENGL J MED, V325, P1579, DOI 10.1056/NEJM199111283252210; McDonald C J, 1983, Stat Med, V2, P417; MCDONALD CJ, 1992, JAMA-J AM MED ASSOC, V267, P932, DOI 10.1001/jama.1992.03480070048022; MUELLER HS, 1974, CIRCULATION, V49, P1078, DOI 10.1161/01.CIR.49.6.1078; NICOD P, 1992, ANN INTERN MED, V116, P779, DOI 10.7326/0003-4819-116-9-779_1; PACE NR, 1993, IND MICROORGANISMS B; PAUKER SG, 1980, NEW ENGL J MED, V302, P1109, DOI 10.1056/NEJM198005153022003; PEDERSEN TR, 1994, LANCET, V344, P1383; Polya G, 1945, SOLVE IT; PSATY BM, 1995, JAMA-J AM MED ASSOC, V274, P620, DOI 10.1001/jama.274.8.620; QUICK RE, 1993, AM J MED, V94, P149, DOI 10.1016/0002-9343(93)90176-P; RAMACHANDRAN VS, 1992, SCI AM, V266, P86, DOI 10.1038/scientificamerican0592-86; Ramsey S D, 1993, Int J Technol Assess Health Care, V9, P253; RANSOHOFF DF, 1983, ANN INTERN MED, V99, P199, DOI 10.7326/0003-4819-99-2-199; RELMAN AS, 1966, CONTROVERSY INTERNAL, P101; REPSHER LH, 1969, NEW ENGL J MED, V281, P1393, DOI 10.1056/NEJM196912182812504; SANAZARO PJ, 1976, WESTERN J MED, V125, P241; SAPIRA JD, 1991, SOUTHERN MED J, V84, P766, DOI 10.1097/00007611-199106000-00023; SASAHARA AA, 1973, CIRCULATION       S2, V47, P1; SHAMOON H, 1993, NEW ENGL J MED, V329, P977, DOI 10.1056/nejm199309303291401; TEDESCO FJ, 1974, ANN INTERN MED, V81, P429, DOI 10.7326/0003-4819-81-4-429; THOMSON DMP, 1969, P NATL ACAD SCI USA, V64, P161, DOI 10.1073/pnas.64.1.161; TOFTE RW, 1981, JAMA-J AM MED ASSOC, V246, P2163; TVERSKY A, 1974, SCIENCE, V185, P1124, DOI 10.1126/science.185.4157.1124; WENNBERG JE, 1990, HEALTH SERV RES, V25, P709; WILHELMSSON C, 1974, LANCET, V2, P1157; WOOLF SH, 1990, J CLIN EPIDEMIOL, V43, P891, DOI 10.1016/0895-4356(90)90073-X; WYSOWSKI DK, 1991, ARCH INTERN MED, V151, P2003, DOI 10.1001/archinte.151.10.2003	64	145	148	0	5	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JAN 1	1996	124	1	1				56	62		10.7326/0003-4819-124-1_Part_1-199601010-00009	http://dx.doi.org/10.7326/0003-4819-124-1_Part_1-199601010-00009			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TL943	7503478				2022-12-28	WOS:A1996TL94300009
J	KOEKEMOER, AM; HENKEL, C; GREENHILL, LJ; DEY, A; VANBREUGEL, W; ANTONUCCI, R; CODELLA, C				KOEKEMOER, AM; HENKEL, C; GREENHILL, LJ; DEY, A; VANBREUGEL, W; ANTONUCCI, R; CODELLA, C			A WATER-VAPOR GIGA-MASER IN THE ACTIVE GALAXY TXFS2226-184	NATURE			English	Article							STAR-FORMING REGIONS; GALACTIC NUCLEI; H2O MASERS; EMISSION; NGC-3079	ACTIVE galactic nuclei are thought to be powered by gas falling into a massive black hole; the different types of active galaxy mag arise because we view them through a thick torus of molecular gas at varying angles of inclination(1). One way to determine whether the black hole is surrounded by a torus, which would obscure the accretion disk around the black hole along certain lines of sight, is to search for water masers, as these exist only in regions with plentiful molecular gas. Since the first detection(2) of an extragalactic water maser in 1979, they have come to be associated primarily with active galaxies, and have even been used to probe the mass of the central engine(3). Here we report the detection of a water giga-maser in the radio galaxy TXFS2226-184. The strength of the emission supports a recently proposed theory of maser pumping(4) that allows for even more powerful masers, which might be detectable at cosmological distances. Water masers may accordingly provide a may to determine distances to galaxies outside the usual distance ladder, providing an independent calibration of the Hubble constant(3,5).	MAX PLANCK INST RADIOASTRON,D-53121 BONN,GERMANY; HARVARD SMITHSONIAN CTR ASTROPHYS,CAMBRIDGE,MA 02138; UNIV CALIF BERKELEY,DEPT ASTRON,BERKELEY,CA 94720; LAWRENCE LIVERMORE NATL LAB,LIVERMORE,CA 94550; UNIV CALIF SANTA BARBARA,DEPT PHYS,SANTA BARBARA,CA 93106	Max Planck Society; Harvard University; Smithsonian Astrophysical Observatory; Smithsonian Institution; University of California System; University of California Berkeley; United States Department of Energy (DOE); Lawrence Livermore National Laboratory; University of California System; University of California Santa Barbara	KOEKEMOER, AM (corresponding author), MT STROMLO & SIDING SPRING OBSERV,WESTON,ACT 2611,AUSTRALIA.		Koekemoer, Anton M./F-8400-2014; Codella, Claudio/AAB-2539-2021	Koekemoer, Anton M./0000-0002-6610-2048; Codella, Claudio/0000-0003-1514-3074				ANTONUCCI RRJ, 1985, ASTROPHYS J, V297, P621, DOI 10.1086/163559; BAARS JWM, 1977, ASTRON ASTROPHYS, V61, P99; BARTHEL PD, 1989, ASTROPHYS J, V336, P606, DOI 10.1086/167038; BICAY MD, 1990, ASTROPHYS J, V362, P59, DOI 10.1086/169243; BRAATZ JA, 1994, ASTROPHYS J, V437, pL99, DOI 10.1086/187692; BRAATZ JA, 1995, P OXF TOR WORKSH, P77; BURDYUZHA VV, 1990, ASTRON ASTROPHYS, V234, P40; CLAUSSEN MJ, 1984, NATURE, V310, P298, DOI 10.1038/310298a0; CLAUSSEN MJ, 1986, ASTROPHYS J, V308, P592, DOI 10.1086/164529; DOSSANTOS PM, 1979, NATURE, V278, P34, DOI 10.1038/278034a0; ELITZUR M, 1992, ASTROPHYS J, V394, P221, DOI 10.1086/171574; ELITZUR M, 1989, ASTROPHYS J, V346, P983, DOI 10.1086/168080; FALCKE H, 1995, ASTRON ASTROPHYS, V298, P395; GREENHILL LJ, 1995, ASTROPHYS J, V440, P619, DOI 10.1086/175301; GREENHILL LJ, 1993, ASTROPHYS J, V406, P482, DOI 10.1086/172460; GREENHILL LJ, 1990, ASTROPHYS J, V364, P513, DOI 10.1086/169433; GREENHILL LJ, IN PRESS ASTR ASTROP; HASCHICK AD, 1985, NATURE, V314, P144, DOI 10.1038/314144a0; HASCHICK AD, 1994, ASTROPHYS J, V437, pL35, DOI 10.1086/187676; HASCHICK AD, 1990, ASTROPHYS J, V356, P149, DOI 10.1086/168825; Heckman T. M., 1980, Astronomy & Astrophysics Supplement Series, V40, P295; HENKEL C, 1990, ASTRON ASTROPHYS, V229, P431; HENKEL C, 1984, ASTRON ASTROPHYS, V141, pL1; HO PTP, 1987, ASTROPHYS J, V320, P663, DOI 10.1086/165583; MAOZ E, 1995, ASTROPHYS J, V447, pL91, DOI 10.1086/175250; MIYOSHI M, 1995, NATURE, V373, P127, DOI 10.1038/373127a0; NEUFELD DA, 1994, ASTROPHYS J, V436, pL127, DOI 10.1086/187649; NEUFELD DA, 1995, ASTROPHYS J, V447, pL17, DOI 10.1086/309553; OTT M, 1994, ASTRON ASTROPHYS, V284, P331; PADOVANI P, 1991, ASTROPHYS J, V368, P373, DOI 10.1086/169701; SHLOSMAN I, 1990, NATURE, V345, P679, DOI 10.1038/345679a0	31	44	46	0	0	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	DEC 14	1995	378	6558					697	699		10.1038/378697a0	http://dx.doi.org/10.1038/378697a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TK379	7501016				2022-12-28	WOS:A1995TK37900044
J	SCHIAVO, G; GMACHL, MJS; STENBECK, G; SOLLNER, TH; ROTHMAN, JE				SCHIAVO, G; GMACHL, MJS; STENBECK, G; SOLLNER, TH; ROTHMAN, JE			A POSSIBLE DOCKING AND FUSION PARTICLE FOR SYNAPTIC TRANSMISSION	NATURE			English	Article							SECRETION; PROTEINS; FAMILY; STEPS	SEVERAL proteins have been implicated in the rapid (millisecond) calcium-controlled release of transmitters at nerve endings(1,2), including soluble N-ethylmaleimide-sensitive fusion protein (NSF3-5) and soluble NSF attachment protein (alpha-SNAP(3,6)), the synaptic SNAP receptor (SNARE)(3,7) and the calcium-binding protein synaptotagmin(2), which may function as a calcium sensor in exocytosis(8). A second SNAP isoform (beta-SNAP), which is 83% identical to alpha-SNAP, is highly expressed in brain(9), but its role is still unclear. Here we show that these proteins assemble cooperatively to form a docking and fusion complex. beta-SNAP (but not alpha-SNAP) binds synaptotagmin and recruits NSF, indicating that the complex may link the process of membrane fusion to calcium entry by attaching a specialized fusion protein (beta-SNAP) to a calcium sensor (synaptotagmin). Polyphosphoinositols that block transmitter release, inositol 1,3,4,5-tetrakisphosphate (InsP(4)), inositol 1,3,4,5,6-pentakisphosphate (InsP(5)) and inositol 1,2,3,4,5,6-hexakisphosphate (InsP(6)), also block the assembly of the particle by preventing beta-SNAP from binding to synaptotagmin.			SCHIAVO, G (corresponding author), MEM SLOAN KETTERING CANC CTR,CELLULAR BIOCHEM & BIOPHYS PROGRAM,1275 YORK AVE,NEW YORK,NY 10021, USA.			Schiavo, Giampietro/0000-0002-4319-8745				BENNETT MK, 1992, SCIENCE, V257, P255, DOI 10.1126/science.1321498; BITTNER MA, 1992, J BIOL CHEM, V267, P16219; BOMMERT K, 1993, NATURE, V363, P163, DOI 10.1038/363163a0; BROADIE K, 1995, NEURON, V15, P663, DOI 10.1016/0896-6273(95)90154-X; CLARY DO, 1990, CELL, V61, P709, DOI 10.1016/0092-8674(90)90482-T; DEBELLO WM, 1995, NATURE, V373, P626, DOI 10.1038/373626a0; DIANTONIO A, 1994, NEURON, V12, P909, DOI 10.1016/0896-6273(94)90342-5; FUKUDA M, 1994, J BIOL CHEM, V269, P29206; GEPPERT M, 1994, CELL, V79, P717, DOI 10.1016/0092-8674(94)90556-8; HAY JC, 1992, J CELL BIOL, V119, P139, DOI 10.1083/jcb.119.1.139; HAY JC, 1995, NATURE, V374, P173, DOI 10.1038/374173a0; HAYASHI T, 1995, EMBO J, V14, P2317, DOI 10.1002/j.1460-2075.1995.tb07226.x; HONG RM, 1994, FEBS LETT, V350, P253, DOI 10.1016/0014-5793(94)00778-0; HUNT JM, 1994, NEURON, V12, P1269, DOI 10.1016/0896-6273(94)90443-X; LLINAS R, 1994, P NATL ACAD SCI USA, V91, P12990, DOI 10.1073/pnas.91.26.12990; PALLANCK L, 1995, NATURE, V376, P25, DOI 10.1038/376025a0; ROTHMAN JE, 1994, NATURE, V372, P55, DOI 10.1038/372055a0; SCHELLER RH, 1993, NEURON, V14, P893; SCHIAVO G, 1994, MOL MICROBIOL, V13, P1; SOLLNER T, 1993, CELL, V75, P409, DOI 10.1016/0092-8674(93)90376-2; SOLLNER T, 1993, NATURE, V362, P318, DOI 10.1038/362318a0; SUDHOF TC, 1995, NATURE, V375, P645, DOI 10.1038/375645a0; SUTTON RB, 1994, CELL, V80, P929; THOMAS P, 1993, NEURON, V11, P93, DOI 10.1016/0896-6273(93)90274-U; WHITEHEART SW, 1994, J CELL BIOL, V126, P945, DOI 10.1083/jcb.126.4.945; WHITEHEART SW, 1993, NATURE, V362, P353, DOI 10.1038/362353a0	26	161	163	1	5	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	DEC 14	1995	378	6558					733	736		10.1038/378733a0	http://dx.doi.org/10.1038/378733a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TK379	7501022				2022-12-28	WOS:A1995TK37900057
J	CANDELISE, L; ARITZU, E; CICCONE, A; RICCI, S; WARDLAW, J; TOGNONI, G; RONCAGLIONI, MC; NEGRI, E; COLOMBO, F; BOCCARDI, E; DEGRANDI, C; SCIALFA, G; ARGENTINO, C; BERTELE, V; MAGGIONI, AP; PERRONE, P; BARNETT, HJM; BOGOUSSLAVSKY, J; DELFAVERO, A; LOI, U; PETO, R; WARLOW, C; CANZI, S; COMPARETTI, S; CLERICI, F; PALUMBO, A; SGARONI, G; POLONARA, S; REGINELLI, R; CERAVOLO, MG; PROVINCIALI, L; DELGOBBO, M; SCARPINO, O; BOTTACCHI, E; DALESSANDRO, G; DIGIOVANNI, M; BLANC, S; ROVEYAZ, L; RALLI, L; VANNI, D; REFI, C; FEDERICO, F; CONTE, C; INCHINGOLO, V; INSABATO, R; SALSA, F; LORIZIO, A; ROTTOLI, MR; BRUNI, L; DEFANTI, CA; FERA, L; CAMERLINGO, M; CASTO, L; CENSORI, B; MAMOLI, A; PORAZZI, D; GRAMPA, G; LASPINA, I; GIGLIA, L; AVENIA, V; GUELI, S; LOLLI, V; MIELE, V; SANTANGELO, M; COPPOLA, G; TRIANNI, G; MARRA, M; GRECO, E; TONTI, D; PRETOLANI, E; STELLIO, M; ARNABOLDI, M; CIOLA, R; DANIELI, G; REZZONICO, M; GUIDOTTI, M; PELLEGRINI, G; RAUDINO, F; DELFAVERO, C; FRATTINI, T; RICCARDI, T; LEVIMINZI, C; LOCATELLI, F; PASSERI, F; LOMBARDO, G; COCCO, F; PRATESI, M; SANTINI, S; CARDOPATRI, F; TAFANI, O; LANDINI, GC; PIERAGNOLI, E; BELLESI, R; BAGNOLI, L; GHETTI, A; MARRAZZA, OB; MENEGAZZO, P; SPOLVERI, S; CAPPELLETTI, C; CANDELIERE, G; COSTANTINO, G; DACUNO, F; LOMUZIO, T; RIZZITELLI, FP; BOVIO, G; GRILLI, GP; ZOCCHI, M; MAZZANTI, I; PISAPIA, G; NUZZI, R; RUSSO, G; LAMA, G; BALDASSARRI, G; BETTINI, R; CANI, E; CERIOLI, E; DEGIORGI, M; GARAGNANI, A; PASQUALI, S; CHIOMA, V; FINI, C; MARZARA, G; BALOTTA, A; BERTUZZI, D; MASINA, M; MATACENA, C; MICHELINI, M; PIRAZZOLI, G; SACCHET, C; MAROTTA, P; CALVI, L; SCACCABAROZZI, C; MENOZZI, C; SASANELLI, F; BASCELLI, C; PONTRELLI, V; SCHIERONI, F; BELVEDERE, D; DECAPITANI, E; DICOSTANZO, M; RASCAROLI, M; CITTERIO, O; MILANI, R; CAPIALBI, R; ARENA, G; MUSOLINO, R; DIPERRI, R; BONAVENTI, C; FINZI, F; MESSINA, A; ROMANAZZI, V; STERZI, R; BOTTINI, G; SANTILLI, I; BRUCATO, A; DEJULI, E; PALMIERI, G; RAGAINI, S; THIELLA, G; ALLI, C; CAROSELLA, L; RIZZATO, G; CANDELISE, L; ARITZU, E; BIANCHI, M; CICCONE, A; MOTTO, C; PINARDI, G; SCARLATO, G; BETTINELLI, A; PORRO, F; RANDAZZO, A; MARINI, U; LATTUADA, P; PIETRA, A; FRANCESCHI, M; VOLOUTE, MA; MALFERRARI, G; BONDI, M; GARUTI, W; MELINI, L; COLOMBO, A; ALBORINI, G; PANZETTI, P; SCARPA, M; SORGATO, P; CRISI, G; BONASERA, N; BASSO, F; NATALI, E; MONACO, P; GASPARRO, AM; TRIOLO, F; LECHI, A; COLONNA, F; DASCOLA, I; GIORGI, C; SCODITTI, U; BASSI, P; MENOZZI, R; PIAZZA, P; DEGLIANTONI, G; DESIMONI, M; GIANNINI, A; MICILI, G; BOSONE, D; CAVALLINI, A; MARTELLI, A; BARZIZZA, F; POLI, M; RICCI, S; BIAGINI, S; CAPOCCHI, G; CELANI, MG; PICCHIARELLI, A; RIGHETTI, E; ZAMPOLINI, M; CAPUTO, N; BARTOLINI, S; SANTONI, M; SITA, D; TAGLIOLI, M; VOLPI, G; ROSSI, F; ALOY, F; CASTELLANO, AE; MINOTTA, F; GATTA, A; VINATTIERI, A; CANTINI, A; REBUCCI, GG; BISSI, G; DEBLASI, F; PASCARELLI, E; TURIAMO, F; GUIDETTI, D; BARATTI, M; FERRARINI, G; GHIDONI, E; GRECO, G; MARCELLO, N; MOTTI, L; SOLIME, F; TERENZIANI, S; ZUCCO, R; TROISO, A; VENEZIANI, M; IORI, I; CURATOLA, L; BOLLETTINI, G; CARBONI, T; GOBBATO, R; INFRICCIOLO, P; SABATINI, D; SFRAPPINI, M; FANCELLU, A; CASU, G; DELEDDA, MG; SPANU, MA; PIRISI, A; MARRAS, FA; ROSATI, G; BRAMBILLA, A; ERLI, GC; FELICE, B; GRANDI, R; MIRABILE, D; ZADRA, M; CAVESTRI, R; GORI, D; LONGHINI, E; MIELE, N; DIVIZIA, G; GRASSELLI, S; PEZZELLA, F; ZUCCARI, F; SALLUSTO, L; LINCESSO, F; SCARPATI, C; IANNONE, G; BARTOCCI, A; COSTANTINI, F; DESANTIS, L; LANCIA, G; MOSCHINI, E; PACI, A; SENSIDONI, A; TRENTA, A; BARTOLINI, N; OTTAVIANO, P; BISCOTTINI, B; ALUNNI, G; BARTOLINI, I; BELLADONNA, D; BOCCALI, A; CRUCIANI, M; IBBA, R; LUCCIOLI, R; MARCECA, A; PACINI, M; PALLONE, M; GIRARDI, P; ORRICO, D; LANZA, E; BALLINI, A; GRANDI, FC; MUSCO, G; STEIDL, L; SANTORO, G; VEMCO, A; DUDINE, P; MILONE, FF; MUNARI, L; PERRETI, A; PORTA, M; LONGONI, C; FERANI, R; WATT, M; SANDERCOCK, P; FENNETRY, A; BANNISTER, P; CLARKE, CE; BAMFORD, J; VENABLES, G; CORREIA, M				CANDELISE, L; ARITZU, E; CICCONE, A; RICCI, S; WARDLAW, J; TOGNONI, G; RONCAGLIONI, MC; NEGRI, E; COLOMBO, F; BOCCARDI, E; DEGRANDI, C; SCIALFA, G; ARGENTINO, C; BERTELE, V; MAGGIONI, AP; PERRONE, P; BARNETT, HJM; BOGOUSSLAVSKY, J; DELFAVERO, A; LOI, U; PETO, R; WARLOW, C; CANZI, S; COMPARETTI, S; CLERICI, F; PALUMBO, A; SGARONI, G; POLONARA, S; REGINELLI, R; CERAVOLO, MG; PROVINCIALI, L; DELGOBBO, M; SCARPINO, O; BOTTACCHI, E; DALESSANDRO, G; DIGIOVANNI, M; BLANC, S; ROVEYAZ, L; RALLI, L; VANNI, D; REFI, C; FEDERICO, F; CONTE, C; INCHINGOLO, V; INSABATO, R; SALSA, F; LORIZIO, A; ROTTOLI, MR; BRUNI, L; DEFANTI, CA; FERA, L; CAMERLINGO, M; CASTO, L; CENSORI, B; MAMOLI, A; PORAZZI, D; GRAMPA, G; LASPINA, I; GIGLIA, L; AVENIA, V; GUELI, S; LOLLI, V; MIELE, V; SANTANGELO, M; COPPOLA, G; TRIANNI, G; MARRA, M; GRECO, E; TONTI, D; PRETOLANI, E; STELLIO, M; ARNABOLDI, M; CIOLA, R; DANIELI, G; REZZONICO, M; GUIDOTTI, M; PELLEGRINI, G; RAUDINO, F; DELFAVERO, C; FRATTINI, T; RICCARDI, T; LEVIMINZI, C; LOCATELLI, F; PASSERI, F; LOMBARDO, G; COCCO, F; PRATESI, M; SANTINI, S; CARDOPATRI, F; TAFANI, O; LANDINI, GC; PIERAGNOLI, E; BELLESI, R; BAGNOLI, L; GHETTI, A; MARRAZZA, OB; MENEGAZZO, P; SPOLVERI, S; CAPPELLETTI, C; CANDELIERE, G; COSTANTINO, G; DACUNO, F; LOMUZIO, T; RIZZITELLI, FP; BOVIO, G; GRILLI, GP; ZOCCHI, M; MAZZANTI, I; PISAPIA, G; NUZZI, R; RUSSO, G; LAMA, G; BALDASSARRI, G; BETTINI, R; CANI, E; CERIOLI, E; DEGIORGI, M; GARAGNANI, A; PASQUALI, S; CHIOMA, V; FINI, C; MARZARA, G; BALOTTA, A; BERTUZZI, D; MASINA, M; MATACENA, C; MICHELINI, M; PIRAZZOLI, G; SACCHET, C; MAROTTA, P; CALVI, L; SCACCABAROZZI, C; MENOZZI, C; SASANELLI, F; BASCELLI, C; PONTRELLI, V; SCHIERONI, F; BELVEDERE, D; DECAPITANI, E; DICOSTANZO, M; RASCAROLI, M; CITTERIO, O; MILANI, R; CAPIALBI, R; ARENA, G; MUSOLINO, R; DIPERRI, R; BONAVENTI, C; FINZI, F; MESSINA, A; ROMANAZZI, V; STERZI, R; BOTTINI, G; SANTILLI, I; BRUCATO, A; DEJULI, E; PALMIERI, G; RAGAINI, S; THIELLA, G; ALLI, C; CAROSELLA, L; RIZZATO, G; CANDELISE, L; ARITZU, E; BIANCHI, M; CICCONE, A; MOTTO, C; PINARDI, G; SCARLATO, G; BETTINELLI, A; PORRO, F; RANDAZZO, A; MARINI, U; LATTUADA, P; PIETRA, A; FRANCESCHI, M; VOLOUTE, MA; MALFERRARI, G; BONDI, M; GARUTI, W; MELINI, L; COLOMBO, A; ALBORINI, G; PANZETTI, P; SCARPA, M; SORGATO, P; CRISI, G; BONASERA, N; BASSO, F; NATALI, E; MONACO, P; GASPARRO, AM; TRIOLO, F; LECHI, A; COLONNA, F; DASCOLA, I; GIORGI, C; SCODITTI, U; BASSI, P; MENOZZI, R; PIAZZA, P; DEGLIANTONI, G; DESIMONI, M; GIANNINI, A; MICILI, G; BOSONE, D; CAVALLINI, A; MARTELLI, A; BARZIZZA, F; POLI, M; RICCI, S; BIAGINI, S; CAPOCCHI, G; CELANI, MG; PICCHIARELLI, A; RIGHETTI, E; ZAMPOLINI, M; CAPUTO, N; BARTOLINI, S; SANTONI, M; SITA, D; TAGLIOLI, M; VOLPI, G; ROSSI, F; ALOY, F; CASTELLANO, AE; MINOTTA, F; GATTA, A; VINATTIERI, A; CANTINI, A; REBUCCI, GG; BISSI, G; DEBLASI, F; PASCARELLI, E; TURIAMO, F; GUIDETTI, D; BARATTI, M; FERRARINI, G; GHIDONI, E; GRECO, G; MARCELLO, N; MOTTI, L; SOLIME, F; TERENZIANI, S; ZUCCO, R; TROISO, A; VENEZIANI, M; IORI, I; CURATOLA, L; BOLLETTINI, G; CARBONI, T; GOBBATO, R; INFRICCIOLO, P; SABATINI, D; SFRAPPINI, M; FANCELLU, A; CASU, G; DELEDDA, MG; SPANU, MA; PIRISI, A; MARRAS, FA; ROSATI, G; BRAMBILLA, A; ERLI, GC; FELICE, B; GRANDI, R; MIRABILE, D; ZADRA, M; CAVESTRI, R; GORI, D; LONGHINI, E; MIELE, N; DIVIZIA, G; GRASSELLI, S; PEZZELLA, F; ZUCCARI, F; SALLUSTO, L; LINCESSO, F; SCARPATI, C; IANNONE, G; BARTOCCI, A; COSTANTINI, F; DESANTIS, L; LANCIA, G; MOSCHINI, E; PACI, A; SENSIDONI, A; TRENTA, A; BARTOLINI, N; OTTAVIANO, P; BISCOTTINI, B; ALUNNI, G; BARTOLINI, I; BELLADONNA, D; BOCCALI, A; CRUCIANI, M; IBBA, R; LUCCIOLI, R; MARCECA, A; PACINI, M; PALLONE, M; GIRARDI, P; ORRICO, D; LANZA, E; BALLINI, A; GRANDI, FC; MUSCO, G; STEIDL, L; SANTORO, G; VEMCO, A; DUDINE, P; MILONE, FF; MUNARI, L; PERRETI, A; PORTA, M; LONGONI, C; FERANI, R; WATT, M; SANDERCOCK, P; FENNETRY, A; BANNISTER, P; CLARKE, CE; BAMFORD, J; VENABLES, G; CORREIA, M			RANDOMIZED CONTROLLED TRIAL OF STREPTOKINASE, ASPIRIN, AND COMBINATION OF BOTH IN TREATMENT OF ACUTE ISCHEMIC STROKE	LANCET			English	Article							TISSUE PLASMINOGEN-ACTIVATOR; THROMBOLYTIC THERAPY; REPERFUSION	In ischaemic stroke, thrombolytic drugs speed the recanalisation of intracerebral arteries. The effects of aspirin are not known. A trial was conducted to determine whether, separately or together, streptokinase and aspirin have clinical benefits in acute ischaemic stroke similar to those in acute myocardial infarction. 622 patients with acute ischaemic stroke within 6 hours of symptom onset were randomised with a 2x2 factorial design to (i) a 1-hour intravenous infusion of 1 . 5 MU streptokinase, (ii) 300 mg/day buffered aspirin for 10 days, (iii) both active treatments, or (iv) neither. Early results raised a question whether the trial should be continued. Streptokinase (alone or with aspirin) was associated with an excess of 10-day case fatality (odds ratio 2 . 7; 95% confidence interval 1 . 7-4 . 3; 2p<0.00001). Of the four groups randomised, only patients allocated to streptokinase plus aspirin had a significantly higher risk of early death than those given neither streptokinase nor aspirin (odds ratio 3 . 5; 95% CI 1 . 9-6 . 5; 2p<0.00001). Streptokinase (alone or with aspirin) and aspirin (alone or with streptokinase) reduced, albeit not significantly, the incidence of combined six-month case fatality and severe disability: odds ratio for streptokinase 0 . 9 (95% CI 0 . 7-1 . 3) and odds ratio for aspirin 0 . 9 (95% CI 0 . 6-1 . 3). The risk of early death with thrombolytic treatments should be weighed against the potential benefit of a marginal reduction of severe disability after the first six months.	IST RIC FARMACOL MARIO NEGRI, MILAN, ITALY; INST NEUROL SCI, GLASGOW, LANARK, SCOTLAND; NEUROL CLIN, PERUGIA, ITALY; OSPED NIGUARDA CA GRANDA, MILAN, ITALY; UNIV ROMA LA SAPIENZA, ROME, ITALY; IST RIC FARMACOL MARIO NEGRI, CONSORZIO MARIO NEGRI SUD, I-66030 SANTA MARIA IMBARO, ITALY; OSPED LEGNANO, LEGNANO, ITALY; JOHN P ROBARTS RES INST, LONDON, ON N6A 5K8, CANADA; CHU VAUDOIS, CH-1011 LAUSANNE, SWITZERLAND; POLICLIN, PERUGIA, ITALY; CORTE APPELLO, PALAZZO GIUSTIZIA, MILAN, ITALY; RADCLIFFE INFIRM, CLIN TRIAL SERV UNIT, OXFORD OX2 6HE, ENGLAND; WESTERN GEN HOSP, EDINBURGH EH4 2XU, MIDLOTHIAN, SCOTLAND; OSPED TORRETTE, NEUROL CLIN, ANCONA, ITALY; IST MALATTIE SISTEMA NERVOSO, ANCONA, ITALY; OSPED INRCA, DIV NEUROL, ANCONA, ITALY; OSPED REG, DIV NEUROL, AOSTA, ITALY; OSPED REG, DIV RADIOL, AOSTA, ITALY; OSPED REG, DIV GERIATR, AOSTA, ITALY; OSPED POLICLIN, NEUROL CLIN 1, BARI, ITALY; OSPED USL 5, DIV NEUROL, BASSANO DEL GRAPPA, ITALY; OSPED USL 23, DIV MED, AREZZO, ITALY; OSPED USL 23, DIV RADIOL, AREZZO, ITALY; OSPED RIUNITI BERGAMO, DIV NEUROL 1, BERGAMO, ITALY; OSPED RIUNITI BERGAMO, DIV NEUROL 2A, BERGAMO, ITALY; OSPED GEN PROV, DIV NEUROL, BUSTO ARSIZIO, ITALY; OSPED S ELIA, DIV NEUROL, CALTANISSETTA, ITALY; OSPED CIVILE F CARRANO, DIV NEUROL, CASARANO, ITALY; OSPED B RAMAZZINI, USL 14, DIV NEUROL, CARPI, ITALY; OSPED GEN PROVINCIALE M BUFALINI, USL 39, DIV MED, CESENA, ITALY; OSPED GEN PROVINCIALE M BUFALINI, USL 39, DIV NEUROFISIOPATOL, CESENA, ITALY; OSPED S ANNA COMO, DIV NEUROL, COMO, ITALY; OSPED VALDUCE, DIV NEUROL, COMO, ITALY; OSPED VALDUCE, DIV RADIOL, COMO, ITALY; OSPED MAGGIORE CREMA, DIV NEUROL, CREMA, ITALY; OSPED S GIUSEPPE, DIV MED, EMPOLI, ITALY; OSPED SM ANNUNZIATA, FLORENCE, ITALY; OSPED S GIOVANNI DI DIO, DIV MED INTERNA, FLORENCE, ITALY; OSPED RIUNITI FOGGIA, DIV NEUROL, FOGGIA, ITALY; OSPED MISERICORDIA, USL 28, DIV NEUROL, GROSSETO, ITALY; OSPED S MARCO, DIV MED REP DONNE, GROTTAGLIE, ITALY; OSPED NUOVO, DIV GEN MED, IMOLA, ITALY; OSPED NUOVO, DIV GERIATR, IMOLA, ITALY; OSPED USL 16, DIV NEUROL, Lecce, ITALY; OSPED PREDABISSI, USL 57, DIV NEUROL, MELEGNANO, ITALY; OSPED S LEOPOLDO MANDIC, USL 14, DIV NEUROL, MERATE, ITALY; OSPED S LEOPOLDO MANDIC, USL 14, SERV RADIODIAGNOST, MERATE, ITALY; POLICLIN UNIV MESSINI, NEUROL CLIN 1, MESSINI, ITALY; OSPED FATEBENEFRATELLI OFTALMICO, DIV NEUROCHIRURG, MILAN, ITALY; OSPED MAGGIORE NIGUARDA CA GRANDA, DIV NEUROL, MILAN, ITALY; OSPED MAGGIORE NIGUARDA CA GRANDA, DIV MED GEN BRERA 2A, MILAN, ITALY; OSPED MAGGIORE NIGUARDA CA GRANDA, DIV MED GEN RIZZI 5A, MILAN, ITALY; OSPED MAGGIORE POLICLIN, CLIN NEUROL PADIGLIONE PONTI, MILAN, ITALY; OSPED MAGGIORE POLICLIN, DIV NEURORADIOL, MILAN, ITALY; OSPED S CARLO BORROMEO, DIV MED, MILAN, ITALY; OSPED S CARLO BORROMEO, DIV NEUROL, MILAN, ITALY; OSPED SAN RAFFAELE, DIV NEUROL, MILAN, ITALY; OSPED CIVILE, DIV MED GEN 1, MODENA, ITALY; OSPED POLICLIN, NEUROL CLIN, MODENA, ITALY; OSPED POLICLIN, SERV NEURORADIOL, MODENA, ITALY; OSPED CIVILE, DIV NEUROL, PALERMO, ITALY; VILLA SOFIA USL 61, DIV NEUROL, PALERMO, ITALY; OSPED RIUNITI PARMA, IST NEUROL, USL 8, PARMA, ITALY; OSPED RIUNITI PARMA, CATTEDRA NEURORADIOL, PARMA, ITALY; FDN IST NEUROL C MONDINO, DIV 3, PAVIA, ITALY; POLICLIN SAN MATTEO, PRESIDIO BELGIOIOSO, I-27100 PAVIA, ITALY; OSPED C MIRA, CASORATE PRIMO, ITALY; OSPED USL 3, NEUROL CLIN, PERUGIA, ITALY; OSPED USL 3, DIV NEURORADIOL, PERUGIA, ITALY; PRESIDIO OSPED RIUNITI, USL 8, DIV NEUROL, PISTOIA, ITALY; IST SCI SANATRIX, DIV NEUROL, POZZILLI, ITALY; IST SCI SANATRIX, REPARTO ANESTESIOL & TERAPIA INTENS, POZZILLI, ITALY; OSPED USL 9, DIV NEUROL, PRATO, ITALY; OSPED S MARIA DELLE CROCI, DIV NEUROL, RAVENNA, ITALY; PRESIDIO OSPED RIUNITI, USL 31, DIV NEUROCHIRURG & MED, Reggio Di Calabria, ITALY; ARCISPEDALE S MARIA NUOVA, DIV NEUROL, REGGIO EMILIA, ITALY; ARCISPEDALE S MARIA NUOVA, DIV RADIOL, REGGIO EMILIA, ITALY; ARCISPEDALE S MARIA NUOVA, DIV RADIOL, REGGIO EMILIA, ITALY; OSPED USL 22, DIV NEUROL, San Benedetto Tronto, ITALY; OSPED USL 22, DIV GERIATR 312, San Benedetto Tronto, ITALY; OSPED USL 1, DIV MED 3, SASSARI, ITALY; UNIV SASSARI, NEUROL CLIN, I-07100 SASSARI, ITALY; PRESIDIO OSPED BOLOGNINI, USL 30, DIV NEUROL, SERIATE, ITALY; PRESIDIO OSPED, USL 65, DIV MED CAMPARI, SESTO SAN GIOVANNI, ITALY; OSPED CIVILE S MATTEO INFERMI, DIV NEUROFISIOPATOL MED GEN GERIATR, SPOLETO, ITALY; OSPED CIVILE, DIV NEUROL, TARANTO, ITALY; OSPED CIVILE, DIV RADIOL, TARANTO, ITALY; OSPED SANTA MARIA, DIV NEUROL, TERNI, ITALY; OSPED SANTA MARIA, DIV NEURORADIOL, TERNI, ITALY; OSPED CIVILE, DIV MED, TODI, ITALY; OSPED S CHIARA, DIV NEUROL, Trento, ITALY; OSPED GEN PROV, USL 32, DIV MED 2A, TREVIGLIO, ITALY; OSPED MAGGIORE TRIESTE, DIV NEUROL, TRIESTE, ITALY; OSPED MULTIZONALE, USL 3, DIV GEN MED, VARESE, ITALY; OSPED S BORTOLO, DIV NEUROL, VICENZA, ITALY; POLICLIN S MARCO, DIV NEUROL, ZINGONIA, ITALY; POLICLIN S MARCO, SERV TERAPIA INTENS, ZINGONIA, ITALY; INST NEUROL SCI, DEPT NEUROL, BELFAST, ANTRIM, NORTH IRELAND; UNIV EDINBURGH, WESTERN GEN HOSP, DEPT CLIN SCI, EDINBURGH, MIDLOTHIAN, SCOTLAND; INST NEUROL SCI, DEPT NEURORADIOL, GLASGOW, LANARK, SCOTLAND; SO GEN HOSP, MED UNIT A, GLASGOW G51 4TF, LANARK, SCOTLAND; BARNES HOSP, ROBERT BARNES MED UNIT, MANCHESTER, LANCS, ENGLAND; HULL ROYAL INFIRM, DEPT NEUROL, Kingston Upon Hull HU3 2JZ, N HUMBERSIDE, ENGLAND; ST JAMES UNIV HOSP, DEPT NEUROL, LEEDS LS9 7TF, W YORKSHIRE, ENGLAND; ROYAL HALLAMSHIRE HOSP, DEPT NEUROL, SHEFFIELD S10 2JF, S YORKSHIRE, ENGLAND; HOSP GERAL SANTO ANTONIO, SERV NEUROL, OPORTO, PORTUGAL	Istituto di Ricerche Farmacologiche Mario Negri IRCCS; University of Glasgow; IRCCS Ca Granda Ospedale Maggiore Policlinico; Ospedale Niguarda Ca' Granda; Sapienza University Rome; Consorzio Mario Negri Sud; Istituto di Ricerche Farmacologiche Mario Negri IRCCS; Western University (University of Western Ontario); University of Lausanne; Centre Hospitalier Universitaire Vaudois (CHUV); Radcliffe Infirmary; University of Oxford; University of Edinburgh; IRCCS INRCA; Azienda USL della Valle d'Aosta; Azienda USL della Valle d'Aosta; Azienda USL della Valle d'Aosta; Ospedali Riuniti di Bergamo; Ospedali Riuniti di Bergamo; Ospedale Sant'Anna di Como; Azienda USL di Imola; Azienda USL di Imola; IRCCS Ca Granda Ospedale Maggiore Policlinico; IRCCS Ca Granda Ospedale Maggiore Policlinico; Vita-Salute San Raffaele University; IRCCS Ospedale San Raffaele; IRCCS Fondazione Casimiro Mondino; IRCCS Fondazione San Matteo; IRCCS Arcispedale S. Maria Nuova; IRCCS Arcispedale S. Maria Nuova; IRCCS Arcispedale S. Maria Nuova; University of Sassari; ULSS 8 Berica; Ospedale San Bortolo di Vicenza; University of Edinburgh; University of Glasgow; University of Glasgow; University of Hull; Saint James's University Hospital; University of Sheffield	CANDELISE, L (corresponding author), UNIV MILAN, IST CLIN NEUROL, VIA F SFORZA 35, I-20122 MILAN, ITALY.		Wardlaw, Joanna M/Y-3456-2019; Ballini, Andrea/R-5821-2016; Bertele, Vittorio/AAA-6461-2020; Bosone, Daniele/AAB-8569-2020; Masina, Marco/J-9585-2019; Hernandez, María/GYU-3543-2022; Negri, Eva Vanna Lorenza/AAC-5698-2019; celani, maria grazia/AAF-4143-2020; boccardi, edoardo/AAC-2904-2019; Bamford, John/ABE-6218-2021; Musco, Giovanna/Q-2756-2019; brucato, antonio/U-6879-2019; cruciani, mario/A-3181-2012; De Simoni, Maria Grazia/I-6021-2012; musco, giovanna/I-7122-2012; roncaglioni, maria carla/AAB-1875-2020; Reginelli, Alfonso/AAL-4730-2020; Ciccone, Alfonso/AAB-8068-2022; Censori, Bruno/ABB-9273-2020; sandercock, peter/GQI-3167-2022	Wardlaw, Joanna M/0000-0002-9812-6642; Bertele, Vittorio/0000-0002-0032-7033; Masina, Marco/0000-0002-5784-7099; Negri, Eva Vanna Lorenza/0000-0001-9712-8526; brucato, antonio/0000-0002-7566-5600; De Simoni, Maria Grazia/0000-0001-6695-5297; musco, giovanna/0000-0002-0469-2994; roncaglioni, maria carla/0000-0002-2029-7847; Ciccone, Alfonso/0000-0002-4590-3575; Censori, Bruno/0000-0001-7235-5909; sandercock, peter/0000-0001-8484-0135				ALTMAN R, 1994, BMJ-BRIT MED J, V308, P81, DOI 10.1136/bmj.308.6921.81; APPLEBY P, 1994, LANCET, V343, P311, DOI 10.1016/S0140-6736(94)91161-4; BELL BA, 1985, J NEUROSURG, V62, P31, DOI 10.3171/jns.1985.62.1.0031; BROTT T, 1991, CEREBROVAS BRAIN MET, V3, P91; BROTT TG, 1992, STROKE, V23, P632, DOI 10.1161/01.STR.23.5.632; CANDELISE L, 1994, CEREBROVASC DIS, V4, P341, DOI 10.1159/000108505; CLARK WM, 1991, STROKE, V22, P872, DOI 10.1161/01.STR.22.7.872; COLLER BS, 1990, NEW ENGL J MED, V322, P33, DOI 10.1056/NEJM199001043220107; DELZOPPO GJ, 1992, ANN NEUROL, V32, P78, DOI 10.1002/ana.410320113; DELZOPPO GJ, 1993, THROMBOLYTIC THERAPY, V2, P86; DONNAN GA, 1995, LANCET, V345, P578; GOMEZ CR, 1994, STROKE, V25, P1920, DOI 10.1161/01.STR.25.10.1920; HOMMEL M, 1995, LANCET, V345, P57, DOI 10.1016/S0140-6736(95)91179-0; LINCOFF AM, 1993, CIRCULATION, V87, P1792; LYDEN PD, 1993, CEREBROVAS BRAIN MET, V5, P1; RINGELSTEIN EB, 1992, NEUROLOGY, V42, P289, DOI 10.1212/WNL.42.2.289; SOLOMON NA, 1994, STROKE, V25, P1721, DOI 10.1161/01.STR.25.9.1721; VANDEWERF F, 1990, LANCET, V336, P71; WARDLAW JM, 1992, STROKE, V23, P1826, DOI 10.1161/01.STR.23.12.1826; 1993, STROKE, V24, P1618	20	492	500	0	25	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	DEC 9	1995	346	8989					1509	1514						6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TJ291	7491044				2022-12-28	WOS:A1995TJ29100008
J	CAIRNCROSS, S				CAIRNCROSS, S			VICTORY OVER GUINEAWORM DISEASE - PARTIAL OR PYRRHIC	LANCET			English	Editorial Material							ERADICATION				CAIRNCROSS, S (corresponding author), LONDON SCH HYG & TROP MED,TROP HLTH EPIDEMIOL UNIT,LONDON WC1,ENGLAND.							EDUNGBOLA LD, 1992, AM J TROP MED HYG, V47, P529, DOI 10.4269/ajtmh.1992.47.529; GARETT L, 1995, COMING PLAGUE NEWLY, P47; GREER G, 1994, AM J TROP MED HYG, V50, P393, DOI 10.4269/ajtmh.1994.50.393; HOPKINS DR, 1990, AM J TROP MED HYG, V43, P296, DOI 10.4269/ajtmh.1990.43.296; HOURS M, 1994, T ROY SOC TROP MED H, V88, P559, DOI 10.1016/0035-9203(94)90163-5; RUIZTIBEN E, 1995, EMERG INFECT DIS, V1, P58, DOI 10.3201/eid0102.950205; 1995, GUINEA WORM WRAP UP, V48, P1; 1995, WKLY EPIDEMIOL REC, V70, P29; 1994, WKLY EPIDEMIOL REC, V69, P121; 1995, WKLY EPIDEMIOL REC, V70, P77	10	2	2	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	DEC 2	1995	346	8988					1440	1440		10.1016/S0140-6736(95)92465-5	http://dx.doi.org/10.1016/S0140-6736(95)92465-5			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TH156	7490984				2022-12-28	WOS:A1995TH15600002
J	KATO, S; ENDOH, H; MASUHIRO, Y; KITAMOTO, T; UCHIYAMA, S; SASAKI, H; MASUSHIGE, S; GOTOH, Y; NISHIDA, E; KAWASHIMA, H; METZGER, D; CHAMBON, P				KATO, S; ENDOH, H; MASUHIRO, Y; KITAMOTO, T; UCHIYAMA, S; SASAKI, H; MASUSHIGE, S; GOTOH, Y; NISHIDA, E; KAWASHIMA, H; METZGER, D; CHAMBON, P			ACTIVATION OF THE ESTROGEN-RECEPTOR THROUGH PHOSPHORYLATION BY MITOGEN-ACTIVATED PROTEIN-KINASE	SCIENCE			English	Article							DEPENDENT TRANSCRIPTIONAL ACTIVATION; HUMAN-BREAST-CANCER; DOMAINS; IDENTIFICATION; BINDING; GROWTH; 4-HYDROXYTAMOXIFEN; TAMOXIFEN; ONCOGENE; ELEMENT	The phosphorylation of the human estrogen receptor (ER) serine residue at position 118 is required for full activity of the ER activation function 1 (AF-1). This Ser(118) is phosphorylated by mitogen-activated protein kinase (MAPK) in vitro and in cells treated with epidermal growth factor (EGF) and insulin-like growth factor (IGF) in vivo. Overexpression of MAPK kinase (MAPKK) or of the guanine nucleotide binding protein Ras, both of which activate MAPK, enhanced estrogen-induced and antiestrogen (tamoxifen);induced transcriptional activity of wild-type ER, but not that of a mutant ER with an alanine in place of Ser(118). Thus, the activity of the amino-terminal AF-1 of the ER is modulated by the phosphorylation of Ser(118) through the Ras-MAPK cascade of the growth factor signaling pathways.	UNIV STRASBOURG 1, INSERM, CNRS, INST GENET BIOL MOLEC & CELLULAIRE, F-67404 ILLKIRCH GRAFFENSTADEN, FRANCE; TOKYO UNIV AGR, DEPT AGR CHEM, SETAGAYA KU, TOKYO 156, JAPAN; YAMANOUCHI INST DRUG DISCOVERY RES CO LTD, MOLEC MED RES LAB 2, TSUKUBA, IBARAKI 305, JAPAN; KYOTO UNIV, INST VIRUS RES, SAKYO KU, KYOTO 606, JAPAN	Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg; Tokyo University of Agriculture; Kyoto University				Kitamoto, Takuya/0000-0002-4008-5497; Metzger, Daniel/0000-0002-5555-046X				ALI S, 1993, EMBO J, V12, P1153, DOI 10.1002/j.1460-2075.1993.tb05756.x; ARNOLD SF, 1995, J STEROID BIOCHEM, V52, P159, DOI 10.1016/0960-0760(94)00166-J; ARONICA SM, 1993, MOL ENDOCRINOL, V7, P743, DOI 10.1210/me.7.6.743; BEATO M, 1989, CELL, V56, P335, DOI 10.1016/0092-8674(89)90237-7; BERRY M, 1990, EMBO J, V9, P2811, DOI 10.1002/j.1460-2075.1990.tb07469.x; BRUNNER N, 1993, CANCER RES, V53, P3229; DANIELIAN PS, 1992, EMBO J, V11, P1025, DOI 10.1002/j.1460-2075.1992.tb05141.x; DENTON RR, 1992, J BIOL CHEM, V267, P7263; Efremidis AP, 1989, CANCER J, V2, P288; EVANS RM, 1988, SCIENCE, V240, P889, DOI 10.1126/science.3283939; FUJIOKA H, 1992, J BIOL CHEM, V267, P926; GONZALEZ FA, 1991, J BIOL CHEM, V266, P22159; GOTOH Y, 1995, EMBO J, V14, P2491, DOI 10.1002/j.1460-2075.1995.tb07246.x; GOTOH Y, 1991, NATURE, V349, P251, DOI 10.1038/349251a0; GOTOH Y, 1994, ONCOGENE, V9, P1891; GOTTARDIS MM, 1988, CANCER RES, V48, P5183; GREEN S, 1988, TRENDS GENET, V4, P309, DOI 10.1016/0168-9525(88)90108-4; GRONEMEYER H, 1991, ANNU REV GENET, V25, P89, DOI 10.1146/annurev.ge.25.120191.000513; GULLICK W J, 1990, Progress in Growth Factor Research, V2, P1, DOI 10.1016/0955-2235(90)90006-6; HARRIS AL, 1988, BREAST CANCER CELLUL, P93; HILL CS, 1995, CELL, V80, P199, DOI 10.1016/0092-8674(95)90403-4; IGNARTROWBRIDGE DM, 1993, MOL ENDOCRINOL, V7, P992, DOI 10.1210/me.7.8.992; JANES PW, 1994, ONCOGENE, V9, P3601; JOEL PB, 1995, MOL ENDOCRINOL, V9, P1041, DOI 10.1210/me.9.8.1041; JORDAN VC, 1987, BREAST CANCER RES TR, V10, P31, DOI 10.1007/BF01806132; Kastner P., 1994, Vitamin A in health and disease., P189; KATO S, 1992, CELL, V68, P731, DOI 10.1016/0092-8674(92)90148-6; KATO S, UNPUB; KUMAR V, 1987, CELL, V51, P941, DOI 10.1016/0092-8674(87)90581-2; LEES JA, 1989, J STEROID BIOCHEM, V34, P33, DOI 10.1016/0022-4731(89)90063-0; LEGOFF P, 1994, J BIOL CHEM, V269, P4458; LOVE RR, 1988, BREAST CANCER RES TR, V12, P297, DOI 10.1007/BF01811242; MANGELSDORF DJ, 1994, RETINOIDS, pCH8; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; MASON S, 1995, BREAST, V4, P11, DOI 10.1016/0960-9776(95)90022-5; MCGUIRE WL, 1991, MOL ENDOCRINOL, V5, P157; MELLON PL, 1989, P NATL ACAD SCI USA, V86, P4887, DOI 10.1073/pnas.86.13.4887; METZGER D, 1995, MOL ENDOCRINOL, V9, P579, DOI 10.1210/me.9.5.579; METZGER D, 1995, J BIOL CHEM, V270, P9535, DOI 10.1074/jbc.270.16.9535; Murphy L C, 1990, Semin Cancer Biol, V1, P305; PETECH SL, 1992, SCIENCE, V257, P1355; ROCHLITZ CF, 1989, CANCER RES, V49, P357; SLAMON DJ, 1989, SCIENCE, V244, P707, DOI 10.1126/science.2470152; TORA L, 1989, CELL, V59, P477, DOI 10.1016/0092-8674(89)90031-7; TSAI MJ, 1994, ANNU REV BIOCHEM, V63, P451, DOI 10.1146/annurev.bi.63.070194.002315; WASBURN T, 1991, MOL ENDOCRINOL, V5, P235; WEBSTER NJG, 1988, CELL, V54, P199, DOI 10.1016/0092-8674(88)90552-1	47	1605	1669	0	92	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	DEC 1	1995	270	5241					1491	1494		10.1126/science.270.5241.1491	http://dx.doi.org/10.1126/science.270.5241.1491			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TH375	7491495				2022-12-28	WOS:A1995TH37500038
J	DILLNER, J; KNEKT, P; SCHILLER, JT; HAKULINEN, T				DILLNER, J; KNEKT, P; SCHILLER, JT; HAKULINEN, T			PROSPECTIVE SEROEPIDEMIOLOGICAL EVIDENCE THAT HUMAN PAPILLOMAVIRUS TYPE-16 INFECTION IS A RISK FACTOR FOR ESOPHAGEAL SQUAMOUS-CELL CARCINOMA	BRITISH MEDICAL JOURNAL			English	Article							CANCER		NATL PUBL HLTH INST,HELSINKI,FINLAND; FINNISH SOCIAL INSURANCE INST,HELSINKI,FINLAND; NCI,CELLULAR ONCOL LAB,BETHESDA,MD 20892; KAROLINSKA INST,DEPT CANC EPIDEMIOL,STOCKHOLM,SWEDEN; FINNISH CANC REGISTRY,SF-00170 HELSINKI,FINLAND	Finland National Institute for Health & Welfare; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Karolinska Institutet; Finnish Cancer Registry	DILLNER, J (corresponding author), KAROLINSKA INST,CTR MICROBIOL & TUMOR BIOL,S-17177 STOCKHOLM,SWEDEN.		Schiller, John/ABK-8287-2022					CHANG FJ, 1992, GASTROENTEROLOGY, V103, P1336, DOI 10.1016/0016-5085(92)91526-A; HEINO P, 1995, J NATL CANCER I, V87, P437, DOI 10.1093/jnci/87.6.437; KIRNBAUER R, 1994, JNCI-J NATL CANCER I, V86, P494, DOI 10.1093/jnci/86.7.494; KNEKT P, 1988, AM J EPIDEMIOL, V127, P28, DOI 10.1093/oxfordjournals.aje.a114788; SCHIFFMAN MH, 1993, JNCI-J NATL CANCER I, V85, P958, DOI 10.1093/jnci/85.12.958	5	70	72	0	3	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	NOV 18	1995	311	7016					1346	1346		10.1136/bmj.311.7016.1346	http://dx.doi.org/10.1136/bmj.311.7016.1346			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TF901	7496288	Green Published			2022-12-28	WOS:A1995TF90100026
J	STEER, P				STEER, P			RECENT ADVANCES - OBSTETRICS	BRITISH MEDICAL JOURNAL			English	Article							INTRAUTERINE GROWTH-RETARDATION; RANDOMIZED CONTROLLED TRIAL; HIGH-RISK PREGNANCIES; FETAL BLOOD-FLOW; UMBILICAL-ARTERY; DOWNS-SYNDROME; DOPPLER ULTRASOUND; VELOCIMETRY; PREDICTION				STEER, P (corresponding author), CHELSEA & WESTMINSTER HOSP,CHARING CROSS & WESTMINSTER MED SCH,ACAD DEPT OBSTET & GYNAECOL,LONDON SW10 9NH,ENGLAND.							ALBERMAN E, 1995, BRIT J OBSTET GYNAEC, V102, P445, DOI 10.1111/j.1471-0528.1995.tb11315.x; ALMSTROM H, 1992, LANCET, V340, P936, DOI 10.1016/0140-6736(92)92818-Z; [Anonymous], 1994, LANCET, P619; BEATTIE RB, 1989, BRIT MED J, V298, P631, DOI 10.1136/bmj.298.6674.631; BENTOVIM A, 1993, BRIT MED J, V307, P146; BERKOWITZ GS, 1988, OBSTET GYNECOL, V71, P742; BEWLEY S, 1995, BRIT J OBSTET GYNAEC, V102, P386, DOI 10.1111/j.1471-0528.1995.tb11290.x; BRIZOT ML, 1995, BRIT J OBSTET GYNAEC, V102, P127, DOI 10.1111/j.1471-0528.1995.tb09065.x; CHERVENAK FA, 1995, BRIT J OBSTET GYNAEC, V102, P434, DOI 10.1111/j.1471-0528.1995.tb11311.x; COLLIS RE, 1995, LANCET, V345, P1413, DOI 10.1016/S0140-6736(95)92602-X; CONNOR EM, 1994, NEW ENGL J MED, V331, P1173, DOI 10.1056/NEJM199411033311801; CONNOR M, 1993, BRIT MED J, V306, P1705, DOI 10.1136/bmj.306.6894.1705; Cumberlege J, 1993, CHANGING CHILDBIRT 1; DAVIES JA, 1992, LANCET, V340, P1299, DOI 10.1016/0140-6736(92)92490-7; DAWSON AJ, 1993, BRIT J OBSTET GYNAEC, V100, P874; DEVORE GR, 1995, OBSTET GYNECOL, V85, P378, DOI 10.1016/0029-7844(94)00384-P; DONNENFELD AE, 1994, OBSTET GYNECOL, V84, P844; EIKNES SH, 1980, BRIT MED J, V280, P283, DOI 10.1136/bmj.280.6210.283; GRANDJEAN H, 1995, OBSTET GYNECOL, V85, P103, DOI 10.1016/0029-7844(94)00327-A; GREEN JM, 1994, BRIT MED J, V309, P769, DOI 10.1136/bmj.309.6957.769; GREEN JM, 1995, BRIT J OBSTET GYNAEC, V102, P228, DOI 10.1111/j.1471-0528.1995.tb09099.x; GROSS SJ, 1995, AM J OBSTET GYNECOL, V172, P83, DOI 10.1016/0002-9378(95)90088-8; HACKETT GA, 1987, BRIT MED J, V294, P13, DOI 10.1136/bmj.294.6563.13; KARSDORP VHM, 1994, LANCET, V344, P1664, DOI 10.1016/S0140-6736(94)90457-X; LAURIN J, 1987, OBSTET GYNECOL, V69, P895; LEES C, 1994, LANCET, V343, P1325, DOI 10.1016/S0140-6736(94)92468-6; MACARTHUR C, 1990, BRIT MED J, V301, P9, DOI 10.1136/bmj.301.6742.9; MONCADA S, 1991, PHARMACOL REV, V43, P109; MORRIS NH, 1995, BRIT J OBSTET GYNAEC, V102, P711; NAVA S, 1994, ULTRASOUND OBST GYN, V4, P448, DOI 10.1046/j.1469-0705.1994.04060448.x; Neilson James P., 1995, British Medical Journal, V311, P702; NEWNHAM JP, 1991, BRIT J OBSTET GYNAEC, V98, P956, DOI 10.1111/j.1471-0528.1991.tb15332.x; NICOLAIDES KH, 1992, BRIT MED J, V304, P867, DOI 10.1136/bmj.304.6831.867; NICOLAIDES KH, 1988, BRIT MED J, V297, P1026, DOI 10.1136/bmj.297.6655.1026; NOORDAM MJ, 1994, BRIT J OBSTET GYNAEC, V101, P504, DOI 10.1111/j.1471-0528.1994.tb13151.x; PATTINSON RC, 1994, BRIT J OBSTET GYNAEC, V101, P114, DOI 10.1111/j.1471-0528.1994.tb13075.x; ROBERTS LJ, 1995, BRIT J OBSTET GYNAEC, V102, P381, DOI 10.1111/j.1471-0528.1995.tb11289.x; ROBERTS SW, 1995, OBSTET GYNECOL, V85, P79, DOI 10.1016/0029-7844(94)P4401-9; SANUSI FA, 1994, BRIT J OBSTET GYNAEC, V101, P710, DOI 10.1111/j.1471-0528.1994.tb13191.x; SCHULMAN H, 1984, AM J OBSTET GYNECOL, V148, P985, DOI 10.1016/0002-9378(84)90541-6; SELIGMAN SP, 1994, AM J OBSTET GYNECOL, V171, P944, DOI 10.1016/S0002-9378(94)70064-8; SHENNAN A, 1995, BRIT J OBSTET GYNAEC, V102, P192, DOI 10.1111/j.1471-0528.1995.tb09093.x; SIBAI BM, 1993, NEW ENGL J MED, V329, P1213, DOI 10.1056/NEJM199310213291701; SMITH DK, 1994, BRIT MED J, V309, P776, DOI 10.1136/bmj.309.6957.776; STATHAM H, 1993, BRIT MED J, V307, P174, DOI 10.1136/bmj.307.6897.174; THORP JA, 1993, AM J OBSTET GYNECOL, V169, P851, DOI 10.1016/0002-9378(93)90015-B; TRUDINGER BJ, 1985, AM J OBSTET GYNECOL, V152, P155, DOI 10.1016/S0002-9378(85)80016-8; TYRRELL SN, 1990, BRIT J OBSTET GYNAEC, V97, P909, DOI 10.1111/j.1471-0528.1990.tb02446.x; WALD NJ, 1992, BMJ-BRIT MED J, V305, P391, DOI 10.1136/bmj.305.6850.391; WATSON WJ, 1994, AM J OBSTET GYNECOL, V170, P583, DOI 10.1016/S0002-9378(94)70232-2; WHITTLE MJ, 1994, AM J OBSTET GYNECOL, V170, P555, DOI 10.1016/S0002-9378(94)70226-8; WINTERTON N, 1992, 1991 92 HLTH COMM 2N; 1995, LANCET, V345, P1455; 1993, LANCET, V341, P396; 1992, LANCET, V339, P1007; 1995, UNLINKED ANONYMOUS H; 1994, LANCET, V343, P1464	57	11	11	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	NOV 4	1995	311	7014					1209	1212		10.1136/bmj.311.7014.1209	http://dx.doi.org/10.1136/bmj.311.7014.1209			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TD768	7488904	Green Published			2022-12-28	WOS:A1995TD76800028
J	ALLENMERSH, TG; EARLAM, S; FORDY, C; ABRAMS, K; HOUGHTON, J				ALLENMERSH, TG; EARLAM, S; FORDY, C; ABRAMS, K; HOUGHTON, J			QUALITY-OF-LIFE AND SURVIVAL WITH CONTINUOUS HEPATIC-ARTERY FLOXURIDINE INFUSION FOR COLORECTAL LIVER METASTASES	LANCET			English	Article							PROSPECTIVE RANDOMIZED TRIAL; CANCER-PATIENTS; OF-LIFE; CHEMOTHERAPY; 5-FLUOROURACIL; COMPLICATIONS; LEUCOVORIN; CARCINOMA	Very few patients with liver metastases from colorectal cancer can be cured. We have investigated whether a treatment to slow the growth of liver metastases, hepatic-artery infusion of floxuridine, improves palliation in this setting. In a randomised study of 100 patients, we compared quality of life and survival in patients who received hepatic-artery infusion of floxuridine and in those who received conventional symptom palliation. 95% of control patient survival time was spent with normal quality-of-life scores, which suggests that the aim of treatment should be to prolong normal-quality survival rather than merely to sustain quality of life. There was a significant prolongation (p=0.03) in overall survival in floxuridine-treated patients compared with controls (median 405 vs 226 days). There were similar significant prolongations in normal-quality (ie, normal symptom scores) survival for physical symptoms (p=0.04), anxiety (p=0.04), and depression (p=0.04). This survival benefit was associated with significant reductions in metastasis size on computed tomography (p=0.001) and in serum carcinoembryonic antigen concentration (p=0.006) in floxuridine-treated patients. There was no evidence of treatment-related hepatotoxicity as assessed by serum aspartate aminotransferase and bilirubin measurements. This is the first demonstration that survival can be prolonged with normal quality of life in patients with colorectal liver metastases. We conclude that hepatic-artery floxuridine infusion can be recommended for suitable patients.	CHARING CROSS & WESTMINSTER MED SCH,LONDON,ENGLAND; RAYNE INST,CANC RES CAMPAIGN,CTR CLIN TRIALS,LONDON,ENGLAND	Imperial College London; University of London; King's College London			Abrams, Keith/AAA-2557-2020	Abrams, Keith/0000-0002-7557-1567				ARBUCK SG, 1989, CANCER, V63, P1036, DOI 10.1002/1097-0142(19890315)63:6+<1036::AID-CNCR2820631309>3.0.CO;2-K; AUGUST DA, 1984, CANCER METAST REV, V3, P303, DOI 10.1007/BF00051457; BYRNE M, 1992, BRIT MED J, V304, P1523, DOI 10.1136/bmj.304.6841.1523; CHANG AE, 1987, ANN SURG, V206, P685, DOI 10.1097/00000658-198712000-00001; DEHAES JCJM, 1986, EUR J SURG ONCOL, V12, P337; DWORKIN MJ, 1991, CANCER TREAT REV, V18, P213, DOI 10.1016/0305-7372(91)90013-P; FELDSTEIN ML, 1991, CANCER, V67, P851, DOI 10.1002/1097-0142(19910201)67:3+<851::AID-CNCR2820671417>3.0.CO;2-G; GREENWAY B, 1988, BRIT J SURG, V75, P511; HOHN DC, 1986, CANCER, V57, P465, DOI 10.1002/1097-0142(19860201)57:3<465::AID-CNCR2820570311>3.0.CO;2-S; HYRNIUK WM, 1987, SEMIN ONCOL, V12, P3; JAFFE BM, 1968, SURG GYNECOL OBSTETR, V127, P1; KEMENY N, 1992, CANCER, V69, P327, DOI 10.1002/1097-0142(19920115)69:2<327::AID-CNCR2820690209>3.0.CO;2-U; KEMENY N, 1983, AM J MED, V74, P786, DOI 10.1016/0002-9343(83)91066-5; KEMENY N, 1993, CANCER, V71, P9, DOI 10.1002/1097-0142(19930101)71:1<9::AID-CNCR2820710104>3.0.CO;2-Y; KEMENY N, 1986, J CLIN ONCOL S, V5, P349; MAGUIRE P, 1989, BRIT J CANCER, V60, P437, DOI 10.1038/bjc.1989.301; MARTIN JK, 1990, ARCH SURG-CHICAGO, V125, P1022; MOONEY B, 1980, GUT, V21, pA903; MUELLER BU, 1992, J CLIN ONCOL, V10, P1943, DOI 10.1200/JCO.1992.10.12.1943; OCONNELL MJ, 1989, CANCER, V63, P1026, DOI 10.1002/1097-0142(19890315)63:6+<1026::AID-CNCR2820631307>3.0.CO;2-R; ONEILL WM, 1993, PRESCRIBERS J, V33, P250; PETO R, 1977, BRIT J CANCER, V35, P1, DOI 10.1038/bjc.1977.1; ROUGIER P, 1992, J CLIN ONCOL, V10, P1112, DOI 10.1200/JCO.1992.10.7.1112; STEELE G, 1989, ANN SURG, V210, P127, DOI 10.1097/00000658-198908000-00001; TRAVES DR, 1974, CLIN PHARMACOL THER, V15, P443; WOOD CB, 1980, RECENT ADV SURG, V10, P259; ZIGMOND AS, 1983, ACTA PSYCHIAT SCAND, V67, P361, DOI 10.1111/j.1600-0447.1983.tb09716.x; Zwinderman A H, 1992, Qual Life Res, V1, P219, DOI 10.1007/BF00635621; 1992, J CLIN ONCOL, V10, P904; 1992, J CLIN ONCOL, V10, P896	30	439	443	1	7	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	NOV 5	1994	344	8932					1255	1260		10.1016/S0140-6736(94)90750-1	http://dx.doi.org/10.1016/S0140-6736(94)90750-1			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PP701	7526096				2022-12-28	WOS:A1994PP70100008
J	KLEIN, I; BECKER, DV; LEVEY, GS				KLEIN, I; BECKER, DV; LEVEY, GS			TREATMENT OF HYPERTHYROID DISEASE	ANNALS OF INTERNAL MEDICINE			English	Article							GRAVES-DISEASE; THYROID-HORMONE; INDUCED AGRANULOCYTOSIS; FOLLOW-UP; THERAPY; THYROTOXICOSIS; OPHTHALMOPATHY; MANAGEMENT; EXPRESSION; PREVALENCE	Purpose: To evaluate treatments for hyperthyroid disease. Data Sources: Selected studies published during the last 20 years addressing the diagnosis, causes, and treatment of hyperthyroid disease. Study Selection: Studies were chosen based on their usefulness in addressing specific points in the treatment of hyperthyroid disease. Data Extraction: Various treatment principles extracted from the references form the basis for the conclusions and recommendations made here. Results: Hyperthyroid disease is a common endocrine disease. Although Graves disease is the most common cause of thyrotoxicosis, other primary and secondary causes exist. With classic signs and symptoms accompanied by confirmatory laboratory measures of thyroid hyperfunction, the diagnosis can be established firmly. Radioiodine is the preferred method to treat Graves disease; however, recent data concerning treatment with a combination of propylthiouracil and thyroxine require further evaluation to establish its efficacy. Radioiodine is also the preferred treatment for the other forms of hyperthyroid disease; however, patient-specific considerations in both may require patient-tailored therapies. Conclusions: Hyperthyroid disease can be treated definitively for most patients. Palliative therapy with P-adrenergic blockade is useful in some patients. Further studies are needed to determine whether more recently described treatments have improved efficacy and whether therapy directed specifically at the underlying immunologic cause of Graves disease can be used successfully.	NEW YORK HOSP, CORNELL MED CTR, NEW YORK, NY USA; MERCK & CO INC, WHITE HOUSE STN, NJ USA	Cornell University; NewYork-Presbyterian Hospital; Merck & Company	KLEIN, I (corresponding author), N SHORE UNIV HOSP, CORNELL UNIV MED COLL, DIV ENDOCRINOL, 300 COMMUNITY DR, MANHASSET, NY 11030 USA.							AMICO JA, 1984, ARCH INTERN MED, V144, P487, DOI 10.1001/archinte.144.3.487; BAKER JR, 1993, J CLIN ENDOCR METAB, V77, P16, DOI 10.1210/jc.77.1.16; BARTALENA L, 1989, NEW ENGL J MED, V321, P1349, DOI 10.1056/NEJM198911163212001; BECKER D, 1988, DIAGNOSTIC NUCL MED, P778; BECKER DV, 1991, PROGRESS IN THYROID RESEARCH, P223; BECKER DV, 1984, NEW ENGL J MED, V311, P464, DOI 10.1056/NEJM198408163110710; BECKER DV, 1982, NUCLEAR MED ANN 1982, P265; BIONDI B, 1993, J CLIN ENDOCR METAB, V77, P334, DOI 10.1210/jc.77.2.334; BRADLEY EL, 1980, SURGERY, V87, P623; BURROW GN, 1993, ENDOCR REV, V14, P194, DOI 10.1210/er.14.2.194; CHANG DCS, 1987, SURGERY, V102, P1055; COOPER DS, 1984, NEW ENGL J MED, V311, P1353, DOI 10.1056/NEJM198411223112106; COOPER DS, 1991, THYROID, P887; CRUZ FES, 1990, J AM COLL CARDIOL, V16, P739, DOI 10.1016/0735-1097(90)90368-Y; DELIT C, 1961, JAMA-J AM MED ASSOC, V176, P262, DOI 10.1001/jama.1961.03040170008003; DUNN JT, 1984, ANN INTERN MED, V100, P891, DOI 10.7326/0003-4819-100-6-891; DUNN M, 1989, CHEST, V95, pS118, DOI 10.1378/chest.95.2_Supplement.118S; FORT P, 1988, J CLIN ENDOCR METAB, V66, P645, DOI 10.1210/jcem-66-3-645; FRADKIN JE, 1983, MEDICINE, V62, P1; GESUNDHEIT N, 1989, ANN INTERN MED, V111, P827, DOI 10.7326/0003-4819-111-10-827; GOODWIN TM, 1992, J CLIN ENDOCR METAB, V75, P1333, DOI 10.1210/jc.75.5.1333; HAMADA N, 1981, ENDOCRINOL JAPON, V28, P823; HAMBURGER JI, 1992, THYROID, V2, P219, DOI 10.1089/thy.1992.2.219; HAMBURGER JI, 1986, ANN INTERN MED, V104, P219, DOI 10.7326/0003-4819-104-2-219; HASHIZUME K, 1991, NEW ENGL J MED, V324, P947, DOI 10.1056/NEJM199104043241403; KLEIN I, 1994, J CLIN ENDOCR METAB, V78, P1026, DOI 10.1210/jc.78.5.1026; KLEIN I, 1990, AM J MED, V88, P631, DOI 10.1016/0002-9343(90)90531-H; KLEIN I, 1988, ARCH INTERN MED, V148, P387, DOI 10.1001/archinte.148.2.387; KLEIN I, 1983, ANN INTERN MED, V98, P406, DOI 10.7326/0003-4819-98-3-406; KLEIN I, 1984, TOPICS EMERGENCY MED, P533; KOURIDES IA, 1977, J CLIN ENDOCR METAB, V45, P534, DOI 10.1210/jcem-45-3-534; LEE TC, 1982, ANN SURG, V195, P766, DOI 10.1097/00000658-198206000-00013; LEVEY GS, 1990, AM J MED, V88, P642, DOI 10.1016/0002-9343(90)90533-J; LEVEY GS, 1993, INTERNAL MED DIAGNOS; MAZZAFERRI EL, 1990, J CLIN ENDOCR METAB, V70, P826; MCGREGOR AM, 1980, LANCET, V1, P1101; MIASKIEWICZ SL, 1987, ANN INTERN MED, V107, P118, DOI 10.7326/0003-4819-107-1-118_3; MINTZ G, 1991, J CLIN ENDOCR METAB, V73, P146, DOI 10.1210/jcem-73-1-146; NAKAZAWA HK, 1982, AM J MED, V72, P903, DOI 10.1016/0002-9343(82)90850-6; NIKOLAI TF, 1987, ARCH INTERN MED, V147, P221, DOI 10.1001/archinte.147.2.221; Olson B R, 1991, Thyroid, V1, P137, DOI 10.1089/thy.1991.1.137; OPPENHEIMER JH, 1991, THYROID FUNDAMENTAL, P486; REFETOFF S, 1982, AM J PHYSIOL, V243, pE88, DOI 10.1152/ajpendo.1982.243.2.E88; ROSS DS, 1984, ANN INTERN MED, V101, P488, DOI 10.7326/0003-4819-101-4-488; ROTI E, 1993, METABOLISM, V42, P403, DOI 10.1016/0026-0495(93)90094-5; ROTI E, 1993, ENDOCR REV, V14, P401, DOI 10.1210/er.14.4.401; SALATA R, 1987, J LAB CLIN MED, V110, P130; SAMUELS HH, 1988, J CLIN INVEST, V81, P957, DOI 10.1172/JCI113449; SPENCER CA, 1988, MAYO CLIN PROC, V63, P1214, DOI 10.1016/S0025-6196(12)65408-1; SRIDAMA V, 1989, AM J MED, V87, P70, DOI 10.1016/S0002-9343(89)80485-1; SUGRUE D, 1980, Q J MED, V49, P51; TAJIRI J, 1990, ARCH INTERN MED, V150, P621, DOI 10.1001/archinte.150.3.621; TALLSTEDT L, 1992, NEW ENGL J MED, V326, P1733, DOI 10.1056/NEJM199206253262603; TOTH EL, 1988, AM J MED, V85, P725; TRZEPACZ PT, 1989, AM J MED, V87, P558; VENTRELLA S, 1994, IN PRESS ENDOCRINOLO; Volpe R, 1988, Autoimmunity, V2, P55, DOI 10.3109/08916938809019943; Wartofsky L, 1991, Thyroid, V1, P129, DOI 10.1089/thy.1991.1.129; WU SY, 1978, J CLIN ENDOCR METAB, V46, P691, DOI 10.1210/jcem-46-4-691	59	86	92	1	4	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	AUG 15	1994	121	4					281	288		10.7326/0003-4819-121-4-199408150-00010	http://dx.doi.org/10.7326/0003-4819-121-4-199408150-00010			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PB102	7518659				2022-12-28	WOS:A1994PB10200010
J	GAVIS, ER; LEHMANN, R				GAVIS, ER; LEHMANN, R			TRANSLATIONAL REGULATION OF NANOS BY RNA LOCALIZATION	NATURE			English	Article							SEGMENTATION GENE HUNCHBACK; POSTERIOR DETERMINANT NANOS; POLE CELL-FORMATION; DROSOPHILA-MELANOGASTER; MATERNAL GENE; EMBRYONIC POLARITY; ANTERIOR PATTERN; GERM PLASM; OSKAR; PROTEIN	LOCALIZATION of the maternally synthesized nanos (nos) RNA to the posterior pole of the Drosophila embryo provides the source for a posterior-to-anterior gradient of Nos protein(1,2). Correct spatial regulation of nos activity is essential for normal pattern formation. High local concentrations of Nos protein in the posterior of the embryo are necessary to inhibit translation of the transcription factor Hunchback in this region(3,4), ana thus permit expression of genes required for abdomen formation (see ref. 5 for review). By contrast, misexpression of Nos protein at the anterior of the embryo prevents translation of the anterior morphogen Bicoid, suppressing head and thorax development(1,6-9). Posterior localization of nos RNA is mediated by sequences within the nos 3' untranslated region (3'UTR)(1) and requires the function of eight genes of the 'posterior group'(2,6). Although the unlocalized nos RNA is stable in embryos from females mutant for any of the posterior group genes, these embryos appear to lack nos activity because they develop the abdominal defects characteristic of embryos produced by nos mutant females(2,6,10-14). We report here that unlocalized nos RNA is translationally repressed. Translational repression is mediated by the nos 3'UTR and can be alleviated either by replacement of the 3'UTR with heterologous 3'UTR sequences or by posterior localization. Thus, RNA localization provides a novel mechanism for translational regulation.	MIT, DEPT BIOL, CAMBRIDGE, MA 02142 USA	Massachusetts Institute of Technology (MIT)	GAVIS, ER (corresponding author), MIT, WHITEHEAD INST BIOMED RES, HOWARD HUGHES MED INST, 9 CAMBRIDGE CTR, CAMBRIDGE, MA 02142 USA.			Gavis, Elizabeth/0000-0003-0251-0760; Lehmann, Ruth/0000-0002-8454-5651				BERLETH T, 1988, EMBO J, V7, P1749, DOI 10.1002/j.1460-2075.1988.tb03004.x; BOSWELL RE, 1985, CELL, V43, P97, DOI 10.1016/0092-8674(85)90015-7; BOSWELL RE, 1991, DEVELOPMENT, V113, P373; EPHRUSSI A, 1991, CELL, V66, P37, DOI 10.1016/0092-8674(91)90137-N; EPHRUSSI A, 1992, NATURE, V358, P387, DOI 10.1038/358387a0; Ephrussi B, 1936, AM NAT, V70, P218, DOI 10.1086/280658; Evans T.C., 1992, Seminars in Developmental Biology, V3, P381; FROHNHOFER HG, 1986, NATURE, V324, P120, DOI 10.1038/324120a0; GAVIS ER, 1992, CELL, V71, P301, DOI 10.1016/0092-8674(92)90358-J; GAVIS ER, 1991, DEVELOPMENT, V112, P1077; GAVIS ER, IN PRESS ADV DEV BIO, V3; HULSKAMP M, 1991, BIOESSAYS, V13, P261, DOI 10.1002/bies.950130602; KOLODZIEJ PA, 1991, METHOD ENZYMOL, V194, P508; LEHMANN R, 1991, DEVELOPMENT, V112, P679; LEHMANN R, 1986, CELL, V47, P141, DOI 10.1016/0092-8674(86)90375-2; MANSEAU LJ, 1989, GENE DEV, V3, P1437, DOI 10.1101/gad.3.9.1437; MOHLER J, 1986, GENETICS, V112, P808; OCONNELL P, 1984, NUCLEIC ACIDS RES, V12, P5495, DOI 10.1093/nar/12.13.5495; SCHUEPBACH T, 1986, Wilhelm Roux's Archives of Developmental Biology, V195, P302; SMITH JL, 1992, CELL, V70, P849, DOI 10.1016/0092-8674(92)90318-7; Spradling AC, 1986, DROSOPHILA PRACTICAL, P175; Standart Nancy, 1992, Seminars in Developmental Biology, V3, P367; SUTER B, 1989, GENE DEV, V3, P1957, DOI 10.1101/gad.3.12a.1957; TAUTZ D, 1988, NATURE, V332, P281, DOI 10.1038/332281a0; TAUTZ D, 1989, CHROMOSOMA, V98, P81, DOI 10.1007/BF00291041; THEURKAUF WE, 1986, P NATL ACAD SCI USA, V83, P8477, DOI 10.1073/pnas.83.22.8477; WANG C, 1991, CELL, V66, P637, DOI 10.1016/0092-8674(91)90110-K; WANG C, 1994, DEV DYNAM, V199, P103, DOI 10.1002/aja.1001990204; WHARTON RP, 1989, CELL, V59, P881, DOI 10.1016/0092-8674(89)90611-9; WILHELM JE, 1993, J CELL BIOL, V123, P269, DOI 10.1083/jcb.123.2.269	30	243	247	0	11	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	MAY 26	1994	369	6478					315	318		10.1038/369315a0	http://dx.doi.org/10.1038/369315a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	NN109	7514276				2022-12-28	WOS:A1994NN10900048
J	SPRINGER, TA				SPRINGER, TA			TRAFFIC SIGNALS FOR LYMPHOCYTE RECIRCULATION AND LEUKOCYTE EMIGRATION - THE MULTISTEP PARADIGM	CELL			English	Review							CELL-ADHESION MOLECULE-1; MEMORY T-CELLS; NODE HOMING RECEPTOR; MONOCLONAL-ANTIBODY; VASCULAR ADDRESSIN; COUNTER-RECEPTOR; PERTUSSIS TOXIN; CHEMOTACTIC FACTORS; MIGRATION PATHWAYS; ENDOTHELIAL-CELLS				SPRINGER, TA (corresponding author), HARVARD UNIV,SCH MED,CTR BLOOD RES,BOSTON,MA 02115, USA.				NATIONAL CANCER INSTITUTE [R01CA031798, R01CA031799, R37CA031798, R37CA031799] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [U01AI031921] Funding Source: NIH RePORTER; NCI NIH HHS [CA31798, CA31799] Funding Source: Medline; NIAID NIH HHS [AI31921] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ANDERSON DC, 1987, ANNU REV MED, V38, P175, DOI 10.1146/annurev.med.38.1.175; ARFORS KE, 1987, BLOOD, V69, P338; Barclay A.N., 1993, LEUCOCYTE ANTIGEN FA; BARGATZE RF, 1993, J EXP MED, V178, P367, DOI 10.1084/jem.178.1.367; BAUMHUETER S, 1993, SCIENCE, V262, P436, DOI 10.1126/science.7692600; BERG EL, 1991, J CELL BIOL, V114, P343, DOI 10.1083/jcb.114.2.343; BERG EL, 1993, NATURE, V366, P695, DOI 10.1038/366695a0; BERG EL, 1991, J EXP MED, V174, P1461, DOI 10.1084/jem.174.6.1461; BERLIN C, 1993, CELL, V74, P185, DOI 10.1016/0092-8674(93)90305-A; BEVILACQUA MP, 1993, ANNU REV IMMUNOL, V11, P767, DOI 10.1146/annurev.iy.11.040193.004003; BJERKNES M, 1986, SCIENCE, V231, P402, DOI 10.1126/science.3941903; BRADLEY LM, 1992, J IMMUNOL, V148, P324; BRISKIN MJ, 1993, NATURE, V363, P461, DOI 10.1038/363461a0; BUTCHER EC, 1991, CELL, V67, P1033, DOI 10.1016/0092-8674(91)90279-8; CAMP RL, 1993, J EXP MED, V178, P497, DOI 10.1084/jem.178.2.497; CEPEK KL, 1993, J IMMUNOL, V150, P3459; CERFBENSUSSAN N, 1987, EUR J IMMUNOL, V17, P1279, DOI 10.1002/eji.1830170910; CHAFFIN KE, 1991, EUR J IMMUNOL, V21, P2565, DOI 10.1002/eji.1830211038; CHAN BMC, 1992, J BIOL CHEM, V267, P8366; CHISHOLM PL, 1993, EUR J IMMUNOL, V23, P682, DOI 10.1002/eji.1830230317; COFFMAN RL, 1989, J EXP MED, V170, P1039, DOI 10.1084/jem.170.3.1039; COHNHEIM J, 1989, LECTURES GENERA PATH; COLDITZ IG, 1991, VASCULAR ENDOTHELIUM, P175; COTRAN RS, 1986, J EXP MED, V164, P661, DOI 10.1084/jem.164.2.661; DEFOUGEROLLES AR, 1991, J EXP MED, V174, P253, DOI 10.1084/jem.174.1.253; DEFOUGEROLLES AR, 1992, J EXP MED, V175, P185, DOI 10.1084/jem.175.1.185; DEFOUGEROLLES AR, 1994, IN PRESS J EXP MED; DEVREOTES PN, 1988, ANNU REV CELL BIOL, V4, P649, DOI 10.1146/annurev.cb.04.110188.003245; DIAMOND MS, 1993, J CELL BIOL, V120, P545, DOI 10.1083/jcb.120.2.545; DIAMOND MS, 1993, J CELL BIOL, V120, P1031, DOI 10.1083/jcb.120.4.1031; DIAMOND MS, 1991, CELL, V65, P961, DOI 10.1016/0092-8674(91)90548-D; GALLATIN WM, 1983, NATURE, V304, P30, DOI 10.1038/304030a0; GERARD C, 1994, IN PRESS HDB IMMUNOP, V4; HAMANN A, 1991, EUR J IMMUNOL, V21, P2925, DOI 10.1002/eji.1830211205; HAMANN A, 1988, J IMMUNOL, V140, P693; HAMANN A, 1994, IN PRESS J IMMUNOL; HARLAN JM, 1992, ADHESION ITS ROLE IN, P117; HECHTMAN DH, 1991, J IMMUNOL, V147, P883; HEMLER ME, 1990, ANNU REV IMMUNOL, V8, P365, DOI 10.1146/annurev.iy.08.040190.002053; HIBBS ML, 1991, J EXP MED, V174, P1227, DOI 10.1084/jem.174.5.1227; HOLZMANN B, 1989, CELL, V56, P37, DOI 10.1016/0092-8674(89)90981-1; HOOD L, 1987, J SUPRAMOL STRUCT, V7, P531; HU MCT, 1992, P NATL ACAD SCI USA, V89, P8254, DOI 10.1073/pnas.89.17.8254; HUBER AR, 1991, SCIENCE, V254, P99, DOI 10.1126/science.1718038; ISSEKUTZ TB, 1991, J IMMUNOL, V147, P4178; ISSEKUTZ TB, 1994, IN PRESS AM J PATHOL; KANSAS GS, 1993, J EXP MED, V177, P833, DOI 10.1084/jem.177.3.833; KIRCHHAUSEN T, 1993, J LEUKOCYTE BIOL, V53, P342, DOI 10.1002/jlb.53.3.342; KISHIMOTO TK, 1989, SCIENCE, V245, P1238, DOI 10.1126/science.2551036; KUNA P, 1993, J IMMUNOL, V150, P1932; LANDIS RC, 1993, J CELL BIOL, V120, P1519, DOI 10.1083/jcb.120.6.1519; LARSON RS, 1990, IMMUNOL REV, V114, P181, DOI 10.1111/j.1600-065X.1990.tb00565.x; LASKY LA, 1992, SCIENCE, V258, P964, DOI 10.1126/science.1439808; LAWRENCE MB, 1991, CELL, V65, P859, DOI 10.1016/0092-8674(91)90393-D; LEWINSOHN DM, 1987, J IMMUNOL, V138, P4313; LEY K, 1991, BLOOD, V77, P2553; LOFTUS JC, 1990, SCIENCE, V249, P915, DOI 10.1126/science.2392682; LOLLO BA, 1994, IN PRESS J BIOL CHEM, V268; Mackay C R, 1992, Semin Immunol, V4, P51; MACKAY CR, 1992, EUR J IMMUNOL, V22, P887, DOI 10.1002/eji.1830220402; MACKAY CR, 1992, EUR J IMMUNOL, V22, P2205, DOI 10.1002/eji.1830220904; MAYADAS TN, 1993, CELL, V74, P541, DOI 10.1016/0092-8674(93)80055-J; MEBIUS RE, 1991, J CELL BIOL, V115, P85, DOI 10.1083/jcb.115.1.85; MEBIUS RE, 1994, IN PRESS J IMMUNOL; MICHISHITA M, 1993, CELL, V72, P857, DOI 10.1016/0092-8674(93)90575-B; MILLER MD, 1992, CRIT REV IMMUNOL, V12, P17; MOORE KL, 1992, J CELL BIOL, V118, P445, DOI 10.1083/jcb.118.2.445; MOY P, 1993, J BIOL CHEM, V268, P8835; MULLIGAN MS, 1991, J CLIN INVEST, V88, P1396, DOI 10.1172/JCI115446; NOURSHARGH S, 1990, J IMMUNOL, V145, P2633; OPPENHEIM JJ, 1991, ANNU REV IMMUNOL, V9, P617, DOI 10.1146/annurev.iy.09.040191.003153; OSBORN L, 1992, J EXP MED, V176, P99, DOI 10.1084/jem.176.1.99; PARKER CM, 1992, P NATL ACAD SCI USA, V89, P1924, DOI 10.1073/pnas.89.5.1924; PICKER LJ, 1990, J IMMUNOL, V145, P3247; PICKER LJ, 1991, NATURE, V349, P796, DOI 10.1038/349796a0; PICKER LJ, 1992, ANNU REV IMMUNOL, V10, P561, DOI 10.1146/annurev.immunol.10.1.561; Rosen S D, 1993, Semin Immunol, V5, P237, DOI 10.1006/smim.1993.1028; ROT A, 1992, IMMUNOL TODAY, V13, P291, DOI 10.1016/0167-5699(92)90039-A; RUEGG C, 1992, J CELL BIOL, V117, P179, DOI 10.1083/jcb.117.1.179; SAKO D, 1993, CELL, V75, P1179, DOI 10.1016/0092-8674(93)90327-M; SCHALL TJ, 1990, NATURE, V347, P669, DOI 10.1038/347669a0; SCHEYNIUS A, 1993, J IMMUNOL, V150, P655; SCHWEIGHOFFER T, 1993, J IMMUNOL, V151, P717; SEKIDO N, 1993, NATURE, V365, P654, DOI 10.1038/365654a0; SHIMIZU Y, 1991, NATURE, V349, P799, DOI 10.1038/349799a0; SHIMIZU Y, 1992, IMMUNOL TODAY, V13, P106, DOI 10.1016/0167-5699(92)90151-V; SMITH CW, 1991, J CLIN INVEST, V87, P609, DOI 10.1172/JCI115037; SNYDERMAN R, 1992, INFLAMMATION BASIC P, P421; SPANGRUDE GJ, 1985, J IMMUNOL, V135, P4135; SPANGRUDE GJ, 1984, J IMMUNOL, V132, P354; SPRENT J, 1994, CELL, V76, P315, DOI 10.1016/0092-8674(94)90338-7; SPRINGER TA, 1990, NATURE, V346, P425, DOI 10.1038/346425a0; SPRINGER TA, 1990, CELL TO CELL INTERACTION, P16; STAMPER HB, 1976, J EXP MED, V144, P828, DOI 10.1084/jem.144.3.828; STREETER PR, 1988, J CELL BIOL, V107, P1853, DOI 10.1083/jcb.107.5.1853; STREETER PR, 1988, NATURE, V331, P41, DOI 10.1038/331041a0; TANAKA Y, 1993, NATURE, V361, P79, DOI 10.1038/361079a0; USHIYAMA S, 1993, J BIOL CHEM, V268, P15229; VONANDRIAN UH, 1993, J CLIN INVEST, V91, P2893, DOI 10.1172/JCI116535; VONANDRIAN UH, 1993, BLOOD, V82, P182, DOI 10.1182/blood.V82.1.182.bloodjournal821182; VONANDRIAN UH, 1991, P NATL ACAD SCI USA, V88, P7538, DOI 10.1073/pnas.88.17.7538; VONDERHEIDE RH, 1992, J EXP MED, V175, P1433, DOI 10.1084/jem.175.6.1433; WALSH LJ, 1990, LAB INVEST, V63, P592; WOODRUFF JJ, 1987, ANNU REV IMMUNOL, V5, P201, DOI 10.1146/annurev.immunol.5.1.201; WU DQ, 1993, SCIENCE, V261, P101, DOI 10.1126/science.8316840	105	6269	6571	3	324	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	JAN 28	1994	76	2					301	314		10.1016/0092-8674(94)90337-9	http://dx.doi.org/10.1016/0092-8674(94)90337-9			14	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	MU678	7507411				2022-12-28	WOS:A1994MU67800013
